PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Oneyama, C; Ikeda, J; Okuzaki, D; Suzuki, K; Kanou, T; Shintani, Y; Morii, E; Okumura, M; Aozasa, K; Okada, M				Oneyama, C.; Ikeda, J.; Okuzaki, D.; Suzuki, K.; Kanou, T.; Shintani, Y.; Morii, E.; Okumura, M.; Aozasa, K.; Okada, M.			MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways	ONCOGENE			English	Article						c-Src; tumor; miRNA; mTOR; FGFR3	PROTEIN-TYROSINE KINASE; HUMAN LUNG-CANCER; FACTOR RECEPTORS; FAMILY KINASES; C-SRC; V-SRC; MTOR; EXPRESSION; PHOSPHORYLATION; TRANSFORMATION	The tyrosine kinase c-Src is upregulated in various human cancers, but the molecular mechanisms underlying c-Src-mediated tumor growth remain unclear. Here we examined the involvement of microRNAs in the c-Src-mediated tumor growth. Microarray profiling revealed that c-Src activation downregulates a limited set of microRNAs, including miR-99a, which targets oncogenic mammalian target of rapamycin (mTOR) and fibroblast growth factor receptor 3 (FGFR3). Re-expression of miR-99a suppressed tumor growth of c-Src-transformed cells, and this effect was restored by the overexpression of mTOR. The downregulation of miR-99a was also observed in epidermal growth factor-and Ras-transformed cells, and it was suppressed by inhibiting the mitogen-activated protein kinase (MAPK) pathway. Furthermore, miR-99a downregulation is associated with mTOR/FGFR3 upregulation in various human lung cancer cells/tissues. The tumorigenicity of these cells was suppressed by the introduction of miR-99a. These findings suggest that the miR-99a-mTOR/FGFR3 pathway is crucial for controlling tumor growth in a wide range of human cancers that harbor upregulation of the Src-related oncogenic pathways. Oncogene (2011) 30, 3489-3501; doi:10.1038/onc.2011.63; published online 7 March 2011	[Oneyama, C.; Suzuki, K.; Kanou, T.; Okada, M.] Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan; [Ikeda, J.; Morii, E.; Aozasa, K.] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; [Okuzaki, D.] Osaka Univ, Microbial Dis Res Inst, DNA Chip Dev Ctr Infect Dis, Suita, Osaka 5650871, Japan; [Kanou, T.; Shintani, Y.; Okumura, M.] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University	Oneyama, C (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	coneyama@biken.osaka-u.ac.jp	Okumura, Mitsutaka/L-5388-2013; Okuzaki, Daisuke/AAN-5641-2020	Okumura, Mitsutaka/0000-0001-7403-1318; Okuzaki, Daisuke/0000-0002-4552-783X	Ministry of Education, Culture, Sports, Science and Technology of Japan; Osaka University; Grants-in-Aid for Scientific Research [22689009] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Osaka University; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs A Imamoto, T Akagi and M Yutsudo for generous gifts of reagents. This work was supported by a Grant-in-aid for Young Scientists from the Ministry of Education, Culture, Sports, Science and Technology of Japan and The Exciting Leading-Edge Research Project at Osaka University.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Catto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nagayama K, 2007, GENE CHROMOSOME CANC, V46, P1000, DOI 10.1002/gcc.20485; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Noro R, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-277; Nozawa H, 2007, CANCER LETT, V251, P105, DOI 10.1016/j.canlet.2006.11.008; OKADA M, 1991, J BIOL CHEM, V266, P24249; Oneyama C, 2008, GENES CELLS, V13, P1, DOI 10.1111/j.1365-2443.2007.01145.x; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Vojtechova M, 2008, NEOPLASIA, V10, P99, DOI 10.1593/neo.07905; Wang FZ, 2008, J VIROL, V82, P9065, DOI 10.1128/JVI.00961-08; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu Jianmin, 2011, J CANCER RES CLIN, V137, P1379, DOI [10.1007/s00432-011-0999-8, DOI 10.1007/S00432-011-0999-8, DOI 10.1007/S00432-011-0976-2]; Yamada H, 2008, GENE CHROMOSOME CANC, V47, P810, DOI 10.1002/gcc.20582; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x	49	86	90	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3489	3501		10.1038/onc.2011.63	http://dx.doi.org/10.1038/onc.2011.63			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21383697				2022-12-28	WOS:000293782300002
J	Donati, G; Bertoni, S; Brighenti, E; Vici, M; Trere, D; Volarevic, S; Montanaro, L; Derenzini, M				Donati, G.; Bertoni, S.; Brighenti, E.; Vici, M.; Trere, D.; Volarevic, S.; Montanaro, L.; Derenzini, M.			The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells	ONCOGENE			English	Article						p53 expression; rRNA transcription; ribosomal proteins; nucleolus; mammalian cells	TRANSCRIPTION FACTOR UBF; POLYMERASE-I TRANSCRIPTION; DEPENDENT REGULATION; GENE-TRANSCRIPTION; BIOGENESIS; MDM2; ACTIVATION; INHIBITION; PATHWAY; CANCER	Data on the relationship between ribosome biogenesis and p53 function indicate that the tumour suppressor can be activated by either nucleolar disruption or ribosomal protein defects. However, there is increasing evidence that the induction of p53 does not always require these severe cellular changes, and data are still lacking on a possible role of ribosome biogenesis in the downregulation of p53. Here, we studied the effect of the up-and downregulation of the rRNA transcription rate on p53 induction in mammalian cells. We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells. p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building. p53 stabilisation did not occur when rRNA synthesis downregulation was associated with a contemporary reduction of protein synthesis. Furthermore, we demonstrated that in three different experimental models characterised by an upregulation of rRNA synthesis, cancer cells treated with insulin or exposed to the insulin-like growth factor 1, rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy, the p53 protein level was reduced due to a lowered ribosomal protein availability for MDM2 binding. It is worth noting that the upregulation of rRNA synthesis was responsible for a decreased p53-mediated response to cytotoxic stresses. These findings demonstrated that the balance between rRNA and ribosomal protein synthesis controls the function of p53 in mammalian cells, that p53 can be induced without the occurrence of severe changes of the cellular components controlling ribosome biogenesis, and that conditions characterised by an upregulated rRNA synthesis are associated with a reduced p53 response. Oncogene (2011) 30, 3274-3288; doi:10.1038/onc.2011.48; published online 14 March 2011	[Derenzini, M.] Univ Bologna, Dipartimento Clin Sci Radiol & Isocitopatol, I-40138 Bologna, Italy; [Donati, G.; Bertoni, S.; Brighenti, E.; Vici, M.; Trere, D.; Montanaro, L.] Univ Bologna, Dipartimento Patol Sperimentale, I-40138 Bologna, Italy; [Brighenti, E.] Univ Bologna, Ctr Interdipartimentale Ric Canc G Prodi, I-40138 Bologna, Italy; [Volarevic, S.] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia	University of Bologna; University of Bologna; University of Bologna; University of Rijeka	Derenzini, M (corresponding author), Univ Bologna, Dipartimento Clin Sci Radiol & Isocitopatol, Via Massarenti 9, I-40138 Bologna, Italy.	massimo.derenzini@unibo.it	Trere', Davide/AAC-4725-2021; Montanaro, Lorenzo/I-4236-2019; Volarevic, Sinisa/O-4349-2018	Trere', Davide/0000-0003-1127-1052; Montanaro, Lorenzo/0000-0001-9776-9518; Volarevic, Sinisa/0000-0003-4893-389X; Donati, Giulio/0000-0003-0875-9233	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Vanini-Cavagnino Grant; Italian Ministry of Education, University and Research (MIUR)	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Vanini-Cavagnino Grant; Italian Ministry of Education, University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was supported by the Roberto and Cornelia Pallotti's Legacy for Cancer Research, the Vanini-Cavagnino Grant and the Italian Ministry of Education, University and Research (MIUR: grants for orientated fundamental research). We thank Professor U Scheer for the generous gift of the anti-ribosomal protein S14 antibody. We are indebted with Dr Maurizio Brigotti for performing polysomal fraction analysis.	Abmayr S.M., 2006, CURR PROTOC MOL BIOL; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Barkic M, 2009, MOL CELL BIOL, V29, P2489, DOI 10.1128/MCB.01588-08; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Caldarola S, 2004, J BIOL CHEM, V279, P13522, DOI 10.1074/jbc.M310574200; Cannata D, 2010, MT SINAI J MED, V77, P197, DOI 10.1002/msj.20167; Chan PK, 1996, CANCER LETT, V100, P191, DOI 10.1016/0304-3835(95)04100-1; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; DERENZINI M, 1981, J ULTRA MOL STRUCT R, V75, P229, DOI 10.1016/S0022-5320(81)80138-4; DERENZINI M, 1978, J ULTRA MOL STRUCT R, V62, P213, DOI 10.1016/S0022-5320(78)80018-5; DONATI G, 2010, SELECTIVE INHI UNPUB; Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; GLIBETIC M, 1993, MOL CELL ENDOCRINOL, V94, P243, DOI 10.1016/0303-7207(93)90173-H; GLIBETIC M, 1995, J BIOL CHEM, V270, P4209, DOI 10.1074/jbc.270.9.4209; Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higgins GM, 1931, ARCH PATHOL, V12, P186; Holzel M, 2005, J CELL BIOL, V170, P367, DOI 10.1083/jcb.200501141; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Khutornenko AA, 2010, P NATL ACAD SCI USA, V107, P12828, DOI 10.1073/pnas.0910885107; Kruger T, 2007, J CELL BIOL, V177, P573, DOI 10.1083/jcb.200612048; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liu Y, 2009, CELL STEM CELL, V4, P37, DOI 10.1016/j.stem.2008.11.006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montanaro L, 2007, CELL PROLIFERAT, V40, P532, DOI 10.1111/j.1365-2184.2007.00448.x; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; NADAL C, 1995, LIVER, V15, P63; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Panic L, 2007, CELL CYCLE, V6, P20, DOI 10.4161/cc.6.1.3666; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Renehan Andrew G., 2008, Archives of Physiology and Biochemistry, V114, P71, DOI [10.1080/13813450801954303, 10.1080/13813450801954303 ]; Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; SIRRI V, 1995, J HISTOCHEM CYTOCHEM, V43, P887, DOI 10.1177/43.9.7642962; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; THOMPSON NL, 1986, CANCER RES, V46, P3111; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wu A, 2005, J BIOL CHEM, V280, P2863, DOI 10.1074/jbc.M406138200; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	67	68	71	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3274	3288		10.1038/onc.2011.48	http://dx.doi.org/10.1038/onc.2011.48			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21399665				2022-12-28	WOS:000293006800006
J	Lee, M; Daniels, MJ; Garnett, MJ; Venkitaraman, AR				Lee, M.; Daniels, M. J.; Garnett, M. J.; Venkitaraman, A. R.			A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor	ONCOGENE			English	Article						HMG20b; mitosis; BRCA2; BRC repeats; cytokinesis	CANCER SUSCEPTIBILITY; DNA-BINDING; BREAST; CYTOKINESIS; GENETICS; COMPLEX; DEFICIENT; ANILLIN; MYOSIN	The inactivation of BRCA2, a suppressor of breast, ovarian and other epithelial cancers, triggers instability in chromosome structure and number, which are thought to arise from defects in DNA recombination and mitotic cell division, respectively. Human BRCA2 controls DNA recombination via eight BRC repeats, evolutionarily conserved motifs of similar to 35 residues, that interact directly with the recombinase RAD51. How BRCA2 controls mitotic cell division is debated. Several studies by different groups report that BRCA2 deficiency affects cytokinesis. Moreover, its interaction with HMG20b, a protein of uncertain function containing a promiscuous DNA-binding domain and kinesin-like coiled coils, has been implicated in the G2-M transition. We show here that HMG20b depletion by RNA interference disturbs the completion of cell division, suggesting a novel function for HMG20b. In vitro, HMG20b binds directly to the BRC repeats of BRCA2, and exhibits the highest affinity for BRC5, a motif that binds poorly to RAD51. Conversely, the BRC4 repeat binds strongly to RAD51, but not to HMG20b. In vivo, BRC5 overexpression inhibits the BRCA2-HMG20b interaction, recapitulating defects in the completion of cell division provoked by HMG20b depletion. In contrast, BRC4 inhibits the BRCA2-RAD51 interaction and the assembly of RAD51 at sites of DNA damage, but not the completion of cell division. Our findings suggest that a novel function for HMG20b in cytokinesis is regulated by its interaction with the BRC repeats of BRCA2, and separate this unexpected function for the BRC repeats from their known activity in DNA recombination. We propose that divergent tumor-suppressive pathways regulating chromosome segregation as well as chromosome structure may be governed by the conserved BRC motifs in BRCA2. Oncogene (2011) 30, 3360-3369; doi:10.1038/onc.2011.55; published online 14 March 2011	[Venkitaraman, A. R.] Univ Cambridge, Dept Oncol, MRC, Canc Cell Unit,Hutchison MRC Res Ctr, Cambridge CB2 0XZ, Cambs, England	University of Cambridge	Venkitaraman, AR (corresponding author), Univ Cambridge, Dept Oncol, MRC, Canc Cell Unit,Hutchison MRC Res Ctr, Hills Rd, Cambridge CB2 0XZ, Cambs, England.	arv22@cam.ac.uk	Lee, MiYoung/G-3748-2014	Daniels, Matthew/0000-0002-9250-6214	Canadian Institute for Health Research; Medical Research Council; Medical Research Council [G9900064, MC_U105359877, G0600332, G0700651] Funding Source: researchfish; MRC [MC_U105359877, G0600332, G9900064, G0700651] Funding Source: UKRI	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	ML performed the experiments reported here and conceived them with ARV. MJD and MJG generated preliminary data, suggested experiments and assisted with data interpretation. We thank Dr Mark Petronczki (Clare Hall Labs, London) for sharing protocols and the siRNA sequences Q#6 and I#7 (Lekomtsev et al., 2010), and the members of our lab for helpful discussions. MJG was supported in part by a fellowship from the Canadian Institute for Health Research, and ARV was supported by a grant from the Medical Research Council, which also funded ML and MJD.	Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Ayoub Nabieh, 2009, Curr Biol, V19, P1075, DOI 10.1016/j.cub.2009.05.057; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Carreira A, 2009, CELL, V136, P1032, DOI 10.1016/j.cell.2009.02.019; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Jonsdottir AB, 2009, CELL ONCOL, V31, P191, DOI 10.3233/CLO-2009-0465; King TA, 2007, ANN SURG ONCOL, V14, P2510, DOI 10.1245/s10434-007-9372-1; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lee YM, 2003, BIOCHEM J, V374, P497, DOI 10.1042/BJ20030452; Lekomtsev S, 2010, J CELL SCI, V123, P1395, DOI 10.1242/jcs.068015; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Meng X, 2007, ONCOGENE, V26, P6253, DOI 10.1038/sj.onc.1210460; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rajendra E, 2010, NUCLEIC ACIDS RES, V38, P82, DOI 10.1093/nar/gkp873; Rowley M, 2011, GASTROENTEROLOGY, V140, P1303, DOI 10.1053/j.gastro.2010.12.039; Shivji MKK, 2006, NUCLEIC ACIDS RES, V34, P4000, DOI 10.1093/nar/gkl505; Shivji MKK, 2009, P NATL ACAD SCI USA, V106, P13254, DOI 10.1073/pnas.0906208106; Straight AF, 2005, MOL BIOL CELL, V16, P193, DOI 10.1091/mbc.E04-08-0758; Sumoy L, 2000, CYTOGENET CELL GENET, V88, P62, DOI 10.1159/000015486; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vinciguerra P, 2010, J CLIN INVEST, V120, P3834, DOI 10.1172/JCI43391; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhao WM, 2005, J BIOL CHEM, V280, P33516, DOI 10.1074/jbc.M504657200; Zhu CJ, 2005, P NATL ACAD SCI USA, V102, P343, DOI 10.1073/pnas.0408438102	34	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3360	3369		10.1038/onc.2011.55	http://dx.doi.org/10.1038/onc.2011.55			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21399666	Green Published, hybrid			2022-12-28	WOS:000293215700006
J	Sreekanth, CN; Bava, SV; Sreekumar, E; Anto, RJ				Sreekanth, C. N.; Bava, S. V.; Sreekumar, E.; Anto, R. J.			Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer	ONCOGENE			English	Article						chemical carcinogenesis; survival factors; xenograft tumors; natural products; chemosensitization; apoptosis	FACTOR-KAPPA-B; TAXOL-INDUCED APOPTOSIS; MULTIDRUG-RESISTANCE; TRANSCRIPTION FACTOR; OVARIAN-CANCER; DOWN-REGULATION; UTERINE CERVIX; P-GLYCOPROTEIN; BREAST-CANCER; CONSTITUTIVE ACTIVATION	The microtubule-targeting antineoplastic agent, paclitaxel, is highly efficacious against a wide spectrum of human cancers. However, dose-limiting toxicity and development of drug resistance limit its clinical application. Development of novel strategies that overcome chemoresistance and sensitize cancer cells to paclitaxel can enhance the therapeutic effect of this drug. We have previously shown that curcumin, a natural polyphenol, enhances paclitaxel-induced cytotoxicity in vitro through downregulation of nuclear factor (NF)-kappa B and Akt pathways. This study was undertaken to determine whether this synergism exists in vivo and to elucidate the underlying molecular mechanisms. Mouse cervical multistage squamous cell carcinoma model using 3-methylcholanthrene (3-MC) and a xenograft model of human cervical cancer in nonobese diabetic severe combined immunodeficient ( NOD-SCID) mice using HeLa cells were used to evaluate the synergism. We observed that the combined treatment of curcumin and paclitaxel induced a synergestic reduction in the tumor incidence as well as tumor volume of animals compared with the individual treatments of paclitaxel or curcumin, although curcumin alone could not induce any significant effect at the concentration used. The results suggest that a suboptimal concentration of curcumin augments the antitumor action of paclitaxel by down-regulating the activation and downstream signaling of antiapoptotic factors and survival signals such as NF-kappa B, Akt and mitogen-activated protein kinases that have significant roles in proliferation, survival, angiogenesis and metastasis. This study revealed for the first time that 3-MC-induced tumorigenesis in mice is associated with a strong constitutive activation of NF-kappa B activity. Furthermore, we also observed that pre-exposure of carcinoma cells isolated from 3-MC-induced tumors to curcumin potentiates paclitaxel-induced apoptosis. Overall, the findings of this preclinical study provide a strong rationale for the validation of this combination through clinical trials. As curcumin could effectively downregulate all these survival signals induced by paclitaxel, we suggest it as a potent chemosensitizer to improve the therapeutic index of paclitaxel. Oncogene (2011) 30, 3139-3152; doi:10.1038/onc.2011.23; published online 14 February 2011	[Sreekanth, C. N.; Bava, S. V.; Anto, R. J.] Rajiv Gandhi Ctr Biotechnol, Div Canc Res, Integrated Canc Res Program, Thiruvananthapuram 695014, Kerala, India; [Sreekumar, E.] Rajiv Gandhi Ctr Biotechnol, Mol Virol Lab, Thiruvananthapuram, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Anto, RJ (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Res, Integrated Canc Res Program, Thycaud PO, Thiruvananthapuram 695014, Kerala, India.	rjanto@rgcb.res.in	Narayanapillai, Sreekanth Chanickal/AAQ-4442-2020		Department of Biotechnology, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India)	This work was supported by the Department of Biotechnology, Government of India. We thank Dr Marie Lue Antony, Dr TR Santhoshkumar and Arun Kumar T Thulasidasan for technical advice and help and Dr Thara Somanathan for verifying the histopathology data.	Aggarwal BB, 2005, CLIN CANCER RES, V11, P7490, DOI 10.1158/1078-0432.CCR-05-1192; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal BB, 2007, MOL TARGETS THERAPEU; Aggarwal S, 2006, MOL PHARMACOL, V69, P195, DOI 10.1124/mol.105.017400; Ahn KS, 2007, CURR MOL MED, V7, P619, DOI 10.2174/156652407782564363; Ahn KS, 2008, BIOCHEM PHARMACOL, V75, P907, DOI 10.1016/j.bcp.2007.10.010; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Anuchapreeda S, 2002, BIOCHEM PHARMACOL, V64, P573, DOI 10.1016/S0006-2952(02)01224-8; Banerjee S, 2002, CANCER RES, V62, P4945; Bava SV, 2011, INT J BIOCHEM CELL B, V43, P331, DOI 10.1016/j.biocel.2010.09.011; Bava SV, 2005, J BIOL CHEM, V280, P6301, DOI 10.1074/jbc.M410647200; Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang YF, 1996, CANCER, V77, P14, DOI 10.1002/(SICI)1097-0142(19960101)77:1<14::AID-CNCR4>3.0.CO;2-N; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; CHHABRA SK, 1995, ONCOLOGY, V52, P32; Choi BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003; Gagnon V, 2008, APOPTOSIS, V13, P259, DOI 10.1007/s10495-007-0165-6; Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Hokeness K, 2005, ONCOL REP, V13, P965; Hou XL, 2008, INT J PHARM, V358, P224, DOI 10.1016/j.ijpharm.2008.03.010; HUSSAIN SP, 1991, CANCER LETT, V56, P231, DOI 10.1016/0304-3835(91)90007-5; Inoue M, 2008, INT J CANCER, V123, P2696, DOI 10.1002/ijc.23867; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim SH, 2007, ANN NY ACAD SCI, V1095, P82, DOI 10.1196/annals.1397.012; Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009; Kuo HC, 2006, TOXICOL APPL PHARM, V210, P55, DOI 10.1016/j.taap.2005.06.020; KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4; Kutuk O, 2008, CANCER RES, V68, P7985, DOI 10.1158/0008-5472.CAN-08-1418; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Leland GD, 2002, CULTURE EPITHELIAL C, Vsecond, P277; Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300; Li L, 2007, MOL CANCER THER, V6, P1276, DOI 10.1158/1535-7163.MCT-06-0556; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logan RM, 2007, ORAL ONCOL, V43, P395, DOI 10.1016/j.oraloncology.2006.04.011; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609; MURPHY ED, 1961, JNCI-J NATL CANCER I, V27, P611; Nair A, 2003, ONCOGENE, V22, P50, DOI 10.1038/sj.onc.1206043; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Narayanan NK, 2009, INT J CANCER, V125, P1, DOI 10.1002/ijc.24336; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Saunders DE, 1997, INT J CANCER, V70, P214, DOI 10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Sur I, 2008, INT REV IMMUNOL, V27, P205, DOI 10.1080/08830180802130319; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yagi H, 2009, INT J CANCER, V124, P1429, DOI 10.1002/ijc.24031; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754; Zhang ZF, 2006, ANN THORAC SURG, V82, P243, DOI 10.1016/j.athoracsur.2006.01.049; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	65	122	126	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3139	3152		10.1038/onc.2011.23	http://dx.doi.org/10.1038/onc.2011.23			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21317920				2022-12-28	WOS:000292726300003
J	Booy, EP; Henson, ES; Gibson, SB				Booy, E. P.; Henson, E. S.; Gibson, S. B.			Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer	ONCOGENE			English	Article						Mcl-1; Elk-1; breast cancer; regulation; drug resistance	ACTIVATED PROTEIN-KINASE; BCL-2 FAMILY PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; COLORECTAL-CANCER; MULTIPLE-MYELOMA; MEK INHIBITION; FACTOR COMPLEX; APOPTOSIS; RESISTANCE; GENE	Myeloid cell leukaemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 family that is elevated in a variety of tumour types including breast cancer. In breast tumours, increased Mcl-1 expression correlates with high tumour grade and poor patient survival. We have previously demonstrated that Her-2 levels correspond to increased Mcl-1 expression in breast tumours. Epidermal growth factor (EGF) receptor signalling is frequently deregulated in breast cancer and leads to increased proliferation and survival. Herein, we determined the critical downstream signals responsible for the EGF mediated increase of Mcl-1 and their role in cell survival. We found that both Mcl-1 mRNA and protein levels are rapidly induced upon stimulation with EGF. Promoter analysis revealed that an Elk-1 transcription factor-binding site is critical for EGF activation of the Mcl-1 promoter. Furthermore, we found that knockdown of Elk-1 or inhibition of the Erk signalling pathway was sufficient to block EGF upregulation of Mcl-1 and EGF mediated cell survival. Using chromatin immunoprecipitation and biotin labelled probes of the Mcl-1 promoter, we found that Elk-1 and serum response factor are bound to the promoter after EGF stimulation. To determine whether Mcl-1 confers a survival advantage, we found that knockdown of Mcl-1 expression increased apoptosis whereas overexpression of Mcl-1 inhibited drug induced cell death. In human breast tumours, we found a correlation between phosphorylated Elk-1 and Mcl-1 protein levels. These results indicate that the EGF induced activation of Elk-1 is an important mediator of Mcl-1 expression and cell survival and therefore a potential therapeutic target in breast cancer. Oncogene (2011) 30, 2367-2378; doi: 10.1038/onc.2010.616; published online 24 January 2011	[Booy, E. P.; Henson, E. S.; Gibson, S. B.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; [Booy, E. P.; Henson, E. S.; Gibson, S. B.] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	gibsonsb@cc.umanitoba.ca		Gibson, Spencer/0000-0003-0119-732X	Canadian Breast Cancer Foundation; Prairie chapter; Canadian Institutes for Health Research (CIHR)	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Prairie chapter; Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	The work is supported by a grant from the Canadian Breast Cancer Foundation, Prairie chapter. Evan Booy is supported by the Canadian Institutes for Health Research (CIHR) CGS Doctoral award. Dr Gibson is a Manitoba Research Chair. The Manitoba Tumour Bank is a member of the Canadian Tumour Repository Network (CTRNet) and is supported by a grant from the CIHR	Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Backus HHJ, 2001, ANN ONCOL, V12, P779, DOI 10.1023/A:1011112227044; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Boros J, 2009, NUCLEIC ACIDS RES, V37, P7368, DOI 10.1093/nar/gkp804; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Cetin Z, 2010, MED ONCOL, V27, P853, DOI 10.1007/s12032-009-9296-7; Chen FM, 2006, BIOORG MED CHEM LETT, V16, P6281, DOI 10.1016/j.bmcl.2006.09.038; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Johnston JB, 2006, CURR MED CHEM, V13, P3483, DOI 10.2174/092986706779026174; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Martin AP, 2009, CANCER BIOL THER, V8, P2084; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Nanda R, 2007, REV RECENT CLIN TRIA, V2, P111, DOI 10.2174/157488707780599375; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Sambade MJ, 2009, RADIOTHER ONCOL, V93, P639, DOI 10.1016/j.radonc.2009.09.006; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Schulze-Bergkamen H, 2008, WORLD J GASTROENTERO, V14, P3829, DOI 10.3748/wjg.14.3829; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Skliris GP, 2008, HISTOPATHOLOGY, V52, P355, DOI 10.1111/j.1365-2559.2007.02955.x; Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Tsutsui M, 2010, INT J LAB HEMATOL, V32, P419, DOI 10.1111/j.1751-553X.2009.01204.x; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vickers ER, 2004, MOL CELL BIOL, V24, P10340, DOI 10.1128/MCB.24.23.10340-10351.2004; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Watson PH, 1996, CAN MED ASSOC J, V155, P281; Witters LM, 2007, ONCOL REP, V17, P465; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zoppoli G, 2010, CURR CANCER DRUG TAR, V10, P168, DOI 10.2174/156800910791054211	57	92	95	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2367	2378		10.1038/onc.2010.616	http://dx.doi.org/10.1038/onc.2010.616			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258408	Green Published, hybrid			2022-12-28	WOS:000290789200008
J	Hsu, JH; Lawlor, ER				Hsu, J. H.; Lawlor, E. R.			BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma	ONCOGENE			English	Article						BMI-1; polycomb; YAP; contact inhibition; Hippo pathway; Ewing sarcoma	POLYCOMB GROUP PROTEINS; CELL SELF-RENEWAL; GENE-PRODUCT; ORGAN SIZE; HIPPO; GROWTH; STEM; PROLIFERATION; MERLIN; KIBRA	The polycomb group family protein BMI-1 is over-expressed by and functions as an oncogene in many different human cancers. We have previously shown that BMI-1 promotes the tumorigenicity of Ewing sarcoma family tumors (ESFTs) and that this is mediated independently of CDKN2A repression. In this study, we have discovered that high levels of BMI-1 confer resistance to contact inhibition in ESFT cells. Using stable retroviral transduction, we evaluated the consequences of BMI-1 knockdown on the growth of CDKN2A wild-type and mutant ESFT cells in subconfluent and confluent conditions. Although knockdown of BMI-1 had no effect on proliferation in low-density cultures, at high cell densities it resulted in cell cycle arrest and death. The normal cell contact inhibition response is mediated, in large part, by the recently described Hippo pathway which functions to inhibit cell proliferation and promote cell death by inactivating the Yes-Associated Protein (YAP). Significantly, we found that YAP levels, activity and expression did not diminish in confluent ESFT cells that expressed high levels of BMI-1. In contrast, YAP expression and nuclear localization were reduced in confluent BMI-1 knockdown cells suggesting that silencing of BMI-1 restored contact inhibition by restoring normal activation of the Hippo-YAP growth-suppressor pathway. Importantly, knockdown of YAP in ESFT cells resulted in profound inhibition of cell proliferation and anchorage-independent colony formation suggesting that stabilization and continued expression of YAP is critical for ESFT growth and tumorigenicity. Together, these studies reveal a previously unrecognized link between BMI-1, contact inhibition and the Hippo-YAP pathway and suggest that resistance to contact inhibition in BMI-1 overexpressing cancer cells may be in part a result of Hippo inhibition and aberrant stabilization of YAP. Oncogene (2011) 30, 2077-2085; doi:10.1038/onc.2010.571; published online 20 December 2010	[Hsu, J. H.; Lawlor, E. R.] Univ Michigan, Dept Pediat, Div Hematol Oncol, Ann Arbor, MI 48109 USA; [Hsu, J. H.] Univ So Calif, Genet Mol & Cellular Biol Program, Los Angeles, CA USA; [Lawlor, E. R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Southern California; University of Michigan System; University of Michigan	Lawlor, ER (corresponding author), Univ Michigan, Dept Pediat, Div Hematol Oncol, 1150 Med Ctr Dr,MSRBIII Room 1220A, Ann Arbor, MI 48109 USA.	elawlor@med.umich.edu			TJ Martell Foundation; NIH/NCI [1R01CA134604-01]; California Institute for Regenerative Medicine Training (CIRM) [1R01CA134604-01, T1-00004]; NATIONAL CANCER INSTITUTE [R01CA134604] Funding Source: NIH RePORTER	TJ Martell Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); California Institute for Regenerative Medicine Training (CIRM)(California Institute for Regenerative Medicine); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Long Hung and Asim Beg for technical support, members of the Lawlor lab for helpful discussion, Dr T Triche and the Children's Oncology Cell Bank (COGCELL.org) for cell lines. This work was initiated at Childrens Hospital Los Angeles (CHLA) with support from the TJ Martell Foundation. JHH was supported by CIRM training Grant T1-00004 and ERL by NIH/NCI 1R01CA134604-01.; Grant support: California Institute for Regenerative Medicine Training Grant T1-00004 (JHH), 1R01CA134604-01 ( ERL).	ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1954, EXP CELL RES, V6, P293, DOI 10.1016/0014-4827(54)90176-7; ABERCROMBIE M, 1958, EXP CELL RES, V15, P332, DOI 10.1016/0014-4827(58)90034-X; Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Ban J, 2006, ADV EXP MED BIOL, V587, P41; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chatoo W, 2009, J NEUROSCI, V29, P529, DOI 10.1523/JNEUROSCI.5303-08.2009; Datta S, 2007, CANCER RES, V67, P10286, DOI 10.1158/0008-5472.CAN-07-1636; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; LIM R, 1981, P NATL ACAD SCI-BIOL, V78, P4373, DOI 10.1073/pnas.78.7.4373; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Meltzer Paul S, 2007, Cell Stem Cell, V1, P13, DOI 10.1016/j.stem.2007.05.011; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Parrish JZ, 2007, GENE DEV, V21, P956, DOI 10.1101/gad.1514507; Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; RODESCH F, 1973, EXP CELL RES, V76, P55, DOI 10.1016/0014-4827(73)90418-7; SILLETTI S, 1995, INT J CANCER, V63, P100, DOI 10.1002/ijc.2910630118; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Striedinger K, 2008, NEOPLASIA, V10, P1204, DOI 10.1593/neo.08642; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Wiederschain D, 2007, MOL CELL BIOL, V27, P4968, DOI 10.1128/MCB.02244-06; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	40	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2077	2085		10.1038/onc.2010.571	http://dx.doi.org/10.1038/onc.2010.571			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21170084	Green Accepted			2022-12-28	WOS:000289977400011
J	Montero, JC; Seoane, S; Ocana, A; Pandiella, A				Montero, J. C.; Seoane, S.; Ocana, A.; Pandiella, A.			P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer	ONCOGENE			English	Article						P-Rex; ErbB; tyrosine kinases; breast cancer	NUCLEOTIDE EXCHANGE FACTOR; GROWTH-FACTOR RECEPTOR; BETA-GAMMA-SUBUNITS; HEREGULIN; RAC; METASTASIS; (3,4,5)-TRISPHOSPHATE; TUMORIGENICITY; ACTIVATION; KINASE	The Neuregulins and their receptors, the ErbB/HER subfamily of receptor tyrosine kinases, have critical roles in animal physiology, and their deregulation is frequent in cancer. Here we report the identification of the guanine nucleotide exchange factor, phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (P-Rex1), as a novel mediator in signalling by ErbB/HER receptors. P-Rex1 was formerly described as a phosphoinositide 3-kinase and G beta gamma activated protein that regulates Rac function. We define how ErbB/HER receptors regulate P-Rex1 function, which involves dephosphorylation of inhibitory residues, and phosphorylation of activating residues of P-Rex. The net balance resulting from activation of this phosphorylation/dephosphorylation cycle of P-Rex1 favours Rac activation. Molecular and biological studies indicated that P-Rex1 phosphorylation regulated the proliferation of breast cancer cells, and P-Rex1 knockdown affected their migration or invasiveness, as well as their in vivo tumourigenic potential. Moreover, as we found correlation between high P-Rex1 expression and poor patient outcome in breast cancer, P-Rex1 targeting may be therapeutically relevant in cancer. Oncogene (2011) 30, 1059-1071; doi:10.1038/onc.2010.489; published online 1 November 2010	[Montero, J. C.; Seoane, S.; Pandiella, A.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; [Ocana, A.] Complejo Hosp Univ Albacete, Med Oncol Serv, Albacete, Spain; [Ocana, A.] AECC Unit, Albacete, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Pandiella, A (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Campus Miguel de Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain.	atanasio@usal.es	Seoane, Samuel/H-6299-2015; Seoane, Samuel/L-1309-2014; Montero, Juan Carlos/AAO-1780-2020; Pandiella, Atanasio/O-5180-2014	Seoane, Samuel/0000-0002-9178-0887; Montero, Juan Carlos/0000-0003-4773-053X; Pandiella, Atanasio/0000-0002-4704-8971; Ocana, Alberto/0000-0002-1067-9630	Ministry of Science and Innovation of Spain [BFU2006-01813/BMC, BFU2009-07728/BMC]; Consejeria de Sanidad de la JCYL; ISCIII [RD06/0020/0041]; Juan de la Cierva Program; European Community; Fundacion Ramon Areces	Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Consejeria de Sanidad de la JCYL; ISCIII(Instituto de Salud Carlos III); Juan de la Cierva Program; European Community(European Commission); Fundacion Ramon Areces	This work was supported by grants from the Ministry of Science and Innovation of Spain (BFU2006-01813/BMC and BFU2009-07728/BMC) and by the Consejeria de Sanidad de la JCYL. JCM receives support from the Cancer Center Network Program from the ISCIII (RD06/0020/0041), and SS from the Juan de la Cierva Program. Our Cancer Research Institute, and the work carried out at our laboratory receive support from the European Community through the regional development funding program (FEDER), and from the Fundacion Ramon Areces. We thank Drs Heidi CE Welch and Mikio Hoshino for providing the myc-tagged P-Rex1 and an anti-P-Rex antibody, respectively.	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Atlas E, 2003, MOL CANCER RES, V1, P165; Barber MA, 2007, J BIOL CHEM, V282, P29967, DOI 10.1074/jbc.M701877200; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Breuleux M, 2007, CELL MOL LIFE SCI, V64, P2358, DOI 10.1007/s00018-007-7120-0; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; de Alava E, 2007, J CLIN ONCOL, V25, P2656, DOI 10.1200/JCO.2006.08.6850; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Joseph RE, 2005, J BIOL CHEM, V280, P27508, DOI 10.1074/jbc.M412495200; Krane IM, 1996, ONCOGENE, V12, P1781; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1921, DOI 10.1074/jbc.M506035200; Montero JC, 2007, MOL BIOL CELL, V18, P380, DOI 10.1091/mbc.E06-06-0511; Montero JC, 2008, CLIN CANCER RES, V14, P3237, DOI 10.1158/1078-0432.CCR-07-5133; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Yang C, 2008, BIOCHEM J, V410, P167, DOI 10.1042/BJ20070781; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023	31	68	70	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1059	1071		10.1038/onc.2010.489	http://dx.doi.org/10.1038/onc.2010.489			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042280				2022-12-28	WOS:000287964100005
J	Patrick, BA; Gong, X; Jaiswal, AK				Patrick, B. A.; Gong, X.; Jaiswal, A. K.			RETRACTED: Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer (Retracted article. See vol. 36, pg. 2919, 2017)	ONCOGENE			English	Article; Retracted Publication						NQO1; p63; 20S proteasome; skin differentiation; carcinogenicity	QUINONE OXIDOREDUCTASE-1; INCREASES SUSCEPTIBILITY; EPIDERMAL MORPHOGENESIS; SKIN CARCINOGENESIS; MENADIONE TOXICITY; MOUSE SKIN; IN-VIVO; ACTIVATION; ROLES; NQO1	NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytosolic enzyme that protects cells against chemical and radiation-induced oxidative stress and skin cancer. Disruption of NQO1 gene in mice showed thinning of skin epithelium and loss of cytokeratin 14, an early marker of skin differentiation. Immunohistochemistry and western analysis demonstrated downregulation of p63 in NQO1-/- mouse skin, as compared with wild-type (WT) mouse. Further analysis including modulation of NQO1 expression revealed a direct correlation between the levels of NQO1 and p63 in skin-derived keratinocytes and dermal fibroblasts. Modulation of proteasomal activity revealed that p63 is degraded by 20S proteasome and that this degradation is significantly rescued by NQO1. Coimmunoprecipitation studies showed that NQO1 interacts directly with p63 but not 20S to protect against this degradation. In addition, benzo[a]pyrene treatment led to induction of NQO1 and stabilization of p63 in WT but not in NQO1-/- mouse skin and keratinocytes. These data suggest that NQO1 controls stabilization of p63 and progression towards keratinocyte differentiation leading to normal skin development and presumably skin carcinogenesis. Oncogene (2011) 30, 1098-1107; doi:10.1038/onc.2010.491; published online 1 November 2010	[Patrick, B. A.; Jaiswal, A. K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA; [Gong, X.] Baylor Coll Med, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; Baylor College of Medicine	Jaiswal, AK (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA.	ajaiswal@som.umaryland.edu			NIH [RO1 ES007943]; NIEHS [ES007263]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263, R01ES007943] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank our colleagues for helpful discussions and suggestions. This work was supported by NIH Grant RO1 ES007943. BAP was supported by Grant RO1 ES007943 and also in part is supported by NIEHS training Grant ES007263.	Ahn KS, 2006, J BIOL CHEM, V281, P19798, DOI 10.1074/jbc.M601162200; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Asher G, 2006, BIOCHEMISTRY-US, V45, P6372, DOI 10.1021/bi0600087; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Chen S, 2000, FREE RADICAL BIO MED, V29, P276, DOI 10.1016/S0891-5849(00)00308-7; Das A, 2006, FREE RADICAL BIO MED, V40, P1843, DOI 10.1016/j.freeradbiomed.2006.01.025; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323; GUENGERICH FP, 1988, CANCER RES, V48, P2946; Iskander K, 2004, CANCER RES, V64, P5925, DOI 10.1158/0008-5472.CAN-04-0763; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Joseph P, 1998, BRIT J CANCER, V77, P709, DOI 10.1038/bjc.1998.117; Joseph P, 1998, BRIT J CANCER, V78, P312, DOI 10.1038/bjc.1998.492; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, J BIOL CHEM, V277, P46131, DOI 10.1074/jbc.M208675200; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Radjendirane Venugopal, 1997, P441; Romano RA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005623; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; Shen J, 2010, CANCER RES, V70, P1006, DOI 10.1158/0008-5472.CAN-09-2938; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	34	22	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1098	1107		10.1038/onc.2010.491	http://dx.doi.org/10.1038/onc.2010.491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042282	Green Accepted			2022-12-28	WOS:000287964100008
J	Booth, BW; Boulanger, CA; Anderson, LH; Smith, GH				Booth, B. W.; Boulanger, C. A.; Anderson, L. H.; Smith, G. H.			The normal mammary microenvironment suppresses the tumorigenic phenotype of mouse mammary tumor virus-neu-transformed mammary tumor cells	ONCOGENE			English	Article						erbB2/HER2; mammary; microenvironment; regeneration; suppression of tumorigenesis	ESTROGEN-RECEPTOR-ALPHA; HUMAN-BREAST-CANCER; TRANSGENIC MICE; GLAND DEVELOPMENT; TERATOCARCINOMA CELLS; METASTATIC-DISEASE; EPITHELIAL-CELLS; STEM-CELLS; IN-VIVO; ONCOGENE	The microenvironment of the mammary gland has been shown to exert a deterministic control over cells from different normal organs during murine mammary gland regeneration in transplantation studies. When mouse mammary tumor virus (MMTV)-neu-induced tumor cells were mixed with normal mammary epithelial cells (MECs) in a dilution series and inoculated into epithelium-free mammary fat pads, they were redirected to noncarcinogenic cell fates by interaction with untransformed MECs during regenerative growth. In the presence of non-transformed MECs (50:1), tumor cells interacted with MECs to generate functional chimeric outgrowths. When injected alone, tumor cells invariably produced tumors. Here, the normal microenvironment redirects MMTV-neu-transformed tumorigenic cells to participate in the regeneration of a normal, functional mammary gland. In addition, the redirected tumor cells show the capacity to differentiate into normal mammary cell types, including luminal, myoepithelial and secretory. The results indicate that signals emanating from a normal mammary microenvironment, comprised of stromal, epithelial and host-mediated signals, combine to suppress the cancer phenotype during glandular regeneration. Clarification of these signals offers improved therapeutic possibilities for the control of mammary cancer growth. Oncogene (2011) 30, 679-689; doi:10.1038/onc.2010.439; published online 4 October 2010	[Booth, B. W.; Boulanger, C. A.; Anderson, L. H.; Smith, G. H.] NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, GH (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bldg 10,Room 5B56,9000 Rockville Pike, Bethesda, MD 20892 USA.	gs4d@nih.gov			Center for Cancer Research, NCI; NIH; Institute for Biological Interfaces of Engineering of Clemson University; NATIONAL CANCER INSTITUTE [ZIABC010021] Funding Source: NIH RePORTER	Center for Cancer Research, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Institute for Biological Interfaces of Engineering of Clemson University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank KU Wagner for the gift of the triple transgenic WAP-Cre/Rosa26/MMTV-neu cell lines and for providing paraffin blocks from WAP-Cre/Rosa26R/MMTV-neu mouse mammary tissues. BK Vonderhaar, DS Salomon, R Callahan and GW Robinson for critical evaluation of the manuscript. The intramural research program of the Center for Cancer Research, NCI, NIH and the Institute for Biological Interfaces of Engineering of Clemson University contributed support to this work.	Bissell MJ, 2008, P NATL ACAD SCI USA, V105, P15637, DOI 10.1073/pnas.0808457105; Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982; Booth BW, 2008, P NATL ACAD SCI USA, V105, P14891, DOI 10.1073/pnas.0803214105; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Boulanger CA, 2007, P NATL ACAD SCI USA, V104, P3871, DOI 10.1073/pnas.0611637104; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Choong LY, 2007, MOL CANCER THER, V6, P2828, DOI 10.1158/1535-7163.MCT-06-0809; DEOME KB, 1959, CANCER RES, V19, P515; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; McCullough KD, 1998, P NATL ACAD SCI USA, V95, P15333, DOI 10.1073/pnas.95.26.15333; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323	32	59	59	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					679	689		10.1038/onc.2010.439	http://dx.doi.org/10.1038/onc.2010.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890308	Green Accepted			2022-12-28	WOS:000287192000005
J	Bordoli, MR; Stiehl, DP; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, RH; Camenisch, G				Bordoli, M. R.; Stiehl, D. P.; Borsig, L.; Kristiansen, G.; Hausladen, S.; Schraml, P.; Wenger, R. H.; Camenisch, G.			Prolyl-4-hydroxylase PHD2-and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis	ONCOGENE			English	Article						amphiregulin; hypoxia-inducible factors; mammary carcinoma; prolyl-4-hydroxylases; tumor vascularization	HYDROXYLASE DOMAIN PROTEIN-2; GROWTH-FACTOR-ALPHA; PROLYL HYDROXYLASE; GENE-EXPRESSION; CELL CARCINOMA; HUMAN CANCERS; OVEREXPRESSION; FACTOR-1-ALPHA; ANGIOGENESIS; INDUCTION	Hypoxia-elicited adaptations of tumor cells are essential for tumor growth and cancer progression. Although ample evidence exists for a positive correlation between hypoxia-inducible factors (HIFs) and tumor formation, metastasis and bad prognosis, the function of the HIF-alpha protein stability regulating prolyl-4-hydroxylase domain enzyme PHD2 in carcinogenesis is less well understood. In this study, we demonstrate that downregulation of PHD2 leads to increased tumor growth in a hormone-dependent mammary carcinoma mouse model. Tissue microarray analysis of PHD2 protein expression in 281 clinical samples of human breast cancer showed significantly shorter survival times of patients with low-level PHD2 tumors over a period of 10 years. An angiogenesis-related antibody array identified, amongst others, amphiregulin to be increased in the absence of PHD2 and normalized after PHD2 reconstitution. Cultivation of endothelial cells in conditioned media derived from PHD2-downregulated cells resulted in enhanced tube formation that was blocked by the addition of neutralizing anti-amphiregulin antibodies. Functionally, amphiregulin was regulated on the transcriptional level specifically by HIF-2 but not HIF-1. Our data suggest that PHD2/HIF-2/amphiregulin signaling has a critical role in the regulation of breast tumor progression and propose PHD2 as a potential tumor suppressor in breast cancer. Oncogene (2011) 30, 548-560; doi: 10.1038/onc.2010.433; published online 20 September 2010	[Wenger, R. H.] Univ Zurich, Cellular Oxygen Physiol Grp, Inst Physiol, CH-8057 Zurich, Switzerland; [Bordoli, M. R.; Stiehl, D. P.; Borsig, L.; Wenger, R. H.; Camenisch, G.] Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Kristiansen, G.; Hausladen, S.; Schraml, P.] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital	Wenger, RH (corresponding author), Univ Zurich, Cellular Oxygen Physiol Grp, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	roland.wenger@access.uzh.ch	Wenger, Roland H./B-7953-2009; Stiehl, Daniel/A-3622-2008	Wenger, Roland H./0000-0001-7592-4839; Borsig, Lubor/0000-0003-2263-9545; Stiehl, Daniel/0000-0002-0076-4874; Bordoli, Mattia/0000-0001-6917-8753	Swiss National Science Foundation; Krebsliga des Kantons Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Krebsliga des Kantons Zurich	We thank P Spielmann for excellent technical assistance, K Wollenick, TF Luscher, PJ Ratcliffe (University of Oxford, Oxford, UK), SB Lee (National Institutes of Health, Bethesda, MD, USA), DA Chan (University of California, San Francisco, CA, USA) for gifts of antibodies, cells and plasmids and D Neri (Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland) for helpful discussions. This work was supported by the Swiss National Science Foundation and Krebsliga des Kantons Zurich (GC).	Aebersold DM, 2001, CANCER RES, V61, P2911; Balamurugan K, 2009, ONCOGENE, V28, P3274, DOI 10.1038/onc.2009.186; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Barth S, 2007, MOL CELL BIOL, V27, P3758, DOI 10.1128/MCB.01324-06; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chokki M, 2006, LIFE SCI, V78, P3051, DOI 10.1016/j.lfs.2005.12.023; Couvelard A, 2008, CLIN CANCER RES, V14, P6634, DOI 10.1158/1078-0432.CCR-07-5258; ELSTON CW, 1993, J CLIN PATHOL, V46, P189; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erez N, 2003, CANCER RES, V63, P8777; Franovic A, 2009, P NATL ACAD SCI USA, V106, P21306, DOI 10.1073/pnas.0906432106; Giusti C, 2003, INT J CANCER, V105, P769, DOI 10.1002/ijc.11158; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jokilehto T, 2006, CLIN CANCER RES, V12, P1080, DOI 10.1158/1078-0432.CCR-05-2022; Kato H, 2006, INT J CANCER, V118, P1144, DOI 10.1002/ijc.21488; Lamber EP, 2010, CANCER RES, V70, P996, DOI 10.1158/0008-5472.CAN-09-2842; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Lee K, 2008, MOL CANCER RES, V6, P829, DOI 10.1158/1541-7786.MCR-07-2113; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; McBryan J, 2008, J MAMMARY GLAND BIOL, V13, P159, DOI 10.1007/s10911-008-9075-7; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; O'Reilly SM, 2006, AM J PHYSIOL-CELL PH, V290, pC592, DOI 10.1152/ajpcell.00278.2005; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Takeda K, 2007, CIRCULATION, V116, P774, DOI 10.1161/CIRCULATIONAHA.107.701516; Theurillat JP, 2007, INT J CANCER, V120, P2411, DOI 10.1002/ijc.22376; Wagenaar GTA, 2004, FREE RADICAL BIO MED, V36, P782, DOI 10.1016/j.freeradbiomed.2003.12.007; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Willmarth NE, 2008, J MAMMARY GLAND BIOL, V13, P171, DOI 10.1007/s10911-008-9081-9; Wu SR, 2008, MOL THER, V16, P1227, DOI 10.1038/mt.2008.90; Xue J, 2010, GASTROENTEROLOGY, V138, P606, DOI 10.1053/j.gastro.2009.09.049; Zhang Q, 2009, CANCER CELL, V16, P413, DOI 10.1016/j.ccr.2009.09.029; Zhong H, 1999, CANCER RES, V59, P5830	52	60	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					548	560		10.1038/onc.2010.433	http://dx.doi.org/10.1038/onc.2010.433			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20856199	Green Published			2022-12-28	WOS:000286922300004
J	Chan, SW; Lim, CJ; Huang, C; Chong, YF; Gunaratne, HJ; Hogue, KA; Blackstock, WP; Harvey, KF; Hong, W				Chan, S. W.; Lim, C. J.; Huang, C.; Chong, Y. F.; Gunaratne, H. J.; Hogue, K. A.; Blackstock, W. P.; Harvey, K. F.; Hong, W.			WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ	ONCOGENE			English	Article						TAZ; Wbp2; Hippo pathway; cancer; transcription factors	YES-ASSOCIATED PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR PATHWAY; CELL CONTACT INHIBITION; ORGAN SIZE CONTROL; HIPPO PATHWAY; BREAST-CANCER; TRANSCRIPTIONAL OUTPUT; BANTAM MICRORNA; GROWTH-CONTROL	The transcriptional co-activators YAP and TAZ are downstream targets inhibited by the Hippo tumor suppressor pathway. YAP and TAZ both possess WW domains, which are important protein-protein interaction modules that mediate interaction with proline-rich motifs, most commonly PPXY. The WW domains of YAP have complex regulatory roles as exemplified by recent reports showing that they can positively or negatively influence YAP activity in a cell and context-specific manner. In this study, we show that the WW domain of TAZ is important for it to transform both MCF10A and NIH3T3 cells and to activate transcription of ITGB2 but not CTGF, as introducing point mutations into the WW domain of TAZ (WWm) abolished its transforming and transcription-promoting ability. Using a proteomic approach, we discovered potential regulatory proteins that interact with TAZ WW domain and identified Wbp2. The interaction of Wbp2 with TAZ is dependent on the WW domain of TAZ and the PPXY-containing C-terminal region of Wbp2. Knockdown of endogenous Wbp2 suppresses, whereas overexpression of Wbp2 enhances, TAZ-driven transformation. Forced interaction of WWm with Wbp2 by direct C-terminal fusion of full-length Wbp2 or its TAZ-interacting C-terminal domain restored the transforming and transcription-promoting ability of TAZ. These results suggest that the WW domain-mediated interaction with Wbp2 promotes the transforming ability of TAZ. Oncogene (2011) 30, 600-610; doi: 10.1038/onc.2010.438; published online 25 October 2010	[Chan, S. W.; Lim, C. J.; Huang, C.; Chong, Y. F.; Hong, W.] Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, Singapore 138673, Singapore; [Gunaratne, H. J.; Hogue, K. A.; Blackstock, W. P.] Inst Mol & Cell Biol, Mass Spectrometry & Syst Biol Lab, Singapore 138673, Singapore; [Harvey, K. F.] Peter MacCallum Canc Ctr, Cell Growth & Proliferat Lab, Melbourne, Vic, Australia; [Harvey, K. F.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Hong, W.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Peter Maccallum Cancer Center; University of Melbourne; National University of Singapore	Hong, W (corresponding author), Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbhwj@imcb.a-star.edu.sg	Harvey, Kieran/AAD-5268-2022; HONG, Wanjin/E-9927-2010	Harvey, Kieran/0000-0001-7845-369X	Agency for Science, Technology, and Research (A*STAR), Singapore	Agency for Science, Technology, and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR))	This work is funded by Agency for Science, Technology, and Research (A*STAR), Singapore.	Bandura JL, 2008, DEV CELL, V14, P315, DOI 10.1016/j.devcel.2008.02.010; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen YH, 2007, MOL CELL PROTEOMICS, V6, P2072, DOI 10.1074/mcp.M700395-MCP200; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Lam-Himlin DM, 2006, J GASTROINTEST CANC, V37, P103, DOI 10.1007/s12029-007-0010-8; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; Nolo R, 2006, CURR BIOL, V16, P1895, DOI 10.1016/j.cub.2006.08.057; Oh H, 2009, ONCOGENE, V28, P1916, DOI 10.1038/onc.2009.43; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Peng HW, 2009, GENE DEV, V23, P2307, DOI 10.1101/gad.1820009; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wang KN, 2009, BIOCHEM CELL BIOL, V87, P77, DOI 10.1139/O08-114; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997	41	80	82	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	5					600	610		10.1038/onc.2010.438	http://dx.doi.org/10.1038/onc.2010.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20972459	Green Published, hybrid			2022-12-28	WOS:000286922300008
J	Takayama, K; Tsutsumi, S; Katayama, S; Okayama, T; Horie-Inoue, K; Ikeda, K; Urano, T; Kawazu, C; Hasegawa, A; Ikeo, K; Gojyobori, T; Ouchi, Y; Hayashizaki, Y; Aburatani, H; Inoue, S				Takayama, K.; Tsutsumi, S.; Katayama, S.; Okayama, T.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Kawazu, C.; Hasegawa, A.; Ikeo, K.; Gojyobori, T.; Ouchi, Y.; Hayashizaki, Y.; Aburatani, H.; Inoue, S.			Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; prostate cancer; CAGE; Chip-chip	TRANSCRIPTION FACTOR; GROWTH; IDENTIFICATION; NETWORK; PROTEIN; BIOINFORMATICS; PROGRESSION; REGION; ETV1	The androgen receptor (AR) is a critical transcriptional factor that contributes to the development and the progression of prostate cancer (PCa) by regulating the transcription of various target genes. Genome-wide screening of androgen target genes provides useful information to understand a global view of AR-mediated gene network in PCa. In this study, we performed 50-cap analysis of gene expression (CAGE) to determine androgen-regulated transcription start sites (TSSs) and chromatin immunoprecipitation (ChIP) on array (ChIP-chip) analysis to identify AR binding sites (ARBSs) and histone H3 acetylated (AcH3) sites in the human genome. CAGE determined 13 110 distinct, androgen-regulated TSSs (P<0.01), and ChIP-chip analysis identified 2872 androgen-dependent ARBSs (P<1e-5) and 25 945 AcH3 sites (P<1e-4). Both androgen-regulated coding genes and noncoding RNAs, including microRNAs (miRNAs) were determined as androgen target genes. Besides prototypic androgen-regulated TSSs in annotated gene promoter regions, there are many androgen-dependent TSSs that are widely distributed throughout the genome, including those in antisense (AS) direction of RefSeq genes. Several pairs of sense/antisense promoters were newly identified within single RefSeq gene regions. The integration of CAGE and ChIP-chip analyses successfully identified a cluster of androgen-inducible miRNAs, as exemplified by the miR-125b-2 cluster on chromosome 21. Notably, the number of androgen-upregulated genes was larger in LNCaP cells treated with R1881 for 24 h than for 6 h, and the percentage of androgen-upregulated genes accompanied with adjacent ARBSs was also much higher in cells treated with R1881 for 24 h than 6 h. On the basis of the Oncomine database, the majority of androgen-upregulated genes containing adjacent ARBSs and CAGE tag clusters in our study were previously confirmed as androgen target genes in PCa. The integrated high-throughput genome analyses of CAGE and ChIP-chip provide useful information for elucidating the AR-mediated transcriptional network that contributes to the development and progression of PCa. Oncogene (2011) 30, 619-630; doi: 10.1038/onc.2010.436; published online 4 October 2010	[Takayama, K.; Urano, T.; Inoue, S.] Univ Tokyo, Dept Antiaging Med, Grad Sch Med, Bunkyo Ku, Tokyo 1130032, Japan; [Takayama, K.; Urano, T.; Ouchi, Y.; Inoue, S.] Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130032, Japan; [Takayama, K.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Inoue, S.] Saitama Med Univ, Div Gene Regulat & Signal Transduct, Res Ctr Genom Med, Hidaka, Saitama, Japan; [Tsutsumi, S.; Aburatani, H.] Univ Tokyo, Genome Sci Div, Res Ctr Adv Sci & technol, Meguro Ku, Tokyo 1130032, Japan; [Katayama, S.; Kawazu, C.; Hasegawa, A.; Hayashizaki, Y.] RIKEN Yokohama Inst, Riken Om Sci Ctr, Kanagawa, Japan; [Okayama, T.; Ikeo, K.; Gojyobori, T.] Natl Inst Genet, Shizuoka, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; University of Tokyo; RIKEN; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Inoue, S (corresponding author), Univ Tokyo, Dept Antiaging Med, Grad Sch Med, Bunkyo Ku, Tokyo 1130032, Japan.	INOUE-GER@h.u-tokyo.ac.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022; Katayama, Shintaro/F-2958-2010	Katayama, Shintaro/0000-0001-7581-5157	MEXT; Japan Society for the Promotion of Science; MHLW; NIBIO; Grants-in-Aid for Scientific Research [22591016] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MHLW(Ministry of Health, Labour and Welfare, Japan); NIBIO(National Institute of Biomedical Innovation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by the Genome Network Project, Cell Innovation Program and Support Project of Strategic Research Center in Private Universities from the MEXT, grants from the Japan Society for the Promotion of Science, grants-in-aid from the MHLW and the Program for Promotion of Fundamental Studies in Health Sciences of the NIBIO. We are grateful to T Murata for helpful discussion and Hiromi Sano and Kazumi Yamaguchi for their assistance.	Attard G, 2008, BRIT J CANCER, V99, P314, DOI 10.1038/sj.bjc.6604472; Balint I, 2004, GENE, V332, P45, DOI 10.1016/j.gene.2004.02.045; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hermans KG, 2008, CANCER RES, V68, P7541, DOI 10.1158/0008-5472.CAN-07-5930; Ho LL, 2008, PROSTATE, V68, P1421, DOI 10.1002/pros.20809; Horie-Inoue K, 2006, BIOCHEM BIOPH RES CO, V339, P99, DOI 10.1016/j.bbrc.2005.10.188; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Katayama S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-r42; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LEITE KR, 2009, UROL ONCOL; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Louro R, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-4; Luo J, 2002, CANCER RES, V62, P2220; Maeda N, 2008, BIOTECHNIQUES, V45, P95, DOI 10.2144/000112814; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Pandini G, 2009, ANN NY ACAD SCI, V1155, P263, DOI 10.1111/j.1749-6632.2009.04361.x; Pflueger D, 2009, NEOPLASIA, V11, P804, DOI 10.1593/neo.09572; Prescott JL, 1998, PROSTATE, V35, P71, DOI 10.1002/(SICI)1097-0045(19980401)35:1<71::AID-PROS10>3.0.CO;2-H; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Takayama KI, 2009, CANCER RES, V69, P137, DOI 10.1158/0008-5472.CAN-08-3633; Takayama K, 2008, BIOCHEM BIOPH RES CO, V374, P388, DOI 10.1016/j.bbrc.2008.07.056; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wilson BJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-419; Yochum GS, 2007, J BIOL CHEM, V282, P871, DOI 10.1074/jbc.M609391200; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu SYM, 2009, TUMOR BIOL, V30, P80, DOI 10.1159/000216843	46	81	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					619	630		10.1038/onc.2010.436	http://dx.doi.org/10.1038/onc.2010.436			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20890304				2022-12-28	WOS:000286922300010
J	Dwyer, J; Le Guelte, A; Moya, EMG; Sumbal, M; Carlotti, A; Douguet, L; Gutkind, JS; Grange, PA; Dupin, N; Gavard, J				Dwyer, J.; Le Guelte, A.; Moya, E. M. Galan; Sumbal, M.; Carlotti, A.; Douguet, L.; Gutkind, J. S.; Grange, P. A.; Dupin, N.; Gavard, J.			Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor	ONCOGENE			English	Article						cell junctions; permeability; rac; PI(3)K; VE-cadherin; kaposi sarcoma	SARCOMA-ASSOCIATED-HERPESVIRUS; KAPOSIS-SARCOMA; ENDOTHELIAL PERMEABILITY; VASCULAR-PERMEABILITY; PARACRINE NEOPLASIA; ADHERENS JUNCTIONS; GENE-EXPRESSION; GROWTH-FACTOR; CELL; VGPCR	Kaposi Sarcoma (KS) are opportunistic tumors, associated with human herpes virus 8 (HHV8) infection. KS development is highly favored by immune-depression and remains the second most frequent tumor in acquired immune deficiency syndrome patients. Although it has been shown that experimental expression of the HHV8 G-protein-coupled receptor (vGPCR) in the endothelial compartment is alone sufficient to recapitulate the formation and progression of KS-like lesions, its functional effects on endothelial homeostasis are not fully understood. Here we show that vGPCR expression in endothelial cells induces an increase in paracellular permeability both in vivo and in vitro. By using pharmacological inhibitors and small interference RNA-based knockdown, we demonstrate an essential role for the PI(3)Kinase-gamma/Rac nexus in vGPCR-mediated permeability. This was further accompanied by dramatic remodeling of VE-cadherin-dependent cell-cell junctions. Importantly, this in vitro vGPCR-initiated signaling signature was observed in a large panel of human KS. Altogether, our results support the hypothesis that endothelial vGPCR signaling is co-opted in KS, and unveil new key cellular targets for therapeutic intervention. Oncogene (2011) 30, 190-200; doi: 10.1038/onc.2010.411; published online 6 September 2010	[Dwyer, J.; Le Guelte, A.; Moya, E. M. Galan; Sumbal, M.; Douguet, L.; Gavard, J.] Univ Paris 05, Inst Cochin, CNRS UMR 8104, INSERM,U1016, F-75014 Paris, France; [Carlotti, A.] Univ Paris 05, Grp Hosp Cochin Port Royal, AP HP, Serv Anat & Cytol Pathol,Fac Med, F-75014 Paris, France; [Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Grange, P. A.; Dupin, N.] Univ Paris 05, Lab Rech Dermatol, EA 1833, Fac Med, F-75014 Paris, France; [Dupin, N.] Univ Paris 05, Grp Hosp Cochin Port Royal Pavillon Tarnier, AP HP, Serv Dermatol,Fac Med, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Gavard, J (corresponding author), Univ Paris 05, Inst Cochin, CNRS UMR 8104, INSERM,U1016, 22 Rue Mechain,Rm 306, F-75014 Paris, France.	julie.gavard@inserm.fr	Gavard, Julie/I-5487-2012; Galan-Moya, Eva M/I-2912-2015; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Gavard, Julie/I-5487-2012; Grange, Philippe/W-3442-2017	Gavard, Julie/0000-0002-7985-9007; Galan-Moya, Eva M/0000-0001-5758-7592; Gutkind, J. Silvio/0000-0002-5150-4482; Dupin, Nicolas/0000-0002-6237-4951; Gavard, Julie/0000-0003-3107-2026; Grange, Philippe/0000-0001-8151-748X; Douguet, Laetitia/0000-0003-4319-491X	Ligue Nationale contre le Cancer, comite de Paris; European Community [PIRG04-GA-2008-239126]; Fondation pour la Recherche Medicale; Association pour la Recherche sur le Cancer; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER	Ligue Nationale contre le Cancer, comite de Paris; European Community(European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We would like to thank N. Bidere (Inserm U1014, Universite Paris-Sud, Hopital Paul Brousse, Villejuif, France) for helpful discussions and comments, A Schmitt (Institut Cochin, Paris, France) for technical help on electron microscopy experiments, Anne Audebourg and Brigitte Radenen (Service d'Anatomie et de Cytologie Pathologique, Hopital Cochin, Paris, France) for technical help on histological staining, and Nina Feinberg (OPCB, NIDCR, NIH, Bethesda, MD, USA) for technical help on the initial project. This research was funded by Ligue Nationale contre le Cancer, comite de Paris and by a Marie Curie International Reintegration Grant within the 7th European Community Framework Programme (PIRG04-GA-2008-239126). JD is supported by a post-doctoral fellowship from Fondation pour la Recherche Medicale, ALG by the PhD program from Universite Paris 5 and EMGM by a post-doctoral fellowship from Association pour la Recherche sur le Cancer.	Ascherl G, 1999, BLOOD, V93, P4232; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cesarman E, 2007, CURR TOP MICROBIOL, V312, P263; Chaisuparat R, 2008, CANCER RES, V68, P8361, DOI 10.1158/0008-5472.CAN-08-0878; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Dupin N, 2006, J INVEST DERMATOL, V126, P545, DOI 10.1038/sj.jid.5700132; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gavard J, 2009, MOL CELL BIOL, V29, P2469, DOI 10.1128/MCB.01304-08; Grisotto MG, 2006, J CLIN INVEST, V116, P1264, DOI 10.1172/JCI26666; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Maurer T, 2007, NEW ENGL J MED, V357, P1352, DOI 10.1056/NEJMc070508; Mitsuyasu RT, 2000, CURR OPIN ONCOL, V12, P174, DOI 10.1097/00001622-200003000-00013; Monini P, 2009, AIDS, V23, P534, DOI 10.1097/QAD.0b013e3283262a8d; Montaner S, 2006, CANCER RES, V66, P168, DOI 10.1158/0008-5472.CAN-05-1026; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Oksenhendler E, 2002, BLOOD, V99, P2331, DOI 10.1182/blood.V99.7.2331; Orenstein JM, 1997, AIDS, V11, pF35, DOI 10.1097/00002030-199705000-00001; Qian LW, 2008, J VIROL, V82, P11902, DOI 10.1128/JVI.01042-08; Sgadari C, 2002, NAT MED, V8, P225, DOI 10.1038/nm0302-225; Sodhi A, 2000, CANCER RES, V60, P4873; Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Sodhi A, 2006, CANCER CELL, V10, P133, DOI 10.1016/j.ccr.2006.05.026; Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831; Szajerka T, 2007, AIDS REV, V9, P230; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987	38	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					190	200		10.1038/onc.2010.411	http://dx.doi.org/10.1038/onc.2010.411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818438				2022-12-28	WOS:000286438900007
J	Sommer, G; Dittmann, J; Kuehnert, J; Reumann, K; Schwartz, PE; Will, H; Coulter, BL; Smith, MT; Heise, T				Sommer, G.; Dittmann, J.; Kuehnert, J.; Reumann, K.; Schwartz, P. E.; Will, H.; Coulter, B. L.; Smith, M. T.; Heise, T.			The RNA-binding protein La contributes to cell proliferation and CCND1 expression	ONCOGENE			English	Article						La autoantigen; La protein; cyclin D1; CCND1; cell proliferation; cervical cancer	CYCLIN D1; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; HUMAN-PAPILLOMAVIRUS; AUTOANTIGEN; TRANSLATION; SITE; CARCINOMA; NUCLEAR; CANCER	The La protein is an essential RNA-binding protein implicated in different aspects of RNA metabolism. Herein, we report that small interfering (siRNA)mediated La depletion reduces cell proliferation of different cell lines concomitant with a reduction in cyclin D1 (CCND1) protein. To exclude off-target effects we demonstrate that exogenous La expression in La-depleted cells restores cell proliferation and CCND1 protein levels. In contrast, proliferation of immortalized CCND1 knockout cells is not affected by La depletion, supporting a functional coherence between La, CCND1 and proliferation. Furthermore, we document by reversible in vivo crosslinking and ribonucleoprotein (RNP) immunoprecipitation an association of the La protein with CCND1 messengerRNA and that CCND1 internal ribosome entry site (IRES)-dependent translation is modulated by La protein level within the cell. In addition, we show elevated La protein expression in cervical cancer tissue and its correlation with aberrant CCND1 protein levels in cervical tumor tissue lysates. In conclusion, this study establishes a role of La in cell proliferation and CCND1 expression and demonstrates for the first time an overexpression of the RNA-binding protein La in solid tumors. Oncogene (2011) 30, 434-444; doi: 10.1038/onc.2010.425; published online 20 September 2010	[Sommer, G.; Dittmann, J.; Kuehnert, J.; Heise, T.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Dittmann, J.; Reumann, K.; Will, H.; Heise, T.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; [Schwartz, P. E.] Prot Biotechnol Inc, Ramona, CA USA; [Coulter, B. L.; Smith, M. T.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Medical University of South Carolina; Heinrich Pette Institute; University of Hamburg; Medical University of South Carolina	Heise, T (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	heise@musc.edu			Deutsche Forschungsgemeinschaft [HE 2814/3-2]; Bundesministerium fur Gesundheit and Freie und Hansestadt Hamburg	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Gesundheit and Freie und Hansestadt Hamburg	We thank Arne Du "sedau (HPI) for sorting GFP-positive cells and Rick Peppler for FACS analysis (MUSC). We are grateful to R G Pestell (Thomas Jefferson University) for providing the MEF<SUP>CCND1-/-</SUP> cells, to M Bachmann (Technical University Dresden, Germany) for providing La antibodies, to Josef Gera for providing the CCND1-IRES reporter plasmid pRCD1F, to D Watson (MUSC) for experimental advice during this study, and D Fernandes (MUSC) and J Schnellmann (MUSC) for critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft, HE 2814/3-2 (TH). The Heinrich-Pette-Institut (HPI) is financially supported by the Bundesministerium fur Gesundheit and Freie und Hansestadt Hamburg.	Al-Ejeh F, 2007, CLIN CANCER RES, V13, p5509S, DOI 10.1158/1078-0432.CCR-07-0922; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Ali N, 2000, J BIOL CHEM, V275, P27531; Bae DS, 2001, GYNECOL ONCOL, V81, P341, DOI 10.1006/gyno.2001.6196; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; Brenet F, 2005, MOL CELL BIOL, V25, P7505, DOI 10.1128/MCB.25.17.7505-7521.2005; Brenet F, 2009, ONCOGENE, V28, P128, DOI 10.1038/onc.2008.376; Calkhoven CF, 2000, GENE DEV, V14, P1920; Carreras R, 2007, HISTOL HISTOPATHOL, V22, P587, DOI 10.14670/HH-22.587; CHANG YN, 1995, J VIROL, V69, P618, DOI 10.1128/JVI.69.1.618-619.1995; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Conesa-Zamora P, 2009, AM J CLIN PATHOL, V132, P378, DOI 10.1309/AJCPO0WY1VIFCYDC; Cordes S, 2008, BIOCHEM BIOPH RES CO, V368, P1014, DOI 10.1016/j.bbrc.2008.01.163; Costa-Mattioli M, 2004, MOL CELL BIOL, V24, P6861, DOI 10.1128/mcb.24.15.6861-6870.2004; Cowling VH, 2010, ONCOGENE, V29, P930, DOI 10.1038/onc.2009.368; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Ehlers I, 2004, J BIOL CHEM, V279, P43437, DOI 10.1074/jbc.M402227200; Frost P, 2009, MOL CANCER THER, V8, P83, DOI 10.1158/1535-7163.MCT-08-0254; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Horke S, 2004, J BIOL CHEM, V279, P26563, DOI 10.1074/jbc.M401017200; Inge LJ, 2008, MOL CANCER THER, V7, P1386, DOI 10.1158/1535-7163.MCT-07-2029; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; Maraia RJ, 2001, J CELL BIOL, V153, pF13, DOI 10.1083/jcb.153.4.F13; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Nichols GE, 1996, MODERN PATHOL, V9, P418; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Park JM, 2006, MOL CELL BIOL, V26, P1445, DOI 10.1128/MCB.26.4.1445-1451.2006; Pudi R, 2004, J BIOL CHEM, V279, P29879, DOI 10.1074/jbc.M403417200; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033	48	56	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					434	444		10.1038/onc.2010.425	http://dx.doi.org/10.1038/onc.2010.425			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856207				2022-12-28	WOS:000286621600006
J	Lacher, MD; Pincheira, R; Zhu, Z; Camoretti-Mercado, B; Matli, M; Warren, RS; Castro, AF				Lacher, M. D.; Pincheira, R.; Zhu, Z.; Camoretti-Mercado, B.; Matli, M.; Warren, R. S.; Castro, A. F.			Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis	ONCOGENE			English	Article						Rheb; p27; AMPK; mTORC1; TSC/LAM; cancer	TUBEROUS SCLEROSIS COMPLEX; PROTEIN-KINASE; MAMMALIAN TARGET; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; CYTOPLASMIC SEQUESTRATION; PROMOTES BINDING; CANCER-THERAPY; NULL-CELLS; PHOSPHORYLATION; TSC2	Tuberous sclerosis complex (TSC) is an autosomally inherited disorder that causes tumors to form in many organs. It is frequently caused by inactivating mutations in the TSC2 tumor-suppressor gene. TSC2 negatively regulates the activity of the GTPase Rheb and thereby inhibits mammalian target of rapamycin complex 1 (mTORC1) signaling. Activation of mTORC1 as a result of lack of TSC2 function is observed in TSC and sporadic lymphangioleiomyomatosis (LAM). TSC2 deficiency has recently been associated with elevated AMP-activated protein kinase (AMPK) activity, which in turn correlated with cytoplasmic localization of p27Kip1 (p27), a negative regulator of cyclin-dependent kinase 2 (Cdk2). How AMPK in the absence of TSC2 is stimulated is not fully understood. In this study, we demonstrate that Rheb activates AMPK and reduces p27 levels in Tsc2-null cells. Importantly, both effects occur largely independent of mTORC1. Furthermore, increased p27 levels following Rheb depletion correlated with reduced Cdk2 activity and cell proliferation in vitro, and with inhibition of tumor formation by Tsc2-null cells in vivo. Taken together, our data suggest that Rheb controls proliferation of TSC2-deficient cells by a mechanism that involves regulation of AMPK and p27, and that Rheb is a potential target for TSC/LAM therapy. Oncogene (2010) 29, 6543-6556; doi:10.1038/onc.2010.393; published online 6 September 2010	[Lacher, M. D.; Castro, A. F.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Pincheira, R.] Univ Concepcion, Dept Biochem & Mol Biol, Concepcion, Chile; [Zhu, Z.; Matli, M.; Warren, R. S.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Camoretti-Mercado, B.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Castro, A. F.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Universidad de Concepcion; University of California System; University of California San Francisco; University of Chicago; University of California System; University of California San Francisco	Castro, AF (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.	arcastro@udec.cl	Lacher, Markus D/F-3772-2012	Pincheira, Roxana/0000-0003-4277-5245	Department of Defense (DOD) [DOD TS043006, TS043006]; Academic Senate (UCSF); LAM Foundation; ATS; ALA; Blowitz-Ridgeway Foundation; DOD [TS043006]	Department of Defense (DOD)(United States Department of Defense); Academic Senate (UCSF); LAM Foundation; ATS; ALA; Blowitz-Ridgeway Foundation; DOD(United States Department of Defense)	We are grateful to the NIH-LAM registry, the LAM foundation and especially to the LAM patients for providing LAM specimens. We thank Prema S Idumalla and Xiaochen Yuan for technical assistance, and Drs David Donner and Martin McMahon for review of the paper and suggestions. Special thanks to Pamela Derish at UCSF for editing the paper. We also thank Dr Geoffrey Clark for providing the custom Rheb antibody, Dr Cheryl Walker for the ELT3 cells and Dr David Kwiatkowski for the MEFs Tsc2-/- and Tsc2+/+. This work was supported by grants from the Department of Defense (DOD TS043006) and Academic Senate (UCSF) (AFC), and LAM Foundation, ATS, ALA, and Blowitz-Ridgeway Foundation (BC-M). Zhe Zhu was supported by the DOD TS043006 grant to AFC.	Alkarain A, 2004, BREAST CANCER RES, V6, P13, DOI 10.1186/bcr722; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Choo AY, 2006, CANCER CELL, V9, P77, DOI 10.1016/j.ccr.2006.01.021; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; Finlay GA, 2007, CANCER RES, V67, P9878, DOI 10.1158/0008-5472.CAN-07-1394; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gau CL, 2005, MOL CANCER THER, V4, P918, DOI 10.1158/1535-7163.MCT-04-0347; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197, DOI 10.1152/ajplung.1999.276.1.L197; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; HOWE SR, 1995, AM J PATHOL, V146, P1568; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Inoki K, 2009, HUM MOL GENET, V18, pR94, DOI 10.1093/hmg/ddp032; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Ma L, 2007, CANCER RES, V67, P7106, DOI 10.1158/0008-5472.CAN-06-4798; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Paul E, 2008, NEW ENGL J MED, V358, P190, DOI 10.1056/NEJMe0707153; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; Rosner M, 2007, HUM MOL GENET, V16, P1541, DOI 10.1093/hmg/ddm103; Rosner M, 2006, MUTAT RES-REV MUTAT, V613, P10, DOI 10.1016/j.mrrev.2006.03.001; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sato M, 2004, DEV CELL, V6, P458, DOI 10.1016/S1534-5807(04)00103-0; Sato T, 2002, J HUM GENET, V47, P20, DOI 10.1007/s10038-002-8651-8; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Short JD, 2008, CANCER RES, V68, P6496, DOI 10.1158/0008-5472.CAN-07-5756; Short JD, 2010, MOL CARCINOGEN, V49, P429, DOI 10.1002/mc.20613; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Viollet B, 2009, FRONT BIOSCI-LANDMRK, V14, P19, DOI 10.2741/3229; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Yu JJ, 2009, P NATL ACAD SCI USA, V106, P2635, DOI 10.1073/pnas.0810790106; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	52	32	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6543	6556		10.1038/onc.2010.393	http://dx.doi.org/10.1038/onc.2010.393			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818424				2022-12-28	WOS:000285380200004
J	Liu, RY; Dong, Z; Liu, J; Yin, JY; Zhou, L; Wu, X; Yang, Y; Mo, W; Huang, W; Khoo, SK; Chen, J; Petillo, D; Teh, BT; Qian, CN; Zhang, JT				Liu, R-Y; Dong, Z.; Liu, J.; Yin, J-Y; Zhou, L.; Wu, X.; Yang, Y.; Mo, W.; Huang, W.; Khoo, S. K.; Chen, J.; Petillo, D.; Teh, B. T.; Qian, C-N; Zhang, J-T			Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma	ONCOGENE			English	Article						cisplatin sensitivity; eIF3a; nasopharyngeal carcinoma; nucleotide excision repair; translational control	RIBONUCLEOTIDE REDUCTASE M2; INITIATION-FACTOR EIF3; BREAST-CANCER CELLS; DNA-DAMAGE; DRUG-RESISTANCE; OVEREXPRESSION; IDENTIFICATION; EXPRESSION; P150; CHEMORADIOTHERAPY	Translational control at the initiation step has been recognized as a major and important regulatory mechanism of gene expression. Eukaryotic initiation factor-3a (eIF3a), a putative subunit of the eIF3 complex, has recently been shown to have an important role in regulating the translation of a subset of mRNAs and is found to correlate with the prognosis of cancers. In this study, using nasopharyngeal carcinoma (NPC) cells as a model system, we tested the hypothesis that eIF3a negatively regulates the synthesis of nucleotide excision repair (NER) proteins, and, in turn, cellular response to treatments with DNA-damaging agents such as cisplatin (cis-dichlorodiammine platinum(II) (CDDP)). We found that a CDDP-sensitive sub-clone S16 isolated through limited dilution from an NPC cell line CNE-2 has increased eIF3a expression. Knocking down its expression in S16 cells increased cellular resistance to CDDP, NER activity and synthesis of the NER proteins XPA, XPC, RAD23B and RPA32. Altering eIF3a expression also changed the cellular response to CDDP and UV treatment in other NPC cell lines. Taken together, we conclude that eIF3a has an important role in the CDDP response and in NER activity of NPCs by suppressing the synthesis of NER proteins. Oncogene (2011) 30, 4814-4823; doi: 10.1038/onc.2011.189; published online 30 May 2011	[Zhang, J-T] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, IU Simon Canc Ctr, Indianapolis, IN 46202 USA; [Liu, R-Y; Zhou, L.; Huang, W.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Khoo, S. K.] Van Andel Res Inst, Lab Microarray Technol, Grand Rapids, MI USA; [Chen, J.; Petillo, D.; Teh, B. T.] Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI USA; [Petillo, D.; Teh, B. T.; Qian, C-N] Van Andel Res Inst, Lab Genome Biol, Grand Rapids, MI USA; [Teh, B. T.; Qian, C-N] Natl Canc Ctr Singapore, NCCS VARI Translat Res Lab, Singapore, Singapore; [Qian, C-N] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China	Indiana University System; Indiana University Bloomington; Sun Yat Sen University; Van Andel Institute; Van Andel Institute; Van Andel Institute; National Cancer Centre Singapore (NCCS); Sun Yat Sen University	Zhang, JT (corresponding author), Indiana Univ Sch Med, Dept Pharmacol & Toxicol, IU Simon Canc Ctr, 980 W Walnut St,R3-510, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Liu, Ran-yi/L-1008-2019; Zhang, Jian-Ting/L-8334-2015; huang, wen/GXW-0661-2022; Yin, Ji-Ye/AAE-6794-2020; mo, wei/N-5636-2014	Yin, Ji-Ye/0000-0002-1244-5045; Teh, Bin Tean/0000-0003-1514-1124	National Institutes of Health [CA94961]; Showalter Trust; National Natural Science Foundation of China [81071822]; NATIONAL CANCER INSTITUTE [R01CA094961] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Showalter Trust; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The CDDP-sensitive clone S16 was established and characterized at Van Andel Research Institute. The stable CNE-2 cells with eIF3a overexpression and the SUNE-1 cell line were studied at Sun Yat-sen University Cancer Center. All other studies were performed at the Indiana University School of Medicine. The VARI team dedicate this paper to the memory of a friend and co-worker, Dr Han-Mo Koo. This work was supported in part by the National Institutes of Health Grant CA94961 (JTZ), the Showalter Trust Fund (ZD) and the National Natural Science Foundation of China (no. 81071822) (RYL).	Afqir S, 2009, J CANCER RES THER, V5, P3, DOI 10.4103/0973-1482.48763; Agulnik M, 2005, BRIT J CANCER, V92, P799, DOI 10.1038/sj.bjc.6602449; Bachmann F, 1997, CANCER RES, V57, P988; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chen GP, 1999, INT J CANCER, V84, P95, DOI 10.1002/(SICI)1097-0215(19990420)84:2<95::AID-IJC1>3.0.CO;2-N; Chen GP, 2004, INT J CANCER, V112, P393, DOI 10.1002/ijc.20443; Dellas A, 1998, CANCER, V83, P1376, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1376::AID-CNCR15>3.0.CO;2-1; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2009, EXP CELL RES, V315, P1889, DOI 10.1016/j.yexcr.2009.03.009; Dong ZZ, 2005, NUCLEIC ACIDS RES, V33, P2715, DOI 10.1093/nar/gki569; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Furuta T, 2002, CANCER RES, V62, P4899; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Li Zhaomin, 2010, BMC Cancer, V10, P598, DOI 10.1186/1471-2407-10-598; Liu HL, 2008, MOL CANCER THER, V7, P263, DOI 10.1158/1535-7163.MCT-07-0445; Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Neher TM, 2010, ACS CHEM BIOL, V5, P953, DOI 10.1021/cb1000444; Neher TM, 2010, BIOCHEMISTRY-US, V49, P669, DOI 10.1021/bi901575h; Nouspikel T, 2009, CELL MOL LIFE SCI, V66, P994, DOI 10.1007/s00018-009-8737-y; OLDROYD NJ, 1995, ELECTROPHORESIS, V16, P334, DOI 10.1002/elps.1150160155; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Qiao YW, 2002, MUTAT RES-FUND MOL M, V509, P165, DOI 10.1016/S0027-5107(02)00219-1; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Thephamongkhol K, 2004, J CLIN ONCOL, V22, p493S; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; Xiao WW, 2009, INT J RADIAT ONCOL, V74, P1070, DOI 10.1016/j.ijrobp.2008.09.008; Xu JK, 2007, CANCER RES, V67, P4373, DOI 10.1158/0008-5472.CAN-06-3169; Yang YY, 2007, J BIOL CHEM, V282, P8821, DOI 10.1074/jbc.M700152200; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Yin JY, 2011, BIOSCIENCE REP, V31, P1, DOI 10.1042/BSR20100077; Yin JY, 2011, CLIN CANC R IN PRESS; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	39	60	65	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4814	4823		10.1038/onc.2011.189	http://dx.doi.org/10.1038/onc.2011.189			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625209	Green Accepted			2022-12-28	WOS:000298134700005
J	Zhang, S; Wang, X; Osunkoya, AO; Iqbal, S; Wang, Y; Chen, Z; Muller, S; Chen, Z; Josson, S; Coleman, IM; Nelson, PS; Wang, YA; Wang, R; Shin, DM; Marshall, FF; Kucuk, O; Chung, LWK; Zhau, HE; Wu, D				Zhang, S.; Wang, X.; Osunkoya, A. O.; Iqbal, S.; Wang, Y.; Chen, Z.; Mueller, S.; Chen, Z.; Josson, S.; Coleman, I. M.; Nelson, P. S.; Wang, Y. A.; Wang, R.; Shin, D. M.; Marshall, F. F.; Kucuk, O.; Chung, L. W. K.; Zhau, H. E.; Wu, D.			EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis	ONCOGENE			English	Article						EPLIN; epithelial-mesenchymal transition; prostate cancer; lymph node metastasis; cytoskeleton	GENE-EXPRESSION; PROTEIN LOST; PROTEOMIC IDENTIFICATION; ACTIN-CYTOSKELETON; GROWTH; INVASION; BONE; PROGRESSION; NEOPLASM; REVEALS	Epithelial-mesenchymal transition (EMT) is a crucial mechanism for the acquisition of migratory and invasive capabilities by epithelial cancer cells. By conducting quantitative proteomics in experimental models of human prostate cancer (PCa) metastasis, we observed strikingly decreased expression of EPLIN (epithelial protein lost in neoplasm; or LIM domain and actin binding 1, LIMA-1) upon EMT. Biochemical and functional analyses demonstrated that EPLIN is a negative regulator of EMT and invasiveness in PCa cells. EPLIN depletion resulted in the disassembly of adherens junctions, structurally distinct actin remodeling and activation of beta-catenin signaling. Microarray expression analysis identified a subset of putative EPLIN target genes associated with EMT, invasion and metastasis. By immunohistochemistry, EPLIN downregulation was also demonstrated in lymph node metastases of human solid tumors including PCa, breast cancer, colorectal cancer and squamous cell carcinoma of the head and neck. This study reveals a novel molecular mechanism for converting cancer cells into a highly invasive and malignant form, and has important implications in prognosis and treating metastasis at early stages. Oncogene (2011) 30, 4941-4952; doi:10.1038/onc.2011.199; published online 30 May 2011	[Zhang, S.; Osunkoya, A. O.; Iqbal, S.; Wang, Y.; Kucuk, O.; Wu, D.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; [Zhang, S.; Osunkoya, A. O.; Iqbal, S.; Wang, Y.; Marshall, F. F.; Wu, D.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; [Wang, X.; Chen, Z.; Shin, D. M.; Kucuk, O.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Osunkoya, A. O.; Mueller, S.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Osunkoya, A. O.; Mueller, S.] Emory Univ, Sch Med, Lab Med, Atlanta, GA 30322 USA; [Chen, Z.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA; [Josson, S.; Wang, R.; Chung, L. W. K.; Zhau, H. E.] Cedars Sinai Med Ctr, Dept Med, Uro Oncol Res Program, Los Angeles, CA 90048 USA; [Coleman, I. M.; Nelson, P. S.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98195 USA; [Wang, Y. A.] Ocean NanoTech LLC, Springdale, AR USA	Emory University; Emory University; Emory University; Emory University; Emory University; Emory University; Rollins School Public Health; Cedars Sinai Medical Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Wu, D (corresponding author), Emory Univ, Sch Med, Dept Urol, 1365 Clifton Rd,NE,Bldg B,B4108, Atlanta, GA 30322 USA.	Haiyen.Zhau@cshs.org; dwu2@emory.edu	Ray, Dana M/C-3470-2013; Shin, Dong Moon/G-9649-2013	Shin, Dong Moon/0000-0002-8245-4174; , Shareen/0000-0002-9489-7781	Department of Defense [PC060566, PC060866]; American Cancer Society [RSG-10-140-01]; Georgia Cancer Coalition Cancer Research Award; Kennedy Seed Grant; Emory University Research Committee; Winship MPB Seed Grant; National Cancer Institute [P01 CA98912, R01 CA122602, 1R43CA141870]; Georgia Cancer Coalition Distinguished Scholar Grant; NATIONAL CANCER INSTITUTE [P01CA098912, R43CA141870, R01CA122602] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); Georgia Cancer Coalition Cancer Research Award; Kennedy Seed Grant; Emory University Research Committee; Winship MPB Seed Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Georgia Cancer Coalition Distinguished Scholar Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jin-Tang Dong for critical reading of the manuscript, and Dr Anthea Hammond for editorial assistance. This work was supported by the Department of Defense PC060566, American Cancer Society RSG-10-140-01, Georgia Cancer Coalition Cancer Research Award, Kennedy Seed Grant, Emory University Research Committee Award, Winship MPB Seed Grant (DW), National Cancer Institute grants P01 CA98912, R01 CA122602 and Department of Defense PC060866 (LWKC), Georgia Cancer Coalition Distinguished Scholar Grant (OK) and National Cancer Institute grant 1R43CA141870 (YAW).	Abe K, 2008, P NATL ACAD SCI USA, V105, P13, DOI 10.1073/pnas.0710504105; Arnold RS, 2009, PROSTATE, V69, P1, DOI 10.1002/pros.20854; Baygi ME, 2010, CELL BIOL TOXICOL, V26, P553, DOI 10.1007/s10565-010-9163-5; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen SX, 2000, GENE, V248, P69, DOI 10.1016/S0378-1119(00)00144-X; Chircop M, 2009, CELL CYCLE, V8, P757, DOI 10.4161/cc.8.5.7878; Dong JT, 2009, CELL MOL LIFE SCI, V66, P2691, DOI 10.1007/s00018-009-0045-z; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Larriba MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010221; Jiang WG, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-71; Katiyar Santosh K., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P17; Keshamouni VG, 2009, J PROTEOME RES, V8, P35, DOI 10.1021/pr8006478; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Khwaja FW, 2006, ONCOGENE, V25, P7650, DOI 10.1038/sj.onc.1209969; Khwaja FW, 2007, J PROTEOME RES, V6, P559, DOI 10.1021/pr060240z; Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2; Koreckij TD, 2009, NEOPLASIA, V11, P1216, DOI 10.1593/neo.09960; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Lang SH, 2009, J PATHOL, V217, P299, DOI 10.1002/path.2478; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Liu J, 2010, PROSTATE, V70, P1768, DOI 10.1002/pros.21213; Machesky LM, 2009, CANCER CELL, V16, P5, DOI 10.1016/j.ccr.2009.06.009; Mathias RA, 2009, BBA-PROTEINS PROTEOM, V1794, P1325, DOI 10.1016/j.bbapap.2009.05.001; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; McKeithen D, 2010, PROSTATE, V70, P982, DOI 10.1002/pros.21132; O'Connell PA, 2010, BLOOD, V116, P1136, DOI 10.1182/blood-2010-01-264754; Percipalle P, 2009, RNA BIOL, V6, P171, DOI 10.4161/rna.6.2.8195; Pokutta S, 2007, ANNU REV CELL DEV BI, V23, P237, DOI 10.1146/annurev.cellbio.22.010305.104241; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sakko AJ, 2003, CANCER RES, V63, P4786; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Song YH, 2002, MOL BIOL CELL, V13, P1408, DOI 10.1091/mbc.01-08-0414; Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008-5472.CAN-08-2492; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiolloy S, 2011, SEMIN CANCER BIOL, V21, P89, DOI 10.1016/j.semcancer.2010.12.008; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wei JC, 2008, ANTICANCER RES, V28, P327; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Wong SY, 2007, P NATL ACAD SCI USA, V104, P12784, DOI 10.1073/pnas.0705499104; Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316; Xu JC, 2006, PROSTATE, V66, P1664, DOI 10.1002/pros.20488; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-9; Zhau HE, 2008, CLIN EXP METASTAS, V25, P601, DOI 10.1007/s10585-008-9183-1	53	54	56	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4941	4952		10.1038/onc.2011.199	http://dx.doi.org/10.1038/onc.2011.199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21625216	Green Accepted			2022-12-28	WOS:000298346500003
J	Krishnamurthy, N; Ngam, CR; Berdis, AJ; Montano, MM				Krishnamurthy, N.; Ngam, C. R.; Berdis, A. J.; Montano, M. M.			The exonuclease activity of hPMC2 is required for transcriptional regulation of the QR gene and repair of estrogen-induced abasic sites	ONCOGENE			English	Article						EpRE; hPMC2; quninone reductase; tamoxifen	QUINONE REDUCTASE GENE; DNA-BINDING; RECEPTOR; BREAST; TAMOXIFEN; MECHANISM; IDENTIFICATION; ACTIVATION; CANCER; RNA	We have previously reported that the expression of antioxidative stress enzymes is upregulated by trans-hydroxytamoxifen (TOT) in breast epithelial cell lines providing protection against estrogen-induced DNA damage. This regulation involves Estrogen Receptor beta (ER beta) recruitment to the Electrophile Response Element (EpRE) and a novel protein, human homolog of Xenopus gene which Prevents Mitotic Catastrophe (hPMC2). We have also demonstrated that ER beta and hPMC2 are required for TOT-dependent recruitment of poly (ADP-ribose) polymerase 1 (PARP-1) and Topoisomerase II beta (Topo II beta) to the EpRE. Sequence analysis reveals that the C-terminus of hPMC2 encodes a putative exonuclease domain. Using in vitro kinetic assays, we found that hPMC2 is a 3'-5' non-processive exonuclease that degrades both single-stranded and double-stranded substrates. Mutation of two conserved carboxylate residues drastically reduced the exonuclease activity of hPMC2, indicating the relative importance of the catalytic residues. Western blot analysis of breast cancer cell lines for Quinone Reductase (QR) levels revealed that the intrinsic exonuclease activity of hPMC2 was required for TOT-induced QR upregulation. Chromatin immunoprecipitation (ChIP) assays also indicated that hPMC2 was involved in the formation of strand breaks observed with TOT treatment and is specific for the EpRE-containing region of the QR gene. We also determined that the transcription factor NF-E2-related factor-2 (Nrf2) is involved in the specificity of hPMC2 for the EpRE. In addition, we determined that the catalytic activity of hPMC2 is required for repair of abasic sites that result from estrogen-induced DNA damage. Thus, our study provides a mechanistic basis for transcriptional regulation by hPMC2 and provides novel insights into its role in cancer prevention. Oncogene (2011) 30, 4731-4739; doi:10.1038/onc.2011.186; published online 23 May 2011	[Montano, M. M.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu			Department of Defense [BC087610]; NIH [CA92240]; NATIONAL CANCER INSTITUTE [R01CA092240, R01CA092440] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Defense Breast Cancer Postdoctoral award (BC087610) to NK and NIH Grant (CA92240) to MMM.	Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; Berdis AJ, 2001, BIOCHEMISTRY-US, V40, P7180, DOI 10.1021/bi0101594; Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx700191p; Cavalieri E, 2006, BBA-REV CANCER, V1766, P63, DOI 10.1016/j.bbcan.2006.03.001; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gaikwad NW, 2007, FREE RADICAL BIO MED, V43, P1289, DOI 10.1016/j.freeradbiomed.2007.07.021; Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Marti TM, 2004, CELL MOL LIFE SCI, V61, P336, DOI 10.1007/s00018-003-3223-4; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Montano MM, 2007, ONCOGENE, V26, P3587, DOI 10.1038/sj.onc.1210144; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Nakamura T, 2008, STROKE, V39, P463, DOI 10.1161/STROKEAHA.107.486654; Nakopoulou L, 2004, J CLIN PATHOL, V57, P523, DOI 10.1136/jcp.2003.008599; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Saji S, 2005, CANCER CHEMOTH PHARM, V56, pS21, DOI 10.1007/s0028-005-0107-3; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Sripathy SP, 2008, ONCOGENE, V27, P6376, DOI 10.1038/onc.2008.235; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	33	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4731	4739		10.1038/onc.2011.186	http://dx.doi.org/10.1038/onc.2011.186			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602889	Green Accepted, Green Submitted			2022-12-28	WOS:000298033700005
J	Wang, Y; Romigh, T; He, X; Tan, MH; Orloff, MS; Silverman, RH; Heston, WD; Eng, C				Wang, Y.; Romigh, T.; He, X.; Tan, M-H; Orloff, M. S.; Silverman, R. H.; Heston, W. D.; Eng, C.			Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers	ONCOGENE			English	Article						androgen receptor; PTEN; prostate cancer; breast cancer; Cowden syndrome	TUMOR-SUPPRESSOR; PHOSPHOINOSITOL-3-KINASE/AKT PATHWAY; TRANSCRIPTIONAL ACTIVITY; 3-KINASE/AKT PATHWAY; PROMOTER MUTATIONS; CELL-PROLIFERATION; COWDEN-DISEASE; GENE; AKT; COACTIVATOR	Prostate cancer and breast cancer are the most common malignancies in the western world. Androgen receptor (AR) and PTEN both have been well documented to have important roles in prostate carcinogenesis. In contrast, AR and PTEN in breast carcinogenesis have not been well studied. Furthermore, the crosstalk and connection between those two pathways remain unclear. Increased AR expression in prostate cancers, combined with decreased PTEN expression, portends a poor clinical outcome. Paradoxically, both high AR and high PTEN levels, detected by immunohistochemistry, in primary breast carcinomas have been associated with better disease-free survival. Here, we performed in silico analysis of publicly available microarray data sets from prostate or breast carcinomas. We found an inverse correlation between AR and PTEN transcript expression in prostate cancer tissues in contrast to the positive correlation in breast cancer. These data led us to hypothesize that AR may directly affect PTEN transcriptional regulation in prostate and breast cancer cells. Here, we show for the first time that AR inhibits PTEN transcription in prostate cancer cells, whereas AR upregulates PTEN transcription in breast cancer cells, which mechanistically explains both the immunohistochemical PTEN-AR expressional data noted in clinical trials and in our in silico analysis of the transcriptomes of breast and prostate cancers. In addition, we have fine-mapped the AR-binding motif within the PTEN promoter. Here we show that, in patients with Cowden syndrome, an inherited cancer syndrome caused by germline mutations scattered throughout PTEN, point variants affecting the 30 end of the AR-binding motif result in abrogation of androgen-mediated transcriptional regulation of PTEN expression. We may speculate that the differential AR effect on PTEN may begin to explain organ-specific and perhaps sex-specific neoplasia predisposition in Cowden syndrome, as well as why only a fraction of women with germline PTEN mutations develop breast cancer, depending on the androgen steroid milieu and levels. Oncogene (2011) 30, 4327-4338; doi: 10.1038/onc.2011.144; published online 2 May 2011	[Wang, Y.; Romigh, T.; He, X.; Tan, M-H; Orloff, M. S.; Eng, C.] Cleveland Clin, Genom Med Inst, Lerner Res Inst, Cleveland, OH 44195 USA; [Orloff, M. S.; Silverman, R. H.; Heston, W. D.; Eng, C.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA; [Silverman, R. H.; Heston, W. D.] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; [Silverman, R. H.; Heston, W. D.; Eng, C.] Case Western Reserve Univ, Sch Med, CASE Comprehens Canc Ctr, Cleveland, OH USA; [Eng, C.] Cleveland Clin, Stanley Shalom Zielony Inst Nursing Excellence, Cleveland, OH 44195 USA; [Eng, C.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University	Eng, C (corresponding author), Cleveland Clin, Genom Med Inst, Lerner Res Inst, 9500 Euclid Ave,Mailcode NE-50, Cleveland, OH 44195 USA.	engc@ccf.org	Tan, Min Han/D-9205-2014; he, xin/C-3122-2011; WANG, YU/E-4655-2013	Tan, Min Han/0000-0002-0644-3457; Eng, Charis/0000-0002-3693-5145	William Randolph Hearst Foundations; Susan G Komen for the Cure Breast Cancer Research Foundation; FM Kirby Foundation	William Randolph Hearst Foundations; Susan G Komen for the Cure Breast Cancer Research Foundation(Susan G. Komen Breast Cancer Foundation); FM Kirby Foundation	We are grateful to Dr George Stark for critical review of manuscript drafts and for helpful discussions. This work was supported, in part, by the William Randolph Hearst Foundations and Susan G Komen for the Cure Breast Cancer Research Foundation. CE is the Sondra J and Stephen R Hardis Chair of Cancer Genomic Medicine at the Cleveland Clinic, was a Doris Duke Distinguished Clinical Scientist and is an American Cancer Society Clinical Research Professor, generously funded, in part, by the FM Kirby Foundation.	Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT; Agrawal S, 2005, HUM MOL GENET, V14, P2459, DOI 10.1093/hmg/ddi246; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bedolla R, 2007, CLIN CANCER RES, V13, P3860, DOI 10.1158/1078-0432.CCR-07-0091; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; Ihaka S., 1996, J COMPUT GRAPH STAT, V5, P299; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Mikhailova M, 2008, ADV EXP MED BIOL, V617, P397, DOI 10.1007/978-0-387-69080-3_38; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nan B, 2003, J MOL ENDOCRINOL, V31, P169, DOI 10.1677/jme.0.0310169; Ogawa Y, 2008, INT J CLIN ONCOL, V13, P431, DOI 10.1007/s10147-008-0770-6; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Teresi RE, 2008, HUM MOL GENET, V17, P919, DOI 10.1093/hmg/ddm364; Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang Y, 2008, ONCOGENE, V27, P7106, DOI 10.1038/onc.2008.318; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; Wen Y, 2000, CANCER RES, V60, P6841; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109	36	70	71	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4327	4338		10.1038/onc.2011.144	http://dx.doi.org/10.1038/onc.2011.144			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21532617				2022-12-28	WOS:000296356400004
J	Guigon, CJ; Kim, DW; Willingham, MC; Cheng, SY				Guigon, C. J.; Kim, D. W.; Willingham, M. C.; Cheng, S-y			Mutation of thyroid hormone receptor-beta in mice predisposes to the development of mammary tumors	ONCOGENE			English	Article						thyroid hormone receptor; breast cancer; mammary tumors; Pten; mouse models	BREAST-CANCER RISK; C-ERBA-BETA; HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; TRANSGENIC MICE; LIGAND-BINDING; MOUSE MODEL; GENE; EXPRESSION; DISEASE	Correlative data suggest that thyroid hormone receptor-beta (TR beta) mutations could increase the risk of mammary tumor development, but unequivocal evidence is still lacking. To explore the role of TR beta mutants in vivo in breast tumor development and progression, we took advantage of a knock-in mouse model harboring a mutation in the Thrb gene encoding TR beta (Thrb(PV) mouse). Although in adult nulliparous females, a single ThrbPV allele did not contribute to mammary gland abnormalities, the presence of two ThrbPV alleles led to mammary hyperplasia in similar to 36% Thrb(PV/PV) mice. The ThrbPV mutation further markedly augmented the risk of mammary hyperplasia in a mouse model with high susceptibility to mammary tumors (Pten(+/-) mouse), as demonstrated by the occurrence of mammary hyperplasia in similar to 60% of Thrb(PV/+) Pten(+/-) and similar to 77% of Thrb(PV/PV) Pten(+/-) mice versus similar to 33% of Thrb(+/+) Pten(+/-) mice. The Thrb(PV) mutation increased the activity of signal transducer and activator of transcription (STAT5) to increase cell proliferation and the expression of the STAT5 target gene encoding beta-casein in the mammary gland. We next sought to understand the molecular mechanism underlying STAT5 overactivation by TR beta PV. Cell-based studies with a breast cancer cell line (T47D cells) showed that thyroid hormone (T3) repressed STAT5 signaling in TR beta-expressing cells through decreasing STAT5-mediated transcription activity and target gene expression, whereas sustained STAT5 signaling was observed in TR beta PV-expressing cells. Collectively, these findings show for the first time that a TR beta mutation promotes the development of mammary hyperplasia via aberrant activation of STAT5, thereby conferring a fertile genetic ground for tumorigenesis. Oncogene (2011) 30, 3381-3390; doi:10.1038/onc.2011.50; published online 14 March 2011	[Guigon, C. J.; Kim, D. W.; Cheng, S-y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov	guigon, celine/L-3518-2017	guigon, celine/0000-0002-4489-4304	Center for Cancer Research, National Cancer Institute, National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC011191] Funding Source: NIH RePORTER	Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr L Fozzatti for her help in mouse dissection, Dr C Lu for taking mouse body pictures, and Drs B Vonderhaar and E Ginsburg for providing T47D cells and helpful technical advice. This research was supported by the Intramural Research Program of Center for Cancer Research, National Cancer Institute, National Institutes of Health.	Agarwal Dwarka P, 2007, J Cancer Res Ther, V3, P172; Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347; Banneau G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2626; Barash I, 2006, J CELL PHYSIOL, V209, P305, DOI 10.1002/jcp.20771; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BRINTON LA, 1984, J CHRON DIS, V37, P877, DOI 10.1016/0021-9681(84)90062-6; BRONNEGARD M, 1994, J CLIN ENDOCR METAB, V79, P384, DOI 10.1210/jc.79.2.384; Conde I, 2006, ANN ONCOL, V17, P60, DOI 10.1093/annonc/mdj040; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Ditsch N, 2010, ANTICANCER RES, V30, P1713; Eilon T, 2007, INT J CANCER, V121, P1892, DOI 10.1002/ijc.22954; Eng C, 2002, ANN NY ACAD SCI, V968, P213, DOI 10.1111/j.1749-6632.2002.tb04337.x; Fang F, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-11; FRANCESCHI S, 1990, EUR J CANCER, V26, P781, DOI 10.1016/0277-5379(90)90151-I; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Giani C, 1996, J CLIN ENDOCR METAB, V81, P990, DOI 10.1210/jc.81.3.990; GOLDMAN MB, 1992, ONCOLOGY-BASEL, V49, P461; Guigon CJ, 2009, ONCOGENE, V28, P509, DOI 10.1038/onc.2008.407; Guigon CJ, 2008, MOL CELL BIOL, V28, P4598, DOI 10.1128/MCB.02192-07; HAYDEN TJ, 1977, J ENDOCRINOL, V75, pP38; HEDLEY AJ, 1981, LANCET, V1, P131; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; KALACHE A, 1982, BRIT J SURG, V69, P434, DOI 10.1002/bjs.1800690731; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kuijpens JLP, 2005, THYROID, V15, P1253, DOI 10.1089/thy.2005.15.1253; LEMAIRE M, 1986, EUR J CANCER CLIN ON, V22, P301, DOI 10.1016/0277-5379(86)90395-0; Li G, 2002, DEVELOPMENT, V129, P4159; Li Z, 2002, CANCER RES, V62, P1939; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Manhes C, 2006, J ENDOCRINOL, V190, P271, DOI 10.1677/joe.1.06829; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MITTRA I, 1974, NATURE, V248, P525, DOI 10.1038/248525a0; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Rhei E, 1997, CANCER RES, V57, P3657; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Saraiva PP, 2005, BRAZ J MED BIOL RES, V38, P761, DOI 10.1590/S0100-879X2005000500014; Silva JM, 2002, ONCOGENE, V21, P4307, DOI 10.1038/sj.onc.1205534; Simon MS, 2002, CANCER EPIDEM BIOMAR, V11, P1574; SMYTH PPA, 1993, J ENDOCRINOL INVEST, V16, P396, DOI 10.1007/BF03348865; Smyth PPA, 1997, ANN MED, V29, P189, DOI 10.3109/07853899708999335; Stambolic V, 2000, CANCER RES, V60, P3605; Strain JJ, 1997, NUTR CANCER, V27, P48, DOI 10.1080/01635589709514500; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; TAKATANI O, 1989, CANCER RES, V49, P3109; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tosovic A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2587; Turken O, 2003, BREAST CANCER RES, V5, pR110, DOI 10.1186/bcr609; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; WALLIN G, 1992, THYROID, V2, P307, DOI 10.1089/thy.1992.2.307; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZUMOFF B, 1981, ANTICANCER RES, V1, P287	65	38	41	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3381	3390		10.1038/onc.2011.50	http://dx.doi.org/10.1038/onc.2011.50			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21399657	Green Accepted			2022-12-28	WOS:000293215700008
J	Thurber, AE; Douglas, G; Sturm, EC; Zabierowski, SE; Smit, DJ; Ramakrishnan, SN; Hacker, E; Leonard, JH; Herlyn, M; Sturm, RA				Thurber, A. E.; Douglas, G.; Sturm, E. C.; Zabierowski, S. E.; Smit, D. J.; Ramakrishnan, S. N.; Hacker, E.; Leonard, J. H.; Herlyn, M.; Sturm, R. A.			Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway	ONCOGENE			English	Article						cell adhesion; invasion; melanoma; metastasis; NOTCH; transcription factor	EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN MELANOCYTES; STEM-CELLS; IN-VITRO; PHENOTYPE; GENE; SUBPOPULATION; SIGNATURE; REVEALS; PROGRAM	The use of adherent monolayer cultures have produced many insights into melanoma cell growth and differentiation, but often novel therapeutics demonstrated to act on these cells are not active in vivo. It is imperative that new methods of growing melanoma cells that reflect growth in vivo are investigated. To this end, a range of human melanoma cell lines passaged as adherent cultures or induced to form melanoma spheres (melanospheres) in stem cell media have been studied to compare cellular characteristics and protein expression. Melanoma spheres and tumours grown from cell lines as mouse xenografts had increased heterogeneity when compared with adherent cells and 3D-spheroids in agar (aggregates). Furthermore, cells within the melanoma spheres and mouse xenografts each displayed a high level of reciprocal BRN2 or MITF expression, which matched more closely the pattern seen in human melanoma tumours in situ, rather than the propensity for co-expression of these important melanocytic transcription factors seen in adherent cells and 3D-spheroids. Notably, when the levels of the BRN2 and MITF proteins were each independently repressed using siRNA treatment of adherent melanoma cells, members of the NOTCH pathway responded by decreasing or increasing expression, respectively. This links BRN2 as an activator, and conversely, MITF as a repressor of the NOTCH pathway in melanoma cells. Loss of the BRN2-MITF axis in antisense-ablated cell lines decreased the melanoma sphere-forming capability, cell adhesion during 3D-spheroid formation and invasion through a collagen matrix. Combined, this evidence suggests that the melanoma sphere-culture system induces subpopulations of cells that may more accurately portray the in vivo disease, than the growth as adherent melanoma cells. Oncogene (2011) 30, 3036-3048; doi: 10.1038/onc.2011.33; published online 28 February 2011	[Thurber, A. E.; Douglas, G.; Sturm, E. C.; Smit, D. J.; Ramakrishnan, S. N.; Sturm, R. A.] Univ Queensland, Inst Mol Biosci, Melanogenix Grp, Brisbane, Qld 4072, Australia; [Zabierowski, S. E.; Herlyn, M.; Sturm, R. A.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Hacker, E.; Leonard, J. H.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia	University of Queensland; The Wistar Institute; QIMR Berghofer Medical Research Institute	Sturm, RA (corresponding author), Univ Queensland, Inst Mol Biosci, Melanogenix Grp, 306 Carmody Rd, Brisbane, Qld 4072, Australia.	R.Sturm@imb.uq.edu.au	Hacker, Elke/J-1265-2012; Sturm, Richard A/C-9943-2009; Leonard, Helen/F-2022-2013	Hacker, Elke/0000-0003-2759-8244; Sturm, Richard A/0000-0003-1301-0294; SMIT, Darren/0000-0002-3288-3659	University of Queensland; Cancer Council Queensland; NIH [CA-25874]; NATIONAL CANCER INSTITUTE [P01CA025874] Funding Source: NIH RePORTER	University of Queensland(University of Queensland); Cancer Council Queensland(Cancer Council Queensland); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor N Hayward (QIMR) for providing some of the cell lines that were tested for melanoma sphere formation as part of this manuscript. RAS is a Senior Research Fellow of the Australian NHMRC, and in conducting part of this work, was supported by an SSP award from the University of Queensland. This work was supported by grants from the Cancer Council Queensland to RAS and JHL and NIH grant CA-25874 to MH.	Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; ANGUS J, 1995, ONCOGENE, V11, P691; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Castro DS, 2006, DEV CELL, V11, P831, DOI 10.1016/j.devcel.2006.10.006; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Cook AL, 2005, EXP CELL RES, V308, P222, DOI 10.1016/j.yexcr.2005.04.019; Cook AL, 2003, J INVEST DERMATOL, V121, P1150, DOI 10.1046/j.1523-1747.2003.12562.x; Cook AL, 2008, PIGM CELL MELANOMA R, V21, P611, DOI 10.1111/j.1755-148X.2008.00510.x; Cook AL, 2006, FROM MELANOCYTES TO MELANOMA: THE PROGRESSION TO MALIGNANCY, P149, DOI 10.1007/978-1-59259-994-3_8; Dodd IB, 2007, CELL, V129, P813, DOI 10.1016/j.cell.2007.02.053; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mouriaux F, 2003, EXP EYE RES, V76, P653, DOI 10.1016/S0014-4835(03)00082-4; Na YR, 2009, TUMOR BIOL, V30, P300, DOI 10.1159/000261073; Na YR, 2009, CANCER SCI, V100, P1429, DOI 10.1111/j.1349-7006.2009.01218.x; Newton RA, 2007, J INVEST DERMATOL, V127, P2216, DOI 10.1038/sj.jid.5700840; Ohsie SJ, 2008, J CUTAN PATHOL, V35, P433, DOI 10.1111/j.1600-0560.2007.00891.x; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pinnix CC, 2007, PIGM CELL RES, V20, P458, DOI 10.1111/j.1600-0749.2007.00410.x; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Richmond-Sinclair NM, 2008, MELANOMA RES, V18, P336, DOI 10.1097/CMR.0b013e32830d8329; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smit DJ, 2007, INT J CANCER, V121, P2653, DOI 10.1002/ijc.23039; Smith AG, 1998, MELANOMA RES, V8, P2, DOI 10.1097/00008390-199802000-00002	36	67	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	27					3036	3048		10.1038/onc.2011.33	http://dx.doi.org/10.1038/onc.2011.33			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21358674	Green Submitted, Green Accepted			2022-12-28	WOS:000292510100004
J	Fan, LC; Chiang, WF; Liang, CH; Tsai, YT; Wong, TY; Chen, KC; Hong, TM; Chen, YL				Fan, L-C; Chiang, W-F; Liang, C-H; Tsai, Y-T; Wong, T-Y; Chen, K-C; Hong, T-M; Chen, Y-L			alpha-Catulin knockdown induces senescence in cancer cells	ONCOGENE			English	Article						alpha-catulin; senescence; p53; DNA damage; cDNA microarray; cancer	ONCOGENE-INDUCED SENESCENCE; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; NUCLEOTIDE EXCISION-REPAIR; CELLULAR SENESCENCE; IN-VIVO; CHROMOSOMAL INSTABILITY; TUMORIGENESIS; CATENIN; ACTIVATION	Cellular senescence functions as a tumor suppressor that protects against cancer progression. alpha-Catulin, an alpha-catenin-related protein, is reported to have tumorigenic potential because it regulates the nuclear factor-kappa B (NF-kappa B) pathway, but little is known about its clinical relevance and the mechanism through which it regulates cancer progression. Here, we found that alpha-catulin mRNA levels were significantly upregulated in cancer cell lines and clinical oral squamous cell carcinomas, which positively correlated with tumor size (P = 0.001) and American Joint Committee on Cancer (AJCC) stage (P = 0.004). alpha-Catulin knockdown in the OC2 and A549 cancer cell lines dramatically decreased cell proliferation and contributed to cellular senescence, and inhibited OC2 xenograft growth. Mechanistic dissection showed that alpha-catulin depletion strongly induced the DNA-damage response (DDR) in both cell lines, via a p53/p21-dependent pathway in A549 cells, but a p53/p21-independent pathway in OC2 cells carrying mutant p53. Global gene expression analysis revealed that alpha-catulin knockdown altered cell-cycle regulation and DDR pathways at the presenescent stage as well as significantly downregulate several crucial genes related to mitotic chromosome condensation, DDR and DNA repair systems, which suggests that its depletion-induced cellular senescence might be caused by chromosome condensation failures, severe DNA damage and impaired DNA repair ability. Our study provides evidence that alpha-catulin promotes tumor growth by preventing cellular senescence and suggests that downregulating alpha-catulin may be a promising therapeutic approach for cancer treatment. Oncogene (2011) 30, 2610-2621; doi:10.1038/onc.2010.637; published online 31 January 2011	[Tsai, Y-T; Wong, T-Y; Chen, K-C; Chen, Y-L] Natl Cheng Kung Univ, Inst Oral Med, Coll Med, Tainan 70101, Taiwan; [Fan, L-C; Liang, C-H; Hong, T-M; Chen, Y-L] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chiang, W-F] Chi Mei Med Ctr, Dept Dent, Liouying, Taiwan; [Chiang, W-F] Natl Yang Ming Univ, Sch Dent, Taipei 112, Taiwan; [Hong, T-M] Natl Cheng Kung Hosp, Dept Clin Med Res, Tainan, Taiwan; [Hong, T-M] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; Chi Mei Hospital; National Yang Ming Chiao Tung University; National Cheng Kung University; National Cheng Kung University	Chen, YL (corresponding author), Natl Cheng Kung Univ, Inst Oral Med, Coll Med, 1 Univ Rd, Tainan 70101, Taiwan.	tmhong@mail.ncku.edu.tw; yuhling@mail.ncku.edu.tw	Chiang, Wei-Fan/L-6537-2019; Chen, Yuh-Ling/AAS-7957-2021	Chiang, Wei-Fan/0000-0002-9240-1404; 	National Science Council [NSC 96-2311-B-006-005-MY3, NSC 97-2314-B-384-003-MY3, NSC 99-3112-B-006-011, NSC 99-2627-B-006-003]; Department of Health, Taiwan [DOH99-TD-C-111-003]; National Science Council, Taiwan [NSC 97-3112-B-001-016]	National Science Council(Ministry of Science and Technology, Taiwan); Department of Health, Taiwan; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants NSC 96-2311-B-006-005-MY3, NSC 97-2314-B-384-003-MY3, NSC 99-3112-B-006-011 and NSC 99-2627-B-006-003 from the National Science Council, and DOH99-TD-C-111-003 from the Department of Health, Taiwan. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of National Science Council, Taiwan (NSC 97-3112-B-001-016).	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Coelho PA, 2003, J CELL SCI, V116, P4763, DOI 10.1242/jcs.00799; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Hudson DF, 2009, CHROMOSOME RES, V17, P131, DOI 10.1007/s10577-008-9009-7; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Li YF, 2009, J GENE MED, V11, P3, DOI 10.1002/jgm.1270; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410-2422.2004; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Miura K, 1996, CANCER RES, V56, P1629; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Park B, 2002, J BIOL CHEM, V277, P45361, DOI 10.1074/jbc.M202447200; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Siafakas AR, 2009, INT J BIOCHEM CELL B, V41, P986, DOI 10.1016/j.biocel.2008.06.018; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Suzuki T, 2002, EXP GERONTOL, V37, P1005, DOI 10.1016/S0531-5565(02)00061-X; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Walen KH, 2007, CELL BIOL INT, V31, P1447, DOI 10.1016/j.cellbi.2007.06.015; Wiesner C, 2008, ONCOGENE, V27, P2159, DOI 10.1038/sj.onc.1210863; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	41	15	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	23					2610	2621		10.1038/onc.2010.637	http://dx.doi.org/10.1038/onc.2010.637			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21278790				2022-12-28	WOS:000291677800002
J	Copeland, E; Balgobin, S; Lee, CM; Rozakis-Adcock, M				Copeland, E.; Balgobin, S.; Lee, C. M.; Rozakis-Adcock, M.			hTID-1 defines a novel regulator of c-Met Receptor signaling in renal cell carcinomas	ONCOGENE			English	Article						hTid-1; molecular chaperones; c-Met receptor tyrosine kinase; renal cell carcinoma; cell migration	DROSOPHILA TUMOR-SUPPRESSOR; HUMAN DNAJ PROTEIN; HEPATOCYTE GROWTH-FACTOR; HUMAN HOMOLOG; MOLECULAR CHAPERONES; MAMMALIAN HOMOLOG; MET/HGF RECEPTOR; TYROSINE KINASE; IMAGINAL-DISCS; GENE-PRODUCT	The c-Met receptor tyrosine kinase (MetR) is frequently overexpressed and constitutively phosphorylated in a number of human malignancies. Activation of the receptor by its ligand, hepatocyte growth factor (HGF), leads to increased cell proliferation, motility, survival and disruption of adherens junctions. In this study, we show that hTid-1, a DNAJ/Hsp40 chaperone, represents a novel modulator of the MetR signaling pathway. hTid-1 is a co-chaperone of the Hsp70 family of proteins, and has been shown to regulate a number of cellular signaling proteins including several involved in tumorigenic and apoptotic pathways. In this study we demonstrate that hTid-1 binds to unphosphorylated MetR and becomes dissociated from the receptor upon HGF stimulation. Overexpression of the short form of hTid-1 (hTid-1(S)) in 786-0 renal clear cell carcinomas (RCCs) enhances MetR kinase activity leading to an increase in HGF-mediated cell migration with no discernible effect on cell proliferation. By contrast, knockdown of hTid-1 markedly impairs both the onset and amplitude of MetR phosphorylation in response to HGF without altering receptor protein levels. hTid-1-depleted cells display defective migratory properties, coincident with inhibition of ERK/MAP kinase and STAT3 pathways. Taken together, our findings denote hTid-1(S) as an essential regulatory component of MetR signaling. We propose that the binding of hTid-1(S) to MetR may stabilize the receptor in a ligand-competent state and this stabilizing function may influence conformational changes that take place during the catalytic cycle that promote kinase activation. Given the prevalence of HGF/MetR pathway activation in human cancers, targeted inhibition of hTid-1 may be a useful therapeutic in the management of MetR-dependent malignancies. Oncogene (2011) 30, 2252-2263; doi:10.1038/onc.2010.601; published online 17 January 2011	[Rozakis-Adcock, M.] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Rozakis-Adcock, M (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Med Sci Bldg,1 Kings Coll Circle,Room 6238A, Toronto, ON M5S 1A8, Canada.	maria.rozakis@utoronto.ca			National Cancer Institure of Canada; Ontario Graduate Scholarship; Canadian Institutes of Health Research	National Cancer Institure of Canada; Ontario Graduate Scholarship(Ontario Graduate Scholarship); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a grant from the National Cancer Institure of Canada (to MRA). ER was supported by an Ontario Graduate Scholarship and CML by a Canadian Institutes of Health Research Master's Award. We thank Kevin Conway for assistance with immunofluorescence microscopy.	Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413; Bae MK, 2005, CANCER RES, V65, P2520, DOI 10.1158/0008-5472.CAN-03-2735; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen CY, 2009, J PATHOL, V219, P347, DOI 10.1002/path.2604; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; FERRACINI R, 1995, ONCOGENE, V10, P739; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hov H, 2004, CLIN CANCER RES, V10, P6686, DOI 10.1158/1078-0432.CCR-04-0874; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Koga F, 2007, CELL CYCLE, V6, P1393, DOI 10.4161/cc.6.11.4296; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kurzik-Dumke U, 2007, CELL SIGNAL, V19, P1973, DOI 10.1016/j.cellsig.2007.05.008; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Lesko E, 2007, ANTI-CANCER DRUG, V18, P1173, DOI 10.1097/CAD.0b013e3282ef532d; Linnoila J, 2008, NEURON, V60, P625, DOI 10.1016/j.neuron.2008.09.025; Liu HY, 2005, J BIOL CHEM, V280, P19461, DOI 10.1074/jbc.M500313200; Maulik G, 2002, CLIN CANCER RES, V8, P620; Nakaigawa N, 2006, CANCER RES, V66, P3699, DOI 10.1158/0008-5472.CAN-05-0617; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peruzzi B, 2006, P NATL ACAD SCI USA, V103, P14531, DOI 10.1073/pnas.0606850103; Peruzzi B, 2006, CELL CYCLE, V5, P2839, DOI 10.4161/cc.5.24.3581; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Qian J, 2010, GASTROENTEROLOGY, V138, P1418, DOI 10.1053/j.gastro.2009.10.044; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sangwan V, 2008, J BIOL CHEM, V283, P34374, DOI 10.1074/jbc.M805916200; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trentin GA, 2004, FEBS LETT, V578, P323, DOI 10.1016/j.febslet.2004.11.034; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Wakabayashi Y, 2007, NATURE, V445, P761, DOI 10.1038/nature05489; WALL D, 1994, J BIOL CHEM, V269, P5446; Webb CP, 2000, CANCER RES, V60, P342; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zia MK, 2007, INT J MOL MED, V20, P605	51	13	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2252	2263		10.1038/onc.2010.601	http://dx.doi.org/10.1038/onc.2010.601			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242965	Green Published, hybrid			2022-12-28	WOS:000290514600008
J	Kalamarides, M; Stemmer-Rachamimov, AO; Niwa-Kawakita, M; Chareyre, F; Taranchon, E; Han, ZY; Martinelli, C; Lusis, EA; Hegedus, B; Gutmann, DH; Giovannini, M				Kalamarides, M.; Stemmer-Rachamimov, A. O.; Niwa-Kawakita, M.; Chareyre, F.; Taranchon, E.; Han, Z-Y; Martinelli, C.; Lusis, E. A.; Hegedus, B.; Gutmann, D. H.; Giovannini, M.			Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes	ONCOGENE			English	Article						neurofibromatosis type 2; arachnoid; brain tumours	PROSTAGLANDIN-D SYNTHASE; BETA-TRACE; NATURAL-HISTORY; CHOROID-PLEXUS; SKULL BASE; NF2; EXPRESSION; MICE; LOCALIZATION; MUTATION	Meningiomas are among the most common primary central nervous system tumours in adults. Studies focused on the molecular basis for meningioma development are hampered by a lack of information with regard to the cell of origin for these brain tumours. Herein, we identify a prostaglandin D synthase-positive meningeal precursor as the cell of origin for murine meningioma, and show that neurofibromatosis type 2 (Nf2) inactivation in prostaglandin D2 synthase (PGDS) (+) primordial meningeal cells, before the formation of the three meningeal layers, accounts for the heterogeneity of meningioma histological subtypes. Using a unique PGDSCre strain, we define a critical embryonic and early postnatal developmental window in which biallelic Nf2 inactivation in PGDS (+) progenitor cells results in meningioma formation. Moreover, we identify differentially expressed markers that characterize the two major histological meningioma subtypes both in human and mouse tumours. Collectively, these findings establish the cell of origin for these common brain tumours as well as a susceptible developmental period in which signature genetic mutations culminate in meningioma formation. Oncogene (2011) 30, 2333-2344; doi: 10.1038/onc.2010.609; published online 17 January 2011	[Giovannini, M.] House Ear Res Inst, Ctr Neural Tumor Res, Los Angeles, CA 90057 USA; [Kalamarides, M.; Niwa-Kawakita, M.; Chareyre, F.; Taranchon, E.; Han, Z-Y; Martinelli, C.; Giovannini, M.] INSERM, U674, Paris, France; [Kalamarides, M.; Niwa-Kawakita, M.; Chareyre, F.; Taranchon, E.; Han, Z-Y; Martinelli, C.; Giovannini, M.] Univ Paris 07, Inst Univ Hematol, Paris, France; [Kalamarides, M.] Hop Beaujon, AP HP, Serv Neurochirurg, Clichy, France; [Stemmer-Rachamimov, A. O.] Massachusetts Gen Hosp, Mol Neurooncol & Pathol Dept, Boston, MA 02114 USA; [Stemmer-Rachamimov, A. O.] Harvard Univ, Sch Med, Boston, MA USA; [Lusis, E. A.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO USA; [Hegedus, B.; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	House Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL); Washington University (WUSTL)	Giovannini, M (corresponding author), House Ear Res Inst, Ctr Neural Tumor Res, 2100W 3rd St, Los Angeles, CA 90057 USA.	mgiovannini@hei.org	Hegedus, Balazs/B-6076-2008	Hegedus, Balazs/0000-0002-4341-4153; Gutmann, David/0000-0002-3127-5045; Kawakita, Michiko/0000-0002-9450-583X	US Army Medical Research and Materiel Command [DAMD17-02-1-0645]; James S McDonnell Foundation; Association Neurofibromatoses et Recklinghausen; Vincent Buono Research Fund; Inserm	US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); James S McDonnell Foundation; Association Neurofibromatoses et Recklinghausen; Vincent Buono Research Fund; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank A Berns for p16<SUP>Ink4a</SUP> and p53<SUP>flox</SUP> mutant mice; S Dufour and JP Thiery for HtPACre mice; Y Urade for the PGDS genomic fragment; M Pla and staff of the Institut Universitaire d'Hematologie (IUH), Universite Paris 7, for mouse housing; N Karboul for technical assistance; and M Catala and W Van Furth for helpful discussions. This work was supported by Grants from the US Army Medical Research and Materiel Command (DAMD17-02-1-0645 to MG), James S McDonnell Foundation (to DHG and MG), Association Neurofibromatoses et Recklinghausen, the Vincent Buono Research Fund (to DHG and MG) and Inserm.	Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; ANGELOV DN, 1989, CELL TISSUE RES, V257, P207; Beuckmann CT, 2000, J COMP NEUROL, V428, P62, DOI 10.1002/1096-9861(20001204)428:1<62::AID-CNE6>3.0.CO;2-E; Catala M., 1998, Archives d'Anatomie et de Cytologie Pathologiques, V46, P153; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; da Cruz MJ, 2000, BRIT J NEUROSURG, V14, P101; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Fevre-Montange M, 2009, INT J ONCOL, V35, P1395, DOI 10.3892/ijo_00000457; Giovannini M, 2000, GENE DEV, V14, P1617; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hartmann C, 2006, BRAIN PATHOL, V16, P15, DOI 10.1111/j.1750-3639.2006.tb00557.x; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kalamarides M, 2008, BRAIN PATHOL, V18, P62, DOI 10.1111/j.1750-3639.2007.00105.x; KAMIRYO T, 1990, ANAT RECORD, V227, P207, DOI 10.1002/ar.1092270209; Kawashima M, 2001, MODERN PATHOL, V14, P197, DOI 10.1038/modpathol.3880285; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909; Krutilkova V, 2005, EUR J CANCER, V41, P1597, DOI 10.1016/j.ejca.2005.01.026; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; Lee JH, 2006, J NEUROSURG, V105, P60, DOI 10.3171/jns.2006.105.1.60; Louis DN, 2000, PATHOLOGY GENETICS T, P176; Marino S, 2000, GENE DEV, V14, P994; McBratney-Owen B, 2008, DEV BIOL, V322, P121, DOI 10.1016/j.ydbio.2008.07.016; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MCLONE DG, 1975, AM J ANAT, V142, P273, DOI 10.1002/aja.1001420302; Nakamura M, 2003, NEUROSURGERY, V53, P62, DOI 10.1227/01.NEU.0000068730.76856.58; NAKASU S, 1987, SURG NEUROL, V27, P319, DOI 10.1016/0090-3019(87)90005-X; OLIVERO WC, 1995, J NEUROSURG, V83, P222, DOI 10.3171/jns.1995.83.2.0222; Pietri T, 2003, DEV BIOL, V259, P176, DOI 10.1016/S0012-1606(03)00175-1; Robanus-Maandag E, 2004, ONCOGENE, V23, P6541, DOI 10.1038/sj.onc.1207858; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; SCHWECHHEIMER K, 1984, LAB INVEST, V51, P584; Stuart JE, 2010, J NEUROPATHOL EXP NE; TOHMA Y, 1992, CANCER RES, V52, P1981; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; Vandenabeele F, 1996, J ANAT, V189, P417; Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972; Yamashima T, 1997, J NEUROSCI, V17, P2376; Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007	44	91	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2333	2344		10.1038/onc.2010.609	http://dx.doi.org/10.1038/onc.2010.609			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21242963	Bronze			2022-12-28	WOS:000290789200005
J	Romagosa, C; Simonetti, S; Lopez-Vicente, L; Mazo, A; Lleonart, ME; Castellvi, J; Cajal, SRY				Romagosa, C.; Simonetti, S.; Lopez-Vicente, L.; Mazo, A.; Lleonart, M. E.; Castellvi, J.; Ramon y Cajal, S.			p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors	ONCOGENE			English	Review						p16(Ink4a); overexpression; cancer; senescence; high grade	GASTROINTESTINAL STROMAL TUMORS; CDKN2A GERMLINE MUTATIONS; SQUAMOUS-CELL CARCINOMA; ONCOGENE-INDUCED SENESCENCE; P16 EXPRESSION; BREAST-CANCER; DNA-DAMAGE; CYCLIN D1; IN-VIVO; SUBCELLULAR-LOCALIZATION	p16(Ink4a) is a protein involved in regulation of the cell cycle. Currently, p16(Ink4a) is considered a tumor suppressor protein because of its physiological role and downregulated expression in a large number of tumors. Intriguingly, overexpression of p16(Ink4a) has also been described in several tumors. This review attempts to elucidate when and why p16(Ink4a) overexpression occurs, and to suggest possible implications of p16(Ink4a) in the diagnosis, prognosis and treatment of cancer. Oncogene (2011) 30, 2087-2097; doi:10.1038/onc.2010.614; published online 7 February 2011	[Romagosa, C.; Lopez-Vicente, L.; Lleonart, M. E.; Castellvi, J.; Ramon y Cajal, S.] Univ Autonoma Barcelona, Dept Pathol, Fundacio Inst Recerca, Hosp Univ Vall Hebron, E-08193 Barcelona, Spain; [Simonetti, S.] USP Dexeus Univ Inst, Oncol Lab, Barcelona, Spain; [Mazo, A.] Univ Barcelona, Inst Biomed IBUB, Dept Biochem & Mol Biol, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Barcelona	Cajal, SRY (corresponding author), Hosp Univ Vall Hebron, Fundacio Inst Recerca, Dept Pathol, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sramon@vhebron.net	Ramon y Cajal, Santiago/H-4955-2016; Castellvi, Josep/C-5092-2014; Pérez-Portabell, Cleofé Romagosa/Q-3342-2016; LLeonart, Matilde E./Q-2662-2019; Simonetti, Sara/AAD-7963-2020	Ramon y Cajal, Santiago/0000-0002-3867-1390; Castellvi, Josep/0000-0001-5745-9996; LLeonart, Matilde E./0000-0002-6196-7405; Simonetti, Sara/0000-0003-2406-030X	Fondo de Investigaciones Sanitarias [05/0818, 08/0143]; Fundacio Marato TV3 [052710]; Mutua Madrilena [FMMA/2009/02]; Redes tematicas de Investigacion Cooperativa en Salud [RD06/0020/0104, RD06/0020/1020]; Generalitat de Catalunya [2005SGR00144, 2009SGR624]; Ministerio de Ciencia y Tecnologia [BIO2008-04692-C03-03]; Grupo espanol de Investigacion en Sarcomas [GEIS/2008]	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacio Marato TV3; Mutua Madrilena; Redes tematicas de Investigacion Cooperativa en Salud; Generalitat de Catalunya(Generalitat de Catalunya); Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Grupo espanol de Investigacion en Sarcomas	We are grateful to M Serrano for his careful reading and suggestions, and C Cavallo and S Illing for English editing. SRC is supported by grants from the 'Fondo de Investigaciones Sanitarias' (Ref.05/0818 and 08/0143), 'Fundacio Marato TV3' (Ref.052710), 'Mutua Madrilena' (FMMA/2009/02), 'Redes tematicas de Investigacion Cooperativa en Salud' (Ref.RD06/0020/0104 and RD06/0020/1020) and 'Generalitat de Catalunya' (Ref.2005SGR00144), AM is supported by grants from the 'Ministerio de Ciencia y Tecnologia (Ref.BIO2008-04692-C03-03) and Generalitat de Catalunya (Ref 2009SGR624), and CR is supported by a grant from the 'Grupo espanol de Investigacion en Sarcomas' (Ref. GEIS/2008).	Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Andujar P, 2010, LUNG CANCER, V67, P23, DOI 10.1016/j.lungcan.2009.03.018; Angiero F, 2008, ANTICANCER RES, V28, P2535; Arifin MT, 2006, J NEURO-ONCOL, V77, P273, DOI 10.1007/s11060-005-9037-5; Armes JE, 2005, INT J GYNECOL PATHOL, V24, P363, DOI 10.1097/01.pgp.0000172083.94934.1e; Atkins KA, 2008, AM J SURG PATHOL, V32, P98, DOI 10.1097/PAS.0b013e3181574d1e; Ayhan S, 2010, HEPATO-GASTROENTEROL, V57, P251; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bartsch DK, 2002, ANN SURG, V236, P730, DOI 10.1097/00000658-200212000-00005; Bastide K, 2009, LUNG CANCER, V63, P348, DOI 10.1016/j.lungcan.2008.06.007; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; Brambilla E, 1999, CLIN CANCER RES, V5, P243; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Buajeeb W, 2009, J ORAL PATHOL MED, V38, P104, DOI 10.1111/j.1600-0714.2008.00710.x; Calbo J, 2004, CELL DEATH DIFFER, V11, P1055, DOI 10.1038/sj.cdd.4401481; Calbo J, 2001, CANCER GENE THER, V8, P740, DOI 10.1038/sj.cgt.7700374; Campo-Trapero J, 2008, ACTA ONCOL, V47, P1464, DOI 10.1080/02841860802183612; Canepa ET, 2007, IUBMB LIFE, V59, P419, DOI 10.1080/15216540701488358; Carnero A, 2011, BIOL REV, V86, P443, DOI 10.1111/j.1469-185X.2010.00154.x; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chao DL, 2008, CLIN CANCER RES, V14, P6988, DOI 10.1158/1078-0432.CCR-07-5063; Chen JH, 2005, DNA REPAIR, V4, P1140, DOI 10.1016/j.dnarep.2005.06.003; Chien WW, 2010, CELL CYCLE, V9, P3286, DOI 10.4161/cc.9.16.12600; Chim CS, 2003, ANN HEMATOL, V82, P738, DOI 10.1007/s00277-003-0744-8; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Crea F, 2009, MOL CANCER THER, V8, P1964, DOI 10.1158/1535-7163.MCT-09-0027; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Daniotti M, 2009, J INVEST DERMATOL, V129, P1759, DOI 10.1038/jid.2008.422; Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771; Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K; Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739; Evangelou K, 2004, BIOTECH HISTOCHEM, V79, P5, DOI 10.1080/10520290310001659466; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Fischer CA, 2010, INT J CANCER, V126, P1256, DOI 10.1002/ijc.24842; Fordyce C, 2010, CANCER PREV RES, V3, P190, DOI 10.1158/1940-6207.CAPR-09-0229; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Garcia V, 2004, MUTAT RES-FUND MOL M, V554, P215, DOI 10.1016/j.mrfmmm.2004.04.008; Ghiorzo P, 2004, ANN ONCOL, V15, P70, DOI 10.1093/annonc/mdg498; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gonzalez S, 2006, CELL CYCLE, V5, P1382, DOI 10.4161/cc.5.13.2901; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Guenova M, 1999, MODERN PATHOL, V12, P1062; Guida M, 2009, EUR J GYNAECOL ONCOL, V30, P267; Gump J, 2003, J BIOL CHEM, V278, P6619, DOI 10.1074/jbc.C200622200; Gupta AK, 2009, INT J RADIAT ONCOL, V74, P928, DOI 10.1016/j.ijrobp.2009.03.004; Haller F, 2010, HISTOPATHOLOGY, V56, P305, DOI 10.1111/j.1365-2559.2010.03478.x; Hara E, 1996, MOL CELL BIOL, V16, P859; Harada H, 1999, CANCER RES, V59, P3783; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERMAN JG, 1995, CANCER RES, V55, P4525; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hilliard NJ, 2009, J CUTAN PATHOL, V36, P753, DOI 10.1111/j.1600-0560.2008.01154.x; Hiroyasu M, 2002, AM J PATHOL, V160, P419, DOI 10.1016/S0002-9440(10)64860-2; Horree N, 2007, HUM PATHOL, V38, P1232, DOI 10.1016/j.humpath.2007.01.008; Hruban Ralph H, 2007, Expert Rev Gastroenterol Hepatol, V1, P81, DOI 10.1586/17474124.1.1.81; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; Ivanova TA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-47; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kannengiesser C, 2009, HUM MUTAT, V30, P564, DOI 10.1002/humu.20845; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Ksiazek K, 2006, J APPL PHYSIOL, V100, P988, DOI 10.1152/japplphysiol.01086.2005; Lam AKY, 2008, PATHOLOGY, V40, P580, DOI 10.1080/00313020802320713; Lassen P, 2009, J CLIN ONCOL, V27, P1992, DOI 10.1200/JCO.2008.20.2853; Li LY, 2010, J CANCER, V1, P126; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Lobo GP, 2008, HUM MOL GENET, V17, P2877, DOI 10.1093/hmg/ddn185; Lopez-Vicente L, 2009, CLIN CANCER RES, V15, P4546, DOI 10.1158/1078-0432.CCR-08-3159; Lynch BC, 2008, ANN DIAGN PATHOL, V12, P161, DOI 10.1016/j.anndiagpath.2007.06.003; Magnusson S, 2008, FAM CANCER, V7, P331, DOI 10.1007/s10689-008-9195-7; Marchan S, 2010, ANAL CELL PATHOL, V33, P191, DOI [10.1155/2010/917013, 10.3233/ACP-CLO-2010-0538]; Marsh KL, 1998, BRIT J CANCER, V77, P1460, DOI 10.1038/bjc.1998.240; Martin A, 2000, AM J PATHOL, V156, P1573, DOI 10.1016/S0002-9440(10)65029-8; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275; Minami R, 2003, EXP HEMATOL, V31, P355, DOI 10.1016/S0301-472X(03)00040-7; Modesitt SC, 2001, CLIN CANCER RES, V7, P1765; Monnerat C, 2007, FAM CANCER, V6, P453, DOI 10.1007/s10689-007-9143-y; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Mulvany NJ, 2008, PATHOLOGY, V40, P335, DOI 10.1080/00313020802035907; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Natarajan E, 2003, AM J PATHOL, V163, P477, DOI 10.1016/S0002-9440(10)63677-2; Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1; Nilsson K, 2006, INT J CANCER, V118, P1120, DOI 10.1002/ijc.21466; Nilsson K, 2004, MODERN PATHOL, V17, P1464, DOI 10.1038/modpathol.3800220; O'Neill CJ, 2007, HISTOPATHOLOGY, V50, P851, DOI 10.1111/j.1365-2559.2007.02699.x; Ohtani N, 2003, J CELL BIOL, V162, P173, DOI 10.1083/jcb.200302085; Orlow I, 2007, J INVEST DERMATOL, V127, P1234, DOI 10.1038/sj.jid.5700689; Palmqvist R, 2000, AM J PATHOL, V157, P1947, DOI 10.1016/S0002-9440(10)64833-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Paulson TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003809; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Perrone F, 2003, CLIN CANCER RES, V9, P4132; Quereda V, 2007, ONCOGENE, V26, P7665, DOI 10.1038/sj.onc.1210578; Ressler S, 2006, AGING CELL, V5, P379, DOI 10.1111/j.1474-9726.2006.00231.x; Reuschenbach M, 2008, INT J CANCER, V123, P2626, DOI 10.1002/ijc.23837; ROMAGOSA C, 2009, VIRCHOWS ARCH, V455, P372; Ruas M, 2007, MOL CELL BIOL, V27, P4273, DOI 10.1128/MCB.02286-06; Rutter JL, 2003, ONCOGENE, V22, P4444, DOI 10.1038/sj.onc.1206564; Sabah M, 2006, APPL IMMUNOHISTO M M, V14, P97, DOI 10.1097/01.pai.0000143787.80564.f5; Sanchez-Beato M, 1999, BLOOD, V94, P765, DOI 10.1182/blood.V94.2.765.414a29_765_772; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt Estelle, 2007, Journal of Zhejiang University-Science B, V8, P377, DOI 10.1631/jzus.2007.B0377; Schneider-Stock R, 2005, CLIN CANCER RES, V11, P638; Schwabe M, 2007, CURR PHARM BIOTECHNO, V8, P382, DOI 10.2174/138920107783018372; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Serrano C, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.10043; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Serrano M, 2007, NEW ENGL J MED, V356, P1996, DOI 10.1056/NEJMcibr071461; Shen WW, 2007, NEOPLASIA, V9, P812, DOI 10.1593/neo.07403; Souza-Rodrigues E, 2007, PROTEOMICS, V7, P4102, DOI 10.1002/pmic.200700133; Steigen SE, 2008, MODERN PATHOL, V21, P46, DOI 10.1038/modpathol.3800976; Svensson S, 2003, CANCER RES, V63, P1737; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; Ueki K, 1996, CANCER RES, V56, P150; Wang YA, 2005, ONCOGENE, V24, P3042, DOI 10.1038/sj.onc.1208390; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu JF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000164; Yogev O, 2006, J BIOL CHEM, V281, P34475, DOI 10.1074/jbc.M602865200; Zhang ZH, 2006, MODERN PATHOL, V19, P1339, DOI 10.1038/modpathol.3800655; Zhao P, 2006, WORLD J GASTROENTERO, V12, P6391, DOI 10.3748/wjg.v12.i39.6391; Zhu DG, 2002, J CELL PHYSIOL, V193, P19, DOI 10.1002/jcp.10147; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	136	309	329	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2087	2097		10.1038/onc.2010.614	http://dx.doi.org/10.1038/onc.2010.614			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21297668				2022-12-28	WOS:000290249600001
J	van Veelen, W; Korsse, SE; van de Laar, L; Peppelenbosch, MP				van Veelen, W.; Korsse, S. E.; van de Laar, L.; Peppelenbosch, M. P.			The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling	ONCOGENE			English	Review						mTOR; rapamycin; hamartoma syndromes; cancer; PTEN/PI3K/PKB signaling	TUBEROUS SCLEROSIS COMPLEX; PEUTZ-JEGHERS-SYNDROME; ACTIVATED PROTEIN-KINASE; RAPAMYCIN ANALOG CCI-779; RENAL-CELL CARCINOMA; EKER RAT MODEL; TUMOR-SUPPRESSOR; MOUSE MODEL; MAMMALIAN TARGET; UP-REGULATION	The liver kinase B1 (LKB1)/adenosine mono-phosphate-activated protein kinase (AMPK)/tuberous sclerosis complex (TSC)/mammalian target of rapamycin (mTOR) complex (mTORC1) cassette constitutes a canonical signaling pathway that integrates information on the metabolic and nutrient status and translates this into regulation of cell growth. Alterations in this pathway are associated with a wide variety of cancers and hereditary hamartoma syndromes, diseases in which hyperactivation of mTORC1 has been described. Specific mTORC1 inhibitors have been developed for clinical use, and these drugs have been anticipated to provide efficient treatment for these diseases. In the present review, we provide an overview of the metabolic LKB1/AMPK/TSC/mTORC1 pathway, describe how its aberrant signaling associates with cancer development, and indicate the difficulties encountered when biochemical data are extrapolated to provide avenues for rational treatment of disease when targeting this signaling pathway. A careful examination of preclinical and clinical studies performed with rapamycin or derivatives thereof shows that although results are encouraging, we are only half way in the long and winding road to design rationale treatment targeted at the LKB1/AMPK/TSC/mTORC1 pathway. Inherited cancer syndromes associated with this pathway such as the Peutz-Jeghers syndrome and TSC, provide perfect models to study the relationship between genetics and disease phenotype, and to delineate the complexities that underlie translation of biochemical and genetical information to clinical management, and thus provide important clues for devising novel rational medicine for cancerous diseases in general. Oncogene (2011) 30, 2289-2303; doi: 10.1038/onc.2010.630; published online 24 January 2011	[van Veelen, W.; Korsse, S. E.; van de Laar, L.; Peppelenbosch, M. P.] Erasmus Med Univ Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Peppelenbosch, MP (corresponding author), Erasmus MC, Dept Gastroenterol & Hepatol, Room L-457,S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	m.peppelenbosch@erasmusmc.nl	Peppelenbosch, Maikel P./U-5304-2019	Peppelenbosch, Maikel/0000-0001-9112-6028	Foundation 'Michelle'; TOP-institute pharma scheme of the Dutch government	Foundation 'Michelle'; TOP-institute pharma scheme of the Dutch government	We wish to acknowledge the financial support from the Foundation 'Michelle' as well as from the TOP-institute pharma scheme of the Dutch government for their studies.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Baybis M, 2004, ANN NEUROL, V56, P478, DOI 10.1002/ana.20211; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Calva D, 2008, SURG CLIN N AM, V88, P779, DOI 10.1016/j.suc.2008.05.002; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Chan HY, 2010, ADV THER, V27, P495, DOI 10.1007/s12325-010-0045-2; Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Contreras CM, 2008, CANCER RES, V68, P759, DOI 10.1158/0008-5472.CAN-07-5014; Cook JD, 2004, CURR MOL MED, V4, P813, DOI 10.2174/1566524043359656; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Corsenca A, 2007, NEPHROL DIAL TRANSPL, V22, P3330, DOI 10.1093/ndt/gfm552; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Davies DM, 2008, NEW ENGL J MED, V358, P200, DOI 10.1056/NEJMc072500; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dorfman J, 2008, MOL BIOL CELL, V19, P1614, DOI 10.1091/mbc.E07-05-0454; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; Dworakowska D, 2009, ENDOCR-RELAT CANCER, V16, P45, DOI 10.1677/ERC-08-0142; Ehninger D, 2008, NAT MED, V14, P843, DOI 10.1038/nm1788; El-Hashemite N, 2003, CANCER RES, V63, P5173; Ess KC, 2010, CURR OPIN NEUROL, V23, P189, DOI 10.1097/WCO.0b013e32832c4ff5; Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784; Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Habib SL, 2010, CARCINOGENESIS, V31, P2022, DOI 10.1093/carcin/bgq189; Haemel AK, 2010, ARCH DERMATOL, V146, P715, DOI 10.1001/archdermatol.2010.125; Haidinger M, 2010, TRANSPL INT, V23, P777, DOI 10.1111/j.1432-2277.2009.01041.x; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herry I, 2007, EUR J INTERN MED, V18, P76, DOI 10.1016/j.ejim.2006.07.017; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hezel AF, 2008, MOL CELL BIOL, V28, P2414, DOI 10.1128/MCB.01621-07; Hino O, 2004, CURR MOL MED, V4, P807, DOI 10.2174/1566524043359692; Hofbauer GFL, 2008, BRIT J DERMATOL, V159, P473, DOI 10.1111/j.1365-2133.2008.08677.x; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ikeda Y, 2009, J BIOL CHEM, V284, P35839, DOI 10.1074/jbc.M109.057273; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jaleel M, 2005, FEBS LETT, V579, P1417, DOI 10.1016/j.febslet.2005.01.042; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Jozwiak J, 2009, AM J DERMATOPATH, V31, P68, DOI 10.1097/DAD.0b013e3181882c09; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kantidakis T, 2010, P NATL ACAD SCI USA, V107, P11823, DOI 10.1073/pnas.1005188107; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Katajisto P, 2008, NAT GENET, V40, P455, DOI 10.1038/ng.98; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Knowles MA, 2003, BIOCHEM SOC T, V31, P597, DOI 10.1042/BST0310597; Kobayashi T, 1999, CANCER RES, V59, P1206; Koenig MK, 2008, J CHILD NEUROL, V23, P1238, DOI 10.1177/0883073808321764; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; Krischock L, 2010, ARCH DIS CHILD, V95, P391, DOI 10.1136/adc.2009.159210; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lam C, 2010, PEDIATR BLOOD CANCER, V54, P476, DOI 10.1002/pbc.22298; Law BK, 2005, CRIT REV ONCOL HEMAT, V56, P47, DOI 10.1016/j.critrevonc.2004.09.009; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lee L, 2006, GENE CHROMOSOME CANC, V45, P933, DOI 10.1002/gcc.20357; Lee PS, 2010, AM J RESP CELL MOL, V42, P227, DOI 10.1165/rcmb.2009-0050OC; Lim CT, 2010, J MOL ENDOCRINOL, V44, P87, DOI 10.1677/JME-09-0063; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Massoumi R, 2007, THESCIENTIFICWORLDJO, V7, P1413, DOI 10.1100/tsw.2007.200; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; McGarrity TJ, 2006, CELL MOL LIFE SCI, V63, P2135, DOI 10.1007/s00018-006-6080-0; MCNAMARA EK, 2010, J DERMATOLOG TREAT; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Mi RF, 2009, J GENET GENOMICS, V36, P355, DOI 10.1016/S1673-8527(08)60124-1; Michels AA, 2010, MOL CELL BIOL, V30, P3749, DOI 10.1128/MCB.00319-10; Missiaglia E, 2010, J CLIN ONCOL, V28, P245, DOI 10.1200/JCO.2008.21.5988; Miyata H, 2004, ANN NEUROL, V56, P510, DOI 10.1002/ana.20234; Miyoshi H, 2002, CANCER RES, V62, P2261; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Muncy J, 2009, J CHILD NEUROL, V24, P477, DOI 10.1177/0883073808324535; NELLIST M, 1993, CELL, V75, P1305; Onda H, 2002, MOL CELL NEUROSCI, V21, P561, DOI 10.1006/mcne.2002.1184; Orlova KA, 2010, ANN NY ACAD SCI, V1184, P87, DOI 10.1111/j.1749-6632.2009.05117.x; Ouyang JY, 2011, J BIOL CHEM, V286, P1, DOI 10.1074/jbc.M110.121806; Papanas N, 2010, EXPERT OPIN INV DRUG, V19, P913, DOI 10.1517/13543784.2010.499122; Parrinello S, 2009, TRENDS CELL BIOL, V19, P395, DOI 10.1016/j.tcb.2009.05.003; Pearson HB, 2008, CANCER RES, V68, P2223, DOI 10.1158/0008-5472.CAN-07-5169; Peces R, 2010, NEPHROL DIAL TRANSPL, V25, P3787, DOI 10.1093/ndt/gfq456; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; Pressey JG, 2010, PEDIATR BLOOD CANCER, V54, P1035, DOI 10.1002/pbc.22401; Rennebeck G, 1998, P NATL ACAD SCI USA, V95, P15629, DOI 10.1073/pnas.95.26.15629; Robinson J, 2009, J PATHOL, V219, P35, DOI 10.1002/path.2562; Rosner M, 2008, MUTAT RES-REV MUTAT, V658, P234, DOI 10.1016/j.mrrev.2008.01.001; Sancak O, 2005, EUR J HUM GENET, V13, P731, DOI 10.1038/sj.ejhg.5201402; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schwartz RA, 2007, J AM ACAD DERMATOL, V57, P189, DOI 10.1016/j.jaad.2007.05.004; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Sparagana SP, 2010, PEDIATR NEUROL, V42, P443, DOI 10.1016/j.pediatrneurol.2010.01.016; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Tarasewicz A, 2009, TRANSPL P, V41, P3677, DOI 10.1016/j.transproceed.2009.06.227; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; Uhlmann EJ, 2004, GLIA, V47, P180, DOI 10.1002/glia.20036; Uhlmann EJ, 2002, ANN NEUROL, V52, P285, DOI 10.1002/ana.10283; van Lier MGF, 2010, J CELL MOL MED, V14, P181, DOI 10.1111/j.1582-4934.2009.00977.x; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wei C, 2008, CLIN CANCER RES, V14, P1167, DOI 10.1158/1078-0432.CCR-07-4007; Wei CJ, 2009, CANCER LETT, V277, P149, DOI 10.1016/j.canlet.2008.11.036; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wienecke R, 2006, AM J KIDNEY DIS, V48, pE27, DOI 10.1053/j.ajkd.2006.05.018; Woodrum C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-14; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yalon M, 2011, CHILD NERV SYST, V27, P179, DOI 10.1007/s00381-010-1222-y; Yeung RS, 2004, CURR MOL MED, V4, P799, DOI 10.2174/1566524043359791; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	149	100	103	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2289	2303		10.1038/onc.2010.630	http://dx.doi.org/10.1038/onc.2010.630			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258412				2022-12-28	WOS:000290789200001
J	Chae, KS; Kang, MJ; Lee, JH; Ryu, BK; Lee, MG; Her, NG; Ha, TK; Han, J; Kim, YK; Chi, SG				Chae, K. S.; Kang, M. J.; Lee, J. H.; Ryu, B. K.; Lee, M. G.; Her, N. G.; Ha, T. K.; Han, J.; Kim, Y. K.; Chi, S. G.			Opposite functions of HIF-alpha isoforms in VEGF induction by TGF-beta 1 under non-hypoxic conditions	ONCOGENE			English	Article						TGF-beta 1; VEGF; Smad3; HIF-2 alpha; HuR; prostate cancer	ENDOTHELIAL GROWTH-FACTOR; HUMAN PROSTATE-CANCER; HYPOXIA-INDUCIBLE FACTOR-1; MESSENGER-RNA STABILITY; FACTOR GENE-EXPRESSION; RENAL-CELL CARCINOMA; FACTOR-BETA; CYCLOOXYGENASE-2 EXPRESSION; HIF-2-ALPHA EXPRESSION; FACTOR (HIF)-1-ALPHA	Transforming growth factor (TGF)-beta 1 has biphasic functions in prostate tumorigenesis, having a growth-inhibitory effect in the early stages, but in the late stages promoting tumor angiogenesis and metastasis. We demonstrate here that tumor-producing TGF-beta 1 induces vascular endothelial growth factor (VEGF) in prostate cancer cells, and hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha has opposite functions in TGF-beta 1 regulation of VEGF expression under non-hypoxic conditions. The promoter response of VEGF to TGF-beta 1 was upregulated by the transfection of HIF-2 alpha or siHIF-1 alpha but downregulated by HIF-1 alpha and siHIF-2 alpha. Both HIF-1 alpha and HIF-2 alpha were induced by TGF-beta 1 at mRNA and protein levels, however, their nuclear translocation was differentially regulated by TGF-beta 1, suggesting its association with their opposite effects. VEGF induction by TGF-beta 1 occurred in a Smad3-dependent manner, and the Smad-binding element 2 (SBE2, -992 to -986) and hypoxia response element (-975 to -968) in the VEGF promoter were required for the promoter response to TGF-beta 1. Smad3 cooperated with HIF-2 alpha in TGF-beta 1 activation of VEGF transcription and Smad3 binding to the SBE2 site was greatly impaired by knockdown of HIF-2 alpha expression. Moreover, the VEGF promoter response to TGF-beta 1 was synergistically elevated by co-transfection of Smad3 and HIF-2 alpha but attenuated by HIF-1 alpha in a dose-dependent manner. Additionally, TGF-beta 1 was found to increase the stability of VEGF transcript by facilitating the cytoplasmic translocation of a RNA-stabilizing factor HuR. Collectively, our data show that tumor-producing TGF-beta 1 induces VEGF at the both transcription and post-transcriptional levels through multiple routes including Smad3, HIF-2 alpha and HuR. This study thus suggests that autocrine TGF-beta 1 production may contribute to tumor angiogenesis via HIF-2 alpha signaling under non-hypoxic conditions, providing a selective growth advantage for prostate tumor cells. Oncogene (2011) 30, 1213-1228; doi:10.1038/onc.2010.498; published online 8 November 2010	[Chae, K. S.; Kang, M. J.; Lee, J. H.; Ryu, B. K.; Lee, M. G.; Her, N. G.; Ha, T. K.; Han, J.; Kim, Y. K.; Chi, S. G.] Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; [Chae, K. S.] Kyungpook Natl Univ, Dept Biol Educ, Teachers Coll, Taegu, South Korea	Korea University; Kyungpook National University	Chi, SG (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	chi6302@korea.ac.kr	Han, Jikhyon/L-7891-2014; Her, Nam-Gu/AGY-5470-2022; Kang, Min-Ju/AAY-8706-2021	Han, Jikhyon/0000-0002-7767-3305; Kim, Yoon Ki/0000-0003-1303-072X; KANG, MIN-JU/0000-0001-5040-1388	National Research Foundation of Korea [0000794, 0001197]; Korea Research Foundation [2008-314-C00247]; National Cancer Center, Republic of Korea [0820070]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Research Foundation(National Research Foundation of Korea); National Cancer Center, Republic of Korea	This work was supported in part by grants from National Research Foundation of Korea (0000794 and 0001197), the Korea Research Foundation (2008-314-C00247) and the National Cancer Center (0820070), Republic of Korea.	Benckert C, 2003, CANCER RES, V63, P1083; Benjamin D, 2007, EXPERT OPIN BIOL TH, V7, P1515, DOI 10.1517/14712598.7.10.1515; Blancher C, 2000, CANCER RES, V60, P7106; Boddy JL, 2005, CLIN CANCER RES, V11, P7658, DOI 10.1158/1078-0432.CCR-05-0460; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fukuda R, 2003, CANCER RES, V63, P2330; Giatromanolaki A, 2003, MELANOMA RES, V13, P493, DOI 10.1097/00008390-200310000-00008; Goodyear SM, 2009, PROSTATE, V69, P982, DOI 10.1002/pros.20945; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Jackson MW, 2002, CANCER RES, V62, P854; Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005; Lu S, 2007, CLIN CANCER RES, V13, P5692, DOI 10.1158/1078-0432.CCR-07-1078; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nabors LB, 2001, CANCER RES, V61, P2154; Noguera R, 2009, CLIN CANCER RES, V15, P7130, DOI 10.1158/1078-0432.CCR-09-0223; Pallares J, 2006, HISTOL HISTOPATHOL, V21, P857, DOI 10.14670/HH-21.857; Park BJ, 2000, CANCER RES, V60, P3031; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Pietras A, 2008, J PATHOL, V214, P482, DOI 10.1002/path.2304; Pu H, 2009, CANCER RES, V69, P7366, DOI 10.1158/0008-5472.CAN-09-0758; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stearns ME, 1999, CLIN CANCER RES, V5, P711; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; TRUONG LD, 1993, HUM PATHOL, V24, P4, DOI 10.1016/0046-8177(93)90055-L; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang L, 2004, J BIOL CHEM, V279, P33213, DOI 10.1074/jbc.M403758200; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Williams RH, 1996, CLIN CANCER RES, V2, P635; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009; Zhong H, 2000, CANCER RES, V60, P1541; Zhu B, 2005, CANC TREAT, V126, P157, DOI 10.1007/0-387-24361-5_7	55	44	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1213	1228		10.1038/onc.2010.498	http://dx.doi.org/10.1038/onc.2010.498			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057546				2022-12-28	WOS:000288202400008
J	Lui, VWY; Wong, EYL; Ho, K; Ng, PKS; Lau, CPY; Tsui, SKW; Tsang, CM; Tsao, SW; Cheng, SH; Ng, MHL; Ng, YK; Lam, EKY; Hong, B; Lo, KW; Mok, TSK; Chan, ATC; Mills, GB				Lui, V. W. Y.; Wong, E. Y. L.; Ho, K.; Ng, P. K. S.; Lau, C. P. Y.; Tsui, S. K. W.; Tsang, C-M; Tsao, S-W; Cheng, S. H.; Ng, M. H. L.; Ng, Y. K.; Lam, E. K. Y.; Hong, B.; Lo, K. W.; Mok, T. S. K.; Chan, A. T. C.; Mills, G. B.			Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death	ONCOGENE			English	Article						c-Met tyrosine kinase inhibitor; TIGAR; NADPH	NASOPHARYNGEAL CARCINOMA; ACTIVATION; RECEPTOR; INVASION; CANCER	c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent head and neck cancer, nasopharyngeal cancer (NPC). c-Met tyrosine kinase inhibitors (TKIs; AM7 and c-Met TKI tool compound SU11274) downregulated c-Met phosphorylation, resulting in marked inhibition of NPC cell growth and invasion. Strikingly, inhibition of c-Met resulted in significant downregulation of TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) and subsequent depletion of intracellular NADPH. Importantly, overexpression of TIGAR ameliorated the effects of c-Met kinase inhibition, confirming the importance of TIGAR downregulation in the growth inhibitory activity of c-Met TKI. The effects of c-Met inhibition on TIGAR and NADPH levels were observed with two different c-Met TKIs (AM7 and SU11274) and with multiple cell lines. As NADPH provides a crucial reducing power required for cell survival and proliferation, our findings reveal a novel mechanistic action of c-Met TKI, which may represent a key effect of c-Met kinase inhibition. Our data provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers. Oncogene (2011) 30, 1127-1134; doi:10.1038/onc.2010.490; published online 8 November 2010	[Lui, V. W. Y.; Wong, E. Y. L.; Ho, K.; Lau, C. P. Y.; Lam, E. K. Y.; Hong, B.; Mok, T. S. K.; Chan, A. T. C.] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, State Key Lab Oncol S China, Canc Signaling Lab,Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Ng, P. K. S.; Tsui, S. K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Tsang, C-M; Tsao, S-W] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Cheng, S. H.; Ng, M. H. L.; Lo, K. W.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Ng, Y. K.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Texas System; UTMD Anderson Cancer Center	Chan, ATC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Sha Tin, Hong Kong, Peoples R China.	anthony@clo.cuhk.edu.hk	Chan, Anthony Tak Cheung/R-3940-2018; Lui, Vivian W. Y./I-5458-2016; Cheng, Suk Hang/A-6177-2009; Mok, Tony Shu Kam/B-2310-2019; Tsui, Stephen Kwok-Wing/E-4385-2015; Hong, Bo/ABA-3687-2021; Ng, Yuen-Keng/ABC-3906-2020	Chan, Anthony Tak Cheung/0000-0002-6912-8091; Lui, Vivian W. Y./0000-0001-6918-1573; Cheng, Suk Hang/0000-0002-2880-2289; Mok, Tony Shu Kam/0000-0002-8251-0551; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Hong, Bo/0000-0001-8117-5029; Ng, Yuen-Keng/0000-0003-4491-5221; Lo, Kwok Wai/0000-0002-3488-6124	Research Grant Council, Hong Kong Government [471607]; Head and Neck SPORE [P50 CA097007]; CCSG [P30CA16672];  [2006.1.027];  [2007.1.025];  [2009.1.012]; NATIONAL CANCER INSTITUTE [P50CA098258, P50CA097007, P30CA016672] Funding Source: NIH RePORTER	Research Grant Council, Hong Kong Government(Hong Kong Research Grants Council); Head and Neck SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CCSG; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Amgen, Inc. (USA) for the kind provision of the novel c-Met tyrosine kinase inhibitor, AM7. This study was supported by Research Grant Council, Hong Kong Government (471607) and Direct Grants for Research (2006.1.027; 2007.1.025; 2009.1.012) to VWYL. GBM is supported by Head and Neck SPORE P50 CA097007 and CCSG grant P30CA16672.	Anderson KE, 2006, CANC EPIDEMIOLOGY PR, P721; Bellon SF, 2008, J BIOL CHEM, V283, P2675, DOI 10.1074/jbc.M705774200; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Horikawa T, 2001, AM J PATHOL, V159, P27, DOI 10.1016/S0002-9440(10)61669-0; Lui VWY, 2009, CARCINOGENESIS, V30, P2085, DOI 10.1093/carcin/bgp253; Lui VWY, 2007, MOL PHARMACOL, V71, P1435, DOI 10.1124/mol.106.032284; Lui VWY, 2010, BIOCHEM PHARMACOL, V79, P1772, DOI 10.1016/j.bcp.2010.02.012; Lui VWY, 2009, INT J CANCER, V125, P1884, DOI 10.1002/ijc.24567; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Qian CN, 2002, CANCER RES, V62, P589; Stabile LP, 2004, GENE THER, V11, P325, DOI 10.1038/sj.gt.3302169; Tulasne D, 2008, CELL DEATH DIFFER, V15, P427, DOI 10.1038/sj.cdd.4402229; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; WONG JH, 2009, CANC LETT; Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103	19	51	53	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1127	1134		10.1038/onc.2010.490	http://dx.doi.org/10.1038/onc.2010.490			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21057531	Green Accepted			2022-12-28	WOS:000287964100011
J	Asciutti, S; Akiri, G; Grumolato, L; Vijayakumar, S; Aaronson, SA				Asciutti, S.; Akiri, G.; Grumolato, L.; Vijayakumar, S.; Aaronson, S. A.			Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells	ONCOGENE			English	Article						beta-catenin; DNTCF4; c-Myc; gastric cancer	BETA-CATENIN; SIGNALING PATHWAY; CANCER-CELLS; MAMMARY TUMORIGENESIS; EPITHELIAL-CELLS; GAMMA-CATENIN; C-MYC; APC; MUTATIONS; TRANSCRIPTION	Human gastric carcinomas are among the most treatment-refractory epithelial malignancies. Increased understanding of the underlying molecular aberrations in such tumors could provide insights leading to improved therapeutic approaches. In this study, we characterized diverse genetic aberrations leading to constitutive Wnt signaling activation in a series of human gastric carcinoma cell lines. Downregulation of TCF signaling by stable transduction of dominant negative TCF4 (DNTCF4) resulted in inhibition of proliferation in Wnt-activated AGS tumor cells. c-Myc downregulation and the associated upregulation of its repression target, p21 observed in these tumor cells, as well as the profound growth inhibition induced by c-Myc small hairpin RNA (shRNA) implied their c-Myc addiction. In striking contrast, Wnt-activated MKN-28 and MKN-74 tumor cells appeared refractory to DNTCF4 inhibition of proliferation despite comparably decreased c-Myc expression levels. The resistance of these same tumor cells to growth inhibition by c-Myc shRNA established that their refractoriness to DNTCF was because of their independence from c-Myc for proliferation. There was no correlation between this resistance phenotype and the presence or absence of constitutive mitogen-activated protein kinase (MAPK) and/or AKT pathway activation, commonly observed in gastrointestinal tumors. However, in both DNTCF-sensitive and -resistant tumor cells with MAPK and/or AKT pathway activation, the ability of small molecule antagonists directed against either pathway to inhibit tumor cell growth was enhanced by Wnt pathway inhibition. These findings support the concept that although certain Wnt-activated tumors may escape c-Myc dependence for proliferation, disruption of other oncogenic pathways can unmask cooperative antiproliferative effects for Wnt pathway downregulation. Oncogene (2011) 30, 956-966; doi:10.1038/onc.2010.475; published online 1 November 2010	[Asciutti, S.; Akiri, G.; Grumolato, L.; Vijayakumar, S.; Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	stuart.aaronson@mssm.edu	Grumolato, Luca/A-1697-2015	Grumolato, Luca/0000-0001-8231-3032	American Urological Association; National Cancer Institute [5R01CA071672]; NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER	American Urological Association; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Yoshio Yamaoka (Baylor College of Medicine, Houston, TX, USA) for MKN-7 and MKN-28 cells; Dr Gary Schwartz (Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA) for MKN-74 cells and Dr Reuben Lotan (MD Anderson Cancer Center, Houston, TX, USA) for KATO-II cells. SV is a recipient of a post-doctoral fellowship award from the American Urological Association. Grant support: This work was supported by grant number 5R01CA071672 from the National Cancer Institute.	Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; BAS PLW, 2000, INT J CANCER, V86, P533; Bechard M, 2009, MOL CELL BIOL, V29, P2092, DOI 10.1128/MCB.01405-08; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Clements WM, 2002, CANCER RES, V62, P3503; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; Grabsch H, 2001, HISTOPATHOLOGY, V39, P141, DOI 10.1046/j.1365-2559.2001.01177.x; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213, DOI 10.1111/j.1349-7006.2002.tb01226.x; Jang JW, 2006, MOL CELL BIOL, V26, P8109, DOI 10.1128/MCB.00404-06; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kim JS, 2002, CANCER RES, V62, P2744; Kim SE, 2007, CELL SIGNAL, V19, P511, DOI 10.1016/j.cellsig.2006.08.008; Kolligs FT, 2000, GENE DEV, V14, P1319; Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Overman Michael J, 2009, Gastrointest Cancer Res, V3, P90; Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shimizu M, 2008, MOL CELL BIOL, V28, P825, DOI 10.1128/MCB.02375-06; Slinker BK, 1998, J MOL CELL CARDIOL, V30, P723, DOI 10.1006/jmcc.1998.0655; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Suriano G, 2005, GENE CHROMOSOME CANC, V42, P238, DOI 10.1002/gcc.20135; Teuliere J, 2004, MOL CELL BIOL, V24, P8649, DOI 10.1128/MCB.24.19.8649-8661.2004; Tomita H, 2007, CANCER RES, V67, P4079, DOI 10.1158/0008-5472.CAN-06-4025; Van Cutsem E, 2006, ANN ONCOL, V17, P13, DOI 10.1093/annonc/mdl976; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	39	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					956	966		10.1038/onc.2010.475	http://dx.doi.org/10.1038/onc.2010.475			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21042278	Green Accepted			2022-12-28	WOS:000287695900007
J	Jang, MS; Lee, SJ; Kim, CJ; Lee, CW; Kim, E				Jang, M-S; Lee, S-J; Kim, C-J; Lee, C-W; Kim, E.			Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD	ONCOGENE			English	Article						FADD; Plk1; phosphorylation; tumor suppressor; negative feedback	FAS-ASSOCIATED PROTEIN; NECROTIC CELL-DEATH; INDUCED APOPTOSIS; CANCER-CELLS; SIGNALING PATHWAY; FACTOR-I; DOMAIN; PLK1; INHIBITOR; EXPRESSION	Phosphorylation of the Fas-associated death domain (FADD) protein sensitizes cancer cells to various chemotherapeutics. However, the molecular mechanism underlying chemosensitization by phosphorylated FADD (P-FADD) is poorly understood. In this study, we describe the physical interactions and functional interplay between Polo-like kinase 1 (Plk1) and FADD. Plk1 phosphorylates FADD at Ser-194 in response to treatment with taxol. Overexpression of a phosphorylation-mimicking mutant, FADD S194D, caused degradation of Plk1 in an ubiquitin-independent manner, and delayed cytokinesis, consistent with the expected cellular phenotype of Plk1 deficiency. This demonstrates that Plk1 is regulated via a negative feedback loop by its substrate, FADD. Overexpression of FADD S194D sensitized HeLa cells to a low dose of taxol independently of caspase activation, whereas overexpression of FADD S194D resulted in caspase activation in response to a high dose of taxol. Therefore, we examined whether the death potential of P-FADD affected Plk1-mediated tumorigenesis. Transfection of FADD S194D inhibited colony formation by Plk1-overexpressing HeLa cells (HeLa-Plk1). Moreover, overexpression of FADD S194D suppressed tumorigenesis in nude mice xenografted with HeLa-Plk1. Therefore, this study reports the first in vivo validation of tumor-suppressing activity of P-FADD. Collectively, our data demonstrate that in response to taxol, Plk1 endows death-promoting and tumor-suppressor functions to its substrate, FADD. Oncogene (2011) 30, 471-481; doi: 10.1038/onc.2010.423; published online 4 October 2010	[Jang, M-S; Lee, S-J; Kim, E.] Chungnam Natl Univ, Coll Biol Sci & Biotechnol, Taejon 305764, South Korea; [Kim, C-J] Chungnam Natl Univ, Coll Vet Med, Taejon 305764, South Korea; [Lee, C-W] Sungkyunkwan Univ, Dept Mol Cell Biol, Sch Med, Suwon, South Korea; [Kim, E.] Chungnam Natl Univ, Daedeok R&D Innopolis Bio Brain Ctr BK21, Taejon 305764, South Korea	Chungnam National University; Chungnam National University; Sungkyunkwan University (SKKU); Chungnam National University	Kim, E (corresponding author), Chungnam Natl Univ, Coll Biol Sci & Biotechnol, 220 Gung Dong, Taejon 305764, South Korea.	eunhee@cnu.ac.kr	ê, ìí/F-5894-2013	Kim, Chul-Joong/0000-0001-8827-6332	21C Frontier Functional Human Genome Project [FG09-21-02]; Center for Biological Modulators [CMB34-A2300-01-00-00]; National Research foundation at the Ministry of Education, Science and Technology in Korea [2009-0093957]	21C Frontier Functional Human Genome Project(Ministry of Education, Science & Technology (MEST), Republic of Korea); Center for Biological Modulators(Ministry of Education, Science & Technology (MEST), Republic of Korea); National Research foundation at the Ministry of Education, Science and Technology in Korea	This work was supported by a grant (FG09-21-02) from the 21C Frontier Functional Human Genome Project, by a grant (CMB34-A2300-01-00-00) from the Center for Biological Modulators of the 21st Century Frontier R&D Program and by the National Research foundation (2009-0093957) at the Ministry of Education, Science and Technology in Korea. We thank Dr Soojin Lee (Department of Microbiology, Chungnam National University, Daejeon, Korea) for assistance with the colony formation studies, and Byung-Jung Choi (Medical Genomics Research Center, KRIBB, Daejeon, Korea) for assistance with the FPLC.	Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Eckerdt F, 2006, CANCER RES, V66, P6895, DOI 10.1158/0008-5472.CAN-06-0358; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gilmartin AG, 2009, CANCER RES, V69, P6969, DOI 10.1158/0008-5472.CAN-09-0945; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Jang MS, 2008, J BIOL CHEM, V283, P32344, DOI 10.1074/jbc.M804199200; Jariel-Encontre I, 2008, BBA-REV CANCER, V1786, P153, DOI 10.1016/j.bbcan.2008.05.004; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Krelin Y, 2008, CELL DEATH DIFFER, V15, P1350, DOI 10.1038/cdd.2008.88; Lahav G, 2008, ADV EXP MED BIOL, V641, P28; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; Luschen S, 2005, EXP CELL RES, V310, P33, DOI 10.1016/j.yexcr.2005.07.022; Matsuyoshi S, 2006, BRIT J CANCER, V94, P532, DOI 10.1038/sj.bjc.6602955; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Park MY, 2005, INT J CANCER, V115, P412, DOI 10.1002/ijc.20857; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Preisinger C, 2005, EMBO J, V24, P753, DOI 10.1038/sj.emboj.7600569; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Shimada K, 2005, J PATHOL, V206, P423, DOI 10.1002/path.1791; Shimada K, 2004, CARCINOGENESIS, V25, P1089, DOI 10.1093/carcin/bgh130; Shimada K, 2002, JPN J CANCER RES, V93, P1164, DOI 10.1111/j.1349-7006.2002.tb01219.x; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Xu H, 2009, CANCER INVEST, V27, P836, DOI 10.1080/07357900902849681; Yamaguchi H, 2006, MOL CELL BIOL, V26, P569, DOI 10.1128/MCB.26.2.569-579.2006; Yamaguchi T, 2005, J CELL BIOL, V171, P431, DOI 10.1083/jcb.200504091; Yang Qin, 2005, Ai Zheng, V24, P321; Yoo NJ, 2007, PATHOL RES PRACT, V203, P73, DOI 10.1016/j.prp.2006.11.002; Zhande R, 2007, MOL CELL BIOL, V27, P7394, DOI 10.1128/MCB.00600-07; Zhang J, 2009, CANCER BIOL THER, V8, P2374, DOI 10.4161/cbt.8.24.10182; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	50	29	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					471	481		10.1038/onc.2010.423	http://dx.doi.org/10.1038/onc.2010.423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20890306				2022-12-28	WOS:000286621600009
J	Kaplan, FM; Shao, Y; Mayberry, MM; Aplin, AE				Kaplan, F. M.; Shao, Y.; Mayberry, M. M.; Aplin, A. E.			Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells	ONCOGENE			English	Article						apoptosis; B-RAF; N-RAS; PLX4720	KINASE INHIBITOR; BRAF; MUTATIONS; ACTIVATION; PATHWAY; PHOSPHORYLATION; PROGRESSION	Activating mutations in B-RAF and N-RAS occur in similar to 60 and similar to 15% of melanomas, respectively. The most common mutation in B-RAF is V600E, which activates B-RAF and the downstream MEK-ERK1/2 pathway. Thus, B-RAF(V600E) is a viable therapeutic target. PLX4720 is a selective inhibitor of mutant B-RAF and its analog, PLX4032, is currently undergoing clinical trials in melanoma. However, the effects of PLX4720 across the genotypic spectrum in melanoma remain unclear. Here, we describe that PLX4720 treatment rapidly induces hyperactivation of the MEK-ERK1/2 pathway in mutant N-RAS melanoma cells. Furthermore, we demonstrate that C-RAF is the major RAF isoform involved in this process. Importantly, PLX4720-induced hyperactivation of the MEK-ERK1/2 pathway promotes resistance to apoptosis in both non-invasive and invasive mutant N-RAS melanoma cells but does not enhance cell cycle properties. These findings underscore the need to genotypically stratify melanoma patients before enrollment on a mutant B-RAF inhibitor trial. Oncogene (2011) 30, 366-371; doi:10.1038/onc.2010.408; published online 6 September 2010	[Aplin, A. E.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Aplin, AE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	Andrew.Aplin@KimmelCancerCenter.Org	Shao, Yongping/D-9966-2011		National Institutes of Health [R01-GM067893, R01-CA125103]; Pennsylvania Department of Health [AF0301]; NATIONAL CANCER INSTITUTE [R01CA125103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Gideon Bollag (Plexxikon) for providing PLX4720, Dr Meenhard Herlyn (Wistar Institute) for cell lines and Dr Michele Weiss for comments on the manuscript. This work was supported by National Institutes of Health Grants (R01-GM067893 and R01-CA125103), and Pennsylvania Department of Health (AF0301) to AE Aplin.	ALBINO AP, 1989, ONCOGENE, V4, P1363; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; FLAHERTY K, 2009, J CLIN ONCOL S, V27, pNIL18; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hunger-Glaser I, 2004, J CELL PHYSIOL, V200, P213, DOI 10.1002/jcp.20018; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Salerno P, 2010, J CLIN ENDOCR METAB, V95, P450, DOI 10.1210/jc.2009-0373; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sondak Vernon K, 2009, Pigment Cell Melanoma Res, V22, P386, DOI 10.1111/j.1755-148X.2009.00593.x; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6	26	93	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					366	371		10.1038/onc.2010.408	http://dx.doi.org/10.1038/onc.2010.408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20818433	Green Accepted			2022-12-28	WOS:000286418800011
J	Olanich, ME; Moss, BL; Piwnica-Worms, D; Townsend, RR; Weber, JD				Olanich, M. E.; Moss, B. L.; Piwnica-Worms, D.; Townsend, R. R.; Weber, J. D.			Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation	ONCOGENE			English	Article						FBP1; Nucleophosmin; ribosome biogenesis; translation	RIBOSOME BIOGENESIS; STRESS GRANULES; PROCESSING BODIES; MAMMALIAN TARGET; P53 TRANSLATION; NUCLEAR EXPORT; C-MYC; PHOSPHORYLATION; EXPRESSION; RAPAMYCIN	Nucleophosmin (NPM/B23) is a multifunctional oncoprotein whose protein expression levels dictate cellular growth and proliferation rates. NPM is translationally responsive to hyperactive mammalian target of rapamycin (mTOR) signals, but the mechanism of this regulation is not understood. Using chimeric translational reporters, we found that the 30 untranslated region (UTR) of the NPM messenger (m) RNA is sufficient to mediate its translational modulation by mTOR signalling. We show that far upstream element (FUSE)-binding protein 1 (FBP1) interacts specifically with the 30 UTR of NPM to repress translation. Overexpression of FBP1 resulted in translational repression of NPM mRNAs, whereas depletion of FBP1 caused a dramatic increase in NPM translation and resulted in enhanced overall cell proliferation. Thus, we propose that FBP1 is a key regulator of cell growth and proliferation through its ability to selectively bind the NPM 30 UTR and repress NPM translation. Oncogene (2011) 30, 77-86; doi: 10.1038/onc.2010.404; published online 30 August 2010	[Olanich, M. E.; Weber, J. D.] Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med, St Louis, MO 63110 USA; [Olanich, M. E.; Moss, B. L.; Piwnica-Worms, D.; Weber, J. D.] Washington Univ, Sch Med, BRIGHT Inst, St Louis, MO 63110 USA; [Moss, B. L.; Piwnica-Worms, D.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA; [Townsend, R. R.] Washington Univ, Sch Med, Siteman Canc Ctr, Div Metab & Prote Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8069, St Louis, MO 63110 USA.	jweber@dom.wustl.edu		Moss, Britney/0000-0002-1037-5717; Weber, Jason/0000-0002-1069-6983	Washington University Imaging Center; NIH [5T32 GM007067, P30 CA91842, P50 CA94056, CA128007]; National Center for Research Resources [P41RR000954, UL1 RR024992]; Era of Hope Scholar Award in Breast Cancer Research [BC007304]; NATIONAL CANCER INSTITUTE [R01CA127008, P30CA091842, P50CA094056] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER	Washington University Imaging Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Era of Hope Scholar Award in Breast Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of the Weber, Townsend and Piwnica-Worms laboratories for their advice and technical assistance. The luciferase reporter work was initiated through a Pilot Grant from the Washington University Imaging Center. MEO was supported by NIH 5T32 GM007067. This research was supported with Grants from the National Institutes of Health, P30 CA91842 to the Siteman Comprehensive Cancer Center and P41RR000954 and UL1 RR024992 from the National Center for Research Resources to the Proteomics Center. DPW and BLM were supported by NIH P50 CA94056. This work was supported by NIH Grant CA128007 and an Era of Hope Scholar Award in Breast Cancer Research (BC007304) to JDW.	Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2009, ONCOGENE, V28, P3209, DOI 10.1038/onc.2009.178; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Briata P, 2005, MOL CELL, V20, P891, DOI 10.1016/j.molcel.2005.10.021; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; de Moor CH, 2005, SEMIN CELL DEV BIOL, V16, P49, DOI 10.1016/j.semcdb.2004.11.007; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Gross S, 2005, NAT METHODS, V2, P607, DOI 10.1038/NMETH779; Hamilton BJ, 2008, J BIOL CHEM, V283, P25606, DOI 10.1074/jbc.M802492200; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; He YW, 2009, CELL MOL LIFE SCI, V66, P1239, DOI 10.1007/s00018-008-8532-1; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jiang Y, 2006, MOL CELL BIOL, V26, P2419, DOI 10.1128/MCB.26.6.2419-2429.2006; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; King JB, 2006, ANAL CHEM, V78, P2171, DOI 10.1021/ac051520l; Kroll TT, 2002, DEVELOPMENT, V129, P5609, DOI 10.1242/dev.00160; Li H, 2009, J LIPID RES, V50, P820, DOI 10.1194/jlr.M800375-JLR200; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08; Pelletier CL, 2007, CANCER RES, V67, P1609, DOI 10.1158/0008-5472.CAN-06-2875; Pontrelli L, 2004, BIOCHEMISTRY-US, V43, P6734, DOI 10.1021/bi049887s; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227; Qi W, 2008, ONCOGENE, V27, P4210, DOI 10.1038/onc.2008.54; Sandsmark DK, 2007, HISTOL HISTOPATHOL, V22, P895, DOI 10.14670/HH-22.895; Sidiropoulos KG, 2007, ARCH BIOCHEM BIOPHYS, V459, P10, DOI 10.1016/j.abb.2006.11.003; Snee M, 2002, J CELL SCI, V115, P4661, DOI 10.1242/jcs.00137; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Wilczynska A, 2005, J CELL SCI, V118, P981, DOI 10.1242/jcs.01692; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang WH, 2006, RNA, V12, P547, DOI 10.1261/rna.2302706; Yu JH, 2005, RNA, V11, P1795, DOI 10.1261/rna.2142405; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; Zhang J, 2008, CANCER RES, V68, P1046, DOI 10.1158/0008-5472.CAN-07-1927; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	57	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					77	86		10.1038/onc.2010.404	http://dx.doi.org/10.1038/onc.2010.404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802533	Green Accepted			2022-12-28	WOS:000285959300007
J	Schouwey, K; Aydin, IT; Radtke, F; Beermann, F				Schouwey, K.; Aydin, I. T.; Radtke, F.; Beermann, F.			RBP-J kappa-dependent Notch signaling enhances retinal pigment epithelial cell proliferation in transgenic mice	ONCOGENE			English	Article						RPE; transgenic; Notch; eye; melanoma; knockout	EARLY EYE DEVELOPMENT; TUMOR-SUPPRESSOR; EXPRESSION; FATE; TRANSCRIPTION; PATHWAY; GENE; DIFFERENTIATION; MELANOCYTE; MORPHOGENESIS	The Notch signaling pathway is an ubiquitous cell-cell interaction mechanism, which is essential in controlling processes like cell proliferation, cell fate decision, differentiation or stem cell maintenance. Recent data have shown that Notch signaling is RBP-J kappa-dependent in melanocytes, being required for survival of these pigment cells that are responsible for coloration of the skin and hairs in mammals. In addition, Notch is believed to function as an oncogene in melanoma, whereas it is a tumor suppressor in mouse epidermis. In this study, we addressed the implication of the Notch signaling in the development of another population of pigment cells forming the retinal pigment epithelium (RPE) in mammalian eyes. The constitutive activity of Notch in Tyrp1::NotchIC/degrees transgenic mice enhanced RPE cell proliferation, and the resulting RPE-derived pigmented tumor severely affected the overall eye structure. This RPE cell proliferation is dependent on the presence of the transcription factor RBP-J kappa, as it is rescued in mice lacking RBP-J kappa in the RPE. In conclusion, Notch signaling in the RPE uses the canonical pathway, which is dependent on the transcription factor RBP-J kappa. In addition, it is of importance for RPE development, and constitutive Notch activity leads to hyperproliferation and benign tumors of these pigment cells. Oncogene (2011) 30, 313-322; doi:10.1038/onc.2010.428; published online 20 September 2010	[Schouwey, K.; Aydin, I. T.; Radtke, F.; Beermann, F.] Ecole Polytech Fed Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res ISREC, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research	Beermann, F (corresponding author), Ecole Polytech Fed Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res ISREC, Stn 19,Batiment SV, CH-1015 Lausanne, Switzerland.	Friedrich.Beermann@epfl.ch	Radtke, Freddy/Q-3198-2017	Radtke, Freddy/0000-0003-4315-4045; Aydin, Iraz Toprak/0000-0001-9608-8577	Oncosuisse; Novartis; Fondation Emma Muschamps; Swiss National Science Foundation	Oncosuisse; Novartis(Novartis); Fondation Emma Muschamps; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Pierre Chambon, Tatsuko Honjo, Ursula Zimber-Strobl, Lothar Strobl and Ian J Jackson for mouse strains; to Simon Saule, Vince Hearing and Mickey Marks for antibodies; and to Alessandra Solero and Sabrina Guichard for initial help with the Tyrp1::NotchIC construct and mice. The Pax6 antibody developed by A Kawakami was obtained from the Developmental Studies Hybridoma Bank at the University of Iowa. Work in the laboratory of FB was supported by grants from Oncosuisse, Novartis, the Fondation Emma Muschamps and The Swiss National Science Foundation.	Adler R, 1999, MOL VIS, V5; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aubin-Houzelstein G, 2008, J INVEST DERMATOL, V128, P2686, DOI 10.1038/jid.2008.120; Aydin IT, 2009, PIGM CELL MELANOMA R, V22, P854, DOI 10.1111/j.1755-148X.2009.00629.x; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Baumer N, 2003, DEVELOPMENT, V130, P2903, DOI 10.1242/dev.00450; Besseyrias V, 2007, J EXP MED, V204, P331, DOI 10.1084/jem.20061442; Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x; BODENSTEIN L, 1987, DEV BIOL, V121, P192, DOI 10.1016/0012-1606(87)90152-7; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Cao TY, 1997, J CELL SCI, V110, P1563; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; Dakubo GD, 2008, DEV BIOL, V320, P242, DOI 10.1016/j.ydbio.2008.05.528; Das AV, 2008, DEV NEUROSCI-BASEL, V30, P389, DOI 10.1159/000178017; Defoe DM, 2007, MOL VIS, V13, P273; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Finger PT, 1996, GRAEF ARCH CLIN EXP, V234, pS22, DOI 10.1007/BF02343044; Fuhrmann S, 2000, DEVELOPMENT, V127, P4599; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GARNER A, 1970, BRIT J OPHTHALMOL, V54, P715, DOI 10.1136/bjo.54.11.715; Gimenez E, 2001, LAB ANIM-UK, V35, P153, DOI 10.1258/0023677011911525; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Haass NK, 2005, J INVEST DERM SYMP P, V10, P153, DOI 10.1111/j.1087-0024.2005.200407.x; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hingorani M, 1999, OPHTHALMOLOGY, V106, P330, DOI 10.1016/S0161-6420(99)90072-6; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135; Krebs LT, 2000, GENE DEV, V14, P1343; Krebs LT, 2003, GENE DEV, V17, P1207, DOI 10.1101/gad.1084703; Kumano K, 2008, PIGM CELL MELANOMA R, V21, P70, DOI 10.1111/j.1755-148X.2007.00423.x; Lee HY, 2005, DEV BIOL, V284, P464, DOI 10.1016/j.ydbio.2005.06.010; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Lutty G, 1999, MOL VIS, V5; Ma A, 2007, INVEST OPHTH VIS SCI, V48, P3576, DOI 10.1167/iovs.06-1373; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x; Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064; Matt N, 2005, DEVELOPMENT, V132, P4789, DOI 10.1242/dev.02031; May CA, 1996, EXP EYE RES, V63, P75; Mori M, 2002, INVEST OPHTH VIS SCI, V43, P1384; Moriyama M, 2006, J CELL BIOL, V173, P333, DOI 10.1083/jcb.200509084; Murisier F, 2007, DEV BIOL, V303, P838, DOI 10.1016/j.ydbio.2006.11.038; Murisier F, 2006, DEV BIOL, V298, P644, DOI 10.1016/j.ydbio.2006.05.011; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nishikawa SI, 2007, PIGM CELL RES, V20, P263, DOI 10.1111/j.1600-0749.2007.00388.x; Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196; Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Porret Andree, 2006, V337, P185; Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; Rowan S, 2008, DEV BIOL, V321, P111, DOI 10.1016/j.ydbio.2008.06.002; Schmidt A, 1999, INT J CANCER, V80, P600, DOI 10.1002/(SICI)1097-0215(19990209)80:4<600::AID-IJC19>3.0.CO;2-2; Schouwey K, 2008, HISTOL HISTOPATHOL, V23, P609, DOI 10.14670/HH-23.609; Schouwey K, 2007, DEV DYNAM, V236, P282, DOI 10.1002/dvdy.21000; Schouwey K, 2010, PIGM CELL MELANOMA R, V23, P134, DOI 10.1111/j.1755-148X.2009.00651.x; Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shields JA, 2009, OPHTHALMOLOGY, V116, P2213, DOI 10.1016/j.ophtha.2009.04.048; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Vauclair S, 2007, DEV CELL, V13, P242, DOI 10.1016/j.devcel.2007.06.012; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson A, 2006, FEBS LETT, V580, P2860, DOI 10.1016/j.febslet.2006.03.024; Yashiro-Ohtani Y, 2009, GENE DEV, V23, P1665, DOI 10.1101/gad.1793709; Yoshida K, 2004, ANAT EMBRYOL, V208, P145, DOI 10.1007/s00429-004-0382-5; Zhao SL, 2001, MOL VIS, V7, P277; Zheng MH, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-38	85	27	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					313	322		10.1038/onc.2010.428	http://dx.doi.org/10.1038/onc.2010.428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856205				2022-12-28	WOS:000286418800006
J	Mayeenuddin, LH; Yu, Y; Kang, Z; Helman, LJ; Cao, L				Mayeenuddin, L. H.; Yu, Y.; Kang, Z.; Helman, L. J.; Cao, L.			Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L)	ONCOGENE			English	Article						IGF1R therapeutic antibody; apoptosis; tumor regression; predictive biomarker; Bcl-x(L); Bcl-2	FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY; CYTOCHROME-C; TUMOR-GROWTH; IGF-I; APOPTOSIS; SURVIVAL; BCL-2; INHIBITION; THERAPY	Insulin-like growth factors (IGFs) and their receptor, IGF-1 receptor (IGF1R), have important roles in growth, development, stress response, aging and cancer. There are many agents that inhibit IGF1R in oncology clinical development, and in some cases, they have been associated with rapid tumor regression. However, it is not clear by which process these targeted agents induce cancer cell death and how to predict such tumor responses. Here, we showed that IGF1R antibody led to rapid cell death and tumor regression in some rhabdomyosarcoma (RMS) cells. Mechanistic analysis revealed a rapid onset of mitochondrial-dependent apoptosis, including mitochondrial depolarization, cytochrome C release and the activation of specific caspases. The antibody sensitive cells had greater dependence on AKT for maintaining downstream signaling and the expression of a constitutively active AKT, which restored AKT-signaling in these cells, inhibited anti-IGF1R induced cell death. Further analysis showed IGF1R antibody-induced hypophosphorylation of BAD and activation of downstream BAX. Interestingly, the examination of RMS cell lines and tumors revealed an inverse correlation between elevated IGF1R and Bcl-2 level (P = 0.033), with the sensitive cells lacking Bcl-2 expression. The overexpression of BAD specific target, Bcl-x(L), conferred resistance, whereas Bcl-x(L) knockdown sensitized cells lacking Bcl-2 to anti-IGF1R-induced cell death. We propose that RMS pathogenesis involves increased IGF1R expression that enhances AKT and Bcl-x(L)-mediated cell survival, and the blockage of IGF1R results in inhibition of survival signal from Bcl-x(L) and cell death in the sensitive Bcl-2 negative cells. Oncogene (2010) 29, 6367-6377; doi:10.1038/onc.2010.364; published online 6 September 2010	[Mayeenuddin, L. H.; Yu, Y.; Kang, Z.; Cao, L.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Mayeenuddin, L. H.; Yu, Y.; Kang, Z.] NCI Frederick, Lab Prote & Analyt Technol, SAIC Frederick Inc, Frederick, MD USA; [Helman, L. J.] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cao, L (corresponding author), NCI, Genet Branch, Ctr Canc Res, 37 Convent Dr,MSC 4265,Bldg 37,Room 6134, Bethesda, MD 20892 USA.	caoli@mail.nih.gov	Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338; Kang, zhigang/0000-0003-3444-4315	US National Cancer Institute (NCI); NCI, NIH [N01-CO-12400]; NATIONAL CANCER INSTITUTE [ZIASC006892, ZICBC011048] Funding Source: NIH RePORTER	US National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Andrius Kazlauskas for providing the lentivirus expressing Bcl-x<INF>L</INF>, and Arnulfo Mendoza, Vanessa Moore, Susan Garfield and Barbara Taylor for excellent technical assistance. This research was supported by the Intramural Research Program of the US National Cancer Institute (NCI). This project was also funded in part with federal funds from the NCI, NIH, under contract N01-CO-12400.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Barcia RN, 2007, AM J TRANSPLANT, V7, P2082, DOI 10.1111/j.1600-6143.2007.01897.x; Burtrum D, 2003, CANCER RES, V63, P8912; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kooijman R, 2006, CYTOKINE GROWTH F R, V17, P305, DOI 10.1016/j.cytogfr.2006.02.002; Kurmasheva RT, 2006, BBA-REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Minshall C, 1997, J IMMUNOL, V159, P1225; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Phillips DC, 2007, CANCER RES, V67, P756, DOI 10.1158/0008-5472.CAN-06-2374; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Sachdev D, 2003, CANCER RES, V63, P627; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Tolcher AW, 2009, J CLIN ONCOL, V27, P5800, DOI 10.1200/JCO.2009.23.6745; Troiano L, 2007, NAT PROTOC, V2, P2719, DOI 10.1038/nprot.2007.405; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Wu JD, 2005, CLIN CANCER RES, V11, P3065, DOI 10.1158/1078-0432.CCR-04-1586; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JH, 2004, DEV BRAIN RES, V152, P255, DOI 10.1016/j.devbrainres.2004.07.008	33	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6367	6377		10.1038/onc.2010.364	http://dx.doi.org/10.1038/onc.2010.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20818434	Green Accepted			2022-12-28	WOS:000284874700007
J	Yen, KE; Bittinger, MA; Su, SM; Fantin, VR				Yen, K. E.; Bittinger, M. A.; Su, S. M.; Fantin, V. R.			Cancer-associated IDH mutations: biomarker and therapeutic opportunities	ONCOGENE			English	Review						IDH; mutations; cancer	ACUTE MYELOID-LEUKEMIA; DEPENDENT ISOCITRATE DEHYDROGENASE; INTEGRATED GENOMIC ANALYSIS; CODON 132 MUTATION; MYELOPROLIFERATIVE NEOPLASMS; L-2-HYDROXYGLUTARIC ACIDURIA; BETA-OXIDATION; FATTY-ACIDS; GLIOMAS; TUMORS	The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-wide mutational analysis in glioblastoma represents a milestone event in cancer biology. The nature of the heterozygous, point mutations mapping to arginine residues involved in the substrate binding inspired several research teams to investigate their impact on the biochemical activity of these enzymes. Soon, it became clear that the mutations identified impaired the ability of IDH1 and IDH2 to catalyze the conversion of isocitrate to alpha-ketoglutarate (alpha KG), whereas conferring a gain of a novel enzymatic activity leading to the reduction of alpha KG to the metabolite D2-hydroxyglutarate (D-2HG). Across glioma as well as several hematologic malignancies, mutations in IDH1 and IDH2 have shown prognostic value. Several hypotheses implicating the elevated levels of D-2HG and tumorigenesis, and the therapeutic potential of targeting mutant IDH enzymes will be discussed. Oncogene (2010) 29, 6409-6417; doi:10.1038/onc.2010.444; published online 25 October 2010	[Yen, K. E.; Bittinger, M. A.; Su, S. M.; Fantin, V. R.] Agios Pharmaceut, Mol Oncol, Cambridge, MA 02139 USA	Agios Pharmaceuticals	Fantin, VR (corresponding author), Agios Pharmaceut, Mol Oncol, 2nd Floor,38 Sidney St, Cambridge, MA 02139 USA.	valeria.fantin@agios.com						Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878; Abdel-Wahab O, 2010, CANCER RES, V70, P447, DOI 10.1158/0008-5472.CAN-09-3783; Aydin K, 2003, PEDIATR RADIOL, V33, P872, DOI 10.1007/s00247-003-1029-z; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; Chalmers R A, 1980, J Inherit Metab Dis, V3, P11, DOI 10.1007/BF02312516; Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Frezza C, 2010, CANCER CELL, V17, P7, DOI 10.1016/j.ccr.2009.12.031; Gaal J, 2010, J CLIN ENDOCR METAB, V95, P1274, DOI 10.1210/jc.2009-2170; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; Gillies RJ, 2007, CANCER METAST REV, V26, P311, DOI 10.1007/s10555-007-9065-z; Green A, 2010, NEW ENGL J MED, V362, P369, DOI 10.1056/NEJMc0910063; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hayden JT, 2009, CELL CYCLE, V8, P1806, DOI 10.4161/cc.8.11.8594; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Ho PA, 2010, LEUKEMIA, V24, P909, DOI 10.1038/leu.2010.56; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaelin WG, 2009, CANCER CELL, V16, P180, DOI 10.1016/j.ccr.2009.08.013; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; KAUFMAN EE, 1988, J NEUROCHEM, V51, P1079, DOI 10.1111/j.1471-4159.1988.tb03071.x; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Kolker S, 2002, EUR J NEUROSCI, V16, P21, DOI 10.1046/j.1460-9568.2002.02055.x; Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lalisang RI, 1997, J CLIN ONCOL, V15, P1367, DOI 10.1200/JCO.1997.15.4.1367; LINDAHL G, 1967, ARCH BIOCHEM BIOPHYS, V119, P347, DOI 10.1016/0003-9861(67)90463-8; Loenarz C, 2008, NAT CHEM BIOL, V4, P152, DOI 10.1038/nchembio0308-152; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Murugan AK, 2010, BIOCHEM BIOPH RES CO, V393, P555, DOI 10.1016/j.bbrc.2010.02.095; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Pardanani A, 2010, LEUKEMIA, V24, P1370, DOI 10.1038/leu.2010.98; Pardanani A, 2010, LEUKEMIA, V24, P1146, DOI 10.1038/leu.2010.77; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Rzem R, 2007, J INHERIT METAB DIS, V30, P681, DOI 10.1007/s10545-007-0487-0; Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sener RN, 2003, J COMPUT ASSIST TOMO, V27, P38, DOI 10.1097/00004728-200301000-00008; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; THOL F, 2010, HAEMATOLOGICA, DOI DOI 10.3324/HAEMAT0L.2010.025494; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Voelzke WR, 2008, CURR TREAT OPTION ON, V9, P23, DOI 10.1007/s11864-008-0053-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yoshihara T, 2001, J HISTOCHEM CYTOCHEM, V49, P1123, DOI 10.1177/002215540104900906; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	62	219	226	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6409	6417		10.1038/onc.2010.444	http://dx.doi.org/10.1038/onc.2010.444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20972461				2022-12-28	WOS:000285138900001
J	Cherkasova, E; Malinzak, E; Rao, S; Takahashi, Y; Senchenko, VN; Kudryavtseva, AV; Nickerson, ML; Merino, M; Hong, JA; Schrump, DS; Srinivasan, R; Linehan, WM; Tian, X; Lerman, MI; Childs, RW				Cherkasova, E.; Malinzak, E.; Rao, S.; Takahashi, Y.; Senchenko, V. N.; Kudryavtseva, A. V.; Nickerson, M. L.; Merino, M.; Hong, J. A.; Schrump, D. S.; Srinivasan, R.; Linehan, W. M.; Tian, X.; Lerman, M. I.; Childs, R. W.			Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer	ONCOGENE			English	Article						renal cell carcinoma; endogenous retrovirus; VHL; HIF; DNA methylation	RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTORS; HERV-K18 SUPERANTIGEN; BREAST-CANCER; MESSENGER-RNA; B-CELLS; GENE; METHYLATION; TRANSPLANTATION; PROTEIN	A human endogenous retrovirus type E (HERV-E) was recently found to be selectively expressed in most renal cell carcinomas (RCCs). Importantly, antigens derived from this provirus are immunogenic, stimulating cytotoxic T cells that kill RCC cells in vitro and in vivo. Here, we show HERV-E expression is restricted to the clear cell subtype of RCC (ccRCC) characterized by an inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene with subsequent stabilization of hypoxia-inducible transcription factors (HIFs)-1 alpha and -2 alpha. HERV-E expression in ccRCC linearly correlated with HIF-2 alpha levels and could be silenced in tumor cells by either transfection of normal VHL or small interfering RNA inhibition of HIF-2 alpha. Using chromatin immunoprecipitation, we demonstrated that HIF-2 alpha can serve as transcriptional factor for HERV-E by binding with HIF response element (HRE) localized in the proviral 5' long terminal repeat (LTR). Remarkably, the LTR was found to be hypomethylated only in HERV-E-expressing ccRCC while other tumors and normal tissues possessed a hypermethylated LTR preventing proviral expression. Taken altogether, these findings provide the first evidence that inactivation of a tumor suppressor gene can result in aberrant proviral expression in a human tumor and give insights needed for translational research aimed at boosting human immunity against antigenic components of this HERV-E. Oncogene (2011) 30, 4697-4706; doi:10.1038/onc.2011.179; published online 23 May 2011	[Cherkasova, E.; Malinzak, E.; Rao, S.; Takahashi, Y.; Lerman, M. I.; Childs, R. W.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; [Senchenko, V. N.; Kudryavtseva, A. V.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia; [Nickerson, M. L.] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA; [Merino, M.] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; [Hong, J. A.; Schrump, D. S.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA; [Srinivasan, R.; Linehan, W. M.] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; [Tian, X.] NHLBI, Off Biostat Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Childs, RW (corresponding author), NHLBI, Hematol Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	childsr@mail.nih.gov	Kudryavtseva, Anna V/C-9032-2014; Takahashi, Yoshiyuki/I-1929-2012; Senchenko, Vera N/C-8992-2014	Kudryavtseva, Anna V/0000-0002-3722-8207; Senchenko, Vera N/0000-0002-3119-515X; Cherkasova, Elena/0000-0002-7269-6516	NIH, National Heart, Lung, and Blood Institute, Hematology Branch; ACKC (Action to Cure Kidney Cancer); Dean R O'Neill Memorial Fellowship; NATIONAL CANCER INSTITUTE [ZIDBC011089, ZIABC011028, ZIABC011038, ZIABC011043, ZIABC011405, ZIABC010696, ZIDBC011092] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002345] Funding Source: NIH RePORTER	NIH, National Heart, Lung, and Blood Institute, Hematology Branch; ACKC (Action to Cure Kidney Cancer); Dean R O'Neill Memorial Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the intramural research program of NIH, National Heart, Lung, and Blood Institute, Hematology Branch. We wish to acknowledge ACKC (Action to Cure Kidney Cancer) for their support of the ACKC fellow who conducted this research and the Dean R O'Neill Memorial Fellowship for generous contributions supporting this research. We also thank Bill and Giuliana Rancic for their contributions supporting kidney cancer research. We thank Robert Worrell for his assistance in providing tissue samples.	Bregni M, 2002, BLOOD, V99, P4234, DOI 10.1182/blood.V99.11.4234; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Cohen CJ, 2009, GENE, V448, P105, DOI 10.1016/j.gene.2009.06.020; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686; Gimenez J, 2010, NUCLEIC ACIDS RES, V38, P2229, DOI 10.1093/nar/gkp1214; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hahn S, 2008, AIDS RES HUM RETROV, V24, P717, DOI 10.1089/aid.2007.0286; Hsiao FC, 2006, J IMMUNOL, V177, P2056, DOI 10.4049/jimmunol.177.4.2056; Hsiao FC, 2009, VIROLOGY, V385, P261, DOI 10.1016/j.virol.2008.11.025; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kim CM, 2006, J UROLOGY, V175, P1908, DOI 10.1016/S0022-5347(05)00890-6; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lavie L, 2005, J VIROL, V79, P876, DOI 10.1128/JVI.79.2.876-883.2005; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Rao S, 2008, P 99 ANN M AM ASS CA; Rini BI, 2002, J CLIN ONCOL, V20, P2017, DOI 10.1200/JCO.2002.08.068; Romanish MT, 2010, SEMIN CANCER BIOL, V20, P246, DOI 10.1016/j.semcancer.2010.05.005; Ruprecht K, 2008, CELL MOL LIFE SCI, V65, P3366, DOI 10.1007/s00018-008-8496-1; Sandlund J, 2009, ACTA ONCOL, V48, P909, DOI 10.1080/02841860902824891; Szpakowski S, 2009, GENE, V448, P151, DOI 10.1016/j.gene.2009.08.006; Takahashi Y, 2008, J CLIN INVEST, V118, P1099, DOI 10.1172/JCI34409; Turner KJ, 2002, CANCER RES, V62, P2957; Wang-Johanning F, 2008, CANCER RES, V68, P5869, DOI 10.1158/0008-5472.CAN-07-6838; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Wright TM, 2010, J BIOL CHEM, V285, P12916, DOI 10.1074/jbc.M109.073924	30	42	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	47					4697	4706		10.1038/onc.2011.179	http://dx.doi.org/10.1038/onc.2011.179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602888	Green Accepted			2022-12-28	WOS:000298033700002
J	Lee, YH; Judge, AD; Seo, D; Kitade, M; Gomez-Quiroz, LE; Ishikawa, T; Andersen, JB; Kim, BK; Marquardt, JU; Raggi, C; Avital, I; Conner, EA; MacLachlan, I; Factor, VM; Thorgeirsson, SS				Lee, Y-H; Judge, A. D.; Seo, D.; Kitade, M.; Gomez-Quiroz, L. E.; Ishikawa, T.; Andersen, J. B.; Kim, B-K; Marquardt, J. U.; Raggi, C.; Avital, I.; Conner, E. A.; MacLachlan, I.; Factor, V. M.; Thorgeirsson, S. S.			Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response	ONCOGENE			English	Article						hepatocellular carcinoma; CSN5; targeted siRNA therapeutics; SNALP	BINDING PROTEIN-1 EXPRESSION; CYCLE INHIBITOR P27(KIP1); COP9 SIGNALOSOME; RNA INTERFERENCE; BREAST-CANCER; IN-VIVO; PANCREATIC-CANCER; SYNTHETIC SIRNA; GENE-EXPRESSION; C-MYC	Development of targeted therapy for hepatocellular carcinoma (HCC) remains a major challenge. We have recently identified an elevated expression of the fifth subunit of COP9 signalosome (CSN5) in early HCC as compared with dysplastic stage. In the present study, we explored the possibility of CSN5 being a potential therapeutic target for HCC. Our results show that CSN5 knockdown by small-interfering (si) RNA caused a strong induction of apoptosis and inhibition of cell-cycle progression in HCC cells in vitro. The down-regulation of CSN5 was sufficient to interfere with CSN function as evidenced by the accumulation of neddylated Cullin 1 and changes in the protein levels of CSN-controlled substrates SKP2, p53, p27 and nuclear factor-kappa B, albeit to a different degree depending on the HCC cell line, which could account for the CSN5 knockdown phenotype. The transcriptomic analysis of CSN5 knockdown signature showed that the anti-proliferative effect was driven by a common subset of molecular alterations including down-regulation of cyclin-dependent kinase 6 (CDK6) and integrin beta 1 (ITGB1), which were functionally interconnected with key oncogenic regulators MYC and TGF beta 1 involved in the control of proliferation, apoptotic cell death and HCC progression. Consistent with microarray analysis, western blotting revealed that CSN5 depletion increased phosphorylation of Smad 2/3, key mediators of TGF beta 1 signaling, decreased the protein levels of ITGB1, CDK6 and cyclin D1 and caused reduced expression of anti-apoptotic Bcl-2, while elevating the levels of proapoptotic Bak. A chemically modified variant of CSN5 siRNA was then selected for in vivo application based on the growth inhibitory effect and minimal induction of unwanted immune response. Systemic delivery of the CSN5 3/8 variant by stable-nucleic-acid-lipid particles significantly suppressed the tumor growth in Huh7-luc(+) orthotopic xenograft model. Taken together, these results indicate that CSN5 has a pivotal role in HCC pathogenesis and maybe an attractive molecular target for systemic HCC therapy. Oncogene (2011) 30, 4175-4184; doi:10.1038/onc.2011.126; published online 18 April 2011	[Lee, Y-H; Seo, D.; Kitade, M.; Gomez-Quiroz, L. E.; Ishikawa, T.; Andersen, J. B.; Kim, B-K; Marquardt, J. U.; Raggi, C.; Conner, E. A.; Factor, V. M.; Thorgeirsson, S. S.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Judge, A. D.; MacLachlan, I.] Tekmira Pharmaceut Corp, Burnaby, BC, Canada; [Avital, I.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr Dr MSC,Room 4146A, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov	RAGGI, Chiara/U-3081-2017; Gomez-Quiroz, Luis/L-8415-2013	RAGGI, Chiara/0000-0003-2473-3535; Marquardt, Jens/0000-0002-8314-2682; Andersen, Jesper B/0000-0003-1760-5244; Gomez-Quiroz, Luis Enrique/0000-0002-5704-5985	Center for Cancer Research, NCI; NATIONAL CANCER INSTITUTE [ZIABC011175] Funding Source: NIH RePORTER	Center for Cancer Research, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by the Intramural Research Program of the Center for Cancer Research, NCI.	Adler AS, 2008, CANCER RES, V68, P506, DOI 10.1158/0008-5472.CAN-07-3060; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Arsura M, 2005, CANCER LETT, V229, P157, DOI 10.1016/j.canlet.2005.07.008; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Berasain C, 2003, HEPATOLOGY, V38, P148, DOI 10.1053/jhep.2003.50269; Brasse D, 2010, INT J CANCER, V127, P1347, DOI 10.1002/ijc.25309; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839; Chamovitz DA, 2009, EMBO REP, V10, P352, DOI 10.1038/embor.2009.33; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esteva FJ, 2003, CLIN CANCER RES, V9, P5652; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukumoto A, 2004, ONCOL REP, V11, P277; Fukumoto A, 2006, FEBS LETT, V580, P5836, DOI 10.1016/j.febslet.2006.09.042; Goto A, 2004, PATHOL INT, V54, P675, DOI 10.1111/j.1440-1827.2004.01679.x; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Hokaiwado N, 2008, IDRUGS, V11, P274; Ito Y, 2003, ANTICANCER RES, V23, P4121; Ivan D, 2004, MODERN PATHOL, V17, P811, DOI 10.1038/modpathol.3800123; Jeffs LB, 2005, PHARM RES-DORDR, V22, P362, DOI 10.1007/s11095-004-1873-z; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002; Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Kashiwakura Y, 2008, CANCER RES, V68, P8333, DOI 10.1158/0008-5472.CAN-08-0080; Kato JY, 2009, GENES CELLS, V14, P1209, DOI 10.1111/j.1365-2443.2009.01349.x; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Okabe H, 2001, CANCER RES, V61, P2129; Pai SI, 2006, GENE THER, V13, P464, DOI 10.1038/sj.gt.3302694; Panattoni M, 2008, J EXP MED, V205, P465, DOI 10.1084/jem.20070725; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Rossi JJ, 2006, GENE THER, V13, P583, DOI 10.1038/sj.gt.3302661; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Sui L, 2001, CLIN CANCER RES, V7, P4130; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Wei N, 2008, TRENDS BIOCHEM SCI, V33, P592, DOI 10.1016/j.tibs.2008.09.004; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	53	57	59	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4175	4184		10.1038/onc.2011.126	http://dx.doi.org/10.1038/onc.2011.126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21499307	Green Accepted			2022-12-28	WOS:000295924600004
J	Halder, G; Mills, GB				Halder, G.; Mills, G. B.			Drosophila in cancer research: to boldly go where no one has gone before	ONCOGENE			English	Editorial Material							TRANSGENIC RNAI; GENOME; GENE; SCREEN; GROWTH; MORPHOGENESIS; MELANOGASTER; MOSAICS; NOTCH	Transformation and metastasis are complex processes that depend on integration of effects from multiple mutations. Modeling this complexity requires manipulating multiple genes in particular sub-populations of cells in vivo. This is technically challenging in mammalian model systems and has limited the rate of progress in understanding the effects of the complex aberrations present in cancer cells. In contrast, powerful genetic methods in the fruit fly Drosophila allow efficient generation and analysis of complex genotypes in defined cell populations. These methods are already fruitful in exploring the interactions among cancer mutations, and between cell populations that mimic the tumor micro-environment. In this issue of Oncogene, Willecke et al. (2011) describe the implementation of a novel genetic screen in Drosophila to identify genes required for tumor growth in vivo. This report illustrates the power of using Drosophila to perform systematic genome-wide genetic screens in complex genetic backgrounds and for the resulting data to inform our understanding of transformation and metastasis in human systems. Oncogene (2011) 30, 4063-4066; doi:10.1038/onc.2011.128; published online 18 April 2011	[Halder, G.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Halder, G.] Univ Texas MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Chair Syst Biol, Houston, TX 77030 USA; [Halder, G.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Halder, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ghalder@mdanderson.org	Halder, Georg/F-2966-2015	Halder, Georg/0000-0001-7580-3236				Baker NE, 2007, CURR OPIN GENET DEV, V17, P287, DOI 10.1016/j.gde.2007.05.005; Bier E, 2005, NAT REV GENET, V6, P9, DOI 10.1038/nrg1503; Blair SS, 2003, DEVELOPMENT, V130, P5065, DOI 10.1242/dev.00774; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Fortini ME, 2000, J CELL BIOL, V150, pF23, DOI 10.1083/jcb.150.2.F23; Grewal SS, 2009, INT J BIOCHEM CELL B, V41, P1006, DOI 10.1016/j.biocel.2008.10.010; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Mummery-Widmer JL, 2009, NATURE, V458, P987, DOI 10.1038/nature07936; Neely GG, 2010, CELL, V143, P628, DOI 10.1016/j.cell.2010.09.047; Neely GG, 2010, CELL, V141, P142, DOI 10.1016/j.cell.2010.02.023; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pospisilik JA, 2010, CELL, V140, P148, DOI 10.1016/j.cell.2009.12.027; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schnorrer F, 2010, NATURE, V464, P287, DOI 10.1038/nature08799; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Willecke M, 2011, ONCOGENE, V30, P4067, DOI 10.1038/onc.2011.125; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; XU T, 1993, DEVELOPMENT, V117, P1223	27	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	39					4063	4066		10.1038/onc.2011.128	http://dx.doi.org/10.1038/onc.2011.128			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499298				2022-12-28	WOS:000295357500001
J	Xiang, X; Zhuang, X; Ju, S; Zhang, S; Jiang, H; Mu, J; Zhang, L; Miller, D; Grizzle, W; Zhang, HG				Xiang, X.; Zhuang, X.; Ju, S.; Zhang, S.; Jiang, H.; Mu, J.; Zhang, L.; Miller, D.; Grizzle, W.; Zhang, H-G			miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT	ONCOGENE			English	Article						miR-155; tumor metastasis; epithelial-to-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; E-CADHERIN; GENE-EXPRESSION; BHLH FACTORS; CELL; MICRORNA-155; METASTASIS; GROWTH; PROGRESSION	A micro-RNA, miR-155, is overexpressed in many types of cancer cells, including breast cancer, and its role(s) in tumor metastasis has been studied on a very limited basis. Tumor metastasis is a multi-step process with the last step in the process being formation of macroscopic tumor in organs distant from the primary tumor site. This step is the least studied. Here, we report that stable expression of miR-155 in 4T1 breast tumor cells reduces significantly the aggressiveness of tumor cell dissemination as a result of preventing epithelial-to-mesenchymal transition (EMT) of tumor cells in vivo. Further, miR-155 directly suppresses the expression of the transcription factor TCF4, which is an important regulator of EMT. However, when tumor cells are injected directly into the bloodstream, miR-155 remarkably promotes macroscopic tumor formation in the lung. Analysis of gene expression profiling identified a group of genes that are associated with promoting macroscopic tumor formation in the lung. Importantly, most of these genes are overexpressed in epithelial cells. Our findings provide new insight into how miR-155 modulates the development of tumor metastasis. This study suggests that the location of tumor cells overexpressing miR-155 is a critical factor: in mammary fat pads miR-155 prevents tumor dissemination; whereas in the lung miR-155 apparently maintains the epithelial phenotype of tumor cells that is critical for macroscopic tumor formation. Oncogene (2011) 30, 3440-3453; doi:10.1038/onc.2011.54; published online 4 April 2011	[Xiang, X.; Zhuang, X.; Ju, S.; Jiang, H.; Mu, J.; Zhang, L.; Miller, D.; Zhang, H-G] Univ Louisville, James Graham Brown Canc Ctr, Dept Microbiol & Immunol, Louisville, KY 40202 USA; [Zhang, S.; Grizzle, W.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; [Zhang, H-G] Louisville Vet Adm Med Ctr, Louisville, KY USA	University of Louisville; University of Alabama System; University of Alabama Birmingham	Xiang, X (corresponding author), Univ Louisville, Brown Canc Ctr, 505 Hancock St,CTRB 309, Louisville, KY 40202 USA.	x0xian02@louisville.edu; H0Zhan17@louisvile.edu			National Institutes of Health (NIH) [RO1CA137037, R01AT004294, RO1CA107181, RO1CA116092]; Louisville Veterans Administration Medical Center (VAMC); Susan G Komen Breast Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA107181, R01CA116092, R01CA137037] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT004294] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisville Veterans Administration Medical Center (VAMC); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	We thank Dr David L Turner for providing plasmid UAS-luc-miR-155as, Dr David P Bartel for MDH1-PGK-GFP-miR-223 plasmid and Dr Jeffrey Schlom for the AT-3 breast tumor cell line. This work was supported by grants from the National Institutes of Health (NIH) (RO1CA137037, R01AT004294, RO1CA107181 and RO1CA116092), the Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants (H-G Z) and a grant from the Susan G Komen Breast Cancer Foundation. We thank Dr Jerald Ainsworth for editorial assistance.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Aokage K, 2011, INT J CANCER, V128, P1585, DOI 10.1002/ijc.25500; Bukholm IK, 2000, J PATHOL, V190, P15; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Grizzle WE, 2002, INT J CANCER, V101, P270, DOI 10.1002/ijc.10606; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Johnson MH, 2009, ANNU REV CELL DEV BI, V25, P483, DOI 10.1146/annurev.cellbio.042308.113348; Katoh M, 2005, INT J ONCOL, V27, P1677; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Logullo AF, 2010, ONCOL REP, V23, P313, DOI 10.3892/or_00000638; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Nakaya Y, 2004, DEV CELL, V7, P425, DOI 10.1016/j.devcel.2004.08.003; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; PULASKI BA, 2001, CURRENT PROTOCOLS IM, V4, pCH20; Ryu JK, 2010, PANCREATOLOGY, V10, P66, DOI 10.1159/000231984; Sobrado VR, 2009, J CELL SCI, V122, P1014, DOI 10.1242/jcs.028241; Soltermann A, 2008, CLIN CANCER RES, V14, P7430, DOI 10.1158/1078-0432.CCR-08-0935; Stewart TJ, 2007, J IMMUNOL, V179, P2851, DOI 10.4049/jimmunol.179.5.2851; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thompson EW, 2008, CLIN EXP METASTAS, V25, P591, DOI 10.1007/s10585-008-9189-8; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047	44	79	90	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	31					3440	3453		10.1038/onc.2011.54	http://dx.doi.org/10.1038/onc.2011.54			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21460854	Green Accepted			2022-12-28	WOS:000293508100005
J	Zhang, Y; Wang, C				Zhang, Y.; Wang, C.			Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells	ONCOGENE			English	Article						fusion transcription factor; rhabdomyosarcoma; skeletal muscle; transcription; matricellular protein; CCN3	GROWTH-FACTOR CTGF/CCN2; CCN FAMILY; DNA-BINDING; FUSION PROTEIN; MYOGENIC DIFFERENTIATION; IN-VIVO; PAX3; EXPRESSION; IDENTIFICATION; HOMEODOMAIN	The CCN (Cy61, CTGF and NOV) family of proteins is a group of matricellular biomolecules involved in both physiological and pathological processes. Elevated expression of the CCN3 (also known as NOV, Nephroblastoma overexpressed) gene has been detected in clinical samples of the skeletal muscle cancer rhabdomyosarcoma, with the highest expression found in the alveolar subtype (aRMS). Over 80% of aRMSs are characterized by a chromosomal translocation-derived fusion transcription factor PAX3-FKHR. In this study, we linked elevated CCN3 levels in aRMS cells to PAX3-FKHR expression. We found reduced CCN3 levels in aRMS cells following small interfering RNA knockdown of PAX3-FKHR, and increased CCN3 levels in C2 myoblasts following ectopic expression of PAX3-FKHR. Promoter, electrophoretic mobility shift assay and chromatin immunoprecipitation analyses confirmed that the CCN3 gene was a direct target for PAX3-FKHR transcriptional activation through a paired-domain DNA sequence in the first intron of the CCN3 gene. To determine the function of CCN3, we showed that knockdown and ectopic expression of CCN3 decreased survival and increased differentiation in aRMS cells, respectively. In addition, we found that exogenously supplied CCN3 protein promoted aRMS cell adhesion, migration and Matrigel invasion. Taken together, data from this study have (1) provided a mechanistic basis for the CCN3 overexpression in aRMS cells, and (2) identified CCN3 as an autocrine/paracrine factor that contributes to the aggressive behavior of aRMS cells, perhaps through a positive feedback loop. Thus, CCN3 may be an attractive target for therapeutic intervention in aRMS. Oncogene (2011) 30, 3549-3562; doi:10.1038/onc.2011.69; published online 21 March 2011	[Zhang, Y.; Wang, C.] Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,RM 530CB, Chicago, IL 60612 USA.	chiayeng@uic.edu			NIH [CA074904]; NATIONAL CANCER INSTITUTE [R01CA074907, R29CA074907, R01CA074904] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Lester Lau (University of Illinois at Chicago) for providing antibody against mouse CCN3 protein, and Mr Jian Zhou for his technical assistance in protein and RNA analysis. We thank Dr Peter Tontonoz (Pathology and Laboratory Medicine, UCLA) for assisting in microarray analysis confirming the molecular link between CCN3 and PAX3-FKHR, and Drs Reed Graves and Peter Tontonoz for their valuable suggestions in the preparation of this manuscript. This work is supported by NIH Grant (CA074904) to C.W.	Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Apuzzo S, 2004, J BIOL CHEM, V279, P33601, DOI 10.1074/jbc.M402949200; Armoni M, 2002, J CLIN ENDOCR METAB, V87, P5312, DOI 10.1210/jc.2002-020318; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Ayalon D., 2001, Growth Hormone and IGF Research, V11, P289, DOI 10.1054/ghir.2001.0244; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; Benini S, 2005, ONCOGENE, V24, P4349, DOI 10.1038/sj.onc.1208620; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Bohlig L, 2008, CELL CYCLE, V7, P1254, DOI 10.4161/cc.7.9.5812; Calhabeua F, 2006, EXP CELL RES, V312, P1876, DOI 10.1016/j.yexcr.2006.02.027; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Croci S, 2004, CANCER RES, V64, P1730, DOI 10.1158/0008-5472.CAN-3502-02; Croci S, 2007, PATHOL ONCOL RES, V13, P336, DOI 10.1007/BF02940313; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Diomedi-Camassei F, 2004, J PEDIATR SURG, V39, P1673, DOI 10.1016/j.jpedsurg.2004.07.014; Durbin AD, 2009, J CLIN INVEST, V119, P1558, DOI 10.1172/JCI37958; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Katsube K, 2009, DEV GROWTH DIFFER, V51, P55, DOI 10.1111/j.1440-169X.2009.01077.x; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Lafont J, 2005, CELL COMMUN ADHES, V12, P41, DOI 10.1080/15419060500383069; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin CG, 2005, J BIOL CHEM, V280, P8229, DOI 10.1074/jbc.M404903200; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Mercado GE, 2008, GENE CHROMOSOME CANC, V47, P510, DOI 10.1002/gcc.20554; Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1058>3.0.CO;2-2; Oberlin O, 2008, J CLIN ONCOL, V26, P2384, DOI 10.1200/JCO.2007.14.7207; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Perbal B, 2001, B CANCER, V88, P645; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perbal B, 2006, ADV EXP MED BIOL, V587, P23; Perbal B, 2009, J CELL COMMUN SIGNAL, V3, P153, DOI 10.1007/s12079-009-0051-9; Perbal B, 2008, J CELL COMMUN SIGNAL, V2, P57, DOI 10.1007/s12079-008-0033-3; Perbal B, 2008, J CELL COMMUN SIGNAL, V2, P3, DOI 10.1007/s12079-008-0028-0; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Planque N, 2006, J CELL BIOCHEM, V99, P105, DOI 10.1002/jcb.20887; Ren YX, 2008, CANCER RES, V68, P6587, DOI 10.1158/0008-5472.CAN-08-0859; Rikhof B, 2009, J PATHOL, V217, P469, DOI 10.1002/path.2499; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Taniguchi E, 2008, ONCOGENE, V27, P6550, DOI 10.1038/onc.2008.255; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vallacchi V, 2008, CANCER RES, V68, P715, DOI 10.1158/0008-5472.CAN-07-2103; Wang W, 2005, INT J ONCOL, V27, P1087; Wang-Wuu S, 1988, Cancer Res, V48, P983; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yeger H, 2007, J CELL COMMUN SIGNAL, V1, P159, DOI 10.1007/s12079-008-0022-6; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958; Zhang YB, 2009, INT J CLIN EXP PATHO, V2, P370	68	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3549	3562		10.1038/onc.2011.69	http://dx.doi.org/10.1038/onc.2011.69			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423212	Green Accepted, hybrid			2022-12-28	WOS:000293782300007
J	Albasri, A; Al-Ghamdi, S; Fadhil, W; Aleskandarany, M; Liao, YC; Jackson, D; Lobo, DN; Lo, SH; Kumari, R; Durrant, L; Watson, S; Kindle, KB; Ilyas, M				Albasri, A.; Al-Ghamdi, S.; Fadhil, W.; Aleskandarany, M.; Liao, Y-C; Jackson, D.; Lobo, D. N.; Lo, S. H.; Kumari, R.; Durrant, L.; Watson, S.; Kindle, K. B.; Ilyas, M.			Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer	ONCOGENE			English	Article						Cten; integrin-linked kinase; metastasis	MESSENGER-RNA EXPRESSION; E-CADHERIN EXPRESSION; UP-REGULATION; TUMOR PROGRESSION; TENSIN; OVEREXPRESSION; MIGRATION; MARKER	CTEN/TNS4 is an oncogene in colorectal cancer (CRC), which can induce cell motility although its mechanistic basis of activity and the clinical implications of Cten expression are unknown. As Cten is in complex with integrins at focal adhesions, we hypothesised that it may interact with integrin-linked kinase (ILK). Through forced expression and knockdown of Cten in HCT116 and SW620 (respectively, showing low and high Cten expression), we showed that Cten could regulate ILK. However, inhibition of ILK after forced expression of Cten abrogated the motility-inducing effects of Cten, thereby demonstrating that the Cten-ILK interaction was functionally relevant. Combined knockdown of Cten and ILK had no additive effects on cell motility compared with knockdown of each individually. In order to investigate the clinical implications of Cten expression, a series of 462 CRCs were evaluated by immunohistochemistry. High expression of Cten was associated with advanced Dukes' stage (P < 0.001), poor prognosis (P < 0.001) and distant metastasis (P = 0.008). The role of Cten in metastasis was tested by (a) intrasplenic injection of CRC cells stably transfected with a Cten expression vector into nude mice and (b) testing a series of primary human CRCs and their metastases by immunohistochemistry. Compared with controls, mice injected with cells expressing Cten developed larger tumours in the spleen (P < 0.05) and liver (P < 0.05). In the human cases, compared with primary tumours, the metastatic deposits had a significantly higher frequency of nuclear localisation of Cten (P = 0.002). We conclude that Cten expression is of prognostic significance in CRC, and we delineate a Cten-ILK pathway controlling cell motility and possibly promoting metastasis. Oncogene (2011) 30, 2997-3002; doi:10.1038/onc.2011.26; published online 21 February 2011	[Ilyas, M.] Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Div Pathol, Nottingham NG7 2UH, Notts, England; [Liao, Y-C; Lo, S. H.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Lobo, D. N.] Univ Nottingham, Div Gastrointestinal Surg, Nottingham NG7 2UH, Notts, England; [Lobo, D. N.; Watson, S.; Ilyas, M.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, NIHR Biomed Res Unit, Nottingham Digest Dis Ctr, Nottingham, England; [Kumari, R.; Watson, S.] Univ Nottingham, Div Preclin Oncol, Nottingham NG7 2UH, Notts, England; [Durrant, L.] Univ Nottingham, Div Acad Oncol, Nottingham NG7 2UH, Notts, England	University of Nottingham; University of California System; University of California Davis; University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; University of Nottingham	Ilyas, M (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Div Pathol, Nottingham NG7 2UH, Notts, England.	mohammad.ilyas@nottingham.ac.uk	Liao, Yi-Chun/H-2383-2014; Aleskandarany, Mohammed/D-9162-2018; Aleskandarany, Mohammed/X-8585-2019; Lobo, Dileep/AAC-6207-2020; Hsiao, Wei-Hung/B-9931-2013; AlGhamdi, Saleh/S-2515-2019	Aleskandarany, Mohammed/0000-0001-5538-5946; Lobo, Dileep/0000-0003-1187-5796; Albasri, Abdulkader/0000-0002-1824-4025; Liao, Yi-Chun/0000-0002-0399-0201; Fadhil, Wakkas/0000-0002-0529-0460; Garrie, Karin/0000-0003-2204-9975; Lo, Su Hao/0000-0002-2675-9387	University of Nottingham and Cancer Research Nottingham; National Association for Colitis and Crohn's Disease (NACC)	University of Nottingham and Cancer Research Nottingham; National Association for Colitis and Crohn's Disease (NACC)	Funding: The study was funded by the University of Nottingham and Cancer Research Nottingham. KBK is funded by the National Association for Colitis and Crohn's Disease (NACC).	Ahmed MAH, 2009, J CLIN PATHOL, V62, P1117, DOI 10.1136/jcp.2009.069310; Albasri A, 2011, BREAST CANCER RES TR, V126, P47, DOI 10.1007/s10549-010-0890-3; Albasri A, 2009, J PATHOL, V218, P57, DOI 10.1002/path.2508; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Katz M, 2007, NAT CELL BIOL, V9, P961, DOI 10.1038/ncb1622; Liao YC, 2009, CANCER RES, V69, P4563, DOI 10.1158/0008-5472.CAN-09-0117; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Lo SH, 2002, CANCER RES, V62, P4217; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Sakashita K, 2008, ANN SURG ONCOL, V15, P2606, DOI 10.1245/s10434-008-9989-8; Sasaki H, 2003, TUMOR BIOL, V24, P271, DOI 10.1159/000076141; Sasaki H, 2003, LUNG CANCER, V40, P151, DOI 10.1016/S0169-5002(03)00037-0; Somasiri A, 2001, J CELL SCI, V114, P1125; Ullenhag GJ, 2007, CLIN CANCER RES, V13, P5070, DOI 10.1158/1078-0432.CCR-06-2547	18	45	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2997	3002		10.1038/onc.2011.26	http://dx.doi.org/10.1038/onc.2011.26			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21339732	Bronze			2022-12-28	WOS:000292245100010
J	Strub, T; Giuliano, S; Ye, T; Bonet, C; Keime, C; Kobi, D; Le Gras, S; Cormont, M; Ballotti, R; Bertolotto, C; Davidson, I				Strub, T.; Giuliano, S.; Ye, T.; Bonet, C.; Keime, C.; Kobi, D.; Le Gras, S.; Cormont, M.; Ballotti, R.; Bertolotto, C.; Davidson, I.			Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma	ONCOGENE			English	Article						senescence; DNA repair; cancer; metastasis	CELL-DIVISION; MALIGNANT-MELANOMA; LINEAGE SURVIVAL; GENE-EXPRESSION; DAMAGE RESPONSE; GROWTH-FACTOR; NEURAL CREST; HUMAN CANCER; MITF; APOPTOSIS	Malignant melanoma is an aggressive cancer known for its notorious resistance to most current therapies. The basic helix-loop-helix microphthalmia transcription factor (MITF) is the master regulator determining the identity and properties of the melanocyte lineage, and is regarded as a lineage-specific 'oncogene' that has a critical role in the pathogenesis of melanoma. MITF promotes melanoma cell proliferation, whereas sustained supression of MITF expression leads to senescence. By combining chromatin immunoprecipitation coupled to high throughput sequencing (ChIP-seq) and RNA sequencing analyses, we show that MITF directly regulates a set of genes required for DNA replication, repair and mitosis. Our results reveal how loss of MITF regulates mitotic fidelity, and through defective replication and repair induces DNA damage, ultimately ending in cellular senescence. These findings reveal a lineage-specific control of DNA replication and mitosis by MITF, providing new avenues for therapeutic intervention in melanoma. The identification of MITF-binding sites and gene-regulatory networks establish a framework for understanding oncogenic basic helix-loop-helix factors such as N-myc or TFE3 in other cancers. Oncogene (2011) 30, 2319-2332; doi: 10.1038/onc.2010.612; published online 24 January 2011	[Giuliano, S.; Bonet, C.; Ballotti, R.; Bertolotto, C.] CHU Nice, INSERM, U895, Team 1, Nice, France; [Giuliano, S.; Bonet, C.; Ballotti, R.; Bertolotto, C.] CHU Nice, Dept Dermatol, Nice, France; [Strub, T.; Ye, T.; Keime, C.; Kobi, D.; Le Gras, S.; Davidson, I.] Univ Strasbourg, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; [Cormont, M.] Fac Med Nice, INSERM, U895, Team 7, F-06034 Nice, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bertolotto, C (corresponding author), CHU Nice, INSERM, U895, Team 1, Nice, France.	corine.bertolotto@unice.fr; irwin@igbmc.fr	Strub, Thomas/AAH-3573-2019; BALLOTTI, Robert/F-8825-2013; Bertolotto-Ballotti, Corine/O-2155-2016; Giuliano, Sandy/U-2498-2019; Bertolotto, Corine/AAF-6634-2021; Ye, Tao/D-8026-2011	Bertolotto, Corine/0000-0001-6971-7753; BALLOTTI, Robert/0000-0002-7322-4908; Strub, Thomas/0000-0001-6252-0181; CORMONT, Mireille/0000-0001-6918-2410; Davidson, Irwin/0000-0001-5533-1171; KEIME, Celine/0000-0001-7604-3814; Le Gras, Stephanie/0000-0001-6293-6507	CNRS; INSERM; Association pour la Recherche contre le Cancer [4985, 7823]; Ligue Nationale contre le Cancer; Institut national du Cancer [R08009AP]; ANR; Conseil Regional de la Region Provence-Alpes-Cote d'Azur; Nice University Hospital; Conseil General des Alpes Maritimes	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut national du Cancer(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); Conseil Regional de la Region Provence-Alpes-Cote d'Azur(Region Provence-Alpes-Cote d'Azur); Nice University Hospital; Conseil General des Alpes Maritimes(Region Provence-Alpes-Cote d'Azur)	We thank B Jost for Illumina sequencing, A Hamiche and E Soutoglou for antibodies. This work was supported by grants from the CNRS, the INSERM, the Association pour la Recherche contre le Cancer grant 4985 and 7823, the Ligue Nationale contre le Cancer, the Institut national du Cancer grant R08009AP and the ANR Regulome project grant. We thank the Conseil Regional de la Region Provence-Alpes-Cote d'Azur, the Nice University Hospital and the Conseil General des Alpes Maritimes for funding of the C3M MiCa Cell Imaging Facility. ID and CB are 'equipes labellisees' of the Ligue Nationale contre le Cancer.	Abraham J, 2003, EMBO J, V22, P6137, DOI 10.1093/emboj/cdg580; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Bentley DJ, 2002, J CELL SCI, V115, P1551; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Beuret L, 2007, J BIOL CHEM, V282, P14140, DOI 10.1074/jbc.M611563200; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carroll CW, 2009, NAT CELL BIOL, V11, P896, DOI 10.1038/ncb1899; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Chiaverini C, 2008, J BIOL CHEM, V283, P12635, DOI 10.1074/jbc.M800130200; Delacroix L, 2010, MOL CELL BIOL, V30, P231, DOI 10.1128/MCB.00756-09; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Dynek JN, 2008, CANCER RES, V68, P3124, DOI 10.1158/0008-5472.CAN-07-6622; Fagiani E, 2007, CANCER RES, V67, P3064, DOI 10.1158/0008-5472.CAN-06-2301; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Garraway LA, 2005, COLD SH Q B, V70, P25, DOI 10.1101/sqb.2005.70.016; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goding C R, 2000, Forum (Genova), V10, P176; Goding CR, 2000, GENE DEV, V14, P1712; Gomez-Baldo L, 2010, CELL CYCLE, V9, P1143, DOI 10.4161/cc.9.6.11018; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hou L, 2008, CELL RES, V18, P1163, DOI 10.1038/cr.2008.303; Kim DS, 2004, INT J BIOCHEM CELL B, V36, P1482, DOI 10.1016/j.biocel.2003.10.023; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Koyanagi K, 2006, CLIN CANCER RES, V12, P1137, DOI 10.1158/1078-0432.CCR-05-1847; Krebs A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-533; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Levy C, 2010, CELL, V141, P994, DOI 10.1016/j.cell.2010.05.004; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Moore R, 2004, ONCOGENE, V23, P6726, DOI 10.1038/sj.onc.1207675; Neumann B, 2010, NATURE, V464, P721, DOI 10.1038/nature08869; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Ouhtit A, 2009, BBA-REV CANCER, V1795, P130, DOI 10.1016/j.bbcan.2009.01.002; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Rothhammer T, 2005, CANCER RES, V65, P448; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Schmit TL, 2009, J INVEST DERMATOL, V129, P2843, DOI 10.1038/jid.2009.172; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Steingrimsson E, 2008, PIGM CELL MELANOMA R, V21, P412, DOI 10.1111/j.1755-148X.2008.00473.x; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wu GK, 2008, MOL CELL BIOL, V28, P3652, DOI 10.1128/MCB.01923-07; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	52	166	172	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2319	2332		10.1038/onc.2010.612	http://dx.doi.org/10.1038/onc.2010.612			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258399				2022-12-28	WOS:000290789200004
J	Xiang, T; Jia, Y; Sherris, D; Li, S; Wang, H; Lu, D; Yang, Q				Xiang, T.; Jia, Y.; Sherris, D.; Li, S.; Wang, H.; Lu, D.; Yang, Q.			Targeting the Akt/mTOR pathway in Brca1-deficient cancers	ONCOGENE			English	Article						Brca1; PKB/Akt; mTOR	AKT ACTIVATION; PALOMID 529; CELL-CYCLE; MTOR; BRCA1; BREAST; EXPRESSION; GENE; INHIBITOR; GROWTH	The breast cancer susceptibility gene 1 (Brca1) has a key role in both hereditary and sporadic mammary tumorigenesis. However, the reasons why Brca1-deficiency leads to the development of cancer are not clearly understood. Activation of Akt kinase is one of the most common molecular alterations associated with human malignancy. Increased Akt kinase activity has been reported in most breast cancers. We previously found that downregulation of Brca1 expression or mutations of the Brca1 gene activate the Akt oncogenic pathway. To further investigate the role of Brca1/Akt in tumorigenesis, we analyzed Brca1/Akt expression in human breast cancer samples and found that reduced expression of Brca1 was highly correlated with increased phosphorylation of Akt. Consistent with the clinical data, knockdown of Akt1 by short-hairpin RNA inhibited cellular proliferation of Brca1 mutant cells. Importantly, depletion of Akt1 significantly reduced tumor formation induced by Brca1-deficiency in mice. The third generation inhibitor of mammalian target of rapamycin (mTOR), Palomid 529, significantly suppressed Brca1-deficient tumor growth in mice through inhibition of both Akt and mTOR signaling. Our results indicate that activation of Akt is involved in Brca1-deficiency mediated tumorigenesis and that the mTOR pathway can be used as a novel target for treatment of Brca1-deficient cancers. Oncogene (2011) 30, 2443-2450; doi:10.1038/onc.2010.603; published online 17 January 2011	[Yang, Q.] Washington Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, St Louis, MO 63108 USA; [Sherris, D.] Paloma Pharmaceut, Jamaica Plain, MA USA; [Li, S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63108 USA; [Li, S.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63108 USA; [Wang, H.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, St Louis, MO USA; [Lu, D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Cedars Sinai Medical Center; Washington University (WUSTL)	Yang, Q (corresponding author), Washington Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, 4511 Forest Pk, St Louis, MO 63108 USA.	qyang@wustl.edu			Susan G Komen Foundation; Siteman Cancer Center; NIH [CA129440]; NATIONAL CANCER INSTITUTE [R01CA129440] Funding Source: NIH RePORTER	Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Siteman Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Junjie Chen for providing the wild type and mutant GST-Brca1-BRCT constructs and Bing-Hua Jiang for providing Akt1-473D construct and Thomas Ludwig for providing Brca1<SUP>+/+</SUP> and Brca1<SUP>tr/tr</SUP> MEFs. We thank Buck Rogers, Andrei Laszlo and Xiaowei Wang for proof-reading. This work is supported in part by grants from the Susan G Komen Foundation (QY), Siteman Cancer Center Award (QY) and NIH CA129440 (QY).	Aaltonen K, 2009, BREAST CANCER RES TR, V113, P75, DOI 10.1007/s10549-008-9908-5; Aleskandarany M, 2010, BREAST CANC RES TREA; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Diaz R, 2009, BRIT J CANCER, V100, P932, DOI 10.1038/sj.bjc.6604938; Dinesh KPB, 2006, MOL CELL BIOCHEM, V287, P177, DOI 10.1007/s11010-005-9097-z; Ding SL, 2004, J BIOMED SCI, V11, P911, DOI 10.1159/000081838; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2006, TRENDS CELL BIOL, V16, P206, DOI 10.1016/j.tcb.2006.02.002; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; O'Reilly T, 2010, TRANSL ONCOL, V3, P65, DOI 10.1593/tlo.09277; Pallares J, 2005, INT J GYNECOL PATHOL, V24, P247, DOI 10.1097/01.pgp.0000163849.37129.d4; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; van der Groep P, 2009, J CLIN PATHOL, V62, P926, DOI 10.1136/jcp.2009.065524; Wickenden JA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2558; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058; Yang Q, 2000, BRIT J CANCER, V82, P763, DOI 10.1054/bjoc.1999.0995	40	39	41	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2443	2450		10.1038/onc.2010.603	http://dx.doi.org/10.1038/onc.2010.603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21242970	Green Accepted			2022-12-28	WOS:000291008000006
J	Mazot, P; Cazes, A; Boutterin, MC; Figueiredo, A; Raynal, V; Combaret, V; Hallberg, B; Palmer, RH; Delattre, O; Janoueix-Lerosey, I; Vigny, M				Mazot, P.; Cazes, A.; Boutterin, M. C.; Figueiredo, A.; Raynal, V.; Combaret, V.; Hallberg, B.; Palmer, R. H.; Delattre, O.; Janoueix-Lerosey, I.; Vigny, M.			The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking	ONCOGENE			English	Article						ALK; neuroblastoma; phosphorylation; ER retention; RTK	ANAPLASTIC LYMPHOMA KINASE; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; NPM-ALK; NEUROBLASTOMA; GENE; IDENTIFICATION; GROWTH; PLEIOTROPHIN	Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK), which is transiently expressed during development of the central and peripheral nervous system. ALK has been recently identified as a major neuroblastoma predisposition gene and activating mutations have also been identified in a subset of sporadic neuroblastoma tumors. Two hot spots of ALK mutations have been observed at positions F1174 and R1275. Here, we studied stably transfected cell lines expressing wild-type or F1174L- or R1275Q-mutated ALK in parallel with a neuroblastoma cell line (CLB-GE) in which the allele mutated at position F1174 is amplified. We observed that the mutated ALK variants were essentially intracellular and were largely retained in the reticulum/Golgi compartments. This localization was corroborated by a defect of N-linked glycosylation. Although the mutated receptors exhibited a constitutive activation, the minor pool of receptor addressed to the plasma membrane was much more tyrosine phosphorylated than the intracellular pool. The use of antagonist monoclonal antibodies suggested that the constitutive activity of the mutated receptors did not require the dimerization of the receptor, whereas adequate dimerization triggered by agonist monoclonal antibodies increased this activity. Finally, kinase inactivation of the mutated receptors restored maturation and cell-surface localization. Our results show that constitutive activation of ALK results in its impaired maturation and intracellular retention. Furthermore, they provide a rationale for the potential use of kinase inhibitors and antibodies in ALK-dependent tumors. Oncogene (2011) 30, 2017-2025; doi:10.1038/onc.2010.595; published online 17 January 2011	[Vigny, M.] Univ Paris 06, UPMC, INSERM, UMR S839, F-75005 Paris, France; [Mazot, P.; Boutterin, M. C.; Figueiredo, A.; Vigny, M.] INSERM, UMRS 839, Paris, France; [Mazot, P.; Boutterin, M. C.; Figueiredo, A.; Vigny, M.] IFM, Paris, France; [Cazes, A.; Raynal, V.; Delattre, O.; Janoueix-Lerosey, I.] Ctr Rech, Inst Curie, Paris, France; [Combaret, V.] Ctr Leon Berard, FNCLCC, Lab Rech Translat, F-69373 Lyon, France; [Hallberg, B.; Palmer, R. H.] Umea Univ, Dept Mol Biol, Umea, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard; Umea University	Vigny, M (corresponding author), Univ Paris 06, UPMC, INSERM, UMR S839, 17 Rue Fer Moulin, F-75005 Paris, France.	marc.vigny@inserm.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; Cazes, Alex/K-9899-2019	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; delattre, olivier/0000-0002-8730-2276; Figueiredo, Ana Leonor/0000-0003-2329-2854	Inserm [UMR-S839]; Universite Pierre et Marie Curie; Institut National du Cancer,; Nationale contre le Cancer (Equipe labellisee); Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante	Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Pierre et Marie Curie; Institut National du Cancer,(Institut National du Cancer (INCA) France); Nationale contre le Cancer (Equipe labellisee); Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante	Work at the Institut du Fer a Moulin UMR-S839 was supported by Inserm and Universite Pierre et Marie Curie. The U830 Inserm laboratory is supported by grants from the Institut National du Cancer, the Ligue Nationale contre le Cancer (Equipe labellisee), the Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante. We are grateful to Dr JA Girault for helpful discussions.	Buchwald M, 2010, LEUKEMIA, V24, P1412, DOI 10.1038/leu.2010.114; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Honorat JF, 2006, BLOOD, V107, P4130, DOI 10.1182/blood-2005-06-2421; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2010, ONCOGENE, V29, P1566, DOI 10.1038/onc.2009.518; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lievens PMJ, 2004, J BIOL CHEM, V279, P43254, DOI 10.1074/jbc.M405247200; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; Mathivet T, 2007, CELL SIGNAL, V19, P2434, DOI 10.1016/j.cellsig.2007.07.011; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2009, CLIN CANCER RES, V15, P5609, DOI 10.1158/1078-0432.CCR-08-2762; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Perez-Pinera P, 2007, J BIOL CHEM, V282, P28683, DOI 10.1074/jbc.M704505200; Reiner DJ, 2008, CURR BIOL, V18, P1101, DOI 10.1016/j.cub.2008.06.060; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Vernersson E, 2006, GENE EXPR PATTERNS, V6, P448, DOI 10.1016/j.modgep.2005.11.006; Webb TR, 2009, EXPERT REV ANTICANC, V9, P331, DOI 10.1586/14737140.9.3.331; Yang HL, 2007, J EXP ZOOL PART B, V308B, P269, DOI 10.1002/jez.b.21146	32	39	43	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	17					2017	2025		10.1038/onc.2010.595	http://dx.doi.org/10.1038/onc.2010.595			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242967				2022-12-28	WOS:000289977400005
J	Mitra, AK; Sawada, K; Tiwari, P; Mui, K; Gwin, K; Lengyel, E				Mitra, A. K.; Sawada, K.; Tiwari, P.; Mui, K.; Gwin, K.; Lengyel, E.			Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis	ONCOGENE			English	Article						ovarian cancer; alpha(5)beta(1)-integrin; c-Met; Src; FAK; fibronectin	HEPATOCYTE GROWTH-FACTOR; FOCAL ADHESION KINASE; CONSTITUTIVE ACTIVATION; EMBRYOID BODIES; MMP-2 FUNCTIONS; CELL INVASION; INTEGRIN; DISSEMINATION; EXPRESSION; RECEPTOR	The role of the fibronectin receptor, alpha(5)beta(1)-integrin, as an adhesion receptor and in angiogenesis is well established. However, its role in cancer cell invasion and metastasis is less clear. We describe a novel mechanism by which fibronectin regulates ovarian cancer cell signaling and promotes metastasis. Fibronectin binding to alpha(5)beta(1)-integrin led to a direct association of alpha(5)-integrin with the receptor tyrosine kinase, c-Met, activating it in a hepatocyte growth factor/scatter factor (HGF/SF) independent manner. Subsequently, c-Met associated with Src, and activated Src and focal adhesion kinase (FAK). Inhibition of alpha(5)beta(1)-integrin decreased the phosphorylation of c-Met, FAK and Src, both in vitro and in vivo. Independent activation of c-Met by its native ligand, HGF/SF, or overexpression of a constitutively active FAK in HeyA8 cells could overcome the effect of alpha(5)beta(1)-integrin inhibition on tumor cell invasion, indicating that alpha(5)beta(1)-integrin is upstream of c-Met, Src and FAK. Inhibition of alpha(5)beta(1)-integrin on cancer cells in two xenograft models of ovarian cancer metastasis resulted in a significant decrease of tumor burden, which was independent of the effect of alpha(5)beta(1)-integrin on angiogenesis. These data suggest that fibronectin promotes ovarian cancer invasion and metastasis through an alpha(5)beta(1)-integrin/c-Met/FAK/Src-dependent signaling pathway, transducing signals through c-Met in an HGF/SF-independent manner. Oncogene (2011) 30, 1566-1576; doi: 10.1038/onc.2010.532; published online 29 November 2010	[Mitra, A. K.; Sawada, K.; Tiwari, P.; Mui, K.; Lengyel, E.] Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, Chicago, IL 60637 USA; [Gwin, K.] Univ Chicago, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, 5841 S Maryland Ave,MC 2050, Chicago, IL 60637 USA.	elengyel@uchicago.edu	Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507; Tiwari, Payal/0000-0002-7822-6857	Facet Biotech Corp.; Burroughs Wellcome Fund; Ovarian Cancer Research Fund; NCI [RO1 CA111882]; NATIONAL CANCER INSTITUTE [R01CA111882] Funding Source: NIH RePORTER	Facet Biotech Corp.; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Ovarian Cancer Research Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Facet Biotech Corp. provided funding and antibodies for the animal experiments (Figure 1).; We thank Dr Alan Horwitz, Department of Cell Biology, University of Virginia School of Medicine for providing us with the FAK constructs. We thank Gail Isenberg for critically reviewing the manuscript. We appreciate the inputs of Dr Vinay Bhaskar and Dr Vanitha Ramakrishnan during the initial part of the project. Funding: Ernst Lengyel holds a Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund and is supported by grants from the Ovarian Cancer Research Fund (Liz Tilberis Scholars Program), and the NCI (RO1 CA111882).	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Bhaskar V, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-61; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Chan PC, 2006, J BIOMED SCI, V13, P215, DOI 10.1007/s11373-005-9061-7; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; Francis SE, 2002, ARTERIOSCL THROM VAS, V22, P927, DOI 10.1161/01.ATV.0000016045.93313.F2; Franke FE, 2003, ANTICANCER RES, V23, P4261; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; HAFTER R, 1984, THROMB RES, V35, P53, DOI 10.1016/0049-3848(84)90312-8; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jin EJ, 2007, DEV BIOL, V308, P474, DOI 10.1016/j.ydbio.2007.06.003; Kenny HA, 2009, CELL CYCLE, V8, P683, DOI 10.4161/cc.8.5.7703; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Magnussen A, 2005, CANCER RES, V65, P2712, DOI 10.1158/0008-5472.CAN-04-2691; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Radjabi AR, 2008, J BIOL CHEM, V283, P2822, DOI 10.1074/jbc.M704855200; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Rusciano D, 1996, J BIOL CHEM, V271, P20763, DOI 10.1074/jbc.271.34.20763; Saga Y, 2001, GENE THER, V8, P1450, DOI 10.1038/sj.gt.3301553; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Taverna D, 2001, CANCER RES, V61, P5255; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; WINGERTER P, 2005, AM J PATHOL, V167, P193; Wong AST, 2004, EXP CELL RES, V299, P248, DOI 10.1016/j.yexcr.2004.06.002; YANG JT, 1993, DEVELOPMENT, V119, P1093; Yokoyama Y, 2007, CANCER RES, V67, P10813, DOI 10.1158/0008-5472.CAN-07-0172; Yu D, 1992, CANCER RES, V53, P891; Zillhardt M, 2010, NEOPLASIA, V12, P1, DOI 10.1593/neo.09948	38	189	194	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1566	1576		10.1038/onc.2010.532	http://dx.doi.org/10.1038/onc.2010.532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119598	Green Accepted			2022-12-28	WOS:000288998300007
J	Pong, WW; Gutmann, DH				Pong, W. W.; Gutmann, D. H.			The ecology of brain tumors: lessons learned from neurofibromatosis-1	ONCOGENE			English	Review						glioma; astrocytoma; neurofibromatosis type 1; NF1; stroma; microenvironment	MONOCYTE CHEMOTACTIC ACTIVITY; TRANSFORMING-GROWTH-FACTOR; OPTIC PATHWAY GLIOMAS; NF1(+/-) MAST-CELLS; MOUSE MODEL; IN-VIVO; K-RAS; MAMMALIAN TARGET; EPITHELIAL-CELLS; NATURAL-HISTORY	Traditionally, cancer studies have primarily focused on mutations that activate growth or survival pathways in susceptible pre-neoplastic/neoplastic cells. However, recent research has revealed a critical role for nonneoplastic cells within the tumor microenvironment in the process of cancer formation and progression. In addition, the existence of regional and developmental variations in susceptible cell types and supportive microenvironments support a model of tumorigenesis in which the dynamic symbiotic relationship between neoplastic and non-neoplastic cell types dictate where and when cancers form and grow. In this review, we highlight advances in neurofibromatosis type 1 (NF1) genetically engineered mouse brain tumor (glioma) modeling to reveal how cellular and molecular heterogeneity in both the pre-neoplastic/neoplastic and non-neoplastic cellular compartments contribute to gliomagenesis and glioma growth. Oncogene (2011) 30, 1135-1146; doi:10.1038/onc.2010.519; published online 15 November 2010	[Pong, W. W.; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu	Pong, Winnie/J-4471-2012	Gutmann, David/0000-0002-3127-5045; Pong, Winnie/0000-0001-8254-3305	National Cancer Institute [U01-CA141549]; NATIONAL CANCER INSTITUTE [U01CA141549] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Gutmann Laboratory for their suggestions and comments during the preparation of this manuscript. We also thank Ms Samantha Higer for generating the illustrations. This work was supported in part by a grant from the National Cancer Institute (U01-CA141549) to DHG.	Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Badie B, 1999, NEUROSURGERY, V44, P1077, DOI 10.1097/00006123-199905000-00075; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2005, ANN NEUROL, V57, P119, DOI 10.1002/ana.20337; Bajenaru ML, 2003, CANCER RES, V63, P8573; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Banerjee S, 2010, CANCER RES, V70, P1356, DOI 10.1158/0008-5472.CAN-09-2178; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; Brown JA, 2010, J NEUROSCI, V30, P5579, DOI 10.1523/JNEUROSCI.3994-09.2010; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Charles NA, 2010, CELL STEM CELL, V6, P6, DOI 10.1016/j.stem.2009.12.005; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DABBOUS MK, 1986, BRIT J CANCER, V54, P459, DOI 10.1038/bjc.1986.198; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Daginakatte GC, 2008, CANCER RES, V68, P10358, DOI 10.1158/0008-5472.CAN-08-2506; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; Dasgupta B, 2005, CANCER RES, V65, P236; Dasgupta B, 2003, J NEUROSCI, V23, P8949; De Haas AH, 2008, GLIA, V56, P888, DOI 10.1002/glia.20663; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423; Donovan S, 2002, CANCER CELL, V2, P507, DOI 10.1016/S1535-6108(02)00214-3; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Elkabes S, 1996, J NEUROSCI, V16, P2508; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6; GABBIANI G, 1978, J CELL BIOL, V76, P561, DOI 10.1083/jcb.76.3.561; GABBIANI G, 1972, J EXP MED, V135, P719, DOI 10.1084/jem.135.4.719; Giordano MJ, 1996, J NEUROSCI RES, V43, P246; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; GRAVES DT, 1989, SCIENCE, V245, P1490, DOI 10.1126/science.2781291; Green SR, 2006, J IMMUNOL, V176, P7412, DOI 10.4049/jimmunol.176.12.7412; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HART IR, 1980, CANCER RES, V40, P2281; Hawes JJ, 2007, NEUROGENETICS, V8, P121, DOI 10.1007/s10048-006-0078-5; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; Hegedus B, 2009, J NEUROPATH EXP NEUR, V68, P542, DOI 10.1097/NEN.0b013e3181a3240b; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Huettner C, 1997, ANTICANCER RES, V17, P3217; HUETTNER C, 1995, AM J PATHOL, V146, P317; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Kerber M, 2008, CANCER RES, V68, P7342, DOI 10.1158/0008-5472.CAN-07-6241; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Khalaf WF, 2007, J IMMUNOL, V178, P2527, DOI 10.4049/jimmunol.178.4.2527; Klein RS, 2004, TRENDS IMMUNOL, V25, P306, DOI 10.1016/j.it.2004.04.002; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kunkel P, 2001, NEURO-ONCOLOGY, V3, P82, DOI 10.1093/neuonc/3.2.82; Lee DY, 2010, GENE DEV, V24, P2317, DOI 10.1101/gad.1957110; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Leung SY, 1997, ACTA NEUROPATHOL, V93, P518, DOI 10.1007/s004010050647; Li F, 2006, HUM MOL GENET, V15, P1921, DOI 10.1093/hmg/ddl114; Li HM, 2009, PEDIATR RES, V65, P613, DOI 10.1203/PDR.0b013e3181a1c607; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; LISTERNICK R, 1994, J PEDIATR-US, V125, P63, DOI 10.1016/S0022-3476(94)70122-9; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1995, J PEDIATR-US, V127, P718, DOI 10.1016/S0022-3476(95)70159-1; LISTERNICK R, 1989, J PEDIATR-US, V114, P778, DOI 10.1016/s0022-3476(89)80137-4; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Ludwig HC, 2000, ANTICANCER RES, V20, P299; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MARTINET N, 1992, CANCER, V70, P854, DOI 10.1002/1097-0142(19920815)70:4<854::AID-CNCR2820700422>3.0.CO;2-#; McDaniel AS, 2008, BLOOD, V112, P4646, DOI 10.1182/blood-2008-04-155085; Morgan KJ, 2007, LEUKEMIA RES, V31, P1107, DOI 10.1016/j.leukres.2006.11.022; Munchhof AM, 2006, HUM MOL GENET, V15, P1858, DOI 10.1093/hmg/ddl108; Olumi AF, 1999, CANCER RES, V59, P5002; Pemov A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-194; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Roumier A, 2004, J NEUROSCI, V24, P11421, DOI 10.1523/JNEUROSCI.2251-04.2004; Rozario T, 2010, DEV BIOL, V341, P126, DOI 10.1016/j.ydbio.2009.10.026; Sandsmark DK, 2007, CANCER RES, V67, P4790, DOI 10.1158/0008-5472.CAN-06-4470; Sasaki A, 2001, Brain Tumor Pathol, V18, P13, DOI 10.1007/BF02478920; SCHOR SL, 1988, J CELL SCI, V90, P391; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Singhal S, 2002, ARCH DIS CHILD, V87, P65, DOI 10.1136/adc.87.1.65; Sonoda Y, 2001, CANCER RES, V61, P4956; STERN J, 1980, ARCH OPHTHALMOL-CHIC, V98, P505; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; SUN T, 2010, J NEUROIMMUNOL, V1, P1; Suzuki M, 2006, AM J PATHOL, V169, P673, DOI 10.2353/ajpath.2006.060053; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; The WHO, 2020, CLASSIFICATION TUMOU; Thiagalingam S, 2004, OPHTHALMOLOGY, V111, P568, DOI 10.1016/j.ophtha.2003.06.008; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; TREMBLAY G, 1979, EXP MOL PATHOL, V31, P248, DOI 10.1016/0014-4800(79)90026-1; Ueoka DI, 2009, J NEUROL SCI, V281, P20, DOI 10.1016/j.jns.2009.03.009; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wagner S, 1999, INT J CANCER, V82, P12, DOI 10.1002/(SICI)1097-0215(19990702)82:1<12::AID-IJC3>3.0.CO;2-O; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wang H, 2009, STEM CELLS, V27, P2393, DOI 10.1002/stem.188; Warrington NM, 2007, CANCER RES, V67, P8588, DOI 10.1158/0008-5472.CAN-06-2220; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638; Williams JA, 2000, J INTERF CYTOK RES, V20, P291, DOI 10.1089/107999000312423; Xu J, 2007, CIRCULATION, V116, P2148, DOI 10.1161/CIRCULATIONAHA.107.707752; Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366; Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092; Yeh TH, 2009, GLIA, V57, P1239, DOI 10.1002/glia.20845; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162	123	14	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1135	1146		10.1038/onc.2010.519	http://dx.doi.org/10.1038/onc.2010.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21076468				2022-12-28	WOS:000288202400001
J	Hornle, M; Peters, N; Thayaparasingham, B; Vorsmann, H; Kashkar, H; Kulms, D				Hoernle, M.; Peters, N.; Thayaparasingham, B.; Voersmann, H.; Kashkar, H.; Kulms, D.			Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis	ONCOGENE			English	Article						caspase-3; XIAP; melanoma; apoptosis	X-LINKED INHIBITOR; NF-KAPPA-B; PROTEIN LIGASE ACTIVITY; DOWN-REGULATION; PROTEASOMAL DEGRADATION; UBIQUITIN LIGASE; RESISTANCE; IAPS; SURVIVAL; SMAC	Successful treatment of melanoma is still challenging, because metastasis remain chemoresistant and radioresistant. Accordingly, combinational treatments involving death ligands are mandatory. In a recent study from our lab, the majority out of 18 melanoma cell lines remained resistant against treatment with the death ligand TRAIL (tumor necrosis factor related apoptosis inducing ligand). Resistance was shown to be mainly due to incomplete processing of caspase-3 into catalytically inactive p21 by binding of the anti-apoptotic protein X-linked inhibitor of apoptosis protein (XIAP). Co-irradiation with sub-lethal ultraviolet (UV) B caused depletion of XIAP resulting in synergistic sensitization of all but two melanoma cell lines to TRAIL. We show here the XIAP depletion to essentially require initial caspasemediated cleavage, which promotes proteasomal degradation of XIAP. Utilizing specific caspase inhibitors and small interfering RNA-mediated knockdown, we further identified caspase-3 to be responsible for performing the initial cleavage of XIAP after UVB treatment. Additional evidence suggests an accelerated mitochondrial outer membrane permeabilization in response to co-treatment with TRAIL and UVB, which directs the release of XIAP antagonizing factors including Smac. Distraction of XIAP consequently liberates caspase-3 to autocatalytically process into active p17. Activated caspase-3 cleaves XIAP and further enhances its activation in a positive regulatory feedback loop. The molecular mechanism discovered here appears to have broader implications, because cleavage of XIAP was also shown to accompany cisplatin-induced sensitization of melanoma cells to TRAIL. Oncogene (2011) 30, 575-587; doi: 10.1038/onc.2010.434; published online 20 September 2010	[Hoernle, M.; Peters, N.; Thayaparasingham, B.; Voersmann, H.; Kulms, D.] Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Baden Wurttembe, Germany; [Kashkar, H.] Univ Cologne, Inst Med Microbiol Immunol & Hyg, Ctr Mol Med Cologne, Cologne, Germany	University of Stuttgart; University of Cologne	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Baden Wurttembe, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Kulms, Dagmar/H-1653-2014		Deutsche Krebshilfe [108717]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank the Deutsche Krebshilfe/108717 for funding this project.	Blankenship JW, 2009, BIOCHEM J, V417, P149, DOI 10.1042/BJ20081885; Chen L, 2003, MOL PHARMACOL, V64, P334, DOI 10.1124/mol.64.2.334; Cheung HH, 2008, MOL BIOL CELL, V19, P2729, DOI 10.1091/mbc.E08-01-0107; Creagh EM, 2004, J BIOL CHEM, V279, P26906, DOI 10.1074/jbc.M313859200; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Denault JB, 2007, BIOCHEM J, V405, P11, DOI 10.1042/BJ20070288; Desplanques G, 2009, HAEMATOL-HEMATOL J, V94, P87, DOI 10.3324/haematol.13483; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Edmondson SR, 1999, J CLIN ENDOCR METAB, V84, P1638, DOI 10.1210/jc.84.5.1638; Flaherty KT, 2006, CLIN CANCER RES, V12, p2366S, DOI 10.1158/1078-0432.CCR-05-2505; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Gyrd-Hansen M, 2008, NAT CELL BIOL, V10, P1309, DOI 10.1038/ncb1789; Hougardy BMT, 2006, INT J CANCER, V118, P1892, DOI 10.1002/ijc.21580; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Hussain AR, 2009, LEUKEMIA LYMPHOMA, V50, P1204, DOI 10.1080/10428190902951799; Inoue T, 2006, ANTI-CANCER DRUG, V17, P261, DOI 10.1097/00001813-200603000-00004; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; Kashkar H, 2007, BLOOD, V109, P3982, DOI 10.1182/blood-2006-10-053959; Kashkar H, 2006, BLOOD, V108, P3434, DOI 10.1182/blood-2006-05-021675; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Lasithiotakis KG, 2006, CANCER-AM CANCER SOC, V107, P1331, DOI 10.1002/cncr.22126; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Liou JY, 2007, J CELL PHYSIOL, V212, P840, DOI 10.1002/jcp.21082; Liu L, 2010, BIOCHEM PHARMACOL, V79, P137, DOI 10.1016/j.bcp.2009.08.015; Liu WH, 2007, EMBO J, V26, P1660, DOI 10.1038/sj.emboj.7601611; Maas C, 2010, CELL DEATH DIFFER, V17, P1613, DOI 10.1038/cdd.2010.39; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; McStay GP, 2008, CELL DEATH DIFFER, V15, P322, DOI 10.1038/sj.cdd.4402260; Morizane Y, 2005, J BIOCHEM, V137, P125, DOI 10.1093/jb/mvi029; Ndozangue-Touriguine O, 2008, ONCOGENE, V27, P6012, DOI 10.1038/onc.2008.197; Rehm M, 2006, EMBO J, V25, P4338, DOI 10.1038/sj.emboj.7601295; Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179, DOI 10.1038/sj.cdd.4401826; Shi RX, 2005, CANCER RES, V65, P7815, DOI 10.1158/0008-5472.CAN-04-3875; Silke J, 2005, P NATL ACAD SCI USA, V102, P16182, DOI 10.1073/pnas.0502828102; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Sohn D, 2006, MOL CELL BIOL, V26, P1967, DOI 10.1128/MCB.26.5.1967-1978.2006; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Sun HY, 2008, J MED CHEM, V51, P7169, DOI 10.1021/jm8006849; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thayaparasingham B, 2009, ONCOGENE, V28, P345, DOI 10.1038/onc.2008.397; Twiddy Davina, 2007, Biochem J, V405, pe1; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zeise E, 2004, J INVEST DERMATOL, V123, P746, DOI 10.1111/j.0022-202X.2004.23420.x; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084	51	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					575	587		10.1038/onc.2010.434	http://dx.doi.org/10.1038/onc.2010.434			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20856198				2022-12-28	WOS:000286922300006
J	Latonen, L; Moore, HM; Bai, B; Jaamaa, S; Laiho, M				Latonen, L.; Moore, H. M.; Bai, B.; Jaamaa, S.; Laiho, M.			Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability	ONCOGENE			English	Article						proteasome inhibitor; proteasome; ubiquitin; polyadenylated RNA; nuclear export; aggresome	NUCLEAR EXPORT; RIBOSOMAL-SUBUNITS; DNA-DAMAGE; P53; CRM1; ATAXIN-1; LOCALIZATION; BIOGENESIS; AGGRESOMES; COMPONENT	The ubiquitin-proteasome pathway is essential for most cellular processes, including protein quality control, cell cycle, transcription, signaling, protein transport, DNA repair and stress responses. Hampered proteasome activity leads to the accumulation of polyubiquitylated proteins, endoplastic reticulum (ER) stress and even cell death. The ability of chemical proteasome inhibitors (PIs) to induce apoptosis is utilized in cancer therapy. During PI treatment, misfolded proteins accrue to cytoplasmic aggresomes. The formation of aggresome-like structures in the nucleus has remained obscure. We identify here a nucleolus-associated RNA-protein aggregate (NoA) formed by the inhibition of proteasome activity in mammalian cells. The aggregate forms within the nucleolus and is dependent on nucleolar integrity, yet is a separate structure, lacking nucleolar marker proteins, ribosomal RNA (rRNA) and rRNA synthesis activity. The NoAs contain polyadenylated RNA, conjugated ubiquitin and numerous nucleoplasmic proteasome target proteins. Several of these are key factors in oncogenesis, including transcription factors p53 and retinoblastoma protein (Rb), several cell cycle-regulating cyclins and cyclin-dependent kinases (CDKs), and stress response kinases ataxia-telangiectasia mutated (ATM) and Chk1. The aggregate formation depends on ubiquitin availability, as shown by modulating the levels of ubiquitin and deubiquitinases. Furthermore, inhibition of chromosome region maintenance 1 protein homolog (CRM1) export pathway aggravates the formation of NoAs. Taken together, we identify here a novel nuclear stress body, which forms upon proteasome inactivity within the nucleolus and is detectable in mammalian cell lines and in human tissue. These findings show that the nucleolus controls protein and RNA surveillance and export by the ubiquitin pathway in a previously unidentified manner, and provide mechanistic insight into the cellular effects of PIs. Oncogene (2011) 30, 790-805; doi:10.1038/onc.2010.469; published online 18 October 2010	[Bai, B.; Laiho, M.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA; [Latonen, L.; Moore, H. M.; Jaamaa, S.; Laiho, M.] Univ Helsinki, Mol Canc Biol Program, Helsinki, Finland; [Latonen, L.; Moore, H. M.; Jaamaa, S.; Laiho, M.] Univ Helsinki, Haartman Inst, Helsinki, Finland	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; University of Helsinki	Laiho, M (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Radiat Oncol & Mol Radiat Sci, 1550 Orleans St,CRB 2,Room 444, Baltimore, MD 21231 USA.	mlaiho1@jhmi.edu	Latonen, Leena/C-8787-2016; Bai, Baoyan/A-8584-2012	Latonen, Leena/0000-0003-4502-2193; 	Academy of Finland [129699, 108828]; Biocentrum Helsinki; Helsinki Biomedical Graduate School	Academy of Finland(Academy of Finland); Biocentrum Helsinki; Helsinki Biomedical Graduate School	We thank Drs M Olson, A Miyawaki, I Dikic, B Vogelstein and A Salminen for providing reagents and cell lines. M Salo and H Liu are thanked for excellent technical assistance. Members of Laiho lab at Helsinki and Hopkins, O Matilainen and C Holmberg are thanked for helpful discussions. University of Helsinki Molecular Imaging Unit is thanked for assistance in image acquisition. University of Helsinki Advanced Imaging Unit is thanked for assistance in TEM imaging and sample preparation. This work was supported by Academy of Finland (ML Grant No. 129699, LL Grant No. 108828), Biocentrum Helsinki and Helsinki Biomedical Graduate School (HMM).	Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boulon S, 2004, MOL CELL, V16, P777, DOI 10.1016/j.molcel.2004.11.013; Carter S, 2008, CELL CYCLE, V7, P2519, DOI 10.4161/cc.7.16.6422; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Daelemans D, 2005, MOL CELL BIOL, V25, P728, DOI 10.1128/MCB.25.2.728-739.2005; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Ernoult-Lange M, 2009, MOL BIOL CELL, V20, P176, DOI 10.1091/mbc.E08-09-0904; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fujii K, 2009, GENE DEV, V23, P963, DOI 10.1101/gad.1775609; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hallstrom TMKA, 2007, P NATL ACAD SCI USA, V104, P7211, DOI 10.1073/pnas.0609299104; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019; Hutten S, 2007, TRENDS CELL BIOL, V17, P193, DOI 10.1016/j.tcb.2007.02.003; Ikeda F, 2008, EMBO REP, V9, P536, DOI 10.1038/embor.2008.93; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Karni-Schmidt O, 2007, ONCOGENE, V26, P3878, DOI 10.1038/sj.onc.1210162; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Klibanov SA, 2001, J CELL SCI, V114, P1867; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kurki S, 2004, CELL CYCLE, V3, P976; Lafontaine DLJ, 2001, NAT REV MOL CELL BIO, V2, P514, DOI 10.1038/35080045; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; Li LB, 2008, NATURE, V453, P1107, DOI 10.1038/nature06909; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Matafora V, 2009, MOL CELL PROTEOMICS, V8, P2243, DOI 10.1074/mcp.M900079-MCP200; Matsumoto M, 2005, PROTEOMICS, V5, P4145, DOI 10.1002/pmic.200401280; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Navon A, 2009, J BIOL CHEM, V284, P33713, DOI 10.1074/jbc.R109.018481; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Saeki Y, 2009, EMBO J, V28, P359, DOI 10.1038/emboj.2008.305; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Stavreva DA, 2006, MOL CELL BIOL, V26, P5131, DOI 10.1128/MCB.02227-05; SUDHA T, 1995, CHROMOSOME RES, V3, P115, DOI 10.1007/BF00710672; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Thomsen R, 2008, RNA, V14, P706, DOI 10.1261/rna.718708; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25	63	89	92	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					790	805		10.1038/onc.2010.469	http://dx.doi.org/10.1038/onc.2010.469			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956947				2022-12-28	WOS:000287444600004
J	Moncho-Amor, V; Ibanez de Caceres, I; Bandres, E; Martinez-Poveda, B; Orgaz, JL; Sanchez-Perez, I; Zazo, S; Rovira, A; Albanell, J; Jimenez, B; Rojo, F; Belda-Iniesta, C; Garcia-Foncillas, J; Perona, R				Moncho-Amor, V.; Ibanez de Caceres, I.; Bandres, E.; Martinez-Poveda, B.; Orgaz, J. L.; Sanchez-Perez, I.; Zazo, S.; Rovira, A.; Albanell, J.; Jimenez, B.; Rojo, F.; Belda-Iniesta, C.; Garcia-Foncillas, J.; Perona, R.			DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer	ONCOGENE			English	Article						non-small-cell lung cancer; DUSP1/MKP1; VEGFC; angiogenesis; metastasis; DUSP6/MKP3	PROTEIN-KINASE PHOSPHATASE-1; LYMPH-NODE METASTASIS; BREAST-CANCER; TUMOR-GROWTH; MAP KINASE; ACTIVATION; PROGNOSIS; CARCINOMAS; EXPRESSION; PATHWAYS	DUSP1/MKP1 is a dual-specific phosphatase that regulates MAPKs activity, with an increasingly recognized role in tumor biology. To understand more about the involvement of DUSP1 in lung cancer, we performed gene expression analyses of parental and DUSP1-interfered H460 non-small-cell lung cancer (NSCLC) cells. Downregulation of DUSP1 induced changes in the expression levels of genes involved in specific biological pathways, including angiogenesis, MAP kinase phosphatase activity, cell-cell signaling, growth factor and tyrosine-kinase receptor activity. Changes in the expression of some of these genes were due to modulation of c-Jun-N-terminal kinase and/or p38 activity by DUSP1. Complementary functional assays were performed to focus on the implication of DUSP1 in angiogenesis and metastasis. In H460 cells, interference of DUSP1 resulted in a diminished capacity to invade through Matrigel, to grow tumors in nude mice and also to induce metastasis through tail-vein injection. Furthermore, the angiogenic potential of H460 cells was also impaired, correlating with a decrease in VEGFC production and indicating that DUSP1 could be required to induce angiogenesis. Finally, we studied whether a similar relationship occurred in patients. In human NSCLC specimens, DUSP1 was mainly expressed in those tumor cells close to CD31 vascular structures and a statistically significant correlation was found between VEGFC and DUSP1 expression. Overall, these results provide evidence for a role of DUSP1 in angiogenesis, invasion and metastasis in NSCLC. Oncogene (2011) 30, 668-678; doi:10.1038/onc.2010.449; published online 4 October 2010	[Moncho-Amor, V.; Sanchez-Perez, I.; Perona, R.] CSIC UAM, Inst Invest Biomed, CIBER Enfermedades Raras CIBERER, IdiPAZ, Madrid 28029, Spain; [Ibanez de Caceres, I.] FIB La Paz Univ Hosp, IdiPAZ, Oncol Res Lab, Res Unit, Madrid, Spain; [Bandres, E.; Garcia-Foncillas, J.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, Lab Pharmacogenom, Navarra, Spain; [Martinez-Poveda, B.; Orgaz, J. L.; Jimenez, B.] CSIC UAM, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Madrid 28029, Spain; [Zazo, S.; Rojo, F.] Capio Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain; [Rovira, A.; Albanell, J.; Rojo, F.] Autonomous Univ Barcelona, Hosp Mar IMAS, Dept Med Oncol, Barcelona, Spain; [Rovira, A.; Albanell, J.; Rojo, F.] Autonomous Univ Barcelona, Canc Res Program, IMIM Hosp Mar, Barcelona, Spain; [Belda-Iniesta, C.] La Paz Univ Hosp, Dept Med Oncol, IdiPAZ, Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Universitario La Paz	Perona, R (corresponding author), CSIC UAM, Inst Invest Biomed, CIBER Enfermedades Raras CIBERER, IdiPAZ, C Arturo Duperier 4, Madrid 28029, Spain.	RPerona@iib.uam.es	Rojo, Federico/S-6551-2016; Moncho, Veronica/AAB-5931-2019; Martinez-Poveda, Beatriz/T-6973-2017; Orgaz, Jose L./ABH-1835-2020; Sánchez-Pérez, Isabel/R-4107-2016; Albanell, Joan/R-9470-2019; Cuenca, Benilde Jimenez/K-9959-2014; Rovira, Ana/ABH-5661-2020	Moncho, Veronica/0000-0001-7914-6683; Martinez-Poveda, Beatriz/0000-0003-3927-3877; Orgaz, Jose L./0000-0002-9776-7544; Sánchez-Pérez, Isabel/0000-0002-4829-201X; Rovira, Ana/0000-0003-1301-2599; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Belda Iniesta, Cristobal/0000-0003-3254-7492; Rojo, Federico/0000-0001-9989-0290; J, Garcia-Foncillas/0000-0002-7591-8006; BANDRES, EVA/0000-0002-9497-5356	Fondo de Investigacion Sanitaria (ISCIII) [CP 08/000689]; Spanish Ministerio de Educacion y Ciencia; Spanish Health Ministry grant 'Fondo de Investigacion Sanitaria' [PI05/2019, PI05/1305, PI06/1513, PI081485, PI09/1296, PS09/01285, PS09/00472]; Ministerio de Educacion y Ciencia [SAF2007-62292]; Comunidad Autonoma de Madrid [SAL-0311-2006];  [RTICC 06/0020/19]	Fondo de Investigacion Sanitaria (ISCIII)(Instituto de Salud Carlos III); Spanish Ministerio de Educacion y Ciencia(Spanish Government); Spanish Health Ministry grant 'Fondo de Investigacion Sanitaria'; Ministerio de Educacion y Ciencia(Spanish Government); Comunidad Autonoma de Madrid(Comunidad de Madrid); 	Ibanez de Caceres was partially supported by the Fondo de Investigacion Sanitaria (ISCIII) through the 'Miguel Servet' program (CP 08/000689); VM-A is a recipient of FIS fellowship. IS-P is in receipt of career development awards from the Ramon y Cajal program funded by the Spanish Ministerio de Educacion y Ciencia. We acknowledge Leandro Sastre for helping with cTAP constructs and helpful discussions. We thank Silvia Menendez (Hospital del Mar-IMAS) and Nuria Perez-Gonzalez (Fundacion Jimenez Diaz) for the technical support. We also thank Javier Perez and Fernando Nunez (IIB) for the artwork and animal facility, respectively. This work was supported by PI05/2019, PI05/1305, PI06/1513, PI081485, PI09/1296, PS09/01285 and PS09/00472 (Spanish Health Ministry grant 'Fondo de Investigacion Sanitaria'), SAF2007-62292 (Ministerio de Educacion y Ciencia grant), SAL-0311-2006 (Comunidad Autonoma de Madrid) and RTICC 06/0020/19 grant. We especially thank Fundacio Privada Cellex (Barcelona) and Fundacion Medical Mutua Madrilena for a generous grant to the Medical Oncology Service, Hospital del Mar-IMAS and to Instituto de Investigaciones Biomedicas (IIB), respectively.	Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Downward J, 2008, NAT MED, V14, P1315, DOI 10.1038/nm1208-1315; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Espina C, 2008, AM J PATHOL, V172, P156, DOI 10.2353/ajpath.2008.070561; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; LING L, 1995, MOL CELL BIOL, V15, P6582; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Loda M, 1996, AM J PATHOL, V149, P1553; Lu X, 2010, CANCER RES, V70, P3905, DOI 10.1158/0008-5472.CAN-09-3739; Marinov M, 2009, CLIN CANCER RES, V15, P1277, DOI 10.1158/1078-0432.CCR-08-2166; Morrison DJ, 2008, MOL CANCER RES, V6, P1225, DOI 10.1158/1541-7786.MCR-08-0078; Nutt JE, 2007, BRIT J CANCER, V96, P762, DOI 10.1038/sj.bjc.6603620; Offersen BV, 2007, LUNG CANCER, V56, P43, DOI 10.1016/j.lungcan.2006.11.018; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Renyi-Vamos F, 2005, CLIN CANCER RES, V11, P7344, DOI 10.1158/1078-0432.CCR-05-1077; Rojo F, 2009, CLIN CANCER RES, V15, P3530, DOI 10.1158/1078-0432.CCR-08-2070; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369; Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020; Zhang SC, 2006, CLIN CANCER RES, V12, P1735, DOI 10.1158/1078-0432.CCR-05-1982	34	64	67	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					668	678		10.1038/onc.2010.449	http://dx.doi.org/10.1038/onc.2010.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890299				2022-12-28	WOS:000287192000004
J	Qiu, JJ; Chu, H; Lu, X; Jiang, X; Dong, S				Qiu, J. J.; Chu, H.; Lu, X.; Jiang, X.; Dong, S.			The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia	ONCOGENE			English	Article						PAX5; PAX5-PML; dimerization; FRAP; acute lymphocytic leukemia (ALL)	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR PAX5; B-CELL DIFFERENTIATION; PML-RAR-ALPHA; INTRANUCLEAR MOBILITY; DECREASED MOBILITY; RECEPTOR-ALPHA; GENES; DIMERIZATION	The paired box domain of PAX5 was reported to fuse with the sequence of promyelocytic leukemia (PML) to produce PAX5-PML chimeric protein in two patients with B-cell acute lymphoblastic leukemia. In the present studies, we found, by gel shift assays, that PAX5-PML bound to a panel of PAX5-consensus sequence acts as a homodimer with reduction of its DNA-binding affinities in comparison with wild-type PAX5. In transient transfection assays using 293T and HeLa cells, and retrovirus transduction of murine hematopoietic stem/progenitor cells together with quantitative real-time polymerase chain reaction analysis, PAX5-PML inhibited wild-type PAX5 target gene transcriptional activity. Studies comparing PAX5-PML with PAX5-PML(Delta CC) demonstrated that the coiled-coil (CC) protein interaction domain located within the PML moiety was required for PAX5-PML homodimer complex formation and partial transcriptional repression of genes controlled by PAX5. Fluorescent microscopic examination of transiently expressed YFP-tagged proteins in HeLa and 293T cells demonstrated that YFP-PAX5-PML and YFP-PAX5-PML(Delta CC) exhibited a diffuse granular pattern within the nucleus, similar to PAX5 but not PML. By fluorescent recovery after photobleach (FRAP), we have shown that PAX5-PML fusion protein has reduced intranuclear mobility compared with wild-type PAX5. Furthermore, the dimerization domain (CC) of PML was responsible for the reduced intranuclear mobility of PAX5-PML. These results indicate that the CC domain of PAX5-PML is important for each of the known activities of PAX5-PML fusion proteins. Oncogene (2011) 30, 967-977; doi:10.1038/onc.2010.473; published online 25 October 2010	[Dong, S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Dong, S (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,BCM 286,Room N1317-03, Houston, TX 77030 USA.	jqiu@bcm.edu; sdong@bcm.edu			Albert and Margaret alkek Foundation; Leukemia Research Foundation (LRF)	Albert and Margaret alkek Foundation; Leukemia Research Foundation (LRF)	We thank Dr M Busslinger (Research Institute of Molecular Pathology, Vienna, Austria) for the CD19-luciferase and PAX5 expression vectors, Dr AS Belmont (University of Illinois Champagne-Urbana) for the A03_1 cell line, and Dr CWE So (King's College London, London, UK) for critical reading of the manuscript. This work was supported in part, by funds from the Albert and Margaret alkek Foundation and Leukemia Research Foundation (LRF).	ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Delogu A, 2006, IMMUNITY, V24, P269, DOI 10.1016/j.immuni.2006.01.012; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dong S, 2003, ONCOGENE, V22, P858, DOI 10.1038/sj.onc.1206182; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Huang Y, 2008, BIOCHEM BIOPH RES CO, V365, P258, DOI 10.1016/j.bbrc.2007.10.184; Kawamata N, 2008, P NATL ACAD SCI USA, V105, P11921, DOI 10.1073/pnas.0711039105; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kwok C, 2009, P NATL ACAD SCI USA, V106, P2853, DOI 10.1073/pnas.0810558106; Lauring J, 1999, MOL CELL BIOL, V19, P2601; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nebral K, 2009, LEUKEMIA, V23, P134, DOI 10.1038/leu.2008.306; Nebral K, 2007, BRIT J HAEMATOL, V139, P269, DOI 10.1111/j.1365-2141.2007.06731.x; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Pridans C, 2008, J IMMUNOL, V180, P1719, DOI 10.4049/jimmunol.180.3.1719; Qiu J, 2006, ONCOGENE, V25, P3982, DOI 10.1038/sj.onc.1209431; Qiu J, 2003, LEUKEMIA, V17, P1891, DOI 10.1038/sj.leu.2403073; Qiu J, 2007, MOL BIOL CELL, V18, P3941, DOI 10.1091/mbc.E07-03-0245; Qiu JH, 2010, CELL RES, V20, P908, DOI 10.1038/cr.2010.81; Qiu JHJ, 2010, BLOOD, V115, P643, DOI 10.1182/blood-2009-07-232652; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Schebesta A, 2007, IMMUNITY, V27, P49, DOI 10.1016/j.immuni.2007.05.019; Schebesta M, 2002, IMMUNITY, V17, P473, DOI 10.1016/S1074-7613(02)00418-1; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006	35	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					967	977		10.1038/onc.2010.473	http://dx.doi.org/10.1038/onc.2010.473			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20972455				2022-12-28	WOS:000287695900008
J	Pavet, V; Portal, MM; Moulin, JC; Herbrecht, R; Gronemeyer, H				Pavet, V.; Portal, M. M.; Moulin, J. C.; Herbrecht, R.; Gronemeyer, H.			Towards novel paradigms for cancer therapy	ONCOGENE			English	Review						apoptosis; TRAIL/Apo2L/TNFSF10; epigenetic drug; tumor-initiating cell; dependence receptor; non-coding RNA	APOPTOSIS-INDUCING LIGAND; ACUTE PROMYELOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR-RECEPTOR; METASTATIC COLORECTAL-CANCER; SESQUITERPENE LACTONE PARTHENOLIDE; HISTONE DEACETYLASE INHIBITORS; AGONISTIC MONOCLONAL-ANTIBODY; ACUTE MYELOGENOUS LEUKEMIA; TRAIL-INDUCED APOPTOSIS	Cancer is a complex progressive multistep disorder that results from the accumulation of genetic and epigenetic abnormalities, which lead to the transformation of normal cells into malignant derivatives. Despite enormous progress in the understanding of cancer biology including the decryption of multiple regulatory networks governing cell growth and death, and despite the possibility of analyzing (epi)genetic deregulation at the genome-wide scale, cancer-targeted therapy is still the exception. In fact, to date there are still far too few examples of therapies leading to cure; treatment-derived toxicity is a major issue, and cancer remains to be one of the largest causes of death worldwide. The purpose of this review is to discuss the state of the art of cancer therapy with respect to the key issue of any treatment, namely its target selectivity. Therefore, we recapitulate and discuss current concepts and therapies targeting tumor-specific features, including oncofusion proteins, aberrant kinase activities and epigenetic tumor makeup. We analyze strategies designed to induce tumor-selective death such as the use of oncolytic virus, tumoricidal proteins (NS1, Eorf4, apoptin, HAMLET (human alpha-lactalbumin made lethal to tumor cells)) and activation of signaling pathways involved in tumor surveillance. We emphasize the potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, an essential component of the evolutionary developed defense systems that eradicate malignant cells. Finally, we discuss the necessity of targeting tumor-initiating cells (TICs) to avoid relapse and increase the chances of complete remission, and describe emerging concepts that might provide novel avenues for cancer therapy. Oncogene (2011) 30, 1-20; doi: 10.1038/onc.2010.460; published online 11 October 2010	[Pavet, V.; Portal, M. M.; Moulin, J. C.; Gronemeyer, H.] IGBMC, Dept Canc Biol, F-67404 Illkirch Graffenstaden, Alsace, France; [Moulin, J. C.; Herbrecht, R.] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pavet, V (corresponding author), IGBMC, Dept Canc Biol, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, Alsace, France.	vpavet@igbmc.fr; hg@igbmc.fr	Gronemeyer, Hinrich/AAH-5575-2019; Herbrecht, Raoul/D-3471-2013; Herbrecht, Raoul/AAT-1763-2021; Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011; Herbrecht, Raoul/GVU-1333-2022	Gronemeyer, Hinrich/0000-0001-9454-2449; Herbrecht, Raoul/0000-0002-9381-4876; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; PORTAL, Maximiliano/0000-0002-2884-6900	Agence Nationale de la Recherche [ANR-07-PCVI-0031-01]; European Commission [LSHC-CT-2005-518417, HEALTH-F4-2007-200767]; La Ligue Contre le Cancer; Fondation pour la Recherche Medicale	Agence Nationale de la Recherche(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); La Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Work in our laboratory is supported by Agence Nationale de la Recherche (ANR-07-PCVI-0031-01), the European Commission (LSHC-CT-2005-518417 'Epitron,' HEALTH-F4-2007-200767 'Apo-Sys,' H Gronemeyer laboratory), La Ligue Contre le Cancer (H Gronemeyer, laboratoire labellisee; MMP post-doctoral fellow) and Fondation pour la Recherche Medicale (JCM master fellow).	Aits S, 2009, INT J CANCER, V124, P1008, DOI 10.1002/ijc.24076; Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Backendorf C, 2008, ANNU REV PHARMACOL, V48, P143, DOI 10.1146/annurev.pharmtox.48.121806.154910; Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483; Belyanskaya LL, 2008, LUNG CANCER, V60, P355, DOI 10.1016/j.lungcan.2007.11.005; Berdis AJ, 2008, BIOCHEMISTRY-US, V47, P8253, DOI 10.1021/bi801179f; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bianco R, 2007, INT J BIOCHEM CELL B, V39, P1416, DOI 10.1016/j.biocel.2007.05.008; Blundell TL, 2002, NAT REV DRUG DISCOV, V1, P45, DOI 10.1038/nrd706; Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707; Castets M, 2009, DEV CELL, V16, P614, DOI 10.1016/j.devcel.2009.02.006; Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cortes J, 2007, CANCER, V110, P1295, DOI 10.1002/cncr.22901; Costa FF, 2008, GENE, V410, P9, DOI 10.1016/j.gene.2007.12.008; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Dorer DE, 2009, ADV DRUG DELIVER REV, V61, P554, DOI 10.1016/j.addr.2009.03.013; Druker B, 2001, SEMIN HEMATOL, V38, P9, DOI 10.1053/shem.2001.27079; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; Eager R, 2008, EXPERT OPIN BIOL TH, V8, P1633, DOI [10.1517/14712598.8.10.1633, 10.1517/14712598.8.10.1633 ]; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ekmekcioglu S, 2008, CYTOKINE, V43, P34, DOI 10.1016/j.cyto.2008.04.010; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; Emdad L, 2009, CANCER BIOL THER, V8, P402, DOI 10.4161/cbt.8.5.7581; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Flygare JA, 2010, EXPERT OPIN THER PAT, V20, P251, DOI 10.1517/13543770903567077; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; Fukuhara H, 2005, CLIN CANCER RES, V11, P7886, DOI 10.1158/1078-0432.CCR-05-1090; Fukuhara H, 2010, INT J UROL, V17, P20, DOI 10.1111/j.1442-2042.2009.02383.x; Fulda S, 2009, LEUKEMIA, V23, P467, DOI 10.1038/leu.2008.329; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Georgakis GV, 2005, BRIT J HAEMATOL, V130, P501, DOI 10.1111/j.1365-2141.2005.05656.x; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Gopal YV, 2007, CHEM BIOL, V14, P813, DOI 10.1016/j.chembiol.2007.06.007; Gopalan B, 2005, CANCER RES, V65, P3017, DOI 10.1158/0008-5472.CAN-04-3758; Granchi C, 2010, CURR MED CHEM, V17, P672, DOI 10.2174/092986710790416263; Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227; Greco FA, 2008, LUNG CANCER, V61, P82, DOI 10.1016/j.lungcan.2007.12.011; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gustafsson L, 2004, NEW ENGL J MED, V350, P2663, DOI 10.1056/NEJMoa032454; Gustafsson L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005229; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hallgren O, 2008, ADV EXP MED BIOL, V606, P217, DOI 10.1007/978-0-387-74087-4_8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hasegawa H, 2005, BRIT J HAEMATOL, V128, P253, DOI 10.1111/j.1365-2141.2004.05289.x; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Idogawa M, 2009, CLIN CANCER RES, V15, P3725, DOI 10.1158/1078-0432.CCR-08-2396; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63; Jiang HP, 1995, ONCOGENE, V11, P2477; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kantarjian HM, 2006, INT J HEMATOL, V83, P289, DOI 10.1532/IJH97.06024; Kantarjian HM, 2006, ANN INTERN MED, V145, P913, DOI 10.7326/0003-4819-145-12-200612190-00008; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasuya H, 2005, CANCER GENE THER, V12, P725, DOI 10.1038/sj.cgt.7700830; Kawasaki BT, 2009, PROSTATE, V69, P827, DOI 10.1002/pros.20931; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kogan SC, 2009, CANCER CELL, V15, P7, DOI 10.1016/j.ccr.2008.12.012; Kohler C, 1999, EXP CELL RES, V249, P260, DOI 10.1006/excr.1999.4472; Landry MC, 2006, B CANCER, V93, P921; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; le Coutre P, 2008, BLOOD, V111, P1834, DOI 10.1182/blood-2007-04-083196; Lebedeva IV, 2007, INT J ONCOL, V31, P985; Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422; Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658; Leverkus M, 2000, CANCER RES, V60, P553; Li JH, 2003, J IMMUNOL, V171, P1526, DOI 10.4049/jimmunol.171.3.1526; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Li SY, 2009, J VIROL, V83, P8340, DOI 10.1128/JVI.00711-09; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TC, 2008, GENE THER, V15, P877, DOI 10.1038/gt.2008.72; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Lurje G, 2008, CLIN CANCER RES, V14, P7884, DOI 10.1158/1078-0432.CCR-07-5165; Maddika S, 2006, CANCER BIOL THER, V5, P10, DOI 10.4161/cbt.5.1.2400; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; MASUI H, 1986, CANCER RES, V46, P5592; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 2010, CURR OPIN ONCOL, V22, P46, DOI 10.1097/CCO.0b013e328333dcd1; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mitrus I, 2005, ANTICANCER RES, V25, P1087; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mom CH, 2009, CLIN CANCER RES, V15, P5584, DOI 10.1158/1078-0432.CCR-09-0996; Morel J, 2005, J BIOL CHEM, V280, P15709, DOI 10.1074/jbc.M414469200; Mossberg AK, 2007, INT J CANCER, V121, P1352, DOI 10.1002/ijc.22810; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Naka T, 2002, CANCER RES, V62, P5800; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158/1078-0432.CCR-09-0209; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Noteborn MHM, 2009, EUR J PHARMACOL, V625, P165, DOI 10.1016/j.ejphar.2009.06.068; Nuesch JPF, 2008, CANCER BIOL THER, V7, P1376; Nuesch JPF, 2007, P NATL ACAD SCI USA, V104, P12482, DOI 10.1073/pnas.0705533104; Nuesch JPF, 2006, J VIROL, V80, P4729, DOI 10.1128/JVI.80.10.4729-4739.2006; O'Brien S, 2007, J CLIN ONCOL, V25, P1114, DOI 10.1200/JCO.2006.07.1191; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Ozoren N, 2000, CANCER RES, V60, P6259; Pallasch CP, 2009, BLOOD, V114, P3255, DOI 10.1182/blood-2009-06-229898; Pavet V, 2010, CANCER RES, V70, P1101, DOI 10.1158/0008-5472.CAN-09-2889; Peng DJ, 2007, CANCER GENE THER, V14, P66, DOI 10.1038/sj.cgt.7700985; Persson H, 2009, NAT CELL BIOL, V11, P1268, DOI 10.1038/ncb1972; Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rohn JL, 2004, APOPTOSIS, V9, P315, DOI 10.1023/B:APPT.0000025808.48885.9c; Sarkar D, 2008, CANCER BIOL THER, V7, P109, DOI 10.4161/cbt.7.1.5693; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schessl C, 2005, J CLIN INVEST, V115, P2159, DOI 10.1172/JCI24225; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shankaranarayanan P, 2009, CANCER CELL, V16, P220, DOI 10.1016/j.ccr.2009.07.029; Shanker M, 2007, CANCER LETT, V254, P217, DOI 10.1016/j.canlet.2007.03.004; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Shipley JL, 2009, EXP HEMATOL, V37, P649, DOI 10.1016/j.exphem.2009.04.002; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sieger KA, 2004, MOL THER, V9, P355, DOI 10.1016/j.ymthe.2003.11.014; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Spannhoff A, 2009, CHEMMEDCHEM, V4, P1568, DOI 10.1002/cmdc.200900301; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Steele AJ, 2006, LEUKEMIA, V20, P1073, DOI 10.1038/sj.leu.2404230; Sun J, 2009, INT J CANCER, V124, P2973, DOI 10.1002/ijc.24279; Sun Y, 2008, CANCER BIOL THER, V7, P1420; Svanborg C, 2003, ADV CANCER RES, V88, P1; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tan ML, 2009, PHARM RES-DORDR, V26, P1547, DOI 10.1007/s11095-009-9895-1; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thibert C, 2010, CELL CYCLE, V9, P2085, DOI 10.4161/cc.9.11.11809; Thorburn A, 2008, DRUG RESIST UPDATE, V11, P17, DOI 10.1016/j.drup.2008.02.001; Tolcher AW, 2007, J CLIN ONCOL, V25, P1390, DOI 10.1200/JCO.2006.08.8898; Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Tsimberidou AM, 2006, LEUKEMIA LYMPHOMA, V47, P1062, DOI 10.1080/10428190500463932; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vilimanovich U, 2008, CELL MOL LIFE SCI, V65, P814, DOI 10.1007/s00018-008-7513-8; Volkmann X, 2007, HEPATOLOGY, V46, P1498, DOI 10.1002/hep.21846; Wakelee HA, 2010, ANN ONCOL, V21, P376, DOI 10.1093/annonc/mdp292; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang M, 2005, IMMUNOLOGY, V114, P166, DOI 10.1111/j.1365-2567.2005.02094.x; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021; Zhenchuk A, 2009, BIOCHEM PHARMACOL, V78, P1351, DOI 10.1016/j.bcp.2009.06.094; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	209	88	93	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					1	20		10.1038/onc.2010.460	http://dx.doi.org/10.1038/onc.2010.460			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20935674				2022-12-28	WOS:000285959300001
J	Gotte, M; Mohr, C; Koo, CY; Stock, C; Vaske, AK; Viola, M; Ibrahim, SA; Peddibhotla, S; Teng, YHF; Low, JY; Ebnet, K; Kiesel, L; Yip, GW				Goette, M.; Mohr, C.; Koo, C-Y; Stock, C.; Vaske, A-K; Viola, M.; Ibrahim, S. A.; Peddibhotla, S.; Teng, Y. H-F; Low, J-Y; Ebnet, K.; Kiesel, L.; Yip, G. W.			miR-145-dependent targeting of Junctional Adhesion Molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness	ONCOGENE			English	Article						F11R; microRNA; actin cytoskeleton; metastasis; nuclear rotation; endometrial carcinoma	SUPPRESSIVE MICRORNAS; PROSTATE-CANCER; MIR-145; METASTASIS; MIGRATION; PROTEIN; INVASION; GROWTH; MATURATION; PHENOTYPE	Micro RNAs are small non-coding RNAs, which regulate fundamental cellular and developmental processes at the transcriptional and translational level. In breast cancer, miR-145 expression is downregulated compared with healthy control tissue. As several predicted targets of miR-145 potentially regulate cell motility, we aimed at investigating a potential role for miR-145 in breast cancer cell motility and invasiveness. Assisted by Affymetrix array technology, we demonstrate that overexpression of miR-145 in MDA-MB-231, MCF-7, MDA-MB-468 and SK-BR-3 breast cancer cells and in Ishikawa endometrial carcinoma cells leads to a downregulation of the cell-cell adhesion protein JAM-A and of the actin bundling protein fascin. Moreover, podocalyxin and Serpin E1 mRNA levels were downregulated, and gamma-actin, transgelin and MYL9 were upregulated upon miR-145 overexpression. These miR-145-dependent expression changes drastically decreased cancer cell motility, as revealed by time-lapse video microscopy, scratch wound closure assays and matrigel invasion assays. Immunofluorescence microscopy demonstrated restructuring of the actin cytoskeleton and a change in cell morphology by miR-145 overexpression, resulting in a more cortical actin distribution, and reduced actin stress fiber and filopodia formation. Nuclear rotation was observed in 10% of the pre-miR-145 transfected MDA-MB-231 cells, accompanied by a reduction of perinuclear actin. Luciferase activation assays confirmed direct miR-145-dependent regulation of the 3'UTR of JAM-A, whereas siRNA-mediated knockdown of JAM-A expression resulted in decreased motility and invasiveness of MDA-MB-231 and MCF-7 breast cancer cells. Our data identify JAM-A and fascin as novel targets of miR-145, firmly establishing a role for miR-145 in modulating breast cancer cell motility. Our data provide a rationale for future miR-145-targeted approaches of antimetastatic cancer therapy. Oncogene (2010) 29, 6569-6580; doi:10.1038/onc.2010.386; published online 6 September 2010	[Goette, M.; Mohr, C.; Vaske, A-K; Viola, M.; Ibrahim, S. A.; Kiesel, L.] Munster Univ Hosp, Dept Gynecol & Obstet, D-48149 Munster, Germany; [Yip, G. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Stock, C.] Munster Univ Hosp, Inst Physiol 2, D-48149 Munster, Germany; [Ibrahim, S. A.] Cairo Univ, Fac Sci, Dept Zool, Giza, Egypt; [Peddibhotla, S.; Ebnet, K.] Univ Munster, ZMBE, Inst Med Biochem, Cell Adhes & Cell Polar Grp, Munster, Germany	University of Munster; National University of Singapore; University of Munster; Egyptian Knowledge Bank (EKB); Cairo University; University of Munster	Gotte, M (corresponding author), Munster Univ Hosp, Dept Gynecol & Obstet, Domagkstr 11, D-48149 Munster, Germany.	mgotte@uni-muenster.de; georgeyip@nus.edu.sg	Gotte, M/Z-5878-2019; Viola, Manuela/B-7120-2011; Ebnet, Klaus T/C-8314-2009; Götte, Martin/G-2254-2018; Kiesel, Ludwig/ABC-5333-2020	Gotte, M/0000-0003-2360-2496; Viola, Manuela/0000-0002-0634-6390; Ebnet, Klaus T/0000-0002-0417-7888; Götte, Martin/0000-0003-2360-2496; Kiesel, Ludwig/0000-0002-7247-9247; Koo, Chuay Yeng/0000-0002-9495-0554; Ibrahim, Sherif Abdelaziz/0000-0001-6403-7345	National Medical Research Council, Singapore [NMRC/1023/2005]; German Academic Exchange Service DAAD [A/08/15601, A/06/90277]; Forderkreis Universitat Munster	National Medical Research Council, Singapore(National Medical Research Council, Singapore); German Academic Exchange Service DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); Forderkreis Universitat Munster	We would like to thank Birgit Pers, Ruth Goez, and Barbara Kloke for expert technical assistance, Professor Anna Starzinski-Powitz for providing Ishikawa cells, and Christian Adams MSc, for help with luciferase assays. Funding was provided by Grant NMRC/1023/2005 from the National Medical Research Council, Singapore (to GWY), by German Academic Exchange Service DAAD Grants A/08/15601 (to MV), and A/06/90277 (to SAI), and by the Forderkreis Universitat Munster (to MG).	Baehrecke EH, 2003, CURR BIOL, V13, pR473, DOI 10.1016/S0960-9822(03)00405-6; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cera MR, 2009, J CELL SCI, V122, P268, DOI 10.1242/jcs.037127; Cheng YH, 2009, CIRC RES, V105, P158, DOI 10.1161/CIRCRESAHA.109.197517; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Darnel AD, 2009, CLIN CANCER RES, V15, P1376, DOI 10.1158/1078-0432.CCR-08-1789; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Gerashchenko MV, 2009, CELL BIOL INT, V33, P1057, DOI 10.1016/j.cellbi.2009.06.020; Gotte M, 2008, HUM MOL GENET, V17, P996, DOI 10.1093/hmg/ddm372; Gotte M, 2010, AM J PATHOL, V176, P25, DOI 10.2353/ajpath.2010.090775; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hashimoto Y, 2007, MOL BIOL CELL, V18, P4591, DOI 10.1091/mbc.E07-02-0157; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; ISHIWATA I, 1984, GYNECOL ONCOL, V17, P281, DOI 10.1016/0090-8258(84)90212-9; Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim SJ, 2010, GASTROENTEROLOGY, V138, P1035, DOI 10.1053/j.gastro.2009.09.061; KIM SJ, 2009, GASTROENTEROLOGY, V138, pE1; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Larrucea S, 2008, EXP CELL RES, V314, P2004, DOI 10.1016/j.yexcr.2008.03.009; Larsson E, 2009, GENOME MED, V1, DOI 10.1186/gm108; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Levy JR, 2008, J CELL SCI, V121, P3187, DOI 10.1242/jcs.033878; Liu X, 2009, CLIN CANCER RES, V15, P1177, DOI 10.1158/1078-0432.CCR-08-1355; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; McSherry EA, 2009, INT J CANCER, V125, P1343, DOI 10.1002/ijc.24498; Megraw M, 2007, NUCLEIC ACIDS RES, V35, pD149, DOI 10.1093/nar/gkl904; Naik MU, 2008, CANCER RES, V68, P2194, DOI 10.1158/0008-5472.CAN-07-3057; Naik MU, 2003, ARTERIOSCL THROM VAS, V23, P2165, DOI 10.1161/01.ATV.0000093982.84451.87; Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001; Ostenfeld MS, 2010, ONCOGENE, V29, P1073, DOI 10.1038/onc.2009.395; Qualtrough D, 2009, BRIT J CANCER, V101, P1124, DOI 10.1038/sj.bjc.6605286; Quintavalle M, 2010, J CELL BIOL, V189, P13, DOI 10.1083/jcb.200912096; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Seidler DG, 2006, J MOL MED, V84, P583, DOI 10.1007/s00109-006-0046-4; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Sempere LF, 2009, THESCIENTIFICWORLDJO, V9, P626, DOI 10.1100/tsw.2009.88; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; Sizemore S, 2007, CANCER RES, V67, P6183, DOI 10.1158/0008-5472.CAN-06-3575; Spizzo R, 2010, CELL DEATH DIFFER, V17, P246, DOI 10.1038/cdd.2009.117; Stuwe L, 2007, J PHYSIOL-LONDON, V585, P351, DOI 10.1113/jphysiol.2007.145185; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Vignjevic D, 2007, CANCER RES, V67, P6844, DOI 10.1158/0008-5472.CAN-07-0929; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yoder BJ, 2005, CLIN CANCER RES, V11, P186; Zeng L, 2009, P NATL ACAD SCI USA, V106, P17793, DOI 10.1073/pnas.0903693106	56	175	187	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6569	6580		10.1038/onc.2010.386	http://dx.doi.org/10.1038/onc.2010.386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818426	Bronze			2022-12-28	WOS:000285380200006
J	Gonfloni, S				Gonfloni, S.			DNA damage stress response in germ cells: role of c-Abl and clinical implications	ONCOGENE			English	Review						c-Abl tyrosine kinase; DNA damage response; germ cells; TAp63; chemotherapy	DOUBLE-STRAND BREAKS; TYROSINE KINASE; IONIZING-RADIATION; BCR-ABL; TUMOR-SUPPRESSOR; DROSOPHILA-MELANOGASTER; DIFFERENTIAL EXPRESSION; APOPTOTIC RESPONSE; CELLULAR-RESPONSE; ATM ACTIVATION	Cells experiencing DNA damage undergo a complex response entailing cell-cycle arrest, DNA repair and apoptosis, the relative importance of the three being modulated by the extent of the lesion. The observation that Abl interacts in the nucleus with several proteins involved in different aspects of DNA repair has led to the hypothesis that this kinase is part of the damage-sensing mechanism. However, the mechanistic details underlying the role of Abl in DNA repair remain unclear. Here, I will review the evidence supporting our current understanding of Abl activation following DNA insults, while focusing on the relevance of these mechanisms in protecting DNA-injured germ cells. Early studies have shown that Abl transcripts are highly expressed in the germ line. Abl-deficient mice exhibit multiple abnormalities, increased perinatal mortality and reduced fertility. Recent findings have implicated Abl in a cisplatin-induced signaling pathway eliciting death of immature oocytes. A p53-related protein, TAp63, is an important immediate downstream effector of this pathway. Of note, pharmacological inhibition of Abl protects the ovarian reserve from the toxic effects of cisplatin. This suggests that the extent of Abl catalytic outputs may shift the balance between survival (likely through DNA repair) and activation of a death response. Taken together, these observations are consistent with the evolutionary conserved relationship between DNA damage and activation of the p53 family of transcription factors, while shedding light on the key role of Abl in dictating the fate of germ cells upon genotoxic insults. Oncogene (2010) 29, 6193-6202; doi:10.1038/onc.2010.410; published online 6 September 2010	Univ Rome, Dept Biol, I-00133 Rome, Italy	Sapienza University Rome	Gonfloni, S (corresponding author), Univ Rome, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	Stefania.Gonfloni@uniroma2.it		GONFLONI, STEFANIA/0000-0002-9392-4258				Adrian FJ, 2006, NAT CHEM BIOL, V2, P95, DOI 10.1038/nchembio760; Agami R, 1999, NATURE, V399, P809; Backhus Leilah E., 2007, V138, P235; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Belyi VA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001198; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen XA, 2006, MOL CELL, V22, P489, DOI 10.1016/j.molcel.2006.04.021; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Cong F, 2002, J BIOL CHEM, V277, P34870, DOI 10.1074/jbc.M204416200; David-Cordonnier MH, 1998, BIOCHEMISTRY-US, V37, P6065, DOI 10.1021/bi973030w; Deng XZ, 2004, NAT GENET, V36, P906, DOI 10.1038/ng1396; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Dery U, 2007, DNA REPAIR, V6, P561, DOI 10.1016/j.dnarep.2006.12.009; Dunn L, 2009, CURR OPIN OBSTET GYN, V21, P68, DOI 10.1097/GCO.0b013e32831e13b9; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Gardino SL, 2010, J ASSIST REPROD GEN, V27, P227, DOI 10.1007/s10815-010-9413-8; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2010, CELL CYCLE, V9, P217, DOI 10.4161/cc.9.2.10563; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Gong JG, 1999, NATURE, V399, P806; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gu JJ, 2009, IMMUNOL REV, V228, P170, DOI 10.1111/j.1600-065X.2008.00751.x; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; Her C, 1998, GENOMICS, V52, P50, DOI 10.1006/geno.1998.5374; Her C, 2007, FRONT BIOSCI-LANDMRK, V12, P905, DOI 10.2741/2112; Hulvat MC, 2009, CURR TREAT OPTION ON, V10, P308, DOI 10.1007/s11864-010-0116-2; IWAOKI Y, 1993, EXP CELL RES, V206, P212, DOI 10.1006/excr.1993.1140; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jeruss JS, 2009, NEW ENGL J MED, V360, P902, DOI 10.1056/NEJMra0801454; Johnston RJ, 2009, PEDIATR BLOOD CANCER, V53, P296, DOI 10.1002/pbc.22012; Jones EV, 2007, BIOCHEM J, V405, P617, DOI 10.1042/BJ20061778; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Kharbanda S, 1997, BBA-REV CANCER, V1333, pO1, DOI 10.1016/S0304-419X(97)00020-6; Kitao H, 2002, J BIOL CHEM, V277, P48944, DOI 10.1074/jbc.M208151200; Kneitz B, 2000, GENE DEV, V14, P1085; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kurita T, 2005, MECH DEVELOP, V122, P1043, DOI 10.1016/j.mod.2005.04.008; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; LEV Z, 1984, MOL CELL BIOL, V4, P982, DOI 10.1128/MCB.4.5.982; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lobo RA, 2005, NEW ENGL J MED, V353, P64, DOI 10.1056/NEJMra043475; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Maltaris T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1991; Maltaris T, 2009, IN VIVO, V23, P123; Mandon-Pepin B, 2008, EUR J ENDOCRINOL, V158, P107, DOI 10.1530/EJE-07-0400; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nagar B, 2007, J NUTR, V137, p1518S, DOI 10.1093/jn/137.6.1518S; Nehme A, 1997, CANCER RES, V57, P3253; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Ohren JF, 2006, NAT CHEM BIOL, V2, P63, DOI 10.1038/nchembio0206-63; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; Pandita Tej K, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403006318; Panier S, 2009, DNA REPAIR, V8, P436, DOI 10.1016/j.dnarep.2009.01.013; Peate M, 2009, BREAST CANCER RES TR, V116, P215, DOI 10.1007/s10549-009-0401-6; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1988, ONCOGENE, V2, P227; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Richardson C, 2004, DNA REPAIR, V3, P1149, DOI 10.1016/j.dnarep.2004.05.007; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rutkowski R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001131; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; Shimizu H, 2009, BIOCHEM BIOPH RES CO, V382, P286, DOI 10.1016/j.bbrc.2009.03.020; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takao N, 2000, J BIOL CHEM, V275, P725, DOI 10.1074/jbc.275.2.725; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; Tompkins JD, 2009, EXP CELL RES, V315, P2420, DOI 10.1016/j.yexcr.2009.05.004; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; VANDERKAAIJ MAE, 2010, HEMATOL ONCOL; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Wang JYJ, 2001, BIOCHEM SOC T, V29, P666, DOI 10.1042/0300-5127:0290666; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; West ER, 2009, PEDIATR BLOOD CANCER, V53, P289, DOI 10.1002/pbc.21999; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Woodruff Teresa K., 2007, V138, P3; Woodruff TK, 2008, NAT MED, V14, P1190, DOI 10.1038/nm1108-1190; Woodruff TK, 2009, NAT MED, V15, P1124, DOI 10.1038/nm1009-1124; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yi W, 2006, CANCER RES, V66, P151, DOI 10.1158/0008-5472.CAN-05-3019; Yi W, 2005, BIOCHEM BIOPH RES CO, V332, P524, DOI 10.1016/j.bbrc.2005.04.154; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yoshida K, 2008, TRENDS MOL MED, V14, P305, DOI 10.1016/j.molmed.2008.05.003; Yuan JS, 2010, J BIOL CHEM, V285, P1097, DOI 10.1074/jbc.M109.078436; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Yuan SSF, 1999, CANCER RES, V59, P3547; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	141	24	26	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6193	6202		10.1038/onc.2010.410	http://dx.doi.org/10.1038/onc.2010.410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20818431				2022-12-28	WOS:000284601700001
J	Braconi, C; Kogure, T; Valeri, N; Huang, N; Nuovo, G; Costinean, S; Negrini, M; Miotto, E; Croce, CM; Patel, T				Braconi, C.; Kogure, T.; Valeri, N.; Huang, N.; Nuovo, G.; Costinean, S.; Negrini, M.; Miotto, E.; Croce, C. M.; Patel, T.			microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer	ONCOGENE			English	Article						MEG3; methylation; HCC; non-coding RNA	ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENE; LIVER-CANCER; CARCINOMA; CELLS; HYPERMETHYLATION; METHYLATION; TUMORIGENICITY; ACTIVATION; APOPTOSIS	The human genome is replete with long non-coding RNAs (lncRNA), many of which are transcribed and likely to have a functional role. Microarray analysis of 423 000 lncRNAs revealed downregulation of 712 (similar to 3%) lncRNA in malignant hepatocytes, among which maternally expressed gene 3 (MEG3) was downregulated by 210-fold relative to expression in non-malignant hepatocytes. MEG3 expression was markedly reduced in four human hepatocellular cancer (HCC) cell lines compared with normal hepatocytes by real-time PCR. RNA in situ hybridization showed intense cytoplasmic expression of MEG3 in non-neoplastic liver with absent or very weak expression in HCC tissues. Enforced expression of MEG3 in HCC cells significantly decreased both anchorage-dependent and -independent cell growth, and induced apoptosis. MEG3 promoter hypermethylation was identified by methylation-specific PCR and MEG3 expression was increased with inhibition of methylation with either 5-Aza-2-Deoxycytidine, or siRNA to DNA Methyltransferase (DNMT) 1 and 3b in HCC cells. MiRNA-dependent regulation of MEG3 expression was studied by evaluating the involvement of miR-29, which can modulate DNMT 1 and 3. Overexpression of mir-29a increased expression of MEG3. GTL2, the murine homolog of MEG3, was reduced in liver tissues from hepatocyte-specific miR-29a/b1 knock-out mice compared with wild-type controls. These data show that methylation-dependent tissue-specific regulation of the lncRNA MEG3 by miR-29a may contribute to HCC growth and highlight the inter-relationship between two classes of non-coding RNA, miRNAs and lncRNAs, and epigenetic regulation of gene expression. Oncogene (2011) 30, 4750-4756; doi:10.1038/onc.2011.193; published online 30 May 2011	[Patel, T.] Mayo Clin, Dept Transplantat, Jacksonville, FL 32224 USA; [Braconi, C.; Kogure, T.; Valeri, N.; Huang, N.; Costinean, S.; Croce, C. M.; Patel, T.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Braconi, C.; Kogure, T.; Valeri, N.; Huang, N.; Costinean, S.; Croce, C. M.; Patel, T.] Ohio State Univ, Ohio State Univ Comprehens Canc Ctr, Columbus, OH 43210 USA; [Nuovo, G.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Negrini, M.; Miotto, E.] Univ Ferrara, Dept Expt & Diagnost Med, I-44100 Ferrara, Italy	Mayo Clinic; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Ferrara	Patel, T (corresponding author), Mayo Clin, Dept Transplantat, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	patel.tushar@mayo.edu	patel, tushar/J-3976-2013; Young, Richard A/F-6495-2012; Kogure, Takayuki/AAI-3946-2021; Negrini, Massimo/J-2377-2016	patel, tushar/0000-0001-7021-9532; Young, Richard A/0000-0001-8855-8647; Negrini, Massimo/0000-0002-0007-1920; braconi, chiara/0000-0003-4835-1259; valeri, nicola/0000-0002-5426-5683	NCI NIH HHS [P30 CA016058] Funding Source: Medline; NIDDK NIH HHS [R01 DK069370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benetatos L, 2008, CLIN LYMPHOMA MYELOM, V8, P171, DOI 10.3816/CLM.2008.n.021; Benetatos L, 2010, LEUKEMIA RES, V34, P148, DOI 10.1016/j.leukres.2009.06.019; Braconi C, 2011, P NATL ACAD SCI USA, V108, P786, DOI 10.1073/pnas.1011098108; Braconi C, 2010, CLIN CANCER RES, V16, P957, DOI 10.1158/1078-0432.CCR-09-2123; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Cazals-Hatem D, 2004, J HEPATOL, V41, P292, DOI 10.1016/j.jhep.2004.04.030; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092; Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352; Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Kawaji H, 2011, NUCLEIC ACIDS RES, V39, pD856, DOI 10.1093/nar/gkq1112; Louro R, 2009, GENOMICS, V93, P291, DOI 10.1016/j.ygeno.2008.11.009; Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Oliva J, 2009, EXP MOL PATHOL, V87, P12, DOI 10.1016/j.yexmp.2009.03.006; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100; Wojcik SE, 2010, CARCINOGENESIS, V31, P208, DOI 10.1093/carcin/bgp209; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380; Zhang X, 2003, J CLIN ENDOCR METAB, V88, P5119, DOI 10.1210/jc.2003-030222; Zhang X, 2010, CANCER RES, V70, P2350, DOI 10.1158/0008-5472.CAN-09-3885; Zhang X, 2010, ENDOCRINOLOGY, V151, P939, DOI 10.1210/en.2009-0657; Zhao J, 2005, J CLIN ENDOCR METAB, V90, P2179, DOI 10.1210/jc.2004-1848; Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200	36	521	581	1	201	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	47					4750	4756		10.1038/onc.2011.193	http://dx.doi.org/10.1038/onc.2011.193			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21625215	Green Published, Green Accepted			2022-12-28	WOS:000298033700007
J	Pal, J; Bertheau, R; Buon, L; Qazi, A; Batchu, RB; Bandyopadhyay, S; Ali-Fehmi, R; Beer, DG; Weaver, DW; Reis, RJS; Goyal, RK; Huang, Q; Munshi, NC; Shammas, MA				Pal, J.; Bertheau, R.; Buon, L.; Qazi, A.; Batchu, R. B.; Bandyopadhyay, S.; Ali-Fehmi, R.; Beer, D. G.; Weaver, D. W.; Reis, R. J. Shmookler; Goyal, R. K.; Huang, Q.; Munshi, N. C.; Shammas, M. A.			Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome	ONCOGENE			English	Article						Barrett's adenocarcinoma; recombination; evolution; alu; hsRad51	TELOMERASE INHIBITION; DNA-REPAIR; CHROMOSOMAL INSTABILITY; GENETIC-CONTROL; GROWTH ARREST; UP-REGULATION; T-ANTIGEN; APC GENE; CANCER; ESOPHAGUS	A prominent feature of most cancers including Barrett's adenocarcinoma (BAC) is genetic instability, which is associated with development and progression of disease. In this study, we investigated the role of recombinase (hsRAD51), a key component of homologous recombination (HR)/repair, in evolving genomic changes and growth of BAC cells. We show that the expression of RAD51 is elevated in BAC cell lines and tissue specimens, relative to normal cells. HR activity is also elevated and significantly correlates with RAD51 expression in BAC cells. The suppression of RAD51 expression, by short hairpin RNA (shRNA) specifically targeting this gene, significantly prevented BAC cells from acquiring genomic changes to either copy number or heterozygosity (P<0.02) in several independent experiments employing single-nucleotide polymorphism arrays. The reduction in copy-number changes, following shRNA treatment, was confirmed by Comparative Genome Hybridization analyses of the same DNA samples. Moreover, the chromosomal distributions of mutations correlated strongly with frequencies and locations of Alu interspersed repetitive elements on individual chromosomes. We conclude that the hsRAD51 protein level is systematically elevated in BAC, contributes significantly to genomic evolution during serial propagation of these cells and correlates with disease progression. Alu sequences may serve as substrates for elevated HR during cell proliferation in vitro, as they have been reported to do during the evolution of species, and thus may provide additional targets for prevention or treatment of this disease. Oncogene (2011) 30, 3585-3598; doi:10.1038/onc.2011.83; published online 21 March 2011	[Pal, J.; Bertheau, R.; Buon, L.; Munshi, N. C.; Shammas, M. A.] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; [Pal, J.; Bertheau, R.; Goyal, R. K.; Huang, Q.; Munshi, N. C.; Shammas, M. A.] VA Hlth Care Syst, Dept Med Pathol, Boston, MA USA; [Qazi, A.; Batchu, R. B.; Bandyopadhyay, S.; Ali-Fehmi, R.; Weaver, D. W.] Wayne State Univ, Dept Surg Pathol, Detroit, MI USA; [Qazi, A.; Batchu, R. B.; Bandyopadhyay, S.; Ali-Fehmi, R.; Weaver, D. W.] Karmanos Canc Inst, Detroit, MI USA; [Beer, D. G.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Reis, R. J. Shmookler] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; [Reis, R. J. Shmookler] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; [Reis, R. J. Shmookler] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA; [Goyal, R. K.; Munshi, N. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; University of Michigan System; University of Michigan; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; Harvard University; Harvard Medical School	Shammas, MA (corresponding author), Dana Farber Canc Inst, 1400 VFW Pkwy,Bldg 3,Room 2A111, W Roxbury, MA 02132 USA.	Masood_Shammas@DFCI.Harvard.Edu	Munshi, Nikhil/ABE-2338-2021; Qazi, Aamer M/V-4249-2018	Qazi, Aamer M/0000-0003-0425-4246	National Cancer Institute [R01CA125711]; Department of Veterans Affairs; National Institutes of Health [RO1-1375555, P50-100007, PO1-78378]; NATIONAL CANCER INSTITUTE [R01CA125711, R01CA124929] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Cheng Li, Department of Bioinformatics and Dr Samir Amin, Departments of Medical Oncology and Bioinformatics, Dana Farber Cancer Institute, Boston, MA, USA, for their critical review of paper and guidance in data analyses. This work was supported in part by grants from National Cancer Institute (R01CA125711 to MAS), from the Department of Veterans Affairs (Merit Review Awards to NCM and RJSR and a Research Career Scientist Award to RJSR) and from the National Institutes of Health (RO1-1375555, P50-100007 and PO1-78378 to NCM).	Abdurashitov MA, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-305; Aggarwal S, 2000, NEOPLASIA, V2, P346, DOI 10.1038/sj.neo.7900097; Akagi T, 2009, INT J CANCER, V125, P2349, DOI 10.1002/ijc.24620; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; Barlund M, 2000, CANCER RES, V60, P5340; Bastos HN, 2009, THYROID, V19, P1067, DOI 10.1089/thy.2009.0099; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Beerenwinkel N, 2007, PLOS COMPUT BIOL, V3, P2239, DOI 10.1371/journal.pcbi.0030225; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; BROOKFIELD JFY, 1994, BIOESSAYS, V16, P793, DOI 10.1002/bies.950161104; BRUNNER AM, 1986, BIOCHEMISTRY-US, V25, P5028, DOI 10.1021/bi00366a009; Cai JC, 2008, WORLD J GASTROENTERO, V14, P4070, DOI 10.3748/wjg.14.4070; Cheng RZ, 1997, EXP CELL RES, V234, P300, DOI 10.1006/excr.1997.3649; Croft J, 2002, EUR J GASTROEN HEPAT, V14, P1179, DOI 10.1097/00042737-200211000-00004; ECONOMOUPACHNIS A, 1985, P NATL ACAD SCI USA, V82, P2857, DOI 10.1073/pnas.82.9.2857; ECONOMOUPACHNIS A, 1985, NUCLEIC ACIDS RES, V13, P8379, DOI 10.1093/nar/13.23.8379; FARBER E, 1984, CANCER RES, V44, P4217; Finley JC, 2006, CANCER EPIDEM BIOMAR, V15, P1451, DOI 10.1158/1055-9965.EPI-05-0837; Frank B, 2010, CARCINOGENESIS, V31, P442, DOI 10.1093/carcin/bgp293; GALLI A, 1995, MOL GEN GENET, V248, P301, DOI 10.1007/BF02191597; GEE CJ, 1979, J CELL SCI, V36, P223; Graves JAM, 2006, CELL, V124, P901, DOI 10.1016/j.cell.2006.02.024; Graves JAM, 2004, REPROD FERT DEVELOP, V16, P527, DOI 10.1071/RD03096; Hansen LT, 2003, INT J CANCER, V105, P472, DOI 10.1002/ijc.11106; HESS JF, 1983, P NATL ACAD SCI-BIOL, V80, P5970, DOI 10.1073/pnas.80.19.5970; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; HORII A, 1992, CANCER RES, V52, P3231; Jara L, 2010, BREAST CANCER RES TR, V122, P813, DOI 10.1007/s10549-009-0709-2; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kolomietz E, 2002, GENE CHROMOSOME CANC, V35, P97, DOI 10.1002/gcc.10111; Koppert LB, 2005, J SURG ONCOL, V92, P169, DOI 10.1002/jso.20359; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li HZ, 2001, GENOME BIOL, V2; Li J, 1997, MUTAT RES-DNA REPAIR, V385, P173, DOI 10.1016/S0921-8777(97)00054-2; Lynch HT, 1998, ONCOLOGY-BASEL, V55, P103, DOI 10.1159/000011843; Lynch HT, 1998, DIGESTION, V59, P481, DOI 10.1159/000007525; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Maciejewski JP, 2008, BLOOD, V112, P965, DOI 10.1182/blood-2008-02-130435; MIKI H, 1991, CANCER LETT, V58, P107, DOI 10.1016/0304-3835(91)90031-C; MIKI Y, 1992, CANCER RES, V52, P643; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; NEIMAN PE, 1991, NEW BIOL, V3, P347; Ogunwobi OO, 2008, AM J GASTROENTEROL, V103, P825, DOI 10.1111/j.1572-0241.2007.01773.x; Pathak S., 1994, In Vivo (Attiki), V8, P843; Paulson TG, 2009, CLIN CANCER RES, V15, P3305, DOI 10.1158/1078-0432.CCR-08-2494; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RADMAN M, 1982, MUTAT RES, V98, P249, DOI 10.1016/0165-1110(82)90035-5; RESNICK MA, 1989, P NATL ACAD SCI USA, V86, P2276, DOI 10.1073/pnas.86.7.2276; RODARTERAMON US, 1972, RADIAT RES, V49, P148, DOI 10.2307/3573379; Romagnoli S, 2001, LAB INVEST, V81, P241, DOI 10.1038/labinvest.3780232; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; SCHIMENTI JC, 1984, NUCLEIC ACIDS RES, V12, P1641, DOI 10.1093/nar/12.3.1641; SENGSTAG C, 1994, CRIT REV TOXICOL, V24, P323, DOI 10.3109/10408449409017922; Shammas MA, 1997, GENETICS, V146, P1417; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; Shammas MA, 2004, GASTROENTEROLOGY, V126, P1337, DOI 10.1053/j.gastro.2004.01.026; Shammas MA, 2003, MOL CANCER THER, V2, P825; Shammas MA, 2008, CLIN CANCER RES, V14, P4971, DOI 10.1158/1078-0432.CCR-08-0473; Shammas MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814; Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Silva SN, 2010, CANCER EPIDEMIOL, V34, P85, DOI 10.1016/j.canep.2009.11.002; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; Steinemann S, 2005, BIOESSAYS, V27, P1076, DOI 10.1002/bies.20288; Stilgenbauer S, 2007, HAEMATOLOGICA, V92, P1242, DOI 10.3324/haematol.10720; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; Sturgis EM, 1999, ARCH OTOLARYNGOL, V125, P185, DOI 10.1001/archotol.125.2.185; Tal A, 2009, J MOL BIOL, V393, P1007, DOI 10.1016/j.jmb.2009.09.011; Tsancheva M, 1997, Khirurgiia (Sofiia), V50, P40; Tselepis C, 2003, GUT, V52, P174, DOI 10.1136/gut.52.2.174; van Dekken H, 2001, AM J PATHOL, V158, P1961, DOI 10.1016/S0002-9440(10)64666-4; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; YAMADA Y, 1991, CANCER RES, V51, P5800; Ye CJ, 2007, CYTOGENET GENOME RES, V118, P237, DOI 10.1159/000108306; Yoshida N, 2007, INT J MOL MED, V19, P335	79	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	33					3585	3598		10.1038/onc.2011.83	http://dx.doi.org/10.1038/onc.2011.83			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423218	Green Accepted			2022-12-28	WOS:000294005100003
J	Tomita, T; Sakurai, Y; Ishibashi, S; Maru, Y				Tomita, T.; Sakurai, Y.; Ishibashi, S.; Maru, Y.			Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis	ONCOGENE			English	Article						Clara cell; lung metastasis; serum amyloid A3; Toll-like receptor 4	TUMOR-NECROSIS-FACTOR; ALLERGIC PULMONARY INFLAMMATION; SERUM AMYLOID A3; NF-KAPPA-B; TRANSENDOTHELIAL MIGRATION; NEGATIVE REGULATOR; EPITHELIAL-CELLS; DANGER SIGNAL; MYELOID CELLS; PROTEIN	We have previously shown that tumor necrosis factor (TNF)alpha produced from primary tumor-induced expression of two endogenous Toll-like receptor 4 (TLR4) ligands, S100A8 and serum amyloid A3 (SAA3), in pre-metastatic lungs. However, mechanistic details of the signaling network and relevance to pulmonary physiology are poorly understood. Here, we identify Clara cells as a control tower of the network. Clara cell ablation by naphthalene suppressed pulmonary recruitment of CD11b+ TLR4+ cells and spontaneous lung metastasis. Clara cells turned out to express TLR4 through which SAA3 was auto-amplified. Reciprocal bone marrow transplantation between wild-type and TLR4 knockout mice demonstrated that pulmonary TLR4+ Clara cells could be derived from bone marrow. SAA3-induced TNF alpha expression in both alveolar type II cells and macrophages. Primary co-cultures of alveolar type II cells and Clara cells revealed that the induction of TNF alpha in alveolar type II cells was dependent on the Clara cell-mediated amplification of SAA3. SAA3 induction by bacterial endotoxin also required both Clara cells and TLR4. Thus, pulmonary metastatic soil may feature deregulation of homeostatic inflammatory responses to constant assaults of microbes with endotoxin. Oncogene (2011) 30, 3429-3439; doi:10.1038/onc.2011.53; published online 14 March 2011	[Maru, Y.] Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan	Tokyo Women's Medical University	Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	ymaru@research.twmu.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; Tomita, Takeshi/0000-0001-6815-2244	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [21117008, 21790330]; Sato Memorial Foundation for Cancer Research; Multidisciplinary Education and Research Center for Regenerative Medicine (MERCREM), from MEXT, Japan	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Sato Memorial Foundation for Cancer Research; Multidisciplinary Education and Research Center for Regenerative Medicine (MERCREM), from MEXT, Japan	We thank Dr Shioko Kimura at National Institute of Health for providing resources including cell lines. This work was supported by Grant-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, 21117008 (YM) and 21790330 (TT), Sato Memorial Foundation for Cancer Research (TT), and the Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine (MERCREM), from MEXT, Japan.	Armstrong L, 2004, AM J RESP CELL MOL, V31, P241, DOI 10.1165/rcmb.2004-0078OC; Arsalane K, 2000, AM J RESP CRIT CARE, V161, P1624, DOI 10.1164/ajrccm.161.5.9812157; Atkinson JJ, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-1; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bing ZY, 2000, J BIOL CHEM, V275, P31616, DOI 10.1074/jbc.M005378200; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Devoogdt N, 2003, P NATL ACAD SCI USA, V100, P5778, DOI 10.1073/pnas.1037154100; DOBBS LG, 1978, AM REV RESPIR DIS, V134, P141; Franklin GA, 2003, AM J SURG, V186, P493, DOI 10.1016/j.amjsurg.2003.07.012; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gilchrist M, 2008, J EXP MED, V205, P2349, DOI 10.1084/jem.20072254; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kerkhoff C, 2005, FASEB J, V19, P467, DOI 10.1096/fj.04-2377fje; Kerkhoff C, 1999, PATHOBIOLOGY, V67, P230, DOI 10.1159/000028098; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019; Maru Y, 2010, CELL MOL IMMUNOL, V7, P94, DOI 10.1038/cmi.2009.113; Maru Yoshiro, 2009, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V8, P337; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Passey RJ, 1999, J IMMUNOL, V163, P2209; Raquil MA, 2008, J IMMUNOL, V180, P3366, DOI 10.4049/jimmunol.180.5.3366; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Saha A, 2010, J BIOL CHEM, V285, P10822, DOI 10.1074/jbc.M109.083550; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Son DS, 2004, ENDOCRINOLOGY, V145, P2245, DOI 10.1210/en.2003-1261; Taranova AG, 2008, CANCER RES, V68, P8582, DOI 10.1158/0008-5472.CAN-08-1673; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; van Zoelen MAD, 2009, J IMMUNOL, V182, P4349, DOI 10.4049/jimmunol.0801199; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wong AP, 2009, J CLIN INVEST, V119, P336, DOI 10.1172/JCI36882; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107; Yao XL, 1998, AM J RESP CELL MOL, V19, P629, DOI 10.1165/ajrcmb.19.4.3129; Yatera K, 2001, ENVIRON HEALTH PERSP, V109, P795, DOI 10.2307/3454821; Zhang XC, 2006, J CLIN INVEST, V116, P3050, DOI 10.1172/JCI28139; ZUGMAIER G, 1991, CANCER RES, V51, P3590	43	44	47	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3429	3439		10.1038/onc.2011.53	http://dx.doi.org/10.1038/onc.2011.53			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21399660				2022-12-28	WOS:000293508100004
J	Pollina, EA; Brunet, A				Pollina, E. A.; Brunet, A.			Epigenetic regulation of aging stem cells	ONCOGENE			English	Review						neural stem cells; hematopoietic stem cells; aging; epigenetic; chromatin; FOXO transcription factors	FOXO TRANSCRIPTION FACTORS; ADULT MAMMALIAN FOREBRAIN; NUCLEAR RECEPTOR TAILLESS; MURINE HEMATOPOIETIC STEM; MUSCLE SATELLITE CELLS; DNA-DAMAGE RESPONSE; AGE-RELATED-CHANGES; HISTONE METHYLTRANSFERASE ACTIVITY; DEMETHYLASE JMJD3 CONTRIBUTES; CHROMATIN REMODELING COMPLEX	The function of adult tissue-specific stem cells declines with age, which may contribute to the physiological decline in tissue homeostasis and the increased risk of neoplasm during aging. Old stem cells can be 'rejuvenated' by environmental stimuli in some cases, raising the possibility that a subset of age-dependent stem cell changes is regulated by reversible mechanisms. Epigenetic regulators are good candidates for such mechanisms, as they provide a versatile checkpoint to mediate plastic changes in gene expression and have recently been found to control organismal longevity. Here, we review the importance of chromatin regulation in adult stem cell compartments. We particularly focus on the roles of chromatin-modifying complexes and transcription factors that directly impact chromatin in aging stem cells. Understanding the regulation of chromatin states in adult stem cells is likely to have important implications for identifying avenues to maintain the homeostatic balance between sustained function and neoplastic transformation of aging stem cells. Oncogene (2011) 30, 3105-3126; doi:10.1038/onc.2011.45; published online 28 March 2011	[Pollina, E. A.; Brunet, A.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Pollina, E. A.; Brunet, A.] Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA	Stanford University; Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, 300 Pasteur Dr,Alway M336, Stanford, CA 94305 USA.	anne.brunet@stanford.edu			California Institute of Regenerative Medicine; Ellison Medical Foundation; NSF; NATIONAL INSTITUTE ON AGING [P01AG036695, F31AG043232] Funding Source: NIH RePORTER	California Institute of Regenerative Medicine(California Institute for Regenerative Medicine); Ellison Medical Foundation(Lawrence Ellison Foundation); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Eric L Greer and Wendy W Pang for critical reading of the manuscript and helpful suggestions. This work was supported by a California Institute of Regenerative Medicine New Faculty Award (AB), an Ellison Medical Foundation Senior Award (AB) and an NSF graduate fellowship (EAP).	Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Ahlenius H, 2009, J NEUROSCI, V29, P4408, DOI 10.1523/JNEUROSCI.6003-08.2009; Anselmi CV, 2009, REJUV RES, V12, P95, DOI 10.1089/rej.2008.0827; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Arantes-Oliveira N, 2002, SCIENCE, V295, P502, DOI 10.1126/science.1065768; Attema JL, 2009, ONCOGENE, V28, P2238, DOI 10.1038/onc.2009.94; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Beckervordersandforth R, 2010, CELL STEM CELL, V7, P744, DOI 10.1016/j.stem.2010.11.017; Beerman I, 2010, CURR OPIN IMMUNOL, V22, P500, DOI 10.1016/j.coi.2010.06.007; Beerman I, 2010, P NATL ACAD SCI USA, V107, P5465, DOI 10.1073/pnas.1000834107; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024; Biteau B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001159; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Bockhold KJ, 1998, MUSCLE NERVE, V21, P173, DOI 10.1002/(SICI)1097-4598(199802)21:2<173::AID-MUS4>3.0.CO;2-8; Bondolfi L, 2004, NEUROBIOL AGING, V25, P333, DOI 10.1016/S0197-4580(03)00083-6; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107; Boyle M, 2007, CELL STEM CELL, V1, P470, DOI 10.1016/j.stem.2007.08.002; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Brack AS, 2009, DEV BIOL, V335, P93, DOI 10.1016/j.ydbio.2009.08.014; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Breton-Provencher V, 2009, J NEUROSCI, V29, P15245, DOI 10.1523/JNEUROSCI.3606-09.2009; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Buszczak M, 2006, CELL, V125, P233, DOI 10.1016/j.cell.2006.04.004; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Carlson ME, 2008, NATURE, V454, P528, DOI 10.1038/nature07034; Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x; Carlson ME, 2009, EMBO MOL MED, V1, P381, DOI 10.1002/emmm.200900045; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Challen GA, 2010, CELL STEM CELL, V6, P265, DOI 10.1016/j.stem.2010.02.002; Chambers SM, 2007, PLOS BIOL, V5, P1750, DOI 10.1371/journal.pbio.0050201; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Chen S, 2009, P NATL ACAD SCI USA, V106, P1496, DOI 10.1073/pnas.0802674106; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Cheung I, 2010, P NATL ACAD SCI USA, V107, P8824, DOI 10.1073/pnas.1001702107; Cho RH, 2008, BLOOD, V111, P5553, DOI 10.1182/blood-2007-11-123547; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Chuikov S, 2010, NAT CELL BIOL, V12, P999, DOI 10.1038/ncb2101; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Conboy IM, 2005, CELL CYCLE, V4, P407, DOI 10.4161/cc.4.3.1518; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Corbu A, 2010, NEUROL RES, V32, P63, DOI 10.1179/174313209X385725; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dang WW, 2009, NATURE, V459, P802, DOI 10.1038/nature08085; de Haan G, 1999, BLOOD, V93, P3294, DOI 10.1182/blood.V93.10.3294.410k07_3294_3301; deHaan G, 1997, BLOOD, V89, P1543, DOI 10.1182/blood.V89.5.1543.1543_1543_1550; Deka J, 2010, CANCER RES, V70, P6619, DOI 10.1158/0008-5472.CAN-10-0148; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dumble M, 2007, BLOOD, V109, P1736, DOI 10.1182/blood-2006-03-010413; Dykstra B, 2007, CELL STEM CELL, V1, P218, DOI 10.1016/j.stem.2007.05.015; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fiedler M, 2008, MOL CELL, V30, P507, DOI 10.1016/j.molcel.2008.03.011; Flachsbart F, 2009, P NATL ACAD SCI USA, V106, P2700, DOI 10.1073/pnas.0809594106; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; GIBSON MC, 1983, MUSCLE NERVE, V6, P574, DOI 10.1002/mus.880060807; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Goodman RH, 2000, GENE DEV, V14, P1553; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Greer EL, 2010, NATURE, V466, P383, DOI 10.1038/nature09195; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133; Guerrettaz LM, 2008, P NATL ACAD SCI USA, V105, P11898, DOI 10.1073/pnas.0805498105; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hatta M, 2007, J BIOL CHEM, V282, P35583, DOI 10.1074/jbc.M704735200; Hattiangady B, 2008, NEUROBIOL AGING, V29, P129, DOI 10.1016/j.neurobiolaging.2006.09.015; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Hirabayashi Y, 2009, NEURON, V63, P600, DOI 10.1016/j.neuron.2009.08.021; Hisahara S, 2008, P NATL ACAD SCI USA, V105, P15599, DOI 10.1073/pnas.0800612105; Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911; Ho L, 2009, P NATL ACAD SCI USA, V106, P5181, DOI 10.1073/pnas.0812889106; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; Jawerka M, 2010, NEURON GLIA BIOL, V6, P93, DOI 10.1017/S1740925X10000049; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; Jones DL, 2007, STEM CELL REV, V3, P192, DOI 10.1007/s12015-007-0009-3; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585; Kamminga LM, 2005, STEM CELLS, V23, P82, DOI 10.1634/stemcells.2004-0066; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; Kawakami K, 2009, BIOGERONTOLOGY, V10, P415, DOI 10.1007/s10522-008-9176-0; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Ketel CS, 2005, MOL CELL BIOL, V25, P6857, DOI 10.1128/MCB.25.16.6857-6868.2005; Kim HS, 2010, CELL METAB, V12, P224, DOI 10.1016/j.cmet.2010.06.009; Kim M, 2003, ANN NY ACAD SCI, V996, P195, DOI 10.1111/j.1749-6632.2003.tb03247.x; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kronenberg G, 2006, NEUROBIOL AGING, V27, P1505, DOI 10.1016/j.neurobiolaging.2005.09.016; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Kung AL, 2000, GENE DEV, V14, P272; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lagace DC, 2007, J NEUROSCI, V27, P12623, DOI 10.1523/JNEUROSCI.3812-07.2007; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; LEWIS PD, 1968, NATURE, V217, P974, DOI 10.1038/217974a0; Li J, 2008, PLOS BIOL, V6, P1870, DOI 10.1371/journal.pbio.0060233; Li Y, 2009, HUM MOL GENET, V18, P4897, DOI 10.1093/hmg/ddp459; Liang Y, 2005, BLOOD, V106, P1479, DOI 10.1182/blood-2004-11-4282; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Lim DA, 2009, NATURE, V458, P529, DOI 10.1038/nature07726; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu HK, 2008, GENE DEV, V22, P2473, DOI 10.1101/gad.479308; Liu HK, 2010, GENE DEV, V24, P683, DOI 10.1101/gad.560310; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lugert S, 2010, CELL STEM CELL, V6, P445, DOI 10.1016/j.stem.2010.03.017; Ma DKK, 2010, NAT NEUROSCI, V13, P1338, DOI 10.1038/nn.2672; Ma DK, 2009, SCIENCE, V323, P1074, DOI 10.1126/science.1166859; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Martin C, 2007, CURR OPIN CELL BIOL, V19, P266, DOI 10.1016/j.ceb.2007.04.002; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; McMahon KA, 2007, CELL STEM CELL, V1, P338, DOI 10.1016/j.stem.2007.07.002; Merkle FT, 2007, SCIENCE, V317, P381, DOI 10.1126/science.1144914; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Michallet M, 2000, EXP HEMATOL, V28, P858, DOI 10.1016/S0301-472X(00)00169-7; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Miyamoto K, 2008, BLOOD, V112, P4485, DOI 10.1182/blood-2008-05-159848; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morgan DE, 2010, DEV BIOL, V346, P204, DOI 10.1016/j.ydbio.2010.07.022; Morgan JE, 2003, INT J BIOCHEM CELL B, V35, P1151, DOI 10.1016/S1357-2725(03)00042-6; Morita Y, 2010, J EXP MED, V207, P1173, DOI 10.1084/jem.20091318; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Morshead CM, 1998, DEVELOPMENT, V125, P2251; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narala SR, 2008, MOL BIOL CELL, V19, P1210, DOI 10.1091/mbc.E07-09-0965; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Ogawa T, 2000, MECH AGEING DEV, V117, P57, DOI 10.1016/S0047-6374(00)00137-8; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; OH YH, 1972, LIFE SCI 2-BIOCH GEN, V11, P1207, DOI 10.1016/0024-3205(72)90188-9; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Ou XA, 2011, BLOOD, V117, P440, DOI 10.1182/blood-2010-03-273011; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Parent JM, 1997, J NEUROSCI, V17, P3727; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Pastrana E, 2009, P NATL ACAD SCI USA, V106, P6387, DOI 10.1073/pnas.0810407106; Pawlikowska L, 2009, AGING CELL, V8, P460, DOI 10.1111/j.1474-9726.2009.00493.x; Pearce DJ, 2007, STEM CELLS, V25, P828, DOI 10.1634/stemcells.2006-0405; Peinado MA, 1998, MICROSC RES TECHNIQ, V43, P34, DOI 10.1002/(SICI)1097-0029(19981001)43:1<34::AID-JEMT6>3.3.CO;2-7; Peleg S, 2010, SCIENCE, V328, P753, DOI 10.1126/science.1186088; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Ramadori G, 2010, CELL METAB, V12, P78, DOI 10.1016/j.cmet.2010.05.010; Rando TA, 2005, NAT MED, V11, P829, DOI 10.1038/nm0805-829; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Renault V, 2002, AGING CELL, V1, P132, DOI 10.1046/j.1474-9728.2002.00017.x; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; RINE J, 1979, GENETICS, V93, P877; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rossi DJ, 2007, CELL CYCLE, V6, P2371, DOI 10.4161/cc.6.19.4759; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Roy K, 2004, J NEUROSCI, V24, P8333, DOI 10.1523/JNEUROSCI.1148-04.2004; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387; SCHULTZ E, 1982, MECH AGEING DEV, V20, P377, DOI 10.1016/0047-6374(82)90105-1; SCHULTZ E, 1978, J EXP ZOOL, V206, P451, DOI 10.1002/jez.1402060314; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Sgarra R, 2005, PROTEOMICS, V5, P1494, DOI 10.1002/pmic.200401028; Sgarra R, 2008, PROTEOMICS, V8, P4721, DOI 10.1002/pmic.200800193; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Shen SM, 2008, NAT NEUROSCI, V11, P1024, DOI 10.1038/nn.2172; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Siebold AP, 2010, P NATL ACAD SCI USA, V107, P169, DOI 10.1073/pnas.0907739107; Siebzehnrubl FA, 2007, EXP BRAIN RES, V176, P672, DOI 10.1007/s00221-006-0831-x; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Song ZF, 2009, EXP GERONTOL, V44, P75, DOI 10.1016/j.exger.2008.06.009; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Sudo K, 2000, J EXP MED, V192, P1273, DOI 10.1084/jem.192.9.1273; Sun GQ, 2007, P NATL ACAD SCI USA, V104, P15282, DOI 10.1073/pnas.0704089104; Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09; Taraldsrud E, 2009, SCAND J CLIN LAB INV, V69, P79, DOI 10.1080/00365510802419447; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Thomas T, 2000, DEVELOPMENT, V127, P2537; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Tropepe V, 1997, J NEUROSCI, V17, P7850; Trowbridge Jennifer J, 2010, Epigenetics, V5, P189; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; Uchida N, 1998, J CLIN INVEST, V101, P961, DOI 10.1172/JCI1681; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; VICK NA, 1977, ACTA NEUROPATHOL, V40, P63, DOI 10.1007/BF00688574; Vidanes GM, 2005, CELL, V121, P973, DOI 10.1016/j.cell.2005.06.013; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Voog J, 2010, CELL STEM CELL, V6, P103, DOI 10.1016/j.stem.2010.01.011; Wagers AJ, 2002, GENE THER, V9, P606, DOI 10.1038/sj.gt.3301717; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Waterstrat Amanda, 2008, P111, DOI 10.1007/978-3-540-73709-4_6; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485; Xing ZL, 2006, BLOOD, V108, P2190, DOI 10.1182/blood-2005-12-010272; Yalcin S, 2008, J BIOL CHEM, V283, P25692, DOI 10.1074/jbc.M800517200; Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599; Zammit PS, 2002, EXP CELL RES, V281, P39, DOI 10.1006/excr.2002.5653; Zencak D, 2005, J NEUROSCI, V25, P5774, DOI 10.1523/JNEUROSCI.3452-04.2005; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	308	82	88	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3105	3126		10.1038/onc.2011.45	http://dx.doi.org/10.1038/onc.2011.45			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21441951				2022-12-28	WOS:000292726300001
J	Crescenzi, E; Pacifico, F; Lavorgna, A; De Palma, R; D'Aiuto, E; Palumbo, G; Formisano, S; Leonardi, A				Crescenzi, E.; Pacifico, F.; Lavorgna, A.; De Palma, R.; D'Aiuto, E.; Palumbo, G.; Formisano, S.; Leonardi, A.			NF-kappa B-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells	ONCOGENE			English	Article						premature senescence; NF-kappa B; apoptosis; Fas; senescence-associated secretory phenotype	ONCOGENE-INDUCED SENESCENCE; IMMUNE-SYSTEM; DNA-DAMAGE; IN-VIVO; CELLULAR SENESCENCE; MEDIATED APOPTOSIS; CANCER-THERAPY; P53; PHENOTYPE; DEATH	Induction of a senescent phenotype in tumor cells has been linked to anticancer immune response, however, the molecular mechanisms mediating these phenomenon have not yet been determined. In this study, we present evidence that induction of premature senescence in human cancer cell lines induces Fas expression, and loss of resistance to Fas-induced apoptosis. Triggering of Fas by using the agonistic antibody CH11 or the recombinant ligand APO010, activates an apoptotic pathway responsible for cell death. Secretion of pro-inflammatory cytokines by the senescent cells, particularly TNF-alpha and IFN-gamma, mediates Fas upregulation. Indeed, treatment of proliferating cancer cell lines with TNF-alpha and IFN-gamma, upregulates Fas expression, while blocking TNF-alpha and IFN-gamma by using neutralizing antibodies, decreases Fas expression in senescent cells. We also demonstrate that NF-kappa B has a central role in controlling the senescence-associated secretory phenotype (SASP) by the premature senescent cells, and that TNF-alpha and IFN-gamma, transcriptionally controlled by NF-kappa B, are the main mediators of Fas upregulation. Our data suggest the existence of an NF-kappa B- dependent autocrine loop, mediated by TNF-alpha and IFN-gamma, responsible for expression of Fas on the surface of senescent cells, and for their killing. Oncogene (2011) 30, 2707-2717; doi: 10.1038/onc.2011.1; published online 31 January 2011	[Lavorgna, A.; Palumbo, G.; Formisano, S.; Leonardi, A.] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Crescenzi, E.; Pacifico, F.] Ist Endocrinol & Oncol Sperimentale, Naples, Italy; [De Palma, R.; D'Aiuto, E.] Univ Naples 2, Dipartimento Internist Clin & Sperimentale, Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universita della Campania Vanvitelli	Leonardi, A (corresponding author), Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	leonardi@unina.it	Pacifico, Francesco/AAX-3958-2020; leonardi, antonio/A-2887-2009; Lavorgna, Alfonso/A-5357-2012; Palumbo, Giuseppe/N-3136-2016	Pacifico, Francesco/0000-0001-9563-3596; leonardi, antonio/0000-0001-8636-9623; Palumbo, Giuseppe/0000-0001-9380-8436; CRESCENZI, ELVIRA/0000-0002-9258-8053; De Palma, Raffaele/0000-0001-9070-8878	MIUR [2008CCPKRP, 2007WJZZR2]	MIUR(Ministry of Education, Universities and Research (MIUR))	MIUR # 2008CCPKRP to AL; MIUR # 2007WJZZR2 to GP	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Chang BD, 1999, CANCER RES, V59, P3761; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Crescenzi E, 2008, CLIN CANCER RES, V14, P1877, DOI 10.1158/1078-0432.CCR-07-4298; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fluhr H, 2007, J CELL SCI, V120, P4126, DOI 10.1242/jcs.009761; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Gasser S, 2006, CANCER RES, V66, P3959, DOI 10.1158/0008-5472.CAN-05-4603; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Kimura M, 2003, CELL DEATH DIFFER, V10, P718, DOI 10.1038/sj.cdd.4401219; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Mirzayans R, 2005, RADIAT RES, V163, P53, DOI 10.1667/RR3280; NAUMANN M, 1993, ONCOGENE, V8, P2275; Neumann L, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.6; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Russo M, 2010, BIOCHEM PHARMACOL, V80, P674, DOI 10.1016/j.bcp.2010.03.011; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Soriani A, 2009, BLOOD, V113, P3503, DOI 10.1182/blood-2008-08-173914; te Poele RH, 2002, CANCER RES, V62, P1876; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verbrugge I, 2009, CLIN CANCER RES, V15, P2031, DOI 10.1158/1078-0432.CCR-08-2125; WAJAPEYEE N, 2008, CELL, V133, P1006; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22	39	49	51	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2707	2717		10.1038/onc.2011.1	http://dx.doi.org/10.1038/onc.2011.1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278794				2022-12-28	WOS:000291678500002
J	McGivern, DR; Lemon, SM				McGivern, D. R.; Lemon, S. M.			Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer	ONCOGENE			English	Review						hepatitis C virus; hepatocellular carcinoma; cirrhosis; tumor suppressor	BOX RNA HELICASE; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA INCIDENCE; RETINOBLASTOMA TUMOR-SUPPRESSOR; CORE PROTEIN INTERACTS; OXIDATIVE STRESS; GENE-EXPRESSION; UNITED-STATES; ADAPTER PROTEIN; MOUSE MODEL	The development of hepatocellular carcinoma (HCC) in persons who are persistently infected with hepatitis C virus (HCV) is a growing problem worldwide. Current antiviral therapies are not effective in many patients with chronic hepatitis C, and a greater understanding of the factors leading to progression of HCC will be necessary to design novel approaches to prevention of HCV-associated HCC. The lack of a small animal model of chronic HCV infection has hampered understanding of these factors. As HCV is an RNA virus with little potential for integration of its genetic material into the host genome, the mechanisms underlying HCV promotion of cancer are likely to differ from other models of viral carcinogenesis. In patients persistently infected with HCV, chronic inflammation resulting from immune responses against infected hepatocytes is associated with progressive fibrosis and cirrhosis. Cirrhosis is an important risk factor for HCC independent of HCV infection, and a majority of HCV-associated HCC arises in the setting of cirrhosis. However, a significant minority arises in the absence of cirrhosis, indicating that cirrhosis is not a prerequisite for cancer. Other lines of evidence suggest that direct, virus-specific mechanisms may be involved. Transgenic mice expressing HCV proteins develop cancer in the absence of inflammation or immune recognition of the transgene. In vitro studies have revealed multiple interactions of HCV-encoded proteins with cell cycle regulators and tumor suppressor proteins, raising the possibility that HCV can disrupt control of cellular proliferation, or impair the cell's response to DNA damage. A combination of virus-specific, host genetic, environmental and immune-related factors are likely to determine the progression to HCC in patients who are chronically infected with HCV. Here, we summarize current knowledge of the virus-specific mechanisms that may contribute to HCV-associated HCC. Oncogene (2011) 30, 1969-1983; doi:10.1038/onc.2010.594; published online 24 January 2011	[Lemon, S. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Infect Dis, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Ctr Translat Res, Inflammatory Dis Inst, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	McGivern, DR (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Infect Dis, Dept Med, Chapel W Dr,8-034 Burnett Womack, Chapel Hill, NC 27599 USA.	smlemon@med.unc.edu	Mcgivern, David/H-6210-2019; Ibrahim, Essam Hassan/G-1960-2018	Mcgivern, David/0000-0003-3497-5087; Ibrahim, Essam Hassan/0000-0003-0130-2257	University Cancer Research Fund; National Institutes of Health [P20-CA127004, R21-AI081058]; NATIONAL CANCER INSTITUTE [P20CA150343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI081058] Funding Source: NIH RePORTER	University Cancer Research Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by the University Cancer Research Fund and grants from the National Institutes of Health: P20-CA127004 and R21-AI081058.	Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Angus AGN, 2010, J GEN VIROL, V91, P122, DOI 10.1099/vir.0.015909-0; Ariumi Y, 2008, J VIROL, V82, P9639, DOI 10.1128/JVI.00351-08; Ariumi Y, 2007, J VIROL, V81, P13922, DOI 10.1128/JVI.01517-07; Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Azechi H, 2001, ONCOLOGY-BASEL, V60, P346, DOI 10.1159/000058531; Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774; Baroni GS, 1999, LIVER, V19, P212, DOI 10.1111/j.1478-3231.1999.tb00038.x; Bartsch H, 2004, CANCER DETECT PREV, V28, P385, DOI 10.1016/j.cdp.2004.07.004; Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079; Bralet MP, 2000, HEPATOLOGY, V32, P200, DOI 10.1053/jhep.2000.9033; Brenner David A, 2009, Trans Am Clin Climatol Assoc, V120, P361; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; Chou AH, 2005, J IMMUNOL, V174, P2160, DOI 10.4049/jimmunol.174.4.2160; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Cross TJS, 2010, HEPATOL RES, V40, P237, DOI 10.1111/j.1872-034X.2010.00626.x; Davis GL, 2010, GASTROENTEROLOGY, V138, P513, DOI 10.1053/j.gastro.2009.09.067; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Degos F, 2000, GUT, V47, P131, DOI 10.1136/gut.47.1.131; Deng L, 2008, J VIROL, V82, P10375, DOI 10.1128/JVI.00395-08; Deng L, 2006, J GEN VIROL, V87, P1703, DOI 10.1099/vir.0.81735-0; Dharel N, 2008, HEPATOLOGY, V47, P1136, DOI 10.1002/hep.22176; Diamond DL, 2007, HEPATOLOGY, V46, P649, DOI 10.1002/hep.21751; Dolganiuc A, 2004, GASTROENTEROLOGY, V127, P1513, DOI 10.1053/j.gastro.2004.08.067; Dutta U, 1998, HUM PATHOL, V29, P1279, DOI 10.1016/S0046-8177(98)90257-X; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Erdtmann L, 2003, J BIOL CHEM, V278, P18256, DOI 10.1074/jbc.M209732200; Farinati F, 1996, HEPATOLOGY, V23, P1468; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Fox JG, 2010, GUT, V59, P88, DOI 10.1136/gut.2009.183749; Furutani T, 2006, GASTROENTEROLOGY, V130, P2087, DOI 10.1053/j.gastro.2006.02.060; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gao YZ, 2009, CARCINOGENESIS, V30, P2064, DOI 10.1093/carcin/bgp283; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Goh PY, 2004, J VIROL, V78, P5288, DOI 10.1128/JVI.78.10.5288-5298.2004; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Honda A, 1999, J MED VIROL, V59, P281, DOI 10.1002/(SICI)1096-9071(199911)59:3<281::AID-JMV4>3.0.CO;2-S; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; Jangra RK, 2010, J VIROL, V84, P6810, DOI 10.1128/JVI.00397-10; Jangra RK, 2010, J VIROL, V84, P6615, DOI 10.1128/JVI.00417-10; Jopling CL, 2008, CELL HOST MICROBE, V4, P77, DOI 10.1016/j.chom.2008.05.013; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Joyce MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000291; Kamegaya Y, 2005, HEPATOLOGY, V41, P660, DOI 10.1002/hep.20621; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Kato T, 2003, CANCER SCI, V94, P679, DOI 10.1111/j.1349-7006.2003.tb01502.x; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; Keasler VV, 2006, VIROLOGY, V347, P466, DOI 10.1016/j.virol.2005.11.050; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Kim TY, 2003, J BIOL CHEM, V278, P15272, DOI 10.1074/jbc.M205792200; Klopstock N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005025; KOIKE K, 1995, J GEN VIROL, V76, P3031, DOI 10.1099/0022-1317-76-12-3031; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Koskinas J, 2005, J VIRAL HEPATITIS, V12, P635, DOI 10.1111/j.1365-2893.2005.00635.x; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Kwun HJ, 2001, J GEN VIROL, V82, P2235, DOI 10.1099/0022-1317-82-9-2235; Lai CK, 2008, VIROLOGY, V370, P295, DOI 10.1016/j.virol.2007.08.037; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lanford RE, 2011, HEPATITIS C: ANTIVIRAL DRUG DISCOVERY AND DEVELOPMENT, P103; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x; Lee SH, 2005, J IMMUNOL, V175, P8226, DOI 10.4049/jimmunol.175.12.8226; LEMON SM, 2007, FIELDS VIROLOGY, P1253; Lemon SM, 2010, J BIOL CHEM, V285, P22739, DOI 10.1074/jbc.R109.099556; Lentini L, 2002, NEOPLASIA, V4, P380, DOI 10.1038/sj.neo.7900256; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li K, 2002, HEPATOLOGY, V35, P1237, DOI 10.1053/jhep.2002.32968; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Liang YQ, 2009, GASTROENTEROLOGY, V137, P1448, DOI 10.1053/j.gastro.2009.07.050; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu XY, 2010, VIROLOGY, V398, P57, DOI 10.1016/j.virol.2009.11.036; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lok AS, 2009, GASTROENTEROLOGY, V136, P138, DOI 10.1053/j.gastro.2008.09.014; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Machida K, 2009, J VIROL, V83, P12590, DOI 10.1128/JVI.02643-08; Machida K, 2009, P NATL ACAD SCI USA, V106, P1548, DOI 10.1073/pnas.0807390106; Majumder M, 2003, FEBS LETT, V555, P528, DOI 10.1016/S0014-5793(03)01337-1; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marukian S, 2008, HEPATOLOGY, V48, P1843, DOI 10.1002/hep.22550; Masuzaki R, 2008, BEST PRACT RES CL GA, V22, P1137, DOI 10.1016/j.bpg.2008.11.005; Mateu G, 2008, VIROLOGY, V376, P397, DOI 10.1016/j.virol.2008.03.027; Mazzocca A, 2005, J BIOL CHEM, V280, P11329, DOI 10.1074/jbc.M410161200; McGivern DR, 2009, J VIROL, V83, P7422, DOI 10.1128/JVI.00262-09; McHutchison John G, 2003, Clin Liver Dis, V7, P149, DOI 10.1016/S1089-3261(02)00077-6; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Milward A, 2010, J GEN VIROL, V91, P373, DOI 10.1099/vir.0.015305-0; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 2001, CANCER RES, V61, P4365; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Munakata T, 2005, P NATL ACAD SCI USA, V102, P18159, DOI 10.1073/pnas.0505605102; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; Naas T, 2005, J GEN VIROL, V86, P2185, DOI 10.1099/vir.0.80969-0; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nomura-Takigawa Y, 2006, J GEN VIROL, V87, P1935, DOI 10.1099/vir.0.81701-0; Norman KL, 2010, J VIROL, V84, P666, DOI 10.1128/JVI.01156-09; O'Connor S., 2010, Morbidity and Mortality Weekly Report, V59, P517; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Oshiumi H, 2010, EUR J IMMUNOL, V40, P940, DOI 10.1002/eji.200940203; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Park CY, 2009, J HEPATOL, V51, P853, DOI 10.1016/j.jhep.2009.06.026; Pasquinelli C, 1997, HEPATOLOGY, V25, P719, DOI 10.1002/hep.510250338; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; Perz JF, 2006, J HEPATOL, V44, P441, DOI 10.1016/j.jhep.2005.12.007; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Prikhod'ko EA, 2004, VIROLOGY, V329, P53, DOI 10.1016/j.virol.2004.08.012; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Quinkert D, 2005, J VIROL, V79, P13594, DOI 10.1128/JVI.79.21.13594-13605.2005; Randall G, 2007, P NATL ACAD SCI USA, V104, P12884, DOI 10.1073/pnas.0704894104; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Sacco R, 2003, VIROLOGY, V317, P24, DOI 10.1016/j.virol.2003.08.028; Saito T, 2008, NATURE, V454, P523, DOI 10.1038/nature07106; Sato Y, 2006, GUT, V55, P1801, DOI 10.1136/gut.2005.070417; Schroder M, 2008, EMBO J, V27, P2147, DOI 10.1038/emboj.2008.143; Shackel NA, 2002, AM J PATHOL, V160, P641, DOI 10.1016/S0002-9440(10)64884-5; Shih JW, 2008, ONCOGENE, V27, P700, DOI 10.1038/sj.onc.1210687; Shimakami T, 2009, CURR OPIN PHARMACOL, V9, P537, DOI 10.1016/j.coph.2009.08.008; Shimizu YK, 1998, J GEN VIROL, V79, P1383, DOI 10.1099/0022-1317-79-6-1383; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Sun B, 2008, ONCOGENE, V27, P6228, DOI 10.1038/onc.2008.300; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takahashi K, 2010, P NATL ACAD SCI USA, V107, P7431, DOI 10.1073/pnas.1002301107; Takahashi Y, 2000, GENE DEV, V14, P804; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tanaka M, 2006, BIOCHEM BIOPH RES CO, V340, P792, DOI 10.1016/j.bbrc.2005.12.076; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P15584, DOI 10.1073/pnas.242608099; Taura M, 2008, MOL CELL BIOL, V28, P6557, DOI 10.1128/MCB.01202-08; Teufel A, 2009, WORLD J GASTROENTERO, V15, P578, DOI 10.3748/wjg.15.578; Thenappan A, 2010, HEPATOLOGY, V51, P1373, DOI 10.1002/hep.23449; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Umemura T, 2009, J GASTROENTEROL, V44, P102, DOI 10.1007/s00535-008-2251-0; Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Walters KA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000269; Wang AG, 2009, J PATHOL, V219, P253, DOI 10.1002/path.2592; Wang N, 2009, J VIROL, V83, P9824, DOI 10.1128/JVI.01125-09; Waris G, 2005, J VIROL, V79, P1569, DOI 10.1128/JVI.79.3.1569-1580.2005; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yeh MM, 2010, MODERN PATHOL, V23, P276, DOI 10.1038/modpathol.2009.174; Yeoman AD, 2008, HEPATOLOGY, V48, P863, DOI 10.1002/hep.22432; Yi M, 2006, P NATL ACAD SCI USA, V103, P2310, DOI 10.1073/pnas.0510727103; Yoshizawa H, 2002, ONCOLOGY-BASEL, V62, P8, DOI 10.1159/000048270; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	176	157	167	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					1969	1983		10.1038/onc.2010.594	http://dx.doi.org/10.1038/onc.2010.594			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21258404	Green Submitted, Green Accepted			2022-12-28	WOS:000289977400001
J	Cordani, N; Pozzi, S; Martynova, E; Fanoni, D; Borrelli, S; Alotto, D; Castagnoli, C; Berti, E; Vigano, MA; Mantovani, R				Cordani, N.; Pozzi, S.; Martynova, E.; Fanoni, D.; Borrelli, S.; Alotto, D.; Castagnoli, C.; Berti, E.; Vigano, M. A.; Mantovani, R.			Mutant p53 subverts p63 control over KLF4 expression in keratinocytes	ONCOGENE			English	Article						KLF4; p63; mutant p53; keratinocytes	KRUPPEL-LIKE FACTOR-4; SQUAMOUS-CELL CARCINOMA; INDUCED DNA-DAMAGE; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; SKIN-CANCER; STEM-CELL; TRANSCRIPTIONAL CONTROL; CYCLE REGULATION; BREAST-CANCER	Genetic experiments established that p63 is crucial for the development and maintenance of pluri-stratified epithelia and KLF4 for the barrier function of the skin. KLF4 is one of the factors that reprogram differentiated cells to iPS. We investigated the relationship between p63 and KLF4 using RNA interference, overexpression, chromatin immunoprecipitation and transient transfections with reporter constructs. We find that p63 directly represses KLF4 in normal keratinocytes (KCs) by binding to upstream promoter sites. Unlike p63, KLF4 levels are high in the upper layers of human skin and increase upon differentiation of KCs in vitro. In HaCaT KCs, which harbor two mutant alleles of p53, inactivation of p63 and of mutant p53 leads to KLF4 repression. p63 and p53 mutants are bound to sites in the KLF4 core promoter. Importantly, expression of the H179Y and R282Q p53 mutants in primary KCs is sufficient to activate endogenous KLF4. Finally, immunohistochemical analysis of tissue arrays confirms increased coexpression of KLF4 and mutant p53 in squamous cell carcinomas. Our data indicate that suppression of KLF4 is part of the growth-promoting strategy of p63 in the lower layers of normal epidermis, and that tumor-predisposing p53 mutations hijack p63 to a different location on the promoter, turning it into an activator of this reprogramming factor. Oncogene (2011) 30, 922-932; doi:10.1038/onc.2010.474; published online 25 October 2010	[Cordani, N.; Pozzi, S.; Martynova, E.; Borrelli, S.; Vigano, M. A.; Mantovani, R.] Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; [Fanoni, D.; Berti, E.] Univ Milan, Ist Sci Dermatol, IRCCS Fdn Osped Maggiore Policlin, I-20133 Milan, Italy; [Alotto, D.; Castagnoli, C.] Osped CTO, Dipartimento Chirurg Plast, Banca Cute, Turin, Italy; [Berti, E.] Univ Milano Bicocca, Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milano-Bicocca	Mantovani, R (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, Via Celoria 26, I-20133 Milan, Italy.	mantor@unimi.it	Cordani, Nicoletta/AAC-1978-2022; Berti, Emilio/F-5256-2012; Cordani, Nicoletta/ABG-8636-2020	Cordani, Nicoletta/0000-0002-3227-8280; Berti, Emilio/0000-0001-6753-4910; vigano, maria alessandra/0000-0003-2009-0384	European Union [EPISTEM LSHB-CT-2005-019067]; MIUR; Associazione Italiana per la Ricerca sul Cancro	European Union(European Commission); MIUR(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We thank V Yang (Emory University, USA) and C Ishioka (Tohoru U Jp) for gift of the KLF4-Luciferase vector and mutant p53 vectors, respectively. We thank K Vousden and P Muller (Beatson I, UK) for information on the p53 siRNA oligonucleotide. This work was supported by grants from the European Union (EPISTEM LSHB-CT-2005-019067), MIUR and Associazione Italiana per la Ricerca sul Cancro (to RM).	Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; Barbaro V, 2007, J CELL BIOL, V177, P1037, DOI 10.1083/jcb.200703003; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Carroll DK, 2007, CELL CYCLE, V6, P255, DOI 10.4161/cc.6.3.3799; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen YJ, 2008, CANCER BIOL THER, V7, P777, DOI 10.4161/cbt.7.5.5768; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dai X, 2004, CURR OPIN GENET DEV, V14, P485, DOI 10.1016/j.gde.2004.07.002; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; de Gruijl FR, 2008, PHOTOCHEM PHOTOBIOL, V84, P382, DOI 10.1111/j.1751-1097.2007.00275.x; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Donzelli S, 2008, CURR GENOMICS, V9, P200, DOI 10.2174/138920208784340713; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Furlan-Magaril M, 2009, METHODS MOL BIOL, V543, P253, DOI 10.1007/978-1-60327-015-1_17; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Ghaleb AM, 2007, ONCOGENE, V26, P2365, DOI 10.1038/sj.onc.1210022; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Pfeifer GP, 2009, HUM GENET, V125, P493, DOI 10.1007/s00439-009-0657-2; Pozzi S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005008; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rinne T, 2006, AM J MED GENET A, V140A, P1396, DOI 10.1002/ajmg.a.31271; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Smith C, 2004, BIOCHEM J, V380, P757, DOI 10.1042/BJ20040077; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Swamynathan SK, 2008, INVEST OPHTH VIS SCI, V49, P3360, DOI 10.1167/iovs.08-1811; Swamynathan SK, 2007, MOL CELL BIOL, V27, P182, DOI 10.1128/MCB.00846-06; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Testoni B, 2006, CELL CYCLE, V5, P2805, DOI 10.4161/cc.5.23.3525; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Vigano MA, 2007, CELL CYCLE, V6, P233, DOI 10.4161/cc.6.3.3802; Vigano MA, 2006, EMBO J, V25, P5105, DOI 10.1038/sj.emboj.7601375; Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243; Whitney EM, 2006, GENE EXPRESSION, V13, P85, DOI 10.3727/000000006783991908; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhou QB, 2009, CANCER RES, V69, P8284, DOI 10.1158/0008-5472.CAN-09-1345; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	72	28	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					922	932		10.1038/onc.2010.474	http://dx.doi.org/10.1038/onc.2010.474			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20972454				2022-12-28	WOS:000287695900004
J	Dangi-Garimella, S; Strouch, MJ; Grippo, PJ; Bentrem, DJ; Munshi, HG				Dangi-Garimella, S.; Strouch, M. J.; Grippo, P. J.; Bentrem, D. J.; Munshi, H. G.			Collagen regulation of let-7 in pancreatic cancer involves TGF-beta 1-mediated membrane type 1-matrix metalloproteinase expression	ONCOGENE			English	Article						TGF-beta 1; collagen; ERK1/2; MT1-MMP; let-7; fibrosis	EXTRACELLULAR-MATRIX; TRANSFORMING GROWTH-FACTOR-BETA-1; DUCTAL ADENOCARCINOMA; MICRORNA EXPRESSION; CELL-PROLIFERATION; TUMOR-DEVELOPMENT; INVASION; MT1-MMP; FAMILY; RAS	Pancreatic ductal adenocarcinoma (PDAC) is associated with a pronounced collagen-rich fibrosis known as desmoplastic reaction; however, the role of fibrosis in PDAC is poorly understood. In this report we show that collagen can regulate the tumor suppressive let-7 family of microRNAs in pancreatic cancer cells. PDAC cells growing in 3D collagen gels repress mature let-7 without affecting the precursor form of let-7 in part through increased expression of membrane type 1-matrix metallo-proteinase (MT1-MMP, MMP-14) and ERK1/2 activation. PDAC cells in collagen also demonstrate increased TGF-beta 1 signaling, and blocking TGF-beta 1 signaling attenuated collagen-induced MT1-MMP expression, ERK1/2 activation and repression of let-7 levels. Although MT1-MMP overexpression was not sufficient to inhibit let-7 on 2D tissue culture plastic, overexpression of MT1-MMP in PDAC cells embedded in 3D collagen gels or grown in vivo repressed let-7 levels. Importantly, MT1-MMP expression significantly correlated with decreased levels of let-7 in human PDAC tumor specimens. Overall, our study emphasizes the interplay between the key proteinase MT1-MMP and its substrate type I collagen in modulating microRNA expression, and identifies an additional mechanism by which fibrosis may contribute to PDAC progression. Oncogene (2011) 30, 1002-1008; doi:10.1038/onc.2010.485; published online 8 November 2010	[Dangi-Garimella, S.; Munshi, H. G.] Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Strouch, M. J.; Grippo, P. J.; Bentrem, D. J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Surg Oncol, Chicago, IL 60611 USA; [Grippo, P. J.; Bentrem, D. J.; Munshi, H. G.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Bentrem, D. J.; Munshi, H. G.] Jesse Brown VA Med Ctr, Chicago, IL USA	Northwestern University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Dangi-Garimella, S (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, 303 E Super Ave,Lurie 3-117, Chicago, IL 60611 USA.	s-dangi-garimella@northwestern.edu; h-munshi@northwestern.edu			NCI [R01CA126888]; Elsa U Pardee Foundation; National Pancreas Foundation; NATIONAL CANCER INSTITUTE [R01CA126888] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Elsa U Pardee Foundation; National Pancreas Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This research was supported by Grant R01CA126888 (HGM) from the NCI, and funding from the Elsa U Pardee Foundation (HGM) and the National Pancreas Foundation (HGM).	Aoyagi Y, 2004, BRIT J CANCER, V91, P1316, DOI 10.1038/sj.bjc.6602141; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Dangi-Garimella S, 2010, J BIOL CHEM, V285, P28363, DOI 10.1074/jbc.M110.146019; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dillhoff M, 2008, J GASTROINTEST SURG, V12, P2171, DOI 10.1007/s11605-008-0584-x; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; IMAMURA T, 1995, PANCREAS, V11, P357, DOI 10.1097/00006676-199511000-00007; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lohr M, 2001, CANCER RES, V61, P550; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; MORRIS JP, 2005, SCI STKE, pPE41; Oh JS, 2010, INT J RADIAT ONCOL, V76, P5, DOI 10.1016/j.ijrobp.2009.08.028; Ottaviano AJ, 2006, CANCER RES, V66, P7032, DOI 10.1158/0008-5472.CAN-05-4421; Park JK, 2009, PANCREAS, V38, pE190, DOI 10.1097/MPA.0b013e3181ba82e1; Paroo Z, 2009, CELL, V139, P112, DOI 10.1016/j.cell.2009.06.044; Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Roy S, 2009, CARDIOVASC RES, V82, P21, DOI 10.1093/cvr/cvp015; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sounnil NE, 2010, INT J CANCER, V126, P1067, DOI 10.1002/ijc.24690; Torrisani J, 2009, HUM GENE THER, V20, P831, DOI 10.1089/hum.2008.134; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	33	61	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	8					1002	1008		10.1038/onc.2010.485	http://dx.doi.org/10.1038/onc.2010.485			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21057545	Green Accepted			2022-12-28	WOS:000287695900011
J	Tonino, SH; van Laar, J; van Oers, MH; Wang, JY; Eldering, E; Kater, AP				Tonino, S. H.; van Laar, J.; van Oers, M. H.; Wang, J. Y.; Eldering, E.; Kater, A. P.			ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia	ONCOGENE			English	Article						CLL; chemoresistance; p53; ROS; platinum-based compounds; Noxa	NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE; INDUCE APOPTOSIS; PROTEASOME INHIBITOR; PROGNOSTIC MARKERS; OXIDATIVE STRESS; IN-VITRO; B-CELLS; FLUDARABINE; EXPRESSION	In recent years considerable progress has been made in treatment strategies for chronic lymphocytic leukemia (CLL). However, the disease remains incurable because of the development of chemoresistance. Strategies to overcome resistance mechanisms are therefore highly needed. At least two mechanisms contribute to the development of resistance to drugs; acquired mutations resulting in a dysfunctional p53 response and shifts in the balance between apoptosis-regulating proteins. Platinum-based compounds have been successfully applied in relapsed lymphoma and recently also in high-risk CLL. In this study we investigated the efficacy and mechanism of action of cisplatinum (CDDP) in chemorefractory CLL. Independent of p53-functional status, CDDP acted synergistically with fludarabine (F-ara-A). The response involved generation of reactive oxygen species (ROS), which led to specific upregulation of the proapoptotic BH3-only protein Noxa. Induction of Noxa resulted in cell death by apoptosis as inhibition of caspase activation completely abrogated cell death. Furthermore, drug-resistance upon CD40-ligand stimulation, a model for the protective stimuli provided in lymph nodes, could also be overcome by CDDP/F-ara-A. ROS accumulation resulted in Noxa upregulation mainly at the transcriptional level and this was, at least in part, mediated by the mitogen-activated protein kinase p38. Finally, Noxa RNA-interference markedly decreased sensitivity to CDDP/F-ara-A, supporting a key role for Noxa as mediator between ROS signaling and apoptosis induction. Our data indicate that interference in the cellular redox balance can be exploited to overcome chemoresistance in CLL. Oncogene (2011) 30, 701-713; doi:10.1038/onc.2010.441; published online 11 October 2010	[Tonino, S. H.; van Oers, M. H.; Kater, A. P.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands; [van Laar, J.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Expt Immunol Lab, NL-1105 AZ Amsterdam, Netherlands; [Wang, J. Y.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Wang, J. Y.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of California System; University of California San Diego; University of California System; University of California San Diego	Kater, AP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Hematol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.p.kater@amc.nl			Netherlands Organization for Health Research and Development; NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Baou and GM Cohen of the MRC Toxicology Unit, University of Leicester, United Kingdom for sharing their experience with nucleofection-procedures. APK is personally supported by a 'Veni' grant from the Netherlands Organization for Health Research and Development.	AKABOSHI M, 1994, JPN J CANCER RES, V85, P106, DOI 10.1111/j.1349-7006.1994.tb02893.x; Ali MS, 2005, J INORG BIOCHEM, V99, P795, DOI 10.1016/j.jinorgbio.2004.12.015; Baou M, 2010, HAEMATOL-HEMATOL J, V95, P1510, DOI 10.3324/haematol.2010.022368; Bhalla S, 2009, CLIN CANCER RES, V15, P3354, DOI 10.1158/1078-0432.CCR-08-2365; Bouzar AB, 2009, BRIT J HAEMATOL, V144, P41, DOI 10.1111/j.1365-2141.2008.07426.x; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Deriano L, 2005, BLOOD, V105, P4776, DOI 10.1182/blood-2004-07-2888; Dicker F, 2006, BLOOD, V108, P3450, DOI 10.1182/blood-2006-04-017749; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Garrido N, 2008, BIOCHEM J, V414, P93, DOI 10.1042/BJ20071615; GELEZIUNAS R, 1991, J NATL CANCER I, V83, P557, DOI 10.1093/jnci/83.8.557; Gong JG, 1999, NATURE, V399, P806; Hagrman D, 2004, J PHARMACOL EXP THER, V308, P658, DOI 10.1124/jpet.103.059410; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Husain K, 1998, MOL CELL BIOCHEM, V178, P127, DOI 10.1023/A:1006889427520; Kater AP, 2004, BRIT J HAEMATOL, V127, P404, DOI 10.1111/j.1365-2141.2004.05225.x; Kater AP, 2010, CL LYMPH MYELOM LEUK, V10, pS34, DOI 10.3816/CLML.2010.s.005; Li L, 1997, CANCER RES, V57, P1487; Mackus WJM, 2005, LEUKEMIA, V19, P427, DOI 10.1038/sj.leu.2403623; Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Miller CP, 2009, BLOOD, V113, P4289, DOI 10.1182/blood-2008-08-174797; Monjanel-Mouterde S, 2003, J CLIN PHARM THER, V28, P109, DOI 10.1046/j.1365-2710.2003.00468.x; Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614; Moufarij MA, 2006, BLOOD, V108, P4187, DOI 10.1182/blood-2006-05-023259; Mous R, 2009, LEUKEMIA, V23, P1352, DOI 10.1038/leu.2009.71; Nys K, 2010, J INVEST DERMATOL, V130, P2269, DOI 10.1038/jid.2010.93; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltra AM, 2001, FREE RADICAL BIO MED, V30, P1286, DOI 10.1016/S0891-5849(01)00521-4; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rosato RR, 2008, MOL CANCER THER, V7, P3285, DOI 10.1158/1535-7163.MCT-08-0385; Rosenwald A, 2004, BLOOD, V104, P1428, DOI 10.1182/blood-2003-09-3236; Roue G, 2008, CLIN CANCER RES, V14, P6907, DOI 10.1158/1078-0432.CCR-08-0388; SEYMOUR JF, 1995, LEUKEMIA LYMPHOMA, V18, P493, DOI 10.3109/10428199509059650; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; SPITZ DR, 1993, J CELL PHYSIOL, V156, P72, DOI 10.1002/jcp.1041560111; Tonino SH, 2010, LEUKEMIA, V24, P652, DOI 10.1038/leu.2009.240; Trachootham D, 2008, BLOOD, V112, P1912, DOI 10.1182/blood-2008-04-149815; Tsimberidou AM, 2008, J CLIN ONCOL, V26, P196, DOI 10.1200/JCO.2007.11.8513; Van Bockstaele F, 2009, BLOOD REV, V23, P25, DOI 10.1016/j.blre.2008.05.003; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Zenz T, 2008, BLOOD, V112, P3322, DOI 10.1182/blood-2008-04-154070; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	51	39	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	6					701	713		10.1038/onc.2010.441	http://dx.doi.org/10.1038/onc.2010.441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20935673	Green Accepted			2022-12-28	WOS:000287192000007
J	De Carvalho, DD; Binato, R; Pereira, WO; Leroy, JMG; Colassanti, MD; Proto-Siqueira, R; Bueno-Da-Silva, AEB; Zago, MA; Zanichelli, MA; Abdelhay, E; Castro, FA; Jacysyn, JF; Amarante-Mendes, GP				De Carvalho, D. D.; Binato, R.; Pereira, W. O.; Leroy, J. M. G.; Colassanti, M. D.; Proto-Siqueira, R.; Bueno-Da-Silva, A. E. B.; Zago, M. A.; Zanichelli, M. A.; Abdelhay, E.; Castro, F. A.; Jacysyn, J. F.; Amarante-Mendes, G. P.			BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients	ONCOGENE			English	Article						PRAME; TRAIL; TNFSF10; EZH2; CML; BCR-ABL	APOPTOSIS-INDUCING LIGAND; GENE-EXPRESSION PROFILES; CHRONIC MYELOID-LEUKEMIA; DOWN-REGULATION; ANTIGEN PRAME; TNF-FAMILY; TUMOR; MELANOMA; CELLS; ACTIVATION	Tumor necrosis factor-related apoptosis-inducing ligand-TNFSF10 (TRAIL), a member of the TNF-alpha family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, TRAIL is downregulated in a variety of tumor cells, including BCR-ABL-positive leukemia. Although we know much about the molecular basis of TRAIL-mediated cell killing, the mechanism responsible for TRAIL inhibition in tumors remains elusive because (a) TRAIL can be regulated by retinoic acid (RA); (b) the tumor antigen preferentially expressed antigen of melanoma (PRAME) was shown to inhibit transcription of RA receptor target genes through the polycomb protein, enhancer of zeste homolog 2 (EZH2); and (c) we have found that TRAIL is inversely correlated with BCR-ABL in chronic myeloid leukemia (CML) patients. Thus, we decided to investigate the association of PRAME, EZH2 and TRAIL in BCR-ABL-positive leukemia. Here, we demonstrate that PRAME, but not EZH2, is upregulated in BCR-ABL cells and is associated with the progression of disease in CML patients. There is a positive correlation between PRAME and BCR-ABL and an inverse correlation between PRAME and TRAIL in these patients. Importantly, knocking down PRAME or EZH2 by RNA interference in a BCR-ABL-positive cell line restores TRAIL expression. Moreover, there is an enrichment of EZH2 binding on the promoter region of TRAIL in a CML cell line. This binding is lost after PRAME knockdown. Finally, knocking down PRAME or EZH2, and consequently induction of TRAIL expression, enhances Imatinib sensibility. Taken together, our data reveal a novel regulatory mechanism responsible for lowering TRAIL expression and provide the basis of alternative targets for combined therapeutic strategies for CML. Oncogene (2011) 30, 223-233; doi:10.1038/onc.2010.409; published online 13 September 2010	[De Carvalho, D. D.; Pereira, W. O.; Leroy, J. M. G.; Bueno-Da-Silva, A. E. B.; Amarante-Mendes, G. P.] Univ Sao Paulo, Dept Immunol, Inst Ciencias Biomed, BR-05508900 Sao Paulo, Brazil; [De Carvalho, D. D.; Pereira, W. O.; Leroy, J. M. G.; Bueno-Da-Silva, A. E. B.; Castro, F. A.; Amarante-Mendes, G. P.] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, Brazil; [Binato, R.; Abdelhay, E.] Inst Nacl Canc, Div Labs CEMO, Rio De Janeiro, Brazil; [Colassanti, M. D.; Zanichelli, M. A.] Hosp Brigadeiro, Sao Paulo, Brazil; [Proto-Siqueira, R.] Fleury Med & Hlth, Sao Paulo, Brazil; [Zago, M. A.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-05508900 Sao Paulo, Brazil; [Castro, F. A.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-05508900 Sao Paulo, Brazil; [Jacysyn, J. F.] Univ Sao Paulo, Fac Med LIM62, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo; National Cancer Institute (Inca); Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Amarante-Mendes, GP (corresponding author), Univ Sao Paulo, Dept Immunol, Inst Ciencias Biomed, Av Prof Lineu Prestes,1730 Cidade Univ, BR-05508900 Sao Paulo, Brazil.	gpam@usp.br	ZAGO, MARCO A/E-9442-2017; De Carvalho, Daniel/F-4794-2011; de Castro, Fabiola Attie/D-4693-2012; Mendes, Gustavo P Amarante/C-8187-2012; Jacysyn, Jacqueline/C-9960-2012; De Carvalho, Daniel D/J-5503-2014	De Carvalho, Daniel/0000-0003-0771-2265; de Castro, Fabiola Attie/0000-0003-3347-5873; Mendes, Gustavo P Amarante/0000-0002-7851-6205; De Carvalho, Daniel D/0000-0002-8572-5259; Oliveira Pereira, Welbert/0000-0001-9546-1317	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil); FAPESP; Brazilian Research Council (CNPq-Brazil)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian Research Council (CNPq-Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	DDC, JMGL, WOP and AEBBS were recipients of fellowships from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil). This work was supported by grants from FAPESP and from the Brazilian Research Council (CNPq-Brazil). We thank Drs Phillippa Taberlay, Jueng Soo You and Theresa Kelly for their critical review of the paper.	Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; BEDI A, 1994, BLOOD, V83, P2038; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0; Bueno-da-Silva AEB, 2003, CELL DEATH DIFFER, V10, P592, DOI 10.1038/sj.cdd.4401210; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311; Epping MT, 2007, P NATL ACAD SCI USA, V104, P17777, DOI 10.1073/pnas.0702518104; Epping MT, 2006, CANCER RES, V66, P10639, DOI 10.1158/0008-5472.CAN-06-2522; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kikuchi S, 2007, CANCER SCI, V98, P1949, DOI 10.1111/j.1349-7006.2007.00623.x; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; McGahon AJ, 1997, CELL DEATH DIFFER, V4, P95, DOI 10.1038/sj.cdd.4400213; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nimmanapalli R, 2001, CLIN CANCER RES, V7, P350; Oberthuer A, 2004, CLIN CANCER RES, V10, P4307, DOI 10.1158/1078-0432.CCR-03-0813; Popnikolov NK, 2006, APPL IMMUNOHISTO M M, V14, P161, DOI 10.1097/01.pai.0000157905.30872.9f; Proto-Siqueira R, 2006, LEUKEMIA RES, V30, P1333, DOI 10.1016/j.leukres.2006.02.031; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Souza-Fagundes EM, 2003, EXP CELL RES, V290, P420, DOI 10.1016/S0014-4827(03)00350-1; Stearman RS, 2005, AM J PATHOL, V167, P1763, DOI 10.1016/S0002-9440(10)61257-6; Steinbach D, 2007, CANCER GENET CYTOGEN, V177, P51, DOI 10.1016/j.cancergencyto.2007.05.011; Tajeddine N, 2008, LEUKEMIA LYMPHOMA, V49, P1123, DOI 10.1080/10428190802035933; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2001, CELL IMMUNOL, V214, P194, DOI 10.1006/cimm.2001.1896; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Umlauf David, 2004, Methods Mol Biol, V287, P99; Uno K, 2003, BLOOD, V101, P3658, DOI 10.1182/blood-2002-06-1770; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vigneswaran N, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-108; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Watari K, 2000, FEBS LETT, V466, P367, DOI 10.1016/S0014-5793(00)01112-1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yong ASM, 2008, LEUKEMIA, V22, P1721, DOI 10.1038/leu.2008.161	49	42	42	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					223	233		10.1038/onc.2010.409	http://dx.doi.org/10.1038/onc.2010.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20838376				2022-12-28	WOS:000286438900010
J	Di Marcotullio, L; Greco, A; Mazza, D; Canettieri, G; Pietrosanti, L; Infante, P; Coni, S; Moretti, M; De Smaele, E; Ferretti, E; Screpanti, I; Gulino, A				Di Marcotullio, L.; Greco, A.; Mazza, D.; Canettieri, G.; Pietrosanti, L.; Infante, P.; Coni, S.; Moretti, M.; De Smaele, E.; Ferretti, E.; Screpanti, I.; Gulino, A.			Numb activates the E3 ligase Itch to control Gli1 function through a novel degradation signal	ONCOGENE			English	Article						Hedgehog; Gli1; Itch; Numb; ubiquitination; medulloblastoma	UBIQUITIN-PROTEIN LIGASE; WW DOMAINS; IN-VITRO; MEDULLOBLASTOMA; TARGETS; PROLIFERATION; ENZYME; FAMILY; PHOSPHORYLATION; TRANSCRIPTION	Hedgehog pathway regulates tissue patterning and cell proliferation. Gli1 transcription factor is the major effector of Hedgehog signaling and its deregulation is often associated to medulloblastoma formation. Proteolytic processes represent a critical mechanism by which this pathway is turned off. Here, we characterize the regulation of an ubiquitin-mediated mechanism of Gli1 degradation, promoted by the coordinated action of the E3 ligase Itch and the adaptor protein Numb. We show that Numb activates the catalytic activity of Itch, releasing it from an inhibitory intramolecular interaction between its homologous to E6-AP C-terminus and WW domains. The consequent activation of Itch, together with the recruitment of Gli1 through direct binding with Numb, allows Gli1 to enter into the complex, resulting in Gli1 ubiquitination and degradation. This process is mediated by a novel Itch-dependent degron, composed of a combination of two PPXYs and a phospho-serine/proline motifs, localized in Gli1 C-terminal region, indicating the role of two different WW docking sites in Gli1 ubiquitination. Remarkably, Gli1 protein mutated in these modules is no longer regulated by Itch and Numb, and determines enhanced Gli1-dependent medulloblastoma growth, migration and invasion abilities, as well as in vitro transforming activity. Our data reveal a novel mechanism of regulation of Gli1 stability and function, which influences Hedgehog/Gli1 oncogenic potential. Oncogene (2011) 30, 65-76; doi: 10.1038/onc.2010.394; published online 6 September 2010	[Moretti, M.; De Smaele, E.; Ferretti, E.; Gulino, A.] Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy; [Di Marcotullio, L.; Greco, A.; Mazza, D.; Canettieri, G.; Pietrosanti, L.; Infante, P.; Coni, S.; Screpanti, I.; Gulino, A.] Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy; [Screpanti, I.; Gulino, A.] Univ Roma La Sapienza, Inst Pasteur, Cenci Bolognetti Fdn, I-00161 Rome, Italy; [Gulino, A.] Neuromed Inst, Pozzilli, Italy	Sapienza University Rome; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; IRCCS Neuromed	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med, 324 Viale Regina Elena, I-00161 Rome, Italy.	alberto.gulino@uniroma1.it	Infante, Paola/G-9094-2018; De Smaele, Enrico/C-1124-2013; Mazzà, Daniela/AAK-3687-2021; Moretti, Marta/AAQ-7090-2020; Ferretti, Elisabetta/G-5413-2013	De Smaele, Enrico/0000-0003-4524-4423; Mazzà, Daniela/0000-0003-4754-9394; Infante, Paola/0000-0003-0682-3916; CANETTIERI, Gianluca/0000-0001-6694-2613; Ferretti, Elisabetta/0000-0001-7265-6429; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178	Associazione Italiana per la Ricerca sul Cancro (AIRC); Telethon [GGP07118]; Ministry of University and Research, (FIRB); Ministry of Health, Fondazione Roma and Fondazione Mariani	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); Ministry of University and Research, (FIRB)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministry of Health, Fondazione Roma and Fondazione Mariani	We thank Dr A Oro for providing the various Gli1 mutants and G Giannini for advice and critical discussion. This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Telethon Grant GGP07118 and the Ministry of University and Research, (FIRB), the Ministry of Health, Fondazione Roma and Fondazione Mariani.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Argenti B, 2005, J NEUROSCI, V25, P8338, DOI 10.1523/JNEUROSCI.2438-05.2005; Bar EE, 2007, AM J PATHOL, V170, P347, DOI 10.2353/ajpath.2007.060066; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Cayouette M, 2002, NAT NEUROSCI, V5, P1265, DOI 10.1038/nn1202-1265; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Galvin KE, 2008, STEM CELLS, V26, P1027, DOI 10.1634/stemcells.2007-0879; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guerreiro AS, 2008, CLIN CANCER RES, V14, P6761, DOI 10.1158/1078-0432.CCR-08-0385; Gulino A, 2010, EXP CELL RES, V316, P900, DOI 10.1016/j.yexcr.2009.11.017; Haas AL, 1997, FASEB J, V11, P1257; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ingham PW, 2006, NAT REV GENET, V7, P841, DOI 10.1038/nrg1969; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jia JH, 2005, DEV CELL, V9, P819, DOI 10.1016/j.devcel.2005.10.006; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Laner-Plamberger S, 2009, ONCOGENE, V28, P1639, DOI 10.1038/onc.2009.10; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Lohr NJ, 2010, AM J HUM GENET, V86, P447, DOI 10.1016/j.ajhg.2010.01.028; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Mouchantaf R, 2006, J BIOL CHEM, V281, P38738, DOI 10.1074/jbc.M605959200; Mund T, 2009, EMBO REP, V10, P501, DOI 10.1038/embor.2009.30; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038/ni1563; Sudol M, 2005, IUBMB LIFE, V57, P773, DOI 10.1080/15216540500389039; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Van Sant C, 2001, P NATL ACAD SCI USA, V98, P8815, DOI 10.1073/pnas.161283098; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Zhang Q, 2006, DEV CELL, V10, P719, DOI 10.1016/j.devcel.2006.05.004	55	82	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					65	76		10.1038/onc.2010.394	http://dx.doi.org/10.1038/onc.2010.394			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818436				2022-12-28	WOS:000285959300006
J	Nam, SY; Sabapathy, K				Nam, S. Y.; Sabapathy, K.			p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1	ONCOGENE			English	Article						haeme-oxygenease-1; hydrogen peroxide; p53; survival	MALIGNANT GLIOMA-CELLS; HEME OXYGENASE-1 INDUCTION; NITRIC-OXIDE; ANTICANCER TREATMENT; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; SENSITIVITY; PROTEIN; MICE; O-6-METHYLGUANINE	A variety of cellular insults activate the tumour suppressor p53, leading generally to cell-cycle arrest or apoptosis. However, it is not inconceivable that cellular protective mechanisms may be required to keep cells alive while cell-fate decisions are made. In this respect, p53 has been suggested to perform functions that allow cells to survive, by halting of the cell-cycle, and thus preventing immediate cell death. Nonetheless, the existence of direct prosurvival p53 target genes regulating cellular survival is lacking. We show here evidence for p53-dependent cellular survival in a context-dependent manner. Both mouse and human cells lacking p53 are hypersensitive to hydrogen peroxide (H2O2)-induced cell death compared with their isogenic wild-type counterparts. By contrast, p53(-/-) cells are expectedly resistant to cell death upon exposure to DNA-damaging agents such as cisplatin (CDDP) and etoposide. Although p53 and its classical targets such as p21 and Mdm2 are activated by both H2O2 and CDDP, we found that the expression of haeme-oxygenase-1 (HO-1)-an antioxidant and antiapoptotic protein-was directly induced only upon H2O2 treatment in a p53-dependent manner. Consistently, p53, but not its homologue p73, activated HO-1 expression and was bound to the HO-1 promoter specifically only upon H2O2 treatment. Moreover, silencing HO-1 expression enhanced cell death upon H2O2 treatment only in p53-proficient cells. Finally, H2O2-mediated cell death was rescued significantly in p53-deficient cells by antioxidant treatment, as well as by bilirubin, a by-product of HO-1 metabolism. Taken together, these data demonstrate a direct role for p53 in promoting cellular survival in a context-specific manner through the activation of a direct transcriptional target, HO-1. Oncogene (2011) 30, 4476-4486; doi: 10.1038/onc.2011.150; published online 9 May 2011	[Nam, S. Y.; Sabapathy, K.] Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore; [Sabapathy, K.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore; [Sabapathy, K.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg			National Medical Research Council of Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We thank Dr Vogelstein for the gift of the RKO cells; Ms Amy Chua HW for technical assistance during the revision phase; Dr Lee MK for critical reading of the paper and the National Medical Research Council of Singapore for the funding to KS.	Batista LFZ, 2007, CANCER RES, V67, P11886, DOI 10.1158/0008-5472.CAN-07-2964; Brooks CL, 2010, CELL RES, V20, P614, DOI 10.1038/cr.2010.53; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Burdelya LG, 2006, CANCER RES, V66, P9356, DOI 10.1158/0008-5472.CAN-06-1223; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Fang J, 2004, APOPTOSIS, V9, P27, DOI 10.1023/B:APPT.0000012119.83734.4e; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Gudkov AV, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001180; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Meiller A, 2007, NUCLEIC ACIDS RES, V35, P6924, DOI 10.1093/nar/gkm824; Motterlini R, 2002, ANTIOXID REDOX SIGN, V4, P615, DOI 10.1089/15230860260220111; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Roepke M, 2007, CANCER BIOL THER, V6, P160, DOI 10.4161/cbt.6.2.3575; Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang Y, 2009, INT J BIOCHEM CELL B, V41, P907, DOI 10.1016/j.biocel.2008.08.040; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	37	25	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4476	4486		10.1038/onc.2011.150	http://dx.doi.org/10.1038/onc.2011.150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21552291				2022-12-28	WOS:000296733200003
J	Yang, L; Wu, X; Wang, Y; Zhang, K; Wu, J; Yuan, YC; Deng, X; Chen, L; Kim, CCH; Lau, S; Somlo, G; Yen, Y				Yang, L.; Wu, X.; Wang, Y.; Zhang, K.; Wu, J.; Yuan, Y-C; Deng, X.; Chen, L.; Kim, C. C. H.; Lau, S.; Somlo, G.; Yen, Y.			FZD7 has a critical role in cell proliferation in triple negative breast cancer	ONCOGENE			English	Article						FZD7; TNBC; Wnt canonical signaling pathway; proliferation; potential therapeutic target	MAMMARY-GLAND DEVELOPMENT; STEM-CELLS; WNT; THERAPY; RECEPTOR; FAMILY; MEMBER; TUMORS; LRP6; MICE	Breast cancer is genetically and clinically heterogeneous. Triple negative breast cancer (TNBC) is a subtype of breast cancer that is usually associated with poor outcome and lack of benefit from targeted therapy. We used microarray analysis to perform a pathway analysis of TNBC compared with non-triple negative breast cancer (non-TNBC). Overexpression of several Wnt pathway genes, such as frizzled homolog 7 (FZD7), low density lipoprotein receptor-related protein 6 and transcription factor 7 (TCF7) was observed in TNBC, and we directed our focus to the Wnt pathway receptor, FZD7. To validate the function of FZD7, FZD7shRNA was used to knock down FZD7 expression. Notably, reduced cell proliferation and suppressed invasiveness and colony formation were observed in TNBC MDA-MB-231 and BT-20 cells. Study of the possible mechanism indicated that these effects occurred through silencing of the canonical Wnt signaling pathway, as evidenced by loss of nuclear accumulation of beta-catenin and decreased transcriptional activity of TCF7. In vivo studies revealed that FZD7shRNA significantly suppressed tumor formation, through reduced cell proliferation, in mice bearing xenografts without FZD7 expression. Our findings suggest that FZD7-involved canonical Wnt signaling pathway is essential for tumorigenesis of TNBC, and thus, FZD7 shows promise as a biomarker and a potential therapeutic target for TNBC. Oncogene (2011) 30, 4437-4446; doi:10.1038/onc.2011.145; published online 2 May 2011	[Yang, L.; Kim, C. C. H.; Yen, Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA; [Wu, X.; Yuan, Y-C; Deng, X.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Wang, Y.; Zhang, K.; Chen, L.] City Hope Natl Med Ctr, Beckman Res Inst, Translat Res Lab, Duarte, CA 91010 USA; [Wu, J.] City Hope Natl Med Ctr, Beckman Res Inst, Div Comparat Med, Duarte, CA 91010 USA; [Lau, S.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA; [Somlo, G.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Yen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Beckman Bldg,Room 4117,1500 E Duarte Rd, Duarte, CA 91010 USA.	yyen@coh.org	Yen, Yun/H-9591-2016; Zhang, Keqiang/P-7082-2019		City of Hope National Medical Center for Translational Research	City of Hope National Medical Center for Translational Research	We thank Mariko Lee in the Light Microscopy and Digital Imaging Core for assistance with immunofluorescence and immunohistochemical microscopy, Arthur Li in the Division of Information Science for statistical analysis and Yan Wang in the Division of Comparative Medicine for tumor inoculation, tumor measurement and tumor collection. We thank Dr Keely Walker and Mansze Kong for critical editing of the manuscript. Grant Support was received from City of Hope National Medical Center for Translational Research.	Amir E, 2010, NAT REV CLIN ONCOL, V7, P79, DOI 10.1038/nrclinonc.2009.231; Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Jones KA, 2008, GENE DEV, V22, P3077, DOI 10.1101/gad.1741008; Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005; Komiya Yuko, 2008, Organogenesis, V4, P68; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Li Y, 2005, J MAMMARY GLAND BIOL, V10, P17, DOI 10.1007/s10911-005-2537-2; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813; Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Ojalvo LS, 2010, J IMMUNOL, V184, P702, DOI 10.4049/jimmunol.0902360; Perez EA, 2010, BREAST CANCER RES TR, V120, P285, DOI 10.1007/s10549-010-0736-z; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Rahman M, 2009, ADV CANCER RES, V103, P43, DOI 10.1016/S0065-230X(09)03003-6; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sonderegger S, 2007, PLACENTA, V28, pS97, DOI 10.1016/j.placenta.2006.11.003; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192	33	194	207	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	43					4437	4446		10.1038/onc.2011.145	http://dx.doi.org/10.1038/onc.2011.145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21532620	hybrid			2022-12-28	WOS:000296356500006
J	Bist, P; Leow, SC; Phua, QH; Shu, S; Zhuang, Q; Loh, WT; Nguyen, TH; Zhou, JB; Hooi, SC; Lim, LHK				Bist, P.; Leow, S. C.; Phua, Q. H.; Shu, S.; Zhuang, Q.; Loh, W. T.; Nguyen, T. H.; Zhou, J. B.; Hooi, S. C.; Lim, L. H. K.			Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-kappa B: implication in breast cancer metastasis	ONCOGENE			English	Article						metastasis; transcription factor; NF-kappa B; CXCR4	CHEMOKINE RECEPTOR CXCR4; A1 EXPRESSION; TUMOR-CELLS; BONE-MARROW; IN-VITRO; PROTEIN; PROGRESSION; PATHWAY; DOMAIN; MIGRATION	The molecular mechanisms underlying constitutive nuclear factor-kappa B (NF-kappa B) activation in solid tumors has not been elucidated. We show that Annexin-1 (ANXA1) is involved in this process, and suppression of ANXA1 in highly metastatic breast cancer cells impedes migration and metastasis capabilities in vitro and in vivo. ANXA1 expression correlates with NF-kappa B activity, suggesting that ANXA1 may be required for the constitutive activity of I kappa B kinase (IKK) and NF-kappa B in highly metatstatic breast cancer. Gel-filtration analysis demonstrated that ANXA1 co-elutes with the members of the IKK complex and NF-kappa B signaling pathway, and immunoprecipitation confirmed that ANXA1 can bind to and interact with IKK gamma or NEMO, but not IKK alpha or IKK beta. Importantly, silencing of ANXA1 prevents the interaction of NEMO and RIP1, which indicates that ANXA1 is required for the recruitment of RIP1 to the IKK complex, which may be important for the activation of NF-kappa B. Downstream targets of NF-kappa B include uPA and CXCR4, which can be modulated by ANXA1 silencing. CXCR4-mediated migration of breast cancer cell lines in response to CXCL12 was significantly modulated by ANXA1, indicating its importance in the tissue-specific migration of breast cancer cells. Chromatin immunoprecipitation experiments confirmed that in ANXA1 overexpressed cells, NF-kappa B was recruited to CXCR4 promoter without external stimulation, indicating that ANXA1 is critical for the constitutive activation of NF-kappa B in breast cancer to promote metastasis. Finally, we show that ANXA1 overexpression enhances metastasis and reduces survival in an intracardiac metastasis model, while ANXA1-deficient mice crossed with MMTV-PyMT mice display significantly less metastasis than their heterozygous littermates, indicating that ANXA1 is an important gene in breast cancer metastasis. Our data reveal that ANXA1 can constitutively activate NF-kappa B in breast cancer cells through the interaction with the IKK complex, and suggests that modulating ANXA1 levels has therapeutic potential to suppress breast cancer metastasis. Oncogene (2011) 30, 3174-3185; doi:10.1038/onc.2011.28; published online 7 March 2011	[Lim, L. H. K.] Natl Univ Singapore, Dept Physiol, Inflammat & Canc Lab, Yong Loo Lin Sch Med,Ctr Life Sci, Singapore 117456, Singapore; [Bist, P.; Leow, S. C.; Phua, Q. H.; Shu, S.; Zhuang, Q.; Loh, W. T.; Nguyen, T. H.; Lim, L. H. K.] Natl Univ Singapore, NUS Immunol Program, Inflammat & Canc Lab, Singapore 117456, Singapore; [Zhou, J. B.] Natl Univ Singapore, Oncol Res Inst, Singapore 117456, Singapore; [Lim, L. H. K.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore	Lim, LHK (corresponding author), Natl Univ Singapore, Dept Physiol, Inflammat & Canc Lab, Yong Loo Lin Sch Med,Ctr Life Sci, Level 3,28 Med Dr, Singapore 117456, Singapore.	linalim@nus.edu.sg	Nguyen, Hung/M-8118-2014; Hooi, Shing/C-8588-2012; BIST, PRADEEP/AAG-7986-2019	Nguyen, Hung/0000-0001-8378-555X; Lim, Lina/0000-0002-2935-2275; Hooi, Shing Chuan/0000-0003-3249-903X	Biomedical Research Council of Singapore [07/1/21/19/507, 04/1/21/19/319]; A*Star [SIgN 07-011]	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); A*Star(Agency for Science Technology & Research (A*STAR))	This work was supported by grants from the Biomedical Research Council of Singapore (07/1/21/19/507) and A*Star (SIgN 07-011) to LL and Biomedical Research Council of Singapore (04/1/21/19/319) to SCH. We thank Professor Rod Flower (William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, London) for generously providing us with the pCDNA3.1-V5 ANXA1 construct and Professor Michael Karin (University of California San Diego, CA, USA) for the HA-IKK alpha, HA-IKK beta and HA-IKK gamma plasmid constructs.	Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Ang EZF, 2009, MOL CANCER RES, V7, P266, DOI 10.1158/1541-7786.MCR-08-0147; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Cabioglu N, 2005, CLIN EXP METASTAS, V22, P39, DOI 10.1007/s10585-005-3222-y; Cao Y, 2008, APPL IMMUNOHISTO M M, V16, P530, DOI 10.1097/PAI.0b013e31817432c3; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Cicek M, 2004, CLIN EXP METASTAS, V21, P149, DOI 10.1023/B:CLIN.0000024729.19084.f0; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kreunin P, 2007, PROTEOMICS, V7, P299, DOI 10.1002/pmic.200600272; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Lim LHK, 2007, FASEB J, V21, P968, DOI 10.1096/fj.06-7464rev; Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120; Monks NR, 2006, J CELL BIOCHEM, V98, P221, DOI 10.1002/jcb.20789; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Palkowitsch L, 2008, J BIOL CHEM, V283, P76, DOI 10.1074/jbc.M708856200; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pencil SD, 1998, CLIN EXP METASTAS, V16, P113, DOI 10.1023/A:1021917017109; Perretti M, 2003, NEWS PHYSIOL SCI, V18, P60, DOI 10.1152/nips.01424.2002; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Shen DJ, 2006, HUM PATHOL, V37, P1583, DOI 10.1016/j.humpath.2006.06.001; Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; Zhang ZQ, 2010, CANCER RES, V70, P2379, DOI 10.1158/0008-5472.CAN-09-4204	37	91	93	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3174	3185		10.1038/onc.2011.28	http://dx.doi.org/10.1038/onc.2011.28			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383699				2022-12-28	WOS:000292726300006
J	Jiang, Y; Scott, KL; Kwak, SJ; Chen, R; Mardon, G				Jiang, Y.; Scott, K. L.; Kwak, S-J; Chen, R.; Mardon, G.			Sds22/PP1 links epithelial integrity and tumor suppression via regulation of myosin II and JNK signaling	ONCOGENE			English	Article						tumor suppressor; epithelial integrity; cell invasion; sds22; protein phosphatase 1	PROTEIN PHOSPHATASE-1; CELL POLARITY; NONMUSCLE MYOSIN; MATRIX METALLOPROTEINASES; DROSOPHILA-MELANOGASTER; NEURAL DEVELOPMENT; INDUCED APOPTOSIS; GENETIC MOSAICS; IMAGINAL DISCS; CANCER	Loss of epithelial integrity often correlates with the progression of malignant tumors. Sds22, a regulatory subunit of protein phosphatase 1 (PP1), has recently been linked to regulation of epithelial polarity in Drosophila. However, its role in tumorigenesis remains obscure. In this study, using Drosophila imaginal tissue as an in vivo model system, we show that sds22 is a new potential tumor suppressor gene in Drosophila. Without sds22, cells lose epithelial architecture, and become invasive and tumorigenic when combined with Ras overexpression; conversely, sds22 overexpression can largely suppress tumorigenic growth of Ras(V12)scrib(-/-) mutant cells. Mechanistically, we show that sds22 prevents cell invasion and metastasis by inhibiting myosin II and Jun N-terminal kinase (JNK) activity downstream of PP1. Loss of this inhibition causes cells to lose epithelial organization and promotes cell invasion. Finally, human Sds22 is focally deleted and downregulated in multiple carcinomas, and this downregulation correlates with tumor progression, suggesting that sds22 inactivation may contribute to tumorigenesis and metastatic potential in human cancers via a similar mechanism. Oncogene (2011) 30, 3248-3260; doi:10.1038/onc.2011.46; published online 14 March 2011	[Jiang, Y.; Scott, K. L.; Chen, R.; Mardon, G.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Kwak, S-J; Mardon, G.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Chen, R.; Mardon, G.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Chen, R.; Mardon, G.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Mardon, G.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Mardon, G.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mardon, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	gmardon@bcm.edu			National Eye Institute [R01 EY011232, EY016853]; Retina Research Foundation; NATIONAL EYE INSTITUTE [R01EY016853, R01EY011232] Funding Source: NIH RePORTER	National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Retina Research Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Andreas Bergmann, Yasuyoshi Nishida, Tian Xu, the Bloomington Stock Center, VDRC, and the DSHB for stocks and antibodies. We especially thank Georg Halder, Rui Chen, Mardelle Atkins, Umesh Karandikar, and Nicholas Justice for helpful comments on the manuscript. This work was supported by the National Eye Institute (R01 EY011232 [GM] and EY016853 [RC]) and the Retina Research Foundation (GM).	AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett D, 2006, J MOL BIOL, V364, P196, DOI 10.1016/j.jmb.2006.08.094; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cengiz B, 2007, ORAL ONCOL, V43, P241, DOI 10.1016/j.oraloncology.2006.03.004; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; DOMBRADI V, 1993, EUR J BIOCHEM, V212, P177, DOI 10.1111/j.1432-1033.1993.tb17648.x; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Grusche FA, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-14; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jasper H, 2001, DEV CELL, V1, P579, DOI 10.1016/S1534-5807(01)00045-4; Kabbarah O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010770; Kirchner J, 2007, GENETICS, V175, P1741, DOI 10.1534/genetics.106.067488; Kirchner J, 2007, GENETICS, V176, P273, DOI 10.1534/genetics.106.069914; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Llano E, 2000, J BIOL CHEM, V275, P35978, DOI 10.1074/jbc.M006045200; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; Martin FA, 2009, INT J DEV BIOL, V53, P1341, DOI 10.1387/ijdb.072447fm; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; McEwen DG, 2005, DEVELOPMENT, V132, P3935, DOI 10.1242/dev.01949; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Narayan G, 2003, ONCOGENE, V22, P3489, DOI 10.1038/sj.onc.1206432; Newsome TP, 2000, DEVELOPMENT, V127, P851; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; Page-McCaw A, 2003, DEV CELL, V4, P95, DOI 10.1016/S1534-5807(02)00400-8; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pepple KL, 2008, DEVELOPMENT, V135, P4071, DOI 10.1242/dev.028951; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Shao W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009938; Singh J, 2010, ONCOGENE, V29, P4033, DOI 10.1038/onc.2010.155; Smith DP, 1999, NEURON, V22, P203, DOI 10.1016/S0896-6273(00)81078-8; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Traweger A, 2008, P NATL ACAD SCI USA, V105, P10402, DOI 10.1073/pnas.0804102105; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vereshchagina N, 2004, MOL BIOL CELL, V15, P4395, DOI 10.1091/mbc.E04-02-0139; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Winter SL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-85; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; XU T, 1993, DEVELOPMENT, V117, P1223; Young MRI, 1997, ADV EXP MED BIOL, V407, P311; Zhu MW, 2010, CELL RES, V20, P242, DOI 10.1038/cr.2010.2	64	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3248	3260		10.1038/onc.2011.46	http://dx.doi.org/10.1038/onc.2011.46			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21399659	Green Accepted			2022-12-28	WOS:000293006800004
J	Knauf, JA; Sartor, MA; Medvedovic, M; Lundsmith, E; Ryder, M; Salzano, M; Nikiforov, YE; Giordano, TJ; Ghossein, RA; Fagin, JA				Knauf, J. A.; Sartor, M. A.; Medvedovic, M.; Lundsmith, E.; Ryder, M.; Salzano, M.; Nikiforov, Y. E.; Giordano, T. J.; Ghossein, R. A.; Fagin, J. A.			Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF beta signaling	ONCOGENE			English	Article						BRAF; TGF beta; epithelial-mesenchymal transition; thyroid	GROWTH-FACTOR-BETA; GENE-EXPRESSION DATA; FALSE DISCOVERY RATE; BRAF(V600E) MUTATION; HIGH PREVALENCE; CARCINOMA; CELLS; METASTASIS; ACTIVATION; MICE	Mice with thyroid-specific expression of oncogenic BRAF (Tg-Braf) develop papillary thyroid cancers (PTCs) that are locally invasive and have well-defined foci of poorly differentiated thyroid carcinoma (PDTC). To investigate the PTC-PDTC progression, we performed a microarray analysis using RNA from paired samples of PDTC and PTC collected from the same animals by laser capture microdissection. Analysis of eight paired samples revealed a profound deregulation of genes involved in cell adhesion and intracellular junctions, with changes consistent with an epithelial-mesenchymal transition (EMT). This was confirmed by immunohistochemistry, as vimentin expression was increased and E-cadherin lost in PDTC compared with adjacent PTC. Moreover, PDTC stained positively for phospho-Smad2, suggesting a role for transforming growth factor (TGF)beta in mediating this process. Accordingly, TGF beta-induced EMT in primary cultures of thyroid cells from Tg-Braf mice, whereas wild-type thyroid cells retained their epithelial features. TGF beta-induced Smad2 phosphorylation, transcriptional activity and induction of EMT required mitogen-activated protein kinase (MAPK) pathway activation in Tg-Braf thyrocytes. Hence, tumor initiation by oncogenic BRAF renders thyroid cells susceptible to TGF beta-induced EMT, through a MAPK-dependent process. Oncogene (2011) 30, 3153-3162; doi:10.1038/onc.2011.44; published online 7 March 2011	[Knauf, J. A.; Lundsmith, E.; Ryder, M.; Salzano, M.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Knauf, J. A.; Lundsmith, E.; Ryder, M.; Salzano, M.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Sartor, M. A.; Medvedovic, M.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA; [Nikiforov, Y. E.] Univ Cincinnati, Dept Pathol, Cincinnati, OH USA; [Giordano, T. J.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Ghossein, R. A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center	Knauf, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.	knaufj@mskcc.org	Sartor, Maureen/L-2902-2019	Salzano, Marcella/0000-0002-1856-8281; Giordano, Thomas/0000-0003-0641-8873; Knauf, Jeffrey/0000-0003-4456-8792	NIH [CA 50706]; Margot Rosenberg Pulitzer Foundation; NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706, R01CA072597] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Margot Rosenberg Pulitzer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH CA 50706, and a grant from the Margot Rosenberg Pulitzer Foundation. We are grateful to the MSKCC Genetically Engineered Mouse Phenotyping core facility and Dr Katia Manova of the MSKCC Molecular Cytology core for help with immunohistochemical experiments.	Ball DW, 2007, J CLIN ENDOCR METAB, V92, P4712, DOI 10.1210/jc.2007-1184; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Elisei R, 2008, J CLIN ENDOCR METAB, V93, P3943, DOI 10.1210/jc.2008-0607; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Franco AT, 2011, P NATL ACAD SCI USA, V108, P1615, DOI 10.1073/pnas.1015557108; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Guo JH, 2004, TOXICOL APPL PHARM, V194, P79, DOI 10.1016/j.taap.2003.09.002; Inoue Y, 2008, CANCER SCI, V99, P2107, DOI 10.1111/j.1349-7006.2008.00925.x; Jechlinger M, 2002, J MAMMARY GLAND BIOL, V7, P415, DOI 10.1023/A:1024090116451; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kimura ET, 2003, CANCER RES, V63, P1454; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Leboeuf R, 2008, J CLIN ENDOCR METAB, V93, P2194, DOI 10.1210/jc.2007-2825; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Saltman B, 2006, SURGERY, V140, P899, DOI 10.1016/j.surg.2006.07.027; Sartor MA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-538; Sartor MA, 2010, BIOINFORMATICS, V26, P456, DOI 10.1093/bioinformatics/btp683; Sartor MA, 2009, BIOINFORMATICS, V25, P211, DOI 10.1093/bioinformatics/btn592; Savage NDL, 2008, J IMMUNOL, V181, P2220, DOI 10.4049/jimmunol.181.3.2220; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; TSUSHIMA T, 1988, ENDOCRINOLOGY, V123, P1187, DOI 10.1210/endo-123-2-1187; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Weinberg RA, 2008, NAT CELL BIOL, V10, P1021, DOI 10.1038/ncb0908-1021; Wiseman SM, 2007, ARCH SURG-CHICAGO, V142, P717, DOI 10.1001/archsurg.142.8.717; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	53	132	135	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3153	3162		10.1038/onc.2011.44	http://dx.doi.org/10.1038/onc.2011.44			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383698	Green Accepted			2022-12-28	WOS:000292726300004
J	Lanigan, F; Geraghty, JG; Bracken, AP				Lanigan, F.; Geraghty, J. G.; Bracken, A. P.			Transcriptional regulation of cellular senescence	ONCOGENE			English	Review						cellular senescence; transcription; cancer therapy	ONCOGENE-INDUCED SENESCENCE; INK4A TUMOR-SUPPRESSOR; DEMETHYLASE JMJD3 CONTRIBUTES; INDUCED PREMATURE SENESCENCE; E2F TARGET GENES; HISTONE DEACETYLASE; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; CANCER-THERAPY; IN-VIVO	Cellular senescence is an irreversible arrest of proliferation. It is activated when a cell encounters stress such as DNA damage, telomere shortening or oncogene activation. Like apoptosis, it impedes tumour progression and acts as a barrier that pre-neoplastic cells must overcome during their evolution toward the full tumourigenic state. This review focuses on the role of transcriptional regulators in the control of cellular senescence, explores how their function is perturbed in cancer and discusses the potential to harness this knowledge for future cancer therapies. Oncogene (2011) 30, 2901-2911; doi:10.1038/onc.2011.34; published online 7 March 2011	[Lanigan, F.; Bracken, A. P.] Trinity Coll Dublin, Smurfit Genet Dept, Smurfit Inst Genet, Dublin 2, Ireland; [Bracken, A. P.] Natl Childrens Hosp, Adelaide & Meath Hosp, Dublin, Ireland; [Geraghty, J. G.] Univ Coll Dublin, St Vincents Hosp, Dept Breast & Endocrine Surg, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin; University College Dublin	Bracken, AP (corresponding author), Trinity Coll Dublin, Smurfit Genet Dept, Smurfit Inst Genet, Lincoln Pl, Dublin 2, Ireland.	adrian.bracken@tcd.ie		Bracken, Adrian/0000-0002-1547-9443	Science Foundation Ireland [SFI PICA SFI/10/IN.1/B3002]; Health Research Board [HRA_POR/2010/124]; Irish Research Council for Science, Engineering and Technology (IRCSET)	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board; Irish Research Council for Science, Engineering and Technology (IRCSET)(Irish Research Council for Science, Engineering and Technology)	We thank Eros Lazzerini and Jean-Christophe Marine for critical reading of the manuscript. Work in the Bracken Lab is supported by Science Foundation Ireland under the Principal Investigator Career Advancement Award (SFI PICA SFI/10/IN.1/B3002), the Health Research Board under the Health Research Awards 2010 (HRA_POR/2010/124), and the Irish Research Council for Science, Engineering and Technology (IRCSET).	Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bachmann IM, 2008, MODERN PATHOL, V21, P583, DOI 10.1038/modpathol.2008.17; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bea S, 2001, CANCER RES, V61, P2409; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Bishop CL, 2010, MOL CELL, V40, P533, DOI 10.1016/j.molcel.2010.10.027; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Call JA, 2008, LANCET ONCOL, V9, P1002, DOI 10.1016/S1470-2045(08)70209-2; Calses C, 2008, MOL CELL BIOL, V28, P1018, DOI 10.1128/MCB.01136-07; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chen HA, 2009, GENE DEV, V23, P975, DOI 10.1101/gad.1742509; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; del Arroyo AG, 2007, CELL CYCLE, V6, P2697; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; Engelsen IB, 2008, BRIT J CANCER, V98, P1662, DOI 10.1038/sj.bjc.6604360; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Haugstetter AM, 2010, BRIT J CANCER, V103, P505, DOI 10.1038/sj.bjc.6605784; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayden A, 2011, BREAST CANCER RES TR, V127, P109, DOI 10.1007/s10549-010-0982-0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Holst CR, 2003, CANCER RES, V63, P1596; Irelan JT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005067; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Komori H, 2005, EMBO J, V24, P3724, DOI 10.1038/sj.emboj.7600836; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Kotake Y, 2009, CANCER RES, V69, P1809, DOI 10.1158/0008-5472.CAN-08-2739; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kumamoto K, 2008, CANCER RES, V68, P3193, DOI 10.1158/0008-5472.CAN-07-2780; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 2010, ONCOGENE, V29, P5083, DOI 10.1038/onc.2010.252; Liu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005027; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Martin-Perez D, 2010, AM J PATHOL, V177, P930, DOI 10.2353/ajpath.2010.090769; Matheu A, 2005, J BIOL CHEM, V280, P42433, DOI 10.1074/jbc.M508270200; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESSAOUDIAUBERT SE, 2010, NAT STRUCT MOL BIOL, V17, P862, DOI DOI 10.1038/NSMB.1824; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Monahan KB, 2010, ONCOGENE, V29, P5809, DOI 10.1038/onc.2010.314; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Mroz EA, 2008, CANCER RES, V68, P6049, DOI 10.1158/0008-5472.CAN-08-1279; Muller J, 2009, CURR OPIN GENET DEV, V19, P150, DOI 10.1016/j.gde.2009.03.001; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Negishi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012373; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; QUELLE DE, 1995, CELL, V83, P993; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; te Poele RH, 2002, CANCER RES, V62, P1876; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yamaguchi J, 2010, CANCER SCI, V101, P355, DOI 10.1111/j.1349-7006.2009.01387.x; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011	149	67	69	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2901	2911		10.1038/onc.2011.34	http://dx.doi.org/10.1038/onc.2011.34			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21383691				2022-12-28	WOS:000292245100001
J	Zhang, X; George, J; Deb, S; Degoutin, JL; Takano, EA; Fox, SB; Bowtell, DDL; Harvey, KF				Zhang, X.; George, J.; Deb, S.; Degoutin, J. L.; Takano, E. A.; Fox, S. B.; Bowtell, D. D. L.; Harvey, K. F.		AOCS Study Grp	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene	ONCOGENE			English	Article						ovarian cancer; Hippo pathway; YAP; oncogenic transformation; clear cell cancer	YES-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR GENE; CELL CONTACT INHIBITION; SIZE-CONTROL; PROMOTES APOPTOSIS; CYCLE EXIT; ORGAN SIZE; PROLIFERATION; DROSOPHILA; SALVADOR	The Salvador-Warts-Hippo (SWH) pathway was first discovered in Drosophila melanogaster as a potent inhibitor of tissue growth. The SWH pathway is highly conserved between D. melanogaster and mammals, both in function and in the mechanism of signal transduction. The mammalian SWH pathway limits tissue growth by inhibiting the nuclear access and expression of the transcriptional co-activator, Yes-associated protein (YAP). Mutation and altered expression of SWH pathway proteins has been observed in several types of human cancer, but the contribution of these events to tumorigenesis has been unclear. Here we show that YAP can enhance the transformed phenotype of ovarian cancer cell lines and that YAP confers resistance to chemotherapeutic agents that are commonly used to treat ovarian cancer. We find that high nuclear YAP expression correlates with poor patient prognosis in a cohort of 268 invasive epithelial ovarian cancer samples. Segregation by histo-type shows that the correlation between nuclear YAP and poor survival is predominantly associated with clear cell tumors, independent of stage. Collectively our findings suggest that YAP derepression contributes to the genesis of ovarian clear cell carcinoma and that the SWH pathway is an attractive therapeutic target. Oncogene (2011) 30, 2810-2822; doi: 10.1038/onc.2011.8; published online 14 February 2011	[Zhang, X.; George, J.; Deb, S.; Degoutin, J. L.; Takano, E. A.; Fox, S. B.; Bowtell, D. D. L.; Harvey, K. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Zhang, X.; George, J.; Degoutin, J. L.; Bowtell, D. D. L.; Harvey, K. F.] Univ Melbourne, Melbourne, Vic, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [AOCS Study Grp] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2006, Australia	Peter Maccallum Cancer Center; University of Melbourne; QIMR Berghofer Medical Research Institute; University of Sydney; Westmead Institute for Medical Research	Harvey, KF (corresponding author), Peter MacCallum Canc Ctr, 7 St Andrews Pl, Melbourne, Vic 3072, Australia.	kieran.harvey@petermac.org	Bowtell, David/H-1007-2016; George, Joshy/K-4841-2019; Harvey, Kieran/AAD-5268-2022; Fox, Stephen/G-9719-2016	Bowtell, David/0000-0001-9089-7525; Harvey, Kieran/0000-0001-7845-369X; Fox, Stephen/0000-0002-7648-8896	US Army Medical Research and Materiel Command [DAMD17-01-1-0729]; Cancer Council Victoria; Queensland Cancer Fund; Cancer Council New South Wales; Cancer Council South Australia; Cancer Foundation of Western Australia; Cancer Council Tasmania; National Health and Medical Research Council of Australia (NHMRC); International Human Frontier Science Program Organization; NHMRC of Australia; Victorian Breast Cancer Research Consortium	US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Queensland Cancer Fund; Cancer Council New South Wales(Cancer Council New South Wales); Cancer Council South Australia(Cancer Council South Australia); Cancer Foundation of Western Australia(Cancer Council Western Australia); Cancer Council Tasmania(Cancer Council Tasmania); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); International Human Frontier Science Program Organization(Human Frontier Science Program); NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Breast Cancer Research Consortium	We thank the study nurses and research assistants for their contribution to AOCS (http://www.aocstudy.org/) and thank all the women who participated in the study. AOCS was approved by the Human Research Ethics Committees at the Peter Mac, QIMR and participating hospitals. The study was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC). We thank D Thomas for comments, D Haber for pBABE-YAP2L and the Peter Mac, Pfizer Incorporated TORCH program for ovarian cancer cell lines. KFH is a Sylvia and Charles Viertel Senior Medical Research Fellow. This work was supported by a Career Development Award from the International Human Frontier Science Program Organization and a Project Grant from the NHMRC of Australia to KFH and the Victorian Breast Cancer Research Consortium to SBF.	Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; Chosdol K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-5; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Nakaya K, 2007, ONCOGENE, V26, P5300, DOI 10.1038/sj.onc.1210330; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Qi C, 2009, INT J CANCER, V124, P793, DOI 10.1002/ijc.23775; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; SMYTH GK, 2005, LIMMA LINEAR MODELS, P397; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Stewart B.W., 2003, WORLD CANC REPORT; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Tan DSP, 2007, J CLIN PATHOL, V60, P355, DOI 10.1136/jcp.2006.040030; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tian W, 2010, P NATL ACAD SCI USA, V107, P7293, DOI 10.1073/pnas.1000293107; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	48	232	249	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2810	2822		10.1038/onc.2011.8	http://dx.doi.org/10.1038/onc.2011.8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317925				2022-12-28	WOS:000291977800002
J	Shields, DJ; Murphy, EA; Desgrosellier, JS; Mielgo, A; Lau, SKM; Barnes, LA; Lesperance, J; Huang, M; Schmedt, C; Tarin, D; Lowy, AM; Cheresh, DA				Shields, D. J.; Murphy, E. A.; Desgrosellier, J. S.; Mielgo, A.; Lau, S. K. M.; Barnes, L. A.; Lesperance, J.; Huang, M.; Schmedt, C.; Tarin, D.; Lowy, A. M.; Cheresh, D. A.			Oncogenic Ras/Src cooperativity in pancreatic neoplasia	ONCOGENE			English	Article						pancreatic cancer; Src; Ras; oncogenic cooperativity	EPIDERMAL-GROWTH-FACTOR; SRC FAMILY KINASES; DUCTAL ADENOCARCINOMA; TYROSINE KINASE; C-SRC; HUMAN CANCER; INTRAEPITHELIAL NEOPLASIA; TUMOR PROGRESSION; TRANSGENIC MICE; MOUSE MODEL	Pancreas cancer is one of the most lethal malignancies and is characterized by activating mutations of Kras, present in 95% of patients. More than 60% of pancreatic cancers also display increased c-Src activity, which is associated with poor prognosis. Although loss of tumor suppressor function (for example, p16, p53, Smad4) combined with oncogenic Kras signaling has been shown to accelerate pancreatic duct carcinogenesis, it is unclear whether elevated Src activity contributes to Kras-dependent tumorigenesis or is simply a biomarker of disease progression. Here, we demonstrate that in the context of oncogenic Kras, activation of c-Src through deletion of C-terminal Src kinase (CSK) results in the development of invasive pancreatic ductal adenocarcinoma (PDA) by 5-8 weeks. In contrast, deletion of CSK alone fails to induce neoplasia, while oncogenic Kras expression yields PDA at low frequency after a latency of 12 months. Analysis of cell lines derived from Ras/Src-induced PDA's indicates that oncogenic Ras/Src cooperativity may lead to genomic instability, yet Ras/Src-driven tumor cells remain dependent on Src signaling and as such, Src inhibition suppresses growth of Ras/Src-driven tumors. These findings demonstrate that oncogenic Ras/Src cooperate to accelerate PDA onset and support further studies of Src-directed therapies in pancreatic cancer. Oncogene (2011) 30, 2123-2134; doi:10.1038/onc.2010.589; published online 17 January 2011	[Shields, D. J.; Murphy, E. A.; Desgrosellier, J. S.; Mielgo, A.; Lau, S. K. M.; Barnes, L. A.; Lesperance, J.; Huang, M.; Tarin, D.; Cheresh, D. A.] Moores UCSD Canc Ctr, Dept Pathol, La Jolla, CA 92093 USA; [Schmedt, C.] Novartis Res Fdn, Genom Inst, San Diego, CA USA; [Lowy, A. M.] Moores UCSD Canc Ctr, Dept Surg, La Jolla, CA 92093 USA	Novartis	Cheresh, DA (corresponding author), Moores UCSD Canc Ctr, Dept Pathol, Room 2344,3855 Hlth Sci Dr,MC 0803, La Jolla, CA 92093 USA.	dcheresh@ucsd.edu	Desgrosellier, Jay S/A-8756-2008	Huang, Miller/0000-0002-3371-0100; Lau, Steven/0000-0002-6433-8735	NIH [R21CA104898, P01-CA078045]; Moores UCSD Cancer Center; NATIONAL CANCER INSTITUTE [T32CA121938, P01CA078045, P01CA104898] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Moores UCSD Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Charles Yi and Dana Wu for excellent technical assistance. We acknowledge Richard Aspinall, Lisette Acevedo, Josh Greenberg and David Tuveson for valuable discussions, Greg Boivin for histological analysis, as well as Richard Levenson and Kristin Lane for NuBrio imaging. This work was supported by NIH grants R21CA104898, P01-CA078045 (DAC) and Collaborative Translational Research grants from Moores UCSD Cancer Center (DAC, DJS and AML).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; Billadeau DD, 2006, J GASTROINTEST CANC, V37, P110, DOI 10.1007/s12029-007-0011-7; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; Desgrosellier JS, 2009, NAT MED, V15, P1163, DOI 10.1038/nm.2009; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Grimm J, 2003, INT J CANCER, V106, P806, DOI 10.1002/ijc.11281; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Hernandez-Munoz I, 2008, PANCREATOLOGY, V8, P462, DOI 10.1159/000151537; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kabil A, 2008, CARCINOGENESIS, V29, P1862, DOI 10.1093/carcin/bgn138; Kasahara K, 2007, J BIOL CHEM, V282, P5327, DOI 10.1074/jbc.M608396200; Kline CLB, 2008, INT J CANCER, V122, P2665, DOI 10.1002/ijc.23445; Koreckij T, 2009, BRIT J CANCER, V101, P263, DOI 10.1038/sj.bjc.6605178; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Matsumoto T, 2004, MOL CARCINOGEN, V40, P189, DOI 10.1002/mc.20027; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Murphy EA, 2008, P NATL ACAD SCI USA, V105, P9343, DOI 10.1073/pnas.0803728105; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas RM, 2008, GUT, V57, P1555, DOI 10.1136/gut.2007.143941; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vitali R, 2009, INT J CANCER, V125, P2547, DOI 10.1002/ijc.24606; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078-0432.CCR-04-0621	51	53	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2123	2134		10.1038/onc.2010.589	http://dx.doi.org/10.1038/onc.2010.589			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21242978	Green Accepted			2022-12-28	WOS:000290249600004
J	Wu, SM; Huang, YH; Yeh, CT; Tsai, MM; Liao, CH; Cheng, WL; Chen, WJ; Lin, KH				Wu, S-M; Huang, Y-H; Yeh, C-T; Tsai, M-M; Liao, C-H; Cheng, W-L; Chen, W-J; Lin, K-H			Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells	ONCOGENE			English	Article						cysteine proteases; receptors; migration; hepatocellular carcinoma	LYSOSOMAL CYSTEINE PROTEASES; GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; EPITHELIAL-CELLS; PITUITARY-TUMOR; MOUSE MODEL; B ACTIVITY; V-ERBA; CANCER; EXPRESSION	Thyroid hormone, 3, 3', 5-triiodo-L-thyronine (T-3), mediates cell growth, development and differentiation by binding to its nuclear receptors (TRs). The role of TRs in cancer is still undefined. Notably, hyperthyroxinemia has been reported to influence the rate of colon cancer in an experimental model of carcinogenesis in rats. Previous microarray analysis revealed that cathepsin H (CTSH) is upregulated by T-3 in HepG2-TR cells. We verified that mRNA and protein expression of CTSH are induced by T3 in HepG2-TR cells and in thyroidectomized rats following administration of T-3. The possible thyroid hormone-responsive elements of the CTSH promoter localized to the nucleotides -2038 to -1966 and -1565 to -1501 regions. An in vitro functional assay showed that CTSH can increase metastasis. J7 cells overexpressing CTSH were inoculated into severe combined immune-deficient mice and these J7-CTSH mice displayed a greater metastatic potential than did J7-control mice. The clinicopathologic significance of CTSH expression in hepatocellular carcinoma (HCC) was also investigated. The CTSH overexpressing in HCC was associated with the presence of microvascular invasion (P = 0.037). The microvascular invasion characteristic is closely related to our in vitro characterization of CTSH function. Our results show that T-3-mediated upregulation of CTSH led to matrix metallopeptidase or extracellular signal-regulated kinase activation and increased cell migration. This study demonstrated that CTSH overexpression in a subset hepatoma may be TR dependent and suggests that this overexpression has an important role in hepatoma progression. Oncogene (2011) 30, 2057-2069; doi:10.1038/onc.2010.585; published online 10 January 2011	[Wu, S-M; Tsai, M-M; Liao, C-H; Cheng, W-L; Lin, K-H] Chang Gung Univ, Sch Med, Dept Biochem, Tao Yuan 333, Taiwan; [Huang, Y-H] Chang Gung Mem Hosp, Med Res Ctr, Tao Yuan, Taiwan; [Yeh, C-T] Chang Gung Med Ctr, Liver Res Unit, Taipei, Taiwan; [Tsai, M-M] Chang Gung Inst Technol, Dept Nursing, Tao Yuan, Taiwan; [Chen, W-J] Chang Gung Mem Hosp, Cardiovasc Div 1, Tao Yuan, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chang Gung Memorial Hospital	Lin, KH (corresponding author), Chang Gung Univ, Sch Med, Dept Biochem, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	khlin@mail.cgu.edu.tw		Liao, Hsiang-Ruei/0000-0003-0843-4375	Chang-Gung University, Taoyuan, Taiwan [CMRPD 34013, NMRP 140511]; National Science Council of the Republic of China [NSC 94-2320-B-182-052]	Chang-Gung University, Taoyuan, Taiwan; National Science Council of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang-Gung University, Taoyuan, Taiwan (CMRPD 34013, NMRP 140511) and from the National Science Council of the Republic of China (NSC 94-2320-B-182-052).	Ando S, 2001, MOL ENDOCRINOL, V15, P1529, DOI 10.1210/me.15.9.1529; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Berdowska I, 2004, CLIN CHIM ACTA, V342, P41, DOI 10.1016/j.cccn.2003.12.016; Chamba A, 1996, J CLIN ENDOCR METAB, V81, P360, DOI 10.1210/jc.81.1.360; Chen RN, 2008, ENDOCRINOLOGY, V149, P3817, DOI 10.1210/en.2007-0989; Chen RN, 2008, CANCER RES, V68, P1697, DOI 10.1158/0008-5472.CAN-07-5492; Chiloeches A, 2008, MOL ENDOCRINOL, V22, P2466, DOI 10.1210/me.2008-0107; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; del Re EC, 2000, BRIT J CANCER, V82, P1317; Dickinson DP, 2002, CRIT REV ORAL BIOL M, V13, P238, DOI 10.1177/154411130201300304; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008; Hassan MM, 2009, HEPATOLOGY, V49, P1563, DOI 10.1002/hep.22793; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang YH, 2010, J CELL PHYSIOL, V222, P347, DOI 10.1002/jcp.21959; Huang Ya-Hui, 2008, Chang Gung Med J, V31, P325; Huang YH, 2006, ENDOCRINOLOGY, V147, P2481, DOI 10.1210/en.2005-1166; Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289; Kos J, 1997, CLIN CANCER RES, V3, P1815; Kress E, 2010, GASTROENTEROLOGY, V138, P1863, DOI 10.1053/j.gastro.2010.01.041; Kress E, 2009, J BIOL CHEM, V284, P1234, DOI 10.1074/jbc.M806548200; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liao CS, 2009, MOL CELL ENDOCRINOL, V307, P109, DOI 10.1016/j.mce.2009.04.013; Lin KH, 2000, ENDOCRINOLOGY, V141, P2540, DOI 10.1210/en.141.7.2540; Lin KH, 2001, ENDOCRINOLOGY, V142, P653, DOI 10.1210/en.142.2.653; Martinez-Iglesias O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006428; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nelson D, 2006, J LEUKOCYTE BIOL, V80, P685, DOI 10.1189/jlb.1105646; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Plateroti M, 2006, MOL CELL BIOL, V26, P3204, DOI 10.1128/MCB.26.8.3204-3214.2006; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Rosen MD, 2009, MOL ENDOCRINOL, V23, P1183, DOI 10.1210/me.2009-0126; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Schraufstatter IU, 2003, J IMMUNOL, V171, P6714, DOI 10.4049/jimmunol.171.12.6714; Shih CH, 2004, ENDOCRINOLOGY, V145, P2804, DOI 10.1210/en.2003-1372; Sivaparvathi M, 1996, CANCER LETT, V104, P121, DOI 10.1016/0304-3835(96)04242-5; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Teranishi S, 2009, INVEST OPHTH VIS SCI, V50, P5646, DOI 10.1167/iovs.08-2534; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tsui KH, 2008, PROSTATE, V68, P610, DOI 10.1002/pros.20725; TSUSHIMA H, 1991, INT J CANCER, V48, P726, DOI 10.1002/ijc.2910480516; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wilson TJ, 2008, BBA-REV CANCER, V1785, P85, DOI 10.1016/j.bbcan.2007.11.001; Wu SM, 2010, CELL MOL LIFE SCI, V67, P1831, DOI 10.1007/s00018-010-0281-2; Yang H, 1999, ENDOCRINOLOGY, V140, P43, DOI 10.1210/en.140.1.43; Yang L, 2008, CANCER RES, V68, P9107, DOI 10.1158/0008-5472.CAN-08-2556; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; YEN PM, 1994, J BIOL CHEM, V269, P903; Zhu XG, 2010, ONCOGENE, V29, P1909, DOI 10.1038/onc.2009.476	52	29	30	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2057	2069		10.1038/onc.2010.585	http://dx.doi.org/10.1038/onc.2010.585			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217776				2022-12-28	WOS:000289977400009
J	Tabaries, S; Dong, Z; Annis, MG; Omeroglu, A; Pepin, F; Ouellet, V; Russo, C; Hassanain, M; Metrakos, P; Diaz, Z; Basik, M; Bertos, N; Park, M; Guettier, C; Adam, R; Hallett, M; Siegel, PM				Tabaries, S.; Dong, Z.; Annis, M. G.; Omeroglu, A.; Pepin, F.; Ouellet, V.; Russo, C.; Hassanain, M.; Metrakos, P.; Diaz, Z.; Basik, M.; Bertos, N.; Park, M.; Guettier, C.; Adam, R.; Hallett, M.; Siegel, P. M.			Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes	ONCOGENE			English	Article						breast cancer; liver metastasis; claudins; extracellular matrix; adhesion; integrins	SINUSOIDAL ENDOTHELIAL-CELLS; TO-MESENCHYMAL TRANSITION; PROGNOSTIC-FACTORS; COLORECTAL-CANCER; CARCINOMA CELLS; GENE-EXPRESSION; POOR-PROGNOSIS; 1ST RECURRENCE; ADHESION; TETRASPANINS	The liver represents the third most frequent site of metastasis in patients with breast cancer. We performed in vivo selection using 4T1 breast cancer cells to identify genes associated with the liver metastatic phenotype. Coincident with the loss of numerous tight-junctional proteins, we observe claudin-2 overexpression, specifically in liver-aggressive breast cancer cells. We further demonstrate that claudin-2 is both necessary and sufficient for the ability of 4T1 breast cancer cells to colonize and grow in the liver. The liver-aggressive breast cancer cells display a claudin-2-mediated increase in their ability to adhere to extracellular matrix (ECM) components, such as fibronectin and type IV collagen. Claudin-2 facilitates these cell/matrix interactions by increasing the cell surface expression of alpha(2)beta(1)- and alpha(5)beta(1)-integrin complexes in breast cancer cells. Indeed, claudin-2-mediated adhesion to fibronectin and type IV collagen can be blocked with neutralizing antibodies that target alpha(5)beta(1) and alpha(2)beta(1) complexes, respectively. Immunohistochemical analyses reveal that claudin-2, although weakly expressed in primary human breast cancers, is readily detected in all liver metastasis samples examined to date. Together, these results uncover novel roles for claudin-2 in promoting breast cancer adhesion to the ECM and define its importance during breast cancer metastasis to the liver. Oncogene (2011) 30, 1318-1328; doi:10.1038/onc.2010.518; published online 15 November 2010	[Tabaries, S.; Dong, Z.; Annis, M. G.; Pepin, F.; Ouellet, V.; Russo, C.; Bertos, N.; Park, M.; Hallett, M.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Tabaries, S.; Dong, Z.; Annis, M. G.; Ouellet, V.; Russo, C.; Bertos, N.; Park, M.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada; [Omeroglu, A.; Park, M.; Siegel, P. M.] McGill Univ, Dept Pathol, Ctr Hlth, Montreal, PQ H3A 1A3, Canada; [Pepin, F.; Hallett, M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Pepin, F.] McGill Univ, McGill Ctr Bioinformat, Montreal, PQ H3A 1A3, Canada; [Hassanain, M.; Metrakos, P.] McGill Univ, Dept Hepatopancreatobiliary Surg, Ctr Hlth, Montreal, PQ H3A 1A3, Canada; [Hassanain, M.; Metrakos, P.] King Saud Univ, Coll Med, Dept Surg, Riyadh 11461, Saudi Arabia; [Diaz, Z.; Basik, M.] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Montreal, PQ, Canada; [Guettier, C.; Adam, R.] Hop Paul Brousse, AP HP, Unite Chronotherapie,Dept Cancerol, Ctr Hepatobiliaire,Serv Anat Pathol, Villejuif, France; [Guettier, C.; Adam, R.] Hop Paul Brousse, AP HP, Serv Biochim, Villejuif, France	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; King Saud University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP	Tabaries, S (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave W,Room 513, Montreal, PQ H3A 1A3, Canada.	peter.siegel@mcgill.ca	Hassanain, Mazen/C-7256-2011; metrakos, peter/D-3726-2013	Hassanain, Mazen/0000-0002-2441-5142; Hallett, Michael/0000-0001-6738-6786; Diaz, Zuanel/0000-0002-4866-9614; Annis, Matthew/0000-0002-8776-004X	Terry Fox Foundation [020002]; Banque de tissu et de donnees of the Reseau de la recherche sur le cancer (RR Cancer) of the Fonds de recherche en sante du Quebec (FRSQ); McGill University Department of Medicine; US Department of Defense; Fonds de la Recherche en Sante du Quebec (FRSQ); Canadian Cancer Society	Terry Fox Foundation; Banque de tissu et de donnees of the Reseau de la recherche sur le cancer (RR Cancer) of the Fonds de recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); McGill University Department of Medicine; US Department of Defense(United States Department of Defense); Fonds de la Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); Canadian Cancer Society(Canadian Cancer Society (CCS))	We acknowledge the McGill Centre for Bone and Periodontal Research and the Goodman Cancer Research Centre for routine histological services. We thank Dr Jeanine Quillard for her invaluable assistance in identifying the liver resection specimens analyzed in this study. We thank J Ursini-Siegel and members of the Siegel laboratory for thoughtful discussions and critical reading of the manuscript. This work was supported by a program project grant from the Terry Fox Foundation (Grant #020002) (to PMS and MP) and by a grant from the Banque de tissu et de donnees of the Reseau de la recherche sur le cancer (RR Cancer) of the Fonds de recherche en sante du Quebec (FRSQ) (to MP). ST acknowledges support from the McGill University Department of Medicine, FP was the recipient of a Breast Cancer Pre-doctoral Traineeship Award from the US Department of Defense, VO is supported by a Fellowship from the Fonds de la Recherche en Sante du Quebec (FRSQ) and PMS was a research scientist supported by the Canadian Cancer Society and is currently a Chercheur-Junior2 of the FRSQ.	Aung PP, 2006, VIRCHOWS ARCH, V448, P428, DOI 10.1007/s00428-005-0120-2; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berkowitz N, 2000, Value Health, V3, P23, DOI 10.1046/j.1524-4733.2000.31003.x; Blanchard AA, 2009, VIRCHOWS ARCH, V454, P647, DOI 10.1007/s00428-009-0770-6; Braet Filip, 2002, Comp Hepatol, V1, P1, DOI 10.1186/1476-5926-1-1; Braet F, 2009, LIVER INT, V29, P603, DOI 10.1111/j.1478-3231.2008.01836.x; Buchert M, 2010, P NATL ACAD SCI USA, V107, P2628, DOI 10.1073/pnas.0903747107; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Diamond JR, 2009, LANCET ONCOL, V10, P615, DOI 10.1016/S1470-2045(09)70029-4; Eichbaum MHR, 2006, BREAST CANCER RES TR, V96, P53, DOI 10.1007/s10549-005-9039-1; Enns AE, 2004, J GASTROINTEST SURG, V8, P1049, DOI 10.1016/j.gassur.2004.08.016; Er O, 2008, CANCER J, V14, P62, DOI 10.1097/PPO.0b013e3181629a7b; Erin N, 2009, INT J CANCER, V124, P1503, DOI 10.1002/ijc.24131; FIDLER IJ, 1986, CANCER METAST REV, V5, P29, DOI 10.1007/BF00049529; Friedrichs J, 2008, J BIOL CHEM, V283, P32264, DOI 10.1074/jbc.M803634200; GIAVAZZI R, 1986, J NATL CANCER I, V77, P1303; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Insa A, 1999, BREAST CANCER RES TR, V56, P67, DOI 10.1023/A:1006285726561; KEMPERMAN H, 1995, CANCER SURV, V24, P67; Kim TH, 2008, HISTOPATHOLOGY, V53, P48, DOI 10.1111/j.1365-2559.2008.03052.x; Kinugasa T, 2007, ANTICANCER RES, V27, P3729; Kominsky SL, 2004, AM J PATHOL, V164, P1627, DOI 10.1016/S0002-9440(10)63721-2; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Kuhn S, 2007, MOL CANCER RES, V5, P553, DOI 10.1158/1541-7786.MCR-06-0384; Kulka J, 2009, PATHOL ONCOL RES, V15, P59, DOI 10.1007/s12253-008-9089-x; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Lazo PA, 2007, CANCER SCI, V98, P1666, DOI 10.1111/j.1349-7006.2007.00584.x; Magro Gaetano, 1997, General and Diagnostic Pathology, V143, P203; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; MARTINEZHERNANDEZ A, 1993, VIRCHOWS ARCH A, V423, P1, DOI 10.1007/BF01606425; Mima S, 2008, CARCINOGENESIS, V29, P1994, DOI 10.1093/carcin/bgn134; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Mourskaia AA, 2009, ONCOGENE, V28, P1005, DOI 10.1038/onc.2008.454; Naik MU, 2008, CANCER RES, V68, P2194, DOI 10.1158/0008-5472.CAN-07-3057; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x; Osanai M, 2006, CANCER RES, V66, P9125, DOI 10.1158/0008-5472.CAN-06-1864; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Pentheroudakis G, 2006, BREAST CANCER RES TR, V97, P237, DOI 10.1007/s10549-005-9117-4; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541-7786.MCR-07-0119; Rosenow Felix, 2008, Neoplasia, V10, P168, DOI 10.1593/neo.07898; Sauer T, 2005, CYTOPATHOLOGY, V16, P193, DOI 10.1111/j.1365-2303.2005.00257.x; Schluter K, 2006, AM J PATHOL, V169, P1064, DOI 10.2353/ajpath.2006.050566; Selzner M, 2000, SURGERY, V127, P383, DOI 10.1067/msy.2000.103883; Soini Y, 2004, HUM PATHOL, V35, P1531, DOI 10.1016/j.humpath.2004.09.015; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458; Tiwari-Woodruff SK, 2001, J CELL BIOL, V153, P295, DOI 10.1083/jcb.153.2.295; Tokes AM, 2005, PATHOL RES PRACT, V201, P537, DOI 10.1016/j.prp.2005.05.005; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Ugnat AM, 2004, BRIT J CANCER, V90, P1138, DOI 10.1038/sj.bjc.6601662; Ura H, 1998, SURG TODAY, V28, P1001, DOI 10.1007/BF02483952; Wisse E, 2008, GENE THER, V15, P1193, DOI 10.1038/gt.2008.60; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yokomori H, 2008, MED MOL MORPHOL, V41, P1, DOI 10.1007/s00795-007-0390-7; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315	64	94	99	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	11					1318	1328		10.1038/onc.2010.518	http://dx.doi.org/10.1038/onc.2010.518			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21076473				2022-12-28	WOS:000288492100006
J	Thobe, MN; Gray, JK; Gurusamy, D; Paluch, AM; Wagh, PK; Pathrose, P; Lentsch, AB; Waltz, SE				Thobe, M. N.; Gray, J. K.; Gurusamy, D.; Paluch, A. M.; Wagh, P. K.; Pathrose, P.; Lentsch, A. B.; Waltz, S. E.			The Ron receptor promotes prostate tumor growth in the TRAMP mouse model	ONCOGENE			English	Article						Ron receptor; hepatoctye growth factor-like protein; prostate cancer; MST1R; receptor tyrosine kinase	TYROSINE KINASE RON; NF-KAPPA-B; TRANSGENIC MOUSE; CANCER CELLS; MURINE MODEL; BETA-CATENIN; MET FAMILY; FACTOR-I; OVEREXPRESSION; ACTIVATION	The Ron receptor tyrosine kinase (TK) is overexpressed in many cancers, including prostate cancer. To examine the significance of Ron in prostate cancer in vivo, we utilized a genetically engineered mouse model, referred to as TRAMP mice, that is predisposed to develop prostate tumors. In this model, we show that prostate tumors from 30-week-old TRAMP mice have increased Ron expression compared with age-matched wild-type prostates. Based on the upregulation of Ron in human prostate cancers and in this murine model of prostate tumorigenesis, we hypothesized that this receptor has a functional role in the development of prostate tumors. To test this hypothesis, we crossed TRAMP mice with mice that are deficient in Ron signaling (TK-/-). Interestingly, TK-/- TRAMP+ mice show a significant decrease in prostate tumor mass relative to TRAMP mice containing functional Ron. Moreover, TK-/- TRAMP+ prostate tumors exhibited decreased tumor vascularization relative to TK+/+ TRAMP+ prostate tumors, which correlated with reduced levels of the angiogenic molecules vascular endothelial growth factor and CXCL2. Although Ron loss did not alter tumor cell proliferation, a significant decrease in cell survival was observed. Similarly, murine prostate cancer cell lines containing a Ron deficiency exhibited decreased levels of active nuclear factor-kappa B, suggesting that Ron may be important in regulating prostate cell survival at least partly through this pathway. In total, our data show for the first time that Ron promotes prostate tumor growth, prostate tumor angiogenesis and prostate cancer cell survival in vivo. Oncogene (2011) 30, 4990-4998; doi:10.1038/onc.2011.205; published online 30 May 2011	[Thobe, M. N.; Gray, J. K.; Gurusamy, D.; Paluch, A. M.; Wagh, P. K.; Pathrose, P.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA; [Lentsch, A. B.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Waltz, SE (corresponding author), Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Vontz Bldg Mol Studies,3125 Eden Ave, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu	Gurusamy, Devikala/T-3410-2019	Gurusamy, Devikala/0000-0002-1727-8653; Waltz, Susan/0000-0003-3572-4642	National Institutes of Health [CA-125379]; Department of Defense [PC060821]; NATIONAL CANCER INSTITUTE [R01CA125379] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sandy Schwemberger for her assistance with the flow cytometry experiments as well as Gina Ciovacco for her technical contributions. This work was supported by Public Health Services Grant CA-125379 (SEW) from the National Institutes of Health, and by Grant Project No. PC060821 (MNT) from the Department of Defense Congressionally Directed Medical Research Program.	Agus DB, 1999, CANCER RES, V59, P4761; Becker CM, 2002, CANCER BIOL THER, V1, P548, DOI 10.4161/cbt.1.5.176; Chan EL, 2005, ONCOGENE, V24, P479, DOI 10.1038/sj.onc.1208231; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; de Bono JS, 2007, CLIN CANCER RES, V13, P3611, DOI 10.1158/1078-0432.CCR-07-0268; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kojima S, 2009, INT J UROL, V16, P161, DOI 10.1111/j.1442-2042.2008.02224.x; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Leonis NA, 2002, HEPATOLOGY, V36, P1053, DOI 10.1053/jhep.2002.36822; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mallakin A, 2006, AM J RESP CELL MOL, V34, P15, DOI 10.1165/rcmb.2005-0093OC; Meyer SE, 2009, DEV BIOL, V333, P173, DOI 10.1016/j.ydbio.2009.06.028; Meyer SE, 2009, MOL CARCINOGEN, V48, P995, DOI 10.1002/mc.20551; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; RONSIN C, 1993, ONCOGENE, V8, P1195; Shen H, 2004, AM J PHYSIOL-CELL PH, V286, pC840, DOI 10.1152/ajpcell.00335.2003; Shen H, 2006, PROSTATE, V66, P1721, DOI 10.1002/pros.20476; Shukla S, 2005, PROSTATE, V64, P224, DOI 10.1002/pros.20217; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Vicentini C, 2003, J CANCER RES CLIN, V129, P165, DOI 10.1007/s00432-003-0420-3; Wagh PK, 2011, ONCOGENE, V30, P3694, DOI 10.1038/onc.2011.86; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang Jun, 2007, J Carcinog, V6, P3, DOI 10.1186/1477-3163-6-3; Wilson CB, 2008, J IMMUNOL, V181, P2303, DOI 10.4049/jimmunol.181.4.2303; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	35	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4990	4998		10.1038/onc.2011.205	http://dx.doi.org/10.1038/onc.2011.205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21625214	Green Accepted			2022-12-28	WOS:000298346500007
J	Gerstel, D; Wegwitz, F; Jannasch, K; Ludewig, P; Scheike, K; Alves, F; Beauchemin, N; Deppert, W; Wagener, C; Horst, AK				Gerstel, D.; Wegwitz, F.; Jannasch, K.; Ludewig, P.; Scheike, K.; Alves, F.; Beauchemin, N.; Deppert, W.; Wagener, C.; Horst, A. K.			CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation	ONCOGENE			English	Article						CEACAM1; angiogenesis; tumor microenvironments; vessel maturation; MMP9-expressing leukocytes	CELL-ADHESION MOLECULE-1; VOLUME COMPUTED-TOMOGRAPHY; VASCULAR MORPHOGENESIS; BLOOD-VESSELS; MOUSE MODEL; IN-VIVO; CANCER; EXPRESSION; GROWTH; CARCINOGENESIS	We have studied the effects of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) on tumor angiogenesis in murine ductal mammary adenocarcinomas. We crossed transgenic mice with whey acidic protein promoter-driven large T-antigen expression (WAP-T mice) with oncogene-induced mammary carcinogenesis with CEA-CAM1null mice, and with Tie2-Ceacam1 transgenics, in which the Tie2 promoter drives endothelial overexpression of CEACAM1 (WAP-T x CEACAM1(endo+) mice), and analyzed tumor vascularization, angiogenesis and vessel maturation in these mice. Using flat-panel volume computed tomography (fpVCT) and histology, we found that WAP-T x CEACAM1(endo+) mice exhibited enhanced tumoral vascularization owing to CEACAM1(+) vessels in the tumor periphery, and increased intratumoral angiogenesis compared with controls. In contrast, vascularization of CEACAM1null/WAP-T-derived tumors was poor, and tumor vessels were dilated, leaky and showed poor pericyte coverage. Consequently, the tumoral vasculature could not be visualized in CEACAM1null/WAP-T mice by fpVCT, and we observed poor organization of the perivascular extracellular matrix (ECM), accompanied by the accumulation of collagen IV-degrading matrix metalloproteinase 9(+) (MMP9(+)) leukocytes and stromal cells. Vascular instability and alterations in ECM structure were accompanied by a significant increase in pulmonary metastases in CEACAM1null/WAP-T mice, whereas only occasional metastases were observed in CEACAM1(+) hosts. In CEACAM1(+) hosts, intratumoral vessels did not express CEACAM1, but they were intact, extensively covered with pericytes and framed by a well-organized perivascular ECM. MMP9(+) accessory cells were largely absent. Orthotopic transplantation of primary WAP-T- and CEACAM1null/WAP-T tumors into all three mouse lines confirmed that a CEACAM1(+) host environment is a prerequisite for productive angiogenic remodeling of the tumor microenvironment. Hence, CEACAM1 expression in the tumor periphery determines the vascular phenotype in a tumor, whereas systemic absence of CEACAM1 interferes with the formation of an organized tumor matrix and intratumoral vessel maturation. Oncogene (2011) 30, 4275-4288; doi: 10.1038/onc.2011.146; published online 2 May 2011	[Gerstel, D.; Ludewig, P.; Scheike, K.; Wagener, C.; Horst, A. K.] Univ Med Ctr Hamburg Eppendorf, Ctr Diagnost, Inst Clin Chem, D-20246 Hamburg, Germany; [Wegwitz, F.; Deppert, W.] Heinrich Pette Inst, Dept Tumor Virol, Hamburg, Germany; [Jannasch, K.; Alves, F.] Univ Gottingen, Dept Hematol & Oncol, Univ Med Ctr Gottingen, Gottingen, Germany; [Beauchemin, N.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada	University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; University of Gottingen; McGill University	Horst, AK (corresponding author), Univ Med Ctr Hamburg Eppendorf, Ctr Diagnost, Inst Clin Chem, CAMPUS Res Bldg N27,02-089,52 Martinistr, D-20246 Hamburg, Germany.	ahorst@uke.de			German Research Foundation [SPP1190]	German Research Foundation(German Research Foundation (DFG))	This work was supported by the German Research Foundation, Priority Program SPP1190: the tumor vessel interface to WD, CW, AKH and FA.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7; Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Betsholtz C, 2005, EXP SUPPL, V94, P115; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187; Dango S, 2008, LUNG CANCER, V60, P426, DOI 10.1016/j.lungcan.2007.11.015; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Fathers KE, 2005, AM J PATHOL, V167, P1753, DOI 10.1016/S0002-9440(10)61256-4; Francis SH, 2010, PHARMACOL REV, V62, P525, DOI 10.1124/pr.110.002907; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Heinlein C, 2008, INT J CANCER, V122, P1701, DOI 10.1002/ijc.23317; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Horst AK, 2004, HANDB EXP PHARM, V165, P283, DOI 10.1007/978-3-540-68170-0_10; Horst AK, 2009, BLOOD, V113, P6726, DOI 10.1182/blood-2008-10-184556; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; Huang FJ, 2010, DEV BIOL, V344, P1035, DOI 10.1016/j.ydbio.2010.06.023; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jannasch K, 2009, INT J CANCER, V125, P62, DOI 10.1002/ijc.24332; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kilic N, 2007, BLOOD, V110, P4223, DOI 10.1182/blood-2007-06-097592; Kirshner J, 2004, J MOL HISTOL, V35, P287, DOI 10.1023/B:HIJO.0000032360.01976.81; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kohler S, 2010, BRIT J CANCER, V102, P602, DOI 10.1038/sj.bjc.6605492; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Li CX, 2009, EXP CELL RES, V315, P1225, DOI 10.1016/j.yexcr.2008.12.015; Missbach-Guentner J, 2007, NEOPLASIA, V9, P755, DOI 10.1593/neo.07466; Nouvion AL, 2010, J CELL SCI, V123, P4221, DOI 10.1242/jcs.073635; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; SAWA H, 1994, DEV BRAIN RES, V78, P35, DOI 10.1016/0165-3806(94)90006-X; Sawamiphak S, 2010, NATURE, V465, P487, DOI 10.1038/nature08995; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; Seandel M, 2008, CANCER CELL, V13, P181, DOI 10.1016/j.ccr.2008.02.016; Tilki D, 2006, ONCOGENE, V25, P4965, DOI 10.1038/sj.onc.1209514; Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002; Wegwitz F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012103	42	42	43	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	41					4275	4288		10.1038/onc.2011.146	http://dx.doi.org/10.1038/onc.2011.146			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21532628				2022-12-28	WOS:000296356300005
J	Su, Y; Wagner, ER; Luo, Q; Huang, J; Chen, L; He, BC; Zuo, GW; Shi, Q; Zhang, BQ; Zhu, G; Bi, Y; Luo, J; Luo, X; Kim, SH; Shen, J; Rastegar, F; Huang, E; Gao, Y; Gao, JL; Yang, K; Wietholt, C; Li, M; Qin, J; Haydon, RC; He, TC; Luu, HH				Su, Y.; Wagner, E. R.; Luo, Q.; Huang, J.; Chen, L.; He, B-C; Zuo, G-W; Shi, Q.; Zhang, B-Q; Zhu, G.; Bi, Y.; Luo, J.; Luo, X.; Kim, S. H.; Shen, J.; Rastegar, F.; Huang, E.; Gao, Y.; Gao, J-L; Yang, K.; Wietholt, C.; Li, M.; Qin, J.; Haydon, R. C.; He, T-C; Luu, H. H.			Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma	ONCOGENE			English	Article						osteosarcoma; tumorigenesis; metastasis; IGFBP5; animal model	MESENCHYMAL STEM-CELLS; BREAST-CANCER CELLS; OSTEOBLAST DIFFERENTIATION; RECOMBINANT ADENOVIRUSES; CLEAR-CELL; IN-VIVO; EXPRESSION; INHIBITOR; IGFBP-5; SYSTEM	Osteosarcoma (OS) is the most common primary malignancy of bone. There is a critical need to identify the events that lead to the poorly understood mechanism of OS development and metastasis. The goal of this investigation is to identify and characterize a novel marker of OS progression. We have established and characterized a highly metastatic OS subline that is derived from the less metastatic human MG63 line through serial passages in nude mice via intratibial injections. Microarray analysis of the parental MG63, the highly metastatic MG63.2 subline, as well as the corresponding primary tumors and pulmonary metastases revealed insulin-like growth factor binding protein 5 (IGFBP5) to be one of the significantly downregulated genes in the metastatic subline. Confirmatory quantitative RT-PCR on 20 genes of interest demonstrated IGFBP5 to be the most differentially expressed and was therefore chosen to be one of the genes for further investigation. Adenoviral mediated overexpression and knockdown of IGFBP5 in the MG63 and MG63.2 cell lines, as well as other OS lines (143B and MNNG/HOS) that are independent of our MG63 lines, were employed to examine the role of IGFBP5. We found that overexpression of IGFBP5 inhibited in vitro cell proliferation, migration and invasion of OS cells. Additionally, IGFBP5 overexpression promoted apoptosis and cell cycle arrest in the G1 phase. In an orthotopic xenograft animal model, overexpression of IGFBP5 inhibited OS tumor growth and pulmonary metastases. Conversely, siRNA-mediated knockdown of IGFBP5 promoted OS tumor growth and pulmonary metastases in vivo. Immunohistochemical staining of patient-matched primary and metastatic OS samples demonstrated decreased IGFBP5 expression in the metastases. These results suggest 1) a role for IGFBP5 as a novel marker that has an important role in the pathogenesis of OS, and 2) that the loss of IGFBP5 function may contribute to more metastatic phenotypes in OS. Oncogene (2011) 30, 3907-3917; doi:10.1038/onc.2011.97; published online 4 April 2011	[Luu, H. H.] Univ Chicago, Suzanne Berman Oncol Lab, Dept Surg, Med Ctr, Chicago, IL 60637 USA; [Su, Y.; Luo, Q.; Zhu, G.; Bi, Y.; Li, M.; Qin, J.; He, T-C] Chongqing Med Univ, Stem Cell Biol & Therapy Lab, Childrens Hosp, Chongqing, Peoples R China; [Su, Y.; Luo, Q.; Huang, J.; Chen, L.; He, B-C; Zuo, G-W; Shi, Q.; Zhang, B-Q; Zhu, G.; Bi, Y.; Luo, J.; Luo, X.; Li, M.; Qin, J.; He, T-C] Chinese Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China; [Su, Y.; Luo, Q.; Huang, J.; Chen, L.; He, B-C; Zuo, G-W; Shi, Q.; Zhang, B-Q; Zhu, G.; Bi, Y.; Luo, J.; Luo, X.; Li, M.; Qin, J.; He, T-C] Chongqing Med Univ, Affiliated Hosp, Chongqing, Peoples R China; [Huang, E.] Chongqing Univ, Sch Bioengn, Chongqing, Peoples R China; [Gao, Y.] Shanghai Jiatong Univ, Dept Geriatr, Xinhua Hosp, Shanghai, Peoples R China; [Yang, K.] Third Mil Med Univ, Dept Cell Biol, Chongqing, Peoples R China; [Wietholt, C.] Univ Chicago, Dept Radiol, Med Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; Chongqing Medical University; Chongqing Medical University; Chongqing University; Shanghai Jiao Tong University; Army Medical University; University of Chicago; University of Chicago Medical Center	Luu, HH (corresponding author), Univ Chicago, Suzanne Berman Oncol Lab, Dept Surg, Med Ctr, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.	hluu@surgery.bsd.uchicago.edu		Wagner, Eric/0000-0001-9241-5702	American Cancer Society; Brinson Foundation; National Institute of Health; Orthopaedic Research and Education Foundation; Natural Science Foundation of China [81001197]; Ministry of Science and Technology of China [2011CB707906]	American Cancer Society(American Cancer Society); Brinson Foundation; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Orthopaedic Research and Education Foundation; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Dr Xinmin Li, PhD (Director of The UCLA Clinical Microarray Core) for his help with the microarray and cluster analysis. We also sincerely thank Dr Anthony Montag, Leslie Martin and Guarav Luther for the creation of the tissue array. We also thank Dr Theodore Karrison for help with the statistical analysis. This work was supported in part by research grants from The American Cancer Society (HHL and TCH), the Brinson Foundation (HHL, TCH, RCH), The National Institute of Health (HHL, TCH, RCH), the Orthopaedic Research and Education Foundation (HHL, RCH), the Natural Science Foundation of China (#81001197 to YS), and the 973 Program of the Ministry of Science and Technology of China (#2011CB707906 to JL and TCH).	Akkiprik M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2116; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008-5472.CAN-08-2645; Butt AJ, 2005, ENDOCRINOLOGY, V146, P3113, DOI 10.1210/en.2004-1408; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Cheung C, 2005, INT J UROL, V12, P17, DOI 10.1111/j.1442-2042.2004.00993.x; DAVIS AM, 1994, J CLIN ONCOL, V12, P423, DOI 10.1200/JCO.1994.12.2.423; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130; Kaste SC, 1999, CANCER-AM CANCER SOC, V86, P1602, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1602::AID-CNCR31>3.0.CO;2-R; Letson G D, 2001, Cancer Control, V8, P239; Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135; Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200; Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030; Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999-008-0361-x; Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015; Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585-005-0365-9; Luu HH, 1998, CANCER RES, V58, P3561; Manara MC, 2007, CLIN CANCER RES, V13, P1322, DOI 10.1158/1078-0432.CCR-06-1518; Mankin HJ, 2004, CLIN ORTHOP RELAT R, P286, DOI 10.1097/01.blo.0000145991.65770.e6; Mukherjee A, 2007, GROWTH HORM IGF RES, V17, P179, DOI 10.1016/j.ghir.2007.01.005; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Ragland BD, 2002, LAB INVEST, V82, P365, DOI 10.1038/labinvest.3780431; Rosenzweig SA, 2004, GROWTH HORM IGF RES, V14, P329, DOI 10.1016/j.ghir.2004.02.003; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785; Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200; Song H, 2001, J MOL ENDOCRINOL, V26, P229, DOI 10.1677/jme.0.0260229; Stolf BS, 2003, CANCER LETT, V191, P193, DOI 10.1016/S0304-3835(02)00679-1; Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6; Takahash M, 2005, INT J ONCOL, V26, P923; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang HM, 2006, MODERN PATHOL, V19, P1149, DOI 10.1038/modpathol.3800637; Whelan JS, 1997, EUR J CANCER, V33, P1611, DOI 10.1016/S0959-8049(97)00251-7; Xu C, 2007, PROSTATE, V67, P1621, DOI 10.1002/pros.20655; Yonemoto T, 1998, CLIN ORTHOP RELAT R, P194	39	109	111	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3907	3917		10.1038/onc.2011.97	http://dx.doi.org/10.1038/onc.2011.97			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21460855				2022-12-28	WOS:000294890400001
J	Maas, C; de Vries, E; Tait, SWG; Borst, J				Maas, C.; de Vries, E.; Tait, S. W. G.; Borst, J.			Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53	ONCOGENE			English	Article						Bid; apoptosis; DNA damage; p53	BH3-ONLY PROTEINS PUMA; CYTOCHROME-C RELEASE; DNA-DAMAGE; LYMPHOID-CELLS; MITOCHONDRIA; TRANSLOCATION; ACTIVATION; NOXA; DRUG; LIFE	BH3-only protein Bid is a key player in death receptor-induced apoptosis, because it provides the link with the mitochondrial route for caspase activation. In this pathway, Bid is activated upon cleavage by caspase-8. Its BH3 domain-containing carboxy-terminal fragment subsequently provokes mitochondrial outer membrane permeabilization by Bak/Bax activation. Bid has also been implicated in the apoptotic response to ionizing radiation (IR) and the topoisomerase inhibitor etoposide, anti-cancer regimens that cause double-strand (ds) DNA breaks. We confirm the existence of this pathway and show that it is p53-independent. However, the degree of Bid participation in the apoptotic response to dsDNA breaks depends on the nature of cell transformation. We used Bid-deficient mouse embryonic fibroblast (MEF) lines that were reconstituted with Bid to control the cellular background and demonstrated that the Bid-dependent apoptotic pathway induced by IR and etoposide operates in MEFs that are transformed by SV40, but is not evident in E1A/Ras-transformed MEFs. The Bid-dependent apoptotic response in p53-deficient SV40-transformed MEFs contributed to clonogenic execution of the cells, implying relevance for treatment outcome. In these cells, Bid acted in a conventional manner in that it required its BH3 domain to mediate apoptosis in response to IR and etoposide, and triggered apoptotic execution by indirect activation of Bak/Bax, mitochondrial permeabilization and caspase-9 activation. However, the mechanism of Bid activation was unconventional, because elimination of all known or suspected cleavage sites for caspases or other proteolytic enzymes and even complete elimination of its unstructured cleavage loop left Bid's pro-apoptotic role in the response to IR and etoposide unaffected. Oncogene (2011) 30, 3636-3647; doi:10.1038/onc.2011.75; published online 21 March 2011	[Maas, C.; de Vries, E.; Tait, S. W. G.; Borst, J.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl		Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009	Dutch Cancer Society [NKI 2008-4110]	Dutch Cancer Society(KWF Kankerbestrijding)	This work was supported by grant NKI 2008-4110 from the Dutch Cancer Society. We thank Dr Atan Gross for MEF cell lines, Rogier Rooswinkel for data analysis, Inge Verbrugge, Bert van de Kooij and Rogier Rooswinkel for discussions and critical reading of the manuscript, and personnel of the flow cytometry facility of the Netherlands Cancer Institute for experimental assistance.	Anguissola S, 2009, MOL PHARMACOL, V76, P998, DOI 10.1124/mol.109.058156; Brown JM, 1999, CANCER RES, V59, P1391; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gross A, 2006, CELL CYCLE, V5, P582, DOI 10.4161/cc.5.6.2575; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kohler B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002844; Krajewska M, 2002, NEOPLASIA, V4, P129, DOI 10.1038/sj.neo.7900222; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Oberkovitz G, 2007, CELL DEATH DIFFER, V14, P1628, DOI 10.1038/sj.cdd.4402181; Ploner C, 2008, ONCOGENE, V27, pS84, DOI 10.1038/onc.2009.46; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Shelton SN, 2009, J BIOL CHEM, V284, P11247, DOI 10.1074/jbc.M809392200; Simmen T, 2005, EMBO J, V24, P717, DOI 10.1038/sj.emboj.7600559; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Tait SWG, 2007, J CELL BIOL, V179, P1453, DOI 10.1083/jcb.200707063; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang XD, 2001, GENE DEV, V15, P2922; Ward MW, 2006, J BIOL CHEM, V281, P5837, DOI 10.1074/jbc.M511562200; Werner AB, 2004, J BIOL CHEM, V279, P28771, DOI 10.1074/jbc.M400268200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zinkel SS, 2007, CELL, V130, P9, DOI 10.1016/j.cell.2007.06.035; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	42	11	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	33					3636	3647		10.1038/onc.2011.75	http://dx.doi.org/10.1038/onc.2011.75			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423217	Green Published, hybrid			2022-12-28	WOS:000294005100007
J	Jiffar, T; Yilmaz, T; Lee, J; Hanna, E; El-Naggar, A; Yu, D; Myers, JN; Kupferman, ME				Jiffar, T.; Yilmaz, T.; Lee, J.; Hanna, E.; El-Naggar, A.; Yu, D.; Myers, J. N.; Kupferman, M. E.			KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck squamous cell carcinoma; KiSS1; chemotherapy resistance; cisplatin; metastasis	NF-KAPPA-B; CISPLATIN-INDUCED APOPTOSIS; S-TRANSFERASE-PI; GENE-EXPRESSION; OVARIAN-CANCER; IMMUNOHISTOCHEMICAL EXPRESSION; POLY(ADP-RIBOSE) POLYMERASE; FUNCTIONAL-CHARACTERIZATION; LUNG-CANCER; P53 GENE	Although surgery and radiotherapy have been the standard treatment modalities for head and neck squamous cell carcinoma (HNSCC), the integration of cisplatin (CDDP)-based therapy has led to improvements in local and regional control of disease for patients. However, many trials show that only 10-20% of patients benefit from this treatment intensification, which can result in profound treatment-associated morbidity and mortality. Moreover, the marginal survival improvement suggests that CDDP resistance is an innate characteristic of HNSCC. To elucidate the biological mechanisms underpinning CDDP resistance in HNSCC, we utilized an experimental model of CDDP resistance in this disease. We first observed significant enhancements in local tumor growth and metastasis, as well as adverse survival, in CDDP-resistant (CR) tumors compared with sensitive tumors. To elucidate the molecular mechanisms of this phenotype, we undertook a systems biology-based approach utilizing high-throughput PCR arrays, and we identified a significant suppression of KiSS1 mRNA and protein expression in the CR cells, but no significant regions of genomic loss with array comparative genomic hybridization. Genetic suppression of KiSS1 in CDDP-sensitive cell lines rendered them CR, an observation that was mechanistically linked to alterations in glutathione S-transferase-pi expression and function. We next confirmed that, in human HNSCC tumors, loss of KiSS1 expression was associated with metastatic human HNSCC tumors compared with non-metastatic tumors. Genetic reconstitution of KiSS1 in CR cells abrogated cellular migration and induced CDDP sensitivity. To confirm these findings in a murine model, either CR or KiSS1-transfected CR cells were studied in an orthotopic model of HNSCC, or survival studies revealed significant improvement in survival of the mice bearing CR-KiSS1 tumors. Mechanistically, alterations in apoptotic pathways and CDDP metabolism contributed to KiSS1-associated chemotherapy sensitization. These studies provided further direct evidence for the role of KiSS1 loss in biologically aggressive HNSCC and suggest potential targets for therapy in CR cancers. Oncogene (2011) 30, 3163-3173; doi:10.1038/onc.2011.39; published online 7 March 2011	[Jiffar, T.; Yilmaz, T.; Lee, J.; Hanna, E.; Myers, J. N.; Kupferman, M. E.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surgery Holcombe 1515, Houston, TX 77030 USA; [El-Naggar, A.] Dept Pathol 1515 Holcombe, Houston, TX USA; [Yu, D.] Dept Mol & Cellular Oncol 1515 Holcombe, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Kupferman, ME (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surgery Holcombe 1515, 1400 Pressler St,Unit 1445, Houston, TX 77030 USA.	mekupfer@mdanderson.org	Lee, Jack/P-7331-2019; Hanna, Ehab Y/B-1593-2017	Lee, Jack/0000-0002-4584-929X; Hanna, Ehab Y/0000-0003-3241-2440; Lee, J. Jack/0000-0001-5469-9214; Yu, Dihua/0000-0001-6231-9381	NIH [K08-DE019185]; Triological Society; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE019185] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Triological Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Yongxiang Li BS for technical assistance and Terri Astin for administrative assistance. We also thank the members of the Small Animal Imaging Facility for their assistance with the mouse studies, Taylor Appleberry for assistance with the array CGH studies and Dr Douglas Boyd (MDACC) for providing the KiSS1 construct. This work is supported by the following funding sources: NIH Grant K08-DE019185 (MEK), Triological Society Career Development Award (MEK), MD Anderson	Antoun G, 2000, J CELL BIOCHEM, V77, P372, DOI 10.1002/(SICI)1097-4644(20000601)77:3<372::AID-JCB3>3.0.CO;2-P; Arai T, 2000, CANCER DETECT PREV, V24, P252; Bai F, 1996, CANCER, V78, P416; Chanvorachote P, 2006, CANCER RES, V66, P6353, DOI 10.1158/0008-5472.CAN-05-4533; Cho SG, 2009, CANCER RES, V69, P7062, DOI 10.1158/0008-5472.CAN-09-0476; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; Cullen KJ, 2003, CANCER RES, V63, P8097; Di Pietro G, 2010, EXPERT OPIN DRUG MET, V6, P153, DOI 10.1517/17425250903427980; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Ganjavi H, 2005, CANCER GENE THER, V12, P397, DOI 10.1038/sj.cgt.7700798; Goldberg SF, 2003, CANCER RES, V63, P432; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; Hu HB, 2005, CLIN CANCER RES, V11, P2379, DOI 10.1158/1078-0432.CCR-04-2084; Jiang Y, 2005, CLIN EXP METASTAS, V22, P369, DOI 10.1007/s10585-005-8186-4; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Khan K, 2010, HEAD NECK-J SCI SPEC, V32, P381, DOI 10.1002/hed.21195; Kigawa J, 2000, ADV EXP MED BIOL, V465, P207; Kim SJ, 2010, J MOL MED, V88, P1123, DOI 10.1007/s00109-010-0652-z; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Kupferman Michael E, 2009, J Exp Ther Oncol, V8, P117; Lee JH, 1997, CANCER RES, V57, P2384; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Lo HW, 2008, MOL CANCER RES, V6, P843, DOI 10.1158/1541-7786.MCR-07-2105; Marot D, 2007, ENDOCR-RELAT CANCER, V14, P691, DOI 10.1677/ERC-07-0012; Masanek U, 1997, ANTI-CANCER DRUG, V8, P189, DOI 10.1097/00001813-199702000-00010; Michaud WA, 2009, CLIN CANCER RES, V15, P1645, DOI 10.1158/1078-0432.CCR-08-2581; Mitchell DC, 2007, ONCOGENE, V26, P1739, DOI 10.1038/sj.onc.1209963; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Morceau F, 2004, BIOCHEM PHARMACOL, V67, P1227, DOI 10.1016/j.bcp.2003.10.036; Nash KT, 2007, JNCI-J NATL CANCER I, V99, P309, DOI 10.1093/jnci/djk053; Nash KT, 2006, FRONT BIOSCI-LANDMRK, V11, P647, DOI 10.2741/1824; Navenot JM, 2009, MOL PHARMACOL, V75, P1300, DOI 10.1124/mol.109.055095; Navenot JM, 2009, MOL PHARMACOL, V75, P1074, DOI 10.1124/mol.108.054270; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001; SUNGGOOK C, 2009, J CELL BIOCHEM, V107, P1139; WELCH DR, 1994, ONCOGENE, V9, P255; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yazlovitskaya EM, 2001, BIOCHEM BIOPH RES CO, V283, P732, DOI 10.1006/bbrc.2001.4849; Yilmaz T, 2010, CANCER BIOL THER, V10, P644, DOI 10.4161/cbt.10.6.12782	49	26	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	28					3163	3173		10.1038/onc.2011.39	http://dx.doi.org/10.1038/onc.2011.39			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383688	Green Accepted			2022-12-28	WOS:000292726300005
J	Andorfer, P; Rotheneder, H				Andorfer, P.; Rotheneder, H.			EAPP: Gatekeeper at the crossroad of apoptosis and p21-mediated cell-cycle arrest	ONCOGENE			English	Article						EAPP; p21; apoptosis; DNA damage; cell-cycle arrest	DEPENDENT KINASE INHIBITOR; S-PHASE ENTRY; DNA-REPLICATION; P53-MEDIATED APOPTOSIS; HISTONE DEACETYLASE-1; TRANSCRIPTION FACTORS; MULTIDRUG-RESISTANCE; TUMOR SUPPRESSION; P21; P53	We previously identified and characterized E2F-associated phospho-protein (EAPP), a nuclear phosphoprotein that interacts with the activating members of the E2F transcription factor family. EAPP levels are frequently elevated in transformed human cells. To examine the biological relevance of EAPP, we studied its properties in stressed and unstressed cells. Overexpression of EAPP in U2OS cells increased the fraction of G1 cells and lead to heightened resistance against DNA damage-or E2F1-induced apoptosis in a p21-dependent manner. EAPP itself becomes upregulated in confluent cells and after DNA damage and stimulates the expression of p21 independently of p53. It binds to the p21 promoter and seems to be required for the assembly of the transcription initiation complex. RNAi-mediated knockdown of EAPP expression brought about increased sensitivity towards DNA damage and resulted in apoptosis even in the absence of stress. Our results indicate that the level of EAPP is critical for cellular homeostasis. Too much of it results in G1 arrest and resistance to apoptosis, which, paradoxically, might favor cellular transformation. Too little EAPP seems to retard the expression not only of the p21 gene, but also of a number of other genes and ultimately results in apoptosis. Oncogene (2011) 30, 2679-2690; doi:10.1038/onc.2010.639; published online 24 January 2011	[Andorfer, P.; Rotheneder, H.] Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Rotheneder, H (corresponding author), Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	Johann.Rotheneder@meduniwien.ac.at			Austrian FWF [P18417]; Herzfelder'sche Familienstiftung	Austrian FWF(Austrian Science Fund (FWF)); Herzfelder'sche Familienstiftung	We are grateful to H Nomura, BH Park, A Ashworth, and N Heintz for expression vectors. We thank Christian Seiser for helpful discussions and the histone antibodies, Erhard Wintersberger and Christian Seiser for critically reading this manuscript, Ingrid Mudrak and Egon Ogris for help with the generation of the monoclonal EAPP antibody, and Thomas Sauer for assistance with the FACS analysis. This work was supported by the Austrian FWF (Grant P18417) and by the Herzfelder'sche Familienstiftung.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Baptiste-Okoh N, 2008, CELL CYCLE, V7, P1133, DOI 10.4161/cc.7.9.5805; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN K, 2010, MOL PHARM; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Goda K, 2009, CURR CANCER DRUG TAR, V9, P281, DOI 10.2174/156800909788166493; GOUBIN F, 1995, ONCOGENE, V10, P2281; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; Gutmann DAP, 2010, TRENDS BIOCHEM SCI, V35, P36, DOI 10.1016/j.tibs.2009.07.009; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Janicke RU, 2007, CELL CYCLE, V6, P407; Karakas B, 2007, CANCER BIOL THER, V6, P1025, DOI 10.4161/cbt.6.7.4202; Kawasaki T, 1996, INT J CANCER, V68, P501, DOI 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kornberg RD, 2007, P NATL ACAD SCI USA, V104, P12955, DOI 10.1073/pnas.0704138104; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Li AG, 2007, MOL CELL, V28, P408, DOI 10.1016/j.molcel.2007.09.006; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Novy M, 2005, MOL BIOL CELL, V16, P2181, DOI 10.1091/mbc.E04-11-0975; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Perucca P, 2009, CELL CYCLE, V8, P105, DOI 10.4161/cc.8.1.7507; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Rozan LM, 2007, CELL DEATH DIFFER, V14, P3, DOI 10.1038/sj.cdd.4402058; Schwarzmayr L, 2008, INT J BIOCHEM CELL B, V40, P2845, DOI 10.1016/j.biocel.2008.06.001; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sikorski TW, 2009, CURR OPIN CELL BIOL, V21, P344, DOI 10.1016/j.ceb.2009.03.006; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	51	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	23					2679	2690		10.1038/onc.2010.639	http://dx.doi.org/10.1038/onc.2010.639			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21258403	Green Published, hybrid			2022-12-28	WOS:000291677800008
J	Normant, E; Paez, G; West, KA; Lim, AR; Slocum, KL; Tunkey, C; McDougall, J; Wylie, AA; Robison, K; Caliri, K; Palombella, VJ; Fritz, CC				Normant, E.; Paez, G.; West, K. A.; Lim, A. R.; Slocum, K. L.; Tunkey, C.; McDougall, J.; Wylie, A. A.; Robison, K.; Caliri, K.; Palombella, V. J.; Fritz, C. C.			The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models	ONCOGENE			English	Article						Hsp90; EML4-ALK; IPI-504; NSCLC; ALK inhibitor	PROTEIN 90 INHIBITOR; GASTROINTESTINAL STROMAL TUMOR; CELL LUNG-CANCER; KINASE INHIBITOR; BREAST-CANCER; HEAT-SHOCK-PROTEIN-90 INHIBITION; FUSION GENE; CHAPERONE; SURVIVAL; IDENTIFICATION	Heat shock protein 90 (Hsp90) is an emerging target for cancer therapy due to its important role in maintaining the activity and stability of key oncogenic signaling proteins. We show here that the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presumed to be the oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC), is associated with Hsp90 in cells and is rapidly degraded upon exposure of cells to IPI-504. We find EML4-ALK to be more sensitive to Hsp90 inhibition than either HER2 or mutant epidermal growth factor receptor (EGFR) with an inhibitory concentration (IC)(50) for protein degradation in the low nanomolar range. This degradation leads to a potent inhibition of downstream signaling pathways and to the induction of growth arrest and apoptosis in cells carrying the EML4-ALK fusion. To generate a causative link between the expression of EML4-ALK and sensitivity to IPI-504, we introduced an EML4-ALK cDNA into HEK293 cells and show that the expression of the fusion protein sensitizes cells to IPI-504 both in vitro and in vivo. In a xenograft model of a human NSCLC cell line containing the ALK rearrangement, we observe tumor regression at clinically relevant doses of IPI-504. Finally, cells that have been selected for resistance to ALK kinase inhibitors retain their sensitivity to IPI-504. We have recently observed partial responses to administration of IPI-504 as a single agent in a phase 2 clinical trial in patients with NSCLC, specifically in patients that carry an ALK rearrangement. This study provides a molecular explanation for these clinical observations. Oncogene (2011) 30, 2581-2586; doi:10.1038/onc.2010.625; published online 24 January 2011	[Normant, E.; Paez, G.; West, K. A.; Lim, A. R.; Slocum, K. L.; Tunkey, C.; McDougall, J.; Wylie, A. A.; Robison, K.; Caliri, K.; Palombella, V. J.; Fritz, C. C.] Infin Pharmaceut, Cambridge, MA 02139 USA		Normant, E (corresponding author), Infin Pharmaceut, 780 Mem Dr, Cambridge, MA 02139 USA.	emmanuel.normant@infi.com						An WG, 2000, CELL GROWTH DIFFER, V11, P355; Bauer S, 2006, CANCER RES, V66, P9153, DOI 10.1158/0008-5472.CAN-06-0165; Choi YL, 2008, CANCER RES, V68, P4971, DOI 10.1158/0008-5472.CAN-07-6158; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dewaele B, 2008, CLIN CANCER RES, V14, P5749, DOI 10.1158/1078-0432.CCR-08-0533; Fumo G, 2004, BLOOD, V103, P1078, DOI 10.1182/blood-2003-07-2477; Ge J, 2006, J MED CHEM, V49, P4606, DOI 10.1021/jm0603116; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038; Li CF, 2008, CLIN CANCER RES, V14, P7822, DOI 10.1158/1078-0432.CCR-08-1369; McCarthy MM, 2008, ANN ONCOL, V19, P590, DOI 10.1093/annonc/mdm545; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y; PARK J, 2008, AACR M; Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738; Peng C, 2007, BLOOD, V110, P678, DOI 10.1182/blood-2006-10-054098; Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511; Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722; Sequist LV, 2010, J CLIN ONCOL, V28, P4953, DOI 10.1200/JCO.2010.30.8338; Sequist LV, 2010, J CLIN ONCOL, V28; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shimamura T, 2008, CANCER RES, V68, P5827, DOI 10.1158/0008-5472.CAN-07-5428; Shimamura T, 2008, J THORAC ONCOL, V3, pS152, DOI 10.1097/JTO.0b013e318174ea3a; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Song D, 2008, MOL CANCER THER, V7, P3275, DOI 10.1158/1535-7163.MCT-08-0508; Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103; Takeuchi K, 2009, CLIN CANCER RES, V15, P3143, DOI 10.1158/1078-0432.CCR-08-3248; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Tillotson B, 2010, J BIOL CHEM, V285, P39835, DOI 10.1074/jbc.M110.141580; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	31	114	122	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2581	2586		10.1038/onc.2010.625	http://dx.doi.org/10.1038/onc.2010.625			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258415				2022-12-28	WOS:000291198400009
J	Wani, AA; Jafarnejad, SM; Zhou, J; Li, G				Wani, A. A.; Jafarnejad, S. M.; Zhou, J.; Li, G.			Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappa B/interleukin-6 signaling pathway	ONCOGENE			English	Article						ILK; angiogenesis; melanoma; NF-kappa B; IL-6; VEGF	ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE; PROSTATE-CANCER CELLS; PROTEIN-KINASE; DEPENDENT ANGIOGENESIS; EXPRESSION INCREASES; EXTRACELLULAR-MATRIX; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS	Integrin-linked kinase (ILK) is a highly conserved serine-threonine protein kinase involved in cell-extracellular matrix interactions, cytoskeletal organization and cell signaling. Overexpression of ILK in epithelial cells leads to anchorage-independent growth with increased cell cycle progression. Previously, we have shown that ILK upregulation strongly correlates with melanoma progression, invasion and inversely correlates with 5-year survival of melanoma patients. However, the molecular mechanism by which ILK enhances melanoma progression is currently unknown. In the present study, we found that proangiogenic molecule interleukin-6 (IL-6) is the downstream target of ILK in melanoma cells. ILK overexpression increased IL-6, whereas silencing of ILK suppressed IL-6 expression at both messenger RNA and protein levels. ILK also altered the activity and subcellular localization of nuclear factor-kappaB (NF-kappa B) subunit p65. We further found that ILK enhanced the IL-6 gene transcription by promoting the binding of NF-kB p65 to IL-6 promoter. Moreover, ILK overexpression in melanoma cells enhanced the tube-forming ability of endothelial cells in vitro and microvessel formation in vivo. ILK-induced tube and blood vessel formation of endothelial cells was significantly reduced upon IL-6 inhibition in ILK-overexpressing melanoma cells. To delineate the mechanism by which ILK-induced IL-6 production can enhance angiogenesis, further analysis of the downstream targets of IL-6 signaling showed an increased activity of the signal transducer and activator of transcription 3 (STAT3) in ILK-overexpressing cells. As STAT3 binds to vascular endothelial growth factor (VEGF) promoter, we found that VEGF levels were elevated in ILK-overexpressing cells and declined upon transfection of IL-6 small interfering RNA, suggesting that ILK may regulate VEGF expression through IL-6 pathway by activating STAT3. Oncogene (2011) 30, 2778-2788; doi: 10.1038/onc.2010.644; published online 31 January 2011	[Wani, A. A.; Jafarnejad, S. M.; Li, G.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada; [Zhou, J.] Nanjing Med Univ, Sch Publ Hlth, Ctr Canc, Dept Mol Cell Biol & Toxicol, Nanjing, Peoples R China	University of British Columbia; Vancouver Coastal Health Research Institute; Nanjing Medical University	Li, G (corresponding author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011	Jafarnejad, Seyed Mehdi/0000-0002-5129-7081	Canadian Institutes of Health Research [MOP-84559, MOP-93810]; Cancer Research Society; Canadian Dermatology Foundation; Michael Smith Foundation for Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Canadian Dermatology Foundation; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	We thank Drs R Byers and AP Albinos for providing melanoma cell lines, Dr M Garate and Mr K Assi for valuable suggestions, and Dr S Hendy for technical assistance. This study was supported by the Canadian Institutes of Health Research (MOP-84559 and MOP-93810), the Cancer Research Society and the Canadian Dermatology Foundation to GL. AAW is supported by the Postdoctoral Fellowship from Michael Smith Foundation for Health Research.	Adachi Y, 2006, INT J CANCER, V119, P1303, DOI 10.1002/ijc.22006; Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Bravou V, 2003, BRIT J CANCER, V89, P2340, DOI 10.1038/sj.bjc.6601482; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Delrieu I, 1999, BIOCHEM J, V340, P201, DOI 10.1042/0264-6021:3400201; Dutcher J P, 2001, Curr Oncol Rep, V3, P353, DOI 10.1007/s11912-001-0089-1; Gao K, 2006, CANCER RES, V66, P8382, DOI 10.1158/0008-5472.CAN-05-4402; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hershko DD, 2002, AM J PHYSIOL-REG I, V283, pR1140, DOI 10.1152/ajpregu.00161.2002; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Huang SP, 2004, J BIOMED SCI, V11, P517, DOI 10.1159/000077902; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Jee SH, 2004, J INVEST DERMATOL, V123, P1169, DOI 10.1111/j.0022-202X.2004.23497.x; Jerant AF, 2000, AM FAM PHYSICIAN, V62, P357; Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mahnke JL, 2000, FERTIL STERIL, V73, P166, DOI 10.1016/S0015-0282(99)00466-5; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Mouawad R, 2002, CYTOKINES CELL MOL T, V7, P151, DOI 10.1080/13684730210002328; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ries LAG, 2000, CANCER-AM CANCER SOC, V88, P2398, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I; Saidi A, 2009, INT J CANCER, V125, P1054, DOI 10.1002/ijc.24380; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Watanabe M, 2005, BIOL PROCED ONLINE, V7, P41, DOI 10.1251/bpo104; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wong RPC, 2007, MOL CANCER THER, V6, P1692, DOI 10.1158/1535-7163.MCT-07-0134; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Xiao WH, 2004, PROSTATE, V61, P354, DOI 10.1002/pros.20113	48	62	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2778	2788		10.1038/onc.2010.644	http://dx.doi.org/10.1038/onc.2010.644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278793				2022-12-28	WOS:000291678500008
J	Hwang-Verslues, WW; Chang, PH; Wei, PC; Yang, CY; Huang, CK; Kuo, WH; Shew, JY; Chang, KJ; Lee, EYHP; Lee, WH				Hwang-Verslues, W. W.; Chang, P-H; Wei, P-C; Yang, C-Y; Huang, C-K; Kuo, W-H; Shew, J-Y; Chang, K-J; Lee, E. Y-H P.; Lee, W-H			miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1	ONCOGENE			English	Article						miR-495; breast cancer stem cell; REDD1; E-cadherin; E12/E47; hypoxia resistance	INDUCIBLE FACTORS; SELF-RENEWAL; EXPRESSION; MICRORNA; METASTASIS; GROWTH; GENES; MTOR; PROLIFERATION; ACTIVATION	MicroRNAs (miRNAs) are involved in tumorigenecity by regulating specific oncogenes and tumor suppressor genes, and their roles in breast cancer stem cells (BCSCs) are becoming apparent. Distinct from the CD44(+)/CD24(-/low) sub-population, we have isolated a novel PROCR(+)/ESA(+) BCSC sub-population. To explore miRNA-regulatory mechanisms in this sub-population, we performed miRNA expression profiling and found miR-495 as the most highly upegulated miRNA in PROCR(+)/ESA(+) cells. Coincidently, high upregulation of miR-495 was also found in CD44(+)/CD24(-/low) BCSCs, reflecting its potential importance in maintaining common BCSC properties. Ectopic expression of miR-495 in breast cancer cells promoted their colony formation in vitro and tumorigenesis in mice. miR-495 directly suppressed E-cadherin expression to promote cell invasion and inhibited REDD1 expression to enhance cell proliferation in hypoxia through post-transcriptional mechanism. miR-495 expression was directly modulated by transcription factor E12/E47, which itself is highly expressed in BCSCs. These findings reveal a novel regulatory pathway centered on miR-495 that contributes to BCSC properties and hypoxia resistance. Oncogene (2011) 30, 2463-2474; doi:10.1038/onc.2010.618; published online 24 January 2011	[Lee, W-H] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; [Hwang-Verslues, W. W.; Chang, P-H; Wei, P-C; Yang, C-Y; Huang, C-K; Shew, J-Y; Lee, E. Y-H P.; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Kuo, W-H; Chang, K-J] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chang, K-J] Cheng Ching Gen Hosp, Taichung, Taiwan; [Lee, E. Y-H P.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	whlee@uci.edu		KUO, WEN-HUNG/0000-0002-9881-4605; Wei, Pei-Chi/0000-0002-3309-0511; Chang, King jen/0000-0001-9811-3422; Hwang-Verslues, Wendy/0000-0002-0383-1710	Academia Sinica [2371, 4012]; Postdocotral Research Fellowship; NATIONAL CANCER INSTITUTE [R01CA094170] Funding Source: NIH RePORTER	Academia Sinica(Academia Sinica - Taiwan); Postdocotral Research Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Academia Sinica Peak Project (grant number 2371, 4012); and an Academia Sinica Distinguished Postdocotral Fellowship and a Postdocotral Research Fellowship to WWHV. We thank Dr Paul E Verslues (Institute of Plant and Microbial Biology, Academia Sinica) for critical proofreading of the manuscript and Ms Meng-Han Wang for her kind assistance through this study.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Hwang-Verslues WW, 2008, MOL ENDOCRINOL, V22, P78, DOI 10.1210/me.2007-0298; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; McCord AM, 2009, MOL CANCER RES, V7, P489, DOI 10.1158/1541-7786.MCR-08-0360; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Qi JL, 2009, CELL CYCLE, V8, P3729, DOI 10.4161/cc.8.22.10033; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Semerad CL, 2009, P NATL ACAD SCI USA, V106, P1930, DOI 10.1073/pnas.0808866106; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Slattery C, 2006, FEBS LETT, V580, P4021, DOI 10.1016/j.febslet.2006.06.039; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yang XM, 2009, BREAST CANCER RES TR, V117, P423, DOI 10.1007/s10549-008-0133-z; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	44	157	164	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	21					2463	2474		10.1038/onc.2010.618	http://dx.doi.org/10.1038/onc.2010.618			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258409				2022-12-28	WOS:000291008000008
J	Li, LY; Dai, HY; Yeh, FL; Kan, SF; Lang, J; Hsu, JL; Jeng, LB; Chen, YH; Sher, YP; Lin, WC; Hung, MC				Li, L-Y; Dai, H-Y; Yeh, F-L; Kan, S-F; Lang, J.; Hsu, J. L.; Jeng, L-B; Chen, Y-H; Sher, Y-P; Lin, W-C; Hung, M-C			Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy	ONCOGENE			English	Article						liver cancer; alpha-fetoprotein; non-viral gene therapy; VISA	ALPHA-FETOPROTEIN PROMOTER; LIVER-CANCER; EXPRESSION; VECTOR; TUMOR; CONSTRUCTION; REPLICATION; SURVIVAL; CELL; DNA	Hepatocellular carcinoma (HCC), the third leading cause of cancer death in the world, is the most general type of primary liver cancer. Although current treatment modalities, such as liver transplantation, resection, percutaneous ablation, transarterial embolization, chemotherapy and radiotherapy are potentially curative, these methods are not universally applicable to all of HCC patients, especially for those with poor prognosis in which no effective remedy is available. Therefore, development of novel therapeutic approach for the treatment of HCC is urgently needed. In the current study, we developed a promising HCC-targeted gene therapy vector driven by liver cancer-specific alpha-fetoprotein promoter/enhancer coupled to an established platform technology. The activity of this expression vector is comparable with or even higher than that of strong cytomegalovirus (CMV) promoter and exhibits strong promoter activity in liver cancer cells/tumors, but has nearly no or very low activity in normal cells/organs in vitro and in orthotopic animal models in vivo. Its cancer specificity exceeds that of the CMV promoter, which expresses non-specifically in both normal and tumor cells. In addition, targeted expression of a therapeutic BikDD, a mutant of proapoptotic gene Bik effectively and preferentially killed liver cancer cells, but not normal cells and significantly repressed growth of HCC tumors, and prolonged survival in multiple xenograft and syngeneic orthotopic mouse models of HCC through intravenous systemic gene delivery. Importantly, systemic administration of BikDD by our expression vector exerted no systemically acute toxicity compared with CMV-BikDD in mice. Taken together, this study elucidates a relatively safe and highly effective and specific systemic gene therapy strategy for liver cancer, and is worthy of further development for future clinical trials. Oncogene (2011) 30, 1773-1783; doi:10.1038/onc.2010.558; published online 13 December 2010	[Li, L-Y; Dai, H-Y; Yeh, F-L; Kan, S-F; Chen, Y-H; Sher, Y-P; Hung, M-C] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Li, L-Y; Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Li, L-Y] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Lang, J.; Hsu, J. L.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Jeng, L-B] China Med Univ, Dept Surg, Taichung, Taiwan; [Jeng, L-B] China Med Univ, Dept Med, Taichung, Taiwan; [Lin, W-C] China Med Univ, Dept Pharmacol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan	Li, LY (corresponding author), China Med Univ & Hosp, Ctr Mol Med, Taichung 40447, Taiwan.	lyl@mail.cmu.edu.tw; mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Li, Long-Yuan/0000-0001-7472-8318	 [DOH97-TD-I-111-TM003];  [DOH98-TD-I-111-TM002];  [NHRI-EX98-9603BC];  [DOH98-TD-G-111-030];  [NSC96-3111-B-039];  [NSC97-3111-B-039];  [DOH99-TD-C-111-005]	; ; ; ; ; ; 	This work was supported by grants from DOH97-TD-I-111-TM003, DOH98-TD-I-111-TM002, NHRI-EX98-9603BC (to L-YL), DOH98-TD-G-111-030 (to M-CH), NSC96-3111-B-039, NSC97-3111-B-039 and DOH99-TD-C-111-005 (to M-CH and L-YL).	Abelev GI, 1999, SEMIN CANCER BIOL, V9, P95, DOI 10.1006/scbi.1998.0084; Avila MA, 2006, ONCOGENE, V25, P3866, DOI 10.1038/sj.onc.1209550; Bui LA, 1997, HUM GENE THER, V8, P2173, DOI 10.1089/hum.1997.8.18-2173; Chen JS, 2004, CANCER GENE THER, V11, P740, DOI 10.1038/sj.cgt.7700752; CHEN SH, 1992, CANCER RES, V52, P1329; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Guan M, 2006, CANCER RES, V66, P1620, DOI 10.1158/0008-5472.CAN-05-0877; Hoofnagle JH, 2004, GASTROENTEROLOGY, V127, pS319, DOI 10.1053/j.gastro.2004.09.047; Ido A, 2001, CANCER RES, V61, P3016; IZUMI R, 1992, J SURG ONCOL, V49, P151, DOI 10.1002/jso.2930490305; Kim JW, 2003, CARCINOGENESIS, V24, P363, DOI 10.1093/carcin/24.3.363; Lemken ML, 2005, WORLD J GASTROENTERO, V11, P5295, DOI 10.3748/wjg.v11.i34.5295; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lu SY, 2003, WORLD J GASTROENTERO, V9, P688, DOI 10.3748/wjg.v9.i4.688; Ma SH, 2010, GENE THER, V17, P905, DOI 10.1038/gt.2010.34; Mawatari F, 1998, CANCER GENE THER, V5, P301; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ren XW, 2006, CANCER GENE THER, V13, P159, DOI 10.1038/sj.cgt.7700868; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Sher YP, 2009, ONCOGENE, V28, P3286, DOI 10.1038/onc.2009.187; Shi YJ, 2004, WORLD J GASTROENTERO, V10, P186; STILLWAGON GB, 1991, INT J RADIAT ONCOL, V20, P65, DOI 10.1016/0360-3016(91)90139-U; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; Takahashi M, 2002, MOL THER, V5, P627, DOI 10.1006/mthe.2002.0589; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Xie XM, 2009, MOL CANCER THER, V8, P2375, DOI 10.1158/1535-7163.MCT-09-0056; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	29	26	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1773	1783		10.1038/onc.2010.558	http://dx.doi.org/10.1038/onc.2010.558			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151169	Bronze			2022-12-28	WOS:000289512200005
J	Colombi, M; Molle, KD; Benjamin, D; Rattenbacher-Kiser, K; Schaefer, C; Betz, C; Thiemeyer, A; Regenass, U; Hall, MN; Moroni, C				Colombi, M.; Molle, K. D.; Benjamin, D.; Rattenbacher-Kiser, K.; Schaefer, C.; Betz, C.; Thiemeyer, A.; Regenass, U.; Hall, M. N.; Moroni, C.			Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction	ONCOGENE			English	Article						shRNA screen; mTOR addiction; IL-3 dependence; mitochondria; drug targets	LENTIVIRAL RNAI LIBRARY; CANCER-CELLS; GLUT4 TRANSLOCATION; PROTEIN; KINASE; EXPRESSION; METABOLISM; GENE; IDENTIFICATION; INHIBITION	Release from growth factor dependence and acquisition of signalling pathway addiction are critical steps in oncogenesis. To identify genes required on mammalian target of rapamycin (mTOR) addiction, we performed a genome-wide short hairpin RNA screen on a v-H-ras-transformed Pten-deficient cell line that displayed two alternative growth modes, interleukin (IL)-3-independent/mTOR-addicted proliferation (transformed growth mode) and IL-3-dependent/mTOR-non-addicted proliferation (normal growth mode). We screened for genes required only in the absence of IL-3 and thus specifically for the transformed growth mode. The top 800 hits from this conditional lethal screen were analyzed in silico and 235 hits were subsequently rescreened in two additional Pten-deficient cell lines to generate a core set of 47 genes. Hits included genes encoding mTOR and the mTOR complex 2 (mTORC2) component rictor and several genes encoding mitochondrial functions including components of the respiratory chain, adenosine triphosphate synthase, the mitochondrial ribosome and mitochondrial fission factor. Small interfering RNA knockdown against a sizeable fraction of these genes triggered apoptosis in human cancer cell lines but not in normal fibroblasts. We conclude that mTORC2-addicted cells require mitochondrial functions that may be novel drug targets in human cancer. Oncogene (2011) 30, 1551-1565; doi: 10.1038/onc.2010.539; published online 20 December 2010	[Colombi, M.; Molle, K. D.; Benjamin, D.; Betz, C.; Thiemeyer, A.; Hall, M. N.; Moroni, C.] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; [Rattenbacher-Kiser, K.; Schaefer, C.] Univ Basel, Inst Med Microbiol, CH-4056 Basel, Switzerland; [Regenass, U.] Actel Pharmaceut Ltd, Allschwil, Switzerland	University of Basel; University of Basel; Actelion Pharmaceuticals Ltd	Hall, MN (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	m.hall@unibas.ch; christoph.moroni@unibas.ch	Betz, Charles/B-7444-2008	Betz, Charles/0000-0002-9837-6916; Hall, Michael N/0000-0002-2998-0757	Commission of Technology and Innovation (CTI); Swiss National Science Foundation; Swiss Cancer League; Louis-Jeantet Foundation	Commission of Technology and Innovation (CTI); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Louis-Jeantet Foundation	We thank TW Sturgill for comments and Dr F Wenzel for providing normal human fibroblasts. We acknowledge support from the Commission of Technology and Innovation (CTI) (CM, MNH and UR), the Swiss National Science Foundation (CM and MNH) and the Swiss Cancer League and the Louis-Jeantet Foundation (MNH).	Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Bandyopadhyay G, 2001, J BIOL CHEM, V276, P35537, DOI 10.1074/jbc.M106042200; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; Dang CV, 2010, MOL CELL BIOL, V30, P1300, DOI 10.1128/MCB.01661-09; Fan YJ, 2010, J BIOL CHEM, V285, P7324, DOI 10.1074/jbc.M109.035584; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Gandre-Babbe S, 2008, MOL BIOL CELL, V19, P2402, DOI 10.1091/mbc.E07-12-1287; Gonez LJ, 2008, MOL MED, V14, P697, DOI 10.2119/2008-00072.Gonez; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Heyward CA, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-25; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Jung HC, 2005, LIFE SCI, V77, P1249, DOI 10.1016/j.lfs.2005.02.009; Kiser KF, 2006, ONCOGENE, V25, P6595, DOI 10.1038/sj.onc.1209673; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mueller BA, 2009, CURR PHARM DESIGN, V15, P120, DOI 10.2174/138161209787002933; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; NAIR APK, 1992, ONCOGENE, V7, P1963; Nilsson R, 2009, CELL METAB, V10, P119, DOI 10.1016/j.cmet.2009.06.012; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Polak P, 2008, CELL METAB, V8, P399, DOI 10.1016/j.cmet.2008.09.003; Pytel D, 2009, ANTI-CANCER AGENT ME, V9, P66, DOI 10.2174/187152009787047752; Ramanathan A, 2009, P NATL ACAD SCI USA, V106, P22229, DOI 10.1073/pnas.0912074106; Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200; Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Thaimattam R, 2007, CURR PHARM DESIGN, V13, P2751, DOI 10.2174/138161207781757042; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; WITTWER AJ, 1980, P NATL ACAD SCI-BIOL, V77, P4484, DOI 10.1073/pnas.77.8.4484; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	46	32	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1551	1565		10.1038/onc.2010.539	http://dx.doi.org/10.1038/onc.2010.539			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21170086				2022-12-28	WOS:000288998300006
J	Draheim, KM; Hermance, N; Yang, Y; Arous, E; Calvo, J; Kelliher, MA				Draheim, K. M.; Hermance, N.; Yang, Y.; Arous, E.; Calvo, J.; Kelliher, M. A.			A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice	ONCOGENE			English	Article						TAL1; Lmo2; E47; HEB; T cell acute lymphoblastic leukemia (T-ALL)	ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; C-KIT EXPRESSION; TRANSCRIPTION FACTOR; GENE-THERAPY; TRANSGENIC MICE; TRANSACTIVATION DOMAIN; HEMATOPOIETIC-CELLS; COMPLEX; SCL	The most common translocation in childhood T-cell acute lymphoblastic leukemia (T-ALL) involves the LMO2 locus, resulting in ectopic expression of the LMO2 gene in human thymocytes. The LMO2 gene was also activated in patients with X-linked Severe Combined Immune Deficiency treated with gene therapy because of retroviral insertion in the LMO2 locus. The LMO2 insertions predisposed these children to T-ALL, yet how LMO2 contributes to T cell transformation remains unclear. The LIM (Lin 11, Isl-1, Mec-3) domain containing LMO2 protein regulates erythropoiesis as part of a large transcriptional complex consisting of LMO2, TAL1, E47, GATA1 and LDB1 that recognizes bipartite E-box-GATA1 sites on target genes. Similarly, a TAL1/E47/LMO2/LDB1 complex is observed in human T-ALL and Tal1 and Lmo2 expression in mice results in disease acceleration. To address the mechanism(s) of Tal1/Lmo2 synergy in leukemia, we generated Lmo2 transgenic mice and mated them with mice that express wild-type Tal1 or a DNA-binding mutant of TAL1. Tal1/Lmo2 and MutTAL1/Lmo2 bitransgenic mice exhibit perturbations in thymocyte development due to reduced E47/HEB transcriptional activity and develop leukemia with identical kinetics. These data demonstrate that the DNA-binding activity of Tal1 is not required to cooperate with Lmo2 to cause leukemia in mice and suggest that Lmo2 may cooperate with Tal1 to interfere with E47/HEB function(s). Oncogene (2011) 30, 1252-1260; doi:10.1038/onc.2010.495; published online 8 November 2010	[Draheim, K. M.; Hermance, N.; Yang, Y.; Arous, E.; Kelliher, M. A.] UMass Med Sch, Dept Canc Biol, Worcester, MA USA; [Calvo, J.] MIT, Ctr Environm Hlth Sci, Dept Biol Engn, Cambridge, MA 02139 USA	University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT)	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01605 USA.	Michelle.Kelliher@umassmed.edu			NIH/NCI [CA096899]; Diabetes Endocrinology Research Center [DK32520]; NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Diabetes Endocrinology Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by an NIH/NCI CA096899 Grant to MK. Core resources supported by the Diabetes Endocrinology Research Center Grant DK32520 were also used.	ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BOEHM T, 1990, ONCOGENE, V5, P1103; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Davenport J, 2000, LEUKEMIA, V14, P1986, DOI 10.1038/sj.leu.2401913; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; FISCH P, 1992, ONCOGENE, V7, P2389; GARCIA IS, 1991, ONCOGENE, V6, P577; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Greenbaum S, 2002, SEMIN IMMUNOL, V14, P405, DOI 10.1016/S1044532302000751; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; Hsu LY, 2003, IMMUNITY, V19, P105, DOI 10.1016/S1074-7613(03)00181-X; Huang EY, 2003, J IMMUNOL, V171, P2296, DOI 10.4049/jimmunol.171.5.2296; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Krosl G, 1998, J EXP MED, V188, P439, DOI 10.1084/jem.188.3.439; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Nam CH, 2008, ONCOGENE, V27, P4962, DOI 10.1038/onc.2008.130; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ryan DP, 2008, PROTEINS, V70, P1461, DOI 10.1002/prot.21638; Schlaeger TM, 2004, MOL CELL BIOL, V24, P7491, DOI 10.1128/MCB.24.17.7491-7502.2004; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	44	24	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1252	1260		10.1038/onc.2010.495	http://dx.doi.org/10.1038/onc.2010.495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057528	Green Accepted			2022-12-28	WOS:000288202400011
J	Huang, RY; Li, MY; Hsin, MKY; Underwood, MJ; Ma, LT; Mok, TSK; Warner, TD; Chen, GG				Huang, R-Y; Li, M-Y; Hsin, M. K. Y.; Underwood, M. J.; Ma, L. T.; Mok, T. S. K.; Warner, T. D.; Chen, G. G.			4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A(2) and its receptor	ONCOGENE			English	Article						lung cancer; NNK; thromboxane A(2); cell proliferation; CREB	ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; AIRWAY EPITHELIAL-CELLS; LIPID-PEROXIDATION; BCL-2 EXPRESSION; N-NITROSAMINES; CYCLOOXYGENASE-2; SYNTHASE; ADENOCARCINOMA; PROLIFERATION	The role of thromboxane A(2) (TxA(2)) in smoking-associated lung cancer is poorly understood. This study was conducted to study the role of TxA(2) in smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-promoted cell survival and growth in human lung cancer cells. We found that NNK increased TxA(2) synthase (TxAS) expression and thromboxane B-2 (TxB(2)) generation in cultured lung cancer cells, the result of which was supported by the increased level of TxAS in lung cancer tissues of smokers. Both TxAS-specific inhibitor furegrelate and TxA(2) receptor antagonist SQ29548 completely blocked NNK-mediated cell survival and growth via inducting apoptosis. TxA(2) receptor agonist U46619 reconstituted a near-full survival and growth response to NNK when TxAS was inhibited, affirming the role of TxA(2) receptor in NNK-mediated cell survival and growth. Suppression of cyclic adenosine monophosphate response element binding protein (CREB) activity by its small interference RNA blocked the effect of NNK. Phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) also had a positive role. Altogether, our results have revealed that NNK stimulates TxA(2) synthesis and activates its receptor in lung cancer cells. The increased TxA(2) may then activate CREB through PI3K/Akt and extracellular ERK pathways, thereby contributing to the NNK-promoted survival and growth of lung cancer cells. Oncogene (2011) 30, 106-116; doi: 10.1038/onc.2010.390; published online 6 September 2010	[Huang, R-Y; Li, M-Y; Hsin, M. K. Y.; Underwood, M. J.; Chen, G. G.] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Ma, L. T.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Mok, T. S. K.] Chinese Univ Hong Kong, Dept Clin Oncol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Warner, T. D.] Queen Mary Univ London, William Harvey Res Inst, London, England	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of London; Queen Mary University London	Chen, GG (corresponding author), Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	gchen@cuhk.edu.hk	Mok, Tony Shu Kam/B-2310-2019; Underwood, Malcolm John/L-6823-2016; Warner, Timothy D/A-1980-2009; Chen, George Gong/I-2757-2016; LI, Ming-Yue/I-2727-2016	Mok, Tony Shu Kam/0000-0002-8251-0551; Warner, Timothy D/0000-0003-3988-4408; 	CUHK [2007.2.045, 2008.2.038]	CUHK(Chinese University of Hong Kong)	We thank Suk Ying Chun, Ernest Chi Wai Chak and Billy Cheuk Sing Leung for their technical assistance. This study was supported by the CUHK direct grants (2007.2.045 and 2008.2.038).	Aggarwal S, 2008, CANCER RES, V68, P981, DOI 10.1158/0008-5472.CAN-06-0249; Amin S, 1996, CRIT REV TOXICOL, V26, P139, DOI 10.3109/10408449609017927; Aronov AM, 2007, J MED CHEM, V50, P1280, DOI 10.1021/jm061381f; Cailleteau C, 2008, ANAL BIOCHEM, V380, P26, DOI 10.1016/j.ab.2008.05.026; Calapai G, 2009, INHAL TOXICOL, V21, P1138, DOI 10.3109/08958370902798455; Cathcart MC, 2010, BBA-REV CANCER, V1805, P153, DOI 10.1016/j.bbcan.2010.01.006; Chen GG, 2006, CANCER LETT, V234, P193, DOI 10.1016/j.canlet.2005.03.032; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; COLEMAN RA, 1981, BRIT J PHARMACOL, V73, P773, DOI 10.1111/j.1476-5381.1981.tb16814.x; Daniel TO, 1999, CANCER RES, V59, P4574; de Leval X, 2006, J PHARMACOL EXP THER, V318, P1057, DOI 10.1124/jpet.106.101188; El-Bayoumy K, 1999, CANCER RES, V59, P1400; Ermert L, 2003, CLIN CANCER RES, V9, P1577; Fahn HJ, 1998, AM J RESP CELL MOL, V19, P901, DOI 10.1165/ajrcmb.19.6.3130; Grozio A, 2007, ANTI-CANCER AGENT ME, V7, P461; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; HOFFMANN D, 1994, J TOXICOL ENV HEALTH, V41, P1, DOI 10.1080/15287399409531825; Huang JS, 2004, CELL SIGNAL, V16, P521, DOI 10.1016/j.cellsig.2003.10.008; Hung YH, 2009, CHEM-BIOL INTERACT, V179, P154, DOI 10.1016/j.cbi.2008.10.042; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Kim Y, 2006, CARCINOGENESIS, V27, P1410, DOI 10.1093/carcin/bgi340; Laag E, 2006, INT J CANCER, V119, P1547, DOI 10.1002/ijc.21987; Leung KC, 2009, EXP CELL RES, V315, P2974, DOI 10.1016/j.yexcr.2009.06.025; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Li MY, 2010, AM J RESP CELL MOL, V42, P113, DOI 10.1165/rcmb.2008-0463OC; Li XL, 2007, ARCH BIOCHEM BIOPHYS, V467, P20, DOI 10.1016/j.abb.2007.08.005; Li XL, 2009, CARCINOGENESIS, V30, P1606, DOI 10.1093/carcin/bgp161; Lu G, 2006, CANCER RES, V66, P11494, DOI 10.1158/0008-5472.CAN-06-1497; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; MCLEMORE TL, 1988, CANCER RES, V48, P3140; Merighi Stefania, 2006, Purinergic Signal, V2, P627, DOI 10.1007/s11302-006-9020-4; Miggin SM, 2001, BBA-MOL CELL RES, V1539, P147, DOI 10.1016/S0167-4889(01)00103-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Moussa O, 2008, ONCOGENE, V27, P55, DOI 10.1038/sj.onc.1210629; Moussa O, 2008, CANCER RES, V68, P4097, DOI 10.1158/0008-5472.CAN-07-6560; Nakahata N, 2008, PHARMACOL THERAPEUT, V118, P18, DOI 10.1016/j.pharmthera.2008.01.001; Nie DT, 2004, AM J PATHOL, V164, P429, DOI 10.1016/S0002-9440(10)63133-1; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Nishioka T, 2010, J CELL BIOCHEM, V109, P152, DOI 10.1002/jcb.22392; Parsons A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5569; Proulx LI, 2005, CLIN EXP IMMUNOL, V140, P46, DOI 10.1111/j.1365-2249.2005.02739.x; Sakai H, 2006, FEBS LETT, V580, P3368, DOI 10.1016/j.febslet.2006.05.007; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Stolimenov I, 2009, BIOCHEM SOC T, V37, P605, DOI 10.1042/BST0370605; Wei J, 2007, BIOCHEM PHARMACOL, V74, P787, DOI 10.1016/j.bcp.2007.06.008; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147	47	49	52	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					106	116		10.1038/onc.2010.390	http://dx.doi.org/10.1038/onc.2010.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818420				2022-12-28	WOS:000285959300010
J	Pineiro, R; Maffucci, T; Falasca, M				Pineiro, R.; Maffucci, T.; Falasca, M.			The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation	ONCOGENE			English	Article						G-protein-coupled receptor; lysophosphatidylinositol; GPR55; prostate cancer; ABC transporters; phospholipase A2	PROTEIN-COUPLED RECEPTOR; L-ALPHA-LYSOPHOSPHATIDYLINOSITOL; HUMAN PROSTATE-CANCER; DRUG-RESISTANCE; LYSOPHOSPHOLIPIDS; IDENTIFICATION; ACTIVATION; EXPRESSION; MIGRATION	Recently, the orphan receptor G protein-coupled receptor 55 (GPR55) has been proposed as a potential cannabinoid receptor, although controversy remains on its physiological roles. Current evidence suggests a role for GPR55 as a receptor for the lysophospholipid lysophosphatidylinositol (LPI). In this study, we show that GPR55 is expressed in several prostate and ovarian cancer cell lines, both at the mRNA and at the protein level, and that it has a critical role in regulating proliferation and anchorage-independent growth. We further show that GPR55 mediates the effects of LPI in prostate and ovarian cancer cells. Indeed we demonstrate that LPI is able to induce calcium mobilization and activation of Akt and extracellular signal-regulated kinase (ERK)1/2 in these cells and that both pharmacological blockade of GPR55 and its downregulation using specific small interfering RNA strongly inhibits these processes. We further identify an autocrine loop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-binding cassette transporter ABCC1/MRP1, and is then able to initialize cascades downstream of GPR55. All together, these data demonstrate a role of LPI and its receptor GPR55 in cancer cells in activating an autocrine loop that regulates cell proliferation. These findings may have important implications for LPI as a novel cancer biomarker and for its receptor GPR55 as a potential therapeutic target. Oncogene (2011) 30, 142-152; doi:10.1038/onc.2010.417; published online 13 September 2010	[Pineiro, R.; Maffucci, T.; Falasca, M.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Diabet,Inositide Signalling Grp, London E1 2AT, England	University of London; Queen Mary University London	Falasca, M (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Diabet,Inositide Signalling Grp, 4 Newark St, London E1 2AT, England.	m.falasca@qmul.ac.uk	Piñeiro, Roberto/AAN-5561-2020; Falasca, Marco/S-4020-2016	Piñeiro, Roberto/0000-0001-9479-139X; Falasca, Marco/0000-0002-9801-7235	British Heart Foundation [PG/06/022/204348]	British Heart Foundation(British Heart Foundation)	We thank Prof D Baker (Queen Mary University of London), Prof WH Moolenaar (The Netherlands Cancer Institute), Dr N Divecha (The Paterson Institute for Cancer Research, Manchester) and Dr R Sabatini (LPath Inc) for critical reading of the paper. We also thank the National Institute of Drug Abuse, Bethesda, MD, USA for providing SR141716A. RP was supported by the British Heart Foundation (grant PG/06/022/204348 to MF).	Davies MA, 1999, CANCER RES, V59, P2551; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1995, ONCOGENE, V10, P2113; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Hoffmann U, 2004, DRUG METAB REV, V36, P669, DOI 10.1081/DMR-200033473; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Kreitzer FR, 2009, PHARMACOL THERAPEUT, V122, P83, DOI 10.1016/j.pharmthera.2009.01.005; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Monet M, 2009, BBA-MOL CELL RES, V1793, P528, DOI 10.1016/j.bbamcr.2009.01.003; Nevalainen T, 2010, CURR TOP MED CHEM, V10, P799, DOI 10.2174/156802610791164229; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; Patel MI, 2008, CLIN CANCER RES, V14, P8070, DOI 10.1158/1078-0432.CCR-08-0566; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169-328X(98)00277-0; Sharir H, 2010, PHARMACOL THERAPEUT, V126, P301, DOI 10.1016/j.pharmthera.2010.02.004; Soga T, 2005, BIOCHEM BIOPH RES CO, V326, P744, DOI 10.1016/j.bbrc.2004.11.120; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; Sutphen R, 2004, CANCER EPIDEM BIOMAR, V13, P1185; Waldeck-Weiermair M, 2008, J CELL SCI, V121, P1704, DOI 10.1242/jcs.020958; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200	31	162	169	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					142	152		10.1038/onc.2010.417	http://dx.doi.org/10.1038/onc.2010.417			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20838378				2022-12-28	WOS:000286438900003
J	Czeh, M; Loddenkemper, C; Shalapour, S; Schon, C; Robine, S; Goldscheid, E; Stein, H; Schuler, T; Willimsky, G; Blankenstein, T				Czeh, M.; Loddenkemper, C.; Shalapour, S.; Schoen, C.; Robine, S.; Goldscheid, E.; Stein, H.; Schueler, T.; Willimsky, G.; Blankenstein, T.			The immune response to sporadic colorectal cancer in a novel mouse model	ONCOGENE			English	Article						colorectal cancer; sporadic cancer; mouse model; antitumor immune response	SV40 T-ANTIGEN; ONCOGENIC K-RAS; TRANSGENIC MICE; GENE-EXPRESSION; TUMOR-ANTIGEN; VILLIN GENE; JC VIRUS; INTESTINAL EPITHELIUM; CELL TOLERANCE; DEVELOP TUMORS	Current mouse models do not reflect the sporadic nature of colon cancer and do not allow the analysis of antitumor immune response because of the lack of known tumor-specific antigens. Two transgenic mouse models with spontaneous tumor development were generated, directing the expression of SV40T antigen (Tag) either constitutively (Vil-Cre x LoxP-Tag-transgenic mice) or stochastically (Vil-Cre-ERT2 x LoxP-Tag-transgenic mice) into the putative stem cell region of the crypt of Lieberkuhn. Tumor development and antitumor immune response were monitored. Vil-Cre x LoxP-Tag mice developed multiple adenocarcinomas of the small intestine and colon at an average age of 6 months. During the tumor development, Tag-specific immunoglobulin G (IgG) antibodies were induced in half of the mice, although they had developed neonatal cytotoxic T lymphocyte (CTL) tolerance. This model shows similarity to hereditary colon cancer but not to the sporadic tumor development. Therefore, the conditional Vil-Cre-ERT2 x LoxP-Tag mice were established, in which expression of the dormant Tag was induced by stochastic, tissue-specific activation of Cre recombinase. These mice spontaneously developed highly invasive, metastasizing colon carcinomas at an average age of 20 months. Colon carcinomas expressed epithelial and/or neuroendocrine markers depending on the grade of differentiation. Young Vil-Cre-ERT2 x LoxP-Tag mice had retained CTL responses against epitope IV of Tag. The tumors induced strong anti-Tag IgG responses. We report, for the first time, a mouse model based on stochastic, tissue-specific activation of a dormant oncogene in the colon allowing the analysis of antitumor immune response against primary colorectal cancer. Oncogene (2010) 29, 6591-6602; doi:10.1038/onc.2010.388; published online 6 September 2010	[Goldscheid, E.; Willimsky, G.; Blankenstein, T.] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Czeh, M.; Shalapour, S.; Schoen, C.; Schueler, T.; Willimsky, G.; Blankenstein, T.] Charite Campus Benjamin Franklin, Inst Immunol, Berlin, Germany; [Loddenkemper, C.; Stein, H.] Charite Campus Benjamin Franklin, Inst Pathol, Berlin, Germany; [Loddenkemper, C.] Charite Campus Benjamin Franklin, Res Ctr ImmunoSci, Berlin, Germany; [Robine, S.] Inst Curie, CNRS, Dept Morphogenesis & Intracellular Signali, F-75231 Paris, France	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Blankenstein, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	tblanke@mdc-berlin.de	Willimsky, Gerald/AAA-2445-2021	Willimsky, Gerald/0000-0002-9693-948X	Sonderforschungsbereich [SFB 633, TR 36]	Sonderforschungsbereich(German Research Foundation (DFG))	We thank S Spieckermann, M Rosch, C Westen and S Horn for excellent technical assistance and JC Schmollinger for reading the paper. This study was supported by the Research grants Sonderforschungsbereich SFB 633 and TR 36.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Bos R, 2008, CANCER RES, V68, P8446, DOI 10.1158/0008-5472.CAN-08-1864; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BURKE AB, 1991, AM J CLIN PATHOL, V95, P315, DOI 10.1093/ajcp/95.3.315; Calcagno SR, 2008, INT J CANCER, V122, P2462, DOI 10.1002/ijc.23383; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CORBETT TH, 1975, CANCER RES, V35, P2434; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Enam S, 2002, CANCER RES, V62, P7093; FAAS SJ, 1987, J EXP MED, V165, P417, DOI 10.1084/jem.165.2.417; Gum JR, 2004, MOL CANCER RES, V2, P504; Gum JR, 2001, CANCER RES, V61, P3472; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; HORI R, 2005, VIRCHOWS ARCH, V14, P1; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lauwen MM, 2008, CANCER RES, V68, P893, DOI 10.1158/0008-5472.CAN-07-3166; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Newcomb PA, 2004, CANCER EPIDEM BIOMAR, V13, P662; Otahal P, 2006, J IMMUNOL, V177, P3089, DOI 10.4049/jimmunol.177.5.3089; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; SARSFIELD P, 1990, HISTOPATHOLOGY, V16, P357, DOI 10.1111/j.1365-2559.1990.tb01139.x; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schell TD, 2000, CANCER RES, V60, P3002; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Syder AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI 10.1073/pnas.0307983101; Weinreb D, 2006, VIRCHOWS ARCH, V448, P239, DOI 10.1007/s00428-005-0128-7; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Willimsky G, 2008, J EXP MED, V205, P1687, DOI 10.1084/jem.20072016; Yen TH, 2006, STEM CELL REV, V2, P203, DOI 10.1007/s12015-006-0048-1	45	16	17	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6591	6602		10.1038/onc.2010.388	http://dx.doi.org/10.1038/onc.2010.388			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818425				2022-12-28	WOS:000285380200008
J	Bug, M; Dobbelstein, M				Bug, M.; Dobbelstein, M.			Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms	ONCOGENE			English	Article						anthracyclines; doxorubicin; idarubicin; p53; WRAP53; E2F1	DRUG-INTERACTION DOMAINS; TOPOISOMERASE-II; DNA-DAMAGE; APOPTOTIC RESPONSE; MOUSE MODEL; TRANSCRIPTION; P73; PHOSPHORYLATION; GAIN; GENE	Mutant p53 frequently accumulates in cancer cells and promotes tumor cell invasion, as part of its gain of function. Its accumulation is partially due to enhanced stability, but little is known about how the mRNA levels of mutant p53 can be regulated. Likewise, the impact of cancer therapy on the levels of mutant p53 is poorly understood. We show here that the anthracyclines doxorubicin, daunorubicin and epirubicin further increase the amounts of mutant p53 mRNA and protein in cancer cells. Moreover, we show for the first time that the transcription factor E2F1 associates with the promoter DNA of TP53. Upon genotoxic treatment, E2F1 contributed to the expression of mutant p53, both directly and through induction of TAp73. In contrast, the anthracycline idarubicin and also another topoisomerase inhibitor, etoposide, failed to increase the levels of p53 mRNA, despite their ability to induce the synthesis of TAp73 mRNA. Instead, a natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide, but only less so by the other anthracyclines under study. RNA corresponding to the first exon of WRAP53 was mainly found in cell nuclei and it reduced the levels of mutant p53. Taken together, this suggests a reciprocal activation pattern of TP53 and WRAP53 by different chemotherapeutics. Reducing the levels of mutant p53 by small-interfering RNA increased chemosensitivity, and idarubicin prevented cell survival more efficiently than the mutant p53-inducing doxorubicin. We conclude that even closely related anthracyclines induce the synthesis of different, opposing transcripts from the TP53 locus. When using these drugs for cancer therapy, the increased levels of mutant p53 may augment its gain of function and thus favor unwanted chemoresistance and tumor progression. Oncogene (2011) 30, 3612-3624; doi:10.1038/onc.2011.72; published online 28 March 2011	[Bug, M.; Dobbelstein, M.] Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci GZMB, D-37077 Gottingen, Germany	University of Gottingen	Dobbelstein, M (corresponding author), Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci GZMB, Ernst Caspari Haus,Justus von Liebig Weg 11, D-37077 Gottingen, Germany.	mdobbel@uni-goettingen.de		Dobbelstein, Matthias/0000-0001-5052-3967	German excellence initiative; German Cancer Aid/Dr Mildred Scheel Stiftung; EU; German Research Foundation DFG; Wilhelm Sander Stiftung	German excellence initiative; German Cancer Aid/Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); EU(European Commission); German Research Foundation DFG(German Research Foundation (DFG)); Wilhelm Sander Stiftung	We thank M Haubrock for the analysis of E2F1 promoter sequences and C Hippel and A Dickmanns for excellent technical assistance. We further thank M Farnebo, K Wiman, K Heyninck and C Bamberger for providing plasmids used in this study and helpful advice. MB was supported by the Master/PhD Program Molecular Biology and the Gottingen Graduate School of Neurosciences and Molecular Biosciences, funded by the German excellence initiative (funding line 1). Our work was supported by the German Cancer Aid/Dr Mildred Scheel Stiftung, the EU 6th Framework Program, the German Research Foundation DFG and the Wilhelm Sander Stiftung.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bush JA, 2002, INT J CANCER, V98, P323, DOI 10.1002/ijc.10226; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAPRANICO G, 1995, CANCER RES, V55, P312; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; Cashman DJ, 2004, J MED CHEM, V47, P1360, DOI 10.1021/jm030529h; Collins I, 2001, MOL CELL BIOL, V21, P8437, DOI 10.1128/MCB.21.24.8437-8451.2001; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; Crampton N, 2006, NUCLEIC ACIDS RES, V34, P5416, DOI 10.1093/nar/gkl668; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; HARGRAVE RM, 1995, ANTI-CANCER DRUG, V6, P432, DOI 10.1097/00001813-199506000-00011; Heinlein C, 2008, INT J CANCER, V122, P1701, DOI 10.1002/ijc.23317; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu H, 2007, MOL CELL BIOL, V27, P8480, DOI 10.1128/MCB.01126-07; Liu HS, 2009, BIOCHEM J, V422, P543, DOI 10.1042/BJ20090342; Lotfi K, 2002, CANCER LETT, V178, P141, DOI 10.1016/S0304-3835(01)00824-2; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Mahmoudi S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000521; Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Prescott EM, 2002, P NATL ACAD SCI USA, V99, P8796, DOI 10.1073/pnas.132270899; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tanaka T, 2007, CELL CYCLE, V6, P371, DOI 10.4161/cc.6.3.3835; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; van Hille B, 1999, ANTI-CANCER DRUG, V10, P551, DOI 10.1097/00001813-199907000-00007; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	51	19	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3612	3624		10.1038/onc.2011.72	http://dx.doi.org/10.1038/onc.2011.72			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21441950				2022-12-28	WOS:000294005100005
J	Grandinetti, KB; Stevens, TA; Ha, S; Salamone, RJ; Walker, JR; Zhang, J; Agarwalla, S; Tenen, DG; Peters, EC; Reddy, VA				Grandinetti, K. B.; Stevens, T. A.; Ha, S.; Salamone, R. J.; Walker, J. R.; Zhang, J.; Agarwalla, S.; Tenen, D. G.; Peters, E. C.; Reddy, V. A.			Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBP alpha	ONCOGENE			English	Article						tribbles; lung; C/EBP alpha; TRIM21	STEM-CELLS; PROSPECTIVE IDENTIFICATION; TRIBBLES; MORPHOGENESIS; DIFFERENTIATION; PROLIFERATION; DEGRADATION; EXPRESSION; DROSOPHILA; PROTEINS	Lung cancer is the most common cause of cancer-related mortality worldwide. Here, we report elevated expression of tribbles homolog 2 (TRIB2) in primary human lung tumors and in non-small cell lung cancer cells that express low levels of differentiation-inducing transcription factor CCAAT/enhancer-binding protein alpha (C/EBP alpha). In approximately 10-20% of cases, elevated TRIB2 expression resulted from gene amplification. TRIB2 knockdown was found to inhibit cell proliferation and in vivo tumor growth. In addition, TRIB2 knockdown led to morphological changes similar to C/EBP alpha overexpression and correlated with increased expression and activity of C/EBP alpha. TRIB2-mediated regulation of C/EBP alpha was found to occur through the association of TRIB2 with the E3 ligase TRIM21. Together, these data identify TRIB2 as a potential driver of lung tumorigenesis through a mechanism that involves downregulation of C/EBP alpha. Oncogene (2011) 30, 3328-3335; doi:10.1038/onc.2011.57; published online 14 March 2011	[Grandinetti, K. B.; Stevens, T. A.; Ha, S.; Salamone, R. J.; Walker, J. R.; Zhang, J.; Agarwalla, S.; Peters, E. C.; Reddy, V. A.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Grandinetti, K. B.] Scripps Res Inst, San Diego, CA USA; [Tenen, D. G.] Natl Univ Singapore, Canc Sci Inst, Singapore, Singapore; [Tenen, D. G.] Harvard Stem Cell Inst, Ctr Life Sci, Boston, MA USA	Novartis; Scripps Research Institute; National University of Singapore; Harvard University	Grandinetti, KB (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	bgrandinetti@gnf.org	Peters, Eric/W-2739-2019	Tenen, Daniel/0000-0002-6423-3888	NIH [HL56745, CA90578]; NATIONAL CANCER INSTITUTE [P50CA090578, P20CA090578] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the NIH (HL56745 and CA90578) to DGT.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Cassel TN, 2003, AM J PHYSIOL-LUNG C, V285, pL773, DOI 10.1152/ajplung.00023.2003; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Costa DB, 2007, LUNG CANCER, V56, P97, DOI 10.1016/j.lungcan.2006.11.023; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dedhia PH, 2010, BLOOD, V116, P1321, DOI 10.1182/blood-2009-07-229450; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Halmos B, 2002, CANCER RES, V62, P528; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Keeshan K, 2010, BLOOD, V116, P4948, DOI 10.1182/blood-2009-10-247361; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Koschmieder S, 2009, J CLIN ONCOL, V27, P619, DOI 10.1200/JCO.2008.17.9812; Maddika S, 2009, NAT CELL BIOL, V11, P409, DOI 10.1038/ncb1848; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Naiki T, 2007, J BIOL CHEM, V282, P24075, DOI 10.1074/jbc.M701409200; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pan H, 2008, J IMMUNOL METHODS, V329, P31, DOI 10.1016/j.jim.2007.09.009; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sabile A, 2006, MOL CELL BIOL, V26, P5994, DOI 10.1128/MCB.01630-05; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Singh SK, 2003, CANCER RES, V63, P5821; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Wada K, 2006, BIOCHEM BIOPH RES CO, V339, P415, DOI 10.1016/j.bbrc.2005.11.029; Wada K, 2009, J BIOCHEM, V146, P821, DOI 10.1093/jb/mvp127; Yoshimi R, 2009, J IMMUNOL, V182, P7527, DOI 10.4049/jimmunol.0804121; Zanella F, 2010, ONCOGENE, V29, P2973, DOI 10.1038/onc.2010.58	41	68	72	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3328	3335		10.1038/onc.2011.57	http://dx.doi.org/10.1038/onc.2011.57			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21399661	Green Accepted			2022-12-28	WOS:000293215700003
J	Lee, C; Longo, VD				Lee, C.; Longo, V. D.			Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients	ONCOGENE			English	Review						fasting; dietary restriction; chemotherapy; differential stress resistance; starvation	GROWTH-FACTOR-I; LIFE-SPAN EXTENSION; CALORIC RESTRICTION; STRESS RESISTANCE; OXIDATIVE STRESS; IGF-I; PROLONGED STARVATION; INSULIN SENSITIVITY; ENERGY RESTRICTION; PROTEIN-METABOLISM	The dietary recommendation for cancer patients receiving chemotherapy, as described by the American Cancer Society, is to increase calorie and protein intake. Yet, in simple organisms, mice, and humans, fasting-no calorie intake-induces a wide range of changes associated with cellular protection, which would be difficult to achieve even with a cocktail of potent drugs. In mammals, the protective effect of fasting is mediated, in part, by an over 50% reduction in glucose and insulin-like growth factor 1 (IGF-I) levels. Because proto-oncogenes function as key negative regulators of the protective changes induced by fasting, cells expressing oncogenes, and therefore the great majority of cancer cells, should not respond to the protective signals generated by fasting, promoting the differential protection (differential stress resistance) of normal and cancer cells. Preliminary reports indicate that fasting for up to 5 days followed by a normal diet, may also protect patients against chemotherapy without causing chronic weight loss. By contrast, the long-term 20 to 40% restriction in calorie intake (dietary restriction, DR), whose effects on cancer progression have been studied extensively for decades, requires weeks-months to be effective, causes much more modest changes in glucose and/or IGF-I levels, and promotes chronic weight loss in both rodents and humans. In this study, we review the basic as well as clinical studies on fasting, cellular protection and chemotherapy resistance, and compare them to those on DR and cancer treatment. Although additional pre-clinical and clinical studies are necessary, fasting has the potential to be translated into effective clinical interventions for the protection of patients and the improvement of therapeutic index. Oncogene (2011) 30, 3305-3316; doi:10.1038/onc.2011.91; published online 25 April 2011	[Longo, V. D.] Univ So Calif, Andrus Gerontol Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA; [Longo, V. D.] Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Longo, VD (corresponding author), Univ So Calif, Andrus Gerontol Ctr, Dept Biol Sci, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	vlongo@usc.edu						Al-Regaiey KA, 2007, J GERONTOL A-BIOL, V62, P18, DOI 10.1093/gerona/62.1.18; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Bartke A, 2001, J ANTI-AGING MED, V4, P197, DOI 10.1089/109454501753249966; BLOOM WL, 1959, METABOLISM, V8, P214; Bonkowski MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004567; Bonorden MJL, 2009, NUTR CANCER, V61, P265, DOI 10.1080/01635580802419798; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; Brown-Borg HM, 2000, EXP GERONTOL, V35, P199, DOI 10.1016/S0531-5565(00)00079-6; Brown-Borg HM, 2002, EXP BIOL MED, V227, P94, DOI 10.1177/153537020222700203; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Buschemeyer WC, 2010, PROSTATE, V70, P1037, DOI 10.1002/pros.21136; Cahill G F Jr, 1970, N Engl J Med, V282, P668, DOI 10.1056/NEJM197003052821026; Cahill G J Jr, 1968, Adv Enzyme Regul, V6, P143, DOI 10.1016/0065-2571(68)90011-3; Cahill G Jr, 1970, Nord Med, V83, P89; Cahill GF, 2006, ANNU REV NUTR, V26, P1, DOI 10.1146/annurev.nutr.26.061505.111258; CAHILL GF, 1966, J CLIN INVEST, V45, P1751, DOI 10.1172/JCI105481; CAHILL GF, 1968, T AM CLIN CLIMAT ASS, V79, P13; Campisi J, 2009, J GERONTOL A-BIOL, V64, P175, DOI 10.1093/gerona/gln065; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chen Y, 2007, MOL INTERV, V7, P147, DOI 10.1124/mi.7.3.6; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; CUBBERLEY PT, 1965, NEW ENGL J MED, V272, P628, DOI 10.1056/NEJM196503252721208; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Doyle C, 2006, CA-CANCER J CLIN, V56, P323, DOI 10.3322/canjclin.56.6.323; DRENICK EJ, 1964, JAMA-J AM MED ASSOC, V187, P100; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Dunn SE, 1997, CANCER RES, V57, P4667; Escriva F, 2007, J ENDOCRINOL, V194, P131, DOI 10.1677/joe.1.07043; FABER M, 1995, BIOL TRACE ELEM RES, V47, P117, DOI 10.1007/BF02790108; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2003, GENETICS, V163, P35; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fearon KCH, 2003, GUT, V52, P1479, DOI 10.1136/gut.52.10.1479; Felgines C, 1999, JPEN-PARENTER ENTER, V23, P32, DOI 10.1177/014860719902300132; FILAIRE E, 2004, J EXERC PHYSIOLOGYON, V7, P8; Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x; Fontana L, 2006, AM J CLIN NUTR, V84, P1456, DOI 10.1093/ajcn/84.6.1456; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Fox KM, 2009, J ONCOL, V2009, DOI 10.1155/2009/693458; Frystyk J, 1999, AM J PHYSIOL-ENDOC M, V277, pE245, DOI 10.1152/ajpendo.1999.277.2.E245; GARNETT ES, 1969, LANCET, V1, P914; Giannakou ME, 2007, TRENDS BIOCHEM SCI, V32, P180, DOI 10.1016/j.tibs.2007.02.007; GO KG, 1988, METAB BRAIN DIS, V3, P257, DOI 10.1007/BF00999535; Goldhamer A, 2001, J MANIP PHYSIOL THER, V24, P335, DOI 10.1067/mmt.2001.115263; Goldhamer AC, 2002, J ALTERN COMPLEM MED, V8, P696, DOI 10.1089/10755530260511694; GOODRICK CL, 1983, J GERONTOL, V38, P36, DOI 10.1093/geronj/38.1.36; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heijboer AC, 2005, J LIPID RES, V46, P582, DOI 10.1194/jlr.M400440-JLR200; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Henis-Korenblit S, 2010, P NATL ACAD SCI USA, V107, P9730, DOI 10.1073/pnas.1002575107; HOLEHAN AM, 1985, MECH AGEING DEV, V33, P19, DOI 10.1016/0047-6374(85)90106-X; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honjoh S, 2009, NATURE, V457, P726, DOI 10.1038/nature07583; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; ISLEY WL, 1983, J CLIN INVEST, V71, P175, DOI 10.1172/JCI110757; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; Johnson A., 2002, MOL BIOL CELL; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Johnstone AM, 2007, OBES REV, V8, P211, DOI 10.1111/j.1467-789X.2006.00266.x; Jones RA, 2010, ONCOGENE, V29, P4779, DOI 10.1038/onc.2010.231; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kalm LM, 2005, J NUTR, V135, P1347, DOI 10.1093/jn/135.6.1347; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KERNDT PR, 1982, WESTERN J MED, V137, P379; Kim SK, 1996, HEMATOL ONCOL CLIN N, V10, P377, DOI 10.1016/S0889-8588(05)70344-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOIZUMI A, 1992, J NUTR, V122, P1446, DOI 10.1093/jn/122.7.1446; Kristan DM, 2008, AGE, V30, P147, DOI 10.1007/s11357-008-9056-1; Kritchevsky D, 2001, J NUTR SCI VITAMINOL, V47, P13, DOI 10.3177/jnsv.47.13; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008-5472.CAN-09-3228; Lee SJ, 2009, CELL METAB, V10, P379, DOI 10.1016/j.cmet.2009.10.003; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Links M, 1999, DRUGS, V57, P293, DOI 10.2165/00003495-199957030-00003; Locher C, 2010, ANN NY ACAD SCI, V1209, P99, DOI 10.1111/j.1749-6632.2010.05763.x; Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Longo VD, 1999, NEUROBIOL AGING, V20, P479, DOI 10.1016/S0197-4580(99)00089-5; LOOK MP, 1994, CHEMOTHERAPY, V40, P8, DOI 10.1159/000239163; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma YT, 2010, SEMIN IMMUNOL, V22, P113, DOI 10.1016/j.smim.2010.03.001; Maccario M, 2001, INT J OBESITY, V25, P1233, DOI 10.1038/sj.ijo.0801671; Madia F, 2008, J CELL BIOL, V180, P67, DOI 10.1083/jcb.200707154; Madia F, 2009, J CELL BIOL, V186, P509, DOI 10.1083/jcb.200906011; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; Marino G, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3124pe19; MCCLURE TJ, 1959, J PHYSIOL-LONDON, V147, P221, DOI 10.1113/jphysiol.1959.sp006237; McColl G, 2010, CELL METAB, V12, P260, DOI 10.1016/j.cmet.2010.08.004; McDougald D, 2002, ANTON LEEUW INT J G, V81, P3, DOI 10.1023/A:1020540503200; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MENAHAN LA, 1983, COMP BIOCHEM PHYS B, V74, P859, DOI 10.1016/0305-0491(83)90157-8; MERIMEE TJ, 1982, J CLIN ENDOCR METAB, V55, P999, DOI 10.1210/jcem-55-5-999; MERIMEE TJ, 1974, J CLIN ENDOCR METAB, V39, P385, DOI 10.1210/jcem-39-2-385; Michalsen A, 2005, J ALTERN COMPLEM MED, V11, P601, DOI 10.1089/acm.2005.11.601; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Moller N, 2009, ENDOCR REV, V30, P152, DOI 10.1210/er.2008-0027; Moreschi C., 1909, ZIMMUNITATSFORSCH, V2, P651; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Morselli E, 2009, AGING-US, V1, P961, DOI 10.18632/aging.100110; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; Muller EE, 1999, PHYSIOL REV, V79, P511, DOI 10.1152/physrev.1999.79.2.511; Murakami S, 2006, EXP GERONTOL, V41, P1014, DOI 10.1016/j.exger.2006.06.061; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; Norrelund H, 2005, GROWTH HORM IGF RES, V15, P95, DOI 10.1016/j.ghir.2005.02.005; PALMBLAD J, 1977, ACTA MED SCAND, V201, P15; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Racette SB, 2006, J GERONTOL A-BIOL, V61, P943, DOI 10.1093/gerona/61.9.943; Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105; Reed MJ, 1996, MECH AGEING DEV, V89, P21, DOI 10.1016/0047-6374(96)01737-X; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; Ruckenstuhl C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004592; RUNCIE J, 1970, BRIT MED J, V3, P432, DOI 10.1136/bmj.3.5720.432; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; Safdie FM, 2009, AGING-US, V1, P988, DOI 10.18632/aging.100114; Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004; SANGEETHA P, 1990, PROSTAG LEUKOTR ESS, V39, P27, DOI 10.1016/0952-3278(90)90167-J; Sans MD, 2004, AM J PHYSIOL-GASTR L, V287, pG667, DOI 10.1152/ajpgi.00505.2003; SAUDEK CD, 1976, AM J MED, V60, P117, DOI 10.1016/0002-9343(76)90540-4; SCRIMSHAW NS, 1987, ANNU REV NUTR, V7, P1, DOI 10.1146/annurev.nu.07.070187.000245; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; Sharma HS, 2000, AMINO ACIDS, V19, P351, DOI 10.1007/s007260070066; Shelton LM, 2010, ASN NEURO, V2, DOI 10.1042/AN20100002; Shen JW, 2009, CELL IMMUNOL, V259, P66, DOI 10.1016/j.cellimm.2009.05.015; Shimokawa I, 2003, FASEB J, V17, P1108, DOI 10.1096/fj.02-0819fje; SPENCER IOB, 1968, LANCET, V2, P679; SPINDLER SR, 1990, J NUTR, V120, P1412, DOI 10.1093/jn/120.11.1412; Takenaka A, 2000, J NUTR, V130, P2910, DOI 10.1093/jn/130.12.2910; TANNENBAUM A, 1945, CANCER RES, V5, P616; TANNENBAUM GS, 1979, ENDOCRINOLOGY, V104, P1733, DOI 10.1210/endo-104-6-1733; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thissen JP, 1999, NUTR REV, V57, P167, DOI 10.1111/j.1753-4887.1999.tb06939.x; THOMSON TJ, 1966, LANCET, V2, P992; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; UNGER RH, 1963, J CLIN INVEST, V42, P1031, DOI 10.1172/JCI104788; van Ginhoven TM, 2009, LIVER TRANSPLANT, V15, P1183, DOI 10.1002/lt.21871; vandenBerghe G, 1996, J INHERIT METAB DIS, V19, P470, DOI 10.1007/BF01799108; Varady KA, 2007, AM J CLIN NUTR, V86, P7, DOI 10.1093/ajcn/86.1.7; Vaughn AE, 2008, NAT CELL BIOL, V10, P1477, DOI 10.1038/ncb1807; Vigne P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005422; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang T, 2006, ANNU REV PHYSIOL, V68, P223, DOI 10.1146/annurev.physiol.68.040104.105739; Wedding U, 2007, J CANCER RES CLIN, V133, P945, DOI 10.1007/s00432-007-0233-x; Wei M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040013; Wei M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000467; WEINDRUCH R, 1982, P NATL ACAD SCI-BIOL, V79, P898, DOI 10.1073/pnas.79.3.898; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Weinkove D, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-1; Xie LL, 2007, J BIOL CHEM, V282, P28025, DOI 10.1074/jbc.M604857200; Yan L, 2007, CELL, V130, P247, DOI 10.1016/j.cell.2007.05.038; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; ZAPF J, 1995, EUR J ENDOCRINOL, V132, P645, DOI 10.1530/eje.0.1320645; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107	175	181	195	1	64	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3305	3316		10.1038/onc.2011.91	http://dx.doi.org/10.1038/onc.2011.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21516129				2022-12-28	WOS:000293215700001
J	Lau, MT; Klausen, C; Leung, PCK				Lau, M-T; Klausen, C.; Leung, P. C. K.			E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression	ONCOGENE			English	Article						E-cadherin; PTEN; PI3K/Akt; beta-catenin; ovarian cancer	GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; OVARIAN-CANCER; PHOSPHATASE-ACTIVITY; CARCINOMA-CELLS; FACTOR RECEPTOR; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; INCREASES SENSITIVITY	E-cadherin is a cell-cell adhesion protein and tumor suppressor that is silenced in many malignancies. E-cadherin is thought to suppress tumor cell growth by antagonizing beta-catenin signaling. However, the role of E-cadherin in ovarian cancer progression is still controversial. In this study, we showed that loss of E-cadherin induced ovarian cancer cell growth and constitutive activation of phosphoinositide 3-kinase (PI3K)/Akt signaling by the inhibition of phosphatase and tensin homolog (PTEN) transcription through the downregulation of early growth response gene 1 (Egr1). In addition, immunofluorescence microscopy and T-cell factor promoter/luciferase reporter assays showed that E-cadherin loss was associated with enhanced nuclear beta-catenin signaling. Constitutive activation of PI3K/Akt signaling reinforced nuclear beta-catenin signaling by inactivating glycogen synthase kinase-3 beta indicating cross-talk between the PI3K/Akt and beta-catenin signaling pathways. Finally, we found that E-cadherin negatively regulates tumor cell growth, in part, by positively regulating PTEN expression via beta-catenin-mediated Egr1 regulation, thus influencing PI3K/Akt signaling. In summary, endogenous E-cadherin inhibits PI3K/Akt signaling by antagonizing beta-catenin-Egr1-mediated repression of PTEN expression. Thus, the loss of E-cadherin itself may contribute to dysregulated PI3K/Akt signaling through its effects on PTEN, or it may exacerbate the frequent activation of PI3K/Akt signaling that occurs as a result of overexpression, mutation and/or amplification. Oncogene (2011) 30, 2753-2766; doi: 10.1038/onc.2011.6; published online 7 February 2011	[Lau, M-T; Klausen, C.; Leung, P. C. K.] Univ British Columbia, Dept Obstet Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3N1, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Dept Obstet Gynecol, Child & Family Res Inst, 2H30,4490 Oak St, Vancouver, BC V6H 3N1, Canada.	peleung@interchange.ubc.ca		Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health Research; Interdisciplinary Women's Reproductive Health Research Training Program	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Interdisciplinary Women's Reproductive Health Research Training Program	We thank Dr H Clevers (University Hospital, the Netherlands), Dr E Fearon (University of Michigan School of Medicine, Detroit, MI, USA), Dr A Passaniti (University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA), Dr AH Ross (University of Massachusetts Medical School, Worcester, MA, USA), Dr V Stambolic (Ontario Cancer Institute, Toronto, Ontario, Canada), Dr RA Weinberg (Massachusetts Institute of Technology, Cambridge, MA, USA) and Dr J Woodgett (Ontario Cancer Institute) for kindly and generously giving us the constructs. This work was supported by the Canadian Institutes of Health Research (PCKL). PCKL is recipient of a Distinguished Scientist Award from the Child and Family Research Institute and MTL is the recipient of a Graduate Studentship Award from the Interdisciplinary Women's Reproductive Health Research Training Program.	Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Black PC, 2008, CLIN CANCER RES, V14, P1478, DOI 10.1158/1078-0432.CCR-07-1593; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Santis G, 2009, ONCOGENE, V28, P1206, DOI 10.1038/onc.2008.470; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Fournier MV, 2009, CANCER RES, V69, P4545, DOI 10.1158/0008-5472.CAN-08-1694; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Furnari FB, 1998, CANCER RES, V58, P5002; Geiger B, 1995, ACTA ANAT, V154, P46; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hu YL, 2007, ARCH BIOCHEM BIOPHYS, V467, P1, DOI 10.1016/j.abb.2007.07.027; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li ZX, 2007, BIOCHEM BIOPH RES CO, V363, P165, DOI 10.1016/j.bbrc.2007.08.154; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Maher MT, 2009, J CELL BIOL, V186, P219, DOI 10.1083/jcb.200811108; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reddy P, 2005, MOL ENDOCRINOL, V19, P2564, DOI 10.1210/me.2004-0342; Sasaki CY, 2000, INT J CANCER, V86, P660, DOI 10.1002/(SICI)1097-0215(20000601)86:5<660::AID-IJC9>3.0.CO;2-X; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soto E, 2008, J CELL BIOL, V183, P737, DOI 10.1083/jcb.200805113; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Woenckhaus J, 2007, VIRCHOWS ARCH, V450, P387, DOI 10.1007/s00428-006-0358-3; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wu C, 2008, DIFFERENTIATION, V76, P193, DOI 10.1111/j.1432-0436.2007.00193.x; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200; Yagi T, 2000, GENE DEV, V14, P1169; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492; Yu YC, 2006, CLIN EXP METASTAS, V23, P65, DOI 10.1007/s10585-006-9020-3	58	90	100	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2753	2766		10.1038/onc.2011.6	http://dx.doi.org/10.1038/onc.2011.6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21297666				2022-12-28	WOS:000291678500006
J	Serra, V; Scaltriti, M; Prudkin, L; Eichhorn, PJA; Ibrahim, YH; Chandarlapaty, S; Markman, B; Rodriguez, O; Guzman, M; Rodriguez, S; Gili, M; Russillo, M; Parra, JL; Singh, S; Arribas, J; Rosen, N; Baselga, J				Serra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, P. J. A.; Ibrahim, Y. H.; Chandarlapaty, S.; Markman, B.; Rodriguez, O.; Guzman, M.; Rodriguez, S.; Gili, M.; Russillo, M.; Parra, J. L.; Singh, S.; Arribas, J.; Rosen, N.; Baselga, J.			PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer	ONCOGENE			English	Article						PI3K/mTOR; HER2; feedback; ERK; BEZ235	PHASE-II; TRASTUZUMAB RESISTANCE; PATHWAY ACTIVATION; ANTITUMOR-ACTIVITY; PTEN; RECEPTOR; PIK3CA; MUTATIONS; GENE; MEK	There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease and it also mediates resistance to anti-HER2 therapies. However, initial studies with rapalogs, allosteric inhibitors of mTORC1, have resulted in limited clinical efficacy probably due to the release of a negative regulatory feedback loop that triggers AKT and ERK signaling. Since activation of AKT occurs via PI3K, we decided to explore whether PI3K inhibitors prevent the activation of these compensatory pathways. Using HER2-overexpressing breast cancer cells as a model, we observed that PI3K inhibitors abolished AKT activation. However, PI3K inhibition resulted in a compensatory activation of the ERK signaling pathway. This enhanced ERK signaling occurred as a result of activation of HER family receptors as evidenced by induction of HER receptors dimerization and phosphorylation, increased expression of HER3 and binding of adaptor molecules to HER2 and HER3. The activation of ERK was prevented with either MEK inhibitors or anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. Combined administration of PI3K inhibitors with either HER2 or MEK inhibitors resulted in decreased proliferation, enhanced cell death and superior anti-tumor activity compared with single agent PI3K inhibitors. Our findings indicate that PI3K inhibition in HER2-overexpressing breast cancer activates a new compensatory pathway that results in ERK dependency. Combined anti-MEK or anti-HER2 therapy with PI3K inhibitors may be required in order to achieve optimal efficacy in HER2-overexpressing breast cancer. This approach warrants clinical evaluation. Oncogene (2011) 30, 2547-2557; doi:10.1038/onc.2010.626; published online 31 January 2011	[Baselga, J.] Vall Hebron Univ Hosp, VHIO, Expt Therapeut Program, E-08035 Barcelona, Spain; [Scaltriti, M.; Baselga, J.] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Res, Boston, MA USA; [Prudkin, L.; Rodriguez, S.] Vall Hebron Inst Oncol, Mol Pathol Program, Barcelona, Spain; [Chandarlapaty, S.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; [Chandarlapaty, S.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA; [Markman, B.; Baselga, J.] Vall Hebron Univ Hosp, Dept Med Oncol, E-08035 Barcelona, Spain; [Parra, J. L.; Arribas, J.] Vall Hebron Inst Oncol, Growth Factors Lab, Barcelona, Spain; [Singh, S.] Prometheus Therapeut & Diagnost, San Diego, CA USA; [Arribas, J.; Baselga, J.] Univ Autonoma Barcelona, E-08193 Barcelona, Spain; [Arribas, J.] Inst Catalana Recerca & Estudis Acancats, Barcelona, Spain; [Baselga, J.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA	Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Harvard University; Massachusetts General Hospital; Vall d'Hebron Institut d'Oncologia (VHIO); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; ICREA; Harvard University; Massachusetts General Hospital	Baselga, J (corresponding author), Vall Hebron Univ Hosp, VHIO, Expt Therapeut Program, Passeig Vall Hebron 119-129, E-08035 Barcelona, Spain.	jbaselga@vhio.net	Serra, Violeta/AAG-8328-2019; Arribas, Joaquin/M-4482-2014; Rosen, Neal/ABF-2677-2020	Arribas, Joaquin/0000-0002-0504-0664; Serra, Violeta/0000-0001-6620-1065; Eichhorn, Pieter/0000-0001-5840-943X	Instituto de Salud Carlos III [PSO9/00623]; Breast Cancer Research Foundation; ERC [AdG09 250244]; NATIONAL CANCER INSTITUTE [K08CA134833] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Breast Cancer Research Foundation; ERC(European Research Council (ERC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ICREA(ICREA)	This research was supported by grants from the Instituto de Salud Carlos III (Intrasalud PSO9/00623), from the Breast Cancer Research Foundation and from the ERC (AdG09 250244). BEZ235 and NVP-AEW541 were kindly provided by C Garcia-Echeverria from Novartis, Basel, Switzerland. The AKT1/2/3 inhibitor was provided by Pradip Majumder at Merck Research Laboratories, Boston. Lapatinib was kindly provided by GlaxoSmithKline, Research Triangle Park, NJ. Torin1 was obtained from Whitehead/DFCI. Trastuzumab was kindly provided by F Hoffmann-La Roche, Basel, Switzerland.	Andre F, 2008, J CLIN ONCOL S, V26; Banerji U, 2010, CLIN CANCER RES, V16, P1613, DOI 10.1158/1078-0432.CCR-09-2483; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chaturvedi D, 2009, ONCOGENE, V28, P1187, DOI 10.1038/onc.2008.490; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Clark AS, 2002, MOL CANCER THER, V1, P707; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Flaherty K, 2009, J CLIN ONCOL, V27; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; GARRETT J, 2009, CANC RES S, V69; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Ihle NT, 2009, CANCER RES, V69, P143, DOI 10.1158/0008-5472.CAN-07-6656; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Makhija S, 2010, J CLIN ONCOL, V28, P1215, DOI 10.1200/JCO.2009.22.3354; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shapiro G, 2009, J CLIN ONCOL S, V27, p15s; Shi Y, 2005, INT J INF TECH DECIS, V4, P1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yao E, 2009, CLIN CANCER RES, V15, P4147, DOI 10.1158/1078-0432.CCR-08-2814; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	54	395	411	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2547	2557		10.1038/onc.2010.626	http://dx.doi.org/10.1038/onc.2010.626			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21278786	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000291198400006
J	Trinh, BQ; Barengo, N; Naora, H				Trinh, B. Q.; Barengo, N.; Naora, H.			Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-beta cytostatic program and blocks the antiproliferative effect of TGF-beta	ONCOGENE			English	Article						cell growth; homeobox genes; Smad; Sp1; TGF-beta	GROWTH-FACTOR-BETA; HOMEOBOX GENE-EXPRESSION; MICROSATELLITE INSTABILITY; BREAST-CANCER; C-MYC; EPITHELIAL-CELLS; LUNG CANCERS; COLON-CANCER; II RECEPTOR; DNA-BINDING	The antiproliferative activity of transforming growth factor-beta (TGF-beta) is essential for maintaining normal tissue homeostasis and is lost in many types of tumors. Gene responses that are central to the TGF-beta cytostatic program include activation of the cyclin-dependent kinase inhibitors, p15(Ink4B) and p21(WAF1/Cip1), and repression of c-myc. These gene responses are tightly regulated by a repertoire of transcription factors that include Smad proteins and Sp1. The DLX4 homeobox patterning gene encodes a transcription factor that is absent from most normal adult tissues, but is expressed in a wide variety of malignancies, including lung, breast, prostate and ovarian cancers. In this study, we demonstrate that DLX4 blocks the antiproliferative effect of TGF-b. DLX4 inhibited TGF-beta-mediated induction of p15(Ink4B) and p21(WAF1/Cip1) expression. DLX4 bound and prevented Smad4 from forming complexes with Smad2 and Smad3, but not with Sp1. However, DLX4 also bound and inhibited DNA-binding activity of Sp1. In addition, DLX4 induced expression of c-myc independently of TGF-beta/Smad signaling. The ability of DLX4 to counteract key transcriptional control mechanisms of the TGF-beta cytostatic program could explain, in part, the resistance of tumors to the antiproliferative effect of TGF-beta Oncogene (2011) 30, 2718-2729; doi: 10.1038/onc.2011.4; published online 7 February 2011	[Trinh, B. Q.; Barengo, N.; Naora, H.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77054 USA; [Trinh, B. Q.; Naora, H.] Univ Texas Hlth Sci Ctr, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Naora, H (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St,Unit 950, Houston, TX 77054 USA.	hnaora@mdanderson.org	Trinh, Bon/K-7132-2014	Trinh, Bon/0000-0002-0956-8941	Schissler Foundation; Vietnam Education Foundation; US Department of Defense [W81XWH-06-1-0259]; National Institutes of Health [R01 CA141078]; NATIONAL CANCER INSTITUTE [R01CA141078] Funding Source: NIH RePORTER	Schissler Foundation; Vietnam Education Foundation; US Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Schissler Foundation Fellowship (B Trinh), the Vietnam Education Foundation (B Trinh), the US Department of Defense grant W81XWH-06-1-0259 (H Naora) and the National Institutes of Health grant R01 CA141078 (H Naora). We thank Sabine Thonard for technical assistance, and Song Yi Ko, Gary Gallick, Michelle Barton, Janet Price, Peng Huang and Miles Wilkinson	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Bello-DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118; Berghorn KA, 2006, J BIOL CHEM, V281, P20357, DOI 10.1074/jbc.M603049200; Boogerd KJ, 2008, CARDIOVASC RES, V78, P485, DOI 10.1093/cvr/cvn049; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Francis-Thickpenny KM, 2001, BRIT J CANCER, V85, P687, DOI 10.1054/bjoc.2001.1950; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Haga SB, 2000, LEUKEMIA, V14, P1867, DOI 10.1038/sj.leu.2401912; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hara F, 2007, AM J PATHOL, V170, P1594, DOI 10.2353/ajpath.2007.061025; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hyman E, 2002, CANCER RES, V62, P6240; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Man YG, 2005, BREAST CANCER RES TR, V90, P241, DOI 10.1007/s10549-004-4492-9; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nagatake M, 1996, CANCER RES, V56, P2718; Naora H, 2001, P NATL ACAD SCI USA, V98, P4060, DOI 10.1073/pnas.071594398; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park GT, 2002, NUCLEIC ACIDS RES, V30, P515, DOI 10.1093/nar/30.2.515; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Schutte M, 1996, CANCER RES, V56, P2527; Schwartz AM, 2009, MODERN PATHOL, V22, P1, DOI 10.1038/modpathol.2008.168; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Takenoshita S, 1998, ONCOL REP, V5, P367; Takenoshita S, 1997, CARCINOGENESIS, V18, P1427, DOI 10.1093/carcin/18.7.1427; Tokunaga H, 1999, CLIN CANCER RES, V5, P2520; Tomida S, 2007, ONCOGENE, V26, P4600, DOI 10.1038/sj.onc.1210242; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Wang D, 2000, CANCER RES, V60, P4507; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Williams TM, 2005, NUCLEIC ACIDS RES, V33, P4475, DOI 10.1093/nar/gki761; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yamada SD, 1999, GYNECOL ONCOL, V75, P72, DOI 10.1006/gyno.1999.5535; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	53	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2718	2729		10.1038/onc.2011.4	http://dx.doi.org/10.1038/onc.2011.4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21297662	Green Accepted			2022-12-28	WOS:000291678500003
J	Ban, J; Jug, G; Mestdagh, P; Schwentner, R; Kauer, M; Aryee, DNT; Schaefer, KL; Nakatani, F; Scotlandi, K; Reiter, M; Strunk, D; Speleman, F; Vandesompele, J; Kovar, H				Ban, J.; Jug, G.; Mestdagh, P.; Schwentner, R.; Kauer, M.; Aryee, D. N. T.; Schaefer, K-L; Nakatani, F.; Scotlandi, K.; Reiter, M.; Strunk, D.; Speleman, F.; Vandesompele, J.; Kovar, H.			Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma	ONCOGENE			English	Article						Ewing's sarcoma; microRNA; mir-145; EWS-FLI1	CELL-GROWTH; MIR-145; EWS-FLI1; EXPRESSION; P53; DIFFERENTIATION	EWS-FLI1 is a chromosome translocation-derived chimeric transcription factor that has a central and rate-limiting role in the pathogenesis of Ewing's sarcoma. Although the EWS-FLI1 transcriptomic signature has been extensively characterized on the mRNA level, information on its impact on non-coding RNA expression is lacking. We have performed a genome-wide analysis of microRNAs affected by RNAi-mediated silencing of EWS-FLI1 in Ewing's sarcoma cell lines, and differentially expressed between primary Ewing's sarcoma and mesenchymal progenitor cells. Here, we report on the identification of hsa-mir-145 as the top EWS-FLI1-repressed microRNA. Upon knockdown of EWS-FLI1, hsa-mir-145 expression dramatically increases in all Ewing's sarcoma cell lines tested. Vice versa, ectopic expression of the microRNA in Ewing's sarcoma cell lines strongly reduced EWS-FLI1 protein, whereas transfection of an anti-mir to hsa-mir-145 increased the EWS-FLI1 levels. Reporter gene assays revealed that this modulation of EWS-FLI1 protein was mediated by the microRNA targeting the FLI1 3'-untranslated region. Mutual regulations of EWS-FLI1 and hsa-mir-145 were mirrored by an inverse correlation between their expression levels in four of the Ewing's sarcoma cell lines tested. Consistent with the role of EWS-FLI1 in Ewing's sarcoma growth regulation, forced hsa-mir-145 expression halted Ewing's sarcoma cell line growth. These results identify feedback regulation between EWS-FLI1 and hsa-mir-145 as an important component of the EWS-FLI1-mediated Ewing's sarcomagenesis that may open a new avenue to future microRNA-mediated therapy of this devastating malignant disease. Oncogene (2011) 30, 2173-2180; doi:10.1038/onc.2010.581; published online 10 January 2011	[Ban, J.; Jug, G.; Schwentner, R.; Kauer, M.; Aryee, D. N. T.; Reiter, M.; Kovar, H.] St Anna Childrens Hosp, Childrens Canc Res Inst, St Anna Kinderkrebsforschung, A-1090 Vienna, Austria; [Mestdagh, P.; Speleman, F.; Vandesompele, J.] Univ Med Ctr, Ctr Med Genet, Ghent, Belgium; [Schaefer, K-L] Univ Dusseldorf, Inst Pathol, Fac Med, Dusseldorf, Germany; [Nakatani, F.; Scotlandi, K.] CRS Dev Biomol Therapies, Expt Oncol Lab, Ist Ortoped Rizzoli, Bologna, Italy; [Strunk, D.] Med Univ, Div Hematol, Graz, Austria	Saint Anna Children's Hospital; Ghent University; Heinrich Heine University Dusseldorf; IRCCS Istituto Ortopedico Rizzoli; Medical University of Graz	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, St Anna Kinderkrebsforschung, Zimmermannpl 10, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at	Vandesompele, Jo/W-3411-2018; Strunk, Dirk/V-4598-2017; Scotlandi, Katia/J-9009-2016; speleman, frank/AAR-5184-2020	Vandesompele, Jo/0000-0001-6274-0184; Strunk, Dirk/0000-0003-1810-867X; Scotlandi, Katia/0000-0001-6114-9499; speleman, frank/0000-0002-6628-8559; Mestdagh, Pieter/0000-0001-7821-9684; Schwentner, Raphaela/0000-0001-6839-0322; Kovar, Heinrich/0000-0001-6873-9109	Austrian Research Fund FWF [P20665-B12]; European Commission [LSHC-CT-2006-037260]; Ghent University [BOF 01D31406]	Austrian Research Fund FWF(Austrian Science Fund (FWF)); European Commission(European CommissionEuropean Commission Joint Research Centre); Ghent University(Ghent University)	We thank Aykut Uren for help in the analysis of the PDGF/mir-145 axis and Stephan Baldus for supplying primary tumor tissue, and Karin Muhlbacher for technical assistance. This study was supported by grants from the Austrian Research Fund FWF (P20665-B12) and the European Commission (EET-pipeline, LSHC-CT-2006-037260). PM is supported by the Ghent University research fund (BOF 01D31406).	Aryee DNT, 2010, CANCER RES, V70, P4015, DOI 10.1158/0008-5472.CAN-09-4333; Bachmaier R, 2009, ONCOGENE, V28, P1280, DOI 10.1038/onc.2008.484; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregersen LH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008836; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Kano M, 2010, INT J CANC; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2010, GENOME MED, V2, DOI 10.1186/gm129; Larsson E, 2009, GENOME MED, V1, DOI 10.1186/gm108; Le Deley MC, 2010, J CLIN ONCOL, V28, P1982, DOI 10.1200/JCO.2009.23.3585; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Mar JC, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-110; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Nozawa S, 2005, J BIOL CHEM, V280, P27544, DOI 10.1074/jbc.M411626200; Quintavalle M, 2010, J CELL BIOL, V189, P13, DOI 10.1083/jcb.200912096; Rao YL, 2008, STAT APPL GENET MOL, V7, DOI 10.2202/1544-6115.1287; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sartipy P, 2009, IDRUGS, V12, P492; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Torchia EC, 2003, CANCER RES, V63, P3464; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zeng L, 2009, P NATL ACAD SCI USA, V106, P17793, DOI 10.1073/pnas.0903693106	38	69	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2173	2180		10.1038/onc.2010.581	http://dx.doi.org/10.1038/onc.2010.581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217773	Green Accepted			2022-12-28	WOS:000290249600008
J	Meyer, RD; Husain, D; Rahimi, N				Meyer, R. D.; Husain, D.; Rahimi, N.			c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLC gamma 1	ONCOGENE			English	Article						VEGFR-2; PLC gammal; c-Cbl; angiogenesis; ubiquitination	ENDOTHELIAL-CELL PROLIFERATION; PHOSPHOLIPASE C-GAMMA-1; CHOROIDAL NEOVASCULARIZATION; NEGATIVE REGULATION; T-CELLS; MICE; VEGFR-2; PROTEINS; VASCULOGENESIS; RECEPTOR-2	Angiogenesis is regulated by highly coordinated function of various proteins with pro- and anti-angiogenic functions. Among the many cytoplasmic signaling proteins that are activated by VEGFR-2, activation of PLC gamma 1 is considered to have a pivotal role in angiogenic signaling. In previous study we have identified c-Cbl as a negative regulator of PLC gamma 1 in endothelial cells, the biochemical and biological significance of c-Cbl, however, in angiogenesis in vivo and molecular mechanisms involved were remained elusive. In this study, we report that genetic inactivation of c-Cbl in mice results in enhanced tumor angiogenesis and retinal neovascularization. Endothelial cells derived from c-Cbl null mice displayed elevated cell proliferation and tube formation in response to VEGF stimulation. Loss of c-Cbl also resulted in robust activation of PLC gamma 1 and increased intracellular calcium release. c-Cbl-dependent ubiquitination selectively inhibited tyrosine phosphorylation of PLC gamma 1 and mostly refrained from ubiquitin-mediated degradation. Hence, we propose c-Cbl as an angiogenic suppressor protein where upon activation it uniquely modulates PLC gamma 1 activation by ubiquitination and subsequently inhibits VEGF-driven angiogenesis. Oncogene (2011) 30, 2198-2206; doi:10.1038/onc.2010.597; published online 17 January 2011	[Meyer, R. D.; Rahimi, N.] Boston Univ, Dept Pathol, Boston, MA 02118 USA; [Husain, D.; Rahimi, N.] Boston Univ, Dept Ophthalmol, Boston, MA 02118 USA	Boston University; Boston University	Rahimi, N (corresponding author), Boston Univ, Dept Pathol, Med Campus,670 Albany St,Room 429, Boston, MA 02118 USA.	nrahimi@bu.edu		Husain, Deeba/0000-0002-8494-0950; Rahimi, Nader/0000-0002-6745-1725	National Institutes of Health (NIH/NEI); Department of Ophthalmology; BU; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY017955] Funding Source: NIH RePORTER	National Institutes of Health (NIH/NEI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Department of Ophthalmology; BU(Bogazici University); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This study was supported by grants from the National Institutes of Health (NIH/NEI) to NR and Massachusetts Lions Foundation grant to Department of Ophthalmology, and also by BU CTSI grant (NR). The c-Cbl knockout mice were generously provided by Jeffrey Chiang (National Cancer Institute, Frederick, MD).	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Funakoshi T, 2006, EXP EYE RES, V83, P1102, DOI 10.1016/j.exer.2006.05.016; Graham LJ, 1998, BIOCHEM BIOPH RES CO, V249, P537, DOI 10.1006/bbrc.1998.9177; Graham LJ, 2003, ONCOGENE, V22, P2493, DOI 10.1038/sj.onc.1206318; Hochstrasser M, 2009, NATURE, V458, P422, DOI 10.1038/nature07958; Husain D, 2010, INVEST OPHTH VIS SCI, V51, P6803, DOI 10.1167/iovs.10-5255; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Lawson ND, 2003, GENE DEV, V17, P1346, DOI 10.1101/gad.1072203; Liao HJ, 2002, J BIOL CHEM, V277, P9335, DOI 10.1074/jbc.M109955200; Meyer RD, 2004, ONCOGENE, V23, P5523, DOI 10.1038/sj.onc.1207712; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Meyer RD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003848; Miura-Shimura Y, 2003, J BIOL CHEM, V278, P38495, DOI 10.1074/jbc.M305656200; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818; Rahimi N, 2009, CANCER RES, V69, P2607, DOI 10.1158/0008-5472.CAN-08-2905; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Singh AJ, 2005, MOL BIOL CELL, V16, P2106, DOI 10.1091/mbc.E04-08-0749; Singh AJ, 2007, P NATL ACAD SCI USA, V104, P5413, DOI 10.1073/pnas.0700809104; Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Woodman SE, 2003, AM J PATHOL, V162, P2059, DOI 10.1016/S0002-9440(10)64337-4; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zhang HF, 2008, J CLIN INVEST, V118, P3904, DOI 10.1172/JCI36168	37	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2198	2206		10.1038/onc.2010.597	http://dx.doi.org/10.1038/onc.2010.597			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242968	Green Accepted			2022-12-28	WOS:000290514600003
J	Altman, BJ; Jacobs, SR; Mason, EF; Michalek, RD; MacIntyre, AN; Coloff, JL; Ilkayeva, O; Jia, W; He, YW; Rathmell, JC				Altman, B. J.; Jacobs, S. R.; Mason, E. F.; Michalek, R. D.; MacIntyre, A. N.; Coloff, J. L.; Ilkayeva, O.; Jia, W.; He, Y-W; Rathmell, J. C.			Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis	ONCOGENE			English	Article						autophagy; BCR-Abl; Puma; apoptosis; metabolism; p53	INDUCED ACTIVATION; INDUCED APOPTOSIS; METABOLIC STRESS; TUMOR-SUPPRESSOR; STEM-CELLS; SURVIVAL; PROTEIN; DEATH; CANCER; GROWTH	Hematopoietic cells normally require cell extrinsic signals to maintain metabolism and survival. In contrast, cancer cells can express constitutively active oncogenic kinases such as BCR-Abl that promote these processes independent of extrinsic growth factors. When cells receive insufficient growth signals or when oncogenic kinases are inhibited, glucose metabolism decreases and the self-digestive process of autophagy is elevated to degrade bulk cytoplasm and organelles. Although autophagy has been proposed to provide a cell-intrinsic nutrient supply for mitochondrial oxidative metabolism and to maintain cellular homeostasis through degradation of damaged organelles or protein aggregates, its acute role in growth factor deprivation or inhibition of oncogenic kinases remains poorly understood. We therefore developed a growth factor-dependent hematopoietic cell culture model in which autophagy can be acutely disrupted through conditional Cre-mediated excision of the autophagy-essential gene Atg3. Treated cells rapidly lost their ability to perform autophagy and underwent cell cycle arrest and apoptosis. Although Atg3 was essential for optimal upregulation of mitochondrial oxidative pathways in growth factor withdrawal, this metabolic contribution of autophagy did not appear critical for cell survival, as provision of exogenous pyruvate or lipids could not completely rescue Atg3 deficiency. Instead, autophagy suppressed a stress response that otherwise led to p53 phosphorylation and upregulation of p21 and the proapoptotic Bcl-2 family protein Puma. Importantly, BCR-Abl-expressing cells had low basal levels of autophagy, but were highly dependent on this process, and rapidly underwent apoptosis upon disruption of autophagy through Atg3 deletion or treatment with chemical autophagy inhibitors. This dependence on autophagy extended in vivo, as Atg3 deletion also prevented BCR-Abl-mediated leukemogenesis in a cell transfer model. Together these data demonstrate a critical role for autophagy to mitigate cell stress, and that cells expressing the oncogenic kinase BCR-Abl appear particularly dependent on autophagy for cell survival and leukemogenesis. Oncogene (2011) 30, 1855-1867; doi: 10.1038/onc.2010.561; published online 13 December 2010	[Altman, B. J.; Jacobs, S. R.; Mason, E. F.; Michalek, R. D.; MacIntyre, A. N.; Coloff, J. L.; Ilkayeva, O.; Rathmell, J. C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Ilkayeva, O.; Rathmell, J. C.] Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; [Jia, W.; He, Y-W; Rathmell, J. C.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Rathmell, JC (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	jeff.rathmell@duke.edu	Altman, Brian J./X-2783-2019	Altman, Brian J./0000-0002-3954-4916; Macintyre, Andrew/0000-0002-5297-0207	NIH [R01 CA123350, F30 HL094044]; Leukemia and Lymphoma Society Scholar Award; Cancer Research Institute; NATIONAL CANCER INSTITUTE [R01CA123350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL094044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI074944] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society Scholar Award(Leukemia and Lymphoma Society); Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH R01 CA123350 (JCR), Leukemia and Lymphoma Society Scholar Award (JCR), Alex's Lemonade Stand (JCR) and Gabrielle's Angel Foundation for Cancer Research (JCR). JCR is the Bernard Osher Fellow of the American Asthma Foundation. EFM is supported by NIH F30 HL094044 and RDM is supported by the Irvington Institute Postdoctoral Fellowship from the Cancer Research Institute.	Altman BJ, 2009, AUTOPHAGY, V5, P569, DOI 10.4161/auto.5.4.8254; Altman BJ, 2009, MOL BIOL CELL, V20, P1180, DOI 10.1091/mbc.E08-08-0829; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Darzynkiewicz Z, 2001, Curr Protoc Cytom, VChapter 7, DOI 10.1002/0471142956.cy0705s00; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Ishihara T, 2007, BIOCHEM BIOPH RES CO, V356, P711, DOI 10.1016/j.bbrc.2007.03.034; Iwata J, 2006, J BIOL CHEM, V281, P4035, DOI 10.1074/jbc.M512283200; Jacobs SR, 2010, J IMMUNOL, V184, P3461, DOI 10.4049/jimmunol.0902593; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349; Kamitsuji Y, 2008, CELL DEATH DIFFER, V15, P1712, DOI 10.1038/cdd.2008.107; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karawajew L, 2005, BLOOD, V105, P4767, DOI 10.1182/blood-2004-09-3428; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lainez S, 2010, FASEB J, V24, P1958, DOI 10.1096/fj.09-151472; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mason EF, 2010, CANCER RES, V70, P8066, DOI 10.1158/0008-5472.CAN-10-0608; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Modi H, 2007, BLOOD, V109, P5411, DOI 10.1182/blood-2006-06-032490; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200; Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74; Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	59	100	111	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1855	1867		10.1038/onc.2010.561	http://dx.doi.org/10.1038/onc.2010.561			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151168	Green Accepted			2022-12-28	WOS:000289777700002
J	Kim, MKH; Min, DJ; Rabin, M; Licht, JD				Kim, M. K-H; Min, D. J.; Rabin, M.; Licht, J. D.			Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants	ONCOGENE			English	Article						WTX; WT1; microarray; tumor suppressor; G(0)/G(1) arrest; p21	BECKWITH-WIEDEMANN SYNDROME; KIDNEY DEVELOPMENT; BETA-CATENIN; BONE MASS; GENE; MUTATIONS; INDUCTION; FREQUENT; EVENT; TUMORIGENESIS	The WTX, Wilms tumor-associated tumor-suppressor gene, is present on the X chromosome and a single WTX mutation may be sufficient to promote carcinogenesis. Unlike the WT1 tumor suppressor, a transcription factor, WTX lacks conserved functional protein domains. To study the function of WTX, we constructed inducible cell lines expressing WTX and tumor-associated WTX mutants. Induction of WTX inhibited cell growth and caused G(1)/G(0) arrest. In contrast, a short, tumor-associated truncation mutant of WTX358 only slightly inhibited cell growth without a significant cell-cycle arrest, although expression of a longer truncation mutant WTX565 led to the growth inhibition and cell-cycle arrest to a similar extent as wild-type WTX. Like WT1, WTX slowed growth and caused cell-cycle arrest through p21 induction. Gene expression profiling showed that these two tumor-suppressors regulated genes in similar pathways, including those implicated in control of the cellular growth, cell cycle, cell death, cancer and cardiovascular system development. When gene expression changes mediated by wild-type WTX were compared with those affected by mutant forms, WTX565 showed a 55% overlap (228 genes) in differentially regulated genes, whereas WTX358 regulated only two genes affected by wild-type WTX, implying that amino-acid residues 358-561 are critical for WTX function. Oncogene (2011) 30, 832-842; doi:10.1038/onc.2010.452; published online 18 October 2010	[Kim, M. K-H; Min, D. J.; Rabin, M.; Licht, J. D.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr,Dept Med, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Licht, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr,Dept Med, Lurie 5-123,303 E Super St, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Licht, Jonathan/L-4239-2019; Licht, Jonathan/AAL-9184-2020	Licht, Jonathan/0000-0002-3942-1369	Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE [R01CA059998] Funding Source: NIH RePORTER	Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by a grant from the Northwestern Memorial Foundation.	BARDEESY N, 1995, CANCER RES, V55, P215; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Chung NG, 2008, LEUKEMIA LYMPHOMA, V49, P1616, DOI 10.1080/10428190802105082; Englert C, 1997, CANCER RES, V57, P1429; Grohmann A, 2007, J CELL SCI, V120, P3738, DOI 10.1242/jcs.011320; Huff V, 1998, AM J MED GENET, V79, P260, DOI 10.1002/(SICI)1096-8628(19981002)79:4<260::AID-AJMG6>3.0.CO;2-Q; Jenkins ZA, 2009, NAT GENET, V41, P95, DOI 10.1038/ng.270; Kim MKH, 2009, P NATL ACAD SCI USA, V106, P11154, DOI 10.1073/pnas.0901591106; Koesters R, 1999, CANCER RES, V59, P3880; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Licht JD, 2008, NEOPLASIA, V10, P69, DOI 10.1593/neo.07869; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Morrison DJ, 2008, MOL CANCER RES, V6, P1225, DOI 10.1158/1541-7786.MCR-08-0078; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Owen C, 2008, HAEMATOLOGICA, V93, P947, DOI 10.3324/haematol.12509; Park JS, 2007, DEVELOPMENT, V134, P2533, DOI 10.1242/dev.006155; Perotti D, 2008, ONCOGENE, V27, P4625, DOI 10.1038/onc.2008.93; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Rivera MN, 2009, P NATL ACAD SCI USA, V106, P8338, DOI 10.1073/pnas.0811349106; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Ruteshouser EC, 2008, GENE CHROMOSOME CANC, V47, P461, DOI 10.1002/gcc.20553; Schmidt-Ott KM, 2007, DEVELOPMENT, V134, P3177, DOI 10.1242/dev.006544; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Wegert J, 2009, GENE CHROMOSOME CANC, V48, P1102, DOI 10.1002/gcc.20712; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Yoo NJ, 2009, DIGEST DIS SCI, V54, P1011, DOI 10.1007/s10620-008-0458-9	30	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					832	842		10.1038/onc.2010.452	http://dx.doi.org/10.1038/onc.2010.452			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956941				2022-12-28	WOS:000287444600007
J	Liu, W; Xin, H; Eckert, DT; Brown, JA; Gnarra, JR				Liu, W.; Xin, H.; Eckert, D. T.; Brown, J. A.; Gnarra, J. R.			Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor	ONCOGENE			English	Article						von Hippel-Lindau protein; renal cell carcinoma; anaphase-promoting complex/cyclosome; hypoxia; cell cycle	DNA-DAMAGE; GENE; ARREST; PROLIFERATION; TRANSLATION; EXPRESSION; COMPLEX; PROTEIN; GROWTH; DEGRADATION	Inactivation of von Hippel-Lindau tumor-suppressor protein (pVHL) is associated with von Hippel-Lindau disease, an inherited cancer syndrome, as well as the majority of patients with sporadic clear cell renal cell carcinoma (RCC). Although the involvement of pVHL in oxygen sensing through targeting hypoxia-inducible factor-alpha subunits to ubiquitin-dependent proteolysis has been well documented, less is known about pVHL regulation under both normoxic and hypoxic conditions. We found that pVHL levels decreased in hypoxia and that hypoxia-induced cell cycle arrest is associated with pVHL expression in RCC cells. pVHL levels fluctuate during the cell cycle, paralleling cyclin B1 levels, with decreased levels in mitosis and G1. pVHL contains consensus destruction (D) box sequences, and pVHL associates with Cdh1, an activator of the anaphase-promoting complex/cyclosome (APC/C) E3 ubiquitin ligase. We show that pVHL has a decreased half-life in G1, Cdh1 down-regulation results in increased pVHL expression, whereas Cdh1 overexpression results in decreased pVHL expression. Taken together, these results suggest that pVHL is a novel substrate of APC/C-Cdh1. D box-independent pVHL degradation was also detected, indicating that other ubiquitin ligases are also activated for pVHL degradation. Oncogene (2011) 30, 21-31; doi: 10.1038/onc.2010.395; published online 30 August 2010	[Gnarra, J. R.] Univ Pittsburgh, Sch Med, Dept Urol, Shadyside Med Ctr, Pittsburgh, PA 15232 USA; [Xin, H.; Brown, J. A.; Gnarra, J. R.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA USA; [Gnarra, J. R.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gnarra, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Urol, Shadyside Med Ctr, Suite G37,5200 Ctr Ave, Pittsburgh, PA 15232 USA.	gnarrajr@upmc.edu	Liu, Weijun/D-5291-2017; Liu, Weijun/B-5896-2008	Liu, Weijun/0000-0002-4426-6148; Gnarra, James/0000-0002-6369-3110	Cancer Association of Greater New Orleans; LSUHSC-NO; NIH [CA125930];  [T32DK007774]; NATIONAL CANCER INSTITUTE [R01CA125930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007774] Funding Source: NIH RePORTER	Cancer Association of Greater New Orleans; LSUHSC-NO; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Arthur Haas, for support and discussions, Eric Hittle, Kimberlee Rankin, Mike Meyer, and Miki Katuwal for technical assistance, and the Cancer Association of Greater New Orleans for support to HX. This work was supported by the LSUHSC-NO Dean's Research Fund and NIH grant CA125930. DTE was supported by T32DK007774.	Baker DJ, 2007, CELL MOL LIFE SCI, V64, P589, DOI 10.1007/s00018-007-6443-1; Beroud C, 2000, HUM MUTAT, V15, P86, DOI 10.1002/(SICI)1098-1004(200001)15:1<86::AID-HUMU16>3.0.CO;2-4; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Fahling M, 2009, ACTA PHYSIOL, V195, P205, DOI 10.1111/j.1748-1716.2008.01894.x; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hackenbeck T, 2009, CELL CYCLE, V8, P1386, DOI 10.4161/cc.8.9.8306; Harper Jane V., 2004, V296, P157; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jackson PK, 2004, TRENDS CELL BIOL, V14, P331, DOI 10.1016/j.tcb.2004.05.005; Jung CR, 2006, NAT MED, V12, P809, DOI 10.1038/nm1440; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Listovsky T, 2004, EMBO J, V23, P1619, DOI 10.1038/sj.emboj.7600149; Liu LP, 2004, CANCER BIOL THER, V3, P492, DOI 10.4161/cbt.3.6.1010; Liu WJ, 2008, CARCINOGENESIS, V29, P263, DOI 10.1093/carcin/bgm251; Liu WJ, 2007, MOL CELL BIOL, V27, P2967, DOI 10.1128/MCB.01830-06; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Semenza GL, 2009, BLOOD, V114, P2015, DOI 10.1182/blood-2009-05-189985; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stickle NH, 2005, MUTAT RES-FUND MOL M, V578, P23, DOI 10.1016/j.mrfmmm.2005.02.016; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Warnecke C, 2008, EXP CELL RES, V314, P2016, DOI 10.1016/j.yexcr.2008.03.003; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699	43	22	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					21	31		10.1038/onc.2010.395	http://dx.doi.org/10.1038/onc.2010.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802534	Green Accepted			2022-12-28	WOS:000285959300002
J	Choi, HH; Gully, C; Su, CH; Velazquez-Torres, G; Chou, PC; Tseng, C; Zhao, R; Phan, L; Shaiken, T; Chen, J; Yeung, SC; Lee, MH				Choi, H. H.; Gully, C.; Su, C-H; Velazquez-Torres, G.; Chou, P-C; Tseng, C.; Zhao, R.; Phan, L.; Shaiken, T.; Chen, J.; Yeung, S. C.; Lee, M-H			COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3 sigma	ONCOGENE			English	Article						14-3-3 sigma; CSN6; COP1; ubiquitination	REGULATES C-JUN; DNA-DAMAGE; NEGATIVE REGULATOR; LIGHT CONTROL; TUMOR-GROWTH; ARABIDOPSIS; PROTEINS; BREAST; CANCER; P53	14-3-3 sigma, a gene upregulated by p53 in response to DNA damage, exists as part of a positive-feedback loop, which activates p53 and is a human cancer epithelial marker downregulated in various cancer types. 14-3-3 sigma levels are critical for maintaining p53 activity in response to DNA damage and regulating signal mediators such as Akt. In this study, we identify mammalian constitutive photomorphogenic 1 (COP1) as a novel E3 ubiquitin ligase for targeting 14-3-3 sigma through proteasomal degradation. We show for the first time that COP9 signalosome subunit 6 (CSN6) associates with COP1 and is involved in 14-3-3 sigma ubiquitin-mediated degradation. Mechanistic studies show that CSN6 expression leads to stabilization of COP1 through reducing COP1 self-ubiquitination and decelerating COP1's turnover rate. We also show that CSN6-mediated 14-3-3 sigma ubiquitination is compromised when COP1 is knocked down. Thus, CSN6-mediates 14-3-3 sigma ubiquitination through enhancing COP1 stability. Subsequently, we show that CSN6 causes 14-3-3 sigma downregulation, thereby activating Akt and promoting cell survival. Also, CSN6 overexpression leads to increased cell growth, transformation and promotes tumorigenicity. Significantly, 14-3-3 sigma expression can correct the abnormalities mediated by CSN6 expression. These data suggest that the CSN6-COP1 axis is involved in 14-3-3 sigma degradation, and that deregulation of this axis will promote cell growth and tumorigenicity. Oncogene (2011) 30, 4791-4801; doi:10.1038/onc.2011.192; published online 30 May 2011	[Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, Houston, TX 77030 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; [Choi, H. H.; Gully, C.; Su, C-H; Velazquez-Torres, G.; Chou, P-C; Tseng, C.; Zhao, R.; Phan, L.; Shaiken, T.; Chen, J.; Lee, M-H] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Choi, H. H.; Velazquez-Torres, G.; Chou, P-C; Tseng, C.; Lee, M-H] Univ Texas Grad Sch Biomed Sci Houston, Program Canc Biol, Houston, TX USA; [Gully, C.; Su, C-H; Lee, M-H] Univ Texas Grad Sch Biomed Sci Houston, Program Genes & Dev, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yeung, SC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, 1515 Holcombe Blvd, Houston, TX 77030 USA.	syeung@mdanderson.org; mhlee@mdanderson.org	Yeung, Sai-Ching/AAI-6178-2021; Yeung, Sai-Ching/AAP-8079-2020	Yeung, Sai-Ching/0000-0001-5170-0822; Lee, Mong-Hong/0000-0001-8675-8215; Shaiken (Shaikenov), Tattym/0000-0002-8808-6229	National Institutes of Health (NIH) [R01CA089266]; Directed Medical Research Programs [DOD SIDA BC062166]; Susan G Komen Breast Cancer Foundation [KG081048]; cancer prevention fellowship [R25T CA57730]; NIH [CA16672]; NATIONAL CANCER INSTITUTE [R56CA089266, R01CA089266, R25CA057730, P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Directed Medical Research Programs; Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); cancer prevention fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (NIH) (R01CA089266), Directed Medical Research Programs (DOD SIDA BC062166 to SJY and MHL) and Susan G Komen Breast Cancer Foundation (KG081048). This research was supported in part, by a cancer prevention fellowship for GVT (R25T CA57730). The University of Texas MD Anderson Cancer Center is supported by NIH core Grant CA16672.	Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gusmaroli G, 2007, PLANT CELL, V19, P564, DOI 10.1105/tpc.106.047571; Hardtke CS, 2000, EMBO J, V19, P4997, DOI 10.1093/emboj/19.18.4997; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Horie-Inoue K, 2006, SEMIN CANCER BIOL, V16, P235, DOI 10.1016/j.semcancer.2006.03.006; Karniol B, 2000, CURR OPIN PLANT BIOL, V3, P387, DOI 10.1016/S1369-5266(00)00101-1; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li L, 2003, TRENDS CELL BIOL, V13, P507, DOI 10.1016/j.tcb.2003.08.002; Li ZM, 2009, AM J TRANSL RES, V1, P326; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Peng ZH, 2001, PLANT CELL, V13, P2393, DOI 10.1105/tpc.13.11.2393; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Richardson KS, 2005, MOL CANCER RES, V3, P645, DOI 10.1158/1541-7786.MCR-05-0233; Savio MG, 2008, ONCOGENE, V27, P2401, DOI 10.1038/sj.onc.1210892; Su CH, 2011, CANCER RES, V71, P884, DOI 10.1158/0008-5472.CAN-10-2518; Su CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-243; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wang HY, 2001, SCIENCE, V294, P154, DOI 10.1126/science.1063630; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HY, 2007, ONCOGENE, V26, P7355, DOI 10.1038/sj.onc.1210540; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007; Yi CL, 2005, CANCER RES, V65, P5835, DOI 10.1158/0008-5472.CAN-05-0423; Zhao RY, 2011, J CLIN INVEST, V121, P851, DOI 10.1172/JCI44111; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	45	46	50	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	48					4791	4801		10.1038/onc.2011.192	http://dx.doi.org/10.1038/onc.2011.192			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625211	Green Accepted			2022-12-28	WOS:000298134700003
J	Smit, MA; Peeper, DS				Smit, M. A.; Peeper, D. S.			Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis	ONCOGENE			English	Article						Zeb1; TrkB; EMT; anoikis; metastasis	NEUROTROPHIC RECEPTOR TRKB; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; CANCER-CELLS; TUMOR PROGRESSION; MIR-200 FAMILY; PROMOTES METASTASIS; GENE-EXPRESSION; REPRESSORS ZEB1; BREAST-CANCER	Anoikis (detachment-induced apoptosis) prevents the survival of cells at inappropriate sites of the body and can therefore act as a barrier to metastasis. In a function-based genome-wide screen, we have previously identified the neurotrophic tyrosine kinase receptor TrkB as a potent suppressor of anoikis. Consistently, activated TrkB oncogenically transforms non-malignant epithelial cells and causes them to invade and produce metastatic tumors in vivo. Overexpression of activated TrkB also results in morphological transformation, resembling epithelial-mesenchymal transition (EMT). E-cadherin, an important EMT regulator, and two E-cadherin repressors, Twist and Snail, are critical for these TrkB functions. As Snail has been shown to induce Zeb1, another E-cadherin repressor, we hypothesized that Zeb1 could be a TrkB target, too. We show here that Zeb1 is required for TrkB-induced EMT in epithelial cells, as RNAi-mediated knockdown of Zeb1 reverted the morphological changes induced by TrkB. Furthermore, Zeb1 is involved in TrkB-induced anoikis resistance, migration and invasion. In vivo, knockdown of Zeb1 strongly reduced TrkB-induced metastasis. Finally, epistasis experiments showed that Zeb1 acts downstream of Twist and Snail. We conclude that Zeb1 is required for several TrkB-induced effects in vitro and in vivo, including metastasis. Oncogene (2011) 30, 3735-3744; doi:10.1038/onc.2011.96; published online 11 April 2011	[Smit, M. A.; Peeper, D. S.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121,Room P1-011, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020		Dutch Cancer Society; European Union	Dutch Cancer Society(KWF Kankerbestrijding); European Union(European Commission)	We thank M Voetel, S Greven, H Grimminck and all other animal caretakers for their excellent technical help with the in vivo experiments, JY Song and the animal pathology department for help with the pathological analysis and performing IHC stainings, L Brocks and L Oomen for help with the confocal images, F Van Diepen and A Pfauth for fluorescence-activated cell sorting, M Heimerikx, M Nieuwland, J de Ronde, D Sie, A Velds, I de Rink and R Kerkhoven for performing the microarray analysis and ML Yurda for statistical analysis. We thank Dr Nakshatri for providing the Zeb1 plasmid, R Weinberg for the Twist plasmid, A Munoz for the Snail plasmid and K Becker for the Snail antibody. We thank all members of the Peeper laboratory for their valuable input and T Geiger for useful discussions and help with the microarray experiments. This work was supported by grants from MAS and DSP from the Dutch Cancer Society (KWF) and a European Union FP6 grant.	Adachi Y, 2009, FEBS LETT, V583, P430, DOI 10.1016/j.febslet.2008.12.042; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Aigner K, 2007, FEBS LETT, V581, P1617, DOI 10.1016/j.febslet.2007.03.026; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bendoraite A, 2010, GYNECOL ONCOL, V116, P117, DOI 10.1016/j.ygyno.2009.08.009; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Desmet CJ, 2006, CELL MOL LIFE SCI, V63, P755, DOI 10.1007/s00018-005-5490-8; Dionne CA, 1998, CLIN CANCER RES, V4, P1887; Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Geiger TR, 2005, CANCER RES, V65, P7033, DOI 10.1158/0008-5472.CAN-05-0709; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Singh M, 2008, MODERN PATHOL, V21, P912, DOI 10.1038/modpathol.2008.82; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Spoelstra NS, 2006, CANCER RES, V66, P3893, DOI 10.1158/0008-5472.CAN-05-2881; Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yin T, 2007, J SURG RES, V141, P196, DOI 10.1016/j.jss.2006.09.027	57	67	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3735	3744		10.1038/onc.2011.96	http://dx.doi.org/10.1038/onc.2011.96			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21478908				2022-12-28	WOS:000294481400001
J	Wu, Z; Zheng, S; Li, Z; Tan, J; Yu, Q				Wu, Z.; Zheng, S.; Li, Z.; Tan, J.; Yu, Q.			E2F1 suppresses Wnt/beta-catenin activity through transactivation of beta-catenin interacting protein ICAT	ONCOGENE			English	Article						E2F1; Wnt/beta-catenin; ICAT; cancer cells	WNT; PATHWAY; TRANSCRIPTION; TARGET; APOPTOSIS; CANCER; LIFE	Deregulation of the pRb/E2F or Wnt/beta-catenin pathway occurs frequently in human cancers, which is often associated with inappropriate cell proliferation. Although the oncogenic roles of pRb/E2F1 and Wnt/beta-catenin pathways have been well studied, the functional interaction between the two pathways has only recently been characterized. In particular, E2F1 has been recently reported to negatively regulate Wnt/beta-catenin activity in human colorectal cancers, though the mechanism underlying this regulation is not fully understood. Here we provide evidence that beta-catenin interacting protein 1 (CTNNBIP1), also known as ICAT (inhibitor of beta-catenin and TCF4), functions as a crucial node to mediate the cross talk between E2F1 and beta-catenin signaling. We show that ICAT is a direct transcriptional target of E2F1, and that activation of ICAT by E2F1 is required for E2F1 to inhibit beta-catenin activity. This study provides a mechanistic insight into the antagonistic interaction between E2F1 and beta-catenin signaling. Oncogene (2011) 30, 3979-3984; doi:10.1038/onc.2011.129; published online 2 May 2011	[Wu, Z.; Zheng, S.; Li, Z.; Tan, J.; Yu, Q.] ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, Singapore 138672, Singapore; [Yu, Q.] Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore	Yu, Q (corresponding author), ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, Genome 02-01,60 Biopolis St, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg		Yu, Qiang/0000-0003-2132-8278	Agency for Science, Technology and Research of Singapore	Agency for Science, Technology and Research of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Kristian Helin (European Institute of Oncology, Milan) for the ER-E2F1 plasmids and Dr Claudio Brancolini for providing the IMR90/E1A cells. This work was supported by the Agency for Science, Technology and Research of Singapore.	Bernards R, 2008, NATURE, V455, P479, DOI 10.1038/455479a; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bramis J, 2004, ANTICANCER RES, V24, P3041; Cadigan KM, 2008, CURR BIOL, V18, pR943, DOI 10.1016/j.cub.2008.08.017; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Kim SM, 2009, EXP CELL RES, V315, P943, DOI 10.1016/j.yexcr.2009.01.013; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Tago K, 2000, GENE DEV, V14, P1741; Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Xie W, 2009, J CELL MOL MED, V13, P1719, DOI 10.1111/j.1582-4934.2008.00423.x; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102	23	32	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	37					3979	3984		10.1038/onc.2011.129	http://dx.doi.org/10.1038/onc.2011.129			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21532622				2022-12-28	WOS:000294890400007
J	Cheung, HH; Davis, AJ; Lee, TL; Pang, AL; Nagrani, S; Rennert, OM; Chan, WY				Cheung, H-H; Davis, A. J.; Lee, T-L; Pang, A. L.; Nagrani, S.; Rennert, O. M.; Chan, W-Y			Methylation of an intronic region regulates miR-199a in testicular tumor malignancy	ONCOGENE			English	Article						intronic methylation; miR-199a; testicular tumor; PODXL; malignancy	GERM-CELL TUMORS; OVARIAN-CANCER CELLS; DNA METHYLATION; MICRORNA EXPRESSION; PROSTATE-CANCER; BLADDER-CANCER; IDENTIFICATION; PODOCALYXIN; METASTASIS; CARCINOMA	In the testicular cancer cell line, NT2, we previously demonstrated that differentially methylated regions were located in introns or intergenic regions, and postulated these might regulate non-coding RNAs. Three microRNAs and three small nucleolar RNAs were differentially methylated; one, miR-199a, was associated with the progression and prognosis of gastric and ovarian cancers. In this report we document, by epigenomic profiling of testicular tissue, that miR-199a is transcribed as antisense of dynamin 3 (chromosome 1q24.3), and hypermethylation of this region is correlated with miR-199a-5p/3p repression and tumor malignancy. Re-expression of miR-199a in testicular cancer cells led to suppression of cell growth, cancer migration, invasion and metastasis. The miR-199a-5p, one of two mature miRNA species derived from miR-199a, is associated with tumor malignancy. We further identified the embryonal carcinoma antigen podocalyxin-like protein 1 (PODXL), an anti-adhesive protein expressed in aggressive tumors, as a target of miR-199a-5p. We demonstrated PODXL is overexpressed in malignant testicular tumor, and cellular depletion of PODXL resulted in suppression of cancer invasion. The inverse relationship between PODXL and miR-199a-5p expression suggests PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy. Oncogene (2011) 30, 3404-3415; doi:10.1038/onc.2011.60; published online 7 March 2011	[Cheung, H-H; Chan, W-Y] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Shatin, Hong Kong, Peoples R China; [Cheung, H-H; Davis, A. J.; Lee, T-L; Pang, A. L.; Nagrani, S.; Rennert, O. M.; Chan, W-Y] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Clin & Dev Genom, NIH, Bethesda, MD USA	Chinese University of Hong Kong; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chan, WY (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Room 518B,Choh Ming Li Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	chanwy@cuhk.edu.hk	Lee, Tin-Lap/A-7853-2009; Chan, Wai Yee/R-7442-2018; Cheung, Hoi-Hung/AAE-2670-2020; Rennert, owen/AAI-7374-2020; Lee, Tin-Lap/W-6595-2019; Cheung, Hoi-Hung/G-7605-2011	Lee, Tin-Lap/0000-0002-6654-0988; Chan, Wai Yee/0000-0002-9714-0936; Cheung, Hoi-Hung/0000-0001-7178-9289; Lee, Tin-Lap/0000-0002-6654-0988; Davis, Andrew/0000-0001-9556-4498	National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development; Chinese University of Hong Kong; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008817, ZIAHD008820] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Chinese University of Hong Kong(Chinese University of Hong Kong); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Dr Yun-Fai Chris Lau for providing the 833K cell line. This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Chinese University of Hong Kong.	Aleman A, 2008, CLIN CANCER RES, V14, P8236, DOI 10.1158/1078-0432.CCR-08-0778; ANDREWS PW, 1984, LAB INVEST, V50, P147; Casey G, 2006, HUM MOL GENET, V15, P735, DOI 10.1093/hmg/ddi487; Chakrabarty A, 2007, P NATL ACAD SCI USA, V104, P15144, DOI 10.1073/pnas.0705917104; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505; Cheung HH, 2009, BIRTH DEFECTS RES C, V87, P335, DOI 10.1002/bdrc.20163; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Friedman LM, 2009, P NATL ACAD SCI USA, V106, P7915, DOI 10.1073/pnas.0812446106; Godwin JG, 2010, P NATL ACAD SCI USA, V107, P14339, DOI 10.1073/pnas.0912701107; Hayatsu N, 2008, BIOCHEM BIOPH RES CO, V374, P394, DOI 10.1016/j.bbrc.2008.07.049; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200; Koch LK, 2008, HUM PATHOL, V39, P1597, DOI 10.1016/j.humpath.2008.03.008; Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Li YM, 2007, HUM PATHOL, V38, P1470, DOI 10.1016/j.humpath.2007.03.011; Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Netto GJ, 2008, MODERN PATHOL, V21, P1337, DOI 10.1038/modpathol.2008.127; Pang ALY, 2009, BIOL REPROD, V81, P302, DOI 10.1095/biolreprod.108.073221; Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908; Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Santhakumar D, 2010, P NATL ACAD SCI USA, V107, P13830, DOI 10.1073/pnas.1008861107; Schopperle WM, 2003, BIOCHEM BIOPH RES CO, V300, P285; Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; Somasiri A, 2004, CANCER RES, V64, P5068, DOI 10.1158/0008-5472.CAN-04-0240; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Tsai ZY, 2010, J CELL BIOCHEM, V109, P93, DOI 10.1002/jcb.22385; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Watts GS, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-47; Worley LA, 2008, MELANOMA RES, V18, P184, DOI 10.1097/CMR.0b013e3282feeac6; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	45	109	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3404	3415		10.1038/onc.2011.60	http://dx.doi.org/10.1038/onc.2011.60			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21383689	Green Accepted			2022-12-28	WOS:000293508100002
J	Gibert, B; Hadchity, E; Czekalla, A; Aloy, MT; Colas, P; Rodriguez-Lafrasse, C; Arrigo, AP; Diaz-Latoud, C				Gibert, B.; Hadchity, E.; Czekalla, A.; Aloy, M-T; Colas, P.; Rodriguez-Lafrasse, C.; Arrigo, A-P; Diaz-Latoud, C.			Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers	ONCOGENE			English	Article						Hsp27; HspB1; peptide aptamers; proliferation; apoptosis; therapeutic target	INDUCED APOPTOSIS; TUMOR-CELLS; AKT ACTIVATION; CYTOCHROME-C; IN-VITRO; HSP27; CANCER; STRESS; ALPHA; OLIGOMERIZATION	Human heat shock protein 27 (Hsp27, HspB1) is an antiapoptotic protein characterized for its tumorigenic and metastatic properties, and now referenced as a major therapeutic target in many types of cancer. Hsp27 biochemical properties rely on a structural oligomeric and dynamic organization. Downregulation by small interfering RNA or inhibition with dominant-negative mutant have proven their efficiency to counteract the antiapoptotic and protective properties of Hsp27. In this study, we report the isolation and characterization of Hsp27-targeted molecules interfering with its structural organization. Using the peptide aptamer (PA) strategy, we isolated PAs that specifically interact with Hsp27 and not with the other members of the small heat shock protein family. In mammalian cell cultures, PAs expression perturbed the dimerization and oligomerization of Hsp27, and acted as negative regulators of the antiapoptotic and cytoprotective activities of this protein. Further studies analyzing SQ20B cell xenografts in immunocompromised mice showed that PAs strongly reduced tumor development through cell cycle arrest. Our data suggest that PAs could provide a potential tool to develop strategies for the discovery of Hsp27 chemical inhibitors. Oncogene (2011) 30, 3672-3681; doi:10.1038/onc.2011.73;published online 21 March 2011	[Gibert, B.; Czekalla, A.; Arrigo, A-P; Diaz-Latoud, C.] Univ Lyon 1, Ctr Genet Mol & Cellulaire, CNRS, UMR5534, F-69365 Lyon, France; [Hadchity, E.; Aloy, M-T; Rodriguez-Lafrasse, C.] Univ Lyon 1, Lab Radiobiol Cellulaire & Mol, EA 3738, Fac Med Lyon Sud, Oullins, France; [Colas, P.] CNRS, Biol Stn, USR 3151, Roscoff, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Diaz-Latoud, C (corresponding author), Univ Lyon 1, Ctr Genet Mol & Cellulaire, CNRS, UMR5534, 43,Bd 11 Novembre 1918, F-69365 Lyon, France.	chantal.diaz@univ-lyon1.fr	Rodriguez-Lafrasse, Claire/G-7741-2018	Colas, Pierre/0000-0001-7436-3718; GIBERT, Benjamin/0000-0002-5295-3124	Comite du Rhone of la Ligue Contre le Cancer; Region Rhone-Alpes and Retina France; La Region Rhone-Alpes	Comite du Rhone of la Ligue Contre le Cancer; Region Rhone-Alpes and Retina France(Region Auvergne-Rhone-Alpes); La Region Rhone-Alpes(Region Auvergne-Rhone-Alpes)	We wish to thank D Guillet for excellent technical assistance and Marc Bickle for helpful discussions. This work was supported by a research grant from the Comite du Rhone of la Ligue Contre le Cancer and the Region Rhone-Alpes and Retina France for APA. GB was supported by a PhD training grant from the La Region Rhone-Alpes.	Aloy MT, 2008, INT J RADIAT ONCOL, V70, P543, DOI 10.1016/j.ijrobp.2007.08.061; Arrigo AP, 2007, FEBS LETT, V581, P3665, DOI 10.1016/j.febslet.2007.04.033; Arrigo AP, 2005, ANTIOXID REDOX SIGN, V7, P414, DOI 10.1089/ars.2005.7.414; Baines IC, 2006, DRUG DISCOV TODAY, V11, P334, DOI 10.1016/j.drudis.2006.02.007; Bickle MBT, 2006, NAT PROTOC, V1, P1066, DOI 10.1038/nprot.2006.32; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Cervantes-Gomez F, 2009, CANCER RES, V69, P3947, DOI 10.1158/0008-5472.CAN-08-4406; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Chattopadhyay A, 2006, ONCOGENE, V25, P2223, DOI 10.1038/sj.onc.1209252; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Diaz-Latoud C, 2005, ANTIOXID REDOX SIGN, V7, P436, DOI 10.1089/ars.2005.7.436; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Hansen RK, 1999, BREAST CANCER RES TR, V56, P187; Javouhey E, 2008, VIROLOGY, V376, P31, DOI 10.1016/j.virol.2008.02.031; Kim EH, 2007, CANCER RES, V67, P6333, DOI 10.1158/0008-5472.CAN-06-4344; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; Matsui Y, 2009, MOL CANCER THER, V8, P2402, DOI 10.1158/1535-7163.MCT-09-0148; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Nouvion AL, 2007, ONCOGENE, V26, P701, DOI 10.1038/sj.onc.1209832; O'Callaghan-Sunol C, 2007, CANCER RES, V67, P11779, DOI 10.1158/0008-5472.CAN-07-2441; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Parcellier A, 2006, FASEB J, V20, P1179, DOI 10.1096/fj.05-4184fje; Paul C, 2010, EXP CELL RES, V316, P1535, DOI 10.1016/j.yexcr.2010.03.006; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Zhang Y, 2007, CLIN CANCER RES, V13, P2855, DOI 10.1158/1078-0432.CCR-06-2090	35	67	69	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3672	3681		10.1038/onc.2011.73	http://dx.doi.org/10.1038/onc.2011.73			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423207				2022-12-28	WOS:000294244500003
J	Neumann, M; Klar, S; Wilisch-Neumann, A; Hollenbach, E; Kavuri, S; Leverkus, M; Kandolf, R; Brunner-Weinzierl, MC; Klingel, K				Neumann, M.; Klar, S.; Wilisch-Neumann, A.; Hollenbach, E.; Kavuri, S.; Leverkus, M.; Kandolf, R.; Brunner-Weinzierl, M. C.; Klingel, K.			Glycogen synthase kinase-3 beta is a crucial mediator of signal-induced RelB degradation	ONCOGENE			English	Article						RelB; NF-kappa B; GSK-3 beta; proteasomal degradation	NF-KAPPA-B; LIVER DEGENERATION; MICE LACKING; KINASE; PHOSPHORYLATION; GLYCOGEN-SYNTHASE-KINASE-3-BETA; TRANSCRIPTION; REQUIREMENT; INHIBITION; GSK-3-BETA	The immediate early transcription factor nuclear factor (I kappa Bs) kappa B (NF-kappa B) is crucially involved in the regulation of numerous physiological or pathophysiological processes such as inflammation and tumourigenesis. Therefore, the control of NF-kappa B activity, which is mainly regulated by signal-induced degradation of cytoplasmic inhibitors of NF-kappa B (I kappa Bs), is of high relevance. One known alternative pathway of NF-kappa B regulation is the stimulus-induced proteasomal degradation of RelB, a component of the NF-kappa B dimer. Here, we identified the serine/threonine protein kinase glycogen synthase kinase-3 beta (GSK-3 beta) as a critical signalling component leading to RelB degradation. In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycinand CD3/CD28-induced RelB degradation were impaired by a GSK-3 beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3 beta mutant and by small-interfering RNA-mediated silencing of GSK-3 beta expression. Furthermore, a physical interaction between RelB and GSK-3 beta was shown by co-immunoprecipitation, which was already notable in unstimulated cells. Most importantly, as demonstrated by in vitro kinase assays, human RelB is inducibly phosphorylated by GSK-3 beta, indicating a direct substrate-enzyme relationship. The serine residue 552 is a target of GSK-3 beta-mediated phosphorylation in vitro and in vivo. We conclude that GSK-3 beta is a crucial regulator of RelB degradation, stressing the relevant linkage between the NF-kappa B system and GSK-3 beta. Oncogene (2011) 30, 2485-2492; doi:10.1038/onc.2010.580; published online 10 January 2011	[Neumann, M.; Kandolf, R.; Klingel, K.] Univ Tubingen, Univ Hosp, Inst Pathol, Dept Mol Pathol, D-72076 Tubingen, Germany; [Klar, S.] Robert Koch Inst, D-1000 Berlin, Germany; [Wilisch-Neumann, A.] Otto von Guericke Univ, Inst Neuropathol, Magdeburg, Germany; [Hollenbach, E.] Univ Leipzig, Univ Hosp, Intens Care Unit, Leipzig, Germany; [Kavuri, S.; Leverkus, M.] Univ Heidelberg, Med Fac Mannheim, Dept Dermatol Venereol & Allergol, Mol Dermatol Sect, Heidelberg, Germany; [Brunner-Weinzierl, M. C.] Otto von Guericke Univ, Dept Pediat, Magdeburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Robert Koch Institute; Otto von Guericke University; Leipzig University; Ruprecht Karls University Heidelberg; Otto von Guericke University	Neumann, M (corresponding author), Univ Tubingen, Univ Hosp, Inst Pathol, Dept Mol Pathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.	manfred.neumann@med.uni-tuebingen.de	Brunner-Weinzierl, Monika/AAB-8813-2019	Brunner-Weinzierl, Monika/0000-0002-6838-3568; Klar, Stefanie/0000-0001-5852-5692	Deutsche Forschungsgemeinschaft [NE608/3-2, LE953/5-1]; DFG [SFB-TR19]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	This work was supported by grants from the Deutsche Forschungsgemeinschaft (NE608/3-2 to MN; LE953/5-1 to ML) and by DFG grant SFB-TR19 (to KK and RK). We thank Sandra Bundschuh, Beatrix Kramer and Konstantin Klein for their excellent technical assistance.	Avraham E, 2005, J BIOL CHEM, V280, P42877, DOI 10.1074/jbc.M505608200; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Billadeau DD, 2007, PANCREATOLOGY, V7, P398, DOI 10.1159/000108955; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Dar AA, 2009, ONCOGENE, V28, P866, DOI 10.1038/onc.2008.434; DEGROOT RP, 1993, ONCOGENE, V8, P841; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Marienfeld R, 2003, J BIOL CHEM, V278, P19852, DOI 10.1074/jbc.M301945200; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Vincent T, 2008, ONCOGENE, V27, P5254, DOI 10.1038/onc.2008.152; Yuan J, 2005, CELL DEATH DIFFER, V12, P1097, DOI 10.1038/sj.cdd.4401652	28	18	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	21					2485	2492		10.1038/onc.2010.580	http://dx.doi.org/10.1038/onc.2010.580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21217772				2022-12-28	WOS:000291008000010
J	Kotake, Y; Nakagawa, T; Kitagawa, K; Suzuki, S; Liu, N; Kitagawa, M; Xiong, Y				Kotake, Y.; Nakagawa, T.; Kitagawa, K.; Suzuki, S.; Liu, N.; Kitagawa, M.; Xiong, Y.			Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene	ONCOGENE			English	Article						long non-coding RNA; ANRIL; polycomb; p15(INK4B); p16(INK4A); ARF	GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; INK4A LOCUS; P16(INK4A); CHROMATIN; PROTEINS; SUSCEPTIBILITY; EXPRESSION; FAMILY; BMI-1	A 42 kb region on human chromosome 9p21 encodes for three distinct tumor suppressors, p16(INK4A), p14(ARF) and p15(INK4B), and is altered in an estimated 30-40% of human tumors. The expression of the INK4A-ARF-INK4B gene cluster is silenced by polycomb during normal cell growth and is activated by oncogenic insults and during aging. How the polycomb is recruited to repress this gene cluster is unclear. Here, we show that expression of oncogenic Ras, which stimulates the expression of p15(INK4B) and p(16INK4A), but not p14ARF, inhibits the expression of ANRIL (antisense non-coding RNA in the INK4 locus), a 3.8 kblong non-coding RNA expressed in the opposite direction from INK4A-ARF-INK4B. We show that the p15(INK4B) locus is bound by SUZ12, a component of polycomb repression complex 2 (PRC2), and is H3K27-trimethylated. Notably, depletion of ANRIL disrupts the SUZ12 binding to the p15(INK4B) locus, increases the expression of p15(INK4B), but not p16(INK4A) or p14(ARF), and inhibits cellular proliferation. Finally, RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15INK4B locus. Oncogene (2011) 30, 1956-1962; doi: 10.1038/onc.2010.568; published online 13 December 2010	[Kitagawa, M.] Hamamatsu Univ Sch Med, Dept Biochem 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Kotake, Y.; Nakagawa, T.; Xiong, Y.] Univ N Carolina, Program Mol Biol & Biotechnol, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Hamamatsu University School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Kitagawa, M (corresponding author), Hamamatsu Univ Sch Med, Dept Biochem 1, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kitamasa@hama-med.ac.jp; yxiong@email.unc.edu			Ministry of Education, Science, Sports, Culture, and Technology of Japan; NIH [CA68377]; NATIONAL CANCER INSTITUTE [R01CA068377] Funding Source: NIH RePORTER	Ministry of Education, Science, Sports, Culture, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Howard Chang for the insightful discussion during this study, Yaxue Zeng and Matt Smith for helpful discussion and reading the manuscript, Mika Matsumoto, Michiyo Hakamata and Harumi Shiratori for technical assistance. This study is supported by grants from the Ministry of Education, Science, Sports, Culture, and Technology of Japan (YK, MK, SS and KK) and NIH grant CA68377 (YX).	Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Broadbent HM, 2008, HUM MOL GENET, V17, P806, DOI 10.1093/hmg/ddm352; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Kotake Y, 2009, CANCER RES, V69, P1809, DOI 10.1158/0008-5472.CAN-08-2739; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802; Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Terranova R, 2008, DEV CELL, V15, P668, DOI 10.1016/j.devcel.2008.08.015; Visel A, 2010, NATURE, V464, P409, DOI 10.1038/nature08801; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	35	760	820	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1956	1962		10.1038/onc.2010.568	http://dx.doi.org/10.1038/onc.2010.568			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151178	Green Accepted, Green Published			2022-12-28	WOS:000289777700011
J	Lees, JG; Bach, CTT; Bradbury, P; Paul, A; Gunning, PW; O'Neill, GM				Lees, J. G.; Bach, C. T. T.; Bradbury, P.; Paul, A.; Gunning, P. W.; O'Neill, G. M.			The actin-associating protein Tm5NM1 blocks mesenchymal motility without transition to amoeboid motility	ONCOGENE			English	Article						tropomyosin; amoeboid; mesenchymal; actin cytoskeleton; metastasis; adhesion	TUMOR-CELL INVASION; TROPOMYOSIN ISOFORM; CYTOSKELETON; MIGRATION; CANCER; SRC; PLASTICITY; ADHESIONS; DYNAMICS; PROMOTES	Cell migration is an integral component of metastatic disease. The ability of cells to transit between mesenchymal and amoeboid modes of migration has complicated the development of successful therapies designed to target cell migration as a means of inhibiting metastasis. Therefore, investigations of the mechanisms that regulate cell migration and render cells stationary are necessary. Tropomyosins are actin-associating proteins that regulate the activity of several effectors of actin filament dynamics. Previously, we have shown that the tropomyosin isoform Tm5NM1 stabilizes actin filaments and inhibits cell migration in a two-dimensional culture system. Here, we show that Tm5NM1 inhibits the mesenchymal migration of multiple cell lines in an isoform-specific manner. Tm5NM1 stimulates the downregulation of Src kinase activity and a rounded or elliptical morphology in three-dimensional collagen gels, and cells have dramatically reduced capacity to form pseudopodia. Importantly, we find that Tm5NM1 inhibits both the mesenchymal to amoeboid and amoeboid to mesenchymal transitions. Collectively, our data suggest that mimicking the action of Tm5NM1 overexpression represents an approach for effectively inhibiting the mesenchymal mode of migration. Oncogene (2011) 30, 1241-1251; doi:10.1038/onc.2010.516; published online 15 November 2010	[Lees, J. G.; Bach, C. T. T.; Bradbury, P.; Paul, A.; O'Neill, G. M.] Childrens Hosp, Childrens Canc Res Unit, Kids Res Inst, Westmead, NSW 2145, Australia; [Bach, C. T. T.; O'Neill, G. M.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Gunning, P. W.] Univ New S Wales, Sch Med Sci, Dept Pharmacol, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of New South Wales Sydney	O'Neill, GM (corresponding author), Childrens Hosp, Childrens Canc Res Unit, Kids Res Inst, Locked Bag 4001, Westmead, NSW 2145, Australia.	geraldio@chw.edu.au	O'Neill, Geraldine/F-3112-2014; Bradbury, Peta/A-4864-2017; Gunning, Peter W/E-9058-2010	Bradbury, Peta/0000-0001-6360-9591; Gunning, Peter/0000-0003-0833-3128; Lees, Justin/0000-0002-0874-2856; O'Neill, Geraldine/0000-0001-9997-8794	National Health and Medical Research Council (NHMRC) [512251]; Ramaciotti Establishment grant; NSW Cancer Institute; Oncology Children's Foundation	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Ramaciotti Establishment grant; NSW Cancer Institute; Oncology Children's Foundation	This study was supported by National Health and Medical Research Council (NHMRC) grant 512251 (GO and PG). PG is a Principal Research Fellow of the NHMRC, JL is the recipient of a Ramaciotti Establishment grant, CB is the recipient of an NHMRC post-graduate scholarship and a NSW Cancer Institute Scholar award, and AP holds an Oncology Children's Foundation-C4 fellowship. We thank Rose Boutros for critical review of the paper and also gratefully acknowledge the generous support of Kaise Stephan and Channel Crossing for Life.	Bach CTT, 2009, MOL CELL BIOL, V29, P1506, DOI 10.1128/MCB.00857-08; Bargon SD, 2005, BBA-MOL CELL RES, V1746, P143, DOI 10.1016/j.bbamcr.2005.10.008; Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; Bryce NS, 2003, MOL BIOL CELL, V14, P1002, DOI 10.1091/mbc.E02-04-0244; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Creed SJ, 2008, EUR J CELL BIOL, V87, P709, DOI 10.1016/j.ejcb.2008.03.004; DesMarais V, 2002, J CELL SCI, V115, P4649, DOI 10.1242/jcs.00147; Drappatz J, 2009, EXPERT REV NEUROTHER, V9, P519, DOI [10.1586/ern.09.10, 10.1586/ERN.09.10]; Eichinger L, 1999, MICROSC RES TECHNIQ, V47, P124, DOI 10.1002/(SICI)1097-0029(19991015)47:2<124::AID-JEMT5>3.0.CO;2-8; Fath T, 2010, EUR J CELL BIOL, V89, P489, DOI 10.1016/j.ejcb.2009.11.028; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gunning P, 2008, PHYSIOL REV, V88, P1, DOI 10.1152/physrev.00001.2007; Gunning PW, 2005, TRENDS CELL BIOL, V15, P333, DOI 10.1016/j.tcb.2005.04.007; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Hillberg L, 2006, EUR J CELL BIOL, V85, P399, DOI 10.1016/j.ejcb.2005.12.005; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KITZING TM, 2010, ONCOGENE, V1, P1; Kruger A, 2001, CANCER RES, V61, P1272; O'Neill GM, 2009, CELL ADHES MIGR, V3, P355, DOI 10.4161/cam.3.4.9468; Percival JM, 2004, MOL BIOL CELL, V15, P268, DOI 10.1091/mbc.e03-03-0176; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Schevzov G, 2005, J HISTOCHEM CYTOCHEM, V53, P557, DOI 10.1369/jhc.4A6505.2005; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yamazaki D, 2009, ONCOGENE, V28, P1570, DOI 10.1038/onc.2009.2; Zheng Q, 2008, INT J CANCER, V122, P78, DOI 10.1002/ijc.23025	36	20	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1241	1251		10.1038/onc.2010.516	http://dx.doi.org/10.1038/onc.2010.516			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21076470				2022-12-28	WOS:000288202400010
J	Roy, LD; Sahraei, M; Subramani, DB; Besmer, D; Nath, S; Tinder, TL; Bajaj, E; Shanmugam, K; Lee, YY; Hwang, SIL; Gendler, SJ; Mukherjee, P				Roy, L. D.; Sahraei, M.; Subramani, D. B.; Besmer, D.; Nath, S.; Tinder, T. L.; Bajaj, E.; Shanmugam, K.; Lee, Y. Y.; Hwang, S. I. L.; Gendler, S. J.; Mukherjee, P.			MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition	ONCOGENE			English	Article						MUCI; pancreatic cancer; epithelial to mesenchymal transition; metastasis	CARCINOMA-ASSOCIATED ANTIGEN; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; SOLUBLE P-SELECTIN; BETA-CATENIN; TUMOR PROGRESSION; CYTOPLASMIC TAIL; MAMMARY-GLAND; C-SRC; PROTEIN	Increased motility and invasiveness of pancreatic cancer cells are associated with epithelial to mesenchymal transition (EMT). Snai1 and Slug are zinc-finger transcription factors that trigger this process by repressing E-cadherin and enhancing vimentin and N-cadherin protein expression. However, the mechanisms that regulate this activation in pancreatic tumors remain elusive. MUC1, a transmembrane mucin glycoprotein, is associated with the most invasive forms of pancreatic ductal adenocarcinomas (PDA). In this study, we show that over expression of MUC1 in pancreatic cancer cells triggers the molecular process of EMT, which translates to increased invasiveness and metastasis. EMT was significantly reduced when MUC1 was genetically deleted in a mouse model of PDA or when all seven tyrosines in the cytoplasmic tail of MUC1 were mutated to phenylalanine (mutated MUC1 CT). Using proteomics, RT-PCR and western blotting, we revealed a significant increase in vimentin, Slug and Snail expression with repression of E-Cadherin in MUC1-expressing cells compared with cells expressing the mutated MUC1 CT. In the cells that carried the mutated MUC1 CT, MUC1 failed to co-immunoprecipitate with beta-catenin and translocate to the nucleus, thereby blocking transcription of the genes associated with EMT and metastasis. Thus, functional tyrosines are critical in stimulating the interactions between MUC1 and b-catenin and their nuclear translocation to initiate the process of EMT. This study signifies the oncogenic role of MUC1 CT and is the first to identify a direct role of the MUC1 in initiating EMT during pancreatic cancer. The data may have implications in future design of MUC1-targeted therapies for pancreatic cancer. Oncogene (2011) 30, 1449-1459; doi:10.1038/onc.2010.526; published online 22 November 2010	[Roy, L. D.; Sahraei, M.; Besmer, D.; Nath, S.; Mukherjee, P.] Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; [Subramani, D. B.; Tinder, T. L.; Bajaj, E.; Shanmugam, K.; Gendler, S. J.] Mayo Clin, Sch Med Arizona, Dept Biochem & Mol Biol, Scottsdale, AZ USA; [Lee, Y. Y.; Hwang, S. I. L.] Carolinas Healthcare Ctr, Charlotte, NC USA	University of North Carolina; University of North Carolina Charlotte; Mayo Clinic; Mayo Clinic Phoenix; Carolinas HealthCare System	Mukherjee, P (corresponding author), Univ N Carolina, Dept Biol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	pmukherj@uncc.edu	Nath, Sritama/J-7725-2019; Subramani, Durai/N-1448-2013	Subramani, Durai/0000-0002-2256-3096; Hwang, Sunil/0000-0003-0600-3694	NIH [CA R01CA118944]; NATIONAL CANCER INSTITUTE [R01CA064389, P50CA102701, R01CA118944] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Drs Mukherjee and Gendler work have been funded by the NIH. All other authors declare no conflict of interest.; We acknowledge the funding provided by NIH CA R01CA118944. We thank Dr Jennifer Curry for critically reviewing the manuscript. We thank Cathy S Madison and Carole M Viso for their technical help with the confocal microscopy. We also acknowledge all the technicians in the animal facility and in the histology core facilities at The Mayo Clinic.	Al Masri A, 2005, ONCOGENE, V24, P5799, DOI 10.1038/sj.onc.1208738; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chang BW, 2010, J PANCREAS, V11, P313; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Das Roy L, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2345; Dymicka-Piekarska V, 2007, THROMB RES, V120, P585, DOI 10.1016/j.thromres.2006.11.002; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Glinskii AB, 2003, CANCER RES, V63, P4239; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hwang SI, 2006, MOL CELL PROTEOMICS, V5, P1131, DOI 10.1074/mcp.M500162-MCP200; Justinger C, 2008, ONCOL REP, V20, P1527, DOI 10.3892/or_00000175; KAIKITA K, 1995, CIRCULATION, V92, P1726, DOI 10.1161/01.CIR.92.7.1726; Kufe DW, 2008, CANCER BIOL THER, V7, P81, DOI 10.4161/cbt.7.1.5631; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Mroczko B, 2005, CLIN CHEM LAB MED, V43, P146, DOI 10.1515/CCLM.2005.024; Mukherjee P, 2005, J LEUKOCYTE BIOL, V77, P90, DOI 10.1189/jlb.0604333; Mukherjee P, 2009, J IMMUNOL, V182, P216, DOI 10.4049/jimmunol.182.1.216; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Quin RJ, 2000, INT J CANCER, V87, P499, DOI 10.1002/1097-0215(20000815)87:4<499::AID-IJC6>3.0.CO;2-9; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIMPSONHERREN L, 1970, CANCER CHEMOTH REP 1, V54, P143; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EJ, 2006, MOL CANCER RES, V4, P489, DOI 10.1158/1541-7786.MCR-06-0038; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Wolpin BM, 2007, BRIT J CANCER, V97, P98, DOI 10.1038/sj.bjc.6603826; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	44	196	206	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1449	1459		10.1038/onc.2010.526	http://dx.doi.org/10.1038/onc.2010.526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102519	Green Accepted			2022-12-28	WOS:000288743800007
J	Welti, JC; Gourlaouen, M; Powles, T; Kudahetti, SC; Wilson, P; Berney, DM; Reynolds, AR				Welti, J. C.; Gourlaouen, M.; Powles, T.; Kudahetti, S. C.; Wilson, P.; Berney, D. M.; Reynolds, A. R.			Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib	ONCOGENE			English	Article						angiogenesis; growth factors; sunitinib; renal cancer; resistance	TYROSINE KINASE INHIBITOR; IN-VITRO; ANTITUMOR-ACTIVITY; TARGETED THERAPY; INTERFERON-ALPHA; TUMOR-GROWTH; ANGIOGENESIS; VEGF; RESISTANCE; EXPRESSION	The vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor sunitinib has been approved for first-line treatment of patients with metastatic renal cancer and is currently being trialled in other cancers. However, the effectiveness of this anti-angiogenic agent is limited by the presence of innate and acquired drug resistance. By screening a panel of candidate growth factors we identified fibroblast growth factor 2 (FGF2) as a potent regulator of endothelial cell sensitivity to sunitinib. We show that FGF2 supports endothelial proliferation and de novo tubule formation in the presence of sunitinib and that FGF2 can suppress sunitinib-induced retraction of tubules. Importantly, these effects of FGF2 were ablated by PD173074, a small molecule inhibitor of FGF receptor signalling. We also show that FGF2 can stimulate pro-angiogenic signalling pathways in endothelial cells despite the presence of sunitinib. Finally, analysis of clinical renal-cancer samples demonstrates that a large proportion of renal cancers strongly express FGF2. We suggest that therapeutic strategies designed to simultaneously target both VEGF and FGF2 signalling may prove more efficacious than sunitinib in renal cancer patients whose tumours express FGF2. Oncogene (2011) 30, 1183-1193; doi:10.1038/onc.2010.503; published online 8 November 2010	[Welti, J. C.; Gourlaouen, M.; Reynolds, A. R.] Inst Canc Res, Tumour Angiogenesis Grp, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Powles, T.; Kudahetti, S. C.; Berney, D. M.] Queen Mary Univ London, Ctr Mol Oncol, Barts & London Sch Med & Dent, John Vane Sci Ctr,Inst Canc, London, England; [Wilson, P.] Dept Med Oncol, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Queen Mary University London	Reynolds, AR (corresponding author), Inst Canc Res, Tumour Angiogenesis Grp, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	andrew.reynolds@icr.ac.uk		Berney, Daniel/0000-0001-5474-8696; Welti, Jonathan/0000-0002-9433-8138	Breakthrough Breast Cancer; Pfizer Global Pharmaceuticals	Breakthrough Breast Cancer; Pfizer Global Pharmaceuticals(Pfizer)	Thomas Powles is the recipient of an educational research grant from Pfizer Global Pharmaceuticals. The other authors declare no potential conflict of interest.; We would like to thank Alan Ashworth, Clare Isacke and Nicholas Turner for critical comments on the paper and Breakthrough Breast Cancer for research funding.	Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Britten CD, 2008, CANCER CHEMOTH PHARM, V61, P515, DOI 10.1007/s00280-007-0498-4; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095; EGUCHI J, 1992, BIOCHEM BIOPH RES CO, V183, P937, DOI 10.1016/S0006-291X(05)80280-3; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Faivre S, 2006, J CLIN ONCOL, V24, P25, DOI 10.1200/JCO.2005.02.2194; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; Fukata S, 2005, CANCER-AM CANCER SOC, V103, P931, DOI 10.1002/cncr.20887; Giavazzi R, 2003, AM J PATHOL, V162, P1913, DOI 10.1016/S0002-9440(10)64325-8; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008-5472.CAN-09-3722; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nakatsu MN, 2008, METHOD ENZYMOL, V443, P65, DOI 10.1016/S0076-6879(08)02004-1; NANUS DM, 1993, J NATL CANCER I, V85, P1597, DOI 10.1093/jnci/85.19.1597; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pardo OE, 2009, CANCER RES, V69, P8645, DOI 10.1158/0008-5472.CAN-09-1576; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Ravaud A, 2008, J CLIN ONCOL, V26, P2285, DOI 10.1200/JCO.2007.14.5029; Relf M, 1997, CANCER RES, V57, P963; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Slaton JW, 2001, AM J PATHOL, V158, P735, DOI 10.1016/S0002-9440(10)64016-3; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780	51	101	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1183	1193		10.1038/onc.2010.503	http://dx.doi.org/10.1038/onc.2010.503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057538				2022-12-28	WOS:000288202400005
J	Pittoni, P; Piconese, S; Tripodo, C; Colombo, MP				Pittoni, P.; Piconese, S.; Tripodo, C.; Colombo, M. P.			Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors	ONCOGENE			English	Review						c-Kit; mast cells; tyrosine kinase inhibitors; off-target; mouse mutants	GASTROINTESTINAL STROMAL TUMORS; ADENOID CYSTIC CARCINOMA; DOSE-DEPENDENT MANNER; REGULATORY T-CELLS; STEM-CELL; IN-VIVO; BONE-MARROW; IMATINIB MESYLATE; GROWTH-FACTOR; MOUSE MODEL	c-Kit tyrosine kinase receptor and its ligand stem cell factor have multiple functions during development, whereas in adulthood they are mostly needed for stem cell (SC) maintenance and mast cell (MC) biology. c-Kit plays an essential tumor-cell-intrinsic role in many types of cancer, either providing the tumorigenic force when aberrantly activated or conferring stem-like features characterizing the most aggressive variants. A tumor-cell-extrinsic role occurs through c-Kit-dependent accessory cells (such as MCs) that infiltrate tumors and deeply influence their progression. c-Kit-targeted therapy with tyrosine kinase inhibitors (TKIs) may ideally work against both tumor and stromal cells. Here, we summarize the tumor-intrinsic and -extrinsic roles of c-Kit in cancer and discuss TKIs with their on-and off-targets, with a special emphasis on MCs as paradigmatic c-Kit-dependent accomplices for tumor progression. Oncogene (2011) 30, 757-769; doi:10.1038/onc.2010.494; published online 8 November 2010	[Pittoni, P.; Piconese, S.; Colombo, M. P.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, I-20133 Milan, Italy; [Tripodo, C.] Univ Palermo, Dept Human Pathol, Palermo, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Palermo	Colombo, MP (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, Via Amadeo 42, I-20133 Milan, Italy.	mario.colombo@istitutotumori.mi.it	Tripodo, Claudio/O-4536-2016; Colombo, Mario P./V-7166-2017; Tripodo, Claudio/AAB-6004-2022	Tripodo, Claudio/0000-0002-0821-6231; Colombo, Mario P./0000-0003-0042-7955; Tripodo, Claudio/0000-0002-0821-6231; Piconese, Silvia/0000-0002-9685-5227	Italian Ministry of Health; Associazione Italiana Ricerca sul Cancro [8726]; FIRC (Fondazione Italiana Ricerca sul Cancro)	Italian Ministry of Health(Ministry of Health, Italy); Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); FIRC (Fondazione Italiana Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Italian Ministry of Health and Associazione Italiana Ricerca sul Cancro (to MPC). SP is supported by My First AIRC grant (8726). PP is supported by a fellowship from FIRC (Fondazione Italiana Ricerca sul Cancro).	ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; Beaven MA, 2009, EUR J IMMUNOL, V39, P11, DOI 10.1002/eji.200838899; Bellone G, 2006, INT J ONCOL, V29, P851; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berrozpe G, 1999, BLOOD, V94, P2658, DOI 10.1182/blood.V94.8.2658.420k23_2658_2666; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blatner NR, 2010, P NATL ACAD SCI USA, V107, P6430, DOI 10.1073/pnas.0913683107; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chen J, 2007, INT J ONCOL, V31, P1133; Colombo MP, 2009, CANCER RES, V69, P5619, DOI 10.1158/0008-5472.CAN-09-1351; Corless CL, 2008, ANNU REV PATHOL-MECH, V3, P557, DOI 10.1146/annurev.pathmechdis.3.121806.151538; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crivellato E, 2008, CANCER LETT, V269, P1, DOI 10.1016/j.canlet.2008.03.031; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Dietz AB, 2004, BLOOD, V104, P1094, DOI 10.1182/blood-2003-12-4266; Dubreuil P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007258; Freier K, 2005, ORAL ONCOL, V41, P934, DOI 10.1016/j.oraloncology.2005.05.005; Fritsche-Polanz R, 2010, MOL ONCOL, V4, P335, DOI 10.1016/j.molonc.2010.04.008; Frossi B, 2010, TRENDS IMMUNOL, V31, P97, DOI 10.1016/j.it.2009.12.007; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; GADD SJ, 1985, LEUKEMIA RES, V9, P1329, DOI 10.1016/0145-2126(85)90119-5; Galinsky DST, 2008, CRIT REV ONCOL HEMAT, V68, P115, DOI 10.1016/j.critrevonc.2008.06.001; GALLI SJ, 1993, AM J PATHOL, V142, P965; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Gleixner KV, 2006, BLOOD, V107, P752, DOI 10.1182/blood-2005-07-3022; Gomes AL, 2007, CELL ONCOL, V29, P399; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; Gounaris E, 2009, CANCER RES, V69, P5490, DOI 10.1158/0008-5472.CAN-09-0304; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Gunawan B, 2008, J PATHOL, V214, P407, DOI 10.1002/path.2315; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hirashima K, 2009, SURG TODAY, V39, P979, DOI 10.1007/s00595-009-3963-3; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Huang SY, 1996, ONCOGENE, V13, P2339; Hutt KJ, 2006, MOL HUM REPROD, V12, P61, DOI 10.1093/molehr/gal010; IKEDA H, 1991, BLOOD, V78, P2962; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ishikawa T, 2009, LAB INVEST, V89, P1161, DOI 10.1038/labinvest.2009.78; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Johansson A, 2010, AM J PATHOL, V177, P1031, DOI 10.2353/ajpath.2010.100070; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Khalaf WF, 2007, J IMMUNOL, V178, P2527, DOI 10.4049/jimmunol.178.4.2527; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Kinet JP, 2007, IMMUNOL REV, V217, P5, DOI 10.1111/j.1600-065X.2007.00528.x; KITAMURA Y, 1978, BLOOD, V52, P447; Ko CD, 2003, CLIN EXP METASTAS, V20, P593, DOI 10.1023/A:1027323210736; Ko JS, 2010, CANCER RES, V70, P3526, DOI 10.1158/0008-5472.CAN-09-3278; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Krystal GW, 1996, CANCER RES, V56, P370; Larmonier N, 2008, J IMMUNOL, V181, P6955, DOI 10.4049/jimmunol.181.10.6955; LASSAM N, 1992, ONCOGENE, V7, P51; Laurson J, 2007, CELLS TISSUES ORGANS, V186, P180, DOI 10.1159/000106360; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Liegl-Atzwanger B, 2010, VIRCHOWS ARCH, V456, P111, DOI 10.1007/s00428-010-0891-y; Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; LYON MF, 1982, GENET RES, V39, P315, DOI 10.1017/S001667230002098X; MAEDA H, 1992, DEVELOPMENT, V116, P369; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; Maltby S, 2009, BBA-REV CANCER, V1796, P19, DOI 10.1016/j.bbcan.2009.02.001; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MEININGER CJ, 1992, BLOOD, V79, P958; Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008-5472.CAN-07-1882; Menard C, 2009, CANCER RES, V69, P3563, DOI 10.1158/0008-5472.CAN-08-3807; Molin D, 2002, BRIT J HAEMATOL, V119, P122, DOI 10.1046/j.1365-2141.2002.03768.x; Moller C, 2005, BLOOD, V106, P1330, DOI 10.1182/blood-2004-12-4792; Morales JK, 2010, GENES IMMUN, V11, P599, DOI 10.1038/gene.2010.35; Musch W, 2008, GENESIS, V46, P163, DOI 10.1002/dvg.20378; Nakai N, 2008, J PATHOL, V214, P302, DOI 10.1002/path.2296; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; Nigrovic PA, 2008, AM J PATHOL, V173, P1693, DOI 10.2353/ajpath.2008.080407; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Palmu S, 2002, ANTICANCER RES, V22, P411; Pan J, 2007, BLOOD, V109, P315, DOI 10.1182/blood-2006-04-013805; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Piconese S, 2009, BLOOD, V114, P2639, DOI 10.1182/blood-2009-05-220004; Pierotti MA, 2010, MOL ONCOL, V4, P19, DOI 10.1016/j.molonc.2009.10.003; Robson ME, 2004, CLIN CANCER RES, V10, P1250, DOI 10.1158/1078-0432.CCR-03-0110; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2005, CANCER RES, V65, P6631, DOI 10.1158/0008-5472.CAN-05-0891; Sakurai S, 2004, HUM PATHOL, V35, P1223, DOI 10.1016/j.humpath.2004.07.008; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Seggewiss R, 2005, BLOOD, V105, P2473, DOI 10.1182/blood-2004-07-2527; Shah NP, 2006, BLOOD, V108, P286, DOI 10.1182/blood-2005-10-3969; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; STANULLA M, 1995, ACTA NEUROPATHOL, V89, P158; Staser K, 2010, BLOOD, V116, P157, DOI 10.1182/blood-2009-09-242875; Swerdlow SH, 2008, WHO CLASSIFICATION T; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Tang YL, 2010, ORAL ONCOL, V46, P311, DOI 10.1016/j.oraloncology.2010.02.001; Taskinen M, 2008, BLOOD, V111, P4664, DOI 10.1182/blood-2007-11-125823; TAYLOR AM, 1995, IMMUNOLOGY, V86, P427; Teitell M, 1998, HUM PATHOL, V29, P1546, DOI 10.1016/S0046-8177(98)90029-6; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Theoharides TC, 2008, NEW ENGL J MED, V358, P1860, DOI 10.1056/NEJMcibr0801519; TONO T, 1992, BLOOD, V80, P1448; Tournilhac O, 2006, ANN ONCOL, V17, P1275, DOI 10.1093/annonc/mdl109; Tripodo C, 2010, AM J PATHOL, V177, P792, DOI 10.2353/ajpath.2010.091286; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Wasiuk A, 2009, CLIN EXP IMMUNOL, V155, P140, DOI 10.1111/j.1365-2249.2008.03840.x; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Westphal E, 1891, FARBENANALYTISCHE UN, P17; WINSHIP I, 1991, CLIN GENET, V39, P330; Woodman SE, 2010, BIOCHEM PHARMACOL, V80, P568, DOI 10.1016/j.bcp.2010.04.032; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yang ZS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008922; Yared Marwan A, 2004, Breast J, V10, P323, DOI 10.1111/j.1075-122X.2004.21351.x; Young SM, 2007, CELL SIGNAL, V19, P2572, DOI 10.1016/j.cellsig.2007.08.004; Zappulla JP, 2005, J EXP MED, V202, P1635, DOI 10.1084/jem.20050807; Zaruba MM, 2010, CIRCULATION, V121, P1992, DOI 10.1161/CIRCULATIONAHA.109.909093; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; Zudaire E, 2006, AM J PATHOL, V168, P280, DOI 10.2353/ajpath.2006.050291	141	57	64	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					757	769		10.1038/onc.2010.494	http://dx.doi.org/10.1038/onc.2010.494			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	21057534				2022-12-28	WOS:000287444600001
J	Bender, A; Opel, D; Naumann, I; Kappler, R; Friedman, L; von Schweinitz, D; Debatin, KM; Fulda, S				Bender, A.; Opel, D.; Naumann, I.; Kappler, R.; Friedman, L.; von Schweinitz, D.; Debatin, K-M; Fulda, S.			PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis	ONCOGENE			English	Article						apoptosis; PI3K; neuroblastoma; chemotherapy	TRAIL-INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE PERMEABILIZATION; CONFORMATIONAL-CHANGE; PANCREATIC-CARCINOMA; UP-REGULATION; IN-VIVO; CANCER; MCL-1; BAX	We recently identified activation of phosphatidylinositol 30'-kinase (PI3K)/Akt as a novel predictor of poor outcome in neuroblastoma. Here, we investigated the effect of small-molecule PI3K inhibitors on chemosensitivity. We provide first evidence that PI3K inhibitors, for example PI103, synergize with various chemotherapeutics (Doxorubicin, Etoposide, Topotecan, Cisplatin, Vincristine and Taxol) to trigger apoptosis in neuroblastoma cells (combination index: high synergy). Mechanistic studies reveal that PI103 cooperates with Doxorubicin to reduce Mcl-1 expression and Bim(EL) phosphorylation and to upregulate Noxa and BimEL levels. This shifted ratio of pro-and antiapoptotic Bcl-2 proteins results in increased Bax/Bak conformational change, loss of mitochondrial membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Although Mcl-1 knockdown enhances Doxorubicin- and PI103-induced apoptosis, silencing of Noxa, Bax/Bak or p53 reduces apoptosis, underscoring the functional relevance of the Doxorubicin-and PI103-mediated modulation of these proteins for chemosensitization. Bcl-2 overexpression inhibits Bax activation, mitochondrial perturbations, cleavage of caspases and Bid, and apoptosis, confirming the central role of the mitochondrial pathway for chemosensitization. Interestingly, the broad-range caspase inhibitor zVAD.fmk does not interfere with Bax activation or mitochondrial outer membrane permeabilization, whereas it blocks caspase activation and apoptosis, thus placing mitochondrial events upstream of caspase activation. Importantly, PI103 and Doxorubicin cooperate to induce apoptosis and to suppress tumor growth in patients' derived primary neuroblastoma cells and in an in vivo neuroblastoma model, underlining the clinical relevance of the results. Thus, targeting PI3K presents a novel and promising strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis, which has important implications for the development of targeted therapies for neuroblastoma. Oncogene (2011) 30, 494-503; doi: 10.1038/onc.2010.429; published online 20 September 2010	[Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Bender, A.; Opel, D.; Naumann, I.; Debatin, K-M] Univ Childrens Hosp, Dept Hematol Oncol, Ulm, Germany; [Kappler, R.; von Schweinitz, D.] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat Surg, Munich, Germany; [Friedman, L.] Genentech Inc, Dept Canc Signaling, San Francisco, CA 94080 USA	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Roche Holding; Genentech	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Kappler, Roland/0000-0002-8581-2803; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; BMBF; Novartis Stiftung fur Therapeutische Forschung; European Community [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); BMBF(Federal Ministry of Education & Research (BMBF)); Novartis Stiftung fur Therapeutische Forschung; European Community(European Commission)	We thank CA Schmitt (Berlin, Germany) for providing mouse Bcl-2 vector, C Haag (Ulm, Germany) for providing Mcl-1 knockdown SH-EP cells, A Dittrich (Ulm, Germany) for providing expert technical assistance and B Welz (Ulm, Germany) for providing excellent secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, BMBF, Novartis Stiftung fur Therapeutische Forschung, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Ammann JU, 2009, INT J CANCER, V124, P1301, DOI 10.1002/ijc.24068; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chiarini F, 2009, CANCER RES, V69, P3520, DOI 10.1158/0008-5472.CAN-08-4884; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fakler M, 2009, BLOOD, V113, P1710, DOI 10.1182/blood-2007-09-114314; Fei PW, 2002, CANCER RES, V62, P7316; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2009, CURR CANCER DRUG TAR, V9, P729, DOI 10.2174/156800909789271521; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Guillard S, 2009, CELL CYCLE, V8, P443, DOI 10.4161/cc.8.3.7643; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Jaboin J, 2002, CANCER RES, V62, P6756; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Niedermeier M, 2009, BLOOD, V113, P5549, DOI 10.1182/blood-2008-06-165068; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Vogler M, 2009, CANCER RES, V69, P2425, DOI 10.1158/0008-5472.CAN-08-2436; Warr MR, 2008, CURR MOL MED, V8, P138; Westhoff MA, 2009, ONCOGENE, V28, P3586, DOI 10.1038/onc.2009.215; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200	40	77	79	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					494	503		10.1038/onc.2010.429	http://dx.doi.org/10.1038/onc.2010.429			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856197				2022-12-28	WOS:000286621600011
J	Moore, HC; Jordan, LB; Bray, SE; Baker, L; Quinlan, PR; Purdie, CA; Thompson, AM; Bourdon, JC; Fuller-Pace, FV				Moore, H. C.; Jordan, L. B.; Bray, S. E.; Baker, L.; Quinlan, P. R.; Purdie, C. A.; Thompson, A. M.; Bourdon, J-C; Fuller-Pace, F. V.			The RNA helicase p68 modulates expression and function of the Delta 133 isoform(s) of p53, and is inversely associated with Delta 133p53 expression in breast cancer	ONCOGENE			English	Article						breast cancer; p68 RNA helicase; p53; Delta 133p53; gene expression/regulation	TUMOR-SUPPRESSOR P53; ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTIONAL COACTIVATOR; RIBOSOMAL-RNA; DNA-DAMAGE; BOX; PROTEINS; GENE; DIFFERENTIATION; ACTIVATION	The RNA helicase p68 is a potent co-activator of p53-dependent transcription in response to DNA damage. Previous independent studies have indicated that p68 and the Delta 133p53 isoforms, which modulate the function of full-length p53, are aberrantly expressed in breast cancers. Here we identify a striking inverse association of p68 and Delta 133p53 expression in primary breast cancers. Consistent with these findings, small interfering RNA depletion of p68 in cell lines results in a p53-dependant increase of Delta 133p53 in response to DNA damage, suggesting that increased Delta 133p53 expression could result from downregulation of p68 and provide a potential mechanistic explanation for our observations in breast cancer. Delta 133p53 alpha, which has been shown to negatively regulate the function of full-length p53, reciprocally inhibits the ability of p68 to stimulate p53-dependent transcription from the p21 promoter, suggesting that Delta 133p53 alpha may be competing with p68 to regulate p53 function. This hypothesis is underscored by our observations that p68 interacts with the C-terminal domain of p53, co-immunoprecipitates 133p53 alpha from cell extracts and interacts only with p53 molecules that are able to form tetramers. These data suggest that p68, p53 and 133p53 alpha may form part of a complex feedback mechanism to regulate the expression of Delta 133p53, with consequent modification of p53-mediated transcription, and may modulate the function of p53 in breast and other cancers that harbour wild-type p53. Oncogene (2010) 29, 6475-6484; doi:10.1038/onc.2010.381; published online 6 September 2010	[Moore, H. C.; Baker, L.; Thompson, A. M.; Bourdon, J-C; Fuller-Pace, F. V.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Dundee DD1 9SY, Tayside, Scotland; [Jordan, L. B.; Purdie, C. A.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Pathol, Dundee DD1 9SY, Tayside, Scotland; [Thompson, A. M.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Dundee; University of Dundee; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Dundee DD1 9SY, Tayside, Scotland.	f.v.fullerpace@dundee.ac.uk	JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386; Purdie, Colin/0000-0002-1258-4010; Quinlan, Philip/0000-0002-3012-6646	Tenovus Scotland; Cancer Research UK; Breast Cancer Research Scotland	Tenovus Scotland; Cancer Research UK(Cancer Research UK); Breast Cancer Research Scotland	This work was supported by grants from Tenovus Scotland, Cancer Research UK and Breast Cancer Research Scotland. We thank David Meek for helpful discussions.	Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Balakrishnan SK, 2008, ONCOGENE, V27, P2661, DOI 10.1038/sj.onc.1210935; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bertheau P, 2008, PATHOBIOLOGY, V75, P132, DOI 10.1159/000123851; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bond AT, 2001, MOL CELL BIOL, V21, P7366, DOI 10.1128/MCB.21.21.7366-7379.2001; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caretti G, 2007, CELL CYCLE, V6, P1172, DOI 10.4161/cc.6.10.4228; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Carter S, 2009, CURR OPIN GENET DEV, V19, P18, DOI 10.1016/j.gde.2008.11.010; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; Graupner V, 2009, CELL CYCLE, V8, P1238, DOI 10.4161/cc.8.8.8251; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Jensen ED, 2008, J CELL BIOCHEM, V103, P1438, DOI 10.1002/jcb.21526; Liu ZR, 2002, MOL CELL BIOL, V22, P5443, DOI 10.1128/MCB.22.15.5443-5450.2002; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Salzman DW, 2007, J BIOL CHEM, V282, P32773, DOI 10.1074/jbc.M705054200; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang Jin, 2008, Curr Mol Med, V8, P845, DOI 10.2174/156652408786733748	44	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6475	6484		10.1038/onc.2010.381	http://dx.doi.org/10.1038/onc.2010.381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20818423	Green Accepted			2022-12-28	WOS:000285138900007
J	Fu, G; Peng, C				Fu, G.; Peng, C.			Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells	ONCOGENE			English	Article						Nodal; ALK7; cyclin G2; FoxO3a; Smad; ovarian cancer	VERTEBRATE DEVELOPMENT; PHOSPHOINOSITIDE 3-KINASE; PROMOTES TUMORIGENESIS; DEPENDENT REGULATION; TUMOR SUPPRESSION; UP-REGULATION; FORKHEAD; APOPTOSIS; EXPRESSION; GROWTH	Nodal, a member of the transforming growth factor-beta superfamily, has been recently shown to suppress cell proliferation and to stimulate the expression of cyclin G2 (CCNG2) in human epithelial ovarian cancer cells. However, the precise mechanisms underlying these events are not fully understood. In this study, we investigated the transcriptional regulation of CCNG2 by the Nodal signaling pathway. In ovarian cancer cells, overexpression of Nodal or its receptors, activin receptor-like kinase 7 (ALK7) or ALK4, resulted in an increase in the CCNG2 promoter activity. Several putative Forkhead box class O (FoxO)3a-binding sites are present in the human CCNG2 promoter and overexpression of FoxO3a enhanced the CCNG2 promoter activity. The functional FoxO3a-binding element (FBE) was mapped to a proximal region located between -398 and -380 bp (FBE1) through deletion and mutation analyses, as well as chromatin immunoprecipitation (IP) assay. Interestingly, mutation of the FBE1 not only abolished the effect of FoxO3a, but also blocked Nodal-induced CCNG2 transcription. Nodal stimulated FoxO3a mRNA and protein expression through the canonical Smad pathway and suppressed FoxO3a inactivation by inhibiting AKT activity. Silencing of FoxO3a using small interfering RNA significantly reduced the effect of Nodal on the CCNG2 promoter activity. On the other hand, overexpression of Smad2 and Smad3 enhanced the FoxO3a-induced CCNG2 promoter activity whereas knockdown of Smad4 blocked the activity of FoxO3a. Furthermore, IP assays revealed that FoxO3a formed complexes with Smad proteins and that Nodal enhanced the binding of FoxO3a to the CCNG2 promoter. Finally, silencing of FoxO3a reversed the inhibitory effect of Nodal on cell proliferation. Taken together, these findings demonstrated that Nodal signaling promotes CCNG2 transcription by upregulating FoxO3a expression, inhibiting FoxO3a phosphorylation and enhancing its synergistic interaction with Smads. These results also suggest that FoxO3a is an important mediator of Nodal signaling in ovarian cancer cells. Oncogene (2011) 30, 3953-3966; doi:10.1038/onc.2011.127; published online 2 May 2011	[Fu, G.; Peng, C.] York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada	York University - Canada	Peng, C (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	cpeng@yorku.ca	Fu, Guodong/AGF-1991-2022		CIHR [MOP-89931]; CIHR/OWHC	CIHR(Canadian Institutes of Health Research (CIHR)); CIHR/OWHC(Canadian Institutes of Health Research (CIHR))	This work was supported by a CIHR grant (MOP-89931) and a CIHR/OWHC Mid-Career Award to CP.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Baker K, 2008, P NATL ACAD SCI USA, V105, P13924, DOI 10.1073/pnas.0802159105; Bates S, 1996, ONCOGENE, V13, P1103; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen J, 2006, J IMMUNOL, V176, P2711, DOI 10.4049/jimmunol.176.5.2711; Cornforth AN, 2008, ONCOGENE, V27, P4422, DOI 10.1038/onc.2008.80; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Fei M, 2009, CANCER INVEST, V27, P52, DOI 10.1080/07357900802146204; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Hauck L, 2007, CIRC RES, V100, P50, DOI 10.1161/01.RES.0000254704.92532.b9; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Katayama K, 2008, ONCOGENE, V27, P1677, DOI 10.1038/sj.onc.1210813; Kenney NJ, 2004, J MAMMARY GLAND BIOL, V9, P133, DOI 10.1023/B:JOMG.0000037158.91940.1c; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar A, 2001, J BIOL CHEM, V276, P656, DOI 10.1074/jbc.M004649200; Le XF, 2007, MOL CANCER THER, V6, P2843, DOI 10.1158/1535-7163.MCT-07-0109; Li YW, 2007, J BIOL CHEM, V282, P21542, DOI 10.1074/jbc.M701978200; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matsuyama S, 2003, CANCER RES, V63, P7791; Munir S, 2004, J BIOL CHEM, V279, P31277, DOI 10.1074/jbc.M400641200; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Ogawa K, 2007, J CELL SCI, V120, P55, DOI 10.1242/jcs.03296; Papageorgiou I, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-122; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shen MM, 2007, DEVELOPMENT, V134, P1023, DOI 10.1242/dev.000166; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Strizzi Luigi, 2008, Breast Dis, V29, P91; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tian J, 2008, DEVELOPMENT, V135, P2649, DOI 10.1242/dev.019794; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Wang H, 2006, MOL ENDOCRINOL, V20, P2469, DOI 10.1210/me.2005-0446; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Xu GX, 2006, MOL CANCER RES, V4, P235, DOI 10.1158/1541-7786.MCR-05-0174; Xu GX, 2004, J CLIN ENDOCR METAB, V89, P5523, DOI 10.1210/jc.2004-0893; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Zhang N, 2006, DIABETOLOGIA, V49, P506, DOI 10.1007/s00125-005-0095-1; Zhang YQ, 2008, DEV DYNAM, V237, P1255, DOI 10.1002/dvdy.21527	62	54	57	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3953	3966		10.1038/onc.2011.127	http://dx.doi.org/10.1038/onc.2011.127			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21532621				2022-12-28	WOS:000294890400005
J	Fujii, S; Tokita, K; Wada, N; Ito, K; Yamauchi, C; Ito, Y; Ochiai, A				Fujii, S.; Tokita, K.; Wada, N.; Ito, K.; Yamauchi, C.; Ito, Y.; Ochiai, A.			MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes	ONCOGENE			English	Article						EZH2/MEK-ERK pathway; histone; triple negative; breast cancer; ERBB2-overexpressing breast cancer	H3 LYSINE-27 METHYLATION; GENE-EXPRESSION; GASTRIC-CANCER; POLYCOMB; CELLS; CARCINOMAS; HER-2/NEU; PHENOTYPE; PROSTATE; ENHANCER	EZH2 overexpression occurs in various malignancies and is associated with a poor outcome. We have so far demonstrated that EZH2 downregulates the important genes such as E-cadherin and RUNX3 by increasing histone H3K27 trimethylation. However, the mechanism of EZH2 overexpression in various cancer cells remains unclear. In this study we carried out a promoter analysis of the EZH2 gene and investigated whether a survival signal that is upregulated in cancer cells is related to overexpression at the transcription level. We also explored the clinical relevance of the signaling pathway that leads to EZH2 overexpression in breast cancer and demonstrated that MEK-ERK1/2-Elk-1 pathway leads to EZH2 overexpression. The triple-negative and ERBB2-overexpressing subtypes of breast cancer are known to contain more rapidly proliferating breast cancer cells. The signaling pathway connected to EZH2 overexpression was associated with both aggressive subtypes of breast cancer. We show the significance that overexpression of histone modifier protein EZH2 in cancer cells and our study could pave the way for EZH2 inhibition to become an efficient treatment for more aggressive breast cancers. Oncogene (2011) 30, 4118-4128; doi:10.1038/onc.2011.118; published online 18 April 2011	[Fujii, S.; Tokita, K.; Yamauchi, C.; Ochiai, A.] Natl Canc Ctr Kashiwa, Div Pathol, Res Ctr Innovat Oncol, Chiba 2778577, Japan; [Wada, N.] Natl Canc Ctr Hosp E, Breast Surg Div, Chiba, Japan; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan; [Ito, Y.] Canc Sci Inst Singapore, Proteos, Singapore	National Cancer Center - Japan; National Cancer Center - Japan; Nagasaki University	Ochiai, A (corresponding author), Natl Canc Ctr Kashiwa, Div Pathol, Res Ctr Innovat Oncol, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.	aochiai@east.ncc.go.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [21590453]; Grants-in-Aid for Scientific Research [21590453] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We wish to acknowledge the assistance of Ms Hiroko Hashimoto for cell culture support and the assistance of Mr Shinya Yanagi for making paraffin-embedded thin sections for immunohistochemistry. The research described in this report has been funded by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (21590453), to SF. Individual contributions of each author; Study concept and design; SF, AO, Acquisition of data; SF, KT, Analysis and interpretation of data; SF, KT, NW, Drafting the manuscript; SF, Critical revision of the manuscript for important intellectual content; SF, KI, YI, AO. Statistical analysis; SF, KT, NW Obtained funding; SF, Material support; NW, KI, YI, CY, Study supervision; SF.	Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475; Morris DP, 2005, J BIOL CHEM, V280, P31368, DOI 10.1074/jbc.M501546200; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395	28	94	99	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4118	4128		10.1038/onc.2011.118	http://dx.doi.org/10.1038/onc.2011.118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499305				2022-12-28	WOS:000295357500007
J	Jin, HO; Seo, SK; Kim, YS; Woo, SH; Lee, KH; Yi, JY; Lee, SJ; Choe, TB; Lee, JH; An, S; Hong, SI; Park, IC				Jin, H-O; Seo, S-K; Kim, Y-S; Woo, S-H; Lee, K-H; Yi, J-Y; Lee, S-J; Choe, T-B; Lee, J-H; An, S.; Hong, S-I; Park, I-C			TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1	ONCOGENE			English	Article						ATF4; mTOR; Redd1; TXNIP; 2-deoxyglucose	THIOREDOXIN-INTERACTING PROTEIN; CELL-GROWTH; OXIDATIVE STRESS; MAMMALIAN TARGET; ENERGY STRESS; EXPRESSION; KINASE; RAPAMYCIN; HYPOXIA; CANCER	The mammalian target of rapamycin (mTOR) is a highly conserved serine-threonine kinase activated in response to growth factors and nutrients. Because of frequent dysregulation of the mTOR signaling pathway in diverse human cancers, this kinase is a key therapeutic target. Redd1 is a negative regulator of mTOR, mediating dissociation of 14-3-3 from tuberous sclerosis complex (TSC)2, which allows formation of a TSC-TSC2 complex. In the present study, we identify TXNIP that inhibits mTOR activity by binding to and stabilizing Redd1 protein. Redd1 and TXNIP expression was induced by a synthetic glucose analog, 2-deoxyglucose (2-DG). Moreover, Redd1 expression in response to 2-DG was regulated by activating transcription factor 4 (ATF4). Overexpression of TXNIP was associated with reduced mTOR activity mediated by an increase in Redd1 level, whereas knockdown of TXNIP using small interfering RNA resulted in recovery of mTOR activity via downregulation of Redd1 during treatment with 2-DG. Interestingly, Redd1 was additionally stabilized via interactions with N-terminal-truncated TXNIP, leading to suppression of mTOR activity. Our results collectively demonstrate that TXNIP stabilizes Redd1 protein induced by ATF4 in response to 2-DG, resulting in potentiation of mTOR suppression. To the best of our knowledge, this is the first study to identify TXNIP as a novel member of the mTOR upstream that acts as a negative regulator in response to stress signals. Oncogene (2011) 30, 3792-3801; doi:10.1038/onc.2011.102; published online 4 April 2011	[Jin, H-O; Seo, S-K; Kim, Y-S; Woo, S-H; Lee, K-H; Hong, S-I; Park, I-C] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Yi, J-Y] Korea Inst Radiol & Med Sci, Lab Modulat Radiobiol Responses, Seoul 139706, South Korea; [Lee, S-J] Hanyang Univ, Dept Chem, Lab Mol Biochem, Seoul 133791, South Korea; [Choe, T-B; Lee, J-H; An, S.] Konkuk Univ, Dept Microbiol Engn, Seoul, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Hanyang University; Konkuk University	Jin, HO (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Res, 215-4 Gongneung Dong, Seoul 139706, South Korea.	hyeonok@kirams.re.kr; parkic@kirams.re.kr			National Nuclear RD Program; Basic Science Research Program; Ministry of Education, Science and Technology in Republic of Korea [2010-0009503]	National Nuclear RD Program; Basic Science Research Program; Ministry of Education, Science and Technology in Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the National Nuclear R&D Program and the Basic Science Research Program and the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0009503) in Republic of Korea.	Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chung JW, 2006, J DERMATOL, V33, P662, DOI 10.1111/j.1346-8138.2006.00156.x; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Fidler IJ, 1996, J NATL CANCER I, V88, P1700, DOI 10.1093/jnci/88.23.1700; Goldberg SF, 2003, CANCER RES, V63, P432; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Horak P, 2010, P NATL ACAD SCI USA, V107, P4675, DOI 10.1073/pnas.0907705107; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jin HO, 2009, IUBMB LIFE, V61, P1153, DOI 10.1002/iub.271; Jin HO, 2009, FREE RADICAL BIO MED, V46, P1158, DOI 10.1016/j.freeradbiomed.2009.01.015; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kang HT, 2006, LIFE SCI, V78, P1392, DOI 10.1016/j.lfs.2005.07.001; Katiyar S, 2009, EMBO REP, V10, P866, DOI 10.1038/embor.2009.93; Kim KY, 2004, BIOCHEM BIOPH RES CO, V315, P369, DOI 10.1016/j.bbrc.2004.01.047; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Nakamura H, 2006, SEMIN CANCER BIOL, V16, P444, DOI 10.1016/j.semcancer.2006.09.001; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Oka S, 2006, FASEB J, V20, pA45, DOI 10.1096/fj.05-4439fje; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Saxena G, 2010, J BIOL CHEM, V285, P3997, DOI 10.1074/jbc.M109.034421; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586; Schulze PC, 2004, J BIOL CHEM, V279, P30369, DOI 10.1074/jbc.M400549200; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394; Shor B, 2009, CELL CYCLE, V8, P3831, DOI 10.4161/cc.8.23.10070; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Stoltzman CA, 2008, P NATL ACAD SCI USA, V105, P6912, DOI 10.1073/pnas.0712199105; Sudarsanam S, 2010, CURR OPIN DRUG DISC, V13, P31; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang HM, 2006, J BIOL CHEM, V281, P39128, DOI 10.1074/jbc.M610023200; Wang Z, 2006, ONCOGENE, V25, P1903, DOI 10.1038/sj.onc.1209218; Whitney ML, 2009, BIOCHEM BIOPH RES CO, V379, P451, DOI 10.1016/j.bbrc.2008.12.079	40	59	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	35					3792	3801		10.1038/onc.2011.102	http://dx.doi.org/10.1038/onc.2011.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21460850				2022-12-28	WOS:000294481400006
J	Chen, LP; Lai, YD; Li, DC; Zhu, XN; Yang, P; Li, WX; Zhu, W; Zhao, J; Li, XD; Xiao, YM; Zhang, Y; Xing, XM; Wang, Q; Zhang, B; Lin, YC; Zeng, JL; Zhang, SX; Liu, CX; Li, ZF; Zeng, XW; Lin, ZN; Zhuang, ZX; Chen, W				Chen, L-P; Lai, Y-D; Li, D-C; Zhu, X-N; Yang, P.; Li, W-X; Zhu, W.; Zhao, J.; Li, X-D; Xiao, Y-M; Zhang, Y.; Xing, X-M; Wang, Q.; Zhang, B.; Lin, Y-C; Zeng, J-L; Zhang, S-X; Liu, C-X; Li, Z-F; Zeng, X-W; Lin, Z-N; Zhuang, Z-X; Chen, W.			alpha 4 is highly expressed in carcinogen-transformed human cells and primary human cancers	ONCOGENE			English	Article						alpha 4; protein phosphatase 2A; cell transformation; human cancers	PROTEIN PHOSPHATASE 2A; SENSITIVE SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR PP2A; CATALYTIC SUBUNIT; UBIQUITIN LIGASE; BINDING PROTEIN; OPITZ-SYNDROME; A-ALPHA; TARGETS; GROWTH	A regulator of the protein phosphatase 2A (PP2A), alpha 4, has been implicated in a variety of functions that regulate many cellular processes. To explore the role of alpha 4 in human cell transformation and tumorigenesis, we show that alpha 4 is highly expressed in human cells transformed by chemical carcinogens including benzo(a) pyrene, aflatoxin B(1), N-methyl-N'-nitro- N-nitrosoguanidine, nickel sulfate and in several hepatic and lung cancer cell lines. In addition, overexpression of a4 was detected in 87.5% (74/80) of primary hepatocellular carcinomas, 84.0% (21/25) of primary lung cancers and 81.8% (9/11) of primary breast cancers, indicating that a4 is ubiquitously highly expressed in human cancer. Functional studies revealed that elevated alpha 4 expression results in an increase in cell proliferation, promotion of cell survival and decreased PP2A-attributable activity. Importantly, ectopic expression of alpha 4 permits non-transformed human embryonic kidney cells (HEKTER) and L02R cells to form tumors in immunodeficient mice. Furthermore, we show that the highly expressed alpha 4 in transformed cells or human tumors is not regulated by DNA hypomethylation. A microRNA, miR-34b, that suppresses the expression of alpha 4 through specific binding to the 3'-untranslated region of alpha 4 is downregulated in transformed or human lung tumors. Taken together, these observations identify that alpha 4 possesses an oncogenic function. Reduction of PP2A activity due to an enhanced alpha 4-PP2A interaction contributes directly to chemical carcinogen-induced tumorigenesis. Oncogene (2011) 30, 2943-2953; doi:10.1038/onc.2011.20; published online 21 February 2011	[Chen, L-P; Lai, Y-D; Li, D-C; Zhu, X-N; Yang, P.; Li, W-X; Xiao, Y-M; Xing, X-M; Wang, Q.; Zhang, B.; Lin, Y-C; Zeng, J-L; Zhang, S-X; Liu, C-X; Li, Z-F; Zeng, X-W; Lin, Z-N; Zhuang, Z-X; Chen, W.] Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Prov Key Lab Food Nutr & Hlth, Dept Toxicol,Fac Prevent Med, Guangzhou 510080, Guangdong, Peoples R China; [Lai, Y-D] Guangzhou Med Coll, Inst Chem Carcinogenesis, Guangzhou, Guangdong, Peoples R China; [Li, W-X; Zhu, W.] Guangzhou Ctr Dis Control, Unit Toxicol, Guangzhou, Guangdong, Peoples R China; [Zhao, J.] Guangzhou Med Univ, Affiliated Canc Hosp, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China; [Li, X-D] Sun Yat Sen Univ, Ctr Canc, Dept Thorac Surg, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, Y.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Zhuang, Z-X] Shenzhen Ctr Dis Control & Prevent, Dept Toxicol, Shenzhen, Peoples R China	Sun Yat Sen University; Guangzhou Medical University; Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University; Shenzhen Center for Disease Control & Prevention (SZCDC)	Chen, W (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Prov Key Lab Food Nutr & Hlth, Dept Toxicol,Fac Prevent Med, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	chenwen@mail.sysu.edu.cn	ZHANG, BO/K-4561-2013; li, wenxue/K-7505-2014	ZHANG, BO/0000-0002-6352-1757; li, wenxue/0000-0002-0346-5300	NSFC [30925029, 30630055, 30800930, 30771832, 30901211]; National Key Basic Research and Development Program [2010CB912803]; National High Technology Research and Development Key Program of China [2008AA062504]; Ministry of Health of China [200902006]; Fundamental Research Funds for the Central Universities [10ykjc05, 10lgzd10]; Guangdong Province Universities and Colleges Pearl River	NSFC(National Natural Science Foundation of China (NSFC)); National Key Basic Research and Development Program(National Basic Research Program of China); National High Technology Research and Development Key Program of China(National High Technology Research and Development Program of China); Ministry of Health of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Province Universities and Colleges Pearl River	We thank Dr Richard Possemato for critical reading of the manuscript. This work was supported by a Distinguished Young Scholar of NSFC (30925029), Key Program of NSFC (30630055) and NSFC (30800930, 30771832, 30901211), National Key Basic Research and Development Program (2010CB912803), National High Technology Research and Development Key Program of China (2008AA062504), Ministry of Health of China (200902006), the Fundamental Research Funds for the Central Universities (10ykjc05 and 10lgzd10) and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme GDUPS (2010).	Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bielinski VA, 2007, EXP CELL RES, V313, P3117, DOI 10.1016/j.yexcr.2007.05.008; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Smetana JHC, 2006, BBA-PROTEINS PROTEOM, V1764, P724, DOI 10.1016/j.bbapap.2006.01.018; Deichmann M, 2001, MELANOMA RES, V11, P577, DOI 10.1097/00008390-200112000-00004; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Gibbons James J, 2009, Semin Oncol, V36 Suppl 3, pS3, DOI 10.1053/j.seminoncol.2009.10.011; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Irigaray P, 2010, CARCINOGENESIS, V31, P135, DOI 10.1093/carcin/bgp252; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Ji WD, 2008, CARCINOGENESIS, V29, P1267, DOI 10.1093/carcin/bgn012; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Kong M, 2007, J BIOL CHEM, V282, P29712, DOI 10.1074/jbc.M703159200; Kong M, 2009, MOL CELL, V36, P51, DOI 10.1016/j.molcel.2009.09.025; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; Ma Ru-lin, 2008, Zhonghua Yufang Yixue Zazhi, V42, P395; McConnell JL, 2010, BIOCHEMISTRY-US, V49, P1713, DOI 10.1021/bi901837h; McDonald WJ, 2010, J CELL BIOCHEM, V110, P1123, DOI 10.1002/jcb.22624; Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Onda M, 1997, GENOMICS, V46, P373, DOI 10.1006/geno.1997.5048; Pang YQ, 2008, TOXICOL APPL PHARM, V232, P478, DOI 10.1016/j.taap.2008.08.009; Pigazzi M, 2009, CANCER RES, V69, P2471, DOI 10.1158/0008-5472.CAN-08-3404; Prickett TD, 2007, MOL CELL BIOL, V27, P4217, DOI 10.1128/MCB.00067-07; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang B, 2008, CELL RES, V18, P974, DOI 10.1038/cr.2008.274; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang J, 2007, BIOCHEMISTRY-US, V46, P8807, DOI 10.1021/bi7007118; Yorimitsu T, 2009, AUTOPHAGY, V5, P616, DOI 10.4161/auto.5.5.8091; Zhang YY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000438	44	37	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2943	2953		10.1038/onc.2011.20	http://dx.doi.org/10.1038/onc.2011.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21339737				2022-12-28	WOS:000292245100005
J	Li, Y; Bavarva, JH; Wang, Z; Guo, J; Qian, C; Thibodeau, SN; Golemis, EA; Liu, W				Li, Y.; Bavarva, J. H.; Wang, Z.; Guo, J.; Qian, C.; Thibodeau, S. N.; Golemis, E. A.; Liu, W.			HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression	ONCOGENE			English	Article						HEF1; Wnt signaling; colorectal cancer; tumorigenesis	ENDOTHELIAL GROWTH-FACTOR; BETA-CATENIN; COLORECTAL-CANCER; EXPRESSION; TRANSCRIPTION; ACTIVATION; MUTATIONS; PHOSPHORYLATION; RECEPTORS; EFFECTOR	Misregulation of the canonical Wnt/beta-catenin pathway and aberrant activation of Wnt signaling target genes are common in colorectal cancer (CRC) and contribute to cancer progression. Altered expression of human enhancer of filamentation 1 (HEF1; also known as NEDD9 or Cas-L) has been implicated in progression of melanoma, breast, and CRC. However, the regulation of HEF1 and the role of HEF1 in CRC tumorigenesis are not fully understood. We here identify HEF1 as a novel Wnt signaling target. The expression of HEF1 was upregulated by Wnt-3a, beta-catenin, and Dvl2 in a dose-dependent manner, and was suppressed following beta-catenin downregulation by shRNA. In addition, elevated HEF1 mRNA and protein levels were observed in CRC cell lines and primary tumor tissues, as well as in the colon and adenoma polyps of Apc(Min/+) mice. Moreover, HEF1 levels in human colorectal tumor tissues increased with the tumor grade. Chromatin immunoprecipitation (ChIP) assays and promoter analyses revealed three functional T-cell factor (TCF)-binding sites in the promoter of HEF1 responsible for HEF1 induction by Wnt signaling. Ectopic expression of HEF1 increased cell proliferation and colony formation, while downregulation of HEF1 in SW480 cells by shRNA had the opposite effects and inhibited the xenograft tumor growth. Furthermore, overexpression of HEF1 in SW480 cells promoted cell migration and invasion. Together, our results determined a novel role of HEF1 as a mediator of the canonical Wnt/beta-catenin signaling pathway for cell proliferation, migration, and tumorigenesis, as well as an important player in colorectal tumorigenesis and progression. HEF1 may represent an attractive candidate for drug targeting in CRC. Oncogene (2011) 30, 2633-2643; doi:10.1038/onc.2010.632; published online 14 February 2011	[Li, Y.; Bavarva, J. H.; Wang, Z.; Guo, J.; Qian, C.; Liu, W.] Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Genet, New Orleans, LA 70112 USA; [Qian, C.; Thibodeau, S. N.; Liu, W.] Mayo Clin, Mayo Clin Coll Med, Dept Lab Med & Pathol, Rochester, MN USA; [Golemis, E. A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Mayo Clinic; Fox Chase Cancer Center	Liu, W (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Genet, 533 Bolivar St,CSRB 416, New Orleans, LA 70112 USA.	wliu2@lsuhsc.edu	LI, YINGCHUN/F-1238-2013	Golemis, Erica/0000-0003-3618-3673; Wang, Zemin/0000-0003-4189-578X	Louisiana Cancer Research Consortium; NIH [R01s CA63366, CA113342, CA06927]; NATIONAL CANCER INSTITUTE [R01CA113342, R01CA063366, P30CA006927, R29CA063366] Funding Source: NIH RePORTER	Louisiana Cancer Research Consortium; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Minjung Kim and Dr Lynda Chin (Harvard Medical School) for providing the shRNA-targeting HEF1. This study is supported by the funding from Louisiana Cancer Research Consortium (to WL). EAG is supported by NIH R01s CA63366 and CA113342, and by NIH core grant CA06927 (to Fox Chase Cancer Center).	Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Batistatou A, 2006, VIRCHOWS ARCH, V448, P763, DOI 10.1007/s00428-006-0183-8; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Donninger H, 2004, ONCOGENE, V23, P8065, DOI 10.1038/sj.onc.1207959; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Easwaran V, 2003, CANCER RES, V63, P3145; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Fashena SJ, 2002, J CELL SCI, V115, P99; Fritzmann J, 2009, GASTROENTEROLOGY, V137, P165, DOI 10.1053/j.gastro.2009.03.041; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; LEONE A, 1993, ONCOGENE, V8, P2325; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Liu T, 2002, J BIOL CHEM, V277, P47671, DOI 10.1074/jbc.M207458200; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lu DS, 2005, P NATL ACAD SCI USA, V102, P18567, DOI 10.1073/pnas.0509316102; Lucas JT, 2010, ONCOGENE, V29, P4449, DOI 10.1038/onc.2010.185; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Merrill RA, 2004, DEV DYNAM, V231, P564, DOI 10.1002/dvdy.20159; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Velmurugan B, 2010, NEOPLASIA, V12, P95, DOI 10.1593/neo.91718; Xia DR, 2010, CANCER RES, V70, P824, DOI 10.1158/0008-5472.CAN-09-2105; Yasuhara R, 2010, J BIOL CHEM, V285, P317, DOI 10.1074/jbc.M109.053926; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zheng MZ, 2002, J BIOL CHEM, V277, P39599, DOI 10.1074/jbc.M202263200	45	66	69	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2633	2643		10.1038/onc.2010.632	http://dx.doi.org/10.1038/onc.2010.632			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21317929	Green Published, Green Accepted			2022-12-28	WOS:000291677800004
J	Sangster-Guity, N; Conrad, BH; Papadopoulos, N; Bunz, F				Sangster-Guity, N.; Conrad, B. H.; Papadopoulos, N.; Bunz, F.			ATR mediates cisplatin resistance in a p53 genotype-specific manner	ONCOGENE			English	Article						p53; ATR; cisplatin; synthetic lethality; gene targeting	HUMAN CANCER-CELLS; DNA-DAMAGE RESPONSE; REPLICATION CHECKPOINT; ATAXIA-TELANGIECTASIA; CYCLE CHECKPOINTS; SECKEL-SYNDROME; ACTIVATION; SURVIVAL; PATHWAY; PHOSPHORYLATION	The protein kinase encoded by the ataxia telangiectasia and Rad3-related (ATR) gene is activated by DNA-damaging agents that are frequently used as anticancer therapeutics. Inhibition of ATR expression in cultured cancer cells has been demonstrated to increase sensitivity to chemotherapeutic drugs, including the DNA-cross-linking agent cisplatin. Cisplatin is a widely used and effective drug, but its use is associated with significant toxicity. Here, we demonstrate that genetic inhibition of ATR expression selectively enhanced cisplatin sensitivity in human colorectal cancer cells with inactivated p53. A knock-in strategy was used to restore wild-type p53 in cells harboring wild-type or mutant ATR alleles. Knock-in of functional p53 in ATR-deficient cells restored checkpoint function, suppressed apoptotic pathways and markedly increased clonogenic survival after cisplatin treatment. These results suggest that a strategy that combines specific inhibitors of ATR and conventional therapies might promote synthetic lethality in p53-deficient tumors, and thus minimize toxicity to normal tissues. Oncogene (2011) 30, 2526-2533; doi:10.1038/onc.2010.624; published online 24 January 2011	[Sangster-Guity, N.; Conrad, B. H.; Bunz, F.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA; [Sangster-Guity, N.; Papadopoulos, N.; Bunz, F.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Bunz, F (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, David H Koch Canc Res Bldg,1550 Orleans St,Room 4, Baltimore, MD 21231 USA.	fbunz@jhmi.edu	Papadopoulos, Nickolas/K-7272-2012	Conrad, Bogdan/0000-0002-2984-099X	Flight Attendant Medical Research Institute; NCI [T32CA121937]; NATIONAL CANCER INSTITUTE [T32CA121937, R01CA104253] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Flight Attendant Medical Research Institute and the NCI (T32CA121937).	Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Blasina A, 2008, MOL CANCER THER, V7, P2394, DOI 10.1158/1535-7163.MCT-07-2391; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Chung JH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000863; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Collis SJ, 2003, CANCER RES, V63, P1550; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Hurley PJ, 2007, ONCOGENE, V26, P2535, DOI 10.1038/sj.onc.1210049; Hurley PJ, 2007, CELL CYCLE, V6, P414, DOI 10.4161/cc.6.4.3886; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jirmanova L, 2005, CELL CYCLE, V4, P1428, DOI 10.4161/cc.4.10.2055; Karnitz LM, 2005, MOL PHARMACOL, V68, P1636, DOI 10.1124/mol.105.012716; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kodama M, 2010, MOL CELL BIOL, V30, P1620, DOI 10.1128/MCB.00810-09; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Murga M, 2009, NAT GENET, V41, P891, DOI 10.1038/ng.420; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Pirollo KF, 2000, ANTI-CANCER DRUG, V11, P419, DOI 10.1097/00001813-200007000-00002; Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Ruzankina Y, 2009, NAT GENET, V41, P1144, DOI 10.1038/ng.441; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wagner JM, 2010, PHARMACEUTICALS, V3, P1311, DOI 10.3390/ph3051311; Wagner JM, 2009, MOL PHARMACOL, V76, P208, DOI 10.1124/mol.109.055178; WALDMAN T, 1995, CANCER RES, V55, P5187; Wilsker D, 2007, MOL CANCER THER, V6, P1406, DOI 10.1158/1535-7163.MCT-06-0679; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Zenvirt S, 2010, ONCOGENE, V29, P6149, DOI 10.1038/onc.2010.343; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	49	52	54	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2526	2533		10.1038/onc.2010.624	http://dx.doi.org/10.1038/onc.2010.624			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258400	Green Accepted			2022-12-28	WOS:000291198400004
J	Ehata, S; Johansson, E; Katayama, R; Koike, S; Watanabe, A; Hoshino, Y; Katsuno, Y; Komuro, A; Koinuma, D; Kano, MR; Yashiro, M; Hirakawa, K; Aburatani, H; Fujita, N; Miyazono, K				Ehata, S.; Johansson, E.; Katayama, R.; Koike, S.; Watanabe, A.; Hoshino, Y.; Katsuno, Y.; Komuro, A.; Koinuma, D.; Kano, M. R.; Yashiro, M.; Hirakawa, K.; Aburatani, H.; Fujita, N.; Miyazono, K.			Transforming growth factor-beta decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells	ONCOGENE			English	Article						ABCG2; cancer-initiating cell; diffuse type gastric carcinoma; SP cell; TGF-beta	STEM-CELLS; TGF-BETA; SIDE-POPULATION; SCIRRHOUS CARCINOMA; METASTATIC MODEL; TUMOR-GROWTH; PROTEIN; GROWTH-FACTOR-BETA-1; DIFFERENTIATION; OVEREXPRESSION	Stem cells in normal tissues and cancer-initiating cells (CICs) are known to be enriched in side population (SP) cells. However, the factors responsible for the regulation of expression of ABCG2, involved in efflux of dyes, in SP cells have not been fully investigated. Here, we characterized the SP cells within diffuse-type gastric carcinoma, and examined the effects of transforming growth factor-beta (TGF-beta) on SP cells. Diffuse-type gastric carcinoma cells established from four independent patients universally contained SP cells between 1 and 4% of total cells, which displayed greater tumorigenicity than non-SP cells did. TGF-beta repressed the transcription of ABCG2 through direct binding of Smad2/3 to its promoter/enhancer, and the number of SP cells and the tumor-forming ability of cancer cells were decreased by TGF-beta, although ABCG2 is not directly involved in the tumor-forming ability of SP cells. Cancer cells from metastatic site expressed much higher levels of ABCG2 and included a greater percentage of SP cells than parental cancer cells did. SP cells are thus responsible for the progression of diffuse-type gastric carcinoma, and TGF-beta negatively contributes to maintain the CICs within the cancer. Oncogene (2011) 30, 1693-1705; doi:10.1038/onc.2010.546; published online 6 December 2010	[Ehata, S.; Johansson, E.; Hoshino, Y.; Katsuno, Y.; Komuro, A.; Koinuma, D.; Kano, M. R.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; [Ehata, S.; Katayama, R.; Koike, S.; Fujita, N.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku, Tokyo 170, Japan; [Watanabe, A.; Aburatani, H.] Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo, Japan; [Yashiro, M.; Hirakawa, K.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 558, Japan	University of Tokyo; Japanese Foundation for Cancer Research; University of Tokyo; Osaka Metropolitan University	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018; Katayama, Ryohei/K-8537-2014; Fujita, Naoya/A-7349-2010	Koinuma, Daizo/0000-0001-5611-2122; Katayama, Ryohei/0000-0001-7394-895X; Fujita, Naoya/0000-0002-9631-9264; Ehata, Shogo/0000-0002-6740-9391; Kano, Mitsunobu/0000-0003-1593-1855	Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Dr H Miyoshi (RIKEN) for the lentivirus vector system and Dr K Yanagihara (Yasuda Women's University) for HSC-43 cells. This study was supported by Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Grants-in-Aid for Young Scientists (Start-up) from the Japan Society for the Promotion of Science.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Fujihara T, 1998, CLIN EXP METASTAS, V16, P389; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Gradhand U, 2008, DRUG METAB REV, V40, P317, DOI [10.1080/03602530801952617, 10.1080/03602530801952617 ]; Grady William M., 2008, P889; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Inoue T, 1997, JPN J CANCER RES, V88, P152, DOI 10.1111/j.1349-7006.1997.tb00360.x; Iwasaki H, 2009, CANCER SCI, V100, P1166, DOI 10.1111/j.1349-7006.2009.01177.x; Katayama R, 2009, CANCER SCI, V100, P2060, DOI 10.1111/j.1349-7006.2009.01288.x; Kinugasa S, 1998, ONCOLOGY-BASEL, V55, P582, DOI 10.1159/000011916; Kiyono K, 2009, CANCER SCI, V100, P1809, DOI 10.1111/j.1349-7006.2009.01248.x; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Komuro A, 2009, JNCI-J NATL CANCER I, V101, P592, DOI 10.1093/jnci/djp058; LABOISSE CL, 1981, CANCER RES, V41, P310; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; MIZOI T, 1993, CANCER RES, V53, P183; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Rabindran SK, 2000, CANCER RES, V60, P47; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Takemura S, 2004, CANCER SCI, V95, P893, DOI 10.1111/j.1349-7006.2004.tb02199.x; Vagenas K, 2007, J SURG RES, V139, P182, DOI 10.1016/j.jss.2006.10.005; Velamakanni S, 2007, J BIOENERG BIOMEMBR, V39, P465, DOI 10.1007/s10863-007-9122-x; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; YANAGIHARA K, 1993, INT J CANCER, V54, P200, DOI 10.1002/ijc.2910540207; YASHIRO M, 1994, JPN J CANCER RES, V85, P883, DOI 10.1111/j.1349-7006.1994.tb02963.x; Yashiro M, 1996, CLIN EXP METASTAS, V14, P43, DOI 10.1007/BF00157685; Yashiro M, 2009, INT J ONCOL, V35, P997, DOI 10.3892/ijo_00000414; Yin LQ, 2008, CANCER RES, V68, P800, DOI 10.1158/0008-5472.CAN-07-2545; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	55	62	64	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1693	1705		10.1038/onc.2010.546	http://dx.doi.org/10.1038/onc.2010.546			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132002				2022-12-28	WOS:000289239400007
J	Bakiri, L; Reschke, MO; Gefroh, HA; Idarraga, MH; Polzer, K; Zenz, R; Schett, G; Wagner, EF				Bakiri, L.; Reschke, M. O.; Gefroh, H. A.; Idarraga, M. H.; Polzer, K.; Zenz, R.; Schett, G.; Wagner, E. F.			Functions of Fos phosphorylation in bone homeostasis, cytokine response and tumourigenesis	ONCOGENE			English	Article						AP-1; Fos; knock-in; mouse; phosphorylation	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; SKIN TUMOR-DEVELOPMENT; LACKING C-FOS; TRANSCRIPTIONAL ACTIVATION; PROTEASOMAL DEGRADATION; TRANSFORMING ACTIVITY; TRANSGENIC MICE; GROWTH-FACTOR; GENE	Mice lacking c-fos develop osteopetrosis due to a block in osteoclast differentiation. Carboxy-terminal phosphorylation of Fos on serine 374 by ERK1/2 and serine 362 by RSK1/2 regulates Fos stability and transactivation potential in vitro. To assess the physiological relevance of Fos phosphorylation in vivo, serine 362 and/or serine 374 was replaced by alanine (Fos362A, Fos374A and FosAA) or by phospho-mimetic aspartic acid (FosDD). Homozygous mutants were healthy and skeletogenesis was largely unaffected. Fos C-terminal phosphorylation, predominantly on serine 374, was found important for osteoclast differentiation in vitro and affected lipopolysaccharide (LPS)-induced cytokine response in vitro and in vivo. Importantly, skin papilloma development was delayed in FosAA, Fos362A and Rsk2-deficient mice, accelerated in FosDD mice and unaffected in Fos374A mutants. Furthermore, the related Fos protein and putative RSK2 target Fra1 failed to substitute for Fos in papilloma development. This indicates that phosphorylation of serines 362 and 374 exerts context-dependent roles in modulating Fos activity in vivo. Inhibition of Fos C-terminal phosphorylation on serine 362 by targeting RSK2 might be of therapeutic relevance for skin tumours. Oncogene (2011) 30, 1506-1517; doi: 10.1038/onc.2010.542; published online 29 November 2010	[Bakiri, L.; Reschke, M. O.; Gefroh, H. A.; Idarraga, M. H.; Polzer, K.; Zenz, R.; Schett, G.; Wagner, E. F.] CNIO, Canc Cell Biol Programme, F BBVA, Genes Dev & Dis Grp, E-28029 Madrid, Spain; [Idarraga, M. H.] Research Inst Mol Pathol IMP, Vienna, Austria; [Polzer, K.; Schett, G.] Univ Erlangen Nurenberg, Dept Internal Med 3, Erlangen, Germany	Centro Nacional de Investigaciones Oncologicas (CNIO); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Erlangen Nuremberg	Wagner, EF (corresponding author), CNIO, Canc Cell Biol Programme, F BBVA, Genes Dev & Dis Grp, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	ewagner@cnio.es	Bakiri, Latifa/AAP-1674-2020; Bakiri, Latifa/N-5780-2014	Wagner, Erwin F/0000-0001-7872-0196; bakiri, latifa/0000-0002-6300-2420	Boehringer Ingelheim (BI); BBVA-Foundation; ERC; EMBO; European Community [LSHM-CT-2003-504468]	Boehringer Ingelheim (BI)(Boehringer Ingelheim); BBVA-Foundation(BBVA Foundation); ERC(European Research Council (ERC)European Commission); EMBO(European Molecular Biology Organization (EMBO)); European Community(European Commission)	We are very grateful to Drs K Matsuo, Y Takada and R Khokha for critical comments and helpful suggestions, Drs F Mulero and RP Marshall for help with micro-computed tomography, U Moehle-Steinlein, E Andres, HC Theussl and V Komnenovic for technical assistance. The project was initiated at the IMP, which is funded by Boehringer Ingelheim (BI). EFW is funded by the BBVA-Foundation and by an ERC advanced Grant. Part of this work was funded by an EMBO postdoctoral fellowship to LB and the NoE Cells into Organs (LSHM-CT-2003-504468) program of the European Community.	Bakiri L, 2007, BONE, V40, P867, DOI 10.1016/j.bone.2006.11.005; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; CURRAN T, 1984, CELL, V36, P259; David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Durchdewald M, 2008, CANCER RES, V68, P6877, DOI 10.1158/0008-5472.CAN-08-0299; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Fleischmann A, 2003, J NEUROSCI, V23, P9116; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Koga K, 2009, IMMUNITY, V30, P372, DOI 10.1016/j.immuni.2008.12.021; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakakuki T, 2010, CELL, V141, P884, DOI 10.1016/j.cell.2010.03.054; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pellegrino MJ, 2006, J NEUROCHEM, V99, P1480, DOI 10.1111/j.1471-4159.2006.04250.x; Ray N, 2006, INT IMMUNOL, V18, P671, DOI 10.1093/intimm/dxl004; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Takada Y, 2010, J IMMUNOL, V184, P1014, DOI 10.4049/jimmunol.0901196; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	43	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1506	1517		10.1038/onc.2010.542	http://dx.doi.org/10.1038/onc.2010.542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119595	Green Accepted			2022-12-28	WOS:000288998300002
J	Chu, Y; Yang, X				Chu, Y.; Yang, X.			SUMO E3 ligase activity of TRIM proteins	ONCOGENE			English	Article						TRIM proteins; SUMO E3 ligase; sumoylation; PML; Mdm2; p53	RET FINGER PROTEIN; REGULATES P53; TUMOR-SUPPRESSOR; FAMILY PROTEINS; NUCLEAR-BODIES; C-JUN; PML; UBIQUITIN; SUMOYLATION; RING	SUMOylation governs numerous cellular processes and is essential to most eukaryotic life. Despite increasing recognition of the importance of this process, an extremely limited number of small ubiquitin-like modifier (SUMO) protein ligases (E3s) have been identified. Here we show that at least some members of the functionally diverse tripartite motif (TRIM) superfamily are SUMO E3s. These TRIM proteins bind both the SUMO-conjugating enzyme Ubc9 and substrates and strongly enhance transfer of SUMOs from Ubc9 to these substrates. Among the substrates of TRIM SUMO E3s are the tumor suppressor p53 and its principal antagonist Mdm2. The E3 activity depends on the TRIM motif, suggesting it to be the first widespread SUMO E3 motif. Given the large number of TRIM proteins, our results may greatly expand the identified SUMO E3s. Furthermore, TRIM E3 activity may be an important contributor to SUMOylation specificity and the versatile functions of TRIM proteins. Oncogene (2011) 30, 1108-1116; doi:10.1038/onc.2010.462; published online 25 October 2010	[Yang, X.] Univ Penn, Sch Med, Dept Canc Biol, 610 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19096 USA; [Yang, X.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19096 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Yang, X (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, 610 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19096 USA.	xyang@mail.med.upenn.edu			NIH [CA088868, GM060911]; NATIONAL CANCER INSTITUTE [R01CA088868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr PP Pandolfi for providing Pml<SUP>-/-</SUP> MEF cells and Drs V Yu, A-M Herr, F Rauscher III and TC Cox for TRIM-expressing plasmids. We also thank E Fischer and S Slattery for technical assistance and A Stonestrom for help with manuscript preparation. Supported by NIH (CA088868 and GM060911) to XY.	Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Cao TY, 1998, J CELL SCI, V111, P1319; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Duprez E, 1999, J CELL SCI, V112, P381; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; GILLOT I, 2009, INT J CELL BIOL; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lee MH, 2006, NAT CELL BIOL, V8, P1424, DOI 10.1038/ncb1512; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Quimby BB, 2006, ONCOGENE, V25, P2999, DOI 10.1038/sj.onc.1209335; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Townson SM, 2006, BIOCHEM BIOPH RES CO, V349, P540, DOI 10.1016/j.bbrc.2006.08.063; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wolf D, 2007, CELL, V131, P46, DOI 10.1016/j.cell.2007.07.026; Zhu SS, 2009, MOL CELL, V33, P570, DOI 10.1016/j.molcel.2009.02.008	43	136	141	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1108	1116		10.1038/onc.2010.462	http://dx.doi.org/10.1038/onc.2010.462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972456	Green Accepted			2022-12-28	WOS:000287964100009
J	Park, SY; Jeong, KJ; Panupinthu, N; Yu, S; Lee, J; Han, JW; Kim, JM; Lee, JS; Kang, J; Park, CG; Mills, GB; Lee, HY				Park, S. Y.; Jeong, K. J.; Panupinthu, N.; Yu, S.; Lee, J.; Han, J. W.; Kim, J. M.; Lee, J-S; Kang, J.; Park, C. G.; Mills, G. B.; Lee, H. Y.			Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression	ONCOGENE			English	Article						lysophosphatidic acid; human hepatocellular carcinoma cells; invasion; LPA1; matrix metalloproteinase-9	CANCER; ACTIVATION; MIGRATION; AUTOTAXIN; SECRETION; MOTILITY; GENE	Lysophosphatidic acid (LPA), produced extracellularly by autotaxin (ATX), has diverse biological activities implicated in tumor initiation and progression, including increasing cell survival, angiogenesis, invasion and metastasis. ATX, LPA and the matrix metalloproteinase (MMP)-9 have all been implicated in hepatocellular carcinoma (HCC) invasion and metastasis. We, thus sought to determine whether ATX with subsequent LPA production and action, including induction of MMP-9 could provide a unifying mechanism. ATX transcripts and LPA receptor type 1 (LPA1) protein are elevated in HCC compared with normal tissues. Silencing or pharmacological inhibition of LPA1 significantly attenuated LPA-induced MMP-9 expression and HCC cell invasion. Further, reducing MMP-9 activity or expression significantly inhibits LPA-induced HCC cell invasion, demonstrating that MMP-9 is downstream of LPA1. Inhibition of phosphoinositide-3 kinase (PI3K) signaling or dominant-negative mutants of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK) abrogated LPA-induced MMP-9 expression and subsequent invasion. We thus demonstrate a mechanistic cascade of ATX-producing LPA with LPA activating LPA1 and inducing MMP-9 through coordinate activation of the PI3K and the p38 MPAK signaling cascades, providing novel biomarkers and potential therapeutic targets for HCC. Oncogene (2011) 30, 1351-1359; doi: 10.1038/onc.2010.517; published online 22 November 2010	[Park, S. Y.; Jeong, K. J.; Kang, J.; Park, C. G.; Lee, H. Y.] Konyang Univ, Dept Pharmacol, Coll Med, Taejon 302718, South Korea; [Panupinthu, N.; Yu, S.; Lee, J-S; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Lee, J.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Han, J. W.] Sungkyunkwan Univ, Dept Biochem & Mol Biol, Sch Pharm, Suwon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Canc Res Inst, Reg Canc Ctr, Taejon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Taejon, South Korea	Konyang University; Konyang University Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Sungkyunkwan University (SKKU); Chungnam National University; Chungnam National University	Lee, HY (corresponding author), Konyang Univ, Dept Pharmacol, Coll Med, 821 Med Sci Bldg,681 Gasuwon Dong, Taejon 302718, South Korea.	hoi@konyang.ac.kr	Kang, Jaeku/D-4933-2011; Jeong, Kangjin/HGT-9268-2022	Kang, Jaeku/0000-0002-8660-7940; KIM, JIN MAN/0000-0003-0905-9730	Cancer Metastasis Research Center at Yonsei University; Ministry of Education, Science and Technology [2010-0022216]; Korean Institute of Environmental Science and Technology; Korea Science & Engineering Foundation through the Infection Signaling Network Research Center at Chungnam National University [R13-2007-020-01000-0]; Breast Cancer Research foundation; NCI [RO1CA092160]; NATIONAL CANCER INSTITUTE [R01CA092160] Funding Source: NIH RePORTER	Cancer Metastasis Research Center at Yonsei University; Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Institute of Environmental Science and Technology; Korea Science & Engineering Foundation through the Infection Signaling Network Research Center at Chungnam National University; Breast Cancer Research foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by the Korea Science and the Engineering Fund through the Cancer Metastasis Research Center at Yonsei University (HYL), by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0022216, HYL) and by the Korean Institute of Environmental Science and Technology and the Korea Science & Engineering Foundation through the Infection Signaling Network Research Center (R13-2007-020-01000-0) at Chungnam National University (JMK). GBM and NP are supported by a grant from the Breast Cancer Research foundation and NCI RO1CA092160.	Arii S, 1996, HEPATOLOGY, V24, P316; Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103; Brinkmann V, 2007, PHARMACOL THERAPEUT, V115, P84, DOI 10.1016/j.pharmthera.2007.04.006; Byun HS, 2008, EXP MOL MED, V40, P186, DOI 10.3858/emm.2008.40.2.186; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hayasaka A, 1996, HEPATOLOGY, V24, P1058; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Jiang YF, 2000, WORLD J GASTROENTERO, V6, P61, DOI 10.3748/wjg.v6.i1.61; Kim JH, 2008, CHEM-BIOL INTERACT, V171, P133, DOI 10.1016/j.cbi.2007.07.008; Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; McKenna GJ, 2002, AM J SURG, V183, P588, DOI 10.1016/S0002-9610(02)00833-4; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Murph MM, 2008, BBA-MOL CELL BIOL L, V1781, P547, DOI 10.1016/j.bbalip.2008.04.007; Murph MM, 2003, J CELL SCI, V116, P1969, DOI 10.1242/jcs.00397; Noguchi K, 2009, CURR OPIN PHARMACOL, V9, P15, DOI 10.1016/j.coph.2008.11.010; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Seo EH, 2008, J MICROBIOL BIOTECHN, V18, P1606; Shida D, 2003, CANCER RES, V63, P1706; Simon C, 1998, CANCER RES, V58, P1135; SKILL NJ, 2009, J SURG RES IN PRESS; Wang DS, 2004, WORLD J GASTROENTERO, V10, P299; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Wu JM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-71; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330; Zhao Z, 1999, Zhonghua Gan Zang Bing Za Zhi, V7, P140; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	34	110	122	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1351	1359		10.1038/onc.2010.517	http://dx.doi.org/10.1038/onc.2010.517			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21102517				2022-12-28	WOS:000288492100009
J	Rugo, RE; Mutamba, JT; Mohan, KN; Yee, T; Chaillet, JR; Greenberger, JS; Engelward, BP				Rugo, R. E.; Mutamba, J. T.; Mohan, K. N.; Yee, T.; Chaillet, J. R.; Greenberger, J. S.; Engelward, B. P.			Methyltransferases mediate cell memory of a genotoxic insult	ONCOGENE			English	Article						epigenetics; memory; genomic instability; methyltransferase; bystander effect; persistent effects	DELAYED GENOMIC INSTABILITY; IONIZING-RADIATION; IN-VIVO; CHROMOSOMAL INSTABILITY; UNIRRADIATED CELLS; ALPHA-PARTICLES; DNA METHYLATION; BYSTANDER CELLS; EXPOSURE; DNMT1	Characterization of the direct effects of DNA-damaging agents shows how DNA lesions lead to specific mutations. Yet, serum from Hiroshima survivors, Chernobyl liquidators and radiotherapy patients can induce a clastogenic effect on naive cells, showing indirect induction of genomic instability that persists years after exposure. Such indirect effects are not restricted to ionizing radiation, as chemical genotoxins also induce heritable and transmissible genomic instability phenotypes. Although such indirect induction of genomic instability is well described, the underlying mechanism has remained enigmatic. Here, we show that mouse embryonic stem cells exposed to gamma-radiation bear the effects of the insult for weeks. Specifically, conditioned media from the progeny of exposed cells can induce DNA damage and homologous recombination in naive cells. Notably, cells exposed to conditioned media also elicit a genome-destabilizing effect on their neighbouring cells, thus demonstrating transmission of genomic instability. Moreover, we show that the underlying basis for the memory of an insult is completely dependent on two of the major DNA cytosine methyltransferases, Dnmt1 and Dnmt3a. Targeted disruption of these genes in exposed cells completely eliminates transmission of genomic instability. Furthermore, transient inactivation of Dnmt1, using a tet-suppressible allele, clears the memory of the insult, thus protecting neighbouring cells from indirect induction of genomic instability. We have thus demonstrated that a single exposure can lead to long-term, genome-destabilizing effects that spread from cell to cell, and we provide a specific molecular mechanism for these persistent bystander effects. Collectively, our results impact the current understanding of risks from toxin exposures and suggest modes of intervention for suppressing genomic instability in people exposed to carcinogenic genotoxins. Oncogene (2011) 30, 751-756; doi:10.1038/onc.2010.480; published online 8 November 2010	[Rugo, R. E.; Mutamba, J. T.; Yee, T.; Engelward, B. P.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Mohan, K. N.; Chaillet, J. R.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Greenberger, J. S.] Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA USA	Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Engelward, BP (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave,16-743, Cambridge, MA 02139 USA.	bevin@mit.edu	Mohan, Kommu Naga/HIK-1746-2022		NIH [RO1-CA83876-8]; NIH/NIAID CMCR [U19 AI068021]; Department of Energy [DE-FG02-05ER64053]; NIEHS Center for Environmental Health Sciences [P30-ES002109]; TY; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD044133] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA083876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIAID CMCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Energy(United States Department of Energy (DOE)); NIEHS Center for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); TY; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank M Okano and E Li for MTase-deficient ES cells. This work was supported primarily by NIH Grant RO1-CA83876-8, NIH/NIAID CMCR U19 AI068021, with partial support from the Department of Energy DE-FG02-05ER64053. We thank the NIEHS Center for Environmental Health Sciences (P30-ES002109), the Cancer Research Center Flow Cytometry Facility and Debby Pheasant for technical support. We thank Benjamin Greenberger, Paavni Komanduri and Werner Olipitz for their contributions.; RER designed and performed all experiments with support from TY; KNM and JRC engineered the dox controllable Dnmt1 system and performed western analysis; BPE prepared the paper with support from JTM; BPE and JSG oversaw the study design. All authors discussed the results and commented on the paper.	Azzam EI, 2002, CANCER RES, V62, P5436; BENDER MA, 1962, RADIAT RES, V16, P44, DOI 10.2307/3571128; Borowczyk E, 2009, P NATL ACAD SCI USA, V106, P20806, DOI 10.1073/pnas.0905668106; Burr KL, 2010, RADIAT RES, V173, P760, DOI 10.1667/RR1937.1; CHANG WP, 1992, CARCINOGENESIS, V13, P923, DOI 10.1093/carcin/13.6.923; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Dickey JS, 2009, CARCINOGENESIS, V30, P1686, DOI 10.1093/carcin/bgp192; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Goldberg Z, 2002, INT J ONCOL, V21, P337; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Huang L, 2007, CANCER RES, V67, P1099, DOI 10.1158/0008-5472.CAN-06-3697; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kim M, 2004, NUCLEIC ACIDS RES, V32, P5742, DOI 10.1093/nar/gkh912; Koturbash I, 2006, ONCOGENE, V25, P4267, DOI 10.1038/sj.onc.1209467; Kovalchuk O, 2008, ENVIRON MOL MUTAGEN, V49, P16, DOI 10.1002/em.20361; Lei H, 1996, DEVELOPMENT, V122, P3195; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Limoli CL, 1998, PHOTOCHEM PHOTOBIOL, V67, P233, DOI 10.1562/0031-8655(1998)067<0233:IOCAAD>2.3.CO;2; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; Lorimore SA, 2005, CANCER RES, V65, P5668, DOI 10.1158/0008-5472.CAN-05-0834; Lorimore SA, 2003, ONCOGENE, V22, P7058, DOI 10.1038/sj.onc.1207044; Maltseva DV, 2010, BIOCHEMISTRY-MOSCOW+, V75, P173, DOI 10.1134/S0006297910020070; Maxwell CA, 2008, CANCER RES, V68, P8304, DOI 10.1158/0008-5472.CAN-08-1212; Morgan WF, 2005, P NATL ACAD SCI USA, V102, P14127, DOI 10.1073/pnas.0507119102; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT PROT DOSIM, V99, P163, DOI 10.1093/oxfordjournals.rpd.a006752; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Mothersill Carmel, 2006, Dose-Response, V4, P283, DOI 10.2203/dose-response.06-111.Mothersill; Mothersill C, 2007, ENVIRON SCI TECHNOL, V41, P3382, DOI 10.1021/es062978n; Mothersill Carmel, 2005, Med Confl Surviv, V21, P101, DOI 10.1080/13623690500073398; Nagar S, 2003, CANCER RES, V63, P324; NAGASAWA H, 1992, CANCER RES, V52, P6394; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; PANT GS, 1977, HIROSHIMA J MED SCI, V26, P149; Rodier F, 2009, NAT CELL BIOL, V11, P1272, DOI 10.1038/ncb1009-1272a; Rugo RE, 2005, ONCOGENE, V24, P5016, DOI 10.1038/sj.onc.1208690; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; Tsumura A, 2006, GENES CELLS, V11, P805, DOI 10.1111/j.1365-2443.2006.00984.x; Watson GE, 2000, CANCER RES, V60, P5608; Yang G, 2008, RADIAT RES, V170, P372, DOI 10.1667/RR1324.1; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	55	25	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					751	756		10.1038/onc.2010.480	http://dx.doi.org/10.1038/onc.2010.480			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	21057543	Green Accepted, Green Submitted			2022-12-28	WOS:000287192000011
J	Legros, S; Boxus, M; Gatot, JS; Van Lint, C; Kruys, V; Kettmann, R; Twizere, JC; Dequiedt, F				Legros, S.; Boxus, M.; Gatot, J. S.; Van Lint, C.; Kruys, V.; Kettmann, R.; Twizere, J. C.; Dequiedt, F.			The HTLV-1 Tax protein inhibits formation of stress granules by interacting with histone deacetylase 6	ONCOGENE			English	Article						HTLV-I; Tax; p-bodies; stress	VIRUS TYPE-1 TAX; NF-KAPPA-B; DNA-DAMAGE-RESPONSE; T-LYMPHOTROPIC-VIRUS; I TAX; MESSENGER-RNA; PROCESSING BODIES; EIF2-ALPHA PHOSPHORYLATION; GENE-EXPRESSION; ONCOPROTEIN	Human T cell leukemia virus type-1 (HTLV-1) is the causative agent of a fatal adult T-cell leukemia. Through deregulation of multiple cellular signaling pathways the viral Tax protein has a pivotal role in T-cell transformation. In response to stressful stimuli, cells mount a cellular stress response to limit the damage that environmental forces inflict on DNA or proteins. During stress response, cells postpone the translation of most cellular mRNAs, which are gathered into cytoplasmic mRNA-silencing foci called stress granules (SGs) and allocate their available resources towards the production of dedicated stress-management proteins. Here we demonstrate that Tax controls the formation of SGs and interferes with the cellular stress response pathway. In agreement with previous reports, we observed that Tax relocates from the nucleus to the cytoplasm in response to environmental stress. We found that the presence of Tax in the cytoplasm of stressed cells prevents the formation of SGs and counteracts the shutoff of specific host proteins. Unexpectedly, nuclear localization of Tax promotes spontaneous aggregation of SGs, even in the absence of stress. Mutant analysis revealed that the SG inhibitory capacity of Tax is independent of its transcriptional abilities but relies on its interaction with histone deacetylase 6, a critical component of SGs. Importantly, the stress-protective effect of Tax was also observed in the context of HTLV-1 infected cells, which were shown to be less prone to form SGs and undergo apoptosis under arsenite exposure. These observations identify Tax as the first virally encoded inhibitory component of SGs and unravel a new strategy developed by HTLV-1 to deregulate normal cell processes. We postulate that inhibition of the stress response pathway by Tax would favor cell survival under stressful conditions and may have an important role in HTLV-1-induced cellular transformation. Oncogene (2011) 30, 4050-4062; doi:10.1038/onc.2011.120; published online 2 May 2011	[Legros, S.; Boxus, M.; Kettmann, R.; Twizere, J. C.; Dequiedt, F.] Univ Liege ULg, Gembloux Agrobio Tech, Ctr Mol & Cellular Biol, Gembloux, Belgium; [Gatot, J. S.; Van Lint, C.] Free Univ Brussels ULB, IBMM, Ctr Mol Virol, Gosselies, Belgium; [Kruys, V.] Free Univ Brussels ULB, IBMM, Ctr Mol Biol Gene, Gosselies, Belgium; [Twizere, J. C.; Dequiedt, F.] Univ Liege ULg, GIGA Res, Lab Prot Signaling & Interact, Liege, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; University of Liege	Dequiedt, F (corresponding author), Univ Liege ULg, Gembloux Agrobio Tech, Ctr Mol & Cellular Biol, 13 Av Marechal Juin,Bat92, B-5030 Namur, Belgium.	fdequiedt@ulg.ac.be	Twizere, Jean-Claude/AAG-3706-2019; Kruys, Veronique I/N-6613-2018	Dequiedt, Franck/0000-0003-1234-7477; TWIZERE, Jean-Claude/0000-0002-8683-705X; Kruys, Veronique/0000-0002-3144-5403	Belgian Foundation Against Cancer [IUAP-BELSPOPVI/28]	Belgian Foundation Against Cancer	We thank all members of the Dequiedt laboratory for helpful and stimulating discussions. This work was supported by the Belgian National Fund for Scientific Research, the Televie (7.4613.09), the Belgian Foundation Against Cancer, the Interuniversity Attraction Poles Program-Belgian Science Policy (IUAP-BELSPOPVI/28). FD and JCT are Research Associates, MB is a Postdoctoral Researcher, SL is a FRIA Fellow and R.K. is a Research Director of the Belgian National Fund for Scientific Research.	Alefantis T, 2005, J BIOMED SCI, V12, P961, DOI 10.1007/s11373-005-9026-x; Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003; Anderson P, 2009, NAT REV MOL CELL BIO, V10, P430, DOI 10.1038/nrm2694; Asquith B, 2008, TRENDS IMMUNOL, V29, P4, DOI 10.1016/j.it.2007.09.006; Beckham CJ, 2008, CELL HOST MICROBE, V3, P206, DOI 10.1016/j.chom.2008.03.004; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Buchan JR, 2009, MOL CELL, V36, P932, DOI 10.1016/j.molcel.2009.11.020; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; Dunand-Sauthier I, 2002, MOL BIOL CELL, V13, P1626, DOI 10.1091/mbc.01-06-0301; Durkin SS, 2008, J BIOL CHEM, V283, P36311, DOI 10.1074/jbc.M804931200; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Emara MM, 2007, P NATL ACAD SCI USA, V104, P9041, DOI 10.1073/pnas.0703348104; Esclatine A, 2004, J VIROL, V78, P8582, DOI 10.1128/JVI.78.16.8582-8592.2004; Gatza ML, 2006, J VIROL, V80, P6657, DOI 10.1128/JVI.02270-05; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Gupta SK, 2007, J BIOL CHEM, V282, P29431, DOI 10.1074/jbc.M704110200; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kedersha N, 2007, METHOD ENZYMOL, V431, P61, DOI 10.1016/S0076-6879(07)31005-7; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kinjo T, 2010, J VIROL, V84, P5431, DOI 10.1128/JVI.02460-09; Kwon S, 2007, GENE DEV, V21, P3381, DOI 10.1101/gad.461107; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Legros S, 2009, FRONT BIOSCI-LANDMRK, V14, P4138, DOI 10.2741/3518; Lodewick J, 2009, VIROLOGY, V386, P68, DOI 10.1016/j.virol.2008.12.043; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McInerney GM, 2005, MOL BIOL CELL, V16, P3753, DOI 10.1091/mbc.E05-02-0124; MIWA M, 1984, GANN, V75, P752; Montero H, 2008, J VIROL, V82, P1496, DOI 10.1128/JVI.01779-07; MYDLARSKI MB, 1993, BRAIN RES, V627, P113, DOI 10.1016/0006-8993(93)90754-B; Nasr R, 2005, ONCOGENE, V24, P419, DOI 10.1038/sj.onc.1208212; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pothof J, 2009, CELL CYCLE, V8, P3462, DOI 10.4161/cc.8.21.9835; Pothof J, 2009, EMBO J, V28, P2090, DOI 10.1038/emboj.2009.156; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Raaben M, 2007, CELL MICROBIOL, V9, P2218, DOI 10.1111/j.1462-5822.2007.00951.x; Schutz S, 2007, CELL HOST MICROBE, V2, P284, DOI 10.1016/j.chom.2007.10.009; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SIVANANDHAM M, 1989, IMMUNOL LETT, V23, P149, DOI 10.1016/0165-2478(89)90128-4; Smith JA, 2006, J VIROL, V80, P2019, DOI 10.1128/JVI.80.4.2019-2033.2006; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Tsuji T, 2007, J BIOL CHEM, V282, P13875, DOI 10.1074/jbc.M611629200; Twizere JC, 2003, J NATL CANCER I, V95, P1846, DOI 10.1093/jnci/djg118; Ventoso I, 2006, GENE DEV, V20, P87, DOI 10.1101/gad.357006; Villanueva R, 2006, ONCOL REP, V16, P581; White JP, 2007, CELL HOST MICROBE, V2, P295, DOI 10.1016/j.chom.2007.08.006; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x	61	39	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4050	4062		10.1038/onc.2011.120	http://dx.doi.org/10.1038/onc.2011.120			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21532619	Green Published			2022-12-28	WOS:000295121600006
J	Lind, GE; Raiborg, C; Danielsen, SA; Rognum, TO; Thiis-Evensen, E; Hoff, G; Nesbakken, A; Stenmark, H; Lothe, RA				Lind, G. E.; Raiborg, C.; Danielsen, S. A.; Rognum, T. O.; Thiis-Evensen, E.; Hoff, G.; Nesbakken, A.; Stenmark, H.; Lothe, R. A.			SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis	ONCOGENE			English	Article						colorectal neoplasia; cytokinesis; early detection; methylation; Spartin; SPG20	HEREDITARY SPASTIC PARAPLEGIA; TROYER-SYNDROME; PROTEIN SPARTIN; HYPERMETHYLATED GENES; DNA METHYLATION; FECAL DNA; CELLS; IDENTIFICATION; TUMORIGENESIS; INTERACTS	Colorectal cancer is a common disease with high mortality. Suitable biomarkers for detection of tumors at an early curable stage would significantly improve patient survival. Here, we show that the SPG20 (spastic paraplegia-20) promoter, encoding the multifunctional Spartin protein, is hypermethylated in 89% of colorectal carcinomas, 78% of adenomas and only 1% of normal mucosa samples. SPG20 methylation was also present in a pilot series of stool samples and corresponding tumors from colorectal cancer patients. SPG20 promoter hypermethylation resulted in loss of mRNA expression in various cancer types and subsequent depletion of Spartin. We further showed that Spartin down-regulation in cancer cells resulted in cytokinesis arrest, which was reversed when SPG20 methylation was inhibited. The present study identifies SPG20 promoter hypermethylation as a biomarker suitable for non-invasive detection of colorectal cancer, and a possible mechanism for cytokinesis arrest in colorectal tumorigenesis. Oncogene (2011) 30, 3967-3978; doi:10.1038/onc.2011.109; published online 18 April 2011	[Lind, G. E.; Danielsen, S. A.; Lothe, R. A.] Oslo Univ Hosp, Dept Canc Prevent, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway; [Lind, G. E.; Raiborg, C.; Danielsen, S. A.; Nesbakken, A.; Stenmark, H.; Lothe, R. A.] Univ Oslo, Ctr Canc Biomed, Fac Med, Oslo, Norway; [Raiborg, C.; Stenmark, H.] Oslo Univ Hosp, Dept Biochem, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway; [Rognum, T. O.] Oslo Univ Hosp, Inst Forens Med, Rikshosp, N-0310 Oslo, Norway; [Thiis-Evensen, E.] Oslo Univ Hosp, Dept Med, Rikshosp, N-0310 Oslo, Norway; [Hoff, G.] Telemark Hosp, Dept Med, Div Gastroenterol, Skien, Norway; [Nesbakken, A.] Oslo Univ Hosp, Dept Surg, Aker Hosp, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Telemark Hospital Trust; University of Oslo	Lothe, RA (corresponding author), Oslo Univ Hosp, Dept Canc Prevent, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway.	rlothe@rr-research.no	Stenmark, Harald/B-8868-2008	Lothe, Ragnhild A./0000-0002-1693-1032	Norwegian Cancer Society [PR-2008-0163, PR-2007-0063, PR-2006-0442, A95068]; European Research Council	Norwegian Cancer Society(Norwegian Cancer Society); European Research Council(European Research Council (ERC)European Commission)	We are grateful to Dr Hans Geir Eiken for providing expertise on stool DNA extraction and Hilde Honne, Mette Eknaes, Merete Hektoen and Kim Andresen for technical assistance. The breast cancer and pancreatic cancer cell lines were provided by Dr Anne Kallioniemi (Tampere University Hospital, Finland). The non-commercially available colon cancer cell lines were provided by Dr Richard Hamelin (INSERM, Paris, France). Financial support: This study is supported by grants from the Norwegian Cancer Society: GEL as a senior research fellow (PR-2008-0163), CR as a postdoctoral fellow (PR-2007-0063, HS) and SAD as a PhD student (PR-2006-0442, RAL), long-term grant (A95068, RAL). HS is supported by an Advanced Grant from the European Research Council.	Bakowska JC, 2005, BIOCHEM BIOPH RES CO, V334, P1042, DOI 10.1016/j.bbrc.2005.06.201; Bakowska JC, 2008, ARCH NEUROL-CHICAGO, V65, P520, DOI 10.1001/archneur.65.4.520; Bakowska JC, 2007, MOL BIOL CELL, V18, P1683, DOI 10.1091/mbc.E06-09-0833; Bu YQ, 2008, ONCOLOGY-BASEL, V74, P198, DOI 10.1159/000151367; Cabezas A, 2005, J CELL SCI, V118, P2625, DOI 10.1242/jcs.02382; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204; Ciccarelli FD, 2003, GENOMICS, V81, P437, DOI 10.1016/S0888-7543(03)00011-9; Connell JW, 2009, TRAFFIC, V10, P42, DOI 10.1111/j.1600-0854.2008.00847.x; deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808; Eastman SW, 2009, J CELL BIOL, V184, P881, DOI 10.1083/jcb.200808041; Edwards TL, 2009, BIOCHEM J, V423, P31, DOI 10.1042/BJ20082398; Errico A, 2004, HUM MOL GENET, V13, P2121, DOI 10.1093/hmg/ddh223; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Goh L, 2007, BIOINFORMATICS, V23, P281, DOI 10.1093/bioinformatics/btl620; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Hooper C, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-72; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6; Kron K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004830; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lind GE, 2007, GASTROENTEROLOGY, V132, P1631, DOI 10.1053/j.gastro.2007.03.003; Lind GE, 2006, CELL ONCOL, V28, P259; Lu J, 2006, J NEUROCHEM, V98, P1908, DOI 10.1111/j.1471-4159.2006.04008.x; Milewska M, 2009, J NEUROCHEM, V111, P1022, DOI 10.1111/j.1471-4159.2009.06382.x; Muller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Patel H, 2002, NAT GENET, V31, P347, DOI 10.1038/ng937; Pointis G, 2010, PHILOS T R SOC B, V365, P1607, DOI 10.1098/rstb.2009.0114; Proukakis C, 2004, J NEUROL, V251, P1105, DOI 10.1007/s00415-004-0491-3; Renvoise B, 2010, MOL BIOL CELL, V21, P3293, DOI 10.1091/mbc.E09-10-0879; Robay D, 2006, EXP CELL RES, V312, P2764, DOI 10.1016/j.yexcr.2006.05.003; Sagona AP, 2010, FEBS LETT, V584, P2652, DOI 10.1016/j.febslet.2010.03.044; Sagona AP, 2010, NAT CELL BIOL, V12, P362, DOI 10.1038/ncb2036; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Steigemann P, 2009, TRENDS CELL BIOL, V19, P606, DOI 10.1016/j.tcb.2009.07.008; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Tsang HTH, 2009, HUM MOL GENET, V18, P3805, DOI 10.1093/hmg/ddp324; Ventela S, 2003, MOL BIOL CELL, V14, P2768, DOI 10.1091/mbc.E02-10-0647; Vidulescu C, 2004, J CELL MOL MED, V8, P388, DOI 10.1111/j.1582-4934.2004.tb00328.x; Zhang WP, 2007, SCI CHINA SER G, V50, P1, DOI 10.1007/s11433-007-0010-5; Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967	46	57	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3967	3978		10.1038/onc.2011.109	http://dx.doi.org/10.1038/onc.2011.109			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21499309	Green Published, hybrid			2022-12-28	WOS:000294890400006
J	Chen, R; Liliental, JE; Kowalski, PE; Lu, Q; Cohen, SN				Chen, R.; Liliental, J. E.; Kowalski, P. E.; Lu, Q.; Cohen, S. N.			Regulation of transcription of hypoxia-inducible factor-1 alpha (HIF-1 alpha) by heat shock factors HSF2 and HSF4	ONCOGENE			English	Article						heat shock factor; heat shock element; angiogenesis; HSE; VEGF; HIF-1 alpha	ENDOTHELIAL GROWTH-FACTOR; PROTEOTOXIC STRESS; FACTOR FAMILY; RESPONSE ELEMENT; LENS DEVELOPMENT; EXPRESSION; CELLS; GENE; INDUCTION; PROMOTER	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a principal regulator of angiogenesis and other cellular responses to hypoxic stress in both normal and tumor cells. To identify novel mechanisms that regulate expression of HIF-1 alpha, we designed a genome-wide screen for expressed sequence tags (ESTs) that when transcribed in the antisense direction increase production of the HIF-1 alpha target, vascular endothelial growth factor (VEGF), in human breast cancer cells. We discovered that heat shock factor (HSF) proteins 2 and 4-which previously have been implicated in the control of multiple genes that modulate cell growth and differentiation and protect against effects of environmental and cellular stresses-function together to maintain a steady state level of HIF-1 alpha transcription and VEGF production in these cells. We show both HSFs bind to discontinuous heat shock element (HSE) sequences we identified in the HIF-1 alpha promoter region and that downregulation of either HSF activates transcription of HIF-1 alpha. We further demonstrate that HSF2 and HSF4 displace each other from HSF/HSE complexes in the HIF-1 alpha promoter so that HIF-1 alpha transcription is also activated by overexpression of either HSFs. These results argue that HSF2 and HSF4 regulate transcription of HIF-1 alpha and that a critical balance between these HSF is required to maintain HIF-alpha expression in a repressed state. Our findings reveal a previously unsuspected role for HSFs in control of VEGF and other genes activated by canonical HIF-1 alpha-mediated signaling. Oncogene (2011) 30, 2570-2580; doi:10.1038/onc.2010.623; published online 24 January 2011	[Chen, R.; Liliental, J. E.; Kowalski, P. E.; Lu, Q.; Cohen, S. N.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Cohen, S. N.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Dept Genet, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	sncohen@stanford.edu			Kwoh-Ting Li Professorship; National Foundation for Cancer Research (NFCR)	Kwoh-Ting Li Professorship; National Foundation for Cancer Research (NFCR)	The study was supported by funds from the Kwoh-Ting Li Professorship to SNC, and by a grant from the National Foundation for Cancer Research (NFCR) to SNC.	Akerfelt M, 2008, P NATL ACAD SCI USA, V105, P11224, DOI 10.1073/pnas.0800620105; Akerfelt M, 2007, ANN NY ACAD SCI, V1113, P15, DOI 10.1196/annals.1391.005; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brahimi-Horn MC, 2007, BIOCHEM PHARMACOL, V73, P450, DOI 10.1016/j.bcp.2006.10.013; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Chang YH, 2006, GENE DEV, V20, P836, DOI 10.1101/gad.366906; Chi NC, 2004, CARDIOVASC RES, V61, P437, DOI 10.1016/j.cardiores.2003.11.033; Fraisl P, 2009, DEV CELL, V16, P167, DOI 10.1016/j.devcel.2009.01.003; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Fujimoto M, 2008, J BIOL CHEM, V283, P29961, DOI 10.1074/jbc.M804629200; Fujimoto M, 2010, FEBS J, V277, P4112, DOI 10.1111/j.1742-4658.2010.07827.x; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Jiang BH, 1997, CANCER RES, V57, P5328; Loison F, 2006, BIOCHEM J, V395, P223, DOI 10.1042/BJ20051190; Lu Q, 2004, P NATL ACAD SCI USA, V101, P17246, DOI 10.1073/pnas.0407794101; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Mazure NM, 1996, CANCER RES, V56, P3436; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Min JN, 2004, GENESIS, V40, P205, DOI 10.1002/gene.20087; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Murphy LA, 2008, EXP CELL RES, V314, P2224, DOI 10.1016/j.yexcr.2008.04.015; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nardinocchi L, 2009, BBA-MOL CELL RES, V1793, P368, DOI 10.1016/j.bbamcr.2008.10.013; Ng YS, 2006, EXP CELL RES, V312, P527, DOI 10.1016/j.yexcr.2005.11.008; Olenyuk BZ, 2004, P NATL ACAD SCI USA, V101, P16768, DOI 10.1073/pnas.0407617101; Ostling P, 2007, J BIOL CHEM, V282, P7077, DOI 10.1074/jbc.M607556200; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pipinikas C, 2008, BIOMARKERS, V13, P680, DOI 10.1080/13547500802591992 ; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Sandqvist A, 2009, MOL BIOL CELL, V20, P1340, DOI 10.1091/mbc.E08-08-0864; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Somasundaram T, 2004, J BIOL CHEM, V279, P44497, DOI 10.1074/jbc.M405813200; Tsuzuki Y, 2000, CANCER RES, V60, P6248; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Xing HY, 2005, SCIENCE, V307, P421, DOI 10.1126/science.1106478; Yamamoto N, 2009, FEBS J, V276, P1962, DOI 10.1111/j.1742-4658.2009.06923.x; Zhang J, 2008, J BIOL CHEM, V283, P7464, DOI 10.1074/jbc.M707122200; Zhang Y, 2001, J CELL BIOCHEM, V82, P692, DOI 10.1002/jcb.1191	43	31	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2570	2580		10.1038/onc.2010.623	http://dx.doi.org/10.1038/onc.2010.623			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258402				2022-12-28	WOS:000291198400008
J	Perier, A; Fregni, G; Wittnebel, S; Gad, S; Allard, M; Gervois, N; Escudier, B; Azzarone, B; Caignard, A				Perier, A.; Fregni, G.; Wittnebel, S.; Gad, S.; Allard, M.; Gervois, N.; Escudier, B.; Azzarone, B.; Caignard, A.			Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma	ONCOGENE			English	Article						von Hippel-Lindau mutation; NK cells; renal cell carcinoma; immunotherapy	TUMOR-SUPPRESSOR GENE; NK CELLS; IFN-GAMMA; HLA-G; DOWN-REGULATION; POOR SURVIVAL; EXPRESSION; CANCER; RECEPTORS; HYPOXIA	The tumor suppressor gene von Hippel-Lindau (VHL) is involved in the development of sporadic clear-cell renal cell carcinoma (RCC). VHL interferes with angiogenesis and also controls cell adhesion and invasion. Therapies that target VHL-controlled genes are currently being evaluated in RCC patients. RCC is a immunogenic tumor and treatment with interleukin-2 (IL2) or interferon (IFN)-alpha results in regression in some patients. We used two renal tumor cell lines (RCC6 and RCC4) carrying VHL loss-of-function mutations to investigate the role of mutant VHL in susceptibility to natural killer (NK) cell-mediated lysis. The RCC6 and RCC4 cell lines were transfected with the wild-type gene to restore the function of VHL. The presence of the gene in RCC cells downregulated hypoxia-inducible factor (HIF)-1 alpha and subsequently decreased vascular endothelial growth factor (VEGF) production. Relative to control transfectants and parental cells, pVHL-transfected cell lines activated resting and IL2-activated NK cells less strongly, as assessed by IFN gamma secretion, NK degranulation and cell lysis. NKG2A, a human leukocyte antigen (HLA)-I-specific inhibitory NK receptor, controls the lysis of tumor targets. We show that HLA-I expression in RCC-pVHL cells is stronger than that in parental and controls cells, although the expression of activating receptor NK ligands remains unchanged. Blocking NKG2A/HLA-I interactions substantially increased lysis of RCC-pVHL, but had little effect on the lysis of VHL-mutated RCC cell lines. In addition, in response to IFN alpha, the exponential growth of RCC-pVHL was inhibited more than that of RCC-pE cells, indicating that VHL mutations may be involved in IFN alpha resistance. These results indicate that a decreased expression of HLA-I molecules in mutated VHL renal tumor cells sensitizes them to NK-mediated lysis. These results suggest that combined immunotherapy with anti-angiogenic drugs may be beneficial for patients with mutated VHL. Oncogene (2011) 30, 2622-2632; doi:10.1038/onc.2010.638; published online 24 January 2011	[Perier, A.; Fregni, G.; Caignard, A.] Univ Paris 05, CNRS, INSERM, Inst Cochin,UMR 8104,U1016, F-75014 Paris, France; [Fregni, G.] Inst Gustave Roussy, INSERM, U753, F-94805 Villejuif, France; [Gad, S.] Inst Gustave Roussy, INSERM, U753, Lab Genet Oncol EPHE, F-94805 Villejuif, France; [Allard, M.; Gervois, N.] INSERM, U892, Nantes, France; [Escudier, B.] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France; [Azzarone, B.] Univ Paris 11, Hop Paul Brousse, INSERM, UMR 542, Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Caignard, A (corresponding author), Univ Paris 05, CNRS, INSERM, Inst Cochin,UMR 8104,U1016, Batiment Gustave Roussy,27 Rue Faubourg St Jacque, F-75014 Paris, France.	anne.caignard@inserm.fr	allard, mathilde/C-9577-2018; Gervois, Nadine/K-6658-2015; Azzarone, Bruno/AAH-9251-2019; Caignard, Anne/F-8159-2013	allard, mathilde/0000-0002-2217-1295; Gervois, Nadine/0000-0002-0092-3919; Azzarone, Bruno/0000-0002-5962-3849; Caignard, Anne/0000-0001-9923-6045; GAD (LAPITEAU), Sophie/0000-0002-3158-6791	INSERM; INCa; la Fondation pour la Recherche Medicale (FRM); la Ligue Nationale contre le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); INCa(Institut National du Cancer (INCA) France); la Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); la Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by grants from INSERM, INCa, la Fondation pour la Recherche Medicale (FRM) and la Ligue Nationale contre le Cancer. AP had a grant from FRM. We thank Dr Nadege Bercovici for helpful discussion and reading of manuscript.	Aggelis V, 2009, PROTEOMICS, V9, P2118, DOI 10.1002/pmic.200800756; Alberti L, 2004, INT J CANCER, V111, P653, DOI 10.1002/ijc.20287; Atkins D, 2004, J UROLOGY, V171, P885, DOI 10.1097/01.ju.0000094807.95420.fe; Atkins MB, 2009, CANCER-AM CANCER SOC, V115, P2327, DOI 10.1002/cncr.24231; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chuang SS, 2001, J IMMUNOL, V167, P6210, DOI 10.4049/jimmunol.167.11.6210; Cozar J, 2005, CANCER IMMUNOL IMMUN, V54, P858, DOI 10.1007/s00262-004-0646-1; Donskov F, 2002, BRIT J CANCER, V87, P194, DOI 10.1038/sj.bjc.6600437; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gad S, 2007, BRIT J CANCER, V96, P336, DOI 10.1038/sj.bjc.6603492; Gati A, 2004, INT J CANCER, V109, P393, DOI 10.1002/ijc.11730; Gilfillan S, 2008, J EXP MED, V205, P2965, DOI 10.1084/jem.20081752; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gobin SJP, 2000, HUM IMMUNOL, V61, P1102, DOI 10.1016/S0198-8859(00)00198-1; Grabmaier K, 2004, ONCOGENE, V23, P5624, DOI 10.1038/sj.onc.1207764; Ibrahim EC, 2001, CANCER RES, V61, P6838; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Kilburn BA, 2000, BIOL REPROD, V62, P739, DOI 10.1095/biolreprod62.3.739; Kopper L, 2006, PATHOL ONCOL RES, V12, P5, DOI 10.1007/BF02893425; Lahn M, 1999, EUR UROL, V35, P70, DOI 10.1159/000019821; Lanier LL, 2000, J EXP MED, V191, P1259, DOI 10.1084/jem.191.8.1259; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Linehan WM, 2009, CANCER-AM CANCER SOC, V115, P2252, DOI 10.1002/cncr.24230; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Mouillot G, 2007, HUM IMMUNOL, V68, P277, DOI 10.1016/j.humimm.2006.10.016; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Parker AS, 2005, UROLOGY, V65, P1090, DOI 10.1016/j.urology.2004.12.040; Patard JJ, 2009, BRIT J CANCER, V101, P1417, DOI 10.1038/sj.bjc.6605298; Patard JJ, 2008, INT J CANCER, V123, P395, DOI 10.1002/ijc.23496; Rajagopalan S, 2001, J IMMUNOL, V167, P1877, DOI 10.4049/jimmunol.167.4.1877; Reefman E, 2010, J IMMUNOL, V184, P4852, DOI 10.4049/jimmunol.0803954; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Schleypen JS, 2006, CLIN CANCER RES, V12, P718, DOI 10.1158/1078-0432.CCR-05-0857; Schleypen JS, 2003, INT J CANCER, V106, P905, DOI 10.1002/ijc.11321; Segerer S, 2006, KIDNEY INT, V69, P1765, DOI 10.1038/sj.ki.5000337; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Smits KM, 2008, CLIN CANCER RES, V14, P782, DOI 10.1158/1078-0432.CCR-07-1753; Urcan E, 2010, DENT MATER, V26, P51, DOI 10.1016/j.dental.2009.08.007; Viey E, 2005, J IMMUNOL, V174, P1338, DOI 10.4049/jimmunol.174.3.1338; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; Wittnebel S, 2007, CANCER RES, V67, P5594, DOI 10.1158/0008-5472.CAN-06-4406; Wysocki PJ, 2010, CANCER GENE THER, V17, P465, DOI 10.1038/cgt.2010.2; Yang JC, 2003, J CLIN ONCOL, V21, P3127, DOI 10.1200/JCO.2003.02.122; Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569; Zagzag D, 2005, LAB INVEST, V85, P328, DOI 10.1038/labinvest.3700233; Zhu J, 2006, J IMMUNOL METHODS, V309, P25, DOI 10.1016/j.jim.2005.10.018	54	22	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2622	2632		10.1038/onc.2010.638	http://dx.doi.org/10.1038/onc.2010.638			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21258414				2022-12-28	WOS:000291677800003
J	Dalvai, M; Mondesert, O; Bourdon, JC; Ducommun, B; Dozier, C				Dalvai, M.; Mondesert, O.; Bourdon, J-C; Ducommun, B.; Dozier, C.			Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors	ONCOGENE			English	Article						Cdc25B; p53; Sp1; NF-Y	CELL-CYCLE REGULATION; WILD-TYPE P53; BREAST-CANCER; DNA-DAMAGE; EXPRESSION; ACTIVATION; PHOSPHATASE; APOPTOSIS; GENES; TRIGGERS	Cdc25B phosphatases function as key players in G2/M cell cycle progression by activating the CDK1-cyclinB1 complexes. They also have an essential role in recovery from the G2/M checkpoint activated in response to DNA damage. Overexpression of Cdc25B results in bypass of the G2/M checkpoint and illegitimate entry into mitosis, and also causes replicative stress, leading to genomic instability. Thus, fine-tuning of Cdc25B expression level is critical for correct cell cycle progression and G2 checkpoint recovery. However, the transcriptional regulation of Cdc25B remains largely unknown. Earlier studies have shown that the tumor suppressor p53 overexpression transcriptionally represses Cdc25B; however, the molecular mechanism of this repression has not yet been elucidated, although it was suggested to occur through the induction of p21. Here we show that Cdc25B is downregulated by the basal level of p53 in multiple cell types. This downregulation also occurs in p21-/- cell lines, indicating that p21 is not required for p53-mediated regulation of Cdc25B. Deletion and mutation analyses of the Cdc25B promoter revealed that downregulation by p53 is dependent on the presence of functional Sp1/Sp3 and NF-Y binding sites. Furthermore, chromatin immuno-precipitation analyses show that p53 binds to the Cdc25B promoter and mediates transcriptional attenuation through the Sp1 and NF-Y transcription factors. Our results suggest that the inability to downregulate Cdc25B after loss of p53 might contribute to tumorigenesis. Oncogene (2011) 30, 2282-2288; doi:10.1038/onc.2010.588; published online 17 January 2011	[Dalvai, M.; Mondesert, O.; Ducommun, B.; Dozier, C.] Univ Toulouse, CNRS, LBCMCP, UMR 5088, F-31062 Toulouse, France; [Bourdon, J-C] Univ Dundee, Dept Surg & Mol Oncol, European Associated Lab, INSERM,U858,Coll Med, Dundee, Scotland; [Ducommun, B.] CHU Toulouse, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Dundee; CHU de Toulouse	Dozier, C (corresponding author), Univ Toulouse, CNRS, LBCMCP, UMR 5088, Bat 4R3B1,118 Route Narbonne, F-31062 Toulouse, France.	dozier@cict.fr	DOZIER, Christine/P-1539-2014; DUCOMMUN, Bernard/B-3208-2008; JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386; DUCOMMUN, Bernard/0000-0002-7126-8368	CNRS (Centre National de la Recherche Scientifique); Universite Paul Sabatier; CNRS, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer; Canceropole; la Ligue Nationale Contre le Cancer	CNRS (Centre National de la Recherche Scientifique)(Centre National de la Recherche Scientifique (CNRS)); Universite Paul Sabatier; CNRS, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer(Region Occitanie); Canceropole(Region Ile-de-France); la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	We thank Dr Bert Vogelstein (Howard Hughes Medical Institute, Baltimore USA) for providing the WT, p53-/- and p21-/- HCT116 cells. MD was a recipient of a postdoctoral fellowship from the CNRS (Centre National de la Recherche Scientifique). This work was supported by CNRS, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer, the Canceropole Grand Sud-Ouest and la Ligue Nationale Contre le Cancer (Equipe labellisee 2008).	Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Benatti P, 2008, NUCLEIC ACIDS RES, V36, P1415, DOI 10.1093/nar/gkm1046; Bocangel D, 2009, ANTICANCER RES, V29, P3741; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Brosh R, 2010, MOL BIOSYST, V6, P17, DOI 10.1039/b911416e; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Bugler B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-29; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Essafi-Benkhadir K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004478; Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Jin W, 2008, J BIOL CHEM, V283, P29671, DOI 10.1074/jbc.M802785200; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Lambertini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010369; Langerod A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1675; Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Miyata H, 2001, CANCER RES, V61, P3188; Muller GA, 2010, FEBS J, V277, P877, DOI 10.1111/j.1742-4658.2009.07508.x; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Scian MJ, 2008, ONCOGENE, V27, P2583, DOI 10.1038/sj.onc.1210898; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Troester MA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-276; Varmeh S, 2009, J BIOL CHEM, V284, P9475, DOI 10.1074/jbc.M900037200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	39	35	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2282	2288		10.1038/onc.2010.588	http://dx.doi.org/10.1038/onc.2010.588			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242964				2022-12-28	WOS:000290514600011
J	Rovillain, E; Mansfield, L; Caetano, C; Alvarez-Fernandez, M; Caballero, OL; Medema, RH; Hummerich, H; Jat, PS				Rovillain, E.; Mansfield, L.; Caetano, C.; Alvarez-Fernandez, M.; Caballero, O. L.; Medema, R. H.; Hummerich, H.; Jat, P. S.			Activation of nuclear factor-kappa B signalling promotes cellular senescence	ONCOGENE			English	Article						cellular senescence; conditional immortalisation; senescence bypass; differential expression, NF-kappa B signalling	HUMAN MAMMARY FIBROBLASTS; TELOMERASE ACTIVITY; CANCER; FOXM1; CELLS; NETWORK; PROLIFERATION; PROGRESSION; PATHWAYS; GENES	Cellular senescence is a programme of irreversible cell cycle arrest that normal cells undergo in response to progressive shortening of telomeres, changes in telomeric structure, oncogene activation or oxidative stress. The underlying signalling pathways, of major clinicopathological relevance, are unknown. We combined genome-wide expression profiling with genetic complementation to identify genes that are differentially expressed when conditionally immortalised human fibroblasts undergo senescence upon activation of the p16-pRB and p53-p21 tumour suppressor pathways. This identified 816 up and 961 downregulated genes whose expression was reversed when senescence was bypassed. Overlay of this data set with the meta-signatures of genes upregulated in cancer showed that nearly 50% of them were downregulated upon senescence showing that even though overcoming senescence may only be one of the events required for malignant transformation, nearly half of the genes upregulated in cancer are related to it. Moreover 65 of the up and 26 of the downregulated genes are known downstream targets of nuclear factor (NF)-kappa B suggesting that senescence was associated with activation of the NF-kappa B pathway. Direct perturbation of this pathway bypasses growth arrest indicating that activation of NF-kappa B signalling has a causal role in promoting senescence. Oncogene (2011) 30, 2356-2366; doi: 10.1038/onc.2010.611; published online 17 January 2011	[Rovillain, E.; Mansfield, L.; Caetano, C.; Jat, P. S.] UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England; [Alvarez-Fernandez, M.; Medema, R. H.] Univ Med Ctr, Dept Med Oncol, Utrecht, Netherlands; [Caballero, O. L.] Ludwig Inst Canc Res Ltd, New York, NY USA; [Hummerich, H.] UCL Inst Neurol, MRC Prion Unit, London WC1N 3BG, England	University of London; University College London; Utrecht University; Utrecht University Medical Center; Ludwig Institute for Cancer Research; University of London; University College London	Jat, PS (corresponding author), UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England.	p.jat@prion.ucl.ac.uk	Medema, Rene H/E-2981-2013; Fernández, Mónica Alvarez/C-5972-2009	Fernández, Mónica Alvarez/0000-0002-6454-5128; Medema, Rene/0000-0002-6754-0381	Wellcome Trust [078305]; Brain Research Trust; Medical Research Council [MC_U123160651] Funding Source: researchfish; MRC [MC_U123160651] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Brain Research Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are indebted to AM Neville, A Baldwin, P Meier, M Resnicoff and N Perkins for advice, helpful discussions and critical reading of the manuscript. We thank J Downward, X Lu, P Meier, G Towers and C King (the UCL shRNA library core facility) for providing reagents. We are grateful to E Ortenberg and J White of Biotrove Inc. for the qPCR analysis, S Shah and A Grigoriadis for bioinformatic analysis and R Young for graphics. PSJ gratefully acknowledges financial support from the Wellcome Trust (078305) and an equipment grant from the Brain Research Trust.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; AGGARWAL BB, 1995, EXP CELL RES, V218, P381, DOI 10.1006/excr.1995.1169; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; Batsi C, 2009, MECH AGEING DEV, V130, P409, DOI 10.1016/j.mad.2009.04.002; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Besnier C, 2003, J VIROL, V77, P13403, DOI 10.1128/JVI.77.24.13403-13406.2003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; DIMRI GP, 1994, EXP CELL RES, V212, P132, DOI 10.1006/excr.1994.1127; Dodeller F, 2008, J BIOL CHEM, V283, P21487, DOI 10.1074/jbc.M801908200; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardy K, 2005, MOL BIOL CELL, V16, P943, DOI 10.1091/mbc.E04-05-0392; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kriete Andres, 2008, Immun Ageing, V5, P5, DOI 10.1186/1742-4933-5-5; Kriete A, 2009, EXP GERONTOL, V44, P250, DOI 10.1016/j.exger.2008.12.005; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Laoukili J, 2008, MOL CELL BIOL, V28, P3076, DOI 10.1128/MCB.01710-07; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MANSFIELD LV, 2006, THESIS U LONDON LOND; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Penzo M, 2009, J CELL PHYSIOL, V218, P215, DOI 10.1002/jcp.21596; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Salminen A, 2008, AGEING RES REV, V7, P83, DOI 10.1016/j.arr.2007.09.002; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Walia V, 2009, CANCER RES, V69, P6624, DOI 10.1158/0008-5472.CAN-08-4101; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	54	118	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	20					2356	2366		10.1038/onc.2010.611	http://dx.doi.org/10.1038/onc.2010.611			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21242976	Green Accepted			2022-12-28	WOS:000290789200007
J	Prazeres, H; Torres, J; Rodrigues, F; Pinto, M; Pastoriza, MC; Gomes, D; Cameselle-Teijeiro, J; Vidal, A; Martins, TC; Sobrinho-Simoes, M; Soares, P				Prazeres, H.; Torres, J.; Rodrigues, F.; Pinto, M.; Pastoriza, M. C.; Gomes, D.; Cameselle-Teijeiro, J.; Vidal, A.; Martins, T. C.; Sobrinho-Simoes, M.; Soares, P.			Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells	ONCOGENE			English	Article						tumor suppressor gene; low-density lipoprotein receptor family; EP300 histone-acetyltransferase; microRNA; matrix metalloproteinase 2; endocytosis and tumor microenvironment	RECEPTOR-RELATED PROTEIN; TUMOR-SUPPRESSOR GENE; LINKAGE ANALYSIS; SUSCEPTIBILITY LOCUS; DNA METHYLATION; LUNG-CANCER; UROKINASE; CARCINOMA; FAMILY; EXPRESSION	The low-density lipoprotein receptor-related protein (LRP1B), encoding an endocytic LDL-family receptor, is among the 10 most significantly deleted genes across 3312 human cancer specimens. However, currently the apparently crucial role of this lipoprotein receptor in carcinogenesis is not clear. Here we show that LRP1B inactivation (by chromosomal, epigenetic and microRNA (miR)-mediated mechanisms) results in changes to the tumor environment that confer cancer cells an increased growth and invasive capacity. LRP1B displays frequent DNA copy number loss and CpG island methylation, resulting in mRNA underexpression. By using CpG island reporters methylated in vitro, we found that DNA methylation disrupts a functional binding site for the histone-acetyltransferase p300 located at intron 1. We identified and validated an miR targeting LRP1B (miR-548a-5p), which is overexpressed in cancer cell lines as a result of 8q22 DNA gains. Restoration of LRP1B impaired in vitro and in vivo tumor growth, inhibited cell invasion and led to a reduction of matrix metalloproteinase 2 in the extracellular medium. We emphasized the role of an endocytic receptor acting as a tumor suppressor by modulating the extracellular environment composition in a way that constrains the invasive behavior of the cancer cells. Oncogene (2011) 30, 1302-1317; doi:10.1038/onc.2010.512; published online 8 November 2010	[Prazeres, H.; Torres, J.; Pinto, M.; Sobrinho-Simoes, M.; Soares, P.] Univ Porto IPATIMUP, Dept Canc Biol, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal; [Prazeres, H.; Sobrinho-Simoes, M.; Soares, P.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Prazeres, H.; Martins, T. C.] EPE, Dept Mol Pathol, Serv Portuguese Inst Oncol Coimbra, Coimbra, Portugal; [Rodrigues, F.] EPE, Dept Endocrinol, Serv Portuguese Inst Oncol Coimbra, Coimbra, Portugal; [Pastoriza, M. C.; Vidal, A.] Univ Santiago de Compostela, Inst Sanitary Res IDIS, Dept Physiol, Sch Med, Santiago De Compostela, Spain; [Gomes, D.] EPE, Anat Pathol Serv, Portuguese Inst Oncol Coimbra, Coimbra, Portugal; [Cameselle-Teijeiro, J.] Univ Santiago de Compostela, Dept Anat Pathol, Clin Univ Hosp CHUS, SERGAS, Santiago De Compostela, Spain	Universidade do Porto; Universidade do Porto; Universidade de Coimbra; Universidade de Coimbra; Universidade de Santiago de Compostela; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Santiago de Compostela	Soares, P (corresponding author), Univ Porto IPATIMUP, Dept Canc Biol, Inst Mol Pathol & Immunol, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	psoares@ipatimup.pt	Sobrinho-Simões, Manuel/J-8290-2013; Soares, Paula/B-6054-2008; Pinto, Marta T/J-2519-2013; Vidal, Anxo/B-5010-2015	Soares, Paula/0000-0001-9607-6998; Pinto, Marta T/0000-0002-8521-2904; Vidal, Anxo/0000-0002-0866-4202; Martins, Teresa/0000-0003-4271-2869; Rodrigues, Fernando/0000-0002-4913-3889; Torres, Joana/0000-0002-5651-4575; Sobrinho-Simoes, Manuel/0000-0003-1613-1235; Prazeres, Hugo/0000-0002-5504-6642	Portuguese Foundation for Science and Technology [SFRH/BD30041/2006, PTDC/SAU-OBD/101242/2008]; Portuguese Society of Endocrinology and Metabolism; Portuguese Ministry of Health [13/2007]; Ministry of Science and Innovation (Instituto de Salud Carlos III), Spain [PS09/02050-FEDER]; Portuguese Foundation for Science and Technology	Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); Portuguese Society of Endocrinology and Metabolism; Portuguese Ministry of Health; Ministry of Science and Innovation (Instituto de Salud Carlos III), Spain(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology)	We would like to acknowledge funding from grants from the Portuguese Foundation for Science and Technology (SFRH/BD30041/2006 and PTDC/SAU-OBD/101242/2008), the Portuguese Society of Endocrinology and Metabolism (Edward Limber Prize) and the Portuguese Ministry of Health (project 13/2007). Jose Cameselle-Teijeiro was supported by Grant PS09/02050-FEDER, from the Ministry of Science and Innovation (Instituto de Salud Carlos III), Spain. IPATIMUP is an associated laboratory of the Portuguese Ministry of Science, Technology and Higher Education and is partially supported by the Portuguese Foundation for Science and Technology.	ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Asami Y, 2009, J ANTIBIOT, V62, P105, DOI 10.1038/ja.2008.17; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bignell GR, 1997, AM J HUM GENET, V61, P1123, DOI 10.1086/301610; Canzian F, 1998, AM J HUM GENET, V63, P1743, DOI 10.1086/302164; Cavaco BM, 2008, J CLIN ENDOCR METAB, V93, P4426, DOI 10.1210/jc.2008-0449; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; Dedieu S, 2008, MOL CELL BIOL, V28, P2980, DOI 10.1128/MCB.02238-07; Desrosiers RR, 2006, PEDIATR BLOOD CANCER, V46, P40, DOI 10.1002/pbc.20566; Emonard H, 2005, BIOCHIMIE, V87, P369, DOI 10.1016/j.biochi.2004.11.013; Emonard H, 2004, J BIOL CHEM, V279, P54944, DOI 10.1074/jbc.M406792200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gustafsdottir SM, 2007, P NATL ACAD SCI USA, V104, P3067, DOI 10.1073/pnas.0611229104; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; He HL, 2009, CANCER RES, V69, P625, DOI 10.1158/0008-5472.CAN-08-1071; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horlings HM, 2010, CLIN CANCER RES, V16, P651, DOI 10.1158/1078-0432.CCR-09-0709; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Knisely JM, 2007, EXP CELL RES, V313, P3298, DOI 10.1016/j.yexcr.2007.05.026; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Li YH, 2002, J BIOL CHEM, V277, P42366, DOI 10.1074/jbc.M207705200; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu CX, 2007, J BIOL CHEM, V282, P7504, DOI 10.1074/jbc.M608088200; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; Liu CX, 2000, CANCER RES, V60, P1961; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Malchoff CD, 2000, J CLIN ENDOCR METAB, V85, P1758, DOI 10.1210/jc.85.5.1758; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Marschang P, 2004, MOL CELL BIOL, V24, P3782, DOI 10.1128/MCB.24.9.3782-3793.2004; Mateus AR, 2009, EXP CELL RES, V315, P1393, DOI 10.1016/j.yexcr.2009.02.020; May P, 2007, ANN MED, V39, P219, DOI 10.1080/07853890701214881; McKay JD, 2001, AM J HUM GENET, V69, P440, DOI 10.1086/321979; Muraoka M, 1996, ONCOGENE, V12, P1565; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Prazeres HJ, 2008, FAM CANCER, V7, P141, DOI 10.1007/s10689-007-9160-x; Ribeiro AS, 2010, ONCOGENE, V29, P392, DOI 10.1038/onc.2009.338; Ribeiro FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-371; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Shiroshima T, 2009, FEBS LETT, V583, P43, DOI 10.1016/j.febslet.2008.11.045; Song H, 2009, CANCER RES, V69, P879, DOI 10.1158/0008-5472.CAN-08-3379; Stankov K, 2004, INT J CANCER, V111, P463, DOI 10.1002/ijc.20259; Suh I, 2009, SURGERY, V146, P1073, DOI 10.1016/j.surg.2009.09.012; Tanaga K, 2004, ARTERIOSCL THROM VAS, V24, P1422, DOI 10.1161/01.ATV.0000133607.80554.09; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Ulisse S, 2009, CURR CANCER DRUG TAR, V9, P32, DOI 10.2174/156800909787314002; Walker LC, 2008, GENE CHROMOSOME CANC, V47, P405, DOI 10.1002/gcc.20545; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200	55	62	64	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1302	1317		10.1038/onc.2010.512	http://dx.doi.org/10.1038/onc.2010.512			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057533	Green Published			2022-12-28	WOS:000288492100005
J	Dunn, EF; Iida, M; Myers, RA; Campbell, DA; Hintz, KA; Armstrong, EA; Li, C; Wheeler, DL				Dunn, E. F.; Iida, M.; Myers, R. A.; Campbell, D. A.; Hintz, K. A.; Armstrong, E. A.; Li, C.; Wheeler, D. L.			Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab	ONCOGENE			English	Article						colorectal cancer; KRAS mutation; cetuximab resistance; Src family kinases; dasatinib	GROWTH-FACTOR RECEPTOR; SRC-FAMILY KINASES; COLON-CANCER CELLS; CARCINOMA-ASSOCIATED ANTIGEN; PP60C-SRC PROTEIN-KINASE; FOCAL-ADHESION KINASE; C-SRC; ACQUIRED-RESISTANCE; TYROSINE KINASES; SIGNAL-TRANSDUCTION	KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs). We analyzed 16 CRC lines for: (1) KRAS mutation status, (2) dependence on mutant KRAS signaling and (3) expression level of epidermal growth factor receptor (EGFR) and SFKs. From these analyses, we selected three KRAS mutant (LS180, LoVo and HCT116) cell lines and two KRAS wild-type cell lines (SW48 and CaCo2). In vitro, using poly-D-lysine/laminin plates, KRAS mutant cell lines were resistant to cetuximab, whereas KRAS wild-type lines showed sensitivity to cetuximab. Treatment with cetuximab and dasatinib showed a greater antiproliferative effect on KRAS mutant lines when compared with either agent alone in vitro and in vivo. To investigate potential mechanisms for this antiproliferative response in the combinatorial therapy, we performed Human Phospho-Kinase Antibody Array analysis, measuring the relative phosphorylation levels of 39 intracellular proteins in untreated, cetuximab, dasatinib or the combinatorial treatment in the KRAS mutant lines LS180, LoVo and HCT116 cells. The results of this experiment showed a decrease in a broad spectrum of kinases centered on the beta-catenin pathway, the mitogen-activated protein kinase (MAPK) pathway, AKT/mammalian target of rapamycin (mTOR) pathway and the family of signal transducers and activators of transcription (STATs) when compared with the untreated control or monotherapy treatments. Next, we analyzed tumor growth with cetuximab, dasatinib or their combination in vivo. KRAS mutant xenografts showed resistance to cetuximab therapy, whereas KRAS wild type demonstrated an antitumor response when treated with cetuximab. KRAS mutant tumors exhibited minimal response to dasatinib monotherapy. However, as in vitro, KRAS mutant lines exhibited a response to the combination of cetuximab and dasatinib. Combinatorial treatment of KRAS mutant xenografts resulted in decreased cell proliferation, as measured by Ki67, and higher rates of apoptosis, as measured by TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling). The data presented in this study indicate that dasatinib can sensitize KRAS mutant CRC tumors to cetuximab and may do so by altering the activity of several key signaling pathways. Furthermore, these results suggest that signaling via EGFR and SFKs may be necessary for cell proliferation and survival of KRAS mutant CRC tumors. These data strengthen the rationale for clinical trials combining cetuximab and dasatinib in the KRAS mutant CRC genetic setting. Oncogene (2011) 30, 561-574; doi: 10.1038/onc.2010.430; published online 18 October 2010	[Wheeler, D. L.] Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, 1111 Highland Ave,WIMR 3159, Madison, WI 53705 USA.	dlwheeler@wisc.edu	Li, Chunrong/F-6955-2011; Wheeler, Deric/B-7175-2013	Wheeler, Deric/0000-0001-5915-3675	Bristol-Myers Squibb; National Cancer Institute [P30CA014520]; National Center for Research Resources, National Institutes of Health [1UL1RR025011]; American Cancer Society [RSG-10-193-01TBG]; National Institutes of Health [CA009614-17]; NATIONAL CANCER INSTITUTE [P30CA014520, T32CA009614] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	DLW has held a sponsored research agreement with Bristol-Myers Squibb.; This project was supported, in part, by grant P30CA014520 from the National Cancer Institute, grant 1UL1RR025011 from the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (to DLW), by grant RSG-10-193-01TBG from the American Cancer Society (to DLW) and T32 grant CA009614-17 Physician Scientist Training in Cancer Medicine from the National Institutes of Health (to EFD).	Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Belsches A P, 1997, Front Biosci, V2, pd501; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fu YN, 2008, ONCOGENE, V27, P957, DOI 10.1038/sj.onc.1210684; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Hantschel O, 2008, LEUKEMIA LYMPHOMA, V49, P615, DOI 10.1080/10428190801896103; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kantarjian H, 2006, NAT REV DRUG DISCOV, V5, P717, DOI 10.1038/nrd2135; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Rini BI, 2008, CLIN CANCER RES, V14, P1286, DOI 10.1158/1078-0432.CCR-07-4719; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706	78	102	107	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					561	574		10.1038/onc.2010.430	http://dx.doi.org/10.1038/onc.2010.430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20956938	Green Accepted			2022-12-28	WOS:000286922300005
J	Ahmad, I; Morton, JP; Singh, LB; Radulescu, SM; Ridgway, RA; Patel, S; Woodgett, J; Winton, DJ; Taketo, MM; Wu, XR; Leung, HY; Sansom, OJ				Ahmad, I.; Morton, J. P.; Singh, L. B.; Radulescu, S. M.; Ridgway, R. A.; Patel, S.; Woodgett, J.; Winton, D. J.; Taketo, M. M.; Wu, X-R; Leung, H. Y.; Sansom, O. J.			beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation	ONCOGENE			English	Article						beta-catenin; PTEN; urothelial cell carcinoma; bladder cancer	PROGNOSTIC VALUE; EPIGENETIC INACTIVATION; ADENOMATOUS POLYPOSIS; GAMMA-CATENIN; E-CADHERIN; CYCLIN D1; C-MYC; APC; EXPRESSION; GENE	Although deregulation of the Wnt signalling pathway has been implicated in urothelial cell carcinoma (UCC), the functional significance is unknown. To test its importance, we have targeted expression of an activated form of beta-catenin to the urothelium of transgenic mice using Cre-Lox technology (UroIICRE(+) beta-catenin(exon3/+)). Expression of this activated form of beta-catenin led to the formation of localized hyperproliferative lesions by 3 months, which did not progress to malignancy. These lesions were characterized by a marked increase of the phosphatase and tensin homologue (PTEN) tumour suppressor protein. This appears to be a direct consequence of activating Wnt signalling in the bladder as conditional deletion of the adenomatous polyposis coli (Apc) gene within the adult bladder led rapidly to coincident beta-catenin and PTEN expression. This PTEN expression blocked proliferation. Next, we combined PTEN deficiency with beta-catenin activation and found that this caused papillary UCC. These tumours had increased pAKT signalling and were dependent on mammalian target of rapamycin (mTOR). Importantly, in human UCC, there was a significant correlation between high levels of beta-catenin and pAKT (and low levels of PTEN). Taken together these data show that deregulated Wnt signalling has a critical role in promoting UCC, and suggests that human UCC that have high levels of Wnt and PI3 kinase signalling may be responsive to mTOR inhibition. Oncogene (2011) 30, 178-189; doi:10.1038/onc.2010.399; published online 6 September 2010	[Ahmad, I.; Morton, J. P.; Singh, L. B.; Radulescu, S. M.; Ridgway, R. A.; Leung, H. Y.; Sansom, O. J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Morton, J. P.] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Glasgow, Lanark, Scotland; [Patel, S.; Woodgett, J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Winton, D. J.] Addenbrookes Hosp, Cambridge Inst Med Res, Dept Oncol, Cambridge, England; [Taketo, M. M.] Kyoto Univ, Dept Pharmacol, Grad Sch Med, Kyoto, Japan; [Wu, X-R] NYU, Sch Med, Dept Urol, New York, NY 10003 USA; [Wu, X-R] NYU, Sch Med, Dept Pathol, New York, NY 10003 USA	Beatson Institute; University of Glasgow; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Kyoto University; New York University; New York University	Sansom, OJ (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Morton, Jennifer/AAJ-5113-2021; Woodgett, Jim/F-1087-2010; Morton, Jennifer P/E-1633-2011	Morton, Jennifer/0000-0001-5766-9141; Woodgett, Jim/0000-0003-3731-5797; Morton, Jennifer P/0000-0001-5766-9141; Sansom, Owen J./0000-0001-9540-3010; Ahmad, Imran/0000-0002-4404-1926; Wu, Xue-Ru/0000-0001-6058-6291; Leung, Hing Y./0000-0002-3933-3975	Cancer Research UK; MRC; AICR; Cancer Research UK [12481] Funding Source: researchfish; Medical Research Council [G0802141, G0900871] Funding Source: researchfish; MRC [G0900871, G0802141] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AICR; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Cancer Research UK and a MRC fellowship to Imran Ahmad and AICR grant to Sorina Radulescu. We thank BICR services, biological services unit, and Colin Nixon and his histology department. We also thank the 'Think Pink' charity for the purchase of the Aperio slide scanner and the Slidepath software.	Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bohm M, 1997, INT J CANCER, V74, P291; Burger M, 2008, EUR UROL, V54, P835, DOI 10.1016/j.eururo.2007.12.026; Cordon-Cardo C, 2008, SCAND J UROL NEPHROL, V42, P154, DOI 10.1080/03008880802291915; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; DIAZ DS, 2008, MINERVA UROL NEFROL, V60, P205; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; GARCIA DX, 2000, EUR J CANCER, V36, P357; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He F, 2009, CANCER RES, V69, P9413, DOI 10.1158/0008-5472.CAN-09-2158; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kashibuchi K, 2006, EUR UROL, V49, P839, DOI 10.1016/j.eururo.2005.12.023; Kastritis E, 2009, INT J CANCER, V124, P103, DOI 10.1002/ijc.23917; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kirkegaard T, 2006, HISTOPATHOLOGY, V48, P787, DOI 10.1111/j.1365-2559.2006.02412.x; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Luis NM, 2007, CLIN TRANSL ONCOL, V9, P5, DOI 10.1007/s12094-007-0003-x; MacAulay K, 2007, CELL METAB, V6, P329, DOI 10.1016/j.cmet.2007.08.013; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Miyamoto H, 1996, J UROLOGY, V155, P1444, DOI 10.1016/S0022-5347(01)66304-3; Mo L, 2005, AM J PHYSIOL-RENAL, V289, pF562, DOI 10.1152/ajprenal.00368.2004; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Nakopoulou L, 2000, ANTICANCER RES, V20, P4571; Namba R, 2006, CLIN CANCER RES, V12, P2613, DOI 10.1158/1078-0432.CCR-05-2170; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Polakis P, 2000, GENE DEV, V14, P1837; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Schulz WA, 2006, INT J CANCER, V119, P1513, DOI 10.1002/ijc.21852; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shiina H, 2002, J UROLOGY, V168, P2220, DOI 10.1016/S0022-5347(05)64359-5; Shiina H, 2001, CANCER RES, V61, P7101; Shimazui T, 1996, CANCER RES, V56, P4154; Stoehr R, 2002, INT J ONCOL, V20, P905; Teng DHF, 1997, CANCER RES, V57, P5221; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuruta H, 2006, CANCER RES, V66, P8389, DOI 10.1158/0008-5472.CAN-05-4627; Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315; Zhu XD, 2000, PATHOL INT, V50, P945, DOI 10.1046/j.1440-1827.2000.01139.x	58	74	74	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					178	189		10.1038/onc.2010.399	http://dx.doi.org/10.1038/onc.2010.399			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818428	Green Accepted			2022-12-28	WOS:000286438900006
J	Bhatia, B; Hsieh, M; Kenney, AM; Nahle, Z				Bhatia, B.; Hsieh, M.; Kenney, A. M.; Nahle, Z.			Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma	ONCOGENE			English	Article						sonic hedgehog; medulloblastoma; E2F1; Rb; lipogenesis; metabolism	FATTY-ACID SYNTHASE; ACTIVATED PROTEIN-KINASE; REDUCES FOOD-INTAKE; N-MYC; CYCLE PROGRESSION; E2F1 EXPRESSION; HUMAN HOMOLOG; MICE LACKING; PROLIFERATION; INHIBITION	Deregulation of the Rb/E2F tumor suppressor complex and aberrantion of Sonic hedgehog (Shh) signaling are documented across the spectrum of human malignancies. Exaggerated de novo lipid synthesis is also found in certain highly proliferative, aggressive tumors. Here, we show that in Shh-driven medulloblastomas, Rb is inactivated and E2F1 is upregulated, promoting lipogenesis. Extensive lipid accumulation and elevated levels of the lipogenic enzyme fatty acid synthase (FASN) mark those tumors. In primary cerebellar granule neuron precursors (CGNPs), proposed Shh-associated medulloblastoma cells-of-origin, Shh signaling triggers E2F1 and FASN expression, whereas suppressing fatty acid oxidation (FAO), in a smoothened-dependent manner. In the developing cerebellum, E2F1 and FASN co-localize in proliferating CGNPs. in vivo and in vitro, E2F1 is required for FASN expression and CGNP proliferation, and E2F1 knockdown impairs Shh-mediated FAO inhibition. Pharmacological blockade of Rb inactivation and/or lipogenesis inhibits CGNP proliferation, drives medulloblastoma cell death and extends survival of medulloblastoma-bearing animals In vivo. These findings identify a novel mechanism through which Shh signaling links cell cycle progression to lipid synthesis, through E2F1-dependent regulation of lipogenic enzymes. These findings pertinent to the etiology of tumor metabolism also underscore the key role of the Shh-->E2F1-->FASN axis in regulating de novo lipid synthesis in cancers, and as such its value as a global therapeutic target in hedgehog-dependent and/or Rb-inactivated tumors. Oncogene (2011) 30, 410-422; doi: 10.1038/onc.2010.454; published online 4 October 2010	[Bhatia, B.; Kenney, A. M.] Weill Cornell Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA; [Hsieh, M.; Nahle, Z.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Nahle, Z (corresponding author), Weill Cornell Med Coll, Dept Cardiothorac Surg, 1300 York Ave, New York, NY 10021 USA.	zan2003@med.cornell.edu			Lung Cancer Center and the division of thoracic surgery at Weill Cornell Medical College; NIH [NINDS R01NS061070]; Memorial Sloan-Kettering Brain Tumor Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	Lung Cancer Center and the division of thoracic surgery at Weill Cornell Medical College; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Memorial Sloan-Kettering Brain Tumor Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Michael J Klein and the Pathology and Laboratory Medicine group at the Hospital for Special Surgery and MSKCC microcyteometry facility. We also thank Lori A Mainwaring, Cedric Dray, Cemille Guldal, Elisa DeStanchina and Fajun Yang for helpful discussions. These studies were funded by the Lung Cancer Center and the division of thoracic surgery at Weill Cornell Medical College (ZN), the NIH (NINDS R01NS061070) (AMK) and the Memorial Sloan-Kettering Brain Tumor Center (BB).	Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bhatia B, 2009, CANCER RES, V69, P7224, DOI 10.1158/0008-5472.CAN-09-1299; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cooper-Kuhn CM, 2002, MOL CELL NEUROSCI, V21, P312, DOI 10.1006/mcne.2002.1176; Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103; Dahmane N, 1999, DEVELOPMENT, V126, P3089; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Djouadi F, 2003, MOL GENET METAB, V78, P112, DOI 10.1016/S1096-7192(03)00017-9; Dowell P, 2005, ANNU REV BIOCHEM, V74, P515, DOI 10.1146/annurev.biochem.73.011303.074027; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Eberhart CG, 2008, CANCER CELL, V14, P105, DOI 10.1016/j.ccr.2008.07.011; Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Ferretti E, 2006, ONCOGENE, V25, P7267, DOI 10.1038/sj.onc.1209716; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hepker J, 1997, DEVELOPMENT, V124, P549; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Ho KS, 2002, CURR OPIN NEUROBIOL, V12, P57, DOI 10.1016/S0959-4388(02)00290-8; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027; KolfClauw M, 1996, TERATOLOGY, V54, P115, DOI 10.1002/(SICI)1096-9926(199609)54:3<115::AID-TERA1>3.0.CO;2-2; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Marino S, 2000, GENE DEV, V14, P994; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; MENENDEZ JA, 2009, BIOCH BIOPHYS ACTA; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Olson MV, 2007, CANCER RES, V67, P4005, DOI 10.1158/0008-5472.CAN-06-2973; Orita H, 2008, CLIN CANCER RES, V14, P2458, DOI 10.1158/1078-0432.CCR-07-4177; Orita H, 2007, CLIN CANCER RES, V13, P7139, DOI 10.1158/1078-0432.CCR-07-1186; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	67	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					410	422		10.1038/onc.2010.454	http://dx.doi.org/10.1038/onc.2010.454			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20890301	Green Accepted			2022-12-28	WOS:000286621600004
J	Nitta, RT; Del Vecchio, CA; Chu, AH; Mitra, SS; Godwin, AK; Wong, AJ				Nitta, R. T.; Del Vecchio, C. A.; Chu, A. H.; Mitra, S. S.; Godwin, A. K.; Wong, A. J.			The role of the c-Jun N-terminal kinase 2-alpha-isoform in non-small cell lung carcinoma tumorigenesis	ONCOGENE			English	Article						NSCLC; JNK; STAT3; MAPK	SERINE PHOSPHORYLATION; NH2-TERMINAL KINASE; SIGNAL TRANSDUCER; TUMOR-GROWTH; CANCER CELLS; STAT3; ACTIVATION; PATHWAY; ONCOGENE; JNK	The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family and have been implicated in tumorigenesis. One isoform in particular, JNK2 alpha, has been shown to be frequently activated in primary brain tumors, to enhance several tumorigenic phenotypes and to increase tumor formation in mice. As JNK is frequently activated in non-small cell lung carcinoma (NSCLC), we investigated the role of the JNK2 alpha isoform in NSCLC formation by examining its expression in primary tumors and by modulating its expression in cultured cell lines. We discovered that 60% of the tested primary NSCLC tumors had three-fold higher JNK2 protein and two-to three-fold higher JNK2 alpha mRNA expression than normal lung control tissue. To determine the importance of JNK2 alpha in NSCLC progression, we reduced JNK2 alpha expression in multiple NSCLC cell lines using short hairpin RNA. Cell lines deficient in JNK2 alpha had decreased cellular growth and anchorage-independent growth, and the tumors were four-fold smaller in mass. To elucidate the mechanism by which JNK2 alpha induces NSCLC growth, we analyzed the JNK substrate, signal transducer and activator of transcription 3 (STAT3). Our data demonstrates for the first time that JNK2 alpha can regulate the transcriptional activity of STAT3 by phosphorylating the Ser727 residue, thereby regulating the expression of oncogenic genes, such as c-Myc. Furthermore, reintroduction of JNK2 alpha 2 or STAT3 restored the tumorigenicity of the NSCLC cells, demonstrating that JNK2 alpha is important for NSCLC progression. Our studies reveal a novel mechanism in which phosphorylation of STAT3 is mediated by a constitutively active JNK2 isoform, JNK2 alpha. Oncogene (2011) 30, 234-244; doi: 10.1038/onc.2010.414; published online 27 September 2010	[Wong, A. J.] Stanford Univ, Med Ctr, Dept Neurosurg, Canc Biol Program,Sch Med, Stanford, CA 94305 USA; [Del Vecchio, C. A.; Wong, A. J.] Stanford Univ, Sch Med, Canc Biol Grad Program, Stanford, CA 94305 USA; [Godwin, A. K.] Fox Chase Canc Ctr, Dept Med Oncol, Womens Canc Program, Philadelphia, PA 19111 USA	Stanford University; Stanford University; Fox Chase Cancer Center	Wong, AJ (corresponding author), Stanford Univ, Med Ctr, Dept Neurosurg, Canc Biol Program,Sch Med, 300 Pasteur Dr,Edwards R221, Stanford, CA 94305 USA.	ajwong@stanford.edu			Mark Linder/American Brain Tumor Association; NIH [CA69495, CA124832]; National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE [R01CA096539, R01CA124832, R01CA069495, P30CA124435] Funding Source: NIH RePORTER	Mark Linder/American Brain Tumor Association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Emily Piccione, Shawn Badal, Tiffany Lieu and Marina Holgado-Madruga for their useful discussions and critical review of the paper. This work was supported by the Mark Linder/American Brain Tumor Association Fellowship, NIH grants CA69495 and CA124832 and a research grant from the National Brain Tumor Foundation.	Achcar RDD, 2007, ARCH PATHOL LAB MED, V131, P1350; Alvarez JV, 2006, CANCER RES, V66, P3162, DOI 10.1158/0008-5472.CAN-05-3757; Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481; Berner JM, 1999, GENE CHROMOSOME CANC, V26, P151, DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A; Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Bogoyevitch MA, 2008, BBA-PROTEINS PROTEOM, V1784, P76, DOI 10.1016/j.bbapap.2007.09.013; Bogoyevitch MA, 2006, BIOESSAYS, V28, P923, DOI 10.1002/bies.20458; BROERS JLV, 1993, AM J RESP CELL MOL, V9, P33, DOI 10.1165/ajrcmb/9.1.33; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen NY, 2001, CANCER RES, V61, P3908; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cui J, 2005, J BIOL CHEM, V280, P9913, DOI 10.1074/jbc.M412165200; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; GAO SP, 2006, SCI STKE, pPE30; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; Maeda S, 2003, CANCER CELL, V3, P102, DOI 10.1016/S1535-6108(03)00025-4; Nitta RT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000963; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Nitta R, 2008, NAT STRUCT MOL BIOL, V15, P1067, DOI 10.1038/nsmb.1487; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Onishi A, 2008, EXP CELL RES, V314, P377, DOI 10.1016/j.yexcr.2007.09.018; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Qin HR, 2008, CANCER RES, V68, P7736, DOI 10.1158/0008-5472.CAN-08-1125; Rapp UR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006029; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Tang Gu-Sheng, 2006, Ai Zheng, V25, P269; Tsuiki H, 2003, CANCER RES, V63, P250; Weerasinghe P, 2007, INT J ONCOL, V31, P129; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xie W, 1997, ANTICANCER RES, V17, P2627; Xu X, 1996, ONCOGENE, V13, P135; Yakut T, 2003, LUNG, V181, P245, DOI 10.1007/s00408-003-1026-x; Yang YM, 2003, CLIN CANCER RES, V9, P391; YEAGER T, 1995, CANCER RES, V55, P493; Yeh HH, 2009, DNA CELL BIOL, V28, P131, DOI 10.1089/dna.2008.0762; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhang XL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-149	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					234	244		10.1038/onc.2010.414	http://dx.doi.org/10.1038/onc.2010.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20871632	Green Accepted			2022-12-28	WOS:000286438900011
J	Kalra, J; Sutherland, BW; Stratford, AL; Dragowska, W; Gelmon, KA; Dedhar, S; Dunn, SE; Bally, MB				Kalra, J.; Sutherland, B. W.; Stratford, A. L.; Dragowska, W.; Gelmon, K. A.; Dedhar, S.; Dunn, S. E.; Bally, M. B.			Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1	ONCOGENE			English	Article						integrin-linked kinase; QLT0267; Her2/neu; YB-1; TWIST; STAT-3	INTEGRIN-LINKED KINASE; BOX-BINDING PROTEIN-1; GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN BREAST-CANCER; ANCHORAGE-INDEPENDENT GROWTH; GLYCOGEN-SYNTHASE KINASE; SQUAMOUS-CELL CARCINOMA; POOR PATIENT SURVIVAL; HUMAN COLON-CANCER	In a previous study it was found that the therapeutic effects of QLT0267, a small molecule inhibitor of integrin-linked kinase (ILK), were influenced by Her2/neu expression. To understand how inhibition or silencing of ILK influences Her2/neu expression, Her2/neu signaling was evaluated in six Her2/neu-positive breast cancer cell lines (LCC6(Her2), MCF7(Her2), SKBR3, BT474, JIMT-1 and KPL-4). Treatment with QLT0267 engendered suppression (32-87%) of total Her2/neu protein in these cells. Suppression of Her2/neu was also observed following small interfering RNA-mediated silencing of ILK expression. Time course studies suggest that ILK inhibition or silencing caused transient decreases in P-AKT(ser473), which were not temporally related to Her2/neu down-regulation. Attenuation of ILK activity or expression was, however, associated with decreases in YB-1 (Y-box binding protein-1) protein and transcript levels. YB-1 is a known transcriptional regulator of Her2/neu expression, and in this study it is demonstrated that inhibition of ILK activity using QLT0267 decreased YB-1 promoter activity by 50.6%. ILK inhibition was associated with changes in YB-1 localization, as reflected by localization of cytoplasmic YB-1 into stress granules. ILK inhibition also suppressed TWIST (a regulator of YB-1 expression) protein expression. To confirm the role of ILK on YB-1 and TWIST, cells were engineered to overexpress ILK. This was associated with a fourfold increase in the level of YB-1 in the nucleus, and a 2- and 1.5-fold increase in TWIST and Her2/neu protein levels, respectively. Taken together, these data indicate that ILK regulates the expression of Her2/neu through TWIST and YB-1, lending support to the use of ILK inhibitors in the treatment of aggressive Her2/neu-positive tumors. Oncogene (2010) 29, 6343-6356; doi:10.1038/onc.2010.366; published online 13 September 2010	[Kalra, J.] Univ British Columbia, British Columbia Canc Agcy, Dept Expt Therapeut, Vancouver, BC V5Z 1L3, Canada; [Kalra, J.; Bally, M. B.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada; [Stratford, A. L.; Dunn, S. E.] Women & Childrens Hosp, Child & Family Res Inst, Vancouver, BC, Canada; [Dedhar, S.] Univ British Columbia, BC Canc Agcy, Dept Integrat Biol, Vancouver, BC V5Z 1L3, Canada; [Dedhar, S.] Univ British Columbia, Dept Biochem, Vancouver, BC V5Z 1L3, Canada; [Dunn, S. E.] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1L3, Canada; [Bally, M. B.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V5Z 1L3, Canada; [Bally, M. B.] Ctr Drug Res & Dev, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Child & Family Research Institute; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Kalra, J (corresponding author), Univ British Columbia, British Columbia Canc Agcy, Dept Expt Therapeut, 675 W 10th Ave,5th Floor, Vancouver, BC V5Z 1L3, Canada.	jkalra@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657; Bally, Marcel/0000-0002-1994-4787	Canadian Breast Cancer Research Alliance (CBCRA); Canadian Breast Cancer Foundation; Pacific Century Graduate Scholarship; University of British Columbia University	Canadian Breast Cancer Research Alliance (CBCRA); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Pacific Century Graduate Scholarship; University of British Columbia University	Funding for this research was from the Canadian Breast Cancer Research Alliance (CBCRA) and the Canadian Breast Cancer Foundation (BC/Yukon Chapter). JK is the recipient of the Pacific Century Graduate Scholarship and the University of British Columbia University Graduate Fellowship. We acknowledge BC Cancer Agency's Cancer Integrative Oncology Department (Mykola Maydan, Paul MacDonald and Iveta Dobreva) as well as Hong Yan for excellent management of the departmental tissue culture facilities.	Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Anderson P, 2009, CURR BIOL, V19, pR397, DOI 10.1016/j.cub.2009.03.013; Anderson P, 2009, NAT REV MOL CELL BIO, V10, P430, DOI 10.1038/nrm2694; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bader AG, 2008, ONCOGENE, V27, P1179, DOI 10.1038/sj.onc.1210719; Balagopal V, 2009, CURR OPIN CELL BIOL, V21, P403, DOI 10.1016/j.ceb.2009.03.005; Basaki Y, 2007, ONCOGENE, V26, P2736, DOI 10.1038/sj.onc.1210084; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Bravou V, 2006, J PATHOL, V208, P91, DOI 10.1002/path.1860; Bravou V, 2003, BRIT J CANCER, V89, P2340, DOI 10.1038/sj.bjc.6601482; Cates JMM, 2009, PANCREAS, V38, pE1, DOI 10.1097/MPA.0b013e3181878b7f; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Chernov KG, 2008, FEBS LETT, V582, P2875, DOI 10.1016/j.febslet.2008.07.019; Chernov KG, 2009, J BIOL CHEM, V284, P36569, DOI 10.1074/jbc.M109.042879; Chernov Konstantin G., 2008, BMC Biochemistry, V9, P23, DOI 10.1186/1471-2091-9-23; Coles LS, 2005, FEBS LETT, V579, P5372, DOI 10.1016/j.febslet.2005.08.075; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dragowska WH, 2004, MOL CANCER RES, V2, P606; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Edwards LA, 2008, MOL CANCER THER, V7, P59, DOI 10.1158/1535-7163.MCT-07-0329; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Evdokimova V, 2006, CELL CYCLE, V5, P1143, DOI 10.4161/cc.5.11.2784; Flugel D, 2007, MOL CELL BIOL, V27, P3253, DOI 10.1128/MCB.00015-07; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Fujii T, 2008, CANCER RES, V68, P1504, DOI 10.1158/0008-5472.CAN-07-2362; Gort EH, 2008, ONCOGENE, V27, P1501, DOI 10.1038/sj.onc.1210795; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hasselblatt M, 2009, CANCER RES, V69, P2219, DOI 10.1158/0008-5472.CAN-08-3176; Hu L, 2008, CANCER RES, V68, P4296, DOI 10.1158/0008-5472.CAN-08-0067; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kalra J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2252; Karreth F, 2004, CANCER BIOL THER, V3, P1058, DOI 10.4161/cbt.3.11.1302; Kashihara M, 2009, J THORAC ONCOL, V4, P1066, DOI 10.1097/JTO.0b013e3181ae2828; Kedersha N, 2007, METHOD ENZYMOL, V431, P61, DOI 10.1016/S0076-6879(07)31005-7; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Li YJ, 2007, J AM SOC NEPHROL, V18, P2534, DOI 10.1681/ASN.2007030315; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Luo GQ, 2008, WORLD J GASTROENTERO, V14, P2487, DOI 10.3748/wjg.14.2487; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Matsuo N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-240; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Niu RF, 2007, J EXP CLIN CANC RES, V26, P385; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Oda Y, 2007, CANCER SCI, V98, P1020, DOI 10.1111/j.1349-7006.2007.00492.x; Oloumi A, 2006, ONCOGENE, V25, P7747, DOI 10.1038/sj.onc.1209752; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; OZER J, 1990, J BIOL CHEM, V265, P22143; Peinado H, 2008, NAT CELL BIOL, V10, P253, DOI 10.1038/ncb0308-253; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Sawai H, 2006, ONCOGENE, V25, P3237, DOI 10.1038/sj.onc.1209356; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Shiota M, 2009, CANCER RES, V69, P3148, DOI 10.1158/0008-5472.CAN-08-2334; Skabkina O V, 2004, Dokl Biochem Biophys, V395, P93, DOI 10.1023/B:DOBI.0000025554.28703.bf; Skabkina OV, 2005, MOL CELL BIOL, V25, P3317, DOI 10.1128/MCB.25.8.3317-3323.2005; Skabkina OV, 2003, J BIOL CHEM, V278, P18191, DOI 10.1074/jbc.M209073200; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Takanami I, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-1; Takemoto S, 2009, BRIT J CANCER, V101, P967, DOI 10.1038/sj.bjc.6605212; To K, 2007, MOL PHARMACOL, V72, P641, DOI 10.1124/mol.107.036111; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x; Verreault M, 2009, OLIGONUCLEOTIDES, V19, P129, DOI 10.1089/oli.2008.0157; Warburton C, 2004, CLIN CANCER RES, V10, P2512, DOI 10.1158/1078-0432.CCR-03-0244; Watanabe O, 2004, ANTICANCER RES, V24, P3851; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yamasaki S, 2008, CURR OPIN CELL BIOL, V20, P222, DOI 10.1016/j.ceb.2008.01.013; Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Younes MN, 2007, ARCH OTOLARYNGOL, V133, P15, DOI 10.1001/archotol.133.1.15; Zhang XM, 2007, INT J CANCER, V120, P1891, DOI 10.1002/ijc.22489; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	100	42	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6343	6356		10.1038/onc.2010.366	http://dx.doi.org/10.1038/onc.2010.366			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20838384	Green Published, hybrid			2022-12-28	WOS:000284874700005
J	Tanaka, T; Rabbitts, TH				Tanaka, T.; Rabbitts, T. H.			Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth	ONCOGENE			English	Article						antibody fragment; cancer; lung tumourigenesis; RAS signalling; therapy	SIGNAL-TRANSDUCTION; ONCOGENIC RAS; MOUSE MODEL; LUNG; TUMORIGENICITY; BINDING; ACTIVATION; EXPRESSION; ADDICTION; PATHWAYS	RAS mutations are the most common gain-of-function change in human cancer and promise to be a critical therapy target. As a new approach, we have used a surrogate to drug the 'undruggable' (that is, RAS-effector protein-protein interactions inside cancer cells) in preclinical mouse models of RAS-dependent cancers. Using this novel reagent, we have specifically targeted RAS signalling in a transgenic mouse model of lung cancer by directly blockading RAS-effector interactions with an antibody fragment that binds to activated RAS, and show that the interaction of RAS and effectors, such as phosphoinositide 3-kinase and RAF, is necessary for tumour initiation. Further, interference with oncogenic RAS-effector interactions result in control of tumour growth in human cancer cells but, crucially, does not necessarily cause tumour regression. These findings support the concept that ablating RAS-dependent signalling in cancer will have chemo-preventive effects that confer a chronic state in cancer and suggest that mutant RAS-targeted therapies may require conjoint targeting of other molecules and/or current cancer therapeutic strategies (for example, radiotherapy and chemotherapy) to be curative. In this context, our findings suggest that the oncogene addiction model is not universally correct in its central thesis that cancer cell death is inevitable after loss of oncogenic protein function. Oncogene (2010) 29, 6064-6070; doi:10.1038/onc.2010.346; published online 6 September 2010	[Tanaka, T.; Rabbitts, T. H.] Univ Leeds, Leeds Inst Mol Med, Sect Expt Therapeut, St Jamess Univ Hosp, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Rabbitts, TH (corresponding author), Univ Leeds, Leeds Inst Mol Med, Sect Expt Therapeut, St Jamess Univ Hosp, Wellcome Trust Brenner Bldg,Beckett St, Leeds LS9 7TF, W Yorkshire, England.	thr@leeds.ac.uk	Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council; University of Leeds; Medical Research Council [G0901686, G0600914] Funding Source: researchfish; MRC [G0600914, G0901686] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Leeds; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by grants from the Medical Research Council and the University of Leeds. We wish to thank Dr. Anton Berns for the conditional, Cre-dependent K-Ras<SUP>V12</SUP> transgenic mouse line. We also thank Dr Jeffrey A Whitsett for pCC10CAT-2300 for constructing the CC10 transgenic cassette. We are indebted to Debra Evans, Deborah Carter, Gillian Cardwell for animal husbandry, to Lesley Drynan for expert assistance and to Mike Shires for histology.	Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gatenby RA, 2009, NATURE, V459, P508, DOI 10.1038/459508a; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weir B, 2004, CANCER CELL, V6, P433, DOI 10.1016/j.ccr.2004.11.004	27	50	54	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6064	6070		10.1038/onc.2010.346	http://dx.doi.org/10.1038/onc.2010.346			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20818422				2022-12-28	WOS:000284108700008
J	Bu, W; Chen, J; Morrison, GD; Huang, S; Creighton, CJ; Huang, J; Chamness, GC; Hilsenbeck, SG; Roop, DR; Leavitt, AD; Li, Y				Bu, W.; Chen, J.; Morrison, G. D.; Huang, S.; Creighton, C. J.; Huang, J.; Chamness, G. C.; Hilsenbeck, S. G.; Roop, D. R.; Leavitt, A. D.; Li, Y.			Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer	ONCOGENE			English	Article						Keratin 6; TVA; RCAS; PyMT; mammary gland; normal-like breast cancer	STEM-CELLS; GENE-EXPRESSION; STEM/PROGENITOR CELLS; GLAND DEVELOPMENT; SELF-RENEWAL; MOUSE MODELS; TUMORIGENESIS; POPULATION; RECEPTOR; SYSTEM	Progenitor cells are considered an important cell of origin of human malignancies. However, there has not been any single gene that can define mammary bipotential progenitor cells, and as such it has not been possible to use genetic methods to introduce oncogenic alterations into these cells in vivo to study tumorigenesis from them. Keratin 6a is expressed in a subset of mammary luminal epithelial cells and body cells of terminal end buds. By generating transgenic mice using the Keratin 6a (K6a) gene promoter to express tumor virus A (tva), which encodes the receptor for avian leukosis virus subgroup A (ALV/A), we provide direct evidence that K6a(+) cells are bipotential progenitor cells, and the first demonstration of a non-basal location for some biopotential progenitor cells. These K6a(+) cells were readily induced to form mammary tumors by intraductal injection of RCAS (an ALV/A-derived vector) carrying the gene encoding the polyoma middle T antigen. Tumors in this K6a-tva line were papillary and resembled the normal breast-like subtype of human breast cancer. This is the first model of this subtype of human tumors and thus may be useful for preclinical testing of targeted therapy for patients with normal-like breast cancer. These observations also provide direct in vivo evidence for the hypothesis that the cell of origin affects mammary tumor phenotypes. Oncogene (2011) 30, 4399-4409; doi:10.1038/onc.2011.147; published online 2 May 2011	[Bu, W.; Morrison, G. D.; Huang, J.; Chamness, G. C.; Hilsenbeck, S. G.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Chen, J.; Roop, D. R.; Li, Y.] Univ Colorado Denver, Dermatol & Charles C Gates Regenerat Med & Stem C, Aurora, CO USA; [Huang, S.; Li, Y.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Huang, S.; Creighton, C. J.; Hilsenbeck, S. G.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Leavitt, A. D.] Univ Calif San Francisco, Dept Lab Med & Med, San Francisco, CA 94143 USA	Baylor College of Medicine; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Francisco	Li, Y (corresponding author), Baylor Coll Med, Breast Ctr, 1 Baylor Plaza,BCM 600, Houston, TX 77030 USA.	liyi@bcm.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X	USAMRMC [BC030755, BC073703]; National Institutes of Health [CA113869, CA124820]; MMHCC [U01 CA084243-07]; NCI [P50 CA058183]; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA113869, U01CA084243, R01CA124820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM069234] Funding Source: NIH RePORTER	USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MMHCC; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Tammy Tong, Amanda McGrath, Ekaterina Bogoslovskaia, Andrei Lazarev, Meghali Goswami and Yiqun Zhang for technical assistance, Drs Jeffrey Rosen and Michael Lewis for stimulating discussions and/or critical review of this manuscript, as well as Drs Robert D Cardiff and Barry Gusterson for advice on pathological comparisons. This work was supported in part by funds from USAMRMC BC030755 and BC073703 (to YL), National Institutes of Health CA113869 and CA124820 (to YL), Project 5 of MMHCC U01 CA084243-07 (to YL; U01 PI: Dr Jeffrey Rosen) and a developmental project of NCI P50 CA058183 (to YL; SPORE PI: Dr C Kent Osborne).	Andrechek ER, 2004, P NATL ACAD SCI USA, V101, P4984, DOI 10.1073/pnas.0306802101; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594; Bai LX, 2010, GENE DEV, V24, P1882, DOI 10.1101/gad.1932810; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Fisher GH, 1999, ONCOGENE, V18, P5253, DOI 10.1038/sj.onc.1203087; Grimm SL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1504; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Hughes SH, 2004, FOLIA BIOL-PRAGUE, V50, P107; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Li Y, 2005, J MAMMARY GLAND BIOL, V10, P17, DOI 10.1007/s10911-005-2537-2; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Mollet M, 2008, BIOTECHNOL BIOENG, V100, P260, DOI 10.1002/bit.21762; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Wojcik SM, 2001, J CELL BIOL, V154, P619, DOI 10.1083/jcb.200102079; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	35	35	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	43					4399	4409		10.1038/onc.2011.147	http://dx.doi.org/10.1038/onc.2011.147			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21532625	Green Submitted, Green Accepted			2022-12-28	WOS:000296356500003
J	Li, C; Fan, S; Owonikoko, TK; Khuri, FR; Sun, SY; Li, R				Li, C.; Fan, S.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y; Li, R.			Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway	ONCOGENE			English	Article						EAPII; MAPK-ERK pathway; NSCLC	RECEPTOR-ASSOCIATED FACTORS; NONSMALL CELL; CYCLIN D1; TTRAP; GENE; EXPRESSION; PROTEIN; ETS1; MYC; AMPLIFICATION	Cancer progression involves multiple complex and interdependent steps, including progressive proliferation, angiogenesis and metastases. The complexity of these processes requires a comprehensive elucidation of the integrated signaling networks for better understanding. EAPII interacts with multiple cancer-related proteins, but its biological significance in cancer development remains unknown. In this report we identified the elevated level of EAPII protein in non-small-cell lung carcinoma (NSCLC) patients and NSCLC cell lines in culture. The oncogenic role of EAPII in lung cancer development was demonstrated using NSCLC cells with genetic manipulations that influence EAPII expression: EAPII overexpression increases proliferation of NSCLC cells with an accelerated transition of cell cycle and facilitates xenograft tumor growth in vivo; EAPII knockdown results in apoptosis of NSCLC cells and reduces xenograft tumor formation. To further explore the mechanism of EAPII's oncogenic role in lung cancer development and to elucidate the potential signaling pathway(s) that EAPII may impact, we employed antibody array to investigate the alternation of the major signaling pathways in NSCLC cells with altered EAPII level. We found that EAPII overexpression significantly activated Raf1 and ERK1/2, but not c-Jun N-terminal kinase and p38 pathways. Consistently, the protein and mRNA levels of MYC and cyclin D1, which are targets of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK-ERK) pathway, are significantly increased by EAPII overexpression. Taken together, we demonstrated that EAPII is an oncogenic factor and the activation of MAPK-ERK signaling pathway by EAPII may contribute to lung cancer development. Oncogene (2011) 30, 3802-3812; doi:10.1038/onc.2011.94; published online 11 April 2011	[Li, C.; Fan, S.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y; Li, R.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Li, R (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Room 4090,1365C Clifton Rd, Atlanta, GA 30322 USA.	ssun@emory.edu; r.li@emory.edu	Khuri, Fadlo R./AAU-4942-2020; Owonikoko, Taofeek/C-3012-2011	Khuri, Fadlo R./0000-0002-8638-7618; Owonikoko, Taofeek/0000-0002-7724-7728	National Institutes of Health [K22CA109577, RO1CA118450]; Department of Hematology and Medical Oncology, Emory University; NATIONAL CANCER INSTITUTE [K23CA164015, R01CA118450, K22CA109577] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Hematology and Medical Oncology, Emory University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs JD Minna (University of Texas Southwestern Medical Center, Dallas) and R Lotan (University of Texas MD Anderson Cancer Center, Houston) for providing HBEC3KT and BEAS2B cell lines and Biomolecular Computing Resource (BIMCORE) at the Emory University School of Medicine for assistance with antibody array analysis. This work was supported in part by National Institutes of Health grants K22CA109577 (RL) and RO1CA118450 (SYS), a start-up fund from the Department of Hematology and Medical Oncology, Emory University (RL).	Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028; Borczuk Alain C, 2009, Proc Am Thorac Soc, V6, P152, DOI 10.1513/pats.200807-076LC; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Esguerra CV, 2007, DEVELOPMENT, V134, P4381, DOI 10.1242/dev.000026; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024; Hubner A, 2006, DEV CELL, V11, P752, DOI 10.1016/j.devcel.2006.11.006; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661; Ledesma FC, 2009, NATURE, V461, P674, DOI 10.1038/nature08444; Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P112, DOI 10.1161/ATVBAHA.107.153304; Lee JT, 2010, CELL CYCLE, V9, P857, DOI 10.4161/cc.9.5.11175; Li CY, 2010, J BIOL CHEM, V285, P16096, DOI 10.1074/jbc.M109.072694; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Mitani S, 2001, CLIN EXP MED, V1, P105, DOI 10.1007/s10238-001-8020-5; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Pei HP, 2005, CANCER RES, V65, P7205, DOI 10.1158/0008-5472.CAN-04-3566; Pei HP, 2003, ONCOGENE, V22, P2699, DOI 10.1038/sj.onc.1206374; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; Rapp UR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006029; Rodrigues-Lima F, 2001, BIOCHEM BIOPH RES CO, V285, P1274, DOI 10.1006/bbrc.2001.5328; Salomoni P, 2009, CELL DEATH DIFFER, V16, P1083, DOI 10.1038/cdd.2009.63; Sanchez-Cespedes M, 2009, CLIN TRANSL ONCOL, V11, P263, DOI 10.1007/s12094-009-0353-7; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Singhal S, 2008, LUNG CANCER, V60, P313, DOI 10.1016/j.lungcan.2008.03.007; Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Xu GL, 2008, BIOCHEM BIOPH RES CO, V375, P395, DOI 10.1016/j.bbrc.2008.08.023; Zhang Zheng-Bin, 2007, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V25, P654; Zucchelli S, 2009, CELL DEATH DIFFER, V16, P428, DOI 10.1038/cdd.2008.169	38	31	33	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	35					3802	3812		10.1038/onc.2011.94	http://dx.doi.org/10.1038/onc.2011.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21478903	Green Published, hybrid			2022-12-28	WOS:000294481400007
J	Messina, S; Frati, L; Leonetti, C; Zuchegna, C; Di Zazzo, E; Calogero, A; Porcellini, A				Messina, S.; Frati, L.; Leonetti, C.; Zuchegna, C.; Di Zazzo, E.; Calogero, A.; Porcellini, A.			Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas	ONCOGENE			English	Article						glioblastoma; dual-specificity phosphatase; tumor promoting	CANCER-CELLS; LUNG-CANCER; MALIGNANT PHENOTYPE; DOWN-REGULATION; UP-REGULATION; GROWTH; EXPRESSION; MUTATIONS; RAS; DUSP6/MKP-3	Dual-specificity phosphatase 6 (DUSP6, mitogen-activated protein kinase (MAPK) phosphatase 3 or PYST1) dephosphorylates phosphotyrosine and phosphothreonine residues on extracellular signal-regulated kinase (ERK1/2; MAPK1/2) to inactivate the ERK1/2 kinase. DUSP6 is a critical regulator of the ERK signaling cascade and has been implicated as a tumor suppressor. We report here experimental evidences that DUSP6 is transcriptionally upregulated in primary and long-term cultures of human glioblastoma, as assayed by northern hybridization and real-time quantitative PCR, producing constitutive high level of protein expression. Functional assays were performed with adenovirus-mediated expression of DUSP6 in glioblastoma cultures. Protein overexpression inhibits growth by inducing G1-phase delay and increased mitogenic/anchorage dependence and clonogenic potential in vitro. Changes in cell morphology were associated with an increased tumor growth in vivo. Chemoresistance is a major cause of treatment failure and poor outcome in human glioblastomas. Importantly, DUSP6 overexpression increased resistance to cisplatin-mediated cell death in vitro and in vivo. Antisense-mediated depletion of DUSP6 acted in lowering the threshold to anticancer DNA-damaging drugs. We conclude that upregulation of DUSP6 exerts a tumor-promoting role in human glioblastomas exacerbating the malignant phenotype. Oncogene (2011) 30, 3813-3820; doi:10.1038/onc.2011.99; published online 18 April 2011	[Messina, S.; Frati, L.] IRCCS Neuromed, Dept Pathol, I-86077 Isernia, Italy; [Messina, S.] Univ Cassino, Dept Hlth & Motor Sci, I-03043 Cassino, Italy; [Leonetti, C.] Regina Elena Inst Canc Res, Dept Expt Chemotherapy, Rome, Italy; [Zuchegna, C.; Di Zazzo, E.] Univ Campobasso, Dept Hlth Sci, Campobasso, Italy; [Zuchegna, C.; Porcellini, A.] Univ Naples Federico 2, Dept Struct & Funct Biol, Naples, Italy; [Calogero, A.] Univ Roma La Sapienza, Dept Med & Surg Sci & Biotecnol, Rome, Italy	IRCCS Neuromed; University of Cassino; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Molise; University of Naples Federico II; Sapienza University Rome	Messina, S (corresponding author), IRCCS Neuromed, Dept Pathol, Via Atinense 18, I-86077 Isernia, Italy.	samantha.messina@uniroma1.it; Antonio.Porcellini@unina.it	Porcellini, Antonio/E-1900-2011; Di Zazzo, Erika/Z-5299-2019; calogero, antonella/U-5418-2019; Porcellini, Antonio/AAC-6097-2019; Frati, Luigi/ABI-7437-2020; Leonetti, Carlo/B-2860-2018	Porcellini, Antonio/0000-0001-6882-9518; Di Zazzo, Erika/0000-0001-7621-488X; Leonetti, Carlo/0000-0002-3526-7827; calogero, antonella/0000-0002-3322-2916; Zuchegna, Candida/0000-0002-8494-8602				Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; Bermudez O, 2011, J CELL PHYSIOL, V226, P276, DOI 10.1002/jcp.22339; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Cui YK, 2006, CANCER RES, V66, P5950, DOI 10.1158/0008-5472.CAN-05-3243; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Gozdz A, 2003, J BIOL CHEM, V278, P43663, DOI 10.1074/jbc.M301554200; Hong L, 2007, MED HYPOTHESES, V69, P1379, DOI 10.1016/j.mehy.2007.03.029; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Li YQ, 2008, CANCER RES, V68, P1723, DOI 10.1158/0008-5472.CAN-07-1963; Lucci MA, 2010, CELL ONCOL, V32, P361, DOI 10.3233/CLO-2010-0520; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Marchetti S, 2004, J CELL PHYSIOL, V199, P441, DOI 10.1002/jcp.10465; Mark JK, 2008, J BIOL CHEM, V283, P28574, DOI 10.1074/jbc.M801747200; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Messina S, 2004, BIOCHEM BIOPH RES CO, V320, P493, DOI 10.1016/j.bbrc.2004.06.003; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Nagane M, 1996, CANCER RES, V56, P5079; Nunes-Xavier CE, 2010, J BIOL CHEM, V285, P26417, DOI 10.1074/jbc.M110.121830; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; PETALIDIS LP, 2008, MOL CANCER THER, V7, pOF1; Porcellini A, 1997, ONCOGENE, V15, P781, DOI 10.1038/sj.onc.1201240; Porcellini Antonio, 2004, Methods Mol Biol, V259, P155; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Silvani A, 2009, J NEURO-ONCOL, V94, P57, DOI 10.1007/s11060-009-9800-0; Tanuma N, 2009, ONCOGENE, V28, P752, DOI 10.1038/onc.2008.431; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Waha A, 2010, CANCER RES, V70, P1689, DOI 10.1158/0008-5472.CAN-09-3218; Warmka JK, 2004, J BIOL CHEM, V279, P33085, DOI 10.1074/jbc.M403120200; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	40	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3813	3820		10.1038/onc.2011.99	http://dx.doi.org/10.1038/onc.2011.99			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21499306				2022-12-28	WOS:000294481400008
J	Shouse, GP; Nobumori, Y; Panowicz, MJ; Liu, X				Shouse, G. P.; Nobumori, Y.; Panowicz, M. J.; Liu, X.			ATM-mediated phosphorylation activates the tumor-suppressive function of B56 gamma-PP2A	ONCOGENE			English	Article						ATM; PP2A; B56 gamma; MDM2; p53	PROTEIN PHOSPHATASE 2A; REGULATORY SUBUNIT; B56-DELTA SUBUNIT; C-MYC; PP2A; KINASE; IDENTIFICATION; PATHWAY; P53; TRANSFORMATION	Protein phosphatase 2A (PP2A) is a family of heterotrimeric protein phosphatases that has a multitude of functions inside the cell, acting through various substrate targets in cell-signaling pathways. Recent evidence suggests that a subset of PP2A holoenzymes function as tumor suppressors and one particular family of B subunits, B56, are implicated in this function. However, the regulatory mechanisms that govern activation of B56-PP2A tumor-suppressive function have not been elucidated. In the present study, we demonstrate that ataxia-telangiectasia mutated (ATM) directly phosphorylates and specifically regulates B56 gamma 3, B56 gamma 2 and B56 delta, after DNA damage. We further show that phosphorylation of B56 gamma 3 at Ser510 leads to an increase in B56 gamma 3-PP2A complexes, and direction of PP2A phosphatase activity toward the substrate p53, activating its tumor-suppressive functions. In addition, we found that under cell growth conditions B56 gamma 3 is kept at low levels through the actions of the E3 ubiquitin ligase MDM2, and, importantly, phosphorylation of B56 gamma 3 by ATM leads to upregulation of the protein by blocking MDM2-mediated B56 gamma 3 ubiquitination. Finally, we show that Ser510 phosphorylation significantly enhances the ability of B56 gamma 3 to inhibit cell proliferation and anchorage-independent growth. These results provide mechanistic insight into the regulation of PP2A tumor-suppressive function, and suggest a model for parallel regulation of p53 and B56 gamma 3. Oncogene (2011) 30, 3755-3765; doi:10.1038/onc.2011.95; published online 4 April 2011	[Shouse, G. P.; Nobumori, Y.; Panowicz, M. J.; Liu, X.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Liu, X (corresponding author), Univ Calif Riverside, Dept Biochem, 5414 Boyce Hall, Riverside, CA 92521 USA.	xuan.liu@ucr.edu		Shouse, Geoffrey/0000-0002-7917-5713	National Institute of Cancer [CA075180]; NATIONAL CANCER INSTITUTE [R29CA075180, R01CA075180] Funding Source: NIH RePORTER	National Institute of Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are very grateful to Dr D Virshup for providing B56 delta antibody, to Dr M Kastan for providing ATM plasmids, to Dr J Momand for providing SJSA-1 cells, and to Dr G Smith and Kudos Pharmaceuticals for providing the ATM inhibitor KU55933. We thank Drs E Lee, D Virshup, JA Traugh, and all members of our laboratory for the many helpful discussions. This work was supported by NIH grant CA075180 from the National Institute of Cancer.	Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Muneer S, 2002, GENOMICS, V79, P344, DOI 10.1006/geno.2002.6721; Nousiainen M, 2006, P NATL ACAD SCI USA, V103, P5391, DOI 10.1073/pnas.0507066103; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Ortega-Lazaro JC, 2003, CYTOGENET GENOME RES, V103, P345, DOI 10.1159/000076823; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Shouse GP, 2008, MOL CELL BIOL, V28, P448, DOI 10.1128/MCB.00983-07; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	24	34	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3755	3765		10.1038/onc.2011.95	http://dx.doi.org/10.1038/onc.2011.95			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21460856				2022-12-28	WOS:000294481400003
J	Xing, F; Okuda, H; Watabe, M; Kobayashi, A; Pai, SK; Liu, W; Pandey, PR; Fukuda, K; Hirota, S; Sugai, T; Wakabayshi, G; Koeda, K; Kashiwaba, M; Suzuki, K; Chiba, T; Endo, M; Mo, YY; Watabe, K				Xing, F.; Okuda, H.; Watabe, M.; Kobayashi, A.; Pai, S. K.; Liu, W.; Pandey, P. R.; Fukuda, K.; Hirota, S.; Sugai, T.; Wakabayshi, G.; Koeda, K.; Kashiwaba, M.; Suzuki, K.; Chiba, T.; Endo, M.; Mo, Y-Y; Watabe, K.			Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells	ONCOGENE			English	Article						Jagged2; Notch; breast cancer; hypoxia; cancer stem-like cells	INDUCIBLE-FACTOR 1-ALPHA; NOTCH LIGANDS; ACTIVATION; BONE; SURVIVAL; GENE; AKT; OVEREXPRESSION; ADENOCARCINOMA; PROLIFERATION	Notch signaling is often and aberrantly activated by hypoxia during tumor progression; however, the exact pathological role of hypoxia-induced Notch signaling in tumor metastasis is as yet poorly understood. In this study, we aimed to define the mechanism of Notch-ligand activation by hypoxia in both primary tumor and bone stromal cells in the metastatic niche and to clarify their roles in tumor progression. We have analyzed the expression profiles of various Notch ligands in 779 breast cancer patients in GEO database and found that the expression of Jagged2 among all five ligands is most significantly correlated with the overall-and metastasis-free survival of breast cancer patients. The results of our immunohistochemical (IHC) analysis for Jagged2 in 61 clinical samples also revealed that both Jagged2 and Notch signaling were strongly upregulated at the hypoxic invasive front. Activation of Jagged2 by hypoxia in tumor cells induced EMT and also promoted cell survival in vitro. Notably, a c-secretase inhibitor significantly blocked Notch-mediated invasion and survival under hypoxia by promoting expression of E-cadherin and inhibiting Akt phosphorylation. Importantly, Jagged2 was also found to be upregulated in bone marrow stroma under hypoxia and promoted the growth of cancer stem-like cells by activating their Notch signaling. Therefore, hypoxia-induced Jagged2 activation in both tumor invasive front and normal bone stroma has a critical role in tumor progression and metastasis, and Jagged2 is considered to be a valuable prognostic marker and may serve as a novel therapeutic target for metastatic breast cancer. Oncogene (2011) 30, 4075-4086; doi:10.1038/onc.2011.122; published online 18 April 2011	[Xing, F.; Okuda, H.; Watabe, M.; Kobayashi, A.; Pai, S. K.; Liu, W.; Pandey, P. R.; Fukuda, K.; Mo, Y-Y; Watabe, K.] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62702 USA; [Hirota, S.; Sugai, T.; Wakabayshi, G.; Koeda, K.; Kashiwaba, M.; Suzuki, K.; Chiba, T.; Endo, M.] Iwate Med Univ, Sch Med, Morioka, Iwate, Japan	Southern Illinois University System; Southern Illinois University; Iwate Medical University	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 751 N Rutledge St,POB 19626, Springfield, IL 62702 USA.	kwatabe@siumed.edu	Kobayashi, Aya/AAA-2530-2020; Mo, Yin-Yuan/R-8255-2019	Okuda, Hiroshi/0000-0002-5747-8086; Chiba, Toshimi/0000-0001-7072-3157	NIH [R01CA124650, R01CA129000]; US Department of Defense [BC085424, BC085590]; Susan Komen Foundation [KG080477]; NATIONAL CANCER INSTITUTE [R01CA129000, R01CA124650] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); Susan Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH (R01CA124650, R01CA129000 to KW), the US Department of Defense (BC085424, BC085590 to KW) and Susan Komen Foundation (KG080477 to KW).	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157; Bertout JA, 2009, CANCER RES, V69, P3213, DOI 10.1158/0008-5472.CAN-08-4223; Cejudo-Martin P, 2005, DEV CELL, V9, P575, DOI 10.1016/j.devcel.2005.10.001; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Choi K, 2009, J BIOL CHEM, V284, P17766, DOI 10.1074/jbc.M109.003111; D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070-2153(10)92003-6; Das B, 2008, STEM CELLS, V26, P1818, DOI 10.1634/stemcells.2007-0724; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Horree N, 2007, HUM PATHOL, V38, P1232, DOI 10.1016/j.humpath.2007.01.008; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kominsky SL, 2006, J CLIN ONCOL, V24, P2227, DOI 10.1200/JCO.2005.05.5319; Lambin P, 1998, ANAEROBE, V4, P183, DOI 10.1006/anae.1998.0161; Lee SH, 2007, APMIS, V115, P1357, DOI 10.1111/j.1600-0463.2007.00751.x; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Main H, 2010, EXP CELL RES, V316, P1610, DOI 10.1016/j.yexcr.2009.12.012; Maynard MA, 2007, CELL MOL LIFE SCI, V64, P2170, DOI 10.1007/s00018-007-7082-2; Mullendore ME, 2009, CLIN CANCER RES, V15, P2291, DOI 10.1158/1078-0432.CCR-08-2004; Nam DH, 2008, CLIN CANCER RES, V14, P4059, DOI 10.1158/1078-0432.CCR-07-4039; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001; Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568; Yu XB, 2008, CELL STEM CELL, V2, P461, DOI 10.1016/j.stem.2008.03.001; Zhao NJ, 2010, ONCOL REP, V23, P1443, DOI 10.3892/or_00000782; Zhong H, 1999, CANCER RES, V59, P5830	41	160	167	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4075	4086		10.1038/onc.2011.122	http://dx.doi.org/10.1038/onc.2011.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499308	Green Accepted			2022-12-28	WOS:000295357500003
J	Dong, L; Jiang, CC; Thorne, RF; Croft, A; Yang, F; Liu, H; de Bock, CE; Hersey, P; Zhang, XD				Dong, L.; Jiang, C. C.; Thorne, R. F.; Croft, A.; Yang, F.; Liu, H.; de Bock, C. E.; Hersey, P.; Zhang, X. D.			Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress	ONCOGENE			English	Article						melanoma; Mcl-1; XBP-1; Ets-1; endoplasmic reticulum stress	ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR ETS-1; UNFOLDED PROTEIN RESPONSE; TRAIL-INDUCED APOPTOSIS; TRANSLATIONAL CONTROL; MALIGNANT-MELANOMA; BREAST-CANCER; EXPRESSION; INHIBITION; ACTIVATION	Past studies have shown that upregulation of the antiapoptotic Bcl-2 family protein Mcl-1 is a major adaptive mechanism of melanoma cells to endoplasmic reticulum (ER) stress, and has an important role in resistance of the cells to apoptosis. In this study, we show that the increase in transcription of Mcl-1 in melanoma cells triggered by pharmacological ER stress inducers is mediated by the transcription factor Ets-1. By incremental deletion analysis of the Mcl-1 promoter, we identified a DNA fragment containing an Ets-1 binding site that is transcriptionally responsive to ER stress. Mutations in the Ets-1 binding site or knockdown of Ets-1 inhibited the increase in Mcl-1, indicating that Ets-1 has a critical role in transcriptional upregulation of Mcl-1. Similar to Mcl-1, Ets-1 was transcriptionally upregulated by ER stress. This was mediated by the IRE1 alpha/XBP-1 branch of the unfolded protein response, as upregulation of Ets-1 was inhibited in melanoma cell lines deficient in IRE1 alpha or XBP-1 established by short hairpin RNA knockdown. Activation of the PI3k/Akt pathway downstream of XBP-1 was also involved, in that inhibition of the pathway blocked upregulation of Ets-1. Inhibition of Ets-1 enhanced ER stress-induced apoptosis in melanoma cell lines and in fresh melanoma isolates, recapitulating the effect of inhibition of Mcl-1. These results reveal a key mechanism by which Mcl-1 is transcriptionally upregulated in melanoma cells by ER stress, and identify Ets-1 as a potential target for inhibition to sensitize melanoma cells to apoptosis. Oncogene (2011) 30, 3716-3726; doi:10.1038/onc.2011.87; dpublished online 21 March 2011	[Dong, L.; Jiang, C. C.; Croft, A.; Yang, F.; Liu, H.; Hersey, P.; Zhang, X. D.] Calvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW 2300, Australia; [Thorne, R. F.; de Bock, C. E.] Univ Newcastle, Canc Res Unit, Sch Biomed Sci, Newcastle, NSW 2300, Australia	Calvary Mater Newcastle Hospital; University of Newcastle	Zhang, XD (corresponding author), Calvary Mater Newcastle Hosp, Immunol & Oncol Unit, Room 443,David Maddison Clin Sci Bldg,Cnr King &, Newcastle, NSW 2300, Australia.	Peter.Hersey@newcastle.edu.au; Xu.Zhang@newcastle.edu.au	de Bock, Charles/H-7699-2019; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022; Jiang, Chenchen/C-2902-2014; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022	de Bock, Charles/0000-0001-5182-8535; Zhang, Xu Dong/0000-0001-9457-8003	NSW State Cancer Council; Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia; NHMRC	NSW State Cancer Council(Cancer Council New South Wales); Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the NSW State Cancer Council, Cancer Institute NSW, and National Health and Medical Research Council (NHMRC), Australia. L Dong is a recipient of Australia-China Exchange Fellowship of NHMRC. XD Zhang is supported by a senior research fellowship of NHMRC.	Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davidson B, 2001, AM J SURG PATHOL, V25, P1493, DOI 10.1097/00000478-200112000-00004; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fritsch RM, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702673200; Gillespie S, 2005, MOL CANCER THER, V4, P668, DOI 10.1158/1535-7163.MCT-04-0332; Hahne JC, 2008, MINI-REV MED CHEM, V8, P1095, DOI 10.2174/138955708785909934; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hersey P, 2008, PIGM CELL MELANOMA R, V21, P358, DOI 10.1111/j.1755-148X.2008.00467.x; Hersey P, 2006, INT REV CYTOL, V251, P131, DOI 10.1016/S0074-7696(06)51004-6; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Jiang CC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.48; Jiang CC, 2008, CANCER RES, V68, P6708, DOI 10.1158/0008-5472.CAN-08-0349; Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047; Jiang CC, 2009, NEOPLASIA, V11, P945, DOI 10.1593/neo.09692; Jiang CC, 2009, NEOPLASIA, V11, P436, DOI 10.1593/neo.09208; Jiang CC, 2009, CARCINOGENESIS, V30, P197, DOI 10.1093/carcin/bgn220; Jorcyk CL, 1997, CELL MOL BIOL, V43, P211; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Liu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-122; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; Mhaidat NM, 2007, CLIN CANCER RES, V13, P1308, DOI 10.1158/1078-0432.CCR-06-2216; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200; Poser I, 2004, HISTOL HISTOPATHOL, V19, P173, DOI 10.14670/HH-19.173; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Torlakovic EE, 2004, MODERN PATHOL, V17, P1400, DOI 10.1038/modpathol.3800206; Wagner N, 2008, ONCOGENE, V27, P3662, DOI 10.1038/sj.onc.1211044; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Warr MR, 2008, CURR MOL MED, V8, P138; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhuang LQ, 2007, MODERN PATHOL, V20, P416, DOI 10.1038/modpathol.3800750; Zhuang LQ, 2010, MODERN PATHOL, V23, P45, DOI 10.1038/modpathol.2009.129; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	51	56	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	34					3716	3726		10.1038/onc.2011.87	http://dx.doi.org/10.1038/onc.2011.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423203	hybrid, Green Published			2022-12-28	WOS:000294244500007
J	Wasylishen, AR; Stojanova, A; Oliveri, S; Rust, AC; Schimmer, AD; Penn, LZ				Wasylishen, A. R.; Stojanova, A.; Oliveri, S.; Rust, A. C.; Schimmer, A. D.; Penn, L. Z.			New model systems provide insights into Myc-induced transformation	ONCOGENE			English	Article						Myc; structure-function; cellular transformation; simian virus 40; hTERT	C-MYC; TRANSGENIC MICE; TRANSACTIVATION DOMAIN; CELL-TRANSFORMATION; ESSENTIAL COFACTOR; BURKITTS-LYMPHOMA; INDUCED APOPTOSIS; N-MYC; FIBROBLASTS; MUTATIONS	The ability of Myc to promote cellular transformation is well established; however, a better understanding of the mechanisms through which Myc mediates tumorigenesis is essential for the development of therapeutic approaches to target this potent oncoprotein. Structure-function studies in rodent fibroblast cells have provided the basis for much of our current understanding of these mechanisms. To build on these approaches, we have characterized three novel human cell line models of Myc-dependent transformation: MCF10A, SH-EP Tet21/N-Myc, and LF1/TERT/LT/ST cells. We have also evaluated Myc family proteins (c-Myc and L-Myc), a naturally occurring isoform of Myc (MycS), and a set of N-terminal domain mutants (DMBII, W135E, T58A) for their ability to promote anchorage-independent growth in these models. Taken together, these results provide the field with three new human cell-based models to study Myc activity, highlight the importance of cellular context, and challenge the paradigm that the ability of Myc to promote tumorigenesis is exclusively MBII-dependent. Oncogene (2011) 30, 3727-3734; doi:10.1038/onc.2011.88; published online 28 March 2011	[Wasylishen, A. R.; Stojanova, A.; Oliveri, S.; Rust, A. C.; Schimmer, A. D.; Penn, L. Z.] Princess Margaret Hosp, Ontario Canc Inst, Campbell Family Inst Canc Res, Toronto, ON M5G 2M9, Canada; [Wasylishen, A. R.; Stojanova, A.; Oliveri, S.; Rust, A. C.; Schimmer, A. D.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Campbell Family Inst Canc Res, 9-628,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459; Schimmer, Aaron/0000-0003-4023-3899; Wasylishen, Amanda/0000-0002-1940-5169	Canadian Cancer Society Research Institute; Ontario Graduate Scholarship; Canadian Breast Cancer Foundation; Ontario Ministry of Health and Long Term Care	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Ontario Graduate Scholarship(Ontario Graduate Scholarship); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	We would like to acknowledge technical assistance from Ms Caitlin Latimer. We thank the members of the Penn Lab for helpful discussions and critical review of this manuscript. This research was funded by a grant from the Canadian Cancer Society Research Institute (LZP), an Ontario Graduate Scholarship (AS), and a Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship (ARW). Additional support was provided by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Callus BA, 2008, CELL DEATH DIFFER, V15, P213, DOI 10.1038/sj.cdd.4402245; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Cleveland J L, 1988, Oncogene Res, V3, P357; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Kim SS, 2007, CANCER RES, V67, P9616, DOI 10.1158/0008-5472.CAN-07-0644; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; SOULE HD, 1990, CANCER RES, V50, P6075; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866	38	21	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3727	3734		10.1038/onc.2011.88	http://dx.doi.org/10.1038/onc.2011.88			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441954	Green Accepted			2022-12-28	WOS:000294244500008
J	Nazeer, FI; Devany, E; Mohammed, S; Fonseca, D; Akukwe, B; Taveras, C; Kleiman, FE				Nazeer, F. I.; Devany, E.; Mohammed, S.; Fonseca, D.; Akukwe, B.; Taveras, C.; Kleiman, F. E.			p53 inhibits mRNA 3 ' processing through its interaction with the CstF/BARD1 complex	ONCOGENE			English	Article						p53; cleavage-stimulation factor; BARD1; DNA damage; RNA processing	DNA-DAMAGE; POLYMERASE-II; POLYADENYLATION FACTOR; UNTRANSLATED REGIONS; EXPRESSION; IDENTIFICATION; APOPTOSIS; PROTEIN; CELLS; PHOSPHORYLATION	The mechanisms involved in the p53-dependent control of gene expression following DNA damage have not been completely elucidated. Here, we show that the p53 C terminus associates with factors that are required for the ultraviolet (UV)-induced inhibition of the mRNA 3' cleavage step of the polyadenylation reaction, such as the tumor suppressor BARD1 and the 3' processing factor cleavage-stimulation factor 1 (CstF1). We found that p53 can coexist in complexes with CstF and BARD1 in extracts of UV-treated cells, suggesting a role for p53 in mRNA 3' cleavage following DNA damage. Consistent with this, we found that p53 inhibits 3' cleavage in vitro and that there is a reverse correlation between the levels of p53 expression and the levels of mRNA 3' cleavage under different cellular conditions. Supporting these results, a tumor-associated mutation in p53 not only decreases the interaction with BARD1 and CstF, but also decreases the UV-induced inhibition of 3' processing, all of which is restored by wild-type-p53 expression. We also found that p53 expression levels affect the polyadenylation levels of housekeeping genes, but not of p21 and c-fos genes, which are involved in the DNA damage response (DDR). Here, we identify a novel 3' RNA processing inhibitory function of p53, adding a new level of complexity to the DDR by linking RNA processing to the p53 network. Oncogene (2011) 3', 3'73-3'83; doi: 10.1038/onc.2011.29; published online 7 March 2011	[Nazeer, F. I.; Devany, E.; Mohammed, S.; Fonseca, D.; Akukwe, B.; Taveras, C.; Kleiman, F. E.] CUNY Hunter Coll, Dept Chem, New York, NY 10065 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Kleiman, FE (corresponding author), CUNY Hunter Coll, Dept Chem, 695 Pk Ave, New York, NY 10065 USA.	fkleiman@hunter.cuny.edu		Mathmann, Carmen/0000-0002-7406-2285	National Institute of General Medical Sciences [SC1GM083806]; Minority Access to Research Careers Program (MARC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC1GM083806] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Minority Access to Research Careers Program (MARC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr JL Manley for anti-CstF2 antibodies, Dr B Vogelstein and Dr J Bargonetti for cell lines DLD-1 and D-A2, Dr EK Boamah for technical advice, Dr C Prives for p53 encoding plasmids, Dr R Baer for BARD1 encoding plasmids and Dr S Pinol-Roma and Dr MA Cevher for advice and discussion. This work is supported by National Institute of General Medical Sciences Grant SC1GM083806 to FEK and by Minority Access to Research Careers Program (MARC) to BA and CT.	Akeo K, 2007, TISSUE CULT RES COMM, V26, P149; CEVHER MA, 2010, CONNECTIONS 3 END PR; Cevher MA, 2010, EMBO J, V29, P1674, DOI 10.1038/emboj.2010.59; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Feki A, 2005, ONCOGENE, V24, P3726, DOI 10.1038/sj.onc.1208491; Fong S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-23; Fox JT, 2009, J BIOL CHEM, V284, P31097, DOI 10.1074/jbc.M109.015800; Fu N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000216; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Gry M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-365; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Ji Z, 2009, P NATL ACAD SCI USA, V106, P7028, DOI 10.1073/pnas.0900028106; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Maccoux LJ, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-62; Mandel CR, 2008, CELL MOL LIFE SCI, V65, P1099, DOI 10.1007/s00018-007-7474-3; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mirkin N, 2008, NUCLEIC ACIDS RES, V36, P1792, DOI 10.1093/nar/gkn005; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Rozenblatt-Rosen O, 2009, P NATL ACAD SCI USA, V106, P755, DOI 10.1073/pnas.0812023106; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Sauer M, 2008, NUCLEIC ACIDS RES, V36, P1900, DOI 10.1093/nar/gkn044; Scorilas A, 2002, CRIT REV CL LAB SCI, V39, P193, DOI 10.1080/10408360290795510; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Singh P, 2009, CANCER RES, V69, P9422, DOI 10.1158/0008-5472.CAN-09-2236; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takwi A, 2009, CURR GENOMICS, V10, P194, DOI 10.2174/138920209788185270; Topalian SL, 2001, MOL CELL BIOL, V21, P5614, DOI 10.1128/MCB.21.16.5614-5623.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu ZH, 2009, ONCOGENE, V28, P41, DOI 10.1038/onc.2008.359; Zlotorynski E, 2008, CELL, V134, P208, DOI 10.1016/j.cell.2008.07.003	46	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	27					3073	3083		10.1038/onc.2011.29	http://dx.doi.org/10.1038/onc.2011.29			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21383700				2022-12-28	WOS:000292510100007
J	Omori, E; Matsumoto, K; Ninomiya-Tsuji, J				Omori, E.; Matsumoto, K.; Ninomiya-Tsuji, J.			Non-canonical beta-catenin degradation mediates reactive oxygen species-induced epidermal cell death	ONCOGENE			English	Article						apoptosis; beta-catenin; caspase; epidermis; reactive oxygen species	TUMOR-NECROSIS-FACTOR; IL-1 SIGNALING PATHWAY; PROTEOLYTIC CLEAVAGE; FACTOR-ALPHA; KINASE TAK1; HELA-CELLS; TNF-ALPHA; KAPPA-B; ACTIVATION; APOPTOSIS	beta-Catenin is constantly degraded through the ubiquitin-proteasomal pathway. In this study, we report that a different type of beta-catenin degradation is causally involved in epidermal cell death. We observed that reactive oxygen species (ROS) caused beta-catenin degradation in the epidermal cells through a caspase-dependent mechanism, which results in disruption of cell adhesion. Disruption of cell adhesion increased ROS and activated caspases. Upregulation of the intact beta-catenin blocked ROS accumulation and caspase activation. These results indicate that a feed-forward loop consisting of ROS, caspases activation and beta-catenin degradation induces epidermal cell death. Oncogene (2011) 30, 3336-3344; doi:10.1038/onc.2011.49; published online 7 March 2011	[Omori, E.; Ninomiya-Tsuji, J.] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Matsumoto, K.] Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648601, Japan	University of North Carolina; North Carolina State University; Nagoya University	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu		Ninomiya-Tsuji, Jun/0000-0002-5584-0176	National Institutes of Health [GM068812, GM084406]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812, R01GM084406] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22020016] Funding Source: KAKEN	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank S Akira for tak1-floxed mice, ER Fearon for beta-catenin cDNAs, J Dow, BJ Welker and M Mattmuler for support. This work was supported by National Institutes of Health Grant GM068812 and GM084406 (to J N-T).	Abe K, 2007, NEURON, V53, P387, DOI 10.1016/j.neuron.2007.01.016; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Tafani M, 2001, CANCER RES, V61, P2459; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Van de Craen M, 1999, FEBS LETT, V458, P167, DOI 10.1016/S0014-5793(99)01153-9; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771; Yang HP, 2005, BIOCHEM J, V391, P399, DOI 10.1042/BJ20050795	30	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	30					3336	3344		10.1038/onc.2011.49	http://dx.doi.org/10.1038/onc.2011.49			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21383695	Green Accepted			2022-12-28	WOS:000293215700004
J	Sudol, M				Sudol, M.			From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management	ONCOGENE			English	Review						Rous sarcoma virus; The Rockefeller University; Lipmann; Fischer; urokinase; Affymetrix	DEPENDENT DNA POLYMERASE; SRC/ABL KINASE INHIBITOR; BREAST-CANCER; WW DOMAIN; V-SRC; MESSENGER-RNA; TRANSFORMATION FINGERPRINT; HORMONAL-REGULATION; PLATELET PROTEIN; KIDNEY-CELLS	Plasminogen activator (PLAU) is a serine protease that converts plasminogen to plasmin, a general protease, which promotes fibrinolysis and degradation of extracellular matrix. PLAU was reported in 1970s as one of the robustly induced enzymatic activities in Rous sarcoma virus (RSV)-transformed chicken cells. More than three decades later, with the completion of the sequencing of the chicken genome and the subsequent availability of Affymetrix GeneChip genome arrays, several laboratories have surveyed the transcriptional program affected by the RSV transformation. Interestingly, the PLAU gene was shown to be the most highly upregulated transcript. The induction of PLAU was a transformation-dependent process because viruses with deleted Src gene did not induce the transcription of the PLAU gene. Both Src and PLAU genes are associated with and contribute to the complex phenotype of human cancer. Although the activity and structures of these two enzymes are well characterized, the precise molecular function of these gene products in signaling networks is still not fully understood. Yet, the knowledge of their association with cancer is already translated into the clinical setting. Src kinase inhibitors are being tested in clinical trials of cancer therapy, and PLAU gene and its inhibitor have been included as biomarkers with strong prognostic and therapeutic predictive values. This vignette reviews the history of PLAU and Src discovery, and illuminates the complexity of their relationship, but also points to their emerging impact on public health. Oncogene (2011) 30, 3003-3010; doi: 10.1038/onc.2011.38; published online 7 March 2011	[Sudol, M.] Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA	Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, MC 26-08,100 N Acad Ave, Danville, PA 17822 USA.	msudol1@geisinger.edu			PA Breast Cancer Coalition grants; Geisinger Clinic	PA Breast Cancer Coalition grants; Geisinger Clinic	This work was supported by PA Breast Cancer Coalition grants and by Geisinger Clinic.	Annecke K, 2008, ADV CLIN CHEM, V45, P31, DOI 10.1016/S0065-2423(07)00002-9; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL SM, 1990, J BIOL CHEM, V265, P1333; BING RJ, 2008, DIALOGUES CARDIOVASC, V13, P127; Blasi F, 2010, FEBS LETT, V584, P1923, DOI 10.1016/j.febslet.2009.12.039; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Carriero MV, 2009, MOL CANCER THER, V8, P2708, DOI 10.1158/1535-7163.MCT-09-0174; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; D'Alessio S, 2009, FRONT BIOSCI-LANDMRK, V14, P4575, DOI 10.2741/3550; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DUBOS R, 1979, J EXP MED, V150, P733; Fischer A, 1925, ARCH MIKROSK ANAT EN, V104, P210, DOI 10.1007/BF02108499; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Harbeck N, 2007, CRIT REV CL LAB SCI, V44, P179, DOI 10.1080/10408360601040970; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Hildenbrand R, 2010, EXPERT OPIN INV DRUG, V19, P641, DOI 10.1517/13543781003767400; Huang F, 2007, CANCER RES, V67, P2226, DOI 10.1158/0008-5472.CAN-06-3633; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Hunter T, 2007, J CLIN INVEST, V117, P2036, DOI 10.1172/JCI31691; JAHNER D, 1991, ONCOGENE, V6, P1259; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; LESLIE ND, 1990, J BIOL CHEM, V265, P1339; LIPMANN F, 1971, WANDERINGS BIOCH, P20; Maeda N, 2008, REV MED VIROL, V18, P387, DOI 10.1002/rmv.592; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Martin GS, 2004, ONCOGENE, V23, P7910, DOI 10.1038/sj.onc.1208077; Masker K, 2007, VIROLOGY, V364, P10, DOI 10.1016/j.virol.2007.03.026; Maslikowski BM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-41; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Mekkawy AH, 2009, FUTURE ONCOL, V5, P1487, DOI 10.2217/FON.09.108; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; Patnaik A, 2002, J VIROL, V76, P2789, DOI 10.1128/JVI.76.6.2789-2795.2002; Paz K, 2004, ONCOGENE, V23, P8455, DOI 10.1038/sj.onc.1207803; Pincetic A, 2008, J BIOL CHEM, V283, P29822, DOI 10.1074/jbc.M804157200; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Rous P, 1910, J EXP MED, V12, P696, DOI 10.1084/jem.12.5.696; Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schmitt M, 2004, INT J ONCOL, V25, P1397; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUDOL M, 1985, MOL CELL ENDOCRINOL, V40, P245, DOI 10.1016/0303-7207(85)90180-7; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1984, BIOCHEM J, V219, P971, DOI 10.1042/bj2190971; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SUDOL M, 2006, DANVILLE NEWS   0816; Sudol M, 2010, TRENDS BIOCHEM SCI, V35, P627, DOI 10.1016/j.tibs.2010.05.010; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Suzuki Y, 2010, J PHARMACOL SCI, V113, P203, DOI 10.1254/jphs.10R01CP; Tapia VE, 2010, J BIOL CHEM, V285, P19391, DOI 10.1074/jbc.M109.084525; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Thomssen C, 2009, J NATL CANCER I, V101, P1028, DOI 10.1093/jnci/djp145; Ulisse S, 2009, CURR CANCER DRUG TAR, V9, P32, DOI 10.2174/156800909787314002; UNKELESS JC, 1973, J EXP MED, V137, P85, DOI 10.1084/jem.137.1.85; Vogt Peter K, 2010, Genes Cancer, V1, P6, DOI 10.1177/1947601909356102; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	70	20	21	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3003	3010		10.1038/onc.2011.38	http://dx.doi.org/10.1038/onc.2011.38			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21383693				2022-12-28	WOS:000292510100001
J	Takahashi, F; Chiba, N; Tajima, K; Hayashida, T; Shimada, T; Takahashi, M; Moriyama, H; Brachtel, E; Edelman, EJ; Ramaswamy, S; Maheswaran, S				Takahashi, F.; Chiba, N.; Tajima, K.; Hayashida, T.; Shimada, T.; Takahashi, M.; Moriyama, H.; Brachtel, E.; Edelman, E. J.; Ramaswamy, S.; Maheswaran, S.			Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib	ONCOGENE			English	Article						breast cancer; BTG2; invasion; metastasis; ErbB/HER pathway	TRANSLOCATION GENE-2 PROTEIN; ESTROGEN-RECEPTOR; CANCER PATIENTS; MOLECULAR SIGNATURE; PHASE-II; GROWTH; CELLS; CARCINOMA; PROGNOSIS; GRADE	The B-cell translocation gene-2 (BTG2), a p53-inducible gene, is suppressed in mammary epithelial cells during gestation and lactation. In human breast cancer, decreased BTG2 expression correlates with high tumor grade and size, p53 status, blood and lymph vessel invasion, local and metastatic recurrence and decrease in overall survival, suggesting that suppression of BTG2 has a critical role in disease progression. To analyze the role of BTG2 in breast cancer progression, BTG2 expression was knocked down in mammary epithelial cells. Suppression of BTG2 enhances the motility of cells in vitro and tumor growth and metastasis in vivo. The effects of BTG2 knockdown are mediated through stabilization of the human epidermal growth factor receptor (HER) ligands neuregulin and epiregulin and activation of the HER2 and HER3 receptors, leading to elevated AKT phosphorylation. Suppression of HER activation using the tyrosine kinase inhibitor lapatinib abrogates the effects of BTG2 knockdown, including the increased cell migration observed in vitro and the enhancement of tumorigenesis and metastasis in vivo. These results link BTG2-dependent effects on tumor progression to ErbB receptor signaling, and raise the possibility that targeted inhibition of this pathway may be relevant in the treatment of breast cancers that have reduced BTG2 expression. Oncogene (2011) 30, 3084-3095; doi: 10.1038/onc.2011.24; published online 21 February 2011	[Maheswaran, S.] Massachusetts Gen Hosp, Ctr Canc, Dept Surg, Charlestown, MA 02129 USA; [Takahashi, F.; Chiba, N.; Tajima, K.; Hayashida, T.; Shimada, T.; Takahashi, M.; Moriyama, H.; Brachtel, E.; Edelman, E. J.; Ramaswamy, S.; Maheswaran, S.] Harvard Univ, Sch Med, Charlestown, MA USA; [Takahashi, F.; Chiba, N.; Tajima, K.; Hayashida, T.; Shimada, T.; Takahashi, M.; Edelman, E. J.; Ramaswamy, S.; Maheswaran, S.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; [Moriyama, H.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; [Brachtel, E.] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Dept Surg, Bldg 149,13th St, Charlestown, MA 02129 USA.	maheswaran@helix.mgh.harvard.edu			NIH/NCI [CA89138]; Susan G Komen for the Cure Grants [PDF0600282, KG090412]; ESSCO breast cancer research grant; NATIONAL CANCER INSTITUTE [R01CA089138] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure Grants(Susan G. Komen Breast Cancer Foundation); ESSCO breast cancer research grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Isselbacher, Haber, Engelman and Zou for critically reading the paper. This work was supported by the NIH/NCI Grant CA89138 (to SM), the Susan G Komen for the Cure Grants PDF0600282 and KG090412 (to SM) and ESSCO breast cancer research grant (to SM).	Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boersma BJ, 2008, INT J CANCER, V122, P1324, DOI 10.1002/ijc.23237; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Calzolari F, 2008, NEOPLASIA, V10, P1373, DOI 10.1593/neo.08814; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Farioli-Vecchioli S, 2007, FASEB J, V21, P2215, DOI 10.1096/fj.06-7548com; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gomez HL, 2008, J CLIN ONCOL, V26, P2999, DOI 10.1200/JCO.2007.14.0590; Gril B, 2008, JNCI-J NATL CANCER I, V100, P1092, DOI 10.1093/jnci/djn216; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Ha TU, 2000, J BIOL CHEM, V275, P37101, DOI 10.1074/jbc.M005701200; Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hong JW, 2005, J BIOL CHEM, V280, P21256, DOI 10.1074/jbc.M500318200; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Johnston S, 2008, J CLIN ONCOL, V26, P1066, DOI 10.1200/JCO.2007.13.9949; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; Julka PK, 2008, BRIT J CANCER, V98, P1327, DOI 10.1038/sj.bjc.6604322; Kawakubo H, 2004, ONCOGENE, V23, P8310, DOI 10.1038/sj.onc.1208008; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; Konecny GE, 2008, BRIT J CANCER, V98, P1076, DOI 10.1038/sj.bjc.6604278; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; LIM IK, 1995, J CANCER RES CLIN, V121, P279, DOI 10.1007/BF01209594; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mauxion F, 2008, EMBO J, V27, P1039, DOI 10.1038/emboj.2008.43; Mauxion F, 2009, TRENDS BIOCHEM SCI, V34, P640, DOI 10.1016/j.tibs.2009.07.008; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Park S, 2004, MOL CELL BIOL, V24, P10256, DOI 10.1128/MCB.24.23.10256-10262.2004; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Sithanandam G, 2005, ONCOGENE, V24, P1847, DOI 10.1038/sj.onc.1208381; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tripathy D, 1992, Cancer Treat Res, V63, P15; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Yu K, 2006, CLIN CANCER RES, V12, P3288, DOI 10.1158/1078-0432.CCR-05-1530; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	62	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3084	3095		10.1038/onc.2011.24	http://dx.doi.org/10.1038/onc.2011.24			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339742				2022-12-28	WOS:000292510100008
J	Abdel-Samad, R; Zalzali, H; Rammah, C; Giraud, J; Naudin, C; Dupasquier, S; Poulat, F; Boizet-Bonhoure, B; Lumbroso, S; Mouzat, K; Bonnans, C; Pignodel, C; Raynaud, P; Fort, P; Quittau-Prevostel, C; Blache, P				Abdel-Samad, R.; Zalzali, H.; Rammah, C.; Giraud, J.; Naudin, C.; Dupasquier, S.; Poulat, F.; Boizet-Bonhoure, B.; Lumbroso, S.; Mouzat, K.; Bonnans, C.; Pignodel, C.; Raynaud, P.; Fort, P.; Quittau-Prevostel, C.; Blache, P.			MiniSOX9, a dominant-negative variant in colon cancer cells	ONCOGENE			English	Article						PKC alpha; SOX9; Wnt/beta-catenin signaling pathway	MESSENGER-RNA POLYADENYLATION; BETA-CATENIN; TRANSCRIPTION FACTOR; CAMPOMELIC DYSPLASIA; GENE-EXPRESSION; FACTOR SOX9; MOUSE; IDENTIFICATION; INHIBITION; EPITHELIUM	Inherited and acquired changes in pre-mRNA processing have significant roles in human diseases, especially cancer. Characterization of aberrantly spliced mRNAs may thus contribute to understand malignant transformation. We recently reported an anti-oncogenic potential for the SOX9 transcription factor in the colon. For instance, the Sox9 gene knock out in the mouse intestine results in an excess of proliferation with appearance of hyperplasia. SOX9 is expressed in colon cancer cells but its endogenous activity is weak. We looked for SOX9 variants that may impair SOX9 activity in colon cancer cells and we discovered MiniSOX9, a truncated version of SOX9 devoid of transactivation domain as a result of retention of the second intron. A significant overexpression of MiniSOX9 mRNA in human tumor samples compared with their matched normal tissues was observed by real-time reverse transcriptase-PCR. Immunohistochemistry revealed that MiniSOX9 is expressed at high levels in human colon cancer samples whereas it is undetectable in the surrounding healthy tissues. Finally, we discovered that MiniSOX9 behaves as a SOX9 inhibitor, inhibits protein kinase C alpha promoter activity and stimulates the canonical Wnt pathway. This potential oncogenic activity of the SOX9 locus gives new insights on its role in colon cancer. Oncogene (2011) 30, 2493-2503; doi:10.1038/onc.2010.621; published online 7 February 2011	[Abdel-Samad, R.; Zalzali, H.; Rammah, C.; Giraud, J.; Naudin, C.; Dupasquier, S.; Bonnans, C.; Raynaud, P.; Quittau-Prevostel, C.; Blache, P.] Univ Montpellier 1, INSERM, CNRS, Inst Genom Fonct,UMR 5203,U661, F-34094 Montpellier 5, France; [Abdel-Samad, R.; Zalzali, H.; Rammah, C.; Giraud, J.; Naudin, C.; Dupasquier, S.; Bonnans, C.; Raynaud, P.; Quittau-Prevostel, C.; Blache, P.] Univ Montpellier 2, F-34094 Montpellier 5, France; [Poulat, F.; Boizet-Bonhoure, B.] UPR, CNRS, Inst Genet Humaine, Montpellier, France; [Lumbroso, S.; Mouzat, K.] CHU Nimes, Biochim Lab, Nimes, France; [Pignodel, C.] CHU Nimes, Serv Anat & Cytol Pathol, Nimes, France; [Fort, P.] CNRS, UMR 5237, Ctr Rech Biochim Macromol, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Nimes; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blache, P (corresponding author), Univ Montpellier 1, INSERM, CNRS, Inst Genom Fonct,UMR 5203,U661, 141 Rue Cardonille, F-34094 Montpellier 5, France.	philippe.blache@igf.cnrs.fr	POULAT, FRANCIS/AAV-2170-2020; Fort, Philippe/M-9498-2015; Prevostel, Corinne/AAO-1433-2020; Raynaud, Peggy/AAC-5749-2020; Lumbroso, Serge/AFS-0438-2022	POULAT, FRANCIS/0000-0003-2070-1296; Fort, Philippe/0000-0001-5997-8722; Raynaud, Peggy/0000-0003-1224-8495; Giraud, Julie/0000-0001-6173-4276; Abdel-Samad, Rana/0000-0002-7753-8779; PREVOSTEL, Corinne/0000-0002-7553-087X	Ligue Nationale contre le Cancer (Equipe Labellisee); Ligue Regionale contre le Cancer (Comite Languedoc-Roussillon); Association pour la Recherche sur le Cancer [4994]; Region Languedoc-Roussillon (Chercheur d'Avenir); CNRS du LIBAN; Ligue Nationale contre le Cancer; Association pour la Recherche sur le Cancer	Ligue Nationale contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer); Ligue Regionale contre le Cancer (Comite Languedoc-Roussillon); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Region Languedoc-Roussillon (Chercheur d'Avenir)(Region Occitanie); CNRS du LIBAN; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	This work was supported by the 'Ligue Nationale contre le Cancer (Equipe Labellisee)', the 'Ligue Regionale contre le Cancer (Comite Languedoc-Roussillon)', the 'Association pour la Recherche sur le Cancer (grant number 4994)' and the 'Region Languedoc-Roussillon (Chercheur d'Avenir)'. Rana Abdel-Samad and Hassan Zalzali fellowships were from 'CNRS du LIBAN'. Sebastien Dupasquier fellowships were from 'Ligue Nationale contre le Cancer' and 'Association pour la Recherche sur le Cancer'. Peggy Raynaud post-doctoral fellowship was from 'Association pour la Recherche sur le Cancer'. Cyrine Rammah doctoral fellowship was from the 'Ligue Nationale contre le Cancer'. We thank Dr Christine Perret for providing the APC Delta 14 mice, Dr Pascal Roger 'CHU Nimes tumorotheque' for human colon biopsy samples, Geraldine Leguelinel for preparation of RNA from biopsy samples and Dr Sabine Laurent-Chabalier for statistical analysis.	Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Agrawal R, 2009, FEBS J, V276, P4184, DOI 10.1111/j.1742-4658.2009.07127.x; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143; Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chaboissier MC, 2004, DEVELOPMENT, V131, P1891, DOI 10.1242/dev.01087; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Dupasquier S, 2009, J CELL SCI, V122, P2191, DOI 10.1242/jcs.036483; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Gilmartin GM, 2005, GENE DEV, V19, P2517, DOI 10.1101/gad.1378105; Giordano J, 2001, AM J MED GENET, V98, P176, DOI 10.1002/1096-8628(20010115)98:2<176::AID-AJMG1027>3.0.CO;2-Q; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; Hu J, 2005, RNA, V11, P1485, DOI 10.1261/rna.2107305; Jay P, 2005, CANCER RES, V65, P2193, DOI 10.1158/0008-5472.CAN-04-1484; Jin L, 2008, EXP BIOL MED, V233, P849, DOI 10.3181/0712-RM-352; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee JY, 2008, NUCLEIC ACIDS RES, V36, P5581, DOI 10.1093/nar/gkn540; Leung N, 2008, ONCOGENE, V27, P4943, DOI 10.1038/onc.2008.136; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller P, 2010, BREAST CANCER RES TR, V120, P317, DOI 10.1007/s10549-009-0381-6; Notarnicola C, 2006, GENE EXPR PATTERNS, V6, P695, DOI 10.1016/j.modgep.2006.01.001; Passeron T, 2009, J CLIN INVEST, V119, P954, DOI 10.1172/JCI34015; Pysz MA, 2009, EXP CELL RES, V315, P1415, DOI 10.1016/j.yexcr.2009.02.002; Retelska D, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-176; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Tago K, 2000, GENE DEV, V14, P1741; Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200; Zalzali H, 2008, ONCOGENE, V27, P7131, DOI 10.1038/onc.2008.331; Zhang H, 2000, MOL HUM REPROD, V6, P146, DOI 10.1093/molehr/6.2.146	40	26	28	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2493	2503		10.1038/onc.2010.621	http://dx.doi.org/10.1038/onc.2010.621			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21297661				2022-12-28	WOS:000291198400001
J	Garcia-Marcos, M; Ghosh, P; Farquhar, MG				Garcia-Marcos, M.; Ghosh, P.; Farquhar, M. G.			Molecular basis of a novel oncogenic mutation in GNAO1	ONCOGENE			English	Article						oncoprotein; somatic mutation; heterotrimeric G protein; GAIP/RGS19; neoplasia; STAT3	GUANINE-NUCLEOTIDE-BINDING; PROTEIN ALPHA-SUBUNITS; RECEPTOR-MEDIATED ACTIVATION; GTPASE ACTIVITY; CELL-MIGRATION; NIH-3T3 CELLS; MUTANT; TRANSFORMATION; TUMORS; DOMAIN	Heterotrimeric G proteins are molecular switches that control signal transduction, and their dysregulation can promote oncogenesis. Somatic mutations in GNAS, GNAI2 and GNAQ genes induce oncogenesis by rendering G alpha subunits constitutively activated. Recently the first somatic mutation, arginine(243)-> histidine (R243H) in the GNAO1 (G alpha o) gene was identified in breast carcinomas and shown to promote oncogenic transformation when introduced into cells. Here, we provide the molecular basis for the oncogenic properties of the G alpha o R243H mutant. Using limited proteolysis assays, nucleotide-binding assays, and single-turnover and steady-state GTPase assays, we demonstrate that the oncogenic R234H mutation renders G alpha o constitutively active by accelerating the rate of nucleotide exchange; however, this mutation does not affect G alpha o's ability to become deactivated by GTPase-activating proteins (GAPs) or by its intrinsic GTPase activity. This mechanism differs from that of previously reported oncogenic mutations that impair GTPase activity and GAP sensitivity without affecting nucleotide exchange. The constitutively active G alpha o R243H mutant also enhances Src-STAT3 signaling in NIH-3T3 cells, a pathway previously shown to be directly triggered by active G alpha o proteins to promote cellular transformation. Based on structural analyses, we propose that the enhanced rate of nucleotide exchange in G alpha o R243H results from loss of the highly conserved electrostatic interaction of R243 with E43, located in the in the P-loop that represents the binding site for the alpha- and beta-phosphates of the nucleotide. We conclude that the novel R234H mutation imparts oncogenic properties to G alpha o by accelerating nucleotide exchange and rendering it constitutively active, thereby enhancing signaling pathways, for example, src-STAT3, responsible for neoplastic transformation. Oncogene (2011) 30, 2691-2696; doi:10.1038/onc.2010.645; published online 14 February 2011	[Garcia-Marcos, M.] Univ Calif San Diego, Dept Cellular & Mol Med, San Diego Sch Med, George E Palade Labs Cellular & Mol Med, La Jolla, CA 92093 USA; [Ghosh, P.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Garcia-Marcos, M (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, San Diego Sch Med, George E Palade Labs Cellular & Mol Med, 9500 Gilman Dr,Room 218, La Jolla, CA 92093 USA.	mgarciamarcos@ucsd.edu			NIH [CA100768, DKI7780]; Susan G Komen postdoctoral fellowship [KG080079]; American Gastroenterology Association FDN; NATIONAL CANCER INSTITUTE [R01CA100768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen postdoctoral fellowship(Susan G. Komen Breast Cancer Foundation); American Gastroenterology Association FDN; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by NIH grants CA100768 and DKI7780 (to MGF). MGM was supported by a Susan G Komen postdoctoral fellowship KG080079 and PG by Burroughs Wellcome Fund and Research Scholar Award (American Gastroenterology Association FDN).	Barren B, 2006, MOL VIS, V12, P492; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Doi M, 2002, NEURON, V33, P249, DOI 10.1016/S0896-6273(01)00587-6; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Garcia-Marcos M, 2010, J BIOL CHEM, V285, P12765, DOI 10.1074/jbc.M109.045161; Garcia-Marcos M, 2009, P NATL ACAD SCI USA, V106, P3178, DOI 10.1073/pnas.0900294106; Ghosh P, 2008, J CELL BIOL, V182, P381, DOI 10.1083/jcb.200712066; Ghosh P, 2010, MOL BIOL CELL, V21, P2338, DOI 10.1091/mbc.E10-01-0028; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Johnston CA, 2007, P NATL ACAD SCI USA, V104, P17317, DOI 10.1073/pnas.0704751104; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Lamba S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006833; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Makita N, 2007, P NATL ACAD SCI USA, V104, P17424, DOI 10.1073/pnas.0708561104; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mukhopadhyay S, 2002, METHOD ENZYMOL, V344, P350; Pereira R, 2005, J BIOL CHEM, V280, P35696, DOI 10.1074/jbc.M504935200; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Warner DR, 1999, P NATL ACAD SCI USA, V96, P4268, DOI 10.1073/pnas.96.8.4268; WONG YH, 1995, ONCOGENE, V10, P1927; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zurita AR, 2008, P NATL ACAD SCI USA, V105, P2363, DOI 10.1073/pnas.0712261105	41	43	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	23					2691	2696		10.1038/onc.2010.645	http://dx.doi.org/10.1038/onc.2010.645			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21317923	Green Accepted			2022-12-28	WOS:000291677800009
J	Schramedei, K; Morbt, N; Pfeifer, G; Lauter, J; Rosolowski, M; Tomm, JM; von Bergen, M; Horn, F; Brocke-Heidrich, K				Schramedei, K.; Moerbt, N.; Pfeifer, G.; Laeuter, J.; Rosolowski, M.; Tomm, J. M.; von Bergen, M.; Horn, F.; Brocke-Heidrich, K.			MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4	ONCOGENE			English	Article						miR-21; ANP32A; SMARCA4; prostate; post-transcriptional regulation	CELL-PROLIFERATION; MICRO-RNA; EXPRESSION; PROTEIN; MIR-21; BRG1; IDENTIFICATION; INVASION; COMPLEX; PREDICTION	MicroRNA-21 (miR-21) is a key regulator of oncogenic processes. It is significantly elevated in the majority of human tumors and functionally linked to cellular proliferation, survival and migration. In this study, we used two experimental-based strategies to search for novel miR-21 targets. On the one hand, we performed a proteomic approach using two-dimensional differential gel electrophoresis (2D-DIGE) to identify proteins suppressed upon enhanced miR-21 expression in LNCaP human prostate carcinoma cells. The tumor suppressor acidic nuclear phosphoprotein 32 family, member A (ANP32A) (alias pp32 or LANP) emerged as the most strongly downregulated protein. On the other hand, we applied a mathematical approach to select correlated gene sets that are negatively correlated with primary-miR-21 (pri-miR-21) expression in published transcriptome data from 114 B-cell lymphoma cases. Among these candidates, we found tumor suppressor SMARCA4 (alias BRG1) together with the already validated miR-21 target, PDCD4. ANP32A and SMARCA4, which are both involved in chromatin remodeling processes, were confirmed as direct miR-21 targets by immunoblot analysis and reporter gene assays. Furthermore, knock down of ANP32A mimicked the effect of enforced miR-21 expression by enhancing LNCaP cell viability, whereas overexpression of ANP32A in the presence of high miR-21 levels abrogated the miR-21 mediated effect. In A172 glioblastoma cells, enhanced ANP32A expression compensated for the effects of anti-miR- 21 treatment on cell viability and apoptosis. In addition, miR-21 expression clearly increased the invasiveness of LNCaP cells, an effect also seen in part upon downregulation of ANP32A. In conclusion, these results suggest that downregulation of ANP32A contributes to the oncogenic function of miR-21. Oncogene (2011) 30, 2975-2985; doi:10.1038/onc.2011.15; published online 14 February 2011	[Schramedei, K.; Pfeifer, G.; Horn, F.; Brocke-Heidrich, K.] Univ Leipzig, Inst Clin Immunol, Fac Med, D-04103 Leipzig, Germany; [Moerbt, N.; Tomm, J. M.; von Bergen, M.] UFZ Helmholtz Ctr Environm Res, UFZ, Dept Prote, Leipzig, Germany; [Laeuter, J.; Rosolowski, M.] Univ Leipzig, Inst Med Informat Stat & Epidemiol IMISE, Fac Med, D-04103 Leipzig, Germany; [von Bergen, M.] UFZ Helmholtz Ctr Environm Res, UFZ, Dept Metabol, Leipzig, Germany	Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ)	Brocke-Heidrich, K (corresponding author), Univ Leipzig, Inst Clin Immunol, Fac Med, Johannisallee 30, D-04103 Leipzig, Germany.	kheid@medizin.uni-leipzig.de	von Bergen, Martin/D-7960-2011; Tomm, Janina M/F-8888-2014	von Bergen, Martin/0000-0003-2732-2977; Tomm, Janina M/0000-0001-8161-1812	DFG [BR2892/3-1]; Medical Faculty, University of Leipzig	DFG(German Research Foundation (DFG)); Medical Faculty, University of Leipzig	We thank Riccardo Dalla-Favera (New York) for kindly providing SUDHL-2 cells. The work was partly supported by the DFG grant BR2892/3-1 and a junior research grant by the Medical Faculty, University of Leipzig.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bai JN, 2001, ONCOGENE, V20, P2153, DOI 10.1038/sj.onc.1204294; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Brody JR, 2007, MODERN PATHOL, V20, P1238, DOI 10.1038/modpathol.3800974; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hoffarth S, 2008, CELL DEATH DIFFER, V15, P161, DOI 10.1038/sj.cdd.4402256; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jehmlich N, 2008, ISME J, V2, P1122, DOI 10.1038/ismej.2008.64; John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lauter J, 2009, BIOMETRICAL J, V51, P235, DOI 10.1002/bimj.200800207; Lawrie CH, 2007, INT J CANCER, V121, P1156, DOI 10.1002/ijc.22800; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Martin G, 2007, J BIOSCIENCES, V32, P1049, DOI 10.1007/s12038-007-0106-0; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Morbt N, 2009, PROTEOMICS, V9, P4920, DOI 10.1002/pmic.200800836; Navarro A, 2008, BLOOD, V111, P2825, DOI 10.1182/blood-2007-06-096784; Pan W, 2009, J BIOL CHEM, V284, P6946, DOI 10.1074/jbc.M805801200; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Rodriguez-Nieto S, 2009, CARCINOGENESIS, V30, P547, DOI 10.1093/carcin/bgp035; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Santos PM, 2007, OMICS, V11, P233, DOI 10.1089/omi.2007.0009; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wong AKC, 2000, CANCER RES, V60, P6171; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yang Y, 2010, MOL BIOSYST, V6, P1873, DOI 10.1039/c004401f; Yang Y, 2009, PROTEOMICS, V9, P1374, DOI 10.1002/pmic.200800551; Yao Q, 2009, BIOCHEM BIOPH RES CO, V388, P539, DOI 10.1016/j.bbrc.2009.08.044; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	62	105	110	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2975	2985		10.1038/onc.2011.15	http://dx.doi.org/10.1038/onc.2011.15			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317927	hybrid, Green Published			2022-12-28	WOS:000292245100008
J	Ip, CKM; Cheung, ANY; Ngan, HYS; Wong, AST				Ip, C. K. M.; Cheung, A. N. Y.; Ngan, H. Y. S.; Wong, A. S. T.			p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells	ONCOGENE			English	Article						p70 S6 kinase; ovarian cancer; actin; Rac1; Cdc42	GROWTH-FACTOR; MESSENGER-RNA; RHO-GTPASES; G-PROTEINS; LOCALIZATION; ACTIVATION; EXPRESSION; ONCOGENE; PHOSPHORYLATION; INHIBITION	Ovarian cancer is highly metastatic with a poor prognosis. The serine/threonine kinase, p70 S6 kinase (p70(S6K)), which is a downstream effector of phosphatidylinositol 3-kinase/Akt pathway, is frequently activated in ovarian cancer. Here, we show that p70(S6K) is a critical regulator of the actin cytoskeleton in the acquisition of the metastatic phenotype. This regulation is through two important activities: p70(S6K) acts as an actin filament cross-linking protein and as a Rho family GTPase-activating protein. Ectopic expression of constitutively active p70(S6K) in ovarian cancer cells induced a marked reorganization of the actin cytoskeleton and promoted directional cell migration. Using cosedimentation and differential sedimentation assays, p70(S6K) was found to directly bind to and cross-link actin filaments. Immunofluorescence studies showed p70(S6K) colocalized with cytochalasin D-sensitive actin at the leading edge of motile cells. The p70(S6K) did not affect the kinetics of spontaneous actin polymerization, but could stabilize actin filaments by the inhibition of cofilin-induced actin depolymerization. In addition, we showed that p70(S6K) stimulated the rapid activation of both Rac1 and Cdc42, and their downstream effector p21-activated kinase (PAK1), but not RhoA. Depletion of p70(S6K) expression or inhibition of its activity resulted in significant inhibition of actin cytoskeleton reorganization and reduced migration, with a concomitant reduction in Rac1, Cdc42 and PAK1 activation, confirming that the effect was p70(S6K) specific. Similarly, the actin cytoskeleton reorganization/migratory phenotype could be reversed by expression of dominant negative Rac1 and Cdc42, or inhibition of PAK1. These results reveal a new direction for understanding the oncogenic roles of p70(S6K) in tumor progression. Oncogene (2011) 30, 2420-2432; doi:10.1038/onc.2010.615; published online 24 January 2011	[Ip, C. K. M.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Cheung, A. N. Y.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Ngan, H. Y. S.] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022; Cheung, Annie Nga Yin/C-4231-2009	Wong, Alice/0000-0002-0676-6475; Ip, Carman K.M./0000-0002-6672-5982; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Annie Nga Yin/0000-0002-1584-7568	Research Grant Council [HKU 7599/05M]; HKU	Research Grant Council(Hong Kong Research Grants Council); HKU(University of Hong Kong)	We thank Dr N Auersperg, G Thomas and A Hall for providing cell lines and cDNA constructs. This work was supported by the Research Grant Council grant HKU 7599/05M and the HKU Outstanding Young Research Award (AST Wong).	Ahmed N, 2006, AM J PHYSIOL-CELL PH, V290, pC1532, DOI 10.1152/ajpcell.00478.2005; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; BUICK RN, 1985, CANCER RES, V45, P3668; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Filonenko VV, 2004, EXP ONCOL, V26, P294; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanein D, 1997, J CELL BIOL, V139, P387, DOI 10.1083/jcb.139.2.387; HOLMES GR, 1976, BIOCHIM BIOPHYS ACTA, V446, P445, DOI 10.1016/0005-2795(76)90010-6; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; Liu LZ, 2006, FREE RADICAL BIO MED, V41, P1521, DOI 10.1016/j.freeradbiomed.2006.08.003; Nozawa H, 2007, CANCER LETT, V251, P105, DOI 10.1016/j.canlet.2006.11.008; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Philp AJ, 2001, CANCER RES, V61, P7426; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Siu MKY, 2010, INT J CANCER, V127, P21, DOI 10.1002/ijc.25005; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Wong AST, 2004, EXP CELL RES, V299, P248, DOI 10.1016/j.yexcr.2004.06.002; Zhou HY, 2006, ENDOCRINOLOGY, V147, P2557, DOI 10.1210/en.2005-1404	38	72	76	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2420	2432		10.1038/onc.2010.615	http://dx.doi.org/10.1038/onc.2010.615			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258406	Bronze, Green Submitted			2022-12-28	WOS:000291008000004
J	Kwak, HJ; Kim, YJ; Chun, KR; Woo, YM; Park, SJ; Jeong, JA; Jo, SH; Kim, TH; Min, HS; Chae, JS; Choi, EJ; Kim, G; Shin, SH; Gwak, HS; Kim, SK; Hong, EK; Lee, GK; Choi, KH; Kim, JH; Yoo, H; Park, JB; Lee, SH				Kwak, H-J; Kim, Y-J; Chun, K-R; Woo, Y. M.; Park, S-J; Jeong, J-A; Jo, S. H.; Kim, T. H.; Min, H. S.; Chae, J. S.; Choi, E-J; Kim, G.; Shin, S-H; Gwak, H-S; Kim, S-K; Hong, E-K; Lee, G-K; Choi, K-H; Kim, J. H.; Yoo, H.; Park, J. B.; Lee, S-H			Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas	ONCOGENE			English	Article						glioma; invasion; hyaluronan; miR-21; spry2; PTEN	INVASION; GLIOBLASTOMA; MICRORNA-21; HYALURONAN; ADHESION; TARGETS; SPROUTY	Gliomas are associated with high mortality because of their exceedingly invasive character. As these tumors acquire their invasiveness from low-grade tumors, it is very important to understand the detailed molecular mechanisms of invasion onset. Recent evidences suggest the significant role of microRNAs in tumor invasion. Thus, we hypothesized that deregulation of microRNAs may be important for the malignant progression of gliomas. We found that the aberrant expression of miR-21 is responsible for glioma invasion by disrupting the negative feedback circuit of Ras/MAPK signaling, which is mediated by Spry2. Upregulation of miR-21 was triggered by tumor microenvironmental factors such as hyaluronan and growth factors in glioma cells lacking functional phosphatase and tensin homolog (PTEN), but not harboring wild-type PTEN. Consistently with these in vitro results, Spry2 protein levels were significantly decreased in 79.7% of invasive WHO grade II-IV human glioma tissues, but not in non-invasive grade I and normal tissues. The Spry2 protein levels were not correlated with their mRNA levels, but inversely correlated with miR-21 levels. Taken together, these results suggest that the post-transcriptional regulation of Spry2 by miR-21 has an essential role on the malignant progression of human gliomas. Thus, Spry2 may be a novel therapeutic target for treating gliomas. Oncogene (2011) 30, 2433-2442; doi:10.1038/onc.2010.620; published online 31 January 2011	[Kwak, H-J; Kim, Y-J; Chun, K-R; Woo, Y. M.; Park, S-J; Jeong, J-A; Jo, S. H.; Kim, T. H.; Kim, G.; Choi, K-H; Park, J. B.] Natl Canc Ctr, Res Inst Hosp, Specif Organs Canc Branch, Goyang 411769, Gyeonggi, South Korea; [Kim, Y-J] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Min, H. S.; Hong, E-K; Lee, G-K] Natl Canc Ctr, Res Inst Hosp, Dept Pathol, Goyang 411769, Gyeonggi, South Korea; [Chae, J. S.; Choi, E-J] Korea Univ, Sch Life Sci & Biotechnol, Lab Cell Death & Human Dis, Seoul, South Korea; [Shin, S-H; Gwak, H-S; Yoo, H.; Lee, S-H] Natl Canc Ctr, Res Inst Hosp, Neurooncol Clin, Goyang 411769, Gyeonggi, South Korea; [Kim, S-K] Seoul Natl Univ, Coll Med, Seoul Natl Univ Childrens Hosp, Div Pediat Neurosurg, Seoul, South Korea; [Kim, J. H.] Natl Canc Ctr, Res Inst Hosp, Carcinogenesis Branch, Goyang 411769, Gyeonggi, South Korea	National Cancer Center - Korea (NCC); Korea Advanced Institute of Science & Technology (KAIST); National Cancer Center - Korea (NCC); Korea University; National Cancer Center - Korea (NCC); Seoul National University (SNU); Seoul National University Hospital; National Cancer Center - Korea (NCC)	Park, JB (corresponding author), Natl Canc Ctr, Res Inst Hosp, Specif Organs Canc Branch, 323 Ilsan Ro, Goyang 411769, Gyeonggi, South Korea.	jbp@ncc.re.kr; nslsh@ncc.re.kr	Choi, Kyungho/J-5685-2012; Kim, Seung-Ki/J-2742-2012	Choi, Kyungho/0000-0003-1635-173X	National Cancer Center [1010171, 1010172, 1110120, 1110110]; National Research Foundation [2010-0016811, 2010-0016704]	National Cancer Center; National Research Foundation	This work was supported by the National Cancer Center Grants (1010171, 1010172, and 1110120) and the National Research Foundation Grant (2010-0016811). JHK was supported by the National Cancer Center Grant (1110110) and the National Research Foundation Grant (2010-0016704).	Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Hirschhorn JN, 2009, NEW ENGL J MED, V360, P1699, DOI 10.1056/NEJMp0808934; Kim MS, 2008, MOL CANCER RES, V6, P1657, DOI 10.1158/1541-7786.MCR-08-0034; Kim MS, 2005, INT J ONCOL, V27, P839; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; MERZAK A, 1994, CANCER RES, V54, P3988; Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Park MJ, 2002, CANCER RES, V62, P6318; Roversi G, 2006, ONCOGENE, V25, P1571, DOI 10.1038/sj.onc.1209177; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391	24	113	118	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2433	2442		10.1038/onc.2010.620	http://dx.doi.org/10.1038/onc.2010.620			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21278789				2022-12-28	WOS:000291008000005
J	Chien, WW; Domenech, C; Catallo, R; Kaddar, T; Magaud, JP; Salles, G; Ffrench, M				Chien, W. W.; Domenech, C.; Catallo, R.; Kaddar, T.; Magaud, J-P; Salles, G.; Ffrench, M.			Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway	ONCOGENE			English	Article						p(16INK4a); CDK1; cell cycle; microRNA; E2F; post-transcriptional regulation	ACUTE LYMPHOBLASTIC-LEUKEMIA; LUNG-CANCER CELLS; MESSENGER-RNAS; PROLIFERATION; ACTIVATION; REPRESSION; APOPTOSIS; PROTEINS; TRANSFORMATION; TRANSCRIPTION	The p(16INK4a) protein regulates cell cycle progression mainly by inhibiting the activity of G1-phase cyclin-dependent kinases (CDKs) 4 and 6, the subsequent retinoblastoma protein (pRb) phosphorylation and E2F transcription factor release. The p(16INK4a) protein can also repress the activity of other transcription factors, such as c-myc, nuclear factor-kappaB and c-Jun/AP1. Here, we report that, in two p16(-/-), pRb(WT) and p53(WT) cell lines (MCF7 and U87), p(16INK4a) overexpression induces a dramatic decrease in CDK1 protein expression. In response to p(16INK4a), the decreased rate of CDK1 protein synthesis, its unchanged protein half- life, unreduced CDK1 mRNA steady- state levels and mRNA half- life allow us to hypothesize that p(16INK4a) could regulate CDK1 expression at the post- transcriptional level. This CDK1 downregulation is mediated by the 30-untranslated region (30UTR) of CDK1 mRNA as shown by translational inhibition in luciferase assays and is associated with a modified expression balance of microRNAs (miRNAs) that potentially regulate CDK1, analyzed by TaqMan Human microRNA Array. The p16INK4a-induced expression of two miRNAs (miR-410 and miR-650 chosen as an example) in MCF7 cells is confirmed by individual reverse transcriptionqPCR. Furthermore, we show the interaction of miR-410 or miR-650 with CDK1-30UTR by luciferase assays. Endogenous CDK1 expression decreases upon both miRNA overexpression and increases with their simultaneous inhibition. The induction of miR-410, but not miR-650 could be related to the pRb/ E2F pathway. These results demonstrate the post-transcriptional inhibition of CDK1 by p(16INK4a). We suggest that p(16INK4a) may regulate gene expression by modifying the functional equilibrium of transcription factors and consequently the expression balance of miRNAs. Oncogene (2011) 30, 1880-1891; doi: 10.1038/onc. 2010.570; published online 20 December 2010	[Ffrench, M.] Univ Lyon 1, CNRS, UMR ENS HCL 5239, Lab Pathol Cellules Lymphoides,Fac Med Lyon Sud, F-69495 Oullins, Rhone Alpes, France; [Magaud, J-P; Ffrench, M.] Hosp Civils Lyon, CHLS, Hematol Lab, Pierre Benite, France; [Salles, G.] Hosp Civils Lyon, CHLS, Serv Hematol, Pierre Benite, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CHU Lyon; CHU Lyon	Ffrench, M (corresponding author), Univ Lyon 1, CNRS, UMR ENS HCL 5239, Lab Pathol Cellules Lymphoides,Fac Med Lyon Sud, 165 Chemin Grand Revoyet, F-69495 Oullins, Rhone Alpes, France.	martine.ffrench@chu-lyon.fr	Salles, Gilles/Z-2336-2019; Holt, Janet E/B-2415-2013	Salles, Gilles/0000-0002-9541-8666; 	Ligue contre le Cancer of Saone-et-Loire and Rhone; Fondation pour la Recherche Medicale; Canceropole Lyon-Auvergne-Rhone-Alpes	Ligue contre le Cancer of Saone-et-Loire and Rhone; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Canceropole Lyon-Auvergne-Rhone-Alpes	This work was supported by the Ligue contre le Cancer of Saone-et-Loire and Rhone, by the Fondation pour la Recherche Medicale and by the Canceropole Lyon-Auvergne-Rhone-Alpes.	Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Baghdassarian N, 1999, CELL GROWTH DIFFER, V10, P405; Baghdassarian N, 1998, EXP CELL RES, V240, P263, DOI 10.1006/excr.1998.3942; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Calbo J, 2004, CELL DEATH DIFFER, V11, P1055, DOI 10.1038/sj.cdd.4401481; Chen RW, 2008, BLOOD, V112, P822, DOI 10.1182/blood-2008-03-142182; Chien WW, 2010, CELL CYCLE, V9, P3286, DOI 10.4161/cc.9.16.12600; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Cox CV, 2007, BLOOD, V109, P674, DOI 10.1182/blood-2006-06-030445; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hara E, 1996, MOL CELL BIOL, V16, P859; Harada H, 1999, CANCER RES, V59, P3783; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Kaddar T, 2009, BIOL CELL, V101, P511, DOI 10.1042/BC20080213; Kamb A, 1994, Nat Genet, V8, P23; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kopper L, 2004, PATHOL ONCOL RES, V10, P69, DOI 10.1007/BF02893458; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Leclerc Guy J, 2002, Cancer Cell Int, V2, P1, DOI 10.1186/1475-2867-2-1; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Moser JJ, 2007, J NEUROSCI RES, V85, P3619, DOI 10.1002/jnr.21439; Nalabothula N, 2007, INT J ONCOL, V30, P669; Nishiwaki E, 2000, MOL CELL BIOL, V20, P7726, DOI 10.1128/MCB.20.20.7726-7734.2000; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Souza-Rodrigues E, 2007, PROTEOMICS, V7, P4102, DOI 10.1002/pmic.200700133; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wang B, 2005, J IMMUNOL, V175, P4274, DOI 10.4049/jimmunol.175.7.4274; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	50	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1880	1891		10.1038/onc.2010.570	http://dx.doi.org/10.1038/onc.2010.570			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21170085				2022-12-28	WOS:000289777700004
J	Comb, WC; Cogswell, P; Sitcheran, R; Baldwin, AS				Comb, W. C.; Cogswell, P.; Sitcheran, R.; Baldwin, A. S.			IKK-dependent, NF-kappa B-independent control of autophagic gene expression	ONCOGENE			English	Article						autophagy; IKK; NF-kappa B; LC3; ATG5	TRANSCRIPTION; ACTIVATION; PATHWAYS	The induction of mammalian autophagy, a cellular catabolic bulk-degradation process conserved from humans to yeast, was recently shown to require I kappa B kinase (IKK), the upstream regulator of the nuclear factor (NF)-kappa B pathway. Interestingly, it was shown that this response did not involve NF-kappa B. Thus, the mechanism by which IKK promotes stimulus-induced autophagy is largely unknown. Here, we investigate the role of IKK/NF-kappa B in response to nutrient deprivation, the well-understood autophagy-inducing stimulus. IKK and both the classic and non-canonical pathways of NF-kappa B are robustly induced in response to cellular starvation. Notably, cells lacking either catalytic subunit of IKK (IKK-alpha or IKK-beta) fail to induce autophagy in response to cellular starvation. Importantly, we show that IKK activity but not NF-kappa B controls basal expression of the proautophagic gene LC3. We further demonstrate that starvation induces the expression of LC3 and two other essential autophagic genes ATG5 and Beclin-1 in an IKK-dependent manner. These results indicate that the IKK complex is a central mediator of starvation-induced autophagy in mammalian cells, and suggest that this requirement occurs at least in part through the regulation of autophagic gene expression. Interestingly, NF-kappa B subunits are dispensable for both basal and starvation-induced expression of proautophagic genes. However, starvation-induced activation of NF-kappa B is not inconsequential, as increases in expression of antiapoptotic NF-kappa B target genes such as Birc3 are observed in response to cellular starvation. Thus, IKK likely has multiple roles in response to starvation by regulating NF-kappa B-dependent antiapoptotic gene expression as well as controlling expression of autophagic genes through a yet undetermined mechanism. Oncogene (2011) 30, 1727-1732; doi:10.1038/onc.2010.553; published online 13 December 2010	[Comb, W. C.; Cogswell, P.; Sitcheran, R.; Baldwin, A. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Comb, W. C.; Baldwin, A. S.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Baldwin, A. S.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	albert_baldwin@med.unc.edu		Sitcheran, Raquel/0000-0001-8916-9707	NIH [CA75080, AI035098, CA73756]; Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA075080, R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are grateful to Dr Alexander Hoffmann for the p65/c-Rel DKO cells and to Dr Denis Guttridge for the RelB <SUP>/</SUP> and p52 <SUP>/</SUP> cells. We thank members of the Baldwin lab for thoughtful discussion and manuscript feedback. Research support was provided by NIH grants CA75080, AI035098, CA73756 and the Waxman Cancer Research Foundation.	Araki K, 2008, ONCOGENE, V27, P5696, DOI 10.1038/onc.2008.184; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Bednarski BK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006992; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117; Renner F, 2009, TRENDS BIOCHEM SCI, V34, P128, DOI 10.1016/j.tibs.2008.12.003; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	26	86	90	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1727	1732		10.1038/onc.2010.553	http://dx.doi.org/10.1038/onc.2010.553			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21151171	Green Accepted, Green Submitted			2022-12-28	WOS:000289239400010
J	Hollander, MC; Maier, CR; Hobbs, EA; Ashmore, AR; Linnoila, RI; Dennis, PA				Hollander, M. C.; Maier, C. R.; Hobbs, E. A.; Ashmore, A. R.; Linnoila, R. I.; Dennis, P. A.			Akt1 deletion prevents lung tumorigenesis by mutant K-ras	ONCOGENE			English	Article						Akt1; Akt3; K-ras; lung	PLECKSTRIN HOMOLOGY DOMAIN; GLUCOSE-HOMEOSTASIS; ONCOGENIC MUTATION; THERAPEUTIC TARGET; TUMOR-DEVELOPMENT; MICE LACKING; ACTIVATION; CANCER; IDENTIFICATION; GROWTH	K-ras mutations are associated with smoking-induced lung cancer and poor clinical outcomes. In mice, K-ras mutations are sufficient to induce lung tumors, which require phosphoinoside-3-kinase (PI3K) and further downstream, mammalian target of rapamycin (mTOR) activation. However, the roles of individual Akt isoforms that link PI3K and mTOR are unknown. Here, we show that deletion of Akt1 but not Akt2 or Akt3 prevents lung tumorigenesis in a tobacco carcinogen-induced model and a genetic model. Akt1 deletion prevented tumor initiation as well as tumor progression, coincident with decreased Akt signaling in tumor tissues. In contrast, deletion of Akt3 increased tumor multiplicity in the carcinogen model and increased tumor size in the genetic model. Fibroblasts lacking Akt1 are resistant to transformation by mutant K-ras and stimulation by epidermal growth factor. Human lung cancer cells with mutant K-ras and diminished Akt1 levels fail to grow in vivo. These data suggest that Akt1 is the primary Akt isoform activated by mutant K-ras in lung tumors, and that Akt3 may oppose Akt1 in lung tumorigenesis and lung tumor progression. Given that Akt inhibitors in clinical development as cancer therapeutics are not isoform selective, these studies support specific targeting of Akt1 to mitigate the effects of mutant K-ras in lung cancer. Oncogene (2011) 30, 1812-1821; doi:10.1038/onc.2010.556; published online 17 January 2011	[Hollander, M. C.; Maier, C. R.; Hobbs, E. A.; Ashmore, A. R.; Dennis, P. A.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20889 USA; [Linnoila, R. I.] NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20889 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dennis, PA (corresponding author), NCI, Med Oncol Branch, NIH, NNMC8-5101,8901 Wisconsin Ave, Bethesda, MD 20889 USA.	pdennis@mail.nih.gov			NIH; NATIONAL CANCER INSTITUTE [ZIASC010292, ZIABC010450, ZIASC000167, ZIABC010748, P30CA006973] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was funded through the NIH intramural research program.	Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; BELINSKY SA, 1989, CANCER RES, V49, P5305; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Buzzi F, 2010, MOL CELL BIOL, V30, P601, DOI 10.1128/MCB.00719-09; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101; Cully M, 2008, CELL, V133, P1292, DOI 10.1016/j.cell.2008.06.020; Dannemann N, 2010, INT J CANCER, V127, P239, DOI 10.1002/ijc.25012; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; DiRenzo J, 2002, CANCER RES, V62, P89; Dummler B, 2006, MOL CELL BIOL, V26, P8042, DOI 10.1128/MCB.00722-06; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001; Gills JJ, 2009, CURR ONCOL REP, V11, P102, DOI 10.1007/s11912-009-0016-4; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Granville CA, 2007, CLIN CANCER RES, V13, P2281, DOI 10.1158/1078-0432.CCR-06-2570; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hollander MC, 2008, NEOPLASIA, V10, P866, DOI 10.1593/neo.08406; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jiang HL, 2009, BIOMATERIALS, V30, P5844, DOI 10.1016/j.biomaterials.2009.07.017; John LCH, 2001, BRIT J BIOMED SCI, V58, P159; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; Macdonald JS, 2005, INVEST NEW DRUG, V23, P485, DOI 10.1007/s10637-005-2908-y; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Robertson GP, 2005, CANCER METAST REV, V24, P273, DOI 10.1007/s10555-005-1577-9; Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Steelman LS, 2008, EXPERT OPIN THER TAR, V12, P1139, DOI [10.1517/14728222.12.9.1139, 10.1517/14728222.12.9.1139 ]; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; WITSCHI HP, 1981, TOXICOLOGY, V21, P95, DOI 10.1016/0300-483X(81)90120-7; Xu CX, 2008, AM J RESP CRIT CARE, V178, P60, DOI 10.1164/rccm.200707-1022OC; Zilberman DE, 2009, CANCER GENET CYTOGEN, V191, P34, DOI 10.1016/j.cancergencyto.2009.01.009	49	48	49	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1812	1821		10.1038/onc.2010.556	http://dx.doi.org/10.1038/onc.2010.556			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21242979	Green Accepted			2022-12-28	WOS:000289512200008
J	Walker, MP; Zhang, M; Le, TP; Wu, P; Laine, M; Greene, GL				Walker, M. P.; Zhang, M.; Le, T. P.; Wu, P.; Laine, M.; Greene, G. L.			RAC3 is a pro-migratory co-activator of ER alpha	ONCOGENE			English	Article						transcription; estrogen receptor; RAC3; breast cancer	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; RHO GTPASES; PROTEIN; TRANSCRIPTION; METASTASIS; PHOSPHORYLATION; PROLIFERATION; ACTIVATION; EXPRESSION	Estrogen receptor alpha (ER alpha) is a ligand-dependent nuclear receptor that is important in breast cancer genesis, behavior and response to hormone-based therapies. A T7 phage display screen against full-length human ER alpha, coupled with genome-wide exon arrays, was used to identify RAC3 as a putative ER alpha co-regulator. RAC3 is a Rho family small GTPase that is associated with cytoskeletal rearrangement. We demonstrate a novel role for nuclear RAC3 as an ER alpha transcriptional activator, with prognostic implications for metastatic disease. Through in vitro and cell-based studies, RAC3 was shown to exist in a GTP-bound state and act as a ligand specific ER alpha co-activator of E2-induced transcription. Overexpression of RAC3 induced pro-growth and pro-migratory genes that resulted in increased migration of ER alpha-positive breast cancer cells. Chemical inhibition and genetic knockdown of RAC3 antagonized E2-induced cell proliferation, cell migration and ER alpha mediated gene expression, indicating that RAC3 is necessary for full ER alpha transcriptional activity. In agreement with the molecular and cellular data, RAC3 overexpression in ER alpha-positive breast cancers correlated with a significant decrease in recurrence free survival and a significant increase in the odds ratio of metastasis. In conclusion, RAC3 is a novel ER alpha a co-activator that promotes cell migration and has prognostic value for ER alpha-positive breast cancer metastasis. RAC3 may also be a useful therapeutic target for ER alpha-positive breast cancers. Oncogene (2011) 30, 1984-1994; doi:10.1038/onc.2010.583; published online 10 January 2011	[Zhang, M.; Wu, P.; Laine, M.; Greene, G. L.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; [Walker, M. P.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Le, T. P.] Univ Chicago, Comm Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Greene, GL (corresponding author), Univ Chicago, Ben May Dept Canc Res, 929 57th St GCIS, Chicago, IL 60637 USA.	ggreene@uchicago.edu		Wu, Patricia/0000-0003-3134-3789	NCI [2-RO1-CA089489]; Department of Defense [W81XWH-04-1-0791]; Ludwig Foundation; Cancer Center [5P30-CA01459935]; NIH [5T32GM007183-35]; NATIONAL CANCER INSTITUTE [R01CA089489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Ludwig Foundation; Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NCI 2-RO1-CA089489 (GLG), Department of Defense W81XWH-04-1-0791 (GLG) and a gift from the Ludwig Foundation (GLG). Core services were supported in part by a 5P30-CA01459935 Cancer Center grant. MPW was partially supported by NIH grant 5T32GM007183-35.	Baugher PJ, 2005, BREAST CANCER RES, V7, pR965, DOI 10.1186/bcr1329; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chang CY, 2003, METHOD ENZYMOL, V364, P118; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Gould CM, 2010, NUCLEIC ACIDS RES, V38, pD167, DOI 10.1093/nar/gkp1016; Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103; Hajdo-Milasinovic A, 2007, J CELL SCI, V120, P555, DOI 10.1242/jcs.03364; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Hampf M, 2006, ANAL BIOCHEM, V356, P94, DOI 10.1016/j.ab.2006.04.046; Harrell JC, 2006, CANCER RES, V66, P9308, DOI 10.1158/0008-5472.CAN-06-1769; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Johnston SRD, 2010, CLIN CANCER RES, V16, P1979, DOI 10.1158/1078-0432.CCR-09-1823; Kumar R, 2005, CLIN CANCER RES, V11, P2822, DOI 10.1158/1078-0432.CCR-04-1276; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Leong HY, 2005, MOL ENDOCRINOL, V19, P2930, DOI 10.1210/me.2005-0178; Leung K, 2003, CELLS TISSUES ORGANS, V175, P72, DOI 10.1159/000073751; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Muramatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P1, DOI 10.1006/bbrc.2000.2214; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Oesterreich S, 2001, CANCER RES, V61, P5771; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Pan YF, 2008, J BIOL CHEM, V283, P32977, DOI 10.1074/jbc.M802024200; Pike ACW, 2006, BEST PRACT RES CL EN, V20, P1, DOI 10.1016/j.beem.2005.09.002; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Sanchez AM, 2010, MOL ENDOCRINOL, V24, P2114, DOI 10.1210/me.2010-0252; Sandrock K, 2010, TRAFFIC, V11, P198, DOI 10.1111/j.1600-0854.2009.01015.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Talukder AH, 2006, ONCOGENE, V25, P1311, DOI 10.1038/sj.onc.1209172; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Xie JW, 2008, BREAST CANCER RES TR, V110, P257, DOI 10.1007/s10549-007-9719-0	40	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	17					1984	1994		10.1038/onc.2010.583	http://dx.doi.org/10.1038/onc.2010.583			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217774	Green Accepted			2022-12-28	WOS:000289977400002
J	Yu, X; Wang, Y; DeGraff, DJ; Wills, ML; Matusik, RJ				Yu, X.; Wang, Y.; DeGraff, D. J.; Wills, M. L.; Matusik, R. J.			Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model	ONCOGENE			English	Article						prostate; Wnt/beta-catenin; AR; Foxa2; T-antigen	SMALL-CELL CARCINOMA; BETA-CATENIN; NEUROENDOCRINE DIFFERENTIATION; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; WNT PATHWAY; ANDROGEN; GROWTH; EXPRESSION; MICROENVIRONMENT	Our previous studies have found that activation of Wnt/beta-catenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN). In the large probasin promoter directed SV40-large T-antigen ( LPB- Tag) expressing mouse prostate, mPIN forms with rare areas of adenocarcinoma. Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, we have studied the role of Wnt/beta-catenin signaling in the progression from mPIN to adenocarcinoma. Our results show that the prostates of mice expressing Tag alone or nuclear beta-catenin alone developed mPIN, whereas the activation of both Tag and the Wnt/beta-catenin pathway resulted in invasive prostate adenocarcinoma. Furthermore, Foxa2, a forkhead transcription factor, was induced by active Wnt/beta-catenin signaling, and the expression of Foxa2 was associated with the invasive phenotype in the primary prostate cancer. In the LPB-Tag/dominant active (DA) b-catenin prostates, MMP7, a Wnt/beta-catenin target gene, was upregulated. Furthermore, we also assessed AR and AR signaling pathway in these LPB-Tag/DA beta-catenin mice. Although beta-catenin is a well-known AR co-activator in vitro, our study provides strong in vivo evidences indicating that both AR protein and the AR pathway were downregulated in the prostate of LPB-Tag/DA beta-catenin mice. Histological analysis shows that prostate sections derived from the LPB-Tag/DA beta-catenin mice display neuroendocrine differentiation (NED), but NE cancer does not develop. Together, our findings indicate that Wnt/beta-catenin signaling has an important role in the progression of mPIN to prostate adenocarcinoma. Oncogene (2011) 30, 1868-1879; doi: 10.1038/onc.2010.560; published online 13 December 2010	[Matusik, R. J.] Vanderbilt Univ, Sch Med, Dept Urol Surg, Med Ctr, Nashville, TN 37232 USA; [Wang, Y.] Washington Biotechnol Inc, Columbia, MD USA; [Wills, M. L.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Matusik, RJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Urol Surg, Med Ctr, A-1302 Med Ctr N, Nashville, TN 37232 USA.	robert.matusik@vanderbilt.edu		Matusik, Robert/0000-0003-2057-9892; Yu, Xiuping/0000-0003-2844-7026	NIH [2R01 CA76142-11, 2R01-DK055748-10]; DOD [PC074022]; American Cancer Society Great Lakes Division; NATIONAL CANCER INSTITUTE [T32CA119925, R01CA076142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055748] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); American Cancer Society Great Lakes Division(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Angela Barth, the Stanford University, for kindly providing the mutant beta-catenin expressing vector, Tom Case and Manik Paul for technical support, Dr Barbara Fingleton and Dr Lynn Matrisian for advice and discussion. Grant support was provided by NIH to RJM (Grant Numbers: 2R01 CA76142-11; 2R01-DK055748-10), DOD to RJM (Grant Number: PC074022), and the Joe C. Davis Foundation. David DeGraff, PhD was supported by the American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship.	Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bonfil RD, 2007, UROL ONCOL-SEMIN ORI, V25, P407, DOI 10.1016/j.urolonc.2007.05.008; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Bruxvoort KJ, 2007, CANCER RES, V67, P2490, DOI 10.1158/0008-5472.CAN-06-3028; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Deeb KK, 2007, CANCER RES, V67, P8065, DOI 10.1158/0008-5472.CAN-07-1515; Fingleton B, 2006, FRONT BIOSCI-LANDMRK, V11, P479, DOI 10.2741/1811; Gupta A, 2008, PROSTATE, V68, P50, DOI 10.1002/pros.20650; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Huang D, 2008, WORLD J GASTROENTERO, V14, P1823, DOI 10.3748/wjg.14.1823; Huss WJ, 2007, NEOPLASIA, V9, P938, DOI 10.1593/neo.07562; Kasper S, 2005, J CELL BIOCHEM, V94, P279, DOI 10.1002/jcb.20339; Kasper S, 1998, LAB INVEST, V78, P319; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Masumori N, 2001, CANCER RES, V61, P2239; Millar JBA, 2002, GENOME BIOL, V3; Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2000, GENE DEV, V14, P1837; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Sciarra A, 2003, BJU INT, V91, P438, DOI 10.1046/j.1464-410X.2003.03066.x; Song ZG, 2002, CANCER RES, V62, P5096; Terry S, 2006, J CELL BIOCHEM, V99, P402, DOI 10.1002/jcb.20983; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Wang YQ, 2006, LAB INVEST, V86, P1074, DOI 10.1038/labinvest.3700463; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Yao JL, 2006, AM J SURG PATHOL, V30, P705, DOI 10.1097/00000478-200606000-00005; Yardy GW, 2005, PROSTATE CANCER P D, V8, P119, DOI 10.1038/sj.pcan.4500794; Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877; Yu XP, 2005, ANN NY ACAD SCI, V1061, P77, DOI 10.1196/annals.1336.009; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	44	104	106	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1868	1879		10.1038/onc.2010.560	http://dx.doi.org/10.1038/onc.2010.560			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151173	Green Accepted			2022-12-28	WOS:000289777700003
J	Belloni, E; Veronesi, G; Micucci, C; Javan, S; Minardi, SP; Venturini, E; Maisonneuve, P; Volorio, S; Riboni, M; Bellomi, M; Scanagatta, P; Taliento, G; Pelosi, G; Pece, S; Spaggiari, L; Pelicci, PG				Belloni, E.; Veronesi, G.; Micucci, C.; Javan, S.; Minardi, S. P.; Venturini, E.; Maisonneuve, P.; Volorio, S.; Riboni, M.; Bellomi, M.; Scanagatta, P.; Taliento, G.; Pelosi, G.; Pece, S.; Spaggiari, L.; Pelicci, P. G.			Genomic characterization of asymptomatic CT-detected lung cancers	ONCOGENE			English	Article						whole genome analysis; early diagnosis; cancer	SPIRAL COMPUTED-TOMOGRAPHY; ARYL-HYDROCARBON RECEPTOR; BASE-LINE; INDOLEAMINE 2,3-DIOXYGENASE; MOLECULAR-ORIGINS; ADENOCARCINOMA; EPIDEMIC; SMOKERS; NODULES; DNA	Computed tomography (CT) screening of lung cancer allows the detection of early tumors. The objective of our study was to verify whether initial asymptomatic lung cancers, identified by high-resolution low-dose CT (LD-CT) on a high-risk population, show genetic abnormalities that could be indicative of the early events of lung carcinogenesis. We analyzed 78 tumor samples: 21 (pilot population) from heavy smokers with asymptomatic non-screening detected early-stage lung cancers and 57 from 5203 asymptomatic heavy smoker volunteers, who underwent a LD-CT screening study. During surgical resection of the detected tumors, tissue samples were collected and short-term cultures were started for karyotype evaluation. Samples were classified according to the normal (NK) or aneuploid (AK) karyotype. The NK samples were further analyzed by the Affymetrix single-nucleotide polymorphisms (SNPs) technology. Metaphase spreads were obtained in 73.0% of the selected samples: 80.7% showed an AK. A statistically significant correlation was found between presence of vascular invasion and abnormal karyotype. A total of 10 NK samples were suitable for SNPs analysis. Subtle genomic alterations were found in eight tumors, the remaining two showing no evidence to date of chromosomal aberrations anywhere in the genome. Two common regions of amplification were identified at 5p and 8p11. Mutation analysis by direct sequencing was conducted for the K-RAS, TP53 and EGFR genes, confirming data already described for heavy smokers. We show that: (i) the majority of screening-detected tumors are aneuploid; (ii) early-stage tumors tend to harbor a less abnormal karyotype; (iii) whole genome analysis of NK tumors allows for the detection of common regions of copy number variation (such as amplifications at 5p and 8p11), highlighting genes that might be considered candidate markers of early events in lung carcinogenesis. Oncogene (2011) 30, 1117-1126; doi:10.1038/onc.2010.478; published online 25 October 2010	[Belloni, E.; Micucci, C.; Javan, S.; Volorio, S.; Riboni, M.; Pece, S.; Pelicci, P. G.] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Veronesi, G.; Scanagatta, P.; Taliento, G.; Spaggiari, L.] European Inst Oncol, Div Thorac Surg, I-20141 Milan, Italy; [Minardi, S. P.; Venturini, E.; Volorio, S.; Riboni, M.] Cogentech, Milan, Italy; [Maisonneuve, P.] European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; [Bellomi, M.] European Inst Oncol, Div Radiol, Milan, Italy; [Pelosi, G.] European Inst Oncol, Div Pathol, Milan, Italy; [Pece, S.; Spaggiari, L.; Pelicci, P. G.] Univ Milan, Milan, Italy	IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); University of Milan	Belloni, E (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	elena.belloni@ifom-ieo-campus.it; giulia.veronesi@ieo.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Maisonneuve, Patrick/U-9789-2018; Pece, Salvatore/B-9609-2013; Bellomi, Massimo/AAM-4352-2020; Scanagatta, Paolo/AAX-3226-2020; belloni, elena/H-9909-2013; Veronesi, Giulia/AAA-6327-2021; Spaggiari, Lorenzo/G-7915-2012; Scanagatta, Paolo/I-1215-2013; Pelosi, Giuseppe/F-5073-2012	Maisonneuve, Patrick/0000-0002-5309-4704; Pece, Salvatore/0000-0003-1764-3929; Scanagatta, Paolo/0000-0002-1619-6453; Veronesi, Giulia/0000-0001-9032-1278; Scanagatta, Paolo/0000-0002-1619-6453; Belloni, Elena/0000-0003-3214-0780; Pelosi, Giuseppe/0000-0003-4725-4692; Minardi, Simone Paolo/0000-0001-7303-3821; Spaggiari, Lorenzo/0000-0002-1068-3541	AIRC (Associazione Italiana per la Ricerca sul Cancro); FUV (Fondazione Umberto Veronesi); Eredita' Benilde Viotti	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); FUV (Fondazione Umberto Veronesi)(Fondazione Umberto Veronesi); Eredita' Benilde Viotti	This study was supported by AIRC (Associazione Italiana per la Ricerca sul Cancro), FUV (Fondazione Umberto Veronesi) and Eredita' Benilde Viotti. We would like to thank Daniela Brambilla, Raffaella Bertolotti and Giovanna Ciambrone for data managing; Antonio De Vito and Loris Bernard for technical assistance; the Real Time PCR Service at the IFOM-IEO campus for TaqMan assays; Marco Bianchi, Giovanna Maria Jodice, Paolo Nuciforo and the Molecular Pathology Unit at IFOM for samples characterization; Elvira Gerbino for samples preparation; the staff of the IEO Thoracic Surgery and Radiology Departments for clinical assistance; Paola Dalton for manuscript editing; Francesca Toffalorio for helpful discussion.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bianchi F, 2004, CLIN CANCER RES, V10, P6023, DOI 10.1158/1078-0432.CCR-04-0619; Diederich S, 2004, EUR RADIOL, V14, P691, DOI 10.1007/s00330-003-2200-5; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ebi H, 2009, ONCOGENE, V28, P3371, DOI 10.1038/onc.2009.201; Enstrom JE, 1999, EPIDEMIOLOGY, V10, P500, DOI 10.1097/00001648-199909000-00007; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Horner MJ, 2009, SEER CANC STAT REV 1; Humphrey LL, 2004, ANN INTERN MED, V140, P740, DOI 10.7326/0003-4819-140-9-200405040-00015; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Metz R, 2007, CANCER RES, V67, P7082, DOI 10.1158/0008-5472.CAN-07-1872; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mitsuuchi Y, 2002, AM J MED GENET, V115, P183, DOI 10.1002/ajmg.10692; Mulshine JL, 2005, NEW ENGL J MED, V352, P2714, DOI 10.1056/NEJMcp042630; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; Patel JD, 2004, JAMA-J AM MED ASSOC, V291, P1763, DOI 10.1001/jama.291.14.1763; Pelosi G, 2008, LUNG CANCER, V62, P202, DOI 10.1016/j.lungcan.2008.03.012; Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091; Puppala D, 2007, CARCINOGENESIS, V28, P639, DOI 10.1093/carcin/bgl169; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Veronesi G, 2008, LUNG CANCER, V61, P340, DOI 10.1016/j.lungcan.2008.01.001; Veronesi G, 2007, ANN THORAC SURG, V84, P959, DOI 10.1016/j.athoracsur.2007.04.058; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603; Zudaire E, 2008, J CLIN INVEST, V118, P640, DOI 10.1172/JCI30024	31	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1117	1126		10.1038/onc.2010.478	http://dx.doi.org/10.1038/onc.2010.478			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972464				2022-12-28	WOS:000287964100010
J	Jin, Z; Selaru, FM; Cheng, Y; Kan, T; Agarwal, R; Mori, Y; Olaru, AV; Yang, J; David, S; Hamilton, JP; Abraham, JM; Harmon, J; Duncan, M; Montgomery, EA; Meltzer, SJ				Jin, Z.; Selaru, F. M.; Cheng, Y.; Kan, T.; Agarwal, R.; Mori, Y.; Olaru, A. V.; Yang, J.; David, S.; Hamilton, J. P.; Abraham, J. M.; Harmon, J.; Duncan, M.; Montgomery, E. A.; Meltzer, S. J.			MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro	ONCOGENE			English	Article						microRNA-192 and-215; gastric cancer; ALCAM	CELL-ADHESION MOLECULE; TUMOR PROGRESSION; GENE-EXPRESSION; MESSENGER-RNAS; CYCLE ARREST; METASTASIS; INVOLVEMENT; STATISTICS; MECHANISM; INVASION	The dismal outcome of gastric cancer patients highlights the need for diagnostic biomarkers and effective therapeutic targets, such as microRNAs. We sought to discover microRNAs involved in gastric cancer, and to elucidate their downstream target mechanisms. Both cultured gastric epithelial cells (HFE145 and NCI-N87) and primary human gastric tissues (31 non-neoplastic stomach (NS) and 25 gastric carcinomas (GC)) were studied. MicroRNA microarrays and quantitative RT-PCR were applied to discover and verify differentially expressed microRNAs. in vitro cell migration and invasion, cell proliferation, cell cycle and apoptosis assays were executed to elucidate biological effects of microRNA-192 and -215. Western blotting and luciferase assays were performed to confirm direct messenger RNA targeting by microRNA-192 and -215. MicroRNA microarray analyses revealed that 25 and 20 microRNAs were upregulated and downregulated in GC vs NS, respectively. Expression levels of both microRNA-192 and -215 were significantly higher in GC than in NS (P < 0.05). Luciferase assays suggested that microRNA-215 inhibits activated leukocyte cell adhesion molecule (ALCAM) expression at the posttranscriptional level. In addition, expression levels of ALCAM were significantly lower in GC than in NS. Mimics and inhibitors, respectively, of microRNA-192 or -215 exerted no effect on cell cycle or apoptosis in the immortalized normal gastric cell line HFE145 or the gastric cancer cell line NCI-N87. However, mimics of microRNA-192 or -215 significantly increased growth rates in HFE145 cells, whereas inhibitors of microRNA-192 or -215 caused significant decreases in growth rates in NCI-N87 cells. ALCAM knockdown by an ALCAM-specific siRNA significantly increased cell growth in HFE145 cells. Both transfection of mimics of microRNA-192 or -215 and ALCAM knockdown by an ALCAM-specific siRNA significantly increased the migration of HFE145 cells. In conclusion, in gastric cancer, both microRNA-192 and 215 are overexpressed in vivo and exert cell growth and migration-promoting effects in vitro, thus representing potential microRNAs with a role in cancer in the human stomach. Oncogene (2011) 30, 1577-1585; doi: 10.1038/onc.2010.534; published online 29 November 2010	[Jin, Z.; Selaru, F. M.; Cheng, Y.; Kan, T.; Agarwal, R.; Mori, Y.; Olaru, A. V.; Yang, J.; David, S.; Hamilton, J. P.; Abraham, J. M.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21287 USA; [Harmon, J.; Duncan, M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21287 USA; [Montgomery, E. A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Jin, Z (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Rm 101A, Baltimore, MD 21287 USA.	zjin1@jhmi.edu		Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [P30 CA006973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adiseshaiah P, 2007, CANCER RES, V67, P6204, DOI 10.1158/0008-5472.CAN-06-4687; Agarwal R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008002; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jezierska A, 2006, MED SCI MONITOR, V12, pBR245; Jezierska A, 2009, MED SCI MONITOR, V15, pRA32; Khushalani NI, 2008, MAYO CLIN PROC, V83, P712; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kimura Y, 2004, MODERN PATHOL, V17, P1328, DOI 10.1038/modpathol.3800180; Kristiansen G, 2003, PROSTATE, V54, P34, DOI 10.1002/pros.10161; Li ZR, 2006, BIOCHEM BIOPH RES CO, V348, P229, DOI 10.1016/j.bbrc.2006.07.043; Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104; Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667; Noguchi T, 2001, AM J CLIN PATHOL, V115, P828; Ofori-Acquah SF, 2008, TRANSL RES, V151, P122, DOI 10.1016/j.trsl.2007.09.006; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Rosso O, 2007, MOL CANCER RES, V5, P1246, DOI 10.1158/1541-7786.MCR-07-0060; Shi XB, 2008, CELL CYCLE, V7, P1529, DOI 10.4161/cc.7.11.5977; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Swart GWM, 2002, EUR J CELL BIOL, V81, P313, DOI 10.1078/0171-9335-00256; Tsai NP, 2009, BIOCHEM J, V424, P411, DOI 10.1042/BJ20090915; Tsukamoto Y, 2008, J PATHOL, V216, P471, DOI 10.1002/path.2424; van Kempen LCLT, 2004, J INVEST DERMATOL, V122, P1293, DOI 10.1111/j.0022-202X.2004.22531.x; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Z, 2008, INT J CANCER, V123, P1439, DOI 10.1002/ijc.23643; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Zhou X, 2009, GENETICA, V137, P159, DOI 10.1007/s10709-009-9378-7	35	95	107	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1577	1585		10.1038/onc.2010.534	http://dx.doi.org/10.1038/onc.2010.534			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119604	Green Accepted			2022-12-28	WOS:000288998300008
J	Matsuoka, M; Jeang, KT				Matsuoka, M.; Jeang, K-T			Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy	ONCOGENE			English	Review						human T-cell leukemia virus type 1 (HTLV-1); adult T-cell leukemia (ATL); Tax; HTLV-1 bZIP factor (HBZ); aneuploidy	NF-KAPPA-B; DNA-DAMAGE RESPONSE; TROPICAL SPASTIC PARAPARESIS; SPINDLE ASSEMBLY CHECKPOINT; PROTEASOME INHIBITOR PS-341; 1ST HUMAN RETROVIRUS; I TAX; TRANSCRIPTIONAL ACTIVITY; MONOCLONAL-ANTIBODY; CYCLE PROGRESSION	The human T-cell leukemia virus type 1 (HTLV-1) was the first retrovirus discovered to be causative of a human cancer, adult T-cell leukemia. The transforming entity of HTLV-1 has been attributed to the virally-encoded oncoprotein, Tax. Unlike the v-onc proteins encoded by other oncogenic animal retroviruses that transform cells, Tax does not originate from a c-onc counterpart. In this article, we review progress in our understanding of HTLV-1 infectivity, cellular transformation, anti-sense transcription and therapy, 30 years after the original discovery of this virus. Oncogene (2011) 30, 1379-1389; doi:10.1038/onc.2010.537; published online 29 November 2010	[Jeang, K-T] NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; [Matsuoka, M.] Kyoto Univ, Inst Virus Res, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kyoto University	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008	Matsuoka, Masao/0000-0002-0473-754X	NIAID; Ministry of Education, Science, Sports and Culture of Japan; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, ZIAAI001023] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Work in KTJ's laboratory is supported in part by NIAID intramural funds, and work in MM's laboratory is supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan. We thank Lauren Lee for preparation of manuscript and figures, and Junichiro Yasunaga and Linda Zane for discussions.	Akagi T, 1996, ONCOGENE, V12, P1645; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; Banerjee P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-8; Banerjee P, 2008, STEM CELLS, V26, P3047, DOI 10.1634/stemcells.2008-0353; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Bazarbachi A, 2010, J CLIN ONCOL, V28, P4177, DOI 10.1200/JCO.2010.28.0669; Belgnaoui SM, 2010, J BIOL CHEM, V285, P32897, DOI 10.1074/jbc.M110.146373; Bellon M, 2009, BLOOD, V113, P4914, DOI 10.1182/blood-2008-11-189845; Bernal-Mizrachi L, 2006, P NATL ACAD SCI USA, V103, P9220, DOI 10.1073/pnas.0507809103; Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177; Bouzar AB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-101; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Cavanagh MH, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-15; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Chandhasin C, 2008, J VIROL, V82, P6952, DOI 10.1128/JVI.02331-07; Chi YH, 2007, J CELL BIOCHEM, V102, P531, DOI 10.1002/jcb.21484; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128/JVI.77.9.5286-5294.2003; Durkin SS, 2006, J BIOL CHEM, V281, P31705, DOI 10.1074/jbc.M607011200; Durkin SS, 2008, J BIOL CHEM, V283, P36311, DOI 10.1074/jbc.M804931200; Etoh K, 1997, CANCER RES, V57, P4862; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fraedrich K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-54; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1985, LANCET, V2, P407; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Gotuzzo E, 1999, AM J TROP MED HYG, V60, P146, DOI 10.4269/ajtmh.1999.60.146; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Gupta SK, 2007, J BIOL CHEM, V282, P29431, DOI 10.1074/jbc.M704110200; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Haller K, 2006, ONCOGENE, V25, P2137, DOI 10.1038/sj.onc.1209259; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Harashima N, 2004, CANCER RES, V64, P391, DOI 10.1158/0008-5472.CAN-03-1452; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hein J, 2009, J VIROL, V83, P117, DOI 10.1128/JVI.01515-08; Higuchi M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-117; Hivin P, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-14; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; Iha H, 2008, EMBO J, V27, P629, DOI 10.1038/emboj.2008.5; Ishii T, 2010, CLIN CANCER RES, V16, P1520, DOI 10.1158/1078-0432.CCR-09-2697; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2008, VIROLOGY, V370, P264, DOI 10.1016/j.virol.2007.09.003; Jeong SJ, 2009, BIOCHEM BIOPH RES CO, V381, P294, DOI 10.1016/j.bbrc.2009.02.024; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Jones KS, 2008, NAT MED, V14, P429, DOI 10.1038/nm1745; Jones KS, 2006, J VIROL, V80, P8291, DOI 10.1128/JVI.00389-06; Jones KS, 2005, J VIROL, V79, P12692, DOI 10.1128/JVI.79.20.12692-12702.2005; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kinjo T, 2010, J VIROL, V84, P5431, DOI 10.1128/JVI.02460-09; KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451; Kuhlmann AS, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-92; Lambert S, 2009, BLOOD, V113, P5176, DOI 10.1182/blood-2008-04-150342; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lemasson I, 2007, J VIROL, V81, P1543, DOI 10.1128/JVI.00480-06; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; Lezin A, 2007, BLOOD, V110, P3722, DOI 10.1182/blood-2007-04-085076; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Lodewick J, 2009, VIROLOGY, V386, P68, DOI 10.1016/j.virol.2008.12.043; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Majorovits E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002251; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-71; Mazurov D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000788; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood-2003-11-3967; Miyazato A, 2005, J VIROL, V79, P9346, DOI 10.1128/JVI.79.14.9346-9350.2005; Mori N, 1996, BLOOD, V88, P1035; Morimoto H, 2005, AM J HEMATOL, V78, P100, DOI 10.1002/ajh.20259; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; Nejmeddine M, 2009, BLOOD, V114, P1016, DOI 10.1182/blood-2008-03-136770; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Ohsugi T, 2007, NAT MED, V13, P527, DOI 10.1038/nm0507-527; Okamura J, 2007, INT J HEMATOL, V86, P118, DOI 10.1532/IJH97.07070; OSAME M, 1989, JPN J MED, V28, P412, DOI 10.2169/internalmedicine1962.28.412; Pais-Correia AM, 2010, NAT MED, V16, P83, DOI 10.1038/nm.2065; Pan SH, 2009, CARCINOGENESIS, V30, P366, DOI 10.1093/carcin/bgn291; Park HU, 2006, ONCOGENE, V25, P438, DOI 10.1038/sj.onc.1209059; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Patel D, 2010, J VIROL, V84, P10956, DOI 10.1128/JVI.00259-10; Peloponese JM, 2006, IMMUNOL RES, V34, P1, DOI 10.1385/IR:34:1:1; Peloponese JM, 2009, J VIROL, V83, P3238, DOI 10.1128/JVI.01824-08; Peloponese JM, 2006, J BIOL CHEM, V281, P8927, DOI 10.1074/jbc.M510598200; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Phillips KE, 2000, CANCER RES, V60, P6977; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Ramadan E, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-92; Rauch D, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-116; REID RL, 1993, ONCOGENE, V8, P3029; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Ruggero K, 2010, MOL ASPECTS MED, V31, P367, DOI 10.1016/j.mam.2010.05.001; Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-19; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Shembade N, 2007, EMBO J, V26, P3910, DOI 10.1038/sj.emboj.7601823; Shoji T, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-83; Sibon D, 2006, J CLIN INVEST, V116, P974, DOI 10.1172/JCI27198; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Swaims AY, 2010, BLOOD, V116, P2994, DOI 10.1182/blood-2009-07-231050; Tabakin-Fix Y, 2006, CARCINOGENESIS, V27, P673, DOI 10.1093/carcin/bgi274; Takasaki Y, 2010, BLOOD, V115, P4337, DOI 10.1182/blood-2009-09-242347; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Tamiya S, 1998, BLOOD, V91, P3935; Tan C, 2002, CANCER RES, V62, P1083; Tanosaki R, 2008, BIOL BLOOD MARROW TR, V14, P702, DOI 10.1016/j.bbmt.2008.03.010; Taylor GP, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-63; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Toulza F, 2008, BLOOD, V111, P5047, DOI 10.1182/blood-2007-10-118539; Toulza F, 2010, J IMMUNOL, V185, P183, DOI 10.4049/jimmunol.0903846; Tsukasaki K, 2007, J CLIN ONCOL, V25, P5458, DOI 10.1200/JCO.2007.11.9958; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; Watanabe M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646; Watashi K, 2010, J BIOL CHEM, V285, P24707, DOI 10.1074/jbc.M109.062976; WELLES SL, 1994, INT J CANCER, V56, P337, DOI 10.1002/ijc.2910560307; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto K, 2010, J CLIN ONCOL, V28, P1591, DOI 10.1200/JCO.2009.25.3575; Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; Yasunaga JI, 2007, REV MED VIROL, V17, P301, DOI 10.1002/rmv.548; Yasunaga J, 2009, ENVIRON MOL MUTAGEN, V50, P733, DOI 10.1002/em.20480; Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2008, J VIROL, V82, P9359, DOI 10.1128/JVI.00242-08; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; Zane L, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-17; Zhang Z, 2003, CANCER RES, V63, P6453; Zhang Z, 2003, BLOOD, V102, P284, DOI 10.1182/blood-2002-11-3601; Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729	164	183	189	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1379	1389		10.1038/onc.2010.537	http://dx.doi.org/10.1038/onc.2010.537			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21119600	Green Accepted			2022-12-28	WOS:000288743800001
J	Zhang, XT; Kang, LG; Ding, L; Vranic, S; Gatalica, Z; Wang, ZY				Zhang, X. T.; Kang, L. G.; Ding, L.; Vranic, S.; Gatalica, Z.; Wang, Z-Y			A positive feedback loop of ER-alpha 36/EGFR promotes malignant growth of ER-negative breast cancer cells	ONCOGENE			English	Article						EGFR; ER-alpha 36; estrogen signaling; ER-negative breast cancer	ESTROGEN-RECEPTOR-ALPHA; VARIANT; EXPRESSION; PROLIFERATION; ESTRADIOL	It is prevailingly thought that estrogen signaling is not involved in development of estrogen receptor (ER)negative breast cancer. However, there is evidence indicating that ovariectomy prevents the development of both ER-positive and -negative breast cancer, suggesting that estrogen signaling is involved in the development of ER-negative breast cancer. Previously, our laboratory cloned a variant of ER-alpha, ER-alpha 36, and found that ER-alpha 36 mediated nongenomic estrogen signaling and is highly expressed in ER-negative breast cancer cells. In this study, we found that ER-alpha 36 was highly expressed in 10/12 cases of triple-negative breast cancer. We investigated the role of mitogenic estrogen signaling mediated by ER-alpha 36 in malignant growth of triple-negative breast cancer MDA-MB-231 and MDA-MB-436 cells that express high levels of ER-alpha 36 and found that these cells strongly responded to mitogenic estrogen signaling both in vitro and in vivo. Knockdown of ER-alpha 36 expression in these cells using the small hairpin RNA method diminished their responsiveness to estrogen. ER-alpha 36 physically interacted with the EGFR/Src/Shc complex and mediated estrogen-induced phosphorylation of epidermal growth factor receptor (EGFR) and Src. EGFR signaling activated ER-alpha 36 transcription through an AP1 site in the ER-alpha 36 promoter, and ER-alpha 36 expression was able to stabilize EGFR protein. Our results, thus demonstrated that ER-alpha 36 mediates nongenomic estrogen signaling through the EGFR/Src/ERK signaling pathway in ER-negative breast cancer cells and suggested that a subset of ER-negative breast tumors that expresses ER-alpha 36, retains responsiveness to mitogenic estrogen signaling. Oncogene (2011) 30, 770-780; doi:10.1038/onc.2010.458; published online 11 October 2010	[Zhang, X. T.; Kang, L. G.; Wang, Z-Y] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA; [Ding, L.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Vranic, S.; Gatalica, Z.; Wang, Z-Y] Creighton Univ, Sch Med, Dept Pathol, Omaha, NE 68178 USA; [Vranic, S.] Univ Sarajevo, Ctr Clin, Dept Pathol, Sarajevo 71000, Bosnia & Herceg	Creighton University; Zhejiang University; Creighton University; University of Sarajevo	Wang, ZY (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Criss 3,Room 355,2500 Calif Plaza, Omaha, NE 68178 USA.	zywang@creighton.edu	Vranic, Semir/J-4113-2012; Kang, Lianguo/D-7780-2012; Vranic, Semir/I-6823-2019	Vranic, Semir/0000-0001-9743-7265	National Institute of Health [DK84328]; Nebraska Tobacco Settlement Biomedical Research Program Award [LB-595, LB692]; American Cancer Society [ACS/08/004]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070016] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Tobacco Settlement Biomedical Research Program Award; American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institute of Health Grant DK84328 and by the Nebraska Tobacco Settlement Biomedical Research Program Award (LB-595 and LB692) to ZY Wang. Dr Semir Vranic was a research fellow at Creighton University Medical School, Omaha, NE, USA and had been supported by a UICC American Cancer Society Beginning Investigators Fellowship (ACSBI) (ACS/08/004) funded by the American Cancer Society.	[Anonymous], 1992, Lancet, V339, P1; Behrens D, 2007, MOL CELL ENDOCRINOL, V274, P19, DOI 10.1016/j.mce.2007.05.012; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; FRIEDL A, 1994, EUR J CANCER, V30A, P1559, DOI 10.1016/0959-8049(94)00293-E; FRIEDL A, 1989, CANCER RES, V49, P4758; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Kang LG, 2010, J CELL MOL MED, V14, P1485, DOI 10.1111/j.1582-4934.2009.00877.x; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lee LMJ, 2008, ANTICANCER RES, V28, P479; Lin SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009013; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; Narod SA, 2001, ANN NY ACAD SCI, V952, P36, DOI 10.1111/j.1749-6632.2001.tb02726.x; NISSENMEYER R, 1964, ACTA UNION INT CONTR, V20, P527; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Rai D, 2005, MOL ENDOCRINOL, V19, P1606, DOI 10.1210/me.2004-0468; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Shi L, 2009, J CLIN ONCOL, V27, P3423, DOI 10.1200/JCO.2008.17.2254; Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473; Tsai EM, 2001, CANCER RES, V61, P8390; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Zou Y, 2009, FEBS LETT, V583, P1368, DOI 10.1016/j.febslet.2009.03.047	26	124	133	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					770	780		10.1038/onc.2010.458	http://dx.doi.org/10.1038/onc.2010.458			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20935677	Green Accepted			2022-12-28	WOS:000287444600002
J	Ahn, J; Ko, M; Lee, C; Kim, J; Yoon, H; Seong, RH				Ahn, J.; Ko, M.; Lee, C.; Kim, J.; Yoon, H.; Seong, R. H.			Srg3, a mouse homolog of BAF155, is a novel p53 target and acts as a tumor suppressor by modulating p21(WAF1/CIP1) expression	ONCOGENE			English	Article						SWI/SNF chromatin remodeling complex; tumor suppressor; Srg3; DNA damage signal; p53; p21	CHROMATIN REMODELING COMPLEX; STRAND BREAK REPAIR; CELL-CYCLE ARREST; MAMMALIAN SWI/SNF COMPLEXES; PROTEASOMAL DEGRADATION; RHABDOID TUMORS; DNA-DAMAGE; IN-VIVO; APOPTOSIS; CANCER	Some subunits of the SWI/SNF complex function as tumor suppressors. However, underlying mechanisms are still incompletely defined. Here, we show that Srg3, a mouse homolog of BAF155 that function as a core subunit of this complex, suppresses tumorigenesis in vivo. DNA damage signals promoted Srg3 degradation by inducing p53. Deficiency of Srg3 promoted G1 cell-cycle arrest, but antagonized apoptotic response to DNA damage by robustly inducing p53 and p21 proteins. Srg3 heterozygous mice were prone to sarcoma formation, which was further enhanced by haploinsufficiency of p53. These tumors highly expressed p53 and p21 but lacked Srg3 expression. Our results establish a novel function of Srg3 in tumor suppression and provide insights into genetic pathways dictating tumor suppression by the SWI/SNF complex. Oncogene (2011) 30, 445-456; doi: 10.1038/onc.2010.424; published online 11 October 2010	[Seong, R. H.] Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Res Ctr Funct Cellul, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Seong, RH (corresponding author), Seoul Natl Univ, Dept Biol Sci, Gwanak Ro 599,Bldg 105, Seoul 151742, South Korea.	rhseong@snu.ac.kr		Ko, Myunggon/0000-0002-6007-2570; Seong, Rho/0000-0001-5699-0718	Ministry of Education, Science and Technology [20090094022]; MEST	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from the National Research Foundation of Korea (NRF), funded by Ministry of Education, Science and Technology, in part through the Research Center for Functional Cellulomics and in part through the Priority Research Centers Program (20090094022). JA, MK, JK, HY and CL were supported by the BK21 program from MEST.	Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chan TA, 2000, GENE DEV, V14, P1584; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Gartel AL, 2002, MOL CANCER THER, V1, P639; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Han D, 2008, DEV BIOL, V315, P136, DOI 10.1016/j.ydbio.2007.12.024; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hu G, 1999, MOL CELL BIOL, V19, P724; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Kaneuchi M, 1999, MOL CARCINOGEN, V26, P44, DOI 10.1002/(SICI)1098-2744(199909)26:1<44::AID-MC6>3.3.CO;2-V; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martin-Caballero J, 2001, CANCER RES, V61, P6234; McKenna ES, 2008, MOL CELL BIOL, V28, P6223, DOI 10.1128/MCB.00658-08; Moshkin YM, 2007, MOL CELL BIOL, V27, P651, DOI 10.1128/MCB.01257-06; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ring HZ, 1998, GENOMICS, V51, P140, DOI 10.1006/geno.1998.5343; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Sohn DH, 2007, J BIOL CHEM, V282, P10614, DOI 10.1074/jbc.M610563200; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wong AKC, 2000, CANCER RES, V60, P6171; Yang XF, 2007, NAT STRUCT MOL BIOL, V14, P540, DOI 10.1038/nsmb1238; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	55	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	4					445	456		10.1038/onc.2010.424	http://dx.doi.org/10.1038/onc.2010.424			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20935679				2022-12-28	WOS:000286621600007
J	Hebbard, L; Cecena, G; Golas, J; Sawada, J; Ellies, LG; Charbono, A; Williams, R; Jimenez, RE; Wankell, M; Arndt, KT; DeJoy, SQ; Rollins, RA; Diesl, V; Follettie, M; Chen, L; Rosfjord, E; Cardiff, RD; Komatsu, M; Boschelli, F; Oshima, RG				Hebbard, L.; Cecena, G.; Golas, J.; Sawada, J.; Ellies, L. G.; Charbono, A.; Williams, R.; Jimenez, R. E.; Wankell, M.; Arndt, K. T.; DeJoy, S. Q.; Rollins, R. A.; Diesl, V.; Follettie, M.; Chen, L.; Rosfjord, E.; Cardiff, R. D.; Komatsu, M.; Boschelli, F.; Oshima, R. G.			Control of mammary tumor differentiation by SKI-606 (bosutinib)	ONCOGENE			English	Article						Src; SKI-606; mouse; breast cancer; Ezh2	SRC TYROSINE KINASE; C-SRC; BREAST-CANCER; GENE-EXPRESSION; EZH2; ACTIVATION; INHIBITOR; INDUCTION; GROWTH; MODEL	C-Src is infrequently mutated in human cancers but it mediates oncogenic signals of many activated growth factor receptors and thus remains a key target for cancer therapy. However, the broad function of Src in many cell types and processes requires evaluation of Src-targeted therapeutics within a normal developmental and immune-competent environment. In an effort to understand the appropriate clinical use of Src inhibitors, we tested an Src inhibitor, SKI-606 (bosutinib), in the MMTV-PyVmT transgenic mouse model of breast cancer. Tumor formation in this model is dependent on the presence of Src, but the necessity of Src kinase activity for tumor formation has not been determined. Furthermore, Src inhibitors have not been examined in an autochthonous tumor model that permits assessment of effects on different stages of tumor progression. Here we show that oral administration of SKI-606 inhibited the phosphorylation of Src in mammary tumors and caused a rapid decrease in the Ezh2 Polycomb group histone H3K27 methyltransferase and an increase in epithelial organization. SKI-606 prevented the appearance of palpable tumors in over 50% of the animals and stopped tumor growth in older animals with pre-existing tumors. These antitumor effects were accompanied by decreased cellular proliferation, altered tumor blood vessel organization and dramatically increased differentiation to lactational and epidermal cell fates. SKI-606 controls the development of mammary tumors by inducing differentiation. Oncogene (2011) 30, 301-312; doi:10.1038/onc.2010.412; published online 6 September 2010	[Hebbard, L.; Cecena, G.; Charbono, A.; Williams, R.; Wankell, M.; Oshima, R. G.] Sanford Burnham Med Res Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Golas, J.; Arndt, K. T.; DeJoy, S. Q.; Rollins, R. A.; Diesl, V.; Follettie, M.; Chen, L.; Rosfjord, E.; Boschelli, F.] Pfizer Res, Ctr Integrat Biol & Biotherapeut, Pearl River, NY USA; [Sawada, J.; Komatsu, M.] Sanford Burnham Med Res Inst, Lake Nona, FL USA; [Ellies, L. G.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Jimenez, R. E.] Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; [Cardiff, R. D.] Univ Calif Davis, Ctr Genom Pathol, Davis, CA 95616 USA	Sanford Burnham Prebys Medical Discovery Institute; Pfizer; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Davis	Oshima, RG (corresponding author), Sanford Burnham Med Res Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rgoshima@burnham.org	Hebbard, Lionel/O-1489-2017; Sawada, Junko/C-9199-2012; Hebbard, Lionel w/F-7272-2014; Komatsu, Masanobu/AAV-3013-2020; Hebbard, Lionel/W-4057-2019; Rollins, Robert/R-2978-2019	Hebbard, Lionel/0000-0002-7094-9065; Rosfjord, Edward/0000-0002-3449-7444; Komatsu, Masanobu/0000-0001-7548-137X; Williams, Roy/0000-0002-5442-9166	Pfizer Research; NCI Cancer Center [2 P30 CA030199, R01 CA125255]; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA125255] Funding Source: NIH RePORTER	Pfizer Research(Pfizer); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mina Bissell, Lawrence Berkley National Laboratory for the gift of casein antibody, and Robert Abraham, Pfizer Research for his interest and support of the project. This work was supported by a collaborative research grant from Pfizer Research, and shared resource support from the NCI Cancer Center Support Grant 2 P30 CA030199 and R01 CA125255 (MK).	Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boschelli DH, 2001, J MED CHEM, V44, P3965, DOI 10.1021/jm0102250; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cheung ATW, 1997, INT J ONCOL, V11, P69; Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Golas JM, 2005, CANCER RES, V65, P5358, DOI 10.1158/0008-5472.CAN-04-2484; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Klein A, 2005, J MOL MED, V83, P362, DOI 10.1007/s00109-004-0625-1; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu M, 2005, CANCER RES, V65, P5325, DOI 10.1158/0008-5472.CAN-04-4589; Maglione JE, 2001, CANCER RES, V61, P8298; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Neznanov N, 1999, CANCER RES, V59, P4242; Oshima RG, 2004, CANCER RES, V64, P169, DOI 10.1158/0008-5472.CAN-03-1944; Rix LLR, 2009, LEUKEMIA, V23, P477, DOI 10.1038/leu.2008.334; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Rudolph MC, 2007, PHYSIOL GENOMICS, V28, P323, DOI 10.1152/physiolgenomics.00020.2006; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Silva CM, 2007, MOL ENDOCRINOL, V21, P1499, DOI 10.1210/me.2007-0109; SPECTOR DH, 1978, P NATL ACAD SCI USA, V75, P4102, DOI 10.1073/pnas.75.9.4102; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vultur A, 2008, MOL CANCER THER, V7, P1185, DOI 10.1158/1535-7163.MCT-08-0126; Watkin H, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-6; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130	51	21	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					301	312		10.1038/onc.2010.412	http://dx.doi.org/10.1038/onc.2010.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20818417	Green Accepted, Green Submitted			2022-12-28	WOS:000286418800005
J	Peng, A; Maller, JL				Peng, A.; Maller, J. L.			Serine/threonine phosphatases in the DNA damage response and cancer	ONCOGENE			English	Review						protein phosphatase; DNA damage; checkpoint; cancer	DOUBLE-STRAND BREAK; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR ACTIVITY; CHECKPOINT KINASE RAD53; CHK2 PROTEIN-KINASE; ACTIVATION IN-VIVO; WIP1 PHOSPHATASE; IONIZING-RADIATION; ATM ACTIVATION; DEPHOSPHORYLATES GAMMA-H2AX	The cellular response to DNA damage is a crucial surveillance mechanism that maintains genomic integrity and prevents cancer progression. Previous studies identified multiple Ser/Thr protein kinases that have pivotal roles in the activation of this response. It is interesting that a growing body of evidence suggests that these kinases and their substrates are under tight modulation by numerous Ser/Thr phosphatases. In this study, we review recent reports that reveal new functions and regulation of these phosphatases. Similar to the kinases in this pathway, phosphatases may also be intimately involved in cancer progression and present valuable targets for cancer therapy. Oncogene (2010) 29, 5977-5988; doi:10.1038/onc.2010.371; published online 13 September 2010	[Peng, A.; Maller, J. L.] Univ Colorado, Sch Med, Howard Hughes Med Inst, Aurora, CO 80045 USA; [Peng, A.; Maller, J. L.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Peng, A (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, 12801 E 17th Ave,RC1 S,Rm L1810122,MS 8303, Aurora, CO 80045 USA.	Aimin.Peng@unmc.edu; Jim.Maller@UCDENVER.edu			Howard Hughes Medical Institute	Howard Hughes Medical Institute(Howard Hughes Medical Institute)	We thank members of the Maller lab for stimulating discussions. This work was supported by the Howard Hughes Medical Institute. We apologize to colleagues whose relevant works are not cited here due to space limitations.	Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Austen B, 2007, J CLIN ONCOL, V25, P5448, DOI 10.1200/JCO.2007.11.2649; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bazzi M, 2010, MOL CELL BIOL, V30, P131, DOI 10.1128/MCB.01000-09; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Buscemi G, 2006, MOL CELL BIOL, V26, P7832, DOI 10.1128/MCB.00534-06; Carlessi L, 2010, BBA-MOL CELL RES, V1803, P1213, DOI 10.1016/j.bbamcr.2010.06.002; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Chowdhury D, 2008, MOL CELL, V31, P33, DOI 10.1016/j.molcel.2008.05.016; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Douglas P, 2010, MOL CELL BIOL, V30, P1368, DOI 10.1128/MCB.00741-09; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Feng JJ, 2009, MOL CELL BIOL, V29, P5696, DOI 10.1128/MCB.00191-09; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Freeman AK, 2010, CELL CYCLE, V9, P736, DOI 10.4161/cc.9.4.10613; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guillemain G, 2007, MOL CELL BIOL, V27, P3378, DOI 10.1128/MCB.00863-06; Gumy-Pause F, 2004, LEUKEMIA, V18, P238, DOI 10.1038/sj.leu.2403221; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; Haidar MA, 2000, CANCER-AM CANCER SOC, V88, P1057, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hamilton J, 2009, CANCER BIOL THER, V8, P1577, DOI 10.4161/cbt.8.16.8962; Haneda M, 2004, FEBS LETT, V567, P171, DOI 10.1016/j.febslet.2004.04.066; Heideker J, 2007, CELL CYCLE, V6, P3058, DOI 10.4161/cc.6.24.5100; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Keogh MC, 2006, NATURE, V441, P120, DOI 10.1038/nature04772; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lee DH, 2010, NAT STRUCT MOL BIOL, V17, P365, DOI 10.1038/nsmb.1769; Lee SJ, 2007, CELL DEATH DIFFER, V14, P1106, DOI 10.1038/sj.cdd.4402111; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Liang XB, 2006, INT J MOL MED, V17, P703; Liu Y, 2002, CANCER RES, V62, P6357; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lu G, 2008, CLIN EXP PHARMACOL P, V35, P107, DOI 10.1111/j.1440-1681.2007.04843.x; Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Mi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004395; Mi J, 2009, MOL CANCER THER, V8, P135, DOI 10.1158/1535-7163.MCT-08-0457; Mochan TA, 2003, CANCER RES, V63, P8586; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Moorhead GBG, 2007, NAT REV MOL CELL BIO, V8, P234, DOI 10.1038/nrm2126; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nakada S, 2008, EMBO REP, V9, P1019, DOI 10.1038/embor.2008.162; Nazarov OB, 2003, RADIAT RES, V160, P309, DOI 10.1667/RR3043; O'Neill BM, 2007, P NATL ACAD SCI USA, V104, P9290, DOI 10.1073/pnas.0703252104; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Peng AM, 2010, CURR BIOL, V20, P387, DOI 10.1016/j.cub.2010.01.020; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Shouse GP, 2008, MOL CELL BIOL, V28, P448, DOI 10.1128/MCB.00983-07; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Tang X, 2008, MOL CELL BIOL, V28, P2559, DOI 10.1128/MCB.01711-07; Travesa A, 2008, J BIOL CHEM, V283, P17123, DOI 10.1074/jbc.M801402200; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Wood JL, 2008, TRENDS CELL BIOL, V18, P451, DOI 10.1016/j.tcb.2008.07.006; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Xia Y, 2009, J BIOL CHEM, V284, P17428, DOI 10.1074/jbc.M109.007823; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yan Y, 2010, ONCOGENE, V29, P4317, DOI 10.1038/onc.2010.187; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Yong WD, 2007, J BIOL CHEM, V282, P14690, DOI 10.1074/jbc.C700019200; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2003, CANCER BIOL THER, V2, pS16; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	100	49	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					5977	5988		10.1038/onc.2010.371	http://dx.doi.org/10.1038/onc.2010.371			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20838380				2022-12-28	WOS:000284108700001
J	Banerjee, R; Mani, RS; Russo, N; Scanlon, CS; Tsodikov, A; Jing, X; Cao, Q; Palanisamy, N; Metwally, T; Inglehart, RC; Tomlins, S; Bradford, C; Carey, T; Wolf, G; Kalyana-Sundaram, S; Chinnaiyan, AM; Varambally, S; D'Silva, NJ				Banerjee, R.; Mani, R-S; Russo, N.; Scanlon, C. S.; Tsodikov, A.; Jing, X.; Cao, Q.; Palanisamy, N.; Metwally, T.; Inglehart, R. C.; Tomlins, S.; Bradford, C.; Carey, T.; Wolf, G.; Kalyana-Sundaram, S.; Chinnaiyan, A. M.; Varambally, S.; D'Silva, N. J.			The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma	ONCOGENE			English	Article						miR-101; EZH2; rap1GAP; rap1; promoter hypermethylation	GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE; DOWN-REGULATION; E-CADHERIN; SOMATIC MUTATIONS; MOLECULAR-BIOLOGY; PROMOTES INVASION; HIGH EXPRESSION; NECK-CANCER; POLYCOMB	Rap1GAP is a critical tumor suppressor gene that is downregulated in multiple aggressive cancers, such as head and neck squamous cell carcinoma, melanoma and pancreatic cancer. However, the mechanistic basis of rap1GAP downregulation in cancers is poorly understood. By employing an integrative approach, we demonstrate polycomb-mediated repression of rap1GAP that involves Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase in head and neck cancers. We further demonstrate that the loss of miR-101 expression correlates with EZH2 upregulation, and the concomitant downregulation of rap1GAP in head and neck cancers. EZH2 represses rap1GAP by facilitating the trimethylation of histone 3 at lysine 27, a mark of gene repression, and also hypermethylation of rap1GAP promoter. These results provide a conceptual framework involving a microRNA-oncogene-tumor suppressor axis to understand head and neck cancer progression. Oncogene (2011) 30, 4339-4349; doi: 10.1038/onc.2011.141; published online 2 May 2011	[D'Silva, N. J.] Univ Michigan, Sch Dent, Sch Med, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [Mani, R-S; Jing, X.; Palanisamy, N.; Tomlins, S.; Kalyana-Sundaram, S.; Chinnaiyan, A. M.; Varambally, S.; D'Silva, N. J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Mani, R-S; Jing, X.; Cao, Q.; Palanisamy, N.; Tomlins, S.; Kalyana-Sundaram, S.; Chinnaiyan, A. M.; Varambally, S.; D'Silva, N. J.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Tsodikov, A.] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA; [Bradford, C.; Carey, T.; Wolf, G.] Univ Michigan, Sch Med, Dept Otolaryngol, Ann Arbor, MI 48109 USA; [Kalyana-Sundaram, S.] Bharathidasan Univ, Dept Environm Biotechnol, Tiruchirappalli, Tamil Nadu, India; [Chinnaiyan, A. M.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Bharathidasan University; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Sch Med, Dept Periodont & Oral Med, 1011 N Univ Ave,Room 5217, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu	Palanisamy, Nallasivam/ABC-8844-2020; D'Silva, Nisha J/B-4734-2013; Kalyana-Sundaram, Shanker/F-6860-2012; Cao, Qi/A-5517-2010	Palanisamy, Nallasivam/0000-0002-0633-9772; Cao, Qi/0000-0002-5140-3681; Varambally, Sooryanarayana/0000-0002-2277-1127; Carey, Thomas/0000-0002-5202-7518; Kalyana-Sundaram, Shanker/0000-0002-7309-3848; Mani, Ram/0000-0003-3552-7905	Prostate Cancer Foundation; NIDCR [DE16920-01, DE018512-01]; University of Michigan; National Institutes of Health through the University of Michigan's Cancer Center Support [5 P30 CA46592]; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K02DE019513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE016920, R01DE018512] Funding Source: NIH RePORTER	Prostate Cancer Foundation; NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); University of Michigan(University of Michigan System); National Institutes of Health through the University of Michigan's Cancer Center Support; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr T Giardano for tissue, and Dr Khalid Suleman and Vineeta Sharma for technical assistance for the FISH and methylation studies, respectively. R-SM is the recipient of StewartRahr-PCF Young Investigator Award from the Prostate Cancer Foundation. This work was supported by NIDCR DE16920-01, DE018512-01 grants and funding from University of Michigan Head and Neck Specialized Program of Research Excellence (SPORE) (NJD). This research was made possible, in part, by the use of the Cancer Center Flow Cytometry Core, which was supported (in part) by the National Institutes of Health through the University of Michigan's Cancer Center Support Grant (5 P30 CA46592).	Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chin D, 2006, EXPERT REV ANTICANC, V6, P1111, DOI 10.1586/14737140.6.7.1111; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Glazer CA, 2009, ORAL ONCOL, V45, P440, DOI 10.1016/j.oraloncology.2008.05.013; He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thomas GJ, 2001, CRIT REV ORAL BIOL M, V12, P479, DOI 10.1177/10454411010120060301; Todd R, 1997, J ORAL MAXIL SURG, V55, P613, DOI 10.1016/S0278-2391(97)90495-X; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Tsygankova OM, 2010, MOL CELL BIOL, V30, P3262, DOI 10.1128/MCB.01345-09; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Yang Y, 2010, CANCER GENET CYTOGEN, V200, P127, DOI 10.1016/j.cancergencyto.2010.03.014; Yarbrough WG, 2006, HEAD NECK-J SCI SPEC, V28, P549, DOI 10.1002/hed.20357; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang LZ, 2006, CANCER RES, V66, P898, DOI 10.1158/0008-5472.CAN-05-3025; Zhang ZC, 2006, AM J PATHOL, V168, P585, DOI 10.2353/ajpath.2006.050132; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812	46	79	82	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	42					4339	4349		10.1038/onc.2011.141	http://dx.doi.org/10.1038/onc.2011.141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21532618	Green Accepted			2022-12-28	WOS:000296356400005
J	Zheng, R; Bailey, E; Nguyen, B; Yang, X; Piloto, O; Levis, M; Small, D				Zheng, R.; Bailey, E.; Nguyen, B.; Yang, X.; Piloto, O.; Levis, M.; Small, D.			Further activation of FLT3 mutants by FLT3 ligand	ONCOGENE			English	Article						FLT3; tyrosine kinase receptor; FLT3 ligand; internal tandem duplication mutation; point mutation	ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; TYROSINE KINASE RECEPTOR; CONSTITUTIVE ACTIVATION; HEMATOPOIETIC-CELLS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; C-KIT; EXPRESSION; GENE	Somatic mutations of FLT3 involving internal tandem duplication (ITD) of the juxtamembrane domain or point mutations in the tyrosine kinase domain (TKD) appear to activate FLT3 in a FLT3 ligand (FL)-independent manner. To determine whether or not FLT3 mutants respond to FL for their activation, a FL-deficient (FL-/-) murine embryo fibroblast (MEF) cell line was established. Expression of FLT3/ITD and FLT3/TKD mutations in FL-/- MEF cells resulted in low levels of constitutive phosphorylation of FLT3. However, a more than fourfold increase of FLT3 autophosphorylation was induced by exogenous FL. Rescue of endogenous FL expression in FL-/- MEF cells expressing FLT3 mutants led to more than a threefold increase of FLT3 phosphorylation. FL addition led to further activation of the FLT3 receptors and enhanced survival and/or decreased apoptosis in leukemia-derived cell lines and primary leukemic cells expressing FLT3 mutations. Functional studies revealed that exogenous FL promoted the colony-forming and recloning abilities of FLT3 mutant transduced primary bone marrow cells derived from FL-/- mice. Endogenous FL contributes in vivo to functional signaling through FLT3 as noted by the decreased survival of FL+/+ ITD+/+ mice compared with FL-/- ITD+/+ mice. These data suggest that FL leads to further activation of FLT3 mutants and is especially important in light of recent findings of elevated FL levels in acute myeloid leukemia patients in response to chemotherapy. Oncogene (2011) 30, 4004-4014; doi:10.1038/onc.2011.110; published online 25 April 2011	[Zheng, R.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; [Bailey, E.; Nguyen, B.; Yang, X.; Piloto, O.; Levis, M.; Small, D.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA; [Small, D.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Small, D (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Pediat Oncol, CRB 251,1650 Orleans St, Baltimore, MD 21231 USA.	donsmall@jhmi.edu			Giant Food Pediatric Cancer Research Fund; NIH [CA90668, CA70970, CA095600-01]; Leukemia and Lymphoma Society; NCI (NCI Leukemia SPORE) [P50 CA100632-06, R01 CA128864]; American Society of Clinical Oncology; NATIONAL CANCER INSTITUTE [R01CA128864, R01CA090668, K08CA095600, P50CA100632] Funding Source: NIH RePORTER	Giant Food Pediatric Cancer Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NCI (NCI Leukemia SPORE)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Society of Clinical Oncology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Katharine A Whartenby, Alan Friedman and Linzhao Cheng for their gift of reagents. DS is also supported by the Kyle Haydock Professorship in Oncology and the Giant Food Pediatric Cancer Research Fund. This work was supported by grants from the NIH (CA90668, CA70970 and CA095600-01) and the Leukemia and Lymphoma Society (DS). It was also supported by grants from the NCI (NCI Leukemia SPORE P50 CA100632-06, R01 CA128864) and the American Society of Clinical Oncology (ML). ML is a Clinical Scholar of the Leukemia and Lymphoma Society.	Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P1076, DOI 10.1046/j.1365-2141.2001.02821.x; Bellamy WT, 2001, BLOOD, V97, P1427, DOI 10.1182/blood.V97.5.1427; BIRG F, 1992, BLOOD, V80, P2584; BRASEL K, 1995, LEUKEMIA, V9, P1212; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; Drexler HG, 1996, LEUKEMIA, V10, P588; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; FREEDMAN MH, 1993, BLOOD, V81, P3068; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Iwai T, 1999, LEUKEMIA, V13, P38, DOI 10.1038/sj.leu.2401241; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Levis M, 2011, BLOOD, V117, P3294, DOI 10.1182/blood-2010-08-301796; Li L, 2008, BLOOD, V111, P3849, DOI 10.1182/blood-2007-08-109942; Li YW, 2004, BLOOD, V104, P1137, DOI 10.1182/blood-2003-07-2585; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Nakao M, 1996, LEUKEMIA, V10, P1911; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; PIETSCH T, 1993, NOUV REV FR HEMATOL, V35, P285; Piloto O, 2005, CANCER RES, V65, P1514, DOI 10.1158/0008-5472.CAN-04-3081; ROGERS SY, 1994, EXP HEMATOL, V22, P593; Rosnet O, 1996, ACTA HAEMATOL-BASEL, V95, P218; Sato T, 2011, BLOOD, V117, P3286, DOI 10.1182/blood-2010-01-266742; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zhang SL, 2000, BIOCHEM BIOPH RES CO, V277, P195, DOI 10.1006/bbrc.2000.3662; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, J LEUKOCYTE BIOL, V65, P372, DOI 10.1002/jlb.65.3.372; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969; Zheng R, 2002, BLOOD, V100, P4154, DOI 10.1182/blood-2002-03-0936	41	34	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4004	4014		10.1038/onc.2011.110	http://dx.doi.org/10.1038/onc.2011.110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21516120	Green Accepted			2022-12-28	WOS:000295121600002
J	Ying, M; Wang, S; Sang, Y; Sun, P; Lal, B; Goodwin, CR; Guerrero-Cazares, H; Quinones-Hinojosa, A; Laterra, J; Xia, S				Ying, M.; Wang, S.; Sang, Y.; Sun, P.; Lal, B.; Goodwin, C. R.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Laterra, J.; Xia, S.			Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition	ONCOGENE			English	Article						glioblastoma; cancer stem cell; retinoic acid; differentiation; Notch	HEPATOCYTE GROWTH-FACTOR; 13-CIS-RETINOIC ACID; EMBRYONAL CARCINOMA; DIFFERENTIATION THERAPY; NEURAL DIFFERENTIATION; U87MG CELLS; PHASE-II; CANCER; APOPTOSIS; GLIOMA	It is necessary to understand mechanisms by which differentiating agents influence tumor-initiating cancer stem cells. Toward this end, we investigated the cellular and molecular responses of glioblastoma stem-like cells (GBM-SCs) to all-trans retinoic acid (RA). GBM-SCs were grown as non-adherent neurospheres in growth factor supplemented serum-free medium. RA treatment rapidly induced morphology changes, induced growth arrest at G1/G0 to S transition, decreased cyclin D1 expression and increased p27 expression. Immunofluorescence and western blot analysis indicated that RA induced the expression of lineage-specific differentiation markers Tuj1 and GFAP and reduced the expression of neural stem cell markers such as CD133, Msi-1, nestin and Sox-2. RA treatment dramatically decreased neurosphere-forming capacity, inhibited the ability of neurospheres to form colonies in soft agar and inhibited their capacity to propagate subcutaneous and intracranial xenografts. Expression microarray analysis identified similar to 350 genes that were altered within 48 h of RA treatment. Affected pathways included retinoid signaling and metabolism, cell-cycle regulation, lineage determination, cell adhesion, cell-matrix interaction and cytoskeleton remodeling. Notch signaling was the most prominent of these RA-responsive pathways. Notch pathway downregulation was confirmed based on the downregulation of HES and HEY family members. Constitutive activation of Notch signaling with the Notch intracellular domain rescued GBM neurospheres from the RA-induced differentiation and stem cell depletion. Our findings identify mechanisms by which RA targets GBM-derived stem-like tumor-initiating cells and novel targets applicable to differentiation therapies for glioblastoma. Oncogene (2011) 30, 3454-3467; doi:10.1038/onc.2011.58; published online 7 March 2011	[Xia, S.] Hugo W Moser Res Inst Kennedy Krieger, Johns Hopkins Sch Med, Dept Neurooncol, Baltimore, MD 21205 USA; [Ying, M.; Sun, P.; Lal, B.; Laterra, J.; Xia, S.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; [Guerrero-Cazares, H.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Xia, S (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Johns Hopkins Sch Med, Dept Neurooncol, 707 N Broadway,Room 400K, Baltimore, MD 21205 USA.	xia@kennedykrieger.org		Guerrero-Cazares, Hugo/0000-0003-1307-719X; Goodwin, C. Rory/0000-0002-6540-2751	Maryland Stem Cell Research Fund (MSCRFE) [2009-0126-00]; MSCRF; NIH [NS43987, KO8]; James McDonnell Foundation; HHMI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER	Maryland Stem Cell Research Fund (MSCRFE); MSCRF; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James McDonnell Foundation; HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by the Maryland Stem Cell Research Fund (MSCRFE) 2009-0126-00 (SX); MSCRF (MY, HG); NIH NS43987 and the James McDonnell Foundation (JL); as well as NIH KO8 and HHMI grants (AQ). Dr CR Goodwin is a UNCF-Merck Science postdoc fellow. We thank Dr Jiang Qian and Ms Yanqing Yang from Wilmer Eye Institute, Johns Hopkins University, for their assistance with microarray analysis.	Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; An J, 2005, PROTEOMICS, V5, P1656, DOI 10.1002/pmic.200401049; Bain G., 2000, Functional and Integrative Genomics, V1, P127, DOI 10.1007/s101420000014; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Butowski N, 2005, INT J RADIAT ONCOL, V61, P1454, DOI 10.1016/j.ijrobp.2004.08.023; Chalmers AJ, 2007, DNA REPAIR, V6, P1391, DOI 10.1016/j.dnarep.2007.03.019; Chearwae W, 2008, BRIT J CANCER, V99, P2044, DOI 10.1038/sj.bjc.6604786; Das A, 2008, J NEURO-ONCOL, V87, P9, DOI 10.1007/s11060-007-9485-1; Dragnev KH, 2003, CANCER BIOL THER, V2, pS150; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761; Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570; Harris Thomas M, 2002, Funct Integr Genomics, V2, P105, DOI 10.1007/s10142-002-0062-6; Jaeckle KA, 2003, J CLIN ONCOL, V21, P2305, DOI 10.1200/JCO.2003.12.097; Johannessen TCA, 2008, CANCER TREAT REV, V34, P558, DOI 10.1016/j.ctrv.2008.03.125; Jurcic Joseph G, 2007, Curr Oncol Rep, V9, P337, DOI 10.1007/s11912-007-0045-9; Kageyama R, 2009, CURR OPIN CELL BIOL, V21, P733, DOI 10.1016/j.ceb.2009.08.009; Karmakar S, 2008, CANCER, V112, P596, DOI 10.1002/cncr.23223; Kumar Hari R, 2008, Expert Rev Neurother, V8, P1497, DOI 10.1586/14737175.8.10.1497; Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Massard C, 2006, ANN ONCOL, V17, P1620, DOI 10.1093/annonc/mdl074; Mongan NP, 2007, DIFFERENTIATION, V75, P853, DOI 10.1111/j.1432-0436.2007.00206.x; Murata-Ohsawa M, 2005, LEUKEMIA RES, V29, P197, DOI 10.1016/j.leukres.2004.05.020; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158/1078-0432.CCR-09-0209; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piccirillo SGM, 2007, EXPERT OPIN BIOL TH, V7, P1129, DOI 10.1517/14712598.7.8.1129; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Sangster-Guity N, 2004, CANCER BIOL THER, V3, P1109, DOI 10.4161/cbt.3.11.1190; See SJ, 2004, NEURO-ONCOLOGY, V6, P253, DOI 10.1215/S1152851703000607; Sell S, 2006, TUMOR BIOL, V27, P59, DOI 10.1159/000092323; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Shi YH, 2008, CRIT REV ONCOL HEMAT, V65, P43, DOI 10.1016/j.critrevonc.2007.06.004; Shih AH, 2006, NEOPLASIA, V8, P1072, DOI 10.1593/neo.06526; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sivasankaran B, 2009, CANCER RES, V69, P458, DOI 10.1158/0008-5472.CAN-08-2610; Soprano DR, 2007, VITAM HORM, V75, P69, DOI 10.1016/S0083-6729(06)75003-8; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Walsh J, 2003, APMIS, V111, P197, DOI 10.1034/j.1600-0463.2003.1110124.x; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; Wilson A, 2006, FEBS LETT, V580, P2860, DOI 10.1016/j.febslet.2006.03.024; Yu XB, 2008, CELL STEM CELL, V2, P461, DOI 10.1016/j.stem.2008.03.001; Yung WKA, 1996, CLIN CANCER RES, V2, P1931; Zhang R, 2007, NEUROCHEM RES, V32, P2194, DOI 10.1007/s11064-007-9417-7	54	132	136	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	31					3454	3467		10.1038/onc.2011.58	http://dx.doi.org/10.1038/onc.2011.58			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21383690	Green Accepted			2022-12-28	WOS:000293508100006
J	Bell, EL; Emerling, BM; Ricoult, SJH; Guarente, L				Bell, E. L.; Emerling, B. M.; Ricoult, S. J. H.; Guarente, L.			SirT3 suppresses hypoxia inducible factor 1 alpha and tumor growth by inhibiting mitochondrial ROS production	ONCOGENE			English	Article						SirT3; ROS; HIF; mitochondria; hypoxia	REPLICATIVE LIFE-SPAN; CALORIE RESTRICTION; HIF-ALPHA; PROLYL HYDROXYLATION; OXIDATIVE STRESS; COMPLEX-III; CANCER; TUMORIGENESIS; METABOLISM; PROTEIN	It has become increasing clear that alterations in cellular metabolism have a key role in the generation and maintenance of cancer. Some of the metabolic changes can be attributed to the activation of oncogenes or loss of tumor suppressors. Here, we show that the mitochondrial sirtuin, SirT3, acts as a tumor suppressor via its ability to suppress reactive oxygen species (ROS) and regulate hypoxia inducible factor 1 alpha (HIF-1 alpha). Primary mouse embryo fibroblasts (MEFs) or tumor cell lines expressing SirT3 short-hairpin RNA exhibit a greater potential to proliferate, and augmented HIF-1a protein stabilization and transcriptional activity in hypoxic conditions. SirT3 knockdown increases tumorigenesis in xenograft models, and this is abolished by giving mice the anti-oxidant N-acetyl cysteine. Moreover, overexpression of SirT3 inhibits stabilization of HIF-1 alpha protein in hypoxia and attenuates increases in HIF-1 alpha transcriptional activity. Critically, overexpression of SirT3 decreases tumorigenesis in xenografts, even when induction of the sirtuin occurs after tumor initiation. These data suggest that SirT3 acts to suppress the growth of tumors, at least in part through its ability to suppress ROS and HIF-1 alpha. Oncogene (2011) 30, 2986-2996; doi:10.1038/onc.2011.37;published online 28 February 2011	[Guarente, L.] MIT, Paul F Glenn Lab, Dept Biol, Cambridge, MA 02139 USA; [Emerling, B. M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Syst Biol,Div Signal Transduct, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Guarente, L (corresponding author), MIT, Paul F Glenn Lab, Dept Biol, 77 Massachusetts Ave,Bldg 68 Room 280, Cambridge, MA 02139 USA.	leng@mit.edu			NRSA; American Cancer Society; NIH; Paul F Glenn Foundation; NATIONAL INSTITUTE ON AGING [R01AG015339, R01AG011119] Funding Source: NIH RePORTER	NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Paul F Glenn Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We would like to thank Allyson Evans, Eric Williams, and Matt Vander Heiden for helpful comments on the manuscript and data, as well as Marcia Haigis and Lydia Finley for sharing unpublished information. This work is supported by NRSA postdoctoral fellowship to ELB, an American Cancer Society postdoctoral fellowship to BME and grants from the NIH and a gift from the Paul F Glenn Foundation to LG.	Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Bell EL, 2007, MOL CELL BIOL, V27, P5737, DOI 10.1128/MCB.02265-06; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Bellizzi D, 2005, GENOMICS, V85, P258, DOI 10.1016/j.ygeno.2004.11.003; Breyton C, 2000, BBA-BIOENERGETICS, V1459, P467, DOI 10.1016/S0005-2728(00)00185-7; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000486; Cooper HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004986; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06; Horak P, 2010, P NATL ACAD SCI USA, V107, P4675, DOI 10.1073/pnas.0907705107; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Lin SJ, 2003, CURR OPIN CELL BIOL, V15, P241, DOI 10.1016/S0955-0674(03)00006-1; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038; Rose G, 2003, EXP GERONTOL, V38, P1065, DOI 10.1016/S0531-5565(03)00209-2; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Webb JD, 2009, CELL MOL LIFE SCI, V66, P3539, DOI 10.1007/s00018-009-0147-7; Zhang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006348; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	43	341	359	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2986	2996		10.1038/onc.2011.37	http://dx.doi.org/10.1038/onc.2011.37			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21358671	Green Published, hybrid			2022-12-28	WOS:000292245100009
J	Emde, A; Pradeep, CR; Ferraro, DA; Ben-Chetrit, N; Sela, M; Ribba, B; Kam, Z; Yarden, Y				Emde, A.; Pradeep, C-R; Ferraro, D. A.; Ben-Chetrit, N.; Sela, M.; Ribba, B.; Kam, Z.; Yarden, Y.			Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth	ONCOGENE			English	Article						breast cancer; growth factor; trastuzumab; tyrosine kinase; 3D culture	HUMAN-BREAST-CANCER; ANTI-ERBB-2 MONOCLONAL-ANTIBODIES; FACTOR RECEPTOR; IN-VIVO; TYROSINE KINASES; NEU ONCOGENE; ERBB2; CELL; TRASTUZUMAB; PROGRESSION	Monoclonal antibodies (mAbs) to HER2 are currently used to treat breast cancer, but low clinical efficacy, along with primary and acquired resistance to therapy, commonly limit clinical applications. We previously reported that combinations of antibodies directed at non-overlapping epitopes of HER2 are endowed with enhanced antitumor effects, probably due to accelerated receptor degradation. Here, we extend these observations to three-dimensional mammary cell models, and compare the effects of single mAbs with the effects of antibody combinations. Collectively, our in vitro assays and computational image analyses indicate that combining mAbs against different epitopes of HER2 better inhibits invasive growth. Importantly, while growth factors are able to reduce intraluminal apoptosis and induce an invasive phenotype, combinations of mAbs better than single mAbs can reverse the growth factor-induced phenotypes of HER2-overexpressing spheroids. In conclusion, our studies propose that mAb combinations negate the biological effects of growth factors on invasive growth of HER2-overexpressing cells. Hence, combining mAbs offers a therapeutic strategy, potentially able to enhance clinical efficacy of existing antireceptor immunotherapeutics. Oncogene (2011) 30, 1631-1642; doi:10.1038/onc.2010.547; published online 6 December 2010	[Emde, A.; Pradeep, C-R; Ferraro, D. A.; Ben-Chetrit, N.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Sela, M.] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Ribba, B.] Ecole Normale Super Lyon, Project Team NUMED, INRIA Rhone Alpes, F-69364 Lyon, France; [Kam, Z.] Weizmann Inst Sci, Dept Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Ecole Normale Superieure de Lyon (ENS de LYON); Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012		Minerva Foundation; Centre Leon-Berard; Canceropole Lyon Auvegne Rhone-Alpes; Weizmann Institute; National Cancer Institute [CA072981]; European Commission; Cooperation (DIP/DFG); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Estate of John M, Lang and the MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	Minerva Foundation; Centre Leon-Berard; Canceropole Lyon Auvegne Rhone-Alpes; Weizmann Institute; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Commission(European CommissionEuropean Commission Joint Research Centre); Cooperation (DIP/DFG)(German Research Foundation (DFG)); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Estate of John M, Lang and the MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of our group for insightful comments. AE is supported by a post-doctoral fellowship of the Minerva Foundation. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair, and MS is the incumbent of the W Garfield Weston Professorial Chair in Immunolgy. Our work is supported by a collaborative program between Centre Leon-Berard, Canceropole Lyon Auvegne Rhone-Alpes and the Weizmann Institute, as well as by grants from the National Cancer Institute (CA072981), the European Commission, the German-Israeli Project Cooperation (DIP/DFG), the Israel Cancer Research Fund, the Dr Miriam and Sheldon G Adelson Medical Research Foundation, the Kekst Family Institute for Medical Genetics, the Kirk Center for Childhood Cancer and Immunological Disorders, the Women's Health Research Center funded by Bennett-Pritzker Endowment Fund, the Marvelle Koffler Program for Breast Cancer Research, the Estate of John M, Lang and the MD Moross Institute for Cancer Research.	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Ben-Kasus T, 2007, MOL ONCOL, V1, P42, DOI 10.1016/j.molonc.2007.01.003; Ben-Kasus T, 2009, P NATL ACAD SCI USA, V106, P3294, DOI 10.1073/pnas.0812059106; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DREBIN JA, 1988, ONCOGENE, V2, P273; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; KASPRZYK PG, 1992, CANCER RES, V52, P2771; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Lemieux J, 2009, CURR ONCOL, V16, P316; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2004, CANCER RES, V64, P2343, DOI 10.1158/0008-5472.CAN-03-3856; Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Scheuer W, 2009, CANCER RES, V69, P9330, DOI 10.1158/0008-5472.CAN-08-4597; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Seton-Rogers SE, 2004, CELL CYCLE, V3, P597, DOI 10.4161/cc.3.5.886; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spangler JB, 2010, P NATL ACAD SCI USA, V107, P13252, DOI 10.1073/pnas.0913476107; Spiridon CI, 2002, CLIN CANCER RES, V8, P1720; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; WEINER DB, 1990, CANCER RES, V50, P421; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Xia WY, 1997, CLIN CANCER RES, V3, P3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yip YL, 2001, J IMMUNOL, V166, P5271, DOI 10.4049/jimmunol.166.8.5271; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	38	15	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1631	1642		10.1038/onc.2010.547	http://dx.doi.org/10.1038/onc.2010.547			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132012	Green Accepted			2022-12-28	WOS:000289239400002
J	Zhou, J; Yang, Z; Tsuji, T; Gong, J; Xie, J; Chen, C; Li, W; Amar, S; Luo, Z				Zhou, J.; Yang, Z.; Tsuji, T.; Gong, J.; Xie, J.; Chen, C.; Li, W.; Amar, S.; Luo, Z.			LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth	ONCOGENE			English	Article						AMPK; LITAF; TNFSF15; p53; tumor suppressor; tumorigenesis	TNF-ALPHA FACTOR; ACTIVATED PROTEIN-KINASE; PROSTATE-CANCER CELLS; MARIE-TOOTH-DISEASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; SIMPLE MUTATION; CYTOKINE	Lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) a factor (LITAF) is a multiple functional molecule whose sequence is identical to the small integral membrane protein of the lysosome/ late endosome. LITAF was initially identified as a transcription factor that activates transcription of proinflammatory cytokine in macrophages in response to LPS. Mutations of the LITAF gene are associated with a genetic disease, called Charcot-Marie-Tooth syndrome. Recently, we have reported that mRNA levels of LITAF and TNF superfamily member 15 (TNFSF15) are upregulated by 50 adenosine monophosphate (AMP)-activated protein kinase (AMPK). The present study further assesses their biological functions. Thus, we show that 5-aminoimidazole4- carboxamide ribonucleoside (AICAR), a pharmacological activator of AMPK, increases the abundance of LITAF and TNFSF15 in LNCaP and C4-2 prostate cancer cells, which is abrogated by small hairpin RNA (shRNA) or the dominant-negative mutant of AMPK a1 subunit. Our data further demonstrate that AMPK activation upregulates the transcription of LITAF. Intriguingly, silencing LITAF by shRNA enhances proliferation, anchorageindependent growth of these cancer cells and tumor growth in the xenograft model. In addition, our study reveals that LITAF mediates the effect of AMPK by binding to a specific sequence in the promoter region. Furthermore, we show that TNFSF15 remarkably inhibits the growth of prostate cancer cells and bovine aortic endothelial cells in vitro, with a more potent effect toward the latter. In conjuncture, intratumoral injection of TNFSF15 significantly reduces the size of tumors and number of blood vessels and induces changes that are characteristic of tumor cell differentiation. Therefore, our studies for the first time establish the regulatory axis of AMPK-LITAF-TNFSF15 and also suggest that LITAF may function as a tumor suppressor. Oncogene (2011) 30, 1892-1900; doi: 10.1038/onc.2010.575; published online 10 January 2011	[Zhou, J.; Gong, J.; Xie, J.; Li, W.; Luo, Z.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Yang, Z.] Shaanxi Normal Univ, Coll Life Sci, Dept Biochem & Mol Biol, Xian, Peoples R China; [Tsuji, T.; Chen, C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiat Oncol, Boston, MA 02215 USA; [Amar, S.] Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University; Shaanxi Normal University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Luo, Z (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,Evans 645, Boston, MA 02118 USA.	zluo@bu.edu	Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289; Amar, Salomon/0000-0002-0017-5930	NIH [R01 CA118918, R01 DE014079, CA124490]; NATIONAL CANCER INSTITUTE [R01CA124490, R01CA118918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011340] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work is supported by NIH grants (R01 CA118918 to ZL, R01 DE014079 to SA and CA124490 to CC). We thank Dr Zhixiong Xiao (BUMC) for providing p53 shRNA pSuperRetro construct as a generous gift. We are also thankful to Miss Siu Wong for her assistance in animal dissection, to Dr Wen Guo for helping us with confirmatory qPCR analysis and to Dr Mengwei Zang for her advice on statistical analysis.	Bayry J, 2010, NAT REV RHEUMATOL, V6, P67, DOI 10.1038/nrrheum.2009.263; Beauvais K, 2006, NEUROMUSCULAR DISORD, V16, P14, DOI 10.1016/j.nmd.2005.09.008; Bennett CL, 2004, ANN NEUROL, V55, P713, DOI 10.1002/ana.20094; Chang JY, 2010, EXP BIOL MED, V235, P796, DOI 10.1258/ebm.2010.009351; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; Hong YH, 2006, DEV COMP IMMUNOL, V30, P919, DOI 10.1016/j.dci.2005.12.007; Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Latour P, 2006, J PERIPHER NERV SYST, V11, P148, DOI 10.1111/j.1085-9489.2006.00080.x; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI 10.2217/FON.09.174; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Myokai F, 1999, P NATL ACAD SCI USA, V96, P4518, DOI 10.1073/pnas.96.8.4518; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Niemann A, 2006, NEUROMOL MED, V8, P217, DOI 10.1385/NMM:8:1:217; Pan X, 2004, WORLD J GASTROENTERO, V10, P1409; Parr Christian, 2006, Angiogenesis, V9, P73, DOI 10.1007/s10456-006-9033-1; Picornell Y, 2007, INFLAMM BOWEL DIS, V13, P1333, DOI 10.1002/ibd.20223; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sethi G, 2009, ADV EXP MED BIOL, V647, P207, DOI 10.1007/978-0-387-89520-8_15; Stucchi A, 2006, INFLAMM BOWEL DIS, V12, P581, DOI 10.1097/01.MIB.0000225338.14356.d5; Tang XR, 2007, CANCER RES, V67, P1308, DOI 10.1158/0008-5472.CAN-06-1600; Tang XR, 2006, P NATL ACAD SCI USA, V103, P13777, DOI 10.1073/pnas.0605988103; Tang XR, 2005, P NATL ACAD SCI USA, V102, P5132, DOI 10.1073/pnas.0501159102; Tang XR, 2003, P NATL ACAD SCI USA, V100, P4096, DOI 10.1073/pnas.0630562100; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Young HA, 2006, P NATL ACAD SCI USA, V103, P8303, DOI 10.1073/pnas.0602655103; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhai YF, 1999, INT J CANCER, V82, P131, DOI 10.1002/(SICI)1097-0215(19990702)82:1<131::AID-IJC22>3.3.CO;2-F; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhou J, 2009, ONCOGENE, V28, P1993, DOI 10.1038/onc.2009.63	33	54	59	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1892	1900		10.1038/onc.2010.575	http://dx.doi.org/10.1038/onc.2010.575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21217782	Green Accepted			2022-12-28	WOS:000289777700005
J	Durie, D; Lewis, SM; Liwak, U; Kisilewicz, M; Gorospe, M; Holcik, M				Durie, D.; Lewis, S. M.; Liwak, U.; Kisilewicz, M.; Gorospe, M.; Holcik, M.			RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation	ONCOGENE			English	Article						translation; internal initiation; ITAF; HuR; XIAP; cancer	X-LINKED INHIBITOR; RIBOSOME-ENTRY-SITE; TRANS-ACTING FACTOR; MESSENGER-RNA; APOPTOSIS PROTEIN; PROGNOSTIC-FACTOR; HIGH EXPRESSION; UP-REGULATION; ELEMENT; OVEREXPRESSION	Expression of the intrinsic cellular caspase inhibitor XIAP is regulated primarily at the level of protein synthesis. The 50 untranslated region harbours an Internal Ribosome Entry Site (IRES) motif that supports cap-independent translation of XIAP mRNA during conditions of cellular stress. In this study, we show that the RNA-binding protein HuR, which is known to orchestrate an antiapoptotic cellular program, stimulates translation of XIAP mRNA through XIAP IRES. We further show that HuR binds to XIAP IRES in vitro and in vivo, and stimulates recruitment of the XIAP mRNA into polysomes. Importantly, protection from the apoptosis-inducing agent etoposide by overexpression of HuR requires the presence of XIAP, suggesting that HuR-mediated cytoprotection is partially executed through enhanced XIAP translation. Our data suggest that XIAP belongs to the HuR-regulated RNA operon of antiapoptotic genes, which, along with Bcl-2, Mcl-1 and ProT alpha, contributes to the regulation of cell survival. Oncogene (2011) 30, 1460-1469; doi:10.1038/onc.2010.527; published online 22 November 2010	[Durie, D.; Lewis, S. M.; Liwak, U.; Kisilewicz, M.; Holcik, M.] Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada; [Durie, D.; Liwak, U.; Kisilewicz, M.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Holcik, M.] Univ Ottawa, Dept Paediat, Ottawa, ON, Canada; [Gorospe, M.] NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	martin@mgcheo.med.uottawa.ca	Holcik, Martin/E-5372-2011; Lewis, Stephen/E-5533-2010; Holcik, Martin/AAC-6660-2019	Lewis, Stephen/0000-0001-9537-5822; Holcik, Martin/0000-0002-1922-5299	Canadian Institutes of Health Research (CIHR) [MOP 89737]; National Institute on Aging, National Institutes of Health; NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Drs Nehal Thakor and Stephen Baird for critical discussions. We are grateful to Drs P Anderson and R Screaton for the gift of anti-TIA-1/TIAR and anti-GST antibodies, respectively, and to Dr I Gallouzi for the GFP-HuR, GFP-HuR(CP1), GFP-HuR(CP2), AP-HuR-GST, AP-HuR(CP1)-GST and AP-HuR(CP2)-GST overexpression constructs. This work was supported by an operating grant from the Canadian Institutes of Health Research to MH (CIHR; MOP 89737); MG was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. MH is the CHEO Volunteer Association Endowed Scholar.	Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299; Baird SD, 2007, NUCLEIC ACIDS RES, V35, P4664, DOI 10.1093/nar/gkm483; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Coleman J, 2009, RNA BIOL, V6, P84, DOI 10.4161/rna.6.1.7572; Dean E, 2009, J CLIN ONCOL, V27, P1660, DOI 10.1200/JCO.2008.19.5677; Dean EJ, 2007, EXPERT OPIN THER TAR, V11, P1459, DOI 10.1517/14728222.11.11.1459; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; DENKERT C, 2006, MODERN PATHOL, V23, P23; Dormoy-Raclet V, 2007, MOL CELL BIOL, V27, P5365, DOI 10.1128/MCB.00113-07; Dubrez-Daloz L, 2008, CELL CYCLE, V7, P1036, DOI 10.4161/cc.7.8.5783; ERKINHEIMO TL, 2005, GYNECOL ONCOL, V26, P26; Fialcowitz-White EJ, 2007, J BIOL CHEM, V282, P20948, DOI 10.1074/jbc.M701751200; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Graber TE, 2010, CELL DEATH DIFFER, V17, P719, DOI 10.1038/cdd.2009.164; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; Heinonen M, 2007, CLIN CANCER RES, V13, P6959, DOI 10.1158/1078-0432.CCR-07-1432; Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 2005, RNA, V11, P1605, DOI 10.1261/rna.2158605; Holcik M, 2003, ANN NY ACAD SCI, V1010, P249, DOI 10.1196/annals.1299.043; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; Lewis SM, 2007, MOL BIOL CELL, V18, P1302, DOI 10.1091/mbc.E06-06-0515; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Mazroui R, 2008, J CELL BIOL, V180, P113, DOI 10.1083/jcb.200709030; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Rivas-Aravena A, 2009, VIROLOGY, V392, P178, DOI 10.1016/j.virol.2009.06.050; Schimmer AD, 2009, J CLIN ONCOL, V27, P4741, DOI 10.1200/JCO.2009.21.8172; Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179, DOI 10.1038/sj.cdd.4401826; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Tamm I, 2004, CLIN CANCER RES, V10, P3737, DOI 10.1158/1078-0432.CCR-03-0642; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004; Yeh CH, 2008, MOL BIOL CELL, V25, P25; Yoo PS, 2009, ANN SURG ONCOL, V16, P200, DOI 10.1245/s10434-008-0209-3; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Zhang X, 2009, NUCLEIC ACIDS RES, V37, P7623, DOI 10.1093/nar/gkp755	50	64	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	12					1460	1469		10.1038/onc.2010.527	http://dx.doi.org/10.1038/onc.2010.527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102524	Green Accepted			2022-12-28	WOS:000288743800008
J	Smart, CE; Wronski, A; French, JD; Edwards, SL; Asselin-Labat, ML; Waddell, N; Peters, K; Brewster, BL; Brooks, K; Simpson, K; Manning, N; Lakhani, SR; Grimmond, S; Lindeman, GJ; Visvader, JE; Brown, MA				Smart, C. E.; Wronski, A.; French, J. D.; Edwards, S. L.; Asselin-Labat, M-L; Waddell, N.; Peters, K.; Brewster, B. L.; Brooks, K.; Simpson, K.; Manning, N.; Lakhani, S. R.; Grimmond, S.; Lindeman, G. J.; Visvader, J. E.; Brown, M. A.			Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit	ONCOGENE			English	Article						Brca1; mammary gland; mammary epithelial morphogenesis; luminal progenitor; expression profiling; c-kit	EPITHELIAL-CELLS; STEM-CELL; MUTATION CARRIERS; TRANSGENIC MICE; TUMOR-FORMATION; BREAST-TUMORS; CANCER CELLS; EXPRESSION; GENE; RECEPTOR	Disruption of the breast cancer susceptibility gene Brca1 results in defective lobular-alveolar development in the mammary gland and a predisposition to breast tumourigenesis in humans and in mice. Recent evidence suggests that BRCA1 loss in humans is associated with an expansion of the luminal progenitor cell compartment in the normal breast and tumours with a luminal progenitor-like expression profile. To further investigate the role of BRCA1 in the mammary gland, we examined the consequences of Brca1 loss in mouse mammary epithelial cells in vitro and in vivo. Here, we show that Brca1 loss is associated with defective morphogenesis of SCp2 and HC11 mouse mammary epithelial cell lines and that in the MMTV-Cre Brca1(Co/Co) mouse model of Brca1 loss, there is an accumulation of luminal progenitor (CD61(+)CD29(lo)CD24(+)) cells during pregnancy. By day 1 of lactation, there are marked differences in the expression of 1379 genes, with most significantly altered pathways and networks, including lactation, the immune response and cancer. One of the most differentially expressed genes was the luminal progenitor marker, c-kit. Immunohistochemical analysis revealed that the increase in c-kit levels is associated with an increase in c-kit positivity. Interestingly, an inverse association between Brca1 and c-kit expression was also observed during mammary epithelial differentiation, and small interfering RNA-mediated knockdown of Brca1 resulted in a significant increase in c-kit mRNA levels. We found no evidence that c-kit plays a direct role in regulating differentiation of HC11 cells, suggesting that Brca1-mediated induction of c-kit probably contributes to Brca1-associated tumourigenesis via another cellular process, and that c-kit is likely to be a marker rather than a mediator of defective lobular-alveolar development resulting from Brca1 loss. Oncogene (2011) 30, 1597-1607; doi: 10.1038/onc.2010.538; published online 6 December 2010	[Smart, C. E.; Wronski, A.; French, J. D.; Edwards, S. L.; Peters, K.; Brewster, B. L.; Brooks, K.; Brown, M. A.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Smart, C. E.; Lakhani, S. R.] Univ Queensland, Royal Brisbane & Womens Hosp, Clin Res Ctr, Herston, Qld, Australia; [Smart, C. E.; Lakhani, S. R.] Sch Med, Herston, Qld, Australia; [Asselin-Labat, M-L; Lindeman, G. J.; Visvader, J. E.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; [Waddell, N.; Grimmond, S.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; [Simpson, K.; Manning, N.; Brown, M. A.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	University of Queensland; Royal Brisbane & Women's Hospital; University of Queensland; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Queensland; University of Melbourne	Brown, MA (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, Coopers Rd, St Lucia, Qld 4072, Australia.	melissa.brown@uq.edu.au	Grimmond, Sean M/J-5304-2016; Lakhani, Sunil R/I-1970-2018; French, Juliet D/A-4982-2011; Brown, Melissa A/F-1451-2010; Edwards, Stacey/A-4980-2011; Smart, Chanel E/C-9583-2011; Grimmond, Sean/K-3246-2019; French, Juliet/AAV-4435-2020; Waddell, Nicola/H-4929-2015; Brooks, Kelly M/F-8248-2017	Grimmond, Sean M/0000-0002-8102-7998; Lakhani, Sunil R/0000-0003-4067-2760; Grimmond, Sean/0000-0002-8102-7998; French, Juliet/0000-0002-9770-0198; Waddell, Nicola/0000-0002-3950-2476; Brooks, Kelly M/0000-0002-9751-5961; Simpson, Kaylene/0000-0001-9136-1781; Lindeman, Geoffrey/0000-0001-9386-2416; Brown, Melissa/0000-0002-2830-9259; Edwards, Stacey/0000-0001-7428-4139; Manning, Nathan/0000-0002-9914-6311	National Breast Cancer Foundation of Australia; University of Queensland; NBCF; NHMRC	National Breast Cancer Foundation of Australia; University of Queensland(University of Queensland); NBCF; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We are grateful to Bob Simpson for advice on real-time PCR, Kym Kelly-Taylor for animal husbandry, Vani Selvarajan for mouse genotyping and Lynne Reid for cryosectioning. We acknowledge the ARC Special Research Centre for Functional and Applied Genomics at The Institute of Molecular Bioscience, University of Queensland for support with microarray profiling and analysis. This work was supported by a National Breast Cancer Foundation of Australia and The University of Queensland. JF was supported by an NBCF Training fellowship, SE was supported by an NHMRC CJ Martin Fellowship and JV, GL and SG are Research Fellows of the National Health and Medical Research Council of Australia.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Bogorad RL, 2008, P NATL ACAD SCI USA, V105, P14533, DOI 10.1073/pnas.0800685105; Brown MA, 2002, TRANSGENIC RES, V11, P467, DOI 10.1023/A:1020348025139; Clarkson RWE, 2004, BREAST CANCER RES, V6, pR92, DOI 10.1186/bcr754; Cui Y, 2002, J BIOL CHEM, V277, P17830, DOI 10.1074/jbc.M200186200; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Jernstrom H, 1998, BREAST, V7, P320, DOI 10.1016/S0960-9776(98)90074-1; Kijima T, 2002, CANCER RES, V62, P6304; Kubista M, 2002, ONCOGENE, V21, P4747, DOI 10.1038/sj.onc.1205580; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; LaMarca HL, 2008, ENDOCRINOLOGY, V149, P4317, DOI 10.1210/en.2008-0450; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maddison K, 2005, J PATHOL, V205, P181, DOI 10.1002/path.1698; Maia CJB, 2008, MOL CELL BIOCHEM, V314, P113, DOI 10.1007/s11010-008-9771-z; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naylor MJ, 2005, MOL ENDOCRINOL, V19, P1868, DOI 10.1210/me.2004-0254; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Raafat A, 2007, ONCOGENE, V26, P662, DOI 10.1038/sj.onc.1209823; Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shakya R, 2008, P NATL ACAD SCI USA, V105, P7040, DOI 10.1073/pnas.0711032105; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Smalley MJ, 2005, CYTOTHERAPY, V7, P497, DOI 10.1080/14653240500361145; Smart CE, 2008, BREAST CANCER RES TR, V112, P237, DOI 10.1007/s10549-007-9859-2; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stein T, 2004, BREAST CANCER RES, V6, pR75, DOI 10.1186/bcr753; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Triplett AA, 2008, NEOPLASIA, V10, P1325, DOI 10.1593/neo.08524; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Wright MH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-29; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109	55	19	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1597	1607		10.1038/onc.2010.538	http://dx.doi.org/10.1038/onc.2010.538			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21132007	hybrid			2022-12-28	WOS:000288998300010
J	Song, L; Gao, M; Dong, W; Hu, M; Li, J; Shi, X; Hao, Y; Li, Y; Huang, C				Song, L.; Gao, M.; Dong, W.; Hu, M.; Li, J.; Shi, X.; Hao, Y.; Li, Y.; Huang, C.			p85 alpha mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response	ONCOGENE			English	Article						acetylation; p85 alpha; p53; p300; UVB radiation	TUMOR-SUPPRESSOR P53; NF-KAPPA-B; PHOSPHOINOSITIDE 3-KINASE; DNA-DAMAGE; IN-VIVO; POSTTRANSLATIONAL MODIFICATIONS; APOPTOTIC RESPONSE; IKK-BETA; ACTIVATION; BINDING	Inducible acetylation of p53 at lysine residues has a great impact on regulating the transactivation of this protein, which is associated with cell growth arrest and/or apoptosis under various stress conditions. However, the factor(s) for regulating p53 acetylation remains largely unknown. In the current study, we have shown that p85 alpha, the regulatory subunit of phosphatidylinositol-3-kinase, has a critical role in mediating p53 acetylation and promoter-specific transactivation in the ultraviolet B (UVB) response. Depletion of p85 alpha in mouse embryonic fibroblasts significantly impairs UVB-induced apoptosis, as well as p53 transactivation and acetylation at Lys370 (Lys373 of human p53); however, the accumulation, nuclear translocation and phosphorylation of p53 are not affected. Interestingly, p85 alpha binds to p300, promotes the p300-p53 interaction and the subsequent recruitment of the p53/p300 complex to the promoter region of the specific p53 target gene in response to UVB irradiation. Moreover, ablation of p53 acetylation at Lys370 by site-directed mutagenesis dramatically suppresses UVB-induced expression of the specific p53-responsive gene as well as cell apoptosis. Therefore, we conclude that p85 alpha is a novel regulator of p53-mediated response under certain stress conditions, and targeting the p85 alpha-dependent p53 pathway may be promising for cancer therapy. Oncogene (2011) 30, 1360-1371; doi:10.1038/onc.2010.506; published online 8 November 2010	[Song, L.; Gao, M.; Dong, W.; Hu, M.; Hao, Y.; Li, Y.] Beijing Inst Basic Med Sci, Dept Cellular Immunol, Beijing 100850, Peoples R China; [Song, L.; Li, J.; Shi, X.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA	Academy of Military Medical Sciences - China; New York University	Song, L (corresponding author), Beijing Inst Basic Med Sci, Dept Cellular Immunol, 27 Taiping Rd, Beijing 100850, Peoples R China.	lunsong@yahoo.com; chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA112557, CA119028-05S110]; NIH/NIEHS [ES010344, ES012451]; National Natural Science Foundation of China [30871277, 30970594]; Beijing Natural Science Foundation [5092022, 5102035]; National Key Research and Development Programs on Fundamental Sciences (973 Project) [2011CB503803]; NATIONAL CANCER INSTITUTE [R01CA112557, R01CA119028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451, P42ES010344] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); National Key Research and Development Programs on Fundamental Sciences (973 Project)(National Basic Research Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We appreciate the technical help from Dr Dan Liu and the helpful discussion provided by Dr Ailing Li. This project is partially supported by NIH/NCI CA112557, CA119028-05S110, NIH/NIEHS ES010344 and ES012451 (to Dr C Huang); and National Natural Science Foundation of China No. 30871277, 30970594, Beijing Natural Science Foundation 5092022 and 5102035 and the National Key Research and Development Programs on Fundamental Sciences (973 Project) 2011CB503803 (to Dr L Song).	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Brooks CL, 2008, CANCER CELL, V13, P377, DOI 10.1016/j.ccr.2008.04.009; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CAO CLUS, 2008, J CELL MOL MED, V4, P4; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Eischen CM, 2009, CANCER CELL, V15, P161, DOI 10.1016/j.ccr.2009.02.004; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Geering B, 2007, BIOCHEM SOC T, V35, P199, DOI 10.1042/BST0350199; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kitagawa M, 2008, MOL CELL, V29, P217, DOI 10.1016/j.molcel.2007.11.036; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo J, 2005, J CELL BIOL, V170, P455, DOI 10.1083/jcb.200503088; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Reczek EE, 2003, MOL CANCER RES, V1, P1048; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sasaki T, 2007, GENE DEV, V21, P848, DOI 10.1101/gad.1534107; Song L, 2008, EXP CELL RES, V314, P2187, DOI 10.1016/j.yexcr.2008.04.002; Song L, 2007, MOL CELL BIOL, V27, P2713, DOI 10.1128/MCB.00657-06; Song L, 2006, J CELL BIOL, V175, P607, DOI 10.1083/jcb.200602149; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515; Zhu Z, 2009, HEPATOLOGY, V49, P504, DOI 10.1002/hep.22675	52	24	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	11					1360	1371		10.1038/onc.2010.506	http://dx.doi.org/10.1038/onc.2010.506			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057544	Green Accepted			2022-12-28	WOS:000288492100010
J	Frezzetti, D; De Menna, M; Zoppoli, P; Guerra, C; Ferraro, A; Bello, AM; De Luca, P; Calabrese, C; Fusco, A; Ceccarelli, M; Zollo, M; Barbacid, M; Di Lauro, R; De Vita, G				Frezzetti, D.; De Menna, M.; Zoppoli, P.; Guerra, C.; Ferraro, A.; Bello, A. M.; De Luca, P.; Calabrese, C.; Fusco, A.; Ceccarelli, M.; Zollo, M.; Barbacid, M.; Di Lauro, R.; De Vita, G.			Upregulation of miR-21 by Ras in vivo and its role in tumor growth	ONCOGENE			English	Article						microRNA; miR-21; Ras; anaplastic thyroid carcinoma; non-small-cell lung cancer	LUNG-CANCER; MICRORNA GENES; DNA-DAMAGE; CELL-CYCLE; INDUCTION; PROFILES; AP-1; RNA	miR-21 is a microRNA (miRNA) frequently overexpressed in human cancers. Here we show that miR-21 is upregulated both in vitro and in vivo by oncogenic Ras, thus linking this miRNA to one of the most frequently activated oncogenes in human cancers. Ras regulation of miR-21 occurs with a delayed kinetic and requires at least two Ras downstream pathways. A screen of human thyroid cancers and non-small-cell lung cancers for the expression of miR-21 reveals that it is overexpressed mainly in anaplastic thyroid carcinomas, the most aggressive form of thyroid cancer, whereas in lung its overexpression appears to be inversely correlated with tumor progression. We also show that a LNA directed against miR-21 slows down tumor growth in mice. Consistently, a search for mRNAs downregulated by miR-21 shows an enrichment for mRNAs encoding cell cycle checkpoints regulators, suggesting an important role for miR-21 in oncogenic Ras-induced cell proliferation. Oncogene (2011) 30, 275-286; doi:10.1038/onc.2010.416; published online 18 October 2010	[Frezzetti, D.; Fusco, A.; Di Lauro, R.; De Vita, G.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Frezzetti, D.; Zoppoli, P.; De Luca, P.; Ceccarelli, M.] IRGS Biogem Scarl, Ariano Irpino, Italy; [De Menna, M.] European Sch Mol Med, SEMM, Naples, Italy; [De Menna, M.; Ferraro, A.; Bello, A. M.; Zollo, M.] Ctr Ingn Genet & Biotecnol Avanzate, CEINGE, Naples, Italy; [Zoppoli, P.; Ceccarelli, M.] Univ Sannio, Dept Biol & Environm Studies, Benevento, Italy; [Guerra, C.; Barbacid, M.] CNIO, Mol Oncol Program, Madrid, Spain; [Ferraro, A.; Fusco, A.] Naples Oncogenom Ctr, NOGEC, Naples, Italy; [De Luca, P.] Stn Zool Anton Dohrn, Naples, Italy; [Calabrese, C.] Univ Naples 2, Monaldi Hosp, Dept Cardiothorac & Resp Sci, Naples, Italy; [Fusco, A.] CNR, Ist Endocrinol & Oncol Sperimentale, I-80125 Naples, Italy; [Zollo, M.] Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Naples, Italy	University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Sannio; Centro Nacional de Investigaciones Oncologicas (CNIO); Stazione Zoologica Anton Dohrn di Napoli; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	De Vita, G (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	rdilauro@unina.it; gdevita@unina.it	Ceccarelli, Michele/AGP-1739-2022; De Luca, Pasquale/AAL-5673-2021; De Vita, Gabriella/H-4422-2011; Zoppoli, Pietro/J-9954-2018; Guerra, Carmen/K-5852-2014; Ferraro, Angelo/A-4172-2014; Frezzetti, Daniela/AAI-2410-2019; Bello, Anna Maria/AAA-9139-2020; Ferraro, Angelo/H-3193-2019; Di Lauro, Roberto/A-2746-2012	De Luca, Pasquale/0000-0003-4289-6784; De Vita, Gabriella/0000-0002-7302-1174; Zoppoli, Pietro/0000-0002-7860-9655; Ferraro, Angelo/0000-0002-2044-7569; Frezzetti, Daniela/0000-0002-7500-5506; Bello, Anna Maria/0000-0001-6975-3340; Ferraro, Angelo/0000-0002-2044-7569; Di Lauro, Roberto/0000-0001-9493-3036; Fusco, Alfredo/0000-0003-3332-5197; Ceccarelli, Michele/0000-0002-4702-6617; Guerra, Carmen/0000-0002-3891-046X; Calabrese, Cecilia/0000-0003-4293-4461; De Menna, Marta/0000-0002-6306-3485	EU [LSHG-CT-2006-037900]; Associazione Italiana per la Ricerca sul Cancro (AIRC); AIRC, EUFP7 Tumic	EU(European Commission); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC, EUFP7 Tumic(Fondazione AIRC per la ricerca sul cancro)	We thank Pietro Carotenuto (CROM, Centro Ricerche Oncologiche Mercogliano, Italy), Ilaria Pedicelli (Department of Cardio-Thoracic and Respiratory Sciences, Second University of Naples, Monaldi Hospital, Naples, Italy) and Nicolina De Rosa (Department of Pathology, Monaldi Hospital, Naples, Italy) for collection and technical help in the analysis of lung cancer samples. This work was supported by EU-Project-SIROCCO (Grant LSHG-CT-2006-037900), Associazione Italiana per la Ricerca sul Cancro (AIRC) to RDL and AIRC, EUFP7 Tumic to MZ.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741; Martinsson-Ahlzen HS, 2008, MOL CELL BIOL, V28, P5698, DOI 10.1128/MCB.01833-07; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	33	105	118	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					275	286		10.1038/onc.2010.416	http://dx.doi.org/10.1038/onc.2010.416			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20956945				2022-12-28	WOS:000286418800003
J	Zhu, QS; Rosenblatt, K; Huang, KL; Lahat, G; Brobey, R; Bolshakov, S; Nguyen, T; Ding, Z; Belousov, R; Bill, K; Luo, X; Lazar, A; Dicker, A; Mills, GB; Hung, MC; Lev, D				Zhu, Q-S; Rosenblatt, K.; Huang, K-L; Lahat, G.; Brobey, R.; Bolshakov, S.; Nguyen, T.; Ding, Z.; Belousov, R.; Bill, K.; Luo, X.; Lazar, A.; Dicker, A.; Mills, G. B.; Hung, M-C; Lev, D.			Vimentin is a novel AKT1 target mediating motility and invasion	ONCOGENE			English	Article						soft-tissue sarcoma; AKT1; vimentin; phosphorylation; migration/invasion	EPITHELIAL-MESENCHYMAL TRANSITION; INTERMEDIATE FILAMENT PROTEINS; SOFT-TISSUE SARCOMA; CANCER CELLS; UP-REGULATION; HUMAN BREAST; EXPRESSION; KINASE; PHOSPHORYLATION; CARCINOMA	The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies. Oncogene (2011) 30, 457-470; doi: 10.1038/onc.2010.421; published online 20 September 2010	[Lev, D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Zhu, Q-S; Huang, K-L; Lahat, G.; Bolshakov, S.; Nguyen, T.; Belousov, R.; Bill, K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Ding, Z.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Luo, X.] Univ Texas Med Branch, Mass Spectrometry Core Lab, Galveston, TX USA; [Lazar, A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Dicker, A.] Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center; Jefferson University; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lev, D (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, 8515 Fannin,Unit 1104, Houston, TX 77030 USA.	dlev@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Lazar, Alexander J/A-3416-2008	Hung, Mien-Chie/0000-0003-4317-4740; Lazar, Alexander J/0000-0002-6395-4499; Huang, Kai-Lieh/0000-0001-5407-648X; Dicker, Adam/0000-0003-0733-3337	NIH/NHLBI [NO1-HV-28184]; NIH [CA138345]; RTOG; Welch Foundation Endowment [L-AU-0002]; NCI Cancer Center [16672]; NIH/NCI [CA138345]; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA138345] Funding Source: NIH RePORTER	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RTOG; Welch Foundation Endowment; NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Giranda (Abbot Laboratories, Abbott Park, IL) for providing A674563 (A563), Dr Cryns (Division of Endocrinology, Northwestern University, Chicago, IL) for providing human Vim cDNA and Dr Fletcher (Brigham and Women's Hospital, Boston, MA) for the MPNST724 cell line. We thank the UTMB NHLBI Proteomic Center for assistance with mass spectrometry experiments. (The work was supported by the NIH/NHLBI proteomics Initiative NO1-HV-28184 (to KPR).) Vu is thanked for aid in figure preparation and Lo for her assistance with scientific editing. This paper was supported in part by NIH RO1 Grant CA138345 and a RTOG seed grant (to DL). Dr Rosenblatt is a recipient of a Welch Foundation Endowment in Chemistry and Related Science Fellowship award (Grant # L-AU-0002). All experiments conducted at UT-MDACC Core Facilities were further supported by an NCI Cancer Center Support Grant (CA#16672).; This paper was supported by NIH/NCI RO1 Grant CA138345 and an RTOG seed grant (to DL), and by NIH/NHLBI proteomics Initiative grant NO1-HV-28184 (to KPR).	Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Arboleda MJ, 2003, CANCER RES, V63, P196; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; Bodenstine TM, 2008, CANCER MICROENVIRON, V1, P1, DOI 10.1007/s12307-008-0001-8; BROERS JLV, 1989, DIFFERENTIATION, V40, P119, DOI 10.1111/j.1432-0436.1989.tb00821.x; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Eckes B, 1998, J CELL SCI, V111, P1897; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Grille SJ, 2003, CANCER RES, V63, P2172; Gu YM, 2006, FEBS LETT, V580, P305, DOI 10.1016/j.febslet.2005.12.024; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; Kanda S, 2004, J BIOL CHEM, V279, P4007, DOI 10.1074/jbc.M307569200; Kim MA, 2009, HISTOPATHOLOGY, V54, P442, DOI 10.1111/j.1365-2559.2009.03247.x; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Luo ML, 2007, ENDOCRINOLOGY, V148, P4895, DOI 10.1210/en.2007-0049; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036; Menet V, 2001, J NEUROSCI, V21, P6147; Miyazaki T, 2007, AM J PHYSIOL-CELL PH, V293, pC1216, DOI 10.1152/ajpcell.00083.2007; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; NELSON WJ, 1983, MOL CELL BIOL, V3, P1146, DOI 10.1128/MCB.3.6.1146; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Pittenger JT, 2008, BIOCHEMISTRY-US, V47, P10863, DOI 10.1021/bi801137m; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Sumitani S, 2002, ENDOCRINOLOGY, V143, P820, DOI 10.1210/en.143.3.820; Tanno S, 2001, CANCER RES, V61, P589; Tomita Y, 2006, CLIN CANCER RES, V12, P3070, DOI 10.1158/1078-0432.CCR-05-1732; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhu QS, 2008, CANCER RES, V68, P2895, DOI 10.1158/0008-5472.CAN-07-6268	40	164	173	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					457	470		10.1038/onc.2010.421	http://dx.doi.org/10.1038/onc.2010.421			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856200	Green Accepted, Green Submitted			2022-12-28	WOS:000286621600008
J	Fu, J; Yan, P; Li, S; Qu, Z; Xiao, G				Fu, J.; Yan, P.; Li, S.; Qu, Z.; Xiao, G.			Molecular determinants of PDLIM2 in suppressing HTLV-I Tax-mediated tumorigenesis	ONCOGENE			English	Article						HTLV-I; Tax; PDLIM2; protein shuttling; protein degradation; tumorigenesis	T-CELL LEUKEMIA; VIRUS TYPE-I; NF-KAPPA-B; DOMAIN-CONTAINING PROTEIN-2; 1ST HUMAN RETROVIRUS; TRANSGENIC MICE; DNA METHYLATION; TYPE-1; GENE; TRANSFORMATION	Human T-cell leukemia virus type I (HTLV-I) encodes a Tax oncoprotein that has crucial roles in both virus replication and cell transformation. Our recent studies suggest that the counterbalance between HTLV-I/Tax and PDZ-LIM domain-containing protein PDLIM2 may determine the outcome of HTLV-I infection. Although HTLV-I represses PDLIM2 epigenetically and specifically in transformed cells, PDLIM2 shuttles Tax into the nuclear matrix for ubiquitination-mediated proteasomal degradation, thereby suppressing the transforming ability of HTLV-I. Here, we have further shown that PDLIM2 binds to Tax directly, which was mediated by a putative a-helix motif of PDLIM2 at amino acids 236-254. Consistently, selective disruption of this short-helix crippled PDLIM2 in shutting Tax to the nuclear matrix for ubiquitination-mediated degradation, therefore, PDLIM2 lost the ability in tumor suppression. Although the C-terminal LIM domain of PDLIM2 was not required for Tax binding, it was important for PDLIM2 to interact with the nuclear matrix. Accordingly, the LIM domain was essential for PDLIM2-mediated Tax repression. On the contrary, the N-terminal PDZ domain of PDLIM2 was dispensable for all these events, although the PDZ domain was involved in PDLIM2 binding to cytoskeleton. These studies dissect functional sequences within PDLIM2 and their distinct roles in Tax regulation. Oncogene (2010) 29, 6499-6507; doi:10.1038/onc.2010.374; published online 13 September 2010	[Xiao, G.] Univ Pittsburgh, Inst Canc, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,Sch Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xiao, G (corresponding author), Univ Pittsburgh, Inst Canc, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,Sch Med, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	xiaog2@upmc.edu	fu, jing/G-6084-2012; Yan, Pengrong/H-1150-2012; Fu, Jing/C-7921-2016	Fu, Jing/0000-0002-3894-722X; Yan, Pengrong/0000-0003-0021-6461	NIH/NCI [R01 CA116616]; ACS [RSG-06-066-01-MGO]; NATIONAL CANCER INSTITUTE [R01CA116616] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank N Raab-Traub for Rat-1 cells, OJ Semmes for Tax-GFP mutants, and NIH AIDS Research & Reference Reagent Program for various reagents. This study was supported by NIH/NCI Grant R01 CA116616 and ACS Grant RSG-06-066-01-MGO to G Xiao.	AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Fryrear KA, 2009, J VIROL, V83, P5339, DOI 10.1128/JVI.00232-09; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Kwon H, 2005, J BIOL CHEM, V280, P35713, DOI 10.1074/jbc.M504848200; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OKA T, 1992, J VIROL, V66, P6686, DOI 10.1128/JVI.66.11.6686-6694.1992; PEEBLES RS, 1995, ONCOGENE, V10, P1045; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Qing GL, 2005, J BIOL CHEM, V280, P18, DOI 10.1074/jbc.M406619200; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; Radivojac P, 2007, BIOPHYS J, V92, P1439, DOI 10.1529/biophysj.106.094045; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Torrado M, 2004, INVEST OPHTH VIS SCI, V45, P3955, DOI 10.1167/iovs.04-0721; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005; YAMAOKA S, 1992, ONCOGENE, V7, P43; Yan PR, 2009, NEOPLASIA, V11, P1036, DOI 10.1593/neo.09752; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981	35	29	29	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6499	6507		10.1038/onc.2010.374	http://dx.doi.org/10.1038/onc.2010.374			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20838382	Green Accepted			2022-12-28	WOS:000285138900009
J	Al-Ejeh, F; Kumar, R; Wiegmans, A; Lakhani, SR; Brown, MP; Khanna, KK				Al-Ejeh, F.; Kumar, R.; Wiegmans, A.; Lakhani, S. R.; Brown, M. P.; Khanna, K. K.			Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes	ONCOGENE			English	Review						DNA-damage response; DNA repair; cell cycle checkpoints; cell death; mitotic catastrophe; cellular senescence	DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE-1 INHIBITOR; INDUCED MITOTIC CATASTROPHE; ADP-RIBOSE POLYMERASE; CELL-DEATH PATHWAYS; S-PHASE; HOMOLOGOUS RECOMBINATION; CHECKPOINT KINASE-1; TUMOR-CELLS	The DNA-damage response (DDR) pathways consist of interconnected components that respond to DNA damage to allow repair and promote cell survival. The DNA repair pathways and downstream cellular responses have diverged in cancer cells compared with normal cells because of genetic alterations that underlie drug resistance, disabled repair and resistance to apoptosis. Consequently, abrogating DDR pathways represents an important mechanism for enhancing the therapeutic index of DNA-damaging anticancer agents. In this review, we discuss the DDR pathways that determine antitumor effects of DNA-damaging agents with a specific focus on treatment outcomes in tumors carrying a defective p53 pathway. Finely tuned survival and death pathways govern the cellular responses downstream of the cytotoxic insults inherent in anticancer treatment. The significance and relative contributions of cellular responses including apoptosis, mitotic catastrophe and senescence are discussed in relation to the web of molecular interactions that affect such outcomes. We propose that promising combinations of DNA-damaging anticancer treatments with DDR-pathway inhibition would be further enhanced by activating downstream apoptotic pathways. The proposed rationale ensures that actual cell death is the preferred outcome of cancer treatment instead of other responses, including reversible cell cycle arrest, autophagy or senescence. Finally, to better measure the contribution of different cellular responses to anticancer treatments, multiplex in vivo assessments of therapy-induced response pathways such as cell death, senescence and mitotic catastrophe is desirable rather than the current reliance on the measurement of a single response pathway such as apoptosis. Oncogene (2010) 29, 6085-6098; doi:10.1038/onc.2010.407; published online 6 September 2010	[Al-Ejeh, F.; Wiegmans, A.; Khanna, K. K.] Queensland Inst Med Res, Signal Transduct Lab, Brisbane, Qld 4006, Australia; [Kumar, R.] Univ Adelaide, Breast Canc Genet Grp, Discipline Med, Adelaide, SA, Australia; [Kumar, R.] SA Pathol, Hanson Inst, Adelaide, SA, Australia; [Lakhani, S. R.] UQCCR, Royal Brisbane & Womens Hosp, Sch Med & Pathol Queensland, Brisbane, Qld, Australia; [Brown, M. P.] Royal Adelaide Hosp Canc Ctr, Canc Clin Trials Unit, Adelaide, SA, Australia; [Brown, M. P.] Univ Adelaide, Sch Med, Adelaide, SA, Australia	QIMR Berghofer Medical Research Institute; University of Adelaide; Hanson Institute; SA Pathology; Royal Brisbane & Women's Hospital; University of Queensland; Royal Adelaide Hospital; University of Adelaide	Al-Ejeh, F (corresponding author), Queensland Inst Med Res, Signal Transduct Lab, 300 Herston Rd, Brisbane, Qld 4006, Australia.	Fares.Al-Ejeh@qimr.edu.au	Al-Ejeh, Fares/M-7032-2016; Kumar, Raman/AHE-0538-2022; Lakhani, Sunil R/I-1970-2018; Wiegmans, Adrian/K-1609-2015; Khanna, Kum Kum/I-1747-2013	Al-Ejeh, Fares/0000-0002-1553-0077; Kumar, Raman/0000-0001-7976-8386; Lakhani, Sunil R/0000-0003-4067-2760; Wiegmans, Adrian/0000-0003-4059-5988; 	Cancer Council NSW [IG 09-04]; Cure Cancer Foundation Australia [ID 631924]; Cancer Council SA [ID 631923]; National Health & Medical Research Council [ID 442903]; Australian Research Council [ID DP0880372]	Cancer Council NSW(Cancer Council New South Wales); Cure Cancer Foundation Australia; Cancer Council SA(Cancer Council South Australia); National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)	This work was supported by the Cancer Council NSW (IG 09-04 to FA); The Cure Cancer Foundation Australia (ID 631924 to FA); the Cancer Council SA (ID 631923 to FA); National Health & Medical Research Council Program Grant (ID 442903 to SRL and KKK); and Australian Research Council Grant (ID DP0880372 to KKK)	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Al-Ejeh F, 2007, CLIN CANCER RES, V13, p5509S, DOI 10.1158/1078-0432.CCR-07-0922; ALEJEH F, 2009, PLOS ONE, V4, pNIL12; Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Audebert M, 2008, BIOCHEM BIOPH RES CO, V369, P982, DOI 10.1016/j.bbrc.2007.11.132; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Barlow C, 1998, DEVELOPMENT, V125, P4007; Bentle MS, 2006, J MOL HISTOL, V37, P203, DOI 10.1007/s10735-006-9043-8; Bhattathiri NV, 1998, RADIOTHER ONCOL, V49, P61, DOI 10.1016/S0167-8140(98)00077-2; Blasina A, 2008, MOL CANCER THER, V7, P2394, DOI 10.1158/1535-7163.MCT-07-2391; Boulton SJ, 2010, NATURE, V465, P301, DOI 10.1038/465301a; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; BREDESEN DE, 2008, APOPTOSIS CELLULAR O, P73; Brown EJ, 2000, GENE DEV, V14, P397; Brown JM, 1999, CANCER RES, V59, P1391; Brown JM, 2001, DRUG RESIST UPDATE, V4, P135, DOI 10.1054/drup.2001.0193; Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Calabrese CR, 2003, CLIN CANCER RES, V9, P2711; CAMPISI J, 2008, APOPTOSIS CELLULAR O, P175; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Cohen A, 2007, TECHNOL CANCER RES T, V6, P221, DOI 10.1177/153303460700600310; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Cowell IG, 2005, BIOCHEM PHARMACOL, V71, P13, DOI 10.1016/j.bcp.2005.09.029; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Curtin NJ, 2004, CLIN CANCER RES, V10, P881, DOI 10.1158/1078-0432.CCR-1144-3; de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; DIGIUSEPPE JA, 1995, AM J PATHOL, V147, P884; Duffy MJ, 2007, CANCER LETT, V249, P49, DOI 10.1016/j.canlet.2006.12.020; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; FALKVOLL KH, 1990, STRAHLENTHER ONKOL, V166, P487; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gallmeier E, 2005, CANCER BIOL THER, V4, P703, DOI 10.4161/cbt.4.7.1909; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldsmith KC, 2006, ONCOGENE, V25, P4525, DOI 10.1038/sj.onc.1209489; Griffin RJ, 2005, J MED CHEM, V48, P569, DOI 10.1021/jm049526a; Gudiksen M, 2008, NAT REV DRUG DISCOV, V7, P563, DOI 10.1038/nrd2594; Haince JF, 2005, TRENDS MOL MED, V11, P456, DOI 10.1016/j.molmed.2005.08.003; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardcastle IR, 2005, J MED CHEM, V48, P7829, DOI 10.1021/jm050444b; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Helt CE, 2005, CELL CYCLE, V4, P529, DOI 10.4161/cc.4.4.1598; Hong YL, 2004, P NATL ACAD SCI USA, V101, P14443, DOI 10.1073/pnas.0401346101; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Iliakis G, 2009, RADIOTHER ONCOL, V92, P310, DOI 10.1016/j.radonc.2009.06.024; Ismail IH, 2004, ONCOGENE, V23, P873, DOI 10.1038/sj.onc.1207303; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kartachova M, 2007, J CLIN ONCOL, V25, P2534, DOI 10.1200/JCO.2006.10.1337; Kashishian A, 2003, MOL CANCER THER, V2, P1257; Kass EM, 2010, CANCER CELL, V17, P423, DOI 10.1016/j.ccr.2010.04.021; Kelley MR, 2008, ANTI-CANCER AGENT ME, V8, P417, DOI 10.2174/187152008784220294; Kennedy RD, 2006, J CLIN ONCOL, V24, P3799, DOI 10.1200/JCO.2005.05.4171; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kilic M., 2008, APOPTOSIS CELLULAR O, P273, DOI [10.3109/9781420020502-17, DOI 10.3109/9781420020502-17]; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Lieberman HB, 2008, CURR MED CHEM, V15, P360, DOI 10.2174/092986708783497328; Liu L, 2007, FASEB J, V21, pA1301; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lock RB, 1996, CANCER RES, V56, P4006; LOCKSHIN RA, 2008, APOPTOSIS CELLULAR O, P55; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Lord CJ, 2006, CLIN CANCER RES, V12, P4463, DOI 10.1158/1078-0432.CCR-06-1269; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Martin RW, 2007, CANCER RES, V67, P9658, DOI 10.1158/0008-5472.CAN-07-0290; Matsuura K, 2008, J BIOL CHEM, V283, P25485, DOI 10.1074/jbc.M803111200; Matthews DJ, 2007, CELL CYCLE, V6, P104, DOI 10.4161/cc.6.1.3699; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; Mitchell J, 2009, INT J RADIAT ONCOL, V75, P1520, DOI 10.1016/j.ijrobp.2009.07.1722; Morgan MA, 2005, CANCER RES, V65, P6835, DOI 10.1158/0008-5472.CAN-04-2246; Myer DL, 2005, ONCOGENE, V24, P299, DOI 10.1038/sj.onc.1208278; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Noel G, 2006, MOL CANCER THER, V5, P564, DOI 10.1158/1535-7163.MCT-05-0418; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; O'Shaughnessy J, 2009, J CLIN ONCOL, V27; Okita N, 2007, BIOL PHARM BULL, V30, P359, DOI 10.1248/bpb.30.359; Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277; Parsels LA, 2009, MOL CANCER THER, V8, P45, DOI 10.1158/1535-7163.MCT-08-0662; Plummer ER, 2007, CLIN CANCER RES, V13, P6252, DOI 10.1158/1078-0432.CCR-07-0617; Plummer ER, 2006, CURR OPIN PHARMACOL, V6, P364, DOI 10.1016/j.coph.2006.02.004; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Portugal J, 2009, TUMORI J, V95, P409; Powell SN, 2009, DNA REPAIR, V8, P1153, DOI 10.1016/j.dnarep.2009.04.011; Rajaraman R, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-25; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Richard DJ, 2009, DNA DAMAGE RESPONSE: IMPLICATIONS ON CANCER FORMATION AND TREATMENT, P349, DOI 10.1007/978-90-481-2561-6_16; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Robert I, 2009, J EXP MED, V206, P1047, DOI 10.1084/jem.20082468; Rodriguez R, 2008, CELL DEATH DIFFER, V15, P889, DOI 10.1038/cdd.2008.4; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roninson IB, 2002, DRUG RESIST UPDATE, V5, P204, DOI 10.1016/S1368764602001103; RONINSON IB, 2008, APOPTOSIS CELLULAR O, P223; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shang ZF, 2010, CANCER RES, V70, P3657, DOI 10.1158/0008-5472.CAN-09-3362; Shinohara ET, 2005, CANCER RES, V65, P4987, DOI 10.1158/0008-5472.CAN-04-4250; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Singh R, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-4; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; STREFFER C, 1986, RADIOTHER ONCOL, V5, P303, DOI 10.1016/S0167-8140(86)80179-7; Sturgeon CM, 2006, MOL CANCER THER, V5, P885, DOI 10.1158/1535-7163.MCT-05-0358; Tao Zhi-Fu, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P377, DOI 10.2174/187152006777698132; Taylor BF, 2006, J PHARMACOL EXP THER, V318, P142, DOI 10.1124/jpet.106.103077; te Poele RH, 2002, CANCER RES, V62, P1876; Terzoudi GI, 2008, INT J ONCOL, V33, P871, DOI 10.3892/ijo_00000075; Thierry B, 2009, ADV MATER, V21, P541, DOI 10.1002/adma.200800998; Thornton TM, 2009, INT J BIOL SCI, V5, P44, DOI 10.7150/ijbs.5.44; Torres K, 1998, CANCER RES, V58, P3620; TOUNEKTI O, 1993, CANCER RES, V53, P5462; Tse AN, 2007, CLIN CANCER RES, V13, P591, DOI 10.1158/1078-0432.CCR-06-1424; Tung CH, 2004, CANCER RES, V64, P1579, DOI 10.1158/0008-5472.CAN-03-3226; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; WADDELL N, 2009, BREAST CANC RES TREA; Walensky LD, 2006, CELL DEATH DIFFER, V13, P1339, DOI 10.1038/sj.cdd.4401992; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Wang YM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-8; Widel M, 1999, BRIT J CANCER, V80, P1599, DOI 10.1038/sj.bjc.6690569; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Willmore E, 2008, CLIN CANCER RES, V14, P3984, DOI 10.1158/1078-0432.CCR-07-5158; Wu W, 2008, DNA REPAIR, V7, P329, DOI 10.1016/j.dnarep.2007.11.008; Yashige H, 1999, ACTA HAEMATOL-BASEL, V101, P32, DOI 10.1159/000040918; Zhang C, 2009, CLIN CANCER RES, V15, P4630, DOI 10.1158/1078-0432.CCR-08-3272; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987; ZOLZER F, 1995, RADIOTHER ONCOL, V36, P128, DOI 10.1016/0167-8140(95)01601-C	172	103	110	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6085	6098		10.1038/onc.2010.407	http://dx.doi.org/10.1038/onc.2010.407			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20818418				2022-12-28	WOS:000284356500001
J	Poschl, J; Lorenz, A; Hartmann, W; von Bueren, AO; Kool, M; Li, S; Peraud, A; Tonn, JC; Herms, J; Xiang, M; Rutkowski, S; Kretzschmar, HA; Schuller, U				Poeschl, J.; Lorenz, A.; Hartmann, W.; von Bueren, A. O.; Kool, M.; Li, S.; Peraud, A.; Tonn, J-C; Herms, J.; Xiang, M.; Rutkowski, S.; Kretzschmar, H. A.; Schueller, U.			Expression of BARHL1 in medulloblastoma is associated with prolonged survival in mice and humans	ONCOGENE			English	Article						cerebellum; medulloblastoma; Barhl1; survival; Sonic hedgehog; tumor	CENTRAL-NERVOUS-SYSTEM; HEDGEHOG PATHWAY; GENE-EXPRESSION; HOMEOBOX GENE; MOUSE MODEL; CELLS; CEREBELLUM; SUBTYPES; GROWTH	Medulloblastoma is the most common malignant brain tumor in childhood, and development of targeted therapies is highly desired. Although the molecular mechanisms of malignant transformation are not fully understood, it is known that medulloblastomas may arise from cerebellar granule neuron precursors. The homeodomain transcription factor Barhl1 is known to regulate migration and survival of granule cell precursors, but its functional role in medulloblastoma is unknown. We show here that the expression of BARHL1 is significantly upregulated during human cerebellar development and in human medulloblastoma samples as compared with the normal adult cerebellum. We also detected high levels of Barhl1 expression in medulloblastomas of Math1-cre:SmoM2 mice, a mouse model for Sonic hedgehog-associated medulloblastomas that we developed previously. To investigate Barhl1 function in vivo during tumor development, we generated Barhl1(-/-) Math1-cre: SmoM2 mice. Interestingly, tumors that developed in these mice displayed increased mitotic activity and decreased neuronal differentiation. Moreover, survival of these mice was significantly decreased. Similarly, low expression of BARHL1 in human medulloblastoma cases was associated with a less favorable prognosis for patients. These results suggest that the expression of Barhl1 decelerates tumor growth both in human and in murine medulloblastomas and should be further investigated with respect to potential implications for individualized therapeutic strategies. Oncogene (2011) 30, 4721-4730; doi:10.1038/onc.2011.173; published online 23 May 2011	[Poeschl, J.; Lorenz, A.; Herms, J.; Kretzschmar, H. A.; Schueller, U.] Univ Munich, Ctr Neuropathol, D-81377 Munich, Germany; [Hartmann, W.] Univ Bonn, Med Ctr, Dept Pathol, Bonn, Germany; [von Bueren, A. O.; Rutkowski, S.] Univ Med Ctr, Dept Pediat Hematol & Oncol, Hamburg, Germany; [Kool, M.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; [Li, S.; Xiang, M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; [Li, S.; Xiang, M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08854 USA; [Peraud, A.; Tonn, J-C] Univ Munich, Dept Neurosurg, D-81377 Munich, Germany	University of Munich; University of Bonn; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Amsterdam; Academic Medical Center Amsterdam; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Munich	Schuller, U (corresponding author), Univ Munich, Ctr Neuropathol, Feodor Lynen Str 23, D-81377 Munich, Germany.	ulrich.schueller@lmu.de	von Bueren, Andre/AAF-2065-2020; Kool, Marcel/H-2541-2013; Hartmann, Wolfgang/G-1893-2017; Tonn, Joerg/AAK-8509-2021; Herms, Jochen/D-3518-2011	Hartmann, Wolfgang/0000-0002-7609-5021; von Bueren, Andre/0000-0003-4197-6264; Schuller, Ulrich/0000-0002-8731-1121; Neumann, Julia E./0000-0002-1162-8771	Wilhelm-Sander-Stiftung; Friedrich-Baur-Stiftung; German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung); Fordergemeinschaft Kinderkrebszentrum Hamburg e. V.; NATIONAL CANCER INSTITUTE [P30CA072720] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012020, R01EY015777] Funding Source: NIH RePORTER	Wilhelm-Sander-Stiftung; Friedrich-Baur-Stiftung; German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung); Fordergemeinschaft Kinderkrebszentrum Hamburg e. V.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We are indebted to Michael Schmidt, Veronika Kaltenbrunn, Dagmar Metzger, Philipp Neumann and Silvia Occhionero for excellent technical support, to Dr Mehdi Shakarami and Dr Stefanie Ohlemeyer for animal husbandry. We acknowledge Dr Rosalind Segal for providing Zic antibodies. This work was supported by grants from the Wilhelm-Sander-Stiftung and the Friedrich-Baur-Stiftung (all to US). US is a member of the Max-Eder-junior-research-program of the German Cancer Aid. The HIT-trial-office at the University Medical Center Hamburg-Eppendorf is supported by the German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung) and by the Fordergemeinschaft Kinderkrebszentrum Hamburg e. V.	Bulfone A, 2000, HUM MOL GENET, V9, P1443, DOI 10.1093/hmg/9.9.1443; Chellappa R, 2008, MOL CELL BIOL, V28, P1905, DOI 10.1128/MCB.01454-07; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; Eberhart CG, 2001, J NEUROPATH EXP NEUR, V60, P462, DOI 10.1093/jnen/60.5.462; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Li SG, 2004, J NEUROSCI, V24, P3104, DOI 10.1523/JNEUROSCI.4444-03.2004; Li SG, 2002, DEVELOPMENT, V129, P3523; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Millen KJ, 1995, DEVELOPMENT, V121, P3935; Mo ZQ, 2004, DEVELOPMENT, V131, P1607, DOI 10.1242/dev.01071; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; Sutter R, 2010, ONCOGENE, V29, P1845, DOI 10.1038/onc.2009.472; The WHO, 2020, CLASSIFICATION TUMOU; Weyer A, 2003, J NEUROSCI RES, V73, P400, DOI 10.1002/jnr.10655; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Yokota N, 1996, CANCER RES, V56, P377	27	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	47					4721	4730		10.1038/onc.2011.173	http://dx.doi.org/10.1038/onc.2011.173			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602885	Green Accepted			2022-12-28	WOS:000298033700004
J	Musumeci, M; Coppola, V; Addario, A; Patrizii, M; Maugeri-Sacca, M; Memeo, L; Colarossi, C; Francescangeli, F; Biffoni, M; Collura, D; Giacobbe, A; D'Urso, L; Falchi, M; Venneri, MA; Muto, G; De Maria, R; Bonci, D				Musumeci, M.; Coppola, V.; Addario, A.; Patrizii, M.; Maugeri-Sacca, M.; Memeo, L.; Colarossi, C.; Francescangeli, F.; Biffoni, M.; Collura, D.; Giacobbe, A.; D'Urso, L.; Falchi, M.; Venneri, M. A.; Muto, G.; De Maria, R.; Bonci, D.			Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer	ONCOGENE			English	Article						miRNA; microenvironment; cancer progression	FIBROBLAST-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-LINES; STROMA INTERACTIONS; MICRORNA TARGETS; MULTIPLE-MYELOMA; REACTIVE STROMA; FACTOR-2 FGF-2; FACTOR BFGF	The interaction between cancer cells and microenvironment has a critical role in tumor development and progression. Although microRNAs regulate all the major biological mechanisms, their influence on tumor microenvironment is largely unexplored. Here, we investigate the role of microRNAs in the tumor-supportive capacity of stromal cells. We demonstrated that miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed. Such downregulation of miR-15 and miR-16 in cancer-associated fibroblasts (CAFs) promoted tumor growth and progression through the reduced post-transcriptional repression of Fgf-2 and its receptor Fgfr1, which act on both stromal and tumor cells to enhance cancer cell survival, proliferation and migration. Moreover, reconstitution of miR-15 and miR-16 impaired considerably the tumor-supportive capability of stromal cells in vitro and in vivo. Our data suggest a molecular circuitry in which miR-15 and miR-16 and their correlated targets cooperate to promote tumor expansion and invasiveness through the concurrent activity on stromal and cancer cells, thus providing further support to the development of therapies aimed at reconstituting miR-15 and miR-16 in advanced prostate cancer. Oncogene (2011) 30, 4231-4242; doi: 10.1038/onc.2011.140; published online 2 May 2011	[Musumeci, M.; Coppola, V.; Addario, A.; Patrizii, M.; Maugeri-Sacca, M.; Francescangeli, F.; Biffoni, M.; Venneri, M. A.; De Maria, R.; Bonci, D.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Memeo, L.; Colarossi, C.; De Maria, R.] Mediterranean Inst Oncol, Dept Expt Oncol, Catania, Italy; [Collura, D.; Giacobbe, A.; D'Urso, L.; Muto, G.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy; [Falchi, M.] Ist Super Sanita, AIDS Natl Ctr, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Mediterranean Institute of Oncology; Istituto Superiore di Sanita (ISS)	De Maria, R (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	ruggero.demaria@iss.it; desiree.bonci@iss.it	Bonci, Desiree/K-6488-2016; Coppola, Valeria/K-5120-2016; Addario, Antonio/AAC-4707-2022; Biffoni, Mauro/J-8318-2016; Francescangeli, Federica/K-6500-2016; Giacobbe, alessandro/AAC-6802-2022; De Maria, Ruggero/S-6385-2019; Maugeri-Saccà, Marcello/K-2350-2014	Bonci, Desiree/0000-0002-2472-5140; Coppola, Valeria/0000-0002-5745-2572; Addario, Antonio/0000-0001-8527-8738; Biffoni, Mauro/0000-0002-1304-9060; Francescangeli, Federica/0000-0002-1086-5265; De Maria, Ruggero/0000-0003-2255-0583; Maugeri-Saccà, Marcello/0000-0003-2287-9581; Memeo, Lorenzo/0000-0003-4251-7203; Falchi, Mario/0000-0002-8290-5406; Colarossi, Cristina/0000-0001-5395-8608; collura, devis/0000-0002-8964-5248; Musumeci, Maria/0000-0001-6680-8158; Muto, Giovanni/0000-0003-3593-6450; VENNERI, MARY ANNA/0000-0002-0687-8135	Italian Health Ministry; Italian Association for Cancer Research (AIRC)	Italian Health Ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank Giuseppe Loreto and Maria Rita Pulvirenti for technical assistance. This work was supported by the Italian Health Ministry with 'Under forty researchers 2007' and Italy-USA programs and by the Italian Association for Cancer Research (AIRC).	Acevedo VD, 2009, CELL CYCLE, V8, P580, DOI 10.4161/cc.8.4.7657; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; CHUNG LWK, 1989, INT J CANCER, V43, P1179, DOI 10.1002/ijc.2910430636; CHUNG LWK, 1983, PROSTATE, V4, P503, DOI 10.1002/pros.2990040509; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cronauer MV, 1997, PROSTATE, V31, P223; CUNHA GR, 1983, RECENT PROG HORM RES, V39, P559; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Efstathiou E, 2010, CLIN CANCER RES, V16, P1100, DOI 10.1158/1078-0432.CCR-09-1215; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hayward SW, 2001, CANCER RES, V61, P8135; He QM, 2003, J BIOL CHEM, V278, P21831, DOI 10.1074/jbc.M300880200; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Josson S, 2010, SEMIN CELL DEV BIOL, V21, P26, DOI 10.1016/j.semcdb.2009.11.016; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kaminski A, 2006, INT J MOL MED, V18, P941; Karaa ZS, 2009, RNA, V15, P249, DOI 10.1261/rna.1301109; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; NAKAMOTO T, 1992, CANCER RES, V52, P571; Navarro A, 2011, J SURG ONCOL, V103, P411, DOI 10.1002/jso.21847; Polnaszek N, 2003, CANCER RES, V63, P5754; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Risbridger GP, 2008, ENDOCRINOLOGY, V149, P4303, DOI 10.1210/en.2008-0465; Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408; Sahni A, 2008, J THROMB HAEMOST, V6, P176; Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x; Shin VY, 2011, CARCINOGENESIS, V32, P240, DOI 10.1093/carcin/bgq240; Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Wernert Nicolas, 2007, V382, P223, DOI 10.1007/978-1-59745-304-2_14; Winter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yang F, 2008, ONCOGENE, V27, P450, DOI 10.1038/sj.onc.1210663; Zhang YL, 2001, J PHARMACOL EXP THER, V299, P426	54	187	200	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	41					4231	4242		10.1038/onc.2011.140	http://dx.doi.org/10.1038/onc.2011.140			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21532615				2022-12-28	WOS:000296356300002
J	Rexer, BN; Ham, AJL; Rinehart, C; Hill, S; Granja-Ingram, ND; Gonzalez-Angulo, AM; Mills, GB; Dave, B; Chang, JC; Liebler, DC; Arteaga, CL				Rexer, B. N.; Ham, A-J L.; Rinehart, C.; Hill, S.; Granja-Ingram, N. de Matos; Gonzalez-Angulo, A. M.; Mills, G. B.; Dave, B.; Chang, J. C.; Liebler, D. C.; Arteaga, C. L.			Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition	ONCOGENE			English	Article						breast cancer; HER2; lapatinib; Src kinases; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; TRASTUZUMAB RESISTANCE; LAPATINIB GW572016; CYCLIN D1; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; DASATINIB; ERBB2	Despite the initial effectiveness of the tyrosine kinase inhibitor lapatinib against HER2 gene-amplified breast cancers, most patients eventually relapse after treatment, implying that tumors acquire mechanisms of drug resistance. To discover these mechanisms, we generated six lapatinib-resistant HER2-overexpressing human breast cancer cell lines. In cells that grew in the presence of lapatinib, HER2 autophosphorylation was undetectable, whereas active phosphoinositide-3 kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK) were maintained. To identify networks maintaining these signaling pathways, we profiled the tyrosine phosphoproteome of sensitive and resistant cells using an immunoaffinity-enriched mass spectrometry method. We found increased phosphorylation of Src family kinases (SFKs) and putative Src substrates in several resistant cell lines. Treatment of these resistant cells with Src kinase inhibitors partially blocked PI3K-Akt signaling and restored lapatinib sensitivity. Further, SFK mRNA expression was upregulated in primary HER2+ tumors treated with lapatinib. Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice. These data suggest that increased Src kinase activity is a mechanism of lapatinib resistance and support the combination of HER2 antagonists with Src inhibitors early in the treatment of HER2+ breast cancers in order to prevent or overcome resistance to HER2 inhibitors. Oncogene (2011) 30, 4163-4174; doi:10.1038/onc.2011.130; published online 18 April 2011	[Rexer, B. N.; Rinehart, C.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Ham, A-J L.; Hill, S.; Liebler, D. C.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; [Ham, A-J L.; Liebler, D. C.] Vanderbilt Univ, Sch Med, Ayers Inst Precancer Detect & Diag, Nashville, TN 37212 USA; [Granja-Ingram, N. de Matos] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA; [Gonzalez-Angulo, A. M.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Gonzalez-Angulo, A. M.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Med Oncol, Houston, TX 77030 USA; [Dave, B.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Chang, J. C.] Methodist Hosp, Dept Med, Houston, TX 77030 USA; [Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Arteaga, C. L.] Vanderbilt Ingram Canc Ctr, Dept Breast Canc Res Program, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), VUMC, Div Oncol, 2220 Pierce Ave,777 PRB, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Dave, Bhuvanesh/ABF-8334-2020	Dave, Bhuvanesh/0000-0001-6741-1363; Liebler, Daniel/0000-0002-7873-3031	NIH [R01 CA80195]; Dinah Armstrong Kukes Fund/Phi Mu foundation; Department of Defense [BC087465]; ASCO; Kleberg Center for Molecular Markers at MD Anderson Cancer Center; NCI [1K23CA121994-01]; Susan G Komen Foundation [FAS0703849]; ACS [CRP-07-234]; Lee Jeans Translational Breast Cancer Research Program; Breast Cancer SPORE [P50 CA98131]; Vanderbilt-Ingram Cancer Center [P30 CA68485];  [T32 CA119910]; NATIONAL CANCER INSTITUTE [K23CA121994, R01CA080195, P30CA068485, K08CA143153, T32CA119910, P50CA098131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dinah Armstrong Kukes Fund/Phi Mu foundation; Department of Defense(United States Department of Defense); ASCO; Kleberg Center for Molecular Markers at MD Anderson Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); ACS(American Cancer Society); Lee Jeans Translational Breast Cancer Research Program; Breast Cancer SPORE; Vanderbilt-Ingram Cancer Center; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH R01 CA80195 (CLA), Dinah Armstrong Kukes Fund/Phi Mu foundation (BNR), T32 CA119910 (BNR), Department of Defense BC087465 Post-Doctoral Fellowship (BNR), ASCO Young Investigator Award (BNR), Kleberg Center for Molecular Markers at MD Anderson Cancer Center, ASCO Career Development Award (AMG), NCI 1K23CA121994-01 (AMG), Susan G Komen Foundation FAS0703849 (AMG, GBM), ACS Clinical Research Professorship CRP-07-234 (CLA), Lee Jeans Translational Breast Cancer Research Program (CLA), Breast Cancer SPORE P50 CA98131 and Vanderbilt-Ingram Cancer Center Support Grant P30 CA68485.	Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bose R, 2006, P NATL ACAD SCI USA, V103, P9773, DOI 10.1073/pnas.0603948103; Burris HA, 2005, J CLIN ONCOL, V23, P5305, DOI 10.1200/JCO.2005.16.584; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Erlichman C, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B56; Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291; Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549-006-9463-x; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Green TP, 2009, MOL ONCOL, V3, P248, DOI 10.1016/j.molonc.2009.01.002; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Huang F, 2007, CANCER RES, V67, P2226, DOI 10.1158/0008-5472.CAN-06-3633; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Jones RJ, 2009, BREAST CANCER RES TR, V114, P211, DOI 10.1007/s10549-008-9997-1; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lachmann A, 2009, BIOINFORMATICS, V25, P684, DOI 10.1093/bioinformatics/btp026; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lenferink AEG, 2001, CANCER RES, V61, P6583; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Luo W, 2008, J PROTEOME RES, V7, P3447, DOI 10.1021/pr800187n; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; Moasser MM, 2007, ONCOGENE, V26, P6577, DOI 10.1038/sj.onc.1210478; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Old WM, 2005, MOL CELL PROTEOMICS, V4, P1487, DOI 10.1074/mcp.M500084-MCP200; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Tabb DL, 2007, J PROTEOME RES, V6, P654, DOI 10.1021/pr0604054; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Xu WP, 2007, MOL CELL BIOL, V27, P220, DOI 10.1128/MCB.00899-06; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang B, 2007, J PROTEOME RES, V6, P3549, DOI 10.1021/pr070230d; Zhang B, 2006, J PROTEOME RES, V5, P2909, DOI 10.1021/pr0600273; Zhang HT, 1998, ONCOGENE, V16, P2835, DOI 10.1038/sj.onc.1201820	53	105	111	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	40					4163	4174		10.1038/onc.2011.130	http://dx.doi.org/10.1038/onc.2011.130			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21499296	Green Accepted			2022-12-28	WOS:000295924600003
J	Willecke, M; Toggweiler, J; Basler, K				Willecke, M.; Toggweiler, J.; Basler, K.			Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model	ONCOGENE			English	Article						cell cycle; Drosophila; PI3K; tumor	PHOSPHOINOSITIDE 3-KINASE; IMAGINAL DISC; GENETIC SCREEN; S-PHASE; PATHWAY; GROWTH; RAS; KINASE; PROLIFERATION; CANCER	Tumorigenesis is a complex process, which requires alterations in several tumor suppressor or oncogenes. Here, we use a Drosophila tumor model to identify genes, which are specifically required for tumor growth. We found that reduction of phosphoinositide 3-kinase (PI3K) activity resulted in very small tumors while only slightly affecting growth of wild-type tissue. The observed inhibition on tumor growth occurred at the level of cell-cycle progression. We conclude that tumor cells become dependent on PI3K function and that reduction of PI3K activity synthetically interferes with tumor growth. The results presented here broaden our insights into the intricate mechanisms underling tumorigenesis and illustrate the power of Drosophila genetics in revealing weak points of tumor progression. Oncogene (2011) 30, 4067-4074; doi:10.1038/onc.2011.125; published online 25 April 2011	[Willecke, M.; Toggweiler, J.; Basler, K.] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland	University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Life Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	basler@imls.uzh.ch		Basler, Konrad/0000-0003-3534-1529	FEBS; Swiss National Science Foundation; Kanton of Zurich	FEBS; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Kanton of Zurich	We would like to thank G Hausmann and J Zartman for comments on the manuscript; A Smith for help with experiments; and H Stocker, the Bloomington Stock Center, the National Institute of Genetics (NIG) and the Vienna Drosophila RNAi Center (VDRC) for fly strains. This work was supported by an FEBS Long-term Fellowship to MW, the Swiss National Science Foundation and the Kanton of Zurich.	Bach EA, 2003, GENETICS, V165, P1149; Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cleary JM, 2010, CURR ONCOL REP, V12, P87, DOI 10.1007/s11912-010-0091-6; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Halfar K, 2001, DEVELOPMENT, V128, P1687; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Read RD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000374; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702	32	35	36	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4067	4074		10.1038/onc.2011.125	http://dx.doi.org/10.1038/onc.2011.125			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21516128				2022-12-28	WOS:000295357500002
J	Fullgrabe, J; Kavanagh, E; Joseph, B				Fullgrabe, J.; Kavanagh, E.; Joseph, B.			Histone onco-modifications	ONCOGENE			English	Review						histone modification; histone-modifying enzymes; carcinogenesis; acetylation; methylation	DNA-DAMAGE RESPONSE; H3 LYSINE 9; MODIFICATIONS PREDICT PROGNOSIS; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER CELLS; MODIFICATION PATTERNS; PROSTATE-CANCER; TRANSCRIPTIONAL REPRESSION; METHYLTRANSFERASE G9A; LUNG-CANCER	Post-translational modification of histones provides an important regulatory platform for processes such as gene expression, DNA replication and repair, chromosome condensation and segregation and apoptosis. Disruption of these processes has been linked to the multistep process of carcinogenesis. We review the aberrant covalent histone modifications observed in cancer, and discuss how these epigenetic changes, caused by alterations in histone-modifying enzymes, can contribute to the development of a variety of human cancers. As a conclusion, a new terminology 'histone onco-modifications' is proposed to describe post-translational modifications of histones, which have been linked to cancer. This new term would take into account the active contribution and importance of these histone modifications in the development and progression of cancer. Oncogene (2011) 30, 3391-3403; doi:10.1038/onc.2011.121; published online 25 April 2011	[Fullgrabe, J.; Kavanagh, E.; Joseph, B.] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, R8 03, S-17176 Stockholm, Sweden.	Bertrand.joseph@ki.se		Joseph, Bertrand/0000-0001-5655-9979; Fullgrabe, Jens/0000-0003-0047-4719	Karolinska Institutet Foundations; Swedish Cancer Society; Swedish Research Council	Karolinska Institutet Foundations(Karolinska Institutet); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	We apologize to authors whose primary references could not be cited owing to space limitations. JF is supported by a fellowship from Karolinska Institutet Foundations (KID medel). This work was supported by the Swedish Cancer Society, the Swedish Research Council, and the Karolinska Institutet Foundations (KI Cancer).	Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Ajiro K, 2010, CELL DEATH DIFFER, V17, P984, DOI 10.1038/cdd.2009.199; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120; ANDERTON JA, 2011, ONCOGENE, P17; Ashktorab H, 2009, DIGEST DIS SCI, V54, P2109, DOI 10.1007/s10620-008-0601-7; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bagnyukovay TV, 2008, CARCINOGENESIS, V29, P638, DOI 10.1093/carcin/bgm303; Bai X, 2008, J CANCER RES CLIN, V134, P83, DOI 10.1007/s00432-007-0252-7; Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Dutta D, 2010, J BIOL CHEM, V285, P41567, DOI 10.1074/jbc.M110.190025; Ebbs ML, 2005, MOL CELL BIOL, V25, P10507, DOI 10.1128/MCB.25.23.10507-10515.2005; Ellinger J, 2010, INT J CANCER, V127, P2360, DOI 10.1002/ijc.25250; Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fullgrabe J, 2010, CELL DEATH DIFFER, V17, P1238, DOI 10.1038/cdd.2010.58; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Guo JF, 2011, CANCER SCI, V102, P530, DOI 10.1111/j.1349-7006.2010.01836.x; Hajji N, 2008, ONCOGENE, V27, P3134, DOI 10.1038/sj.onc.1210976; Hajji N, 2010, ONCOGENE, V29, P2192, DOI 10.1038/onc.2009.505; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; He LR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-461; Henckel A, 2009, HUM MOL GENET, V18, P3375, DOI 10.1093/hmg/ddp277; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141; Khare SP, 2011, EXP BIOL MED, V236, P30, DOI 10.1258/ebm.2010.010140; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x; Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kurdistani SK, 2011, PROG DRUG RES, V67, P91, DOI 10.1007/978-3-7643-8989-5_5; Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10; Li Z, 2010, INT J GYNECOL CANCER, V20, P82, DOI 10.1111/IGC.0b013e3181ae3efa; Liu BL, 2010, CANCER EPIDEM BIOMAR, V19, P2888, DOI 10.1158/1055-9965.EPI-10-0454; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639; Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438; Michaud-Levesque J, 2009, J BIOL CHEM, V284, P21338, DOI 10.1074/jbc.M109.005322; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Mohamed MA, 2007, BJU INT, V99, P908, DOI 10.1111/j.1464-410X.2006.06704.x; Muller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Nguyen CT, 2002, CANCER RES, V62, P6456; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; ORZAN F, 2010, NEUROPATHOL APPL NEU, P1365; Ozdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90; Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9; Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108; Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283; Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S; Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364; RAJENDRAN G, 2011, J NEUROONCOL, P13; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Ren T.-N., 2010, MED ONCOL; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rufiange A, 2007, MOL CELL, V27, P393, DOI 10.1016/j.molcel.2007.07.011; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Shogren-Knaak M, 2006, CELL CYCLE, V5, P1361, DOI 10.4161/cc.5.13.2891; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Tzao C, 2009, MODERN PATHOL, V22, P252, DOI 10.1038/modpathol.2008.172; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vempati RK, 2010, J BIOL CHEM, V285, P28553, DOI 10.1074/jbc.M110.149393; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568	141	196	207	12	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3391	3403		10.1038/onc.2011.121	http://dx.doi.org/10.1038/onc.2011.121			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21516126				2022-12-28	WOS:000293508100001
J	Cheong, JK; Nguyen, TH; Wang, H; Tan, P; Voorhoeve, PM; Lee, SH; Virshup, DM				Cheong, J. K.; Nguyen, T. H.; Wang, H.; Tan, P.; Voorhoeve, P. M.; Lee, S. H.; Virshup, D. M.			IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1 delta/epsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation	ONCOGENE			English	Article						casein kinase 1; Wnt; IC261; mitotic spindle; cancer; synthetic lethal	CASEIN KINASE-I; DROSOPHILA CLOCK GENE; DOUBLE-TIME; EPSILON; PHOSPHORYLATION; WNT; CK1-EPSILON; PATHWAY; FAMILY; GROWTH	Casein kinase 1 delta and epsilon (CK1 delta/epsilon) are key regulators of diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. Recent studies suggest that they have an important role in oncogenesis. RNA interference screens identified CK1 epsilon as a pro-survival factor in cancer cells in vitro and the CK1 delta/epsilon-specific inhibitor IC261 is remarkably effective at selective, synthetic lethal killing of cancer cells. The recent development of the nanomolar CK1 delta/epsilon-selective inhibitor, PF670462 (PF670) and the CK1 epsilon-selective inhibitor PF4800567 (PF480) offers an opportunity to further test the role of CK1 delta/epsilon in cancer. Unexpectedly, and unlike IC261, PF670 and PF480 were unable to induce cancer cell death. PF670 is a potent inhibitor of CK1 delta/epsilon in cells; nanomolar concentrations are sufficient to inhibit CK1 delta/epsilon activity as measured by repression of intramolecular autophosphorylation, phosphorylation of disheveled2 proteins and Wnt/beta-catenin signaling. Likewise, small interfering RNA knockdown of CK1 delta and CK1 epsilon reduced Wnt/beta-catenin signaling without affecting cell viability, further suggesting that CK1 delta/epsilon inhibition may not be relevant to the IC261-induced cell death. Thus, while PF670 is a potent inhibitor of Wnt signaling, it only modestly inhibits cell proliferation. In contrast, while sub-micromolar concentrations of IC261 neither inhibited CK1 delta/epsilon kinase activity nor blocked Wnt/beta-catenin signaling in cancer cells, it caused a rapid induction of prometaphase arrest and subsequent apoptosis in multiple cancer cell lines. In a stepwise transformation model, IC261-induced killing required both overactive Ras and inactive p53. IC261 binds to tubulin with an affinity similar to colchicine and is a potent inhibitor of microtubule polymerization. This activity accounts for many of the diverse biological effects of IC261 and, most importantly, for its selective cancer cell killing. Oncogene (2011) 30, 2558-2569; doi:10.1038/onc.2010.627; published online 24 January 2011	[Cheong, J. K.; Nguyen, T. H.; Wang, H.; Tan, P.; Voorhoeve, P. M.; Lee, S. H.; Virshup, D. M.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Voorhoeve, P. M.; Virshup, D. M.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National University of Singapore; National University of Singapore	Virshup, DM (corresponding author), Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg	Nguyen, Hung/M-8118-2014; Virshup, David M/C-1449-2009	Nguyen, Hung/0000-0001-8378-555X; Virshup, David M/0000-0001-6976-850X; Wang, Hannah/0000-0002-0600-2555	Agency for Science, Technology and Research, Singapore; Ministry of Health, Singapore; National Research Foundation; National Medical Research Council; Singapore Millennium Foundation (SMF)	Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR)); Ministry of Health, Singapore(Ministry of Health-Singapore); National Research Foundation; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Singapore Millennium Foundation (SMF)(Singapore Millennium Foundation)	We thank Velani Utomo, Ha Yin Lee, Simran Kaur and Qin Luo (Duke-NUS) for their excellent technical and computational support. We are also grateful to our Duke and Duke-NUS colleagues Tim Haystead, Sin Tiong Ong, Shirish Shenolikar, Patrick Casey and members of the Virshup laboratory for their helpful discussions. This work was supported by the Duke-NUS Signature Research Program funded by the Agency for Science, Technology and Research, Singapore, and the Ministry of Health, Singapore, and a Singapore Translational Research Investigator Award to DMV funded by the National Research Foundation and the National Medical Research Council. JKC was supported by a Singapore Millennium Foundation (SMF) Postdoctoral Fellowship.	Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Arora S, 2009, CANCER RES, V69, P1910, DOI 10.1158/0008-5472.CAN-08-0877; Badura L, 2007, J PHARMACOL EXP THER, V322, P730, DOI 10.1124/jpet.107.122846; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Brockschmidt C, 2008, GUT, V57, P799, DOI 10.1136/gut.2007.123695; Bryant CD, 2009, PSYCHOPHARMACOLOGY, V203, P703, DOI 10.1007/s00213-008-1417-z; Bryja V, 2007, CELL SIGNAL, V19, P610, DOI 10.1016/j.cellsig.2006.08.011; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Clokie S, 2009, FEBS J, V276, P6971, DOI 10.1111/j.1742-4658.2009.07405.x; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fedorov O, 2007, P NATL ACAD SCI USA, V104, P20523, DOI 10.1073/pnas.0708800104; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gigant B, 2009, TOP CURR CHEM, V286, P259, DOI 10.1007/128_2008_11; Grueneberg DA, 2008, P NATL ACAD SCI USA, V105, P16472, DOI 10.1073/pnas.0808019105; Hampton T, 2004, JAMA-J AM MED ASSOC, V292, P419, DOI 10.1001/jama.292.4.419; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 2005, ONKOLOGIE, V28, P508, DOI 10.1159/000087137; Kuo CC, 2004, CANCER RES, V64, P4621, DOI 10.1158/0008-5472.CAN-03-3474; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Meng QJ, 2008, NEURON, V58, P78, DOI 10.1016/j.neuron.2008.01.019; Nakayama GR, 1997, J IMMUNOL METHODS, V204, P205, DOI 10.1016/S0022-1759(97)00043-4; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sprouse J, 2009, PSYCHOPHARMACOLOGY, V204, P735, DOI 10.1007/s00213-009-1503-x; Stoter M, 2005, ONCOGENE, V24, P7964, DOI 10.1038/sj.onc.1208941; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Virshup DM, 2007, COLD SPRING HARB SYM, V72, P413, DOI 10.1101/sqb.2007.72.048; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Yang WS, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-r92; Yu WJ, 2009, MOL CELL BIOL, V29, P1452, DOI 10.1128/MCB.01777-08	47	89	95	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2558	2569		10.1038/onc.2010.627	http://dx.doi.org/10.1038/onc.2010.627			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258417	Green Published, hybrid			2022-12-28	WOS:000291198400007
J	Yu, F; Li, J; Chen, H; Fu, J; Ray, S; Huang, S; Zheng, H; Ai, W				Yu, F.; Li, J.; Chen, H.; Fu, J.; Ray, S.; Huang, S.; Zheng, H.; Ai, W.			Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion	ONCOGENE			English	Article						KLF4; cancer stem cell; breast cancer; migration; invasion	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR; SELF-RENEWAL; TUMOR-SUPPRESSOR; GENE-EXPRESSION; DIFFERENTIATION; IDENTIFICATION; P53; TUMORIGENICITY; TRANSFORMATION	Kruppel-like factor 4 (KLF4) is highly expressed in more than 70% of breast cancers and functions as an oncogene. However, an exact mechanism by which KLF4 enhances tumorigenesis of breast cancer remains unknown. In this study, we show that KLF4 was highly expressed in cancer stem cell (CSC)-enriched populations in mouse primary mammary tumor and breast cancer cell lines. Knockdown of KLF4 in breast cancer cells (MCF-7 and MDA-MB-231) decreased the proportion of stem/progenitor cells as demonstrated by expression of stem cell surface markers such as aldehyde dehydrogenase 1, side population and by in vitro mammosphere assay. Consistently KLF4 overexpression led to an increase of the cancer stem cell population. KLF4 knockdown also suppressed cell migration and invasion in MCF-7 and MDA-MB-231 cells. Furthermore, knockdown of KLF4 reduced colony formation in vitro and inhibited tumorigenesis in immunocompromised non-obese diabetic/severe combined immunodeficiency mice, supporting an oncogenic role for KLF4 in breast cancer development. Further mechanistic studies revealed that the Notch signaling pathway was required for KLF4-mediated cell migration and invasion, but not for CSC maintenance. Taken together, our study provides evidence that KLF4 has a potent oncogenic role in mammary tumorigenesis likely by maintaining stem cell-like features and by promoting cell migration and invasion. Thus, targeting KLF4 may provide an effective therapeutic approach to suppress tumorigenicity in breast cancer. Oncogene (2011) 30, 2161-2172; doi:10.1038/onc.2010.591; published online 17 January 2011	[Yu, F.; Li, J.; Ray, S.; Zheng, H.; Ai, W.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Li, J.; Huang, S.] Huazhong Univ Sci & Technol, Ctr Stem Cell Res & Applicat, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China; [Chen, H.; Fu, J.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Huazhong University of Science & Technology; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Ai, W (corresponding author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, 6439 Garners Ferry Rd,Bldg 2,RM B18, Columbia, SC 29208 USA.	Walden.Ai@uscmed.sc.edu	chen, hexin/F-1714-2011		NIH/NIDDK [1K01DK069489]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR060987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK069489] Funding Source: NIH RePORTER	NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Plasmids containing KLF4 specific shRNA (siKLF4), the control vector (siCon), KLF4 overexpression vector (KLF4-N) and the control vector (Control) were kindly provided by Daniel S Peeper at the Netherlands Cancer Institute. IAP reporter construct was provided by Dr Chunming Liu at the University of Texas Medical Branch. This work was partially supported by an NIH/NIDDK grant to WA (1K01DK069489).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bruce SJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-365; Charafe-Jauffret E, 2008, PATHOBIOLOGY, V75, P75, DOI 10.1159/000123845; Choi BJ, 2006, PATHOL RES PRACT, V202, P585, DOI 10.1016/j.prp.2006.05.001; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Eaton SA, 2008, J BIOL CHEM, V283, P26937, DOI 10.1074/jbc.M804831200; Faherty S, 2007, IN VITRO CELL DEV-AN, V43, P37, DOI 10.1007/s11626-006-9001-5; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 2000, CANCER RES, V60, P6488; Garvey SM, 2010, J PHARMACOL EXP THER, V333, P34, DOI 10.1124/jpet.109.163949; Ghaleb AM, 2008, MOL CANCER RES, V6, P1920, DOI 10.1158/1541-7786.MCR-08-0224; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Hinnebusch BF, 2004, AM J PHYSIOL-GASTR L, V286, pG23, DOI 10.1152/ajpgi.00203.2003; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Lambertini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010369; Lawson JC, 2009, BREAST CANCER RES TR, V118, P241, DOI 10.1007/s10549-009-0524-9; Li Y, 2005, BLOOD, V105, P635, DOI 10.1182/blood-2004-07-2681; Liu ZL, 2009, CANCER BIOL THER, V8, P1840, DOI 10.4161/cbt.8.19.9440; Lyssiotis CA, 2009, P NATL ACAD SCI USA, V106, P8912, DOI 10.1073/pnas.0903860106; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Real PJ, 2009, NAT MED, V15, P50, DOI 10.1038/nm.1900; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wassmann S, 2007, J MOL CELL CARDIOL, V43, P301, DOI 10.1016/j.yjmcc.2007.06.001; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang PL, 2010, J BIOL CHEM, V285, P9180, DOI 10.1074/jbc.M109.077958; Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zheng H, 2009, AM J PHYSIOL-GASTR L, V296, pG490, DOI 10.1152/ajpgi.90393.2008	58	320	334	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2161	2172		10.1038/onc.2010.591	http://dx.doi.org/10.1038/onc.2010.591			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21242971	Green Accepted			2022-12-28	WOS:000290249600007
J	Das, SK; Bhutia, SK; Sokhi, UK; Dash, R; Azab, B; Sarkar, D; Fisher, PB				Das, S. K.; Bhutia, S. K.; Sokhi, U. K.; Dash, R.; Azab, B.; Sarkar, D.; Fisher, P. B.			Human polynucleotide phosphorylase (hPNPaseold(35)): an evolutionary conserved gene with an expanding repertoire of RNA degradation functions	ONCOGENE			English	Review						hPNPase(old-35); senescence; RNA degradation; c-myc; miRNA	HUMAN-MELANOMA CELLS; DOUBLE-STRANDED-RNA; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; POLY(A) POLYMERASE; TRANSCRIPTION FACTOR; MITOCHONDRIAL RNA; OXIDATIVE STRESS; KAPPA-B; C-MYC	Human polynucleotide phosphorylase (hPNPase(old-35)) is an evolutionary conserved RNA-processing enzyme with expanding roles in regulating cellular physiology. hPNPase(old-35) was cloned using an innovative 'overlapping pathway screening' strategy designed to identify genes coordinately regulated during the processes of cellular differentiation and senescence. Although hPNPase(old-35) structurally and biochemically resembles PNPase of other species, overexpression and inhibition studies reveal that hPNPase(old-35) has evolved to serve more specialized and diversified functions in humans. Targeting specific mRNA or non-coding small microRNA, hPNPase(old-35) modulates gene expression that in turn has a pivotal role in regulating normal physiological and pathological processes. In these contexts, targeted overexpression of hPNPase(old-35) represents a novel strategy to selectively downregulate RNA expression and consequently intervene in a variety of pathophysiological conditions. Oncogene (2011) 30, 1733-1743; doi:10.1038/onc.2010.572; published online 13 December 2010	[Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, VCU Inst Mol Med,Dept Human & Mol Genet, Richmond, VA 23298 USA	Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, VCU Inst Mol Med,Dept Human & Mol Genet, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	pbfisher@vcu.edu	Azab, Belal/AAJ-5652-2021	Azab, Belal/0000-0003-0293-6489; SOKHI, UPNEET/0000-0001-5907-5646; Bhutia, Sujit Kumar/0000-0003-0962-3354; dash, rupesh/0000-0001-5740-7053	NIH [R01 CA097318, R01 CA127641, CA134721, P01 CA104177, R01 CA134721]; Samuel Waxman Cancer Research Foundation; National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA134721, P01CA104177, R01CA127641, R01CA097318] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by NIH grants R01 CA097318, R01 CA127641, CA134721, and P01 CA104177, the Samuel Waxman Cancer Research Foundation and the National Foundation for Cancer Research (PBF) and NIH grant R01 CA134721 (DS). DS is the Harrison Endowed Scholar in Cancer Research. PBF holds the Thelma Newmeyer Corman Chair in Cancer Research and is a SWCRF Investigator.	Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Almeida FC, 2008, EVOL BIOINFORM, V4, P109; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARNES PJ, 1997, NEW ENGL J MED, V336, P1; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Buttner K, 2006, MOL MICROBIOL, V61, P1372, DOI 10.1111/j.1365-2958.2006.05331.x; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; CAMPISI J, 1992, ANN NY ACAD SCI, V663, P195, DOI 10.1111/j.1749-6632.1992.tb38663.x; Cao D, 2003, CELL, V113, P533, DOI 10.1016/S0092-8674(03)00353-2; Chan I, 2008, J CELL PHYSIOL, V215, P401, DOI 10.1002/jcp.21320; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen HW, 2007, TRENDS CELL BIOL, V17, P600, DOI 10.1016/j.tcb.2007.09.006; Chen HW, 2006, MOL CELL BIOL, V26, P8475, DOI 10.1128/MCB.01002-06; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chen QM, 2000, ANN NY ACAD SCI, V908, P111; Colavitti R, 2005, IUBMB LIFE, V57, P277, DOI 10.1080/15216540500091890; Das SK, 2010, P NATL ACAD SCI USA, V107, P11948, DOI 10.1073/pnas.0914143107; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; Dodson RE, 2002, PROG NUCLEIC ACID RE, V72, P129, DOI 10.1016/S0079-6603(02)72069-2; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FISHER PB, 1986, ANTICANCER RES, V6, P765; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Fukuhara N, 2006, CANCER SCI, V97, P499, DOI 10.1111/j.1349-7006.2006.00209.x; Gewartowski K, 2006, ACTA BIOCHIM POL, V53, P179; GUARINI L, 1992, PIGM CELL RES, P123; GUARINI L, 1989, CANCER IMMUNOL IMMUN, V30, P262, DOI 10.1007/BF01744892; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hayakawa H, 2006, BIOCHEMISTRY-US, V45, P6749, DOI 10.1021/bi052585l; HAYFLICK L, 1976, NEW ENGL J MED, V295, P1302, DOI 10.1056/NEJM197612022952308; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; HOOF A, 1999, CELL, V99, P347; Jarrige AC, 2002, J MOL BIOL, V321, P397, DOI 10.1016/S0022-2836(02)00645-9; Jarrige AC, 2001, EMBO J, V20, P6845, DOI 10.1093/emboj/20.23.6845; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; JIANG HP, 1995, ONCOGENE, V11, P1179; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Khidr L, 2008, J BIOL CHEM, V283, P27064, DOI 10.1074/jbc.M802991200; Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kirschner LS, 1999, GENOMICS, V62, P21, DOI 10.1006/geno.1999.5957; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Leszczyniecka M, 2003, GENE, V316, P143, DOI 10.1016/S0378-1119(03)00752-2; Leszczyniecka M, 2004, MOL PHYLOGENET EVOL, V31, P123, DOI 10.1016/j.ympev.2003.07.012; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; LITTAUER UZ, 1999, ENCY MOL BIOL, V3, P1911; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Nagaike T, 2005, J BIOL CHEM, V280, P19721, DOI 10.1074/jbc.M500804200; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Passos JF, 2006, REJUV RES, V9, P64, DOI 10.1089/rej.2006.9.64; Piwowarski J, 2003, J MOL BIOL, V329, P853, DOI 10.1016/S0022-2836(03)00528-X; Portnoy V, 2005, EMBO REP, V6, P1188, DOI 10.1038/sj.embor.7400571; Raijmakers R, 2004, EUR J CELL BIOL, V83, P175, DOI 10.1078/0171-9335-00385; Raijmakers R, 2002, J MOL BIOL, V323, P653, DOI 10.1016/S0022-2836(02)00947-6; Ramachandran V, 2008, SCIENCE, V321, P1490, DOI 10.1126/science.1163728; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Regonesi ME, 2004, NUCLEIC ACIDS RES, V32, P1006, DOI 10.1093/nar/gkh268; Sarkar D, 2004, CANCER RES, V64, P7473, DOI 10.1158/0008-5472.CAN-04-1772; Sarkar D, 2006, CELL DEATH DIFFER, V13, P1541, DOI 10.1038/sj.cdd.4401829; Sarkar D, 2005, MOL CELL BIOL, V25, P7333, DOI 10.1128/MCB.25.16.7333-7343.2005; Sarkar D, 2003, J BIOL CHEM, V278, P24542, DOI 10.1074/jbc.M302421200; Sarkar D, 2007, CANCER RES, V67, P7948, DOI 10.1158/0008-5472.CAN-07-0872; Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEE YP, 1972, BIOCHEM J, V130, P343, DOI 10.1042/bj1300343; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Slomovic S, 2005, MOL CELL BIOL, V25, P6427, DOI 10.1128/MCB.25.15.6427-6435.2005; Stickney LM, 2005, J BACTERIOL, V187, P7214, DOI 10.1128/JB.187.21.7214-7221.2005; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Temperley RJ, 2003, HUM MOL GENET, V12, P2341, DOI 10.1093/hmg/ddg238; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tsuchiya S, 2006, J PHARMACOL SCI, V101, P267, DOI 10.1254/jphs.CPJ06013X; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Van Maerken T, 2009, J CELL PHYSIOL, V219, P707, DOI 10.1002/jcp.21719; Wang DDH, 2009, J BIOL CHEM, V284, P20812, DOI 10.1074/jbc.M109.009605; Wang G, 2010, CELL, V142, P456, DOI 10.1016/j.cell.2010.06.035; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wu JH, 2008, BIOCHEM BIOPH RES CO, V372, P288, DOI 10.1016/j.bbrc.2008.05.058; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Yamanaka K, 2001, J BACTERIOL, V183, P2808, DOI 10.1128/JB.183.9.2808-2816.2001; Yehudai-Resheff S, 2003, PLANT CELL, V15, P2003, DOI 10.1105/tpc.013326; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001	98	16	19	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1733	1743		10.1038/onc.2010.572	http://dx.doi.org/10.1038/onc.2010.572			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151174	Green Accepted			2022-12-28	WOS:000289512200001
J	Birts, CN; Bergman, LM; Blaydes, JP				Birts, C. N.; Bergman, L. M.; Blaydes, J. P.			CtBPs promote mitotic fidelity through their activities in the cell nucleus	ONCOGENE			English	Article						aurora B; CtBP proteins; BARS; mitosis; transcriptional repressor	HISTONE DEACETYLASE INHIBITORS; NEGATIVE MODULATION; GENE-EXPRESSION; BINDING CLEFT; PROTEIN; COREPRESSOR; PHOSPHOPROTEIN; SURVIVAL; FISSION; REGION	CtBPs form NADH-sensitive chromatin-modifying complexes, which link cellular metabolism to gene transcription. They also function in the cytoplasm to regulate Golgi fissioning; their inhibition can consequently cause a Golgi-dependent checkpoint in G(2). We have recently identified a novel role of CtBPs in the maintenance of mitotic fidelity; inhibition of CtBP synthesis resulting in reduced association of aurora B with mitotic chromatin and aberrant segregation of chromosomes. Here, we demonstrate that it is the interaction of CtBPs with transcriptional regulators and/or chromatin-modifying enzymes in the cell nucleus, rather than their role in Golgi fission, which is critical for the maintenance of mitotic fidelity. Oncogene (2011) 30, 1272-1280; doi:10.1038/onc.2010.507; published online 8 November 2010	[Birts, C. N.; Blaydes, J. P.] Univ Southampton, Sch Med, Southampton Canc Res UK Ctr, Southampton SO16 6YD, Hants, England; [Bergman, L. M.] Therapeut Goods Adm, Med Toxicol Evaluat Sect, Off Prescript Med, Woden, ACT, Australia	University of Southampton	Blaydes, JP (corresponding author), Univ Southampton, Sch Med, Southampton Gen Hosp, Southampton Canc Res UK Ctr, MP 824, Southampton SO16 6YD, Hants, England.	j.p.blaydes@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019; Birts, Charles N/N-9845-2013	Blaydes, Jeremy/0000-0001-8525-0209; Bergman, Lee/0000-0002-0111-411X; Birts, Charles/0000-0002-0368-8766	UK Breast Cancer Campaign	UK Breast Cancer Campaign	We are grateful to Matthew Darley for the generation of plasmid reagents, Patrick Duriez for the preparation of GST fusion proteins for microinjection, and the Southampton School of Medicine Bioimaging Unit for assistance with live cell imaging. Funding for the work was from the UK Breast Cancer Campaign.	Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35; Bergman LM, 2009, MOL CELL BIOL, V29, P4539, DOI 10.1128/MCB.00439-09; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Carcedo CH, 2004, SCIENCE, V305, P93, DOI 10.1126/science.1097775; Chen YW, 2008, CANCER RES, V68, P476, DOI 10.1158/0008-5472.CAN-07-1960; Cheok CF, 2010, CELL DEATH DIFFER, V17, P1486, DOI 10.1038/cdd.2010.18; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Colanzi A, 2007, EMBO J, V26, P2465, DOI 10.1038/sj.emboj.7601686; Ditchfield Claire, 2004, V296, P371; Eot-Houllier G, 2009, CANCER LETT, V274, P169, DOI 10.1016/j.canlet.2008.06.005; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Kovi RC, 2010, CELL DEATH DIFFER, V17, P513, DOI 10.1038/cdd.2009.140; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8; Mroz EA, 2008, CANCER RES, V68, P6049, DOI 10.1158/0008-5472.CAN-08-1279; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8202, DOI 10.1128/MCB.00445-06; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Stevens FE, 2008, ONCOGENE, V27, P1345, DOI 10.1038/sj.onc.1210779; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje; Yang JS, 2008, NAT CELL BIOL, V10, P1146, DOI 10.1038/ncb1774; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2002, SCIENCE, V295, P1895	29	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1272	1280		10.1038/onc.2010.507	http://dx.doi.org/10.1038/onc.2010.507			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057548				2022-12-28	WOS:000288492100002
J	Connelly, L; Barham, W; Onishko, HM; Sherrill, T; Chodosh, LA; Blackwell, TS; Yull, FE				Connelly, L.; Barham, W.; Onishko, H. M.; Sherrill, T.; Chodosh, L. A.; Blackwell, T. S.; Yull, F. E.			Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden	ONCOGENE			English	Article						NF-kappa B; mammary; tumorigenesis; apoptosis; proliferation	HUMAN BREAST-CANCER; TRANSCRIPTION FACTOR; CYCLIN D1; IN-VIVO; ACTIVATION; PATHWAY; TUMORIGENESIS; REQUIREMENT; PROGRESSION; GROWTH	The transcription factor nuclear factor kappa B (NF-kappa B) is activated in human breast cancer tissues and cell lines. However, it is unclear whether NF-kappa B activation is a consequence of tumor formation or a contributor to tumor development. We developed a doxycycline (dox)-inducible mouse model, termed DNMP, to inhibit NF-kappa B activity specifically within the mammary epithelium during tumor development in the polyoma middle T oncogene (PyVT) mouse mammary tumor model. DNMP females and PyVT littermate controls were treated with dox from 4 to 12 weeks of age. We observed an increase in tumor latency and a decrease in final tumor burden in DNMP mice compared with PyVT controls. A similar effect with treatment from 8 to 12 weeks indicates that outcome is independent of effects on postnatal virgin ductal development. In both cases, DNMP mice were less likely to develop lung metastases than controls. Treatment from 8 to 9 weeks was sufficient to impact primary tumor formation. Inhibition of NF-kappa B increases apoptosis in hyperplastic stages of tumor development and decreases proliferation at least in part by reducing Cyclin D1 expression. To test the therapeutic potential of NF-kappa B inhibition, we generated palpable tumors by orthotopic injection of PyVT cells and then treated systemically with the NF-kappa B inhibitor thymoquinone (TQ). TQ treatment resulted in a reduction in tumor volume and weight as compared with vehicle-treated control. These data indicate that epithelial NF-kappa B is an active contributor to tumor progression and demonstrate that inhibition of NF-kappa B could have a significant therapeutic impact even at later stages of mammary tumor progression. Oncogene (2011) 30, 1402-1412; doi:10.1038/onc.2010.521; published online 15 November 2010	[Connelly, L.; Barham, W.; Onishko, H. M.; Blackwell, T. S.; Yull, F. E.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Connelly, L.] Univ Hawaii, Dept Pharmaceut Sci, Coll Pharm, Hilo, HI 96720 USA; [Sherrill, T.; Blackwell, T. S.] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; [Chodosh, L. A.] Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Blackwell, T. S.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; University of Hawaii System; University Hawaii Hilo; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Yull, FE (corresponding author), Vanderbilt Univ, Dept Canc Biol, 771 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	fiona.yull@vanderbilt.edu	Connelly, Linda/GVS-4612-2022	Barham, Whitney/0000-0002-1130-1971	NIH [CA113734]; US Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA113734] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant CA113734 awarded to FE Yull and a US Department of Veterans Affairs grant awarded to TS Blackwell.	BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Cheng DS, 2007, J IMMUNOL, V178, P6504, DOI 10.4049/jimmunol.178.10.6504; Connelly L, 2007, J BIOL CHEM, V282, P10028, DOI 10.1074/jbc.M611300200; Connelly L, 2010, J CELL PHYSIOL, V222, P73, DOI 10.1002/jcp.21922; Cude K, 2007, J CELL BIOL, V177, P253, DOI 10.1083/jcb.200609166; Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Han YP, 2001, J CELL SCI, V114, P131; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-87; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu MR, 2009, AM J PATHOL, V174, P1910, DOI 10.2353/ajpath.2009.080706; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Mistry P, 2004, J BIOL CHEM, V279, P1482, DOI 10.1074/jbc.M310413200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pratt MAC, 2009, ONCOGENE, V28, P2710, DOI 10.1038/onc.2009.131; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158/1541-7786.MCR-07-2088; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Tapia MA, 2007, CELL CYCLE, V6, P2284, DOI 10.4161/cc.6.18.4721; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0	38	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1402	1412		10.1038/onc.2010.521	http://dx.doi.org/10.1038/onc.2010.521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21076466	Green Accepted			2022-12-28	WOS:000288743800003
J	Morgan, MR; Jazayeri, M; Ramsay, AG; Thomas, GJ; Boulanger, MJ; Hart, IR; Marshall, JF				Morgan, M. R.; Jazayeri, M.; Ramsay, A. G.; Thomas, G. J.; Boulanger, M. J.; Hart, I. R.; Marshall, J. F.			Psoriasin (S100A7) associates with integrin beta 6 subunit and is required for alpha v beta 6-dependent carcinoma cell invasion	ONCOGENE			English	Article						alpha v beta 6; integrins; invasion; psoriasin; cancer; oral SCC	TUMOR PROGRESSION; BINDING-PROTEIN; BREAST-CANCER; TERMINAL DIFFERENTIATION; CYTOPLASMIC DOMAIN; PROMOTES MIGRATION; COLON-CARCINOMA; ORAL-CAVITY; IN-SITU; EXPRESSION	Expression of the integrin alpha v beta 6 is upregulated in a variety of carcinomas where it appears to be involved in malignant progression, although the biology of this integrin is not fully explored. We have generated oral carcinoma cells that express alpha v beta 6 composed of wild-type alpha v and a mutant beta 6 that lacks the unique C-terminal 11 amino acids (aa). We found that these residues, although not required for alpha v beta 6-dependent adhesion or migration, are essential for alpha v beta 6-dependent invasive activity. We have used a proteomic approach to identify novel binding partners for the beta 6 subunit cytoplasmic tail and report that psoriasin (Psor) (S100A7) bound preferentially to the recombinant beta 6 cytoplasmic domain, though not in the absence of the unique C-terminal 11aa. Endogenous cellular Psor co-precipitated with endogenous beta 6 and colocalised with alpha v beta 6 at the cell membrane and intracellular vesicles. Knockdown of Psor, with small interfering RNA, had no effect on alpha v beta 6-dependent adhesion or migration but abrogated alpha v beta 6-mediated oral carcinoma cell invasion both in Transwell and, the more physiologically relevant, organotypic invasion assays, recapitulating the behaviour of the beta 6-mutant cell line. Membrane-permeant Tat-peptides encoding the unique C-terminal residues of beta 6, bound directly to recombinant Psor and inhibited cellular Psor binding to beta 6; this blocked alpha v beta 6-dependent, but not alpha v beta 6-independent, invasion. These data identify a novel interaction between Psor and beta 6 and demonstrate that it is required for alpha v beta 6-dependent invasion by carcinoma cells. Inhibition of this interaction may represent a novel therapeutic strategy to target carcinoma invasion. Oncogene (2011) 30, 1422-1435; doi:10.1038/onc.2010.535; published online 6 December 2010	[Ramsay, A. G.; Marshall, J. F.] Univ London, Barts & London Sch Med & Dent, John Vane Sci Ctr, Inst Canc,Ctr Med Oncol, London EC1M 6BQ, England; [Morgan, M. R.; Jazayeri, M.; Ramsay, A. G.; Thomas, G. J.; Hart, I. R.; Marshall, J. F.] London Sch Med & Dent, John Vane Sci Ctr, Tumor Biol Ctr, London, England; [Boulanger, M. J.] Dept Biochem & Microbiol, Victoria, BC, Canada	University of London; Queen Mary University London; University of London; Queen Mary University London	Marshall, JF (corresponding author), Univ London, Barts & London Sch Med & Dent, John Vane Sci Ctr, Inst Canc,Ctr Med Oncol, Charterhouse Sq, London EC1M 6BQ, England.	j.f.marshall@qmul.ac.uk	Ramsay, Alan G/A-8374-2015	Ramsay, Alan G/0000-0002-0452-0420; Morgan, Mark/0000-0001-7728-9883; Marshall, John/0000-0002-0494-2295				AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Banerjee AG, 2005, MOL CANCER THER, V4, P865, DOI 10.1158/1535-7163.MCT-05-0033; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; BUSK M, 1992, J BIOL CHEM, V267, P5790; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2004, BREAST CANCER RES, V6, pR308, DOI 10.1186/bcr791; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hazelbag S, 2007, J PATHOL, V212, P316, DOI 10.1002/path.2168; Jiang WG, 2004, INT J ONCOL, V25, P81; Jones J, 1996, ONCOGENE, V12, P119; Jones J, 1997, J ORAL PATHOL MED, V26, P63, DOI 10.1111/j.1600-0714.1997.tb00023.x; Kesting MR, 2009, ORAL ONCOL, V45, P731, DOI 10.1016/j.oraloncology.2008.11.012; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Larjava H, 1996, Oral Dis, V2, P77; Leon R, 2009, BIOCHEMISTRY-US, V48, P10591, DOI 10.1021/bi901330g; Li XW, 2003, J BIOL CHEM, V278, P41646, DOI 10.1074/jbc.M306274200; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397; Niu J, 2001, INT J CANCER, V92, P40, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1157>3.0.CO;2-B; Nystrom ML, 2006, CANCER RES, V66, P10833, DOI 10.1158/0008-5472.CAN-06-1640; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Paruchuri V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001741; Petersson S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-205; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Ralhan R, 2008, MOL CELL PROTEOMICS, V7, P1162, DOI 10.1074/mcp.M700500-MCP200; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Ramsay AG, 2007, CANCER RES, V67, P5275, DOI 10.1158/0008-5472.CAN-07-0318; Regezi JA, 2002, ORAL ONCOL, V38, P332, DOI 10.1016/S1368-8375(01)00062-8; RESKA AA, 1992, J CELL BIOL, V117, P1321; Ruse M, 2003, J INVEST DERMATOL, V121, P132, DOI 10.1046/j.1523-1747.2003.12309.x; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; Thomas GJ, 2006, J ORAL PATHOL MED, V35, P1, DOI 10.1111/j.1600-0714.2005.00374.x; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Wang J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2105; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf R, 2008, J IMMUNOL, V181, P1499, DOI 10.4049/jimmunol.181.2.1499; Zhou G, 2008, ONCOGENE, V27, P3527, DOI 10.1038/sj.onc.1211015	51	27	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1422	1435		10.1038/onc.2010.535	http://dx.doi.org/10.1038/onc.2010.535			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21132011				2022-12-28	WOS:000288743800005
J	Deng, R; Tang, J; Ma, JG; Chen, SP; Xia, LP; Zhou, WJ; Li, DD; Feng, GK; Zeng, YX; Zhu, XF				Deng, R.; Tang, J.; Ma, J-G; Chen, S-P; Xia, L-P; Zhou, W-J; Li, D-D; Feng, G-K; Zeng, Y-X; Zhu, X-F			PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation	ONCOGENE			English	Article						Akt; Mre11; DSB repair; ionizing radiation	STRAND-BREAK REPAIR; DNA-REPAIR; HISTONE H2AX; SIGNALING PATHWAY; CERVICAL-CANCER; COLON-CANCER; TUMOR-CELLS; KINASE-B; INHIBITION; COMPLEX	An elevated DNA-repair capacity in cancer cells leads to radiation resistance and severely limits the efficacy of radiation therapy. Activation of Akt is tightly associated with resistance to radiotherapy, and Mre11 protein has important role during the repair of DNA double-strand breaks (DSBs). In this report, our results showed that inhibition of Akt activity impaired the repair of DSBs in CNE2 cells, whereas activated Akt promoted the repair of DSBs in HeLa cells. Knockdown of Mre11 also impaired the process of DSB repair in both these two cell lines. More importantly, we found that Akt could regulate Mre11 expression. Inhibition of Akt activity by small interfering RNA or LY294002 efficiently downregulated the Mre11 expression in CNE2 cells, and transfection with myr-Akt plasmid in HeLa cells upregulated the Mre11 expression. In addition, luciferase reporter analysis revealed that Mre11 reporter activity increased after transfection with myr-Akt1 plasmids, and this myr-Akt1-induced transcriptional activity was blocked in the presence of LY294002. Further study showed GSK3 beta/beta-catenin/LEF-1 pathway was involved in this regulation. Knockdown of beta-catenin or LEF-1 led to the downregulation of Mre11, whereas overexpression of beta-catenin led to upregulation of Mre11. The chromatin immuno-precipitation assay assay showed beta-catenin/LEF-1 heterodimer could directly bind to the promoter of Mre11 in vivo. And the luciferase activity of the pGL3-Mre11 and pGL3-Lef increased in HeLa cells following beta-catenin plasmid co-transfected, but was abolished when the LEF-1- binding conserved sequences of Mre11 promoter were mutated. These results together support Akt can upregulate the expression of Mre11 through GSK3 beta/ beta-catenin/LEF pathway to elevate DSB-repair capacity in cancer cells. Oncogene (2011) 30, 944-955; doi:10.1038/onc.2010.467; published online 18 October 2010	[Deng, R.; Tang, J.; Ma, J-G; Chen, S-P; Xia, L-P; Zhou, W-J; Li, D-D; Feng, G-K; Zeng, Y-X; Zhu, X-F] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	zhuxfeng@mail.sysu.edu.cn			National Significant New Drug Creation [2008ZX09312-002]; 863 program [2006AA02A404]; National Nature Science Foundation of China [81001446]; Medical Scientific Research Foundation of Guangdong province [B2008059]	National Significant New Drug Creation; 863 program(National High Technology Research and Development Program of China); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Scientific Research Foundation of Guangdong province	We thank Professor Bert Vogelstein from the Howard Hughes Medical Institute Research Laboratory Sidney Kimmel Comprehensive Cancer Center for providing us with the beta-catenin plasmid (wild type). This work was supported by grants from Major science and technology project of 'National Significant New Drug Creation' (2008ZX09312-002), 863 program (2006AA02A404), the National Nature Science Foundation of China (81001446), and Medical Scientific Research Foundation of Guangdong province (B2008059).	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Banath JP, 2003, CANCER RES, V63, P4347; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Borde V, 2009, INT J BIOCHEM CELL B, V41, P1249, DOI 10.1016/j.biocel.2008.12.013; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Brognard J, 2001, CANCER RES, V61, P3986; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deng R, 2006, ONCOGENE, V25, P7070, DOI 10.1038/sj.onc.1209686; Deng R, 2009, MOL CANCER THER, V8, P873, DOI 10.1158/1535-7163.MCT-08-1080; Deng YB, 2009, NATURE, V460, P914, DOI 10.1038/nature08196; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding J, 2006, TRENDS PHARMACOL SCI, V27, P338, DOI 10.1016/j.tips.2006.04.007; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; HE X, 2007, LETT BIOTECHNOL, V18, P978; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim IA, 2005, CANCER RES, V65, P7902, DOI 10.1158/0008-5472.CAN-05-0513; Kim TJ, 2006, BRIT J CANCER, V94, P1678, DOI 10.1038/sj.bjc.6603180; Lee CM, 2006, CLIN CANCER RES, V12, P250, DOI 10.1158/1078-0432.CCR-05-1084; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pitts SA, 2001, HUM MOL GENET, V10, P1155, DOI 10.1093/hmg/10.11.1155; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Williams RS, 2008, CELL, V135, P97, DOI 10.1016/j.cell.2008.08.017; Williams RS, 2007, BIOCHEM CELL BIOL, V85, P509, DOI 10.1139/O07-069; Wu Y, 2007, NAT STRUCT MOL BIOL, V14, P832, DOI 10.1038/nsmb1286	42	71	73	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					944	955		10.1038/onc.2010.467	http://dx.doi.org/10.1038/onc.2010.467			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20956948				2022-12-28	WOS:000287695900006
J	von Bubnoff, N; Gorantla, SP; Engh, RA; Oliveira, TM; Thone, S; Aberg, E; Peschel, C; Duyster, J				von Bubnoff, N.; Gorantla, S. P.; Engh, R. A.; Oliveira, T. M.; Thoene, S.; Aberg, E.; Peschel, C.; Duyster, J.			The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro	ONCOGENE			English	Article						myeloid neoplasms; FIP1L1-PDGFRA; signaling therapies; drug resistance	GROWTH-FACTOR-RECEPTOR; GASTROINTESTINAL STROMAL TUMORS; BCR-ABL; HYPEREOSINOPHILIC SYNDROME; EOSINOPHILIC LEUKEMIA; MYELOPROLIFERATIVE DISEASE; NILOTINIB AMN107; T674I MUTATION; C-KIT; IMATINIB	Myeloproliferation with prominent eosinophilia is associated with rearrangements of PDGFR-A or -B. The most common rearrangement is FIP1L1-PDGFRA (FP). The majority of patients with PDGFR-rearranged myeloproliferation respond to treatment with imatinib. In contrast to BCR-ABL-positive chronic myelogenous leukemia, only few cases of imatinib resistance and mutations of the FP kinase domain have been described so far. We hypothesized that the number of critical residues mediating imatinib resistance in FP in contrast to BCR-ABL might be limited. We performed an established systematic and comprehensive in vitro resistance screen to determine the pattern and frequency of possible TKI resistance mutations in FP. We identified 27 different FP kinase domain mutations including 25 novel variants, which attenuated response to imatinib, nilotinib or sorafenib. However, the majority of these exchanges did not confer complete inhibitor resistance. At clinically achievable drug concentrations, FP/T674I predominated with imatinib, whereas with nilotinib and sorafenib, FP/D842V and the compound mutation T674I+T874I became prevalent. Our results suggest that the PDGFR kinase domain contains a limited number of residues where exchanges critically interfere with binding of and inhibition by available PDGFR kinase inhibitors at achievable concentrations, which might explain the low frequency of imatinib resistance in this patient population. In addition, these findings would help to select the appropriate second-line drug in cases of imatinib-resistant disease and may be translated to other neoplasms driven by activated forms of PDGFR-A or -B. Oncogene (2011) 30, 933-943; doi:10.1038/onc.2010.476; published online 25 October 2010	[von Bubnoff, N.; Gorantla, S. P.; Peschel, C.; Duyster, J.] Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin 3, D-81675 Munich, Bavaria, Germany; [Engh, R. A.; Oliveira, T. M.; Aberg, E.] Univ Tromso, Dept Chem, Norwegian Struct Biol Ctr, Tromso, Norway; [Engh, R. A.; Oliveira, T. M.; Aberg, E.] Univ Tromso, Dept Pharm, Norwegian Struct Biol Ctr, Tromso, Norway; [Thoene, S.] Ctr Comprehens Canc, Inst Expt Canc Res, Ulm, Germany; [Thoene, S.] Univ Hosp Ulm, Ulm, Germany	Technical University of Munich; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; Ulm University; Ulm University	von Bubnoff, N (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin 3, Ismaningerstr 22, D-81675 Munich, Bavaria, Germany.	n.bubnoff@lrz.tum.de	Thoene, Silvia/P-2687-2018; von Bubnoff, Nikolas/AAG-1845-2021; von Bubnoff, Nikolas/F-2351-2017	Thoene, Silvia/0000-0003-3155-7293; von Bubnoff, Nikolas/0000-0001-9593-8947; Engh, Richard/0000-0002-6207-0560	Bundesministerium fur Bildung und Forschung (NGFNplus); Wilhelm-Sander Stiftung; Deutsche Forschungsgemeinschaft [SFB 684/A11]; Kommission fur Klinische Forschung (KKF), Technische Universitat Munchen	Bundesministerium fur Bildung und Forschung (NGFNplus)(Federal Ministry of Education & Research (BMBF)); Wilhelm-Sander Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Kommission fur Klinische Forschung (KKF), Technische Universitat Munchen	This work was supported by a grant to JD and NvB from the Bundesministerium fur Bildung und Forschung (NGFNplus), and from the Wilhelm-Sander Stiftung, by a grant to JD from the Deutsche Forschungsgemeinschaft (SFB 684/A11), and by a grant to NvB by the Kommission fur Klinische Forschung (KKF), Technische Universitat Munchen.	Apperley JF, 2007, LANCET ONCOL, V8, P1018, DOI 10.1016/S1470-2045(07)70342-X; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Baccarani M, 2009, J CLIN ONCOL, V27, P6041, DOI 10.1200/JCO.2009.25.0779; Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Branford S, 2009, BLOOD, V114, P5426, DOI 10.1182/blood-2009-08-215939; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corless CL, 2008, ANNU REV PATHOL-MECH, V3, P557, DOI 10.1146/annurev.pathmechdis.3.121806.151538; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; Cortes J, 2007, BLOOD, V110, P4005, DOI 10.1182/blood-2007-03-080838; Cross NCP, 2008, ACTA HAEMATOL-BASEL, V119, P199, DOI 10.1159/000140631; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Dewaele B, 2008, CLIN CANCER RES, V14, P5749, DOI 10.1158/1078-0432.CCR-08-0533; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gotlib J, 2008, LEUKEMIA, V22, P1999, DOI 10.1038/leu.2008.287; Guida T, 2007, CLIN CANCER RES, V13, P3363, DOI 10.1158/1078-0432.CCR-06-2667; Guo T, 2007, CLIN CANCER RES, V13, P4874, DOI 10.1158/1078-0432.CCR-07-0484; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hughes T, 2009, J CLIN ONCOL, V27, P4204, DOI 10.1200/JCO.2009.21.8230; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kindler T, 2005, BLOOD, V105, P335, DOI 10.1182/blood-2004-02-0660; Lahaye T, 2005, CANCER-AM CANCER SOC, V103, P1659, DOI 10.1002/cncr.20922; Lierman E, 2009, LEUKEMIA, V23, P845, DOI 10.1038/leu.2009.2; Lierman E, 2006, BLOOD, V108, P1374, DOI 10.1182/blood-2006-02-004457; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nicolini FE, 2007, LEUKEMIA RES, V31, P865, DOI 10.1016/j.leukres.2006.12.003; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Ohnishi H, 2006, BRIT J HAEMATOL, V134, P547, DOI 10.1111/j.1365-2141.2006.06221.x; Peng B, 2004, J CLIN ONCOL, V22, P935, DOI 10.1200/JCO.2004.03.050; Redaelli S, 2009, J CLIN ONCOL, V27, P469, DOI 10.1200/JCO.2008.19.8853; Score J, 2009, LEUKEMIA, V23, P332, DOI 10.1038/leu.2008.309; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P1054, DOI 10.1016/j.jaci.2007.11.027; Stover EH, 2005, BLOOD, V106, P3206, DOI 10.1182/blood-2005-05-1932; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; von Bubnoff N, 2005, BLOOD, V105, P1652, DOI 10.1182/blood-2004-06-2445; von Bubnoff N, 2005, LEUKEMIA, V19, P286, DOI 10.1038/sj.leu.2403600; von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132; von Bubnoff N, 2006, BLOOD, V107, P4970, DOI 10.1182/blood-2006-01-0285; von Bubnoff N, 2009, CANCER RES, V69, P3032, DOI 10.1158/0008-5472.CAN-08-2923; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Weisberg E, 2006, GASTROENTEROLOGY, V131, P1734, DOI 10.1053/j.gastro.2006.09.017	48	23	24	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					933	943		10.1038/onc.2010.476	http://dx.doi.org/10.1038/onc.2010.476			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20972453				2022-12-28	WOS:000287695900005
J	Hu, G; Ren, G; Shi, Y				Hu, G.; Ren, G.; Shi, Y.			The putative cannabinoid receptor GPR55 promotes cancer cell proliferation	ONCOGENE			English	Editorial Material							LYSOPHOSPHATIDYLINOSITOL; LIGAND; BINDS	Cannabinoids, the active ingredients in marijuana, have dramatic effects on various organ systems. They exert their effects through two receptor types: CB1, primarily located in the brain, and CB2, primarily located in the immune system. Vertebrates also produce their own cannabinoid-like substances called endocannabinoids, including anandamide and 2-arachidonoylglyceral. Interestingly, some effects of endocannabinoids could not be explained by the signals through either CB1 or CB2. Recently, the orphan G protein-coupled receptor 55 (GPR55) was proposed to be an atypical cannabinoid receptor. In this issue of Oncogene, two groups demonstrated that GPR55 is expressed in various cancer types in an aggressiveness-related manner, suggesting a novel cancer biomarker and a potential therapeutic target. Oncogene (2011) 30, 139-141; doi:10.1038/onc.2010.502; published online 8 November 2010	[Hu, G.; Shi, Y.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Key Lab Stem Cell Biol, Shanghai Inst Biol Sci,Sch Med,Inst Hlth Sci, Shanghai 200025, Peoples R China; [Ren, G.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Shi, Y (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Key Lab Stem Cell Biol, Shanghai Inst Biol Sci,Sch Med,Inst Hlth Sci, 225 S Chongqing Rd, Shanghai 200025, Peoples R China.	yufangshi@sibs.ac.cn	Ren, Gary/F-6724-2011; Shi, Yufang/AAE-4431-2020; Ren, Guangwen/D-8895-2012; Ren, Guangwen/H-5671-2011	Shi, Yufang/0000-0001-8964-319X; 				Alexander A, 2009, CANCER LETT, V285, P6, DOI 10.1016/j.canlet.2009.04.005; Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; DAS SK, 1995, P NATL ACAD SCI USA, V92, P4332, DOI 10.1073/pnas.92.10.4332; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Oesch S, 2009, J PHARM PHARMACOL, V61, P839, DOI 10.1211/jpp/61.07.0002; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; PINCIRO R, 2011, ONCOGENE, V30, P142; Sharir H, 2010, PHARMACOL THERAPEUT, V126, P301, DOI 10.1016/j.pharmthera.2010.02.004; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V229, P58, DOI 10.1006/bbrc.1996.1757; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106	14	30	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					139	141		10.1038/onc.2010.502	http://dx.doi.org/10.1038/onc.2010.502			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	21057532				2022-12-28	WOS:000286438900002
J	Deng, Y; Liu, J; Han, G; Lu, SL; Wang, SY; Malkoski, S; Tan, AC; Deng, C; Wang, XJ; Zhang, Q				Deng, Y.; Liu, J.; Han, G.; Lu, S-L; Wang, S-Y; Malkoski, S.; Tan, A. C.; Deng, C.; Wang, X-J; Zhang, Q.			Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1	ONCOGENE			English	Article						Brca1; CtBP1; NADH; transcription; tumor suppressor; HNSCC	SQUAMOUS-CELL CARCINOMA; TERMINAL BINDING-PROTEIN; FANCONI-ANEMIA; NECK-CANCER; NEGATIVE MODULATION; ANTIOXIDANT TEMPOL; DOWN-REGULATION; BREAST-CANCER; E1A PROTEIN; RAT-LIVER	C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor and metabolic sensory protein, which often represses tumor suppressor genes. Hence, we sought to determine if CtBP1 affects expression of the tumor suppressor Brca1 in head and neck tissue, as downregulation of Brca1 begins at the early stages of head and neck squamous cell carcinomas (HNSCCs). We found that CtBP1 represses Brca1 transcription by binding to the E2F4 site of the Brca1 promoter. Additionally, the recruitment of CtBP1 to the Brca1 promoter is redox-dependent, that is, increased at high NADH levels in hypoxic conditions. Further, immunostaining using a human HNSCC tissue array revealed that nuclear CtBP1 staining began to accumulate in hyperplasic lesions and HNSCCs, this staining correlated with Brca1 downregulation in these lesions. Pharmacological disruption of CtBP1 binding to Brca1 promoter by the antioxidant Tempol, which reduces NADH levels, relieved CtBP1-mediated repression of Brca1, leading to increased DNA repair in HNSCC cells. As tumor cells are generally hypoxic with increased NADH levels, the dynamic control of Brca1 by a 'metabolic switch' found in this study not only provides an important link between tumor metabolism and tumor suppressor expression but also suggests a potential chemo preventative or therapeutic strategy for HNSCC by blocking NADH-dependent CtBP1 activity at early stages of HNSCC carcinogenesis. Oncogene (2010) 29, 6603-6608; doi:10.1038/onc.2010.406; published online 6 September 2010	[Han, G.; Wang, X-J] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Deng, Y.; Liu, J.; Zhang, Q.] Univ Colorado, Dept Dermatol, Aurora, CO 80045 USA; [Lu, S-L] Univ Colorado, Dept Otolaryngol, Aurora, CO 80045 USA; [Wang, S-Y] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; [Malkoski, S.] Univ Colorado, Dept Med, Div Pulm, Aurora, CO 80045 USA; [Tan, A. C.] Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO 80045 USA; [Deng, C.] NIDDK, NIH, Bethesda, MD USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wang, XJ (corresponding author), Univ Colorado, Dept Pathol, Aurora, CO 80045 USA.	xj.wang@UCDenver.edu; Qinghong.Zhang@UCDenver.edu	deng, chuxia/N-6713-2016; Tan, Aik Choon/A-3135-2011	Tan, Aik Choon/0000-0003-2955-8369	NIH [R01DE15953, R01CA115468]; NATIONAL CANCER INSTITUTE [R01CA115468, R01CA087849, K08CA131483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by Grants from the NIH, R01DE15953 (to X-JW) and R01CA115468 (to QZ). We thank Dr Petra Boukamp for providing the normal human keratinocytes HaCaT cells and Dr James Mitchell for helpful discussions.	Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Berton TR, 2003, ONCOGENE, V22, P5415, DOI 10.1038/sj.onc.1206825; Bindra RS, 2006, CANCER BIOL THER, V5, P1400, DOI 10.4161/cbt.5.10.3454; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; De Siervi A, 2010, CANCER RES, V70, P532, DOI 10.1158/0008-5472.CAN-09-1477; Erker L, 2005, HUM MOL GENET, V14, P1699, DOI 10.1093/hmg/ddi181; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; IANNONE A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P285, DOI 10.1016/0304-4165(90)90052-X; Kim JH, 2009, CELL DEATH DIFFER, V16, P584, DOI 10.1038/cdd.2008.186; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Metz JM, 2004, CLIN CANCER RES, V10, P6411, DOI 10.1158/1078-0432.CCR-04-0658; Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8; Mitchell JB, 2003, FREE RADICAL BIO MED, V34, P93, DOI 10.1016/S0891-5849(02)01193-0; Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schubert R, 2004, HUM MOL GENET, V13, P1793, DOI 10.1093/hmg/ddh189; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sparano A, 2006, LARYNGOSCOPE, V116, P735, DOI 10.1097/01.mlg.0000205141.54471.7f; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Wu WN, 2007, AM J PHYSIOL-LUNG C, V293, pL952, DOI 10.1152/ajplung.00203.2007; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang QS, 2008, CANCER RES, V68, P1601, DOI 10.1158/0008-5472.CAN-07-5186; Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103	44	27	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6603	6608		10.1038/onc.2010.406	http://dx.doi.org/10.1038/onc.2010.406			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818429	Green Accepted			2022-12-28	WOS:000285380200009
J	Rokaeus, N; Shen, J; Eckhardt, I; Bykov, VJN; Wiman, KG; Wilhelm, MT				Rokaeus, N.; Shen, J.; Eckhardt, I.; Bykov, V. J. N.; Wiman, K. G.; Wilhelm, M. T.			PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73	ONCOGENE			English	Article						PRIMA-1(MET); APR-246; reactivation; mutant p63; mutant p73; apoptosis	TUMOR-SUPPRESSOR FUNCTIONS; DNA-BINDING ACTIVITY; EEC-SYNDROME; HOMOLOG P63; APOPTOSIS; GENE; ACTIVATION; INDUCTION; CELLS; LIMB	The low molecular weight compound PRIMA-1 and the structural analog PRIMA-1(MET), also named APR-246, reactivate mutant p53 through covalent binding to the core domain and induce apoptosis in tumor cells. Here, we asked whether PRIMA-1(MET)/APR-246 can rescue mutant forms of the p53 family members p63 and p73 that share high sequence homology with p53. We found that PRIMA-1(MET)/APR-246 can restore the pro-apoptotic function to mutant TAp63 gamma and TAp73 beta in tumor cells but has less effect on TAp73 alpha. Moreover, PRIMA-1(MET)/APR-246-stimulated DNA binding of mutant TAp63 gamma and induced expression of the p53/p63/p73 downstream targets p21 and Noxa. The reactivation of mutant p53, p63 and p73 by PRIMA-1(MET)/APR-246 indicates a common mechanism, presumably involving homologous structural elements in the p53 family proteins. Our findings may open avenues for therapeutic intervention in human developmental disorders with mutations in p63. Oncogene (2010) 29, 6442-6451; doi:10.1038/onc.2010.382; published online 6 September 2010	[Wiman, K. G.] Karolinska Inst, CCK, Dept Oncol Pathol, Karolinska Univ Hosp R8 04, SE-17176 Stockholm, Sweden; [Wilhelm, M. T.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, CCK, Dept Oncol Pathol, Karolinska Univ Hosp R8 04, SE-17176 Stockholm, Sweden.	Klas.Wiman@ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Nakade Bykov, Vladimir/0000-0002-7199-8942; Wilhelm, Margareta/0000-0002-0516-9724	EU [LSHB-CT-2005-019067]	EU(European Commission)	We thank Dr Jiandong Chen, H Lee Moffitt Cancer Center, for the ts mutant p63/p73-expressing cells, and Dr Bert Vogelstein, Johns Hopkins Oncology Center, for the HCT116 cells. This work was supported by EU 6th Framework Program within the EPISTEM Integrated Project (LSHB-CT-2005-019067).	Bernassola F, 2005, ONCOGENE, V24, P6982, DOI 10.1038/sj.onc.1208843; Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Corn PG, 1999, CANCER RES, V59, P3352; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Demma MJ, 2004, J BIOL CHEM, V279, P45887, DOI 10.1074/jbc.M401854200; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawano S, 1999, BLOOD, V94, P1113; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Rinne T, 2007, CELL CYCLE, V6, P262, DOI 10.4161/cc.6.3.3796; Rokaeus N, 2007, ONCOGENE, V26, P982, DOI 10.1038/sj.onc.1209858; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Scoumanne A, 2005, CANCER BIOL THER, V4, P1178, DOI 10.4161/cbt.4.11.2254; Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zache N, 2008, CELL ONCOL, V30, P411, DOI 10.3233/CLO-2008-0440; Zeng XY, 2001, CARCINOGENESIS, V22, P215, DOI 10.1093/carcin/22.2.215	48	45	47	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6442	6451		10.1038/onc.2010.382	http://dx.doi.org/10.1038/onc.2010.382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20818419				2022-12-28	WOS:000285138900004
J	Atwood, AA; Sealy, L				Atwood, A. A.; Sealy, L.			Regulation of C/EBPbeta1 by Ras in mammary epithelial cells and the role of C/EBPbeta1 in oncogene-induced senescence	ONCOGENE			English	Article						C/EBPbeta; Ras; senescence; MCF10A; IL6	BINDING-PROTEIN-BETA; DIFFERENTIATION; PROLIFERATION; TUMORIGENESIS; PATHWAY; ALPHA	Overexpression of Ras(V12) in MCF10A cells, an immortalized mammary epithelial cell line, leads to transformation of these cells. We demonstrate that this is accompanied by degradation of C/EBPbeta1. C/EBP beta is a transcription factor in which three protein isoforms exist because of alternative translation at three in-frame methionines. When C/EBPbeta1 is expressed in MCF10A-Ras(V12) cells, immunoblot analysis reveals that C/EBPbeta1 is degraded in these cells. Treatment of MCF10A-Ras(V12)-C/EBPbeta1 cells with the cdk inhibitor roscovitine leads to stabilization of C/EBPbeta1. It has been previously shown that cdk2 phosphorylates C/EBPbeta on Thr235. We demonstrate that mutation of Thr235 to alanine in C/EBPbeta1 is sufficient to restore the stability of C/EBPbeta1 expression in MCF10A-Ras( V12) cells. Overexpression of Ras(V12) in primary cells induces senescence rather than transformation, thus suppressing tumorigenesis. C/EBPbeta is required for Ras(V12)-induced senescence in primary mouse embryonic fibroblasts. Upregulation of interleukin-6 (IL6) by C/EBPbeta has been shown to be necessary for oncogene-induced senescence, but the specific isoform of C/EBPbeta has not been investigated. We show that the C/EBPbeta1 isoform upregulates IL6 when introduced into normal fibroblasts. In addition, we show that C/EBPbeta1 induces senescence. Taken together, degradation of C/EBPbeta1 by Ras activation may represent a mechanism to bypass OIS. Oncogene (2010) 29, 6004-6015; doi:10.1038/onc.2010.336; published online 6 September 2010	[Sealy, L.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Atwood, A. A.; Sealy, L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 23rd Ave S Garland,Light Hall 702, Nashville, TN 37232 USA.	Linda.sealy@vanderbilt.edu			NIH [GM69634]; Cell Biology and Molecular Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069634] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cell Biology and Molecular Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Maria Abreu, Kim Boelte, Linda Bundy, Alisha Russell and David Vaught for insightful suggestions and Rachel Jerrell for technical assistance. We thank Gary Nolan (Standford University) for LZRS-BMN-lacZ and Phoenix cells, Scott Lowe (Cold Spring Harbor) for pBABE-Ras(V12)-puromycin, Hal Moses (Vanderbilt University) for WI-38 fibroblasts and S. Akira for CMV-NF-IL6-T235A. We also thank Cathy Alford in the Veterans Affairs flow cytometry core (Nashville, TN) for technical assistance. This work was funded by NIH GM69634 and by the Cell Biology and Molecular Sciences training grant.	Bundy L, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-43; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Calkhoven CF, 2000, GENE DEV, V14, P1920; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Grignani F, 1998, CANCER RES, V58, P14; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Iavarone A, 1997, NATURE, V387, P417; Koslowski M, 2009, J BIOL CHEM, V284, P28607, DOI 10.1074/jbc.M109.031120; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Li X, 2007, P NATL ACAD SCI USA, V104, P11597, DOI 10.1073/pnas.0703771104; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Uematsu S, 2007, J IMMUNOL, V179, P5378, DOI 10.4049/jimmunol.179.8.5378; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	24	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6004	6015		10.1038/onc.2010.336	http://dx.doi.org/10.1038/onc.2010.336			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20818427	Green Accepted			2022-12-28	WOS:000284108700003
J	Arozarena, I; Bischof, H; Gilby, D; Belloni, B; Dummer, R; Wellbrock, C				Arozarena, I.; Bischof, H.; Gilby, D.; Belloni, B.; Dummer, R.; Wellbrock, C.			In melanoma, beta-catenin is a suppressor of invasion	ONCOGENE			English	Article						melanoma; invasion; Rho; ROCK; MMP; MITF	TRANSCRIPTION FACTOR; COLORECTAL-CANCER; PROGNOSTIC MARKER; CELL-MIGRATION; EXPRESSION; MITF; PROLIFERATION; PROGRESSION; TARGET; P16(INK4A)	Cell-type-specific signalling determines cell fate under physiological conditions, but it is increasingly apparent that also in cancer development the impact of any given oncogenic pathway on the individual cancer pathology is dependent on cell-lineage-specific molecular traits. For instance in colon and liver cancer canonical Wnt signalling produces increased cytoplasmic and nuclear localised beta-catenin, which correlates with invasion and poor prognosis. In contrast, in melanoma increased cytoplasmic and nuclear beta-catenin is currently emerging as a marker for good prognosis, and thus seems to have a different function compared with other cancer types; however, this function is unknown. We discovered that in contrast to its function in other cancers, in melanoma, beta-catenin blocks invasion. We demonstrate that this opposing role of nuclear beta-catenin in melanoma is mediated through MITF, a melanoma-specific protein that defines the lineage background of this cancer type. Downstream of beta-catenin MITF not only suppresses the Rho-GTPase-regulated cell morphology of invading melanoma cells, but also interferes with beta-catenin-induced expression of the essential collagenase MT1-MMP, thus affecting all aspects of an invasive phenotype. Importantly, overexpression of MITF in invasive colon cancer cells modifies beta-catenin-directed signalling and induces a 'melanoma phenotype'. In summary, the cell-type-specific presence of MITF in melanoma affects beta-catenin's pro-invasive properties otherwise active in colon or liver cancer. Thus our study reveals the general importance of considering cell-type-specific signalling for the accurate interpretation of tumour markers and ultimately for the design of rational therapies. Oncogene (2011) 30, 4531-4543; doi:10.1038/onc.2011.162; published online 16 May 2011	[Arozarena, I.; Bischof, H.; Gilby, D.; Wellbrock, C.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; [Belloni, B.; Dummer, R.] Univ Spital Zurich, Dept Dermatol, Zurich, Switzerland	University of Manchester; University of Zurich; University Zurich Hospital	Wellbrock, C (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	claudia.wellbrock@manchester.ac.uk	Arozarena, Imanol/A-5981-2017	Arozarena, Imanol/0000-0001-6349-2442; Wellbrock, Claudia/0000-0002-3825-6381	BBSRC [BB/G001111/1]; Wellcome Trust; University of Manchester; Cancer Research UK [C11591/A10202]; Biotechnology and Biological Sciences Research Council [BB/G001111/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); University of Manchester; Cancer Research UK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank Steven Rosenberg (NCI) for the 501mel, 888mel and 1290mel cells and Hector Palmer (Vall d'Hebron) for the beta-catenin reporter plasmids. We thank Peter March for his help with microscopy. The Bioimaging Facility microscopes were funded by the BBSRC, the Wellcome Trust and the University of Manchester Strategic Fund. This work was funded by Cancer Research UK (grant C11591/A10202) and the BBSRC (grant BB/G001111/1).	Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Boye K, 2010, EUR J CANCER, V46, P2919, DOI 10.1016/j.ejca.2010.07.013; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Demirkan NC, 2007, CLIN EXP DERMATOL, V32, P733, DOI 10.1111/j.1365-2230.2007.02507.x; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Itoh Y, 2006, IUBMB LIFE, V58, P589, DOI 10.1080/15216540600962818; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Liu LA, 2010, CLIN CANCER RES, V16, P2740, DOI 10.1158/1078-0432.CCR-09-2610; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Nazarian RM, 2010, J CUTAN PATHOL, V37, P41, DOI 10.1111/j.1600-0560.2010.01505.x; O'Connell MP, 2009, PIGM CELL MELANOMA R, V22, P724, DOI 10.1111/j.1755-148X.2009.00627.x; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Pecina-Slaus N, 2007, J CUTAN PATHOL, V34, P239, DOI 10.1111/j.1600-0560.2006.00601.x; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; ROBBINS PF, 1995, J IMMUNOL, V154, P5944; Rothberg BEG, 2009, J CLIN ONCOL, V27, P5772, DOI 10.1200/JCO.2009.22.8239; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Salti GI, 2000, CANCER RES, V60, P5012; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Zulehner G, 2010, AM J PATHOL, V176, P472, DOI 10.2353/ajpath.2010.090300	50	87	88	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4531	4543		10.1038/onc.2011.162	http://dx.doi.org/10.1038/onc.2011.162			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21577209	Green Accepted			2022-12-28	WOS:000296890700001
J	Uzawa, K; Ishigami, T; Fushimi, K; Kawata, T; Shinozuka, K; Kasamatsu, A; Sakamoto, Y; Ogawara, K; Shiiba, M; Bukawa, H; Ito, H; Tanzawa, H				Uzawa, K.; Ishigami, T.; Fushimi, K.; Kawata, T.; Shinozuka, K.; Kasamatsu, A.; Sakamoto, Y.; Ogawara, K.; Shiiba, M.; Bukawa, H.; Ito, H.; Tanzawa, H.			Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells	ONCOGENE			English	Article						fibroblast growth factor receptor 3 gene; FGFR3; radiosensitivity; squamous cell carcinoma	DIFFERENTIATION; INHIBITION; EXPRESSION	Conventional therapies including radiation therapy cannot cure squamous cell carcinoma (SCC), and new treatments are clearly required. Our recent studies have shown that SCC cell lines exhibiting radioresistance show significant upregulation of the fibroblast growth factor receptor 3 (FGFR3) gene. We hypothesized that inhibiting FGFR3 would suppress tumor cell radioresistance and provide a new treatment approach for human SCCs. In the present study, we found that RNA interference-mediated FGFR3 depletion in HSC-2 cells, a radioresistant cell line, induced radiosensitivity and inhibited tumor growth. Use of an FGFR3 inhibitor (PD173074) obtained similar results with suppression of the autophosphorylation extracellular signal-regulated kinase pathway in HSC-2 cells and lung cancer cell lines. Moreover, the antitumor growth effect of the combination of PD173074 and radiation in vivo was also greater than that with either drug alone or radiation alone. Our results provided novel information on which to base further mechanistic study of radiosensitization by inhibiting FGFR3 in human SCC cells and for developing strategies to improve outcomes with concurrent radiotherapy. Oncogene (2011) 30, 4447-4452; doi:10.1038/onc.2011.159; published online 16 May 2011	[Uzawa, K.] Chiba Univ, Dept Clin Mol Biol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; [Uzawa, K.; Kasamatsu, A.; Sakamoto, Y.; Ogawara, K.; Shiiba, M.; Tanzawa, H.] Chiba Univ Hosp, Div Dent Oral & Maxillofacial Surg, Chiba, Japan; [Kawata, T.; Ito, H.] Chiba Univ, Dept Radiol, Grad Sch Med, Chiba 2608670, Japan; [Shinozuka, K.; Bukawa, H.] Univ Tsukuba, Dept Oral & Maxillofacial Surg, Inst Clin Med, Grad Sch Comprehens Human Sci, Ibaraki, Japan	Chiba University; Chiba University; Chiba University; University of Tsukuba	Uzawa, K (corresponding author), Chiba Univ, Dept Clin Mol Biol, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	uzawak@faculty.chiba-u.jp		Uzawa, Katsuhiro/0000-0002-7036-0859	Ministry of Education, Science, Sports and Culture of Japan [22659364]; Japan Society for Promotion of Science [1952163]; 21st Century Center of Excellence Programs grant;  [19659520]	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); 21st Century Center of Excellence Programs grant; 	We thank Lynda C Charters for proofreading this manuscript. This work was supported by a grant-in-aid from the Ministry of Education, Science, Sports and Culture of Japan (no. 22659364), a grant-in-aid from the Japan Society for Promotion of Science Fellows (1952163), a grant-in-aid for Exploratory Research (19659520) and the 21st Century Center of Excellence Programs grant.	BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FOWLER JF, 1974, INT J RADIAT BIOL, V25, P213, DOI 10.1080/09553007414550271; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Henson B J, 2010, Cytogenet Genome Res, V128, P192, DOI 10.1159/000308303; Ishigami T, 2007, INT J CANCER, V120, P2262, DOI 10.1002/ijc.22561; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Knowles MA, 2008, FUTURE ONCOL, V4, P71, DOI 10.2217/14796694.4.1.71; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Masih-Khan E, 2006, BLOOD, V108, P3465, DOI 10.1182/blood-2006-04-017087; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Pardo OE, 2009, CANCER RES, V69, P8645, DOI 10.1158/0008-5472.CAN-09-1576; Rosty C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-15; Shintani S, 2003, INT J CANCER, V107, P1030, DOI 10.1002/ijc.11437; Studer G, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-16; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650	18	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4447	4452		10.1038/onc.2011.159	http://dx.doi.org/10.1038/onc.2011.159			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21577207				2022-12-28	WOS:000296356500007
J	Morello, V; Cabodi, S; Sigismund, S; Camacho-Leal, MP; Repetto, D; Volante, M; Papotti, M; Turco, E; Defilippi, P				Morello, V.; Cabodi, S.; Sigismund, S.; Camacho-Leal, M. P.; Repetto, D.; Volante, M.; Papotti, M.; Turco, E.; Defilippi, P.			beta 1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells	ONCOGENE			English	Article						EGFR; beta 1 integrin; lung cancer	GROWTH-FACTOR-RECEPTOR; IN-VIVO; TUMOR PROGRESSION; INTEGRIN; KINASE; EXPRESSION; PATHWAY; PHOSPHORYLATION; ACTIVATION; MIGRATION	Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells beta 1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced beta 1 integrin in human NSCLC A549 cells. The beta 1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, beta 1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that beta 1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that beta 1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that beta 1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy. Oncogene (2011) 30, 4087-4096; doi:10.1038/onc.2011.107; published online 11 April 2011	[Morello, V.; Cabodi, S.; Camacho-Leal, M. P.; Repetto, D.; Turco, E.; Defilippi, P.] Univ Turin, Ctr Mol Biotechnol, I-10125 Turin, Italy; [Sigismund, S.] Ist FIRC Oncol Mol, Milan, Italy; [Volante, M.; Papotti, M.] Univ Turin, Orbassano, TO, Italy	University of Turin; IFOM - FIRC Institute of Molecular Oncology; University of Turin	Defilippi, P (corresponding author), Univ Turin, Ctr Mol Biotechnol, Via Nizza 52, I-10125 Turin, Italy.	paola.defilippi@unito.it	DEFILIPPI, Paola/L-2232-2014; Sigismund, Sara/H-3687-2017	Sigismund, Sara/0000-0002-1396-4453; Morello, Virginia/0000-0002-3001-0993	AIRC; AICR; EU; MUR; Regione Piemonte-Progetti Sanita; Oncoprot; PiSTEM; Druidi and CIPE; Compagnia San Paolo, Torino	AIRC(Fondazione AIRC per la ricerca sul cancro); AICR; EU(European Commission); MUR(Ministry of Education, Universities and Research (MIUR)); Regione Piemonte-Progetti Sanita; Oncoprot; PiSTEM; Druidi and CIPE; Compagnia San Paolo, Torino(Compagnia di San Paolo)	We thank Dr Jim Norman (The Beatson Institute for Cancer Research, Glasgow, UK) for kindly providing the RCP construct. We also thank Elona Saraci for initial experiments and Giusy Tornillo for the 3D invasion assays. This work was supported by AIRC, AICR, EU FP7 Metafight, MUR (PRIN, ex-60%), Regione Piemonte-Progetti Sanita, Oncoprot, PiSTEM, Druidi and CIPE, Compagnia San Paolo, Torino.	Adachi M, 2000, CLIN CANCER RES, V6, P96; Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301; Brockbank EC, 2005, BRIT J CANCER, V92, P102, DOI 10.1038/sj.bjc.6602255; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Cabodi S, 2009, J CELL PHYSIOL, V218, P294, DOI 10.1002/jcp.21603; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Cordes N, 2007, INT J RADIAT BIOL, V83, P753, DOI 10.1080/09553000701639694; Cusinato F, 1999, BBA-MOL CELL RES, V1451, P35, DOI 10.1016/S0167-4889(99)00092-0; Damiano L, 2010, ONCOGENE, V29, P3677, DOI 10.1038/onc.2010.128; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dingemans AMC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-152; Erba EB, 2005, MOL CELL PROTEOMICS, V4, P1107, DOI 10.1074/mcp.M500070-MCP200; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Klein EA, 2007, METHOD ENZYMOL, V426, P155, DOI 10.1016/S0076-6879(07)26008-2; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Maione P, 2010, EXPERT OPIN PHARMACO, V11, P2997, DOI 10.1517/14656566.2010.511615; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Okamura M, 2007, HUM PATHOL, V38, P1081, DOI 10.1016/j.humpath.2007.01.003; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Tosoni D, 2005, CELL, V123, P875, DOI 10.1016/j.cell.2005.10.021; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Walker JL, 2005, CANCER METAST REV, V24, P383, DOI 10.1007/s10555-005-5130-7; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yoshida T, 2010, BIOCHEM PHARMACOL, V80, P613, DOI 10.1016/j.bcp.2010.05.014	42	107	110	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4087	4096		10.1038/onc.2011.107	http://dx.doi.org/10.1038/onc.2011.107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21478906	Green Submitted			2022-12-28	WOS:000295357500004
J	Maurer, G; Tarkowski, B; Baccarini, M				Maurer, G.; Tarkowski, B.; Baccarini, M.			Raf kinases in cancer-roles and therapeutic opportunities	ONCOGENE			English	Review						Raf; Ras; ERK pathway; hallmarks of cancer; kinase inhibitors	CELL-CYCLE ARREST; NF-KAPPA-B; MAPK PATHWAY ACTIVATION; C-RAF; WILD-TYPE; INHIBITORY PROTEIN; TUMOR PROGRESSION; SIGNALING PATHWAY; LUNG-CANCER; INCREASED MALIGNANCY	Raf are conserved, ubiquitous serine/protein kinases discovered as the cellular elements hijacked by transforming retroviruses. The three mammalian RAF proteins (A, B and CRAF) can be activated by the human oncogene RAS, downstream from which they exert both kinase-dependent and kinase-independent, tumor-promoting functions. The kinase-dependent functions are mediated chiefly by the MEK/ERK pathway, whose activation is associated with proliferation in a broad range of human tumors. Almost 10 years ago, activating BRAF mutations were discovered in a subset of human tumors, and in the past year treatment with small-molecule RAF inhibitors has yielded unprecedented response rates in melanoma patients. Thus, Raf qualifies as an excellent molecular target for anticancer therapy. This review focuses on the role of BRAF and CRAF in different aspects of carcinogenesis, on the success of molecular therapies targeting Raf and the challenges they present. Oncogene (2011) 30, 3477-3488; doi:10.1038/onc.2011.160; published online 16 May 2011	[Maurer, G.; Tarkowski, B.; Baccarini, M.] Univ Vienna, Ctr Mol Biol, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Baccarini, M (corresponding author), Univ Vienna, Ctr Mol Biol, Max F Perutz Labs, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	manuela.baccarini@univie.ac.at	Baccarini, Manuela/B-6481-2014	Baccarini, Manuela/0000-0002-3033-391X; Tarkowski, Bartosz/0000-0001-8187-1307	Austrian Scientific Research Fund [P19530, SFB 021]; European Community [INFLA-CARE, GROWTHSTOP]	Austrian Scientific Research Fund(Austrian Science Fund (FWF)); European Community(European Commission)	We thank all the members of the Baccarini lab for helpful discussions and apologize to all the colleagues whose work could not be cited in this review for reasons of space. The Baccarini lab is supported by the Austrian Scientific Research Fund (Grants P19530 and SFB 021) and the European Community (Grants INFLA-CARE and GROWTHSTOP).	Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Alavi AS, 2007, CANCER RES, V67, P2766, DOI 10.1158/0008-5472.CAN-06-3648; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Arkenau HT, 2010, BRIT J CANCER, V104, P392; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Beliveau A, 2010, GENE DEV, V24, P2800, DOI 10.1101/gad.1990410; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Calipel A, 2006, J BIOL CHEM, V281, P9238, DOI 10.1074/jbc.M600228200; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Catalanotti F, 2009, NAT STRUCT MOL BIOL, V16, P294, DOI 10.1038/nsmb.1564; Cekanova M, 2007, CANCER-AM CANCER SOC, V109, P1164, DOI 10.1002/cncr.22520; Ceteci F, 2007, CANCER CELL, V12, P145, DOI 10.1016/j.ccr.2007.06.014; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Dai Y, 2008, BLOOD, V112, P2439, DOI 10.1182/blood-2008-05-159392; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Degen A, 2010, DERMATOLOGY, V221, P193, DOI 10.1159/000317081; Dessars B, 2007, J INVEST DERMATOL, V127, P1468, DOI 10.1038/sj.jid.5700725; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Dwyer J, 2007, ANN NY ACAD SCI, V1114, P36, DOI 10.1196/annals.1396.022; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Ehrenreiter K, 2009, CANCER CELL, V16, P149, DOI 10.1016/j.ccr.2009.06.008; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015; Fan S, 2007, ONCOGENE, V26, P4774, DOI 10.1038/sj.onc.1210271; Fedorov LM, 2003, CANCER RES, V63, P2268; Fedorov LM, 2002, CANCER RES, V62, P6297; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fukuyo Y, 2008, CANCER RES, V68, P6324, DOI 10.1158/0008-5472.CAN-07-6602; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Golding SE, 2007, CANCER RES, V67, P1046, DOI 10.1158/0008-5472.CAN-06-2371; Goueli BS, 2004, MOL CELL BIOL, V24, P25, DOI 10.1128/MCB.24.1.25-35.2004; Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Hwang YH, 2004, HEPATOL RES, V29, P113, DOI 10.1016/j.hepres.2004.02.009; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kamata T, 2010, CANCER RES, V70, P8475, DOI 10.1158/0008-5472.CAN-10-0603; Karreth FA, 2009, MOL CELL, V36, P477, DOI 10.1016/j.molcel.2009.10.017; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Kefford R, 2010, ASCO M S, V28; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kinkade R, 2008, CANCER RES, V68, P3810, DOI 10.1158/0008-5472.CAN-07-6672; Klein RM, 2008, MOL BIOL CELL, V19, P498, DOI 10.1091/mbc.E07-09-0895; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Kuznetsov AV, 2008, MOL CELL BIOL, V28, P2304, DOI 10.1128/MCB.00683-07; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Park BJ, 2000, CANCER RES, V60, P3031; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Piazzolla D, 2005, J CELL BIOL, V171, P1013, DOI 10.1083/jcb.200504137; Polzien L, 2009, J BIOL CHEM, V284, P28004, DOI 10.1074/jbc.M109.010702; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Pritchard CA, 2004, MOL CELL BIOL, V24, P5937, DOI 10.1128/MCB.24.13.5937-5952.2004; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Puzanov I, 2011, MOL ONCOL, V5, P116, DOI 10.1016/j.molonc.2011.01.005; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Riva C, 1995, ORAL ONCOL, V31B, P384, DOI 10.1016/0964-1955(95)00045-3; Robert C, 2011, CURR OPIN ONCOL, V23, P177, DOI 10.1097/CCO.0b013e3283436e8c; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Seoane J, 2008, CLIN TRANSL ONCOL, V10, P14, DOI 10.1007/s12094-008-0148-2; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharma A, 2006, CANCER RES, V66, P8200, DOI 10.1158/0008-5472.CAN-06-0809; Shimizu K, 1986, Princess Takamatsu Symp, V17, P85; Simon R, 2001, CANCER RES, V61, P4514; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Sobczak I, 2008, ONCOGENE, V27, P4779, DOI 10.1038/onc.2008.128; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Takezawa K, 2009, CANCER RES, V69, P6515, DOI 10.1158/0008-5472.CAN-09-1076; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Vale T, 2001, CANCER RES, V61, P602; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wang X, 2004, J BIOL CHEM, V279, P2528, DOI 10.1074/jbc.M306489200; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Weber CK, 2001, CANCER RES, V61, P3595; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wimmer R, 2010, TRENDS BIOCHEM SCI, V35, P660, DOI 10.1016/j.tibs.2010.06.001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yu H, 2009, AM J PATHOL, V174, P2367, DOI 10.2353/ajpath.2009.081057; Zebisch A, 2006, CANCER RES, V66, P3401, DOI 10.1158/0008-5472.CAN-05-0115; Zebisch A, 2009, LEUKEMIA, V23, P1049, DOI 10.1038/leu.2009.68; Zeng LC, 2008, EXPERT OPIN THER TAR, V12, P1275, DOI [10.1517/14728222.12.10.1275, 10.1517/14728222.12.10.1275 ]; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	149	187	195	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3477	3488		10.1038/onc.2011.160	http://dx.doi.org/10.1038/onc.2011.160			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21577205				2022-12-28	WOS:000293782300001
J	Nogueira, L; Ruiz-Ontanon, P; Vazquez-Barquero, A; Lafarga, M; Berciano, MT; Aldaz, B; Grande, L; Casafont, I; Segura, V; Robles, EF; Suarez, D; Garcia, LF; Martinez-Climent, JA; Fernandez-Luna, JL				Nogueira, L.; Ruiz-Ontanon, P.; Vazquez-Barquero, A.; Lafarga, M.; Berciano, M. T.; Aldaz, B.; Grande, L.; Casafont, I.; Segura, V.; Robles, E. F.; Suarez, D.; Garcia, L. F.; Martinez-Climent, J. A.; Fernandez-Luna, J. L.			Blockade of the NF kappa B pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo	ONCOGENE			English	Article						NF kappa B; glioblastoma-initiating cells; senescence; differentiation	CANCER STEM-CELLS; BRAIN-TUMORS; ACTIVATION; PHENOTYPE; PROLIFERATION; EXPRESSION; SURVIVAL; THERAPY; GROWTH; MICE	Glioblastoma multiforme is one of the most devastating cancers and presents unique challenges to therapy because of its aggressive behavior. Cancer-initiating or progenitor cells have been described to be the only cell population with tumorigenic capacity in glioblastoma. Therefore, effective therapeutic strategies targeting these cells or the early precursors may be beneficial. We have established different cultures of glioblastoma-initiating cells (GICs) derived from surgical specimens and found that, after induction of differentiation, the NF kappa B transcriptional pathway was activated, as determined by analyzing key proteins such as p65 and I kappa B and the upregulation of a number of target genes. We also showed that blockade of nuclear factor (NF)kappa B signaling in differentiating GICs by different genetic strategies or treatment with small-molecule inhibitors, promoted replication arrest and senescence. This effect was partly mediated by reduced levels of the NF kappa B target gene cyclin D1, because its downregulation by RNA interference reproduced a similar phenotype. Furthermore, these results were confirmed in a xenograft model. Intravenous treatment of immunodeficient mice bearing human GIC-derived tumors with a novel small-molecule inhibitor of the NF kappa B pathway induced senescence of tumor cells but no ultrastructural alterations of the brain parenchyma were detected. These findings reveal that activation of NF kappa B may keep differentiating GICs from acquiring a mature postmitotic phenotype, thus allowing cell proliferation, and support the rationale for therapeutic strategies aimed to promote premature senescence of differentiating GICs by blocking key factors within the NF kappa B pathway. Oncogene (2011) 30, 3537-3548; doi:10.1038/onc.2011.74; published online 21 March 2011	[Nogueira, L.; Ruiz-Ontanon, P.; Grande, L.; Fernandez-Luna, J. L.] Hosp Valdecilla, Mol Genet Unit, Santander 39011, Spain; [Nogueira, L.; Ruiz-Ontanon, P.; Grande, L.; Fernandez-Luna, J. L.] Inst Formac & Invest Marques de Valdecilla IFIMAV, Santander, Spain; [Vazquez-Barquero, A.; Suarez, D.] Hosp Valdecilla, Neurosurg Serv, Santander 39011, Spain; [Lafarga, M.; Berciano, M. T.; Casafont, I.] Univ Cantabria IFIMAV, Dept Anat & Cell Biol, Santander, Spain; [Lafarga, M.; Berciano, M. T.; Casafont, I.] Univ Cantabria IFIMAV, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Santander, Spain; [Aldaz, B.; Robles, E. F.; Martinez-Climent, J. A.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, E-31080 Pamplona, Spain; [Segura, V.] Univ Navarra, Ctr Appl Med Res CIMA, Bioinformat Unit, E-31080 Pamplona, Spain; [Garcia, L. F.] PharmaMar, Madrid, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; CIBERNED; Universidad de Cantabria; University of Navarra; University of Navarra; PharmaMar	Fernandez-Luna, JL (corresponding author), Hosp Valdecilla, Mol Genet Unit, Edificio IFIMAV,Av Cardenal Herrera Oria S-N, Santander 39011, Spain.	fluna@humv.es	Martinez-Climent, Jose A/I-9199-2012; Segura, Victor/E-4531-2010; Lafarga, Miguel/K-3733-2014	Martinez-Climent, Jose A/0000-0002-7938-3950; Segura, Victor/0000-0002-7740-6290; CASAFONT, INIGO/0000-0001-5691-6841; Lafarga, Miguel/0000-0003-3402-1152; Berciano, Maria T./0000-0002-8225-6995	Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation) [RD06/0020/0074, RD06/0020/0088]; Fundacion Marques de Valdecilla [API08/01];  [PI070196];  [PI081878]	Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation)(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion Marques de Valdecilla(Instituto de Salud Carlos III); ; 	This work was supported by Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation) grants RD06/0020/0074 (JLF-L) and RD06/0020/0088 (JAM-C) (Red Tematica de Investigacion Cooperativa en Cancer), PI070196, PI081878, and Accion Transversal del Cancer 2008, and grant API08/01 from Fundacion Marques de Valdecilla (JLF-L). We thank Francisco Moris (EntreChem, Spain) for providing the NF kappa B inhibitor 70124, and Ainara Sagardoy, Silvia Mora, Maria Collantes and Ivan Penuelas (University of Navarra, Spain) for support with intracraneal injections and microPET studies.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Berciano MT, 2004, HUM MOL GENET, V13, P829, DOI 10.1093/hmg/ddh101; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Chang BD, 1999, CANCER RES, V59, P3761; Cheng L, 2010, BIOCHEM PHARMACOL, V80, P654, DOI 10.1016/j.bcp.2010.04.035; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; Gire W, 2004, EMBO J, V23, P2554, DOI 10.1038/sj.emboj.7600259; Gonzalez-Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298-06; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Kang HB, 2007, STEM CELLS DEV, V16, P615, DOI 10.1089/scd.2007.0014; Kawamata H, 2006, CURR PHARM DESIGN, V12, P379, DOI 10.2174/138161206775201947; Lam WA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-35; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee J, 2009, FASEB J, V23, P1739, DOI 10.1096/fj.08-121046; Li XL, 2006, P NATL ACAD SCI USA, V103, P17432, DOI 10.1073/pnas.0607939103; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miura T, 2004, AGING CELL, V3, P333, DOI 10.1111/j.1474-9728.2004.00134.x; Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Ozes ON, 1999, NATURE, V401, P82; Pena E, 2001, J COMP NEUROL, V430, P250, DOI 10.1002/1096-9861(20010205)430:2<250::AID-CNE1029>3.0.CO;2-L; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Sabolek M, 2006, NEUROREPORT, V17, P1719, DOI 10.1097/01.wnr.0000236862.08834.50; Sanchez C, 2009, CHEM COMMUN, P4118, DOI 10.1039/b905068j; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Singh SK, 2003, CANCER RES, V63, P5821; Torres J, 2008, NAT CELL BIOL, V10, P194, DOI 10.1038/ncb1680; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392; Wehling N, 2009, ARTHRITIS RHEUM-US, V60, P801, DOI 10.1002/art.24352; Widera D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-64; Young KM, 2006, J NEUROSCI RES, V83, P39, DOI 10.1002/jnr.20702; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	42	60	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3537	3548		10.1038/onc.2011.74	http://dx.doi.org/10.1038/onc.2011.74			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423202				2022-12-28	WOS:000293782300006
J	Buache, E; Etique, N; Alpy, F; Stoll, I; Muckensturm, M; Reina-San-Martin, B; Chenard, MP; Tomasetto, C; Rio, MC				Buache, E.; Etique, N.; Alpy, F.; Stoll, I.; Muckensturm, M.; Reina-San-Martin, B.; Chenard, M. P.; Tomasetto, C.; Rio, M. C.			Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice	ONCOGENE			English	Article						TFF1/pS2; breast cancer; gain- and loss-of-function; human mammary cell lines; tumorigenicity; TFF1-KO mice	ESTROGEN-RECEPTOR; TRANSGENIC MICE; CATHEPSIN-D; IN-VIVO; EXPRESSION; PS2; INDUCTION; PEPTIDES; PROTEIN; DIFFERENTIATION	Although trefoil factor 1 (TFF1; previously named pS2) is abnormally expressed in about 50% of human breast tumors, its physiopathological role in this disease has been poorly studied. Moreover, controversial data have been reported. TFF1 function in the mammary gland therefore needs to be clarified. In this study, using retroviral vectors, we performed TFF1 gain-or loss-of-function experiments in four human mammary epithelial cell lines: normal immortalized TFF1-negative MCF10A, malignant TFF1-negative MDA-MB-231 and malignant TFF1-positive MCF7 and ZR75.1. The expression of TFF1 stimulated the migration and invasion in the four cell lines. Forced TFF1 expression in MCF10A, MDA-MB-231 and MCF7 cells did not modify anchorage-dependent or -independent cell proliferation. By contrast, TFF1 knockdown in MCF7 enhanced soft-agar colony formation. This increased oncogenic potential of MCF7 cells in the absence of TFF1 was confirmed in vivo in nude mice. Moreover, chemically induced tumorigenesis in TFF1-deficient (TFF1-KO) mice led to higher tumor incidence in the mammary gland and larger tumor size compared with wild-type mice. Similarly, tumor development was increased in the TFF1-KO ovary and lung. Collectively, our results clearly show that TFF1 does not exhibit oncogenic properties, but rather reduces tumor development. This beneficial function of TFF1 is in agreement with many clinical studies reporting a better outcome for patients with TFF1-positive breast primary tumors. Oncogene (2011) 30, 3261-3273; doi:10.1038/onc.2011.41; published online 28 February 2011	[Buache, E.; Etique, N.; Alpy, F.; Stoll, I.; Reina-San-Martin, B.; Tomasetto, C.; Rio, M. C.] Univ Strasbourg, INSERM, U964, IGBMC,CNRS,UMR 7104, Illkirch Graffenstaden, France; [Muckensturm, M.; Chenard, M. P.] CHU Hautepierre, Serv Anat Pathol Gen, F-67098 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg	Rio, MC (corresponding author), Univ Strasbourg, INSERM, U964, IGBMC,CNRS,UMR 7104, Illkirch Graffenstaden, France.	rio@igbmc.fr	Alpy, Fabien/ABD-5893-2020; Tomasetto, Catherine Laure/J-2783-2014; Reina-San-Martin, Bernardo/I-9484-2016; Chenard, Marie-Pierre/O-2373-2016; Alpy, Fabien/H-8941-2016; etique, nicolas/J-4159-2017	Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848; Reina-San-Martin, Bernardo/0000-0003-2083-6166; Alpy, Fabien/0000-0002-0526-0720; etique, nicolas/0000-0001-6613-9257	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer; Ligue Nationale Francaise contre le Cancer (LNCC; Comites du Haut-Rhin et du Bas-Rhin; Fondation pour la Recherche Medicale; LNCC	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Francaise contre le Cancer (LNCC; Comites du Haut-Rhin et du Bas-Rhin; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); LNCC	We would like to thank Corinne Wendling for technical help, and Emmanuelle Liaudet and Susan Chan for helpful discussion. This work was supported by funds from the Institut National de la Sante et de la Recherche Medicale, the Centre National de la Recherche Scientifique, the Hopital Universitaire de Strasbourg, the Association pour la Recherche sur le Cancer, and the Ligue Nationale Francaise contre le Cancer (LNCC; Equipe labellisee 2010) and the Comites du Haut-Rhin et du Bas-Rhin. Etique N and Buache E were recipient of Fondation pour la Recherche Medicale and LNCC fellowship, respectively.	Amiry N, 2009, ENDOCRINOLOGY, V150, P4473, DOI 10.1210/en.2009-0066; Andrew DJ, 2010, DEV BIOL, V341, P34, DOI 10.1016/j.ydbio.2009.09.024; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Buron N, 2008, INVEST OPHTH VIS SCI, V49, P3790, DOI 10.1167/iovs.07-1270; CAPONY F, 1989, CANCER RES, V49, P3904; Chenard MP, 2004, PEPTIDES, V25, P737, DOI 10.1016/j.peptides.2003.11.018; Choi EJ, 2009, DIFFERENTIATION, V77, P412, DOI 10.1016/j.diff.2008.12.004; Corte MD, 2006, BREAST CANCER RES TR, V96, P63, DOI 10.1007/s10549-005-9041-7; Crosier M, 2001, AM J PATHOL, V159, P215, DOI 10.1016/S0002-9440(10)61687-2; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001; Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; FOEKENS JA, 1990, CANCER RES, V50, P3832; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Hoffmann W, 2005, CELL MOL LIFE SCI, V62, P2932, DOI 10.1007/s00018-005-5481-9; Hoffmann W, 2007, CURR MED CHEM, V14, P2716, DOI 10.2174/092986707782023226; Karam SM, 2008, CELL PROLIFERAT, V41, P923, DOI 10.1111/j.1365-2184.2008.00562.x; Katoh M, 2003, INT J MOL MED, V12, P3; Khan ZE, 2003, GASTROENTEROLOGY, V125, P510, DOI 10.1016/S0016-5085(03)00908-9; KIDA N, 1993, EUR J BIOCHEM, V215, P671, DOI 10.1111/j.1432-1033.1993.tb18078.x; Kjellev S, 2009, CELL MOL LIFE SCI, V66, P1350, DOI 10.1007/s00018-008-8646-5; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P1033, DOI 10.1677/ERC-06-0001; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Madsen J, 2007, J HISTOCHEM CYTOCHEM, V55, P505, DOI 10.1369/jhc.6A7100.2007; Markicevic M, 2008, ADV EXP MED BIOL, V617, P341; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Mikhitarian K, 2005, CLIN CANCER RES, V11, P3697, DOI 10.1158/1078-0432.CCR-04-2164; Mira E, 2004, J CELL SCI, V117, P1847, DOI 10.1242/jcs.01035; Perry JK, 2008, TRENDS ENDOCRIN MET, V19, P74, DOI 10.1016/j.tem.2007.10.003; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Poulsom R, 1997, J PATHOL, V183, P30, DOI 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K; Press DJ, 2010, EPIDEMIOLOGY, V21, P566, DOI 10.1097/EDE.0b013e3181e08eb3; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; Regalo G, 2005, CELL MOL LIFE SCI, V62, P2910, DOI 10.1007/s00018-005-5478-4; Ribieras S, 1998, BBA-REV CANCER, V1378, pF61, DOI 10.1016/S0304-419X(98)00016-X; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Rodrigues S, 2006, ONCOGENE, V25, P6628, DOI 10.1038/sj.onc.1209665; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Scott DJ, 2007, INT J ONCOL, V31, P557; Shi SQ, 2006, WORLD J GASTROENTERO, V12, P3119, DOI 10.3748/wjg.v12.i19.3119; Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802; Stotter A, 2010, CRIT REV ONCOL HEMAT, V75, P249, DOI 10.1016/j.critrevonc.2009.10.008; Surowiak P, 2006, BRIT J CANCER, V95, P339, DOI 10.1038/sj.bjc.6603254; Thim L, 1997, CELL MOL LIFE SCI, V53, P888, DOI 10.1007/s000180050108; Thullberg M, 2008, CELL CYCLE, V7, P984, DOI 10.4161/cc.7.8.5674; Thuwajit P, 2007, HEPATOL RES, V37, P295, DOI 10.1111/j.1872-034X.2007.00045.x; Tjensvoll K, 2009, BREAST CANCER RES TR, V116, P329, DOI 10.1007/s10549-008-0204-1; TOMASETTO C, 1989, MOL ENDOCRINOL, V3, P1579, DOI 10.1210/mend-3-10-1579; Tomasetto C, 2005, CELL MOL LIFE SCI, V62, P2916, DOI 10.1007/s00018-005-5479-3; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Tosco A, 2010, CELL MOL LIFE SCI, V67, P1943, DOI 10.1007/s00018-010-0309-7; Vestergaard EM, 2008, EARLY HUM DEV, V84, P631, DOI 10.1016/j.earlhumdev.2008.04.001; Wilson CL, 2006, ENDOCR-RELAT CANCER, V13, P617, DOI 10.1677/erc.1.01165	58	74	76	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	29					3261	3273		10.1038/onc.2011.41	http://dx.doi.org/10.1038/onc.2011.41			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21358676	hybrid, Green Published			2022-12-28	WOS:000293006800005
J	Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, MA				Fiaschetti, G.; Castelletti, D.; Zoller, S.; Schramm, A.; Schroeder, C.; Nagaishi, M.; Stearns, D.; Mittelbronn, M.; Eggert, A.; Westermann, F.; Ohgaki, H.; Shalaby, T.; Pruschy, M.; Arcaro, A.; Grotzer, M. A.			Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma	ONCOGENE			English	Article						BMP7; MYC; medulloblastoma; brain tumor; pediatric cancer	C-MYC; BREAST-CANCER; CHOROID-PLEXUS; HUMAN PROSTATE; TUMOR-GROWTH; IN-VIVO; BMP; EXPRESSION; METASTASIS; RECEPTORS	Medulloblastoma (MB) is the most common malignant brain tumor in children. It is known that overexpression and/or amplification of the MYC oncogene is associated with poor clinical outcome, but the molecular mechanisms and the MYC downstream effectors in MB remain still elusive. Besides contributing to elucidate how progression of MB takes place, most importantly, the identification of novel MYC-target genes will suggest novel candidates for targeted therapy in MB. A group of 209 MYC-responsive genes was obtained from a complementary DNA microarray analysis of a MB-derived cell line, following MYC overexpression and silencing. Among the MYC-responsive genes, we identified the members of the bone morphogenetic protein (BMP) signaling pathway, which have a crucial role during the development of the cerebellum. In particular, the gene BMP7 was identified as a direct target of MYC. A positive correlation between MYC and BMP7 expression was documented by analyzing two distinct sets of primary MB samples. Functional studies in vitro using a small-molecule inhibitor of the BMP/SMAD signaling pathway reproduced the effect of the small interfering RNA-mediated silencing of BMP7. Both approaches led to a block of proliferation in a panel of MB cells and to inhibition of SMAD phosphorylation. Altogether, our findings indicate that high MYC levels drive BMP7 overexpression, promoting cell survival in MB cells. This observation suggests the potential relevance of targeting the BMP/SMAD pathway as a novel therapeutic approach for the treatment of childhood MB. Oncogene (2011) 30, 2823-2835; doi: 10.1038/onc.2011.10; published online 14 February 2011	[Fiaschetti, G.; Castelletti, D.; Shalaby, T.; Grotzer, M. A.] Univ Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland; [Zoller, S.] UZH ETH, Funct Genom Ctr Zurich, Zurich, Switzerland; [Schramm, A.; Eggert, A.] Univ Childrens Hosp Essen, Div Hematol Oncol, Essen, Germany; [Schroeder, C.; Westermann, F.] German Canc Res Ctr, Dept Tumor Genet, Heidelberg, Germany; [Nagaishi, M.; Ohgaki, H.] World Hlth Org, Int Agcy Res Canc, Sect Mol Pathol, Lyon, France; [Stearns, D.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Mittelbronn, M.] Goethe Univ Frankfurt, Inst Neurol, Edinger Inst, Frankfurt, Germany; [Pruschy, M.] Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland; [Arcaro, A.] Univ Bern, Div Pediat Hematol Oncol, Dept Clin Res, Bern, Switzerland	University Children's Hospital Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); World Health Organization; International Agency for Research on Cancer (IARC); Johns Hopkins University; Goethe University Frankfurt; University of Zurich; University Zurich Hospital; University of Bern	Grotzer, MA (corresponding author), Univ Childrens Hosp, Dept Oncol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	Michael.Grotzer@kispi.uzh.ch	Eggert, Angelika/AAE-6907-2022; Arcaro, Alexandre/G-1711-2010; Schramm, Alexander/G-5688-2010; Westermann, Frank/F-7509-2013	Eggert, Angelika/0000-0003-3476-8184; Arcaro, Alexandre/0000-0001-9107-2947; Schramm, Alexander/0000-0001-7670-7529; Grotzer, Michael/0000-0002-1154-2732; Mittelbronn, Michel/0000-0002-2998-052X; Pruschy, Martin/0000-0002-3124-9015	European Community [037260]	European Community(European Commission)	Giulio Fiaschetti and Deborah Castelletti were supported by the European Community FP6, project STREP (EET-pipeline, number: 037260).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alder J, 1999, NAT NEUROSCI, V2, P535, DOI 10.1038/9189; Aldosari N, 2002, ARCH PATHOL LAB MED, V126, P540; Anderson GJ, 2008, NAT CHEM BIOL, V4, P15, DOI 10.1038/nchembio0108-15; Arihiro K, 2001, PATHOL INT, V51, P100, DOI 10.1046/j.1440-1827.2001.01164.x; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Behesti H, 2009, INT J BIOCHEM CELL B, V41, P435, DOI 10.1016/j.biocel.2008.06.017; Calvo MB, 2009, CLIN TRANSL ONCOL, V11, P126, DOI 10.1007/S12094-009-0328-8; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; Buijs JT, 2010, CURR PHARM DESIGN, V16, P1291; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chizhikov VV, 2006, DEVELOPMENT, V133, P2793, DOI 10.1242/dev.02441; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008-5472.CAN-07-6541; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dziegielewska KM, 2001, MICROSC RES TECHNIQ, V52, P5, DOI 10.1002/1097-0029(20010101)52:1<5::AID-JEMT3>3.3.CO;2-A; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Engelhard HH, 2005, CANC TREAT, V125, P71; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grimmer MR, 2008, GENE DEV, V22, P693, DOI 10.1101/gad.1657808; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Grotzer MA, 2009, CURR CANCER DRUG TAR, V9, P176, DOI 10.2174/156800909787580962; Guessous F, 2008, J CELL PHYSIOL, V217, P577, DOI 10.1002/jcp.21542; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Gurney JG, 2001, CURR OPIN ONCOL, V13, P160, DOI 10.1097/00001622-200105000-00005; Herms J, 2000, INT J CANCER, V89, P395; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Krizhanovsky V, 2006, MECH DEVELOP, V123, P67, DOI 10.1016/j.mod.2005.09.005; Kunz F, 2006, NEUROPATHOLOGY, V26, P393, DOI 10.1111/j.1440-1789.2006.00694.x; Lamont JM, 2004, CLIN CANCER RES, V10, P5482, DOI 10.1158/1078-0432.CCR-03-0721; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Littlewood T D, 1990, Adv Dent Res, V4, P69; Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; Piccirillo SGM, 2007, ERNST SCHERING FOUND, V5, P59, DOI 10.1007/2789_2007_044; Polkinghorn WR, 2007, NAT CLIN PRACT ONCOL, V4, P295, DOI 10.1038/ncponc0794; Raida M, 2005, INT J ONCOL, V26, P1465; Redzic ZB, 2004, ADV DRUG DELIVER REV, V56, P1695, DOI 10.1016/j.addr.2004.07.005; Romer J, 2005, CANCER RES, V65, P4975, DOI 10.1158/0008-5472.CAN-05-0481; Rossi A, 2008, CLIN CANCER RES, V14, P971, DOI 10.1158/1078-0432.CCR-07-2072; Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007; Stearns D, 2006, CANCER RES, V66, P673, DOI 10.1158/0008-5472.CAN-05-1580; Sutter R, 2010, ONCOGENE, V29, P1845, DOI 10.1038/onc.2009.472; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; von Bueren AO, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-19; Walsh DW, 2010, TRENDS CELL BIOL, V20, P244, DOI 10.1016/j.tcb.2010.01.008; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yabe T, 2002, J NEUROSCI RES, V68, P161, DOI 10.1002/jnr.10210; Yan WS, 2007, CANCER RES, V67, P9117, DOI 10.1158/0008-5472.CAN-07-0996; Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007; Yanagita M, 2009, BIOFACTORS, V35, P113, DOI 10.1002/biof.15; Ye L, 2007, INT J ONCOL, V30, P521; Ye L, 2009, INT J MOL MED, V24, P591, DOI 10.3892/ijmm_00000269; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	73	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2823	2835		10.1038/onc.2011.10	http://dx.doi.org/10.1038/onc.2011.10			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317922				2022-12-28	WOS:000291977800003
J	Kuroshima, T; Aoyagi, M; Yasuda, M; Kitamura, T; Jehung, JP; Ishikawa, M; Kitagawa, Y; Totsuka, Y; Shindoh, M; Higashino, F				Kuroshima, T.; Aoyagi, M.; Yasuda, M.; Kitamura, T.; Jehung, J. P.; Ishikawa, M.; Kitagawa, Y.; Totsuka, Y.; Shindoh, M.; Higashino, F.			Viral-mediated stabilization of AU-rich element containing mRNA contributes to cell transformation	ONCOGENE			English	Article						adenovirus; AU-rich element; E4orf6; transformation; stabilization	ADENOVIRUS E4ORF6 PROTEIN; ORAL-CANCER CELLS; NUCLEAR EXPORT; E1B55K PROTEINS; LIGASE COMPLEX; HUR; DEGRADATION; P53; MECHANISM; SEQUENCE	E4orf6 is one of the oncogene products of adenovirus, and it also has an important role for transportation of cellular and viral messenger RNA (mRNA) during the late phase of virus infection. We previously revealed that E4orf6 controls the fate of AU-rich element (ARE) containing mRNA by perturbing the chromosome maintenance region 1-dependent export mechanism. Here, we show that E4orf6 stabilizes ARE-mRNA through the region required for its oncogenic activity and ubiquitin E3 ligase assembly. Cells that failed to stabilize ARE-mRNA after HuR knockdown were unable to produce colonies in soft agar, even when E4orf6 was expressed. Furthermore, the stabilized ARE-mRNA induced the transformation of rodent immortalized cells. These findings indicate that stabilized ARE-mRNA is necessary, if not all, for the oncogenic activity of E4orf6 and has the potential to transform cells, at least under a certain condition. Oncogene (2011) 30, 2912-2920; doi:10.1038/onc.2011.14; published online 14 February 2011	[Higashino, F.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathol & Biol, Kita Ku, Sapporo, Hokkaido 0608586, Japan; [Kuroshima, T.; Ishikawa, M.; Kitagawa, Y.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Diag & Med, Sapporo, Hokkaido 0608586, Japan; [Yasuda, M.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Mol Microbiol, Sapporo, Hokkaido 0608586, Japan; [Totsuka, Y.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral & Maxillofacial Surg, Sapporo, Hokkaido 0608586, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Higashino, F (corresponding author), Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathol & Biol, Kita Ku, North 13 West 7, Sapporo, Hokkaido 0608586, Japan.	fhigashi@den.hokudai.ac.jp	Shindoh, Masanobu/A-4799-2012; Kitagawa, Yoshimasa/F-6909-2012; Higashino, Fumihiro/F-8510-2012; Ishikawa, Makoto/D-5488-2012	Shindoh, Masanobu/0000-0002-7782-5823; 	Ministry of Education, Science and Culture of Japan; Akiyama Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Akiyama Foundation	We thank T Dobner for donating the E4orf6 mutant and mutant adenovirus expression plasmids, H Ariga for donating the c-myc expression vector, K Yoshida for donating the c-fos expression vector and L Agami for donating the pSUPER plasmid. This work was supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan, and by a Grant-in Aid from the Akiyama Foundation.	Aoyagi M, 2003, ONCOGENE, V22, P6919, DOI 10.1038/sj.onc.1206743; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Blanchette P, 2008, J VIROL, V82, P2642, DOI 10.1128/JVI.02309-07; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; DOBBELSTEIN M, 1997, EMBO J, V16, P4267; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Esclatine A, 2004, P NATL ACAD SCI USA, V101, P3603, DOI 10.1073/pnas.0400354101; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Hasegawa H, 2009, BRIT J CANCER, V100, P1943, DOI 10.1038/sj.bjc.6605084; Higashino F, 2005, J CELL BIOL, V170, P15, DOI 10.1083/jcb.200405112; Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6; Kakuguchi W, 2010, MOL CANCER RES, V8, P520, DOI 10.1158/1541-7786.MCR-09-0367; Lopez de Silanes I., 2005, RNA BIOL, V2, P11, DOI DOI 10.4161/RNA.2.1.1552; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Orlando JS, 2002, J VIROL, V76, P1475, DOI 10.1128/JVI.76.3.1475-1487.2002; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Shenk T. E., 2001, Fundamental virology, P1053; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Woo JL, 2007, J VIROL, V81, P575, DOI 10.1128/JVI.01725-06	32	14	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2912	2920		10.1038/onc.2011.14	http://dx.doi.org/10.1038/onc.2011.14			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317928	Green Submitted			2022-12-28	WOS:000292245100002
J	Pakala, SB; Singh, K; Reddy, SD; Ohshiro, K; Li, DQ; Mishra, L; Kumar, R				Pakala, S. B.; Singh, K.; Reddy, S. D. N.; Ohshiro, K.; Li, D-Q; Mishra, L.; Kumar, R.			TGF-beta 1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells	ONCOGENE			English	Article						TGF-beta 1 signaling; MTA1; FosB; target gene transcription; epithelial-to-mesenchymal transition	BREAST-CANCER; MESENCHYMAL TRANSITIONS; TGF-BETA; TRANSCRIPTIONAL REPRESSION; ESTROGEN-RECEPTOR; MTA1; GENE; PROGRESSION; EXPRESSION; ALPHA	In spite of a large number of transforming growth factor beta 1 (TGF-beta 1)-regulated genes, the nature of its targets with roles in transformation continues to be poorly understood. Here, we discovered that TGF-beta 1 stimulates transcription of metastasis-associated protein 1 (MTA1), a dual master coregulator, in epithelial cells, and that MTA1 status is a determinant of TGF-beta 1-induced epithelial-to-mesenchymal transition (EMT) phenotypes. In addition, we found that MTA1/polymerase II/activator protein-1 (AP-1) co-activator complex interacts with the FosB-gene chromatin and stimulates its transcription, and FosB in turn, utilizes FosB/histone deacetylase 2 complex to repress E-cadherin expression in TGF-beta 1-stimulated mammary epithelial cells. These findings suggest that TGF-beta 1 regulates the components of EMT via stimulating the expression of MTA1, which in turn, induces FosB to repress E-cadherin expression and thus, revealed an inherent function of MTA1 as a target and effector of TGF-beta 1 signaling in epithelial cells. Oncogene (2011) 30, 2230-2241; doi:10.1038/onc.2010.608; published online 24 January 2011	[Pakala, S. B.; Singh, K.; Reddy, S. D. N.; Ohshiro, K.; Li, D-Q; Kumar, R.] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Pakala, S. B.; Singh, K.; Reddy, S. D. N.; Ohshiro, K.; Li, D-Q; Kumar, R.] George Washington Univ, Med Ctr, Inst Coregulator Biol, Washington, DC 20037 USA; [Mishra, L.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA	George Washington University; George Washington University; University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA.	bcmrxk@gwumc.edu	Kumar, Rakesh/ABD-1065-2020; sirigiri, divijendranathareddy/A-9857-2010; sirigiri, divijendra reddy/E-1031-2017	Kumar, Rakesh/0000-0001-7664-0803; sirigiri, divijendra reddy/0000-0003-4657-2285; Pakala, Suresh Babu/0000-0002-5679-4837	NIH [CA98823]; NATIONAL CANCER INSTITUTE [R01CA098823, P30CA016672, R01CA106614, P01CA130821] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Toshio Matsumoto for FosB-promoter constructs and Dr Eric R. Fearon for E-cadherin promoter construct. The work was supported by NIH Grant CA98823 (RK).	Balasenthil S, 2007, CANCER RES, V67, P7132, DOI 10.1158/0008-5472.CAN-07-0750; Bui-Nguyen TM, 2010, ONCOGENE, V29, P1179, DOI 10.1038/onc.2009.404; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Dannenmann C, 2008, CANCER BIOL THER, V7, P1462, DOI 10.4161/cbt.7.9.6427; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103; Hofer MD, 2004, BRIT J CANCER, V90, P455, DOI 10.1038/sj.bjc.6601535; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; LEE TC, 1994, ONCOGENE, V9, P1047; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Michl P, 2006, CELL CYCLE, V5, P132, DOI 10.4161/cc.5.2.2311; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Molli PR, 2008, ONCOGENE, V27, P1971, DOI 10.1038/sj.onc.1210839; Ohnishi YN, 2008, MOL BIOL CELL, V19, P4717, DOI 10.1091/mbc.E07-08-0768; Pakala SB, 2010, J BIOL CHEM, V285, P23590, DOI 10.1074/jbc.M110.139469; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tong D, 2007, ONCOL RES, V16, P465, DOI 10.3727/096504007783338322; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang H, 2006, CLIN CANCER RES, V12, P1479, DOI 10.1158/1078-0432.CCR-05-1519	30	68	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2230	2241		10.1038/onc.2010.608	http://dx.doi.org/10.1038/onc.2010.608			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21258411	Green Accepted			2022-12-28	WOS:000290514600006
J	Kurahashi, S; Hayakawa, F; Miyata, Y; Yasuda, T; Minami, Y; Tsuzuki, S; Abe, A; Naoe, T				Kurahashi, S.; Hayakawa, F.; Miyata, Y.; Yasuda, T.; Minami, Y.; Tsuzuki, S.; Abe, A.; Naoe, T.			PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML	ONCOGENE			English	Article						PAX5; PML; nuclear body; DNA binding; apoptosis; arsenic trioxide	ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL DEVELOPMENT; ARSENIC-TRIOXIDE; RAR-ALPHA; MEDIATED APOPTOSIS; NUCLEAR-BODIES; FUSION GENES; DNA-DAMAGE; BSAP PAX-5	PAX5 is a transcription factor required for B-cell development and maintenance. PML is a tumor suppressor and a pro-apoptotic factor. A fusion gene, PAX5-PML, was found in acute lymphoblastic leukemia (ALL) with chromosomal translocation t(9;15)(p13;q24), but no functional analysis has been reported. Here, we demonstrate that PAX5-PML had a dominant-negative effect on both PAX5 and PML. PAX5-PML dominant negatively inhibited PAX5 transcriptional activity in the luciferase reporter assay and suppressed the expression of the PAX5 transcriptional targets in B-lymphoid cell line. Surprisingly, PAX5-PML hardly showed DNA-binding activity in vitro although it retained the DNA-binding domain of PAX5. Additional experiments, including chromatin immunoprecipitation (ChIP) assay, suggested that PAX5-PML bound to the promoter through the association with PAX5 on the promoter. On the other hand, coexpression of PAX5-PML inhibited PML sumoylation, disrupted PML nuclear bodies (NBs), and conferred apoptosis resistance on HeLa cells. Furthermore, treatment with arsenic trioxide (ATO) induced PML sumoylation and reconstitution of PML NBs, and overcame the anti-apoptotic effect of PAX5-PML in HeLa cells. These data suggest the possible involvement of this fusion protein in the leukemogenesis of B-ALL in a dual dominant-negative manner and the possibility that ALL with PAX5-PML can be treated with ATO. Oncogene (2011) 30, 1822-1830; doi:10.1038/onc.2010.554; published online 10 January 2011	[Hayakawa, F.] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Tsuzuki, S.] Aichi Canc Ctr, Res Inst, Div Mol Med, Nagoya, Aichi 464, Japan	Nagoya University; Aichi Cancer Center	Hayakawa, F (corresponding author), Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	bun-hy@med.nagoya-u.ac.jp	Yasuda, Takahiko/AGQ-5448-2022; Hayakawa, Fumihiko/I-7288-2014; Naoe, Tomoki/I-1888-2012	Yasuda, Takahiko/0000-0002-4686-0976; Tsuzuki, Shinobu/0000-0002-3209-3550	Kyowa Hakko Kirin Co., Ltd.; Wyeth; Chugai Pharmaceutical Co., Ltd.; National Institute of Biomedical Innovation; Ministry of Education, Culture, Sports, Science, and Technology of Japan	Kyowa Hakko Kirin Co., Ltd.(Kyowa Kirin Ltd); Wyeth(Wyeth); Chugai Pharmaceutical Co., Ltd.; National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Dr Naoe received research funding from Kyowa Hakko Kirin Co., Ltd, Wyeth, and Chugai Pharmaceutical Co., Ltd. The remaining authors declare no conflict of interest.; We thank Dr Martin L Privalsky (University of California at Davis, CA, USA), Dr Masayuki Yamamoto (Tohoku University) and Dr Stefano Rivella (Memorial Sloan-Kettering Cancer Center) for kindly providing vectors. We are very grateful to Ryouhei Tanizaki, Yuka Nomura and Chika Wakamatsu for their technical assistance. This work was supported by Grants-in-Aid from the National Institute of Biomedical Innovation and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Atsumi A, 2006, BIOCHEM BIOPH RES CO, V345, P1471, DOI 10.1016/j.bbrc.2006.05.047; Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; Chen GQ, 1997, BLOOD, V89, P3345; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Familiades J, 2009, LEUKEMIA, V23, P1989, DOI 10.1038/leu.2009.135; Fazio G, 2008, CANCER RES, V68, P181, DOI 10.1158/0008-5472.CAN-07-2778; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; Hayakawa F, 2008, J BIOL CHEM, V283, P24420, DOI 10.1074/jbc.M802217200; Holmes ML, 2006, GENE DEV, V20, P933, DOI 10.1101/gad.1396206; Iida S, 1996, BLOOD, V88, P1787; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jeanne M, 2010, CANCER CELL, V18, P88, DOI 10.1016/j.ccr.2010.06.003; Kawamata N, 2008, P NATL ACAD SCI USA, V105, P11921, DOI 10.1073/pnas.0711039105; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Maier H, 2003, NUCLEIC ACIDS RES, V31, P5483, DOI 10.1093/nar/gkg785; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; Miller WH, 2002, CANCER RES, V62, P3893; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nebral K, 2009, LEUKEMIA, V23, P134, DOI 10.1038/leu.2008.306; Nebral K, 2007, BRIT J HAEMATOL, V139, P269, DOI 10.1111/j.1365-2141.2007.06731.x; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Nutt S L, 2001, Int Rev Immunol, V20, P65, DOI 10.3109/08830180109056723; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Rivella S, 2003, BLOOD, V101, P2932, DOI 10.1182/blood-2002-10-3305; Schebesta M, 2002, IMMUNITY, V17, P473, DOI 10.1016/S1074-7613(02)00418-1; Souabni A, 2002, IMMUNITY, V17, P781, DOI 10.1016/S1074-7613(02)00472-7; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	43	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1822	1830		10.1038/onc.2010.554	http://dx.doi.org/10.1038/onc.2010.554			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21217775				2022-12-28	WOS:000289512200009
J	Patel, JB; Appaiah, HN; Burnett, RM; Bhat-Nakshatri, P; Wang, G; Mehta, R; Badve, S; Thomson, MJ; Hammond, S; Steeg, P; Liu, Y; Nakshatri, H				Patel, J. B.; Appaiah, H. N.; Burnett, R. M.; Bhat-Nakshatri, P.; Wang, G.; Mehta, R.; Badve, S.; Thomson, M. J.; Hammond, S.; Steeg, P.; Liu, Y.; Nakshatri, H.			Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22	ONCOGENE			English	Article						breast cancer; metastasis; microRNA; miR-22; let-7	GENE-EXPRESSION; SIGNATURE; REPRESSION; MIGRATION; INSIGHTS; ESCAPE; LEADS	Metastasis in breast cancer carries a disproportionately worse prognosis than localized primary disease. To identify microRNAs (miRNA) involved in metastasis, the expression of 254 miRNAs was measured across the following cell lines using microarray analysis: MDA-MB-231 breast cancer cells, cells that grew as a tumor in the mammary fat pad of nude mice (TMD-231), metastatic disease to the lungs (LMD-231), bone (BMD-231) and adrenal gland (ADMD-231). A brain-seeking variant of this cell line (231-BR) was used additionally in validation studies. Twenty miRNAs were upregulated and seven were downregulated in metastatic cancer cells compared with TMD-231 cells. The expression of the tumor suppressor miRNAs let-7 and miR-22 was consistently downregulated in metastatic cancer cells. These metastatic cells expressed higher levels of putative/proven miR-22 target oncogenes ERBB3, CDC25C and EVI-1. Introduction of miR-22 into cancer cells reduced the levels of ERBB3 and EVI-1 as well as phospho-AKT, an EVI-1 downstream target. The miR-22 primary transcript is located in the 50-untranslated region of an open reading frame C17orf91, and the promoter/enhancer of C17orf91 drives miR-22 expression. We observed elevated C17orf91 expression in non-basal subtype compared with basal subtype breast cancers. In contrast, elevated expression of EVI-1 was observed in basal subtype and was associated with poor outcome in estrogen receptor-negative breast cancer patients. These results suggest that metastatic cancer cells increase specific oncogenic signaling proteins through downregulation of miRNAs. Identifying such metastasis-specific oncogenic pathways may help to manipulate tumor behavior and aid in the design of more effective targeted therapies. Oncogene (2011) 30, 1290-1301; doi:10.1038/onc.2010.510; published online 8 November 2010	[Patel, J. B.; Appaiah, H. N.; Bhat-Nakshatri, P.; Nakshatri, H.] Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Wang, G.; Liu, Y.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Mehta, R.; Badve, S.] Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; [Thomson, M. J.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Hammond, S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; [Steeg, P.] NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Nakshatri, H.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Univ, Sch Med, Dept Surg, 980 W Walnut St C218E, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu	Nidumanda, HITESH/B-5744-2015; Xie, Huangming/B-2260-2012; Mehta, Rutika/S-2052-2016; Wang, Guohua/GLR-7939-2022	Mehta, Rutika/0000-0003-4277-0153; Badve, Sunil/0000-0001-8861-9980; Nakshatri, Harikrishna/0000-0001-8876-0052	Indiana University Simon Cancer Center; Komen for Cure [BCTR0601111]; National Institutes of Health [T32 DK07519, T32 CA111198]; NATIONAL CANCER INSTITUTE [T32CA111198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	Indiana University Simon Cancer Center; Komen for Cure(Susan G. Komen Breast Cancer Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by Indiana University Simon Cancer Center Pilot grant and by Komen for Cure grant BCTR0601111 to HN. JBP and RMB are supported by National Institutes of Health Training Grants T32 DK07519 and T32 CA111198, respectively. HN is Marian J Morrison Professor of Breast Cancer Research.	Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Goyama S, 2010, LEUKEMIA, V24, P81, DOI 10.1038/leu.2009.202; Gril B, 2008, JNCI-J NATL CANCER I, V100, P1092, DOI 10.1093/jnci/djn216; Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hoser M, 2007, J NEUROSCI, V27, P5495, DOI 10.1523/JNEUROSCI.1384-07.2007; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307; Iliopoulos D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003740; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Koshiol J, 2010, CANCER EPIDEM BIOMAR, V19, P907, DOI 10.1158/1055-9965.EPI-10-0071; Kumano K, 2010, J CELL PHYSIOL, V222, P282, DOI 10.1002/jcp.21953; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	48	94	101	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1290	1301		10.1038/onc.2010.510	http://dx.doi.org/10.1038/onc.2010.510			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057539				2022-12-28	WOS:000288492100004
J	He, X; Wang, J; Messing, EM; Wu, G				He, X.; Wang, J.; Messing, E. M.; Wu, G.			Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness	ONCOGENE			English	Article						VHL; RACK1; IGF-I; renal cell carcinoma	GROWTH-FACTOR RECEPTOR; ALVEOLAR EPITHELIAL-CELLS; BETA-SUBUNIT; PHOSPHOINOSITIDE 3-KINASE; GENE-PRODUCT; INSULIN; RACK1; EXPRESSION; CANCER; IDENTIFICATION	von Hippel-Lindau (VHL) tumor suppressor loss is associated with renal cell carcinoma (RCC) pathogenesis. Meanwhile, aberrant activation of the insulin-like growth factor-I (IGF-I) signaling has been implicated in the development of highly invasive metastatic RCC. However, the link between VHL inactivation and RCC invasiveness is still unexplored. Here, we show that the receptor for activated C kinase 1 (RACK1) is a novel pVHLinteracting protein. pVHL competes with IGF-I receptor (IGF-IR) for binding to RACK1 thus potentially modulating the downstream IGF-I signal pathway. Upon IGFI stimulation, pVHL-deficient RCC cells exhibit increased RACK1/IGF-IR binding and increased IGF-IR tyrosine kinase activity. pVHL-deficient RCC cells also demonstrate elevated PI3K/Akt signaling and matrix metallo-proteinase-2 activity that culminates in enhanced cellular invasiveness, which can be partially suppressed by RACK1 small interfering RNA. Domain mapping analysis showed that the pVHL alpha-domain and the RACK1 WD 6-7 domains are critical for the interaction. Additionally, the RACK1 expression level is not regulated by pVHL expression status, suggesting that pVHL modifies RACK1 functions independent of the VHL/elongin E3 ubiquitin ligase complex. Our data indicate that RACK1 serves as a direct mediator between loss of pVHL function and enhanced IGF-IR signaling pathway in RCC. Oncogene (2011) 30, 535-547; doi: 10.1038/onc.2010.427; published online 27 September 2010	[He, X.; Messing, E. M.; Wu, G.] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; [Wang, J.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; [He, X.; Messing, E. M.; Wu, G.] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Wu, G (corresponding author), Univ Rochester, Med Ctr, Dept Urol, 601 Elmwood Ave, Rochester, NY 14642 USA.	guan_wu@urmc.rochester.edu			James P Wilmot Cancer Center	James P Wilmot Cancer Center	Funding: This work was supported in part by the James P Wilmot Cancer Center grant to X He.	Alberghini A, 2005, J BIOL CHEM, V280, P30120, DOI 10.1074/jbc.M500971200; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Brader S, 2004, TUMORI J, V90, P2, DOI 10.1177/030089160409000102; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Dunn SE, 1998, CANCER RES, V58, P3353; Dupont J, 2003, HORM METAB RES, V35, P740; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hansen WJ, 2002, MOL CELL BIOL, V22, P1947, DOI 10.1128/MCB.22.6.1947-1960.2002; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kugler A, 1998, J UROLOGY, V160, P1914, DOI 10.1016/S0022-5347(01)62443-1; Kugler A, 1999, ANTICANCER RES, V19, P1589; Li ZB, 2002, BIOCHEM BIOPH RES CO, V294, P700, DOI 10.1016/S0006-291X(02)00534-X; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Long L, 1998, CANCER RES, V58, P3243; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Min Y, 2005, GUT, V54, P591, DOI 10.1136/gut.2004.048926; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; O'Connor R, 2003, HORM METAB RES, V35, P771; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Rajala RVS, 2004, BIOCHEMISTRY-US, V43, P5637, DOI 10.1021/bi035913v; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Rosendahl A, 2004, INT J ONCOL, V25, P1327; Schips L, 2004, AM J CLIN PATHOL, V122, P931, DOI 10.1309/G7PY0RE7T86HQYV; Sekharam M, 2003, ANTICANCER RES, V23, P1517; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Stawowy P, 2004, BIOCHEM BIOPH RES CO, V321, P531, DOI 10.1016/j.bbrc.2004.07.001; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Tanno S, 2001, CANCER RES, V61, P589; Wang J, 2005, INFECT IMMUN, V73, P2766, DOI 10.1128/IAI.73.5.2766-2777.2005; Wang J, 2007, AM J PHYSIOL-LUNG C, V292, pL1495, DOI 10.1152/ajplung.00452.2006; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Yoon A, 2001, MOL CELL BIOCHEM, V223, P1, DOI 10.1023/A:1017549222677; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zhou MI, 2004, CANCER RES, V64, P1278, DOI 10.1158/0008-5472.CAN-03-0884	52	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					535	547		10.1038/onc.2010.427	http://dx.doi.org/10.1038/onc.2010.427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20871634				2022-12-28	WOS:000286922300003
J	Inaguma, S; Kasai, K; Ikeda, H				Inaguma, S.; Kasai, K.; Ikeda, H.			GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin	ONCOGENE			English	Article						GLI1; MUC5AC; E-cadherin; beta-catenin; invasion; pancreatic cancer	GENE-EXPRESSION; MUC5AC MUCIN; HEDGEHOG; PROGNOSIS; TARGET; GROWTH; ASSOCIATION; REQUIREMENT; PROTEIN; CHOLANGIOCARCINOMA	The Kruppel-like zinc-finger protein GLI1 functions as a downstream transcription factor of Hedgehog signaling and plays a pivotal role in the cellular proliferation of many types of tumors, including pancreatic ductal adenocarcinoma (PDA). PDA develops from dysplastic lesions called pancreatic intraepithelial neoplasia (PanIN) through a multistep carcinogenesis process that changes its cellular characteristics, including a mucin expression profile. Increased expression of a gel-forming mucin, MUC5AC, was previously revealed as a major biomarker for the poor prognosis of PDA patients, but the molecular mechanisms responsible for its expression and correlation with poor prognosis are not fully understood. Here we show that MUC5AC is a direct transcriptional target of GLI1 in PDA cells. Overexpression of GLI1 enhanced MUC5AC expression, and a double knockdown of GLI1 and GLI2 suppressed endogenous MUC5AC expression in PDA cells. Luciferase reporter assays revealed that GLI1 and GLI2 can activate the MUC5AC promoter through its conserved CACCC-box-like cis-regulatory elements. We also found that GLI1-upregulated MUC5AC was expressed in the intercellular junction between cultured PDA cells and interfered with the membrane localization of E-cadherin, leading to decreased E-cadherin-dependent cell-cell adhesion and promoting the migration and invasion of PDA cells. Consistently, GLI1 induced the nuclear accumulation and target gene expression of beta-catenin in a MUC5AC-dependent manner. Finally, immunohistochemical analysis revealed that GLI1 expression statistically correlated with MUC5AC expression and also with altered subcellular localization of E-cadherin and beta-catenin in PanIN lesions and PDA. This evidence revealed a new aspect of GLI1 function in modulating E-cadherin/beta-catenin-regulated cancer cell properties through the expression of a gel-forming mucin. Oncogene (2011) 30, 714-723; doi:10.1038/onc.2010.459; published online 25 October 2010	[Inaguma, S.; Kasai, K.; Ikeda, H.] Aichi Med Univ, Dept Pathol, Sch Med, Aichi 4801195, Japan	Aichi Medical University	Kasai, K (corresponding author), Aichi Med Univ, Dept Pathol, Sch Med, 21 Karimata, Aichi 4801195, Japan.	kkasai@aichi-med-u.ac.jp	Kasai, Kenji/K-6382-2019	Kasai, Kenji/0000-0001-6566-9483	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Yukiko Matsubara, Motoyasu Takeuchi and Naoki Igari (Aichi Medical University) for their expert technical assistance. We also thank Dr Akiko Tamakoshi (Aichi Medical University) for advice on statistical analyses and Dr Masahide Takahashi (Nagoya University) for comments on the manuscript. This research was supported in part by a Grant-in-Aid for Scientific Research (C) (to KK) and for Young Scientists (B) (to SI) from the Japan Society for the Promotion of Science.	Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Aishima S, 2006, HISTOPATHOLOGY, V49, P35, DOI 10.1111/j.1365-2559.2006.02414.x; Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Boonla C, 2003, CANCER, V98, P1438, DOI 10.1002/cncr.11652; Briggs CD, 2009, EUR J CANCER, V45, P33, DOI 10.1016/j.ejca.2008.08.024; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Gkretsi V, 2005, J CELL SCI, V118, P697, DOI 10.1242/jcs.01638; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Kasai K, 2004, GENES CELLS, V9, P49, DOI 10.1111/j.1356-9597.2004.00701.x; Kasai K, 2008, CANCER RES, V68, P7723, DOI 10.1158/0008-5472.CAN-07-6661; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Lee HS, 2001, CANCER, V92, P1427, DOI 10.1002/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Park ET, 2008, INT J CANCER, V122, P1253, DOI 10.1002/ijc.23225; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Sanada Y, 2006, PANCREAS, V32, P164, DOI 10.1097/01.mpa.0000202947.80117.a0; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Senapati S, 2008, HISTOL HISTOPATHOL, V23, P1541, DOI 10.14670/HH-23.1541; Shimokawa T, 2003, CANCER RES, V63, P6116; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singh AP, 2008, LANCET ONCOL, V9, P1076, DOI 10.1016/S1470-2045(08)70277-8; Takikita M, 2009, CANCER RES, V69, P2950, DOI 10.1158/0008-5472.CAN-08-3879; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Truant S, 2003, INT J CANCER, V104, P683, DOI 10.1002/ijc.11011; Vincent A, 2007, ONCOGENE, V26, P6566, DOI 10.1038/sj.onc.1210479; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Yu CJ, 1996, INT J CANCER, V69, P457, DOI 10.1002/(SICI)1097-0215(19961220)69:6<457::AID-IJC7>3.0.CO;2-3; Yu CJ, 2005, LUNG CANCER, V47, P59, DOI 10.1016/j.lungcan.2004.05.018	35	85	90	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					714	723		10.1038/onc.2010.459	http://dx.doi.org/10.1038/onc.2010.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20972463				2022-12-28	WOS:000287192000008
J	Balzer, EM; Whipple, RA; Thompson, K; Boggs, AE; Slovic, J; Cho, EH; Matrone, MA; Yoneda, T; Mueller, SC; Martin, SS				Balzer, E. M.; Whipple, R. A.; Thompson, K.; Boggs, A. E.; Slovic, J.; Cho, E. H.; Matrone, M. A.; Yoneda, T.; Mueller, S. C.; Martin, S. S.			c-Src differentially regulates the functions of microtentacles and invadopodia	ONCOGENE			English	Article						microtentacle; invadopodia; Src; breast cancer; microtubule; actin	CANCER-CELLS; EXTRACELLULAR-MATRIX; TUMOR-CELLS; METASTASIS; PODOSOMES; INVASION; DEGRADATION; ADHESION; GROWTH; ACTIN	During metastasis, invading cells produce various actin-based membrane protrusions that promote directional migration and proteolysis of extracellular matrix (ECM). Observations of actin staining within thin, tubulin-based microtentacle (McTN) protrusions in suspended MDA-MB-231 tumor cells, prompted an investigation of whether McTNs are structural or functional analogs of invadopodia. We show here that MDA-MB-231 cells are capable of producing invadopodia and McTNs, both of which contain F-actin. Invadopodium formation was enhanced by the expression of a constitutively active c-Src kinase, and repressed by the expression of dominant-negative, catalytically inactive form of c-Src. In contrast, expression of inactive c-Src significantly increased McTN formation. Direct inhibition of c-Src with the SU6656 inhibitor compound also significantly enhanced McTN formation, but suppressed invadopodia, including the appearance of F-actin cores and phospho-cortactin foci, as well as completely blocking focal degradation of ECM. In addition, silencing of Tks5 in Src-transformed fibroblasts blocked invadopodia without affecting McTNs. Genetic modification of c-Src activity that promoted McTN formation augmented capillary retention of circulating tumor cells in vivo and rapid re-attachment of suspended cells in vitro, even though invadopodia were strongly suppressed. These results indicate that McTNs are capable of enhancing tumor cell reattachment, even in the absence of Tks5 and active Src, and define separate cytoskeletal mechanisms and functions for McTNs and invadopodia. Oncogene (2010) 29, 6402-6408; doi:10.1038/onc.2010.360; published online 18 October 2010	[Balzer, E. M.; Whipple, R. A.; Thompson, K.; Cho, E. H.; Matrone, M. A.; Martin, S. S.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum NCI Canc Ctr, Dept Physiol, Baltimore, MD 21201 USA; [Balzer, E. M.; Boggs, A. E.; Slovic, J.; Cho, E. H.; Matrone, M. A.; Martin, S. S.] Univ Maryland, Sch Med, Program Mol Med, Baltimore, MD 21201 USA; [Yoneda, T.] Osaka Univ, Grad Sch Dent, Dept Biochem, Osaka, Japan; [Mueller, S. C.] Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Osaka University; Georgetown University	Martin, SS (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenebaum NCI Canc Ctr, Dept Physiol, 655 W Baltimore St,Room 10-029, Baltimore, MD 21201 USA.	ssmartin@som.umaryland.edu	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X	National Cancer Institute [R01-CA124704]; USA Medical Research and Materiel Command [BC061047]; Susan G Komen investigator-initiated grant [KG100240]; NATIONAL CANCER INSTITUTE [R01CA124704, P30CA134274] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USA Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Susan G Komen investigator-initiated grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by R01-CA124704 grant from the National Cancer Institute, Breast Cancer Idea Award from USA Medical Research and Materiel Command (BC061047) and a Susan G Komen investigator-initiated grant (KG100240). We are very grateful to Darren Seals and Sara Courtneidge for generously providing cell lines and reagents to examine the role of Tks5.	Balzer EM, 2010, BREAST CANCER RES TR, V121, P65, DOI 10.1007/s10549-009-0457-3; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; GUPTON SL, 2007, SCI STKE, pRE5, DOI DOI 10.1126/STKE.4002007RE5; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mendoza M, 2009, INT J BIOCHEM CELL B, V41, P1452, DOI 10.1016/j.biocel.2009.01.015; Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585-007-9098-2; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Whipple RA, 2007, EXP CELL RES, V313, P1326, DOI 10.1016/j.yexcr.2007.02.001; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0	20	53	54	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6402	6408		10.1038/onc.2010.360	http://dx.doi.org/10.1038/onc.2010.360			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20956943	Green Accepted			2022-12-28	WOS:000284874700010
J	Coutts, AS; Pires, IM; Weston, L; Buffa, FM; Milani, M; Li, JL; Harris, AL; Hammond, EM; La Thangue, NB				Coutts, A. S.; Pires, I. M.; Weston, L.; Buffa, F. M.; Milani, M.; Li, J-L; Harris, A. L.; Hammond, E. M.; La Thangue, N. B.			Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1 alpha	ONCOGENE			English	Article						JMY; HIF-1; actin; hypoxia; motility	INDUCIBLE FACTOR-I; P53; COFACTOR; P300; MDM2	Junction-mediating and regulatory protein (JMY) is a novel p53 cofactor that regulates p53 activity during stress. JMY interacts with p300/CBP, which are ubiquitous transcriptional co-activators that interact with a variety of sequence-specific transcription factors, including hypoxia-inducible factor-1 alpha (HIF-1 alpha). In addition, JMY is an actin-nucleating protein, which, through its WH2 domains, stimulates cell motility. In this study, we show that JMY is upregulated during hypoxia in a HIF-1 alpha-dependent manner. The JMY gene contains HIF-responsive elements in its promoter region and HIF-1 alpha is recruited to its promoter during hypoxia. HIF-1 alpha drives transcription of JMY, which accounts for its induction under hypoxia. Moreover, the enhanced cell motility and invasion that occurs during hypoxia requires JMY, as depleting JMY under hypoxic conditions causes decreased cell motility. Our results establish the interplay between JMY and HIF-1 alpha as a new mechanism that controls cell motility under hypoxic stress. Oncogene (2011) 30, 4835-4842; doi: 10.1038/onc.2011.188; published online 30 May 2011	[Coutts, A. S.; Weston, L.; La Thangue, N. B.] Univ Oxford, Dept Oncol, Canc Biol Lab, Oxford OX3 7DQ, Oxon, England; [Pires, I. M.; Hammond, E. M.] Univ Oxford, Dept Oncol, Canc Res UK MRC Gray Inst Radiat Oncol & Biol, Oxford OX3 7DQ, Oxon, England; [Buffa, F. M.; Milani, M.; Li, J-L; Harris, A. L.] Univ Oxford, Dept Oncol, Canc Res UK Mol Oncol Labs, Weatherall Inst Mol Med, Oxford OX3 7DQ, Oxon, England	University of Oxford; Cancer Research UK; University of Oxford; University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Dept Oncol, Canc Biol Lab, Old Rd Campus,Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, Oxon, England.	nick.lathangue@clinpharm.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Buffa, Francesca/D-2574-2013	Harris, Adrian L/0000-0003-1376-8409; Buffa, Francesca/0000-0003-0409-406X; Hammond, Ester/0000-0002-2335-3146; Coutts, Amanda/0000-0002-5005-1864; Pires, Isabel/0000-0002-0417-2710	MRC; CRUK [C300/6731, C6415/A9321]; LRF; AICR; MRC [G1000807, G0500905, G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: researchfish; Medical Research Council [G0500905, G9400953, G1000807] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); LRF; AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the MRC, CRUK, LRF and AICR for support. ASC and LW are funded by MRC and CRUK (grant # C300/6731). IMP and EMH are funded by CRUK (grant # C6415/A9321). We also thank Long Dang, Peter Ratcliffe and Shoumo Bhattacharya for providing invaluable reagents.	Biswas S, 2010, J ONCOL, V2010, DOI 10.1155/2010/757908; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Coutts AS, 2007, EMBO REP, V8, P84, DOI 10.1038/sj.embor.7400855; Coutts AS, 2009, P NATL ACAD SCI USA, V106, P19872, DOI 10.1073/pnas.0906785106; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Demonacos C, 2001, MOL CELL, V8, P71, DOI 10.1016/S1097-2765(01)00277-5; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Rapisarda A, 2009, CELL CYCLE, V8, P4040, DOI 10.4161/cc.8.24.10145; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Spinella F, 2007, CANCER RES, V67, P1725, DOI 10.1158/0008-5472.CAN-06-2606; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; Zuchero JB, 2009, NAT CELL BIOL, V11, P451, DOI 10.1038/ncb1852	25	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4835	4842		10.1038/onc.2011.188	http://dx.doi.org/10.1038/onc.2011.188			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625218	Green Published			2022-12-28	WOS:000298134700007
J	Taniuchi, K; Cerny, RL; Tanouchi, A; Kohno, K; Kotani, N; Honke, K; Saibara, T; Hollingsworth, MA				Taniuchi, K.; Cerny, R. L.; Tanouchi, A.; Kohno, K.; Kotani, N.; Honke, K.; Saibara, T.; Hollingsworth, M. A.			Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth	ONCOGENE			English	Article						polypeptide N-acetylgalactosaminyl-transferase; GalNAc-T3; pancreatic cancer; O-glycosylation; cell growth; apoptosis	ALPHA-D-GALACTOSAMINE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; CDNA CLONING; EXPRESSION; METASTASIS; MUCIN; IDENTIFICATION; GLYCANS; TARGETS; ANTIGEN	O-linked glycans of secreted and membrane-bound proteins have an important role in the pathogenesis of pancreatic cancer by modulating immune responses, inflammation and tumorigenesis. A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts). Thus, GalNAc-Ts regulate the first committed step in O-glycosylated protein biosynthesis, determine sites of O-glycosylation on proteins and are important for understanding normal and carcinoma-associated O-glycosylation. We have found that one of these enzymes, GalNAc-T3, is overexpressed in human pancreatic cancer tissues and suppression of GalNAc-T3 significantly attenuates the growth of pancreatic cancer cells in vitro and in vivo. In addition, suppression of GalNAc-T3 induces apoptosis of pancreatic cancer cells. Our results indicate that GalNAc-T3 is likely involved in pancreatic carcinogenesis. Modification of cellular glycosylation occurs in nearly all types of cancer as a result of alterations in the expression levels of glycosyltransferases. We report guanine the nucleotide-binding protein, a-transducing activity polypeptide-1 (GNAT1) as a possible substrate protein of GalNAc-T3. GalNAc-T3 is associated with O-glycosylation of GNAT1 and affects the subcellular distribution of GNAT1. Knocking down endogenous GNAT1 significantly suppresses the growth/survival of PDAC cells. Our results imply that GalNAc-T3 contributes to the function of O-glycosylated proteins and thereby affects the growth and survival of pancreatic cancer cells. Thus, substrate proteins of GalNAc-T3 should serve as important therapeutic targets for pancreatic cancers. Oncogene (2011) 30, 4843-4854; doi:10.1038/onc.2011.194; published online 30 May 2011	[Taniuchi, K.] Kochi Univ, Sch Med, Dept Gastroenterol & Hepatol, Nanko Ku, Kochi 7838505, Japan; [Taniuchi, K.; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Taniuchi, K.; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Cerny, R. L.] Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; [Kohno, K.] Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Fukuoka, Japan; [Kotani, N.; Honke, K.] Kochi Univ, Sch Med, Dept Biochem, Kochi 7838505, Japan	Kochi University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln; University of Occupational & Environmental Health - Japan; Kochi University	Taniuchi, K (corresponding author), Kochi Univ, Sch Med, Dept Gastroenterol & Hepatol, Nanko Ku, Kochi 7838505, Japan.	jm-ktaniuchi@kochi-u.ac.jp		Kotani, Norihiro/0000-0003-3739-6478	Tamotsu Takeuchi; NIH [U01CA111294, R01CA057362]; NATIONAL CANCER INSTITUTE [U01CA128437, P50CA127297, R01CA057362, U01CA111294, P30CA036727] Funding Source: NIH RePORTER	Tamotsu Takeuchi; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Michel Ouellette for providing the HPNE cells and Tamotsu Takeuchi for supporting pathological experiments and helpful discussion. We also thank Janice Taylor and James Talaska for excellent technical assistance. This work was funded by the NIH with grants to MAH (U01CA111294; R01CA057362).	Alenzi FQB, 2004, BRIT J BIOMED SCI, V61, P1; Andersen MH, 2005, NAT REV DRUG DISCOV, V4, P399, DOI 10.1038/nrd1717; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BRAGA VMM, 1992, DEVELOPMENT, V115, P427; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; GRAY JW, 1980, ANNU REV BIOPHYS BIO, V9, P509, DOI 10.1146/annurev.bb.09.060180.002453; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; IWAMURA T, 1987, JPN J CANCER RES, V78, P54; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jensen ON, 2006, NAT REV MOL CELL BIO, V7, P391, DOI 10.1038/nrm1939; Joshi S. S., 2001, Current Pharmaceutical Biotechnology, V2, P187, DOI 10.2174/1389201013378725; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Kondo A, 2006, BBA-PROTEINS PROTEOM, V1764, P1881, DOI 10.1016/j.bbapap.2006.10.011; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Li M, 2010, J BIOSCIENCES, V35, P665, DOI 10.1007/s12038-010-0073-8; Mayoral MA, 2008, CANCER INVEST, V26, P615, DOI 10.1080/07357900701837051; MELLORS A, 1995, METHOD ENZYMOL, V248, P728; Merighi Stefania, 2006, Purinergic Signal, V2, P627, DOI 10.1007/s11302-006-9020-4; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Nomoto M, 1999, CANCER RES, V59, P6214; Reis CA, 1999, CANCER RES, V59, P1003; Rosenzweig DH, 2007, J NEUROSCI, V27, P5484, DOI 10.1523/JNEUROSCI.1421-07.2007; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Sutherlin ME, 1997, CANCER RES, V57, P4744; Takenaka Y, 2002, GLYCOCONJUGATE J, V19, P543, DOI 10.1023/B:GLYC.0000014084.01324.15; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Wray CJ, 2005, GASTROENTEROLOGY, V128, P1626, DOI 10.1053/j.gastro.2005.03.035	32	63	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4843	4854		10.1038/onc.2011.194	http://dx.doi.org/10.1038/onc.2011.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21625220	Green Accepted, Green Published			2022-12-28	WOS:000298346400001
J	Li, C; Ao, J; Fu, J; Lee, DF; Xu, J; Lonard, D; O'Malley, BW				Li, C.; Ao, J.; Fu, J.; Lee, D-F; Xu, J.; Lonard, D.; O'Malley, B. W.			Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1	ONCOGENE			English	Article						SRC-3/AIB1; tumor suppressor; SPOP; ubiquitin ligase; steroid receptor co-activator; breast cancer	STEROID-RECEPTOR COACTIVATOR-1; CANCER CELL-PROLIFERATION; REG-GAMMA-PROTEASOME; KINASE-I-EPSILON; F-BOX PROTEINS; BREAST-CANCER; NUCLEAR RECEPTORS; TRANSCRIPTIONAL COACTIVATOR; BETA-CATENIN; E3 LIGASE	Steroid receptor co-activator-3 (SRC-3/AIB1) is an oncogene that is amplified and overexpressed in many human cancers. However, the molecular mechanisms that regulate 'activated SRC-3 oncoprotein' turnover during tumorigenesis remain to be elucidated. Here, we report that speckle-type POZ protein (SPOP), a cullin 3 (CUL3)-based ubiquitin ligase, is responsible for SRC-3 ubiquitination and proteolysis. SPOP interacts directly with an SRC-3 phospho-degron in a phosphorylation-dependent manner. Casein kinase I epsilon phosphorylates the S102 in this degron and promotes SPOP-dependent turnover of SRC-3. Short hairpin RNA knockdown and overexpression experiments substantiated that the SPOP/CUL3/Rbx1 ubiquitin ligase complex promotes SRC-3 turnover. A systematic analysis of the SPOP genomic locus revealed that a high percentage of genomic loss or loss of heterozygosity occurs at this locus in breast cancers. Furthermore, we demonstrate that restoration of SPOP expression inhibited SRC-3-mediated oncogenic signaling and tumorigenesis, thus positioning SPOP as a tumor suppressor. Oncogene (2011) 30, 4350-4364; doi: 10.1038/onc.2011.151; published online 16 May 2011	[Li, C.; Ao, J.] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China; [Li, C.; Fu, J.; Xu, J.; Lonard, D.; O'Malley, B. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lee, D-F] Mt Sinai Sch Med, Black Family Stem Cell Res Inst, Dept Gene & Cell Med, New York, NY USA	Shanghai Jiao Tong University; Baylor College of Medicine; Icahn School of Medicine at Mount Sinai	Li, C (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China.	01chao@gmail.com; berto@bcm.edu		Lee, Dung-Fang/0000-0003-2387-597X	State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute; National Natural Science Foundation of China [81072163]; NIH [HD-08188, HD-07857]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857, R01HD008188] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008188, R37HD007857] Funding Source: NIH RePORTER	State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Ming-Jer Tsai and Sophia Y Tsai for their suggestions and Dr Kevin White (University of Chicago) for the monoclonal antibodies against SPOP. This work was supported by funding from State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute and grants (81072163) from National Natural Science Foundation of China (CL), and NIH HD-08188 and HD-07857 grants (BWO).	Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bunce MW, 2008, J BIOL CHEM, V283, P8678, DOI 10.1074/jbc.M710222200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen MH, 2009, GENE DEV, V23, P1910, DOI 10.1101/gad.1794109; Claiborn KC, 2010, J CLIN INVEST, V120, P3713, DOI 10.1172/JCI40440; DeMarchis L, 2004, BRIT J CANCER, V90, P2384, DOI 10.1038/sj.bjc.6601848; Durocher F, 1996, J MED GENET, V33, P814, DOI 10.1136/jmg.33.10.814; Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Glass CK, 2000, GENE DEV, V14, P121; Goel A, 2004, J BIOL CHEM, V279, P14909, DOI 10.1074/jbc.M400036200; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jin JP, 2005, METHOD ENZYMOL, V399, P287, DOI 10.1016/S0076-6879(05)99020-4; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; KUMAR RPD, 2008, NR COREGULATORS HUMA, V11; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lerebours F, 2002, INT J CANCER, V102, P618, DOI 10.1002/ijc.10729; Li C, 2008, MOL CELL, V31, P835, DOI 10.1016/j.molcel.2008.07.019; Li C, 2007, MOL CELL BIOL, V27, P1296, DOI 10.1128/MCB.00336-06; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li B, 2008, CANCER LETT, V261, P64, DOI 10.1016/j.canlet.2007.11.013; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Liu J, 2009, SCIENCE, V323, P1218, DOI 10.1126/science.1157669; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; ONATE SA, 1995, SCIENCE, V270, P1354; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; RADFORD DM, 1995, CANCER RES, V55, P3399; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Shirogane T, 2005, J BIOL CHEM, V280, P26863, DOI 10.1074/jbc.M502862200; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	70	104	115	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	42					4350	4364		10.1038/onc.2011.151	http://dx.doi.org/10.1038/onc.2011.151			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21577200	Green Accepted			2022-12-28	WOS:000296356400006
J	Rajan, N; Elliott, R; Clewes, O; Mackay, A; Reis-Filho, JS; Burn, J; Langtry, J; Sieber-Blum, M; Lord, CJ; Ashworth, A				Rajan, N.; Elliott, R.; Clewes, O.; Mackay, A.; Reis-Filho, J. S.; Burn, J.; Langtry, J.; Sieber-Blum, M.; Lord, C. J.; Ashworth, A.			Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours	ONCOGENE			English	Article						cylindroma; tropomyosin receptor kinase; TRK; microarray; comparative genomic hybridization; CYLD	NF-KAPPA-B; BASAL-CELL CARCINOMAS; NERVE GROWTH-FACTOR; DEUBIQUITINATING ENZYME; NEUROTROPHIN RECEPTORS; DERMAL CYLINDROMA; BREAST CANCERS; EXPRESSION; GENE; MUTATIONS	Individuals with germline mutations in the tumour-suppressor gene CYLD are at high risk of developing disfiguring cutaneous appendageal tumours, the defining tumour being the highly organised cylindroma. Here, we analysed CYLD mutant tumour genomes by array comparative genomic hybridisation and gene expression microarray analysis. CYLD mutant tumours were characterised by an absence of copy-number aberrations apart from LOH chromosome 16q, the genomic location of the CYLD gene. Gene expression profiling of CYLD mutant tumours showed dysregulated tropomyosin kinase (TRK) signalling, with overexpression of TRKB and TRKC in tumours when compared with perilesional skin. Immunohistochemical analysis of a tumour microarray showed strong membranous TRKB and TRKC staining in cylindromas, as well as elevated levels of ERK phosphorylation and BCL2 expression. Membranous TRKC overexpression was also observed in 70% of sporadic BCCs. RNA interference-mediated silencing of TRKB and TRKC, as well as treatment with the small-molecule TRK inhibitor lestaurtinib, reduced colony formation and proliferation in 3D primary cell cultures established from CYLD mutant tumours. These results suggest that TRK inhibition could be used as a strategy to treat tumours with loss of functional CYLD. Oncogene (2011) 30, 4243-4260; doi: 10.1038/onc.2011.133; published online 9 May 2011	[Rajan, N.; Clewes, O.; Burn, J.; Sieber-Blum, M.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Elliott, R.; Mackay, A.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Langtry, J.] Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Newcastle University - UK	Rajan, N (corresponding author), Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	neil.rajan@ncl.ac.uk	Rajan, Neil/AAL-7702-2021; Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Rajan, Neil/0000-0002-5850-5680; Lord, Christopher J/0000-0002-3226-0515; Burn, John/0000-0002-9823-2322	Newcastle Healthcare Charities Trust; North East Skin Research Fund; Breakthrough Breast Cancer; Cancer Research UK; Medical Research Council; MRC [G0701367] Funding Source: UKRI; Medical Research Council [G0701367] Funding Source: researchfish	Newcastle Healthcare Charities Trust; North East Skin Research Fund; Breakthrough Breast Cancer; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded in part by grants from the Newcastle Healthcare Charities Trust, the North East Skin Research Fund, Breakthrough Breast Cancer, Cancer Research UK and the Medical Research Council. N Rajan is a MRC Clinical Training Fellow.	Adly MA, 2005, BRIT J DERMATOL, V153, P514, DOI 10.1111/j.1365-2133.2005.06763.x; Alvarez-Rodiguez R, 2007, J BIOL CHEM, V282, P37170, DOI 10.1074/jbc.M705414200; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; April C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008162; Arevalo JC, 2006, NEURON, V50, P549, DOI 10.1016/j.neuron.2006.03.044; Blasing H, 2005, ARCH DERMATOL RES, V296, P580, DOI 10.1007/s00403-005-0563-y; Bowen S, 2005, J INVEST DERMATOL, V124, P919, DOI 10.1111/j.0022-202X.2005.23688.x; BRUCKNERTUDERMAN L, 1991, J INVEST DERMATOL, V96, P729, DOI 10.1111/1523-1747.ep12470965; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; Chen-Tsai CP, 2004, DERMATOL SURG, V30, P1009, DOI 10.1111/j.1524-4725.2004.30306.x; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Donovan J, 2009, DERMATOL SURG, V35, P1311, DOI 10.1111/j.1524-4725.2009.01236.x; Dunning MJ, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-85; Dutton R, 1999, CLIN EXP PHARMACOL P, V26, P746, DOI 10.1046/j.1440-1681.1999.03108.x; Gao JM, 2008, J BIOL CHEM, V283, P8802, DOI 10.1074/jbc.M708470200; Geetha T, 2005, MOL CELL, V20, P301, DOI 10.1016/j.molcel.2005.09.014; Geetha T, 2008, BIOCHEM BIOPH RES CO, V374, P33, DOI 10.1016/j.bbrc.2008.06.082; GERRETSEN AL, 1993, CANCER-AM CANCER SOC, V72, P1618, DOI 10.1002/1097-0142(19930901)72:5<1618::AID-CNCR2820720521>3.0.CO;2-5; Gunnarsson R, 2008, GENE CHROMOSOME CANC, V47, P697, DOI 10.1002/gcc.20575; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; *ILL INC, 2009, BEADST GEN EXPR MOD; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Jin W, 2007, CANCER RES, V67, P9869, DOI 10.1158/0008-5472.CAN-07-0436; Kavanagh DO, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-1; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kriegl L, 2009, BRIT J DERMATOL, V160, P1353, DOI 10.1111/j.1365-2133.2009.09144.x; Lagadec C, 2009, ONCOGENE, V28, P1960, DOI 10.1038/onc.2009.61; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Liu HH, 2006, P NATL ACAD SCI USA, V103, P11677, DOI 10.1073/pnas.0603089103; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Marshall JL, 2005, INVEST NEW DRUG, V23, P31, DOI 10.1023/B:DRUG.0000047103.64335.b0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Meybehm M, 1997, AM J DERMATOPATH, V19, P154, DOI 10.1097/00000372-199704000-00009; Miller SC, 2010, BIOCHEM PHARMACOL, V79, P1272, DOI 10.1016/j.bcp.2009.12.021; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oosterkamp HM, 2006, BRIT J DERMATOL, V155, P182, DOI 10.1111/j.1365-2133.2006.07224.x; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; Rajan N, 2009, ARCH DERMATOL, V145, P1277, DOI 10.1001/archdermatol.2009.262; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Ricci A, 2001, AM J RESP CELL MOL, V25, P439, DOI 10.1165/ajrcmb.25.4.4470; Saggar S, 2008, J MED GENET, V45, P298, DOI 10.1136/jmg.2007.056127; Saha RN, 2006, J NEUROIMMUNE PHARM, V1, P212, DOI 10.1007/s11481-006-9020-8; Saini HS, 2004, J NEUROCHEM, V89, P951, DOI 10.1111/j.1471-4159.2004.02365.x; Scala S, 1996, CANCER RES, V56, P3737; Shabbir M, 2010, EXPERT OPIN INV DRUG, V19, P427, DOI 10.1517/13543781003598862; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Stokes A, 2006, CELL SIGNAL, V18, P1584, DOI 10.1016/j.cellsig.2005.12.009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Tan DSP, 2007, LAB INVEST, V87, P737, DOI 10.1038/labinvest.3700593; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; TELLECHEA O, 1995, AM J DERMATOPATH, V17, P260, DOI 10.1097/00000372-199506000-00008; Thress K, 2009, MOL CANCER THER, V8, P1818, DOI 10.1158/1535-7163.MCT-09-0036; TIMPL R, 1984, CIBA F SYMP, V108, P25; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Trompouki E, 2009, NEOPLASIA, V11, P469, DOI 10.1593/neo.81424; Tunggal L, 2002, AM J PATHOL, V160, P459, DOI 10.1016/S0002-9440(10)64865-1; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; WORKMAN C, 2002, GENOME BIOL, V0003; Wu CB, 2007, TRAFFIC, V8, P1503, DOI 10.1111/j.1600-0854.2007.00636.x; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041	78	40	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	41					4243	4260		10.1038/onc.2011.133	http://dx.doi.org/10.1038/onc.2011.133			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21552290	Green Accepted			2022-12-28	WOS:000296356300003
J	Wu, J; Ru, NY; Zhang, Y; Li, Y; Wei, D; Ren, Z; Huang, XF; Chen, ZN; Bian, H				Wu, J.; Ru, N-Y; Zhang, Y.; Li, Y.; Wei, D.; Ren, Z.; Huang, X-F; Chen, Z-N; Bian, H.			HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-beta signaling and is transcriptionally regulated by Slug	ONCOGENE			English	Article						hepatocarcinogenesis; epithelial-mesenchymal transition; PI3K/Akt; hepatocellular carcinoma; CD147; TGF-beta	GROWTH-FACTOR-BETA; FETAL-RAT HEPATOCYTES; HEPATOCELLULAR-CARCINOMA; TUMOR PROGRESSION; DOWN-REGULATION; EXPRESSION; METASTASIS; INVASION; RECEPTOR; PATHWAYS	Epithelial-mesenchymal transition (EMT) induced by transforming growth factor-beta (TGF-beta) is implicated in hepatocarcinogenesis and hepatocellular carcinoma (HCC) metastasis. HAb18G/CD147, which belongs to the CD147 family, is an HCC-associated antigen that has a crucial role in tumor invasion and metastasis. The goal of this study was to investigate the role of HAb18G/CD147 during EMT in hepatocarcinogenesis. Human normal hepatic cell lines QZG and L02, primary mouse hepatocytes and nude mouse models were used to determine the role of HAb18G/CD147 in EMT, and the involvement of the TGF-beta-driven pathway. A dual-luciferase reporter assay and ChIP were used to investigate the transcriptional regulation of the CD147 gene. Samples from patients with liver disease were assessed to determine the relationship between HAb18G/CD147 and typical markers for EMT. Our results show that upregulation of HAb18G/CD147 is induced by TGF-beta coupled with downregulation of E-cadherin and upregulation of N-cadherin and vimentin. The expression of HAb18G/CD147 is controlled by the cell survival PI3K/Akt/GSK3 beta signaling pathway, and is directly regulated by the transcription factor Slug. Transfection of CD147 also induces an elevated expression of TGF-beta. CD147-transfected hepatocytes have mesenchymal phenotypes that accelerate tumor formation and tumor metastasis in vivo. Immunohistochemistry analysis shows a negative correlation between HAb18G/CD147 and E-cadherin expression (r(s) = -0.3622, P = 0.0105), and a positive correlation between HAb18G/CD147 and Slug expression (r(s) = 0.3064, P = 0.0323) in human HCC tissues. Our study uncovers a novel role of HAb18G/CD147 in mediating EMT in the process of HCC progression and showed that CD147 is a Slug target gene in the signaling cascade TGF-beta -> PI3K/Akt -> GSK3 beta -> Snail -> Slug -> CD147. Our results suggest that CD147 may be a potential target for the treatment and prevention of HCC. Oncogene (2011) 30, 4410-4427; doi:10.1038/onc.2011.149; published online 2 May 2011	[Wu, J.; Ru, N-Y; Zhang, Y.; Li, Y.; Wei, D.; Chen, Z-N; Bian, H.] Fourth Mil Med Univ, Cell Engn Res Ctr, Xian 710032, Shaanxi, Peoples R China; [Wu, J.; Ru, N-Y; Zhang, Y.; Li, Y.; Wei, D.; Chen, Z-N; Bian, H.] Fourth Mil Med Univ, Dept Cell Biol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China; [Ren, Z.] Third Mil Med Univ, Dept Microbiol, Chongqing, Peoples R China; [Huang, X-F] Fourth Mil Med Univ, Cent Lab, Sch Basic Med, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Army Medical University; Air Force Military Medical University	Chen, ZN (corresponding author), Fourth Mil Med Univ, Cell Engn Res Ctr, 17 Changle W Rd, Xian 710032, Shaanxi, Peoples R China.	znchen@fmmu.edu.cn; hjbian@fmmu.edu.cn			National Natural Science Foundation of China [30870944, 30671196]; Hi-tech Research and Development Programme of China [2009CB521706]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hi-tech Research and Development Programme of China(National High Technology Research and Development Program of China)	We thank Professor Xiao-Long Ji (Department of Pathology, General Hospital of the Chinese People's Armed Police Forces, Beijing, China), Professor Wei Zhang (Department of Pathology, Tangdu Hospital of Fourth Military Medical University, Xi'an, China) and Professor Qiao-Nan Guo (Department of Pathology, Southwest Hospital of Third Military Medical University, Chongqing, China) for their pathology analyses. We thank Professor Mien-Chie Hung (Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) for providing pEGFP-Snail1, and Dr Ling-Min Kong and Xia Ke in our lab for providing pGL3-CD147 (-1761/+37), pGL3-CD147 (-644/+37) and pGL3-CD147 (-338/+37). Financial support: This work was supported by grants from the National Natural Science Foundation of China (Nos. 30870944 and 30671196), and the Hi-tech Research and Development Programme of China (No. 2009CB521706). Writing assistance was provided by American Journal Experts, USA.	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Belton RJ, 2008, J BIOL CHEM, V283, P17805, DOI 10.1074/jbc.M801876200; Chen ZN, 2006, INT J RADIAT ONCOL, V65, P435, DOI 10.1016/j.ijrobp.2005.12.034; Elsharkawy AM, 2007, HEPATOLOGY, V46, P590, DOI 10.1002/hep.21802; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; Gabison EE, 2005, AM J PATHOL, V166, P209, DOI 10.1016/S0002-9440(10)62245-6; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Gou XC, 2009, CANCER SCI, V100, P837, DOI 10.1111/j.1349-7006.2009.01113.x; Huet E, 2008, FASEB J, V22, P1144, DOI 10.1096/fj.07-8748com; Iacono KT, 2007, EXP MOL PATHOL, V83, P283, DOI 10.1016/j.yexmp.2007.08.014; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Liu FF, 2010, BREAST CANCER RES TR, V124, P677, DOI 10.1007/s10549-010-0790-6; Matsuzaki K, 2009, FRONT BIOSCI-LANDMRK, V14, P2923, DOI 10.2741/3423; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Nitta T, 2008, HEPATOLOGY, V48, P909, DOI 10.1002/hep.22397; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Sidhu SS, 2010, ONCOGENE, V29, P4145, DOI 10.1038/onc.2010.166; Song BC, 2002, CANCER-AM CANCER SOC, V94, P175, DOI 10.1002/cncr.10170; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Tang J, 2008, CELL MOL LIFE SCI, V65, P2933, DOI 10.1007/s00018-008-8315-8; Taura K, 2010, HEPATOLOGY, V51, P1027, DOI 10.1002/hep.23368; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Tsai JF, 1997, BRIT J CANCER, V76, P244, DOI 10.1038/bjc.1997.369; Valdes F, 2002, MOL CANCER RES, V1, P68; Valdes F, 2004, EXP CELL RES, V292, P209, DOI 10.1016/j.yexcr.2003.08.015; Vigneswaran N, 2006, EXP MOL PATHOL, V80, P147, DOI 10.1016/j.yexmp.2005.09.011; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu J, 2007, MOL CANCER RES, V5, P605, DOI 10.1158/1541-7786.MCR-06-0286; Xu J, 2007, HEPATOLOGY, V45, P269, DOI 10.1002/hep.21465; Yan L, 2007, AM J HEMATOL, V82, P949, DOI 10.1002/ajh.21030; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang YA, 2006, CANCER CELL, V9, P445, DOI 10.1016/j.ccr.2006.04.025; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Yoshino J, 2007, BIOCHEM BIOPH RES CO, V362, P63, DOI 10.1016/j.bbrc.2007.07.146	40	130	143	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4410	4427		10.1038/onc.2011.149	http://dx.doi.org/10.1038/onc.2011.149			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21532623				2022-12-28	WOS:000296356500004
J	Zhai, Y; Iura, A; Yeasmin, S; Wiese, AB; Wu, R; Feng, Y; Fearon, ER; Cho, KR				Zhai, Y.; Iura, A.; Yeasmin, S.; Wiese, A. B.; Wu, R.; Feng, Y.; Fearon, E. R.; Cho, K. R.			MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma	ONCOGENE			English	Article						MSX2; ovarian cancer; endometrioid; WNT signaling; beta-catenin	BETA-CATENIN GENE; CELL FACTOR; NEOPLASTIC TRANSFORMATION; EXPRESSION ANALYSIS; WNT/BETA-CATENIN; HOMEOBOX GENE; UP-REGULATION; CLEAR-CELL; HOX GENES; CARCINOMAS	Ovarian endometrioid adenocarcinomas (OEAs) frequently exhibit constitutive activation of canonical WNT signaling, usually as a result of oncogenic mutations that stabilize and dysregulate the beta-catenin protein. In previous work, we used microarray-based methods to compare gene expression in OEAs with and without dysregulated beta-catenin as a strategy for identifying novel beta-catenin/TCF target genes with important roles in ovarian cancer pathogenesis. Among the genes highlighted by the microarray studies was MSX2, which encodes a homeobox transcription factor. We found MSX2 expression was markedly increased in primary human and murine OEAs with dysregulated beta-catenin compared with OEAs with intact beta-catenin regulation. WNT pathway activation by WNT3a ligand or GSK3b inhibitor treatment potently induced MSX2 and ectopic expression of a dominant negative form of TCF4 inhibited MSX2 expression in ovarian cancer cells. Chromatin immunoprecipitation studies demonstrated that beta-catenin/TCF directly regulates MSX2 expression via binding to TCF binding elements in multiple regions of the MSX2 gene. Notably, ectopic MSX2 expression was found to promote neoplastic transformation of the rodent RK3E model epithelial cell line and to enhance the invasiveness of immortalized human ovarian epithelial cells in vitro and ovarian carcinoma cells in vivo. Inhibition of endogenous MSX2 expression in ovarian endometrioid cancer cells carrying a beta-catenin mutation using shRNA approaches inhibited neoplastic properties of the cells in vitro and in vivo. Expression of MSX2 in selected ovarian carcinoma cells induced changes suggestive of epithelial-mesenchymal transition (EMT), but based on analysis of ovarian cell lines and primary tumor tissues, effects of MSX2 on EMT appear to be complex and context-dependent. Our findings indicate MSX2 is a direct downstream transcriptional target of beta-catenin/TCF and has a key contributing role in the cancer phenotype of OEAs carrying WNT/beta-catenin pathway defects. Oncogene (2011) 30, 4152-4162; doi:10.1038/onc.2011.123; published online 18 April 2011	[Zhai, Y.; Iura, A.; Yeasmin, S.; Wiese, A. B.; Wu, R.; Fearon, E. R.; Cho, K. R.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Feng, Y.; Fearon, E. R.; Cho, K. R.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; [Fearon, E. R.; Cho, K. R.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Cho, KR (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1506 BSRB,109 Zina Pitcher, Ann Arbor, MI 48109 USA.	kathcho@umich.edu		Cho, Kathleen/0000-0003-0500-9998; Saito, Ayaka/0000-0002-9916-0463	National Cancer Institute [RO1 CA94172, RO1 CA85463]; NATIONAL CANCER INSTITUTE [R01CA094172, R01CA085463] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Rork Kuick for assistance in analyzing the microarray data from human and mouse tissue samples. This work was supported by grants from the National Cancer Institute (RO1 CA94172 and RO1 CA85463).	Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Bommer GT, 2010, J BIOL CHEM, V285, P1928, DOI 10.1074/jbc.M109.060319; Catasus L, 2004, HUM PATHOL, V35, P1360, DOI 10.1016/j.humpath.2004.07.019; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Di Bari MG, 2009, J CELL PHYSIOL, V219, P659, DOI 10.1002/jcp.21712; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang TX, 1999, J INVEST DERMATOL, V113, P230, DOI 10.1046/j.1523-1747.1999.00680.x; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Parker DS, 2008, MOL CELL BIOL, V28, P1815, DOI 10.1128/MCB.01230-07; Ramos C, 2005, TRENDS GENET, V21, P624, DOI 10.1016/j.tig.2005.09.001; Sagae S, 1999, JPN J CANCER RES, V90, P510, DOI 10.1111/j.1349-7006.1999.tb00777.x; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Satoh K, 2008, AM J PATHOL, V172, P926, DOI 10.2353/ajpath.2008.070346; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schwartz DR, 2003, CANCER RES, V63, P2913; Schwartz DR, 2002, CANCER RES, V62, P4722; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140; Song LY, 2009, DEVELOPMENT, V136, P3161, DOI 10.1242/dev.037440; SUZUKI M, 1993, BIOCHEM BIOPH RES CO, V194, P187, DOI 10.1006/bbrc.1993.1802; Takahashi C, 1996, ONCOGENE, V12, P2137; Whyte DB, 2006, BIOCHEM BIOPH RES CO, V340, P469, DOI 10.1016/j.bbrc.2005.12.025; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Wu R, 2001, CANCER RES, V61, P8247; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056	38	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4152	4162		10.1038/onc.2011.123	http://dx.doi.org/10.1038/onc.2011.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21499300	Green Accepted, Bronze			2022-12-28	WOS:000295924600002
J	Giordano, C; Catalano, S; Panza, S; Vizza, D; Barone, I; Bonofiglio, D; Gelsomino, L; Rizza, P; Fuqua, SAW; Ando, S				Giordano, C.; Catalano, S.; Panza, S.; Vizza, D.; Barone, I.; Bonofiglio, D.; Gelsomino, L.; Rizza, P.; Fuqua, S. A. W.; Ando, S.			Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression	ONCOGENE			English	Article						FXR; breast cancer; tamoxifen resistance; HER2; NF-kappa B	ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; CROSS-TALK; IDENTIFICATION; AMPLIFICATION; HER-2/NEU; PROMOTER; THERAPY; TARGET; FXR	Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor-alpha-positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatments with endocrine therapy and novel inhibitors that reduce HER2 expression and signaling and thus inhibit Tam-resistant breast cancer cell growth. In this study, we show that activation of farnesoid X receptor (FXR), by the primary bile acid chenodeoxycholic acid (CDCA) or the synthetic agonist GW4064, inhibited growth of Tam-resistant breast cancer cells (termed MCF-7 TR1), which was used as an in vitro model of acquired Tam resistance. Our results demonstrate that CDCA treatment significantly reduced both anchorage-dependent and anchorage-independent epidermal growth factor (EGF)-induced growth in MCF-7 TR1 cells. Furthermore, results from western blot analysis and real-time reverse transcription-PCR revealed that CDCA treatment reduced HER2 expression and inhibited EGF-mediated HER2 and p42/44 mitogen-activated protein kinase (MAPK) phosphorylation in these Tam-resistant breast cancer cells. Transient transfection experiments, using a vector containing the human HER2 promoter region, showed that CDCA treatment downregulated basal HER2 promoter activity. This occurred through an inhibition of nuclear factor-kappa B transcription factor binding to its specific responsive element located in the HER2 promoter region as revealed by mutagenesis studies, electrophoretic mobility shift assay and chromatin immunoprecipitation analysis. Collectively, these data suggest that FXR ligand-dependent activity, blocking HER2/MAPK signaling, may overcome anti-estrogen resistance in human breast cancer cells and could represent a new therapeutic tool to treat breast cancer patients that develop resistance. Oncogene (2011) 30, 4129-4140; doi:10.1038/onc.2011.124; published online 18 April 2011	[Barone, I.; Rizza, P.; Ando, S.] Univ Calabria, Dept Cell Biol, I-87036 Arcavacata Di Rende, Italy; [Giordano, C.; Catalano, S.; Barone, I.; Bonofiglio, D.; Ando, S.] Univ Calabria, Ctr Sanit, I-87036 Arcavacata Di Rende, Italy; [Catalano, S.; Panza, S.; Vizza, D.; Bonofiglio, D.; Gelsomino, L.] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italy; [Fuqua, S. A. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Fuqua, S. A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	University of Calabria; University of Calabria; University of Calabria; Baylor College of Medicine; Baylor College of Medicine	Ando, S (corresponding author), Univ Calabria, Dept Cell Biol, Via P Bucci, I-87036 Arcavacata Di Rende, Italy.	sebastiano.ando@unical.it	Bonofiglio, Daniela/AAV-8371-2020	BONOFIGLIO, Daniela/0000-0002-4142-0496; GIORDANO, Cinzia/0000-0003-4969-0607; BARONE, Ines/0000-0002-9769-1615; Gelsomino, Luca/0000-0003-3076-3482; CATALANO, Stefania/0000-0002-6352-9628; RIZZA, Pietro/0000-0002-1267-3910	AIRC; MIUR; Lilli Funaro Foundation; NIH/NCI [R01 CA72038]; Cancer Prevention and Research Institute of Texas (SAWF) [RP101251]; NATIONAL CANCER INSTITUTE [R01CA072038] Funding Source: NIH RePORTER	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); Lilli Funaro Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention and Research Institute of Texas (SAWF); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by AIRC grants, MIUR Ex 60% 2009, PRIN 2009 and Lilli Funaro Foundation. NIH/NCI R01 CA72038 and RP101251 from the Cancer Prevention and Research Institute of Texas (SAWF). We thank Dr Mien-Chie Hung for providing the pNeuLite plasmid and Dr T. A. Kocarek for providing the FXR-responsive reporter gene and FXR-DN expression plasmids. We also thank Dr Rachel Schiff for providing the MCF-7/HER2-18 cells.	ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arpino G, 2004, CLIN CANCER RES, V10, P5670, DOI 10.1158/1078-0432.CCR-04-0110; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; BARONE I, 2011, J NATL CANC IN PRESS; Barone I, 2009, CANCER RES, V69, P4724, DOI 10.1158/0008-5472.CAN-08-4194; Bishop-Bailey D, 2004, DRUG NEWS PERSPECT, V17, P499, DOI 10.1358/dnp.2004.17.8.863693; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Catalano S, 2010, J BIOL CHEM, V285, P5581, DOI 10.1074/jbc.M109.052670; Chung YL, 2002, INT J CANCER, V97, P306, DOI 10.1002/ijc.1614; Claudel T, 2002, J CLIN INVEST, V109, P961; De Laurentiis M, 2005, CLIN CANCER RES, V11, P4741, DOI 10.1158/1078-0432.CCR-04-2569; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Giordano C, 2010, BREAST CANCER RES TR, V119, P71, DOI 10.1007/s10549-009-0334-0; Glockner S, 2001, LAB INVEST, V81, P565, DOI 10.1038/labinvest.3780265; Gradishar WJ, 2004, ONCOLOGIST, V9, P378, DOI 10.1634/theoncologist.9-4-378; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; He FT, 2006, CIRC RES, V98, P192, DOI 10.1161/01.RES.0000200400.55539.85; Herynk MH, 2006, MOL CANCER THER, V5, P3023, DOI 10.1158/1535-7163.MCT-06-0394; Hurst HC, 2001, BREAST CANCER RES, V3, P395, DOI 10.1186/bcr329; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; Johnston SRD, 2009, CLIN BREAST CANCER, V9, pS28, DOI 10.3816/CBC.2009.s.003; Journe F, 2008, BREAST CANCER RES TR, V107, P49, DOI 10.1007/s10549-007-9535-6; Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158; Kirkegaard T, 2007, CLIN CANCER RES, V13, P1405, DOI 10.1158/1078-0432.CCR-06-1933; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kocarek TA, 2002, J PHARMACOL TOXICOL, V47, P177, DOI 10.1016/S1056-8719(03)00002-9; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Meng SD, 2004, P NATL ACAD SCI USA, V101, P9393, DOI 10.1073/pnas.0402993101; Morelli C, 2004, ONCOGENE, V23, P7517, DOI 10.1038/sj.onc.1208014; Nicholson RI, 2004, ENDOCR-RELAT CANCER, V11, P623, DOI 10.1677/erc.1.00778; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sirianni R, 2007, CANCER RES, V67, P8368, DOI 10.1158/0008-5472.CAN-06-4064; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Staka CM, 2005, ENDOCR-RELAT CANCER, V12, pS85, DOI 10.1677/erc.1.01006; Swales KE, 2006, CANCER RES, V66, P10120, DOI 10.1158/0008-5472.CAN-06-2399; Vavassori P, 2009, J IMMUNOL, V183, P6251, DOI 10.4049/jimmunol.0803978; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396	49	52	54	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	39					4129	4140		10.1038/onc.2011.124	http://dx.doi.org/10.1038/onc.2011.124			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499302	Green Accepted			2022-12-28	WOS:000295357500008
J	Jakel, H; Weinl, C; Hengst, L				Jaekel, H.; Weinl, C.; Hengst, L.			Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control	ONCOGENE			English	Article						cell cycle control; CDK inhibitors; p27(Kip1); tyrosine kinases; JAK2; JAK2V617F	POLYCYTHEMIA-VERA; TYROSINE KINASE; DEPENDENT KINASES; MYELOPROLIFERATIVE DISEASE; SUBCELLULAR-LOCALIZATION; INHIBITORY-ACTIVITY; PROTEIN-KINASE; P27(KIP1); MUTATION; EXPRESSION	Janus kinase 2 (JAK2) couples ligand activation of cell surface cytokine receptors to the regulation of cellular functions including cell cycle progression, differentiation and apoptosis. It thereby coordinates biological programs such as development and hematopoiesis. Unscheduled activation of JAK2 by point mutations or chromosomal translocations can induce hyperproliferation and hematological malignancies. Typical signal transduction by the JAK2 tyrosine kinase comprises phosphorylation of STAT transcription factors. In this study, we describe the identification of the cyclin-dependent kinase (CDK) inhibitor p27(Kip1) as a novel JAK2 substrate. JAK2 can directly bind and phosphorylate p27(Kip1). Both, the JAK2 FERM domain and its kinase domain bind to p27(Kip1). JAK2 phosphorylates tyrosine residue 88 (Y88) of p27(Kip1). We previously reported that Y88 phosphorylation of p27(Kip1) by oncogenic tyrosine kinases impairs p27(Kip1)-mediated CDK inhibition, and initiates its ubiquitindependent proteasomal degradation. Consistently, we now find that active oncogenic JAK2V617F reduces p27(Kip1) stability and protein levels in patient-derived cell lines harboring the mutant JAK2V617F allele. Moreover, tyrosine phosphorylation of p27(Kip1) is impaired and p27(Kip1) expression is restored upon JAK2V617F inactivation by small hairpin RNA-mediated knockdown or by the pyridone-containing tetracycle JAK inhibitor-I, indicating that direct phosphorylation of p27(Kip1) can contribute to hyperproliferation of JAK2V617F-transformed cells. Activation of endogenous JAK2 by interleukin-3 (IL-3) induces Y88 phosphorylation of p27(Kip1), thus unveiling a novel link between cytokine signaling and cell cycle control in non-transformed cells. Oncogenic tyrosine kinases could use this novel pathway to promote hyperproliferation in tumor cells. Oncogene (2011) 30, 3502-3512; doi:10.1038/onc.2011.68; published online 21 March 2011	[Jaekel, H.; Weinl, C.; Hengst, L.] Innsbruck Med Univ, Bioctr, Div Med Biochem, A-6020 Innsbruck, Tyrolia, Austria	Medical University of Innsbruck	Hengst, L (corresponding author), Innsbruck Med Univ, Bioctr, Div Med Biochem, Fritz Pregl Str 3,6, A-6020 Innsbruck, Tyrolia, Austria.	ludger.hengst@i-med.ac.at		Hengst, Ludger/0000-0002-0605-0223	FWF [SFB F21-B12, P18873-B1]	FWF(Austrian Science Fund (FWF))	We thank Jakob Troppmair and Justus Duyster for providing cell lines, Wolfgang Doppler for providing plasmids and antibodies and Stephan Geley for providing plasmids. We thank Wolfgang Doppler, Michael Kullmann, Jonathan Vosper and all members of the Hengst lab for support, stimulating discussions and critical reading of the manuscript. The work was funded by the FWF Grants SFB F21-B12 and P18873-B1.	Agarwal A, 2008, BLOOD, V112, P1960, DOI 10.1182/blood-2007-09-113860; Baker SJ, 2007, ONCOGENE, V26, P6724, DOI 10.1038/sj.onc.1210757; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Bruchova H, 2009, BLOOD CELL MOL DIS, V43, P81, DOI 10.1016/j.bcmd.2009.02.001; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Dawson MA, 2009, NATURE, V461, P819, DOI 10.1038/nature08448; Desrivieres S, 2006, J MAMMARY GLAND BIOL, V11, P75, DOI 10.1007/s10911-006-9014-4; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Furuhata A, 2009, BIOCHEM BIOPH RES CO, V383, P411, DOI 10.1016/j.bbrc.2009.04.015; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Halfter H, 2006, CANCER RES, V66, P6530, DOI 10.1158/0008-5472.CAN-04-3734; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ihle JN, 2007, CURR OPIN GENET DEV, V17, P8, DOI 10.1016/j.gde.2006.12.009; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Kardinal C, 2006, BLOOD, V107, P1133, DOI 10.1182/blood-2005-05-1771; KELVIN DJ, 1986, J CELL PHYSIOL, V127, P403, DOI 10.1002/jcp.1041270308; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Larrea MD, 2008, MOL CELL BIOL, V28, P6462, DOI 10.1128/MCB.02300-07; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2007, CURR OPIN HEMATOL, V14, P43, DOI 10.1097/00062752-200701000-00009; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Ray A, 2009, MOL CELL BIOL, V29, P986, DOI 10.1128/MCB.00898-08; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Tossidou I, 2008, CELL CYCLE, V7, P3858, DOI 10.4161/cc.7.24.7260; Verstovsek Srdan, 2009, Hematology Am Soc Hematol Educ Program, P636, DOI 10.1182/asheducation-2009.1.636; Wallace TA, 2006, CELL BIOCHEM BIOPHYS, V44, P213, DOI 10.1385/CBB:44:2:213; Walz C, 2006, J BIOL CHEM, V281, P18177, DOI 10.1074/jbc.M600064200; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	41	42	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	32					3502	3512		10.1038/onc.2011.68	http://dx.doi.org/10.1038/onc.2011.68			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423214	Green Accepted			2022-12-28	WOS:000293782300003
J	Wu, YY; Peck, K; Chang, YL; Pan, SH; Cheng, YF; Lin, JC; Yang, RB; Hong, TM; Yang, PC				Wu, Y-Y; Peck, K.; Chang, Y-L; Pan, S-H; Cheng, Y-F; Lin, J-C; Yang, R-B; Hong, T-M; Yang, P-C			SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer	ONCOGENE			English	Article						SCUBE3; lung cancer; epithelial-mesenchymal transition; TGF-beta receptor signaling; tumor microenvironment	BREAST-CANCER; CUB DOMAIN; MATRIX-METALLOPROTEINASES; CLINICAL-SIGNIFICANCE; TRANSCRIPTION FACTORS; TUMOR PROGRESSION; REPRESSOR SNAIL; E-CADHERIN; INVASION; GROWTH	Signal peptide-CUB-EGF-like domain-containing protein 3 (SCUBE3) is a secreted glycoprotein that is overexpressed in lung cancer tumor tissues and is correlated with the invasive ability in a lung cancer cell line model. These observations suggest that SCUBE3 may have a role in lung cancer progression. By exogenous SCUBE3 treatment or knockdown of SCUBE3 expression, we found that SCUBE3 could promote lung cancer cell mobility and invasiveness. Knockdown of SCUBE3 expression also suppressed tumorigenesis and cancer metastasis in vivo. The secreted SCUBE3 proteins were cleaved by gelatinases (matrix metalloprotease-2 (MMP-2) and MMP-9) in media to release two major fragments: the N-terminal epidermal growth factor-like repeats and the C-terminal complement proteins C1r/C1s, Uegf and Bmp1 (CUB) domain. Both the purified SCUBE3 protein and the C-terminal CUB domain fragment, bound to transforming growth factor-beta (TGF-beta) type II receptor through the C-terminal CUB domain, activated TGF-beta signaling and triggered the epithelial-mesenchymal transition (EMT). This process includes the induction of Smad2/3 phosphorylation, the increase of Smad2/3 transcriptional activity and the upregulation of the expression of target genes involved in EMT and cancer progression (such as TGF-beta 1, MMP-2, MMP-9, plasminogen activator inhibitor type-1, vascular endothelial growth factor, Snail and Slug), thus promoting cancer cell mobility and invasion. In conclusion, in lung cancer cells, SCUBE3 could serve as an endogenous autocrine and paracrine ligand of TGF-beta type II receptor, which could regulate TGF-beta receptor signaling and modulate EMT and cancer progression. Oncogene (2011) 30, 3682-3693; doi:10.1038/onc.2011.85; published online 28 March 2011	[Yang, P-C] Natl Taiwan Univ, Dept Internal Med, Coll Med, NTU Ctr Genom Med, Taipei 100, Taiwan; [Wu, Y-Y] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Peck, K.; Pan, S-H; Cheng, Y-F; Yang, R-B; Yang, P-C] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Dept Pathol, Taipei 100, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Grad Inst Pathol, Taipei 100, Taiwan; [Lin, J-C] Fu Jen Catholic Univ, Dept Resp Therapy, Taipei, Taiwan; [Hong, T-M] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 704, Taiwan; [Hong, T-M] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 704, Taiwan; [Yang, P-C] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Taiwan University; National Defense Medical Center; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; Fu Jen Catholic University; National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Taiwan University Hospital	Yang, PC (corresponding author), Natl Taiwan Univ, Dept Internal Med, Coll Med, NTU Ctr Genom Med, 1,Sec 1,Ren Ai Rd, Taipei 100, Taiwan.	tmhong@mail.ncku.edu.tw; pcyang@ntu.edu.tw	Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714; Pan, Szu-Hua/0000-0002-0138-0434; CHANG, YIH-LEONG/0000-0001-5309-0554; YANG, PAN-CHYR/0000-0001-6330-6048	Academia Sinica [AS-97-FP-L16]; National Science Council, Taiwan [NSC98-2628-B-002-086-MY3, NSC97-2314-B-002-146-MY3]	Academia Sinica(Academia Sinica - Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Ker-Chau Li (Institute of Statistical Science, Academia Sinica) for providing EKVX and Hop62 cells and Shih-Han Kao for English language editing. This work was supported by Academia Sinica (Grant AS-97-FP-L16) and the National Science Council, Taiwan (Grants NSC98-2628-B-002-086-MY3 and NSC97-2314-B-002-146-MY3). shRNA constructs were obtained from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan. T-M H and P-C Y co-directed the project and contributed equally to this work.	Binder BR, 2008, IMMUNOL LETT, V118, P116, DOI 10.1016/j.imlet.2008.03.017; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Dean RA, 2007, MOL CELL BIOL, V27, P8454, DOI 10.1128/MCB.00821-07; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Foekens JA, 2000, CANCER RES, V60, P636; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Haworth K, 2007, GENE EXPR PATTERNS, V7, P630, DOI 10.1016/j.modgep.2006.12.004; Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hundsdorfer B, 2004, Mund Kiefer Gesichtschir, V8, P173; Iniesta P, 2007, ONCOL REP, V17, P217; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kuhn W, 1999, BRIT J CANCER, V79, P1746, DOI 10.1038/sj.bjc.6690278; Lader AS, 2004, CANCER BIOL THER, V3, P624, DOI 10.4161/cbt.3.7.914; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Providence KM, 2004, J CELL PHYSIOL, V200, P297, DOI 10.1002/jcp.20016; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Reichenberger F, 2001, SWISS MED WKLY, V131, P273; Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Werle B, 2004, ANTICANCER RES, V24, P4147; Wu BT, 2004, J BIOL CHEM, V279, P37485, DOI 10.1074/jbc.M405912200; Yang HY, 2007, CARDIOVASC RES, V75, P139, DOI 10.1016/j.cardiores.2007.03.014; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu Q, 2000, GENE DEV, V14, P163; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	44	67	70	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3682	3693		10.1038/onc.2011.85	http://dx.doi.org/10.1038/onc.2011.85			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441952				2022-12-28	WOS:000294244500004
J	Ogiwara, H; Ui, A; Otsuka, A; Satoh, H; Yokomi, I; Nakajima, S; Yasui, A; Yokota, J; Kohno, T				Ogiwara, H.; Ui, A.; Otsuka, A.; Satoh, H.; Yokomi, I.; Nakajima, S.; Yasui, A.; Yokota, J.; Kohno, T.			Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors	ONCOGENE			English	Article						non-homologous end joining; DNA double-strand break; DNA repair; chromatin; histone acetyltransferase	DNA-DAMAGE; HUMAN-CELLS; HOMOLOGOUS RECOMBINATION; DISTINCT ROLES; TUMOR-CELLS; REPAIR; PROTEIN; ACETYLTRANSFERASE; CANCER; GAMMA-H2AX	Non-homologous end joining (NHEJ) is a major repair pathway for DNA double-strand breaks (DSBs) generated by ionizing radiation (IR) and anti-cancer drugs. Therefore, inhibiting the activity of proteins involved in this pathway is a promising way of sensitizing cancer cells to both radiotherapy and chemotherapy. In this study, we developed an assay for evaluating NHEJ activity against DSBs in chromosomal DNA in human cells to identify the chromatin modification/remodeling proteins involved in NHEJ. We showed that ablating the activity of the homologous histone acetyltransferases, CBP and p300, using inhibitors or small interfering RNAs-suppressed NHEJ. Ablation of CBP or p300 impaired IR-induced DSB repair and sensitized lung cancer cells to IR and the anti-cancer drug, etoposide, which induces DSBs that are repaired by NHEJ. The CBP/p300 proteins were recruited to sites of DSBs and their ablation suppressed acetylation of lysine 18 within histone H3, and lysines 5, 8, 12, and 16 within histone H4, at the DSB sites. This then suppressed the recruitment of KU70 and KU80, both key proteins for NHEJ, to the DSB sites. Ablation of CBP/p300 also impaired the recruitment of BRM, a catalytic subunit of the SWI/SNF complex involved in chromatin remodeling at DSB sites. These results indicate that CBP and p300 function as histone H3 and H4 acetyltransferases at DSB sites in NHEJ and facilitate chromatin relaxation. Therefore, inhibition CBP and p300 activity may sensitize cancer cells to radiotherapy and chemotherapy. Oncogene (2011) 30, 2135-2146; doi:10.1038/onc.2010.592; published online 10 January 2011	[Ogiwara, H.; Ui, A.; Otsuka, A.; Kohno, T.] Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, Tokyo 1040045, Japan; [Ui, A.; Otsuka, A.; Yokota, J.] Natl Canc Ctr, Res Inst, Div Multistep Carcinogenesis, Tokyo 1040045, Japan; [Ui, A.; Nakajima, S.; Yasui, A.] Tohoku Univ, Div Dynam Proteome Aging & Canc, Dept Mol Genet, Inst Dev, Sendai, Miyagi, Japan; [Satoh, H.; Yokomi, I.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Tumor Cell Biol, Tokyo, Japan; [Yokomi, I.] St Marianna Univ, Sch Med, Dept Pharmacol, Kanagawa, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tohoku University; University of Tokyo; Saint Marianna University	Kohno, T (corresponding author), Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tkkohno@ncc.go.jp	Ui, Ayako/GON-4666-2022	Ui, Ayako/0000-0001-6698-7168; Ogiwara, Hideaki/0000-0003-0860-1807	Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; National Institute of Biomedical Innovation (NiBio)	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); National Institute of Biomedical Innovation (NiBio)(National Institute of Biomedical Innovation)	We thank Dr Maria Jasin of the Memorial Sloan-Kettering Cancer Center, USA, for the pCBASce plasmid, Dr Marc Tini of the University of Western Ontario for the yellow fluorescent protein-Cbp plasmid and Dr Kazunori Aoki of the National Cancer Center Research Institute for the pAD-TK plasmid. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas; from the Ministry of Health, Labor and Welfare of Japan for the 3rd-term Comprehensive 10-year Strategy for Cancer Control and for Cancer Research (19-9); and from the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio).	Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Downs JA, 2007, ONCOGENE, V26, P7765, DOI 10.1038/sj.onc.1210874; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hong ZH, 2008, NUCLEIC ACIDS RES, V36, P2939, DOI 10.1093/nar/gkn146; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Javvadi P, 2008, MOL PHARMACOL, V73, P1491, DOI 10.1124/mol.107.043554; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Karamouzis MV, 2007, CELL RES, V17, P324, DOI 10.1038/cr.2007.10; Khafif A, 2005, OTOLARYNG HEAD NECK, V132, P317, DOI 10.1016/j.otohns.2004.09.006; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Park EJ, 2003, NUCLEIC ACIDS RES, V31, P6819, DOI 10.1093/nar/gkg921; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Sun YL, 2006, FEBS LETT, V580, P4353, DOI 10.1016/j.febslet.2006.06.092; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; Yoshida S, 2001, CYTOGENET CELL GENET, V94, P88, DOI 10.1159/000048791; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275	44	208	216	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	18					2135	2146		10.1038/onc.2010.592	http://dx.doi.org/10.1038/onc.2010.592			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217779				2022-12-28	WOS:000290249600005
J	Kochert, K; Ullrich, K; Kreher, S; Aster, JC; Kitagawa, M; Johrens, K; Anagnostopoulos, I; Jundt, F; Lamprecht, B; Zimber-Strobl, U; Stein, H; Janz, M; Dorken, B; Mathas, S				Koechert, K.; Ullrich, K.; Kreher, S.; Aster, J. C.; Kitagawa, M.; Joehrens, K.; Anagnostopoulos, I.; Jundt, F.; Lamprecht, B.; Zimber-Strobl, U.; Stein, H.; Janz, M.; Doerken, B.; Mathas, S.			High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas	ONCOGENE			English	Article						Mastermind-like; NOTCH; lymphoma; Hodgkin	ACUTE LYMPHOBLASTIC-LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; TRANSCRIPTION FACTOR E2A; NEOPLASTIC B-CELLS; STERNBERG CELLS; HUMAN HOMOLOG; COMPLEX; COACTIVATORS; RESISTANCE; INHIBITION	Inappropriate activation of the NOTCH signaling pathway, for example, by activating mutations, contributes to the pathogenesis of various human malignancies. Here, we demonstrate that aberrant expression of an essential NOTCH coactivator of the Mastermind-like (MAML) family provides an alternative mechanism to activate NOTCH signaling in human lymphoma cells. We detected high-level MAML2 expression in several B cell-derived lymphoma types, including classical Hodgkin lymphoma (cHL) cells, relative to normal B cells. Inhibition of MAML-protein activity by a dominant negative form of MAML or by small hairpin RNAs targeting MAML2 in cHL cells resulted in downregulation of the NOTCH target genes HES7 and HEY1, which we identified as overexpressed in cHL cells, and in reduced proliferation. Furthermore, a NOTCH gene-expression signature in cHL cells confirmed their cell-autonomous NOTCH activity. Finally, in line with the essential role of MAML proteins for assembly and activity of the NOTCH transcriptional complex (NTC), we show that MAML-derived small-peptide constructs block NOTCH activity and disrupt NTC formation in vitro. These data strongly suggest direct targeting of the NTC as treatment strategy for NOTCH-dependent malignancies. Oncogene (2011) 30, 1831-1840; doi:10.1038/onc.2010.544; published online 29 November 2010	[Koechert, K.; Ullrich, K.; Kreher, S.; Jundt, F.; Lamprecht, B.; Janz, M.; Doerken, B.; Mathas, S.] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Koechert, K.; Ullrich, K.; Kreher, S.; Jundt, F.; Lamprecht, B.; Janz, M.; Doerken, B.; Mathas, S.] Charite, CVK, D-13125 Berlin, Germany; [Aster, J. C.; Stein, H.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Kitagawa, M.] Chiba Univ, Grad Sch Med, Dept Mol & Tumor Pathol, Chiba, Japan; [Joehrens, K.; Anagnostopoulos, I.] Charite, Inst Pathol, D-13125 Berlin, Germany; [Zimber-Strobl, U.] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Dept Gene Vectors, Munich, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Brigham & Women's Hospital; Chiba University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mathas, S (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	stephan.mathas@charite.de	Zimber-Strobl, Ursula/M-4618-2014; Jundt, Franziska/E-9748-2014; Mathas, Stephan/I-5589-2015	Zimber-Strobl, Ursula/0000-0002-9765-5251; Jundt, Franziska/0000-0002-8661-7110; Kochert, Karl/0000-0002-5548-2022; Kitagawa, Motoo/0000-0003-1036-840X; Janz, Martin/0000-0002-1127-0044	Deutsche Forschungsgemeinschaft; Berliner Krebsgesellschaft; Wilhelm Sander-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Berliner Krebsgesellschaft; Wilhelm Sander-Stiftung	We thank Caroline Gartner (Berlin), Melanie Manzke (Berlin) and Simone Kressmann (Berlin) for outstanding technical assistance, and Peter Rahn (Berlin) for cell sorting. We thank Raphael Kopan (Washington) for the Hes1-pGL2 reporter construct, Lizi Wu (Gainesville, Florida) for the MAML3 expression construct, Karin Zimmermann (Berlin) and Ulf Leser (Berlin) for helpful suggestions in regard to gene set analysis, and Ariane Buchal and Benedikt Sedlmaier (both Berlin, Germany) for providing human tonsil material. This work was supported in part by grants from the Deutsche Forschungsgemeinschaft, the Berliner Krebsgesellschaft and the Wilhelm Sander-Stiftung.	Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Del Bianco C, 2008, J MOL BIOL, V376, P131, DOI 10.1016/j.jmb.2007.11.061; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jin BF, 2010, J BIOL CHEM, V285, P14356, DOI 10.1074/jbc.M109.078865; Jundt F, 2008, LEUKEMIA, V22, P1587, DOI 10.1038/leu.2008.101; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Li XY, 2008, J EXP MED, V205, P2851, DOI 10.1084/jem.20081561; Lietz A, 2007, BRIT J HAEMATOL, V137, P342, DOI 10.1111/j.1365-2141.2007.06583.x; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Lubman OY, 2007, J MOL BIOL, V365, P577, DOI 10.1016/j.jmb.2006.09.071; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Mathas S, 2006, NAT IMMUNOL, V7, P207, DOI 10.1038/ni1285; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oyama T, 2007, P NATL ACAD SCI USA, V104, P9764, DOI 10.1073/pnas.0700240104; Rosati E, 2009, BLOOD, V113, P856, DOI 10.1182/blood-2008-02-139725; STANELLE J, 2010, BLOOD, DOI DOI 10.1182/BLOOD2010-01-265827; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu L, 2007, BLOOD, V110, P3618, DOI 10.1182/blood-2007-06-097030; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	41	37	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1831	1840		10.1038/onc.2010.544	http://dx.doi.org/10.1038/onc.2010.544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21119597				2022-12-28	WOS:000289512200010
J	Mainwaring, LA; Kenney, AM				Mainwaring, L. A.; Kenney, A. M.			Divergent functions for eIF4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum	ONCOGENE			English	Article						sonic hedgehog; eIF4E; S6 kinase; proliferation	CELL-CYCLE PROGRESSION; TRANSLATION INITIATION; GROWTH-FACTOR; N-MYC; PROTEIN PHOSPHATASES; NEURONAL SURVIVAL; NERVOUS-SYSTEM; PHOSPHORYLATION; PROLIFERATION; PATHWAY	Cerebellar development entails rapid peri-natal proliferation of cerebellar granule neuron precursors (CGNPs), proposed cells-of-origin for certain medulloblastomas. CGNPs require insulin-like growth factor (IGF) for survival and sonic hedgehog (Shh)-implicated in medulloblastoma-for proliferation. The IGF-responsive kinase mammalian target of rapamycin (mTOR) drives proliferation-associated protein synthesis. We asked whether Shh signaling regulates mTOR targets to promote CGNP proliferation despite constitutive IGF signaling under proliferative and differentiation-promoting conditions. Surprisingly, Shh promoted eukaryotic initiation factor 4E (eIF4E) expression, but inhibited S6 kinase (S6K). In vivo, S6K activity specifically marked the CGNP population transitioning from proliferation-competent to post-mitotic. Indeed, eIF4E was required for CGNP proliferation, while S6K activation drove cell cycle exit. Protein phosphatase 2A (PP2A) inhibition rescued S6K activity. Moreover, Shh upregulated the PP2A B56 gamma subunit, which targets S6K for inactivation and was required for CGNP proliferation. These findings reveal unique developmental functions for eIF4E and S6 kinase wherein their activity is specifically uncoupled by mitogenic Shh signaling. Oncogene (2011) 30, 1784-1797; doi:10.1038/onc.2010.564; published online 21 February 2011	[Mainwaring, L. A.; Kenney, A. M.] Cornell Univ, Weill Med Coll, Biochem Cell & Mol Biol Program, New York, NY 10021 USA; [Mainwaring, L. A.; Kenney, A. M.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Kenney, AM (corresponding author), Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37232 USA.	Anna.Kenney@vanderbilt.edu			NINDS [R01NS061070]; Handler Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Handler Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank John Blenis (Harvard Medical School) for providing the HA-tagged S6 kinase plasmid. These studies were supported by grants to AMK from the NINDS (R01NS061070) and the Handler Foundation.	Altman J, 1997, DEV CEREBELLAR SYSTE; Bateman JM, 2004, CELL, V119, P87, DOI 10.1016/j.cell.2004.08.028; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bielinski VA, 2007, EXP CELL RES, V313, P3117, DOI 10.1016/j.yexcr.2007.05.008; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dutton R, 1999, CLIN EXP PHARMACOL P, V26, P746, DOI 10.1046/j.1440-1681.1999.03108.x; Dutton R, 1999, J NEUROSCI, V19, P2601; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fogarty MP, 2007, P NATL ACAD SCI USA, V104, P2973, DOI 10.1073/pnas.0605770104; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Goslin, 1998, CULTURING NERVE CELL, P419; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn K, 2010, CELL METAB, V11, P438, DOI 10.1016/j.cmet.2010.03.015; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hepker J, 1997, DEVELOPMENT, V124, P549; Ho KS, 2002, CURR OPIN NEUROBIOL, V12, P57, DOI 10.1016/S0959-4388(02)00290-8; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MARES V, 1970, BRAIN RES, V23, P323, DOI 10.1016/0006-8993(70)90060-0; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rios I, 2004, DEVELOPMENT, V131, P3159, DOI 10.1242/dev.01188; Rorick AM, 2007, DEV BIOL, V302, P477, DOI 10.1016/j.ydbio.2006.10.011; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Ye P, 1996, DEV BRAIN RES, V95, P44	57	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1784	1797		10.1038/onc.2010.564	http://dx.doi.org/10.1038/onc.2010.564			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21339731	Green Accepted			2022-12-28	WOS:000289512200006
J	Malapeira, J; Esselens, C; Bech-Serra, JJ; Canals, F; Arribas, J				Malapeira, J.; Esselens, C.; Bech-Serra, J. J.; Canals, F.; Arribas, J.			ADAM17 (TACE) regulates TGF beta signaling through the cleavage of vasorin	ONCOGENE			English	Article						vasorin; ADAM17; TACE; ectodomain shedding; TGF beta	EPITHELIAL-MESENCHYMAL TRANSITIONS; ALPHA-CONVERTING ENZYME; GROWTH-FACTOR-BETA; MATRIX METALLOPROTEINASES; BREAST-CANCER; ACTIVATION; PROTEINS; EGFR; METASTASIS; PROTEASES	The activity of a variety of extracellular signaling factors is tightly regulated by proteins containing A Disintegrin And a Metalloprotease domain ( ADAM) metalloproteases through limited proteolysis. Thus, the identification of ADAM substrates may unveil novel components and mechanisms of cell signaling pathways. We report the identification of the transmembrane protein vasorin (VASN), a transforming growth factor-beta (TGF beta) trap, as a substrate of ADAM17. The metalloprotease efficiently generates a soluble fragment encompassing the extracellular domain of VASN. Despite the importance of TGF beta in normal development and tumor progression, the regulation of VASN is completely unknown. Here, we show that only the soluble form of VASN inhibits TGFb and that the secretion of VASN is tightly controlled by ADAM17. Hence, inhibition of ADAM17 leads to the upregulation of TGFb signaling. Adding a new level of complexity to the function of ADAM17, we finally show that, through the cleavage of VASN, the metalloprotease controls TGFb-mediated epithelial-to-mesenchymal transition. Oncogene (2011) 30, 1912-1922; doi: 10.1038/onc.2010.565; published online 20 December 2010	[Malapeira, J.; Esselens, C.; Arribas, J.] Vall Hebron Univ Hosp, VHIO, Med Oncol Res Program, Barcelona 08035, Spain; [Bech-Serra, J. J.; Canals, F.] Vall Hebron Univ Hosp, Res Inst Fdn, Prote Lab, Barcelona 08035, Spain; [Arribas, J.] Autonomous Univ Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Arribas, J.] ICREA, Barcelona, Spain	Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; ICREA	Arribas, J (corresponding author), Vall Hebron Univ Hosp, VHIO, Med Oncol Res Program, Psg Vall Hebron 119-129, Barcelona 08035, Spain.	jarribas@vhio.net	Arribas, Joaquin/M-4482-2014; Bech-Serra, Joan Josep/AAA-2330-2020; Malapeira, Jordi/I-7956-2014	Arribas, Joaquin/0000-0002-0504-0664; Bech-Serra, Joan Josep/0000-0003-3486-781X; Malapeira, Jordi/0000-0003-3503-1272; Esselens, Cary/0000-0001-8876-634X	Instituto de Salud Carlos III [PI081154, RD06/0020/0022, PI071058]; ICREA Funding Source: Custom	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); ICREA(ICREA)	We thank Dr Fernando Lopez-Casillas for critical reading of the manuscript. The Proteomics Laboratory is a member of the National Spanish Institute for Proteomics (PROTEORED) and it is funded in part by Fundacio Cellex. CW Esselens is a postdoctoral fellow from the Juan de la Cierva program (Spanish Ministry of Education). This research was supported by Grants from the Instituto de Salud Carlos III (Intrasalud PI081154 and the network of cooperative cancer research (RTICC-RD06/0020/0022) to JA and PI071058	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Arribas J, 2009, CURR PHARM DESIGN, V15, P2319, DOI 10.2174/138161209788682398; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; de la Torre TV, 2004, BIOCHEM BIOPH RES CO, V314, P1028, DOI 10.1016/j.bbrc.2003.12.186; Esselens CW, 2008, BIOL CHEM, V389, P1075, DOI 10.1515/BC.2008.121; Friedman S, 2009, CANCER RES, V69, p783S; Guo L, 2002, MOL CELL PROTEOMICS, V1, P30, DOI 10.1074/mcp.M100020-MCP200; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hyytiainen M, 2004, CRIT REV CL LAB SCI, V41, P233, DOI 10.1080/10408360490460933; Ikeda Y, 2004, P NATL ACAD SCI USA, V101, P10732, DOI 10.1073/pnas.0404117101; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Liu C, 2009, MOL CELL, V35, P26, DOI 10.1016/j.molcel.2009.06.018; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	29	56	56	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1912	1922		10.1038/onc.2010.565	http://dx.doi.org/10.1038/onc.2010.565			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21170088				2022-12-28	WOS:000289777700007
J	Meng, L; Hsu, JK; Tsai, RYL				Meng, L.; Hsu, J. K.; Tsai, R. Y. L.			GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest	ONCOGENE			English	Article						colorectal carcinoma; G2/M arrest; GNL3L; MDM2; nucleostemin; p53	CELL-CYCLE ARREST; RIBOSOMAL-PROTEIN L23; STEM-CELLS; ACTIVATES P53; NUCLEOSTEMIN; DEGRADATION; INHIBITION; STABILIZES; PROLIFERATION; PROGRESSION	Guanine nucleotide binding protein-like 3-like (GNL3L) is a nucleolar protein and the vertebrate paralogue of nucleostemin (NS). We previously reported that nucleoplasmic mobilization of NS stabilizes MDM2 (mouse double minute 2). Here, we investigated the role of GNL3L as a novel MDM2 regulator. We found that GNL3L binds MDM2 in vivo and displays the same function as NS in stabilizing MDM2 protein and preventing its ubiquitylation. The interaction between GNL3L and MDM2 also takes place in the nucleoplasm. However, the MDM2 regulatory activity of GNL3L occurs constitutively and does not so much depend on the nucleolar release mechanism as NS does. GNL3L depletion triggers G2/M arrest in the p53-wild-type HCT116 cells more than in the p53-null cells, and upregulates specific p53 targets (that is, Bax, 14-3-3 sigma and p21) without affecting the ubiquitylation or stability of p53 proteins. The inhibitory activity of GNL3L on p53-mediated transcription correlates with the increased expression of GNL3L and reduced expression of 14-3-3 sigma and p21 in human gastrointestinal tumors. This work shows that in contrast to most nucleolar proteins that negatively control MDM2, GNL3L and NS are the only two that are designed to stabilize MDM2 protein under basal or induced condition, respectively, and may act as tumor-promoting genes. Oncogene (2011) 30, 1716-1726; doi:10.1038/onc.2010.550; published online 6 December 2010	[Meng, L.; Hsu, J. K.; Tsai, R. Y. L.] Texas A&M Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Tsai, RYL (corresponding author), Texas A&M Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rtsai@ibt.tamhsc.edu	Hsu, Joseph Kuang-Wu/N-2847-2013	Tsai, Robert/0000-0002-8357-0812	NCI-PHS [R01 CA113750]; NATIONAL CANCER INSTITUTE [R01CA113750] Funding Source: NIH RePORTER	NCI-PHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Bert Vogelstein of the Johns Hopkins Oncology Center for providing the HCT116 cells. This work is supported by NCI-PHS grant R01 CA113750 to RY Tsai.	Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Beekman C, 2006, MOL CELL BIOL, V26, P9291, DOI 10.1128/MCB.01183-06; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fu D, 2007, MOL CELL, V28, P773, DOI 10.1016/j.molcel.2007.09.023; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang M, 2009, CANCER RES, V69, P3004, DOI 10.1158/0008-5472.CAN-08-3413; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Ma HH, 2007, MOL BIOL CELL, V18, P2630, DOI 10.1091/mbc.E07-03-0244; Maki N, 2007, DEV DYNAM, V236, P941, DOI 10.1002/dvdy.21027; Meng LJ, 2007, MOL CELL BIOL, V27, P8670, DOI 10.1128/MCB.00635-07; Meng LJ, 2006, J CELL SCI, V119, P5124, DOI 10.1242/jcs.03292; Meng LJ, 2008, J CELL SCI, V121, P4037, DOI 10.1242/jcs.037952; Nikpour P, 2009, CELL PROLIFERAT, V42, P762, DOI 10.1111/j.1365-2184.2009.00635.x; Ohmura M, 2008, STEM CELLS, V26, P3237, DOI 10.1634/stemcells.2008-0506; Pederson T, 2009, J CELL BIOL, V184, P771, DOI 10.1083/jcb.200812014; Siddiqi S, 2008, CIRC RES, V103, P89, DOI 10.1161/CIRCRESAHA.107.169334; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tsai RYL, 2009, INT J BIOCHEM CELL B, V41, P2122, DOI 10.1016/j.biocel.2009.05.020; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Yasumoto H, 2007, J CELL SCI, V120, P2532, DOI 10.1242/jcs.009878; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu QB, 2006, MOL CELL BIOL, V26, P9279, DOI 10.1128/MCB.00724-06; Zhu QB, 2009, J CELL BIOL, V185, P827, DOI 10.1083/jcb.200812121	30	25	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	14					1716	1726		10.1038/onc.2010.550	http://dx.doi.org/10.1038/onc.2010.550			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132010	Green Accepted			2022-12-28	WOS:000289239400009
J	Szabo, R; Rasmussen, AL; Moyer, AB; Kosa, P; Schafer, JM; Molinolo, AA; Gutkind, JS; Bugge, TH				Szabo, R.; Rasmussen, A. L.; Moyer, A. B.; Kosa, P.; Schafer, J. M.; Molinolo, A. A.; Gutkind, J. S.; Bugge, T. H.			c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase	ONCOGENE			English	Article						hepatocyte growth factor; head and neck carcinoma; mTor; protease-activated signaling; cell surface proteases	HEPATOCYTE GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; PLASMINOGEN-ACTIVATOR; IN-VIVO; FACTOR/SCATTER FACTOR; BARRIER FUNCTION; CANCER; MICE; RAPAMYCIN; RECEPTOR	The progression and negative outcome of a variety of human carcinomas are intimately associated with aberrant activity of the c-Met oncogene. The underlying cause of this dysregulation, however, remains a subject of discussion, as the majority of cancer patients do not present with activating mutations in c-Met receptor itself. In this study, we show that the oncogenic protease matriptase is ubiquitously co-expressed with the c-Met in human squamous cell carcinomas and amplifies migratory and proliferative responses of primary epithelial cells to the cognate ligand for c-Met, pro-hepatocyte growth factor/scatter factor (proHGF/SF), through c-Met and Gab1 signaling. Furthermore, the selective genetic ablation of c-Met from matriptase-expressing keratinocytes completely negates the oncogenic potential of matriptase. In addition, matriptase-dependent carcinoma formation could be blocked by the pharmacological inhibition of the Akt-mammalian target of Rapamycin (mTor) pathway. Our data identify matriptase as an initiator of c-Met-Akt-mTor-dependent signaling axis in tumors and reveal mTor activation as an essential component of matriptase/ c-Met-induced carcinogenesis. The study provides a specific example of how epithelial transformation can be promoted by epigenetic acquisition of the capacity to convert a widely available paracrine growth factor precursor to its signaling competent state. Oncogene (2011) 30, 2003-2016; doi:10.1038/onc.2010.586; published online 10 January 2011	[Szabo, R.; Rasmussen, A. L.; Moyer, A. B.; Kosa, P.; Schafer, J. M.; Molinolo, A. A.; Gutkind, J. S.; Bugge, T. H.] NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NIDCR; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551, ZIADE000699] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Snorri Thorgeirsson for floxed Hgfr mice. Supported by NIDCR Intramural Research Program. We thank Dr Mary Jo Danton for critically reviewing this manuscript.	Amornphimoltham P, 2005, CANCER RES, V65, P9953, DOI 10.1158/0008-5472.CAN-05-0921; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Camerer E, 2010, DEV CELL, V18, P25, DOI 10.1016/j.devcel.2009.11.014; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Dai CS, 2010, KIDNEY INT, V77, P962, DOI 10.1038/ki.2010.40; Gailani D, 1997, BLOOD COAGUL FIBRIN, V8, P134, DOI 10.1097/00001721-199703000-00008; Gherardi E, 2006, P NATL ACAD SCI USA, V103, P4046, DOI 10.1073/pnas.0509040103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartmann G, 1998, CURR BIOL, V8, P125, DOI 10.1016/S0960-9822(98)70059-4; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Itoh H, 2004, GASTROENTEROLOGY, V127, P1423, DOI 10.1053/j.gastro.2004.08.027; Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x; Kang JY, 2003, CANCER RES, V63, P1101; Kirchhofer D, 2007, P NATL ACAD SCI USA, V104, P5306, DOI 10.1073/pnas.0700184104; Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Ma H, 2009, KIDNEY INT, V76, P868, DOI 10.1038/ki.2009.304; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Molinolo AA, 2009, ORAL ONCOL, V45, P324, DOI 10.1016/j.oraloncology.2008.07.011; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Owen KA, 2010, BIOCHEM J, V426, P219, DOI 10.1042/BJ20091448; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pauer HU, 2004, THROMB HAEMOSTASIS, V92, P503, DOI 10.1160/TH04-04-0250; Peek M, 2002, J BIOL CHEM, V277, P47804, DOI 10.1074/jbc.M209778200; Raimondi AR, 2009, CANCER RES, V69, P4159, DOI 10.1158/0008-5472.CAN-08-4645; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Seiwert TY, 2009, CANCER RES, V69, P3021, DOI 10.1158/0008-5472.CAN-08-2881; Shanmukhappa K, 2009, J BIOL CHEM, V284, P12917, DOI 10.1074/jbc.M807313200; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Szabo R, 2008, INT J BIOCHEM CELL B, V40, P1297, DOI 10.1016/j.biocel.2007.11.013; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Williams-Simons L, 1999, TRANSGENIC RES, V8, P253, DOI 10.1023/A:1008994831937; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	50	76	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2003	2016		10.1038/onc.2010.586	http://dx.doi.org/10.1038/onc.2010.586			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217780	Green Accepted			2022-12-28	WOS:000289977400004
J	Fielding, AB; Lim, S; Montgomery, K; Dobreva, I; Dedhar, S				Fielding, A. B.; Lim, S.; Montgomery, K.; Dobreva, I.; Dedhar, S.			A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells	ONCOGENE			English	Article						integrin-linked kinase; centrosome clustering; multipolar mitosis; TACC3; ch-TOG/XMAP215; cancer	SPINDLE POLE ORGANIZATION; AURORA-A; CHROMOSOMAL INSTABILITY; EXTRA CENTROSOMES; IN-VITRO; PROTEIN; MICROTUBULES; AMPLIFICATION; ABERRATIONS; PROGRESSION	Many cancer cells contain more than two centrosomes, which imposes a potential for multipolar mitoses, leading to cell death. To circumvent this, cancer cells develop mechanisms to cluster supernumerary centrosomes to form bipolar spindles, enabling successful mitosis. Disruption of centrosome clustering thus provides a selective means of killing supernumerary centrosome-harboring cancer cells. Although the mechanisms of centrosome clustering are poorly understood, recent genetic analyses have identified requirements for both actin and tubulin regulating proteins. In this study, we demonstrate that the integrin-linked kinase (ILK), a protein critically involved in actin and mitotic microtubule organization, is required for centrosome clustering. Inhibition of ILK expression or activity inhibits centrosome clustering in several breast and prostate cancer cell lines that have centrosome amplification. Furthermore, cancer cells with supernumerary centrosomes are significantly more sensitive to ILK inhibition than cells with two centrosomes, demonstrating that inhibiting ILK offers a selective means of targeting cancer cells. Live cell analysis shows ILK perturbation leads cancer cells to undergo multipolar anaphases, mitotic arrest and cell death in mitosis. We also show that ILK performs its centrosome clustering activity in a focal adhesion-independent, but centrosome-dependent, manner through the microtubule regulating proteins TACC3 and ch-TOG. In addition, we identify a specific TACC3 phosphorylation site that is required for centrosome clustering and demonstrate that ILK regulates this phosphorylation in an Aurora-A-dependent manner. Oncogene (2011) 30, 521-534; doi: 10.1038/onc.2010.431; published online 13 September 2010	[Fielding, A. B.; Lim, S.; Montgomery, K.; Dobreva, I.; Dedhar, S.] BC Canc Agcy, Dept Integrat Oncol, British Columbia Canc Res Ctr, Vancouver, BC, Canada; [Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Inst Life Sci, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of British Columbia	Dedhar, S (corresponding author), Univ British Columbia, Dept Biochem, BC Canc Res Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca		Dedhar, Shoukat/0000-0003-4355-1657; Fielding, Andrew/0000-0002-3170-9966	Canadian Institute of Health Research (CIHR); Canadian Cancer Society Research Institute; Canadian Cancer Society	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS))	This work was supported by grants to SD from the Canadian Institute of Health Research (CIHR) and the Canadian Cancer Society Research Institute, with funds raised by the Canadian Cancer Society. We thank Quadra Logic Technology Inc (QLT Inc), Vancouver, BC for supplying QLT-0267. We thank Dr Kazuhisa Kinoshita for the kind gift of anti-phospho-Ser558 TACC3 antibody and Dr Peter Lansdorp for the Aurora-A plasmid.	Albee AJ, 2008, MOL BIOL CELL, V19, P3347, DOI 10.1091/mbc.E07-11-1204; Barr AR, 2008, MOL CELL BIOL, V28, P7199, DOI 10.1128/MCB.01040-08; Barros TP, 2005, J CELL BIOL, V170, P1039, DOI 10.1083/jcb.200504097; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Dobreva I, 2008, J PROTEOME RES, V7, P1740, DOI 10.1021/pr700852r; Edwards LA, 2008, MOL CANCER THER, V7, P59, DOI 10.1158/1535-7163.MCT-07-0329; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gkretsi V, 2007, HEPATOLOGY, V45, P1025, DOI 10.1002/hep.21540; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Margall-Ducos G, 2007, J CELL SCI, V120, P3633, DOI 10.1242/jcs.016907; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Pihan GA, 2003, CANCER RES, V63, P1398; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Rebacz B, 2007, CANCER RES, V67, P6342, DOI 10.1158/0008-5472.CAN-07-0663; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Xu FL, 2008, CANCER CELL, V14, P197, DOI 10.1016/j.ccr.2008.08.007; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	44	65	66	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					521	534		10.1038/onc.2010.431	http://dx.doi.org/10.1038/onc.2010.431			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20838383				2022-12-28	WOS:000286922300002
J	Hill, VK; Underhill-Day, N; Krex, D; Robel, K; Sangan, CB; Summersgill, HR; Morris, M; Gentle, D; Chalmers, AD; Maher, ER; Latif, F				Hill, V. K.; Underhill-Day, N.; Krex, D.; Robel, K.; Sangan, C. B.; Summersgill, H. R.; Morris, M.; Gentle, D.; Chalmers, A. D.; Maher, E. R.; Latif, F.			Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis	ONCOGENE			English	Article						gliomas; RASSF10; epigenetics	GLIOBLASTOMA-MULTIFORME; IDH2 MUTATIONS; METHYLATION; GLIOMAS; DIFFERENTIATION; PROTEINS; FAMILY; CANCER; DOMAIN; MGMT	We have recently described the N-terminal RAS association domain family of genes, RASSF7-10. Previously, we cloned the N-terminal RASSF10 gene and demonstrated frequent methylation of the associated 50-CpG island in acute lymphoblastic leukemia. To characterize RASSF10 gene expression, we demonstrate that in developing Xenopus embryos, RASSF10 shows a very striking pattern in the rhombencephalon (hind brain). It is also expressed in other parts of the brain and other organs. Due to the well-defined expression pattern in the brain of Xenopus embryos, we analyzed the methylation status of the RASSF10-associated 5'-CpG island in astrocytic gliomas. RASSF10 was frequently methylated in WHO grade II-III astrocytomas and WHO grade IV primary glioblastomas (67.5%), but was unmethylated in grade I astrocytomas and in DNA from age matched control brain samples. RASSF10 gene expression both at the mRNA and protein levels could be switched back on in methylated glioma cell lines after treatment with 5-aza-2'-deoxycytidine. In secondary glioblastomas (sGBM), RASSF10 methylation was an independent prognostic factor associated with worst progression-free survival and overall survival and occurred at an early stage in their development. In cell culture experiments, overexpression of RASSF10 mediated a reduction in the colony forming ability of two RASSF10-methylated glioma cell lines. Conversely, RNAi-mediated knockdown of RASSF10-stimulated anchorage-independent growth of U87 glioma cells, increased their viability and caused an increase in the cells' proliferative ability. We generated and characterized a RASSF10-specific antibody and demonstrated for the first time that RASSF10 subcellular localization is cell-cycle dependent with RASSF10 colocalizing to centrosomes and associated microtubules during mitosis. This is the first report demonstrating that RASSF10 can act as a tumor suppressor gene and is frequently methylated in gliomas and can potentially be developed into a prognostic marker for sGBM. Oncogene (2011) 30, 978-989; doi:10.1038/onc.2010.471; published online 18 October 2010 Keywords: gliomas; RASSF10; epigenetics	[Latif, F.] Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England; [Krex, D.; Robel, K.] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin & Poliklin Neurochirurg, Dresden, Germany; [Sangan, C. B.; Summersgill, H. R.; Chalmers, A. D.] Univ Bath, Ctr Regenerat Med, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Birmingham; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Bath	Latif, F (corresponding author), Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Chalmers, Andrew/D-4103-2009; Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Krex, Dietmar/E-6833-2014	Chalmers, Andrew/0000-0003-4182-6717; MAHER, EAMONN R/0000-0002-6226-6918; Morris, Mark/0000-0002-0700-355X	Breast Cancer Campaign; CRUK; Sport Aiding Medical Research for Kids (SPARKS)	Breast Cancer Campaign; CRUK(Cancer Research UK); Sport Aiding Medical Research for Kids (SPARKS)	We thank Dr Reinhard Dammann for providing the RASSF10 construct. F Latif laboratory funded in part by Breast Cancer Campaign, CRUK and Sport Aiding Medical Research for Kids (SPARKS).	Chalmers AD, 2002, DEV CELL, V2, P171, DOI 10.1016/S1534-5807(02)00113-2; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Dallol A, 2009, CURR BIOL, V19, P1227, DOI 10.1016/j.cub.2009.05.064; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538; Hesson Luke B, 2008, Expert Rev Neurother, V8, P1475, DOI 10.1586/14737175.8.10.1475; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; Langton PF, 2009, CURR BIOL, V19, P1969, DOI 10.1016/j.cub.2009.10.027; Lock FE, 2010, ONCOGENE, V29, P4307, DOI 10.1038/onc.2010.192; Martinez R, 2009, EPIGENETICS-US, V4, P255, DOI 10.4161/epi.9130; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Reeves N, 2005, DEV CELL, V8, P413, DOI 10.1016/j.devcel.2005.01.020; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Schagdarsurengin U, 2009, EPIGENETICS-US, V4, P571, DOI 10.4161/epi.4.8.10056; Sherwood V, 2008, MOL BIOL CELL, V19, P1772, DOI 10.1091/mbc.E07-07-0652; Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318; Tommasi S, 2005, CANCER RES, V65, P92; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197; Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631; Yan H, 2009, CANCER RES, V69, P9157, DOI 10.1158/0008-5472.CAN-09-2650; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	28	42	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					978	989		10.1038/onc.2010.471	http://dx.doi.org/10.1038/onc.2010.471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20956940				2022-12-28	WOS:000287695900009
J	Alameda, JP; Moreno-Maldonado, R; Navarro, M; Bravo, A; Ramirez, A; Page, A; Jorcano, JL; Fernandez-Acenero, MJ; Casanova, ML				Alameda, J. P.; Moreno-Maldonado, R.; Navarro, M.; Bravo, A.; Ramirez, A.; Page, A.; Jorcano, J. L.; Fernandez-Acenero, M. J.; Casanova, M. L.			An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells	ONCOGENE			English	Article						CYLD; angiogenesis; skin cancer; tumor progression	NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; MALIGNANT-TRANSFORMATION; EXPRESSION; GENE; ACTIVATION; VEGF; CYLINDROMATOSIS; CARCINOGENESIS; STATE	In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLDC/S) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD results in enhanced cell proliferation and inhibition of apoptosis; it also stimulates cell migration and induces the expression of angiogenic factors, including vascular endothelial growth factor-A. Altogether, these characteristics indicate an increased oncogenicity of the tumorigenic epidermal CYLDC/S mutant cells in vitro. Moreover, we show the increase in malignancy of epidermal squamous cell carcinomas that express the CYLDC/S transgene in an in vivo xenograft model. Tumors carrying the mutated CYLDC/S exhibit a fast growth, are poorly differentiated and present a robust angiogenesis. CYLDC/S tumors are also characterized by their elevated proliferation rate and decreased apoptosis. In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy. Oncogene (2010) 29, 6522-6532; doi:10.1038/onc.2010.378; published online 13 September 2010	[Alameda, J. P.; Moreno-Maldonado, R.; Navarro, M.; Ramirez, A.; Page, A.; Jorcano, J. L.; Casanova, M. L.] CIEMAT, Div Epithelial Biomed, E-28040 Madrid, Spain; [Bravo, A.] Univ Santiago de Compostela, Fac Vet, Dept Vet Clin Sci, Lugo, Spain; [Fernandez-Acenero, M. J.] Fdn Jimenez Diaz, Dept Pathol, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela	Casanova, ML (corresponding author), CIEMAT, Div Epithelial Biomed, Ave Complutense 22, E-28040 Madrid, Spain.	llanos.casanova@ciemat.es	Ramirez, Angel/A-4800-2018; Navarro, Manuel/S-1496-2019; Moral, Ana María Bravo/AAD-3339-2021	Ramirez, Angel/0000-0001-7745-5108; Navarro, Manuel/0000-0003-1118-8531; Moral, Ana María Bravo/0000-0002-5282-8921; Page, Angustias/0000-0002-0231-8536; Casanova, M. Llanos/0000-0001-7742-8265	Ministerio de Sanidad [PI061233, PI060655]; Ministerio de Educacion y Ciencia [PSE-010000-2008-7]	Ministerio de Sanidad(Instituto de Salud Carlos IIISpanish Government); Ministerio de Educacion y Ciencia(Spanish Government)	We thank Dr R Bernards for providing the CYLD<SUP>C/S</SUP> cDNA; M Isabel de los Santos and Federico Sanchez-Sierra for invaluable assistance in the histological and immunohistochemical analyses; Juan Manuel Luque and Soledad Moreno for technical assistance; and Jesus Martinez, Edilia Almeida and the personnel of the CIEMAT Animal Unit for care of the mice used. This work was funded by grant from the Ministerio de Sanidad (PI061233, PI060655) to MLC and AR respectively and a grant from the Ministerio de Educacion y Ciencia (PSE-010000-2008-7).	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Casanova ML, 2004, FASEB J, V18, P1556, DOI 10.1096/fj.04-1683fje; Casanova ML, 2002, CANCER RES, V62, P3402; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Costello CM, 2005, PLOS MED, V2, P771, DOI 10.1371/journal.pmed.0020199; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; De Francesco V, 2005, AM J DERMATOPATH, V27, P21, DOI 10.1097/01.dad.0000141548.69423.c7; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6; Detmar M, 2000, J INVEST DERM SYMP P, V5, P20, DOI 10.1046/j.1087-0024.2000.00003.x; Durani BK, 2001, BRIT J DERMATOL, V145, P653, DOI 10.1046/j.1365-2133.2001.04460.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hashimoto K, 2004, MODERN PATHOL, V17, P617, DOI 10.1038/modpathol.3800107; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; Hirai Y, 2004, INT J ONCOL, V24, P977; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Larcher F, 1996, CANCER RES, V56, P5391; Li HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-110; Limmer B L, 2001, Tex Med, V97, P56; Massoumi R, 2007, BIOESSAYS, V29, P1203, DOI 10.1002/bies.20677; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Mirones I, 2009, J INVEST DERMATOL, V129, P730, DOI 10.1038/jid.2008.292; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Moreno-Maldonado R, 2008, CELL CYCLE, V7, P2021, DOI 10.4161/cc.7.13.6147; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Ren Q, 2006, CANCER RES, V66, P5209, DOI 10.1158/0008-5472.CAN-05-4158; Scharstuhl A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006688; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Solovey A, 1999, BLOOD, V93, P3824, DOI 10.1182/blood.V93.11.3824.411k10_3824_3830; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; Strobel P, 2002, AM J SURG PATHOL, V26, P119, DOI 10.1097/00000478-200201000-00016; Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Thornburg NJ, 2003, CANCER RES, V63, P8293; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; van Hogerlinden M, 1999, CANCER RES, V59, P3299; WINTER H, 1990, DIFFERENTIATION, V43, P105, DOI 10.1111/j.1432-0436.1990.tb00436.x; ZHANG W, 2010, MED ONCOL, V37, P607; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041	59	32	33	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6522	6532		10.1038/onc.2010.378	http://dx.doi.org/10.1038/onc.2010.378			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20838385				2022-12-28	WOS:000285380200002
J	Steer, HJ; Lake, RA; Nowak, AK; Robinson, BWS				Steer, H. J.; Lake, R. A.; Nowak, A. K.; Robinson, B. W. S.			Harnessing the immune response to treat cancer	ONCOGENE			English	Review						tumour immunity; T lymphocytes; cancer chemotherapy; immune escape; immunotherapy	T-CELL RESPONSES; ANTIGEN CROSS-PRESENTATION; GROWTH-FACTOR-BETA; CLASS-I EXPRESSION; DENDRITIC CELLS; TUMOR-CELLS; ANTICANCER CHEMOTHERAPY; HUMAN-MELANOMA; CUTTING EDGE; MEMORY	It is well established that the immune system has the capacity to attack malignant cells. During malignant transformation cells acquire numerous molecular and biochemical changes that render them potentially vulnerable to immune cells. Yet it is self-evident that a growing tumour has managed to evade these host defence mechanisms. The exact ways in which the immune system interacts with tumour cells and how cancers are able to escape immunological eradication have only recently started to be fully elucidated. Understanding the relationship between the tumour and the anti-tumour immune response and how this can be altered with conventional treatments and immune-targeted therapies is crucial to developing new treatments for patients with cancer. In this review, focusing on the anti-tumour T-cell response, we summarize our understanding of how tumours, cancer treatments and the immune system interact, how tumours evade the immune response and how this process could be manipulated for the benefit of patients with cancer. Oncogene (2010) 29, 6301-6313; doi:10.1038/onc.2010.437; published online 20 September 2010	[Steer, H. J.] Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia; [Steer, H. J.; Lake, R. A.; Nowak, A. K.; Robinson, B. W. S.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Nowak, A. K.] Dept Med Oncol, Perth, WA, Australia; [Steer, H. J.; Robinson, B. W. S.] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Steer, HJ (corresponding author), Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, 4th Floor G Block, Perth, WA 6009, Australia.	hsteer@meddent.uwa.edu.au	Robinson, Bruce/N-1900-2014; Nowak, Anna K/B-2487-2013	Nowak, Anna K/0000-0002-9317-9526				Ahmadzadeh M, 2005, J IMMUNOL, V174, P5215, DOI 10.4049/jimmunol.174.9.5215; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Antonia SJ, 2006, CLIN CANCER RES, V12, P878, DOI 10.1158/1078-0432.CCR-05-2013; Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Bannard O, 2009, SCIENCE, V323, P505, DOI 10.1126/science.1166831; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; Beyer M, 2009, CANCER RES, V69, P4346, DOI 10.1158/0008-5472.CAN-08-3796; Bioley G, 2009, CLIN CANCER RES, V15, P4467, DOI 10.1158/1078-0432.CCR-09-0582; Bioley G, 2009, CLIN CANCER RES, V15, P299, DOI 10.1158/1078-0432.CCR-08-1747; Bioley G, 2009, J IMMUNOTHER, V32, P161, DOI 10.1097/CJI.0b013e31819302f6; Blank C, 2004, CANCER RES, V64, P1140, DOI 10.1158/0008-5472.CAN-03-3259; Broomfield S, 2005, CANCER RES, V65, P7580, DOI 10.1158/0008-5472.CAN-05-0328; Broomfield SA, 2009, J IMMUNOL, V182, P5217, DOI 10.4049/jimmunol.0803826; Brossart P, 1997, BLOOD, V90, P1594, DOI 10.1182/blood.V90.4.1594.1594_1594_1599; Bundell CS, 2006, CANCER IMMUNOL IMMUN, V55, P933, DOI 10.1007/s00262-005-0086-6; Burgdorf S, 2008, CURR OPIN IMMUNOL, V20, P89, DOI 10.1016/j.coi.2007.12.002; Burgdorf S, 2008, NAT IMMUNOL, V9, P558, DOI 10.1038/ni.1601; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chaput N, 2007, J MOL MED, V85, P1069, DOI 10.1007/s00109-007-0214-1; Chen X, 2004, J IMMUNOL, V173, P2985, DOI 10.4049/jimmunol.173.5.2985; Cloosen S, 2007, CANCER RES, V67, P3919, DOI 10.1158/0008-5472.CAN-06-2112; Costantino CM, 2008, EUR J IMMUNOL, V38, P921, DOI 10.1002/eji.200738104; Currie AJ, 2008, J IMMUNOL, V180, P1535, DOI 10.4049/jimmunol.180.3.1535; Darrasse-Jeze G, 2009, J CLIN INVEST, V119, P2648, DOI 10.1172/JCI36628; Deeths MJ, 1999, J IMMUNOL, V163, P102; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dummer W, 2002, J CLIN INVEST, V110, P185, DOI 10.1172/JCI200215175; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Feau S, 2009, SCIENCE, V323, P466, DOI [10.1126/SCIENCE.1169409, 10.1126/science.1169409]; Feng HP, 2002, BLOOD, V100, P4108, DOI 10.1182/blood-2002-05-1389; Fife BT, 2006, J EXP MED, V203, P2737, DOI 10.1084/jem.20061577; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Frey DM, 2010, INT J CANCER, V126, P2635, DOI 10.1002/ijc.24989; Gajewski TF, 2006, J IMMUNOTHER, V29, P233, DOI 10.1097/01.cji.0000199193.29048.56; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gilboa E, 2001, NAT IMMUNOL, V2, P789, DOI 10.1038/ni0901-789; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hamilton DH, 2008, CANCER IMMUNOL IMMUN, V57, P1125, DOI 10.1007/s00262-007-0442-9; Hipp MM, 2008, BLOOD, V111, P5610, DOI 10.1182/blood-2007-02-075945; Hodi FS, 2007, CLIN CANCER RES, V13, P5238, DOI 10.1158/1078-0432.CCR-07-0813; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Hu HM, 2002, CANCER RES, V62, P3914; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Hwang ML, 2007, J IMMUNOL, V179, P5829, DOI 10.4049/jimmunol.179.9.5829; Jackaman C, 2003, J IMMUNOL, V171, P5051, DOI 10.4049/jimmunol.171.10.5051; Jackaman C, 2008, INT IMMUNOL, V20, P1467, DOI 10.1093/intimm/dxn104; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Javid B, 2007, J IMMUNOL, V179, P2035, DOI 10.4049/jimmunol.179.4.2035; Kaminski JM, 2005, CANCER TREAT REV, V31, P159, DOI 10.1016/j.ctrv.2005.03.004; Kennedy R, 2008, IMMUNOL REV, V222, P129, DOI 10.1111/j.1600-065X.2008.00616.x; Kennedy R, 2006, J IMMUNOL, V177, P2862, DOI 10.4049/jimmunol.177.5.2862; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kim S, 2008, CANCER RES, V68, P10247, DOI 10.1158/0008-5472.CAN-08-1494; Kim SJ, 2004, IMMUNITY, V21, P643, DOI 10.1016/j.immuni.2004.09.009; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Larmonier N, 2008, J IMMUNOL, V181, P6955, DOI 10.4049/jimmunol.181.10.6955; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Li HF, 2009, J IMMUNOL, V183, P1528, DOI 10.4049/jimmunol.0901080; Li M, 2001, J IMMUNOL, V166, P6099, DOI 10.4049/jimmunol.166.10.6099; Linard B, 2002, J IMMUNOL, V168, P4802, DOI 10.4049/jimmunol.168.9.4802; Lob S, 2009, NAT REV CANCER, V9, P445, DOI 10.1038/nrc2639; Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Marzo AL, 1997, CANCER RES, V57, P3200; Marzo AL, 1999, J IMMUNOL, V162, P5838; Marzo AL, 2000, J IMMUNOL, V165, P6047, DOI 10.4049/jimmunol.165.11.6047; Mattarollo SR, 2006, INT J CANCER, V119, P1630, DOI 10.1002/ijc.22019; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mescher MF, 2007, SEMIN CANCER BIOL, V17, P299, DOI 10.1016/j.semcancer.2007.06.008; Nelson D, 2000, J IMMUNOL, V165, P6123, DOI 10.4049/jimmunol.165.11.6123; Nelson DJ, 2001, J IMMUNOL, V166, P5557, DOI 10.4049/jimmunol.166.9.5557; Nishikawa H, 2003, P NATL ACAD SCI USA, V100, P10902, DOI 10.1073/pnas.1834479100; Nishimura T, 2000, CANCER CHEMOTH PHARM, V46, pS52, DOI 10.1007/PL00014051; Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905; Nowak AK, 2003, CANCER RES, V63, P4490; Nowak AK, 2006, ADV DRUG DELIVER REV, V58, P975, DOI 10.1016/j.addr.2006.04.002; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ohlen C, 2002, J EXP MED, V195, P1407, DOI 10.1084/jem.20011063; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Onizuka S, 1999, CANCER RES, V59, P3128; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Poitrasson-Riviere M, 2008, J IMMUNOL, V180, P7294, DOI 10.4049/jimmunol.180.11.7294; Rad AN, 2003, CANCER RES, V63, P5143; Rech AJ, 2009, ANN NY ACAD SCI, V1174, P99, DOI 10.1111/j.1749-6632.2009.04939.x; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Robinson BWS, 1999, IMMUNOL CELL BIOL, V77, P552, DOI 10.1046/j.1440-1711.1999.00876.x; Robinson BWS, 2001, CLIN CANCER RES, V7, p811S; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; Rovere P, 1999, J LEUKOCYTE BIOL, V66, P345, DOI 10.1002/jlb.66.2.345; Rudge G, 2007, J IMMUNOL, V178, P4089, DOI 10.4049/jimmunol.178.7.4089; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Sarween N, 2004, J IMMUNOL, V173, P2942, DOI 10.4049/jimmunol.173.5.2942; Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035; Schietinger A, 2008, SEMIN IMMUNOL, V20, P276, DOI 10.1016/j.smim.2008.07.001; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sinai P, 2007, J IMMUNOL, V178, P2028, DOI 10.4049/jimmunol.178.4.2028; Skoberne M, 2004, TRENDS MOL MED, V10, P251, DOI 10.1016/j.molmed.2004.04.001; Srivastava N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006094; Stumbles PA, 2004, J IMMUNOL, V173, P5923, DOI 10.4049/jimmunol.173.10.5923; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Tomlinson I, 2002, AM J PATHOL, V160, P755, DOI 10.1016/S0002-9440(10)64896-1; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; van der Most RG, 2006, CANCER RES, V66, P601, DOI 10.1158/0008-5472.CAN-05-2967; van der Most RG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006982; van der Most RG, 2009, CANCER IMMUNOL IMMUN, V58, P1219, DOI 10.1007/s00262-008-0628-9; VANDERBRUGGEN P, 2009, T CELL DEFINED TUMOU; Villablanca EJ, 2010, NAT MED, V16, P98, DOI 10.1038/nm.2074; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Wang HY, 2005, J IMMUNOL, V174, P2661, DOI 10.4049/jimmunol.174.5.2661; Watson NFS, 2006, INT J CANCER, V118, P6, DOI 10.1002/ijc.21303; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Welters MJP, 2010, P NATL ACAD SCI USA, V107, P11895, DOI 10.1073/pnas.1006500107; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Wolchok JD, 2008, ONCOLOGIST, V13, P2, DOI 10.1634/theoncologist.13-S4-2; WORTZEL RD, 1983, J IMMUNOL, V130, P2461; Xiao T, 2009, IMMUNOL RES, V43, P98, DOI 10.1007/s12026-008-8053-x; Yuan JD, 2008, P NATL ACAD SCI USA, V105, P20410, DOI 10.1073/pnas.0810114105; Zheng XF, 2006, J IMMUNOL, V177, P5639, DOI 10.4049/jimmunol.177.8.5639; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	140	59	61	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6301	6313		10.1038/onc.2010.437	http://dx.doi.org/10.1038/onc.2010.437			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20856204				2022-12-28	WOS:000284874700001
J	Belleudi, F; Leone, L; Purpura, V; Cannella, F; Scrofani, C; Torrisi, MR				Belleudi, F.; Leone, L.; Purpura, V.; Cannella, F.; Scrofani, C.; Torrisi, M. R.			HPV16 E5 affects the KGFR/FGFR2b-mediated epithelial growth through alteration of the receptor expression, signaling and endocytic traffic	ONCOGENE			English	Article						HPV16 E5; FGFR2b; KGFR; endocytic pathway; receptor tyrosine kinase; human keratinocytes	HUMAN FORESKIN KERATINOCYTES; LIGAND-DEPENDENT ACTIVATION; DOWN-REGULATION; PROTEIN; ONCOPROTEIN; KGF; EGF; DIFFERENTIATION; CELLS; PROLIFERATION	The E5 oncoprotein of the human papillomavirus type 16 (HPV16 E5) cooperates in cervical carcinogenesis and in epithelial transformation deregulating cell growth, survival and differentiation through the modulation of growth factor receptors. Among the epithelial receptor tyrosine kinases, the keratinocyte growth factor receptor/fibroblast growth factor receptor 2b (KGFR/FGFR2b) is a major paracrine mediator of epithelial homeostasis and appears to have an unique and unusual role in epithelial tissues, exerting a tumor-suppressive function in vitro and in vivo. With the aim to better elucidate the molecular events involved in the pathological activity of 16E5, we investigated if the viral protein would be able to affect the KGFR expression, signaling and turnover by interference with its degradative and recycling endocytic pathways. Quantitative reverse transcriptase-PCR and biochemical approaches on human keratinocytes transfected with 16E5-HA showed that E5 protein is able to induce KGFR down-modulation at both transcript and protein levels. Immunofluorescence microscopy in double-transfected cells expressing both E5 and KGFR revealed that the viral protein alters the receptor endocytic trafficking and triggers its endosomal sorting to the indirect juxtanuclear recycling pathway. The shift from lysosomal degradation to recycling at the plasma membrane correlates with a reduced phosphorylation of the fibroblast growth factor receptor substrate-2 alpha tyrosine 196, the major docking site for Grb2-Cbl complexes responsible for receptor ubiquitination and degradation. 5'-Bromo-deoxyuridine incorporation assay demonstrated that expression of 16E5 induces a decrease in the growth response to the receptor ligands as a consequence of KGFR down-modulation, suggesting that 16E5 might have a role on HPV infection in perturbing the KGFR-mediated physiological behavior of confluent keratinocytes committed to differentiation. Oncogene (2011) 30, 4963-4976; doi:10.1038/onc.2011.203; published online 30 May 2011	[Belleudi, F.; Leone, L.; Purpura, V.; Cannella, F.; Scrofani, C.; Torrisi, M. R.] Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, Dipartimento Med Clin & Mol, I-00161 Rome, Italy; [Torrisi, M. R.] Azienda Osped S Andrea, Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea	Torrisi, MR (corresponding author), Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, Dipartimento Med Clin & Mol, Piazza Sassari 3, I-00161 Rome, Italy.	mara.torrisi@uniroma1.it	Purpura, Valeria/K-3052-2018	PURPURA, VALERIA/0000-0002-1272-313X	MIUR; AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy [IG 10272]	MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy(Fondazione AIRC per la ricerca sul cancro)	This work was partially supported by grants from MIUR and from AIRC-Associazione Italiana per la Ricerca sul Cancro (IG 10272), Italy.	Ashrafi GH, 2006, INT J CANCER, V119, P2105, DOI 10.1002/ijc.22089; Ashrafi GH, 2005, INT J CANCER, V113, P276, DOI 10.1002/ijc.20558; Barbaresi S, 2010, J GEN VIROL, V91, P521, DOI 10.1099/vir.0.016295-0; Belleudi F, 2007, TRAFFIC, V8, P1854, DOI 10.1111/j.1600-0854.2007.00651.x; Belleudi F, 2006, FASEB J, V20, P395, DOI 10.1096/fj.05-3934fje; Belleudi F, 2009, EXP CELL RES, V315, P2181, DOI 10.1016/j.yexcr.2009.03.022; Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Ceccarelli S, 2007, EXP CELL RES, V313, P1758, DOI 10.1016/j.yexcr.2007.03.013; Chen SL, 2007, ONCOGENE, V26, P42, DOI 10.1038/sj.onc.1209768; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Feng S, 1997, CANCER RES, V58, P1509; Fey A, 2004, APPL ENVIRON MICROB, V70, P3618, DOI 10.1128/aem.70.6.3618-3623.2004; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Kivi N, 2008, ONCOGENE, V27, P2532, DOI 10.1038/sj.onc.1210916; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Lotti LV, 2007, J CELL PHYSIOL, V212, P633, DOI 10.1002/jcp.21056; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; Marchese C, 2001, J INVEST DERMATOL, V116, P623, DOI 10.1046/j.0022-202x.2001.01280.x; Maufort JP, 2007, CANCER RES, V67, P6106, DOI 10.1158/0008-5472.CAN-07-0921; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Pedroza-Saavedra A, 2010, VIROLOGY, V400, P44, DOI 10.1016/j.virol.2010.01.009; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PIM D, 1992, ONCOGENE, V7, P27; Regan JA, 2008, J VIROL, V82, P10042, DOI 10.1128/JVI.01240-08; Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suprynowicz FA, 2010, J VIROL, V84, P10619, DOI 10.1128/JVI.00831-10; Talbert-Slagle K, 2009, VIROLOGY, V384, P345, DOI 10.1016/j.virol.2008.09.033; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wakana Y, 2008, MOL BIOL CELL, V19, P1825, DOI 10.1091/mbc.E07-08-0781; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Zhang BY, 2005, ONCOGENE, V24, P2585, DOI 10.1038/sj.onc.1208453; Zhang BY, 2003, VIROLOGY, V310, P100, DOI 10.1016/S0042-6822(03)00103-X; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	49	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4963	4976		10.1038/onc.2011.203	http://dx.doi.org/10.1038/onc.2011.203			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21625213	Bronze			2022-12-28	WOS:000298346500005
J	Kahyo, T; Iwaizumi, M; Shinmura, K; Matsuura, S; Nakamura, T; Watanabe, Y; Yamada, H; Sugimura, H				Kahyo, T.; Iwaizumi, M.; Shinmura, K.; Matsuura, S.; Nakamura, T.; Watanabe, Y.; Yamada, H.; Sugimura, H.			A novel tumor-derived SGOL1 variant causes abnormal mitosis and unstable chromatid cohesion	ONCOGENE			English	Article						chromosomal instability; colon cancer; mitosis; shugoshin; splicing variant	PROTEIN PHOSPHATASE 2A; CHROMOSOMAL INSTABILITY; CENTROMERIC PROTECTION; DROSOPHILA MEI-S332; SPINDLE CHECKPOINT; SISTER CHROMATIDS; DOWN-REGULATION; CANCER-CELLS; MEIOSIS-I; SHUGOSHIN	Mitosis is the most conspicuous cell cycle phase, because it is the phase in which the dynamic physical distributions of cellular components into the two daughter cells occur. The separation of sister chromatids is especially important during mitosis, because of the extreme accuracy required for distribution to the next generation of cells. Shugoshin-like 1 (SGOL1) is a key protein in protecting sister chromatids from precocious separation. We have reported finding that chromosome instability is more likely in SGOL1-downregulated colorectal cancers, but it is still unknown whether there is an association between cancer and SGOL1 transcript variation. Here, we identified a novel SGOL1 variant, SGOL1-P1, in human colon cancer. The SGOL1-P1 transcript contains an exon-skip of exon 3 that results in a stop codon occurring within exon 4. Overexpression of SGOL1-P1 in HCT116 cells resulted in an increased number of cells with aberrant chromosome alignment, precociously separated chromatids and delayed mitotic progression, occasionally followed by inaccurate distribution of the chromosomes. These phenotypes, observed when SGOL1-P1 was present, were also observed very frequently in SGOL1-knockdown cells. Furthermore, the overexpression of SGOL1-P1 inhibited the localization of endogenous SGOL1 and cohesin subunit RAD21/SCC1 to the centromere. These results suggest that SGOL1-P1 may function as a negative factor to native SGOL1, and that abundant expression of SGOL1-P1 may be responsible for chromosomal instability. Oncogene (2011) 30, 4453-4463; doi: 10.1038/onc.2011.152; published online 2 May 2011	[Sugimura, H.] Hamamatsu Univ Sch Med, Dept Pathol 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Iwaizumi, M.] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan; [Matsuura, S.] Hamamatsu Univ Sch Med, Dept Med 2, Hamamatsu, Shizuoka 4313192, Japan; [Nakamura, T.] Hamamatsu Univ Sch Med, Dept Surg 2, Hamamatsu, Shizuoka 4313192, Japan; [Watanabe, Y.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Chromosome Dynam, Tokyo, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; University of Tokyo	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hsugimur@hama-med.ac.jp	YAMADA, Hidetaka/AAK-5085-2021; Matsuura, Shun/AAW-5353-2021; Shinmura, Kazuya/K-8940-2012; Iwaizumi, Moriya/AAG-3173-2019	Matsuura, Shun/0000-0001-8844-6100; Shinmura, Kazuya/0000-0003-4963-746X; Iwaizumi, Moriya/0000-0002-2629-0830; Watanabe, Yoshinori/0000-0002-5488-4812	Japanese Ministry of Education, Culture, Sports, Science and Technology [22590356, 20014007, 221S0001]; Japanese Ministry of Health [21-1]; Smoking Research Foundation; Grants-in-Aid for Scientific Research [22590356] Funding Source: KAKEN	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Ministry of Health; Smoking Research Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Suzuki of The Jikei University School of Medicine for providing the anti-hSgo1 antibody. This work was supported by a Grant-in-Aid for Scientific Research (C) (22590356) and for priority areas (20014007 and 221S0001) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for the 3rd Term Comprehensive 10-Year-Strategy for Cancer Control and Grants-in-Aid for Cancer Research from the Japanese Ministry of Health (21-1) and from the Smoking Research Foundation.	Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Clift D, 2009, GENE DEV, V23, P766, DOI 10.1101/gad.507509; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; Eot-Houllier G, 2008, GENE DEV, V22, P2639, DOI 10.1101/gad.484108; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Iwaizumi M, 2009, GUT, V58, P249, DOI 10.1136/gut.2008.149468; Kahyo T, 2008, FEBS LETT, V582, P2479, DOI 10.1016/j.febslet.2008.06.031; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kapoor TM, 2006, SCIENCE, V311, P388, DOI 10.1126/science.1122142; Karamysheva Z, 2009, J BIOL CHEM, V284, P1772, DOI 10.1074/jbc.M807083200; Kawashima SA, 2010, SCIENCE, V327, P172, DOI 10.1126/science.1180189; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Kienitz A, 2005, ONCOGENE, V24, P4301, DOI 10.1038/sj.onc.1208589; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kitajima TS, 2005, CURR BIOL, V15, P353, DOI 10.1016/j.cub.2004.12.044; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Kothe M, 2007, BIOCHEMISTRY-US, V46, P5960, DOI 10.1021/bi602474j; Lee J, 2008, NAT CELL BIOL, V10, P42, DOI 10.1038/ncb1667; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rabitsch KP, 2004, CURR BIOL, V14, P287, DOI 10.1016/j.cub.2004.01.051; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Sakuno T, 2009, NATURE, V458, P852, DOI 10.1038/nature07876; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; Shinmura K, 2008, J PATHOL, V216, P365, DOI 10.1002/path.2422; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Suzuki H, 2006, CELL CYCLE, V5, P1094, DOI 10.4161/cc.5.10.2747; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Tang ZY, 2004, P NATL ACAD SCI USA, V101, P18012, DOI 10.1073/pnas.0408600102; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Xu Z, 2009, MOL CELL, V35, P426, DOI 10.1016/j.molcel.2009.06.031; Yamagishi Y, 2008, NATURE, V455, P251, DOI 10.1038/nature07217	48	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	44					4453	4463		10.1038/onc.2011.152	http://dx.doi.org/10.1038/onc.2011.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21532624				2022-12-28	WOS:000296733200001
J	Rosner, M; Hengstschlager, M				Rosner, M.; Hengstschlaeger, M.			Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR	ONCOGENE			English	Article						TSC2; mTOR; S6K1; localization	MAMMALIAN TARGET; PROTEIN; MTOR; PHOSPHORYLATION; KINASE; P27(KIP1); COMPLEXES	The tuberous sclerosis complex gene 2 (TSC2)/mammalian target of rapamycin (mTOR) pathway controls many cellular functions via phosphorylation of ribosomal protein S6 kinases (S6Ks). Alternative splicing and translation generate three S6K1 proteins. Although nuclear and cytoplasmic S6K targets are known, the nucleocytoplasmic localization of the S6K1 proteins has not been comparatively elucidated so far. We show that in primary fibroblasts p85 S6K1 is cytoplasmic, p70 can be found in both compartments and p31 is exclusively nuclear. As already known for p70 and p85, our data suggest that p31 is also a target of mTOR-mediated phosphorylation. Blocking mTOR kinase activity via rapamycin and its activation in TSC2(-/-) cells and via TSC2 small interfering RNAs revealed that it regulates the localization of p70, but not of p85 and p31. The mTOR-dependent phosphorylation of p70 S6K1 at T389 is essential for its nuclear localization and exclusively hyperphosphorylated p70 S6K1 can be found in the nucleus. We further demonstrate this mTOR-controlled p70 S6K1 localization to be growth factor dependent. During the cell-cycle phosphorylation and nuclear localization of p70 S6K1 occur in mid G1 phase. We report that the different S6K1 proteins exhibit different nucleocytoplasmic localizations and that the TSC2/mTOR cascade not only regulates p70 S6K1 activity, but also its localization. These findings provide new important insights into the temporal and spatial dynamics of TSC2/mTOR/S6K regulation. Oncogene (2011) 30, 4509-4522; doi:10.1038/onc.2011.165; published online 23 May 2011	[Rosner, M.; Hengstschlaeger, M.] Med Univ Vienna, Inst Med Genet, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at			Herzfelder'sche Familienstiftung; Osterreichische Nationalbank	Herzfelder'sche Familienstiftung; Osterreichische Nationalbank	Research in our laboratory is supported via grants from the Herzfelder'sche Familienstiftung and the Osterreichische Nationalbank.	CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018; Hengstschlager M, 2001, PRENATAL DIAG, V21, P897, DOI 10.1002/pd.154; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim D, 2009, GROWTH FACTORS, V27, P12, DOI 10.1080/08977190802556986; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V234, P681, DOI 10.1006/bbrc.1997.6699; Knowles MA, 2003, CANCER RES, V63, P7652; Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5; Panasyuk G, 2006, J BIOL CHEM, V281, P31188, DOI 10.1074/jbc.M602618200; Plas DR, 2009, CURR OPIN CELL BIOL, V21, P230, DOI 10.1016/j.ceb.2008.12.013; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Rosner M, 2007, HUM MOL GENET, V16, P1541, DOI 10.1093/hmg/ddm103; Rosner M, 2010, NAT PROTOC, V5, P1081, DOI 10.1038/nprot.2010.74; Rosner M, 2009, HUM MOL GENET, V18, P3298, DOI 10.1093/hmg/ddp271; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Shaw RJ, 2008, TRENDS BIOCHEM SCI, V33, P565, DOI 10.1016/j.tibs.2008.09.005; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64	31	56	61	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4509	4522		10.1038/onc.2011.165	http://dx.doi.org/10.1038/onc.2011.165			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21602892				2022-12-28	WOS:000296733200006
J	Serres, MP; Zlotek-Zlotkiewicz, E; Concha, C; Gurian-West, M; Daburon, V; Roberts, JM; Besson, A				Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Gurian-West, M.; Daburon, V.; Roberts, J. M.; Besson, A.			Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro	ONCOGENE			English	Article						p27 Kip1; Ras; Myc; mouse model; lung tumors	CELL-CYCLE PROGRESSION; CDK INHIBITORS; LUNG-CANCER; P27(KIP1) MISLOCALIZATION; DEPENDENT PHOSPHORYLATION; TUMOR SUPPRESSION; NUCLEAR EXPORT; MYC; LOCALIZATION; PROTEOLYSIS	p27(Kip1) (p27) can have opposing roles during malignant transformation depending on cellular context: on one hand it functions as a tumor suppressor by inhibiting cyclin-cyclin-dependent kinase (CDK) activity in the nucleus and on the other it may adopt an oncogenic role that is less well understood. To gain further insight into the roles played by p27 during tumorigenesis, we compared the susceptibility with urethane-induced tumorigenesis of two p27 mouse models, p27(-/-) and p27(CK-) knockin, in which p27 cannot bind or inhibit cyclin-CDKs. In this K-Ras-driven tumorigenesis model, p27(CK-) mice had an increase in both tumor number and aggressiveness compared with p27(-/-), indicating a cooperation between p27(CK-) and activated Ras. In the lung, increased tumorigenesis was associated with cytoplasmic localization of p27(CK-) and bronchiolaveolar stem cell amplification. The ability of p27(CK-) to cooperate with other oncogenes was not universal. When c-Myc was used as a transforming agent, p27 status became irrelevant and c-Myc was equally potent in transforming p27(+/+), p27(-/-) and p27(CK-) cells. In fact, c-Myc induced the degradation of wild-type p27 via the Skp-Cullin-F-box (SCF)-Skp2 pathway. In contrast, p27(CK-) levels were not affected by c-Myc expression, as p27(CK-) is insensitive to Skp2-mediated degradation because of its inability to bind cyclin E/CDK2. However, in presence of c-Myc, p27(CK-) remained mostly nuclear, providing an explanation for its inability to cooperate with Myc during transformation. Thus, we propose that the p27(CK-) protein needs to be localized in the cytoplasm in order to function as an oncogene, otherwise it just behaves similar to a null allele. Oncogene (2011) 30, 2846-2858; doi:10.1038/onc.2011.9; published online 14 February 2011	[Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Daburon, V.; Besson, A.] CNRS, UMR 5088, ERL5294, F-31062 Toulouse 9, France; [Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Daburon, V.; Besson, A.] Canc Res Ctr Toulouse, INSERM, UMR1037, Toulouse, France; [Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Daburon, V.; Besson, A.] Univ Toulouse, Toulouse, France; [Gurian-West, M.; Roberts, J. M.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Fred Hutchinson Cancer Center	Besson, A (corresponding author), CNRS, UMR 5088, ERL5294, 118 Route Narbonne,Batiment 4R3b1, F-31062 Toulouse 9, France.	abesson@cict.fr	zlotek-zlotkiewicz, ewa/M-1774-2015; Besson, Arnaud/J-6254-2014	Besson, Arnaud/0000-0002-9599-3943	Ministere de l'Enseignement Superieur et de la Recherche; Fondation pour la Recherche Medicale; NIH [1R01CA118043]; Association pour la Recherche sur le Cancer; Ligue Nationale Contre le Cancer; NATIONAL CANCER INSTITUTE [R01CA118043] Funding Source: NIH RePORTER	Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MPS is supported by a studentship from the Ministere de l'Enseignement Superieur et de la Recherche. CC is supported by a fellowship from the Fondation pour la Recherche Medicale. This work was supported by NIH grant # 1R01CA118043 to JMR. AB is supported by grants from the Association pour la Recherche sur le Cancer and Ligue Nationale Contre le Cancer.	Berns K, 2000, ONCOGENE, V19, P4822, DOI 10.1038/sj.onc.1203879; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Chu S, 2010, LEUKEMIA, V24, P779, DOI 10.1038/leu.2010.24; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hattori T, 2007, CANCER RES, V67, P10789, DOI 10.1158/0008-5472.CAN-07-2033; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kawauchi T, 2006, NAT CELL BIOL, V8, P17, DOI 10.1038/ncb1338; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Kelly-Spratt KS, 2009, ONCOGENE, V28, P3652, DOI 10.1038/onc.2009.226; Kfir S, 2005, MOL CELL BIOL, V25, P8239, DOI 10.1128/MCB.25.18.8239-8250.2005; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li ZP, 2006, CANCER RES, V66, P9986, DOI 10.1158/0008-5472.CAN-06-1596; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Old JB, 2010, MOL CANCER RES, V8, P353, DOI 10.1158/1541-7786.MCR-09-0232; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Short JD, 2008, CANCER RES, V68, P6496, DOI 10.1158/0008-5472.CAN-07-5756; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304	51	57	59	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	25					2846	2858		10.1038/onc.2011.9	http://dx.doi.org/10.1038/onc.2011.9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317921				2022-12-28	WOS:000291977800005
J	Pode-Shakked, N; Harari-Steinberg, O; Haberman-Ziv, Y; Rom-Gross, E; Bahar, S; Omer, D; Metsuyanim, S; Buzhor, E; Jacob-Hirsch, J; Goldstein, RS; Mark-Danieli, M; Dekel, B				Pode-Shakked, N.; Harari-Steinberg, O.; Haberman-Ziv, Y.; Rom-Gross, E.; Bahar, S.; Omer, D.; Metsuyanim, S.; Buzhor, E.; Jacob-Hirsch, J.; Goldstein, R. S.; Mark-Danieli, M.; Dekel, B.			Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target	ONCOGENE			English	Article						frizzled7; wnt pathway; stem cells; Wilms' tumor; sensitive; resistant	FREQUENT EPIGENETIC INACTIVATION; STEM-CELLS; BETA-CATENIN; CANCER; GENES; IDENTIFICATION; MODEL; ACTIVATION; WTX	Wilms' tumor (WT), the most frequent renal solid tumor in children, has been linked to aberrant Wnt signaling. Herein, we demonstrate that different WTs can be grouped according to either sensitivity or resistance to an antibody (Ab) specific to frizzled7 (FZD7), a Wnt receptor. In the FZD7-sensitive WT phenotype, the Ab induced cell death of the FZD7(+) fraction, which in turn depleted primary WT cultures of their clonogenic and sphere-forming cells and decreased in vivo proliferation and survival on xenografting to the chick chorio-allantoic-membrane. In contrast, FZD7-resistant WT in which no cell death was induced showed a different intracellular route of the Ab-FZD7 complex compared with sensitive tumors and accumulation of beta-catenin. This coincided with a low sFRP1 and DKK1 (Wnt inhibitors) expression pattern, restored epigenetically with de-methylating agents, and lack of beta-catenin or WTX mutations. The addition of exogenous DKK1 and sFRP1 to the tumor cells enabled the sensitization of FZD7-resistant WT to the FZD7 Ab. Finally, although extremely difficult to achieve because of dynamic cellular localization of FZD7, sorting of FZD7(+) cells from resistant WT, showed them to be highly clonogenic/proliferative, overexpressing WT 'stemness' genes, emphasizing the importance of targeting this fraction. FZD7 Ab therapy alone or in combination with Wnt pathway antagonists may have a significant role in the treatment of WT via targeting of a tumor progenitor population. Oncogene (2011) 30, 1664-1680; doi:10.1038/onc.2010.549; published online 17 January 2011	[Pode-Shakked, N.; Harari-Steinberg, O.; Haberman-Ziv, Y.; Bahar, S.; Omer, D.; Metsuyanim, S.; Buzhor, E.; Mark-Danieli, M.; Dekel, B.] Safra Childrens Hosp, Pediat Stem Cell Res Inst, Tel Hashomer, Israel; [Pode-Shakked, N.; Harari-Steinberg, O.; Haberman-Ziv, Y.; Bahar, S.; Omer, D.; Metsuyanim, S.; Buzhor, E.; Mark-Danieli, M.; Dekel, B.] Sheba Med Ctr, Sheba Ctr Regenerat Med, Tel Hashomer, Israel; [Pode-Shakked, N.; Haberman-Ziv, Y.; Bahar, S.; Omer, D.; Buzhor, E.; Dekel, B.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Rom-Gross, E.] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Pediat Surg, Jerusalem, Israel; [Metsuyanim, S.; Jacob-Hirsch, J.] Sheba Med Ctr, Ctr Canc Res, Tel Hashomer, Israel; [Goldstein, R. S.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center; Chaim Sheba Medical Center; Bar Ilan University	Dekel, B (corresponding author), Edmond & Lili Safra Childrens Hosp, Sheba Med Ctr, Pediat Stem Cell Res Inst, IL-52621 Tel Hashomer, Israel.	benjamin.dekel@gmail.com	Goldstein, Ronald/H-5765-2011		ISF [1139/07]; ICRF; TAU Cancer Biology Research Center; TAU Stem Cell Research Center; Schreiber Foundation; Brettler Foundation; Sackler School of Medicine; Tel Aviv University	ISF(Israel Science Foundation); ICRF; TAU Cancer Biology Research Center; TAU Stem Cell Research Center; Schreiber Foundation; Brettler Foundation; Sackler School of Medicine; Tel Aviv University	We thank Lior Zangi, Tsahi Neuman and Igor Grinberg for technical assistance. This work was supported by ISF grant number 1139/07, ICRF Clinical Career Development Award, TAU Cancer Biology Research Center and TAU Stem Cell Research Center, The Schreiber and Brettler Foundations, Sackler School of Medicine, Tel Aviv University (BD). This work is part of the requirements toward a PhD degree, Sackler School of Medicine, Tel Aviv University (NPS).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528; Dekel B, 2006, J AM SOC NEPHROL, V17, P3300, DOI 10.1681/ASN.2005020195; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Feinberg Andrew P, 2003, Methods Mol Biol, V222, P239; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Galmozzi E, 2006, CURR MED CHEM, V13, P603, DOI 10.2174/092986706776055661; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Jost E, 2008, BRIT J HAEMATOL, V142, P745, DOI 10.1111/j.1365-2141.2008.07242.x; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Koesters R, 1999, CANCER RES, V59, P3880; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Metsuyanim S, 2008, STEM CELLS, V26, P1808, DOI 10.1634/stemcells.2007-0322; Metsuyanim S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006709; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259; Park JS, 2007, DEVELOPMENT, V134, P2533, DOI 10.1242/dev.006155; Pfeiffer P, 2007, ONCOGENE, V26, P3661, DOI 10.1038/sj.onc.1210377; Pode-Shakked N, 2009, J CELL MOL MED, V13, P1792, DOI 10.1111/j.1582-4934.2008.00607.x; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; Rashidi H, 2009, BIOESSAYS, V31, P459, DOI 10.1002/bies.200800168; Ren X, 2007, CELL DEATH DIFFER, V14, P2076, DOI 10.1038/sj.cdd.4402220; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Robison Leslie L, 2005, Minn Med, V88, P45; Schedl A, 2007, NAT REV GENET, V8, P791, DOI 10.1038/nrg2205; Schmidt-Ott KM, 2008, KIDNEY INT, V74, P1004, DOI 10.1038/ki.2008.322; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Spreafico F, 2009, EXPERT REV ANTICANC, V9, P693, DOI 10.1586/ERA.09.45; Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259; Taizi M, 2006, EXP HEMATOL, V34, P1698, DOI 10.1016/j.exphem.2006.07.005; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439; Wittmann S, 2008, GENE CHROMOSOME CANC, V47, P386, DOI 10.1002/gcc.20544; Zirn B, 2006, GENE CHROMOSOME CANC, V45, P565, DOI 10.1002/gcc.20319	43	51	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1664	1680		10.1038/onc.2010.549	http://dx.doi.org/10.1038/onc.2010.549			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21472018				2022-12-28	WOS:000289239400005
J	Preston, RS; Philp, A; Claessens, T; Gijezen, L; Dydensborg, AB; Dunlop, EA; Harper, KT; Brinkhuizen, T; Menko, FH; Davies, DM; Land, SC; Pause, A; Baar, K; van Steensel, MAM; Tee, AR				Preston, R. S.; Philp, A.; Claessens, T.; Gijezen, L.; Dydensborg, A. B.; Dunlop, E. A.; Harper, K. T.; Brinkhuizen, T.; Menko, F. H.; Davies, D. M.; Land, S. C.; Pause, A.; Baar, K.; van Steensel, M. A. M.; Tee, A. R.			Absence of the Birt-Hogg-Dube gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility	ONCOGENE			English	Article						Birt-Hogg-Dube; HIF; folliculin; warburg effect	RENAL-CELL CARCINOMA; MAMMALIAN TARGET; FUMARATE HYDRATASE; CANCER; ACTIVATION; EXPRESSION; AMPK; MTOR; PHOSPHORYLATION; RAPAMYCIN	Under conditions of reduced tissue oxygenation, hypoxia-inducible factor (HIF) controls many processes, including angiogenesis and cellular metabolism, and also influences cell proliferation and survival decisions. HIF is centrally involved in tumour growth in inherited diseases that give rise to renal cell carcinoma (RCC), such as Von Hippel-Lindau syndrome and tuberous sclerosis complex. In this study, we examined whether HIF is involved in tumour formation of RCC in Birt-Hogg-Dube syndrome. For this, we analysed a Birt-Hogg-Dube patient-derived renal tumour cell line (UOK257) that is devoid of the Birt-Hogg-Dube protein (BHD) and observed high levels of HIF activity. Knockdown of BHD expression also caused a threefold activation of HIF, which was not as a consequence of more HIF1 alpha or HIF2 alpha protein. Transcription of HIF target genes VEGF, BNIP3 and CCND1 was also increased. We found nuclear localization of HIF1 alpha and increased expression of VEGF, BNIP3 and GLUT1 in a chromophobe carcinoma from a Birt-Hogg-Dube patient. Our data also reveal that UOK257 cells have high lactate dehydrogenase, pyruvate kinase and 3-hydroxyacyl-CoA dehydrogenase activity. We observed increased expression of pyruvate dehydrogenase kinase 1 (a HIF gene target), which in turn leads to increased phosphorylation and inhibition of pyruvate dehydrogenase. Together with increased protein levels of GLUT1, our data reveal that UOK257 cells favour glycolytic rather than lipid metabolism (a cancer phenomenon termed the 'Warburg effect'). UOK257 cells also possessed a higher expression level of the L-lactate influx monocarboxylate transporter 1 and consequently utilized L-lactate as a metabolic fuel. As a result of their higher dependency on glycolysis, we were able to selectively inhibit the growth of these UOK257 cells by treatment with 2-deoxyglucose. This work suggests that targeting glycolytic metabolism may be used therapeutically to treat Birt-Hogg-Dube-associated renal lesions. Oncogene (2011) 30, 1159-1173; doi:10.1038/onc.2010.497; published online 8 November 2010	[Preston, R. S.; Dunlop, E. A.; Harper, K. T.; Davies, D. M.; Tee, A. R.] Cardiff Univ, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; [Philp, A.; Baar, K.] Univ Calif Davis, Davis, CA 95616 USA; [Claessens, T.; Gijezen, L.; Brinkhuizen, T.; van Steensel, M. A. M.] Maastricht Univ, Med Ctr, Dept Dermatol, Maastricht, Netherlands; [Claessens, T.; Gijezen, L.; Brinkhuizen, T.; van Steensel, M. A. M.] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands; [Dydensborg, A. B.; Pause, A.] McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada; [Menko, F. H.] VU Med Ctr Amsterdam, Dept Clin Genet, Amsterdam, Netherlands; [Land, S. C.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Cardiovasc & Lung Biol, Div Med Sci, Dundee DD1 9SY, Scotland	Cardiff University; University of California System; University of California Davis; Maastricht University; Maastricht University; McGill University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Dundee	Tee, AR (corresponding author), Cardiff Univ, Inst Med Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk	van Steensel, Maurice A.M./V-3852-2019; /J-6218-2019	/0000-0002-9209-7561; Philp, Andrew/0000-0003-3860-4136; Tee, Andrew/0000-0002-5577-4631; Land, Stephen/0000-0001-9216-5969; van Steensel, Maurice/0000-0002-7507-2442; Baar, Keith/0000-0001-9337-6186; Davies, Mark/0000-0002-0688-3129	Association for International Cancer Research [06-914/915]; Wellcome Trust [088032/Z/08/Z]; Dutch Cancer Society [UM2009-4352, UM2010-4609]; Engineering and Physical Sciences Research Council [EP/E008925/1]; Biotechnology and Biological Sciences Research Council [BB/F002084/1]; BBSRC [BB/F002084/1] Funding Source: UKRI; EPSRC [EP/E008925/1] Funding Source: UKRI; Worldwide Cancer Research [06-0914] Funding Source: researchfish	Association for International Cancer Research; Wellcome Trust(Wellcome TrustEuropean Commission); Dutch Cancer Society(KWF Kankerbestrijding); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Worldwide Cancer Research	This work was supported by The Association for International Cancer Research Career Development Fellowship (No 06-914/915) (to A Tee). The Myrovlytis Trust supports the labs of A Tee, M v Steensel and A Pause and Partnership for Cures supports A Tee and Mv Steensel. Funding was also provided by the Wellcome Trust (No 088032/Z/08/Z) (to S Land) and the Dutch Cancer Society (grants UM2009-4352 to M v Steensel and UM2010-4609 to T Brinkhuizen). M Kamps, A van Marion and V Winnepenninckx (all of the MUMC) provided valuable assistance with immunohistochemistry. Funding was also provided by the Engineering and Physical Sciences Research Council (EP/E008925/1) and the Biotechnology and Biological Sciences Research Council (BB/F002084/1) (to K Baar). We also thank Wales Gene Park.	Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; Bratslavsky G, 2007, CLIN CANCER RES, V13, P4667, DOI 10.1158/1078-0432.CCR-06-2510; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Deldicque L, 2007, AM J PHYSIOL-CELL PH, V293, pC1263, DOI 10.1152/ajpcell.00162.2007; Dunlop EA, 2009, CELL SIGNAL, V21, P827, DOI 10.1016/j.cellsig.2009.01.012; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Galgani JE, 2008, AM J PHYSIOL-ENDOC M, V295, pE1009, DOI 10.1152/ajpendo.90558.2008; Gao L, 2004, FEBS LETT, V569, P256, DOI 10.1016/j.febslet.2004.06.004; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hartman TR, 2009, ONCOGENE, V28, P1594, DOI 10.1038/onc.2009.14; Hasumi Y, 2009, P NATL ACAD SCI USA, V106, P18722, DOI 10.1073/pnas.0908853106; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hemminki K, 2002, CARCINOGENESIS, V23, P809, DOI 10.1093/carcin/23.5.809; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Khoo SK, 2002, J MED GENET, V39, P906, DOI 10.1136/jmg.39.12.906; Kiuru M, 2004, CURR MOL MED, V4, P869, DOI 10.2174/1566524043359638; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu MY, 2003, CANCER RES, V63, P2675; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Rapisarda A, 2002, CANCER RES, V62, P4316; Robey R.B., 2005, DRUG DISCOV TODAY DI, V2, P239, DOI [10.1016/j.ddmec.2005.05.021, DOI 10.1016/J.DDMEC.2005.05.021, DOI 10.1016/j.ddmec.2005.05.021]; Roland I, 2000, EUR J BIOCHEM, V267, P3567, DOI 10.1046/j.1432-1327.2000.01385.x; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Shah OJ, 2006, MOL CELL BIOL, V26, P6425, DOI 10.1128/MCB.01254-05; SLEGTENHORST MV, 2007, J BIOL CHEM, V282, P24583; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; SUAREZ RK, 1986, AM J PHYSIOL, V251, pR537, DOI 10.1152/ajpregu.1986.251.3.R537; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Treins C, 2006, BIOCHEM BIOPH RES CO, V342, P1197, DOI 10.1016/j.bbrc.2006.02.088; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P319; Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356; Woodward ER, 2008, CLIN CANCER RES, V14, P5925, DOI 10.1158/1078-0432.CCR-08-0608; YANG Y, 2007, CANC GENET CYTOGEN, V96, P336	44	52	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1159	1173		10.1038/onc.2010.497	http://dx.doi.org/10.1038/onc.2010.497			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057536	Green Accepted			2022-12-28	WOS:000288202400003
J	Samuel, S; Fan, F; Dang, LH; Xia, L; Gaur, P; Ellis, LM				Samuel, S.; Fan, F.; Dang, L. H.; Xia, L.; Gaur, P.; Ellis, L. M.			Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells	ONCOGENE			English	Article						VEGF; chemosensitivity; colorectal cancer; autocrine; intracrine; apoptosis	PERMEABILITY FACTOR; TUMOR-CELLS; FACTOR RECEPTOR-1; VEGF; APOPTOSIS; BCL-2; PROLIFERATION; ANGIOGENESIS; EXPRESSION; LETHALITY	Although the effects of vascular endothelial growth factor (VEGF) on angiogenesis and vascular function are well known, the effects of VEGF on tumor cell function remain to be elucidated. We studied phenotypic changes in human colorectal cancer (CRC) cells with homozygous deletion of VEGF alleles to determine the potential direct role of VEGF on tumor cell function. Loss of VEGF expression led to significantly decreased cell growth and increased spontaneous apoptosis in CRC cells (P < 0.01). Loss of VEGF also increased the in vitro sensitivity of cells to the cytotoxic effects of the chemotherapeutic drug 5-fluorouracil, as shown by increased apoptosis (P < 0.05). These effects were mediated via upregulation of the pro-apoptotic mediators caspase-3, cleaved PARP and Bax and downregulation of the pro-survival mediator survivin. Our findings suggest a novel and distinct function of VEGF in mediating autocrine/intracrine CRC cell survival. Oncogene (2011) 30, 1205-1212; doi:10.1038/onc.2010.496; published online 8 November 2010	[Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77230 USA; [Dang, L. H.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL USA; [Gaur, P.; Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77230 USA	University of Texas System; UTMD Anderson Cancer Center; State University System of Florida; University of Florida; University of Texas System; UTMD Anderson Cancer Center	Ellis, LM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, 515 Holcombe Blvd,POB 173, Houston, TX 77230 USA.	lellis@mdanderson.org	Khaitan, Puja/AAQ-6413-2020	Khaitan, Puja/0000-0001-8654-062X	NIH Cancer Center [CA016672]; RE 'Bob' Smith Fund for Cancer Research; NIH [CCSG CA016672, T32 CA09599, R01 CA112390]; William C Liedtke Chair in Cancer Research; NATIONAL CANCER INSTITUTE [R21CA159270, P30CA016672, T32CA009599, R01CA112390] Funding Source: NIH RePORTER	NIH Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RE 'Bob' Smith Fund for Cancer Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); William C Liedtke Chair in Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Cytometry and Cellular Imaging Core Facility at M. D. Anderson Cancer Center (funded by NIH Cancer Center Support Grant CA016672) for assistance with data analysis using the flow cytometers. We thank Sunita Patterson (Department of Scientific Publications) for manuscript editing and Rita Hernandez for editorial assistance. This work was supported by the RE 'Bob' Smith Fund for Cancer Research (SS), NIH grants CCSG CA016672, T32 CA09599 (PG), R01 CA112390 (LME), and the William C Liedtke Chair in Cancer Research.	Bachelder RE, 2001, CANCER RES, V61, P5736; Barr MP, 2008, INT J ONCOL, V32, P41; BROWN LF, 1997, EXS, V79, P233; Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Masuda K, 2008, PLOS MED, V5, P805, DOI 10.1371/journal.pmed.0050094; Nor JE, 2001, CANCER RES, V61, P2183; Pidgeon GP, 2001, BRIT J CANCER, V85, P273, DOI 10.1054/bjoc.2001.1876; Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847; Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD-2003-05-1634; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vincent L, 2005, CANCER RES, V65, P3185, DOI 10.1158/0008-5472.CAN-04-3598	31	48	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1205	1212		10.1038/onc.2010.496	http://dx.doi.org/10.1038/onc.2010.496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057529	Green Accepted			2022-12-28	WOS:000288202400007
J	Shen, RR; Hahn, WC				Shen, R. R.; Hahn, W. C.			Emerging roles for the non-canonical IKKs in cancer	ONCOGENE			English	Review						NF-kappa B; cancer; IKK	NF-KAPPA-B; INNATE IMMUNE-RESPONSE; KINASE-RELATED KINASES; TUMOR-SUPPRESSOR CYLD; INTERFERON REGULATORY FACTOR-3; UBIQUITIN-LIKE DOMAIN; BREAST-CANCER; I INTERFERON; ANTIVIRAL RESPONSE; ADAPTER PROTEIN	The I kappa B Kinase (IKK)-related kinases TBK1 and IKK epsilon have essential roles as regulators of innate immunity by modulating interferon and NF-kappa B signaling. Recent work has also implicated these non-canonical IKKs in malignant transformation. IKK epsilon is amplified in similar to 30% of breast cancers and transforms cells through the activation of NF-kappa B. TBK1 participates in RalB-mediated inflammatory responses and cell survival, and is essential for the survival of non-small cell lung cancers driven by oncogenic KRAS. The delineation of target substrates and downstream activities for TBK1 and IKK epsilon has begun to define their role(s) in promoting tumorigenesis. In this review, we will highlight the mechanisms by which IKKe and TBK1 orchestrate pathways involved in inflammation and cancer. Oncogene (2011) 30, 631-641; doi:10.1038/onc.2010.493; published online 1 November 2010	[Shen, R. R.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hahn, W. C.] Broad Inst Harvard & MIT, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Dana 1538, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu			US NIH [R01 CA130988]; NATIONAL CANCER INSTITUTE [R33CA128625, R01CA130988] Funding Source: NIH RePORTER	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Hahn laboratory for advice. This work was supported in part by the US NIH (R01 CA130988).	Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; An HZ, 2006, IMMUNITY, V25, P919, DOI 10.1016/j.immuni.2006.10.014; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bibeau-Poirier A, 2006, J IMMUNOL, V177, P5059, DOI 10.4049/jimmunol.177.8.5059; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Caillaud A, 2005, J BIOL CHEM, V280, P17671, DOI 10.1074/jbc.M411389200; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; Chau TL, 2008, TRENDS BIOCHEM SCI, V33, P171, DOI 10.1016/j.tibs.2008.01.002; Cheng TF, 2006, J IMMUNOL, V176, P7462, DOI 10.4049/jimmunol.176.12.7462; Chiang SH, 2009, CELL, V138, P961, DOI 10.1016/j.cell.2009.06.046; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Clement JF, 2008, CELL RES, V18, P889, DOI 10.1038/cr.2008.273; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Cui J, 2010, CELL, V141, P483, DOI 10.1016/j.cell.2010.03.040; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Gatot JS, 2007, J BIOL CHEM, V282, P31131, DOI 10.1074/jbc.M701690200; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Gravel SP, 2005, J BIOL CHEM, V280, P7477, DOI 10.1074/jbc.M410392200; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guo BC, 2007, J BIOL CHEM, V282, P11817, DOI 10.1074/jbc.M700017200; Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212; Guo JP, 2009, AM J PATHOL, V175, P324, DOI 10.2353/ajpath.2009.080767; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Ikeda F, 2007, EMBO J, V26, P3451, DOI 10.1038/sj.emboj.7601773; Ikenoue T, 2003, CANCER RES, V63, P8132; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim HS, 2007, CELL SIGNAL, V19, P454, DOI 10.1016/j.cellsig.2006.09.003; Korherr C, 2006, P NATL ACAD SCI USA, V103, P4240, DOI 10.1073/pnas.0511319103; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee DF, 2008, CLIN CANCER RES, V14, P5656, DOI 10.1158/1078-0432.CCR-08-0123; Lerebours F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-41; Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; May MJ, 2004, J BIOL CHEM, V279, P45528, DOI 10.1074/jbc.M408579200; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Michallet MC, 2008, IMMUNITY, V28, P651, DOI 10.1016/j.immuni.2008.03.013; Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Munoz MC, 2009, J ENDOCRINOL, V201, P185, DOI 10.1677/JOE-08-0276; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Parvatiyar K, 2010, J BIOL CHEM, V285, P14999, DOI 10.1074/jbc.M110.109819; Pasparakis M, 2006, CELL DEATH DIFFER, V13, P861, DOI 10.1038/sj.cdd.4401870; Paz S, 2009, MOL CELL BIOL, V29, P3401, DOI 10.1128/MCB.00880-08; Peant B, 2009, PROSTATE, V69, P706, DOI 10.1002/pros.20912; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Renner F, 2010, MOL CELL, V37, P503, DOI 10.1016/j.molcel.2010.01.018; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Ryzhakov G, 2007, EMBO J, V26, P3180, DOI 10.1038/sj.emboj.7601743; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Soulat D, 2008, EMBO J, V27, P2135, DOI 10.1038/emboj.2008.126; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Van Laere SJ, 2006, CLIN CANCER RES, V12, P3249, DOI 10.1158/1078-0432.CCR-05-2800; Wietek C, 2006, J BIOL CHEM, V281, P34973, DOI 10.1074/jbc.M607018200; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yang K, 2006, MOL BIOL CELL, V17, P1461, DOI 10.1091/mbc.E05-09-0853; Yarilina A, 2008, NAT IMMUNOL, V9, P378, DOI 10.1038/ni1576; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang MY, 2008, J BIOL CHEM, V283, P18621, DOI 10.1074/jbc.M801451200	112	107	115	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	6					631	641		10.1038/onc.2010.493	http://dx.doi.org/10.1038/onc.2010.493			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	21042276	Green Accepted			2022-12-28	WOS:000287192000001
J	Pardali, E; van der Schaft, DWJ; Wiercinska, E; Gorter, A; Hogendoorn, PCW; Griffioen, AW; ten Dijke, P				Pardali, E.; van der Schaft, D. W. J.; Wiercinska, E.; Gorter, A.; Hogendoorn, P. C. W.; Griffioen, A. W.; ten Dijke, P.			Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma	ONCOGENE			English	Article						endoglin; tumor cell plasticity; transforming growth factor-beta; bone morphogenetic proteins; Ewing sarcoma; melanoma	VASCULOGENIC MIMICRY; MOLECULAR DETERMINANTS; OSTEOPONTIN EXPRESSION; UVEAL MELANOMA; ANGIOGENESIS; INVASION; PROMOTES; IDENTIFICATION; PROLIFERATION; PROTEIN	Tumor cell plasticity enables certain types of highly malignant tumor cells to dedifferentiate and engage a plastic multipotent embryonic-like phenotype, which enables them to 'adapt' during tumor progression and escape conventional therapeutic strategies. This plastic phenotype of aggressive cancer cells enables them to express endothelial cell-specific markers and form tubelike structures, a phenotype that has been linked to aggressive behavior and poor prognosis. We demonstrate here that the transforming growth factor (TGF)-beta co-receptor endoglin, an endothelial cell marker, is expressed by tumor cells and its expression correlates with tumor cell plasticity in two types of human cancer, Ewing sarcoma and melanoma. Moreover, endoglin expression was significantly associated with worse survival of Ewing sarcoma patients. Endoglin knockdown in tumor cells interferes with tumor cell plasticity and reduces invasiveness and anchorage-independent growth in vitro. Ewing sarcoma and melanoma cells with reduced endoglin levels showed reduced tumor growth in vivo. Mechanistically, we provide evidence that endoglin, while interfering with TGF-beta signaling, is required for efficient bone morphogenetic protein, integrin, focal adhesion kinase and phosphoinositide-3-kinase signaling in order to maintain tumor cell plasticity. The present study delineates an important role of endoglin in tumor cell plasticity and progression of aggressive tumors. Oncogene (2011) 30, 334-345; doi:10.1038/onc.2010.418; published online 20 September 2010	[Pardali, E.; Wiercinska, E.; ten Dijke, P.] Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; [van der Schaft, D. W. J.] Eindhoven Univ Technol, Dept Biomed Engn, Soft Tissue Biomech & Engn, NL-5600 MB Eindhoven, Netherlands; [Gorter, A.; Hogendoorn, P. C. W.] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; [Griffioen, A. W.] Vrije Univ Amsterdam Med Ctr, Angiogenesis Lab, Dept Med Oncol, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Eindhoven University of Technology; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Pardali, E (corresponding author), Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, Bldg 2,Room R-02-024,Postzone S-1-P,Postbus 9600, NL-2300 RC Leiden, Netherlands.	E.Pardali@lumc.nl; p.ten_dijke@lumc.nl	Hogendoorn, Pancras C.W./H-5859-2015; Hogendoorn, Pancras/O-6494-2019; Dijke, Peter ten/AAG-4660-2021	Hogendoorn, Pancras C.W./0000-0002-1513-8104; Hogendoorn, Pancras/0000-0002-1513-8104; Dijke, Peter ten/0000-0002-7234-342X; Wiercinska, Eliza/0000-0002-8434-6492	Centre of Biomedical Genetics, Dutch Cancer Society [RUL 2005-3371]; Ludwig Institute for Cancer Research; EC [504743, 518198, 018814]	Centre of Biomedical Genetics, Dutch Cancer Society(KWF Kankerbestrijding); Ludwig Institute for Cancer Research; EC(European CommissionEuropean Commission Joint Research Centre)	We thank the members of our research groups for help and suggestions during the course of this work. We are grateful to Margriet Ouwens for assistance with PI3K activity assays, Inge Briaire-de Bruijn for excellent technical assistance with the TMA histochemical analysis, Dagmar Berghuis for help with the patient's clinical characteristics, and David de Gorter for critical reading of the paper. This study was supported by grants from the Centre of Biomedical Genetics, Dutch Cancer Society (RUL 2005-3371), the Ludwig Institute for Cancer Research, and FP6 EC Integrated Projects: Angiotargeting (504743), EC STREP Tumor-Host-Genomics (518198) and EuroBoNeT (018814).	Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Ben-Haim N, 2006, DEV CELL, V11, P313, DOI 10.1016/j.devcel.2006.07.005; Bernabeu C, 2009, BBA-MOL BASIS DIS, V1792, P954, DOI 10.1016/j.bbadis.2009.07.003; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Dome B, 2005, INT J CANCER, V116, P27, DOI 10.1002/ijc.20991; El Hallani S, 2010, BRAIN, V133, P973, DOI 10.1093/brain/awq044; Guo BQ, 2004, ANTICANCER RES, V24, P1337; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hendrix MJC, 2002, CANCER RES, V62, P665; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Hess AR, 2003, CANCER RES, V63, P4757; Hess AR, 2001, CANCER RES, V61, P3250; Hillen F, 2008, BIOCHEM BIOPH RES CO, V368, P364, DOI 10.1016/j.bbrc.2008.01.080; Kadkol SS, 2006, INVEST OPHTH VIS SCI, V47, P802, DOI 10.1167/iovs.05-0422; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Mueller AJ, 1998, ARCH OPHTHALMOL-CHIC, V116, P31, DOI 10.1001/archopht.116.1.31; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Rothhammer T, 2005, CANCER RES, V65, P448; Scavelli C, 2008, ONCOGENE, V27, P663, DOI 10.1038/sj.onc.1210691; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Seon BK, 1997, CLIN CANCER RES, V3, P1031; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Shirakawa K, 2002, INT J CANCER, V99, P821, DOI 10.1002/ijc.10423; Sood AK, 2001, AM J PATHOL, V158, P1279, DOI 10.1016/S0002-9440(10)64079-5; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Sun BC, 2007, J CANCER RES CLIN, V133, P979, DOI 10.1007/s00432-007-0245-6; Szuhai K, 2006, CANCER GENET CYTOGEN, V166, P173, DOI 10.1016/j.cancergencyto.2005.11.006; ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/0008-5472.CAN-05-2468; van der Schaft DWJ, 2004, JNCI-J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Wong VCL, 2008, INT J CANCER, V123, P2816, DOI 10.1002/ijc.23882; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x	44	56	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					334	345		10.1038/onc.2010.418	http://dx.doi.org/10.1038/onc.2010.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856203	Green Published			2022-12-28	WOS:000286418800008
J	Xia, M; Knezevic, D; Vassilev, LT				Xia, M.; Knezevic, D.; Vassilev, L. T.			p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation	ONCOGENE			English	Article						p53; MDM2; p21; apoptosis; cell cycle	GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; INHIBITORY-ACTIVITY; SPINDLE CHECKPOINT; SURVIVIN; PATHWAY; MDM2; THERAPY; GENE; PHOSPHORYLATION	p21(Waf1/Cip1) is a p53 transcription target implicated in both major functions of the tumor suppressor-cell cycle arrest and apoptosis. It is a potent inhibitor of the key cyclin-dependent kinases (CDK1-4), and has been thought to be the main mediator of p53-dependent G1 and G2 arrest. However, an increasing body of information suggests that in addition to its cell-cycle inhibitory activity, p21 can affect p53-dependent apoptosis. These data have been obtained from experiments in which p53 is activated primarily by genotoxic stress. In this study, we use the selective MDM2 antagonist, nutlin-3a, as a nongenotoxic p53 activator and show that the cell-cycle arrest function of p21 is dependent on the cellular context. In most cancer cell lines, p53-dependent p21 induction is essential for cell-cycle arrest, but in some, p21 is dispensable. Depletion of p21 did not increase the apoptotic response to nutlin-3a in all seven cancer cell lines tested and p21 overexpression did not protect apoptosis-sensitive lines from death. p21 was found to mediate nutlin-induced p53-dependent downregulation of another antiapoptotic protein, survivin, without significantly affecting the apoptotic outcome. Taken together our results suggest that p21 induction does not affect the apoptotic response to nongenotoxic p53 activation. Oncogene (2011) 30, 346-355; doi:10.1038/onc.2010.413; published online 27 September 2010	[Xia, M.; Knezevic, D.; Vassilev, L. T.] Hoffmann La Roche Inc, Discovery Oncol, Roche Res Ctr, Nutley, NJ 07110 USA	Roche Holding	Vassilev, LT (corresponding author), Hoffmann La Roche Inc, Discovery Oncol, Roche Res Ctr, 340 Kingsland St, Nutley, NJ 07110 USA.	lyubomir.vassilev@roche.com						Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303; Altieri Dario C, 2003, Prog Cell Cycle Res, V5, P447; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chan TA, 2000, GENE DEV, V14, P1584; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Ferrandiz N, 2009, DNA REPAIR, V8, P390, DOI 10.1016/j.dnarep.2008.12.001; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; HARPER JW, 1993, CELL, V75, P805; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Janicke RU, 2007, CELL CYCLE, V6, P407; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Perkins ND, 2002, CELL CYCLE, V1, P39, DOI 10.4161/cc.1.1.98; Qi GY, 2009, ONCOL REP, V22, P557, DOI 10.3892/or_00000471; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Tian H, 2000, CANCER RES, V60, P679; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Xia MX, 2008, CELL CYCLE, V7, P1604, DOI 10.4161/cc.7.11.5929; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang H, 2003, MOL CANCER THER, V2, P1023; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	44	48	48	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					346	355		10.1038/onc.2010.413	http://dx.doi.org/10.1038/onc.2010.413			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20871630				2022-12-28	WOS:000286418800009
J	Stein, SJ; Baldwin, AS				Stein, S. J.; Baldwin, A. S.			NF-kappa B suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death	ONCOGENE			English	Article						IKK beta inhibitor; BCR-ABL; ROS; NF-kappa B; JNK	ALPHA-INDUCED APOPTOSIS; REACTIVE OXYGEN; OXIDATIVE STRESS; C-JUN; TRANSFORMED FIBROBLASTS; IMATINIB RESISTANCE; MEDIATED MECHANISM; SIGNALING PATHWAY; CANCER-CELLS; CML CELLS	Elevated levels of reactive oxygen species (ROS) are found in most oncogenically transformed cells and are proposed to promote cellular transformation through mechanisms such as inhibition of phosphatases. BCR-ABL, the oncoprotein associated with the majority of chronic myeloid leukemias (CMLs), induces accumulation of intracellular ROS, causing enhanced signaling down-stream of PI3K. Previously we have shown that the transcription factor nuclear factor-kappa B (NF-kappa B) is activated by BCR-ABL expression and is required for BCR-ABL-mediated cellular transformation. Inhibition of I kappa B kinase (IKK beta) and NF-kappa B leads to cell death through an unknown mechanism. Here, we analyze the potential involvement of NF-kappa B in moderating BCR-ABL-induced ROS levels to protect from death. The data confirm that BCR-ABL promotes ROS and demonstrate that NF-kappa B prevents excessive levels. Inhibition of NF-kappa B leads to an increase in ROS levels and to cell death, which is at least partially controlled through ROS-induced c-Jun N-terminal kinase activity. The data demonstrate that one function for NF-kappa B in oncogenesis is the suppression of oncoprotein-induced ROS levels and that inhibition of NF-jB in some cancers, including CML, will increase ROS levels and promote cell death. Oncogene (2011) 30, 4557-4566; doi: 10.1038/onc.2011.156; published online 30 May 2011	[Baldwin, A. S.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Baldwin, A. S.] Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, 22-000 LCCC,CB 7295, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			Leukemia and Lymphoma Society; NIH [CA73756, CA75080]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA075080, R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Justina Chen for technical support and members of the Baldwin lab for advice and discussion. We acknowledge grant support from the Leukemia and Lymphoma Society, from the NIH (CA73756 and CA75080), and from the Samuel Waxman Cancer Research Foundation.	Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Chandra J, 2006, BLOOD, V107, P2501, DOI 10.1182/blood-2005-07-2966; Cilloni D, 2006, LEUKEMIA, V20, P61, DOI 10.1038/sj.leu.2403998; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Duncan EA, 2008, MOL CANCER THER, V7, P391, DOI 10.1158/1535-7163.MCT-07-0305; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Iida T, 2001, NEURO-ONCOLOGY, V3, P73, DOI 10.1093/neuonc/3.2.73; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim JH, 2005, BLOOD, V105, P1717, DOI 10.1182/blood-2004-03-0849; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Mao X, 2008, CELL RES, V18, P879, DOI 10.1038/cr.2008.86; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Naughton R, 2009, LEUKEMIA, V23, P1432, DOI 10.1038/leu.2009.49; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schimmel M, 2002, ONCOGENE, V21, P5886, DOI 10.1038/sj.onc.1205740; Senthil K, 2004, CLIN CHIM ACTA, V339, P27, DOI 10.1016/j.cccn.2003.08.017; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhang H, 2008, LEUKEMIA, V22, P1191, DOI 10.1038/leu.2008.74; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	50	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 10	2011	30	45					4557	4566		10.1038/onc.2011.156	http://dx.doi.org/10.1038/onc.2011.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21625221	Green Accepted, Green Submitted			2022-12-28	WOS:000296890700003
J	Burnier, JV; Wang, N; Michel, RP; Hassanain, M; Li, S; Lu, Y; Metrakos, P; Antecka, E; Burnier, MN; Ponton, A; Gallinger, S; Brodt, P				Burnier, J. V.; Wang, N.; Michel, R. P.; Hassanain, M.; Li, S.; Lu, Y.; Metrakos, P.; Antecka, E.; Burnier, M. N.; Ponton, A.; Gallinger, S.; Brodt, P.			Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis	ONCOGENE			English	Article						metastasis; liver; extracellular matrix; collagen IV; anoikis	FOCAL ADHESION KINASE; PANCREATIC ADENOCARCINOMA CELLS; MEMBRANE PROTEINS PLAY; VON-HIPPEL-LINDAU; BASEMENT-MEMBRANE; FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; CARCINOMA-CELLS; TUMOR-METASTASIS	The liver is a major site of metastasis for human malignancies, yet the factors that regulate tumor cell survival and growth in this organ remain elusive. Previously, we reported that M-27(IGF-IR) murine lung carcinoma cells with ectopic insulin-like growth factor-1 (IGF-I) receptor overexpression acquired a site-specific, liver-metastasizing potential. Gene expression profiling and subsequent RNA and protein analyses revealed that this was associated with major changes to the expression of extracellular matrix (ECM) protein-encoding genes including type III, IV and XVIII collagen genes, and these changes were also observed in the respective tumors in vivo. Because type IV collagen was the most prominently altered ECM protein in this model, we further analyzed its functional relevance to liver metastasis. M-27 cells stably overexpressing type IV collagen alpha 1 and alpha 2 chains were generated and their growth and metastatic properties investigated. We found that these cells acquired a site-selective growth advantage in the liver and this was associated with cell rescue from anoikis in a collagen IV/alpha 2 integrin/FAK-dependent manner and increased responsiveness to IGF-I. Conversely, collagen IV or focal adhesion kinase (FAK) silencing by small-interfering RNA in highly metastatic tumor cells enhanced anoikis and decreased liver metastases formation. Moreover, analysis of human surgical specimens revealed uniformly high collagen IV expression in 65/65 hepatic metastases analyzed, regardless of tissue of origin, whereas it was variable and generally low in 50/50 primary colorectal carcinoma specimens examined. The results suggest that collagen IV-conveyed signals are essential cues for liver metastasis in diverse tumor types and identify mediators of collagen IV signaling as potential therapeutic targets in the management of hepatic metastases. Oncogene (2011) 30, 3766-3783; doi:10.1038/onc.2011.89; published online 11 April 2011	[Burnier, J. V.; Wang, N.; Hassanain, M.; Li, S.; Lu, Y.; Metrakos, P.; Burnier, M. N.; Brodt, P.] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; [Wang, N.; Hassanain, M.; Lu, Y.; Metrakos, P.; Brodt, P.] McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; [Michel, R. P.; Antecka, E.; Burnier, M. N.] McGill Univ, Dept Surg, Montreal, PQ H3A 1A1, Canada; [Michel, R. P.; Burnier, M. N.; Brodt, P.] McGill Univ, Dept Pathol, Montreal, PQ H3A 1A1, Canada; [Burnier, M. N.] McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; [Ponton, A.] McGill Univ, Dept Ophthalmol, Montreal, PQ H3A 1A1, Canada; [Gallinger, S.] Univ Hlth Network Toronto, Mt Sinai Hosp, Dept Surg, Toronto, ON, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University Health Network Toronto	Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Room H6-25,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	pnina.brodt@mcgill.ca	Gallinger, Steven/E-4575-2013; metrakos, peter/D-3726-2013; Hassanain, Mazen/C-7256-2011	Hassanain, Mazen/0000-0002-2441-5142; burnier, julia/0000-0002-2184-2157	Canadian Institute for Health Research [MOP-81201]; Research Institute of the McGill University Health Center; Stewart family award for Cancer Research	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Research Institute of the McGill University Health Center; Stewart family award for Cancer Research	We thank Dr Zelia Correa (Department of Ophthalmology, University of Cincinnati) for the kind gift of the uveal melanoma specimens, Dr Yoshihiko Yamada for collagen IV alpha 1 and alpha 2 plasmids, Dr Taina Pihlajaniemi for antibodies to collagen XVIII and Ms Boram Ham for her help with the submission. This work was supported by Grant MOP-81201 from the Canadian Institute for Health Research (to PB). JVB was supported by a doctoral fellowship from the Research Institute of the McGill University Health Center and PB is a recipient of the Stewart family award for Cancer Research.	All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; Andersson S, 2009, BIOCHEM BIOPH RES CO, V387, P36, DOI 10.1016/j.bbrc.2009.06.088; BARSKY SH, 1983, LANCET, V1, P296; Beattie J, 2010, J CELL PHYSIOL, V224, P605, DOI 10.1002/jcp.22183; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brooks SA, 2010, ACTA HISTOCHEM, V112, P3, DOI 10.1016/j.acthis.2008.11.022; Catusse C, 2000, J HISTOCHEM CYTOCHEM, V48, P663, DOI 10.1177/002215540004800510; Clark RAF, 2008, J INVEST DERMATOL, V128, P1354, DOI 10.1038/jid.2008.75; Clemmons DR, 2003, ENDOCRINOLOGY, V144, P1664, DOI 10.1210/en.2002-221102; Decker NK, 2008, AM J PATHOL, V173, P1002, DOI 10.2353/ajpath.2008.080158; Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Edderkaoui M, 2007, J BIOL CHEM, V282, P26646, DOI 10.1074/jbc.M702836200; Enns AE, 2004, J GASTROINTEST SURG, V8, P1049, DOI 10.1016/j.gassur.2004.08.016; ERIN N, 2009, INT J CANCER, V124, P14; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; FENYVESI A, 2003, ARCH ONCOL, V11, P15; Furukawa M, 2005, CLIN CANCER RES, V11, P3233, DOI 10.1158/1078-0432.CCR-04-1915; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Goel HL, 2005, CANCER RES, V65, P6692, DOI 10.1158/0008-5472.CAN-04-4315; Goel HL, 2004, J CELL BIOL, V166, P407, DOI 10.1083/jcb.200403003; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Gulubova MV, 2004, CLIN EXP METASTAS, V21, P485, DOI 10.1007/s10585-004-3171-x; Gydee H, 2004, PEDIATR RES, V55, P709, DOI 10.1203/01.PDR.0000111282.98401.93; Habeck M, 2001, DRUG DISCOV TODAY, V6, P1077, DOI 10.1016/S1359-6446(01)02023-2; HAVENITH MG, 1988, CANCER-AM CANCER SOC, V62, P2207, DOI 10.1002/1097-0142(19881115)62:10<2207::AID-CNCR2820621023>3.0.CO;2-L; Hiki Y, 2002, PATHOL INT, V52, P224, DOI 10.1046/j.1440-1827.2002.01341.x; Iglesias-de la Cruz MC, 2002, KIDNEY INT, V62, P901, DOI 10.1046/j.1523-1755.2002.00528.x; Ikeda K, 2006, AM J PATHOL, V168, P856, DOI 10.2353/ajpath.2006.050384; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeschke MG, 2005, WOUND REPAIR REGEN, V13, P269, DOI 10.1111/j.1067-1927.2005.130309.x; Kahana O, 2002, ONCOGENE, V21, P3969, DOI 10.1038/sj.onc.1205472; Khoshnoodi J, 2008, MICROSC RES TECHNIQ, V71, P357, DOI 10.1002/jemt.20564; Krensel K, 1999, INT J CANCER, V80, P546, DOI 10.1002/(SICI)1097-0215(19990209)80:4<546::AID-IJC11>3.0.CO;2-9; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Liu GY, 2008, CELL BIOL INT, V32, P663, DOI 10.1016/j.cellbi.2008.01.292; Liu WG, 2008, CARCINOGENESIS, V29, P1096, DOI 10.1093/carcin/bgn026; LONG L, 1995, CANCER RES, V55, P1006; Macri L, 2007, ADV DRUG DELIVER REV, V59, P1366, DOI 10.1016/j.addr.2007.08.015; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; Meir T, 2007, INVEST OPHTH VIS SCI, V48, P4890, DOI 10.1167/iovs.07-0215; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Miyamoto S, 2008, ADV EXP MED BIOL, V622, P281, DOI 10.1007/978-0-387-68969-2_23; Nadal C, 2007, WORLD J GASTROENTERO, V13, P5832, DOI 10.3748/wjg.v13.i44.5832; Nakano S, 1999, LAB INVEST, V79, P281; Neubauer K, 2001, CAN J GASTROENTEROL, V15, P187, DOI 10.1155/2001/870205; Oshima T, 2008, ONCOL REP, V20, P359, DOI 10.3892/or_00000015; PAGET S, 1989, CANCER METAST REV, V8, P98; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Rosenow Felix, 2008, Neoplasia, V10, P168, DOI 10.1593/neo.07898; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Sawai H, 2008, J SURG RES, V144, P117, DOI 10.1016/j.jss.2007.03.023; SCHAPERS RFM, 1990, CANCER, V66, P2583, DOI 10.1002/1097-0142(19901215)66:12<2583::AID-CNCR2820661222>3.0.CO;2-S; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Steenhard BM, 2010, AM J PATHOL, V177, P84, DOI 10.2353/ajpath.2010.090767; Tanaka K, 1997, HISTOCHEM J, V29, P563, DOI 10.1023/A:1026428010104; Tang YC, 2003, CANCER RES, V63, P1166; Theret N, 2001, HEPATOLOGY, V34, P82, DOI 10.1053/jhep.2001.25758; Tian B, 2005, J CANCER RES CLIN, V131, P80, DOI 10.1007/s00432-004-0614-3; Ueda S, 2006, MODERN PATHOL, V19, P788, DOI 10.1038/modpathol.3800582; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; Vidal-Vanaclocha F, 2008, CANCER MICROENVIRON, V1, P113, DOI 10.1007/s12307-008-0011-6; Wang JY, 2006, J NEUROSCI RES, V83, P7, DOI 10.1002/jnr.20712; Wang N, 2006, CANCER RES, V66, P3062, DOI 10.1158/0008-5472.CAN-05-2638; Wang N, 2009, MOL THER, V17, P1241, DOI 10.1038/mt.2009.82; Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345; Xie YT, 1999, CANCER RES, V59, P3588; Yakar S, 2006, ENDOCRINOLOGY, V147, P5826, DOI 10.1210/en.2006-0311; Yang CQ, 2003, GASTROENTEROLOGY, V124, P147, DOI 10.1053/gast.2003.50012; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; Zeisberg M, 2006, MOL CELL BIOCHEM, V283, P181, DOI 10.1007/s11010-006-2677-8; Zha JP, 2010, CLIN CANCER RES, V16, P2512, DOI 10.1158/1078-0432.CCR-09-2232; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	83	70	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	35					3766	3783		10.1038/onc.2011.89	http://dx.doi.org/10.1038/onc.2011.89			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21478904				2022-12-28	WOS:000294481400004
J	Gill, RK; Yang, SH; Meerzaman, D; Mechanic, LE; Bowman, ED; Jeon, HS; Chowdhuri, SR; Shakoori, A; Dracheva, T; Hong, KM; Fukuoka, J; Zhang, JH; Harris, CC; Jen, J				Gill, R. K.; Yang, S-H; Meerzaman, D.; Mechanic, L. E.; Bowman, E. D.; Jeon, H-S; Chowdhuri, S. Roy; Shakoori, A.; Dracheva, T.; Hong, K-M; Fukuoka, J.; Zhang, J-H; Harris, C. C.; Jen, J.			Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer	ONCOGENE			English	Article						LKB1 gene; LOH; homozygous deletion; mutation; CISH; primary lung cancer	PEUTZ-JEGHERS-SYNDROME; TUMOR-SUPPRESSOR GENE; SOMATIC MUTATIONS; GLUCOSE-HOMEOSTASIS; LKB1; KINASE; PATHWAYS; KNOCKOUT; PTEN; ADENOCARCINOMA	LKB1/STK11 is a tumor suppressor and a negative regulator of mammalian target of rapamycin signaling. It is inactivated in 30% of lung cancer cell lines but only 5-15% of primary lung adenocarcinomas. There is evidence that homozygous deletion (HD) of chromosome 19p at the LKB locus contributes to the inactivation of the gene in primary human lung cancers. Here, we used several complementary genetic approaches to assess the LKB1 locus in primary non-small cell lung cancers (NSCLCs). We first analyzed 124 NSCLC cases for allelic imbalance using eight microsatellite markers on chromosome 19p, which revealed an overall rate of 65% (80 of 124) loss of heterozygosity (LOH). We next used chromogenic in situ hybridization (CISH) to directly examine the chromosomal status of the LKB1 locus. In all, 65 of 124 LOH tested samples were available for CISH and 58 of those (89%) showed either loss of one copy of chromosome 19p (LOH, 40 of 65 cases, 62%) or both copies (HD 18 of 65 cases, 28%). The occurrence of HD was significantly more frequent in Caucasian (35%) than in African-American patients (6%) (P = 0.04). A total of 62 of 124 samples with LOH at one or both markers immediately flanking the LKB1 gene were further analyzed by directly sequencing the complete coding region, which identified 7 of 62 (11%) tumors with somatic mutations in the gene. Jointly, our data identified total inactivation of the LKB1 gene by either HD or LOH with somatic mutation in 39% of tested samples, whereas loss of chromosome 19p region by HD or LOH at the LKB1 region occured in 90% of NSCLC. Oncogene (2011) 30, 3784-3791; doi:10.1038/onc.2011.98; published online 2 May 2011	[Jen, J.] Mayo Clin Fdn, Div Pulm & Crit Care Med & Microarray Shared Reso, Rochester, MN USA; [Gill, R. K.; Yang, S-H; Mechanic, L. E.; Bowman, E. D.; Jeon, H-S; Shakoori, A.; Dracheva, T.; Fukuoka, J.; Harris, C. C.] NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA; [Meerzaman, D.; Chowdhuri, S. Roy; Hong, K-M; Zhang, J-H] NCI, Lab Populat Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Hong, K-M] Natl Canc Ctr, Res Inst, Goyang, South Korea	Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Korea (NCC)	Jen, J (corresponding author), Mayo Clin, Div Pulm & Crit Care Med & Microarray Shared Reso, Adv Genom Technol Ctr, Stabile 13-74,200 1st St SW, Rochester, MN 55905 USA.	Jen.Jin@mayo.edu	SHAKOORI, ABDUL RAUF/Q-9373-2019; Fukuoka, Junya/AAT-2924-2021	Fukuoka, Junya/0000-0002-2496-3050; shakoori, abbas/0000-0002-4363-1967; Roy-Chowdhuri, Sinchita/0000-0002-9447-7701	Center for Cancer Research at CCR; Mayo Cancer Center; Center for Individualized Medicine, Rochester, MN; NATIONAL CANCER INSTITUTE [P30CA015083, Z01CP010164, ZIABC010874] Funding Source: NIH RePORTER	Center for Cancer Research at CCR; Mayo Cancer Center; Center for Individualized Medicine, Rochester, MN; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank John Cottrell, Ray Jones, Audrey Salabes and Mike Lipsky at University of Maryland Medical Center for tissue collection and clinical information. We thank the members of Dr. Thomas Reid's lab for technical support during the course of this study. We thank Ms Stacy Johnson for editorial and graphical/technical assistance. The current addresses are RKG, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, Bethesda, MD 20892-4258; SHY, Wonkwang University Hospital, Department of Pulmonary and Critical Care Medicine, Iksan, South Korea; HSJ, Laboratory of Biochemistry and Cell Biology, Kyungpook National University, School of Medicine, Deagu, South Korea; SRC, Laboratory of Pathology, National Cancer Institute, Bethesda, MD; AS, Department of Medical Genetics, Tehran University of Medical Sciences, Cancer Institute Hospital, Tehran, Iran; TVD, J. Craig Venter Institute, Rockville, MD; KMH, National Cancer Center, Cancer Cell and Molecular Biology Branch, Goyang, Korea; JF, Toyama University Hospital, Department of Surgical Pathology, Toyama, Japan; and JHZ, St. Jude Children's Research Hospital, Biotechnology, Memphis, TN. This work was supported by intramural research funds from the Center for Cancer Research at CCR and funds for JJ from the Mayo Cancer Center and Center for Individualized Medicine, Rochester, MN.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bignell GR, 1998, CANCER RES, V58, P1384; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Conde E, 2007, HUM PATHOL, V38, P1351, DOI 10.1016/j.humpath.2007.01.022; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Gill RK, 2008, CLIN CANCER RES, V14, P7481, DOI 10.1158/1078-0432.CCR-07-5242; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Koh HJ, 2006, MOL CELL BIOL, V26, P8217, DOI 10.1128/MCB.00979-06; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lim W, 2003, BRIT J CANCER, V89, P308, DOI 10.1038/sj.bjc.6601030; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; Luukko K, 1999, MECH DEVELOP, V83, P187, DOI 10.1016/S0925-4773(99)00050-7; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Mechanic LE, 2005, CARCINOGENESIS, V26, P597, DOI 10.1093/carcin/bgh344; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; Zhong DS, 2006, LUNG CANCER, V53, P285, DOI 10.1016/j.lungcan.2006.05.018	44	80	85	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3784	3791		10.1038/onc.2011.98	http://dx.doi.org/10.1038/onc.2011.98			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21532627	Green Accepted			2022-12-28	WOS:000294481400005
J	Lemarie, A; Grimm, S				Lemarie, A.; Grimm, S.			Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer	ONCOGENE			English	Review						apoptosis; respiratory chain; reactive oxygen species; mitochondria	ELECTRON-TRANSPORT-CHAIN; SUCCINATE-UBIQUINONE OXIDOREDUCTASE; OXYGEN SPECIES GENERATION; GASTROINTESTINAL STROMAL TUMORS; OXIDATIVELY DAMAGED PROTEINS; EHRLICH ASCITES TUMOR; CYTOCHROME-C-OXIDASE; DEPENDENT CELL-DEATH; SDHD GENE-MUTATIONS; DNA MUTATIONS	Mutations in cancer cells affecting subunits of the respiratory chain (RC) indicate a central role of oxidative phosphorylation for tumourigenesis. Recent studies have suggested that such mutations of RC complexes impact apoptosis induction. We review here the evidence for this hypothesis, which in particular emerged from work on how complex I and II mediate signals for apoptosis. Both protein aggregates are specifically inhibited for apoptosis induction through different means by exploiting with protease activation and pH change, two widespread but independent features of dying cells. Nevertheless, both converge on forming reactive oxygen species for the demise of the cell. Investigations into these mitochondrial processes will remain a rewarding area for unravelling the causes of tumourigenesis and for discovering interference options. Oncogene (2011) 30, 3985-4003; doi:10.1038/onc.2011.167; published online 30 May 2011	[Lemarie, A.] Univ Toulouse 3, INSERM CRCT U1037, Dept Expt Therapeut, Inst Claudius Regaud, F-31052 Toulouse, France; [Lemarie, A.] Univ Toulouse 3, Fac Pharmaceut Sci, F-31052 Toulouse, France; [Grimm, S.] Univ London Imperial Coll Sci Technol & Med, Dept Expt Med & Toxicol, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Imperial College London	Lemarie, A (corresponding author), Univ Toulouse 3, INSERM CRCT U1037, Dept Expt Therapeut, Inst Claudius Regaud, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	lemarie.anthony@claudiusregaud.fr; s.grimm@imperial.ac.uk	LEMARIE, Anthony/G-4018-2017	LEMARIE, Anthony/0000-0002-6523-4962	Cancer Research UK; la Ligue Nationale Contre le Cancer (Hautes-Pyrenees and Haute-Garonne committees); Wellcome Trust; CRUK; MRC; Breast Cancer Campaign	Cancer Research UK(Cancer Research UK); la Ligue Nationale Contre le Cancer (Hautes-Pyrenees and Haute-Garonne committees); Wellcome Trust(Wellcome TrustEuropean Commission); CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Campaign	We acknowledge the financial support from Cancer Research UK (to AL and SG) as well as from la Ligue Nationale Contre le Cancer (Hautes-Pyrenees and Haute-Garonne committees; to AL) and support by the Wellcome Trust, CRUK, MRC, Breast Cancer Campaign (to SG).	Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; Akhmedov D, 2010, FASEB J, V24, P4613, DOI 10.1096/fj.10-162222; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Amar L, 2005, J CLIN ONCOL, V23, P8812, DOI 10.1200/JCO.2005.03.1484; Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709; Arrington DD, 2006, AM J PHYSIOL-CELL PH, V291, pC1159, DOI 10.1152/ajpcell.00207.2006; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bayley JP, 2010, CURR OPIN GENET DEV, V20, P324, DOI 10.1016/j.gde.2010.02.008; Bayley JP, 2010, LANCET ONCOL, V11, P366, DOI 10.1016/S1470-2045(10)70007-3; Bayley JP, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-39; Baysal BE, 2008, J MED GENET, V45, P689, DOI 10.1136/jmg.2008.058560; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Belevich I, 2008, ANTIOXID REDOX SIGN, V10, P1, DOI 10.1089/ars.2007.1705; Benit P, 2009, BBA-MOL CELL RES, V1793, P181, DOI 10.1016/j.bbamcr.2008.06.004; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Blank A, 2010, ENDOCR-RELAT CANCER, V17, P919, DOI 10.1677/ERC-09-0316; Boedeker CC, 2007, OTOLARYNG HEAD NECK, V137, P126, DOI 10.1016/j.otohns.2007.01.015; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Brockmann K, 2002, ANN NEUROL, V52, P38, DOI 10.1002/ana.10232; Brusque AM, 2002, NEUROCHEM INT, V40, P593, DOI 10.1016/S0197-0186(01)00130-9; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Burnichon N, 2009, J CLIN ENDOCR METAB, V94, P2817, DOI 10.1210/jc.2008-2504; Byun HO, 2008, J CELL BIOCHEM, V104, P1747, DOI 10.1002/jcb.21741; Campanella M, 2009, TRENDS BIOCHEM SCI, V34, P343, DOI 10.1016/j.tibs.2009.03.006; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cervera AM, 2008, CANCER RES, V68, P4058, DOI 10.1158/0008-5472.CAN-07-5580; Chen CL, 2008, J BIOL CHEM, V283, P27991, DOI 10.1074/jbc.M802691200; Chen YR, 2007, J BIOL CHEM, V282, P32640, DOI 10.1074/jbc.M702294200; Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163; Chen Z, 2010, ONCOGENE, V29, P4362, DOI 10.1038/onc.2010.193; Choksi KB, 2008, FREE RADICAL BIO MED, V45, P826, DOI 10.1016/j.freeradbiomed.2008.06.006; Choksi KB, 2007, FREE RADICAL BIO MED, V43, P1423, DOI 10.1016/j.freeradbiomed.2007.07.027; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cullen SP, 2008, CELL DEATH DIFFER, V15, P251, DOI 10.1038/sj.cdd.4402244; Cuperus R, 2010, CELL MOL LIFE SCI, V67, P807, DOI 10.1007/s00018-009-0212-2; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Dayal D, 2009, RADIAT RES, V172, P737, DOI 10.1667/RR1617.1; Dekker PBD, 2003, J PATHOL, V201, P480, DOI 10.1002/path.1461; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; Diaz F, 2010, BBA-MOL BASIS DIS, V1802, P100, DOI 10.1016/j.bbadis.2009.07.013; Diaz-Ruiz R, 2008, J BIOL CHEM, V283, P26948, DOI 10.1074/jbc.M800408200; Diaz-Ruiz R, 2011, BBA-BIOENERGETICS, V1807, P568, DOI 10.1016/j.bbabio.2010.08.010; Dibrov E, 1998, J BIOL CHEM, V273, P32042, DOI 10.1074/jbc.273.48.32042; Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058; Dong LF, 2008, ONCOGENE, V27, P4324, DOI 10.1038/onc.2008.69; Dong LF, 2007, CANCER RES, V67, P11906, DOI 10.1158/0008-5472.CAN-07-3034; Dong LF, 2011, FREE RADICAL BIO MED, V50, P1546, DOI 10.1016/j.freeradbiomed.2011.02.032; Dong LF, 2011, J BIOL CHEM, V286, P3717, DOI 10.1074/jbc.M110.186643; Dong LF, 2009, CLIN CANCER RES, V15, P1593, DOI 10.1158/1078-0432.CCR-08-2439; Favier J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007094; Feichtinger Rene G, 2011, Front Biosci (Elite Ed), V3, P194, DOI 10.2741/e233; Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013; Fiorucci S, 2004, J IMMUNOL, V173, P874, DOI 10.4049/jimmunol.173.2.874; Frezza C, 2009, SEMIN CANCER BIOL, V19, P4, DOI 10.1016/j.semcancer.2008.11.008; Gasparre G, 2008, HUM MOL GENET, V17, P986, DOI 10.1093/hmg/ddm371; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghezzi D, 2009, NAT GENET, V41, P654, DOI 10.1038/ng.378; Gimenez-Roqueplo AP, 2008, CLIN EXP PHARMACOL P, V35, P376, DOI 10.1111/j.1440-1681.2008.04881.x; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Gogvadze V, 2010, MOL ASPECTS MED, V31, P60, DOI 10.1016/j.mam.2009.12.004; Gogvadze V, 2009, SEMIN CANCER BIOL, V19, P57, DOI 10.1016/j.semcancer.2008.11.007; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Habano W, 2003, ONCOL REP, V10, P1375; HALICKA HD, 1995, CANCER RES, V55, P444; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802; HEINZ A, 1981, J MEMBRANE BIOL, V61, P143, DOI 10.1007/BF01870520; HENSEN EF, 2011, FAM CANC; Hervouet E, 2008, CARCINOGENESIS, V29, P1528, DOI 10.1093/carcin/bgn125; Horvath R, 2006, J NEUROL NEUROSUR PS, V77, P74, DOI 10.1136/jnnp.2005.067041; Huang JZ, 2009, J MOL BIOL, V387, P559, DOI 10.1016/j.jmb.2009.02.028; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii N, 2007, MITOCHONDRION, V7, P24, DOI 10.1016/j.mito.2006.11.012; Ishii T, 2005, CANCER RES, V65, P203; Ishii T, 2011, MITOCHONDRION, V11, P155, DOI 10.1016/j.mito.2010.09.006; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Klanner C, 2000, FEBS LETT, V470, P365, DOI 10.1016/S0014-5793(00)01322-3; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103; Kwong JQ, 2007, J CELL BIOL, V179, P1163, DOI 10.1083/jcb.200704059; Lagadic-Gossmann D, 2004, CELL DEATH DIFFER, V11, P953, DOI 10.1038/sj.cdd.4401466; Lartigue L, 2009, MOL BIOL CELL, V20, P4871, DOI 10.1091/mbc.E09-07-0649; Le SB, 2007, J BIOL CHEM, V282, P8860, DOI 10.1074/jbc.M611777200; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lehtonen HJ, 2007, INT J CANCER, V121, P1386, DOI 10.1002/ijc.22819; Lemarie A, 2011, CELL DEATH DIFFER, V18, P338, DOI 10.1038/cdd.2010.93; Lemarie A, 2009, MITOCHONDRION, V9, P254, DOI 10.1016/j.mito.2009.03.004; Lenaz G, 2010, ANTIOXID REDOX SIGN, V12, P961, DOI 10.1089/ars.2009.2704; Levitas A, 2010, EUR J HUM GENET, V18, P1160, DOI 10.1038/ejhg.2010.83; Liot G, 2009, CELL DEATH DIFFER, V16, P899, DOI 10.1038/cdd.2009.22; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69; Maklashina E, 2010, BBA-BIOENERGETICS, V1797, P1877, DOI 10.1016/j.bbabio.2010.02.015; Mandavilli BS, 2005, MOL BRAIN RES, V133, P215, DOI 10.1016/j.molbrainres.2004.10.033; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Martinvalet D, 2008, CELL, V133, P681, DOI 10.1016/j.cell.2008.03.032; Mason MG, 2006, P NATL ACAD SCI USA, V103, P708, DOI 10.1073/pnas.0506562103; Mast JD, 2008, DEVELOPMENT, V135, P2669, DOI 10.1242/dev.020644; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mbaya E, 2010, CELL DEATH DIFFER, V17, P1855, DOI 10.1038/cdd.2010.51; McLaughlin BA, 1998, NEUROSCIENCE, V86, P279, DOI 10.1016/S0306-4522(97)00594-0; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; McWhinney SR, 2007, NEW ENGL J MED, V357, P1054, DOI 10.1056/NEJMc071191; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miyadera H, 2003, P NATL ACAD SCI USA, V100, P473, DOI 10.1073/pnas.0237315100; Moreira PI, 2006, J BIOL CHEM, V281, P10143, DOI 10.1074/jbc.M510249200; Muntane J, 2010, WORLD J HEPATOL, V2, P337, DOI 10.4254/wjh.v2.i9.337; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; OOSTVEEN FG, 1995, J BIOL CHEM, V270, P26104, DOI 10.1074/jbc.270.44.26104; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Oyedotun KS, 2007, BBA-BIOENERGETICS, V1767, P1436, DOI 10.1016/j.bbabio.2007.09.008; Paddenberg R, 2003, AM J PHYSIOL-LUNG C, V284, pL710, DOI 10.1152/ajplung.00149.2002; Pagnamenta AT, 2006, MOL GENET METAB, V89, P214, DOI 10.1016/j.ymgme.2006.05.003; Pang Z, 1997, J NEUROSCI, V17, P3064; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033; Park JS, 2009, HUM MOL GENET, V18, P1578, DOI 10.1093/hmg/ddp069; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Piantadosi CA, 2008, J BIOL CHEM, V283, P10967, DOI 10.1074/jbc.M709741200; Pollard PJ, 2006, J CLIN ENDOCR METAB, V91, P4593, DOI 10.1210/jc.2006-0920; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Prochazka L, 2010, APOPTOSIS, V15, P782, DOI 10.1007/s10495-010-0482-z; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Putignani L, 2008, BREAST CANCER RES TR, V110, P439, DOI 10.1007/s10549-007-9738-x; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Ralph SJ, 2009, MOL NUTR FOOD RES, V53, P7, DOI 10.1002/mnfr.200890054; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Rikka S, 2011, CELL DEATH DIFFER, V18, P721, DOI 10.1038/cdd.2010.146; Rodriguez-Enriquez S, 2001, EUR J BIOCHEM, V268, P2512, DOI 10.1046/j.1432-1327.2001.02140.x; Rutter J, 2010, MITOCHONDRION, V10, P393, DOI 10.1016/j.mito.2010.03.001; Ryland LK, 2011, CANCER BIOL THER, V11, P138, DOI 10.4161/cbt.11.2.14624; Schapira AHV, 2010, EXP NEUROL, V224, P331, DOI 10.1016/j.expneurol.2010.03.028; Schimke RN, 2010, AM J MED GENET A, V152A, P1531, DOI 10.1002/ajmg.a.33384; Schlisio S, 2008, GENE DEV, V22, P884, DOI 10.1101/gad.1648608; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Selak MA, 2006, BBA-BIOENERGETICS, V1757, P567, DOI 10.1016/j.bbabio.2006.05.015; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Senoo-Matsuda N, 2003, J BIOL CHEM, V278, P22031, DOI 10.1074/jbc.M211377200; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Siskind LJ, 2005, J BIOENERG BIOMEMBR, V37, P143, DOI 10.1007/s10863-005-6567-7; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Smith EH, 2007, HUM MOL GENET, V16, P3136, DOI 10.1093/hmg/ddm275; Solaini G, 2010, BBA-BIOENERGETICS, V1797, P1171, DOI 10.1016/j.bbabio.2010.02.011; Soller M, 2007, MOL PHARMACOL, V71, P1535, DOI 10.1124/mol.107.034371; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Szeto SSW, 2007, J BIOL CHEM, V282, P27518, DOI 10.1074/jbc.M700601200; Tran QM, 2007, P NATL ACAD SCI USA, V104, P18007, DOI 10.1073/pnas.0707732104; Tran QM, 2006, J BIOL CHEM, V281, P32310, DOI 10.1074/jbc.M607476200; Van Coster R, 2003, AM J MED GENET A, V120A, P13, DOI 10.1002/ajmg.a.10202; van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0; Vander Heiden MG, 2002, J BIOL CHEM, V277, P44870, DOI 10.1074/jbc.M204888200; Waldmann J, 2009, ENDOCRINE, V35, P347, DOI 10.1007/s12020-009-9178-y; Walker DW, 2006, P NATL ACAD SCI USA, V103, P16382, DOI 10.1073/pnas.0607918103; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; WINK DA, 2008, NITRIC OXIDE, V19, P192; Wojtczak L, 1996, ACTA BIOCHIM POL, V43, P361; Wojtczak L, 1999, EUR J BIOCHEM, V263, P495, DOI 10.1046/j.1432-1327.1999.00522.x; Xu RH, 2005, CANCER RES, V65, P613; Yang XL, 1997, AM J PHYSIOL-ENDOC M, V272, pE173, DOI 10.1152/ajpendo.1997.272.1.E173; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; Zhao ZW, 2006, BIOCHEM CELL BIOL, V84, P1013, DOI 10.1139/O06-188	196	83	85	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					3985	4003		10.1038/onc.2011.167	http://dx.doi.org/10.1038/onc.2011.167			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21625217	Bronze			2022-12-28	WOS:000295121600001
J	Zhang, Q; Zhong, Q; Evans, AG; Levy, D; Zhong, S				Zhang, Q.; Zhong, Q.; Evans, A. G.; Levy, D.; Zhong, S.			Phosphorylation of histone H3 serine 28 modulates RNA polymerase III-dependent transcription	ONCOGENE			English	Article						phosphorylation; histone H3; EGFR; Pol III transcription; Brf1; cell transformation	B-INDUCED PHOSPHORYLATION; ONCOGENIC TRANSFORMATION; CHROMOSOME CONDENSATION; POL II; GROWTH; TFIIIB; GENES; TRICHOSTATIN; ACETYLATION; DEACETYLASE	Deregulation of RNA polymerase III (Pol III) transcription enhances cellular tRNAs and 5S rRNA production, leading to an increase in translational capacity to promote cell proliferation, transformation and tumor formation. Phosphorylation of histone H3 (H3ph) is induced by tumor promoters (EGF, UV and TPA) and immediate early genes, such as c-myc, c-jun and c-fos. However, it remains to be determined whether H3ph is involved in RNA Pol III transcription. Here, we report that EGF strongly induced H3ph at serine 28 (H3S28ph). EGF significantly increased transcription of RNA Pol III-dependent genes (Pol III genes), tRNA(Leu), tRNA(Tyr), 5S rRNA and 7SL RNA. Inhibition of EGFR, but not PI3K, reduced both H3S28ph and tRNA(Leu) and 5S rRNA transcription. EGF enhanced occupancy of H3S28ph in the promoters of tRNA(Leu) and 5S rRNA. Further analysis indicates that EGF augmented cellular levels of protein and mRNA of TFIIIB subunits, Brf1 and TATA box-binding protein (TBP). Brf1 is a specific transcription factor for RNA Pol III genes. EGF enhanced occupancy of H3S28ph in the Brf1 and TBP promoters. Inhibition of H3S28ph by mutant H3S28A repressed Brf1, TBP and tRNA(Leu) and 5S rRNA expression and decreased occupancy of H3S28ph in their promoters. Reduction of Brf1 significantly decreased tRNA(Leu) and 5S rRNA transcription and repressed EGF-induced anchorage-independent growth. Blocking H3S28ph signaling by using mutant H3S28A reduced EGF-induced cell transformation. Together, these results indicate that EGF activates EGFR signaling to induce H3S28ph, which, in turn, upregulates tRNA(Leu) and 5S rRNA transcription through Brf1 and TBP and promotes cell transformation. The studies demonstrate that epigenetic modification of H3S28ph has a critical role in the activity of Pol III genes. Oncogene (2011) 30, 3943-3952; doi:10.1038/onc.2011.105; published online 4 April 2011	[Zhang, Q.; Zhong, Q.; Evans, A. G.; Levy, D.; Zhong, S.] Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90033 USA; [Zhang, Q.] Jinling Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China	University of Southern California	Zhong, S (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, 2011 Zonal Ave,HMR 605, Los Angeles, CA 90033 USA.	szhong@usc.edu			National Institutes of Health [AA017288, DK025836-26]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA017288, R21AA023247] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We want to thank DL, Johnson and MR Stallcup (University of Southern California) for scientific discussions. We would like to thank Z Dong (University of Minnesota) and C Huang (University of New York) who provided cell lines. This work was supported by National Institutes of Health grants AA017288 to SZ and DK025836-26 to DL.	Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806; Brunmeir R, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000927; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Dieci G, 2007, TRENDS GENET, V23, P614, DOI 10.1016/j.tig.2007.09.001; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Gehani SS, 2010, MOL CELL, V39, P886, DOI 10.1016/j.molcel.2010.08.020; Goodfellow SJ, 2006, EMBO J, V25, P1522, DOI 10.1038/sj.emboj.7601040; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson DL, 2008, SCIENCE, V320, P461, DOI 10.1126/science.1158680; Johnson SAS, 2008, J BIOL CHEM, V283, P19184, DOI 10.1074/jbc.M802872200; Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim HG, 2008, CANCER RES, V68, P2538, DOI 10.1158/0008-5472.CAN-07-6597; Marshall L, 2008, CELL, V133, P78, DOI 10.1016/j.cell.2008.02.035; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Moqtaderi Z, 2010, NAT STRUCT MOL BIOL, V17, P635, DOI 10.1038/nsmb.1794; Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801; Raha D, 2010, P NATL ACAD SCI USA, V107, P3639, DOI 10.1073/pnas.0911315106; Shimada M, 2010, J BIOL CHEM, V285, P9390, DOI 10.1074/jbc.M109.057745; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Woiwode A, 2008, MOL CELL BIOL, V28, P4204, DOI 10.1128/MCB.01912-07; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; Zhong SP, 2009, P NATL ACAD SCI USA, V106, P12682, DOI 10.1073/pnas.0904843106; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2004, MOL CELL BIOL, V24, P5119, DOI 10.1128/MCB.24.12.5119-5129.2004; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	37	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3943	3952		10.1038/onc.2011.105	http://dx.doi.org/10.1038/onc.2011.105			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21460852	Green Accepted			2022-12-28	WOS:000294890400004
J	Ketchart, W; Ogba, N; Kresak, A; Albert, JM; Pink, JJ; Montano, MM				Ketchart, W.; Ogba, N.; Kresak, A.; Albert, J. M.; Pink, J. J.; Montano, M. M.			HEXIM1 is a critical determinant of the response to tamoxifen	ONCOGENE			English	Article						estrogen receptor; tamoxifen; HEXIM1; breast cancer	BREAST CELL-GROWTH; CYCLIN D1; P-TEFB; RESISTANCE; MECHANISMS; CANCER; DISEASE; EXPRESSION; INHIBITOR; RECEPTORS	Tamoxifen resistance is a major problem in the treatment of estrogen receptor (ER)-positive patients. We have previously reported that hexamethylene bis-acetamide-inducible protein 1 (HEXIM1) inhibits ER alpha activity by competing with ER alpha for binding to cyclin T1, a subunit of positive transcription elongation b (P-TEFb). This results in the inhibition of the phosphorylation of RNA polymerase II (RNAPII) at serine 2 and the inhibition of transcription elongation of ER alpha target genes. As HEXIM1 can inhibit ER activity, we examined whether it has a critical role in the inhibitory effects of tamoxifen on ER. We observed that tamoxifen-induced HEXIM1 recruitment to the promoter region of ER target genes and decreased the recruitment of cyclin T1 and serine 2 phosphorylated RNAPII to the coding regions of these genes. Conversely, in cells wherein HEXIM1 expression has been downregulated we observed attenuation of the inhibitory effects of tamoxifen on estrogen-induced cyclin T1 recruitment to coding regions of ER target genes. As a consequence, downregulation of HEXIM1 resulted in the attenuation of the repressive effects of tamoxifen on estrogen-induced gene expression and proliferation. Conferring clinical relevance to our studies is our analysis of human breast cancer tissue samples that indicated association of lower expression of HEXIM1 with tumor recurrence in patients who received tamoxifen. Our studies provide a better understanding of the mechanistic basis for the inhibitory effect of tamoxifen on ER activity and may suggest new therapeutic targets for the treatment of tamoxifen-resistant breast cancer. Oncogene (2011) 30, 3563-3569; doi:10.1038/onc.2011.76; published online 21 March 2011	[Montano, M. M.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Kresak, A.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Albert, J. M.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; [Pink, J. J.] Case Western Reserve Univ, Div Gen Med Sci Oncol Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu	Albert, Jeffrey/P-7273-2019; Ogba, Ndiya/K-8429-2014	Albert, Jeffrey/0000-0003-2245-1745; Ogba, Ndiya/0000-0003-0453-3763	National Institute of Health [CA92440]; American Cancer Society [RSG CCE-110689]; NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Wei Wang (CWRU Department of Epidemiology and Biostatistics) for help with construction of graphs representing the relationship between disease recurrence and expressions levels of HEXIM1 in breast tissue. This work was supported by National Institute of Health grant CA92440 to MMM and American Cancer Society grant RSG CCE-110689 to J.J.P.	Anderson H, 2007, J STEROID BIOCHEM, V106, P49, DOI 10.1016/j.jsbmb.2007.05.024; Cleator SJ, 2009, CLIN BREAST CANCER, V9, pS6, DOI 10.3816/CBC.2009.s.001; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; HURVITZ SA, 2008, CANCER, V9, P2385; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lewis JS, 2005, MUTAT RES-FUND MOL M, V591, P247, DOI 10.1016/j.mrfmmm.2005.02.028; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUSGROVE EA, 1994, SEMIN CANCER BIOL, V5, P381; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Scott DJ, 2007, INT J ONCOL, V31, P557; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Wittmann BM, 2003, CANCER RES, V63, P5151; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zwart W, 2009, MOL ENDOCRINOL, V23, P1335, DOI 10.1210/me.2008-0268	23	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3563	3569		10.1038/onc.2011.76	http://dx.doi.org/10.1038/onc.2011.76			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423213	Green Accepted			2022-12-28	WOS:000294005100001
J	Cheli, Y; Guiliano, S; Botton, T; Rocchi, S; Hofman, V; Hofman, P; Bahadoran, P; Bertolotto, C; Ballotti, R				Cheli, Y.; Guiliano, S.; Botton, T.; Rocchi, S.; Hofman, V.; Hofman, P.; Bahadoran, P.; Bertolotto, C.; Ballotti, R.			Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny	ONCOGENE			English	Article						Mitf; p27; melanoma; cancer-initiating-cells; tumorigenicity	CANCER STEM-CELLS; TRANSCRIPTION FACTOR; DISTINCT SUBPOPULATION; GROWTH; POPULATIONS; MELANOCYTES; PHENOTYPE; APOPTOSIS; DILUTION; PATHWAY	In melanoma, as well as in other solid tumors, the cells within a given tumor exhibit strong morphological, functional and molecular heterogeneity that might reflect the existence of different cancer cell populations, among which are melanoma-initiating cells (MICs) with 'stemness' properties and their differentiated, fast-growing progeny. The existence of a slow-growing population might explain the resistance of melanoma to classical chemotherapies that target fast growing cells. Therefore, elucidating the biologic properties of MICs and, more importantly, the molecular mechanisms that drive the transition between MICs and their proliferating progeny needs to be addressed to develop an efficient melanoma therapy. Using B16 mouse melanoma cells and syngeneic mice, we show that the inhibition of microphthalmia-associated transcription factor (Mitf), the master regulator of melanocyte differentiation, increases the tumorigenic potential of melanoma cells and upregulates the stem cell markers Oct4 and Nanog. Notably, p27, the CDK inhibitor, is increased in Mitf-depleted cells and is required for exacerbation of the tumorigenic properties of melanoma cells. Further, a slow-growing population with low-Mitf level and high tumorigenic potential exists spontaneously in melanoma. Ablation of this population dramatically decreases tumor formation. Importantly, these data were confirmed using human melanoma cell lines and freshly isolated human melanoma cell from lymph node and skin melanoma metastasis. Taken together our data, identified Mitf and p27 as the key molecular switches that control the transition between MICs and their differentiated progeny. Eradication of low-Mitf cells might be an appealing strategy to cure melanoma. Oncogene (2011) 30, 2307-2318; doi: 10.1038/onc.2010.598; published online 31 January 2011	[Cheli, Y.; Guiliano, S.; Botton, T.; Rocchi, S.; Bahadoran, P.; Bertolotto, C.; Ballotti, R.] Ctr Mediterraneen Med Mol C3M, INSERM, U895, Equipe Biol Pathol Melanocytes 1,Equipe Labellise, F-06204 Nice 3, France; [Cheli, Y.; Guiliano, S.; Botton, T.; Rocchi, S.; Hofman, P.; Bahadoran, P.; Bertolotto, C.; Ballotti, R.] Univ Nice Sophia Antipolis, UFR Med, Nice, France; [Hofman, V.; Hofman, P.] ERI21 EA 4319 & Human Biobank, Nice, France; [Bahadoran, P.; Bertolotto, C.; Ballotti, R.] CHU Nice, Dept Dermatol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Ballotti, R (corresponding author), Ctr Mediterraneen Med Mol C3M, INSERM, U895, Equipe Biol Pathol Melanocytes 1,Equipe Labellise, 151 Route St Antoine Ginestiere, F-06204 Nice 3, France.	ballotti@unice.fr	Bertolotto, Corine/AAF-6634-2021; Rocchi, Stephane/O-4152-2016; Hofman, Paul/P-7654-2018; BALLOTTI, Robert/F-8825-2013; Botton, Thomas/AAA-9258-2020; Cheli, Yann/O-5783-2016	Bertolotto, Corine/0000-0001-6971-7753; Rocchi, Stephane/0000-0002-0943-1304; Hofman, Paul/0000-0003-0431-9353; Botton, Thomas/0000-0001-9079-7014; Cheli, Yann/0000-0001-9839-4332; Bahadoran, Philippe/0000-0002-2481-0556; veronique, HOFMAN/0000-0003-0943-1627; BALLOTTI, Robert/0000-0002-7322-4908	Association pour la Recherche contre le Cancer [ARC 4985]; ARC	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); ARC(Australian Research Council)	We wish to thank Genevieve Gozzerino, Agnes Loubat and Karine Bille for their help. This work was supported by the 'Association pour la Recherche contre le Cancer' (grant ARC 4985) and YC and TB have been supported by ARC's fellowships.	Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Botton T, 2009, J INVEST DERMATOL, V129, P1208, DOI 10.1038/jid.2008.346; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Lyons AB, 2001, METHOD CELL BIOL, V63, P375; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Schouwey K, 2008, HISTOL HISTOPATHOL, V23, P609, DOI 10.14670/HH-23.609; Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Strizzi L, 2008, CELL CYCLE, V7, P1931, DOI 10.4161/cc.7.13.6236; Yang G, 2008, MOL CELL, V32, P554, DOI 10.1016/j.molcel.2008.11.002	28	161	165	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	20					2307	2318		10.1038/onc.2010.598	http://dx.doi.org/10.1038/onc.2010.598			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21278797				2022-12-28	WOS:000290789200003
J	Chaturvedi, MM; Sung, B; Yadav, VR; Kannappan, R; Aggarwal, BB				Chaturvedi, M. M.; Sung, B.; Yadav, V. R.; Kannappan, R.; Aggarwal, B. B.			NF-kappa B addiction and its role in cancer: 'one size does not fit all'	ONCOGENE			English	Review						NF-kappa B; constitutive activation; cancer; inflammation; multitargeted therapy	TUMOR-NECROSIS-FACTOR; SQUAMOUS-CELL CARCINOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; REGULATED GENE-PRODUCTS; GROWTH-FACTOR-BETA; PROTEIN-KINASE-A; INTEGRATED GENOMIC ANALYSIS; NUCLEAR FACTOR (NF)-KAPPA-B; ACUTE MYELOID-LEUKEMIA; SERUM RESPONSE FACTOR	Activation of nuclear factor (NF)-kappa B, one of the most investigated transcription factors, has been found to control multiple cellular processes in cancer including inflammation, transformation, proliferation, angiogenesis, invasion, metastasis, chemoresistance and radioresistance. NF-kappa B is constitutively active in most tumor cells, and its suppression inhibits the growth of tumor cells, leading to the concept of 'NF-kappa B addiction' in cancer cells. Why NF-kappa B is constitutively and persistently active in cancer cells is not fully understood, but multiple mechanisms have been delineated including agents that activate NF-kappa B (such as viruses, viral proteins, bacteria and cytokines), signaling intermediates (such as mutant receptors, overexpression of kinases, mutant oncoproteins, degradation of I kappa B alpha, histone deacetylase, overexpression of transglutaminase and iNOS) and cross talk between NF-kappa B and other transcription factors (such as STAT3, HIF-1 alpha, AP1, SP, p53, PPAR gamma, beta-catenin, AR, GR and ER). As NF-kappa B is 'pre-active' in cancer cells through unrelated mechanisms, classic inhibitors of NF-kappa B (for example, bortezomib) are unlikely to mediate their anticancer effects through suppression of NF-kappa B. This review discusses multiple mechanisms of NF-kappa B activation and their regulation by multitargeted agents in contrast to monotargeted agents, thus 'one size does not fit all' cancers. Oncogene (2011) 30, 1615-1630; doi:10.1038/onc.2010.566; published online 20 December 2010	[Chaturvedi, M. M.; Sung, B.; Yadav, V. R.; Kannappan, R.; Aggarwal, B. B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; [Chaturvedi, M. M.] Univ Delhi, Dept Zool, Lab Chromatin Biol, Delhi 110007, India	University of Texas System; UTMD Anderson Cancer Center; University of Delhi	Chaturvedi, MM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mchaturvedi@zoology.du.ac.in; aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013; Sung, Bokyung/AAX-5697-2021		Clayton Foundation for Research; National Institutes of Health [CA-16 672, NIH CA-124787-01A2]; Center for Targeted Therapy of MD Anderson Cancer Center; University of Delhi, Department of Science & Technology, India [Dean(R)/2010/1142]; MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA124787] Funding Source: NIH RePORTER	Clayton Foundation for Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Targeted Therapy of MD Anderson Cancer Center; University of Delhi, Department of Science & Technology, India(Department of Science & Technology (India)); MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Tamara Locke for carefully editing the manuscript. Dr Aggarwal is the Ransom Horne, Jr, Professor of Cancer Research. This work was supported by a grant from the Clayton Foundation for Research (B. B. A.), a core grant from the National Institutes of Health (CA-16 672), a program project grant from National Institutes of Health (NIH CA-124787-01A2), and a grant from the Center for Targeted Therapy of MD Anderson Cancer Center. M. M. C. thanks the University of Delhi, Department of Science & Technology, India-PURSE grant Dean(R)/2010/1142 and MD Anderson Cancer Center for financial support.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal BB, 2009, CURR OPIN PHARMACOL, V9, P351, DOI 10.1016/j.coph.2009.06.020; Aggarwal BB, 2009, CLIN CANCER RES, V15, P425, DOI 10.1158/1078-0432.CCR-08-0149; Aggarwal S, 2006, MOL PHARMACOL, V69, P195, DOI 10.1124/mol.105.017400; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Ahn KS, 2005, ANN NY ACAD SCI, V1056, P218, DOI 10.1196/annals.1352.026; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; Anand P, 2008, CANCER RES, V68, P8861, DOI 10.1158/0008-5472.CAN-08-1902; Arun P, 2009, CLIN CANCER RES, V15, P5974, DOI 10.1158/1078-0432.CCR-09-1352; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bell DW, 2010, J PATHOL, V220, P231, DOI 10.1002/path.2645; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Bijli KM, 2008, J BIOL CHEM, V283, P14674, DOI 10.1074/jbc.M802094200; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Braunstein S, 2008, MOL CANCER RES, V6, P78, DOI 10.1158/1541-7786.MCR-07-0339; Brose MS, 2002, CANCER RES, V62, P6997; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Chapiro E, 2008, LEUKEMIA, V22, P2123, DOI 10.1038/leu.2008.102; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Choudhary C, 2005, INT J HEMATOL, V82, P93, DOI 10.1532/IJH97.05090; Chow JYC, 2010, AM J PHYSIOL-GASTR L, V298, pG275, DOI 10.1152/ajpgi.00344.2009; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dhawan P, 2008, J BIOL CHEM, V283, P15399, DOI 10.1074/jbc.M708272200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Duffy A, 2009, TARGET ONCOL, V4, P267, DOI 10.1007/s11523-009-0125-x; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fan YH, 2009, J BIOL CHEM, V284, P29290, DOI 10.1074/jbc.M109.018994; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gambaryan S, 2010, J BIOL CHEM, V285, P18352, DOI 10.1074/jbc.M109.077602; Gao N, 2008, J BIOL CHEM, V283, P7834, DOI 10.1074/jbc.M710285200; Garcia M, 2007, GLOBAL CANC FACTS FI, P1; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200; Ge JN, 2009, P NATL ACAD SCI USA, V106, P13725, DOI 10.1073/pnas.0907200106; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Gong RJ, 2008, J BIOL CHEM, V283, P7401, DOI 10.1074/jbc.M710396200; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Grosjean-Raillard J, 2008, APOPTOSIS, V13, P1148, DOI 10.1007/s10495-008-0243-4; GuhaThakurta D, 2006, NUCLEIC ACIDS RES, V34, P3585, DOI 10.1093/nar/gkl372; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Harikumar KB, 2009, BLOOD, V113, P2003, DOI 10.1182/blood-2008-04-151944; Hideshima T, 2009, BLOOD, V114, P1046, DOI 10.1182/blood-2009-01-199604; Hideshima T, 2009, BLOOD, V113, P5228, DOI 10.1182/blood-2008-06-161505; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hoffmann A, 2007, CANCER CELL, V11, P99, DOI 10.1016/j.ccr.2007.01.008; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Hymowitz SG, 2010, NAT REV CANCER, V10, P332, DOI 10.1038/nrc2775; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ishinaga H, 2009, BIOCHEM J, V417, P583, DOI 10.1042/BJ20080781; Israel A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000158; Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945; Jamaluddin M, 2009, J VIROL, V83, P10605, DOI 10.1128/JVI.01090-09; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jiang RQ, 2010, INT J CANCER, V126, P1263, DOI 10.1002/ijc.24854; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kai M, 2009, FEBS LETT, V583, P3265, DOI 10.1016/j.febslet.2009.09.017; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim SP, 2004, BIOCHEM BIOPH RES CO, V315, P93, DOI 10.1016/j.bbrc.2004.01.020; Kleinberg L, 2009, HUM PATHOL, V40, P795, DOI 10.1016/j.humpath.2008.10.019; Kobori M, 2004, CELL DEATH DIFFER, V11, P123, DOI 10.1038/sj.cdd.4401325; Koumakpayi IH, 2010, BRIT J CANCER, V102, P1163, DOI 10.1038/sj.bjc.6605571; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kumar A, 2005, MOL CELL BIOL, V25, P5893, DOI 10.1128/MCB.25.14.5893-5903.2005; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Le Page C, 2005, PROSTATE, V65, P130, DOI 10.1002/pros.20234; Ledford H, 2010, NATURE, V464, P972, DOI 10.1038/464972a; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li CY, 2010, J BIOL CHEM, V285, P16096, DOI 10.1074/jbc.M109.072694; Lim CA, 2007, MOL CELL, V27, P622, DOI 10.1016/j.molcel.2007.06.038; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081; Liu B, 2005, MOL CELL BIOL, V25, P1113, DOI 10.1128/MCB.25.3.1113-1123.2005; Lopez-Guerra M, 2010, EXPERT OPIN THER TAR, V14, P275, DOI 10.1517/14728221003598930; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maeda G, 2007, CLIN CANCER RES, V13, P5041, DOI 10.1158/1078-0432.CCR-07-0463; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao XC, 2009, GENE DEV, V23, P849, DOI 10.1101/gad.1748409; Martin-Subero J, 2007, LEUKEMIA, V21, P1532, DOI 10.1038/sj.leu.2404695; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Molinolo AA, 2009, ORAL ONCOL, V45, P324, DOI 10.1016/j.oraloncology.2008.07.011; Morimoto T, 2008, J CLIN INVEST, V118, P868, DOI 10.1172/JCI33160; MOSIALOS G, 1993, ONCOGENE, V8, P721; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Naoki K, 2002, CANCER RES, V62, P7001; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; O'Dea EL, 2008, MOL CELL, V30, P632, DOI 10.1016/j.molcel.2008.03.017; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Pandey MK, 2008, CANCER RES, V68, P5370, DOI 10.1158/0008-5472.CAN-08-0511; Pandey MK, 2007, J BIOL CHEM, V282, P17340, DOI 10.1074/jbc.M700890200; Park J, 2007, J MOL BIOL, V368, P388, DOI 10.1016/j.jmb.2007.02.047; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patel V, 2007, CARCINOGENESIS, V28, P1145, DOI 10.1093/carcin/bgm008; Pepper C, 2009, FUTURE ONCOL, V5, P1027, DOI 10.2217/FON.09.72; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pileri SA, 2003, LEUKEMIA LYMPHOMA, V44, pS21, DOI 10.1080/10428190310001623810; Planavila A, 2005, CARDIOVASC RES, V65, P832, DOI 10.1016/j.cardiores.2004.11.011; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Politi C, 2008, NEUROPATH APPL NEURO, V34, P357, DOI 10.1111/j.1365-2990.2007.00901.x; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Ramsey CS, 2008, ONCOGENE, V27, P3516, DOI 10.1038/sj.onc.1211030; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reber L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004393; Renner F, 2010, MOL CELL, V37, P503, DOI 10.1016/j.molcel.2010.01.018; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Roukos DH, 2010, EXPERT REV MOL DIAGN, V10, P33, DOI 10.1586/ERM.09.69; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Salminen A, 2008, IMMUNOL LETT, V117, P9, DOI 10.1016/j.imlet.2007.12.017; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Scortegagna M, 2008, BLOOD, V111, P3343, DOI 10.1182/blood-2007-10-115758; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158/1541-7786.MCR-07-2088; Sgarbanti M, 2008, J VIROL, V82, P3632, DOI 10.1128/JVI.00599-07; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Sher T, 2008, MAYO CLIN PROC, V83, P355, DOI 10.4065/83.3.355; Shishodia S, 2004, CANCER RES, V64, P5004, DOI 10.1158/0008-5472.CAN-04-0206; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Smith D, 2008, MOL CELL BIOCHEM, V307, P141, DOI 10.1007/s11010-007-9593-4; Son PS, 2010, CARCINOGENESIS, V31, P1442, DOI 10.1093/carcin/bgq099; Sriskantharajah S, 2010, SCIENCE, V327, P1093, DOI 10.1126/science.1187271; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sun HZ, 2010, J ENDOCRINOL, V204, P311, DOI 10.1677/JOE-09-0270; Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood-2007-10-117994; Tago K, 2010, J BIOL CHEM, V285, P30622, DOI 10.1074/jbc.M110.117028; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takahashi S, 2005, LEUKEMIA RES, V29, P893, DOI 10.1016/j.leukres.2005.01.008; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Thomas SM, 2006, CANCER RES, V66, P11831, DOI 10.1158/0008-5472.CAN-06-2876; Toualbi-Abed K, 2008, CARCINOGENESIS, V29, P536, DOI 10.1093/carcin/bgm293; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Vainer GW, 2008, CANCER LETT, V267, P182, DOI 10.1016/j.canlet.2008.03.016; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Van Waes C, 2007, CLIN CANCER RES, V13, P4956, DOI 10.1158/1078-0432.CCR-07-1287; Vatsyayan J, 2008, EMBO REP, V9, P885, DOI 10.1038/embor.2008.122; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Warren JL, 2008, J CLIN ONCOL, V26, P3242, DOI 10.1200/JCO.2007.14.6357; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wieland GD, 2005, J CELL SCI, V118, P3203, DOI 10.1242/jcs.02445; Wilson W, 2008, CANCER RES, V68, P8156, DOI 10.1158/0008-5472.CAN-08-1061; Wittwer T, 2008, BIOCHEM BIOPH RES CO, V371, P294, DOI 10.1016/j.bbrc.2008.04.069; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wright CJ, 2009, AM J PHYSIOL-LUNG C, V296, pL296, DOI 10.1152/ajplung.90499.2008; Wu ZH, 2007, J MOL MED, V85, P1187, DOI 10.1007/s00109-007-0227-9; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JM, 2010, J CLIN INVEST, V120, P2563, DOI 10.1172/JCI42358; Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006; Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200; Yu ZY, 2004, J AM SOC NEPHROL, V15, P585, DOI 10.1097/01.ASN.0000114556.19556.F9; Zhao TJ, 2007, NAT IMMUNOL, V8, P592, DOI 10.1038/ni1465; Zhou W, 2009, GASTROENTEROLOGY, V137, P1403, DOI 10.1053/j.gastro.2009.06.049; Zhu F, 2007, MOL CELL, V27, P214, DOI 10.1016/j.molcel.2007.05.042; Zhu F, 2009, HISTOL HISTOPATHOL, V24, P265, DOI 10.14670/HH-24.265; Zwergal A, 2006, J IMMUNOL, V177, P665, DOI 10.4049/jimmunol.177.1.665	236	383	402	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	14					1615	1630		10.1038/onc.2010.566	http://dx.doi.org/10.1038/onc.2010.566			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21170083	Green Accepted			2022-12-28	WOS:000289239400001
J	Tang, D; Lotze, MT; Kang, R; Zeh, HJ				Tang, D.; Lotze, M. T.; Kang, R.; Zeh, H. J.			Apoptosis promotes early tumorigenesis	ONCOGENE			English	Review						tumorigenesis; CD95; PUMA; apoptosis; autophagy; DAMP	CELL-DEATH; REGULATES AUTOPHAGY; CANCER-CELLS; TUMOR-GROWTH; PUMA; HMGB1; LYMPHOMAGENESIS; INFLAMMATION; MODULATION; CROSSTALK	One hallmark of cancer is intrinsic or acquired resistance to apoptosis. Surprisingly, recent studies demonstrate that CD95/Fas/Apo1 and p53 upregulated mediator of apoptosis/PUMA (potent inducers of the death receptor and the mitochondrial apoptotic pathways, respectively) promote tumorigenesis. These findings provide important insights into the multifaceted roles of apoptosis in tumorigenesis. Oncogene (2011) 30, 1851-1854; doi: 10.1038/onc.2010.573; published online 13 December 2010	[Tang, D.; Lotze, M. T.; Kang, R.; Zeh, H. J.] Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lotze, MT (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, Inst Canc, G-27A Hillman Canc Ctr,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	tangd2@upmc.edu; lotzemt@upmc.edu	Tang, Daolin/B-2905-2010; Kang, Rui/ABD-5291-2021; Tang, Daolin/ABD-5062-2021	Kang, Rui/0000-0003-2725-1574; Tang, Daolin/0000-0002-1903-6180				Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Lindsten T, 2006, CELL DEATH DIFFER, V13, P1272, DOI 10.1038/sj.cdd.4401953; Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Qiu W, 2009, CANCER RES, V69, P4999, DOI 10.1158/0008-5472.CAN-09-0262; Ramenghi U, 2000, BLOOD, V95, P3176; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; TANG D, 2010, ANTIOXID REDOX SIGNA; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	34	42	48	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	16					1851	1854		10.1038/onc.2010.573	http://dx.doi.org/10.1038/onc.2010.573			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151175				2022-12-28	WOS:000289777700001
J	Xiong, X; Zhao, Y; He, H; Sun, Y				Xiong, X.; Zhao, Y.; He, H.; Sun, Y.			Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator	ONCOGENE			English	Article						MDM2; p53; protein interplays; ribosomal proteins; ubiquitination	TUMOR-CELL GROWTH; SACCHAROMYCES-CEREVISIAE; ACTIVATES P53; MDM2 BINDING; IN-VIVO; INHIBITION; CARCINOMA; GENE; METALLOPANSTIMULIN; APOPTOSIS	Several ribosomal proteins regulate p53 function by modulating MDM2. We recently found that RPS27L, a RPS27-like protein, is a direct p53-inducible target. Here we showed that RPS27 itself is a p53-repressible target. Furthermore, the N-terminal region of either RPS27L or RPS27 binds to MDM2 on the central acidic domain of MDM2. RPS27L or RPS27 forms an in vivo triplex with MDM2-p53 and competes with p53 for MDM2 binding. Similar to p53, RPS27L, but not RPS27, is a short-lived protein and a novel MDM2 substrate. Degradation of RPS27L requires the RING or acidic domain of MDM2. Ectopic expression of RPS27L or RPS27 inhibits MDM-2-mediated p53 ubiquitination and increases p53 levels by extending p53 protein half-life, whereas siRNA silencing of RPS27L decreases p53 levels by shortening p53 half-life, with a corresponding reduction in p53 transcription activity. RPS27L is mainly localized in the cytoplasm, but upon p53-activating signals, a portion of RPS27L shuttled to the nucleoplasm where it colocalizes with MDM2. Both the cytoplasmic and the nuclear p53, induced by ribosomal stress, were reduced upon RPS27L silencing. Our study reveals a multilevel interplay between RPS27L/S27 and p53-MDM2 axis, with RPS27L functioning as a p53 target, a MDM2 substrate and a p53 regulator. Oncogene (2011) 30, 1798-1811; doi:10.1038/onc.2010.569; published online 20 December 2010	[Xiong, X.; Zhao, Y.; He, H.; Sun, Y.] Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, 4424B MS-1,1301 Catherine St, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287; Xiong, Xiufang/0000-0001-6842-3673	National Cancer Institute [CA111554, CA118762]; University of Michigan Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R01CA111554, R01CA118762] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Michigan Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by the National Cancer Institute grants (CA111554 and CA118762), and in part by a grant from the Seth Bonder Endowed Research Fund of the University of Michigan Comprehensive Cancer Center to YS.	Atsuta Y, 2002, CANCER LETT, V182, P101, DOI 10.1016/S0304-3835(02)00068-X; Balasubramanian S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-1-r2; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Burch LR, 2000, FEBS LETT, V472, P93, DOI 10.1016/S0014-5793(00)01427-7; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; FernandezPol JA, 1997, ANTICANCER RES, V17, P1519; FERNANDEZPOL JA, 1993, J BIOL CHEM, V268, P21198; FERNANDEZPOL JA, 1994, CELL GROWTH DIFFER, V5, P811; FernandezPol JA, 1996, ANTICANCER RES, V16, P2177; Ganger DR, 1997, ANTICANCER RES, V17, P1993; Ganger DR, 2001, CANCER DETECT PREV, V25, P231; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu QY, 2007, CANCER RES, V67, P3616, DOI 10.1158/0008-5472.CAN-06-4020; He H, 2007, ONCOGENE, V26, P2707, DOI 10.1038/sj.onc.1210073; Jia LJ, 2009, CANCER RES, V69, P4974, DOI 10.1158/0008-5472.CAN-08-4671; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lee WJ, 2004, OTOLARYNG HEAD NECK, V131, P466, DOI 10.1016/j.otohns.2004.03.011; Li J, 2007, CANCER RES, V67, P11317, DOI 10.1158/0008-5472.CAN-07-1088; Lindstrom MS, 2007, CELL CYCLE, V6, P434, DOI 10.4161/cc.6.4.3861; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Robinson M, 2003, CANCER BIOL THER, V2, P406, DOI 10.4161/cbt.2.4.437; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Stack Brendan C Jr, 2004, World J Surg Oncol, V2, P45, DOI 10.1186/1477-7819-2-45; Sun SH, 2008, CANCER BIOL THER, V7, P845, DOI 10.4161/cbt.7.6.5841; Swaroop M, 2003, ANTICANCER RES, V23, P3167; Tan M, 2008, ONCOGENE, V27, P1404, DOI 10.1038/sj.onc.1210780; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Wang YW, 2006, CLIN CANCER RES, V12, P4965, DOI 10.1158/1078-0432.CCR-05-2316; WONG JM, 1993, CANCER RES, V53, P1916; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	44	84	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1798	1811		10.1038/onc.2010.569	http://dx.doi.org/10.1038/onc.2010.569			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21170087	Green Accepted			2022-12-28	WOS:000289512200007
J	Zhi, HY; Hou, SW; Li, RS; Basir, Z; Xiang, Q; Szabo, A; Chen, G				Zhi, H-Y; Hou, S-W; Li, R-S; Basir, Z.; Xiang, Q.; Szabo, A.; Chen, G.			PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization	ONCOGENE			English	Article						PTPH1; VDR; VDR cytoplasmic translocation; mutual stabilization; breast cancer	PROTEIN-TYROSINE-PHOSPHATASE; RETINOID-X-RECEPTOR; ESTROGEN-RECEPTOR; NUCLEAR IMPORT; EXPRESSION; CELLS; TRANSFORMATION; ACTIVATION; RAS; 1B	Tyrosine phosphorylation is tightly regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), and has a critical role in malignant transformation and progression. Although PTKs have a well-established role in regulating breast cancer growth, contribution of PTPs remains mostly unknown. Here, we report that the tyrosine phosphatase PTPH1 stimulates breast cancer growth through regulating vitamin D receptor (VDR) expression. PTPH1 was shown to be overexpressed in 49% of primary breast cancer and levels of its protein expression positively correlate with the clinic metastasis, suggesting its oncogenic activity. Indeed, PTPH1 promotes breast cancer growth by a mechanism independent of its phosphatase activity, but dependent of its stimulatory effect on the nuclear receptor VDR protein expression and depletion of induced VDR abolishes the PTPH1 oncogenic activity. Additional analyses showed that PTPH1 binds VDR and increases its cytoplasmic accumulation, leading to their mutual stabilization and stable expression of a nuclear localization-deficient VDR abolishes the growth-inhibitory activity of the receptor independent of 1,25-dihydroxyvitamin D3. These results reveal a new paradigm in which a PTP may stimulate breast cancer growth through increasing cytoplasmic translocation of a nuclear receptor, leading to their mutual stabilization. Oncogene (2011) 30, 1706-1715; doi:10.1038/onc.2010.543; published online 29 November 2010	[Zhi, H-Y; Hou, S-W; Chen, G.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Li, R-S; Basir, Z.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Xiang, Q.; Szabo, A.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA; [Chen, G.] Zablocki Vet Affairs Med Ctr, Res Serv, Milwaukee, WI USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Chen, G (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	gchen@mcw.edu	Szabo, Aniko/F-9656-2012	Szabo, Aniko/0000-0002-8129-0614	National Institutes of Health [2R01 CA91576]; Department of Veterans Affairs; Cancer Center of Medical College of Wisconsin; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); Cancer Center of Medical College of Wisconsin; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from National Institutes of Health (2R01 CA91576), Department of Veterans Affairs (Merit Review), and Cancer Center of Medical College of Wisconsin (GC). We thank Drs Nicholas K Tonks, JoEllen Welsh, Jiahuai Han, Leonard Freedman, David Shapiro, Lawrence A Donehower and Carol E Lange for providing various reagents that made this work possible. We also appreciate Justin Reitsman and Dr Xiaomei Qi for the technical support and Chen's lab members for suggestions and discussions.	Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; CHEN G, 1994, BIOCHEM PHARMACOL, V47, P1079, DOI 10.1016/0006-2952(94)90420-0; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Garay E, 2007, J CELL PHYSIOL, V213, P816, DOI 10.1002/jcp.21150; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112; Korkola JE, 2003, CANCER RES, V63, P7167; Kure S, 2009, CANCER EPIDEM BIOMAR, V18, P2765, DOI 10.1158/1055-9965.EPI-09-0490; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Li QP, 2007, J BIOL CHEM, V282, P1544, DOI 10.1074/jbc.M604052200; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Loesch M, 2010, J BIOL CHEM, V285, P15149, DOI 10.1074/jbc.M110.105429; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Maruyama R, 2006, CANCER RES, V66, P4574, DOI 10.1158/0008-5472.CAN-05-2562; Menezes RJ, 2008, CANCER EPIDEM BIOMAR, V17, P1104, DOI 10.1158/1055-9965.EPI-07-2713; MHUIRCHEARTAIGH JN, 2006, BRIT J SURG, V95, P827; Obrero M, 2002, J BIOL CHEM, V277, P45695, DOI 10.1074/jbc.M208092200; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Prufer K, 2002, MOL ENDOCRINOL, V16, P961, DOI 10.1210/me.16.5.961; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Qi XM, 2004, J BIOL CHEM, V279, P6769, DOI 10.1074/jbc.M311492200; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tang J, 2005, J BIOL CHEM, V280, P23910, DOI 10.1074/jbc.M500699200; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Yang LM, 2001, J CELL PHYSIOL, V188, P383, DOI 10.1002/jcp.1125; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Yasmin R, 2005, J BIOL CHEM, V280, P40152, DOI 10.1074/jbc.M507708200; Yip SS, 2000, INT J CANCER, V88, P363, DOI 10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zinser GM, 2003, MOL CELL ENDOCRINOL, V200, P67, DOI 10.1016/S0303-7207(02)00416-1	42	31	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1706	1715		10.1038/onc.2010.543	http://dx.doi.org/10.1038/onc.2010.543			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21119599	Green Accepted			2022-12-28	WOS:000289239400008
J	Cheng, JC; Auersperg, N; Leung, PCK				Cheng, J-C; Auersperg, N.; Leung, P. C. K.			Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin	ONCOGENE			English	Article						serous borderline ovarian tumors; p53; ovarian cancer; invasion; E-cadherin	EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN CANCERS; PIK3CA GENE; LOW-GRADE; EXPRESSION; MUTATIONS; TRANSCRIPTION; INVASIVENESS; CARCINOMAS; KINASE	Serous borderline ovarian tumors (SBOTs) are slow-growing, non-invasive ovarian epithelial neoplasms. SBOTs are considered to be distinct entities that give rise to invasive low-grade serous carcinomas (LGCs), which have a relatively poor prognosis and are unrelated to high-grade serous carcinomas (HGCs). The mechanisms underlying the progression of non-invasive SBOTs to invasive epithelial ovarian carcinomas are not understood. We recently established short-term cultures of SBOT cells from tumor biopsies and showed that inactivation of p53, retinoblastoma (Rb) and/or PP2A by the simian virus 40 (SV40) large (LT) and small T antigens extends the life span of the cells and endows them with the ability to invade Matrigel-coated transwells. In this study, we show that concurrent inhibition of p53 and Rb by the SV40 LT produces cells (referred to as SBOT4-LT) with increased life span and cell invasion. To distinguish the roles of p53 and Rb in the progression from SBOTs to invasive ovarian carcinomas, we performed small interfering RNA-mediated knockdown of endogenous p53 in a spontaneously immortalized SBOT cell line, SBOT3.1, which increased cell invasion. This increased invasive activity was associated with the transcriptional downregulation of E-cadherin, correlated with an increase in PIK3CA levels and the increased activation of Akt. Conversely, in invasive LGC-derived MPSC1 cells, enhancing the levels of p53 decreased cell invasion and diminished the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated downregulation of E-cadherin. Inhibition of Rb also enhanced invasiveness, but did not affect the levels of PIK3CA and E-cadherin in SBOT3.1 cells, suggesting that it functions by a different pathway. To our knowledge, this study is the first to show that p53 has an important role in the progression from SBOTs to invasive carcinomas. In addition, our findings suggest that downregulation of E-cadherin by the PI3K/Akt pathway contributes to this progression. Oncogene (2011) 30, 1020-1031; doi:10.1038/onc.2010.486; published online 25 October 2010	[Cheng, J-C; Auersperg, N.; Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3V5, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Dept Obstet & Gynaecol, Room 2H-30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.	peleung@interchange.ubc.ca	Cheng, Jung-Chien/T-4258-2019	Cheng, Jung-Chien/0000-0002-5399-9327; Leung, Peter/0000-0003-3152-3800	National Cancer Institute of Canada; Canadian Cancer Society; Canadian Institutes of Health Research	National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the National Cancer Institute of Canada, with funds from the Canadian Cancer Society to NA and Canadian Institutes of Health Research to PCKL. We thank Dr David Huntsman and Winnie Yang (Centre for Translational and Applied Genomics, BC Cancer Agency) for providing the sequence data. We thank Dr Ie-Ming Shih (Department of Pathology, Johns Hopkins Medical Institutions) for providing the MPSC1 cells. We greatly appreciate the advice and help of Drs Christian Klausen and Michelle Woo.	Arima Y, 2008, CANCER RES, V68, P5104, DOI 10.1158/0008-5472.CAN-07-5680; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Gershenson DM, 1998, CANCER, V83, P2157, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D; Grille SJ, 2003, CANCER RES, V63, P2172; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Parker RL, 2004, INT J GYNECOL PATHOL, V23, P265, DOI 10.1097/01.pgp.0000130049.19643.f6; Pohl G, 2005, CANCER RES, V65, P1994, DOI 10.1158/0008-5472.CAN-04-3625; Roger L, 2010, J CELL SCI, V123, P1295, DOI 10.1242/jcs.061002; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shih IM, 2005, CLIN CANCER RES, V11, P7273, DOI 10.1158/1078-0432.CCR-05-0755; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Woo MMM, 2008, INT J GYNECOL CANCER, V18, P1234, DOI 10.1111/j.1525-1438.2007.01171.x; Woo MM, 2008, GYNECOL ONCOL, V111, P125, DOI 10.1016/j.ygyno.2008.06.021; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhao RB, 2000, GENE DEV, V14, P981	35	29	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1020	1031		10.1038/onc.2010.486	http://dx.doi.org/10.1038/onc.2010.486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972462				2022-12-28	WOS:000287964100002
J	Marzec, M; Liu, X; Wong, W; Yang, Y; Pasha, T; Kantekure, K; Zhang, P; Woetmann, A; Cheng, M; Odum, N; Wasik, MA				Marzec, M.; Liu, X.; Wong, W.; Yang, Y.; Pasha, T.; Kantekure, K.; Zhang, P.; Woetmann, A.; Cheng, M.; Odum, N.; Wasik, M. A.			Oncogenic kinase NPM/ALK induces expression of HIF1 alpha mRNA	ONCOGENE			English	Article						oncogenic tyrosine kinase; anaplastic lymphoma kinase; STAT3; HIF1 alpha	ANAPLASTIC LYMPHOMA KINASE; NON-HODGKINS-LYMPHOMA; TYROSINE KINASE; NPM-ALK; STAT3 EXPRESSION; TUMOR-SUPPRESSOR; CANCER-THERAPY; CELL LYMPHOMA; PROTEIN; ACTIVATION	The mechanisms of malignant cell transformation mediated by the oncogenic anaplastic lymphoma kinase (ALK) tyrosine kinase remain only partially understood. In this study, we report that T-cell lymphoma (TCL) cells carrying the nucleophosmin (NPM)/ALK fusion protein (ALK + TCL) strongly express hypoxia-induced factor 1 alpha (HIF1 alpha) mRNA, even under normoxic conditions, and markedly upregulate HIF1 alpha protein expression under hypoxia. HIF1 alpha expression is strictly dependent on the expression and enzymatic activity of NPM/ALK, as shown in BaF3 cells transfected with wild-type NPM/ALK and kinase-inactive NPM/ALK K210R mutant and by the inhibition of the NPM/ALK function in ALK + TCL cells by a small-molecule ALK inhibitor. NPM/ALK induces HIF1 alpha expression by upregulating its gene transcription through its key signal transmitter signal transducer and activator of transcription 3 (STAT3), which binds to the HIF1 alpha gene promoter as shown by the chromatin immunoprecipitation assay and is required for HIF1 alpha gene expression as demonstrated by its small interfering RNA-mediated depletion. In turn, depletion of HIF1 alpha increases mammalian target of rapamycin complex 1 activation, cell growth and proliferation and decreases vascular endothelial growth factor synthesis. These results identify a novel cell-transforming property of NPM/ALK, namely its ability to induce the expression of HIF1 alpha, a protein with an important role in carcinogenesis. These results also provide another rationale to therapeutically target NPM/ALK and STAT3 in ALK + TCL. Oncogene (2011) 30, 1372-1378; doi:10.1038/onc.2010.505; published online 22 November 2010	[Wasik, M. A.] Univ Penn, Dept Pathol & Lab Med, Med Ctr, Stellar Chance Labs 413A, Philadelphia, PA 19104 USA; [Wong, W.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Wong, W.] Univ Penn, Abramson Canc Res Inst, Philadelphia, PA 19104 USA; [Woetmann, A.; Odum, N.] Univ Copenhagen, Inst Mol Biol, Copenhagen, Denmark; [Cheng, M.] Cephalon Inc, W Chester, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Copenhagen; Teva Pharmaceutical Industries; Cephalon Inc.	Wasik, MA (corresponding author), Univ Penn, Dept Pathol & Lab Med, Med Ctr, Stellar Chance Labs 413A, 422 Curie Blvd, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Woetmann, Anders/AAJ-3171-2020; Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Woetmann, Anders/0000-0002-3008-735X	National Cancer Institute [R01-CA89194, R01-CA96856]; NATIONAL CANCER INSTITUTE [R01CA096856, R01CA089194] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by grants from the National Cancer Institute- R01-CA89194 and R01-CA96856.	Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Evens AM, 2008, BRIT J HAEMATOL, V141, P676, DOI 10.1111/j.1365-2141.2008.07093.x; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Giatromanolaki A, 2008, HEMATOL ONCOL, V26, P219, DOI 10.1002/hon.861; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Li RS, 2008, MED RES REV, V28, P372, DOI 10.1002/med.20109; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Lu LH, 2009, BIOCHEMISTRY-US, V48, P3600, DOI 10.1021/bi8020923; Marzec M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Passam FH, 2009, PATHOL RES PRACT, V205, P11, DOI 10.1016/j.prp.2008.07.007; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHIOTA M, 1994, ONCOGENE, V9, P1567; Wasik MA, 2009, SEMIN ONCOL, V36, pS27, DOI 10.1053/j.seminoncol.2009.02.007; Wright CW, 2009, SCIENCE, V323, P251, DOI 10.1126/science.1162818; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI 10.1517/13543780802565791 ; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang Q, 2007, NAT MED, V13, P1341, DOI 10.1038/nm1659	29	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1372	1378		10.1038/onc.2010.505	http://dx.doi.org/10.1038/onc.2010.505			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21102525				2022-12-28	WOS:000288492100011
J	Rao, X; Di Leva, G; Li, M; Fang, F; Devlin, C; Hartman-Frey, C; Burow, ME; Ivan, M; Croce, CM; Nephew, KP				Rao, X.; Di Leva, G.; Li, M.; Fang, F.; Devlin, C.; Hartman-Frey, C.; Burow, M. E.; Ivan, M.; Croce, C. M.; Nephew, K. P.			MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways	ONCOGENE			English	Article						microRNAs; breast cancer; antiestrogen; drug resistance; fulvestrant	ESTROGEN-RECEPTOR-ALPHA; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; MESSENGER-RNA; ENDOCRINE RESISTANCE; TAMOXIFEN RESISTANCE; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CELLS; MICRORNAS	Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in the majority of breast cancer patients, due to poorly understood mechanisms. To examine a possible role(s) of aberrantly expressed microRNAs (miRNAs) in acquired fulvestrant resistance, we compared antiestrogen-resistant and -sensitive breast cancer cells, revealing the overexpression of miR-221/222 in the SERD-resistant cell lines. Fulvestrant treatment of estradiol (E2)- and fulvestrant-sensitive MCF7 cells resulted in increased expression of endogenous miR-221/222. Ectopic upregulation of miR-221/222 in estrogen receptor-alpha (ER alpha)-positive cell lines counteracted the effects of E2 depletion or fulvestrant-induced cell death, thus also conferring hormone-independent growth and fulvestrant resistance. In cells with acquired resistance to fulvestrant, miR-221/222 expression was essential for cell growth and cell cycle progression. To identify possible miR-221/222 targets, miR-221- or miR-222-induced alterations in global gene expression profiles and target gene expression at distinct time points were determined, revealing that miR-221/222 overexpression resulted in deregulation of multiple oncogenic signaling pathways previously associated with drug resistance. Activation of beta-catenin by miR-221/222 contributed to estrogen-independent growth and fulvestrant resistance, whereas TGF-beta-mediated growth inhibition was repressed by the two miRNAs. This first in-depth investigation into the role of miR-221/222 in acquired fulvestrant resistance, a clinically important problem, demonstrates that these two 'oncomirs' may represent promising therapeutic targets for treating hormone-independent, SERD-resistant breast cancer. Oncogene (2011) 30, 1082-1097; doi:10.1038/onc.2010.487; published online 8 November 2010	[Rao, X.; Nephew, K. P.] Indiana Univ, Dept Mol & Cellular Biochem, Interdisciplinary Biochem Grad Program, Bloomington, IN USA; [Di Leva, G.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Nephew, K. P.] Indiana Univ Sch Med, Med Sci Program, Dept Med Sci, Bloomington, IN 47405 USA; [Devlin, C.; Ivan, M.] Indiana Univ Sch Med, Dept Immunol & Microbiol, Dept Med, Indianapolis, IN USA; [Burow, M. E.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; [Devlin, C.; Ivan, M.; Nephew, K. P.] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN USA; [Devlin, C.; Ivan, M.; Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Tulane University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ Sch Med, Med Sci Program, Dept Med Sci, Jordan Hall 302,1001 E 3rd St, Bloomington, IN 47405 USA.	knephew@indiana.edu	Young, Richard A/F-6495-2012; Ivan, Mircea/A-8109-2012; Burow, Matthew/D-6351-2013	Young, Richard A/0000-0001-8855-8647; Burow, Matthew/0000-0002-0642-6630; Di Leva, Gianpiero/0000-0001-6759-8682; Ivan, Mircea/0000-0003-3424-6642	Indiana Genomics Initiative of Indiana University; Lilly Endowment, Inc.; NIH [CA085289, CA113001, CA125806]; American Cancer Society [09-244-01]; Walther Cancer Foundation (Indianapolis); NATIONAL CANCER INSTITUTE [R01CA125806, U54CA113001, R01CA085289] Funding Source: NIH RePORTER	Indiana Genomics Initiative of Indiana University; Lilly Endowment, Inc.; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Walther Cancer Foundation (Indianapolis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Man-Wook Hur for providing the TOPflash and FOPflash plasmids, Jim Powers for assistance with fluorescence microscopy, Dr Meiyun Fan for advice on experiments and Dr Curt Balch for critical comments and paper preparation. The IUB Light Microscopy Imaging Center provided microscopy resources. The microarray studies were carried out using the facilities of the Center for Medical Genomics (Dr H Edenberg, Director and Dr J McClintick) at Indiana University School of Medicine. The Center for Medical Genomics is supported in part by the Indiana Genomics Initiative of Indiana University, which is supported in part by the Lilly Endowment, Inc. This work was supported in part by NIH grants CA085289, CA113001 and CA125806, American Cancer Society Research Scholar Grant 09-244-01, and the Walther Cancer Foundation (Indianapolis).	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500; Buck MB, 2004, MOL ENDOCRINOL, V18, P1643, DOI 10.1210/me.2003-0278; Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chen Y, 2010, MOL CELL BIOL, V30, P3902, DOI 10.1128/MCB.01237-09; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Felicetti F, 2008, EXPERT REV ANTICANC, V8, P1759, DOI 10.1586/14737140.8.11.1759; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; GORSCH SM, 1992, CANCER RES, V52, P6949; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Heneghan HM, 2010, J ONCOL, V2010, DOI 10.1155/2010/950201; Howell A, 2006, CRIT REV ONCOL HEMAT, V57, P265, DOI 10.1016/j.critrevonc.2005.08.001; Howell A, 2006, ENDOCR-RELAT CANCER, V13, P689, DOI 10.1677/erc.1.00846; Huang JC, 2007, NAT METHODS, V4, P1045, DOI 10.1038/nmeth1130; Iorio MV, 2008, EUR J CANCER, V44, P2753, DOI 10.1016/j.ejca.2008.09.037; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McDonnell DP, 2006, FASEB J, V20, P2432, DOI 10.1096/fj.06-1202ufm; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Nam S, 2009, NUCLEIC ACIDS RES, V37, pW356, DOI 10.1093/nar/gkp294; Nicholson RI, 2005, ENDOCR-RELAT CANCER, V12, pS29, DOI 10.1677/erc.1.00991; Nicholson RI, 2005, BREAST CANCER RES TR, V93, pS3, DOI 10.1007/s10549-005-9036-4; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; O'Brien CS, 2009, J MAMMARY GLAND BIOL, V14, P45, DOI 10.1007/s10911-009-9115-y; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Sagara Y, 2004, BRIT J CANCER, V91, P959, DOI 10.1038/sj.bjc.6602029; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shitashige M, 2008, CANCER SCI, V99, P631, DOI 10.1111/j.1349-7006.2007.00716.x; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Weldon CB, 2004, INT J ONCOL, V24, P1473; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Xin FX, 2009, BIOINFORMATICS, V25, P430, DOI 10.1093/bioinformatics/btn646; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	70	281	295	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1082	1097		10.1038/onc.2010.487	http://dx.doi.org/10.1038/onc.2010.487			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21057537	Green Accepted			2022-12-28	WOS:000287964100007
J	Goh, SH; Hong, SH; Hong, SH; Lee, BC; Ju, MH; Jeong, JS; Cho, YR; Kim, IH; Lee, YS				Goh, S-H; Hong, S-H; Hong, S-H; Lee, B-C; Ju, M-H; Jeong, J-S; Cho, Y-R; Kim, I-H; Lee, Y-S			eIF3m expression influences the regulation of tumorigenesis-related genes in human colon cancer	ONCOGENE			English	Article						eukaryotic translation initiation factor; eIF3m; cell proliferation; cell death; ribonomics	INITIATION-FACTOR EIF3; MIGRATION INHIBITORY FACTOR; MALIGNANT-TRANSFORMATION; TRANSLATIONAL CONTROL; BREAST-CANCER; GROWTH; OVEREXPRESSION; ACTIVATION; DYSADHERIN; COMPLEXES	Abnormal regulation of gene expression is essential for tumorigenesis. Recent studies indicate that regulation of oncogene expression and neoplastic transformation are controlled by subunits of eukaryotic translation initiation factors (eIFs). Here we focused on eIF3 performing a pivotal role in protein synthesis and the differential expression of its subunits in cancer. The most uncharacterized non-core subunit eIF3m was confirmed to be highly expressed in human cancer cell lines and colon cancer patient tissues. By expression silencing with eIF3m-specific small interfering RNA (siRNA), we confirmed that eIF3m influences cell proliferation, cell cycle progression and cell death in human colon cancer cell line HCT-116. Using a ribonomics approach, we identified a subset of elF3m-influenced genes and showed that the expression of two highly represented tumorigenesis-related genes, MIF and MT2, were affected by eIF3m at the mRNA level. We also confirmed eIF3m-dependent regulation of MT2A downstream molecule CDC25A, which is necessary for cell cycle progression in HCT-116 cells. These results suggest that eIF3m mediates regulation of tumorigenesis-related genes in human colon cancer. Further investigations on tumorigenesis-related genes and their regulation by eIFs will provide clues for designing targeted therapy for cancer. Oncogene (2011) 30, 398-409; doi: 10.1038/onc.2010.422; published online 13 September 2010	[Lee, Y-S] Natl Canc Ctr, Res Inst, Funct Genom Branch, Div Convergence Technol, Goyang 410769, Gyeonggi Do, South Korea; [Ju, M-H; Jeong, J-S] Dong A Univ, Dept Pathol, Coll Med, Pusan, South Korea	National Cancer Center - Korea (NCC); Dong A University	Lee, YS (corresponding author), Natl Canc Ctr, Res Inst, Funct Genom Branch, Div Convergence Technol, 111 Jungbalsan Ro,809 Madu Dong, Goyang 410769, Gyeonggi Do, South Korea.	yslee2@ncc.re.kr			National Cancer Center [NCC 0710660, NCC 0810160]	National Cancer Center	We thank Dr Sri Ram for editorial assistance of manuscript. This study was funded by Intramural Research Grants of the National Cancer Center (NCC 0710660, NCC 0810160).	Ahlemann M, 2006, MOL CARCINOGEN, V45, P957, DOI 10.1002/mc.20269; Bach JP, 2009, CANCER-AM CANCER SOC, V115, P2031, DOI 10.1002/cncr.24245; Bifulco C, 2008, CURR PHARM DESIGN, V14, P3790, DOI 10.2174/138161208786898608; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Doldan A, 2008, MOL CARCINOGEN, V47, P235, DOI 10.1002/mc.20379; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Green EM, 2007, NEURON, V55, P615, DOI 10.1016/j.neuron.2007.07.024; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392; Ino Y, 2002, P NATL ACAD SCI USA, V99, P365, DOI 10.1073/pnas.012425299; Jin RX, 2004, PATHOL ONCOL RES, V10, P74, DOI 10.1007/BF02893459; Jin RX, 2002, CARCINOGENESIS, V23, P81, DOI 10.1093/carcin/23.1.81; Kim JH, 2006, MOL CELL, V24, P173, DOI 10.1016/j.molcel.2006.08.016; Koch G, 1980, Ann N Y Acad Sci, V339, P280, DOI 10.1111/j.1749-6632.1980.tb15984.x; Komatsu K, 2000, CLIN CANCER RES, V6, P172; L'Esperance S, 2006, INT J ONCOL, V29, P5; LeFebvre AK, 2006, J BIOL CHEM, V281, P22917, DOI 10.1074/jbc.M605418200; Legendre H, 2003, MODERN PATHOL, V16, P491, DOI 10.1097/01.MP.0000068235.45178.C1; Lim D, 2009, CANCER LETT, V276, P109, DOI 10.1016/j.canlet.2008.10.038; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Morris C, 2007, EMBO REP, V8, P596, DOI 10.1038/sj.embor.7400955; Nam JS, 2007, CANCER LETT, V255, P161, DOI 10.1016/j.canlet.2007.02.018; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Ramachandran A, 2000, J GASTROEN HEPATOL, V15, P109, DOI 10.1046/j.1440-1746.2000.02059.x; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tomko RJ, 2009, CELL CYCLE, V8, P299, DOI 10.4161/cc.8.2.7595; Zhang LL, 2008, J BIOL CHEM, V283, P24047, DOI 10.1074/jbc.M800956200; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	36	39	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	4					398	409		10.1038/onc.2010.422	http://dx.doi.org/10.1038/onc.2010.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20838379				2022-12-28	WOS:000286621600003
J	Watt, SA; Pourreyron, C; Purdie, K; Hogan, C; Cole, CL; Foster, N; Pratt, N; Bourdon, JC; Appleyard, V; Murray, K; Thompson, AM; Mao, X; Mein, C; Bruckner-Tuderman, L; Evans, A; McGrath, JA; Proby, CM; Foerster, J; Leigh, IM; South, AP				Watt, S. A.; Pourreyron, C.; Purdie, K.; Hogan, C.; Cole, C. L.; Foster, N.; Pratt, N.; Bourdon, J-C; Appleyard, V.; Murray, K.; Thompson, A. M.; Mao, X.; Mein, C.; Bruckner-Tuderman, L.; Evans, A.; McGrath, J. A.; Proby, C. M.; Foerster, J.; Leigh, I. M.; South, A. P.			Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma	ONCOGENE			English	Article						cutaneous squamous cell carcinoma; primary cell culture; gene expression analysis; therapeutic targets; PLK1	POLO-LIKE KINASE; GENE-EXPRESSION PATTERNS; CHRONIC MYELOID-LEUKEMIA; NONMELANOMA SKIN-CANCER; EPITHELIAL-CELLS; ANALYSIS DEFINES; BREAST-CANCER; IN-VIVO; LINES; IDENTIFICATION	Identifying therapeutic targets for cancer treatment relies on consistent changes within particular types or sub-types of malignancy. The ability to define either consistent changes or sub-types of malignancy is often masked by tumor heterogeneity. To elucidate therapeutic targets in cutaneous squamous cell carcinoma (cSCC), the most frequent skin neoplasm with malignant potential, we have developed an integrated approach to gene expression profiling beginning with primary keratinocytes in culture. Candidate drivers of cSCC development were derived by first defining a set of in vitro cancer genes and then comparing their expression in a range of clinical data sets containing normal skin, cSCC and the benign hyper-proliferative condition psoriasis. A small interfering RNA (siRNA) screen of the resulting 21 upregulated genes has yielded targets capable of reducing xenograft tumor volume in vivo. Small-molecule inhibitors for one target, Polo-like kinase-1 (PLK1), are already in clinical trials for other malignancies, and our data show efficacy in cSCC. Another target, C20orf20, is identified as being overexpressed in cSCC, and siRNA-mediated knockdown induces apoptosis in vitro and reduces tumor growth in vivo. Thus, our approach has shown established and uncharacterized drivers of tumorigenesis with potent efficacy as therapeutic targets for the treatment of cSCC. Oncogene (2011) 30, 4666-4677; doi:10.1038/onc.2011.180; published online 23 May 2011	[Watt, S. A.; Pourreyron, C.; Hogan, C.; Cole, C. L.; Bourdon, J-C; Appleyard, V.; Murray, K.; Thompson, A. M.; Proby, C. M.; Foerster, J.; Leigh, I. M.; South, A. P.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Div Med Sci, Dundee DD1 9SY, Scotland; [Purdie, K.; Mao, X.] Inst Cell & Mol Sci, Ctr Cutaneous Res, London, England; [Foster, N.; Pratt, N.] Ninewells Hosp Dundee, Dept Human Genet, Dundee, Scotland; [Mein, C.] Queen Mary Univ London, Genome Ctr, London, England; [Bruckner-Tuderman, L.] Univ Med Ctr Freiburg, Dept Dermatol, Freiburg, Germany; [Bruckner-Tuderman, L.] Freiburg Inst Adv Studies, Sch Life Sci LifeNet, Freiburg, Germany; [Evans, A.] Ninewells Hosp Dundee, Dept Pathol, Dundee, Scotland; [McGrath, J. A.] Kings Coll London, St Johns Inst Dermatol, St Thomas Hosp, Div Genet & Mol Med,Genet Skin Dis Grp,Sch Med, London, England	University of Dundee; University of London; Queen Mary University London; University of London; Queen Mary University London; University of Freiburg; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	South, AP (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Div Med Sci, Dundee DD1 9SY, Scotland.	a.p.south@dundee.ac.uk	Pourreyron, Celine/AAE-7362-2020; JC, Bourdon/A-4439-2008; McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	JC, Bourdon/0000-0003-4623-9386; McGrath, John/0000-0002-3708-9964; Mein, Charles/0000-0003-0811-9658	DebRA, the dystrophic epidermolysis bullosa research association; Cancer Research UK [13044] Funding Source: researchfish	DebRA, the dystrophic epidermolysis bullosa research association; Cancer Research UK(Cancer Research UK)	Funding: This work was funded by DebRA, the dystrophic epidermolysis bullosa research association (http://www.debra.org.uk/).	Bertram MJ, 2001, GENE, V266, P111, DOI 10.1016/S0378-1119(01)00372-9; Braakhuis BJM, 2010, CURR OPIN OTOLARYNGO, V18, P67, DOI 10.1097/MOO.0b013e32833693ce; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Cai SQ, 2005, J DERMATOL, V32, P354, DOI 10.1111/j.1346-8138.2005.tb00906.x; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Cheng H, 2010, CIRC RES, V106, P21, DOI 10.1161/CIRCRESAHA.109.206920; Creighton C, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r46; Cunningham J, 2002, BRIT J HAEMATOL, V119, P1062, DOI 10.1046/j.1365-2141.2002.03940.x; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; EPSTEIN E, 1984, J DERMATOL SURG ONC, V10, P418; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fine JD, 2009, J AM ACAD DERMATOL, V60, P203, DOI 10.1016/j.jaad.2008.09.035; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Gleixner KV, 2010, CANCER RES, V70, P1513, DOI 10.1158/0008-5472.CAN-09-2181; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guan R, 2005, CANCER RES, V65, P2698, DOI 10.1158/0008-5472.CAN-04-2131; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa T, 2007, GENES CELLS, V12, P811, DOI 10.1111/j.1365-2443.2007.01089.x; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masters JRW, 2000, NAT REV MOL CELL BIO, V1, P233, DOI 10.1038/35043102; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Nindl I, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-30; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Purdie KJ, 2007, GENE CHROMOSOME CANC, V46, P661, DOI 10.1002/gcc.20447; Purdie KJ, 2009, J INVEST DERMATOL, V129, P1562, DOI 10.1038/jid.2008.408; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Romanowska M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009701; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Schmit TL, 2009, J INVEST DERMATOL, V129, P2843, DOI 10.1038/jid.2009.172; Schmit TL, 2009, CELL CYCLE, V8, P2697, DOI 10.4161/cc.8.17.9413; Schoffski P, 2009, ONCOLOGIST, V14, P559, DOI 10.1634/theoncologist.2009-0010; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Sharma SV, 2010, NAT REV CANCER, V10, P241, DOI 10.1038/nrc2820; SMITH HS, 1981, CANCER RES, V41, P4637; South AP, 2003, J CELL SCI, V116, P3303, DOI 10.1242/jcs.00636; Staples MP, 2006, MED J AUSTRALIA, V184, P6, DOI 10.5694/j.1326-5377.2006.tb00086.x; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Van Haren R, 2009, BRIT J DERMATOL, V161, P1278, DOI 10.1111/j.1365-2133.2009.09338.x; Veness MJ, 2007, HEAD NECK-J SCI SPEC, V29, P621, DOI 10.1002/hed.20576; Wallis S, 2000, MOL BIOL CELL, V11, P1077, DOI 10.1091/mbc.11.3.1077; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Welsh JB, 2001, CANCER RES, V61, P5974; Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40; Yamaguchi K, 2010, BRIT J CANCER, V102, P325, DOI 10.1038/sj.bjc.6605500	56	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	46					4666	4677		10.1038/onc.2011.180	http://dx.doi.org/10.1038/onc.2011.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21602893	Green Published, hybrid			2022-12-28	WOS:000297252100006
J	Liu, G; Gramling, S; Munoz, D; Cheng, D; Azad, AK; Mirshams, M; Chen, Z; Xu, W; Roberts, H; Shepherd, FA; Tsao, MS; Reisman, D				Liu, G.; Gramling, S.; Munoz, D.; Cheng, D.; Azad, A. K.; Mirshams, M.; Chen, Z.; Xu, W.; Roberts, H.; Shepherd, F. A.; Tsao, M. S.; Reisman, D.			Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk	ONCOGENE			English	Article						genetic polymorphism; BRG1; SWI/SNF; chromatin remodeling; lung cancer	SMALL-CELL-LUNG; CHROMATIN REMODELING COMPLEXES; SWI/SNF COMPLEX; BREAST-CANCER; SUSCEPTIBILITY LOCUS; PROTEIN EXPRESSION; CYCLE ARREST; DNA-DAMAGE; GENE; BRG1	SWI/SNF (SWItch/sucrose non-fermentable) complexes are ATP-dependent chromatin remodeling enzymes critically involved in the regulation of multiple functions, including gene expression, differentiation, development, DNA repair, cell adhesion and cell cycle control. BRM, a key SWI/SNF complex subunit, is silenced in 15-20% of many solid tumors. As BRM-deficient mice develop 10-fold more tumors when exposed to carcinogens, BRM is a strong candidate for a cancer susceptibility gene. In this paper, we show that BRM is regulated by transcription, thus demonstrating that the promoter region is important for BRM expression. We sequenced the BRM promoter region, finding two novel promoter indel polymorphisms, BRM -741 and BRM -1321, that are in linkage disequilibrium (D'>= 0.83). The variant insertion alleles of both polymorphisms produce sequence variants that are highly homologous to myocyte enhancer factor-2 (MEF2) transcription factor-binding sites; MEF2 is known to recruit histone deacetylases that silence BRM expression. Each polymorphic BRM insertion variant is found in similar to 20% of Caucasians, and each correlates strongly with the loss of protein expression of BRM, both in cancer cell lines (P = 0.009) and in primary human lung tumor specimens (P = 0.015). With such strong functional evidence, we conducted a case-control study of 1199 smokers. We found an increased risk of lung cancer when both BRM homozygous promoter insertion variants were present: adjusted odds ratio of 2.19 (95% confidence interval, 1.40-3.43). Thus, we here demonstrate a strong functional association between these polymorphisms and loss of BRM expression. These polymorphisms thus have the potential to identify a sub-population of smokers at greater lung cancer risk, wherein this risk could be driven by an aberrant SWI/SNF chromatin-remodeling pathway. Oncogene (2011) 30, 3295-3304; doi:10.1038/onc.2011.81; published online 11 April 2011	[Gramling, S.; Munoz, D.; Reisman, D.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL 32611 USA; [Liu, G.; Shepherd, F. A.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Div Med Oncol & Hematol,Dept Me, Toronto, ON, Canada; [Liu, G.; Cheng, D.; Azad, A. K.; Mirshams, M.; Chen, Z.; Tsao, M. S.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Dept Med Biophys, Toronto, ON, Canada; [Xu, W.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Biostat Dept, Toronto, ON, Canada; [Roberts, H.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Radiol, Toronto, ON, Canada; [Tsao, M. S.] Univ Toronto, Univ Hlth Network, Dept Pathol & Lab Med, Toronto, ON, Canada	State University System of Florida; University of Florida; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Reisman, D (corresponding author), Univ Florida, Dept Med, Div Hematol Oncol, Canc Genet Bldg Off 290,Off 294,2033 Mowry Rd, Gainesville, FL 32611 USA.	dnreisman@ufl.edu	Tsao, Ming Sound/AFQ-7332-2022; Azad, Abul Kalam/G-3729-2010; Liu, Geoffrey/N-4421-2016; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Azad, Abul Kalam/0000-0002-9236-9598; Liu, Geoffrey/0000-0002-2603-7296	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; Ontario Ministry of Health and Long Term Care (OMHLTC); Lucy Wong Fund; NCI [7R03CA128038-02]; NATIONAL CANCER INSTITUTE [T32CA009126, R03CA128038] Funding Source: NIH RePORTER	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; Ontario Ministry of Health and Long Term Care (OMHLTC)(Ministry of Health and Long-Term Care, Ontario); Lucy Wong Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	GL is funded by the Alan B Brown Chair in Molecular Genomics, CCO Chair in Experimental Therapeutics and Population Studies, and Posluns Family Foundation; FAS holds the Scott Taylor Chair in Lung Cancer Research; MST holds the M Qasim Chair in Lung Cancer Translational Research; Supported by the Ontario Ministry of Health and Long Term Care (OMHLTC) and the Lucy Wong Fund. The results presented do not necessarily reflect the views of OMHLTC. Reisman lab funding is from NCI:7R03CA128038-02.	An HX, 1999, CANCER RES, V59, P3941; Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; BARTLETT C, 2010, J CELL PHYSL; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Chen PY, 2005, BIOL CHEM, V386, P1205, DOI 10.1515/BC.2005.139; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fickett JW, 1996, MOL CELL BIOL, V16, P437; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Gaillard H, 2003, J BIOL CHEM, V278, P17655, DOI 10.1074/jbc.M300770200; Gazdar AF, 2010, J NATL CANCER I, V102, P920, DOI 10.1093/jnci/djq220; Girard L, 2000, CANCER RES, V60, P4894; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Gramling S, 2011, LETT DRUG DES DISCOV, V8, P93, DOI 10.2174/157018011793663840; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Gunduz E, 2009, CANCER INVEST, V27, P661, DOI 10.1080/07357900802563010; Hill DA, 2004, J CELL BIOCHEM, V91, P987, DOI 10.1002/jcb.20003; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Landi MT, 2009, AM J HUM GENET, V85, P679, DOI 10.1016/j.ajhg.2009.09.012; Landi MT, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-203; Liu G, 2005, SEMIN RESP CRIT CARE, V26, P265, DOI 10.1055/s-2005-871983; Morrison AJ, 2006, RES PRO CEL, V41, P109, DOI 10.1007/008; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Sabah M, 2005, VIRCHOWS ARCH, V446, P251, DOI 10.1007/s00428-004-1190-2; Sakurai K, 2011, CANCER RES, V71, P1680, DOI 10.1158/0008-5472.CAN-10-2345; Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200; Solomon B, 2009, J THORAC ONCOL, V4, P1450, DOI 10.1097/JTO.0b013e3181c4dedb; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Tripathi A, 2003, J EXP CLIN CANC RES, V22, P289; Truong T, 2010, JNCI-J NATL CANCER I, V102, P959, DOI 10.1093/jnci/djq178; Wang M, 2007, J BIOCHEM, V142, P613, DOI 10.1093/jb/mvm176; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yue JM, 2006, CANCER BIOL THER, V5, P573, DOI 10.4161/cbt.5.6.2872	51	40	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3295	3304		10.1038/onc.2011.81	http://dx.doi.org/10.1038/onc.2011.81			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21478907	Green Accepted			2022-12-28	WOS:000293006800008
J	Tauchi, T; Okabe, S; Ashihara, E; Kimura, S; Maekawa, T; Ohyashiki, K				Tauchi, T.; Okabe, S.; Ashihara, E.; Kimura, S.; Maekawa, T.; Ohyashiki, K.			Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen	ONCOGENE			English	Article						BCR-ABL; tyrosine kinase inhibitor; nilotinib; HSP90; T315I	CHRONIC MYELOID-LEUKEMIA; ABL KINASE INHIBITORS; BCR-ABL; IMATINIB; RESISTANCE; DASATINIB; HEAT-SHOCK-PROTEIN-90; IDENTIFICATION; ACTIVATION; MECHANISMS	To overcome imatinib resistance, more potent ABL tyrosine kinase inhibitors (TKIs), such as nilotinib and dasatinib have been developed, with demonstrable preclinical activity against most imatinib-resistant BCR-ABL kinase domain mutations, with the exception of T315I. However, imatinib-resistant patients already harboring mutations have a higher likelihood of developing further mutations under the selective pressure of potent ABL TKIs. NVP-AUY922 (Novartis) is a novel 4,5-diaryloxazole adenosine triphosphate-binding site heat shock protein 90 (HSP90) inhibitor, which has been shown to inhibit the chaperone function of HSP90 and deplete the levels of HSP90 client protein including BCR-ABL. In this study, we investigated the combined effects of AUY922 and nilotinib on random mutagenesis for BCR-ABL mutation (Blood, 109; 5011, 2007). Compared with single agents, combination with AUY922 and nilotinib was more effective at reducing the outgrowth of resistant cell clones. No outgrowth was observed in the presence of 2 mu M of nilotinib and 20 nM of AUY922. The observed data from the isobologram indicated the synergistic effect of simultaneous exposure to AUY922 and nilotinib even in BaF3 cells expressing BCR-ABL mutants including T315I. In vivo studies also demonstrated that the combination of AUY922 and nilotinib prolonged the survival of mice transplanted with mixture of BaF3 cells expressing wild-type BCR-ABL and mutant forms. Taken together, this study shows that the combination of AUY922 and nilotinib exhibits a desirable therapeutic index that can reduce the in vivo growth of mutant forms of BCR-ABL-expressing cells. Oncogene (2011) 30, 2789-2797; doi: 10.1038/onc.2011.3; published online 31 January 2011	[Tauchi, T.; Okabe, S.; Ohyashiki, K.] Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; [Ashihara, E.] Kyoto Prefectural Univ Med, Dept Mol Cell Physiol, Kyoto, Japan; [Kimura, S.] Saga Univ, Dept Internal Med, Fac Med, Div Hematol Resp Med & Oncol, Saga 840, Japan; [Maekawa, T.] Kyoto Univ, Fac Med, Dept Transfus Med & Cell Therapy, Kyoto, Japan	Tokyo Medical University; Kyoto Prefectural University of Medicine; Saga University; Kyoto University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp			MEXT (Ministry of Education, Culture, Sports, Science and Technology)	MEXT (Ministry of Education, Culture, Sports, Science and Technology)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a 'High-Tech Research Center' Project for private universities: matching fund subsidy from the MEXT (Ministry of Education, Culture, Sports, Science and Technology), and by the 'University-Industry Joint Research Project' for private universities: matching fund subsidy from the MEXT.	Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Branford S, 2009, BLOOD, V114, P5426, DOI 10.1182/blood-2009-08-215939; Brough PA, 2008, J MED CHEM, V51, P196, DOI 10.1021/jm701018h; Deguchi Y, 2008, LEUKEMIA RES, V32, P980, DOI 10.1016/j.leukres.2007.11.008; Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008-5472.CAN-07-5256; Garg RJ, 2009, BLOOD, V114, P4361, DOI 10.1182/blood-2009-05-221531; Gorre ME, 2002, BLOOD, V100, P3041, DOI 10.1182/blood-2002-05-1361; Jabbour E, 2008, BLOOD, V112, P53, DOI 10.1182/blood-2007-11-123950; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; Kantarjian H, 2007, BLOOD, V109, P5143, DOI 10.1182/blood-2006-11-056028; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kantarjian H, 2009, BLOOD, V113, P6322, DOI 10.1182/blood-2008-11-186817; Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332; Nunoda K, 2007, ONCOGENE, V26, P4179, DOI 10.1038/sj.onc.1210179; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Ottmann O, 2007, BLOOD, V110, P2309, DOI 10.1182/blood-2007-02-073528; Ray A, 2007, BLOOD, V109, P5011, DOI 10.1182/blood-2006-01-015347; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Stuhmer T, 2008, LEUKEMIA, V22, P1604, DOI 10.1038/leu.2008.111; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007	23	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2789	2797		10.1038/onc.2011.3	http://dx.doi.org/10.1038/onc.2011.3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278787				2022-12-28	WOS:000291678500009
J	Wang, LT; Lin, CS; Chai, CY; Liu, KY; Chen, JY; Hsu, SH				Wang, L-T; Lin, C-S; Chai, C-Y; Liu, K-Y; Chen, J-Y; Hsu, S-H			Functional interaction of Ugene and EBV infection mediates tumorigenic effects	ONCOGENE			English	Article						EBV; LMP1; LMPIP; tumorigenesis	EPSTEIN-BARR-VIRUS; ENCODED LATENT MEMBRANE-PROTEIN-1; NASOPHARYNGEAL CARCINOMA-CELLS; ZIP TRANSCRIPTION FACTOR; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; BURKITT-LYMPHOMA; CYCLIN D1; LMP1; GROWTH	Epstein-Barr virus (EBV) infection is associated with many human neoplasms, in which EBV-derived latent membrane protein-1 (LMP1) appears to be critical, but its exact oncogenic mechanism remains to be defined. To this end, our initial microarray analyses identified a LMP1-inducible gene, Ugene, originally characterized as a binding partner for uracil DNA glycosylase 2, which is highly expressed in malignant colon cancer. In this report, it was found that Ugene, designated herein as LMP1-induced protein (LMPIP), was induced, in a time-dependent manner, in EBV-infected peripheral blood mononuclear cells and LMP1-transfected 293 cells. Functionally, when compared with mock-transfected cells, overexpression of LMPIP in nasopharyngeal carcinoma (NPC) cell lines resulted in a decrease in reactive oxygen species production and maintained mitochondria membrane potential (Delta psi) loss induced by H2O2. The NPC cells transfected with LMPIP also showed a decrease in G1 population and an increase in the cell population in sub-G1 and multiploid phase, concomitant with increased levels of cell cycle activators, including cyclin D1 and CDK4. In contrast, silencing of LMPIP expression in the NPC tumor cell lines with short hairpin RNA interference revealed significantly decreased cell population at G1/S phase, while the number of cells in multiploid phase increased. Significantly, NPC cells with LMPIP knock-down also showed a decrease in tumorigenic and transforming activity induced by ectopic LMP1 expression, as determined by analyses of soft agar foci and tumor size in nude mice. Further, elevated LMPIP expression was also noted in cytoplasm and nuclei in EBV-infected NPC tumor cell mass and non-EBV-infected tumor cell lines. These results suggested that LMPIP may have an important mediator role in EBV-mediated neoplasm and may serve as a new target for therapy of tumors induced by EBV infection. Oncogene (2011) 30, 2921-2932; doi:10.1038/onc.2011.16; published online 14 February 2011	[Wang, L-T; Lin, C-S; Liu, K-Y; Hsu, S-H] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan; [Chai, C-Y] Kaohsiung Med Univ, Fac Med, Coll Med, Dept Pathol, Kaohsiung 807, Taiwan; [Chen, J-Y] Natl Hlth Res Inst, Inst Canc Res, Zhunan, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; National Health Research Institutes - Taiwan	Hsu, SH (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.	jackhsu@kmu.edu.tw	Lin, Chang-Shen/D-5140-2009; Lin, Chang-Shen/X-2189-2019; Chen, Jen-Yang/D-2085-2010	Lin, Chang-Shen/0000-0001-7415-2187; Chai, Chee-Yin/0000-0003-0486-9742; Hsu, Shih Hsien/0000-0003-2102-0505; Wang, Li-Ting/0000-0002-3335-8055	National Science Council, Taiwan [NSC-97-2311-B-037-002-MY3, NSC-97-2314-B-037-015, NSC-98-2320-B- 037-026-MY3]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr SK Huang for critically reviewing this paper. This work was supported in part by Research Grants NSC-97-2311-B-037-002-MY3, NSC-97-2314-B-037-015 and NSC-98-2320-B- 037-026-MY3 from the National Science Council, Taiwan.	Ai MD, 2005, CELL RES, V15, P777, DOI 10.1038/sj.cr.7290347; Bartosz G, 2009, BIOCHEM PHARMACOL, V77, P1303, DOI 10.1016/j.bcp.2008.11.009; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Burhans WC, 2009, FREE RADICAL BIO MED, V47, P1282, DOI 10.1016/j.freeradbiomed.2009.05.026; Chang Y, 1998, LAB INVEST, V78, P715; Demetriades C, 2009, J VIROL, V83, P5269, DOI 10.1128/JVI.00097-09; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Esposito F, 2001, IUBMB LIFE, V52, P67, DOI 10.1080/15216540252774793; Fang CY, 2009, INT J CANCER, V124, P2016, DOI 10.1002/ijc.24179; Guo CG, 2008, CANCER RES, V68, P6118, DOI 10.1158/0008-5472.CAN-08-1259; Hour TC, 2010, BIOCHEM PHARMACOL, V80, P325, DOI 10.1016/j.bcp.2010.04.007; Hsu SH, 2005, CANCER RES, V65, P4041, DOI 10.1158/0008-5472.CAN-04-3658; Hsu SH, 2004, EXP CELL RES, V294, P185, DOI 10.1016/j.yexcr.2003.10.029; Hsu SH, 2001, MECH DEVELOP, V100, P177, DOI 10.1016/S0925-4773(00)00513-X; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Kanegane H, 2002, CRIT REV ONCOL HEMAT, V44, P239, DOI 10.1016/S1040-8428(02)00115-4; Kieser A, 2008, BIOL CHEM, V389, P1261, DOI 10.1515/BC.2008.144; Kis LL, 2006, BLOOD, V107, P2928, DOI 10.1182/blood-2005-06-2569; Laurent A, 2005, CANCER RES, V65, P948; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LINDAHL T, 1974, INT J CANCER, V13, P764, DOI 10.1002/ijc.2910130605; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Menon SG, 2007, ONCOGENE, V26, P1101, DOI 10.1038/sj.onc.1209895; Menon SG, 2007, CANCER RES, V67, P6392, DOI 10.1158/0008-5472.CAN-07-0225; Menon SG, 2003, CANCER RES, V63, P2109; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Munz C, 2008, SEMIN CANCER BIOL, V18, P381, DOI 10.1016/j.semcancer.2008.10.002; Pai S, 2001, SEMIN CANCER BIOL, V11, P455, DOI 10.1006/scbi.2001.0412; Queiroga EM, 2008, AM J CLIN PATHOL, V130, P186, DOI 10.1309/2CNAWY6GAR0VQAXX; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Sarsour EH, 2009, ANTIOXID REDOX SIGN, V11, P2985, DOI [10.1089/ars.2009.2513, 10.1089/ARS.2009.2513]; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Soni V, 2007, ADV EXP MED BIOL, V597, P173; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Thorley-Lawson DA, 2008, NAT REV MICROBIOL, V6, P913, DOI 10.1038/nrmicro2015; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Yu JS, 2002, ONCOGENE, V21, P8047, DOI 10.1038/sj.onc.1205990	42	16	18	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2921	2932		10.1038/onc.2011.16	http://dx.doi.org/10.1038/onc.2011.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317926				2022-12-28	WOS:000292245100003
J	Hanashiro, K; Brancaccio, M; Fukasawa, K				Hanashiro, K.; Brancaccio, M.; Fukasawa, K.			Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification	ONCOGENE			English	Article						CDK2; cyclin E; nucleophosmin; ROCK II; centrosome; morgana/chp-1	RHO-ASSOCIATED KINASE; CYCLIN-E; PHOSPHORYLATION; MYOSIN; NUCLEOPHOSMIN/B23; GTPASES; TARGET; ROLES	Initiation of centrosome duplication and DNA replication is coupled, which is primarily achieved by the late G1 phase-specific activation of cyclin-dependent kinase 2 (CDK2)-cyclin E, which triggers both centrosome duplication and DNA replication. Uncoupling of these two events contributes to overduplication of centrosomes, resulting in the presence of more than two centrosomes (centrosome amplification). Centrosome amplification, which is frequently observed in cancers, contributes to tumor development through destabilizing genomes. Nucleophosmin (NPM/B23) is one of the phosphorylation targets of CDK2-cyclin E for the initiation of centrosome duplication. It has been found that NPM/B23 phosphorylated on Thr199 by CDK2-cyclin E acquires a high binding affinity to ROCK II kinase. The Thr199-phosphorylated NPM/B23 physically interacts with and super-activates the centrosomally localized ROCK II, which is a critical event for centrosomes to initiate duplication. Here, we provide direct evidence for the activation of ROCK II as a primary and sufficient downstream event of CDK2-cyclin E for the initiation of centrosome duplication and for the induction of centrosome amplification. Oncogene (2011) 30, 2188-2197; doi:10.1038/onc.2010.607; published online 17 January 2011	[Hanashiro, K.; Fukasawa, K.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; [Brancaccio, M.] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Turin	Fukasawa, K (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA.	kenji.fukasawa@moffitt.org			National Institutes of Health [CA90522, GM87328, AIRC2008]; NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087328] Funding Source: NIH RePORTER; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	Cyclin E <SUP>/</SUP> MEFs lacking functional p53 were provided by Dr P Sicinski (Harvard Medical School), and p53 <SUP>/</SUP> MEFs from Dr Donehower (Baylor College of Medicine). We thank M Crow, B Nepon-Sixt and M Rowland for technical assistance, and M Lloyd and J Johnson for technical assistance on microscopic analysis. This research is supported by the grants from the National Institutes of Health (CA90522 and GM87328) to KF and from AIRC2008 to MB.	Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Ferretti R, 2010, DEV CELL, V18, P486, DOI 10.1016/j.devcel.2009.12.020; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Leung T, 1996, MOL CELL BIOL, V16, P5313; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Wu JC, 2005, FEBS LETT, V579, P421, DOI 10.1016/j.febslet.2004.12.005	33	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2188	2197		10.1038/onc.2010.607	http://dx.doi.org/10.1038/onc.2010.607			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242972				2022-12-28	WOS:000290514600002
J	Yeung, CLA; Tsang, TY; Yau, PL; Kwok, TT				Yeung, C. L. Au; Tsang, T. Y.; Yau, P. L.; Kwok, T. T.			Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway	ONCOGENE			English	Article						HPV-16 E6; p53; miR-23b; uPA; cervical cancer	DIFFERENTIAL REGULATION; MICRORNA EXPRESSION; GENE-EXPRESSION; UROKINASE; CARCINOMA; MIR-34A; P53; TRANSCRIPTION; LESIONS; SYSTEM	Deregulation of microRNA (miRNA or miR) expression in human cervical cancer is associated frequently with human papillomavirus (HPV) integration. miR-23b is often downregulated in HPV-associated cervical cancer. Interestingly, urokinase-type plasminogen activator (uPA), the miR-23b target, is detected in cervical cancer, but not in normal cervical tissues. Thus, the importance of miR-23b and uPA in HPV-associated cervical cancer development is investigated. In this study, the high-risk subtype HPV-16 E6 oncoprotein was found to decrease the expression of miR-23b, increase the expression of uPA, and thus induce the migration of human cervical carcinoma SiHa and CaSki cells. uPA is the target gene for miR-23b as the miR repressed uPA expression and interacted with the 30-untranslated region of uPA mRNA. The tumor suppressor p53 is known to be inactivated by HPV-16 E6. A consensus p53 binding site is detected in the promoter region of miR-23b, whereas p53 trans-activated and also interacted with the miR's promoter. Therefore, p53 is believed to mediate the HPV-16 E6 downregulation of miR-23b. From the above, miR-23b/uPA are confirmed to be involved in HPV-16 E6-associated cervical cancer development. Oncogene (2011) 30, 2401-2410; doi:10.1038/onc.2010.613; published online 17 January 2011	[Yeung, C. L. Au; Tsang, T. Y.; Yau, P. L.; Kwok, T. T.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Ctr Sci, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Kwok, TT (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Ctr Sci, Room 177, Shatin, Hong Kong, Peoples R China.	kwok2020@cuhk.edu.hk			Hong Kong Research Grants; Council Earmarked [466908, 467609]	Hong Kong Research Grants(Hong Kong Research Grants Council); Council Earmarked	The study is supported by grants from Hong Kong Research Grants and Council Earmarked Grants 466908, 467609.	Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Bai L, 2006, INT J GYNECOL CANCER, V16, P718, DOI 10.1111/j.1525-1438.2006.00380.x; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Davis BN, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-18; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Muralidhar B, 2007, J PATHOL, V212, P368, DOI 10.1002/path.2179; Riethdorf L, 1999, J PATHOL, V189, P245, DOI 10.1002/(SICI)1096-9896(199910)189:2<245::AID-PATH427>3.0.CO;2-Z; Salvi A, 2009, FEBS J, V276, P2966, DOI 10.1111/j.1742-4658.2009.07014.x; Scaria V, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-82; Shetty P, 2008, AM J RESP CELL MOL, V39, P364, DOI 10.1165/rcmb.2007-0406OC; Soliman PT, 2004, DRUG DISCOV TODAY, V1, P253; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; TURNER MA, 1995, CLIN EXP METASTAS, V13, P260, DOI 10.1007/BF00133481; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Wu W, 2006, MOL ENDOCRINOL, V20, P2304, DOI 10.1210/me.2006-0131; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zuna RE, 2004, MODERN PATHOL, V17, P1314, DOI 10.1038/modpathol.3800223; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	33	96	98	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2401	2410		10.1038/onc.2010.613	http://dx.doi.org/10.1038/onc.2010.613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21242962				2022-12-28	WOS:000291008000002
J	Zhou, Z; Hao, Y; Liu, N; Raptis, L; Tsao, MS; Yang, X				Zhou, Z.; Hao, Y.; Liu, N.; Raptis, L.; Tsao, M-S; Yang, X.			TAZ is a novel oncogene in non-small cell lung cancer	ONCOGENE			English	Article						TAZ; lung cancer; Hippo-LATS pathway; transcriptional coactivator; cell proliferation; transformation	EPITHELIAL-MESENCHYMAL TRANSITION; ORGAN SIZE CONTROL; HIPPO PATHWAY; TUMOR-SUPPRESSOR; CONTACT INHIBITION; YAP; PROLIFERATION; PATHOGENESIS; PROGRESSION; EXPRESSION	Transcriptional coactivator with PDZ-binding motif (TAZ) is a transcriptional coactivator involved in the differentiation of stem cell as well as the development of multiple organs. Recently, TAZ has also been identified as a major component of the novel Hippo-LATS tumor suppressor pathway and to function as an oncogene in breast cancer. We show for the first time that TAZ is an oncogene in non-small cell lung cancer (NSCLC). Our results show that TAZ is overexpressed in NSCLC cells and that lentivirus-mediated overexpression of TAZ in HBE135 immortalized human bronchial epithelial cells causes increased cell proliferation and transformation, which can be restored back to its original levels by knockdown of TAZ. In addition, short-hairpin RNA (shRNA)-mediated knockdown of TAZ expression in NSCLC cells suppresses their proliferation and anchorage-independent growth in vitro, and tumor growth in mice in vivo, which can be reversed by re-introduction of shRNA-resistant TAZ into TAZ-knockdown NSCLC cells. These results indicate that TAZ is an oncogene and has an important role in tumorigenicity of NSCLC cells. Therefore, TAZ may present a novel target for the future diagnosis, prognosis and therapy of lung cancer. Oncogene (2011) 30, 2181-2186; doi:10.1038/onc.2010.606; published online 24 January 2011	[Yang, X.] Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, Kingston, ON K7L 3N6, Canada; [Liu, N.; Tsao, M-S] Princess Margaret Hosp, Dept Pathol, Toronto, ON M4X 1K9, Canada; [Raptis, L.] Queens Univ, Dept Immunol & Microbiol, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Queens University - Canada	Yang, X (corresponding author), Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, 88 Stuart St, Kingston, ON K7L 3N6, Canada.	yang@cliff.path.queensu.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405	Canadian Institute of Health Research; Clinical Trust Fund at Queen's University; Ontario Ministry of Research and Innovation, Canada; Canadian Cancer Society [CCSRI-020527]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Clinical Trust Fund at Queen's University; Ontario Ministry of Research and Innovation, Canada(Ministry of Research and Innovation, Ontario); Canadian Cancer Society(Canadian Cancer Society (CCS))	This work was supported by a grant from the Canadian Institute of Health Research, a grant from the Clinical Trust Fund at Queen's University, a New Investigator Award from the Canadian Institute of Health Research and an Early Researcher Award from the Ontario Ministry of Research and Innovation, Canada to Xiaolong Yang, and a grant from the Canadian Cancer Society (CCSRI-020527) to Ming-Sound Tsao. We thank Dulcie Lai and Stacy Visser for reading the manuscript.	Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Brambilla E, 2009, EUR RESPIR J, V33, P1485, DOI 10.1183/09031936.00014009; Cai D, 2010, CANCER RES, V70, P6477, DOI 10.1158/0008-5472.CAN-10-0005; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chow A, 2010, INT J CANCER, V126, P2079, DOI 10.1002/ijc.24878; Dutt A, 2006, CLIN CANCER RES, V12, p4396S, DOI 10.1158/1078-0432.CCR-06-0414; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hergovich A, 2009, BIOFACTORS, V35, P338, DOI 10.1002/biof.47; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Kim YH, 2010, ONCOGENE, V29, P1421, DOI 10.1038/onc.2009.437; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Lo KC, 2008, LUNG CANCER, V59, P315, DOI 10.1016/j.lungcan.2007.08.037; Mitani A, 2009, AM J RESP CRIT CARE, V180, P326, DOI 10.1164/rccm.200812-1827OC; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Strazisar M, 2009, LUNG CANCER, V64, P257, DOI 10.1016/j.lungcan.2008.09.011; Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Visser S, 2010, CELL CYCLE, V9, P3892, DOI 10.4161/cc.9.19.13386; Wang KN, 2009, BIOCHEM CELL BIOL, V87, P77, DOI 10.1139/O08-114; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	32	138	146	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	18					2181	2186		10.1038/onc.2010.606	http://dx.doi.org/10.1038/onc.2010.606			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21258416				2022-12-28	WOS:000290249600009
J	Anderton, JA; Bose, S; Vockerodt, M; Vrzalikova, K; Wei, W; Kuo, M; Helin, K; Christensen, J; Rowe, M; Murray, PG; Woodman, CB				Anderton, J. A.; Bose, S.; Vockerodt, M.; Vrzalikova, K.; Wei, W.; Kuo, M.; Helin, K.; Christensen, J.; Rowe, M.; Murray, P. G.; Woodman, C. B.			The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma	ONCOGENE			English	Article						KDM6B; histone demethylase; Epstein-Barr virus; latent membrane protein-1; Hodgkins lymphoma	REED-STERNBERG CELLS; JMJD3 CONTRIBUTES; GENE-EXPRESSION; HISTONE; DIFFERENTIATION; INHIBITION; ACTIVATION; ROLES; UTX	There is now evidence for both increased and decreased activity of the enzymes controlling the methylation of lysine 27 on histone 3 (H3K27) in cancer. One of these enzymes, KDM6B formally known as JMJD3, a histone demethylase, which removes the trimethyl mark from H3K27, is required for the lineage commitment and terminal differentiation of neural stem cells and of keratinocytes. Our results suggest that KDM6B may also have a role in antigen-driven B-cell differentiation. KDM6B expression increases in B-cell subsets with increasing stage of differentiation, and gene expression profiling shows that KDM6B transcriptional targets in germinal centre B (GC B) cells are significantly enriched for those differentially expressed during memory and plasma cell differentiation. Our results also suggest that aberrant expression of KDM6B may contribute to the pathogenesis of Hodgkin's Lymphoma (HL), an Epstein-Barr virus (EBV) associated malignancy. KDM6B is over-expressed in primary HL and induced by the EBV oncogene, latent membrane protein (LMP1) in GC B cells, the presumptive progenitors of HL. Consistent with these observations, we found that KDM6B transcriptional targets in GC B cells are enriched for genes differentially expressed in HL, and that KDM6B depletion can restore the tri-methylation of H3K27 on these genes. Oncogene (2011) 30, 2037-2043; doi:10.1038/onc.2010.579; published online 17 January 2011	[Anderton, J. A.; Bose, S.; Vockerodt, M.; Vrzalikova, K.; Wei, W.; Rowe, M.; Murray, P. G.; Woodman, C. B.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Kuo, M.] Birmingham Childrens Hosp, Dept Paediat Otolaryngol, Birmingham, W Midlands, England; [Helin, K.; Christensen, J.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Helin, K.; Christensen, J.] Univ Copenhagen, Ctr Epigenet, Copenhagen, Denmark	University of Birmingham; University of Birmingham; University of Copenhagen; University of Copenhagen	Woodman, CB (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	c.b.woodman@bham.ac.uk	Helin, Kristian/HDM-8306-2022; Rowe, Martin/B-2880-2009; Helin, Kristian/K-2526-2019; Vockerodt, Martina/L-4465-2014	Helin, Kristian/0000-0003-1975-6097; Rowe, Martin/0000-0003-4139-7326; Vockerodt, Martina/0000-0001-7761-5829; Wei, Wenbin/0000-0003-1288-6999	Leukaemia and Lymphoma Research Fund; Medical Research Council [G9818340B] Funding Source: researchfish	Leukaemia and Lymphoma Research Fund; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Leukaemia and Lymphoma Research Fund.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622; Aldinucci D, 2010, J PATHOL, V221, P248, DOI 10.1002/path.2711; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Burgold T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003034; Dai JP, 2010, J CELL BIOCHEM, V110, P1457, DOI 10.1002/jcb.22703; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Dirmeier U, 2005, ONCOGENE, V24, P1711, DOI 10.1038/sj.onc.1208367; Fei T, 2010, GENOME RES, V20, P36, DOI 10.1101/gr.092114.109; Gunther T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000935; HAAFTEN GV, 2010, FUNDERS GROUP HUMAN, V41, P521; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Holland D, 2008, CANCER RES, V68, P9964, DOI 10.1158/0008-5472.CAN-08-1134; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood-2009-04-217620; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Mainou-Fowler T, 2004, LEUKEMIA RES, V28, P159, DOI 10.1016/S0145-2126(03)00216-9; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Neuhierl B, 2002, P NATL ACAD SCI USA, V99, P15036, DOI 10.1073/pnas.232381299; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; SANDVEJ KB, 1993, LEUKEMIA LYMPHOMA, V9, P95, DOI 10.3109/10428199309148510; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Shannon-Lowe C, 2005, J GEN VIROL, V86, P3009, DOI 10.1099/vir.0.81153-0; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Skinnider BF, 2002, BLOOD, V99, P618, DOI 10.1182/blood.V99.2.618; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vockerodt M, 2008, J PATHOL, V216, P83, DOI 10.1002/path.2384	32	104	110	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2037	2043		10.1038/onc.2010.579	http://dx.doi.org/10.1038/onc.2010.579			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242977				2022-12-28	WOS:000289977400007
J	Ou, WB; Corson, JM; Flynn, DL; Lu, WP; Wise, SC; Bueno, R; Sugarbaker, DJ; Fletcher, JA				Ou, W-B; Corson, J. M.; Flynn, D. L.; Lu, W-P; Wise, S. C.; Bueno, R.; Sugarbaker, D. J.; Fletcher, J. A.			AXL regulates mesothelioma proliferation and invasiveness	ONCOGENE			English	Article						AXL; receptor tyrosine kinases; proliferation; invasiveness; mesothelioma	RECEPTOR TYROSINE KINASE; MALIGNANT PLEURAL MESOTHELIOMA; GASTROINTESTINAL STROMAL TUMORS; ENDOTHELIAL GROWTH-FACTOR; FACTOR SCATTER FACTOR; MET RECEPTOR; CELL-LINE; FACTOR-I; C-MET; EXPRESSION	Mesothelioma is an asbestos-associated and notoriously chemotherapy-resistant neoplasm. Activation of the receptor tyrosine kinases (RTKs), epidermal growth factor receptor and MET, has been described in subsets of mesothelioma, suggesting that TKs might represent therapeutic targets in this highly lethal disease. We employed proteomic screening by phosphotyrosine immunoaffinity purification and tandem mass spectrometry to characterize RTK activation in mesothelioma cell lines. These assays demonstrated expression and activation of the AXL protein, which is an RTK with known oncogenic properties in non-mesothelial cancer types. AXL was expressed and activated strongly in 8 of 9 mesothelioma cell lines and 6 of 12 mesothelioma biopsies, including each of 12 mesotheliomas with spindle-cell histology. Somatic AXL mutations were not found, but all mesotheliomas expressed an alternatively spliced AXL transcript with in-frame deletion of exon 10, and six of seven mesothelioma cell lines expressed the AXL ligand, growth arrest-specific 6 (GAS6). GAS6 expression appeared to be functionally relevant, as indicated by modulation of AXL tyrosine phosphorylation by knockdown of endogeneous GAS6, and by administration of exogenous GAS6. AXL silencing by lentivirus-mediated short hairpin RNA suppressed mesothelioma migration and cellular proliferation due to G1 arrest. The AXL inhibitor DP-3975 inhibited cell migration and proliferation in mesotheliomas with strong AXL activation. DP-3975 response in these tumors was characterized by inhibition of PI3-K/AKT/mTOR and RAF/MAPK signaling. AXL inhibition suppressed mesothelioma anchorage-independent growth, with reduction in colony numbers and size. These studies suggest that AXL inhibitors warrant clinical evaluation in mesothelioma. Oncogene (2011) 30, 1643-1652; doi:10.1038/onc.2010.555; published online 6 December 2010	[Ou, W-B; Corson, J. M.; Fletcher, J. A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ou, W-B; Corson, J. M.; Fletcher, J. A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Lu, W-P; Wise, S. C.] Deciphera Pharmaceut LLC, Dept Res Discovery, Lawrence, KS USA; [Bueno, R.; Sugarbaker, D. J.] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ou, WB (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	wou@rics.bwh.harvard.edu; jfletcher@partners.org	Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442	Brigham and Women's Hospital	Brigham and Women's Hospital	This research was supported by funding from the International Mesothelioma Program at Brigham and Women's Hospital.	Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; CARBONE M, 1994, ONCOGENE, V9, P1781; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DEMETRI GD, 1989, BLOOD, V74, P940; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Harir N, 2008, BLOOD, V112, P2463, DOI 10.1182/blood-2007-09-115477; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Janne PA, 2002, CANCER RES, V62, P5242; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; LEE TC, 1993, CANCER RES, V53, P2858; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Meric F, 2002, CLIN CANCER RES, V8, P361; Mukohara T, 2005, CLIN CANCER RES, V11, P8122, DOI 10.1158/1078-0432.CCR-05-1191; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Pache JC, 1998, AM J PATHOL, V152, P333; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Pass HI, 1996, CANCER RES, V56, P4044; QUONG RYY, 1994, MELANOMA RES, V4, P313, DOI 10.1097/00008390-199410000-00008; Rubin BP, 2001, CANCER RES, V61, P8118; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Tsao AS, 2007, MOL CANCER THER, V6, P1962, DOI 10.1158/1535-7163.MCT-07-0052; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Xia GB, 2005, CLIN CANCER RES, V11, P4305, DOI 10.1158/1078-0432.CCR-04-2109; Yang MH, 2007, ONCOGENE, V26, P1459, DOI 10.1038/sj.onc.1209929	43	61	63	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	14					1643	1652		10.1038/onc.2010.555	http://dx.doi.org/10.1038/onc.2010.555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132014				2022-12-28	WOS:000289239400003
J	Plante, I; Stewart, MKG; Barr, K; Allan, AL; Laird, DW				Plante, I.; Stewart, M. K. G.; Barr, K.; Allan, A. L.; Laird, D. W.			Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease	ONCOGENE			English	Article						gap junctions; mammary gland tumor; metastasis; connexin43; ErbB2	GAP-JUNCTIONS; MYOEPITHELIAL CELLS; HUMAN BREAST; GLAND DEVELOPMENT; DOWN-REGULATION; EXPRESSION; CONNEXIN-43; DIFFERENTIATION; CX26; PHOSPHORYLATION	Gap junctions, the channels formed by the connexin (Cx) family of proteins, are responsible for direct intercellular communication. Although connexins are considered as tumor suppressors, their overall role in cancer onset, progression and metastasis is somewhat controversial. This study uses a novel Cx43 mutant mouse model (G60S mice) and cross-breeding strategies to determine the role of Cx43 in all stages of breast tumorigenesis. G60S mice were cross-bred with ErbB2 overexpressing mice, and spontaneous and 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced tumor development was evaluated. Mice were killed when tumors reached similar to 1 cm(3) or when mice showed signs of critical illness. In both spontaneous and DMBA studies, onset of palpable tumors was delayed in G60S mice compared with mice in control groups. Moreover, while tumors from control mice reached the size threshold, most DMBA-exposed Cx43 mutant mice were killed prematurely because of labored breathing, independent of the presence of a palpable tumor. Reduced Cx43 levels in Cx43 mutant mice were accompanied by extensive mammary gland hyperplasia. Lung histology revealed that all Cx43 mutant mice exhibited mammaglobin-positive mammary gland metastases to the lung, and the number of metastases was increased by threefold in Cx43 mutant mice on treatment with DMBA. Thus, while reduced levels of Cx43 delayed the onset of palpable tumors, normal Cx43 levels inhibited mammary gland tumor metastasis to the lungs. Understanding the mechanisms of how Cx43, which is expressed primarily in myoepithelial cells, inhibits mammary gland tumor metastasis is critical as Cx43 is assessed as a candidate for therapeutic intervention. Oncogene (2011) 30, 1681-1692; doi:10.1038/onc.2010.551; published online 13 December 2010	[Plante, I.; Allan, A. L.; Laird, D. W.] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; [Stewart, M. K. G.; Barr, K.; Laird, D. W.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; [Allan, A. L.] Univ Western Ontario, Dept Oncol, London, ON N6A 5C1, Canada; [Allan, A. L.] London Reg Canc Program, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Dent Sci Bldg,Room 00077, London, ON N6A 5C1, Canada.	Dale.laird@schulich.uwo.ca	Laird, Dale W/AAL-2407-2020; Plante, Isabelle/AAK-5997-2021	Laird, Dale W/0000-0002-4568-3285; Plante, Isabelle/0000-0003-2080-6450	Canadian Breast Cancer Research Alliance; Canadian Institutes of Health Research; Fonds de la Recherche en Sante du Quebec	Canadian Breast Cancer Research Alliance; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec)	We thank David Goodale for his technical assistance. We are grateful to Dr Janet Rossant and team at the Centre for Modeling Human Disease (Toronto, ON, Canada) for providing the mouse model. This research was funded by the Canadian Breast Cancer Research Alliance to DWL, and by Fellowships from the Canadian Institutes of Health Research, the Canadian Institutes of Health Research Strategic Training Program and the Fonds de la Recherche en Sante du Quebec to IP. ALA is supported by a Canadian Institutes of Health Research New Investigator Award.	Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; Allred DC, 2008, J MAMMARY GLAND BIOL, V13, P279, DOI 10.1007/s10911-008-9093-5; Barsky SH, 2005, J MAMMARY GLAND BIOL, V10, P249, DOI 10.1007/s10911-005-9585-5; Bodenstine TM, 2008, CANCER MICROENVIRON, V1, P1, DOI 10.1007/s12307-008-0001-8; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; De Flora S, 2006, INT J ONCOL, V29, P521; El-Sabban ME, 2003, J MAMMARY GLAND BIOL, V8, P463, DOI 10.1023/B:JOMG.0000017432.04930.76; Engel J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959-8049(03)00422-2; Flenniken AM, 2005, DEVELOPMENT, V132, P4375, DOI 10.1242/dev.02011; Foschini MP, 1998, VIRCHOWS ARCH, V432, P303, DOI 10.1007/s004280050170; Gudjonsson T, 2005, J MAMMARY GLAND BIOL, V10, P261, DOI 10.1007/s10911-005-9586-4; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Herve JC, 2007, PROG BIOPHYS MOL BIO, V94, P29, DOI 10.1016/j.pbiomolbio.2007.03.010; Hewitt SC, 2002, CANCER RES, V62, P2798; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Jacquemart IC, 2009, INT J ONCOL, V34, P517, DOI 10.3892/ijo_00000177; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; Kalra J, 2006, CARCINOGENESIS, V27, P2528, DOI 10.1093/carcin/bgl110; Kanczuga-Koda L, 2006, J CLIN PATHOL, V59, P429, DOI 10.1136/jcp.2005.029272; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; Manias JL, 2008, CARDIOVASC RES, V80, P385, DOI 10.1093/cvr/cvn203; McLachlan E, 2005, CELL COMMUN ADHES, V12, P279, DOI 10.1080/15419060500514143; McLachlan E, 2007, J MEMBRANE BIOL, V218, P107, DOI 10.1007/s00232-007-9052-x; Medina Daniel, 2007, Breast Dis, V28, P63; Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770; Monaghan P, 1996, EXP CELL RES, V223, P29, DOI 10.1006/excr.1996.0055; Nagata K, 2009, J PEDIATR SURG, V44, P2296, DOI 10.1016/j.jpedsurg.2009.07.070; Naoi Y, 2007, BREAST CANCER RES TR, V106, P11, DOI 10.1007/s10549-006-9465-8; Naus CC, 2010, NAT REV CANCER, V10, P435, DOI 10.1038/nrc2841; Paznekas WA, 2009, HUM MUTAT, V30, P724, DOI 10.1002/humu.20958; PITELKA DR, 1973, J CELL BIOL, V56, P797, DOI 10.1083/jcb.56.3.797; Plante I, 2008, DEV BIOL, V318, P312, DOI 10.1016/j.ydbio.2008.03.033; Plante I, 2010, BIOL REPROD, V82, P837, DOI 10.1095/biolreprod.109.081406; Rowse GJ, 1998, CANCER RES, V58, P2675; Saunders MM, 2001, CANCER RES, V61, P1765; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; Solan JL, 2005, BBA-BIOMEMBRANES, V1711, P154, DOI 10.1016/j.bbamem.2004.09.013; Solan JL, 2007, J MEMBRANE BIOL, V217, P35, DOI 10.1007/s00232-007-9035-y; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Sternlicht MD, 1997, MED HYPOTHESES, V48, P37, DOI 10.1016/S0306-9877(97)90022-0; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Talhouk RS, 2008, EXP CELL RES, V314, P3275, DOI 10.1016/j.yexcr.2008.07.030; Thomas T, 2005, J CELL SCI, V118, P4451, DOI 10.1242/jcs.02569; Tsubura A, 2007, MED MOL MORPHOL, V40, P9, DOI 10.1007/s00795-006-0351-6; van de Wouw AJ, 2003, ANN ONCOL, V14, P191, DOI 10.1093/annonc/mdg068; Yang M, 2010, MODERN PATHOL, V23, P654, DOI 10.1038/modpathol.2010.38	51	73	78	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1681	1692		10.1038/onc.2010.551	http://dx.doi.org/10.1038/onc.2010.551			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21151177				2022-12-28	WOS:000289239400006
J	Henry, LA; Johnson, DA; Sarrio, D; Lee, S; Quinlan, PR; Crook, T; Thompson, AM; Reis, JS; Isacke, CM				Henry, L. A.; Johnson, D. A.; Sarrio, D.; Lee, S.; Quinlan, P. R.; Crook, T.; Thompson, A. M.; Reis-Filho, J. S.; Isacke, C. M.			Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome	ONCOGENE			English	Article						endoglin; CD105; breast cancer; TGF-beta; MCF10A; ErbB2	GROWTH-FACTOR-BETA; MOUSE SKIN CARCINOGENESIS; TGF-BETA; ENDOTHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; RECEPTOR; CANCER; MIGRATION; PROLIFERATION; ACTIVATION	Tumor growth factor-beta (TGF-beta) signaling in cancer has been implicated in growth suppression of early lesions and enhancing tumor cell invasion and metastasis. However, the cellular mechanisms that determine this signaling output in individual tumors are still largely unknown. In endothelial cells, TGF-beta signaling is modulated by the TGF-beta co-receptor endoglin (CD105). Here we demonstrate that endoglin is expressed in a subset of invasive breast cancers and cell lines and is subject to epigenetic silencing by gene methylation. Endoglin downregulation in non-tumorigenic MCF10A breast cells leads to the formation of abnormal acini in 3D culture, but does not promote cell migration or transformation. In contrast, in the presence of activated ErbB2, endoglin downregulation in MCF10A cells leads to enhanced invasion into a 3D matrix. Consistent with these data, ectopic expression of endoglin in MDA-MB-231 cells blocks TGF-beta-enhanced cell motility and invasion and reduces lung colonization in an in vivo metastasis model. Unlike endothelial cells, endoglin does not modulate Smad-mediated TGF-beta signaling in breast cells but attenuates the cytoskeletal remodeling to impair cell migration and invasion. Importantly, in a large cohort of invasive breast cancers, lack of endoglin expression in the tumor cell compartment correlates with ENG gene methylation and poor clinical outcome. Oncogene (2011) 30, 1046-1058; doi:10.1038/onc.2010.488; published online 1 November 2010	[Henry, L. A.; Johnson, D. A.; Sarrio, D.; Lee, S.; Crook, T.; Reis-Filho, J. S.; Isacke, C. M.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Quinlan, P. R.; Thompson, A. M.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Dundee	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk	SARRIO, DAVID/Y-8903-2019	Isacke, Clare/0000-0002-9222-3345; Quinlan, Philip/0000-0002-3012-6646; Sarrio, David/0000-0003-4886-8290	Breakthrough Breast Cancer; NHS; Marie Curie Intra-European Fellowship [PIEF-GA-2008-221083]; Breast Cancer Research Scotland; Tayside Tissue Bank	Breakthrough Breast Cancer; NHS; Marie Curie Intra-European Fellowship(European Commission); Breast Cancer Research Scotland; Tayside Tissue Bank	We thank Kay Savage and Suzanne Parry for immunohistochemical staining, Reshma Shah for help with the methylation analysis, Caterina Marchio for microdissection, Senthil Muthuswamy for the MCF10A.ErbB2 cells and Ariad Pharmaceuticals (www.ariad.com/regulationkits) for the AP1510 reagent. This project was funded by Breakthrough Breast Cancer and from NHS funding to the NIHR Biomedical Research Centre, a Marie Curie Intra-European Fellowship (PIEF-GA-2008-221083) and Breast Cancer Research Scotland with support from the Tayside Tissue Bank.	Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bernabeu C, 2007, J CELL BIOCHEM, V102, P1375, DOI 10.1002/jcb.21594; Bernabeu C, 2009, BBA-MOL BASIS DIS, V1792, P954, DOI 10.1016/j.bbadis.2009.07.003; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Craft CS, 2007, ONCOGENE, V26, P7240, DOI 10.1038/sj.onc.1210533; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012; Ishibashi O, 2010, J CELL PHYSIOL, V222, P465, DOI 10.1002/jcp.21968; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Klingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lee NY, 2007, J BIOL CHEM, V282, P21507, DOI 10.1074/jbc.M700176200; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rodriguez-Barbero A, 2006, CELL PHYSIOL BIOCHEM, V18, P135, DOI 10.1159/000095181; Romero D, 2010, CARCINOGENESIS, V31, P359, DOI 10.1093/carcin/bgp217; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Scherner O, 2007, J BIOL CHEM, V282, P13934, DOI 10.1074/jbc.M611062200; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wong VCL, 2008, INT J CANCER, V123, P2816, DOI 10.1002/ijc.23882; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	40	45	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1046	1058		10.1038/onc.2010.488	http://dx.doi.org/10.1038/onc.2010.488			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042283				2022-12-28	WOS:000287964100004
J	Li, Q; He, Y; Wei, L; Wu, X; Wu, D; Lin, S; Wang, Z; Ye, Z; Lin, SC				Li, Q.; He, Y.; Wei, L.; Wu, X.; Wu, D.; Lin, S.; Wang, Z.; Ye, Z.; Lin, S-C			AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation	ONCOGENE			English	Article						AXIN; PML; p53; PML-nuclear body	TUMOR-SUPPRESSOR; RAR-ALPHA; PML; HIPK2; GENE; PHOSPHORYLATION; IDENTIFICATION; GROWTH; DAXX; TRANSLOCATION	The PML protein is best known for its role as a tumor suppressor for acute promyelocytic leukemia. Both PML and the key Wnt signaling regulator AXIN regulate p53-dependent apoptosis in response to DNA damage. However, how the two major tumor suppressors coordinate with each other is unknown, and the molecular components orchestrating the PML-induced apoptosis remain enigmatic. Here we show that AXIN interacts with PML in vivo, and further that AXIN, PML and p53 form a ternary complex. Exposure to genotoxic signals including UV and doxorubicin induces AXIN to enter into the nucleus where it colocalizes with PML in the nuclear bodies. Domain-mapping experiments revealed that the C-terminal region (aa 597-832) of AXIN is responsible for its interaction with PML. AXIN fails to activate p53 in PML-/- cells, and conversely, PML is unable to activate p53 in AXIN-null SNU475 cells. Consistently, knockdown with respective siRNAs revealed that AXIN and PML depend on each other to elevate p53-Ser-46 phosphorylation and to induce apoptosis after treatment with genotoxins. Moreover, we found that dominant-negative mutants of PML blocked AXIN-induced p53 activation, and that AXIN promotes PML sumoylation, a modification necessary for PML functions. Our finding has thus provided a new avenue for understanding the mechanism by which PML activates p53 and exerts its role as a tumor suppressor. Oncogene (2011) 30, 1194-1204; doi:10.1038/onc.2010.499; published online 8 November 2010	[Li, Q.; He, Y.; Wei, L.; Wu, X.; Wu, D.; Lin, S.; Wang, Z.; Ye, Z.; Lin, S-C] Xiamen Univ, Key Lab, Fujian Lab Canc Biol, Sch Life Sci,Minist Educ Cell Biol & Tumor Cell, Xiamen 361005, Fujian, Peoples R China	Xiamen University	Lin, SC (corresponding author), Xiamen Univ, Key Lab, Fujian Lab Canc Biol, Sch Life Sci,Minist Educ Cell Biol & Tumor Cell, 422 Siming S Rd, Xiamen 361005, Fujian, Peoples R China.	linsc@xmu.edu.cn	Lin, Shu-Yong/B-7726-2012; Wu, Di/D-3595-2017; Lin, SC/G-4666-2010	Lin, Shu-Yong/0000-0002-4419-1713; Wu, Di/0000-0002-5895-2237; 	MOST [2009CB522200, 2006AA02A303, 2007CB914602]; National Natural Science Foundation of China [30730025, 30921005, 30500273, 30770454, 30970613]; Natural Science Foundation of Fujian Province [2008J0109, 2009J06021]; program for NCET	MOST; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); program for NCET(Program for New Century Excellent Talents in University (NCET))	We thank Dr PP Pandolfi for the gift of the wild-type MEF cells and PML <SUP>/</SUP> MEF cells, Dr Qiao Wu for the RARE luciferase reporter. This work was supported by grants from MOST (nos. 2009CB522200 and 2006AA02A303). This work was also supported by grants from National Natural Science Foundation of China (nos. 30730025, 30921005, 30500273, 30770454, 30970613), the National Basic Research Program of MOST (no. 2007CB914602), the Natural Science Foundation of Fujian Province (nos. 2008J0109 and 2009J06021) and the program for NCET.	ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bernardi R, 2008, ONCOGENE, V27, P6299, DOI 10.1038/onc.2008.305; Bruno S, 2003, BLOOD, V101, P3514, DOI 10.1182/blood-2002-11-3335; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Eskiw CH, 2004, J BIOL CHEM, V279, P9577, DOI 10.1074/jbc.M312580200; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Gresko E, 2009, ONCOGENE, V28, P698, DOI 10.1038/onc.2008.420; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jin LH, 2003, INT J CANCER, V107, P696, DOI 10.1002/ijc.11435; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Martic TN, 2010, PATHOL ONCOL RES, V16, P75, DOI 10.1007/s12253-009-9190-9; Moller A, 2003, CANCER RES, V63, P4310; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Shima Y, 2008, MOL CELL BIOL, V28, P7126, DOI 10.1128/MCB.00897-08; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu Q, 2009, J BIOL CHEM, V284, P8738, DOI 10.1074/jbc.M807590200; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	45	11	12	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1194	1204		10.1038/onc.2010.499	http://dx.doi.org/10.1038/onc.2010.499			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057547				2022-12-28	WOS:000288202400006
J	Rai, P; Young, JJ; Burton, DGA; Giribaldi, MG; Onder, TT; Weinberg, RA				Rai, P.; Young, J. J.; Burton, D. G. A.; Giribaldi, M. G.; Onder, T. T.; Weinberg, R. A.			Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence	ONCOGENE			English	Article						cellular senescence; DNA damage; oxidative stress; 8-oxoguanine; MTH1; RAS oncogene	LABILE IRON POOL; CANCER-CELLS; HUMAN FIBROBLASTS; MECHANISM	Approximately 20% of tumors contain activating mutations in the RAS family of oncogenes. As tumors progress to higher grades of malignancy, the expression of oncogenic RAS has been reported to increase, leading to an oncogene-induced senescence (OIS) response. Evasion of this senescence barrier is a hallmark of advanced tumors indicating that OIS serves a critical tumor-suppressive function. Induction of OIS has been attributed to either RAS-mediated production of reactive oxygen species (ROS) or to induction of a DNA damage response (DDR). However, functional links between these two processes in triggering the senescent phenotype have not been explicitly described. Our previous work has shown that, in cultured untransformed cells, preventing elimination of oxidized guanine deoxyribonucleotides, which was achieved by suppressing expression of the cellular 8-oxo-dGTPase, human MutT homolog 1 (MTH1), sufficed to induce a DDR as well as premature senescence. Here, we demonstrate that overexpression of MTH1 can prevent the oncogenic H-RAS-induced DDR and attendant premature senescence, although it does not affect the observed elevation in ROS levels produced by RAS oncoprotein expression. Conversely, we find that loss of MTH1 preferentially induces an in vitro proliferation defect in tumorigenic cells overexpressing oncogenic RAS. These results indicate that the guanine nucleotide pool is a critical target for intracellular ROS produced by oncogenic RAS and that RAS-transformed cells require robust MTH1 expression to proliferate. Oncogene (2011) 30, 1489-1496; doi:10.1038/onc.2010.520; published online 15 November 2010	[Rai, P.; Burton, D. G. A.; Giribaldi, M. G.] Univ Miami, Miller Sch Med, Div Gerontol & Geriatr Med, Dept Med, Miami, FL 33136 USA; [Young, J. J.; Onder, T. T.; Weinberg, R. A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Young, J. J.; Onder, T. T.; Weinberg, R. A.] MIT, Dept Biol, Cambridge, MA USA; [Weinberg, R. A.] Ludwig Ctr Mol Oncol, Cambridge, MA USA	University of Miami; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Rai, P (corresponding author), Univ Miami, Miller Sch Med, Div Gerontol & Geriatr Med, Dept Med, 1600 NW 10th Ave,RMSB 7094,Locator Code D-503, Miami, FL 33136 USA.	prai@med.miami.edu	Burton, Dominick/C-5282-2013; Onder, Tamer T/H-3330-2013; Onder, Tamer/O-3669-2019	Burton, Dominick/0000-0003-3631-6448; Onder, Tamer T/0000-0002-2372-9158; Onder, Tamer/0000-0002-2372-9158; Young-Glazer, Jennifer/0000-0002-3265-9112; Rai, Priyamvada/0000-0001-7822-7553	Leukemia and Lymphoma Society; James and Esther King Florida Biomedical Research Program; Howard Hughes Medical Institute; Ellison Medical Foundation for Aging Research; Ludwig Center for Molecular Oncology; Breast Cancer Research Fund	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); James and Esther King Florida Biomedical Research Program; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Ellison Medical Foundation for Aging Research; Ludwig Center for Molecular Oncology; Breast Cancer Research Fund	We are grateful to Anisleidys Munoz for experimental assistance. We thank Dr Carlos Perez-Stable and Dr Ramiro Verdun for helpful comments on this manuscript. RAW is a Professor at American Cancer Society Research and at Daniel K Ludwig Cancer Research. This work was supported by a Leukemia and Lymphoma Society Postdoctoral fellowship and a James and Esther King Florida Biomedical Research Program New Investigator grant (to PR), a Howard Hughes Medical Institute summer undergraduate fellowship (to JJY) and grants from the Ellison Medical Foundation for Aging Research, The Ludwig Center for Molecular Oncology and the Breast Cancer Research Fund (to RAW).	Algarra Ignacio, 1998, Invasion and Metastasis, V18, P261, DOI 10.1159/000024519; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gackowski D, 2002, J BIOL INORG CHEM, V7, P548, DOI 10.1007/s00775-001-0335-x; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Haghdoost S, 2006, FREE RADICAL BIO MED, V41, P620, DOI 10.1016/j.freeradbiomed.2006.05.003; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Kawanishi S, 2001, MUTAT RES-REV MUTAT, V488, P65, DOI 10.1016/S1383-5742(00)00059-4; Kruszewski M, 2003, MUTAT RES-FUND MOL M, V531, P81, DOI 10.1016/j.mrfmmm.2003.08.004; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; Nakabeppu Y, 2001, MUTAT RES-FUND MOL M, V477, P59, DOI 10.1016/S0027-5107(01)00096-3; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rai P, 2009, P NATL ACAD SCI USA, V106, P169, DOI 10.1073/pnas.0809834106; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serra V, 2003, J BIOL CHEM, V278, P6824, DOI 10.1074/jbc.M207939200; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Struthers L, 1998, ANAL BIOCHEM, V255, P20, DOI 10.1006/abio.1997.2354; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010; Yoon SH, 2005, BIOCHEM BIOPH RES CO, V327, P342, DOI 10.1016/j.bbrc.2004.12.013	32	92	94	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	12					1489	1496		10.1038/onc.2010.520	http://dx.doi.org/10.1038/onc.2010.520			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21076467				2022-12-28	WOS:000288743800011
J	Xu, H; Zheng, L; Dai, H; Zhou, M; Hua, Y; Shen, B				Xu, H.; Zheng, L.; Dai, H.; Zhou, M.; Hua, Y.; Shen, B.			Chemical-induced cancer incidence and underlying mechanisms in Fen1 mutant mice	ONCOGENE			English	Article						FEN1; long-patch base excision repair; methylnitrosourea; tetraploidy; aneuploidy; cancer	BASE EXCISION-REPAIR; DNA-POLYMERASE-BETA; FLAP ENDONUCLEASE-1; LUNG-CANCER; HUMAN-CELLS; DAMAGE; INSTABILITY; GLYCOSYLASES; REPLICATION; STIMULATION	A critical observation in sporadic cancers is that not all individuals are equally prone to developing cancer following exposure to a given environmental carcinogen. Epidemiological studies have suggested that the difference in the timing of cancer onset in response to exogenous DNA damage is likely attributable to genetic variations, such as those associated with base excision repair (BER) genes. To test this long-standing hypothesis and elucidate how a genetic variation in the BER gene flap endonuclease 1 (FEN1) results in susceptibility to environment insults and causes cancer, we established a mutant mouse model carrying a point mutation (E160D) in Fen1. We demonstrate that the E160D mutation impairs the ability of FEN1 to process DNA intermediate structures in long-patch BER using nuclear extracts or reconstituted purified BER proteins. E160D cells were more sensitive to the base-damaging agents methylnitrosourea and hydrogen peroxide, leading to DNA strand breaks, chromosomal breakage and chromosome instabilities in response these DNA insults. We further show that E160D mice are significantly more susceptible to exposure to methylnitrosourea and develop lung adenocarcinoma. Thus, our current study demonstrates that a subtle genetic variation (E160D) in BER genes (FEN1) may cause a functional deficiency in repairing base damage, such that individuals carrying the mutation or similar mutations are predisposed to chemical-induced cancer development. Oncogene (2011) 30, 1072-1081; doi:10.1038/onc.2010.482; published online 25 October 2010	[Xu, H.; Hua, Y.; Shen, B.] Zhejiang Univ, Inst Nucl Agr Sci, Chinese Minist Agr Nucl Agr Sci, Key Lab, Hangzhou 310029, Zhejiang, Peoples R China; [Xu, H.; Zheng, L.; Dai, H.; Zhou, M.; Shen, B.] City Hope Natl Med Ctr, Dept Canc Biol, Duarte, CA 91010 USA; [Xu, H.; Zheng, L.; Dai, H.; Zhou, M.; Shen, B.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	Zhejiang University; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shen, B (corresponding author), City Hope Natl Med Ctr, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	yjhua@zju.edu.cn; bshen@coh.org		Shen, Binghui/0000-0002-4408-407X	NIH [R01 CA073764]; China Scholarship Council (CSC); NATIONAL CANCER INSTITUTE [R01CA073764] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council (CSC)(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the microscopy core facility of City of Hope for technical assistance with immunofluorescence staining of MEF cells. We thank D Finger for technical advice on purification of FEN1 proteins. We thank SR da Costa and K Walker for editorial assistance. All protocols involving animal use were approved by the research animal care committee of City of Hope National Medical Center and Beckman Research Institute in compliance with the Public Health Service Policy on Use of Laboratory Animals. This work was supported by an NIH grant R01 CA073764 to BHS and a scholarship from China Scholarship Council (CSC) to HX.	Asagoshi K, 2010, DNA REPAIR, V9, P109, DOI 10.1016/j.dnarep.2009.11.002; Balakrishnan L, 2009, J BIOL CHEM, V284, P15158, DOI 10.1074/jbc.M109.000505; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Chang JS, 2009, CARCINOGENESIS, V30, P78, DOI 10.1093/carcin/bgn261; Cistulli C, 2004, DNA REPAIR, V3, P581, DOI 10.1016/j.dnarep.2003.09.012; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Donny W, 2004, J BIOL CHEM, V279, P25268, DOI 10.1074/jbc.M400804200; Figueroa JD, 2007, HUM GENET, V121, P233, DOI 10.1007/s00439-006-0294-y; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo ZG, 2009, NUCLEIC ACIDS RES, V37, P3431, DOI 10.1093/nar/gkp201; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 1997, BIOCHEM J, V325, P1; Landi S, 2005, EXP LUNG RES, V31, P223, DOI 10.1080/01902140490495624; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; MING Y, 2009, HUM MUTAT, V30, P1320; Nakamura J, 1998, CANCER RES, V58, P222; Pascucci B, 2005, NUCLEIC ACIDS RES, V33, P280, DOI 10.1093/nar/gki168; Prasad R, 2005, DNA REPAIR, V4, P1347, DOI 10.1016/j.dnarep.2005.08.009; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; VAINIO H, 1994, SCAND J WORK ENV HEA, V20, P235, DOI 10.5271/sjweh.1402; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599	40	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1072	1081		10.1038/onc.2010.482	http://dx.doi.org/10.1038/onc.2010.482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972458	Green Accepted			2022-12-28	WOS:000287964100006
J	Kitajima, S; Miki, T; Takegami, Y; Kido, Y; Noda, M; Hara, E; Shamma, A; Takahashi, C				Kitajima, S.; Miki, T.; Takegami, Y.; Kido, Y.; Noda, M.; Hara, E.; Shamma, A.; Takahashi, C.			Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling	ONCOGENE			English	Article						senescence; negative feedback; RECK; EGFR; RAS; MMP	ONCOGENE-INDUCED SENESCENCE; METASTASIS SUPPRESSOR RECK; CELL LUNG-CANCER; DNA-DAMAGE RESPONSE; MATRIX-METALLOPROTEINASE; DOWN-REGULATION; PROGNOSTIC-SIGNIFICANCE; PROMOTER METHYLATION; NEGATIVE FEEDBACK; EXPRESSION	The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene had been isolated as an antagonist to RAS signaling; however, the mechanism of its action is not clear. In this study, the effect of loss of RECK function was assessed in various ways and cell systems. Successive cell cultivation of mouse embryonic fibroblasts (MEFs) according to 3T3 protocol revealed that the germline knockout of RECK confers accelerated cell proliferation and early escape from cellular senescence associated with downregulation of p19(Arf), Trp53 and p21(Cdkn1a). In contrast, short hairpin RNA-mediated depletion of RECK induced irreversible growth arrest along with several features of the Arf, Trp53 and Cdkn1a-dependent cellular senescence. Within 2 days of RECK depletion, we observed a transient increase in protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) phosphorylation associated with an upregulated expression of cyclin D1, p19(Arf), Trp53, p21(Cdkn1a) and Sprouty 2. On further cultivation, RAS, AKT and ERK activities were then downregulated to a level lower than control, indicating that RECK depletion leads to a negative feedback to RAS signaling and subsequent cellular senescence. In addition, we observed that epidermal growth factor receptor (EGFR) activity was transiently upregulated by RECK depletion in MEFs, and continuously downregulated by RECK overexpression in colon cancer cells. These findings indicate that RECK is a novel modulator of EGFR signaling. Oncogene (2011) 30, 737-750; doi:10.1038/onc.2010.448; published online 4 October 2010	[Kitajima, S.; Kido, Y.; Shamma, A.; Takahashi, C.] Kanazawa Univ, Canc Res Inst, Canc & Stem Cell Res Program, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan; [Kitajima, S.; Miki, T.; Takegami, Y.; Noda, M.; Shamma, A.; Takahashi, C.] Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto, Japan; [Miki, T.; Shamma, A.; Takahashi, C.] Kyoto Univ, Grad Sch Med, 21st Century Ctr Excellence Program, Sakyo Ku, Kyoto, Japan; [Miki, T.] Univ Texas Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX USA; [Hara, E.] Japanese Fdn Canc Res, Inst Canc, Div Canc Biol, Koto Ku, Tokyo 170, Japan	Kanazawa University; Kyoto University; Kyoto University; University of Texas System; University of Texas Health Science Center Houston; Japanese Foundation for Cancer Research	Takahashi, C (corresponding author), Kanazawa Univ, Canc Res Inst, Canc & Stem Cell Res Program, Div Oncol & Mol Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	chtakaha@staff.kanazawa-u.ac.jp		Shamma, Awad/0000-0002-3037-616X	JASSO scholarship; Princess Takamatsu Cancer Research Fund; Astellas Foundation for Research on Metabolic Disorders; Takeda Science Foundation; Japanese Ministry of Education, Culture, Sports, Science and Technology; Grants-in-Aid for Scientific Research [22500998] Funding Source: KAKEN	JASSO scholarship; Princess Takamatsu Cancer Research Fund; Astellas Foundation for Research on Metabolic Disorders; Takeda Science Foundation(Takeda Science Foundation (TSF)); Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H Sato and T Muraguchi for critical reading of the paper; T Kamijo, P Leder, N Sharpless, S Itohara, Y Okada and M Seiki for providing the mice; M Seiki, T Sakamoto and T Nakano for providing cells; S Yano and K Matsumoto and S Higashiyama for providing the reagents; C Sugita for supporting mouse transfer; W Hung, K Lee and J Oh for encouragement; H Gu and A Nishimoto for technical assistance; and A Miyazaki and M Suzuki for secretarial assistance. SK thanks the JASSO scholarship for support. This work was supported by a Research Grant from the Princess Takamatsu Cancer Research Fund, Astellas Foundation for Research on Metabolic Disorders, the Takeda Science Foundation and the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Andratschke Nicolaus H, 2004, Clin Lung Cancer, V5, P340, DOI 10.3816/CLC.2004.n.012; ANKER P, 1994, CR ACAD SCI III-VIE, V317, P869; Bardeesy N, 2006, CANCER CELL, V10, P451, DOI 10.1016/j.ccr.2006.11.015; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001; Chang HC, 2007, CANCER SCI, V98, P169, DOI 10.1111/j.1349-7006.2006.00367.x; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Clark JCM, 2007, CANCER METAST REV, V26, P675, DOI 10.1007/s10555-007-9093-8; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; D'Souza B, 2008, ONCOGENE, V27, P5148, DOI 10.1038/onc.2008.229; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hatta M, 2009, CELL SIGNAL, V21, P1885, DOI 10.1016/j.cellsig.2009.08.005; Hsu MC, 2006, J BIOL CHEM, V281, P4718, DOI 10.1074/jbc.M510937200; Hu SJ, 2008, J BIOL CHEM, V283, P23473, DOI 10.1074/jbc.M800406200; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Janne PA, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.10.004; Jodele S, 2006, CANCER METAST REV, V25, P35, DOI 10.1007/s10555-006-7887-8; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Liu LT, 2003, ONCOGENE, V22, P8263, DOI 10.1038/sj.onc.1207157; Loayza-Puch F, 2010, ONCOGENE, V29, P2638, DOI 10.1038/onc.2010.23; Long NK, 2008, ORAL ONCOL, V44, P1052, DOI 10.1016/j.oraloncology.2008.02.004; LYONS JG, 1993, J BIOL CHEM, V268, P19143; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miki T, 2007, J BIOL CHEM, V282, P12341, DOI 10.1074/jbc.M610948200; Miki T, 2010, MOL CANCER RES, V8, P665, DOI 10.1158/1541-7786.MCR-09-0351; Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Omura A, 2009, J BIOL CHEM, V284, P3461, DOI 10.1074/jbc.M806212200; Rabien A, 2007, EUR UROL, V51, P1259, DOI 10.1016/j.eururo.2006.05.050; RAHMAH NN, 2009, NEUROSURG REV, V173, P167; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Takagi S, 2009, CANCER RES, V69, P1502, DOI 10.1158/0008-5472.CAN-08-2635; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takemoto N, 2007, LUNG CANCER, V58, P376, DOI 10.1016/j.lungcan.2007.07.004; Takenaka K, 2005, ANN SURG ONCOL, V12, P817, DOI 10.1245/ASO.2005.09.018; Takenaka K, 2004, EUR J CANCER, V40, P1617, DOI 10.1016/j.ejca.2004.02.028; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKADA T, 1993, ONCOGENE, V8, P3313; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zolkiewska A, 2008, CELL MOL LIFE SCI, V65, P2056, DOI 10.1007/s00018-008-7586-4	57	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					737	750		10.1038/onc.2010.448	http://dx.doi.org/10.1038/onc.2010.448			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890302	Green Submitted			2022-12-28	WOS:000287192000010
J	Kim, J; Thorne, SH; Sun, L; Huang, B; Mochly-Rosen, D				Kim, J.; Thorne, S. H.; Sun, L.; Huang, B.; Mochly-Rosen, D.			Sustained inhibition of PKC alpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model	ONCOGENE			English	Article						bioluminescence; mammary cancer; metastasis; protein kinase C	PROTEIN-KINASE-C; BREAST-CANCER METASTASIS; MATRIX METALLOPROTEINASES; EPITHELIAL-CELLS; BETA-II; EXPRESSION; ACTIVATION; PEPTIDES; INVASION; THERAPY	Metastasis is the major reason for breast cancer-related deaths. Although there is a host of indirect evidence for a role of protein kinase C (PKC) alpha in primary breast cancer growth, its role in the molecular pathways leading to metastasis has not been studied comprehensively. By treating mice with alpha V5-3, a novel peptide inhibitor selective for PKC alpha, we were able to determine how PKC alpha regulates metastasis of mammary cancer cells using a syngeneic and orthotopic model. The primary tumor growth was not affected by alpha V5-3 treatment. However, the mortality rate was reduced and metastasis in the lung decreased by more than 90% in the alpha V5-3-treated mice relative to the control-treated mice. alpha V5-3 treatment reduced intravasation by reducing matrix metalloproteinase-9 activities. alpha V5-3 treatment also reduced lung seeding of tumor cells and decreased cell migration, effects that were accompanied by a reduction in nuclear factor kappa B activity and cell surface levels of the CXCL12 receptor, CXCR4. alpha V5-3 treatment caused no apparent toxicity in non-tumor-bearing naive mice. Rather, inhibiting PKC alpha protected against liver damage and increased the number of immune cells in tumor-bearing mice. Importantly, alpha V5-3 showed superior efficacy relative to anti-CXCR4 antibody in reducing metastasis in vivo. Together, these data show that pharmacological inhibition of PKC alpha effectively reduces mammary cancer metastasis by targeting intravasation and lung seeding steps in the metastatic process and suggest that PKC alpha-specific inhibitors, such as alpha V5-3, can be used to study the mechanistic roles of PKC alpha specifically and may provide a safe and effective treatment for the prevention of lung metastasis of breast cancer patients. Oncogene (2011) 30, 323-333; doi:10.1038/onc.2010.415; published online 20 September 2010	[Kim, J.; Sun, L.; Mochly-Rosen, D.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Thorne, S. H.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Thorne, S. H.; Huang, B.] Univ Pittsburgh, Div Surg Oncol, Inst Canc, Pittsburgh, PA USA	Stanford University; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, Room 3145-A,269 Campus Dr, Stanford, CA 94305 USA.	mochly@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733; Kim, Jeewon/0000-0002-1063-0239	National Cancer Institute, DHHS [CA09151]; NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER	National Cancer Institute, DHHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Erinn Bruno Rankin in Dr Amato Giaccia's lab at the Department of Radiation Oncology at Stanford University for generous technical support and Dr Adrienne Gordon for critical reading of the paper. This work was supported in part by PHS Grant Number CA09151, awarded by the National Cancer Institute, DHHS (to JK).	Affara NI, 2007, CELL, V129, P25, DOI 10.1016/j.cell.2007.03.029; Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood-2006-07-035857; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; Begley R, 2004, BIOCHEM BIOPH RES CO, V318, P949, DOI 10.1016/j.bbrc.2004.04.121; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Christofori G, 2007, NATURE, V446, P735, DOI 10.1038/446735a; Cindoruk M, 2007, BMC GASTROENTEROL, V7, DOI 10.1186/1471-230X-7-44; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gross S, 2005, NAT METHODS, V2, P607, DOI 10.1038/NMETH779; Harvey JR, 2007, CLIN CANCER RES, V13, P1562, DOI 10.1158/1078-0432.CCR-06-1987; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Inagaki K, 2005, CIRCULATION, V111, P44, DOI 10.1161/01.CIR.0000151614.22282.F1; Kawakami A, 2007, ARTERIOSCL THROM VAS, V27, P219, DOI 10.1161/01.ATV.0000249620.68705.0d; Ke ZJ, 2006, INT J CANCER, V119, P8, DOI 10.1002/ijc.21769; Kim JW, 2008, CANCER RES, V68, P6831, DOI 10.1158/0008-5472.CAN-07-6195; Kim YM, 2000, CANCER RES, V60, P5410; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; Martiny-Baron G, 2007, PHARMACOL RES, V55, P477, DOI 10.1016/j.phrs.2007.04.001; Mi ZY, 2006, CARCINOGENESIS, V27, P1134, DOI 10.1093/carcin/bgi352; Mimeault M, 2007, CANCER METAST REV, V26, P203, DOI 10.1007/s10555-007-9052-4; Mochly-Rosen D, 1998, FASEB J, V12, P35; Molckovsky A, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-20; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Noel A, 2008, SEMIN CELL DEV BIOL, V19, P52, DOI 10.1016/j.semcdb.2007.05.011; OBRIAN CA, 1989, CANCER RES, V49, P3215; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Peter M, 2005, BIOPHYS J, V88, P1224, DOI 10.1529/biophysj.104.050153; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Shin Y, 2007, EXP MOL MED, V39, P97, DOI 10.1038/emm.2007.11; Sledge GW, 2006, SEMIN ONCOL, V33, pS15, DOI 10.1016/j.seminoncol.2006.03.019; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Taichman RS, 2002, CANCER RES, V62, P1832; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; Thorne SH, 2005, P IEEE, V93, P750, DOI 10.1109/JPROC.2005.844261; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; YEE JK, 1987, P NATL ACAD SCI USA, V84, P5197, DOI 10.1073/pnas.84.15.5197; Zorzi D, 2007, BRIT J SURG, V94, P274, DOI 10.1002/bjs.5719; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	48	52	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					323	333		10.1038/onc.2010.415	http://dx.doi.org/10.1038/onc.2010.415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856202	Green Accepted			2022-12-28	WOS:000286418800007
J	Kim, DS; Choi, YB; Han, BG; Park, SY; Jeon, Y; Kim, DH; Ahn, ER; Shin, JE; Lee, BI; Lee, H; Hong, KM; Kim, SY				Kim, D-S; Choi, Y-B; Han, B-G; Park, S-Y; Jeon, Y.; Kim, D-H; Ahn, E-R; Shin, J-E; Lee, B. I.; Lee, H.; Hong, K-M; Kim, S-Y			Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking	ONCOGENE			English	Article						transglutaminase 2; NF-kappa B; von Hippel-Lindau; IGF-1R; HIF-1 alpha; EPO	KAPPA-B ACTIVATION; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; TISSUE TRANSGLUTAMINASE; NECROSIS-FACTOR; DRUG-RESISTANT; FACTOR-I; PATHWAY; EXPRESSION; CARCINOMA	Nuclear factor-kappa B (NF-kappa B) and insulin-like growth factor-1 (IGF-1)-mediated signaling is associated with different tumors including renal cell carcinoma. NF-kappa B- and IGF-1-mediated signaling is found to be inhibited in the presence of wild-type von Hippel-Lindau (VHL) tumor suppresser gene. Therefore, negative regulator of VHL may be a good target for regulating NF-kappa B and IGF-1R. In this study, we found that VHL, a tumor suppressor protein that downregulates the NF-kappa B activity and the stability of IGF-1R was depleted by TGase 2 through polymerization via crosslinking and proteasomal degradation in kidney, breast and ovary cancer cell lines. We also found that TGase 2 knockdown promotes hypoxia-inducible factor 1 alpha (HIF-1 alpha) degradation, and thereby decrease HIF-1 alpha transcriptional activity. Importantly, VHL expression was decreased in vivo in TGase-2-transgenic mice, and this was associated with increased NF-kappa B activity and the levels of expression of IGF-1R, HIF-1 alpha and erythropoietin in kidney tissue. These results suggest a novel mechanism of regulation of the VHL tumor suppressor by TGase 2 that appears to be independent of the known cancer regulatory mechanisms. Oncogene (2011) 30, 4780-4790; doi: 10.1038/onc.2011.183; published online 30 May 2011	[Kim, D-S; Choi, Y-B; Han, B-G; Park, S-Y; Kim, D-H; Ahn, E-R; Shin, J-E; Lee, B. I.; Hong, K-M; Kim, S-Y] Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Res Inst, Goyang 410769, Kyunggi Do, South Korea; [Jeon, Y.; Lee, H.] Res Inst, Div Canc Biol, Canc Resources Branch, Goyang, South Korea	National Cancer Center - Korea (NCC)	Kim, SY (corresponding author), Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Res Inst, 323 Ilsan Ro, Goyang 410769, Kyunggi Do, South Korea.	kimsooyoul@gmail.com			National Cancer Center in Korea [NCC0810180-1, NCC1110011-1]; National Research Foundation of Korea; Ministry of Education, Science and Technology [20090086078]	National Cancer Center in Korea; National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by a research grant (NCC0810180-1 and NCC1110011-1) from the National Cancer Center in Korea and by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (no. 20090086078).	Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Casa AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3273, DOI 10.2741/2925; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Curtis CD, 2005, METH MOLEC MED, V103, P123; Gangadharan C, 2009, J CELL BIOCHEM, V107, P203, DOI 10.1002/jcb.22115; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Iismaa SE, 2009, PHYSIOL REV, V89, P991, DOI 10.1152/physrev.00044.2008; Jang GY, 2010, ONCOGENE, V29, P356, DOI 10.1038/onc.2009.342; Jung YJ, 2003, BIOCHEM J, V370, P1011, DOI 10.1042/BJ20021279; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kim DS, 2006, CANCER RES, V66, P10936, DOI 10.1158/0008-5472.CAN-06-1521; Kim DS, 2010, BIOCHEM BIOPH RES CO, V399, P300, DOI 10.1016/j.bbrc.2010.07.078; Kim DS, 2009, FRONT BIOSCI-LANDMRK, V14, P2514, DOI 10.2741/3394; Kim JM, 2008, J MOL BIOL, V384, P756, DOI 10.1016/j.jmb.2008.10.010; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Maiuri L, 2008, J IMMUNOL, V180, P7697, DOI 10.4049/jimmunol.180.11.7697; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Otrock ZK, 2009, CRIT REV ONCOL HEMAT, V70, P93, DOI 10.1016/j.critrevonc.2009.01.001; Park KS, 2009, FRONT BIOSCI-LANDMRK, V14, P1945, DOI 10.2741/3354; Park SS, 2006, J BIOL CHEM, V281, P34965, DOI 10.1074/jbc.M604150200; Qi H, 2003, CANCER RES, V63, P7076; Seo JS, 2010, J ETHNOPHARMACOL, V130, P578, DOI 10.1016/j.jep.2010.05.055; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Tischoff I, 2008, Z GASTROENTEROL, V46, P1202, DOI 10.1055/s-2008-1027406; Verma A, 2007, DRUG RESIST UPDATE, V10, P144, DOI 10.1016/j.drup.2007.06.002; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474; Yuen JSP, 2009, MOL CANCER THER, V8, P1448, DOI 10.1158/1535-7163.MCT-09-0101	28	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	48					4780	4790		10.1038/onc.2011.183	http://dx.doi.org/10.1038/onc.2011.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625219				2022-12-28	WOS:000298134700002
J	Shen, S; Kepp, O; Michaud, M; Martins, I; Minoux, H; Metivier, D; Maiuri, MC; Kroemer, RT; Kroemer, G				Shen, S.; Kepp, O.; Michaud, M.; Martins, I.; Minoux, H.; Metivier, D.; Maiuri, M. C.; Kroemer, R. T.; Kroemer, G.			Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study	ONCOGENE			English	Article						high-content screen; autophagy; cell death; systematic analysis; cancer therapy	PROGRAMMED CELL-DEATH; DEGRADATION; INHIBITION; STRESS; LYSOSOMES; INDUCTION; PROTEINS; DISEASE; MTORC1; LC3	To address the question of whether established or experimental anticancer chemotherapeutics can exert their cytotoxic effects by autophagy, we performed a high-content screen on a set of cytotoxic agents. We simultaneously determined parameters of autophagy, apoptosis and necrosis on cells exposed to similar to 1400 compounds. Many agents induced a 'pure' autophagic, apoptotic or necrotic phenotype, whereas less than 100 simultaneously induced autophagy, apoptosis and necrosis. A systematic analysis of the autophagic flux induced by the most potent 80 inducers of GFP-LC3 puncta among the NCI panel agents showed that 59 among them truly induced autophagy. The remaining 21 compounds were potent inducers of apoptosis or necrosis, yet failed to stimulate an autophagic flux, which were characterized as microtubule inhibitors. Knockdown of ATG7 was efficient in preventing GFP-LC3 puncta, yet failed to attenuate cell death by the agents that induce GFP-LC3 puncta. Thus there is not a single compound that would induce cell death by autophagy in our screening, underscoring the idea that cell death is rarely, if ever, executed by autophagy in human cells. Oncogene (2011) 30, 4544-4556; doi: 10.1038/onc.2011.168; published online 16 May 2011	[Shen, S.; Kepp, O.; Michaud, M.; Martins, I.; Metivier, D.; Maiuri, M. C.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Shen, S.; Kepp, O.; Michaud, M.; Martins, I.; Metivier, D.; Maiuri, M. C.] Univ Paris 11, Villejuif, France; [Minoux, H.; Kroemer, R. T.] Sanofi Aventis, Struct Design & Informat, Vitry Sur Seine, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@orange.fr	KROEMER, Guido/B-4263-2013; Kepp, Oliver/GPX-8627-2022; Kroemer, Guido/AAY-9859-2020; SHEN, Shensi/AAW-2735-2020; Kepp, Oliver/N-2763-2017	KROEMER, Guido/0000-0002-9334-4405; SHEN, Shensi/0000-0002-5087-8220; Kepp, Oliver/0000-0002-6081-9558	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); European Commission; Fondation pour la Recherche Medicale (FRM); Fondation Bettencourt-Schueller; Institut National du Cancer (INCa); Canceropole Ile-de-France; European Commission Apo-Sys; La Ligue contre le Cancer	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Fondation Bettencourt-Schueller; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); European Commission Apo-Sys(European CommissionEuropean Commission Joint Research Centre); La Ligue contre le Cancer(Ligue nationale contre le cancer)	GK is supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain), Fondation pour la Recherche Medicale (FRM), Fondation Bettencourt-Schueller, Institut National du Cancer (INCa) and Canceropole Ile-de-France. SS is supported by European Commission Apo-Sys and IM is supported by La Ligue contre le Cancer.	Akdemir F, 2006, DEVELOPMENT, V133, P1457, DOI 10.1242/dev.02332; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; ARLIN ZA, 1992, J CLIN ONCOL, V10, P169; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Carmona-Gutierrez D, 2006, MOL CELL, V24, P167, DOI 10.1016/j.molcel.2006.10.004; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Golstein P, 2003, NAT REV MOL CELL BIO, V4, P798, DOI 10.1038/nrm1224; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Gottlieb RA, 2010, ANNU REV PHYSIOL, V72, P45, DOI 10.1146/annurev-physiol-021909-135757; Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lee CY, 2001, DEVELOPMENT, V128, P1443; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Monga M, 2002, LEUKEMIA, V16, P520, DOI 10.1038/sj.leu.2402464; Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Shen S, 2010, CELL CYCLE, V9, P377, DOI 10.4161/cc.9.2.10468; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Steller H, 2008, CELL DEATH DIFFER, V15, P1132, DOI 10.1038/cdd.2008.50; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Xia HG, 2010, AUTOPHAGY, V6, P61, DOI 10.4161/auto.6.1.10326; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; Yuan Junying, 2004, Cell, VS116, pS53, DOI 10.1016/S0092-8674(04)00028-5; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104	55	126	131	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4544	4556		10.1038/onc.2011.168	http://dx.doi.org/10.1038/onc.2011.168			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21577201				2022-12-28	WOS:000296890700002
J	Al-Bahlani, S; Fraser, M; Wong, AYC; Sayan, BS; Bergeron, R; Melino, G; Tsang, BK				Al-Bahlani, S.; Fraser, M.; Wong, A. Y. C.; Sayan, B. S.; Bergeron, R.; Melino, G.; Tsang, B. K.			P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism	ONCOGENE			English	Article						CDDP; p73 alpha; calpain; calcium; ovarian cancer	X-LINKED INHIBITOR; P53 FAMILY; NEUROBLASTOMA-CELLS; CARCINOMA CELLS; FEEDBACK LOOP; IN-VIVO; CALPAIN; PROTEIN; BAX; CHEMOSENSITIVITY	P73 is important in drug-induced apoptosis in some cancer cells, yet its role in the regulation of chemosensitivity in ovarian cancer (OVCA) is poorly understood. Furthermore, if and how the deregulation of p73-mediated apoptosis confers resistance to cisplatin (CDDP) treatment is unclear. Here we demonstrate that TAp73 alpha over-expression enhanced CDDP-induced PARP cleavage and apoptosis in both chemosensitive (OV2008 and A2780s) and their resistant counterparts (C13* and A2780cp) and another chemoresistant OVCA cells (Hey); in contrast, the effect of Delta Np73 alpha over-expression was variable. P73 alpha downregulation attenuated CDDP-induced PUMA and NOXA upregulation and apoptosis in OV2008 cells. CDDP decreased p73 alpha steady-state protein levels in OV2008, but not in C13*, although the mRNA expression was identical. CDDP-induced p73 alpha downregulation was mediated by a calpain-dependent pathway. CDDP induced calpain activation and enhanced its cytoplasmic interaction and co-localization with p73 alpha in OV2008, but not C13* cells. CDDP increased the intracellular calcium concentration ([Ca(2+)](i)) in OV2008 but not C13* whereas cyclopiazonic acid (CPA), a Ca(2+)-ATPase inhibitor, caused this response and calpain activation, p73 alpha processing and apoptosis in both cell types. CDDP-induced [Ca(2+)](i) increase in OV2008 cells was not effected by the elimination of extracellular Ca(2+), but this was attenuated by the depletion of internal Ca(2+) store, indicating that mobilization of intracellular Ca(2+1) stores was potentially involved. These findings demonstrate that p73 alpha and its regulation by the Ca(2+)-mediated calpain pathway are involved in CDDP-induced apoptosis in OVCA cells and that dysregulation of Ca(2+)/calpain/p73 signaling may in part be the pathophysiology of CDDP resistance. Understanding the cellular and molecular mechanisms of chemoresistance will direct the development of effective strategies for the treatment of chemoresistant OVCA. Oncogene (2011) 30, 4219-4230; doi: 10.1038/onc.2011.134; published online 25 April 2011	[Al-Bahlani, S.; Fraser, M.; Tsang, B. K.] Univ Ottawa, Ottawa Hosp, Res Inst, Dept Obstet & Gynaecol, Ottawa, ON K1Y 4E9, Canada; [Al-Bahlani, S.; Fraser, M.; Wong, A. Y. C.; Bergeron, R.; Tsang, B. K.] Univ Ottawa, Ottawa Hosp, Res Inst, Dept Cellular & Mol Med, Ottawa, ON K1Y 4E9, Canada; [Al-Bahlani, S.; Fraser, M.] Ottawa Hosp, Res Inst, Chron Dis Program, Ottawa, ON, Canada; [Al-Bahlani, S.] Sultan Qaboos Univ, Dept Pathol, Muscat, Oman; [Wong, A. Y. C.; Bergeron, R.] Ottawa Hosp, Res Inst, Neurosci Program, Ottawa, ON, Canada; [Sayan, B. S.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Bergeron, R.; Tsang, B. K.] Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada; [Melino, G.] Univ Rome, Dept Expt Med, IDI IRCCS Biochem Lab, Rome, Italy; [Fraser, M.] Princess Margaret Hosp, Ontario Canc Inst, Radiat Med Program, Toronto, ON M4X 1K9, Canada; [Fraser, M.] Princess Margaret Hosp, Ontario Canc Inst, STTARR Innovat Facil, Toronto, ON M4X 1K9, Canada; [Tsang, B. K.] Seoul Natl Univ, World Class Univ WCU Biomodulat Major, Dept Agr Biotechnol, Coll Agr & Life Sci, Seoul, South Korea	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Sultan Qaboos University; University of Ottawa; Ottawa Hospital Research Institute; University of Leicester; University of Ottawa; Sapienza University Rome; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Seoul National University (SNU)	Tsang, BK (corresponding author), Univ Ottawa, Ottawa Hosp, Res Inst, Dept Obstet & Gynaecol, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca	Bahlani, Shadia/AAZ-3711-2020	Tsang, Benjamin K./0000-0003-1213-3946; Bergeron, Richard/0000-0002-5632-750X; Wong, Adrian/0000-0001-5652-3482	Canadian Institute of Health Research [MOP-15691]; WCU (World Class University) through National Research Foundation of Korea [R31-10056]; Ministry of Education, Science and Technology; UK Medical Research Council; Sultan Qaboos University, Sultanate of Oman; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); WCU (World Class University) through National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sultan Qaboos University, Sultanate of Oman; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from the Canadian Institute of Health Research (MOP-15691), the WCU (World Class University) program (R31-10056) through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology and the UK Medical Research Council. SA is a scholarship recipient of Sultan Qaboos University, Sultanate of Oman.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2008, CANCER RES, V68, P4511, DOI 10.1158/0008-5472.CAN-08-0673; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Chen CL, 2000, CLIN CANCER RES, V6, P3910; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Eltabbakh G H, 2001, Expert Opin Pharmacother, V2, P109, DOI 10.1517/14656566.2.1.109; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fraser M, 2003, CANCER RES, V63, P7081; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Fraser Michael, 2003, Reprod Biol Endocrinol, V1, P66, DOI 10.1186/1477-7827-1-66; Gao G, 2000, J CELL BIOCHEM, V80, P53; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gunes DA, 2009, NEUROTOXICOLOGY, V30, P194, DOI 10.1016/j.neuro.2008.12.001; Holcakova J, 2008, CELL MOL BIOL LETT, V13, P404, DOI 10.2478/s11658-008-0011-z; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Marabese M, 2005, CELL DEATH DIFFER, V12, P805, DOI 10.1038/sj.cdd.4401622; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Million K, 2006, INT J ONCOL, V29, P147; Moncoq K, 2007, J BIOL CHEM, V282, P9748, DOI 10.1074/jbc.M611653200; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2005, BIOCHEM BIOPH RES CO, V333, P954, DOI 10.1016/j.bbrc.2005.05.188; Muscolini M, 2008, MOL CANCER THER, V7, P1410, DOI 10.1158/1535-7163.MCT-08-0299; Nyman U, 2005, J BIOL CHEM, V280, P34159, DOI 10.1074/jbc.M500394200; Ozaki T, 2005, CANCER SCI, V96, P729, DOI 10.1111/j.1349-7006.2005.00116.x; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Righetti SC, 2008, CANCER LETT, V263, P140, DOI 10.1016/j.canlet.2007.12.024; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sabatino MA, 2007, INT J CANCER, V120, P506, DOI 10.1002/ijc.22362; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Splettstoesser F, 2007, BRIT J PHARMACOL, V151, P1176, DOI 10.1038/sj.bjp.0707335; Sullivan A, 2007, BRIT J CANCER, V96, P196, DOI 10.1038/sj.bjc.6603525; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Vayssade M, 2005, INT J CANCER, V116, P860, DOI 10.1002/ijc.21033; Vikhanskaya F, 2001, CANCER RES, V61, P935; Yoshida K, 2008, ONCOGENE, V27, P1183, DOI 10.1038/sj.onc.1210722	50	63	63	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	41					4219	4230		10.1038/onc.2011.134	http://dx.doi.org/10.1038/onc.2011.134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21516125	Green Published, hybrid			2022-12-28	WOS:000296356300001
J	Holleman, A; Chung, I; Olsen, RR; Kwak, B; Mizokami, A; Saijo, N; Parissenti, A; Duan, Z; Voest, EE; Zetter, BR				Holleman, A.; Chung, I.; Olsen, R. R.; Kwak, B.; Mizokami, A.; Saijo, N.; Parissenti, A.; Duan, Z.; Voest, E. E.; Zetter, B. R.			miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo	ONCOGENE			English	Article						paclitaxel resistance; miRNA-135a; APC; carcinoma	MICRORNA EXPRESSION PROFILES; BREAST-CANCER CELLS; ALKYLATING-AGENTS; DRUG-RESISTANCE; SENSITIVITY; PROSTATE; APC; MECHANISMS; PROTEIN; GENE	Cancer cell resistance to paclitaxel continues to be a major clinical problem. In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. Our results indicate that paclitaxel resistance is associated with upregulation of miR-135a, both in vitro and in vivo, and is in part determined by miR-135a-mediated downregulation of APC. Oncogene (2011) 30, 4386-4398; doi:10.1038/onc.2011.148; published online 9 May 2011	[Holleman, A.; Chung, I.; Olsen, R. R.; Kwak, B.; Zetter, B. R.] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, Boston, MA 02115 USA; [Holleman, A.] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands; [Mizokami, A.] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Kanazawa, Ishikawa, Japan; [Saijo, N.] Natl Canc Ctr, Res Inst, Div Med Oncol, Tokyo 104, Japan; [Parissenti, A.] Hop Reg Sudbury Reg Hosp, Reg Canc Program, Sudbury, ON, Canada; [Duan, Z.] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA; [Voest, E. E.] Utrecht Med Ctr, Dept Med Oncol, Utrecht, Netherlands	Harvard University; Boston Children's Hospital; Harvard Medical School; Meander Medisch Centrum; Kanazawa University; National Cancer Center - Japan; Health Sciences North; Harvard University; Massachusetts General Hospital; Utrecht University; Utrecht University Medical Center	Zetter, BR (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, 300 Longwood Ave,Karp Bldg,Room 11-125, Boston, MA 02115 USA.	bruce.zetter@childrens.harvard.edu	Chung, Ivy/C-3804-2012	de Haar-Holleman, Amy/0000-0003-4929-2860	National Institutes of Health; Kendle; KWF Cancer Foundation; Stichting Fonds Catherine van Tussenbroek; US Department of Defense; NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kendle; KWF Cancer Foundation; Stichting Fonds Catherine van Tussenbroek; US Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We sincerely thank Dr John Heymach of MD Anderson Cancer Institute, Houston, TX and Jeremy Force, Children's Hospital Boston, for kindly providing us with the A549TR cells. This work was supported in part by grant CA37393 from the National Institutes of Health (BRZ), Kendle (AH), KWF Cancer Foundation (AH), the Stichting Fonds Catherine van Tussenbroek (AH), and a US Department of Defense PCRP fellowship (IC).	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Chu Q, 2005, LUNG CANCER, V50, P355, DOI 10.1016/j.lungcan.2005.06.010; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Dombernowsky P, 1996, SEMIN ONCOL, V23, P23; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fong GH, 2008, ANGIOGENESIS, V11, P121, DOI 10.1007/s10456-008-9107-3; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; Haldar S, 1996, CANCER RES, V56, P1253; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; HOFFMAN RM, 1991, CANCER CELL-MON REV, V3, P86; Huang GC, 2010, J CANCER RES CLIN, V136, P1201, DOI 10.1007/s00432-010-0770-6; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mackler NJ, 2005, NAT CLIN PRACT UROL, V2, P92, DOI 10.1038/ncpuro0099; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Mozzetti S, 2005, CLIN CANCER RES, V11, P298; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Oguri T, 2008, MOL CANCER THER, V7, P1150, DOI 10.1158/1535-7163.MCT-07-2088; Okugawa K, 2004, J CANCER RES CLIN, V130, P178, DOI 10.1007/s00432-003-0516-9; Patel N, 2010, P NATL ACAD SCI USA, V107, P2503, DOI 10.1073/pnas.0910649107; Perkins C, 1998, CANCER RES, V58, P4561; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017; STARLING JJ, 1990, CANCER RES, V50, P7634; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takeda M, 2007, PROSTATE, V67, P955, DOI 10.1002/pros.20581; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Villeneuve DJ, 2006, BREAST CANCER RES TR, V96, P17, DOI 10.1007/s10549-005-9026-6; Wakelee H, 2005, EXPERT REV ANTICANC, V5, P13, DOI 10.1586/14737140.5.1.13; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; Zhang T, 2001, CANCER RES, V61, P8664; Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337	54	86	96	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4386	4398		10.1038/onc.2011.148	http://dx.doi.org/10.1038/onc.2011.148			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21552288	Green Accepted			2022-12-28	WOS:000296356500002
J	Lossaint, G; Besnard, E; Fisher, D; Piette, J; Dulic, V				Lossaint, G.; Besnard, E.; Fisher, D.; Piette, J.; Dulic, V.			Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional	ONCOGENE			English	Article						G2-M checkpoint; cyclin B1; cell cycle; Chk2; ATM	CELL-CYCLE EXIT; G(2) CHECKPOINT; ATAXIA-TELANGIECTASIA; P53-DEFICIENT CELLS; GENOMIC INSTABILITY; MITOTIC CATASTROPHE; CARCINOMA CELLS; PROTEIN-KINASE; P53; CANCER	In the presence of sustained DNA damage occurring in S-phase or G2, normal cells arrest before mitosis and eventually become senescent. The checkpoint kinases Chk1/Chk2 and the CDK inhibitor p21 are known to have important complementary roles in this process, in G2 arrest and cell cycle exit, respectively. However, additional checkpoint roles have been reported for these regulators and it is not clear to what extent their functions are redundant. Here we compared the respective roles of Chk1, Chk2 and p21 in DNA damage-induced G2 arrest in normal human fibroblasts, normal epithelial cells and frequently used p53 proficient cancer cells. We show that in normal cells, Chk1, but not Chk2, is involved in G2 arrest whereas neither are essential. In contrast, p21 is required. However, Chk1, but not Chk2, becomes necessary for arrest in U2OS osteosarcoma cells. We find that their ATM/p53/p21 response in G2 phase is defective, like in other cancer cells with wild-type p53, and conclude that cross-talk between the Chk1 and p21 pathways allows them to switch dependency for G2 arrest onto Chk1. Using the specific ATM inhibitor KU-55933 we confirm the essential role of ATM in the induction of p21 for G2 arrest of normal cells. Efficient p21 induction is required for nuclear sequestration of inactive cyclin B1-Cdk1 complexes preceding irreversible cell cycle exit in G2. Our results demonstrate that p21 is able to fulfill the Chk1 functions in G2 arrest under continuous genotoxic stress, which has important implications for cancer chemotherapy. Oncogene (2011) 30, 4261-4274; doi: 10.1038/onc.2011.135; published online 2 May 2011	[Lossaint, G.; Fisher, D.; Piette, J.; Dulic, V.] Univ Montpellier I, Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier, Herault, France; [Lossaint, G.; Fisher, D.; Piette, J.; Dulic, V.] Univ Montpellier 2, F-34293 Montpellier, Herault, France; [Besnard, E.] CNRS, INSERM, Inst Genet Fonct, UMR 5203,U661, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Piette, J (corresponding author), Univ Montpellier I, Inst Genet Mol Montpellier, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier, Herault, France.	jacques.piette@igmm.cnrs.fr; vjekoslav.dulic@igmm.cnrs.fr	Fisher, Daniel/D-6915-2018; Besnard, Emilie/K-6161-2015	Fisher, Daniel/0000-0002-0822-3482; Dulic, Vjekoslav/0000-0003-1201-3901	ARC [3631, 3793]; Canceropole du Grand Sud Ouest; Ministere de l'Education Nationale et de la Recherche (MENR); LNCC	ARC(Australian Research Council); Canceropole du Grand Sud Ouest; Ministere de l'Education Nationale et de la Recherche (MENR); LNCC	This work was supported by grants of ARC (grant N<SUP>o</SUP> 3631 to JP and N<SUP>o</SUP>3793 to VD) the Canceropole du Grand Sud Ouest and the Ministere de l'Education Nationale et de la Recherche (MENR, EB). The team (GL, VD and DF) is 'Equipe labellise' by the Ligue Nationale Contre le Cancer (LNCC, N<SUP>o</SUP> EL2010.LNCC/DF). GL was recipient of a PhD fellowship from LNCC. We are grateful to KUDOS Pharmaceuticals for gift KU-55933, Dr AM Creighton for gift ICRF-193, Dr D Galloway (Seattle, USA) for the E6 retroviral vector and Dr A Constantinou for DNA-PKcs-specific antibodies. We thank Dr D Fraillery for helping us in analysis of HeLa and U2OS cells, Drs V Gire and J Loncarek for the retroviral transduction of the HMEC-derived cell lines, Drs E Julien, C Sardet, A Camasses, P Coopman and N Taylor for critical reading of the manuscript and Dr A Constantinou for encouragement. We acknowledge the Montpellier RIO imaging facility (Head Dr P Travo) for their help. Finally, we thank the reviewers for insightful suggestions.	Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Andreassen PR, 2001, CANCER RES, V61, P7660; Arlander SJH, 2008, CANCER RES, V68, P89, DOI 10.1158/0008-5472.CAN-07-0675; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Bruno T, 2006, CANCER CELL, V10, P473, DOI 10.1016/j.ccr.2006.10.012; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Foijer F, 2005, CANCER CELL, V8, P455, DOI 10.1016/j.ccr.2005.10.021; Gavet O, 2010, J CELL BIOL, V189, P247, DOI 10.1083/jcb.200909144; Gillis LD, 2009, CELL CYCLE, V8, P253, DOI 10.4161/cc.8.2.7550; Gire W, 2004, EMBO J, V23, P2554, DOI 10.1038/sj.emboj.7600259; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Inoue Y, 2007, EMBO J, V26, P2083, DOI 10.1038/sj.emboj.7601652; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jin J, 2008, J BIOL CHEM, V283, P19322, DOI 10.1074/jbc.M802474200; Jurvansuu J, 2007, J MOL BIOL, V372, P397, DOI 10.1016/j.jmb.2007.06.077; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Meng S, 2009, CELL CYCLE, V8, P2238, DOI 10.4161/cc.8.14.8998; Merry C, 2010, CELL CYCLE, V9, P279, DOI 10.4161/cc.9.2.10445; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Palmero EI, 2010, CURR OPIN ONCOL, V22, P64, DOI 10.1097/CCO.0b013e328333bf00; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Shibata A, 2010, MOL CELL BIOL, V30, P3371, DOI 10.1128/MCB.01644-09; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Toettcher JE, 2009, P NATL ACAD SCI USA, V106, P785, DOI 10.1073/pnas.0806196106; Tomimatsu N, 2009, EMBO REP, V10, P629, DOI 10.1038/embor.2009.60; van Vugt MATM, 2010, CELL CYCLE, V9, P2097, DOI 10.4161/cc.9.11.11840; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	65	58	59	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	41					4261	4274		10.1038/onc.2011.135	http://dx.doi.org/10.1038/onc.2011.135			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21532626				2022-12-28	WOS:000296356300004
J	Rodriguez, MI; Gonzalez-Flores, A; Dantzer, F; Collard, J; de Herreros, AG; Oliver, FJ				Rodriguez, M. I.; Gonzalez-Flores, A.; Dantzer, F.; Collard, J.; de Herreros, A. G.; Oliver, F. J.			Poly(ADP-ribose)-dependent regulation of Snail1 protein stability	ONCOGENE			English	Article						snail1; E-cadherin; PARP-1; poly(ADP-ribosyl)ation; EMT; melanoma	EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; TUMOR-CELLS; DNA-DAMAGE; TGF-BETA; POLYMERASE; CANCER; PROGRESSION; PARP-1	Snail1 is a master regulator of the epithelial-mesenchymal transition (EMT) and has been implicated in key tumor biological processes such as invasion and metastasis. It has been previously shown that poly(ADP-ribose) polymerase-1 (PARP-1) knockdown, but not PARP inhibition, down-regulates the expression of Snail1. In this study we have characterized a novel regulatory mechanism controlling Snail1 protein expression through poly(ADP-ribosyl)ation. The effect is not only limited to repression of Snail1 transcription but also to downregulated Snail1 protein stability. PARP-1 (but not PARP-2) poly(ADP) ribosylates Snail1, both in vivo and in vitro, and interacts with Snail1, an association that is sensitive to PARP inhibitors. PARP inhibition has also clear effects on EMT phenotype of different tumor cells, including Snail1 downregulation, E-cadherin upregulation, decreased cell elongation and invasiveness. Therefore, this study reveals a new regulatory mechanism of Snail1 activation through poly(ADP-ribosyl) ation with consequences in malignant transformation through EMT. Oncogene (2011) 30, 4365-4372; doi: 10.1038/onc.2011.153; published online 16 May 2011	[Rodriguez, M. I.; Gonzalez-Flores, A.; Oliver, F. J.] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18100, Spain; [Dantzer, F.] Ecole Super Biotechnol Strasbourg, Dept Integr Genome, UMR 7175, Strasbourg, France; [Collard, J.] Netherlands Canc Inst, Amsterdam, Netherlands; [de Herreros, A. G.] IMIM Hosp del Mar, Programa Recerca Canc, Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Netherlands Cancer Institute; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Oliver, FJ (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Avda Conocimiento S-N, Granada 18100, Spain.	joliver@ipb.csic.es	Lara, María Isabel Rodríguez/A-1961-2017; Dantzer, Françoise/O-2126-2016; de Herreros, A Garcia/H-3104-2014; Oliver, Javier/S-1725-2018	Lara, María Isabel Rodríguez/0000-0002-2270-0070; de Herreros, A Garcia/0000-0001-5270-0808; Oliver, Javier/0000-0001-8468-1998; Dantzer, Francoise/0000-0003-0945-8483	CSIC; Junta de Andalucia; Ecole Superieure de Biotechnologie de Strasbourg, Strasbourg, France; Ministerio de Ciencia; Netherlands Cancer Institute, Amsterdam, The Netherlands; Ministerio de Ciencia e Innovacion [SAF2006-01094, SAF2009-13281-C02-01]; Fundacion La Caixa [BM06-219-0]; Junta de Andalucia [P07-CTS-0239]; Ministerio de Educacion y Ciencia [SAF2007-64597, SAF2006-03399]; la Fundacion Cientifica de la Asociacion Espanola contra el Cancer	CSIC; Junta de Andalucia(Junta de Andalucia); Ecole Superieure de Biotechnologie de Strasbourg, Strasbourg, France; Ministerio de Ciencia(Spanish Government); Netherlands Cancer Institute, Amsterdam, The Netherlands(Netherlands Government); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion La Caixa(La Caixa Foundation); Junta de Andalucia(Junta de Andalucia); Ministerio de Educacion y Ciencia(Spanish Government); la Fundacion Cientifica de la Asociacion Espanola contra el Cancer	We acknowledge Laura Lopez for her technical assistance. MIR is recipient of a postdoctoral fellowship financed by the program JAE-Doc of CSIC. She was also funded by Junta de Andalucia Short-Term Fellowships to stay at the Departement Integrite du Genome' de I'UMR 7175, Ecole Superieure de Biotechnologie de Strasbourg, Strasbourg, France and Ministerio de Ciencia 'Programa Jose Castillejo' to stay at the Department of Cell Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands. This work was supported by Ministerio de Ciencia e Innovacion SAF2006-01094; SAF2009-13281-C02-01, Fundacion La Caixa BM06-219-0; and Junta de Andalucia P07-CTS-0239 to FJO; Ministerio de Educacion y Ciencia SAF2007-64597 and 'Ministerio de Ciencia y Tecnologia' (SAF2006-03399) and 'la Fundacion Cientifica de la Asociacion Espanola contra el Cancer' to AGH.	Aguilar-Quesada R, 2007, CURR MED CHEM, V14, P1179, DOI 10.2174/092986707780597998; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; GUARINO M, 1995, HISTOL HISTOPATHOL, V10, P171; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Hassa PO, 2008, FRONT BIOSCI-LANDMRK, V13, P3046, DOI 10.2741/2909; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Lasfar A, 2010, CARCINOGENESIS, V31, P1710, DOI 10.1093/carcin/bgq155; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Peinado H, 2005, CELL CYCLE, V4, P1749, DOI 10.4161/cc.4.12.2224; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Sarrio D, 2004, ONCOGENE, V23, P3272, DOI 10.1038/sj.onc.1207439; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375	34	51	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4365	4372		10.1038/onc.2011.153	http://dx.doi.org/10.1038/onc.2011.153			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21577210				2022-12-28	WOS:000296356400007
J	Furu, M; Kajita, Y; Nagayama, S; Ishibe, T; Shima, Y; Nishijo, K; Uejima, D; Takahashi, R; Aoyama, T; Nakayama, T; Nakamura, T; Nakashima, Y; Ikegawa, M; Imoto, S; Katagiri, T; Nakamura, Y; Toguchida, J				Furu, M.; Kajita, Y.; Nagayama, S.; Ishibe, T.; Shima, Y.; Nishijo, K.; Uejima, D.; Takahashi, R.; Aoyama, T.; Nakayama, T.; Nakamura, T.; Nakashima, Y.; Ikegawa, M.; Imoto, S.; Katagiri, T.; Nakamura, Y.; Toguchida, J.			Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas	ONCOGENE			English	Article						AFAP1L1; spindle cell sarcoma; metastasis; prognostic marker	ACTIN-FILAMENT INTEGRITY; SOFT-TISSUE SARCOMAS; MESENCHYMAL STEM-CELLS; GENE-EXPRESSION; SYNOVIAL SARCOMAS; MATRIX METALLOPROTEINASES; MUTATION SPECTRUM; ADAPTER PROTEIN; AFAP-110; CANCER	Spindle cell sarcomas consist of tumors with different biological features, of which distant metastasis is the most ominous sign for a poor prognosis. However, metastasis is difficult to predict on the basis of current histopathological analyses. We have identified actin filament-associated protein 1-like 1 (AFAP1L1) as a candidate for a metastasis-predicting marker from the gene expression profiles of 65 spindle cell sarcomas. A multivariate analysis determined that AFAP1L1 was an independent factor for predicting the occurrence of distant metastasis (P = 0.0001), which was further confirmed in another set of 41 tumors by a quantitative mRNA expression analysis. Immunohistochemical staining using paraffin-embedded tumor tissues revealed that the metastasis-free rate was significantly better in tumors negative for AFAP1L1 (P = 0.0093 by log-rank test). Knocking down the AFAP1L1 gene in sarcoma cells resulted in inhibition of the cell invasion, and forced expression of AFAP1L1 in immortalized human mesenchymal stem cells induced anchorage-independent growth and increased cell invasiveness with high activity levels of matrix metallo-peptidase. Furthermore, tumor growth in vivo was accelerated in AFAP1L1-transduced sarcoma cell lines. These results suggest that AFAP1L1 has a role in the progression of spindle cell sarcomas and is a prognostic biomarker. Oncogene (2011) 30, 4015-4025; doi:10.1038/onc.2011.108; published online 25 April 2011	[Toguchida, J.] Kyoto Univ, Inst Frontier Med Sci, Dept Tissue Regenerat, Sakyo Ku, Kyoto 6068507, Japan; [Furu, M.; Ishibe, T.; Shima, Y.; Nishijo, K.; Nakayama, T.; Nakamura, T.; Toguchida, J.] Kyoto Univ, Dept Orthopaed Surg, Grad Sch Med, Kyoto 6068507, Japan; [Kajita, Y.] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan; [Nagayama, S.; Takahashi, R.] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto 6068507, Japan; [Uejima, D.; Aoyama, T.] Kansai Med Univ, Dept Orthopaed Surg, Osaka, Japan; [Nakashima, Y.] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 606, Japan; [Ikegawa, M.] Kyoto Prefectural Univ Med, Dept Genom Med Sci, Grad Sch Med Sci, Kyoto, Japan; [Imoto, S.] Univ Tokyo, Lab DNA Informat Anal, Ctr Human Genome, Inst Med Sci, Kyoto, Japan; [Katagiri, T.; Nakamura, Y.] Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci, Kyoto, Japan; [Toguchida, J.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University; Kansai Medical University; Kyoto University; Kyoto Prefectural University of Medicine; University of Tokyo; University of Tokyo; Kyoto University	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Tissue Regenerat, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	togjun@frontier.kyoto-u.ac.jp	Katagiri, Toyomasa/I-7344-2012; Ikegawa, Masaya/AAG-5327-2020		Ministry of Education, Culture, Sports, Science and Technology; Grants-in-Aid for Scientific Research [21390420] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs H Sonobe, A Kawai, S Tanaka, O Larsson, A Ogose, and H Kanda for providing cell lines, and T Tsunoda and S Miyano for data analyses. This work was supported by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology.	Aoyama T, 2004, J BIOL CHEM, V279, P28789, DOI 10.1074/jbc.M401273200; Baisden JM, 2001, ONCOGENE, V20, P6607, DOI 10.1038/sj.onc.1204802; Baisden JM, 2001, ONCOGENE, V20, P6435, DOI 10.1038/sj.onc.1204784; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Dorfleutner A, 2007, J CELL PHYSIOL, V213, P740, DOI 10.1002/jcp.21143; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fletcher CDM, 2001, J CLIN ONCOL, V19, P3045, DOI 10.1200/JCO.2001.19.12.3045; Fletcher CDM., 2002, WHO CLASSIFICATION T; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Ishibe T, 2005, CLIN CANCER RES, V11, P2702, DOI 10.1158/1078-0432.CCR-04-2057; Ishibe T, 2008, CLIN ORTHOP RELAT R, V466, P2147, DOI 10.1007/s11999-008-0343-z; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kohno Y, 2006, J BIOL CHEM, V281, P38941, DOI 10.1074/jbc.M608389200; Lee YF, 2004, CANCER RES, V64, P7201, DOI 10.1158/0008-5472.CAN-04-1673; Lodyga M, 2009, ONCOGENE, V28, P937, DOI 10.1038/onc.2008.447; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Nagayama S, 2002, CANCER RES, V62, P5859; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Ottaiano A, 2005, ANTICANCER RES, V25, P4519; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Qian Y, 2004, J CELL BIOCHEM, V91, P602, DOI 10.1002/jcb.10725; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Shibata KR, 2007, STEM CELLS, V25, P2371, DOI 10.1634/stemcells.2007-0225; Shima Y, 2007, BIOCHEM BIOPH RES CO, V353, P60, DOI 10.1016/j.bbrc.2006.11.137; St-Pierre Y, 2004, EXPERT OPIN THER TAR, V8, P473, DOI 10.1517/14728222.8.5.473; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; Toguchida J, 2009, CANCER SCI, V100, P1573, DOI 10.1111/j.1349-7006.2009.01232.x; WADAYAMA B, 1994, CANCER RES, V54, P3042; Xu J, 2007, J BIOL CHEM, V282, P16401, DOI 10.1074/jbc.M701684200; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710	40	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	38					4015	4025		10.1038/onc.2011.108	http://dx.doi.org/10.1038/onc.2011.108			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21516130	Green Submitted			2022-12-28	WOS:000295121600003
J	Shi, Y; Chen, J; Li, Z; Zhang, Z; Yu, H; Sun, K; Wang, X; Song, X; Wang, Y; Zhen, Y; Yang, T; Lou, K; Zhang, Y; Zhang, G; Hu, Y; Ji, J; Hui, R				Shi, Y.; Chen, J.; Li, Z.; Zhang, Z.; Yu, H.; Sun, K.; Wang, X.; Song, X.; Wang, Y.; Zhen, Y.; Yang, T.; Lou, K.; Zhang, Y.; Zhang, G.; Hu, Y.; Ji, J.; Hui, R.			C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer	ONCOGENE			English	Article						C10ORF97; tumor suppressor; non-small-cell lung cancer; genetic variant	DEPENDENT-KINASE INHIBITOR; DOMAIN-BINDING PROTEIN-1; REDUCED EXPRESSION; INVERSE EXPRESSION; COP9 SIGNALOSOME; JAB1 EXPRESSION; POOR-PROGNOSIS; P27(KIP1); P27; DEREGULATION	In an earlier study we showed that C10ORF97 (chromosome-10, open reading frame-97) was expressed in almost all of the tissues and cell lines tested, and that it inhibited the growth of seven tumor cell lines, including two lung carcinoma cell lines (A549 and PG). Here, we show that C10ORF97 is downregulated in non-small-cell lung cancer (NSCLC) tissue compared with normal lung tissue. Overexpression of C10ORF97 significantly suppressed human lung carcinoma A549 cell growth (proliferation and anchorage-independent growth in soft agar) and motility (migration and adhesion). This tumor-suppressive function of C10ORF97 was also verified in vivo. We further found that C10ORF97 caused G(1) arrest of A549 cells and modulated the expression level of several cell-cycle regulators (such as CDK2, cyclin-E and p27). These effects of C10ORF97 were mediated by physical association between C10ORF97 and Jun-activating domain-binding protein-1 (JAB1), and blocking of JAB1-mediated translocation of p27 from the nucleus to the cytoplasm. Together, these results indicated that C10ORF97 functions as a novel tumor suppressor by modulating several key G(1)/S-regulatory proteins by interacting with JAB1. These findings led us to hypothesize that a single-nucleotide polymorphism (SNP) in the C10ORF97 gene that affects its expression might be associated with susceptibility to NSCLC. SNP216 C > T (rs2297882) in the C10ORF97 Kozak sequence was identified, and allele T of SNP216 suppressed C10ORF97 expression in vitro and in vivo. Furthermore, the TT genotype of SNP216 was associated with an increased risk of NSCLC (adjusted odds ratio = 1.73 (95% confidence interval: 1.33-2.25), P = 4.6 x 10(-5)). These data indicated that C10ORF97 is a tumor suppressor of NSCLC progression and C10ORF97-SNP216 may serve as a predictor of NSCLC. Oncogene (2011) 30, 4107-4117; doi:10.1038/onc.2011.116; published online 18 April 2011	[Li, Z.; Zhang, G.; Hu, Y.; Ji, J.] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Surg,Key Lab Carcinogenesis & Translat Res, Beijing 100042, Peoples R China; [Shi, Y.; Zhang, Z.; Yu, H.; Sun, K.; Wang, X.; Song, X.; Wang, Y.; Zhen, Y.; Yang, T.; Lou, K.; Zhang, Y.; Hui, R.] Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Clin Cardiovasc Genet, Sino German Lab Mol Med,Fuwai Hosp,Minist Educ, Beijing 100037, Peoples R China; [Shi, Y.] Sichuan Acad Med Sci, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Peoples R China; [Shi, Y.] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital	Ji, J (corresponding author), Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Surg,Key Lab Carcinogenesis & Translat Res, 52 Fucheng Rd, Beijing 100042, Peoples R China.	jiafuj@hotmail.com; huirutai@sglab.org	Zhang, Zhen/F-8561-2011; Wang, Weili/D-1546-2011		National High Technology Research and Development Program of China (863 Program) [2006AA02Z477]; National Natural Science Foundation of China [30500199, 30900809]; Foundation of Beijing Municipal Committee of Science and Technology [D0905001040631]	National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Beijing Municipal Committee of Science and Technology	We thank Professor Gu Xiaocheng and Zheng Xiaofeng (Department of Biochemistry and Molecular Biology, College of Life Sciences, Peking University, Beijing, China) for preparation and purification of the C10ORF97 protein. Sources of support: This study was supported by the National High Technology Research and Development Program of China (863 Program, No. 2006AA02Z477 to RH), the National Natural Science Foundation of China (No. 30500199 to JC and No. 30900809 to YS) and the Foundation of Beijing Municipal Committee of Science and Technology (No. D0905001040631 to JJ).	Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Catzavelos C, 1999, CANCER RES, V59, P684; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Esposito V, 1997, CANCER RES, V57, P3381; Frolova N, 2009, TUMOR BIOL, V30, P148, DOI 10.1159/000228908; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P2635, DOI 10.1210/jc.87.6.2635; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Liu BH, 2002, BIOCHEM BIOPH RES CO, V293, P1396, DOI 10.1016/S0006-291X(02)00379-0; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Masciullo V, 2003, CLIN CANCER RES, V9, P5332; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Meyerson M, 2004, SEMIN ONCOL, V31, P4, DOI 10.1053/j.seminoncol.2003.12.009; Osoegawa A, 2006, CANCER, V107, P154, DOI 10.1002/cncr.21961; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shintani S, 2003, ONCOLOGY-BASEL, V65, P355, DOI 10.1159/000074649; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsukamoto S, 2001, LUNG CANCER-J IASLC, V34, P83, DOI 10.1016/S0169-5002(01)00216-1; Viglietto G, 2002, CELL CYCLE, V1, P394, DOI 10.4161/cc.1.6.263; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304	36	5	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	39					4107	4117		10.1038/onc.2011.116	http://dx.doi.org/10.1038/onc.2011.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499297				2022-12-28	WOS:000295357500006
J	Tanizaki, J; Okamoto, I; Fumita, S; Okamoto, W; Nishio, K; Nakagawa, K				Tanizaki, J.; Okamoto, I.; Fumita, S.; Okamoto, W.; Nishio, K.; Nakagawa, K.			Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification	ONCOGENE			English	Article						BIM; survivin; HER2 amplification; PIK3CA mutation; apoptosis; breast cancer	MAMMARY EPITHELIAL-CELLS; DUAL PI3K/MTOR INHIBITOR; PIK3CA MUTATIONS; NVP-BEZ235; RESISTANCE; GENE; EXPRESSION; ONCOGENE; EFFICACY; THERAPY	Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification. The mechanism of this anti-tumor action has remained unclear, however. We have now investigated the effects of lapatinib in HER2 amplification-positive breast cancer cells with or without an activating PIK3CA mutation. Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification. RNA interference (RNAi)-mediated depletion of BIM inhibited lapatinib-induced apoptosis, implicating BIM induction in this process. The proapoptotic effect of lapatinib was less pronounced in cells with a PIK3CA mutation than in those without one. Lapatinib failed to inhibit AKT phosphorylation in PIK3CA mutant cells, likely because of hyperactivation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway by the mutation. Depletion of PIK3CA (a catalytic subunit of PI3K) revealed that survivin expression is regulated by the PI3K pathway in these cells, suggesting that insufficient inhibition of PI3K-survivin signaling is responsible for the limited pro-apoptotic effect of lapatinib in HER2 amplification-positive cells with a PIK3CA mutation. Consistent with this notion, depletion of survivin by RNAi or treatment with a PI3K inhibitor markedly increased the level of apoptosis in PIK3CA mutant cells treated with lapatinib. Our results thus suggest that inhibition of both PI3K-survivin and MEK-ERK-BIM pathways is required for effective induction of apoptosis in breast cancer cells with HER2 amplification. Oncogene (2011) 30, 4097-4106; doi:10.1038/onc.2011.111; published online 18 April 2011	[Tanizaki, J.; Okamoto, I.; Fumita, S.; Okamoto, W.; Nakagawa, K.] Kinki Univ, Dept Med Oncol, Fac Med, Osaka, Japan; [Nishio, K.] Kinki Univ, Dept Genome Biol, Fac Med, Osaka, Japan	Kindai University (Kinki University); Kindai University (Kinki University)	Okamoto, I (corresponding author), Kinki Univ, Dept Med Oncol, Fac Med, 377-2 Ohno Higashi, Osaka, Japan.	chi-okamoto@dotd.med.kindai.ac.jp	Okamoto, Wataru/AIE-0808-2022	Fumita, Soichi/0000-0003-0253-0681				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106; Burris HA, 2009, CLIN CANCER RES, V15, P6702, DOI 10.1158/1078-0432.CCR-09-0369; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Di Leo A, 2008, J CLIN ONCOL, V26, P5544, DOI 10.1200/JCO.2008.16.2578; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gomez HL, 2008, J CLIN ONCOL, V26, P2999, DOI 10.1200/JCO.2007.14.0590; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Kataoka Y, 2010, ANN ONCOL, V21, P255, DOI 10.1093/annonc/mdp304; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; LoRusso PM, 2008, J CLIN ONCOL, V26, P3051, DOI 10.1200/JCO.2007.14.9633; McKenzie JA, 2010, CANCER RES, V70, P7927, DOI 10.1158/0008-5472.CAN-10-0194; Olie RA, 2000, CANCER RES, V60, P2805; PEIRCE SK, 2010, CANCER CHEMOTH PHARM, DOI DOI 10.1007/S00280-1010-1486-7; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Slamon D J, 1990, Cancer Invest, V8, P253, DOI 10.3109/07357909009017573; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tanaka K, 2000, CLIN CANCER RES, V6, P127; Toi M, 2009, BRIT J CANCER, V101, P1676, DOI 10.1038/sj.bjc.6605343; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	37	45	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4097	4106		10.1038/onc.2011.111	http://dx.doi.org/10.1038/onc.2011.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499301				2022-12-28	WOS:000295357500005
J	Kim, EK; Yun, SJ; Ha, JM; Kim, YW; Jin, IH; Yun, J; Shin, HK; Song, SH; Kim, JH; Lee, JS; Kim, CD; Bae, SS				Kim, E. K.; Yun, S. J.; Ha, J. M.; Kim, Y. W.; Jin, I. H.; Yun, J.; Shin, H. K.; Song, S. H.; Kim, J. H.; Lee, J. S.; Kim, C. D.; Bae, S. S.			Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis	ONCOGENE			English	Article						Akt; invasion; metastasis; mTOR; P-Rex1	FACTOR-I RECEPTOR; PROTEIN-KINASE-B; ACTIN CYTOSKELETON; INSULIN-RESISTANCE; BREAST-CANCER; GROWTH; MTOR; MOTILITY; AKT/PKB; INHIBITION	Mammalian target of rapamycin complex (mTORC) regulates a variety of cellular responses including proliferation, growth, differentiation and cell migration. In this study, we show that mammalian target of rapamycin complex 2 (mTORC2) regulates invasive cancer cell migration through selective activation of Akt1. Insulin-like growth factor-1 (IGF-1)-induced SKOV-3 cell migration was completely abolished by phosphatidylinositol 3-kinase (PI3K) (LY294002, 10 mu M) or Akt inhibitors (SH-5, 50 mu M), whereas inhibition of extracellular-regulated kinase by an ERK inhibitor (PD98059, 10 mu M) or inhibition of mammalian target of rapamycin complex 1 (mTORC1) by an mTORC1 inhibitor (Rapamycin, 100 nM) did not affect IGF-1-induced SKOV-3 cell migration. Inactivation of mTORC2 by silencing Rapamycin-insensitive companion of mTOR (Rictor), abolished IGF-1-induced SKOV-3 cell migration as well as activation of Akt. However, inactivation of mTORC1 by silencing of Raptor had no effect. Silencing of Akt1 but not Akt2 attenuated IGF-1-induced SKOV-3 cell migration. Rictor was preferentially associated with Akt1 rather than Akt2, and overexpression of Rictor facilitated IGF-1-induced Akt1 activation. Expression of PIP3-dependent Rac exchanger1 (P-Rex1), a Rac guanosine exchange factor and a component of the mTOR complex, strongly stimulated activation of Akt1. Furthermore, knockdown of P-Rex1 attenuated Akt activation as well as IGF-1-induced SKOV-3 cell migration. Silencing of Akt1 or P-Rex1 abolished IGF-1-induced SKOV-3 cell invasion. Finally, silencing of Akt1 blocked in vivo metastasis, whereas silencing of Akt2 did not. Given these results, we suggest that selective activation of Akt1 through mTORC2 and P-Rex1 regulates cancer cell migration, invasion and metastasis. Oncogene (2011) 30, 2954-2963; doi:10.1038/onc.2011.22; published online 21 February 2011	[Kim, E. K.; Yun, S. J.; Ha, J. M.; Kim, Y. W.; Jin, I. H.; Kim, C. D.; Bae, S. S.] Pusan Natl Univ, Sch Med, Dept Pharmacol, MRC Ischem Tissue Regenerat, Yangsan 626870, Kyungnam, South Korea; [Yun, J.] Dong A Univ, Sch Med, Dept Biochem, Yangsan, South Korea; [Shin, H. K.] Pusan Natl Univ, Sch Korean Med, Dept Anat, Yangsan 626870, Kyungnam, South Korea; [Song, S. H.] Pusan Natl Univ, Sch Med, Dept Internal Med, Yangsan 626870, Kyungnam, South Korea; [Kim, J. H.] Pusan Natl Univ, Sch Med, Dept Physiol, Yangsan 626870, Kyungnam, South Korea; [Lee, J. S.] Pusan Natl Univ, Sch Med, Dept Orthoped Surg, Yangsan 626870, Kyungnam, South Korea; [Kim, E. K.; Yun, S. J.; Ha, J. M.; Kim, Y. W.; Jin, I. H.; Kim, C. D.; Bae, S. S.] Pusan Natl Univ, Sch Med, Dept Pharmacol, MRC Med Res Inst, Yangsan 626870, Kyungnam, South Korea	Pusan National University; Pusan National University Hospital; Dong A University; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital	Bae, SS (corresponding author), Pusan Natl Univ, Sch Med, Dept Pharmacol, MRC Ischem Tissue Regenerat, Yangsan 626870, Kyungnam, South Korea.	sunsik@pusan.ac.kr			Korea government (MEST) [2010-0015808]; Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea [0920050]	Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea	This work was supported partly by the MRC program of the NRF (2010-0001247), a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2010-0015808), and the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0920050).	Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Barber Mark A, 2006, Bull Cancer, V93, pE44; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dunn SE, 1998, CANCER RES, V58, P3353; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Grille SJ, 2003, CANCER RES, V63, P2172; Hernandez-Negrete I, 2007, J BIOL CHEM, V282, P23708, DOI 10.1074/jbc.M703771200; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim EK, 2008, CELL SIGNAL, V20, P2030, DOI 10.1016/j.cellsig.2008.07.012; Kim EK, 2008, EXP MOL MED, V40, P445, DOI 10.3858/emm.2008.40.4.445; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sheng SJ, 2009, J CELL PHYSIOL, V218, P451, DOI 10.1002/jcp.21616; van Golen CM, 2006, CANCER RES, V66, P6570, DOI 10.1158/0008-5472.CAN-05-1448; Wu YP, 2002, CANCER RES, V62, P1030; Yun SJ, 2009, FEBS LETT, V583, P685, DOI 10.1016/j.febslet.2009.01.005; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang J, 2008, J BIOL CHEM, V283, P35375, DOI 10.1074/jbc.M806480200; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200	31	81	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2954	2963		10.1038/onc.2011.22	http://dx.doi.org/10.1038/onc.2011.22			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21339740				2022-12-28	WOS:000292245100006
J	Meng, L; Hunt, C; Yaglom, JA; Gabai, VL; Sherman, MY				Meng, L.; Hunt, C.; Yaglom, J. A.; Gabai, V. L.; Sherman, M. Y.			Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis	ONCOGENE			English	Article						Hsp72; HER2; senescence; p21; survivin	NON-ONCOGENE ADDICTION; CANCER-CELLS; INDUCIBLE HEAT-SHOCK-PROTEIN-70; MOLECULAR CHAPERONES; SENESCENCE PATHWAYS; CARCINOMA-CELLS; STRESS; SUPPRESSION; PRINCIPLES; APOPTOSIS	The major heat shock protein Hsp72 is expressed at elevated levels in many human cancers and its expression correlates with tumor progression. Here, we investigated the role of Hsp72 in Her2 oncogene-induced neoplastic transformation and tumorigenesis. Expression of Her2 in untransformed MCF10A mammary epithelial cells caused transformation, as judged by foci formation in culture and tumorigenesis in xenografts. However, expression of Her2 in Hsp72-depleted cells failed to induce transformation. The anti-tumorigenic effects of Hsp72 downregulation were associated with cellular senescence because of accumulation of p21 and depletion of survivin. Accordingly, either knockdown of p21 or expression of survivin reversed this senescence process. Further, we developed an animal model of Hsp72-dependent breast cancer associated with expression of Her2. Knockout (KO) of Hsp72 almost completely suppressed tumorigenesis in the MMTVneu breast cancer mouse model. In young Hsp72 KO mice, expression of Her2 instead of mammary tissue hyperplasia led to suppression of duct development and blocked alveolar budding. These effects were due to massive cell senescence in mammary tissue, which was associated with upregulation of p21 and downregulation of survivin. Therefore, Hsp72 has an essential role in Her2-induced tumorigenesis by regulating oncogene-induced senescence pathways. Oncogene (2011) 30, 2836-2845; doi: 10.1038/onc.2011.5; published online 7 February 2011	[Meng, L.; Yaglom, J. A.; Gabai, V. L.; Sherman, M. Y.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Hunt, C.] Washington Univ, Dept Radiat Oncol, St Louis, MO USA	Boston University; Washington University (WUSTL)	Sherman, MY (corresponding author), Boston Univ, Sch Med, Dept Biochem, 72 E Concord St,K-323, Boston, MA 02118 USA.	gabai@bu.edu; sherma1@bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Yaglom, Julia/0000-0002-8723-3506; Sherman, Michael/0000-0003-3345-073X	National Institute of Health [CA081244]; NATIONAL CANCER INSTITUTE [R01CA081244] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institute of Health CA081244. We thank Dr B Park and Dr C Spangenberg for their kind supply of MCF10A cells and HER2-overexpressing retroviral vector.	Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Gabai VL, 2005, ONCOGENE, V24, P3328, DOI 10.1038/sj.onc.1208495; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gabai VL, 2009, MOL CELL BIOL, V29, P559, DOI 10.1128/MCB.01041-08; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Meng L, 2010, ONCOGENE, V29, P5204, DOI 10.1038/onc.2010.277; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; Tao Y, 2009, CARCINOGENESIS, V30, P175, DOI 10.1093/carcin/bgn256; Trost TM, 2005, CANCER RES, V65, P840; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692	28	67	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	25					2836	2845		10.1038/onc.2011.5	http://dx.doi.org/10.1038/onc.2011.5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21297664	Green Accepted			2022-12-28	WOS:000291977800004
J	Heijink, DM; Fehrmann, RSN; de Vries, EGE; Koornstra, JJ; Oosterhuis, D; van der Zee, AGJ; Kleibeuker, JH; de Jong, S				Heijink, D. M.; Fehrmann, R. S. N.; de Vries, E. G. E.; Koornstra, J. J.; Oosterhuis, D.; van der Zee, A. G. J.; Kleibeuker, J. H.; de Jong, S.			A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer	ONCOGENE			English	Article						pathways; microarray; gene set enrichment; adenoma; chemoprevention	DEPENDENT KINASE INHIBITOR; GENE-EXPRESSION; PROTEIN-KINASE; EARLY EVENT; DNA-DAMAGE; RB-PATHWAY; CYCLIN D1; COLON; ADENOMAS; DASATINIB	Comparing normal colorectal mucosa and adenomas focusing on deregulated pathways obtains insight into the biological processes of early colorectal carcinogenesis. Publicly available microarray expression data from 26 normal mucosa and 47 adenoma samples were analyzed. Biological pathways enriched in adenomas were identified with Gene Set Enrichment Analysis (GSEA). The analysis revealed 10, 11 and 16 gene sets distinguishing adenomas from normal mucosa according to Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Map Annotator and Pathway Profiler (GenMAPP) and Biocarta databases, respectively. Biological pathways known to be involved in colon carcinogenesis such as cell cycle (P = 0.002) and Wnt signaling (P = 0.007) were enriched in adenomas. In addition, we found enrichment of novel pathways such as retinoblastoma (Rb) pathway (P = 0.002), Src pathway (P = 0.004), folate biosynthesis (P = 0.019) and Hedgehog signaling (P = 0.037) in adenomas. Microarray results for Rb and Src pathway genes were validated by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on mRNA isolated from an independent set of adenoma and normal colon samples. A high correlation between microarray data and qRT-PCR expression data was found. The relevance of targeting of identified pathways was shown using the Rb pathway inhibitors roscovitine and PD-0332991 and the Src pathway inhibitor dasatinib. All inhibitors used induced cell growth reduction in adenoma cells. This study shows a bioinformatical and functional approach leading to potentially new options for chemoprevention of colorectal cancer. Oncogene (2011) 30, 2026-2036; doi:10.1038/onc.2010.578; published online 10 January 2011	[Heijink, D. M.; Fehrmann, R. S. N.; de Vries, E. G. E.; Oosterhuis, D.; de Jong, S.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; [Heijink, D. M.; Koornstra, J. J.; Kleibeuker, J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, NL-9713 GZ Groningen, Netherlands; [Fehrmann, R. S. N.; van der Zee, A. G. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol Oncol, NL-9713 GZ Groningen, Netherlands; [Fehrmann, R. S. N.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	de Vries, EGE (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	e.g.e.de.vries@int.umcg.nl	Fehrmann, Rudolf/E-2551-2011; Pillay, Nischalan/F-9536-2012	Fehrmann, Rudolf/0000-0002-7516-315X; de Vries, Elisabeth/0000-0002-8949-7425	Dutch Cancer Society [RUG 2005-3361]	Dutch Cancer Society(KWF Kankerbestrijding)	This study was supported by Grant RUG 2005-3361 from the Dutch Cancer Society.	Aldoss IT, 2009, EXPERT OPIN INV DRUG, V18, P1957, DOI 10.1517/13543780903418445; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Arber N, 2008, GASTROENTEROLOGY, V134, P1224, DOI 10.1053/j.gastro.2008.02.012; Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; Arima Y, 2008, CANCER RES, V68, P5104, DOI 10.1158/0008-5472.CAN-07-5680; Bartkova J, 2001, GASTROENTEROLOGY, V120, P1680, DOI 10.1053/gast.2001.24880; Bild AH, 2006, NAT REV CANCER, V6, P735, DOI 10.1038/nrc1976; Boquoi A, 2009, CANCER PREV RES, V2, P800, DOI 10.1158/1940-6207.CAPR-09-0053; Carey R, 2008, INFLAMM BOWEL DIS, V14, P446, DOI 10.1002/ibd.20342; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chen R, 2009, BLOOD, V113, P4637, DOI 10.1182/blood-2008-12-190256; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Crijns APG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-232; Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Du W, 2009, CURR DRUG TARGETS, V10, P581, DOI 10.2174/138945009788680392; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Einspahr JG, 2006, CANCER EPIDEM BIOMAR, V15, P1443, DOI 10.1158/1055-9965.EPI-06-0144; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fujita T, 2008, AM J PATHOL, V173, P217, DOI 10.2353/ajpath.2008.070957; Galamb O, 2008, DIS MARKERS, V25, P1, DOI 10.1155/2008/586721; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Guillen-Ahlers H, 2008, CARCINOGENESIS, V29, P1421, DOI 10.1093/carcin/bgn123; Hao XP, 1998, VIRCHOWS ARCH, V433, P523, DOI 10.1007/s004280050284; Hong Y, 2007, CLIN CANCER RES, V13, P1107, DOI 10.1158/1078-0432.CCR-06-1633; Imazeki F, 1996, GASTROENTEROLOGY, V110, P362, DOI 10.1053/gast.1996.v110.pm8566581; Jalving M, 2006, CLIN CANCER RES, V12, P4350, DOI 10.1158/1078-0432.CCR-05-2487; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Kantarjian H, 2007, BLOOD, V109, P5143, DOI 10.1182/blood-2006-11-056028; Kita H, 2006, J GASTROENTEROL, V41, P1053, DOI 10.1007/s00535-006-1894-y; Knudsen ES, 2010, CLIN CANCER RES, V16, P1094, DOI 10.1158/1078-0432.CCR-09-0787; Koornstra JJ, 2004, HISTOPATHOLOGY, V44, P9, DOI 10.1111/j.1365-2559.2004.01739.x; Kopetz S, 2009, CANCER RES, V69, P3842, DOI 10.1158/0008-5472.CAN-08-2246; Kwong LN, 2008, ONCOGENE, V27, P1013, DOI 10.1038/sj.onc.1210708; LaPointe LC, 2008, PHYSIOL GENOMICS, V33, P50, DOI 10.1152/physiolgenomics.00185.2006; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Paulson QX, 2008, ONCOGENE, V27, P4954, DOI 10.1038/onc.2008.138; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; RENCHER A, 1998, MUTIVARIATE STAT INT; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Serrels A, 2006, MOL CANCER THER, V5, P3014, DOI 10.1158/1535-7163.MCT-06-0382; Sherlock G, 2001, Brief Bioinform, V2, P350, DOI 10.1093/bib/2.4.350; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Timmerbeul I, 2006, P NATL ACAD SCI USA, V103, P14009, DOI 10.1073/pnas.0606316103; van Geelen CMM, 2003, BRIT J CANCER, V89, P363, DOI 10.1038/sj.bjc.6601065; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wai PY, 2006, J BIOL CHEM, V281, P18973, DOI 10.1074/jbc.M511962200; Wesierska-Gadek J, 2011, J CELL PHYSIOL, V226, P341, DOI 10.1002/jcp.22426; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhao P, 2006, WORLD J GASTROENTERO, V12, P6391, DOI 10.3748/wjg.v12.i39.6391	62	18	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2026	2036		10.1038/onc.2010.578	http://dx.doi.org/10.1038/onc.2010.578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217777				2022-12-28	WOS:000289977400006
J	Xu, MZ; Chan, SW; Liu, AM; Wong, KF; Fan, ST; Chen, J; Poon, RT; Zender, L; Lowe, SW; Hong, W; Luk, JM				Xu, M. Z.; Chan, S. W.; Liu, A. M.; Wong, K. F.; Fan, S. T.; Chen, J.; Poon, R. T.; Zender, L.; Lowe, S. W.; Hong, W.; Luk, J. M.			AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma	ONCOGENE			English	Article						cancer signaling; Hippo pathway; YAP1 oncogene; AXL receptor kinase; HCC; hepatocellular carcinoma	HIPPO SIGNALING PATHWAY; CELL CONTACT INHIBITION; YES-ASSOCIATED PROTEIN; ORGAN SIZE CONTROL; NF-KAPPA-B; LIVER-CANCER; TYROSINE KINASES; GROWTH-CONTROL; TUMOR-GROWTH; EXPRESSION	Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development. We have recently defined the tumorigenic potential and clinical significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC). The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism. In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker alpha-fetoprotein and activation of mitogen-activated protein kinase. Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions. RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade. These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC. Oncogene (2011) 30, 1229-1240; doi: 10.1038/onc.2010.504; published online 15 November 2010	[Xu, M. Z.; Chen, J.; Luk, J. M.] Nanjing Med Univ, Dept Oncol, Affiliated Nanjing Hosp 1, Nanjing, Peoples R China; [Xu, M. Z.; Liu, A. M.; Wong, K. F.; Fan, S. T.; Poon, R. T.; Luk, J. M.] Univ Hong Kong, Dept Surg, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; [Chan, S. W.; Hong, W.] ASTAR, Canc & Dev Cell Biol Div, Inst Mol & Cell Biol, Singapore, Singapore; [Liu, A. M.; Wong, K. F.; Luk, J. M.] Natl Univ Singapore, Canc Sci Inst, Singapore 117597, Singapore; [Zender, L.] Helmholtz Ctr Infect Res, Dept Cell Biol, Braunschweig, Germany; [Lowe, S. W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA; [Lowe, S. W.] Cold Spring Harbor Lab, CSHL Canc Ctr, Cold Spring Harbor, NY 11724 USA	Nanjing Medical University; University of Hong Kong; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Helmholtz Association; Helmholtz-Center for Infection Research; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Cold Spring Harbor Laboratory	Luk, JM (corresponding author), Natl Univ Singapore, Dept Pharmacol, Clin Res Ctr MD11 05 30B, Dept Surg, 10 Med Dr, Singapore 117597, Singapore.	jmluk@nus.edu.sg	HONG, Wanjin/E-9927-2010; Luk, John/A-4085-2008	Luk, John/0000-0002-6323-7940	Biomedical Research Grants Council of Singapore; National University Cancer Institute (NCIS) Centre; National Natural Science Foundation of China [81000880]; National Cancer Institute of NIH [CA13106]; A*STAR; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	Biomedical Research Grants Council of Singapore; National University Cancer Institute (NCIS) Centre; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Cancer Institute of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); A*STAR(Agency for Science Technology & Research (A*STAR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Sources of support: The work was supported by grants to JML from the Biomedical Research Grants Council of Singapore and by the National University Cancer Institute (NCIS) Centre Grant; WH was supported by the A*STAR and MX by the National Natural Science Foundation of China (Grant No. 81000880). SWL is an investigator in the Howard Hughes Medical Institute and Dr Lowe's work is supported by a program grant (CA13106) from the National Cancer Institute of NIH.	Bandura JL, 2008, DEV CELL, V14, P315, DOI 10.1016/j.devcel.2008.02.010; Berclaz G, 2001, ANN ONCOL, V12, P819, DOI 10.1023/A:1011126330233; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bueno L, 2008, EUR J CANCER, V44, P142, DOI 10.1016/j.ejca.2007.10.008; Buttitta LA, 2007, NAT CELL BIOL, V9, P1225, DOI 10.1038/ncb1107-1225; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cao XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Goruppi S, 1996, ONCOGENE, V12, P471; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Liu AM, 2010, EXPERT OPIN THER TAR, V14, P855, DOI 10.1517/14728222.2010.499361; Liu LX, 2009, HEPATOLOGY, V50, P1453, DOI 10.1002/hep.23143; Luk JM, 2005, J IMMUNOL METHODS, V305, P39, DOI 10.1016/j.jim.2005.07.006; Oh H, 2010, TRENDS CELL BIOL, V20, P410, DOI 10.1016/j.tcb.2010.04.005; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Peeper D, 2006, CELL, V125, P1230, DOI 10.1016/j.cell.2006.06.018; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Wong BW, 2003, BIOCHEM BIOPH RES CO, V311, P618, DOI 10.1016/j.bbrc.2003.10.032; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; YIN F, 2007, SCI STKE, pPE12, DOI DOI 10.1126/STKE.3802007PE12; Zender L, 2008, CURR OPIN ONCOL, V20, P72, DOI 10.1097/CCO.0b013e3282f31d5d; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	46	162	166	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1229	1240		10.1038/onc.2010.504	http://dx.doi.org/10.1038/onc.2010.504			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21076472	Green Accepted			2022-12-28	WOS:000288202400009
J	Brenner, C; Subramaniam, K; Pertuiset, C; Pervaiz, S				Brenner, C.; Subramaniam, K.; Pertuiset, C.; Pervaiz, S.			Adenine nucleotide translocase family: four isoforms for apoptosis modulation in cancer	ONCOGENE			English	Review						cancer; cell death; mitochondria; ADP/ATP carrier; mitochondrial membrane permeabilization	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; CELL-DEATH MACHINERY; ADP/ATP CARRIER; GLIOMA-CELLS; DIFFERENTIAL EXPRESSION; TRANSCRIPTIONAL ELEMENT; ADENYLATE TRANSLOCATOR; BAX TRANSLOCATION	Mitochondria have important functions in mammalian cells as the energy powerhouse and integrators of the mitochondrial pathway of apoptosis. The adenine nucleotide translocase (ANT) is a family of proteins involved in cell death pathways that perform distinctly opposite functions to regulate cell fate decisions. On the one hand, ANT catalyzes the adenosine triphosphate export from the mitochondrial matrix to the intermembrane space with the concomitant import of ADP from the intermembrane space to the matrix. On the other hand, during periods of stress, ANT could function as a lethal pore and trigger the process of mitochondrial membrane permeabilization, which leads irreversibly to cell death. In human, ANT is encoded by four homologous genes, whose expression is not only tissue specific, but also varies according to the pathophysiological state of the cell. Recent evidence revealed a differential role of the ANT isoforms in apoptosis and a deregulation of their expression in cancer. In this review, we introduce the current knowledge of ANT in apoptosis and cancer cells and propose a novel classification of ANT isoforms. Oncogene (2011) 30, 883-895; doi:10.1038/onc.2010.501; published online 15 November 2010	[Brenner, C.] Univ Paris 11, Fac Pharm, INSERM, UMR S 769, F-92290 Chatenay Malabry, France; [Brenner, C.; Pertuiset, C.] PRES UniverSud Paris, Chatenay Malabry, France; [Subramaniam, K.; Pervaiz, S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Apoptosis ROS & Canc Biol Program, Singapore 117595, Singapore; [Pervaiz, S.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Pervaiz, S.] Duke NUS Grad Med Sch, Singapore, Singapore; [Pervaiz, S.] Singapore MIT Alliance, Singapore, Singapore	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; National University of Singapore; National University of Singapore; National University of Singapore; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Singapore-MIT Alliance for Research & Technology Centre (SMART)	Brenner, C (corresponding author), Univ Paris 11, Fac Pharm, INSERM, UMR S 769, 5 Rue J-B Clement, F-92290 Chatenay Malabry, France.	catherine.brenner-jan@u-psud.fr	Pervaiz, Shazib/C-4188-2015		le Centre National de la Recherche Scientifique (CNRS); l'Agence Nationale de la Recherche (ANR) [ANR-08PCVI-0008-01]; l'Institut National pour le Cancer (INCa) [2008-1-PL BIO-04-CNS ON1]; l'Universite Paris Sud	le Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); l'Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); l'Institut National pour le Cancer (INCa)(Institut National du Cancer (INCA) France); l'Universite Paris Sud	The work of CB and CP are supported by le Centre National de la Recherche Scientifique (CNRS) and l'Agence Nationale de la Recherche (ANR, ANR-08PCVI-0008-01). CB is also supported by l'Institut National pour le Cancer (INCa, 2008-1-PL BIO-04-CNS ON1) and l'Universite Paris Sud (Programme Attractivite). CB thanks M Nunez for the help in the preparation of Figure 2 and current and past laboratory members for their invaluable contribution.	Adante A, 2008, BBA-BIOENERGETICS, V1777, P1289, DOI 10.1016/j.bbabio.2008.07.004; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Azzu V, 2008, BIOCHEM J, V413, P323, DOI 10.1042/BJ20080321; Baines CP, 2009, J MOL CELL CARDIOL, V46, P969, DOI 10.1016/j.yjmcc.2009.01.016; Barath P, 2004, EUR J BIOCHEM, V271, P1781, DOI 10.1111/j.1432-1033.2004.04090.x; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Beckner ME, 2005, LAB INVEST, V85, P1457, DOI 10.1038/labinvest.3700355; Bellance N, 2009, FRONT BIOSCI-LANDMRK, V14, P4015, DOI 10.2741/3509; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Belzacq AS, 2001, CANCER RES, V61, P1260; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Bouzier AK, 1998, DEV NEUROSCI-BASEL, V20, P331, DOI 10.1159/000017328; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2010, BIOCHEM BIOPH RES CO, V391, P248, DOI 10.1016/j.bbrc.2009.11.044; Brower JV, 2009, REPRODUCTION, V138, P463, DOI 10.1530/REP-09-0201; Brower JV, 2009, BBA-GENE REGUL MECH, V1789, P198, DOI 10.1016/j.bbagrm.2008.12.005; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Chen C, 2004, J BIOL CHEM, V279, P31761, DOI 10.1074/jbc.M401353200; Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5; Chevrollier A, 2005, MOL CARCINOGEN, V42, P1, DOI 10.1002/mc.20059; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Crichton PG, 2010, BIOSCIENCE REP, V30, P187, DOI 10.1042/BSR20090063; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Deniaud E, 2006, ONCOGENE, V25, P7096, DOI 10.1038/sj.onc.1209696; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gallerne C, 2010, INT J BIOCHEM CELL B, V42, P623, DOI 10.1016/j.biocel.2009.12.024; Gazaryan IG, 2007, NEUROCHEM RES, V32, P917, DOI 10.1007/s11064-006-9252-2; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Griguer CE, 2007, J NEURO-ONCOL, V81, P9, DOI 10.1007/s11060-006-9201-6; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; HENDERSON PJ, 1970, J BIOL CHEM, V245, P1319; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2006, BBA-BIOENERGETICS, V1757, P1312, DOI 10.1016/j.bbabio.2006.07.002; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Jang JY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1857; Jang JY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-160; Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/BSE0470053, 10.1042/bse0470053]; Kehoe SM, 2008, BIOL REPROD, V79, P921, DOI 10.1095/biolreprod.108.067645; Khailova LS, 2006, BBA-BIOENERGETICS, V1757, P1324, DOI 10.1016/j.bbabio.2006.04.024; Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lauquin G J, 1979, Methods Enzymol, V56, P414; Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407; Lee J, 2009, BBA-BIOENERGETICS, V1787, P364, DOI 10.1016/j.bbabio.2009.01.014; Leung AWC, 2008, J BIOL CHEM, V283, P26312, DOI 10.1074/jbc.M805235200; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Luciakova K, 2008, BIOCHEM J, V412, P123, DOI 10.1042/BJ20071440; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Malorni W, 2009, CELL DEATH DIFFER, V16, P1480, DOI 10.1038/cdd.2009.100; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Nadtochiy SM, 2006, BIOCHEM J, V395, P611, DOI 10.1042/BJ20051927; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; Notario B, 2003, MOL PHARMACOL, V63, P224, DOI 10.1124/mol.63.1.224; O'Brien TM, 2008, TOXICOL APPL PHARM, V227, P184, DOI 10.1016/j.taap.2007.10.016; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Ortega R, 2009, J BIOENERG BIOMEMBR, V41, P41, DOI 10.1007/s10863-009-9198-6; Palmieri F, 2010, ESSAYS BIOCHEM, V47, P37, DOI [10.1042/BSE0470037, 10.1042/bse0470037]; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pereira C, 2007, MOL MICROBIOL, V66, P571, DOI 10.1111/j.1365-2958.2007.05926.x; Pereira CV, 2008, TOXICOL SCI, V105, P408, DOI 10.1093/toxsci/kfn131; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x; Queiroga CSF, 2010, J BIOL CHEM, V285, P17077, DOI 10.1074/jbc.M109.065052; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rial E, 2010, BBA-BIOENERGETICS, V1797, P800, DOI 10.1016/j.bbabio.2010.04.001; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; Rodriguez-Enriquez S, 2010, INT J BIOCHEM CELL B, V42, P1744, DOI 10.1016/j.biocel.2010.07.010; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; SABOVA L, 1993, EUR J BIOCHEM, V213, P547, DOI 10.1111/j.1432-1033.1993.tb17793.x; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; Shen QF, 2009, MOL CELL BIOL, V29, P3881, DOI 10.1128/MCB.01509-08; Smiraglia DJ, 2008, CANCER BIOL THER, V7, P1182, DOI 10.4161/cbt.7.8.6215; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Toime LJ, 2010, FREE RADICAL BIO MED, V49, P606, DOI 10.1016/j.freeradbiomed.2010.05.010; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; VIGNAIS PV, 1973, BIOCHEMISTRY-US, V12, P1508, DOI 10.1021/bi00732a007; VIGNY HF, 1996, MOL CARCINOG, V16, P165; Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389; Vyssokikh MY, 2001, BIOCHEM J, V358, P349, DOI 10.1042/0264-6021:3580349; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P319; Watabe M, 2000, CANCER RES, V60, P5214; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Zamarin Dmitriy, 2005, PLoS Pathogens, V1, P40; Zamora M, 2004, J BIOL CHEM, V279, P38415, DOI 10.1074/jbc.M404928200; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; Zhivotovsky B, 2009, CELL DEATH DIFFER, V16, P1419, DOI 10.1038/cdd.2009.118; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	115	53	54	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					883	895		10.1038/onc.2010.501	http://dx.doi.org/10.1038/onc.2010.501			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21076465				2022-12-28	WOS:000287695900001
J	Koslowski, M; Luxemburger, U; Tureci, O; Sahin, U				Koslowski, M.; Luxemburger, U.; Tuereci, Oe; Sahin, U.			Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1 alpha	ONCOGENE			English	Article						cancer; hypoxia-inducible factor; methylation	INDUCIBLE FACTOR-I; DNA METHYLATION; ERYTHROPOIETIN GENE; HIF-ALPHA; EXPRESSION; BINDING; CANCER; INDUCTION; FACTOR-1; CELLS	Hypoxia-inducible factor 1 alpha (HIF-1 alpha) is frequently over-expressed in human cancers and controls the expression of several genes that have been implicated in tumor growth and progression. Activity of HIF-1 alpha in cancer cells is regulated at the transcriptional, translational and post-translational level by multiple inter-and coacting molecular pathways. In this report, we reveal for the first time that tumor-associated CpG demethylation facilitates positive autoregulation of HIF-1 alpha, resulting in amplification of hypoxia-induced transactivation of HIF-1 alpha target genes. The HIF-1 alpha promoter harbors a hypoxia response element that is normally repressed by methylation of a CpG dinucleotide located in the core element. In colon cancer cell lines and in primary colon cancer specimens, however, we found frequent aberrant demethylation of this element, enabling binding of HIF-1 alpha to its own promoter resulting in autotransactivation of HIF-1 alpha expression. Our results provide novel and highly unexpected insights into the complexity of HIF-1 alpha regulation in cancer cells and implicate that tumor-associated CpG demethylation augments HIF-1 alpha-mediated effects on malignant cell growth. Oncogene (2011) 30, 876-882; doi:10.1038/onc.2010.481; published online 1 November 2010	[Koslowski, M.; Luxemburger, U.; Sahin, U.] TRON Ctr Translat Oncol & Immunol GmbH, D-55131 Mainz, Germany; [Tuereci, Oe] Ganymed Pharmaceut AG, Mainz, Germany		Sahin, U (corresponding author), TRON Ctr Translat Oncol & Immunol GmbH, Langenbeckstr 1, D-55131 Mainz, Germany.	sahin@uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg A P, 1988, Prog Clin Biol Res, V279, P309; FEINBERG AP, 1988, CANCER RES, V48, P1159; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Koslowski M, 2004, CANCER RES, V64, P5988, DOI 10.1158/0008-5472.CAN-04-1187; Koslowski M, 2006, HUM MOL GENET, V15, P2392, DOI 10.1093/hmg/ddl163; Koslowski M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-77; Koslowski M, 2009, J BIOL CHEM, V284, P28607, DOI 10.1074/jbc.M109.031120; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Sahin U, 2008, CLIN CANCER RES, V14, P7624, DOI 10.1158/1078-0432.CCR-08-1547; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Serfling E, 2006, TRENDS IMMUNOL, V27, P461, DOI 10.1016/j.it.2006.08.005; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WAINFAN E, 1992, CANCER RES, V52, pS2071; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Yin H, 2000, BLOOD, V95, P111, DOI 10.1182/blood.V95.1.111.001k20_111_119; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zundel W, 2000, GENE DEV, V14, P391	44	61	65	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					876	882		10.1038/onc.2010.481	http://dx.doi.org/10.1038/onc.2010.481			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	21042279				2022-12-28	WOS:000287444600011
J	Singh, RR; Kunkalla, K; Qu, C; Schlette, E; Neelapu, SS; Samaniego, F; Vega, F				Singh, R. R.; Kunkalla, K.; Qu, C.; Schlette, E.; Neelapu, S. S.; Samaniego, F.; Vega, F.			ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma	ONCOGENE			English	Article						ABCG2; ATP-binding cassettes; hedgehog pathway; GLI; diffuse large B-cell lymphoma	CANCER RESISTANCE PROTEIN; MULTIDRUG-RESISTANCE; SONIC-HEDGEHOG; P-GLYCOPROTEIN; POOR RESPONSE; EXPRESSION; GENE; TRANSPORTER; SURVIVAL; PATHWAY	Successful treatment of diffuse large B-cell lymphoma (DLBCL) is frequently hindered by the development of resistance to conventional chemotherapy resulting in disease relapse and high mortality. High expression of antiapoptotic and/or drug transporter proteins induced by oncogenic signaling pathways has been implicated in the development of chemoresistance in cancer. Previously, our studies showed that high expression of adenosine triphosphate-binding cassette drug transporter ABCG2 in DLBCL correlated inversely with disease-and failure-free survival. In this study, we have implicated activated hedgehog (Hh) signaling pathway as a key factor behind high ABCG2 expression in DLBCL through direct upregulation of ABCG2 gene transcription. We have identified a single binding site for GLI transcription factors in the ABCG2 promoter and established its functionality using luciferase reporter, site-directed mutagenesis and chromatin-immunoprecipitation assays. Furthermore, in DLBCL tumor samples, significantly high ABCG2 and GLI1 levels were found in DLBCL tumors with lymph node involvement in comparison with DLBCL tumor cells collected from pleural and/or peritoneal effusions. This suggests a role for the stromal microenvironment in maintaining high levels of ABCG2 and GLI1. Accordingly, in vitro co-culture of DLBCL cells with HS-5 stromal cells increased ABCG2 mRNA and protein levels by paracrine activation of Hh signaling. In addition to ABCG2, co-culture of DLBCL cells with HS-5 cells also resulted in increase expression of the antiapoptotic proteins BCL2, BCL-xL and BCL2A1 and in induced chemotolerance to doxorubicin and methotrexate, drugs routinely used for the treatment of DLBCL. Similarly, activation of Hh signaling in DLBCL cell lines with recombinant Shh N-terminal peptide resulted in increased expression of BCL2 and ABCG2 associated with increased chemotolerance. Finally, functional inhibition of ABCG2 drug efflux activity with fumitremorgin C or inhibition of Hh signaling with cyclopamine-KAAD abrogated the stroma-induced chemotolerance suggesting that targeting ABCG2 and Hh signaling may have therapeutic value in overcoming chemoresistance in DLBCL. Oncogene (2011) 30, 4874-4886; doi:10.1038/onc.2011.195; published online 30 May 2011	[Singh, R. R.; Kunkalla, K.; Qu, C.; Schlette, E.; Vega, F.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Neelapu, S. S.; Samaniego, F.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Singh, RR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Unit 72,1515 Holcombe Blvd, Houston, TX 77030 USA.	rsingh@mdanderson.org; fvegava@mdanderson.org	Vega, Francisco/AGY-4571-2022	Vega, Francisco/0000-0001-5956-452X	NCI/NIH [CA16672]; Leukemia and Lymphoma Society; NIH [1 K08 CA143151-01]; UT MD Anderson Cancer Center Lymphoma SPORE [1P50CA136411-01A1]; Lauri Strauss Leukemia Foundation; NATIONAL CANCER INSTITUTE [P50CA136411, P30CA016672, K08CA143151] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UT MD Anderson Cancer Center Lymphoma SPORE; Lauri Strauss Leukemia Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Susan E Bates (NIH) for providing the ABCG2 promoter luciferase constructs. We also thank Professor Michael G Rosenblum, Department of Experimental Therapeutics, MD Anderson Cancer Center for providing OCI-LY3 and OCI-LY10 cell lines. The primary tumor samples were provided by the Hematopathology and Lymphoma Tissue Banks of the UT MD Anderson Cancer Center (supported by the NCI/NIH Grant CA16672). This research was supported by funds from The Translational Grant of The Leukemia and Lymphoma Society (to RRS and FV), K08 Physician-Scientist Award 1 K08 CA143151-01 (NIH) (to FV), SPORE Lymphoma Grant UT MD Anderson Cancer Center Lymphoma SPORE 1P50CA136411-01A1 (to FV) and Lauri Strauss Leukemia Foundation Grant award (to RRS and FV).	Abbott BL, 2002, BLOOD, V100, P4594, DOI 10.1182/blood-2002-01-0271; Alexander DD, 2007, INT J CANCER, P1, DOI 10.1002/ijc.22719; Allikmets R, 1998, CANCER RES, V58, P5337; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Andreadis C, 2007, BLOOD, V109, P3409, DOI 10.1182/blood-2006-09-047621; Armitage JO, 2007, BLOOD, V110, P29, DOI 10.1182/blood-2007-01-041871; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Barnes EA, 2005, ONCOGENE, V24, P902, DOI 10.1038/sj.onc.1208240; Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664; Benderra Z, 2004, CLIN CANCER RES, V10, P7896, DOI 10.1158/1078-0432.CCR-04-0795; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bleau AM, 2009, CELL CYCLE, V8, P2936; Candeil L, 2004, INT J CANCER, V109, P848, DOI 10.1002/ijc.20032; Damiani D, 2010, LEUKEMIA RES, V34, P942, DOI 10.1016/j.leukres.2010.01.008; Dean M, 2001, J BIOENERG BIOMEMBR, V33, P475, DOI 10.1023/A:1012823120935; Desch P, 2010, ONCOGENE, V29, P4885, DOI 10.1038/onc.2010.243; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Fernandez M, 2010, J CELL BIOCHEM, V111, P130, DOI 10.1002/jcb.22676; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grigorieva I, 1998, EXP HEMATOL, V26, P597; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Honjo Y, 2001, CANCER RES, V61, P6635; Hu LL, 2007, CARCINOGENESIS, V28, P1740, DOI 10.1093/carcin/bgm113; Jerkeman M, 2004, ANN HEMATOL, V83, P414, DOI 10.1007/s00277-004-0855-x; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kawabata S, 2003, CLIN CANCER RES, V9, P3052; Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Lwin T, 2009, LEUKEMIA, V23, P170, DOI 10.1038/leu.2008.266; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Miyake K, 1999, CANCER RES, V59, P8; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676; Ohsawa M, 2005, ONCOLOGY-BASEL, V68, P422, DOI 10.1159/000086984; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Queiroz KCS, 2010, ONCOGENE, V29, P6314, DOI 10.1038/onc.2010.375; Rabindran SK, 2000, CANCER RES, V60, P47; Robey RW, 2003, BRIT J CANCER, V89, P1971, DOI 10.1038/sj.bjc.6601370; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; RODRIGUEZ C, 1993, LEUKEMIA RES, V17, P149, DOI 10.1016/0145-2126(93)90060-X; Sacedon R, 2005, J IMMUNOL, V174, P1456, DOI 10.4049/jimmunol.174.3.1456; Sarkadi B, 2004, FEBS LETT, V567, P116, DOI 10.1016/j.febslet.2004.03.123; Sauerbrey A, 2002, BRIT J HAEMATOL, V118, P147, DOI 10.1046/j.1365-2141.2002.03550.x; Schmittgen TD, 2001, METHODS, V25, P383, DOI 10.1006/meth.2001.1260; Sims-Mourtada J, 2007, ONCOGENE, V26, P5674, DOI 10.1038/sj.onc.1210356; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Singh RR, 2010, LEUKEMIA, V24, P1025, DOI 10.1038/leu.2010.35; Singh RR, 2009, CANCER RES, V69, P2550, DOI 10.1158/0008-5472.CAN-08-1808; Stam RW, 2004, LEUKEMIA, V18, P78, DOI 10.1038/sj.leu.2403168; Steinbach D, 2002, LEUKEMIA, V16, P1443, DOI 10.1038/sj.leu.2402541; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; To KKW, 2006, MOL CELL BIOL, V26, P8572, DOI 10.1128/MCB.00650-06; Tsunoda S, 2006, ONCOLOGY-BASEL, V71, P251, DOI 10.1159/000106787; Uggla B, 2005, LEUKEMIA RES, V29, P141, DOI 10.1016/j.leukres.2004.06.004; Winklmayr M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-2; Yasuda S, 2009, MOL BIOL REP, V36, P1889, DOI 10.1007/s11033-008-9395-0; Yoh K, 2004, CLIN CANCER RES, V10, P1691, DOI 10.1158/1078-0432.CCR-0937-3; YUEN AR, 1994, J CLIN ONCOL, V12, P2453, DOI 10.1200/JCO.1994.12.11.2453	66	122	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4874	4886		10.1038/onc.2011.195	http://dx.doi.org/10.1038/onc.2011.195			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21625222	Green Accepted			2022-12-28	WOS:000298346400004
J	Lushnikova, T; Bouska, A; Odvody, J; Dupont, WD; Eischen, CM				Lushnikova, T.; Bouska, A.; Odvody, J.; Dupont, W. D.; Eischen, C. M.			Aging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression	ONCOGENE			English	Article						aging; Mdm2; p53; chromosome instability; aneuploidy	NIJMEGEN BREAKAGE SYNDROME; DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; DNA-DAMAGE; P53; CANCER; CELLS; NBS1; OVEREXPRESSION; TUMORIGENESIS	Aging is thought to negatively affect multiple cellular processes including the ability to maintain chromosome stability. Chromosome instability (CIN) is a common property of cancer cells and may be a contributing factor to cellular transformation. The types of DNA aberrations that arise during aging before tumor development and that contribute to tumorigenesis are currently unclear. Mdm2, a key regulator of the p53 tumor suppressor and modulator of DNA break repair, is frequently over-expressed in malignancies and contributes to CIN. To determine the relationship between aging and CIN and the role of Mdm2, precancerous wild-type C57Bl/6 and littermate-matched Mdm2 transgenic mice at various ages were evaluated. Metaphase analyses of wild-type cells showed a direct correlation between age and increased chromosome and chromatid breaks, chromosome fusions and aneuploidy, but the frequency of polyploidy remained stable over time. Elevated levels of Mdm2 in precancerous mice increased both the numerical and the structural chromosomal abnormalities observed. Chromosome and chromatid breaks, chromosome fusions, aneuploidy and polyploidy were increased in older Mdm2 transgenic mice compared with wild-type littermates. Unexpectedly, chromosome fusions, aneuploidy and polyploidy rates in Mdm2 transgenic mice, but not chromosome and chromatid breaks, showed cooperation between Mdm2 overexpression and age. Notably, Mdm2 overexpression promoted gains in one or more chromosomes with age, while it did not affect the rate of chromosome loss. Therefore, aging increased specific forms of genomic instability, and elevated Mdm2 expression cooperated with aging to increase the likelihood of gaining certain chromosomal abnormalities of the kind thought to lead to cancer development. Oncogene (2011) 30, 4622-4631; doi:10.1038/onc.2011.172; published online 23 May 2011	[Eischen, C. M.] Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, Nashville, TN 37232 USA; [Bouska, A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Dupont, W. D.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA	Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center; Vanderbilt University	Eischen, CM (corresponding author), Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, 1161 21st Ave S,C3321 MCN, Nashville, TN 37232 USA.	christine.eischen@vanderbilt.edu	Dupont, William D./I-4430-2012		NIH/NCI [R01 CA117935]; Vanderbilt Cancer Center [P30 CA068485]; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA117935] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Eischen lab for thoughtful discussions. This work was supported by the NIH/NCI grants: R01 CA117935 (CME) and the Vanderbilt Cancer Center grant P30 CA068485.	Agresti A, 2003, CATEGORICAL DATA ANA; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Bouska A, 2009, CANCER RES, V69, P1697, DOI 10.1158/0008-5472.CAN-08-3732; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Demuth I, 2007, ONCOGENE, V26, P7792, DOI 10.1038/sj.onc.1210876; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Dolle MET, 2002, GENOME RES, V12, P1732, DOI 10.1101/gr.125502; Feng ZH, 2007, P NATL ACAD SCI USA, V104, P16633, DOI 10.1073/pnas.0708043104; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Garagna S, 2001, P NATL ACAD SCI USA, V98, P171, DOI 10.1073/pnas.98.1.171; Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241; Gorbunova V, 2007, NUCLEIC ACIDS RES, V35, P7466, DOI 10.1093/nar/gkm756; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lin HJ, 2001, J CELL BIOL, V155, P1173, DOI 10.1083/jcb.200108119; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NISITANI S, 1990, MUTAT RES, V237, P221, DOI 10.1016/0921-8734(90)90003-A; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Tucker JD, 1999, MUTAT RES-FUND MOL M, V425, P135, DOI 10.1016/S0027-5107(99)00036-6; Vitale I, 2010, EMBO J, V29, P1272, DOI 10.1038/emboj.2010.11; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wu XH, 2004, GENE DEV, V18, P1305, DOI 10.1101/gad.1182804; Zietkiewicz E, 2009, J APPL GENET, V50, P261, DOI 10.1007/BF03195682	38	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4622	4631		10.1038/onc.2011.172	http://dx.doi.org/10.1038/onc.2011.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21602883	Green Accepted			2022-12-28	WOS:000297252100002
J	King, CE; Wang, L; Winograd, R; Madison, BB; Mongroo, PS; Johnstone, CN; Rustgi, AK				King, C. E.; Wang, L.; Winograd, R.; Madison, B. B.; Mongroo, P. S.; Johnstone, C. N.; Rustgi, A. K.			LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms	ONCOGENE			English	Article						LIN28B; LIN28; Let-7; colon cancer; LGR5; PROM1	LET-7 MICRORNA; C-MYC; STEM-CELLS; EXPRESSION; IDENTIFICATION; LIN-28; CONSERVATION; ASSOCIATION; SUPPRESSOR; MATURATION	Lin28b is an RNA-binding protein that inhibits biogenesis of let-7 microRNAs. LIN28B is overexpressed in diverse cancers, yet a specific role in the molecular pathogenesis of colon cancer has to be elucidated. We have determined that human colon tumors exhibit decreased levels of mature let-7 isoforms and increased expression of LIN28B. To determine LIN28B's mechanistic role in colon cancer, we expressed LIN28B in immortalized colonic epithelial cells and human colon cancer cell lines. We found that LIN28B promotes cell migration, invasion and transforms immortalized colonic epithelial cells. In addition, constitutive LIN28B expression increases expression of intestinal stem cell markers LGR5 and PROM1 in the presence of let-7 restoration. This may occur as a result of Lin28b protein binding LGR5 and PROM1 mRNA, suggesting that a subset of LIN28B functions is independent of its ability to repress let-7. Our findings establish a new role for LIN28B in human colon cancer pathogenesis, and suggest LIN28B post-transcriptionally regulates LGR5 and PROM1 through a let-7-independent mechanism. Oncogene (2011) 30, 4185-4193; doi:10.1038/onc.2011.131; published online 30 May 2011	[Rustgi, A. K.] Univ Penn, Dept Med, Dept Genet, Div Gastroenterol,Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Rustgi, AK (corresponding author), Univ Penn, Dept Med, Dept Genet, Div Gastroenterol,Abramson Canc Ctr, 415 Curie Blvd,600 CRB, Philadelphia, PA 19104 USA.	anil2@mail.med.upenn.edu			Pfizer; NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases [P30-DK050306]; NIH [U01-DK085551]; NIH ARRA [NIH P30 DK050306];  [R01-DK056645]; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085551, R01DK056645, P30DK050306] Funding Source: NIH RePORTER	Pfizer(Pfizer); NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH ARRA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by R01-DK056645 (AR, CK and PM). Hauser Foundation, National Colon Cancer Research Alliance (EIF) and American Cancer Society Research Professorship (AR). Catrina King is a Pfizer Animal Health scholarship recipient, a doctoral candidate in Biomedical Graduate Studies, and a student of the School of Veterinary Medicine at the University of Pennsylvania. We thank Dr Joshua Mendell for gifts of LIN28B expression vectors, as well as Ben Rhoades and Mark Bowser for technical assistance. We also acknowledge help from the NIH/NIDDK P30-DK050306 Center for Molecular Studies in Digestive and Liver Diseases and its Molecular Biology and Cell Culture Core Facilities and NIH U01-DK085551. Louise Wang was supported by an NIH ARRA student fellowship through the NIH P30 DK050306.	Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Balzer E, 2010, DEVELOPMENT, V137, P891, DOI 10.1242/dev.042895; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; FLINT N, 1991, BIOCHEM J, V280, P331, DOI 10.1042/bj2800331; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hafner Markus, 2010, J Vis Exp, DOI 10.3791/2034; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; Snippert HJ, 2009, GASTROENTEROLOGY, V136, P2187, DOI 10.1053/j.gastro.2009.03.002; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	40	95	104	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	40					4185	4193		10.1038/onc.2011.131	http://dx.doi.org/10.1038/onc.2011.131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21625210	Green Accepted			2022-12-28	WOS:000295924600005
J	Morinaka, A; Funato, Y; Uesugi, K; Miki, H				Morinaka, A.; Funato, Y.; Uesugi, K.; Miki, H.			Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis	ONCOGENE			English	Article						MST1; PRX-I; reactive oxygen species (ROS); p53; cisplatin	OXIDATIVE-STRESS; HYDROGEN-PEROXIDE; HIPPO PATHWAY; P53-DEPENDENT APOPTOSIS; TUMOR SUPPRESSION; PROTEIN-KINASE; CANCER-CELLS; DNA-DAMAGE; C-MYC; PHOSPHORYLATION	Mammalian Ste20-like kinase-1 (MST1) kinase mediates H(2)O(2)-induced cell death by anticancer drugs such as cisplatin in a p53-dependent manner. However, the mechanism underlying MST1 activation by H(2)O(2) remains unknown. Here we show that peroxiredoxin-I (PRX-I) is an essential intermediate in H(2)O(2)-induced MST1 activation and cisplatin-induced cell death through p53. Cell stimulation with H(2)O(2) resulted in PRX-I oxidation to form homo-oligomers and interaction with MST1, leading to MST1 autophosphorylation and augmentation of kinase activity. In addition, RNA interference knockdown experiments indicated that endogenous PRX-I is required for H(2)O(2)-induced MST1 activation. Live-cell imaging showed H(2)O(2) generation by cisplatin treatment, which likewise caused PRX-I oligomer formation, MST1 activation and cell death. Cisplatin-induced PRX-I oligomer formation was not observed in embryonic fibroblasts obtained from p53-knockout mice, confirming the importance of p53. Indeed, ectopic expression of p53 induced PRX-I oligomer formation and cell death, both of which were cancelled by the antioxidant NAC. Moreover, we succeeded in reconstituting H(2)O(2)-induced MST1 activation in vitro, using purified PRX-I and MST1 proteins. Collectively, our results show a novel PRX-I function to cause cell death in response to high levels of oxidative stress by activating MST1, which underlies the p53-dependent cytotoxicity caused by anticancer agents. Oncogene (2011) 30, 4208-4218; doi:10.1038/onc.2011.139; published online 25 April 2011	[Morinaka, A.; Funato, Y.; Uesugi, K.; Miki, H.] Osaka Univ, Inst Prot Res, Lab Intracellular Signaling, Osaka 5650871, Japan	Osaka University	Miki, H (corresponding author), Osaka Univ, Inst Prot Res, Lab Intracellular Signaling, 3-2 Yamadaoka, Osaka 5650871, Japan.	hmiki@protein.osaka-u.ac.jp			Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Japan; Grants-in-Aid for Scientific Research [22770195] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Yoshiaki Kise (Flanders Institute for Biotechnology, Belgium) for technical assistance in preparing the expression constructs. This study was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) and Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Japan.	Ahn SH, 2005, CELL, V120, P25, DOI 10.1016/j.cell.2004.11.016; Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Colombani J, 2006, CURR BIOL, V16, P1453, DOI 10.1016/j.cub.2006.05.059; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; de Souza PM, 2004, BIOCHEM SOC T, V32, P485, DOI 10.1042/BST0320485; Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Graves JA, 2009, J BIOL CHEM, V284, P6520, DOI 10.1074/jbc.M807564200; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Lee WS, 2007, J BIOL CHEM, V282, P22011, DOI 10.1074/jbc.M610330200; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Moon JC, 2005, J BIOL CHEM, V280, P28775, DOI 10.1074/jbc.M505362200; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; O'Neill EE, 2005, CANCER RES, V65, P5485, DOI 10.1158/0008-5472.CAN-05-1453; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Praskova M, 2008, CURR BIOL, V18, P311, DOI 10.1016/j.cub.2008.02.006; Ren AX, 2008, CANCER RES, V68, P2266, DOI 10.1158/0008-5472.CAN-07-6248; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; TSUKADA T, 1993, ONCOGENE, V8, P3313; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Veal EA, 2007, MOL CELL, V26, P1, DOI 10.1016/j.molcel.2007.03.016; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011	37	64	67	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4208	4218		10.1038/onc.2011.139	http://dx.doi.org/10.1038/onc.2011.139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21516123				2022-12-28	WOS:000295924600007
J	Abdeen, SK; Salah, Z; Maly, B; Smith, Y; Tufail, R; Abu-Odeh, M; Zanesi, N; Croce, CM; Nawaz, Z; Aqeilan, RI				Abdeen, S. K.; Salah, Z.; Maly, B.; Smith, Y.; Tufail, R.; Abu-Odeh, M.; Zanesi, N.; Croce, C. M.; Nawaz, Z.; Aqeilan, R. I.			Wwox inactivation enhances mammary tumorigenesis	ONCOGENE			English	Article						WWOX; WW domains; breast cancer; triple negative; tumor suppressor	BREAST-CANCER; E6-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR; EXPRESSION; GENE; IDENTIFICATION; ESTROGEN; GROWTH	Breast cancer is the leading cause of cancer-related death in women worldwide. Expression of the WWOX tumor suppressor is absent or reduced in a large proportion of breast tumors suggesting that loss of WWOX may contribute to breast tumorigenesis. Wwox-deficient mice die by 3-4 weeks of age precluding adult tumor analysis. To evaluate the effect of WWOX-altered expression on mammary tumor formation, the Wwox-heterozygous allele was back crossed onto the C3H mammary tumor-susceptible genetic background (Wwox(C3H) +/-) and incidence of mammary tumor formation was evaluated. Although 50% of the female Wwox(C3H) +/- mice developed mammary carcinomas, only 7% of Wwox(C3H) +/- mice did. Intriguingly, mammary tumors in Wwox(C3H) +/- mice frequently lost WWOX protein expression suggesting a genetic predisposition toward mammary tumorigenesis. Immunohistochemical staining of hormone receptors revealed loss of estrogen receptor-a (ER) and progesterone receptor in the majority of these tumors. In vitro, depletion of WWOX in MCF7 ER-positive cells led to reduced ER expression and reduced sensitivity to tamoxifen and estrogen treatment and was associated with enhanced survival and anchorage-independent growth. Finally, cDNA array analyses of murine normal mammary epithelial cells and mammary tumors identified 163 significantly downreguated and 129 upregulated genes in the tumors. The majority of differentially expressed genes were part of pathways involved in cellular movement, cell-to-cell signaling and interaction, cellular development, cellular growth and proliferation and cell death. These changes in gene expression of mouse mammary tumors in Wwox(C3H) +/- mice resemble, at least in part, human breast cancer development. Our findings demonstrate the critical role that the WWOX tumor suppressor gene has in preventing tumorigenesis in breast cancer. Oncogene (2011) 30, 3900-3906; doi:10.1038/onc.2011.115; published online 18 April 2011	[Abdeen, S. K.; Salah, Z.; Abu-Odeh, M.; Aqeilan, R. I.] Hebrew Univ Jerusalem, Dept Immunol & Canc Res IMRIC, Lautenberg Ctr Gen & Tumor Immunol, Hadassah Med Sch, IL-91120 Jerusalem, Israel; [Maly, B.] Hebrew Univ Jerusalem, Dept Expt Pathol, Hadassah Med Sch, IL-91120 Jerusalem, Israel; [Smith, Y.] Hebrew Univ Jerusalem, Genom Data Anal Unit, Hadassah Med Sch, IL-91120 Jerusalem, Israel; [Tufail, R.; Nawaz, Z.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL USA; [Zanesi, N.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Miami; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Aqeilan, RI (corresponding author), Hebrew Univ Jerusalem, Dept Immunol & Canc Res IMRIC, Lautenberg Ctr, POB 12272, IL-91120 Jerusalem, Israel.	aqeilan@cc.huji.ac.il	Aqeilan, Rami/R-4443-2016; Young, Richard A/F-6495-2012; Aqeilan, Rami/AAT-7785-2020	Aqeilan, Rami/0000-0002-6034-023X; Young, Richard A/0000-0001-8855-8647; 	NIH [R01DK060907]; Israeli Science Foundation [1331/08]; Israel Cancer Research Funds (ICRF); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060907, R01DK079217] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Israeli Science Foundation(Israel Science Foundation); Israel Cancer Research Funds (ICRF); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to all the Aqeilan's lab members for helpful suggestions and technical assistance. This research was supported by grants from NIH (R01DK060907) to ZN and RIA, Israeli Science Foundation (#1331/08) to RIA and Israel Cancer Research Funds (ICRF) to ZS.	Aqeilan RI, 2007, CANCER RES, V67, P5606, DOI 10.1158/0008-5472.CAN-07-1081; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Aqeilian RI, 2007, CANCER RES, V67, P9330, DOI 10.1158/0008-5472.CAN-07-2147; Bednarek AK, 2000, CANCER RES, V60, P2140; Del Mare S, 2009, J CELL BIOCHEM, V108, P737, DOI 10.1002/jcb.22298; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; Guler G, 2009, CANCER-AM CANCER SOC, V115, P899, DOI 10.1002/cncr.24103; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Klein A, 2007, INT J CANCER, V121, P683, DOI 10.1002/ijc.22630; Kurek KC, 2010, CANCER RES, V70, P5577, DOI 10.1158/0008-5472.CAN-09-4602; Nunez M, 2005, BREAST CANCER RES TR, V89, P99, DOI 10.1007/s10549-004-1474-x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Radmacher MD, 2000, J NATL CANCER I, V92, P48, DOI 10.1093/jnci/92.1.48; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Salah Z, 2010, FUTURE ONCOL, V6, P249, DOI [10.2217/fon.09.152, 10.2217/FON.09.152]; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Turner BC, 2002, CANCER RES, V62, P4054	23	51	53	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	36					3900	3906		10.1038/onc.2011.115	http://dx.doi.org/10.1038/onc.2011.115			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21499303				2022-12-28	WOS:000294687200007
J	Babu, E; Ramachandran, S; CoothanKandaswamy, V; Elangovan, S; Prasad, PD; Ganapathy, V; Thangaraju, M				Babu, E.; Ramachandran, S.; CoothanKandaswamy, V.; Elangovan, S.; Prasad, P. D.; Ganapathy, V.; Thangaraju, M.			Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate	ONCOGENE			English	Article						SLC5A8; dichloroacetate; anticancer drug; Warburg effect; pyruvate dehydrogenase kinase; mitochondrial oxidation in cancer	NA+-COUPLED TRANSPORTER; CANCER-CELLS; COLON-CANCER; GENE SLC5A8; ELECTROGENIC TRANSPORT; PYRUVATE-DEHYDROGENASE; PERIPHERAL NEUROPATHY; IN-VITRO; APOPTOSIS; WARBURG	There has been growing interest among the public and scientists in dichloroacetate (DCA) as a potential anticancer drug. Credible evidence exists for the antitumor activity of this compound, but high concentrations are needed for significant therapeutic effect. Unfortunately, these high concentrations produce detrimental side effects involving the nervous system, thereby precluding its use for cancer treatment. The mechanistic basis of the compound's antitumor activity is its ability to activate the pyruvate dehydrogenase complex through inhibition of pyruvate dehydrogenase kinase. As the compound inhibits the kinase at micromolar concentrations, it is not known why therapeutically prohibitive high doses are needed for suppression of tumor growth. We hypothesized that lack of effective mechanisms for the entry of DCA into tumor cells may underlie this phenomenon. Here we show that SLC5A8 transports DCA very effectively with high affinity. This transporter is expressed in normal cells, but expression is silenced in tumor cells by epigenetic mechanisms. The lack of the transporter makes tumor cells resistant to the antitumor activity of DCA. However, if the transporter is expressed in tumor cells ectopically, the cells become sensitive to the drug at low concentrations. This is evident in breast cancer cells, colon cancer cells and prostate cancer cells. Normal cells, which constitutively express the transporter, are however not affected by the compound, indicating tumor cell-selective therapeutic activity. The mechanism of the compound's antitumor activity still remains its ability to inhibit pyruvate dehydrogenase kinase and force mitochondrial oxidation of pyruvate. As silencing of SLC5A8 in tumors involves DNA methylation and its expression can be induced by treatment with DNA methylation inhibitors, our findings suggest that combining DCA with a DNA methylation inhibitor would offer a means to reduce the doses of DCA to avoid detrimental effects associated with high doses but without compromising antitumor activity. Oncogene (2011) 30, 4026-4037; doi:10.1038/onc. 2011.113; published online 18 April 2011	[Babu, E.; Ramachandran, S.; CoothanKandaswamy, V.; Elangovan, S.; Prasad, P. D.; Ganapathy, V.; Thangaraju, M.] Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Thangaraju, M (corresponding author), Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, 1459 Laney Walker Blvd,CB 2515, Augusta, GA 30912 USA.	mthangaraju@georgiahealth.edu	Elangovan, Selvakumar/ABB-9558-2021	Elangovan, Selvakumar/0000-0001-9906-5477	National Institutes of Health [CA131402]; NATIONAL CANCER INSTITUTE [R01CA131402] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work described here is supported in part by the National Institutes of Health Grant CA131402.	Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; Brandsma D, 2010, J NEUROL, V257, P2099, DOI 10.1007/s00415-010-5654-9; Calcutt NA, 2009, J NEUROPATH EXP NEUR, V68, P985, DOI 10.1097/NEN.0b013e3181b40217; Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Coady MJ, 2004, J PHYSIOL-LONDON, V557, P719, DOI 10.1113/jphysiol.2004.063859; COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625; Ganapathy V, 2005, BIOCHEM SOC T, V33, P237, DOI 10.1042/BST0330237; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Ganapathy V, 2008, AAPS J, V10, P193, DOI 10.1208/s12248-008-9022-y; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gopal E, 2005, BIOCHEM J, V388, P309, DOI 10.1042/BJ20041916; Gopal E, 2004, J BIOL CHEM, V279, P44522, DOI 10.1074/jbc.M405365200; Gupta N, 2006, LIFE SCI, V78, P2419, DOI 10.1016/j.lfs.2005.10.028; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heshe D, 2011, CANCER CHEMOTH PHARM, V67, P647, DOI 10.1007/s00280-010-1361-6; Hong CB, 2005, CANCER RES, V65, P3617, DOI 10.1158/0008-5472.CAN-05-0048; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701; Martin PM, 2006, J NEUROCHEM, V98, P279, DOI 10.1111/j.1471-4159.2006.03878.x; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; Miyauchi S, 2010, BBA-BIOMEMBRANES, V1798, P1164, DOI 10.1016/j.bbamem.2010.03.002; Park JY, 2008, PANCREAS, V36, pE32, DOI 10.1097/MPA.0b013e3181630ffe; Park JY, 2007, CANCER DETECT PREV, V31, P359, DOI 10.1016/j.cdp.2007.09.002; Pearson H, 2007, NATURE, V446, P474, DOI 10.1038/446474a; Porra V, 2005, J CLIN ENDOCR METAB, V90, P3028, DOI 10.1210/jc.2004-1394; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Stacpoole PW, 1998, DRUG METAB REV, V30, P499, DOI 10.3109/03602539808996323; Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637; Stapoole PW, 2008, ADV DRUG DELIVER REV, V60, P1478, DOI 10.1016/j.addr.2008.02.014; Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Thangaraju M, 2008, J GASTROINTEST SURG, V12, P1773, DOI 10.1007/s11605-008-0573-0; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Thangaraju M, 2009, CANCER, V115, P4655, DOI 10.1002/cncr.24532; Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132; Ueno M, 2004, TUMOR BIOL, V25, P134, DOI 10.1159/000079145; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weimer LH, 2009, CURR NEUROL NEUROSCI, V9, P69, DOI 10.1007/s11910-009-0011-z; WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038; Xiao LL, 2010, MOL CELL BIOCHEM, V340, P31, DOI 10.1007/s11010-010-0397-6	49	63	67	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4026	4037		10.1038/onc.2011.113	http://dx.doi.org/10.1038/onc.2011.113			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21499304	Green Accepted			2022-12-28	WOS:000295121600004
J	Fournier, G; Cabaud, O; Josselin, E; Chaix, A; Adelaide, J; Isnardon, D; Restouin, A; Castellano, R; Dubreuil, P; Chaffanet, M; Birnbaum, D; Lopez, M				Fournier, G.; Cabaud, O.; Josselin, E.; Chaix, A.; Adelaide, J.; Isnardon, D.; Restouin, A.; Castellano, R.; Dubreuil, P.; Chaffanet, M.; Birnbaum, D.; Lopez, M.			Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth	ONCOGENE			English	Article						afadin; breast cancer; migration; invasion; tumorigenicity; SRC and MAPK	ACTIVATED PROTEIN-KINASE; PDZ DOMAIN; ACTIN CYTOSKELETON; ADHERENS JUNCTIONS; NEGATIVE REGULATOR; ADHESION MOLECULE; AF-6; DROSOPHILA; BINDING; AFADIN	Afadin/AF6, an F-actin-binding protein, is ubiquitously expressed in epithelia and has a key role during development, through its regulatory role in cell-cell junction organization. Afadin loss of expression in 15% of breast carcinoma is associated with adverse prognosis and increased risk of metastatic relapse. To determine the role of afadin in breast cancer, we studied the functional consequences of afadin protein extinction using in vitro and in vivo models. Three different breast cancer cell lines representative of the major molecular subtypes were stably repressed for afadin expression (knockdown of afadin (afadin KD)) using RNA interference. Collective and individual migrations as well as Matrigel invasion were markedly increased in afadin KD cells. Heregulin-beta 1 (HRG-beta 1)-induced migration and invasion were increased by twofold in afadin KD cells. Conversely, ectopic expression of afadin in the afadin-negative T47D cell line inhibited spontaneous and HRG-beta 1-induced migrations. RAS/MAPK and SRC kinase pathways were activated in afadin KD cells. Activation levels positively correlated with migration and invasion strength. Use of MEK1/2 (U0126) and SRC kinases (SU6656) inhibitors reduced afadin-dependent migration and invasion. Afadin extinction in the SK-BR-3 cell line markedly accelerated tumor growth development in mouse mammary gland and lung metastasis formation. These results may explain why the loss of afadin expression in tumors correlates with high tumor size and poor metastasis-free survival in patients. Oncogene (2011) 30, 3862-3874; doi:10.1038/onc.2011.106; published online 11 April 2011	[Fournier, G.; Cabaud, O.; Josselin, E.; Chaffanet, M.; Birnbaum, D.; Lopez, M.] INSERM, Oncol Mol Lab, UMR 891, CRCM, F-13009 Marseille, France; [Chaix, A.; Dubreuil, P.] INSERM, Lab Hematopoiese Fonct & Mol, UMR 891, CRCM, F-13009 Marseille, France; [Restouin, A.; Castellano, R.] INSERM, Plateforme TrGET Essais Preclin, UMR 891, CRCM, F-13009 Marseille, France; [Fournier, G.; Cabaud, O.; Josselin, E.; Chaix, A.; Adelaide, J.; Isnardon, D.; Restouin, A.; Castellano, R.; Dubreuil, P.; Chaffanet, M.; Lopez, M.] Inst J Paoli I Calmettes, F-13009 Marseille, France; [Fournier, G.; Cabaud, O.; Josselin, E.; Chaix, A.; Adelaide, J.; Isnardon, D.; Restouin, A.; Castellano, R.; Dubreuil, P.; Chaffanet, M.; Lopez, M.] Univ Aix Marseille 2, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Lopez, M (corresponding author), INSERM, Oncol Mol Lab, UMR891, 27 Bd Lei Roure, F-13009 Marseille, France.	marc.lopez@inserm.fr	ADELAIDE, José JA/O-4390-2017; Dubreuil, Patrice/V-4816-2019; CHAFFANET, Max/AAU-5743-2020; dubreuil, patrice/F-5346-2011	ADELAIDE, José JA/0000-0003-4364-9857; Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Birnbaum, Daniel/0000-0001-7920-9883; CHAFFANET, Max/0000-0002-2344-1488	INSERM; Institut Paoli-Calmettes; Ligue Nationale Contre le Cancer (LNCC); Institut National du Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Institut Paoli-Calmettes; Ligue Nationale Contre le Cancer (LNCC)(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France)	We thank F Birg for helpful discussions. We are grateful of M Buchert for providing us with the pCDNA3-FLAG-L-AF6 vector. This work was supported by INSERM, Institut Paoli-Calmettes, and grants from Ligue Nationale Contre le Cancer (LNCC) (Label 2009-2011) and Institut National du Cancer (AO translationnelle). In 2009-2010, GF has been supported by a fellowship from LNCC.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Bae YH, 2009, J CELL PHYSIOL, V219, P354, DOI 10.1002/jcp.21677; Boettner B, 2003, GENETICS, V165, P159; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Buchert M, 2007, J CELL PHYSIOL, V210, P212, DOI 10.1002/jcp.20853; Carmena A, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000066; Ding ZJ, 2006, J CELL SCI, V119, P4127, DOI 10.1242/jcs.03178; Gaengel K, 2003, DEVELOPMENT, V130, P5413, DOI 10.1242/dev.00759; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Letessier A, 2007, ONCOGENE, V26, P298, DOI 10.1038/sj.onc.1209772; Liedtke M, 2010, BLOOD, V116, P63, DOI 10.1182/blood-2009-09-243386; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Lorger M, 2006, J CELL SCI, V119, P3385, DOI 10.1242/jcs.03027; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Martuszewska D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004350; Matsuo T, 1999, CELL TISSUE RES, V298, P397, DOI 10.1007/s004419900107; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Miyata M, 2009, J CELL SCI, V122, P4319, DOI 10.1242/jcs.048439; Nakata S, 2007, J BIOL CHEM, V282, P37815, DOI 10.1074/jbc.M707461200; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PRASAD R, 1993, CANCER RES, V53, P5624; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Radziwill G, 2007, EMBO J, V26, P2633, DOI 10.1038/sj.emboj.7601706; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; Saito S, 1998, DNA Res, V5, P115, DOI 10.1093/dnares/5.2.115; Sawyer JK, 2009, J CELL BIOL, V186, P57, DOI 10.1083/jcb.200904001; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Speicher S, 2008, CURR BIOL, V18, P831, DOI 10.1016/j.cub.2008.04.072; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Takahashi K, 1998, MECH DEVELOP, V78, P97, DOI 10.1016/S0925-4773(98)00151-8; Takai Y, 2008, ANNU REV CELL DEV BI, V24, P309, DOI 10.1146/annurev.cellbio.24.110707.175339; TANAKA M, 1995, CANCER RES, V55, P3228; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3; Zou L, 2007, BRIT J CANCER, V97, P1361, DOI 10.1038/sj.bjc.6604038	43	39	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3862	3874		10.1038/onc.2011.106	http://dx.doi.org/10.1038/onc.2011.106			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21478912				2022-12-28	WOS:000294687200004
J	Zhang, JS; Koenig, A; Harrison, A; Ugolkov, AV; Fernandez-Zapico, ME; Couch, FJ; Billadeau, DD				Zhang, J-S; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Couch, F. J.; Billadeau, D. D.			Mutant K-Ras increases GSK-3 beta gene expression via an ETS-p300 transcriptional complex in pancreatic cancer	ONCOGENE			English	Article						GSK-3 beta; K-Ras; MAPK; ETS; pancreatic cancer	GLYCOGEN-SYNTHASE KINASE-3-BETA; FACTOR-KAPPA-B; PROSTATE-CANCER; SIGNALING PATHWAYS; COLORECTAL-CANCER; BINDING-PROTEIN; CELL-SURVIVAL; C-MYC; ETS-1; FAMILY	Glycogen synthase kinase-3 beta (GSK-3 beta) is overexpressed in a number of human malignancies and has been shown to contribute to tumor cell proliferation and survival. Although regulation of GSK-3 beta activity has been extensively studied, the mechanisms governing GSK-3 beta gene expression are still unknown. Using pancreatic cancer as a model, we find that constitutively active Ras signaling increases GSK-3 beta gene expression via the canonical mitogen-activated protein kinase signaling pathway. Analysis of the mechanism revealed that K-Ras regulates the expression of this kinase through two highly conserved E-twenty six (ETS) binding elements within the proximal region. Furthermore, we demonstrate that mutant K-Ras enhances ETS2 loading onto the promoter, and ETS requires its transcriptional activity to increase GSK-3 beta gene transcription in pancreatic cancer cells. Lastly, we show that ETS2 cooperates with p300 histone acetyltransferase to remodel chromatin and promote GSK-3 beta expression. Taken together, these results provide a general mechanism for increased expression of GSK-3 beta in pancreatic cancer and perhaps other cancers, where Ras signaling is deregulated. Oncogene (2011) 30, 3705-3715; doi:10.1038/onc.2011.90; published online 28 March 2011	[Zhang, J-S; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Billadeau, D. D.] Mayo Clin, Div Oncol Res, Schulze Ctr Novel Therapeut, Coll Med, Rochester, MN 55905 USA; [Zhang, J-S; Koenig, A.; Harrison, A.; Ugolkov, A. V.; Fernandez-Zapico, M. E.; Billadeau, D. D.] Mayo Clin, Dept Immunol, Schulze Ctr Novel Therapeut, Coll Med, Rochester, MN 55905 USA; [Koenig, A.] Univ Marburg, Dept Gastroenterol & Endocrinol, Marburg, Germany; [Couch, F. J.] Mayo Clin, Div Expt Pathol & Lab Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Philipps University Marburg; Mayo Clinic	Zhang, JS (corresponding author), Mayo Clin, Div Oncol Res, Schulze Ctr Novel Therapeut, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	zhang.jinsan@mayo.edu; billadeau.daniel@mayo.edu	Ugolkov, Andrey/T-3012-2019; Harrison, Andrew M./I-3708-2013	Harrison, Andrew M./0000-0003-0063-9421	Mayo Clinic Pancreatic Cancer SPORE [CA102701]; German Cancer Society; NATIONAL CANCER INSTITUTE [P20CA102701, P50CA102701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK084567] Funding Source: NIH RePORTER	Mayo Clinic Pancreatic Cancer SPORE; German Cancer Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Mayo Clinic Pancreatic Cancer SPORE grant CA102701 (DDB and MEF-Z). DDB is a Leukemia and Lymphoma Scholar. AK is supported by a Mildred-Scheel fellowship of German Cancer Society.	Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bilim V, 2009, BRIT J CANCER, V101, P2005, DOI 10.1038/sj.bjc.6605437; Billadeau DD, 2007, PANCREATOLOGY, V7, P398, DOI 10.1159/000108955; Cao Q, 2006, CELL RES, V16, P671, DOI 10.1038/sj.cr.7310078; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fauquette V, 2005, BIOCHEM J, V386, P35, DOI 10.1042/BJ20040706; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Gutierrez-Hartmann A, 2007, TRENDS ENDOCRIN MET, V18, P150, DOI 10.1016/j.tem.2007.03.002; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hollenhorst PC, 2004, NUCLEIC ACIDS RES, V32, P5693, DOI 10.1093/nar/gkh906; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Ito H, 2004, CANCER RES, V64, P7439, DOI 10.1158/0008-5472.CAN-04-1177; Ito T, 1998, MODERN PATHOL, V11, P209; Ito Y, 2002, ONCOL REP, V9, P853; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jedlicka P, 2008, HISTOL HISTOPATHOL, V23, P1417, DOI 10.14670/HH-23.1417; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kobberup S, 2007, DEV DYNAM, V236, P3100, DOI 10.1002/dvdy.21292; Koenig A, 2010, GASTROENTEROLOGY, V138, P1189, DOI 10.1053/j.gastro.2009.10.045; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Lau KF, 1999, GENOMICS, V60, P121, DOI 10.1006/geno.1999.5875; Lefter LP, 2009, CANCER GENE THER, V16, P137, DOI 10.1038/cgt.2008.65; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Li R, 2009, ANTICANCER RES, V29, P2077; Li YY, 2009, CANCER SCI, V100, P396, DOI 10.1111/j.1349-7006.2008.01059.x; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002; Narod SA, 2008, BRIT J CANCER, V99, P847, DOI 10.1038/sj.bjc.6604558; Nelson ML, 2010, P NATL ACAD SCI USA, V107, P10026, DOI 10.1073/pnas.0915137107; Ougolkov AV, 2006, CLIN CANCER RES, V12, P5074, DOI 10.1158/1078-0432.CCR-06-0196; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Polakis P, 2000, GENE DEV, V14, P1837; Rowley M, 2011, GASTROENTEROLOGY; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; Wai PY, 2006, J BIOL CHEM, V281, P18973, DOI 10.1074/jbc.M511962200; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001	47	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3705	3715		10.1038/onc.2011.90	http://dx.doi.org/10.1038/onc.2011.90			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441955	Green Accepted			2022-12-28	WOS:000294244500006
J	Colombo, E; Alcalay, M; Pelicci, PG				Colombo, E.; Alcalay, M.; Pelicci, P. G.			Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases	ONCOGENE			English	Review						nucleophosmin; leukemia; cancer	ACUTE-MYELOID-LEUKEMIA; ARF TUMOR-SUPPRESSOR; ACUTE MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEOLAR PROTEIN B23; NF-KAPPA-B; ONCOGENE-INDUCED SENESCENCE; SUMO-SPECIFIC PROTEASE; TRANS-RETINOIC ACID; NUCLEAR EXPORT	Nucleophosmin (NPM, also known as B23, numatrin or NO38) is a ubiquitously expressed phosphoprotein belonging to the nucleoplasmin family of chaperones. NPM is mainly localized in the nucleolus where it exerts many of its functions, but a proportion of the protein continuously shuttles between the nucleus and the cytoplasm. A growing number of cellular proteins have been described as physical interactors of NPM, and consequently, NPM is thought to have a relevant role in diverse cellular functions, including ribosome biogenesis, centrosome duplication, DNA repair and response to stress. NPM has been implicated in the pathogenesis of several human malignancies and intriguingly, it has been described both as an activating oncogene and a tumor suppressor, depending on cell type and protein levels. In fact, increased NPM expression is associated with different types of solid tumors whereas an impairment of NPM function is characteristic of a subgroup of hematolologic malignancies. A large body of experimental evidence links the deregulation of specific NPM functions to cellular transformation, yet the molecular mechanisms through which NPM contributes to tumorigenesis remain elusive. In this review, we have summarized current knowledge concerning NPM functions, and attempted to interpret its multifaceted and sometimes apparently contradictory activities in the context of both normal cellular homeostasis and neoplastic transformation. Oncogene (2011) 30, 2595-2609; doi:10.1038/onc.2010.646; published online 31 January 2011	[Colombo, E.; Alcalay, M.; Pelicci, P. G.] Ist Europeo Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Colombo, E.; Alcalay, M.; Pelicci, P. G.] Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy	IRCCS European Institute of Oncology (IEO); University of Milan	Colombo, E (corresponding author), Ist Europeo Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	emanuela.colombo@ifom-ieo-campus.it; piergiuseppe.pelicci@ifom-ieo-campus.it	Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Colombo, Emanuela/AAO-8113-2020; Pelicci, Pier Giuseppe/AAL-6572-2020	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Colombo, Emanuela/0000-0003-2079-7398; 	AIRC; EC; Ministero della Salute	AIRC(Fondazione AIRC per la ricerca sul cancro); EC(European CommissionEuropean Commission Joint Research Centre); Ministero della Salute(Ministry of Health, Italy)	This work was supported by grants from AIRC, EC and Ministero della Salute to PGP, EC and MA.	Adon AM, 2010, MOL CELL BIOL, V30, P694, DOI 10.1128/MCB.00253-09; Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Albiero E, 2007, LEUKEMIA, V21, P1099, DOI 10.1038/sj.leu.2404597; Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Amin MA, 2008, FEBS LETT, V582, P3839, DOI 10.1016/j.febslet.2008.10.023; Andersen MT, 2008, LEUKEMIA, V22, P951, DOI 10.1038/leu.2008.17; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berger R, 2006, LEUKEMIA, V20, P319, DOI 10.1038/sj.leu.2404063; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bolli N, 2009, LEUKEMIA, V23, P501, DOI 10.1038/leu.2008.326; Bolli N, 2007, CANCER RES, V67, P6230, DOI 10.1158/0008-5472.CAN-07-0273; Bolli N, 2010, BLOOD, V115, P3329, DOI 10.1182/blood-2009-02-207225; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Brown P, 2007, BLOOD, V110, P979, DOI 10.1182/blood-2007-02-076604; Burnett AK, 2010, BLOOD, V115, P948, DOI 10.1182/blood-2009-08-236588; Caudill JSC, 2006, BRIT J HAEMATOL, V133, P638, DOI 10.1111/j.1365-2141.2006.06081.x; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Chang JH, 1998, BIOCHEM J, V329, P539; Cheng K, 2007, ONCOGENE, V26, P7391, DOI 10.1038/sj.onc.1210549; Cheng K, 2010, BLOOD, V115, P3341, DOI 10.1182/blood-2009-03-208587; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chou CC, 2007, LIFE SCI, V80, P2051, DOI 10.1016/j.lfs.2007.03.004; Cilloni D, 2008, LEUKEMIA, V22, P1234, DOI 10.1038/leu.2008.68; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Dalenc F, 2002, INT J CANCER, V100, P662, DOI 10.1002/ijc.10558; Del Poeta G, 2010, BRIT J HAEMATOL, V149, P383, DOI 10.1111/j.1365-2141.2010.08098.x; den Besten W, 2005, CELL CYCLE, V4, P1593; Dhar SK, 2009, J BIOL CHEM, V284, P16409, DOI 10.1074/jbc.M109.005736; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Du W, 2010, CARCINOGENESIS, V31, P302, DOI 10.1093/carcin/bgp270; Eitoku M, 2008, CELL MOL LIFE SCI, V65, P414, DOI 10.1007/s00018-007-7305-6; Endo A, 2009, J BIOL CHEM, V284, P27918, DOI 10.1074/jbc.M109.037218; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2008, LEUKEMIA, V22, P891, DOI 10.1038/leu.2008.44; Falini B, 2008, HAEMATOLOGICA, V93, P439, DOI 10.3324/haematol.12153; Falini B, 2007, HAEMATOLOGICA, V92, P519, DOI 10.3324/haematol.11007; Falini B, 2006, BLOOD, V108, P1999, DOI 10.1182/blood-2006-03-007013; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Foltz DR, 2009, CELL, V137, P472, DOI 10.1016/j.cell.2009.02.039; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Frelin C, 2005, BLOOD, V105, P804, DOI 10.1182/blood-2004-04-1463; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gao H, 2005, J BIOL CHEM, V280, P10988, DOI 10.1074/jbc.M412720200; Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grummitt Charles G, 2008, J Biol Chem, V283, P23326, DOI 10.1074/jbc.M801706200; Gruszka AM, 2010, BLOOD, V116, P2096, DOI 10.1182/blood-2010-01-266908; Gurumurthy M, 2008, J MOL BIOL, V378, P302, DOI 10.1016/j.jmb.2008.02.055; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Haferlach C, 2009, BLOOD, V114, P3024, DOI 10.1182/blood-2009-01-197871; Haindl M, 2008, EMBO REP, V9, P273, DOI 10.1038/embor.2008.3; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Hsu CY, 2000, INT J CANCER, V88, P392, DOI 10.1002/1097-0215(20001101)88:3<392::AID-IJC11>3.0.CO;2-7; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jian Y, 2009, ONCOGENE, V28, P4201, DOI 10.1038/onc.2009.275; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kau TR, 2003, DRUG DISCOV TODAY, V8, P78, DOI 10.1016/S1359-6446(02)02562-X; Kerr LE, 2007, ONCOGENE, V26, P2554, DOI 10.1038/sj.onc.1210044; Koike A, 2010, CANCER RES, V70, P6746, DOI 10.1158/0008-5472.CAN-10-0382; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krause A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009849; Kuo ML, 2008, CELL CYCLE, V7, P3378, DOI 10.4161/cc.7.21.6930; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee SB, 2008, P NATL ACAD SCI USA, V105, P16584, DOI 10.1073/pnas.0807668105; Leotoing L, 2008, ONCOGENE, V27, P2858, DOI 10.1038/sj.onc.1210942; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li J, 2007, CARCINOGENESIS, V28, P1163, DOI 10.1093/carcin/bgm025; Li J, 2006, J BIOL CHEM, V281, P16536, DOI 10.1074/jbc.M601386200; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Liu H, 2007, EMBO REP, V8, P394, DOI 10.1038/sj.embor.7400909; Liu H, 2008, J EXP MED, V205, P1843, DOI 10.1084/jem.20072102; Liu X, 2007, P NATL ACAD SCI USA, V104, P9679, DOI 10.1073/pnas.0701806104; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Mariano AR, 2006, ONCOGENE, V25, P4376, DOI 10.1038/sj.onc.1209453; Martelli MP, 2010, BLOOD, V116, P3907, DOI 10.1182/blood-2009-08-238899; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; MELONI G, 2008, HAEMATOLOGICA, V94, P298; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mrozek K, 2007, CURR OPIN HEMATOL, V14, P106, DOI 10.1097/MOH.0b013e32801684c7; Mukudai Y, 2008, MOL CELL BIOL, V28, P6134, DOI 10.1128/MCB.00495-08; Murano K, 2008, MOL CELL BIOL, V28, P3114, DOI 10.1128/MCB.02078-07; Mutka SC, 2009, CANCER RES, V69, P510, DOI 10.1158/0008-5472.CAN-08-0858; Naoe T, 2006, CANCER SCI, V97, P963, DOI 10.1111/j.1349-7006.2006.00270.x; Negi SS, 2006, J CELL SCI, V119, P3676, DOI 10.1242/jcs.03090; Nishida T, 2008, BIOCHEM BIOPH RES CO, V374, P382, DOI 10.1016/j.bbrc.2008.07.047; Nousiainen M, 2006, P NATL ACAD SCI USA, V103, P5391, DOI 10.1073/pnas.0507066103; Okada M, 2007, J BIOL CHEM, V282, P36744, DOI 10.1074/jbc.M706169200; Okazuka K, 2007, INT J HEMATOL, V86, P246, DOI 10.1007/BF03006928; Oki Y, 2006, HAEMATOLOGICA, V91, P1147; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; Okuwaki M, 2001, J MOL BIOL, V311, P41, DOI 10.1006/jmbi.2001.4812; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Palaniswamy V, 2006, NAT STRUCT MOL BIOL, V13, P429, DOI 10.1038/nsmb1080; Pang QS, 2003, J BIOL CHEM, V278, P41709, DOI 10.1074/jbc.M301392200; Pasqualucci L, 2006, BLOOD, V108, P4146, DOI 10.1182/blood-2006-06-026716; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; RAMSAMOOJ P, 1995, RADIAT RES, V143, P158, DOI 10.2307/3579152; Redner RL, 2000, BLOOD, V95, P2683; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; ROUSSEL P, 1994, EXP CELL RES, V214, P465, DOI 10.1006/excr.1994.1283; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schlenk RF, 2009, HAEMATOL-HEMATOL J, V94, P54, DOI 10.3324/haematol.13378; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schnittger S, 2005, BLOOD, V106, P3733, DOI 10.1182/blood-2005-06-2248; Schnittger S, 2009, BLOOD, V114, P2220, DOI 10.1182/blood-2009-03-213389; Shandilya J, 2009, MOL CELL BIOL, V29, P5115, DOI 10.1128/MCB.01969-08; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Suzuki T, 2005, BLOOD, V106, P2854, DOI 10.1182/blood-2005-04-1733; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; Szebeni A, 1999, PROTEIN SCI, V8, P905; Szebeni A, 2003, J BIOL CHEM, V278, P9107, DOI 10.1074/jbc.M204411200; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; Tarapore P, 2006, FEBS LETT, V580, P399, DOI 10.1016/j.febslet.2005.12.022; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; Wang GX, 2010, BIOCHEMISTRY-US, V49, P3842, DOI 10.1021/bi9021928; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wilson CS, 2006, BLOOD, V108, P685, DOI 10.1182/blood-2004-12-4633; Wu MH, 2002, INT J CANCER, V97, P297, DOI 10.1002/ijc.1606; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Yao JH, 2004, FEBS LETT, V575, P112, DOI 10.1016/j.febslet.2004.08.047; Yao Z, 2010, ONCOGENE, V29, P1821, DOI 10.1038/onc.2009.473; Yoneda-Kato N, 2005, EMBO J, V24, P1739, DOI 10.1038/sj.emboj.7600656; Yoneda-Kato N, 2008, MOL CELL BIOL, V28, P422, DOI 10.1128/MCB.02335-06; YonedaKato N, 1996, ONCOGENE, V12, P265; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; Yun CW, 2008, J CELL BIOL, V183, P589, DOI 10.1083/jcb.200807185; Yung Benjamin Yat Ming, 2007, Chang Gung Med J, V30, P285; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhang H, 2004, J BIOL CHEM, V279, P35726, DOI 10.1074/jbc.M403264200; Zhang Y, 2007, LEUKEMIA RES, V31, P109, DOI 10.1016/j.leukres.2006.03.013; Zhou Y, 2008, BLOOD, V112, P2474, DOI 10.1182/blood-2007-12-130211; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	173	162	168	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2595	2609		10.1038/onc.2010.646	http://dx.doi.org/10.1038/onc.2010.646			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21278791				2022-12-28	WOS:000291677800001
J	Mohammad, HP; Zhang, W; Prevas, HS; Leadem, BR; Zhang, M; Herman, JG; Hooker, CM; Watkins, DN; Karim, B; Huso, DL; Baylin, SB				Mohammad, H. P.; Zhang, W.; Prevas, H. S.; Leadem, B. R.; Zhang, M.; Herman, J. G.; Hooker, C. M.; Watkins, D. N.; Karim, B.; Huso, D. L.; Baylin, S. B.			Loss of a single Hic1 allele accelerates polyp formation in Apc(Delta 716) mice	ONCOGENE			English	Article						Hic1; Min; Polyp; DNA hypermethylation; colon cancer	TUMOR-SUPPRESSOR GENE; MULTIPLE INTESTINAL NEOPLASIA; STEM-CELLS; SOX9; EXPRESSION; CANCER; SIRT1; COLON; IDENTIFICATION; TUMORIGENESIS	Adenomatous polyposis coli (APC) gene mutations have been implicated in familial and sporadic gastrointestinal (GI) cancers. APC mutations are associated with autosomal dominant inheritance of disease in humans. Similarly, mice that contain a single mutant APC gene encoding a protein truncated at residue 716 (Apc(Delta 716)) develop multiple polyps throughout the GI tract as early as 4 weeks after birth. Inactivation of another tumor suppressor gene, Hypermethylated in Cancer 1 (HIC1), often occurs in human colon cancers, among others, via CpG island hypermethylation. Homozygous deletion of Hic1 in mice results in major developmental defects and embryonic lethality. Hic1 heterozygotes have previously been shown to develop tumors of a variety of tissue types. We now report that loss of a single Hic1 allele can promote crypt hyperplasia and neoplasia of the GI tract, and Hic1(+/-), Apc(+/Delta 716) double heterozygotes (DH) develop increased numbers of polyps throughout the GI tract at 60 days. Hic1 expression is absent in polyps from DH mice, with concomitant increased expression of two transcriptional repression targets of Hic1, Sirt1 and Sox9. Together, our data suggest that loss of a gene frequently silenced via epigenetic mechanisms, Hic1, can cooperate with loss of a gene mutated in GI cancer, Apc, to promote tumorigenesis in an in vivo model of multiple intestinal neoplasia. Oncogene (2011) 30, 2659-2669; doi:10.1038/onc.2010.633; published online 7 February 2011	[Baylin, S. B.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Inst Johns Hopkins, Baltimore, MD 21231 USA; [Watkins, D. N.] Monash Univ, Ctr Canc Res, Monash Inst Med Res, Clayton, Vic, Australia; [Karim, B.; Huso, D. L.] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Baltimore, MD 21231 USA	Johns Hopkins University; Monash University; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Inst Johns Hopkins, 1650 Orleans St,CRB I 541, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu	zhang, wei/A-7015-2011; Watkins, David N/I-6113-2013		National Cancer Institute [CA043318]; National Institutes of Environmental Health Sciences [ES015226, ES011858]; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011858, R01ES015226] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Guosheng Liu for technical assistance with dissection, Kimberly Briggs for primers, Robert Beatty for assistance with Hic1<SUP>+/-</SUP> breeding and Kathy Bender for manuscript submission. This work was supported by grants from the National Cancer Institute CA043318 (SBB), National Institutes of Environmental Health Sciences ES015226 and ES011858 (SBB). Additional support was provided by the American Cancer Society (HM and WZ).	Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BARNARD NJ, 1987, J PATHOL, V152, P287, DOI 10.1002/path.1711520407; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X; Dong SM, 2001, CLIN CANCER RES, V7, P1982; Dupasquier S, 2009, J CELL SCI, V122, P2191, DOI 10.1242/jcs.036483; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Hao LY, 2005, CELL, V123, P1121, DOI 10.1016/j.cell.2005.11.020; Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107; Lu BJ, 2008, AM J CLIN PATHOL, V130, P897, DOI 10.1309/AJCPW1W8GJBQGCNI; Maekawa M, 2001, CLIN CHEM LAB MED, V39, P121, DOI 10.1515/CCLM.2001.021; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Polakis P, 2000, GENE DEV, V14, P1837; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Stuber E, 1998, GASTROENTEROLOGY, V115, P1205, DOI 10.1016/S0016-5085(98)70092-7; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Valenta T, 2006, EMBO J, V25, P2326, DOI 10.1038/sj.emboj.7601147; Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12	44	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2659	2669		10.1038/onc.2010.633	http://dx.doi.org/10.1038/onc.2010.633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21297660	Green Published, hybrid			2022-12-28	WOS:000291677800006
J	Robinson, KS; Clements, A; Williams, AC; Berger, CN; Frankel, G				Robinson, K. S.; Clements, A.; Williams, A. C.; Berger, C. N.; Frankel, G.			Bax Inhibitor 1 in apoptosis and disease	ONCOGENE			English	Review						Bax inhibitor 1; apoptosis; ER stress; UPR; breast cancer	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; BREAST-CANCER CELLS; ENTEROPATHOGENIC ESCHERICHIA-COLI; SIGNALING PATHWAYS; DEATH; EXPRESSION; CALCIUM; BCL-2; GENE	Bax inhibitor 1 (BI-1) was originally discovered as an inhibitor of Bax-induced apoptosis; this review highlights the fundamental importance of BI-1 in a wider context, including in tissue homeostasis and as a regulator of cellular stress. BI-1 has been shown to interact with a broad range of partners to inhibit many facets of apoptosis, such as reactive oxygen species production, cytosolic acidification and calcium levels as well as endoplasmic reticulum stress signalling pathways. BI-1's anti-apoptotic action initially enables the cell to adapt to stress, although if the stress is prolonged or severe the actions of BI-1 may promote apoptosis. This almost universal anti-apoptotic capacity has been shown to be manipulated during infection with enteropathogenic and enterohaemorrhagic Escherichia coli inhibiting host cell death through direct interaction between their effector NleH and BI-1. In addition, BI-1 activity is important in a large number of cancers, promoting metastasis by modulating actin dynamics, a process dependent upon the BI-1 C-terminus and BI-1: actin interaction. Manipulation of BI-1 therefore has the potential for significant therapeutic benefit in a wide range of human diseases. Oncogene (2011) 30, 2391-2400; doi:10.1038/onc.2010.636; published online 7 February 2011	[Robinson, K. S.; Clements, A.; Berger, C. N.; Frankel, G.] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; [Williams, A. C.] Univ Bristol, Sch Med Sci, Univ Walk, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England	Imperial College London; University of Bristol	Frankel, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Ctr Mol Microbiol & Infect, Flowers Bldg, London SW7 2AZ, England.	g.frankel@imperial.ac.uk	Berger, Cedric N/AAY-1438-2021	Berger, Cedric N/0000-0002-1316-5985; Clements, Abigail/0000-0003-2285-777X; Williams, Ann/0000-0002-6009-7137	Marie Curie fellowship [FP7-PEOPLE-2009-IIF]; Wellcome Trust; Cancer Research UK [11975] Funding Source: researchfish	Marie Curie fellowship(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK)	Abigail Clements is supported by a Marie Curie fellowship FP7-PEOPLE-2009-IIF. This work was supported by a grant from the Wellcome Trust.	Ahn T, 2010, CELL CALCIUM, V47, P387, DOI 10.1016/j.ceca.2010.02.003; Ahn T, 2009, FEBS J, V276, P2285, DOI 10.1111/j.1742-4658.2009.06956.x; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Caron E, 2006, CURR OPIN MICROBIOL, V9, P40, DOI 10.1016/j.mib.2005.12.008; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Crane JK, 2001, CELL MICROBIOL, V3, P197, DOI 10.1046/j.1462-5822.2001.00103.x; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grzmil M, 2006, J PATHOL, V208, P340, DOI 10.1002/path.1902; Hemrajani C, 2010, P NATL ACAD SCI USA, V107, P3129, DOI 10.1073/pnas.0911609106; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Imaizumi K, 2001, BBA-MOL BASIS DIS, V1536, P85, DOI 10.1016/S0925-4439(01)00049-7; Jean JC, 1999, GENOMICS, V57, P201, DOI 10.1006/geno.1999.5761; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kim HR, 2009, J CELL SCI, V122, P1126, DOI 10.1242/jcs.038430; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kohno K, 2010, J BIOCHEM, V147, P27, DOI 10.1093/jb/mvp196; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Kurokawa H, 1999, ONCOL REP, V6, P33; Kvansakul M, 2008, CELL DEATH DIFFER, V15, P1564, DOI 10.1038/cdd.2008.83; Lebiedzinska M, 2009, INT J BIOCHEM CELL B, V41, P1805, DOI 10.1016/j.biocel.2009.02.017; Lee GH, 2010, ONCOGENE, V29, P2130, DOI 10.1038/onc.2009.491; Lee GH, 2007, J BIOL CHEM, V282, P21618, DOI 10.1074/jbc.M700053200; Lee GH, 2010, MOL CELL BIOL, V30, P1800, DOI 10.1128/MCB.01357-09; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Nieto N, 2002, HEPATOLOGY, V35, P62, DOI 10.1053/jhep.2002.30362; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Ravi R, 2002, CANCER RES, V62, P1583; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rong JA, 2011, J BIOL CHEM, V286, P1453, DOI 10.1074/jbc.M110.175232; Rong YP, 2009, P NATL ACAD SCI USA, V106, P14397, DOI 10.1073/pnas.0907555106; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmits R, 2002, INT J CANCER, V98, P73, DOI 10.1002/ijc.10170; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Tanaka R, 2006, CANCER-AM CANCER SOC, V106, P648, DOI 10.1002/cncr.21639; TANNOCK IF, 1989, CANCER RES, V49, P4373; Urano W, 2010, ANN RHEUM DIS, V69, P1232, DOI 10.1136/ard.2008.106856; Wahl ML, 2000, J CELL PHYSIOL, V183, P373, DOI 10.1002/(SICI)1097-4652(200006)183:3<373::AID-JCP10>3.0.CO;2-S; Wang E, 1999, J CELL BIOCHEM, P95; Wolgien MDGM, 2005, EUR J GYNAECOL ONCOL, V26, P501; Wyllie AH, 2010, MOL NEUROBIOL, V42, P4, DOI 10.1007/s12035-010-8125-5; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang L, 2003, CANCER RES, V63, P6815	58	57	61	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2391	2400		10.1038/onc.2010.636	http://dx.doi.org/10.1038/onc.2010.636			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21297665	Bronze			2022-12-28	WOS:000291008000001
J	Standiford, TJ; Kuick, R; Bhan, U; Chen, J; Newstead, M; Keshamouni, VG				Standiford, T. J.; Kuick, R.; Bhan, U.; Chen, J.; Newstead, M.; Keshamouni, V. G.			TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth	ONCOGENE			English	Article						IRAK-M; TGF-beta; lung cancer; tumor-associated macrophages; Toll-like receptors	TOLL-LIKE RECEPTORS; TRANSFORMING GROWTH-FACTOR-BETA-1 LEVEL; NEGATIVE REGULATOR; SIGNALING PATHWAY; IMMUNE-RESPONSES; INNATE IMMUNITY; HUMAN MONOCYTES; EARLY-STAGE; CANCER; ADENOCARCINOMA	Tumor-associated macrophages (TAMs) constitute a major component of the immune cell infiltrate observed in the tumor microenvironment (TME). Factors present in the TME, including tumor growth factor-beta (TGF-beta), allow tumors to circumvent host-mediated immune responses to promote tumor progression. However, the molecular mechanism(s) involved are not clear. Toll-like receptors (TLRs) are important mediators of innate immune responses by immune cells, whose activation triggers the production of molecules required for antitumoral responses. Interleukin (IL) receptor-associated kinase (IRAK)-M is an inactive serine/threonine kinase, predominantly expressed in macrophages and is a potent negative regulator of TLR signaling. In this study, we show that TAMs express significantly higher levels of IRAK-M compared with peritoneal macrophages in a syngeneic mouse model of lung cancer. Subcutaneous implantation of Lewis lung carcinoma cells in IRAK-M-/- mice resulted in a five-fold reduction in tumor growth as compared with tumors in wild-type (WT) animals. Furthermore, compared with WT TAMs, TAMs isolated from IRAK-M-/- mice displayed features of a classically activated (M1) rather than alternatively activated (M2) phenotype, as manifest by greater expression of IL-12, interferon-gamma (IFN-gamma) and inducible nitric oxide synthase. Human lung cancer cells induced IRAK-M expression in human peripheral blood mononuclear cells (PBMCs) when co-cultured together. Tumor cell-induced expression of IRAK-M was dependent on the activation of TGF-beta pathway. Similarly, treatment of human PBMCs or mouse macrophage cell line, RAW 264.4, with TGF-beta, induced IRAK-M expression. Interestingly, IRAK-M gene expression in 439 human lung adenocarcinoma tumors correlated with poor survival in patients with lung cancer. Together, our data demonstrates that TGF-beta-dependent induction of IRAK-M expression is an important, clinically relevant mechanism by which tumors may circumvent anti-tumor responses of macrophages. Oncogene (2011) 30, 2475-2484; doi:10.1038/onc.2010.619; published online 31 January 2011	[Standiford, T. J.; Bhan, U.; Chen, J.; Newstead, M.; Keshamouni, V. G.] Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Kuick, R.; Keshamouni, V. G.] Univ Michigan, Med Ctr, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Keshamouni, VG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, 4062 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	vkeshamo@med.umich.edu		Keshamouni, Venkateshwar/0000-0003-1947-791X	NIH/NCI [R01 CA132571-01]; American Cancer Society [RSG-CSM-116801]; NIH/NHLBI [HL25243, HL097564]; NATIONAL CANCER INSTITUTE [R01CA132571] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097564] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research is funded by the NIH/NCI (R01 CA132571-01), and the American Cancer Society (RSG-CSM-116801) grants to VGK, and NIH/NHLBI HL25243 and HL097564 to TJS.	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Ben-Baruch A, 2006, SEMIN CANCER BIOL, V16, P38, DOI 10.1016/j.semcancer.2005.07.006; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; de Vos AF, 2009, J IMMUNOL, V183, P533, DOI 10.4049/jimmunol.0802189; del Fresno C, 2005, J IMMUNOL, V174, P3032, DOI 10.4049/jimmunol.174.5.3032; Deng JC, 2006, J CLIN INVEST, V116, P2532, DOI 10.1172/JCI28054; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Johnson SK, 2000, LUNG CANCER-J IASLC, V27, P27, DOI 10.1016/S0169-5002(99)00095-1; Kim WS, 1999, ANTICANCER RES, V19, P301; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kong FM, 1999, CANCER-AM CANCER SOC, V86, P1712, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1712::AID-CNCR12>3.0.CO;2-V; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McCartney-Francis N, 2004, J IMMUNOL, V172, P3814, DOI 10.4049/jimmunol.172.6.3814; Moustakas A, 2003, GENE DEV, V17, P2855, DOI 10.1101/gad.1161403; Mytar B, 2003, J LEUKOCYTE BIOL, V74, P1094, DOI 10.1189/jlb.0403140; Naiki Y, 2005, J BIOL CHEM, V280, P5491, DOI 10.1074/jbc.C400503200; Pan HJ, 2010, J IMMUNOL, V184, P5502, DOI 10.4049/jimmunol.0901601; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Reddy RC, 2004, AM J PHYSIOL-LUNG C, V286, pL613, DOI 10.1152/ajplung.00206.2003; Rosati O, 2002, BIOCHEM BIOPH RES CO, V293, P1472, DOI 10.1016/S0006-291X(02)00411-4; Scagliotti G, 2003, LUNG CANCER-J IASLC, V42, pS47, DOI 10.1016/S0169-5002(03)00304-0; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Seya T, 2003, ANTICANCER RES, V23, P4369; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Souquet PJ, 2001, LUNG CANCER-J IASLC, V34, pS155, DOI 10.1016/S0169-5002(01)00361-0; Toonkel RL, 2010, J THORAC ONCOL, V5, P153, DOI 10.1097/JTO.0b013e3181c8cc0c; van 't Veer C, 2007, J IMMUNOL, V179, P7110, DOI 10.4049/jimmunol.179.10.7110; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Xie QF, 2007, MOL IMMUNOL, V44, P3453, DOI 10.1016/j.molimm.2007.03.018; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004	44	95	101	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2475	2484		10.1038/onc.2010.619	http://dx.doi.org/10.1038/onc.2010.619			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21278795	Green Accepted			2022-12-28	WOS:000291008000009
J	Yang, Y; Tse, AKW; Li, P; Ma, Q; Xiang, S; Nicosia, SV; Seto, E; Zhang, X; Bai, W				Yang, Y.; Tse, A. K-W; Li, P.; Ma, Q.; Xiang, S.; Nicosia, S. V.; Seto, E.; Zhang, X.; Bai, W.			Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation	ONCOGENE			English	Article						androgen receptor; androgens; HDAC4; prostate cancer; SUMOylation; SUMO E3 ligase	PROSTATE-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; DEPENDENT TRANSCRIPTION; HDAC4 DEACETYLASE; COMPLEMENTARY-DNA; SUPERFAMILY; ACTIVATION; PHOSPHORYLATION; ACETYLATION; APOPTOSIS	The transcriptional activity of the androgen receptor (AR) is regulated by both ligand binding and post-translational modifications, including acetylation and small ubiquitin-like modifier (SUMO)ylation. Histone deacetylases (HDACs) are known to catalyze the removal of acetyl groups from both histones and non-histone proteins. In this study, we report that HDAC4 binds to and inhibits the activity of the AR. This inhibition was found to depend on the SUMOylation, instead of deacetylation, of the AR. Consistently, HDAC4 increases the level of AR SUMOylation in both whole-cell and cell-free assay systems, raising the possibility that the deacetylase may act as an E3 ligase for AR SUMOylation. Knock down of HDAC4 increases the activity of endogenous AR and androgen induction of prostate-specific antigen expression and prostate cancer cell growth, which is associated with decreased SUMOylation of the receptor. Overall, the studies identify HDAC4 as a positive regulator for AR SUMOylation, revealing a deacetylase-independent mechanism of HDAC action in prostate cancer cells. Oncogene (2011) 30, 2207-2218; doi:10.1038/onc.2010.600; published online 17 January 2011	[Yang, Y.; Tse, A. K-W; Li, P.; Ma, Q.; Xiang, S.; Nicosia, S. V.; Zhang, X.; Bai, W.] Univ S Florida, Dept Pathol & Cell Biol, Coll Med, Tampa, FL 33612 USA; [Nicosia, S. V.; Seto, E.; Zhang, X.; Bai, W.] Univ S Florida, Dept Oncol Sci, Coll Med, Tampa, FL 33612 USA; [Seto, E.; Zhang, X.; Bai, W.] Univ S Florida, H Lee Moffitt Canc Ctr, Programs Mol Oncol, Tampa, FL 33682 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Bai, W (corresponding author), Univ S Florida, Dept Pathol & Cell Biol, Coll Med, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@health.usf.edu	XIANG, SHENGYAN/C-3176-2013; Bai, Wenlong/A-8977-2013	XIANG, SHENGYAN/0000-0002-6940-3559; Bai, Wenlong/0000-0002-9536-0556	Public Health Service [CA93666, CA111334]; DOD [DAMD17-02-1-0140]; Florida Department of Health [09KT-03, 06BCBG1]; NATIONAL CANCER INSTITUTE [R01CA093666, R01CA111334] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); DOD(United States Department of Defense); Florida Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs XJ Yang for HDAC4 vector, RJ Matusik for probasin-based AR reporter genes, PR Rennie for the PSA-based reporter gene, G Jenster for GST-AR-NT construct, JJ Palvimo for AR SUMOylation mutants and AP Lieberman for AR acetylation mutants. The work was supported by the Public Health Service Grants CA93666 and CA111334 (WB), a DOD Prostate Cancer Grant DAMD17-02-1-0140 (WB) and Grants 09KT-03 and 06BCBG1 (W.B) from the Florida Department of Health.	Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Jeong BC, 2004, MOL ENDOCRINOL, V18, P13, DOI 10.1210/me.2003-0065; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; Kaikkonen S, 2009, MOL ENDOCRINOL, V23, P292, DOI 10.1210/me.2008-0219; Karvonen U, 2006, EXP CELL RES, V312, P3165, DOI 10.1016/j.yexcr.2006.06.018; Kasper S, 1999, J MOL ENDOCRINOL, V22, P313, DOI 10.1677/jme.0.0220313; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; ONATE SA, 1995, SCIENCE, V270, P1354; Pan Y, 2005, BIOCHEM BIOPH RES CO, V332, P702, DOI 10.1016/j.bbrc.2005.05.012; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Snoek R, 1998, PROSTATE, V36, P256; Thomas M, 2004, J BIOL CHEM, V279, P8389, DOI 10.1074/jbc.M311761200; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Xu Jianming, 2002, Rev Endocr Metab Disord, V3, P185, DOI 10.1023/A:1020016208071; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005	39	53	54	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2207	2218		10.1038/onc.2010.600	http://dx.doi.org/10.1038/onc.2010.600			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242980	Green Accepted			2022-12-28	WOS:000290514600004
J	Morris, MR; Ricketts, CJ; Gentle, D; McRonald, F; Carli, N; Khalili, H; Brown, M; Kishida, T; Yao, M; Banks, RE; Clarke, N; Latif, F; Maher, ER				Morris, M. R.; Ricketts, C. J.; Gentle, D.; McRonald, F.; Carli, N.; Khalili, H.; Brown, M.; Kishida, T.; Yao, M.; Banks, R. E.; Clarke, N.; Latif, F.; Maher, E. R.			Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; methylation; epigenetics	CLEAR-CELL; PROMOTER HYPERMETHYLATION; DNA METHYLATION; ABERRANT METHYLATION; GLUTAMINYL CYCLASE; TARGETED THERAPIES; KIDNEY CANCER; EXPRESSION; DISEASE; ESOPHAGEAL	The detection of promoter region hypermethylation and transcriptional silencing has facilitated the identification of candidate renal cell carcinoma (RCC) tumour suppressor genes (TSGs). We have used a genome-wide strategy (methylated DNA immunoprecipitation (MeDIP) and whole-genome array analysis in combination with high-density expression array analysis) to identify genes that are frequently methylated and silenced in RCC. MeDIP analysis on 9 RCC tumours and 3 non-malignant normal kidney tissue samples was performed, and an initial short-list of 56 candidate genes that were methylated by array analysis was further investigated; 9 genes were confirmed to show frequent promoter region methylation in primary RCC tumour samples (KLHL35 (39%), QPCT (19%), SCUBE3 (19%), ZSCAN18 (32%), CCDC8 (35%), FBN2 (34%), ATP5G2 (36%), PCDH8 (58%) and CORO6 (22%)). RNAi knockdown for KLHL35, QPCT, SCUBE3, ZSCAN18, CCDC8 and FBN2 resulted in an anchorage-independent growth advantage. Tumour methylation of SCUBE3 was associated with a significantly increased risk of cancer death or relapse (P = 0.0046). The identification of candidate epigenetically inactivated RCC TSGs provides new insights into renal tumourigenesis. Oncogene (2011) 30, 1390-1401; doi:10.1038/onc.2010.525; published online 6 December 2010	[Maher, E. R.] Univ Birmingham, Inst Biomed Res W, Dept Med & Mol Genet, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Morris, M. R.; Ricketts, C. J.; Gentle, D.; McRonald, F.; Latif, F.; Maher, E. R.] Univ Birmingham, Canc Res UK Renal Mol Oncol Grp, Birmingham B15 2TT, W Midlands, England; [Morris, M. R.; Ricketts, C. J.; Gentle, D.; Latif, F.; Maher, E. R.] Univ Birmingham, Ctr Rare Dis & Personalised Med, Birmingham B15 2TT, W Midlands, England; [Brown, M.; Clarke, N.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England; [Kishida, T.; Yao, M.] Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan; [Banks, R. E.] St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England; [Maher, E. R.] Birmingham Womens Hosp, W Midlands Region Genet Serv, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; Paterson Institute for Cancer Research; University of Manchester; Yokohama City University; Cancer Research UK; Saint James's University Hospital; University of Leeds; Birmingham Women's Hospital	Maher, ER (corresponding author), Univ Birmingham, Inst Biomed Res W, Dept Med & Mol Genet, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	Ricketts, Christopher/AAV-9580-2020; Brown, Mick D/N-6521-2015; Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Brown, Mick/A-1308-2012	Brown, Mick D/0000-0003-1322-4671; MAHER, EAMONN R/0000-0002-6226-6918; Clarke, Noel/0000-0001-7776-8059; McRonald, Fiona/0000-0001-7226-9461; Morris, Mark/0000-0002-0700-355X; Banks, Rosamonde/0000-0002-0042-8715	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Cancer Research UK for financial support.	Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Battagli C, 2003, CANCER RES, V63, P8695; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Breault JE, 2005, CLIN CANCER RES, V11, P557; Chaudhry SS, 2007, J CELL BIOL, V176, P355, DOI 10.1083/jcb.200608167; Chen H, 2005, LUNG CANCER, V50, P43, DOI 10.1016/j.lungcan.2005.04.013; Chowdhury S, 2008, EUR J CANCER, V44, P2152, DOI 10.1016/j.ejca.2008.06.028; Christoph F, 2006, CLIN CANCER RES, V12, P5040, DOI 10.1158/1078-0432.CCR-06-0144; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Costa LJ, 2007, ONCOLOGIST, V12, P1404, DOI 10.1634/theoncologist.12-12-1404; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Grimmond S, 2000, GENOMICS, V70, P74, DOI 10.1006/geno.2000.6370; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hogg RP, 2002, EUR J CANCER, V38, P1585, DOI 10.1016/S0959-8049(01)00422-1; Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McRonald FE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-31; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Morrissey C, 2001, CANCER RES, V61, P7277; Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Pflug BR, 2007, CANCER LETT, V246, P139, DOI 10.1016/j.canlet.2006.02.007; POHL T, 1991, P NATL ACAD SCI USA, V88, P10059, DOI 10.1073/pnas.88.22.10059; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Roadcap David W., 2008, V48, P124, DOI 10.1007/978-0-387-09595-0_12; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; Sato N, 2003, CANCER RES, V63, P3735; Thouennon E, 2007, J CLIN ENDOCR METAB, V92, P4865, DOI 10.1210/jc.2007-1253; Tsunoda S, 2009, ONCOL REP, V21, P1067, DOI 10.3892/or_00000325; Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Yamada D, 2006, INT J CANCER, V118, P916, DOI 10.1002/ijc.21450; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	51	144	155	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	12					1390	1401		10.1038/onc.2010.525	http://dx.doi.org/10.1038/onc.2010.525			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21132003	Green Published			2022-12-28	WOS:000288743800002
J	Robinson, JP; VanBrocklin, MW; Lastwika, KJ; McKinney, AJ; Brandner, S; Holmen, SL				Robinson, J. P.; VanBrocklin, M. W.; Lastwika, K. J.; McKinney, A. J.; Brandner, S.; Holmen, S. L.			Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo	ONCOGENE			English	Article						MEK; AKT; Ink4a/Arf; glioma; mouse model; targeted therapy	INTEGRATED GENOMIC ANALYSIS; NEURAL PROGENITORS; TUMOR SUPPRESSION; GLIOBLASTOMA; CANCER; GENE; TEMOZOLOMIDE; INHIBITORS; PATHWAYS; MICE	The RAS/RAF mitogen-activated protein kinase pathway (MAPK) is highly active in many tumor types including the majority of high-grade gliomas and expression of activated RAS or RAF in neural progenitor cells combined with either AKT activation or Ink4a/Arf loss leads to the development of high-grade gliomas in vivo. This strongly suggests that this pathway is necessary for glioma formation and maintenance. To further define the role of this pathway in the development of high-grade gliomas, we used the established RCAS/TVA glioma mouse model to test the ability of activated MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK), a RAF effector, to induce tumors in vivo in the context of activated AKT or Ink4a/Arf loss. Although expression of activated MEK alone in neural progenitor cells is not sufficient for tumorigenesis, the combination of activated MEK and AKT or MEK with Ink4a/Arf loss is transforming. The data reveal that activation of the classical RAS/MAPK pathway, which is mediated through MEK, leads to the development of high-grade gliomas in vivo and suggest that MEK may be a relevant target for glioma therapy. To test this, we treated both mouse and human glioma cells with the MEK inhibitor PD0325901. Although this treatment induced apoptosis in a significant percentage of the cells, the effect was enhanced by combined treatment with the phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor NVP-BEZ235. Our results demonstrate that combined inhibition of MEK and PI3K/mTOR is a rational strategy for the treatment of high-grade gliomas and may be an effective adjuvant therapy for this disease. Oncogene (2011) 30, 1341-1350; doi:10.1038/onc.2010.513; published online 8 November 2010	[Robinson, J. P.; VanBrocklin, M. W.; Lastwika, K. J.; McKinney, A. J.; Holmen, S. L.] Nevada Canc Inst, Drug Dev Dept, Las Vegas, NV 89135 USA; [Brandner, S.] UCL Inst Neurol, Div Neuropathol, London, England	University of California System; University of California San Diego; University of London; University College London	Holmen, SL (corresponding author), Nevada Canc Inst, Drug Dev Dept, 1 Breakthrough Way, Las Vegas, NV 89135 USA.	sholmen@nvcancer.org	Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Robinson, James/0000-0002-6585-0116	Nevada Cancer Institute; National Brain Tumor Foundation; American Cancer Society [RSG-06-198-01-TBE]; NATIONAL CANCER INSTITUTE [R01CA121118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073870, R01NS075155] Funding Source: NIH RePORTER	Nevada Cancer Institute(University of California System); National Brain Tumor Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Han-Mo Koo, Eric Holland and Ronald DePinho for reagents and advice. We thank James Symanowski for assistance with statistical analysis of the data. We also thank Novartis Pharmaceuticals for providing the NVP-BEZ235. This work was supported by the Nevada Cancer Institute, the National Brain Tumor Foundation and RSG-06-198-01-TBE from the American Cancer Society.	Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Beier D, 2008, CANCER RES, V68, P5706, DOI 10.1158/0008-5472.CAN-07-6878; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; *COUNC NR RES IOL, 1996, GUID CAR US LAB AN; Federspiel Mark J., 1997, V52, P179; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595; Ichimura K, 1996, ONCOGENE, V13, P1065; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; QUELLE DE, 1995, CELL, V83, P993; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Uhrbom L, 2002, CANCER RES, V62, P5551; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	35	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1341	1350		10.1038/onc.2010.513	http://dx.doi.org/10.1038/onc.2010.513			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057530	Green Accepted			2022-12-28	WOS:000288492100008
J	Vuoriluoto, K; Haugen, H; Kiviluoto, S; Mpindi, JP; Nevo, J; Gjerdrum, C; Tiron, C; Lorens, JB; Ivaska, J				Vuoriluoto, K.; Haugen, H.; Kiviluoto, S.; Mpindi, J-P; Nevo, J.; Gjerdrum, C.; Tiron, C.; Lorens, J. B.; Ivaska, J.			Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer	ONCOGENE			English	Article						vimentin; EMT; Axl	EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR TYROSINE KINASES; BASAL-LIKE PHENOTYPE; INTERMEDIATE-FILAMENTS; TUMOR PROGRESSION; PROGNOSTIC-SIGNIFICANCE; TRANSCRIPTION FACTORS; POTENTIAL TARGET; CELL-ADHESION; METASTASIS	Epithelial-to-mesenchymal transition (EMT) is a critical event in the progression toward cancer metastasis. The intermediate filament protein vimentin is an important marker of EMT and a requisite regulator of mesenchymal cell migration. However, it is not known how vimentin functionally contributes to cancer cell invasion. Here, we report that ectopic expression of oncogenic H-Ras-V12G and Slug induces vimentin expression and migration in pre-malignant breast epithelial cells. Conversely, vimentin expression is necessary for Slug-or H-Ras-V12G-induced EMT-associated migration. Furthermore, silencing of vimentin in breast epithelial cells results in specific changes in invasiveness-related gene expression including upregulation of RAB25 (small GTPase Rab25) and down-regulation of AXL (receptor tyrosine kinase Axl), PLAU (plasminogen activator, urokinase) and ITGB4 (integrin beta 4-subunit). Importantly, gene expression profiling analyses reveal that vimentin expression correlates positively/negatively with these genes also in multiple breast cancer cell lines and breast cancer patient samples. Focusing on the tyrosine kinase Axl, we show that induction of vimentin by EMT is associated with upregulation of Axl expression and that Axl enhances the migratory activity of pre-malignant breast epithelial cells. Using null and knock-down cells and overexpression models, we also show that regulation of breast cancer cell migration in two-and three-dimensional matrices by vimentin is Axl-dependent and that Axl functionally contributes to lung extravasation of breast cancer cells in mice. In conclusion, our data show that vimentin functionally contributes to EMT and is required for induction of Axl expression. Moreover, these results provide a molecular explanation for vimentin-dependent cancer cell migration during EMT by identifying Axl as a key proximal component in this process. Oncogene (2011) 30, 1436-1448; doi:10.1038/onc.2010.509; published online 8 November 2010	[Ivaska, J.] Univ Turku, Ctr Biotechnol, VTT Med Biotechnol, Dept Biochem & Food Chem, Turku 20520, Finland; [Vuoriluoto, K.; Kiviluoto, S.; Mpindi, J-P; Nevo, J.; Ivaska, J.] VTT Tech Res Ctr Finland, Turku, Finland; [Vuoriluoto, K.; Nevo, J.; Ivaska, J.] Univ Turku, Turku Ctr Biotechnol, Turku 20520, Finland; [Haugen, H.; Gjerdrum, C.; Tiron, C.; Lorens, J. B.] Univ Bergen, Dept Biomed, Bergen, Norway	University of Turku; VTT Technical Research Center Finland; VTT Technical Research Center Finland; University of Turku; University of Bergen	Ivaska, J (corresponding author), Univ Turku, Ctr Biotechnol, VTT Med Biotechnol, Dept Biochem & Food Chem, Itainen Pitkakatu 4C, Turku 20520, Finland.	Johanna.Ivaska@vtt.fi	Tiron, Crina Elena/AAQ-3995-2020; Lorens, James/B-9737-2017; Kiviluoto, Santeri/M-2743-2014	Tiron, Crina Elena/0000-0002-1469-9153; Lorens, James/0000-0002-6782-3349; Kiviluoto, Santeri/0000-0001-5010-5327; Ivaska, Johanna/0000-0002-6295-6556	Academy of Finland; Sigrid Juselius Foundation; Emil Aaltonen Foundation; Finnish Cancer Organisations; EMBO; University of Turku; Turku University Foundation; Finnish Concordia Fund; Finnish Cultural Foundation; Ida Montini Foundation; Orion and Farmos Research Foundation; K Albin Johansson's Foundation; Scientific Foundation of Instrumentarium; Turku Graduate School for Biomedical Sciences	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Emil Aaltonen Foundation; Finnish Cancer Organisations; EMBO(European Molecular Biology Organization (EMBO)); University of Turku; Turku University Foundation; Finnish Concordia Fund; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Ida Montini Foundation; Orion and Farmos Research Foundation; K Albin Johansson's Foundation; Scientific Foundation of Instrumentarium; Turku Graduate School for Biomedical Sciences	We thank H Marttila, J Siivonen, L Lahtinen, J Rantala, P Terho, E Mattila and T Hoiby for their excellent technical assistance, H Sara for the bioinformatic analysis of the cDNA microarray, K Hellstrom, S-K Leivonen and the Finnish DNA Microarray Centre for their help with gene expression analysis and TCDM (Turku) for the animal experiments. M Salmi is acknowledged for the Hb116 antibody and for critically reading and editing the manuscript. This work was supported by grants from the Academy of Finland, the Sigrid Juselius Foundation, Emil Aaltonen Foundation, Finnish Cancer Organisations, EMBO Young Investigator Program, University of Turku, Turku University Foundation, Finnish Concordia Fund, Finnish Cultural Foundation, Ida Montini Foundation, Orion and Farmos Research Foundation, K Albin Johansson's Foundation and Scientific Foundation of Instrumentarium. K Vuoriluoto is financially supported by Turku Graduate School for Biomedical Sciences.	Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Burga LN, 2009, CANCER RES, V69, P1273, DOI 10.1158/0008-5472.CAN-08-2954; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Chabottaux V, 2009, J CELL MOL MED, V13, P4002, DOI 10.1111/j.1582-4934.2009.00764.x; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cheng JM, 2006, INT J CANCER, V118, P2957, DOI 10.1002/ijc.21739; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Koskinen K, 2004, BLOOD, V103, P3388, DOI 10.1182/blood-2003-09-3275; Kumar N, 2007, J BIOL CHEM, V282, P9244, DOI 10.1074/jbc.M605571200; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; Marty B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2204; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pellinen T, 2006, J CELL BIOL, V173, P767, DOI 10.1083/jcb.200509019; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Rodriguez-Pinilla SM, 2006, CLIN CANCER RES, V12, P1533, DOI 10.1158/1078-0432.CCR-05-2281; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004; Tuomi S, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000135; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Vuoriluoto K, 2008, EXP CELL RES, V314, P3369, DOI 10.1016/j.yexcr.2008.07.005; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	53	463	485	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1436	1448		10.1038/onc.2010.509	http://dx.doi.org/10.1038/onc.2010.509			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21057535				2022-12-28	WOS:000288743800006
J	Martin-Montalvo, A; Villalba, JM; Navas, P; de Cabo, R				Martin-Montalvo, A.; Villalba, J. M.; Navas, P.; de Cabo, R.			NRF2, cancer and calorie restriction	ONCOGENE			English	Review						calorie restriction; carcinogenesis; NRF2; phytochemicals	ANTIOXIDANT-RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; GLUTATHIONE-S-TRANSFERASE; DIETARY ENERGY RESTRICTION; SKIN TUMOR PROMOTION; SMALL MAF PROTEINS; CHEMICALLY-INDUCED MAMMARY; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; CUL3-BASED E3 LIGASE	The transcription factor NF-E2-related factor (NRF2) is a key regulator of several enzymatic pathways, including cytoprotective enzymes in highly metabolic organs. In this review, we summarize the ongoing research related to NRF2 activity in cancer development, focusing on in vivo studies using NRF2 knockout (KO) mice, which have helped in defining the crucial role of NRF2 in chemoprevention. The lower cancer protection observed in NRF2 KO mice under calorie restriction (CR) suggests that most of the beneficial effects of CR on the carcinogenesis process are likely mediated by NRF2. We propose that future interventions in cancer treatment would be carried out through the activation of NRF2 in somatic cells, which will lead to a delay or prevention of the onset of some forms of human cancers, and subsequently an extension of health-and lifespan. Oncogene (2011) 30, 505-520; doi: 10.1038/onc.2010.492; published online 8 November 2010	[Martin-Montalvo, A.; de Cabo, R.] NIA, Aging Metab & Nutr Unit, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA; [Villalba, J. M.] Univ Cordoba, Dept Biol Celular Fisiol & Inmunol, Cordoba, Spain; [Navas, P.] Univ Pablo Olavide, CSIC, Ctr Andaluz Biol Desarrollo, Seville, Spain; [Navas, P.] ISCIII, Ctr Biomed Res Rare Dis CIBERER, Seville, Spain	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Universidad de Cordoba; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III	de Cabo, R (corresponding author), NIA, Aging Metab & Nutr Unit, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA.	decabora@mail.nih.gov	NAVAS, PLACIDO/R-5943-2019; Martin-Montalvo, Alejandro/C-2031-2017; de Cabo, Rafael/E-7996-2010; de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/J-5230-2016	NAVAS, PLACIDO/0000-0002-4115-7966; Martin-Montalvo, Alejandro/0000-0002-3886-5355; de Cabo, Rafael/0000-0003-2830-5693; de Cabo, Rafael Carlos/0000-0003-2830-5693; Villalba Montoro, Jose Manuel/0000-0001-8554-3802; de Cabo, Rafael/0000-0002-3354-2442	National Institute on Aging, National Institutes of Health; Junta de Andalucia [CVI 4887, CVI-276]; NIH [1R01AG028125-01A1]; Ministry of Health, Spain [PI080500]; NATIONAL INSTITUTE ON AGING [R01AG028125, ZIAAG000361, ZIAAG000368] Funding Source: NIH RePORTER	National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Junta de Andalucia(Junta de Andalucia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Health, Spain(Spanish Government); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	AM-M and RdC are supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. The work was partially supported by Junta de Andalucia International Projects, CVI 4887 and CVI-276, NIH Grant 1R01AG028125-01A1 and FIS Grant PI080500 of the Ministry of Health, Spain. We thank Alex Sossong and Andrew Levette for critiquing the manuscript.	Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Aleksunes LM, 2010, J PHARMACOL EXP THER, V333, P140, DOI 10.1124/jpet.109.162271; ANDREOU KK, 1981, ARCH ORAL BIOL, V26, P525, DOI 10.1016/0003-9969(81)90011-X; ANSHER SS, 1986, FOOD CHEM TOXICOL, V24, P405, DOI 10.1016/0278-6915(86)90205-X; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bae SY, 2006, CANCER SCI, V97, P774, DOI 10.1111/j.1349-7006.2006.00241.x; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Banning A, 2008, CANCER RES, V68, P9746, DOI 10.1158/0008-5472.CAN-08-1321; Bartke Andrzej, 2007, V35, P69; Birt DF, 1999, J NUTR, V129, p571S, DOI 10.1093/jn/129.2.571S; Birt DF, 2004, J CELL BIOCHEM, V91, P258, DOI 10.1002/jcb.10741; BIRT DF, 1993, CANCER RES, V53, P27; Birt DF, 1998, NUTR CANCER, V31, P119, DOI 10.1080/01635589809514690; BIRT DF, 1991, CANCER RES, V51, P1851; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; Brigelius-Flohe R, 2006, FREE RADICAL RES, V40, P775, DOI 10.1080/10715760600722643; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Burton NC, 2006, NEUROTOXICOLOGY, V27, P1094, DOI 10.1016/j.neuro.2006.07.019; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; CABRAL JRP, 1983, CANCER LETT, V19, P125, DOI 10.1016/0304-3835(83)90146-5; Cakatay U, 2001, EXP GERONTOL, V36, P221, DOI 10.1016/S0531-5565(00)00197-2; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Campbell JK, 2004, J NUTR, V134, p3486S, DOI 10.1093/jn/134.12.3486S; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Castello L, 2010, FREE RADICAL BIO MED, V48, P47, DOI 10.1016/j.freeradbiomed.2009.10.003; Chan JM, 2001, EPIDEMIOL REV, V23, P82, DOI 10.1093/oxfordjournals.epirev.a000799; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHANDRASEKAR B, 1995, CLIN IMMUNOL IMMUNOP, V76, P291, DOI 10.1006/clin.1995.1128; Chang XZ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1789; Chartoumpekis D, 2010, BIOCHEM BIOPH RES CO, V396, P463, DOI 10.1016/j.bbrc.2010.04.117; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; CHENEY KE, 1983, J GERONTOL, V38, P420, DOI 10.1093/geronj/38.4.420; Chiao JW, 2004, CARCINOGENESIS, V25, P1403, DOI 10.1093/carcin/bgh136; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; COHEN ND, 1974, CANCER RES, V34, P3245; Collins AR, 2009, CIRC RES, V104, pe42, DOI 10.1161/CIRCRESAHA.108.188771; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dai G, 2007, CIRC RES, V101, P723, DOI 10.1161/CIRCRESAHA.107.152942; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; De Cabo R, 2004, EXP GERONTOL, V39, P297, DOI 10.1016/j.exger.2003.12.003; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Ding Y, 2008, AM J PATHOL, V172, P1529, DOI 10.2353/ajpath.2008.070429; Dinikova-Kostova AT, 2004, METHOD ENZYMOL, V382, P423; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; DJURIC Z, 1993, MUTAT RES, V295, P181, DOI 10.1016/0921-8734(93)90019-Y; Duan WS, 2009, IN VITRO CELL DEV-AN, V45, P388, DOI 10.1007/s11626-009-9194-5; Efferth T, 2005, IN VIVO, V19, P225; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Fialka F, 2008, ORAL ONCOL, V44, P941, DOI 10.1016/j.oraloncology.2007.10.011; Fields WR, 1999, CARCINOGENESIS, V20, P1121, DOI 10.1093/carcin/20.6.1121; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; GARCEA R, 1988, CARCINOGENESIS, V9, P931, DOI 10.1093/carcin/9.6.931; Gerhauser C, 1997, CANCER RES, V57, P272; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; GORDON GB, 1987, ADV ENZYME REGUL, V26, P355, DOI 10.1016/0065-2571(87)90023-9; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; GROSS L, 1986, P NATL ACAD SCI USA, V83, P7928, DOI 10.1073/pnas.83.20.7928; Guo ZM, 2002, MECH AGEING DEV, V123, P1121, DOI 10.1016/S0047-6374(02)00008-8; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Halliwell B, 1996, FREE RADICAL RES, V25, P57, DOI 10.3109/10715769609145656; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HANSEN BC, 1995, OBES RES, V3, pS199, DOI 10.1002/j.1550-8528.1995.tb00464.x; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; HECHT SS, 1995, CANCER EPIDEM BIOMAR, V4, P877; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; HOWELL TH, 1987, AGE AGEING, V16, P194; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Hyun DH, 2007, J NEUROCHEM, V100, P1364, DOI 10.1111/j.1471-4159.2006.04411.x; Hyun DH, 2006, P NATL ACAD SCI USA, V103, P19908, DOI 10.1073/pnas.0608008103; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; INGRAM DK, 1990, J GERONTOL, V45, pB148, DOI 10.1093/geronj/45.5.B148; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang T, 2010, DIABETES, V59, P850, DOI 10.2337/db09-1342; Jimenez-Hidalgo M, 2009, AGING CELL, V8, P140, DOI 10.1111/j.1474-9726.2009.00461.x; Johnson JB, 2007, FREE RADICAL BIO MED, V42, P665, DOI 10.1016/j.freeradbiomed.2006.12.005; Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5; Jung KJ, 2009, INFLAMM RES, V58, P143, DOI 10.1007/s00011-008-7227-2; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kanninen K, 2009, P NATL ACAD SCI USA, V106, P16505, DOI 10.1073/pnas.0908397106; Keller UAD, 2006, MOL CELL BIOL, V26, P3773, DOI 10.1128/MCB.26.10.3773-3784.2006; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; KENSLER TW, 1995, J CELL BIOCHEM, P101; KENSLER TW, 1987, CANCER RES, V47, P4271; Khor TO, 2008, PLANTA MED, V74, P1540, DOI 10.1055/s-0028-1088303; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kiritoshi S, 2003, DIABETES, V52, P2570, DOI 10.2337/diabetes.52.10.2570; Kitamura Y, 2007, CANCER SCI, V98, P19, DOI 10.1111/j.1349-7006.2006.00352.x; Klaassen CD, 2005, CURR DRUG METAB, V6, P309, DOI 10.2174/1389200054633826; KLURFELD DM, 1987, CANCER RES, V47, P2759; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; KRITCHEVSKY D, 1984, CANCER RES, V44, P3174; Kritchevsky D, 2001, J NUTR SCI VITAMINOL, V47, P13, DOI 10.3177/jnsv.47.13; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; LAGOPOULOS L, 1987, CARCINOGENESIS, V8, P33, DOI 10.1093/carcin/8.1.33; Lal S, 2008, CANCER SCI, V99, P2045, DOI 10.1111/j.1349-7006.2008.00903.x; Lapillonne H, 2003, CANCER RES, V63, P5926; Lee HH, 2010, ARCH BIOCHEM BIOPHYS, V501, P142, DOI 10.1016/j.abb.2010.06.011; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Lee SK, 2010, LIFE SCI, V86, P107, DOI 10.1016/j.lfs.2009.11.013; Leifert WR, 2008, NUTR RES, V28, P729, DOI 10.1016/j.nutres.2008.09.001; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje; LI Y, 1992, J BIOL CHEM, V267, P15097; Lii CK, 2010, J NUTR, V140, P885, DOI 10.3945/jn.110.121418; Liu XM, 2007, CARDIOVASC RES, V75, P381, DOI 10.1016/j.cardiores.2007.03.004; LOK E, 1988, CANCER LETT, V38, P249, DOI 10.1016/0304-3835(88)90016-X; Love R, 2005, LANCET NEUROL, V4, P84, DOI 10.1016/S1474-4422(05)00985-3; Maher J, 2010, TOXICOL APPL PHARM, V244, P4, DOI 10.1016/j.taap.2010.01.011; Mandlekar S, 2006, CURR DRUG METAB, V7, P661, DOI 10.2174/138920006778017795; MANJGALADZE M, 1993, MUTAT RES, V295, P201, DOI 10.1016/0921-8734(93)90021-T; Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5; MASORO EJ, 1995, OBES RES, V3, pS241, DOI 10.1002/j.1550-8528.1995.tb00470.x; Mattison Julie A., 2007, V35, P137; Mattson MP, 2003, NEUROLOGY, V60, P690, DOI 10.1212/01.WNL.0000042785.02850.11; Mattson MP, 2001, MECH AGEING DEV, V122, pIII; McKiernan S, 2004, FASEB J, V18, P580, DOI 10.1096/fj.03-0667fje; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Miller EC, 2002, UROL CLIN N AM, V29, P83, DOI 10.1016/S0094-0143(02)00020-4; Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x; Miyagi S, 2003, Asia Pac J Public Health, V15 Suppl, pS3, DOI 10.1177/101053950301500S03; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moreschi C., 1909, Z IMMUNITATSFORSCH, V2, P661; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Muguruma M, 2006, TOXICOLOGY, V228, P178, DOI 10.1016/j.tox.2006.08.029; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Murakami S, 1996, GENETICS, V143, P1207; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nair S, 2006, PHARM RES-DORDR, V23, P2621, DOI 10.1007/s11095-006-9099-x; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen TV, 2009, ONCOL RES, V18, P349, DOI 10.3727/096504010X12626118080064; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Nolan KA, 2010, BIOCHEM PHARMACOL, V80, P977, DOI 10.1016/j.bcp.2010.06.024; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758; Osburn WO, 2008, TOXICOL SCI, V104, P218, DOI 10.1093/toxsci/kfn079; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3&lt;444::AID-IJC21&gt;3.0.CO;2-#; PASHKO LL, 1991, CARCINOGENESIS, V12, P2189, DOI 10.1093/carcin/12.11.2189; PASHKO LL, 1992, CARCINOGENESIS, V13, P1925, DOI 10.1093/carcin/13.10.1925; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Pollak M, 2009, CANCER PREV RES, V2, P698, DOI 10.1158/1940-6207.CAPR-09-0134; POLLARD M, 1984, CANCER TREAT REP, V68, P405; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Pugh TD, 1999, CANCER RES, V59, P1642; Qin WP, 2008, ANN NY ACAD SCI, V1147, P335, DOI 10.1196/annals.1427.024; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Ramsey JJ, 2000, EXP GERONTOL, V35, P1131, DOI 10.1016/S0531-5565(00)00166-2; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; REINHART J, 1993, ARCH BIOCHEM BIOPHYS, V303, P383, DOI 10.1006/abbi.1993.1299; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; RUGGERI BA, 1989, CANCER RES, V49, P4130; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sell C, 2003, HORM METAB RES, V35, P705, DOI 10.1055/s-2004-814156; SHANTZ LM, 1989, P NATL ACAD SCI USA, V86, P3852, DOI 10.1073/pnas.86.10.3852; SHAW PJ, 1995, ANN NEUROL, V38, P691, DOI 10.1002/ana.410380424; Shen GX, 2006, MOL CANCER THER, V5, P39, DOI 10.1158/1535-7163.MCT-05-0293; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Shih PH, 2007, BIOGERONTOLOGY, V8, P71, DOI 10.1007/s10522-006-9033-y; SHIMOKAWA I, 1991, J GERONTOL, V46, pB228, DOI 10.1093/geronj/46.6.B228; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Stack C, 2010, FREE RADICAL BIO MED, V49, P147, DOI 10.1016/j.freeradbiomed.2010.03.017; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Stewart JW, 2005, CARCINOGENESIS, V26, P1077, DOI 10.1093/carcin/bgi051; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suzuki M, 2001, Nihon Ronen Igakkai Zasshi, V38, P163; Suzuki T, 2005, BIOCHEM J, V388, P65, DOI 10.1042/BJ20041860; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; TANNENBAUM A, 1949, CANCER RES, V9, P162; TANNENBAUM A, 1953, ADV CANCER RES, V1, P451, DOI 10.1016/S0065-230X(08)60009-3; TAUB R, 1987, J BIOL CHEM, V262, P10893; Thatcher Gregory R. J., 2005, Current Alzheimer Research, V2, P171, DOI 10.2174/1567205053585945; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Thompson HJ, 2003, J MAMMARY GLAND BIOL, V8, P133, DOI 10.1023/A:1025743607445; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Udenigwe CC, 2008, NUTR REV, V66, P445, DOI 10.1111/j.1753-4887.2008.00076.x; Ungvari Z, 2008, CIRC RES, V102, P519, DOI 10.1161/CIRCRESAHA.107.168369; Volchegorskii I A, 2004, Neurosci Behav Physiol, V34, P303, DOI 10.1023/B:NEAB.0000018736.84877.4f; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang HJ, 2010, J HUAZHONG U SCI-MED, V30, P415, DOI 10.1007/s11596-010-0441-5; Warabi E, 2007, FREE RADICAL BIO MED, V42, P260, DOI 10.1016/j.freeradbiomed.2006.10.043; Warita H, 2001, MOL BRAIN RES, V89, P147, DOI 10.1016/S0169-328X(01)00029-8; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATTENBERG LW, 1972, JNCI-J NATL CANCER I, V48, P1425; Weed JL, 1997, PHYSIOL BEHAV, V62, P97, DOI 10.1016/S0031-9384(97)00147-9; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Westerbeek ZW, 2008, J GERONTOL A-BIOL, V63, P1131, DOI 10.1093/gerona/63.11.1131; Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037; Williams KV, 1998, DIABETES CARE, V21, P2, DOI 10.2337/diacare.21.1.2; Wilson LA, 2005, FASEB J, V19, P2085, DOI 10.1096/fj.05-4401fje; Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300; Xue MZ, 2008, DIABETES, V57, P2809, DOI 10.2337/db06-1003; Yamamoto T, 2006, GENES CELLS, V11, P575, DOI 10.1111/j.1365-2443.2006.00965.x; Yang H, 2004, J GERONTOL A-BIOL, V59, P316; Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516; Ye G, 2004, DIABETES, V53, P1336, DOI 10.2337/diabetes.53.5.1336; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017; Zakkar M, 2009, ARTERIOSCL THROM VAS, V29, P1851, DOI 10.1161/ATVBAHA.109.193375; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	263	95	98	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					505	520		10.1038/onc.2010.492	http://dx.doi.org/10.1038/onc.2010.492			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	21057541	Green Accepted, Green Submitted			2022-12-28	WOS:000286922300001
J	Sachdeva, M; Wu, H; Ru, P; Hwang, L; Trieu, V; Mo, YY				Sachdeva, M.; Wu, H.; Ru, P.; Hwang, L.; Trieu, V.; Mo, Y-Y			MicroRNA-101-mediated Akt activation and estrogen-independent growth	ONCOGENE			English	Article						breast cancer; estrogen receptor; miR-101; tamoxifen resistance	ALPHA MESSENGER-RNA; BREAST-CANCER; TUMOR-SUPPRESSOR; TAMOXIFEN RESISTANCE; RECEPTOR-ALPHA; PROTEIN STABILITY; PTEN; PHOSPHORYLATION; MECHANISMS; EXPRESSION	MicroRNAs are gene regulators that work through a posttranscriptional repression mechanism. Dysregulation of microRNA expression could lead to a variety of disorders, in particular, human cancer, and has also been implicated in antihormone therapy resistance. However, little is known whether microRNAs have a role in estrogen-independent growth, leading to tamoxifen resistance in estrogen receptor (ER)-positive tumors. In this study, we use an in vivo selection system against a microRNA library using the MCF-7 model and demonstrate that miR-101 promotes estrogen-independent growth and causes the upregulation of phosphorylated Akt (pAkt) without impacting the ER level or activity. Importantly, although miR-101 suppresses cell growth in normal estradiol (E2)-containing medium, it promotes cell growth in E2-free medium. Moreover, estrogen deprivation greatly enhances miR-101-mediated Akt activation. Finally, we show that MAGI-2 (membrane-associated guanylate kinase), a scaffold protein required for PTEN (phosphatase and tensin homolog) activity, is a direct target for miR-101; suppression of MAGI-2 by miR-101 reduces PTEN activity, leading to Akt activation. Taken together, these results not only establish a role for miR101 in estrogen-independent signaling but also provide a mechanistic link between miR-101 and Akt activation. Oncogene (2011) 30, 822-831; doi:10.1038/onc.2010.463; published online 18 October 2010	[Sachdeva, M.; Wu, H.; Ru, P.; Mo, Y-Y] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA; [Hwang, L.; Trieu, V.] Abraxis Biosci, Marina Del Rey, CA USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 825 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/R-8255-2019; Mo, Yin-Yuan/B-6141-2011		Susan G Komen for the Cure [KG100027]; Department of Defense [BC085629]; Abraxis Bioscience	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); Abraxis Bioscience	We are grateful to Andy Wilber for the preparation of the viral stock used in this study and to Dr Yutaka Hata for the MAGI2 construct. This work is supported by KG100027 from Susan G Komen for the Cure, by BC085629 from the Department of Defense and the research fund from Abraxis Bioscience.	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Los M, 2009, BIOESSAYS, V31, P492, DOI 10.1002/bies.200900005; Lykkesfeldt AE, 1996, ACTA ONCOL, V35, P9, DOI 10.3109/02841869609083961; Maddika S, 2009, MOL CELL BIOL, V29, P1235, DOI 10.1128/MCB.00668-08; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhang YY, 2009, MOL CANCER RES, V7, P498, DOI 10.1158/1541-7786.MCR-08-0415; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	35	88	94	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					822	831		10.1038/onc.2010.463	http://dx.doi.org/10.1038/onc.2010.463			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956939				2022-12-28	WOS:000287444600006
J	Suo, J; Snider, SJ; Mills, GB; Creighton, CJ; Chen, AC; Schiff, R; Lloyd, RE; Chang, EC				Suo, J.; Snider, S. J.; Mills, G. B.; Creighton, C. J.; Chen, A. C.; Schiff, R.; Lloyd, R. E.; Chang, E. C.			Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium	ONCOGENE			English	Article						eIF3; translation; ubiquitin; proteasomes; tumor suppressor	FISSION YEAST HOMOLOG; BREAST-CANCER; TUMOR VIRUS; STEM-CELLS; PROTEIN; GENE; RESISTANCE; EXPRESSION; COMPLEXES; SUBUNIT	INT6/EIF3E has been implicated in breast tumorigenesis, but its functional activities remain poorly defined. We found that, repressing INT6 expression induced transformed properties in normal human mammary epithelium (MCF10A); in contrast, Int6 silencing induced apoptosis in HeLa cells. As in fission yeast, Int6 in human cells was required for assembly of active proteasomes. A reverse-phase protein array screen identified SRC3/AIB1 as one oncoprotein the level and stability of which increased when Int6 was silenced in MCF10A cells. Our data further show that Int6 binds SRC3 and its ubiquitin ligase Fbw7, thus perhaps mediating the interaction between SRC3-Fbw7 and proteasomes. Consistent with this, Int6 silencing did not increase SRC3 levels in HeLa cells, which have low Fbw7 levels. It is surprising that, however, polyubiquitylated proteins do not accumulate or may even decrease in Int6-silenced cells that contain defective proteasomes. Considering that decreased ubiquitin might explain this observation and that Int6 might control ubiquitin levels in its role as a subunit of eIF3 ((e) under bar ukaryote translation (i) under bar nitiation (f) under bar actor 3), we found that silencing Int6 reduced monoubiquitin protein levels, which correlated with a shift of ubiquitin mRNAs from larger polysomes to non-translating ribosomes. In contrast, levels of many housekeeping proteins did not change. This apparent reduction in the translation of ubiquitin genes correlated with a modest reduction in protein synthesis rate and formation of large polysomes. To further determine whether Int6 can selectively control translation, we analyzed translation of different 5'-untranslated region reporters and found that indeed, loss of Int6 had differential effects on these reporters. Together the data suggest that Int6 depletion blocks ubiquitin-dependent proteolysis by decreasing both ubiquitin levels and the assembly of functional proteasome machinery, leading to accumulation of oncoproteins, such as SRC3 that can transform mammary epithelium. Our data also raise the possibility that Int6 can further fine-tune protein levels by selectively controlling translation of specific mRNAs. Oncogene (2011) 30, 724-736; doi:10.1038/onc.2010.445; published online 4 October 2010	[Suo, J.; Chang, E. C.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Suo, J.; Creighton, C. J.; Chen, A. C.; Schiff, R.; Chang, E. C.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Snider, S. J.; Lloyd, R. E.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Div Biostat, Houston, TX 77030 USA; [Chen, A. C.; Schiff, R.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Chang, EC (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	echang1@bcm.edu			NIH [CA90464, CA107187, P50CA58183, P50CA058183, AI50237, GM59803]; Susan G. Komen Foundation [PDF0402733]; Expedition Inspiration Fund for Breast Cancer Research; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA090464, R01CA107187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050237, R56AI050237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059803] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Expedition Inspiration Fund for Breast Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank John Hershey for providing eIF3 antibodies, and members of the Adrian Lee and Steffi Oesterreich labs for the help with tissue culture. We thank Carlos Rivera for technical assistance in the translation study and Steen Pedersen for assistance in the use of the fluorometer, Chris Threetor, Mike Cubbage and Xinrong Fu for the use of a flow cytometer in the Flow Cytometry core lab at Texas Children's Cancer Center, Michael Lewis for confocal microscopy, Gary Chamness for reading the manuscript, Anna Tsimelzon and Susan Hilsenbeck for database analyses, Jan Sap for assistance in Int6 expression studies, Yiling Lu for assistance in the RRPA screen, members of Robert Callahan's group for discussion and David Lonard and Bert O'Malley in the help of SRC3 study. We are particularly grateful to Sizhen Gao, Joan Brugge and Sean McGuire for sharing unpublished results and comments for the paper. ECC is supported by grants from the NIH (CA90464, CA107187 and P50CA58183), JS by fellowships from the Susan G. Komen Foundation (PDF0402733) and Expedition Inspiration Fund for Breast Cancer Research, RS by grants from NIH, P50CA058183 and SU2C (Stand Up 2 Cancer) and REL by NIH grants (AI50237 and GM59803).	Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Byrd MP, 2005, J BIOL CHEM, V280, P18610, DOI 10.1074/jbc.M414014200; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Dawson PJ, 1996, AM J PATHOL, V148, P313; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diella F, 1997, DNA CELL BIOL, V16, P839, DOI 10.1089/dna.1997.16.839; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Grzmil M, 2010, ONCOGENE, V29, P4080, DOI 10.1038/onc.2010.152; Gunawardane RN, 2005, CANCER RES, V65, P11572, DOI 10.1158/0008-5472.CAN-05-1196; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; HOAREAU AK, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Li C, 2008, MOL CELL, V31, P835, DOI 10.1016/j.molcel.2008.07.019; Lonard DM, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.113pe16; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Massarweh S, 2006, CANCER RES, V66, P8266, DOI 10.1158/0008-5472.CAN-05-4045; Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Rivera CI, 2008, VIROLOGY, V375, P59, DOI 10.1016/j.virol.2008.02.002; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sha Z, 2009, MOL CELL, V36, P141, DOI 10.1016/j.molcel.2009.09.026; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Umar A, 2009, MOL CELL PROTEOMICS, V8, P1278, DOI 10.1074/mcp.M800493-MCP200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; WOODS A, 1989, J CELL SCI, V93, P491; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; Yen HCS, 2003, CELL CYCLE, V2, P81, DOI 10.4161/cc.2.2.340; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	40	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	6					724	736		10.1038/onc.2010.445	http://dx.doi.org/10.1038/onc.2010.445			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890303	Green Accepted			2022-12-28	WOS:000287192000009
J	Azmi, AS; Philip, PA; Beck, FWJ; Wang, Z; Banerjee, S; Wang, S; Yang, D; Sarkar, FH; Mohammad, RM				Azmi, A. S.; Philip, P. A.; Beck, F. W. J.; Wang, Z.; Banerjee, S.; Wang, S.; Yang, D.; Sarkar, F. H.; Mohammad, R. M.			MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy	ONCOGENE			English	Article						MDM2 and p53; small molecule inhibitors; zinc; apoptosis	NF-KAPPA-B; SMALL-MOLECULE INHIBITORS; SUPPRESSOR PROTEIN P53; STRUCTURE-BASED DESIGN; DNA-BINDING ACTIVITY; ZINC-DEFICIENCY; WILD-TYPE; CANCER; APOPTOSIS; NUCLEAR	Zinc has a crucial role in the biology of p53 in that p53 binds to DNA through a structurally complex domain stabilized by zinc atom. The p53 negative regulator MDM2 protein also carries a C-terminal RING domain that coordinates two zinc atoms, which are responsible for p53 nuclear export and proteasomal degradation. In this clinically translatable study, we explored the critical role of zinc on p53 reactivation by MDM2 inhibitor, MI-219, in colon and breast cancer cells. ZnCl2 enhanced MI-219 activity (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), apoptosis and colony formation), and chelation of zinc not only blocked the activity of MI-219, but also suppressed reactivation of the p53 and its downstream effector molecules p21(WAF1) and Bax. N,N,N'N'-tetrakis(-)[2-pyridylmethyl]- ethylenediamine (TPEN), a specific zinc chelator, but not 1,2-bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid (Bapta-AM), a calcium chelator, blocked MI-219-induced apoptosis. Nuclear localization is a prerequisite for proper functioning of p53 and our results confirm that TPEN, and not Bapta-AM, could abrogate p53 nuclear localization and it interfered with p53 transcriptional activation. Addition of zinc suppressed the known p53 feedback MDM2 activation, which could be restored by TPEN. Co-immunoprecipitation studies verified that MI-219-mediated MDM2-p53 disruption could be suppressed by TPEN and restored by zinc. As such, single-agent therapies that target MDM2 inhibition, without supplemental zinc, may not be optimal in certain patients owing to the less recognized mild zinc deficiency among the 'at-risk population' as in the elderly who are more prone to cancers. Therefore, use of supplemental zinc with MI-219 will benefit the overall efficacy of MIs and this potent combination warrants further investigation. Oncogene (2011) 30, 117-126; doi: 10.1038/onc.2010.403; published online 6 September 2010	[Philip, P. A.; Beck, F. W. J.; Mohammad, R. M.] Wayne State Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol,Karmanos Canc Inst, Detroit, MI 48201 USA; [Azmi, A. S.; Wang, Z.; Banerjee, S.; Sarkar, F. H.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; [Wang, S.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Wang, S.] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; [Wang, S.; Yang, D.] Ascenta Therapeut Inc, Malvern, PA USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mohammad, RM (corresponding author), Wayne State Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol,Karmanos Canc Inst, 732 HWCRC,4100 John R St, Detroit, MI 48201 USA.	mohammar@karmanos.org	Wang, Zhiwei/A-6809-2011	Wang, Shaomeng/0000-0002-8782-6950; AZMI, ASFAR/0000-0003-1178-9505	National Cancer Institute, NIH [R01CA109389]; NIH [5R01CA101870]; Guido foundation; NATIONAL CANCER INSTITUTE [R01CA101870, R01CA109389, R01CA121279] Funding Source: NIH RePORTER	National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Guido foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	National Cancer Institute, NIH Grant R01CA109389 (RM Mohammad) and NIH Grant 5R01CA101870 (FH Sarkar) are acknowledged. We sincerely acknowledge the Guido foundation for their support.	Alshatwi AA, 2006, EXP BIOL MED, V231, P611; Azmi AS, 2010, EUR J CANCER, V46, P1122, DOI 10.1016/j.ejca.2010.01.015; Azmi AS, 2008, MOL CANCER THER, V7, P2884, DOI 10.1158/1535-7163.MCT-08-0438; Bao B, 2006, TOXICOL LETT, V166, P222, DOI 10.1016/j.toxlet.2006.07.306; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Beck FWJ, 2004, PROSTATE, V58, P374, DOI 10.1002/pros.10344; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Butler JS, 2007, BIOCHEMISTRY-US, V46, P2630, DOI 10.1021/bi062106y; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Canner JA, 2009, BRIT J CANCER, V101, P774, DOI 10.1038/sj.bjc.6605199; Chen GD, 2006, BIOCHEM BIOPH RES CO, V344, P272, DOI 10.1016/j.bbrc.2006.03.136; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Collins K, 1997, P NATL ACAD SCI USA, V94, P2776, DOI 10.1073/pnas.94.7.2776; Ding K, 2005, J AM CHEM SOC, V127, P10130, DOI 10.1021/ja051147z; Ding K, 2006, J MED CHEM, V49, P3432, DOI 10.1021/jm051122a; Feng ZH, 2008, CELL CYCLE, V7, P842, DOI 10.4161/cc.7.7.5657; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Hambidge KM, 1998, AM J CLIN NUTR, V68, p410S, DOI 10.1093/ajcn/68.2.410S; Ho E, 2004, J NUTR BIOCHEM, V15, P572, DOI 10.1016/j.jnutbio.2004.07.005; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Ho E, 2009, CURR OPIN CLIN NUTR, V12, P640, DOI 10.1097/MCO.0b013e32833106ee; International Zinc Consultative Group, 2004, FOOD NUTR BULL, V25, pS99, DOI DOI 10.1177/15648265040251S205; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 2004, NATURE, V427, P789, DOI 10.1038/427789a; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Meplan C, 1999, P NUTR SOC, V58, P565, DOI 10.1017/S0029665199000749; Mohammad RM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-115; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Prasad AS, 2004, MET IONS BIOL SYST, V41, P103; Prasad AS, 2002, J LAB CLIN MED, V140, P272, DOI 10.1067/mlc.2002.127908; PRASAD AS, 1993, NUTRITION, V9, P218; Prasad AS, 2001, NUTRITION, V17, P685, DOI 10.1016/S0899-9007(01)00598-6; Prasad AS, 2001, J LAB CLIN MED, V138, P250, DOI 10.1067/mlc.2001.118108; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Verma R, 2010, BIOCHEM PHARMACOL, V79, P565, DOI 10.1016/j.bcp.2009.09.020; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wawrzynow B, 2009, J BIOL CHEM, V284, P11517, DOI 10.1074/jbc.M809294200; Yu SH, 2009, J MED CHEM, V52, P7970, DOI 10.1021/jm901400z; Zalewski P D, 1994, Chem Biol, V1, P153, DOI 10.1016/1074-5521(94)90005-1; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403	51	35	36	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					117	126		10.1038/onc.2010.403	http://dx.doi.org/10.1038/onc.2010.403			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818437	Green Accepted			2022-12-28	WOS:000285959300011
J	El Mjiyad, N; Caro-Maldonado, A; Ramirez-Peinado, S; Munoz-Pinedo, C				El Mjiyad, N.; Caro-Maldonado, A.; Ramirez-Peinado, S.; Munoz-Pinedo, C.			Sugar-free approaches to cancer cell killing	ONCOGENE			English	Review						cancer; apoptosis; glucose; tumor metabolism; Bcl-2 proteins	BH3-ONLY PROTEIN BIM; GLUCOSE-METABOLISM; C-MYC; INDUCED APOPTOSIS; GLIOBLASTOMA-MULTIFORME; GLYCOLYTIC INHIBITORS; GLUTAMINE-METABOLISM; DEPENDENT APOPTOSIS; AEROBIC GLYCOLYSIS; TRIGGERS APOPTOSIS	Tumors show an increased rate of glucose uptake and utilization. For this reason, glucose analogs are used to visualize tumors by the positron emission tomography technique, and inhibitors of glycolytic metabolism are being tested in clinical trials. Upregulation of glycolysis confers several advantages to tumor cells: it promotes tumor growth and has also been shown to interfere with cell death at multiple levels. Enforcement of glycolysis inhibits apoptosis induced by cytokine deprivation. Conversely, antiglycolytic agents enhance cell death induced by radio- and chemotherapy. Synergistic effects are likely due to regulation of the apoptotic machinery, as glucose regulates activation and levels of proapoptotic BH3-only proteins such as Bim, Bad, Puma and Noxa, as well as the antiapoptotic Bcl-2 family of proteins. Moreover, inhibition of glucose metabolism sensitizes cells to death ligands. Glucose deprivation and antiglycolytic drugs induce tumor cell death, which can proceed through necrosis or through mitochondrial or caspase-8-mediated apoptosis. We will discuss how oncogenic pathways involved in metabolic stress signaling, such as p53, AMPK (adenosine monophosphate-activated protein kinase) and Akt/mTOR (mammalian target of rapamycin), influence sensitivity to inhibition of glucose metabolism. Finally, we will analyze the rationale for the use of antiglycolytic inhibitors in the clinic, either as single agents or as a part of combination therapies. Oncogene (2011) 30, 253-264; doi:10.1038/onc.2010.466; published online 25 October 2010	[El Mjiyad, N.; Caro-Maldonado, A.; Ramirez-Peinado, S.; Munoz-Pinedo, C.] IDIBELL Bellvitage Biomed Res Inst, Cell Death Regulat Grp, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Munoz-Pinedo, C (corresponding author), Hosp Duran & Reynals, IDIBELL, 3A Planta,Gran Via Hosp 199, Barcelona 08907, Spain.	cmunoz@idibell.cat	Caro-Maldonado, Alfredo/A-7364-2010; Munoz-Pinedo, Cristina/B-6118-2008; Caro-Maldonado, Alfredo/D-3288-2014	Caro-Maldonado, Alfredo/0000-0002-5431-7949; Munoz-Pinedo, Cristina/0000-0002-9120-664X; 	AICR [08-0621]; Fondo de Investigaciones Sanitarias-ISCIII [PI071027, RTICC RD06/0020]	AICR; Fondo de Investigaciones Sanitarias-ISCIII(Instituto de Salud Carlos III)	We thank Ameeta Kelekar for sharing unpublished data and Oscar M. Tirado for critical reading of this manuscript. Research in our group is supported by AICR grant 08-0621 and by grants PI071027 and RTICC RD06/0020 from the Fondo de Investigaciones Sanitarias-ISCIII.	Aft RL, 2002, BRIT J CANCER, V87, P805, DOI 10.1038/sj.bjc.6600547; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Caro-Maldonado A, 2010, CELL DEATH DIFFER, V17, P1335, DOI 10.1038/cdd.2010.21; Chiaradonna F, 2006, ONCOGENE, V25, P5391, DOI 10.1038/sj.onc.1209528; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Concannon CG, 2010, J CELL BIOL, V189, P83, DOI 10.1083/jcb.200909166; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Di Cosimo S, 2003, DRUGS TODAY, V39, P157, DOI 10.1358/dot.2003.39.3.799451; DiPaola RS, 2008, PROSTATE, V68, P1743, DOI 10.1002/pros.20837; Dwarakanath B. S., 1999, Indian Journal of Experimental Biology, V37, P865; Dwarkanath BS, 2001, INT J RADIAT ONCOL, V50, P1051, DOI 10.1016/S0360-3016(01)01534-6; Egler V, 2008, CLIN CANCER RES, V14, P3132, DOI 10.1158/1078-0432.CCR-07-4182; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fan YJ, 2010, J BIOL CHEM, V285, P7324, DOI 10.1074/jbc.M109.035584; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Geschwind JFH, 2002, CANCER RES, V62, P3909; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haga N, 1998, INT J CANCER, V76, P86, DOI 10.1002/(SICI)1097-0215(19980330)76:1<86::AID-IJC14>3.0.CO;2-E; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernlund E, 2009, MOL CANCER THER, V8, P1916, DOI 10.1158/1535-7163.MCT-09-0179; Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842; JAIN VK, 1985, INT J RADIAT ONCOL, V11, P943, DOI 10.1016/0360-3016(85)90117-8; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; KALIA VK, 1982, INDIAN J EXP BIOL, V20, P884; Kang HT, 2006, LIFE SCI, V78, P1392, DOI 10.1016/j.lfs.2005.07.001; KAPLAN O, 1990, CANCER RES, V50, P544; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KERN KA, 1987, SURGERY, V102, P380; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Latz D., 1993, Strahlentherapie und Onkologie, V169, P405; Lee YJ, 1997, J CELL SCI, V110, P681; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu HP, 2002, BIOCHEM PHARMACOL, V64, P1745, DOI 10.1016/S0006-2952(02)01456-9; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Michalek RD, 2010, IMMUNOL REV, V236, P190, DOI 10.1111/j.1600-065X.2010.00911.x; Munoz-Pinedo C, 2004, FEBS LETT, V570, P205, DOI 10.1016/j.febslet.2004.06.044; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Papaldo P, 2003, J CLIN ONCOL, V21, P3462, DOI 10.1200/JCO.2003.03.034; Pathania D, 2009, ADV DRUG DELIVER REV, V61, P1250, DOI 10.1016/j.addr.2009.05.010; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Raez LE, 2007, J CLIN ONCOL, V25; Raez LE, 2005, J CLIN ONCOL, V23, p238S; Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; ROSBE KW, 1989, CANCER CHEMOTH PHARM, V25, P32, DOI 10.1007/BF00694335; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; SINGH SP, 1990, INT J RADIAT BIOL, V58, P791, DOI 10.1080/09553009014552171; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Swamy R. K., 2005, Indian Journal of Experimental Biology, V43, P686; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; TEICHER BA, 1991, CANCER RES, V51, P780; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; THAKKAR NS, 1993, CANCER RES, V53, P2057; Tomida A, 1996, INT J CANCER, V68, P391, DOI 10.1002/(SICI)1097-0215(19961104)68:3<391::AID-IJC19>3.0.CO;2-B; Tong XM, 2009, P NATL ACAD SCI USA, V106, P21660, DOI 10.1073/pnas.0911316106; Uyeda K, 2006, CELL METAB, V4, P107, DOI 10.1016/j.cmet.2006.06.008; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wood TE, 2008, MOL CANCER THER, V7, P3546, DOI 10.1158/1535-7163.MCT-08-0569; Xu RH, 2005, CANCER RES, V65, P613; Yamada M, 1999, CANCER CHEMOTH PHARM, V44, P59, DOI 10.1007/s002800050945; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yi CH, 2007, J CELL BIOL, V179, P619, DOI 10.1083/jcb.200708090; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yun J, 1995, ONCOL RES, V7, P583; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XD, 2006, ANTICANCER RES, V26, P3561; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zhao YX, 2008, J BIOL CHEM, V283, P36344, DOI 10.1074/jbc.M803580200	101	139	142	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					253	264		10.1038/onc.2010.466	http://dx.doi.org/10.1038/onc.2010.466			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20972457				2022-12-28	WOS:000286418800001
J	Wheeler, DS; Barrick, SR; Grubisha, MJ; Brufsky, AM; Friedman, PA; Romero, G				Wheeler, D. S.; Barrick, S. R.; Grubisha, M. J.; Brufsky, A. M.; Friedman, P. A.; Romero, G.			Direct interaction between NHERF1 and Frizzled regulates beta-catenin signaling	ONCOGENE			English	Article						NHERF1; EBP50; breast cancer; Wnt; Frizzled; beta-catenin	PROTEIN-COUPLED-RECEPTORS; HUMAN BREAST-CANCER; CYCLIN D1; EXPRESSION; CELLS; RECOGNITION; ASSOCIATION; ENDOCYTOSIS; PROGNOSIS; MECHANISM	Although Wnt-Frizzled (Fzd) signaling is critical in the pathophysiology of carcinomas, its role in human breast cancer has been difficult to establish. We show here that the adaptor protein Na+/H+ exchange regulatory factor1 (NHERF1), a protein abundantly expressed in normal mammary epithelium, regulates Wnt signaling, maintaining low levels of beta-catenin activation. NHERF1's effects are mediated by direct interactions between one of its PSD-95/drosophila discs large/ZO-1 (PDZ) domains and the C-terminus of a subset of Fzd receptors. Loss of NHERF1 in breast cancer cell lines enhances canonical Wnt signaling and Wnt-dependent cell proliferation. Furthermore, the mammary glands of NHERF1-knockout mice exhibit increased mammary duct density accompanied by increased proliferation and beta-catenin activity. Finally, we demonstrate a negative correlation between NHERF1 expression and nuclear beta-catenin in human breast carcinomas. Taken together, these results provide a novel insight into the regulation of Wnt signaling in normal and neoplastic breast tissues, and identify NHERF1 as an important regulator of the pathogenesis of breast tumors. Oncogene (2011) 30, 32-42; doi: 10.1038/onc.2010.389; published online 30 August 2010	[Wheeler, D. S.; Barrick, S. R.; Grubisha, M. J.; Friedman, P. A.; Romero, G.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Lab GPCR Biol, Pittsburgh, PA 15261 USA; [Wheeler, D. S.; Grubisha, M. J.] Univ Pittsburgh, Sch Med, Med Scientist Training Program, Pittsburgh, PA 15261 USA; [Brufsky, A. M.; Friedman, P. A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA; [Brufsky, A. M.; Romero, G.] Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Romero, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Lab GPCR Biol, E1355 BST, Pittsburgh, PA 15261 USA.	ggr@pitt.edu	Brufsky, Adam/AAE-7470-2020; Barrick, Stacey/J-1595-2015	Brufsky, Adam/0000-0001-8080-7960; Barrick, Stacey/0000-0002-4837-3741	National Institutes of Health [DK083211, DK079864, DK54171]; Office of the Senior Vice Chancellor for the Health Sciences of the University of Pittsburgh; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054171, R56DK079864, F30DK083211, R01DK069998] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Senior Vice Chancellor for the Health Sciences of the University of Pittsburgh(University of Pittsburgh); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants DK083211 (DSW), DK079864 (GR) and DK54171 (PAF) from the National Institutes of Health. We also acknowledge support from the Office of the Senior Vice Chancellor for the Health Sciences of the University of Pittsburgh (GR).	Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bates IR, 2006, BIOPHYS J, V91, P1046, DOI 10.1529/biophysj.106.084830; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Garrido JL, 2009, MOL ENDOCRINOL, V23, P2048, DOI 10.1210/me.2008-0436; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Luyten A, 2008, MOL BIOL CELL, V19, P1594, DOI 10.1091/mbc.E07-08-0832; Mangia A, 2009, HISTOPATHOLOGY, V55, P600, DOI 10.1111/j.1365-2559.2009.03424.x; Pan Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1846; Pan Y, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1616; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umekita Y, 2002, INT J CANCER, V98, P415, DOI 10.1002/ijc.10151; Wang B, 2007, J BIOL CHEM, V282, P36214, DOI 10.1074/jbc.M707263200; Wawrzak D, 2009, ADV ENZYME REGUL, V49, P98, DOI 10.1016/j.advenzreg.2009.01.002; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; Wheeler D, 2007, J BIOL CHEM, V282, P25076, DOI 10.1074/jbc.M701544200; Yao R, 2004, ONCOGENE, V23, P6023, DOI 10.1038/sj.onc.1207817; Yu A, 2007, DEV CELL, V12, P129, DOI 10.1016/j.devcel.2006.10.015	32	37	40	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					32	42		10.1038/onc.2010.389	http://dx.doi.org/10.1038/onc.2010.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802536	Green Accepted			2022-12-28	WOS:000285959300003
J	Mancuso, M; Pasquali, E; Leonardi, S; Rebessi, S; Tanori, M; Giardullo, P; Borra, F; Pazzaglia, S; Naus, CC; Di Majo, V; Saran, A				Mancuso, M.; Pasquali, E.; Leonardi, S.; Rebessi, S.; Tanori, M.; Giardullo, P.; Borra, F.; Pazzaglia, S.; Naus, C. C.; Di Majo, V.; Saran, A.			Role of connexin43 and ATP in long-range bystander radiation damage and oncogenesis in vivo	ONCOGENE			English	Article						Cx43; GJIC; radiation; bystander effect; ATP; brain tumor	DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; IONIZING-RADIATION; SPINAL-CORD; CELLS; EXPRESSION; INVOLVEMENT; METABOLISM	Ionizing radiation is a genotoxic agent and human carcinogen. Recent work has questioned long-held dogmas by showing that cancer-associated genetic alterations occur in cells and tissues not directly exposed to radiation, questioning the robustness of the current system of radiation risk assessment. In vitro, diverse mechanisms involving secreted soluble factors, gap junction intercellular communication (GJIC) and oxidative metabolism are proposed to mediate these indirect effects. In vivo, the mechanisms behind long-range 'bystander' responses remain largely unknown. Here, we investigate the role of GJIC in propagating radiation stress signals in vivo, and in mediating radiation-associated bystander tumorigenesis in mouse central nervous system using a mouse model in which intercellular communication is downregulated by targeted deletion of the connexin43 (Cx43) gene. We show that GJIC is critical for transmission of oncogenic radiation damage to the non-targeted cerebellum, and that a mechanism involving adenosine triphosphate release and upregulation of Cx43, the major GJIC constituent, regulates transduction of oncogenic damage to unirradiated tissues in vivo. Our data provide a novel hypothesis for transduction of distant bystander effects and suggest that the highly branched nervous system, similar to the vascular network, has an important role. Oncogene (2011) 30, 4601-4608; doi: 10.1038/onc.2011.176; published online 23 May 2011	[Mancuso, M.; Pasquali, E.; Leonardi, S.; Rebessi, S.; Tanori, M.; Borra, F.; Pazzaglia, S.; Di Majo, V.; Saran, A.] Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy; [Pasquali, E.; Giardullo, P.] Univ Guglielmo Marconi, Dept Radiat Phys, Rome, Italy; [Naus, C. C.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V5Z 1M9, Canada	Italian National Agency New Technical Energy & Sustainable Economics Development; Guglielmo Marconi University; University of British Columbia	Mancuso, M (corresponding author), Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy.	mariateresa.mancuso@enea.it; anna.saran@enea.it	Pasquali, Emanuela/CAG-4451-2022	Saran, Anna/0000-0002-5587-064X	Associazione Italiana Ricerca sul Cancro (AIRC) [10357]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Grant 10357 from the Associazione Italiana Ricerca sul Cancro (AIRC) to AS. We are grateful to Maria Pia Toni and Maria Pimpinella for assistance with dosimetry and Monte Carlo simulation. We also thank Alessandro Pannicelli for help with photographs and John Bechberger (University of British Columbia, Canada) for assistance with transfer of Cx43<SUP>+/</SUP> mice.	Amino M, 2006, CARDIOVASC RES, V72, P412, DOI 10.1016/j.cardiores.2006.09.010; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; BEIR VII, 2006, COMM ASS HLTH RISKS; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Chai Yunfei, 2009, Acta Medica Nagasakiensia, V53, P65; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Huang L, 2007, CANCER RES, V67, P1099, DOI 10.1158/0008-5472.CAN-06-3697; Kasper M, 1996, HISTOCHEM CELL BIOL, V106, P419; Liu K, 1997, RADIAT RES, V147, P437, DOI 10.2307/3579500; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Mancuso M, 2008, P NATL ACAD SCI USA, V105, P12445, DOI 10.1073/pnas.0804186105; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; NAGASAWA H, 1992, CANCER RES, V52, P6394; Ojima M, 2011, RADIAT RES, V175, P90, DOI 10.1667/RR2223.1; Pazzaglia S, 2006, ONCOGENE, V25, P5575, DOI 10.1038/sj.onc.1209544; Qu Y, 2002, P NATL ACAD SCI USA, V99, P697, DOI 10.1073/pnas.022324499; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Schipke CG, 2001, FASEB J, V15, P255, DOI 10.1096/fj.01-0514fje; Sinclair CJD, 2000, J NEUROCHEM, V75, P1528, DOI 10.1046/j.1471-4159.2000.0751528.x; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Tsuda M, 1999, BRIT J PHARMACOL, V127, P449, DOI 10.1038/sj.bjp.0702582; Tsukimoto M, 2010, RADIAT RES, V173, P298, DOI 10.1667/RR1732.1; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082	29	58	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4601	4608		10.1038/onc.2011.176	http://dx.doi.org/10.1038/onc.2011.176			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21602884				2022-12-28	WOS:000296890700007
J	Hiraoka, D; Okumura, E; Kishimoto, T				Hiraoka, D.; Okumura, E.; Kishimoto, T.			Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt	ONCOGENE			English	Article						activation-loop; Akt; starfish oocytes; TOR; turn motif	PROTEIN-KINASE-B; RICTOR-MTOR COMPLEX; BETA-GAMMA-SUBUNIT; SIGNALING PATHWAY; STARFISH OOCYTES; MAMMALIAN TARGET; CELL-CYCLE; MATURATION; INSULIN; AKT/PKB	Akt, also known as protein kinase B, has a central role in various signaling pathways that regulate cellular processes such as metabolism, proliferation and survival. On stimulation, phosphorylation of the activation loop (A-loop) and hydrophobic motif (HM) of Akt by the kinase phosphoinositide-dependent kinase 1 (PDK1) and the mammalian target of rapamycin complex 2 (mTORC2), respectively, results in Akt activation. A well-conserved threonine in the turn motif (TM) is also constitutively phosphorylated by mTORC2 and contributes to the stability of Akt. The role of TM phosphorylation in HM and A-loop phosphorylation has not been sufficiently evaluated. Using starfish oocytes as a model system, this study provides the first evidence that TM phosphorylation has a negative role in A-loop phosphorylation. In this system, the maturation-inducing hormone, 1-methyladenine, stimulates Akt to reinitiate meiosis through activation of cyclin B-Cdc2. The phosphorylation status of Akt was monitored via introduction of exogenous human Akt (hAkt) in starfish oocytes. TM and HM phosphorylation was inhibited by microinjection of an anti-starfish TOR antibody, but not by rapamycin treatment, suggesting that both phosphorylation events depend on TORC2, as reported in mammalian cells. A single or double alanine substitution at each of three phosphorylation residues revealed that TM phosphorylation renders Akt susceptible to dephosphorylation on the A-loop. When A-loop phosphatase was inhibited by okadaic acid (OA), TMphosphorylation still reduced A-loop phosphorylation, suggesting that the effect is caused at least partially through reduction of sensitivity to PDK1. Negative regulation by TM phosphorylation was also observed in constitutively active Akt and was functionally reflected in meiosis resumption. By contrast, HM phosphorylation enhanced A-loop phosphorylation and achieved full activation of Akt via a mechanism at least partially independent of TM phosphorylation. These observations provide new insight into the mechanism controlling Akt phosphorylation in the cell. Oncogene (2011) 30, 4487-4497; doi:10.1038/onc.2011.155; published online 16 May 2011	[Kishimoto, T.] Tokyo Inst Technol, Grad Sch Biosci, Lab Cell & Dev Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kishimoto, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci, Lab Cell & Dev Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan.	tkishimo@bio.titech.ac.jp			Ministry of Education, Science and Culture, Japan	Ministry of Education, Science and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Mark Terasaki for the gift of the pSP64-S vector and Dr Masatoshi Hara for suggestion of eIF4E and 4E-BP1. This work was supported by grants from the Ministry of Education, Science and Culture, Japan to TK.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Borgatti P, 2003, J CELL PHYSIOL, V196, P79, DOI 10.1002/jcp.10279; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Goren I, 2008, BIOCHEM BIOPH RES CO, V372, P103, DOI 10.1016/j.bbrc.2008.04.185; GUERRIER P, 1975, DEV BIOL, V47, P341, DOI 10.1016/0012-1606(75)90288-2; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Hara M, 2009, DEVELOPMENT, V136, P1687, DOI 10.1242/dev.035261; Hauge C, 2007, EMBO J, V26, P2251, DOI 10.1038/sj.emboj.7601682; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hiraoka D, 2004, DEV BIOL, V276, P330, DOI 10.1016/j.ydbio.2004.08.036; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kalous J, 2006, BIOL CELL, V98, P111, DOI 10.1042/BC20050020; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; KISHIMOTO T, 1986, METHOD CELL BIOL, V27, P379, DOI 10.1016/S0091-679X(08)60359-3; Kishimoto T, 2003, CURR OPIN CELL BIOL, V15, P654, DOI 10.1016/j.ceb.2003.10.010; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Restuccia DF, 2010, DIS MODEL MECH, V3, P705, DOI 10.1242/dmm.004671; Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tomek W, 2005, REPRODUCTION, V130, P423, DOI 10.1530/rep.1.00754; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004	47	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	44					4487	4497		10.1038/onc.2011.155	http://dx.doi.org/10.1038/onc.2011.155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21577208				2022-12-28	WOS:000296733200004
J	Rudner, LA; Brown, KH; Dobrinski, KP; Bradley, DF; Garcia, MI; Smith, ACH; Downie, JM; Meeker, ND; Look, AT; Downing, JR; Gutierrez, A; Mullighan, CG; Schiffman, JD; Lee, C; Trede, NS; Frazer, JK				Rudner, L. A.; Brown, K. H.; Dobrinski, K. P.; Bradley, D. F.; Garcia, M. I.; Smith, A. C. H.; Downie, J. M.; Meeker, N. D.; Look, A. T.; Downing, J. R.; Gutierrez, A.; Mullighan, C. G.; Schiffman, J. D.; Lee, C.; Trede, N. S.; Frazer, J. K.			Shared acquired genomic changes in zebrafish and human T-ALL	ONCOGENE			English	Article						T-cell acute lymphoblastic leukemia (T-ALL); array comparative genome hybridization (aCGH); zebrafish; copy number aberration (CNA); leukemogenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC ZEBRAFISH; CELL TRANSPLANTATION; MODEL; ARRAY; HYBRIDIZATION; MUTATIONS; DELETION; MYC; SELECTION	T-cell acute lymphoblastic leukemia (T-ALL) is a challenging clinical entity with high rates of induction failure and relapse. To discover the genetic changes occurring in T-ALL, and those contributing to relapse, we studied zebrafish (Danio rerio) T-ALL samples using array comparative genomic hybridization (aCGH). We performed aCGH on 17 T-ALLs from four zebrafish T-ALL models, and evaluated similarities between fish and humans by comparing all D. rerio genes with copy number aberrations (CNAs) with a cohort of 75 published human T-ALLs analyzed by aCGH. Within all D. rerio CNAs, we identified 893 genes with human homologues and found significant overlap (67%) with the human CNA dataset. In addition, when we restricted our analysis to primary T-ALLs (14 zebrafish and 61 human samples), 10 genes were recurrently altered in 43 zebrafish cancers and >= 4 human cases, suggesting a conserved role for these loci in T-ALL transformation across species. We also conducted iterative allo-transplantation with three zebrafish malignancies. This technique selects for aggressive disease, resulting in shorter survival times in successive transplant rounds and modeling refractory and relapsed human T-ALL. Fifty-five percent of original CNAs were preserved after serial transplantation, demonstrating clonality between each primary and passaged leukemia. Cancers acquired an average of 34 new CNAs during passaging. Genes in these loci may underlie the enhanced malignant behavior of these neoplasias. We also compared genes from CNAs of passaged zebrafish malignancies with aCGH results from 50 human T-ALL patients who failed induction, relapsed or would eventually relapse. Again, many genes (88/164) were shared by both datasets. Further, nine recurrently altered genes in passaged D. rerio T-ALL were also found in multiple human T-ALL cases. These results suggest that zebrafish and human T-ALLs are similar at the genomic level, and are governed by factors that have persisted throughout evolution. Oncogene (2011) 30, 4289-4296; doi: 10.1038/onc.2011.138; published online 9 May 2011	[Schiffman, J. D.; Trede, N. S.; Frazer, J. K.] Univ Utah, Dept Pediat, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Brown, K. H.; Dobrinski, K. P.; Lee, C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Garcia, M. I.] Univ Texas Brownsville, Brownsville, TX 78520 USA; [Look, A. T.; Gutierrez, A.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Look, A. T.; Gutierrez, A.] Childrens Hosp, Boston, MA 02115 USA; [Downing, J. R.; Mullighan, C. G.] St Jude Childrens Hosp, Memphis, TN 38105 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Harvard University; Brigham & Women's Hospital; University of Texas System; University of Texas Rio Grande Valley; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; St Jude Children's Research Hospital	Frazer, JK (corresponding author), Univ Utah, Dept Pediat, Dept Oncol Sci, Huntsman Canc Inst, 2000 Circle Hope,HCI 4264, Salt Lake City, UT 84112 USA.	kimble.frazer@hsc.utah.edu	Downie, Jonathan/GPK-5981-2022; Mullighan, Charles/H-3253-2011; Downing, James R./N-8102-2018	Downie, Jonathan/0000-0002-5424-4401; Mullighan, Charles/0000-0002-1871-1850; Frazer, John Kimble/0000-0003-2936-2817; Brown, Kim/0000-0002-2358-8578; Gutierrez, Alejandro/0000-0002-0249-9007; Dobrinski, Kimberly/0000-0002-2626-1204	NIAID [R21-AI079784]; Huntsman Cancer Foundation; Eunice Kennedy Shriver NICHD [K08-HD053350]; CHRC at the University of Utah; PCMC Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD053350] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA042014, K08CA133103] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Huntsman Cancer Foundation; Eunice Kennedy Shriver NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); CHRC at the University of Utah; PCMC Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Brett Milash for bioinformatics analyses, Ken Boucher for statistical expertise, and Bradley Demarest for assistance with figure preparation. NST was supported by NIAID award R21-AI079784 and the Huntsman Cancer Foundation. JKF was supported by Eunice Kennedy Shriver NICHD award K08-HD053350, the CHRC at the University of Utah, and the PCMC Foundation. Huntsman Cancer Institute core facilities supported by NCI P30-CA042014 also contributed to this work.	Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Chen J, 2007, LEUKEMIA, V21, P462, DOI 10.1038/sj.leu.2404546; Choi S, 2007, BLOOD, V110, P632, DOI 10.1182/blood-2007-01-067785; Frazer JK, 2009, LEUKEMIA, V23, P1825, DOI 10.1038/leu.2009.116; Freeman JL, 2009, GENE CHROMOSOME CANC, V48, P155, DOI 10.1002/gcc.20623; Gutierrez A, 2010, J CLIN ONCOL, V28, P3816, DOI 10.1200/JCO.2010.28.3390; Gutierrez A, 2010, BLOOD, V115, P2845, DOI 10.1182/blood-2009-07-234377; Haire RN, 2000, IMMUNOGENETICS, V51, P915, DOI 10.1007/s002510000229; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Langenau DM, 2005, P NATL ACAD SCI USA, V102, P6068, DOI 10.1073/pnas.0408708102; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Maydan JS, 2007, GENOME RES, V17, P337, DOI 10.1101/gr.5690307; Meeker ND, 2010, IMMUNOGENETICS, V62, P23, DOI 10.1007/s00251-009-0407-6; Mione MC, 2010, DIS MODEL MECH, V3, P517, DOI 10.1242/dmm.004747; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Panzer-Grumayer ER, 2005, CLIN CANCER RES, V11, P7720, DOI 10.1158/1078-0432.CCR-05-1239; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Peterson SM, 2009, ZEBRAFISH, V6, P355, DOI 10.1089/zeb.2009.0600; Pinkel D, 2005, ANNU REV GENOM HUM G, V6, P331, DOI 10.1146/annurev.genom.6.080604.162140; Remke M, 2009, BLOOD, V114, P1053, DOI 10.1182/blood-2008-10-186536; Ren MQ, 2009, BLOOD, V114, P1576, DOI 10.1182/blood-2009-03-212704; RUDNER LA, 2010, CURR TRENDS IMMUNOL, V10, P119; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; Schorpp M, 2006, J IMMUNOL, V177, P2463, DOI 10.4049/jimmunol.177.4.2463; Smith ACH, 2010, BLOOD, V115, P3296, DOI 10.1182/blood-2009-10-246488; Sulong S, 2009, BLOOD, V113, P100, DOI 10.1182/blood-2008-07-166801; Thomas R, 2007, J HERED, V98, P474, DOI 10.1093/jhered/esm053; Vago L, 2009, NEW ENGL J MED, V361, P478, DOI 10.1056/NEJMoa0811036; Van Vlierberghe P, 2010, NAT GENET, V42, P338, DOI 10.1038/ng.542; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160	33	33	34	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	41					4289	4296		10.1038/onc.2011.138	http://dx.doi.org/10.1038/onc.2011.138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21552289	Green Accepted			2022-12-28	WOS:000296356300006
J	Saji, M; Narahara, K; McCarty, SK; Vasko, VV; La Perle, KM; Porter, K; Jarjoura, D; Lu, C; Cheng, SY; Ringel, MD				Saji, M.; Narahara, K.; McCarty, S. K.; Vasko, V. V.; La Perle, K. M.; Porter, K.; Jarjoura, D.; Lu, C.; Cheng, S-Y; Ringel, M. D.			Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer	ONCOGENE			English	Article						PI3 kinase; thyroid hormone receptor beta; thyrotropin; p27; gelsolin	EPITHELIAL-MESENCHYMAL TRANSITION; MOUSE MODEL; CELL-MIGRATION; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; DISTINCT ROLES; BETA-RECEPTOR; P27(KIP1); GROWTH; MICE	Akt activation is common in progressive thyroid cancer. In breast cancer, Akt1 induces primary cancer growth, but is reported to inhibit metastasis in vivo in several model systems. In contrast, clinical and in vitro studies suggest a metastasis-promoting role for Akt1 in thyroid cancer. The goal of this study was to determine the functional role of Akt1 in thyroid cancer growth and metastatic progression in vivo using thyroid hormone receptor (TR) beta(PV/PV) knock-in (PV) mice, which develop metastatic thyroid cancer. We crossed Akt1(-/-) and PV mice and compared tumor development, local progression, metastasis and histology in TR beta(PV/PV)/Akt1(+/+) (PVPV-Akt1WT) and TR beta(PV/PV)/Akt1(-/-) (PVPV-Akt1KO) mice. Mice were killed at 3, 6, 9, 12 and 15 months; necropsy was performed and serum thyroid stimulating hormone (TSH) was measured. Thyroid hyperplasia occurred in both groups beginning at 3 months; the thyroid size was greater in the PVPV-Akt1WT mice (P<0.001). In comparison with PVPV-Akt1WT mice, thyroid cancer development was delayed in the PVPV-Akt1KO mice (P = 0.003) and the degree of tumor invasiveness was reduced. The PVPV-Akt1WT mice displayed pulmonary metastases at 12 and 15 months of age, by contrast PVPV-Akt1KO mice did not develop distant metastases at 15 months of age. Despite continued expression of Akt2 or Akt3, pAkt levels were decreased and there was evidence of reduced Akt effect on p27 in the PVPV-Akt1KO thyroids. TSH levels were similarly elevated in PV mice regardless of Akt1 expression. In conclusion, thyroid cancer development and progression in TR beta(PV/PV) mice are Akt1-dependent, consistent with a tumor progression-promoting role in this murine thyroid cancer model. Oncogene (2011) 30, 4307-4315; doi: 10.1038/onc.2011.136; published online 2 May 2011	[Saji, M.; Narahara, K.; McCarty, S. K.; Ringel, M. D.] Ohio State Univ, Coll Med, Div Endocrinol, Columbus, OH 43210 USA; [Saji, M.; Narahara, K.; McCarty, S. K.; Ringel, M. D.] Ohio State Univ, Coll Med, Div Diabet, Columbus, OH 43210 USA; [Saji, M.; Narahara, K.; McCarty, S. K.; Ringel, M. D.] Ohio State Univ, Coll Med, Div Metab, Columbus, OH 43210 USA; [Saji, M.; Narahara, K.; McCarty, S. K.; Porter, K.; Jarjoura, D.; Ringel, M. D.] Arthur G James Comprehens Canc Ctr, Columbus, OH USA; [Ringel, M. D.] Ohio State Univ, Coll Med, Div Oncol, Columbus, OH 43210 USA; [Porter, K.; Jarjoura, D.] Ohio State Univ, Coll Med, Ctr Biostat, Columbus, OH 43210 USA; [Vasko, V. V.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA; [La Perle, K. M.] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA; [Lu, C.; Cheng, S-Y] NCI, NIH, Bethesda, MD 20892 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ringel, MD (corresponding author), Ohio State Univ, Coll Med, Div Endocrinol, 445D McCampbell Hall,1581 Dodd Dr, Columbus, OH 43210 USA.	matthew.ringel@osumc.edu	Saji, Motoyasu/E-4007-2011; La Perle, Krista Marie DuBray/B-3099-2015	Ringel, Matthew/0000-0001-8672-3266	NIH [P01CA124570, R01CA102572]; NATIONAL CANCER INSTITUTE [R01CA102572, P01CA124570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding for the work is from NIH grants (P01CA124570 and R01CA102572) to MDR. We appreciate the technical assistance of Michael Ostrowski, John Thompson and Jun Liu.	Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; Chen J, 2010, BLOOD, V115, P4237, DOI 10.1182/blood-2009-11-255323; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coulonval K, 2000, BIOCHEM J, V348, P351, DOI 10.1042/0264-6021:3480351; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Fernandez-Hernando C, 2009, ARTERIOSCL THROM VAS, V29, P2033, DOI 10.1161/ATVBAHA.109.196394; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Furuya F, 2007, CARCINOGENESIS, V28, P2451, DOI 10.1093/carcin/bgm174; Gonzalez E, 2009, P NATL ACAD SCI USA, V106, P7004, DOI 10.1073/pnas.0901933106; Guigon CJ, 2010, CARCINOGENESIS, V31, P1284, DOI 10.1093/carcin/bgq059; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kim CS, 2007, ENDOCRINOLOGY, V148, P1306, DOI 10.1210/en.2006-0923; Kim CS, 2009, THYROID, V19, P1317, DOI 10.1089/thy.2009.1609; Kim CS, 2005, ENDOCRINOLOGY, V146, P4456, DOI 10.1210/en.2005-0172; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Lu CX, 2010, ENDOCRINOLOGY, V151, P1929, DOI 10.1210/en.2009-1017; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Meng Q, 2006, CELL SIGNAL, V18, P2262, DOI 10.1016/j.cellsig.2006.05.019; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Ni XG, 2008, MOL MED, V14, P582, DOI 10.2119/2008-00020.Ni; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Ringel MD, 2001, CANCER RES, V61, P6105; Saito J, 2001, THYROID, V11, P339, DOI 10.1089/10507250152039073; Saji M, 2005, BIOCHEM BIOPH RES CO, V332, P167, DOI 10.1016/j.bbrc.2005.04.109; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tanaka H, 2006, INT J CANCER, V118, P1680, DOI 10.1002/ijc.21559; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200	50	37	37	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4307	4315		10.1038/onc.2011.136	http://dx.doi.org/10.1038/onc.2011.136			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21532616	Green Accepted			2022-12-28	WOS:000296356400002
J	Osei-Sarfo, K; Martello, L; Ibrahim, S; Pellicer, A				Osei-Sarfo, K.; Martello, L.; Ibrahim, S.; Pellicer, A.			The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral	ONCOGENE			English	Article						Rgr; GEFs; Ras GTPases; Ral GTPases; T-cell lymphoma	GUANINE-NUCLEOTIDE EXCHANGE; DISSOCIATION STIMULATOR; HUMAN CANCER; KAPPA-B; ACTIVATION; GENE; GTPASE; PATHWAY; EFFECTOR; SOS	The Ras superfamily of GTPases is involved in the modification of many cellular processes including cellular motility, proliferation and differentiation. Our laboratory has previously identified the RalGDS-related (Rgr) oncogene in a DMBA (7,12-dimethylbenz[alpha]anthracene)-induced rabbit squamous cell carcinoma and its human orthologue, hRgr. In this study, we analyzed the expression levels of the human hRgr transcript in a panel of human hematopoietic malignancies and found that a truncated form (diseased-truncated (Dtr-hrgr)) was significantly overexpressed in many T-cell-derived neoplasms. Although the Rgr proto-oncogene belongs to the RalGDS family of guanine nucleotide exchange factors (GEFs), we show that upon the introduction of hRgr into fibroblast cell lines, it is able to elicit the activation of both Ral and Ras GTPases. Moreover, in vitro guanine nucleotide exchange assays confirm that hRgr promotes Ral and Ras activation through GDP dissociation, which is a critical characteristic of GEF proteins. hRgr has guanine nucleotide exchange activity for both small GTPases and this activity was reduced when a point mutation within the catalytic domain (CDC25) of the protein, (cd) Dtr-hRgr, was utilized. These observations prompted the analysis of the biological effects of hRgr and (cd) hRgr expression in cultured cells. Here, we show that hRgr increases proliferation in low serum, increases invasion, reduces anchorage dependence and promotes the progression into the S phase of the cell cycle; properties that are abolished or severely reduced in the presence of the catalytic dead mutant. We conclude that the ability of hRgr to activate both Ral and Ras is responsible for its transformation-inducing phenotype and it could be an important contributor in the development of some T-cell malignancies. Oncogene (2011) 30, 3661-3671; doi:10.1038/onc.2011.93; published online 28 March 2011	[Osei-Sarfo, K.; Martello, L.; Pellicer, A.] New York Univ, Langone Med Ctr, Dept Pathol, New York, NY 10016 USA; [Ibrahim, S.] New York Univ, Langone Med Ctr, Dept Hematopathol, New York, NY 10016 USA	New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Pellicer, A (corresponding author), New York Univ, Langone Med Ctr, Dept Pathol, 550 1st Ave,MSB 594, New York, NY 10016 USA.	Angel.Pellicer@nyumc.org	MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NIH [CA50434, CA36327]; NATIONAL CANCER INSTITUTE [R01CA036327, R37CA036327, R01CA050434] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs M Philips, D Bar-Sagi and J Bos for the gift of expression plasmids. We thank Kamlesh Yadav and Pamela Sung for their assistance with the mant-guanine nucleotide exchange and cellular proliferation assays, respectively, and Dr M Liu for her assistance with the statistical analysis for the cellular proliferation assay. These studies were supported by NIH Grants CA50434 and CA36327 to AP.	ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; BOS JL, 1989, CANCER RES, V49, P4682; Boykevisch S, 2006, CURR BIOL, V16, P2173, DOI 10.1016/j.cub.2006.09.033; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; Cascone I, 2008, EMBO J, V27, P2375, DOI 10.1038/emboj.2008.166; Ceriani M, 2007, EXP CELL RES, V313, P2293, DOI 10.1016/j.yexcr.2007.03.016; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Das J, 2009, CELL, V136, P337, DOI 10.1016/j.cell.2008.11.051; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; Hernandez-Munoz I, 2003, CANCER RES, V63, P4188; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010; Leonardi P, 2002, ONCOGENE, V21, P5108, DOI 10.1038/sj.onc.1205694; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Linnemann T, 2002, J BIOL CHEM, V277, P7831, DOI 10.1074/jbc.M110800200; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Mittar D, 2004, BIOCHEM BIOPH RES CO, V322, P203, DOI 10.1016/j.bbrc.2004.07.107; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; Paulsson K, 2008, P NATL ACAD SCI USA, V105, P6708, DOI 10.1073/pnas.0800408105; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Roose JP, 2007, MOL CELL BIOL, V27, P2732, DOI 10.1128/MCB.01882-06; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SEKIDO Y, 1995, CANCER RES, V55, P1227; Senga T, 2001, J BIOL CHEM, V276, P32678, DOI 10.1074/jbc.M105749200; Shao HP, 2000, J BIOL CHEM, V275, P26914; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Sondermann H, 2004, CELL, V119, P393, DOI 10.1016/j.cell.2004.10.005; Sood R, 2000, BBA-GENE STRUCT EXPR, V1491, P285, DOI 10.1016/S0167-4781(00)00031-2; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaya A, 2007, MOL BIOL CELL, V18, P1850, DOI 10.1091/mbc.E06-08-0765; Tazmini G, 2009, BBA-MOL CELL RES, V1793, P447, DOI 10.1016/j.bbamcr.2008.12.019; Tchevkina E, 2005, ONCOGENE, V24, P329, DOI 10.1038/sj.onc.1208094; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	52	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3661	3671		10.1038/onc.2011.93	http://dx.doi.org/10.1038/onc.2011.93			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441953	Green Accepted			2022-12-28	WOS:000294244500002
J	Gramling, S; Rogers, C; Liu, G; Reisman, D				Gramling, S.; Rogers, C.; Liu, G.; Reisman, D.			Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy	ONCOGENE			English	Article						SWI/SNF; epigenetic; tumor suppressor; target therapy; chromatin remodeling; cancer therapy	CANCER CELL-LINES; SWI-SNF COMPLEX; SWI/SNF COMPLEX; TRANSCRIPTIONAL ACTIVATORS; EXPRESSION; CHROMATIN; BRG1; GENE; ARREST; ATPASE	Tumor suppressor genes and oncogenes are both commonly altered during carcinogenesis. For oncogenes and other genes that drive growth, targeting mutated or activated forms (such as the EGFR-Her2/Nneu pathway) has been shown to be an effective anti-cancer approach. Pharmacologically targeting tumor suppressor genes has not been as fruitful, as many tumor suppressor genes are irreversibly silenced through somatic mutation or entirely deleted during carcinogenesis, thereby making it difficult to restore gene function. BRM, a key SWI/SNF complex subunit and a putative tumor suppressor gene, is inactivated in 15-20% of many solid tumor types. Unlike other tumor suppressor genes, the loss of BRM has been shown to be a reversible epigenetic change, rather than an irreversible genetic alteration. Using a high throughput drug screen, we identified a number of compounds that could effectively restore BRM expression and function. Two of these compounds, RH (RH02032) and GK (GK0037), were found to be such reactivating agents. Both compounds led to robust re-expression of BRM, induced downstream expression of BRM-dependent genes and inhibited BRM-dependent growth across a wide range of BRM-deficient cancer cell lines of different origins. We therefore show, for the first time, that pharmacologic reversal of epigenetic changes of the SWI/SNF chromatic remodeling complex subunit, BRM, is a potentially viable and novel therapeutic approach. Oncogene (2011) 30, 3289-3294; doi:10.1038/onc.2011.80; published online 11 April 2011	[Gramling, S.; Rogers, C.; Reisman, D.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL 32610 USA; [Liu, G.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Dept Med, Toronto, ON, Canada; [Liu, G.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Dept Med Biophys, Toronto, ON, Canada	State University System of Florida; University of Florida; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Reisman, D (corresponding author), Univ Florida, Dept Med, Div Hematol Oncol, 2033 Mowry Rd,Off 294, Gainesville, FL 32610 USA.	dnreisman@ufl.edu	Liu, Geoffrey/N-4421-2016	Liu, Geoffrey/0000-0002-2603-7296	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; NCI [R03CA128038-02, 1R01CA136683-01A1]; NATIONAL CANCER INSTITUTE [R01CA136683, T32CA009126, R03CA128038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA028854] Funding Source: NIH RePORTER	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	GL is funded by the Alan B Brown Chair in Molecular Genomics, CCO Chair in Experimental Therapeutics and Population Studies, and the Posluns Family Foundation; Reisman lab funding for this paper is from NCI: R03CA128038-02 and 1R01CA136683-01A1.	Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, LETT DRUG DES DISCOV, V8, P93, DOI 10.2174/157018011793663840; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Morrison AJ, 2006, RES PRO CEL, V41, P109, DOI 10.1007/008; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Sansam CG, 2006, CELL CYCLE, V5, P621, DOI 10.4161/cc.5.6.2579; Shen H, 2008, CANCER RES, V68, P10154, DOI 10.1158/0008-5472.CAN-08-1794; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601	30	33	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3289	3294		10.1038/onc.2011.80	http://dx.doi.org/10.1038/onc.2011.80			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21478905	Green Accepted			2022-12-28	WOS:000293006800007
J	Terrinoni, A; Pagani, IS; Zucchi, I; Chiaravalli, AM; Serra, V; Rovera, F; Sirchia, S; Dionigi, G; Miozzo, M; Frattini, A; Ferrari, A; Capella, C; Pasquali, F; Curto, FL; Albertini, A; Melino, G; Porta, G				Terrinoni, A.; Pagani, I. S.; Zucchi, I.; Chiaravalli, A. M.; Serra, V.; Rovera, F.; Sirchia, S.; Dionigi, G.; Miozzo, M.; Frattini, A.; Ferrari, A.; Capella, C.; Pasquali, F.; Curto, F. L.; Albertini, A.; Melino, G.; Porta, G.			OTX1 expression in breast cancer is regulated by p53	ONCOGENE			English	Article						p53; OTX1; human breast cancer; cancer stem cells	HOMEOBOX GENES; MAMMARY-GLAND; STEM-CELLS; HOX GENES; DIFFERENTIATION; DIVISIONS; APOPTOSIS; FAMILY; P63	The p53 transcription factor has a critical role in cell stress response and in tumor suppression. Wild-type p53 protein is a growth modulator and its inactivation is a critical event in malignant transformation. It has been recently demonstrated that wild-type p53 has developmental and differentiation functions. Indeed an overexpression of p53 in tumor cells induces asymmetrical division avoiding self-renewal of cancer stem cells (CSCs) and instead promoting their differentiation. In this study, 28 human breast carcinomas have been analyzed for expression of wild-type p53 and of a pool of non-clustered homeobox genes. We demonstrated that orthodenticle homolog 1 gene (OTX1) is transcribed in breast cancer. We established that the p53 protein directly induces OTX1 expression by acting on its promoter. OTX1 has been described as a critical molecule for axon refinement in the developing cerebral cortex of mice, and its activity in breast cancer suggests a synergistic function with p53 in CSC differentiation. Wild-type p53 may regulate cellular differentiation by an alternative pathway controlling OTX1 signaling only in breast cancer cells and not in physiological conditions. Oncogene (2011) 30, 3096-3103; doi: 10.1038/onc.2011.31; published online 11 April 2011	[Pagani, I. S.; Pasquali, F.; Curto, F. L.; Porta, G.] Univ Insubria, Dept Expt & Clin Biomed Sci, I-21100 Varese, Italy; [Terrinoni, A.; Serra, V.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Biochem Lab, IDI IRCCS, I-00173 Rome, Italy; [Zucchi, I.; Frattini, A.; Albertini, A.] CNR, Inst Biomed Technol, Milan, Italy; [Chiaravalli, A. M.] Osped Circolo Varese, Dept Pathol, Varese, Italy; [Dionigi, G.] Univ Insubria, Dept Surg Sci, Endocrine Surg Res Ctr, I-21100 Varese, Italy; [Sirchia, S.; Miozzo, M.] Univ Milan, Dept Med Surg & Dent, Med Genet Unit, Milan, Italy; [Ferrari, A.] Fdn IRCCS Policlin San Matteo, Pavia, Italy; [Capella, C.] Univ Insubria, Osped Circolo, Ctr Insubre Biotecnol Salute Umana, Dept Human Morphol,Anat Pathol Unit, I-21100 Varese, Italy; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	University of Insubria; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Insubria; University of Milan; IRCCS Fondazione San Matteo; Ospedale Circolo & Fondazione Macchi; University of Insubria; University of Leicester	Porta, G (corresponding author), Univ Insubria, Dept Expt & Clin Biomed Sci, Via Dunant 5, I-21100 Varese, Italy.	giovanni.porta@uninsubria.it	Frattini, Annalisa/B-7684-2015; Miozzo, Monica Rosa/AAC-6401-2022; Chiaravalli, Anna Maria/AAC-4135-2022; Pagani, Ilaria Stefania/J-9856-2019; Sirchia, Silvia/AAB-2620-2019; CHIARAVALLI, Anna Maria/AAC-2679-2022; Dionigi, Gianlorenzo/R-4381-2017; TERRINONI, Alessandro/J-1533-2012	Frattini, Annalisa/0000-0002-1166-3091; Miozzo, Monica Rosa/0000-0002-6523-4575; Pagani, Ilaria Stefania/0000-0002-3216-2966; CHIARAVALLI, Anna Maria/0000-0002-3924-2117; Dionigi, Gianlorenzo/0000-0003-0864-6087; TERRINONI, Alessandro/0000-0002-7442-2252; Ferrari, Alberta/0000-0003-2525-3787; albertini, alberto/0000-0002-7989-649X; Sirchia, Silvia/0000-0002-6106-3721; porta, giovanni/0000-0001-5260-2415	Medical Research Council, UK; Alleanza contro il Cancro [ACC12-ACC6]; MIUR [RBIP06LCA9_0023]; AIRC [2008-2010_33-08]; Italian Human ProteomeNet [RBRN07BMCT_007]; Telethon [GGPO9133]; Ministero della Salute [RF06-RF07]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alleanza contro il Cancro; MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Human ProteomeNet; Telethon(Fondazione Telethon); Ministero della Salute(Ministry of Health, Italy); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Centro Grandi Strumenti University of Insubria, Fondazione Comunitaria del Varesotto-ONLUS, Ministero dell'Istruzione, dell'Universita e della Ricerca DM25591 and Banca del Monte di Lombardia, Pavia, Italy to GP. This work has also been supported by the Medical Research Council, UK; 'Alleanza contro il Cancro' (ACC12-ACC6), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-2010_33-08), Italian Human ProteomeNet RBRN07BMCT_007 and Telethon (GGPO9133) to GM, Ministero della Salute RF06-RF07 to GM. GP thanks to AIL Varese.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; CARBONE D, 1991, ONCOGENE, V6, P1691; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Danilova N, 2008, MECH DEVELOP, V125, P919, DOI 10.1016/j.mod.2008.09.003; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Ford HL, 1998, CELL BIOL INT, V22, P397, DOI 10.1006/cbir.1998.0329; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Larsen KB, 2010, J HISTOCHEM CYTOCHEM, V58, P669, DOI 10.1369/jhc.2010.955757; Levantini E, 2003, P NATL ACAD SCI USA, V100, P10299, DOI 10.1073/pnas.1734071100; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Omodei D, 2009, AM J PATHOL, V175, P2609, DOI 10.2353/ajpath.2009.090542; Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Zhang YA, 2002, MOL CELL NEUROSCI, V19, P430, DOI 10.1006/mcne.2001.1076; Zucchi I, 2008, P NATL ACAD SCI USA, V105, P16940, DOI 10.1073/pnas.0808978105; Zucchi I, 2007, P NATL ACAD SCI USA, V104, P10476, DOI 10.1073/pnas.0703071104	33	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3096	3103		10.1038/onc.2011.31	http://dx.doi.org/10.1038/onc.2011.31			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21478910	Green Published			2022-12-28	WOS:000292510100009
J	Rojas, A; Liu, G; Coleman, I; Nelson, PS; Zhang, M; Dash, R; Fisher, PB; Plymate, SR; Wu, JD				Rojas, A.; Liu, G.; Coleman, I.; Nelson, P. S.; Zhang, M.; Dash, R.; Fisher, P. B.; Plymate, S. R.; Wu, J. D.			IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR	ONCOGENE			English	Article						IL-6; STAT3; tumorigenesis; EMT; IGF-IR; prostate	GROWTH-FACTOR-I; EPITHELIAL-MESENCHYMAL TRANSITIONS; GENE-3 PEG-3 PROMOTER; CANCER-CELLS; PEA3 SITES; EXPRESSION; INTERLEUKIN-6; RECEPTOR; RAS; INFLAMMATION	As an established mediator of inflammation, interleukin-6 (IL-6) is implicated to facilitate prostate cancer progression to androgen independence through transactivation of the androgen receptor. However, whether IL-6 has a causative role in de novo prostate tumorigenesis was never investigated. We now provide the first evidence that IL-6 can induce tumorigenic conversion and further progression to an invasive phenotype of non-tumorigenic benign prostate epithelial cells. Moreover, we find that paracrine IL-6 stimulates the autocrine IL-6 loop and autocrine activation of insulin-like type I growth factor receptor (IGF-IR) to confer the tumorigenic property and also that activation of signal transducer and activator of transcription 3 (STAT3) is critical in these processes. Inhibition of STAT3 activation or IGF-IR signaling suppresses IL-6-mediated malignant conversion and the associated invasive phenotype. Inhibition of STAT3 activation suppresses IL-6-induced upregulation of IGF-IR and its ligands, namely IGF-I and IGF-II. These findings indicate that IL-6 signaling cooperates with IGF-IR signaling in the prostate microenvironment to promote prostate tumorigenesis and progression to aggressiveness. Our findings suggest that STAT3 and IGF-IR may represent potential effective targets for prevention or treatment of prostate cancer. Oncogene (2011) 30, 2345-2355; doi: 10.1038/onc.2010.605; published online 24 January 2011	[Rojas, A.; Liu, G.; Plymate, S. R.; Wu, J. D.] Univ Washington, Dept Med, Seattle, WA 98104 USA; [Coleman, I.; Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98104 USA; [Zhang, M.] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98104 USA; [Dash, R.; Fisher, P. B.] Virginia Commonwealth Univ, Dept Human & Mol Genet, VCU Inst Mol Med, Richmond, VA USA; [Dash, R.; Fisher, P. B.] Virginia Commonwealth Univ, VCU Massy Canc Ctr, Richmond, VA USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Virginia Commonwealth University; Virginia Commonwealth University	Wu, JD (corresponding author), Univ Washington, Dept Med, 325 9th Ave,Box 359625, Seattle, WA 98104 USA.	wuj@uw.edu	Zhang, Miqin/F-5537-2010	Zhang, Miqin/0000-0001-8974-1494; dash, rupesh/0000-0001-5740-7053	National Institute of Health (NIH) [1K01CA116002, NIH 1R01CA149405, PO1 CA085859, P01 CA104177]; DOD-USARMC IDEA Development Award [W81XWH-06-1-0014]; Pacific Northwest Prostate Cancer [SPORE P50-CA097186]; NATIONAL CANCER INSTITUTE [P01CA085859, R01CA097318, K01CA116002, R01CA149405, P01CA104177, P50CA097186] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD-USARMC IDEA Development Award; Pacific Northwest Prostate Cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Institute of Health (NIH) Temin Award 1K01CA116002, NIH 1R01CA149405 and DOD-USARMC IDEA Development Award W81XWH-06-1-0014 to JDW and partially supported by the Pacific Northwest Prostate Cancer SPORE P50-CA097186 (JDW) and the NIH Program Project Grant PO1 CA085859 (SRP) and P01 CA104177 (PBF). PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU Massey Cancer Center.	Al-Shanti N, 2008, GROWTH FACTORS, V26, P61, DOI 10.1080/08977190802025024; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bardia A, 2009, CURR OPIN PHARMACOL, V9, P419, DOI 10.1016/j.coph.2009.06.002; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Berger T, 2010, P NATL ACAD SCI USA, V107, P2995, DOI 10.1073/pnas.1000101107; Burtrum D, 2003, CANCER RES, V63, P8912; Coe KJ, 2007, CHEM RES TOXICOL, V20, P1277, DOI 10.1021/tx7001349; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Corcoran NM, 2003, BJU INT, V91, P545, DOI 10.1046/j.1464-410X.2003.04025.x; Damon SE, 2001, ENDOCRINOLOGY, V142, P21, DOI 10.1210/en.142.1.21; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dorff TB, 2010, CLIN CANCER RES, V16, P3028, DOI 10.1158/1078-0432.CCR-09-3122; Finley DS, 2009, J UROLOGY, V182, P1621, DOI 10.1016/j.juro.2009.06.015; Freedland SJ, 2007, EPIDEMIOL REV, V29, P88, DOI 10.1093/epirev/mxm006; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Haverkamp J, 2008, J CELL BIOCHEM, V103, P1344, DOI 10.1002/jcb.21536; Irigaray P, 2007, BIOMED PHARMACOTHER, V61, P665, DOI 10.1016/j.biopha.2007.10.008; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kojima S, 2009, INT J UROL, V16, P161, DOI 10.1111/j.1442-2042.2008.02224.x; Long RM, 2005, CLIN SCI, V108, P1, DOI 10.1042/CS20040241; Nakashima J, 2000, CLIN CANCER RES, V6, P2702; O'Malley Rebecca L, 2006, Can J Urol, V13 Suppl 2, P11; Paule B, 2007, WORLD J UROL, V25, P477, DOI 10.1007/s00345-007-0175-6; Rosen DG, 2006, METHOD ENZYMOL, V407, P660, DOI 10.1016/S0076-6879(05)07052-7; Rowinsky EK, 2007, CLIN CANCER RES, V13, p5549S, DOI 10.1158/1078-0432.CCR-07-1109; Santer FR, 2010, ENDOCR-RELAT CANCER, V17, P241, DOI 10.1677/ERC-09-0200; Soon L, 1999, MOL CELL BIOL, V19, P3816; Su Z, 2001, NUCLEIC ACIDS RES, V29, P1661, DOI 10.1093/nar/29.8.1661; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Su ZZ, 2005, P NATL ACAD SCI USA, V102, P1059, DOI 10.1073/pnas.0409141102; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Sutcliffe S, 2007, UROL ONCOL-SEMIN ORI, V25, P242, DOI 10.1016/j.urolonc.2006.09.014; Tam L, 2007, BRIT J CANCER, V97, P378, DOI 10.1038/sj.bjc.6603871; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Traynor P, 2008, DIS MARKERS, V24, P157, DOI 10.1155/2008/918087; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang XP, 2009, MOL CANCER THER, V8, P499, DOI 10.1158/1535-7163.MCT-08-0544	46	108	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2345	2355		10.1038/onc.2010.605	http://dx.doi.org/10.1038/onc.2010.605			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258401	Green Accepted			2022-12-28	WOS:000290789200006
J	Wang, X; Lu, H; Urvalek, AM; Li, T; Yu, L; Lamar, J; DiPersio, CM; Feustel, PJ; Zhao, J				Wang, X.; Lu, H.; Urvalek, A. M.; Li, T.; Yu, L.; Lamar, J.; DiPersio, C. M.; Feustel, P. J.; Zhao, J.			KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9	ONCOGENE			English	Article							FOCAL ADHESION KINASE; MATRIX-METALLOPROTEINASE INHIBITORS; KRUPPEL-LIKE FACTOR-8; E-CADHERIN; TUMOR-CELLS; REGULATES MMP-9; BONE METASTASIS; UP-REGULATION; CYCLIN D1; EXPRESSION	Epithelial to mesenchymal transition (EMT) and extracellular matrix degradation are critical for the initiation and progression of tumor invasion. We have recently identified Kruppel-like factor 8 (KLF8) as a critical inducer of EMT and invasion. KLF8 induces EMT primarily by repressing E-cadherin transcription. However, how KLF8 promotes invasion is unknown. Here, we report a novel KLF8-to-matrix metalloproteinase (MMP) 9 signaling that promotes human breast cancer invasion. To identify the potential KLF8 regulation of MMPs in breast cancer, we established two inducible cell lines that allow either KLF8 overexpression in MCF-10A or knockdown in MDA-MB-231 cells. KLF8 overexpression induced a strong increase in MMP9 expression and activity as determined by quantitative real-time PCR and zymography. This induction was well correlated with the MMP inhibitor-sensitive Matrigel invasion. Conversely, KLF8 knockdown caused the opposite changes that could be partially prevented by MMP9 overexpression. Promoter-reporter assays and chromatin and oligonucleotide precipitations determined that KLF8 directly bound and activated the human MMP9 gene promoter. Three-dimensional (3D) glandular culture showed that KLF8 expression disrupted the normal acinus formation, which could be prevented by the MMP inhibitor, whereas KLF8 knockdown corrected the abnormal 3D architecture, which could be protected by MMP9 overexpression. KLF8 knockdown promoted MDA-MB-231 cell aggregation in suspension culture, which could be prevented by MMP9 overexpression. KLF8 knockdown inhibited the lung metastasis of MDA-MB-231 cells in nude mice. Immunohistochemical staining strongly correlated the co-expression of KLF8 and MMP9 with the patient tumor invasion, metastasis and poor survival. Taken together, this work identified the KLF8 activation of MMP9 as a novel and critical signaling mechanism underlying human breast cancer invasion and metastasis. Oncogene (2011) 30, 1901-1911; doi: 10.1038/onc.2010.563; published online 13 December 2010	[Wang, X.; Lu, H.; Urvalek, A. M.; Li, T.; Yu, L.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA; [Lamar, J.; DiPersio, C. M.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Feustel, P. J.] Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA	State University System of Florida; University of Central Florida; Albany Medical College; Albany Medical College	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA.	jizhao@mail.ucf.edu	Li, Tianshu/L-6426-2014; Feustel, Paul/AAW-5157-2021; Lamar, John Michael/R-5053-2019	Li, Tianshu/0000-0002-9972-4644; Feustel, Paul/0000-0002-6963-4349; Lamar, John Michael/0000-0001-5406-8391	NCI [CA132977, CA129637]; Susan G Komen for Cure [KG090444 and KG080616]; NATIONAL CANCER INSTITUTE [R01CA129637, R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Joan Massague for kindly providing the 4175 cells and Dr Chunhong Yan and Qingfen Li and Beihai Jiang of Zhao lab for helpful comments. This work was supported by grants from NCI (CA132977) and Susan G Komen for Cure (KG090444 and KG080616) to JZ and a grant from NCI (CA129637) to CMD. XW is a Komen postdoctoral fellow.	Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Balzer EM, 2010, BREAST CANCER RES TR, V121, P65, DOI 10.1007/s10549-009-0457-3; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Cristofanilli M, 2006, SEMIN ONCOL, V33, pS9, DOI 10.1053/j.seminoncol.2006.03.016; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Dwivedi DJ, 2006, AM J PATHOL, V168, P69, DOI 10.2353/ajpath.2006.041089; Eaton SA, 2008, J BIOL CHEM, V283, P26937, DOI 10.1074/jbc.M804831200; Evans PM, 2010, CELL CYCLE, V9, P649; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Lamar JM, 2008, CANCER RES, V68, P7371, DOI 10.1158/0008-5472.CAN-08-1080; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lloyd JA, 2010, CELL CYCLE, V9, P650; Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396; McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Rahman KMW, 2006, MOL CANCER THER, V5, P2747, DOI 10.1158/1535-7163.MCT-06-0221; Rodriguez E, 2009, CELL RES, V19, P1041, DOI 10.1038/cr.2009.103; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zhang P, 2005, BLOOD CELL MOL DIS, V35, P227, DOI 10.1016/j.bcmd.2005.04.009; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	45	117	130	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1901	1911		10.1038/onc.2010.563	http://dx.doi.org/10.1038/onc.2010.563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151179	hybrid, Green Accepted			2022-12-28	WOS:000289777700006
J	Garcia-Silva, S; Martinez-Iglesias, O; Ruiz-Llorente, L; Aranda, A				Garcia-Silva, S.; Martinez-Iglesias, O.; Ruiz-Llorente, L.; Aranda, A.			Thyroid hormone receptor beta 1 domains responsible for the antagonism with the ras oncogene: role of corepressors	ONCOGENE			English	Article						thyroid hormone receptor; Ras; transformation; cyclin D1; corepressors; coactivators	TUMOR INVASIVENESS; SMRT COREPRESSOR; LIGAND-BINDING; RETINOIC ACID; MOUSE MODEL; CYCLIN D1; N-COR; TRANSCRIPTION; SUPPRESSOR; PATHWAY	The thyroid hormone receptor (TR) is a suppressor of ras-mediated responses. To characterize the receptor domains involved in this function, we analyzed a panel of TR beta 1 mutants for their ability to interfere with ras-driven cyclin D1 activation, formation of transformation foci and tumor growth in nude mice. Our results show that the domains and mechanisms responsible for the anti-transforming and anti-tumorigenic actions of the receptor are divergent from those operating in classical T3-dependent transcriptional activation. TR beta 1 mutants that do not bind co-activators and do not transactivate retained the capacity of suppressing cellular transformation and tumor growth, whereas selective mutations in the hinge region affecting corepressors recruitment abolished these actions, while preserving ligand-dependent transcription. There was a strict parallelism between anti-transforming activity of the various mutants and their ability to antagonize cyclin D1 stimulation by ras, indicating that transrepression mechanisms may have an important function in suppression of the transforming effects of the oncogene by TR beta 1. The inhibitory action of T3 on transformation was further enhanced after over-expression of corepressors, while corepressor depletion by means of small-interference RNA reversed significantly hormonal action. This shows an important functional role of endogenous corepressors in suppression of ras-mediated transformation and tumorigenesis by TR beta 1 Oncogene (2011) 30, 854-864; doi:10.1038/onc.2010.464; published online 18 October 2010	[Aranda, A.] CSIC, Inst Invest Biomed, Dept Endocrine & Nervous Syst Physiopathol, E-28029 Madrid, Spain; [Aranda, A.] Univ Autonoma Madrid, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Dept Endocrine & Nervous Syst Physiopathol, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@iib.uam.es	Aranda, Ana/ABG-8820-2020; Ruiz, Lidia/L-1620-2014; Martínez-Iglesias, Olaia Antía/A-9793-2018; Garcia-Silva, Susana/AAW-8528-2021	Aranda, Ana/0000-0002-8338-9589; Ruiz, Lidia/0000-0003-1430-9618; Martínez-Iglesias, Olaia Antía/0000-0002-7021-6865; Garcia-Silva, Susana/0000-0003-1065-0245	Ministerio de Educacion y Ciencia [BFU2007-62402, RD06/0020/0036]; Fondo de Investigaciones Sanitarias; European Grant CRESCENDO [FP-018652]	Ministerio de Educacion y Ciencia(Spanish Government); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); European Grant CRESCENDO	We are grateful to M Sanchez-Prieto and PA Chavez for technical help and to A Zambrano for TR mutants. This work was supported by Grant BFU2007-62402 from Ministerio de Educacion y Ciencia, RD06/0020/0036 and Accion Transversal de Cancer from the Fondo de Investigaciones Sanitarias and by the European Grant CRESCENDO (FP-018652).	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Aranda A, 2009, TRENDS ENDOCRIN MET, V20, P318, DOI 10.1016/j.tem.2009.03.011; Berghagen H, 2002, J BIOL CHEM, V277, P49517, DOI 10.1074/jbc.M209546200; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castillo AI, 2004, MOL CELL BIOL, V24, P502, DOI 10.1128/MCB.24.2.502-513.2004; Chan IH, 2006, ONCOGENE, V25, P3576, DOI 10.1038/sj.onc.1209389; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; De Bosscher K, 2008, EUR J PHARMACOL, V583, P290, DOI 10.1016/j.ejphar.2007.11.076; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fernandez-Majada V, 2007, CELL CYCLE, V6, P1748, DOI 10.4161/cc.6.14.4429; FILMUS J, 1994, ONCOGENE, V9, P3627; Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2009, STEROIDS, V74, P628, DOI 10.1016/j.steroids.2008.10.009; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lazar Mitchell A, 2003, Nucl Recept Signal, V1, pe001; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Martinez-Iglesias O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006428; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Mendez-Pertuz M, 2003, EMBO J, V22, P3102, DOI 10.1093/emboj/cdg295; Pascual G, 2006, TRENDS ENDOCRIN MET, V17, P321, DOI 10.1016/j.tem.2006.08.005; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Peterson TJ, 2007, MOL CELL BIOL, V27, P5933, DOI 10.1128/MCB.00237-07; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; Sanchez-Martinez R, 2006, EMBO REP, V7, P1030, DOI 10.1038/sj.embor.7400776; Song L, 2005, CANCER RES, V65, P4554, DOI 10.1158/0008-5472.CAN-04-4108; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhu XG, 2010, ONCOGENE, V29, P1909, DOI 10.1038/onc.2009.476	45	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					854	864		10.1038/onc.2010.464	http://dx.doi.org/10.1038/onc.2010.464			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956942				2022-12-28	WOS:000287444600009
J	Sugano, G; Bernard-Pierrot, I; Lae, M; Battail, C; Allory, Y; Stransky, N; Krumeich, S; Lepage, ML; Maille, P; Donnadieu, MH; Abbou, CC; Benhamou, S; Lebret, T; Sastre-Garau, X; Amigorena, S; Radvanyi, F; Thery, C				Sugano, G.; Bernard-Pierrot, I.; Lae, M.; Battail, C.; Allory, Y.; Stransky, N.; Krumeich, S.; Lepage, M-L; Maille, P.; Donnadieu, M-H; Abbou, C. C.; Benhamou, S.; Lebret, T.; Sastre-Garau, X.; Amigorena, S.; Radvanyi, F.; Thery, C.			Milk fat globule-epidermal growth factor-factor VIII (MFGE8)/lactadherin promotes bladder tumor development	ONCOGENE			English	Article						MFGE8; lactadherin; bladder carcinoma; tumor microenvironment; immune response	DISCOIDIN-DOMAIN PROTEIN; APOPTOTIC CELLS; EGF REPEAT; LACTADHERIN; CANCER; CARCINOGENESIS; MOUSE; PROGRESSION; MODEL; MICE	Milk fat globule-epidermal growth factor-factor VIII (MFGE8), also called lactadherin or SED1, is a secreted integrin-binding protein that promotes elimination of apoptotic cells by phagocytes leading to tolerogenic immune responses, and vascular endothelial growth factor (VEGF)induced angiogenesis: two important processes for cancer development. Here, by transcriptomic analysis of 228 biopsies of bladder carcinomas, we observed overexpression of MFGE8 during tumor development, correlated with expression of genes involved in cell adhesion or migration and in immune responses, but not in VEGF-mediated angiogenesis. To test whether MFGE8 expression was instrumental in bladder tumor development, or a simple consequence of this development, we used genetic ablation in a mouse model of carcinogen-induced bladder carcinoma. We showed that Mfge8 was also upregulated in mouse carcinoma, and that in its absence, Mfge8-deficient animals developed less advanced tumors. Angiogenesis was similar in carcinogen-treated Mfge8-expressing or -deficient bladders, thus ruling out a major role of the proangiogenic function of Mfge8 for its protumoral role. By contrast, the tumor-promoting role of Mfge8 was not observed anymore in mice devoid of adaptive immune system, and human tumors overexpressing MFGE8 where invaded with macrophages and regulatory T cells, thus suggesting that MFGE8/lactadherin favors development of bladder tumors at least partly by an immune system-dependent mechanism. Our observations suggest future use of MFGE8-inhibiting molecules as therapies of bladder carcinomas, and of a limited number of other human cancers, in which our analysis of public databases also revealed overexpression of MFGE8. Oncogene (2011) 30, 642-653; doi:10.1038/onc.2010.446; published online 18 October 2010	[Sugano, G.; Krumeich, S.; Amigorena, S.; Thery, C.] Inst Curie, Res Ctr, INSERM, U932, F-75248 Paris 05, France; [Bernard-Pierrot, I.; Battail, C.; Stransky, N.; Lepage, M-L; Radvanyi, F.] CNRS, UMR144, Paris, France; [Lae, M.; Amigorena, S.] Inst Curie Hosp, Dept Tumor Biol, Paris, France; [Allory, Y.; Abbou, C. C.] Hop Henri Mondor, INSERM, U955, F-94010 Creteil, France; [Allory, Y.; Abbou, C. C.] AP HP Henri Mondor Albert Chenevier Grp, Dept Urol, Creteil, France; [Allory, Y.; Maille, P.] AP HP Henri Mondor Albert Chenevier Grp, Dept Pathol, Creteil, France; [Donnadieu, M-H] Inst Curie Hosp, Dept Translat Res, Paris, France; [Abbou, C. C.] Univ Paris 12, Fac Med, Creteil, France; [Benhamou, S.] INSERM, U946, Fdn Jean Dausset, CEPH, Paris, France; [Benhamou, S.] Inst Gustave Roussy, CNRS, FRE 2939, Villejuif, France; [Lebret, T.] Hop Foch, Dept Urol, Suresnes, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Hospital Foch	Thery, C (corresponding author), Inst Curie, Res Ctr, INSERM, U932, 26 Rue Ulm, F-75248 Paris 05, France.	clotilde.thery@curie.fr	Benhamou, Simone/K-6554-2015; Benhamou, Simone/ABD-2590-2020; thery, clotilde/F-6373-2013	thery, clotilde/0000-0001-8294-6884; Sastre-Garau, Xavier/0000-0001-5992-2083; BENHAMOU, Simone/0000-0001-5853-8047; Battail, Christophe/0000-0001-6849-7824; Amigorena, Sebastian/0000-0001-8583-8416; Sugano, Gael/0000-0002-9520-7375; Radvanyi, Francois/0000-0002-5696-6424	Association pour la Recherche Contre le Cancer; La Ligue Nationale Contre le Cancer (FR: equipe labellisee); program 'Carte d'Identite des Tumeurs', initiated, developed; Ligue Nationale Contre le Cancer; Fondation de France 'Impulsion' program (CT)	Association pour la Recherche Contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); La Ligue Nationale Contre le Cancer (FR: equipe labellisee); program 'Carte d'Identite des Tumeurs', initiated, developed; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Fondation de France 'Impulsion' program (CT)	We thank Drs A-C Baglin and Y Denoux (Tumorotheque, Service d'Anatomie et Cytologie Pathologiques, CMC Foch, Suresnes, France), Dr M-J Terrier-Lacombe (Service de Pathologie, Institut Gustave Roussy, Villejuif, France), and Professor K Leroy (Plateforme de Ressources Biologiques, Pole de Recherche Clinique, APHP, Hopital Henri Mondor, Creteil, France) for providing tumor samples. Microbiochips SAS (Paris, France) performed and analyzed antibody microarray hybridizations. This work would not have been possible without the expertise of the Animal Facility and of the Nikon Imaging Center at Institut Curie. We thank S Barrafato and F Valenty (mouse histology), K Zemplenyi (ultrasound analyses), E Chapeaublanc (preparation of Supplementary tables), B Asselain and A Savignoni (statistics) for their help, and V Soumelis, H Kitamura and JW Pollard for critical reading of the manuscript. This work was supported by grants from Association pour la Recherche Contre le Cancer and Fondation de France 'Impulsion' program (CT), La Ligue Nationale Contre le Cancer (FR: equipe labellisee), and the program 'Carte d'Identite des Tumeurs', initiated, developed and funded by Ligue Nationale Contre le Cancer. GS was a fellow from Ministere de la Recherche et des Technologies.	Ait-Oufella H, 2007, CIRCULATION, V115, P2168, DOI 10.1161/CIRCULATIONAHA.106.662080; Andersen MH, 2000, BIOCHEMISTRY-US, V39, P6200, DOI 10.1021/bi992221r; Atabai K, 2005, MOL BIOL CELL, V16, P5528, DOI 10.1091/mbc.E05-02-0128; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; BECCI PJ, 1981, CANCER RES, V41, P927; Bu HF, 2007, J CLIN INVEST, V117, P3673, DOI 10.1172/JCI31841; CERIANI RL, 1982, P NATL ACAD SCI-BIOL, V79, P5420, DOI 10.1073/pnas.79.17.5420; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Eble J, 2004, WHO CLASSIFICATION T; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Ensslin MA, 2007, P NATL ACAD SCI USA, V104, P2715, DOI 10.1073/pnas.0610296104; Fens MHAM, 2008, BLOOD, V111, P4542, DOI 10.1182/blood-2007-06-094763; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jinushi M, 2008, CANCER RES, V68, P8889, DOI 10.1158/0008-5472.CAN-08-2147; Jinushi M, 2007, J CLIN INVEST, V117, P1902, DOI 10.1172/JCI30966; Komura H, 2009, J IMMUNOL, V182, P581, DOI 10.4049/jimmunol.182.1.581; LAROCCA D, 1991, CANCER RES, V51, P4994; MCCORMICK DL, 1981, CARCINOGENESIS, V2, P251, DOI 10.1093/carcin/2.3.251; Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104; Neutzner M, 2007, CANCER RES, V67, P6777, DOI 10.1158/0008-5472.CAN-07-0165; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Saint F, 2001, BJU INT, V88, P602, DOI 10.1046/j.1464-410X.2001.02394.x; Sharma P, 2007, SEMIN ONCOL, V34, P165, DOI 10.1053/j.seminoncol.2006.12.004; Shi JL, 2004, BBA-BIOMEMBRANES, V1667, P82, DOI 10.1016/j.bbamem.2004.09.006; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Veron P, 2005, BLOOD CELL MOL DIS, V35, P81, DOI 10.1016/j.bcmd.2005.05.001; Williams PD, 2008, NEOPLASIA, V10, P838, DOI 10.1593/neo.08432; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344	39	37	37	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					642	653		10.1038/onc.2010.446	http://dx.doi.org/10.1038/onc.2010.446			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20956946				2022-12-28	WOS:000287192000002
J	Jenkins, NC; Liu, T; Cassidy, P; Leachman, SA; Boucher, KM; Goodson, AG; Samadashwily, G; Grossman, D				Jenkins, N. C.; Liu, T.; Cassidy, P.; Leachman, S. A.; Boucher, K. M.; Goodson, A. G.; Samadashwily, G.; Grossman, D.			The p16(INK4A) tumor suppressor regulates cellular oxidative stress	ONCOGENE			English	Article						p16; oxidative stress; melanocyte; 8-oxoguanine	REACTIVE OXYGEN; HUMAN MELANOCYTES; P38 MAPK; MELANOMA; SENESCENCE; INHIBITION; GENE; REPAIR; PHOSPHORYLATION; FIBROBLASTS	Mutations or deletions in the cyclin-dependent kinase inhibitor p16(INK4A) are associated with multiple cancer types, but are more commonly found in melanoma tumors and associated with familial melanoma predisposition. Although p16 is thought to function as a tumor suppressor by negatively regulating the cell cycle, it remains unclear why the genetic compromise of p16 predisposes to melanoma over other cancers. Here we describe a novel role for p16 in regulating oxidative stress in several cell types, including melanocytes. Expression of p16 was rapidly upregulated following ultraviolet-irradiation and in response to H2O2-induced oxidative stress in a p38 stress-activated protein kinase-dependent manner. Knockdown of p16 using small interfering RNA increased intracellular reactive oxygen species (ROS) and oxidative (8-oxoguanine) DNA damage, which was further enhanced by H2O2 treatment. Elevated ROS levels were also observed in p16-depleted human keratinocytes and in whole skin and dermal fibroblasts from Cdkn2a-deficient mice. Aberrant ROS and p38 signaling in Cdkn2a-deficient fibroblasts was normalized by expression of exogenous p16. The effect of p16 depletion on ROS was not recapitulated by the knockdown of retinoblastoma protein (Rb) and did not require Rb. Finally, p16-mediated suppression of ROS could not be attributed to the potential effects of p16 on cell cycle phase. These findings suggest a potential alternate Rb-independent tumor-suppressor function of p16 as an endogenous regulator of carcinogenic intracellular oxidative stress. Compared with keratinocytes and fibroblasts, we also found increased susceptibility of melanocytes to oxidative stress in the context of p16 depletion, which may explain why the compromise of p16 predisposes to melanoma over other cancers. Oncogene (2011) 30, 265-274; doi:10.1038/onc.2010.419; published online 13 September 2010	[Jenkins, N. C.; Liu, T.; Cassidy, P.; Leachman, S. A.; Boucher, K. M.; Samadashwily, G.; Grossman, D.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Jenkins, N. C.; Boucher, K. M.; Grossman, D.] Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Cassidy, P.; Leachman, S. A.; Goodson, A. G.; Samadashwily, G.; Grossman, D.] Univ Utah, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT 84112 USA; [Cassidy, P.] Univ Utah, Hlth Sci Ctr, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, 2000 Circle Hope,Suite 5262, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu		Boucher, Kenneth/0000-0003-2833-0127	NIH [AR050102, CA125761]; Department of Dermatology; Huntsman Cancer Foundation;  [P30 CA042014]; NATIONAL CANCER INSTITUTE [R03CA125761, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Dermatology; Huntsman Cancer Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported in part by NIH grants AR050102 and CA125761, the Department of Dermatology, and the Huntsman Cancer Foundation. We acknowledge use of the DNA/peptide and Flow Cytometry core facilities and a pilot project grant supported by P30 CA042014 awarded to Huntsman Cancer Institute. We thank Bryan Welm for providing the pEI2 plasmid and technical support for our lentiviral production and the MMHCC at the National Cancer Institute for providing B6.129-Cdkn2a<SUP>tm1Rdp</SUP> mice.	Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Becker TM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-4; Becker TM, 2001, CLIN CANCER RES, V7, P3282; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Chung JS, 2009, FREE RADICAL RES, V43, P729, DOI 10.1080/10715760903038432; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Cotter MA, 2007, CLIN CANCER RES, V13, P5952, DOI 10.1158/1078-0432.CCR-07-1187; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Eiberger W, 2008, DNA REPAIR, V7, P912, DOI 10.1016/j.dnarep.2008.03.002; Flores JF, 1996, CANCER RES, V56, P5023; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Goldstein AM, 2006, CANCER RES, V66, P9818, DOI 10.1158/0008-5472.CAN-06-0494; Grammatico P, 1998, EXP DERMATOL, V7, P205, DOI 10.1111/j.1600-0625.1998.tb00325.x; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Haferkamp S, 2008, AGING CELL, V7, P733, DOI 10.1111/j.1474-9726.2008.00422.x; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Herrling T, 2006, SPECTROCHIM ACTA A, V63, P840, DOI 10.1016/j.saa.2005.10.013; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Naidu S, 2009, J IMMUNOL, V182, P7048, DOI 10.4049/jimmunol.0900006; Pashaei S, 2008, J CUTAN PATHOL, V35, P525, DOI 10.1111/j.1600-0560.2007.00865.x; Pavel S, 2004, EUR J CANCER, V40, P1423, DOI 10.1016/j.ejca.2003.11.035; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P741, DOI 10.1067/mjd.2000.103988; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; Wang HT, 2010, P NATL ACAD SCI USA, V107, P12180, DOI 10.1073/pnas.1005244107; Welm Bryan E, 2008, Cell Stem Cell, V2, P90, DOI 10.1016/j.stem.2007.10.002; Wood SR, 2006, P NATL ACAD SCI USA, V103, P4111, DOI 10.1073/pnas.0511248103; Zyrek-Betts J, 2008, J CUTAN PATHOL, V35, P651, DOI 10.1111/j.1600-0560.2007.00878.x	43	80	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					265	274		10.1038/onc.2010.419	http://dx.doi.org/10.1038/onc.2010.419			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20838381	Green Accepted			2022-12-28	WOS:000286418800002
J	Karantza, V				Karantza, V.			Keratins in health and cancer: more than mere epithelial cell markers	ONCOGENE			English	Review						keratins; cancer; invasion; diagnosis; prognosis; drug resistance	HUMAN BREAST-CANCER; PROTEIN-KINASE-C; EPIDERMOLYSIS-BULLOSA SIMPLEX; CIRCULATING TUMOR-CELLS; GENE-EXPRESSION PROFILES; DRUG-RESISTANT PHENOTYPE; MALLORY-DENK BODIES; INTERMEDIATE-FILAMENTS; CULTURED-CELLS; LIVER-DISEASE	Keratins are the intermediate filament (IF)-forming proteins of epithelial cells. Since their initial characterization almost 30 years ago, the total number of mammalian keratins has increased to 54, including 28 type I and 26 type II keratins. Keratins are obligate heteropolymers and, similarly to other IFs, they contain a dimeric central a-helical rod domain that is flanked by non-helical head and tail domains. The 10-nm keratin filaments participate in the formation of a proteinaceous structural framework within the cellular cytoplasm and, as such, serve an important role in epithelial cell protection from mechanical and non-mechanical stressors, a property extensively substantiated by the discovery of human keratin mutations predisposing to tissue-specific injury and by studies in keratin knockout and transgenic mice. More recently, keratins have also been recognized as regulators of other cellular properties and functions, including apico-basal polarization, motility, cell size, protein synthesis and membrane traffic and signaling. In cancer, keratins are extensively used as diagnostic tumor markers, as epithelial malignancies largely maintain the specific keratin patterns associated with their respective cells of origin, and, in many occasions, full-length or cleaved keratin expression (or lack there of) in tumors and/or peripheral blood carries prognostic significance for cancer patients. Quite intriguingly, several studies have provided evidence for active keratin involvement in cancer cell invasion and metastasis, as well as in treatment responsiveness, and have set the foundation for further exploration of the role of keratins as multifunctional regulators of epithelial tumorigenesis. Oncogene (2011) 30, 127-138; doi:10.1038/onc.2010.456; published online 4 October 2010	[Karantza, V.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ 08903 USA; [Karantza, V.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center	Karantza, V (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Div Med Oncol, Room 3550,195 Little Albany St, New Brunswick, NJ 08903 USA.	karantva@umdnj.edu			NIH [R00CA133181]; Damon Runyon Clinical Investigator Award; NATIONAL CANCER INSTITUTE [R00CA133181] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Clinical Investigator Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant R00CA133181 and a Damon Runyon Clinical Investigator Award (VK).	Anderson JM, 1996, CLIN CANCER RES, V2, P97; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Ausch C, 2009, EJSO-EUR J SURG ONC, V35, P1164, DOI 10.1016/j.ejso.2009.02.007; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; Baribault H, 1997, TRANSGENIC RES, V6, P359, DOI 10.1023/A:1018427215923; BAUMAN PA, 1994, P NATL ACAD SCI USA, V91, P5311, DOI 10.1073/pnas.91.12.5311; Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Bluemke K, 2009, CANCER EPIDEM BIOMAR, V18, P2190, DOI 10.1158/1055-9965.EPI-08-1178; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Bragulla HH, 2009, J ANAT, V214, P516, DOI 10.1111/j.1469-7580.2009.01066.x; Buning C, 2004, DIGEST LIVER DIS, V36, P388, DOI 10.1016/S1590-8658(04)00086-6; Casanova ML, 2004, FASEB J, V18, P1556, DOI 10.1096/fj.04-1683fje; Casanova ML, 1999, J CLIN INVEST, V103, P1587, DOI 10.1172/JCI5343; Cavestro GM, 2003, DIGEST LIVER DIS, V35, P416, DOI 10.1016/S1590-8658(03)00159-2; CHAN R, 1986, CANCER RES, V46, P6353; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chen N, 2009, MELANOMA RES, V19, P87, DOI 10.1097/CMR.0b013e3283252feb; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Chu PG, 2000, MODERN PATHOL, V13, P962, DOI 10.1038/modpathol.3880175; Chu PGG, 2002, MODERN PATHOL, V15, P6, DOI 10.1038/modpathol.3880483; Chu YW, 1996, AM J PATHOL, V148, P63; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CRESS AE, 1988, BIOCHEM PHARMACOL, V37, P3043, DOI 10.1016/0006-2952(88)90296-1; Felder E, 2008, AM J PHYSIOL-LUNG C, V295, pL849, DOI 10.1152/ajplung.00503.2007; Fickert P, 2003, J HEPATOL, V38, P387, DOI 10.1016/S0168-8278(02)00439-7; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fortier AM, 2010, FEBS LETT, V584, P984, DOI 10.1016/j.febslet.2010.01.045; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; Glotzer M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Habtezion A, 2005, J CELL SCI, V118, P1971, DOI 10.1242/jcs.02316; Hammer E, 2010, PROTEOMICS, V10, P99, DOI 10.1002/pmic.200800626; Harada M, 2008, EXP CELL RES, V314, P1753, DOI 10.1016/j.yexcr.2008.01.035; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hernandez BY, 2005, HUM PATHOL, V36, P275, DOI 10.1016/j.humpath.2005.01.013; Herrmann H, 2007, NAT REV MOL CELL BIO, V8, P562, DOI 10.1038/nrm2197; Herrmann H, 2009, J CLIN INVEST, V119, P1772, DOI 10.1172/JCI38214; Ignatiadis M, 2007, J CLIN ONCOL, V25, P5194, DOI 10.1200/JCO.2007.11.7762; Irvine AD, 1997, NAT GENET, V16, P184, DOI 10.1038/ng0697-184; Iwaya K, 2003, CANCER SCI, V94, P864, DOI 10.1111/j.1349-7006.2003.tb01368.x; Jaitovich A, 2008, J BIOL CHEM, V283, P25348, DOI 10.1074/jbc.M801635200; Kao WWY, 1996, INVEST OPHTH VIS SCI, V37, P2572; Karantza-Wadsworth V, 2008, METHOD ENZYMOL, V446, P61, DOI 10.1016/S0076-6879(08)01604-2; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Katsuragi K, 2007, BRIT J CANCER, V97, P550, DOI 10.1038/sj.bjc.6603909; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Knosel T, 2006, CELL ONCOL, V28, P167; Kongara S, 2010, MOL CANCER RES, V8, P873, DOI 10.1158/1541-7786.MCR-09-0494; Ku NO, 2007, HEPATOLOGY, V46, P1639, DOI 10.1002/hep.21976; Ku NO, 2006, J CELL BIOL, V174, P115, DOI 10.1083/jcb.200602146; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; Ku NO, 2003, P NATL ACAD SCI USA, V100, P6063, DOI 10.1073/pnas.0936165100; Ku NO, 2003, HEPATOLOGY, V37, P1006, DOI 10.1053/jhep.2003.50181; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; Ku NO, 2001, NEW ENGL J MED, V344, P1580, DOI 10.1056/NEJM200105243442103; Lane EB, 2004, J PATHOL, V204, P355, DOI 10.1002/path.1643; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; Lehr HA, 2000, AM J CLIN PATHOL, V114, P190, DOI 10.1309/CPUX-KWEH-7B26-YE19; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; Linder S, 2010, EXPERT REV MOL DIAGN, V10, P353, DOI 10.1586/ERM.10.14; Liu F, 2008, NEOPLASIA, V10, P1275, DOI 10.1593/neo.08810; Liu F, 2008, LIFE SCI, V83, P496, DOI 10.1016/j.lfs.2008.07.017; Liu L, 2007, ARCH PATHOL LAB MED, V131, P1290; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; Loranger A, 1997, AM J PATHOL, V151, P1673; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Mashukova A, 2009, J CELL SCI, V122, P2491, DOI 10.1242/jcs.046979; Matros E, 2006, CANCER-AM CANCER SOC, V106, P693, DOI 10.1002/cncr.21609; McGregor DK, 2004, AM J SURG PATHOL, V28, P712, DOI 10.1097/01.pas.0000126757.58474.12; Meng YG, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-96; Mertz KD, 2008, INT J CANCER, V123, P569, DOI 10.1002/ijc.23565; Mizuuchi E, 2009, INT J CANCER, V124, P1802, DOI 10.1002/ijc.24111; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1992, AM J PATHOL, V140, P427; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Na N, 2010, FASEB J, V24, P799, DOI 10.1096/fj.08-128967; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; Nikitakis NG, 2004, MODERN PATHOL, V17, P407, DOI 10.1038/modpathol.3800064; Obermajer N, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-88; Omary M B, 1998, Subcell Biochem, V31, P105; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Omary MB, 2009, J CLIN INVEST, V119, P1794, DOI 10.1172/JCI37762; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Oriolo AS, 2007, EXP CELL RES, V313, P2255, DOI 10.1016/j.yexcr.2007.02.030; Peters B, 2001, MOL BIOL CELL, V12, P1775, DOI 10.1091/mbc.12.6.1775; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; Ridge KM, 2005, J BIOL CHEM, V280, P30400, DOI 10.1074/jbc.M504239200; RIOPEL CL, 1993, CELL MOTIL CYTOSKEL, V26, P77, DOI 10.1002/cm.970260108; Rolli CG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008726; Schmitz-Winnenthal FH, 2006, SURGERY, V139, P104, DOI 10.1016/j.surg.2005.06.058; Schutte B, 2004, EXP CELL RES, V297, P11, DOI 10.1016/j.yexcr.2004.02.019; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Sivaramakrishnan S, 2008, P NATL ACAD SCI USA, V105, P889, DOI 10.1073/pnas.0710728105; Sivaramakrishnan S, 2009, MOL BIOL CELL, V20, P2755, DOI 10.1091/mbc.E08-10-1028; Smith FJD, 2003, AM J CLIN DERMATOL, V4, P347, DOI 10.2165/00128071-200304050-00005; Soeth E, 2005, J CANCER RES CLIN, V131, P669, DOI 10.1007/s00432-005-0008-1; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stacey SN, 2009, NAT GENET, V41, P909, DOI 10.1038/ng.412; Stefansson IM, 2006, INT J CANCER, V118, P1227, DOI 10.1002/ijc.21415; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; Strnad P, 2010, GASTROENTEROLOGY, V139, P828, DOI 10.1053/j.gastro.2010.06.007; Styers ML, 2005, TRAFFIC, V6, P359, DOI 10.1111/j.1600-0854.2005.00286.x; Suresh S, 2005, ACTA BIOMATER, V1, P15, DOI 10.1016/j.actbio.2004.09.001; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Toivola DA, 2004, HEPATOLOGY, V40, P459, DOI 10.1002/hep.20277; Toivola DM, 2008, AM J PATHOL, V172, P882, DOI 10.2353/ajpath.2008.070830; Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004; Toivola DM, 2002, MOL BIOL CELL, V13, P1857, DOI 10.1091/mbc.01-12-0591; Treiber M, 2006, J MOL MED, V84, P1015, DOI 10.1007/s00109-006-0096-7; Uenishi T, 2008, ANN SURG ONCOL, V15, P583, DOI 10.1245/s10434-007-9650-y; Ulukaya E, 2007, LUNG CANCER, V56, P399, DOI 10.1016/j.lungcan.2007.01.015; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; van den IJssel P, 1999, CURR BIOL, V9, pR103, DOI 10.1016/S0960-9822(99)80061-X; Vijayaraj Preethi, 2007, Methods Mol Biol, V360, P203; Vijayaraj P, 2009, J CELL BIOL, V187, P175, DOI 10.1083/jcb.200906094; Wang J, 2009, LIVER INT, V29, P1338, DOI 10.1111/j.1478-3231.2009.02081.x; Weckermann D, 2009, J CLIN ONCOL, V27, P1549, DOI 10.1200/JCO.2008.17.0563; Winter H, 1998, J INVEST DERMATOL, V111, P955, DOI 10.1046/j.1523-1747.1998.00456.x; Woelfle U, 2004, CLIN CANCER RES, V10, P2670, DOI 10.1158/1078-0432.CCR-03-0114; Woelfle U, 2003, CANCER RES, V63, P5679; Woll S, 2007, J CELL BIOL, V177, P795, DOI 10.1083/jcb.200703174; Xenidis N, 2009, J CLIN ONCOL, V27, P2177, DOI 10.1200/JCO.2008.18.0497; Yamamoto Y, 2009, BREAST CANCER-TOKYO, V16, P260, DOI 10.1007/s12282-009-0150-8; Yang XR, 2008, CLIN CANCER RES, V14, P3850, DOI 10.1158/1078-0432.CCR-07-4338; Yano S, 2004, J INVEST DERMATOL, V122, P783, DOI 10.1111/j.0022-202X.2004.22328.x; Yaziji H, 2006, MODERN PATHOL, V19, P514, DOI 10.1038/modpathol.3800534; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zatloukal K, 2000, AM J PATHOL, V156, P1263, DOI 10.1016/S0002-9440(10)64997-8; Zatloukal K, 2007, EXP CELL RES, V313, P2033, DOI 10.1016/j.yexcr.2007.04.024	143	317	328	4	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					127	138		10.1038/onc.2010.456	http://dx.doi.org/10.1038/onc.2010.456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20890307	Green Accepted			2022-12-28	WOS:000286438900001
J	Malik, SA; Orhon, I; Morselli, E; Criollo, A; Shen, S; Marino, G; BenYounes, A; Benit, P; Rustin, P; Maiuri, MC; Kroemer, G				Malik, S. A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Marino, G.; BenYounes, A.; Benit, P.; Rustin, P.; Maiuri, M. C.; Kroemer, G.			BH3 mimetics activate multiple pro-autophagic pathways	ONCOGENE			English	Article						autophagy; Beclin 1; Bcl-2 family protein; ABT737	BH3-ONLY PROTEINS; BCL-2 FAMILY; BECLIN 1; INDUCTION; COMPLEX; CELLS; IKK	The BH3 mimetic ABT737 induces autophagy by competitively disrupting the inhibitory interaction between the BH3 domain of Beclin 1 and the anti-apoptotic proteins Bcl-2 and Bcl-XL, thereby stimulating the Beclin 1-dependent allosteric activation of the pro-autophagic lipid kinase VPS34. Here, we examined whether ABT737 stimulates other pro-autophagic signal-transduction pathways. ABT737 caused the activating phosphorylation of AMP-dependent kinase (AMPK) and of the AMPK substrate acetyl CoA carboxylase, the activating phosphorylation of several subunits of the inhibitor of NF-kappa B (I kappa B) kinase (IKK) and the hyperphosphorylation of the IKK substrate I kappa B, inhibition of the activity of mammalian target of rapamycin (mTOR) and consequent dephosphorylation of the mTOR substrate S6 kinase. In addition, ABT737 treatment dephosphorylates (and hence likewise inhibits) p53, glycogen synthase kinase-3 and Akt. All these effects were shared by ABT737 and another structurally unrelated BH3 mimetic, HA14-1. Functional experiments revealed that pharmacological or genetic inhibition of IKK, Sirtuin and the p53-depleting ubiquitin ligase MDM2 prevented ABT737-induced autophagy. These results point to unexpected and pleiotropic proautophagic effects of BH3 mimetics involving the modulation of multiple signalling pathways. Oncogene (2011) 30, 3918-3929; doi:10.1038/onc.2011.104; published online 4 April 2011	[Malik, S. A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Marino, G.; BenYounes, A.; Maiuri, M. C.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, Val De Marne, France; [Malik, S. A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Marino, G.; BenYounes, A.; Maiuri, M. C.; Kroemer, G.] Univ Paris 11, Villejuif, France; [Benit, P.; Rustin, P.] INSERM, U676, Paris, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europe Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, Val De Marne, France.	kroemer@orange.fr	GARCÍA, GUILLERMO MARIÑO/AAI-8015-2020; Kroemer, Guido/AAY-9859-2020; orhon, idil/AAB-1940-2020; Malik, Shoaib Ahmad/O-7022-2017; GARCÍA, GUILLERMO MARIÑO/J-1726-2012; marino, guillermo/HGB-8664-2022; KROEMER, Guido/B-4263-2013; SHEN, Shensi/AAW-2735-2020	orhon, idil/0000-0002-0779-8719; Malik, Shoaib Ahmad/0000-0002-0843-8512; GARCÍA, GUILLERMO MARIÑO/0000-0003-1960-1677; KROEMER, Guido/0000-0002-9334-4405; SHEN, Shensi/0000-0002-5087-8220; Criollo, Alfredo/0000-0002-2737-7751	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); AXA Foundation; European Commission; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France; Higher Education Commission (HEC) of Pakistan	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); AXA Foundation; European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); Higher Education Commission (HEC) of Pakistan(Higher Education Commission of Pakistan)	We thank Drs B Vogelstein (John Hopkins University, Bethesda, MD, USA) and S Korsmeyer (Harvard University) for HCT116 cells and double-knockout MEF, respectively. We thank Dr K-L Guan for Rheb constructs. GK is supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), AXA Foundation (Chair for Longevity Research), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain, ArtForce), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa) and Canceropole Ile-de-France. SA Malik is the recipient of a grant from the Higher Education Commission (HEC) of Pakistan.	Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Benit P, 2006, CLIN CHIM ACTA, V374, P81, DOI 10.1016/j.cca.2006.05.034; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2009, ONCOGENE, V28, P2125, DOI 10.1038/onc.2009.83; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Galluzzi L, 2008, CURR MOL MED, V8, P78; Harborth J, 2001, J CELL SCI, V114, P4557; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kessel D, 2007, CANCER LETT, V249, P294, DOI 10.1016/j.canlet.2006.09.009; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74; Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Zhang XD, 2009, J NEUROSCI RES, V87, P3600, DOI 10.1002/jnr.22152; Zhou XM, 2009, P NATL ACAD SCI USA, V106, P8923, DOI 10.1073/pnas.0903621106	38	91	95	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	37					3918	3929		10.1038/onc.2011.104	http://dx.doi.org/10.1038/onc.2011.104			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21460857				2022-12-28	WOS:000294890400002
J	Lara, R; Mauri, FA; Taylor, H; Derua, R; Shia, A; Gray, C; Nicols, A; Shiner, RJ; Schofield, E; Bates, PA; Waelkens, E; Dallman, M; Lamb, J; Zicha, D; Downward, J; Seckl, MJ; Pardo, OE				Lara, R.; Mauri, F. A.; Taylor, H.; Derua, R.; Shia, A.; Gray, C.; Nicols, A.; Shiner, R. J.; Schofield, E.; Bates, P. A.; Waelkens, E.; Dallman, M.; Lamb, J.; Zicha, D.; Downward, J.; Seckl, M. J.; Pardo, O. E.			An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis	ONCOGENE			English	Article						ribosomal S6 kinase 1; metastasis; lung cancer; siRNA screen; VASP	RIBOSOMAL S6 KINASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN; HUMAN BREAST-CANCER; CELL-MIGRATION; ACTIN CYTOSKELETON; ENA/VASP PROTEINS; PHOSPHORYLATION; EXPRESSION; PROLIFERATION; REGULATORS	We performed a kinome-wide siRNA screen and identified 70 kinases altering cell migration in A549 lung cancer cells. In particular, ribosomal S6 kinase 1 (RSK1) silencing increased, whereas RSK2 and RSK4 downregulation inhibited cell motility. In a secondary collagen-based three-dimensional invasion screen, 38 of our hits cross-validated, including RSK1 and RSK4. In two further lung cancer cell lines, RSK1 but not RSK4 silencing showed identical modulation of cell motility. We therefore selected RSK1 for further investigation. Bioinformatic analysis followed by co-immunoprecipitation-based validation revealed that the actin regulators VASP and Mena interact with RSK1. Moreover, RSK1 phosphorylated VASP on T278, a site regulating its binding to actin. In addition, silencing of RSK1 enhanced the metastatic potential of these cells in vivo using a zebrafish model. Finally, we investigated the relevance of this finding in human lung cancer samples. In isogenically matched tissue, RSK1 was reduced in metastatic versus primary lung cancer lesions. Moreover, patients with RSK1-negative lung tumours showed increased number of metastases. Our results suggest that the findings of our high-throughput in vitro screen can reliably identify relevant clinical targets and as a proof of principle, RSK1 may provide a biomarker for metastasis in lung cancer patients. Oncogene (2011) 30, 3513-3521; doi:10.1038/onc.2011.61; published online 21 March 2011	[Lara, R.; Seckl, M. J.; Pardo, O. E.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W12 0NN, England; [Mauri, F. A.; Shiner, R. J.] Histopathol Imperial Coll London, London, England; [Taylor, H.; Shia, A.; Dallman, M.; Lamb, J.] Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Dept Life Sci, Div Cell & Mol Biol, London W12 0NN, England; [Derua, R.; Waelkens, E.] Katholieke Univ Leuven, Lab Prot Fosforylatie Prote, Louvain, Belgium; [Gray, C.; Nicols, A.; Zicha, D.] London Res Inst, Light Microscopy Dept, London, England; [Schofield, E.; Bates, P. A.] London Res Inst, Biomol Modelling Lab, London, England; [Lara, R.; Downward, J.] London Res Inst, Canc Res UK, Signal Transduct Lab, London, England	Imperial College London; Imperial College London; Imperial College London; KU Leuven; Cancer Research UK	Seckl, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Hammersmith Campus,Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.	m.seckl@imperial.ac.uk; o.pardo@imperial.ac.uk	Bates, Paul A/AAF-8561-2020; Pardo, Oliver/AEM-2071-2022; Lara, Romain/AAE-8108-2020; Zicha, Daniel/H-9310-2016; Downward, Julian/A-3251-2012	Bates, Paul A/0000-0003-0621-0925; Pardo, Oliver/0000-0003-2223-1435; Downward, Julian/0000-0002-2331-4729; Zicha, Daniel/0000-0002-8808-8064; Mauri, Francesco/0000-0003-4818-8500; Dallman, Margaret/0000-0002-9079-3344	Cancer Treatment and Research Trust, Cancer Research UK, Department of Health; Experimental Cancer Medicine Centre; Cancer Research UK [10748] Funding Source: researchfish	Cancer Treatment and Research Trust, Cancer Research UK, Department of Health(Cancer Research UK); Experimental Cancer Medicine Centre; Cancer Research UK(Cancer Research UK)	This work was supported by grants from Cancer Treatment and Research Trust, Cancer Research UK, Department of Health and our Experimental Cancer Medicine Centre.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Benz PM, 2009, J CELL SCI, V122, P3954, DOI 10.1242/jcs.044537; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; Blume C, 2007, J BIOL CHEM, V282, P4601, DOI 10.1074/jbc.M608866200; Cavanna T, 2007, J CELL SCI, V120, P606, DOI 10.1242/jcs.000273; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Clark DE, 2005, CANCER RES, V65, P3108; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Dertsiz L, 2005, THORAX, V60, P576, DOI 10.1136/thx.2004.037622; Fox BP, 2009, ONCOGENE, V28, P1706, DOI 10.1038/onc.2009.18; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gurzu S, 2008, ROM J MORPHOL EMBRYO, V49, P345; Han G, 2008, ONCOL REP, V20, P929, DOI 10.3892/or_00000093; Herberger B, 2007, CLIN CANCER RES, V13, P4795, DOI 10.1158/1078-0432.CCR-07-0738; Hu LD, 2008, ONCOL REP, V19, P1015; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040; Jonsson PF, 2006, BIOINFORMATICS, V22, P2291, DOI 10.1093/bioinformatics/btl390; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Lee SLC, 2009, P NATL ACAD SCI USA, V106, P19485, DOI 10.1073/pnas.0909228106; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Marques IJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-128; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Smith JA, 2005, CANCER RES, V65, P1027; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Toyoda A, 2009, INT J ONCOL, V34, P53, DOI 10.3892/ijo_00000128; Trichet L, 2008, J CELL BIOL, V181, P19, DOI 10.1083/jcb.200710168; Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; Zimmermann J, 2002, BIOCHEMISTRY-US, V41, P11143, DOI 10.1021/bi020379x	38	68	69	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	32					3513	3521		10.1038/onc.2011.61	http://dx.doi.org/10.1038/onc.2011.61			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423205				2022-12-28	WOS:000293782300004
J	Weigelt, B; Warne, PH; Downward, J				Weigelt, B.; Warne, P. H.; Downward, J.			PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs	ONCOGENE			English	Article						PIK3CA; PTEN; mTOR; everolimus; PP242; breast cancer	DUAL PI3K/MTOR INHIBITOR; MAMMALIAN PROTEIN; HIGH-FREQUENCY; PHASE-II; PATHWAY; PI3K; GENE; KINASE; GROWTH; TEMSIROLIMUS	The phosphatidylinositol 3-kinase (PI3K) pathway is commonly activated in breast cancers due to frequent mutations in PIK3CA, loss of expression of PTEN or over-expression of receptor tyrosine kinases. PI3K pathway activation leads to stimulation of the key growth and proliferation regulatory kinase mammalian target of rapamycin (mTOR), which can be inhibited by rapamycin analogues and by kinase inhibitors; the effectiveness of these drugs in breast cancer treatment is currently being tested in clinical trials. To identify the molecular determinants of response to inhibitors that target mTOR via different mechanisms in breast cancer cells, we investigated the effects of pharmacological inhibition of mTOR using the allosteric mTORC1 inhibitor everolimus and the active-site mTORC1/mTORC2 kinase inhibitor PP242 on a panel of 31 breast cancer cell lines. We demonstrate here that breast cancer cells harbouring PIK3CA mutations are selectively sensitive to mTOR allosteric and kinase inhibitors. However, cells with PTEN loss of function are not sensitive to these drugs, suggesting that the functional consequences of these two mechanisms of activation of the mTOR pathway are quite distinct. In addition, a subset of HER2-amplified cell lines showed increased sensitivity to PP242, but not to everolimus, irrespective of the PIK3CA/PTEN status. These selective sensitivities were confirmed in more physiologically relevant three-dimensional cell culture models. Our findings provide a rationale to guide selection of breast cancer patients who may benefit from mTOR inhibitor therapy and highlight the importance of accurately assessing the expression of PTEN protein and not just its mutational status. Oncogene (2011) 30, 3222-3233; doi:10.1038/onc.2011.42; published online 28 February 2011	[Weigelt, B.; Warne, P. H.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	julian.downward@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Miriam Molina Arcas, Ralph Fritsch, Elza de Bruin, Charles Swanton (CRUK London Research Institute) and Maryou Lambros and Jorge Reis-Filho (Breakthrough Breast Cancer Centre, London, UK) for helpful discussions, technical advice or critical reading of the manuscript, members of the LRI Equipment Park for sequencing and of the LRI FACS facility for cell-cycle analysis. We thank Morri Feldman and Kevan Shokat (UCSF) for providing PP242. This work was funded by Cancer Research UK.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Atkins MB, 2009, NAT REV DRUG DISCOV, V8, P535, DOI 10.1038/nrd2924; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130; Cobleigh MA, 2003, SEMIN ONCOL, V30, P117, DOI 10.1053/j.seminoncol.2003.08.013; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dan S, 2010, CANCER RES, V70, P4982, DOI 10.1158/0008-5472.CAN-09-4172; Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21; Del Bufalo D, 2006, CANCER RES, V66, P5549, DOI 10.1158/0008-5472.CAN-05-2825; Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; FORBES SA, 2008, CURR PROTOC HUM GE S, V57; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hu XL, 2009, MOL CANCER RES, V7, P511, DOI 10.1158/1541-7786.MCR-08-0107; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Janku F, 2011, MOL CANCER THER, V10, P558, DOI 10.1158/1535-7163.MCT-10-0994; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107; Masters JRW, 2010, NAT REV CANCER, V10, P441, DOI 10.1038/nrc2852; Pallares J, 2005, MODERN PATHOL, V18, P719, DOI 10.1038/modpathol.3800347; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Roidl A, 2010, ONCOGENE, V29, P1543, DOI 10.1038/onc.2009.432; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Serebriiskii I, 2008, MATRIX BIOL, V27, P573, DOI 10.1016/j.matbio.2008.02.008; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tomlinson GE, 1998, CANCER RES, V58, P3237; Torbett NE, 2008, BIOCHEM J, V415, P97, DOI 10.1042/BJ20080639; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Wang X, 2008, ONCOGENE, V27, P5454, DOI 10.1038/onc.2008.242; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhang SY, 2010, CLIN CANCER RES, V16, P4325, DOI 10.1158/1078-0432.CCR-09-2990	63	148	154	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3222	3233		10.1038/onc.2011.42	http://dx.doi.org/10.1038/onc.2011.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21358673				2022-12-28	WOS:000293006800002
J	Goparaju, CM; Blasberg, JD; Volinia, S; Palatini, J; Ivanov, S; Donington, JS; Croce, C; Carbone, M; Yang, H; Pass, HI				Goparaju, C. M.; Blasberg, J. D.; Volinia, S.; Palatini, J.; Ivanov, S.; Donington, J. S.; Croce, C.; Carbone, M.; Yang, H.; Pass, H. I.			Onconase mediated NFK beta downregulation in malignant pleural mesothelioma	ONCOGENE			English	Article						mesothelioma; microRNA; multidrug resistance	CYTOTOXIC RIBONUCLEASE ONCONASE; TYROSINE KINASE INHIBITOR; HUMAN LUNG-CANCER; KAPPA-B; ANTITUMOR RIBONUCLEASE; CELL-LINES; EXPRESSION PROFILES; RADIATION RESPONSE; INDUCED APOPTOSIS; DRUG-RESISTANCE	Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFK beta) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0-20 mu g/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription-PCR (RT-PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFK beta expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT-PCR and western blotting. Treatment with 20 mu g/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs. Oncogene (2011) 30, 2767-2777; doi: 10.1038/onc.2010.643; published online 14 February 2011	[Goparaju, C. M.; Donington, J. S.; Pass, H. I.] NYU, Med Ctr, Dept Cardiothorac Surg, New York, NY 10016 USA; [Blasberg, J. D.] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Med Ctr, Dept Gen Surg, New York, NY 10032 USA; [Volinia, S.; Palatini, J.; Croce, C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Ivanov, S.] Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nasville, TN USA; [Carbone, M.; Yang, H.] Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA	New York University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Vanderbilt University; Cancer Research Center of Hawaii; University of Hawaii System	Pass, HI (corresponding author), NYU, Med Ctr, Dept Cardiothorac Surg, 530 1st Ave,Suite 9V, New York, NY 10016 USA.	Harvey.Pass@nyumc.org	Young, Richard A/F-6495-2012; Volinia, Stefano/A-3029-2010; Volinia, Stefano/AAA-9264-2019	Young, Richard A/0000-0001-8855-8647; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Pass, Harvey/0000-0003-3222-3471; Palatini, Jeffrey/0000-0001-9280-4417; Ivanov, Sergey/0000-0001-9770-7237	NCI/NIH EDRN Biomarker Discovery Laboratory [UO1CA1111295, 1PO1 CA114047-D1A1]; NATIONAL CANCER INSTITUTE [P01CA114047] Funding Source: NIH RePORTER	NCI/NIH EDRN Biomarker Discovery Laboratory(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Ranpirnase was provided by AlphaCell Corporation, Paramus, NJ, USA. We also wish to acknowledge the generous support of Belluck and Fox, LPA for this project. Supported by NCI/NIH EDRN Biomarker Discovery Laboratory Grant UO1CA1111295 to Dr Pass and 1PO1 CA114047-D1A1 to Dr Carbone.	Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ardelt B, 2007, INT J ONCOL, V31, P663; Ardelt B, 2003, CELL CYCLE, V2, P22, DOI 10.4161/cc.2.1.232; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cao XB, 2007, CANCER BIOL THER, V6, P246, DOI 10.4161/cbt.6.2.3626; Carbone M, 2007, ONCOGENE, V26, P6959, DOI 10.1038/sj.onc.1210515; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Davidson AL, 2008, MICROBIOL MOL BIOL R, V72, P317, DOI 10.1128/MMBR.00031-07; Deptala A, 1998, INT J ONCOL, V13, P11; Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1; Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Gordon GJ, 2007, J PATHOL, V211, P439, DOI 10.1002/path.2120; Halicka DH, 2002, INT J ONCOL, V21, P1245; Iordanov MS, 2000, CANCER RES, V60, P1983; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Kasashima K, 2004, BIOCHEM BIOPH RES CO, V322, P403, DOI 10.1016/j.bbrc.2004.07.130; Kaufman AJ, 2008, EXPERT REV ANTICANC, V8, P293, DOI 10.1586/14737140.8.2.293; Kbeck A, 2008, FUTURE ONCOL, V4, P341, DOI 10.2217/14796694.4.3.341; Khokhar NZ, 2001, CLIN CANCER RES, V7, P3199; Kim DH, 2007, ADV EXP MED BIOL, V599, P53; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lee I, 2008, EXPERT OPIN BIOL TH, V8, P813, DOI 10.1517/14712598.8.6.813 ; Lee I, 2007, IN VIVO, V21, P721; Lee JE, 2008, BIODRUGS, V22, P53, DOI 10.2165/00063030-200822010-00006; Littlejohn JE, 2008, INT J CANCER, V123, P202, DOI 10.1002/ijc.23452; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MIKULSKI SM, 1992, BRIT J CANCER, V66, P304, DOI 10.1038/bjc.1992.261; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Pavlakis N, 2006, EXPERT OPIN BIOL TH, V6, P391, DOI 10.1517/14712598.6.4.391; Porta C, 2008, BIOL-TARGETS THER, V2, P601; RECK M, 2009, J CLIN ONCOL S, V27, pNIL96; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Rybak SM, 1996, J NATL CANCER I, V88, P747, DOI 10.1093/jnci/88.11.747; Saxena SK, 2002, J BIOL CHEM, V277, P15142, DOI 10.1074/jbc.M108115200; Shi Z, 2007, CANCER RES, V67, P11012, DOI 10.1158/0008-5472.CAN-07-2686; Shi Z, 2009, ONCOL REP, V21, P483, DOI 10.3892/or_00000248; Shukla S, 2009, DRUG METAB DISPOS, V37, P359, DOI 10.1124/dmd.108.024612; Singh UP, 2007, J MOL BIOL, V371, P93, DOI 10.1016/j.jmb.2007.04.071; Soini Y, 2001, ANN ONCOL, V12, P1239, DOI 10.1023/A:1012292230480; Soini Y, 1999, CLIN CANCER RES, V5, P3508; Symanowski J, 2009, J THORAC ONCOL, V4, P149, DOI 10.1097/JTO.0b013e318194f991; Tsai SY, 2004, INT J ONCOL, V25, P1745; Varkonyi-Gasic E, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-12; Wang XJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r65; WU YN, 1993, J BIOL CHEM, V268, P10686; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z; Zhao H, 2008, CELL CYCLE, V7, P3258, DOI 10.4161/cc.7.20.6855	57	47	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2767	2777		10.1038/onc.2010.643	http://dx.doi.org/10.1038/onc.2010.643			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21317924	Green Accepted			2022-12-28	WOS:000291678500007
J	Testoni, B; Schinzari, V; Guerrieri, F; Gerbal-Chaloin, S; Blandino, G; Levrero, M				Testoni, B.; Schinzari, V.; Guerrieri, F.; Gerbal-Chaloin, S.; Blandino, G.; Levrero, M.			p53-paralog DNp73 oncogene is repressed by IFN alpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor	ONCOGENE			English	Article						transcription; p53 family; epigenetics; chromatin dynamics; apoptosis	HEPATOCELLULAR-CARCINOMA DEVELOPMENT; INTERFERON-ALPHA; HEPATITIS-C; COMBINATION THERAPY; CURATIVE TREATMENT; GENE-EXPRESSION; PROTEIN EED; APOPTOSIS; P53; METAANALYSIS	The DNp73 proteins act as trans-repressors of p53 and p73-dependent transcription and exert both anti-apoptotic activity and pro-proliferative activity. DNp73s are frequently up-regulated in a variety of human cancers, including human hepatocellular carcinomas (HCCs). Increased levels of DNp73 proteins confer to HCC cells resistance to apoptosis and, irrespective to p53 status, a chemoresistant phenotype. Here, we show that interferon (IFN)alpha down-regulates DNp73 expression in primary human hepatocytes (PHHs) and HCC cell lines. IFN alpha has been used as pro-apoptotic agent in the treatment of malignancies and there is increasing evidence of IFN alpha effectiveness in HCC treatment and prevention of recurrence. The precise mechanisms by which class I IFNs exert their anti-proliferative and anti-tumor activity remain unclear. IFN alpha binding to its receptor activates multiple intracellular signaling cascades regulating the transcription of numerous direct target genes through the recruitment of a complex comprising of STAT1, STAT2 and IFN regulatory factor (IRF) 9 to their promoters. We found that, in response to IFN alpha, the P2p73 promoter undergoes substantial chromatin remodeling. Histone deacetylases (HDACs) replace histone acetyl transferases. STAT2 is recruited onto the endogenous P2p73 promoter together with the polycomb group protein Ezh2, leading to increased H3K27 methylation and transcriptional repression. The reduction of DNp73 levels by IFN alpha is paralleled by an increased susceptibility to IFN alpha-triggered apoptosis of Huh7 hepatoma cells. Our results show, for the first time, that IFN-stimulated gene factor 3 recruitment may serve both in activating and repressing gene expression and identify the down-regulation of DNp73 as an additional mechanism to counteract the chemoresistance of liver cancer cells. Oncogene (2011) 30, 2670-2678; doi:10.1038/onc.2010.635; published online 14 March 2011	[Testoni, B.; Schinzari, V.; Guerrieri, F.; Levrero, M.] Fdn A Cesalpino, Gene Express Lab, Rome, Italy; [Testoni, B.; Levrero, M.] Univ Roma La Sapienza, Dept Internal Med, Rome, Italy; [Testoni, B.; Blandino, G.; Levrero, M.] IRE, Rome Oncogen Ctr, Rome, Italy; [Schinzari, V.; Guerrieri, F.; Levrero, M.] LEA INSERM U785, Villejuif, France; [Gerbal-Chaloin, S.] INSERM U632, Inst Rech Biotherapie, Montpellier, France	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Testoni, B (corresponding author), Univ Roma La Sapienza, Gene Express Lab, Dipartimento Med Interna, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.	barbara.testoni@uniroma1.it; massimo.levrero@uniroma1.it	GERBAL-CHALOIN, sabine/M-8783-2017; Guerrieri, Francesca/K-5504-2016; guerrieri, francesca/G-3908-2013; Levrero, Massimo/G-5680-2016; TESTONI, Barbara/F-3767-2017	GERBAL-CHALOIN, sabine/0000-0002-2549-7899; Guerrieri, Francesca/0000-0003-2751-6050; Levrero, Massimo/0000-0002-4978-0875; Guerrieri, Francesca/0000-0002-2021-4394; TESTONI, Barbara/0000-0001-5588-5465	AIRC; European Community [LSHC-CT-2004-503576]; MIUR-Cofin and Progetti di Ateneo; Sapienza University of Rome; Schering-Plough; AICF (American Italian Cancer Foundation); Fondazione Adriano Buzzati-Traverso; Fondazione A Cesalpino; Rome Oncogenomic Center at the Regina Elena Cancer Institute	AIRC(Fondazione AIRC per la ricerca sul cancro); European Community(European Commission); MIUR-Cofin and Progetti di Ateneo; Sapienza University of Rome; Schering-Plough(Merck & CompanySchering Plough Corporation); AICF (American Italian Cancer Foundation); Fondazione Adriano Buzzati-Traverso; Fondazione A Cesalpino; Rome Oncogenomic Center at the Regina Elena Cancer Institute	ML was supported by grants from AIRC, European Community (LSHC-CT-2004-503576), MIUR-Cofin and Progetti di Ateneo, Sapienza University of Rome and Schering-Plough. BT has been supported by fellowships from the AICF (American Italian Cancer Foundation) and from the Fondazione Adriano Buzzati-Traverso. FG has been supported by fellowships from the Fondazione A Cesalpino and Rome Oncogenomic Center at the Regina Elena Cancer Institute.	Belloni L, 2006, ONCOGENE, V25, P3606, DOI 10.1038/sj.onc.1209321; Breitenstein S, 2009, BRIT J SURG, V96, P975, DOI 10.1002/bjs.6731; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chattopadhyay D, 2007, CURR PHARM DESIGN, V13, P3292, DOI 10.2174/138161207782360717; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Craxi Antonio, 2005, Clin Liver Dis, V9, P329, DOI 10.1016/j.cld.2004.12.008; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Fujioka N, 2006, BIOMED RES-TOKYO, V27, P219, DOI 10.2220/biomedres.27.219; Herzer K, 2009, CANCER RES, V69, P855, DOI 10.1158/0008-5472.CAN-08-2831; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Keskinen P, 1999, VIROLOGY, V263, P364, DOI 10.1006/viro.1999.9983; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levrero M, 2000, J CELL SCI, V113, P1661; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lim R, 2006, HEPATOLOGY, V43, P1074, DOI 10.1002/hep.21170; Lok AS, 2009, GASTROENTEROLOGY, V136, P138, DOI 10.1053/j.gastro.2008.09.014; Lunghi P, 2009, CLIN CANCER RES, V15, P6495, DOI 10.1158/1078-0432.CCR-09-1229; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Melen K, 2000, J HEPATOL, V33, P764, DOI 10.1016/S0168-8278(00)80308-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Miyake Y, 2010, J VIRAL HEPATITIS, V17, P287, DOI 10.1111/j.1365-2893.2009.01181.x; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Nakaji M, 2004, CARCINOGENESIS, V25, P389, DOI 10.1093/carcin/bgh028; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Noguchi R, 2008, INT J ONCOL, V32, P193; Obi S, 2006, CANCER-AM CANCER SOC, V106, P1990, DOI 10.1002/cncr.21832; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pichard-Garcia L, 2002, METHOD ENZYMOL, V357, P311; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Shiratori Y, 2005, ANN INTERN MED, V142, P105, DOI 10.7326/0003-4819-142-2-200501180-00009; Steele JC, 2006, BRIT J CANCER, V95, P1202, DOI 10.1038/sj.bjc.6603369; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; TESTONI B, CHROMATIN DYNA UNPUB; Testoni B, 2006, CELL CYCLE, V5, P2805, DOI 10.4161/cc.5.23.3525; Uddin S, 2004, J BIOCHEM MOL BIOL, V37, P635; Uka K, 2008, ONCOLOGY-BASEL, V75, P8, DOI 10.1159/000151614; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017	48	20	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2670	2678		10.1038/onc.2010.635	http://dx.doi.org/10.1038/onc.2010.635			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21399658	Green Published, hybrid			2022-12-28	WOS:000291677800007
J	Dormoy, V; Beraud, C; Lindner, V; Thomas, L; Coquard, C; Barthelmebs, M; Jacqmin, D; Lang, H; Massfelder, T				Dormoy, V.; Beraud, C.; Lindner, V.; Thomas, L.; Coquard, C.; Barthelmebs, M.; Jacqmin, D.; Lang, H.; Massfelder, T.			LIM-class homeobox gene Lim1, a novel oncogene in human renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; developmental LIM class homeobox gene Lim1; growth; migration; VHL tumor suppressor	HORMONE-RELATED PROTEIN; FACTOR-KAPPA-B; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; MICROVESSEL DENSITY; SIGNALING PATHWAYS; KIDNEY DEVELOPMENT; PANCREATIC-CANCER; GROWTH-FACTOR; TENASCIN-C	Human clear cell renal cell carcinoma (CCC) remains resistant to therapies. The transcription factor LIM-class homeobox gene Lim1 is required for normal organogenesis, including nephrogenesis, by regulating cell movements, differentiation and growth. Its expression is controlled partly by the sonic hedgehog-Gli signaling pathway, which we have recently shown to be reactivated in human CCC. So far, no study has assessed whether Lim1 may be associated with tumorigenesis. Using a panel of human CCC cell lines expressing or not the von Hippel-Lindau tumor suppressor gene and 44 tumor/normal tissues pairs, we found that Lim1 is constitutively and exclusively reexpressed in tumors. Through Lim1 silencing or overexpressing, we show that Lim1 is a growth and survival factor in human CCC, at least through the activation of oncogenic pathways including the phosphoinositide kinase-3/Akt and nuclear factor-kappaB pathways. More importantly, in nude mice bearing human CCC tumors, Lim1 silencing abolished tumor growth through the same mechanism as in vitro. In Lim1-depleted cells and tumors, cell movements were substantially impaired because of the inhibition of expression of various proteins involved in metastatic spread, such as paxillin or tenascin-C. These findings establish that the developmental marker Lim1 acts as an oncogene in cancer cells and targeting Lim1 may constitute an innovative therapeutic intervention in human CCC. Oncogene (2011) 30, 1753-1763; doi:10.1038/onc.2010.557; published online 6 December 2010	[Dormoy, V.; Beraud, C.; Thomas, L.; Coquard, C.; Barthelmebs, M.; Massfelder, T.] Univ Strasbourg, INSERM, U682, Sect Kidney Canc & Renal Physiopathol,Sch Med, F-67085 Strasbourg, France; [Lindner, V.] Hop Mulhouse, Dept Pathol, Mulhouse, France; [Jacqmin, D.; Lang, H.] Nouvel Hop Civil Strasbourg, Dept Urol, Strasbourg, France	CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte; CHU Strasbourg	Massfelder, T (corresponding author), Univ Strasbourg, INSERM, U682, Sect Kidney Canc & Renal Physiopathol,Sch Med, F-67085 Strasbourg, France.	thierry.massfelder@medecine.u-strasbg.fr	Dormoy, Valerian/P-5109-2016; Massfelder, Thierry/I-1260-2016	Dormoy, Valerian/0000-0003-1725-371X; 	INSERM (Institut National de la Sante Et de la Recherche Medicale); University of Strasbourg; French Ligue Contre le Cancer (Comite's du Bas-Rhin et du Haut-Rhin et Comite National)	INSERM (Institut National de la Sante Et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Strasbourg; French Ligue Contre le Cancer (Comite's du Bas-Rhin et du Haut-Rhin et Comite National)	This study was sponsored by INSERM (Institut National de la Sante Et de la Recherche Medicale), by University of Strasbourg and by the French Ligue Contre le Cancer (Comite's du Bas-Rhin et du Haut-Rhin et Comite National, recipient TM). We thank Dr A Donai for helpful suggestions, Dr J Barths for allowing us to perform FACS analysis and RA Hanna for text correction.	Agouni A, 2007, CARCINOGENESIS, V28, P1893, DOI 10.1093/carcin/bgm106; Arsanious A, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-20; Baldewijns MM, 2010, J PATHOL, V221, P125, DOI 10.1002/path.2689; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Chen J, 2009, INT J ONCOL, V34, P1029, DOI 10.3892/ijo_00000228; Clark PE, 2007, CURR OPIN UROL, V17, P331, DOI 10.1097/MOU.0b013e3282c508e0; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Escudier B, 2008, BIOL-TARGETS THER, V2, P517; Friedrich CA, 1999, CANCER-AM CANCER SOC, V86, P2478, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Huang D, 2008, CANCER RES, V68, P81, DOI 10.1158/0008-5472.CAN-07-5311; Hueber PA, 2006, KIDNEY INT, V69, P1139, DOI 10.1038/sj.ki.5000136; Hueber PA, 2008, CANCER LETT, V265, P148, DOI 10.1016/j.canlet.2008.02.016; Imao T, 2004, INT J UROL, V11, P948, DOI 10.1111/j.1442-2042.2004.00931.x; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Kawakami K, 2009, CANCER RES, V69, P8603, DOI 10.1158/0008-5472.CAN-09-2534; Kobayashi A, 2005, DEVELOPMENT, V132, P2809, DOI 10.1242/dev.01858; MACLENNAN GT, 1995, UROLOGY, V46, P27, DOI 10.1016/S0090-4295(99)80153-8; Massfelder T, 2004, CANCER RES, V64, P180, DOI 10.1158/0008-5472.CAN-03-1968; Meng XN, 2009, BRIT J CANCER, V101, P327, DOI 10.1038/sj.bjc.6605154; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nativ O, 1998, UROLOGY, V51, P693, DOI 10.1016/S0090-4295(98)00019-3; Noguelra M, 2008, UROL ONCOL-SEMIN ORI, V26, P113, DOI 10.1016/j.urolonc.2007.03.028; Ohno Y, 2008, ONCOL REP, V20, P511, DOI 10.3892/or_00000035; Reidy KJ, 2009, SEMIN NEPHROL, V29, P321, DOI 10.1016/j.semnephrol.2009.03.009; Ryschich E, 2009, PANCREAS, V38, P804, DOI 10.1097/MPA.0b013e3181b9dfda; Sagalowsky Arthur I, 2002, Curr Opin Urol, V12, P371, DOI 10.1097/00042307-200209000-00001; Schedl A, 2007, NAT REV GENET, V8, P791, DOI 10.1038/nrg2205; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sjolund J, 2008, J CLIN INVEST, V118, P217, DOI 10.1172/JCI32086; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Tang J, 2008, CELL MOL LIFE SCI, V65, P2933, DOI 10.1007/s00018-008-8315-8; Venegas-Ferrin M, 2010, INT J DEV BIOL, V54, P195, DOI 10.1387/ijdb.092870mv; Yao YZ, 2007, ANN CLIN LAB SCI, V37, P39	38	27	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1753	1763		10.1038/onc.2010.557	http://dx.doi.org/10.1038/onc.2010.557			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21132009				2022-12-28	WOS:000289512200003
J	Low, JSW; Tao, Q; Ng, KM; Goh, HK; Shu, XS; Woo, WL; Ambinder, RF; Srivastava, G; Shamay, M; Chan, ATC; Popescu, NC; Hsieh, WS				Low, J. S. W.; Tao, Q.; Ng, K. M.; Goh, H. K.; Shu, X-S; Woo, W. L.; Ambinder, R. F.; Srivastava, G.; Shamay, M.; Chan, A. T. C.; Popescu, N. C.; Hsieh, W-S			A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors	ONCOGENE			English	Article						DLC1; RhoGAP; methylation; tumor suppressor gene; carcinoma; p53	GTPASE-ACTIVATING PROTEIN; STRESS-RESPONSIVE GENE; TRANSCRIPTIONAL REGULATION; HEPATOCELLULAR-CARCINOMA; MORPHOLOGICAL-CHANGES; RHOGAP PROTEIN; CELL-GROWTH; CANCER; NASOPHARYNGEAL; METHYLATION	The critical 8p22 tumor suppressor deleted in liver cancer 1 (DLC1) is frequently inactivated by aberrant CpG methylation and/or genetic deletion and implicated in tumorigeneses of multiple tumor types. Here, we report the identification and characterization of its new isoform, DLC1 isoform 4 (DLC1-i4). This novel isoform encodes an 1125-aa (amino acid) protein with distinct N-terminus as compared with other known DLC1 isoforms. Similar to other isoforms, DLC1-i4 is expressed ubiquitously in normal tissues and immortalized normal epithelial cells, suggesting a role as a major DLC1 transcript. However, differential expression of the four DLC1 isoforms is found in tumor cell lines: Isoform 1 (longest) and 3 (short thus probably nonfunctional) share a promoter and are silenced in almost all cancer and immortalized cell lines, whereas isoform 2 and 4 utilize different promoters and are frequently downregulated. DLC1-i4 is significantly downregulated in multiple carcinoma cell lines, including 2/4 nasopharyngeal, 8/16 (50%) esophageal, 4/16 (25%) gastric, 6/9 (67%) breast, 3/4 colorectal, 4/4 cervical and 2/8(25%) lung carcinoma cell lines. The functional DLC1-i4 promoter is within a CpG island and is activated by wild-type p53. CpG methylation of the DLC1-i4 promoter is associated with its silencing in tumor cells and was detected in 38-100% of multiple primary tumors. Treatment with 5-aza-20-deoxycytidine or genetic double knockout of DNMT1 and DNMT3B led to demethylation of the promoter and reactivation of its expression, indicating a predominantly epigenetic mechanism of silencing. Ectopic expression of DLC1-i4 in silenced tumor cells strongly inhibited their growth and colony formation. Thus, we identified a new isoform of DLC1 with tumor suppressive function. The differential expression of various DLC1 isoforms suggests interplay in modulating the complex activities of DLC1 during carcinogenesis. Oncogene (2011) 30, 1923-1935; doi: 10.1038/onc.2010.576; published online 10 January 2011	[Low, J. S. W.; Tao, Q.; Goh, H. K.; Woo, W. L.; Ambinder, R. F.; Shamay, M.; Hsieh, W-S] Johns Hopkins Singapore, Div Biomed Sci, Singapore, Singapore; [Low, J. S. W.; Goh, H. K.; Ambinder, R. F.; Hsieh, W-S] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117456, Singapore; [Tao, Q.; Ambinder, R. F.; Shamay, M.; Hsieh, W-S] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Tao, Q.; Ng, K. M.; Shu, X-S; Chan, A. T. C.] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol S China, Sir YK Pao Ctr Canc,Hong Kong Canc Inst,Canc Epig, Shatin, Hong Kong, Peoples R China; [Tao, Q.] Chinese Univ Hong Kong, PWH, Ctr Canc, Dept Clin Oncol,Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Srivastava, G.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Popescu, N. C.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; University of Hong Kong; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tao, Q (corresponding author), Chinese Univ Hong Kong, PWH, Ctr Canc, Dept Clin Oncol,Li Ka Shing Inst Hlth Sci, Rm 315, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk; whsieh1@jhem.jhmi.edu	Woo, Wai Lok/T-3662-2018; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Woo, Wai Lok/0000-0002-8698-7605; Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091	A*STAR; Chinese University of Hong Kong; Singapore National Research Foundation; Ministry of Education; NATIONAL CANCER INSTITUTE [ZIABC010038, P50CA096888] Funding Source: NIH RePORTER	A*STAR(Agency for Science Technology & Research (A*STAR)); Chinese University of Hong Kong(Chinese University of Hong Kong); Singapore National Research Foundation(National Research Foundation, Singapore); Ministry of Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by an A*STAR grant (Johns Hopkins Singapore, QT/WS/RA), a Chinese University of Hong Kong grant (QT) and a grant from Singapore National Research Foundation and the Ministry of Education under the Research Center of Excellence Program (WS/RA). We thank Drs Bert Vogelstein, George Tsao, (Dolly Huang), Michael Obster and Guiyuan Li for some cell lines; and DSMZ (German Collection of Microorganisms & Cell Cultures) for the KYSE cell lines (Shimada et al., Cancer 69: 277-284, 1992). We also thank Drs Wenling Han, Thomas Putti, Luke Tan for some tumor samples.	AKIYAMA Y, 1995, TFSEARCH SEARC UNPUB; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; CHEUNG WY, 1993, AM J CLIN PATHOL, V100, P502, DOI 10.1093/ajcp/100.5.502; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990; Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Flicek P, 2010, NUCLEIC ACIDS RES, V38, pD557, DOI 10.1093/nar/gkp972; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171; Guda C, 2004, NUCLEIC ACIDS RES, V32, pW372, DOI 10.1093/nar/gkh374; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Ko FCF, 2010, LIVER INT, V30, P139, DOI 10.1111/j.1478-3231.2009.02133.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Maglott D, 2007, NUCLEIC ACIDS RES, V35, pD26, DOI 10.1093/nar/gkl993; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Ng IOL, 2000, CANCER RES, V60, P6581; Pang JCS, 2005, HUM PATHOL, V36, P36, DOI 10.1016/j.humpath.2004.09.021; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sabbir MG, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-17; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Takai Daiya, 2003, In Silico Biology, V3, P235; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Wong CM, 2003, CANCER RES, V63, P7646; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yuan BZ, 2007, EXP CELL RES, V313, P3868, DOI 10.1016/j.yexcr.2007.08.009; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zhou XL, 1999, CANCER RES, V59, P843	66	44	49	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1923	1935		10.1038/onc.2010.576	http://dx.doi.org/10.1038/onc.2010.576			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21217778	Green Accepted			2022-12-28	WOS:000289777700008
J	Zhang, H; Guttikonda, S; Roberts, L; Uziel, T; Semizarov, D; Elmore, SW; Leverson, JD; Lam, LT				Zhang, H.; Guttikonda, S.; Roberts, L.; Uziel, T.; Semizarov, D.; Elmore, S. W.; Leverson, J. D.; Lam, L. T.			Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines	ONCOGENE			English	Article						Mcl-1; NSCLC; Bcl-x(L)	BCL-2 FAMILY PROTEINS; APOPTOSIS; BAK; INHIBITOR; ABT-737; ACTIVATION; EXPRESSION; RESISTANCE; P53	Non-small-cell lung cancer (NSCLC) is the most deadly type of cancer in the United States and worldwide. Although new therapy is available, the survival rate of NSCLC patients remains low. One hallmark of cancer cells is defects in the apoptotic cell death program. In this study, we investigate the role of B-cell lymphoma 2 (Bcl-2) family members Bcl-2, Bcl-xL and Mcl-1, known to regulate cell survival and death, in a panel of fourteen NSCLC cell lines. NSCLC cell lines express high levels of Mcl-1 and Bcl-xL, but not Bcl-2. Silencing the expression of Mcl-1 with small interfering RNA ( siRNA) oligonucleotides potently killed a subgroup of NSCLC cell lines. In contrast, Bcl-xL siRNA had no effect in these lines unless Mcl-1 siRNA was also introduced. Interestingly, high MCL1 to BCL-xl messenger RNA determines whether the cells depend on Mcl-1 for survival. We further investigated the role of Mcl-1 in NSCLC cells using a Mcl-1-dependent cell line, H23. The expression of a complementary DNA containing only the coding region of MCL1 rescued H23 cells from the toxicity of a 30 untranslated region (UTR) targeting Mcl-1 siRNA but not a siRNA targeting the coding region of MCL1. Furthermore, we show that Mcl-1 sequesters the BH3-only protein Noxa and Bim and the apoptotic effector Bak. Not surprisingly, Noxa, Bim, or Bak knockdown partially rescued H23 cells from toxicity mediated by Mcl-1 siRNA to different degrees. Collectively, our results indicate that targeting Mcl-1 may improve therapy for a subset of NSCLC patients. Oncogene (2011) 30, 1963-1968; doi: 10.1038/onc.2010.559; published online 6 December 2010	[Lam, L. T.] Abbott Labs, Canc Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA	Abbott Laboratories	Lam, LT (corresponding author), Abbott Labs, Canc Res, Global Pharmaceut Res & Dev, AP10,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	Lloyd.Lam@abbott.com						Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Berrieman HK, 2005, CANCER-AM CANCER SOC, V103, P1415, DOI 10.1002/cncr.20907; Borner MM, 1999, BRIT J CANCER, V79, P952, DOI 10.1038/sj.bjc.6690152; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Keuling AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006651; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li J, 2008, CANCER CHEMOTH PHARM, V61, P525, DOI 10.1007/s00280-007-0499-3; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; RODENHUIS S, 1992, CANCER RES, V52, pS2665; Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496; Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Wesarg E, 2007, INT J CANCER, V121, P2387, DOI 10.1002/ijc.22977; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	26	127	132	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1963	1968		10.1038/onc.2010.559	http://dx.doi.org/10.1038/onc.2010.559			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21132008				2022-12-28	WOS:000289777700012
J	Wang, Y; Yu, Y; Tsuyada, A; Ren, X; Wu, X; Stubblefield, K; Rankin-Gee, EK; Wang, SE				Wang, Y.; Yu, Y.; Tsuyada, A.; Ren, X.; Wu, X.; Stubblefield, K.; Rankin-Gee, E. K.; Wang, S. E.			Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM	ONCOGENE			English	Article						TGF-beta; cancer stem cells; microRNA; ATM; CHK2	TGF-BETA; SOLID TUMORS; MICRORNA EXPRESSION; P53; HETEROGENEITY; PATHWAYS; LEUKEMIA; DELETION	Recent studies indicate that a subset of cancer cells possessing stem cell properties, referred to as cancer-initiating or cancer stem cells (CSCs), have crucial roles in tumor initiation, metastasis and resistance to anticancer therapies. Transforming growth factor (TGF)-beta and their family members have been implicated in both normal (embryonic and somatic) stem cells and CSCs. In this study, we observed that exposure to TGF-beta increased the population of breast cancer (BC) cells that can form mammospheres in suspension, a feature endowed by stem cells. This was mediated by the micro (mi) RNA family miR-181, which was upregulated by TGF-beta at the post-transcriptional level. Levels of the miR-181 family members were elevated in mammospheres grown in undifferentiating conditions, compared with cells grown in two-dimensional conditions. Ataxia telangiectasia mutated (ATM), a target gene of miR-181, exhibited reduced expression in mammospheres and upon TGF-b treatment. Overexpression of miR-181a/b, or depletion of ATM or its substrate CHK2, was sufficient to induce sphere formation in BC cells. Finally, knockdown of ATM enhanced in vivo tumorigenesis of the MDA361 BC cells. Our results elucidate a novel mechanism through which the TGF-b pathway regulates the CSC property by interfering with the tumor suppressor ATM, providing insights into the cellular and environmental factors regulating CSCs, which may guide future studies on therapeutic strategies targeting these cells. Oncogene (2011) 30, 1470-1480; doi:10.1038/onc.2010.531; published online 22 November 2010	[Wang, Y.; Yu, Y.; Tsuyada, A.; Stubblefield, K.; Rankin-Gee, E. K.; Wang, S. E.] Beckman Res Inst City Hope, Div Tumor Cell Biol, Duarte, CA 91010 USA; [Yu, Y.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Head & Neck Tumor, Tianjin, Peoples R China; [Ren, X.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol & Biotherapy, Tianjin, Peoples R China; [Wu, X.] City Hope Comprehens Canc Ctr, Bioinformat Core Facil, Duarte, CA USA; [Wang, S. E.] City Hope Comprehens Canc Ctr, Canc Biol Program, Duarte, CA USA	City of Hope; Beckman Research Institute of City of Hope; Tianjin Medical University; Tianjin Medical University; City of Hope; City of Hope	Wang, SE (corresponding author), Beckman Res Inst City Hope, Div Tumor Cell Biol, 1500 E Duarte Rd,KCRB Room 2007, Duarte, CA 91010 USA.	ewang@coh.org	Rankin-Gee, Elyse/B-2776-2013	Rankin-Gee, Elyse/0000-0002-0675-6955; Wang, Shizhen Emily/0000-0002-5036-8175	NCI [R00 CA125892]; CBCRP [16IB-0081]; NATIONAL CANCER INSTITUTE [R00CA125892, K99CA125892] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CBCRP; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI R00 CA125892 (SEW) and CBCRP 16IB-0081 (SEW). We thank Dr John J Rossi for kindly providing reagents, Dr Shiuan Chen and Dr Susan Kane for valuable comments, the Bioinformatics Core for professional service and colleagues in the Division of Tumor Cell Biology for enthusiastic support and discussion. Financial Support: NCI R00 CA125892 (SEW); CBCRP 16IB-0081 (SEW).	Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Austen B, 2007, J CLIN ONCOL, V25, P5448, DOI 10.1200/JCO.2007.11.2649; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dontu G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2130; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Haidar MA, 2000, CANCER-AM CANCER SOC, V88, P1057, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Ren YS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-111; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Tribius S, 2001, INT J RADIAT ONCOL, V50, P511, DOI 10.1016/S0360-3016(01)01489-4; Vallier L, 2009, STEM CELLS, V27, P2655, DOI 10.1002/stem.199; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang SZE, 2007, J BIOL CHEM, V282, P5661, DOI 10.1074/jbc.M608499200; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323	32	212	228	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1470	1480		10.1038/onc.2010.531	http://dx.doi.org/10.1038/onc.2010.531			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102523	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000288743800009
J	Takenobu, H; Shimozato, O; Nakamura, T; Ochiai, H; Yamaguchi, Y; Ohira, M; Nakagawara, A; Kamijo, T				Takenobu, H.; Shimozato, O.; Nakamura, T.; Ochiai, H.; Yamaguchi, Y.; Ohira, M.; Nakagawara, A.; Kamijo, T.			CD133 suppresses neuroblastoma cell differentiation via signal pathway modification	ONCOGENE			English	Article						CD133; neuroblastoma; differentiation; RET p38MAPK; PI3K/Akt	CANCER STEM-CELLS; HEMATOPOIETIC STEM; IN-VITRO; RET; IDENTIFICATION; LINES; EXPRESSION; AC133; GENE; AMPLIFICATION	CD133 (prominin-1) is a transmembrane glycoprotein expressed on the surface of normal and cancer stem cells (tumor-initiating cells), progenitor cells, rod photoreceptor cells and a variety of epithelial cells. Although CD133 is widely used as a marker of various somatic and putative cancer stem cells, its contribution to the fundamental properties of cancer cells, such as tumorigenesis and differentiation, remains to be elucidated. In the present report, we found that CD133 was expressed in several neuroblastoma (NB) cell lines/tumor samples. Intriguingly, CD133 repressed NB cell differentiation, for example neurite extension and the expression of differentiation marker proteins, and was decreased by several differentiation stimuli, but accelerated cell proliferation, anchorage-independent colony formation and in vivo tumor formation of NB cells. NB cell line and primary tumor-sphere experiments indicated that the molecular mechanism of CD133-related differentiation suppression in NB was in part dependent on neurotrophic receptor RET tyrosine kinase regulation. RET transcription was suppressed by CD133 in NB cells and glial cell line-derived neurotrophic factor treatment failed to induce RET in CD133-expressing cells; RET overexpression rescued CD133-related inhibition of neurite elongation. Of note, CD133-related NB cell differentiation and RET repression were mainly dependent on p38MAPK and PI3K/Akt pathways. Furthermore, CD133 has a function in growth and RET expression in NB cell line- and primary tumor cell-derived tumor spheres. To the best of our knowledge, this is the first report of the function of CD133 in cancer cells and our findings may be applied to improve differentiation induction therapy for NB patients. Oncogene (2011) 30, 97-105; doi: 10.1038/onc.2010.383; published online 6 September 2010	[Kamijo, T.] Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, Chiba 2608717, Japan; [Shimozato, O.] Chiba Canc Ctr, Res Inst, Lab Antitumor Res, Chiba 2608717, Japan; [Nakamura, T.] Univ Tokyo, Inst Med Sci, Core Facil Therapeut Vectors, Tokyo, Japan; [Ochiai, H.] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Ohira, M.] Chiba Canc Ctr, Res Inst, Lab Canc Genom, Chiba 2608717, Japan; [Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem & Innovat Canc Therapeut, Chiba 2608717, Japan	Chiba Cancer Center; Chiba Cancer Center; University of Tokyo; Chiba University; Chiba Cancer Center; Chiba Cancer Center	Kamijo, T (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp	Nakamura, Takafumi/AAO-8199-2020	Nakamura, Takafumi/0000-0002-0196-0754; Takenobu, Hisanori/0000-0001-7355-1565	JSPS [19790274]; Ministry of Health, Labor, and Welfare; Ministry of Health, Labor, and Welfare of Japan [20-13]; Ministry of Education, Culture, Sports, Science and Technology, Japan [21591377]; Grants-in-Aid for Scientific Research [21790397, 21591376, 21390317] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank K Sakurai and S Matsushita for technical assistance, Dr Hiroyuki Miyoshi (BioResource Center, RIKEN) for the gift of CSII-CMV-MCS-IRES2-Bsd plasmid and Daniel Mrozek, Medical English Service, for editorial assistance. This work was supported in part by a grant-in-aid from JSPS for Young Scientists (B) (number: 19790274), a grant-in-aid from the Ministry of Health, Labor, and Welfare for Third Term Comprehensive Control Research for Cancer, a grant-in-aid for Cancer Research (20-13) from the Ministry of Health, Labor, and Welfare of Japan and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (number: 21591377).	Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Boivin D, 2009, BIOCHEMISTRY-US, V48, P3998, DOI 10.1021/bi900159d; BRODEUR GM, 2000, NEUROBLASTOMA; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Corbeil D, 2001, BIOCHEM BIOPH RES CO, V285, P939, DOI 10.1006/bbrc.2001.5271; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; Crowder RJ, 2004, J BIOL CHEM, V279, P42072, DOI 10.1074/jbc.M403726200; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; Enomoto H, 2000, DEVELOPMENT, V127, P4877; Enomoto H, 2001, DEVELOPMENT, V128, P3963; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Hasegawa K, 2006, CLIN CANCER RES, V12, P6170, DOI 10.1158/1078-0432.CCR-06-0992; Iehara T, 2006, BRIT J CANCER, V94, P1510, DOI 10.1038/sj.bjc.6603149; ITOH F, 1992, ONCOGENE, V7, P1201; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KLEIN RM, 1994, FASEB J, V8, pA126; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; MYERS SM, 1995, ONCOGENE, V11, P2039; Nakanishi H, 2007, ONCOL REP, V17, P1315; Nikolova T, 2007, DIFFERENTIATION, V75, P100, DOI 10.1111/j.1432-0436.2006.00119.x; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Olempska M, 2007, HEPATOB PANCREAT DIS, V6, P92; Peterson S, 2004, ONCOGENE, V23, P213, DOI 10.1038/sj.onc.1206980; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Weinberg RA, 2006, BIOL CANC; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476; Zacchigna S, 2009, J NEUROSCI, V29, P2297, DOI 10.1523/JNEUROSCI.2034-08.2009	42	93	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					97	105		10.1038/onc.2010.383	http://dx.doi.org/10.1038/onc.2010.383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818439				2022-12-28	WOS:000285959300009
J	Swietach, P; Hulikova, A; Vaughan-Jones, RD; Harris, AL				Swietach, P.; Hulikova, A.; Vaughan-Jones, R. D.; Harris, A. L.			New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation	ONCOGENE			English	Review						cancer; pH; carbonic anhydrase IX; acid/base transport; buffers	PIG VENTRICULAR MYOCYTE; H+-ION MOBILITY; INTRACELLULAR PH; EXTRACELLULAR-PH; CELL-GROWTH; MN/CA IX; ANTIPORT ACTIVITY; GENE-EXPRESSION; MELANOMA-CELLS; BREAST-CANCER	In this review, we discuss the role of the tumour-associated carbonic anhydrase isoform IX (CAIX) in the context of pH regulation. We summarise recent experimental findings on the effect of CAIX on cell growth and survival, and present a diffusion-reaction model to help in the assessment of CAIX function under physiological conditions. CAIX emerges as an important facilitator of acid diffusion and acid transport, helping to overcome large cell-to-capillary distances that are characteristic of solid tumours. The source of substrate for CAIX catalysis is likely to be CO2, generated by adequately oxygenated mitochondria or from the titration of metabolic acids with HCO3- taken up from the extracellular milieu. The relative importance of these pathways will depend on oxygen and metabolite availability, the spatiotemporal patterns of the cell's exposure to hypoxia and on the regulation of metabolism by genes. This is now an important avenue for further investigation. The importance of CAIX in regulating tumour pH highlights the protein as a potential target for cancer therapy. Oncogene (2010) 29, 6509-6521; doi: 10.1038/onc.2010.455; published online 4 October 2010	[Swietach, P.; Hulikova, A.; Vaughan-Jones, R. D.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX1 3PT, England	University of Oxford; University of Oxford	Swietach, P (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Sherrington Bldg,S Parks Rd, Oxford OX1 3PT, England.	pawel.swietach@dpag.ox.ac.uk	Swietach, Pawel/AAK-4169-2020; Harris, Adrian L/ABA-3343-2020	Swietach, Pawel/0000-0002-9945-9473; Harris, Adrian L/0000-0003-1376-8409	Royal Society; Medical Research Council; British Heart Foundation; Cancer Research UK; European Union; MRC [G0700698] Funding Source: UKRI; British Heart Foundation [RG/08/016/26423] Funding Source: researchfish; Medical Research Council [G0700698] Funding Source: researchfish	Royal Society(Royal Society of London); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); European Union(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was supported by the Royal Society, Medical Research Council, British Heart Foundation, the Cancer Research UK and the European Union Framework 7 Metoxia.	Ahlskog JKJ, 2009, BIOORG MED CHEM LETT, V19, P4851, DOI 10.1016/j.bmcl.2009.06.022; Airley RE, 2003, INT J CANCER, V104, P85, DOI 10.1002/ijc.10904; Alper SL, 2006, EXP PHYSIOL, V91, P153, DOI 10.1113/expphysiol.2005.031765; Alterio V, 2009, P NATL ACAD SCI USA, V106, P16233, DOI 10.1073/pnas.0908301106; Beasley NJP, 2001, CANCER RES, V61, P5262; Boron WF, 2010, BBA-PROTEINS PROTEOM, V1804, P410, DOI 10.1016/j.bbapap.2009.10.021; Boron WF, 2004, ADV PHYSIOL EDUC, V28, P160, DOI 10.1152/advan.00045.2004; CHAMBARD JC, 1986, EXP CELL RES, V164, P282, DOI 10.1016/0014-4827(86)90029-7; Chegwidden WR, 2000, EXS, V90, P343; Chia SK, 2001, J CLIN ONCOL, V19, P3660, DOI 10.1200/JCO.2001.19.16.3660; Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; De Simone G, 2010, BBA-PROTEINS PROTEOM, V1804, P404, DOI 10.1016/j.bbapap.2009.07.027; Dorai T, 2005, EUR J CANCER, V41, P2935, DOI 10.1016/j.ejca.2005.09.011; Fang JS, 2008, SEMIN CANCER BIOL, V18, P330, DOI 10.1016/j.semcancer.2008.03.011; FRANCHI A, 1981, INT J CANCER, V27, P819, DOI 10.1002/ijc.2910270614; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Generali D, 2006, ENDOCR-RELAT CANCER, V13, P921, DOI 10.1677/erc.1.01216; Giatromanolaki A, 2001, CANCER RES, V61, P7992; GILLIES R J, 1992, Cellular Physiology and Biochemistry, V2, P159, DOI 10.1159/000154638; Gillies RJ, 2004, IEEE ENG MED BIOL, V23, P57, DOI 10.1109/MEMB.2004.1360409; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; Giusti I, 2008, NEOPLASIA, V10, P481, DOI 10.1593/neo.08178; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Griffiths J R, 2001, Novartis Found Symp, V240, P46; GRIFFITHS JR, 1981, BIOSCIENCE REP, V1, P319, DOI 10.1007/BF01114871; Guler OO, 2010, CURR MED CHEM, V17, P1516, DOI 10.2174/092986710790979999; Haapasalo JA, 2006, CLIN CANCER RES, V12, P473, DOI 10.1158/1078-0432.CCR-05-0848; Haapasalo J, 2008, NEURO-ONCOLOGY, V10, P131, DOI 10.1215/15228517-2007-065; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOLM E, 1995, CANCER RES, V55, P1373; Huang WC, 2008, CURR BIOL, V18, P781, DOI 10.1016/j.cub.2008.04.049; Hulikova A, 2009, FEBS LETT, V583, P3563, DOI 10.1016/j.febslet.2009.10.060; Innocenti A, 2009, BIOORG MED CHEM LETT, V19, P5825, DOI 10.1016/j.bmcl.2009.08.088; IRVING M, 1990, BIOPHYS J, V57, P717, DOI 10.1016/S0006-3495(90)82592-3; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; KALLINOWSKI F, 1989, CANCER RES, V49, P3759; Koukourakis MI, 2001, CLIN CANCER RES, V7, P3399; Kunz-Schughart L, 2000, AM J PHYSIOL-CELL PH, V278, pC765, DOI 10.1152/ajpcell.2000.278.4.C765; LAGARDE AE, 1988, J CELL BIOCHEM, V36, P249, DOI 10.1002/jcb.240360306; LALLEMAIN G, 1985, J BIOL CHEM, V260, P4877; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Lee AH, 1998, CANCER RES, V58, P1901; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; Liao SY, 2000, CANCER, V88, P1108, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1108::AID-CNCR23>3.0.CO;2-D; Lindner D, 2009, BRIT J CANCER, V100, P1287, DOI 10.1038/sj.bjc.6605022; Loncaster JA, 2001, CANCER RES, V61, P6394; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; Morgan PE, 2007, AM J PHYSIOL-CELL PH, V293, pC738, DOI 10.1152/ajpcell.00157.2007; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; NEWELL K, 1993, P NATL ACAD SCI USA, V90, P1127, DOI 10.1073/pnas.90.3.1127; Niederer SA, 2008, BIOPHYS J, V94, P2385, DOI 10.1529/biophysj.107.118885; Pan PW, 2006, J PHYSIOL-LONDON, V571, P319, DOI 10.1113/jphysiol.2005.102590; PASTOREK J, 1994, ONCOGENE, V9, P2877; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; Pastorekova S., 2004, CARBONIC ANHYDRASE I; Potter CPS, 2003, BRIT J CANCER, V89, P2, DOI 10.1038/sj.bjc.6600936; POUYSSEGUR J, 1985, FEBS LETT, V190, P115, DOI 10.1016/0014-5793(85)80439-7; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Saarnio J, 1998, AM J PATHOL, V153, P279, DOI 10.1016/S0002-9440(10)65569-1; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Sauvant C, 2008, INT J CANCER, V123, P2532, DOI 10.1002/ijc.23818; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Spitzer KW, 2002, J PHYSIOL-LONDON, V541, P159, DOI 10.1113/jphysiol.2001.013268; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Stewart AK, 2009, J BIOL CHEM, V284, P6126, DOI 10.1074/jbc.M802051200; Stock C, 2007, CELL PHYSIOL BIOCHEM, V20, P679, DOI 10.1159/000107550; Sun B, 1996, J PHYSIOL-LONDON, V495, P65, DOI 10.1113/jphysiol.1996.sp021574; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Svastova E, 2003, EXP CELL RES, V290, P332, DOI 10.1016/S0014-4827(03)00351-3; Swietach P, 2003, PROG BIOPHYS MOL BIO, V83, P69, DOI 10.1016/S0079-6107(03)00027-0; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; Swietach P, 2007, BIOPHYS J, V92, P641, DOI 10.1529/biophysj.106.096560; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; THOMAS RC, 1989, NATURE, V337, P601, DOI 10.1038/337601a0; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Turner JR, 1997, HUM PATHOL, V28, P740, DOI 10.1016/S0046-8177(97)90185-4; Turner KJ, 2002, BRIT J CANCER, V86, P1276, DOI 10.1038/sj.bjc.6600215; VASSEUR M, 1989, BIOCHEM J, V263, P775, DOI 10.1042/bj2630775; Vaughan-Jones RD, 2002, J PHYSIOL-LONDON, V541, P139, DOI 10.1113/jphysiol.2001.013267; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V428, P441, DOI 10.1113/jphysiol.1990.sp018221; VAUPEL P, 1989, CANCER RES, V49, P6449; WOHLHUETER RM, 1981, J BIOL CHEM, V256, P869; Wykoff CC, 2000, CANCER RES, V60, P7075; Xu C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009625; Zavada J, 2000, BRIT J CANCER, V82, P1808, DOI 10.1054/bjoc.2000.1111	95	175	178	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	50					6509	6521		10.1038/onc.2010.455	http://dx.doi.org/10.1038/onc.2010.455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20890298				2022-12-28	WOS:000285380200001
J	Chen, J; Xie, J; Jiang, Z; Wang, B; Wang, Y; Hu, X				Chen, J.; Xie, J.; Jiang, Z.; Wang, B.; Wang, Y.; Hu, X.			Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2	ONCOGENE			English	Article						shikonin; alkannin; pyruvate kinase-M2; glycolysis; inhibitor	ALLOSTERIC REGULATION; DRUG-RESISTANCE; DEATH; M2; IDENTIFICATION; INDUCTION; ISOZYMES; METABOLISM; APOPTOSIS; GROWTH	We recently reported that shikonin and its analogs were a class of necroptotic inducers that could bypass cancer drug resistance. However, the molecular targets of shikonin are not known. Here, we showed that shikonin and its analogs are inhibitors of tumor-specific pyruvate kinase-M2 (PKM2), among which shikonin and its enantiomeric isomer alkannin were the most potent and showed promising selectivity, that is, shikonin and alkannin at concentrations that resulted in over 50% inhibition of PKM2 activity did not inhibit PKM1 and pyruvate kinase-L (PKL). Shikonin and alkannin significantly inhibited the glycolytic rate, as manifested by cellular lactate production and glucose consumption in drug-sensitive and resistant cancer cell lines (MCF-7, MCF-7/Adr, MCF-7/Bcl-2, MCF-7/Bcl-x(L) and A549) that primarily express PKM2. HeLa cells transfected with PKM1 showed reduced sensitivity to shikonin-or alkannin-induced cell death. To the best of our knowledge, shikonin and alkannin are the most potent and specific inhibitors to PKM2 reported so far. As PKM2 universally expresses in cancer cells and dictates the last rate-limiting step of glycolysis vital for cancer cell proliferation and survival, enantiomeric shikonin and alkannin may have potential in future clinical application. Oncogene (2011) 30, 4297-4306; doi: 10.1038/onc.2011.137; published online 25 April 2011	[Chen, J.; Xie, J.; Wang, B.; Hu, X.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310009, Zhejiang, Peoples R China; [Jiang, Z.; Wang, Y.] Zhejiang Univ, Dept Chem, Hangzhou 310009, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Hu, X (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Inst Canc, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	huxun@zju.edu.cn			China National 863 project [2007AA02Z143]; China Natural Sciences Foundation [30772544, 81071802]; Fundamental Research Funds for the Central Universities, National Ministry of Education, China	China National 863 project(National High Technology Research and Development Program of China); China Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities, National Ministry of Education, China	We thank BPS Bioscience Inc (San Diego, CA, USA) for technical support of their product-recombinant human PKM2. This work was supported in part by the China National 863 project (2007AA02Z143) to XH; China Natural Sciences Foundation projects (30772544, 81071802) to XH and the Fundamental Research Funds for the Central Universities, National Ministry of Education, China, to XH.	AHN BZ, 1995, J MED CHEM, V38, P1044, DOI 10.1021/jm00006a025; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; ANDERSON SR, 1964, J BIOL CHEM, V239, P2991; Bailly C, 2000, CURR MED CHEM, V7, P39, DOI 10.2174/0929867003375489; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Guo X P, 1991, Zhong Xi Yi Jie He Za Zhi, V11, P598; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hu X, 2008, CANCER LETT, V259, P127, DOI 10.1016/j.canlet.2007.11.007; IBSEN KH, 1977, CANCER RES, V37, P341; Ikeda Y, 1998, J BIOL CHEM, V273, P12227, DOI 10.1074/jbc.273.20.12227; IMAMURA K, 1973, J BIOCHEM, V74, P1165, DOI 10.1093/oxfordjournals.jbchem.a130344; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Kim SH, 2001, CANCER LETT, V172, P171, DOI 10.1016/S0304-3835(01)00665-6; Li L, 2007, CANCER RES, V67, P4894, DOI 10.1158/0008-5472.CAN-06-3818; Liu K, 2008, J MED CHEM, V51, P7843, DOI 10.1021/jm800869t; Masuda Y, 2004, J BIOL CHEM, V279, P42503, DOI 10.1074/jbc.M404256200; Masuda Y, 2003, ONCOGENE, V22, P1012, DOI 10.1038/sj.onc.1206200; Mazurek S, 2008, ERNST SCHERING FOUND, V4, P99, DOI 10.1007/2789_2008_091; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Mazurek S, 2002, BRIT J NUTR, V87, pS23, DOI [10.1079/BJN2001455, 10.1079/BJN2001454]; Nakaya K, 2003, ANTI-CANCER DRUG, V14, P683, DOI 10.1097/01.cad.0000092781.37568.df; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; PAPAGEORGIOU VPA, 1999, ANGEW CHEM INT EDIT, V38, P32; PARKISON C, 1991, BIOCHEM BIOPH RES CO, V179, P668, DOI 10.1016/0006-291X(91)91424-B; Shimada N, 2008, GENES CELLS, V13, P245, DOI 10.1111/j.1365-2443.2008.01165.x; Spoden GA, 2008, INT J CANCER, V123, P312, DOI 10.1002/ijc.23512; Spoden GA, 2009, EXP CELL RES, V315, P2765, DOI 10.1016/j.yexcr.2009.06.024; Vander Heiden MG, 2010, BIOCHEM PHARMACOL, V79, P1118, DOI 10.1016/j.bcp.2009.12.003; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Xuan YY, 2009, CANCER LETT, V274, P233, DOI 10.1016/j.canlet.2008.09.029; Yang HJ, 2009, INT J CANCER, V124, P2450, DOI 10.1002/ijc.24195	43	312	325	14	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	42					4297	4306		10.1038/onc.2011.137	http://dx.doi.org/10.1038/onc.2011.137			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21516121				2022-12-28	WOS:000296356400001
J	Charoenfuprasert, S; Yang, YY; Lee, YC; Chao, KC; Chu, PY; Lai, CR; Hsu, KF; Chang, KC; Chen, YC; Chen, LT; Chang, JY; Leu, SJ; Shih, NY				Charoenfuprasert, S.; Yang, Y-Y; Lee, Y-C; Chao, K-C; Chu, P-Y; Lai, C-R; Hsu, K-F; Chang, K-C; Chen, Y-C; Chen, L-T; Chang, J-Y; Leu, S-J; Shih, N-Y			Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer	ONCOGENE			English	Article						tumor-associated antigen; ovarian cancer; CA125; malignant ascitic fluid; phage display	RECEPTOR; GROWTH; CELLS; SIK1; LKB1; STEROIDOGENESIS; STANNIOCALCIN; ADIPOGENESIS; EXPRESSION; CREB	Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21(Waf/Cip1) and p27(Kip) expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55% of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97%) to CA125 (65%) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21(Waf/Cip1) expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85% of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer. Oncogene (2011) 30, 3570-3584; doi:10.1038/onc.2011.77; published online 14 March 2011	[Charoenfuprasert, S.; Leu, S-J] Taipei Med Univ, Coll Med, Sch Med, Dept Microbiol & Immunol, Taipei 110, Taiwan; [Charoenfuprasert, S.; Leu, S-J] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan; [Yang, Y-Y; Lee, Y-C] Taipei Med Univ, Coll Med Sci & Technol, Sch Med Lab Sci & Biotechnol, Taipei 110, Taiwan; [Chao, K-C] Taipei Vet Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; [Chu, P-Y] Changhua Christian Hosp, Dept Surg Pathol, Changhua, Taiwan; [Lai, C-R] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan; [Hsu, K-F] Natl Cheng Kung Univ, Dept Obstet & Gynecol, Tainan 70101, Taiwan; [Chang, K-C] Natl Cheng Kung Univ, Dept Pathol, Tainan 70101, Taiwan; [Charoenfuprasert, S.; Chen, Y-C; Chen, L-T; Chang, J-Y; Shih, N-Y] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Veterans General Hospital; Changhua Christian Hospital; Taipei Veterans General Hospital; National Cheng Kung University; National Cheng Kung University; National Health Research Institutes - Taiwan	Leu, SJ (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Microbiol & Immunol, Taipei 110, Taiwan.	cmbsycl@tmu.edu.tw; jshih@nhri.org.tw	Shih, Neng-Yao/D-2086-2010; Chen, Li-Tzong/D-2071-2010; Chang, Jang-Yang/D-2099-2010	Chu, Pei-Yi/0000-0001-7336-2465	National Health Research Institutes; Department of Health, Executive Yuan, Taiwan [DOH97-TD-G-111-022 (NYS)]; National Science Council of Taiwan [NSC 99-2320-B-400-011-MY3, NSC 96-2314-B-038-022, NSC 97-2314-B-038-004-MY3, NSC 96-2320-B-038-005/NSC 97-2320-B-038-012-MY2]	National Health Research Institutes(National Health Research Institutes, Japan); Department of Health, Executive Yuan, Taiwan; National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was partially supported by the Intramural Research Grant of the National Health Research Institutes, the National Research Program for Genomic Medicine Grant from the Department of Health, Executive Yuan, Taiwan, DOH97-TD-G-111-022 (NYS), and by the National Science Council Grants of Taiwan, NSC 99-2320-B-400-011-MY3 (NYS), NSC 96-2314-B-038-022 (SJL), NSC 97-2314-B-038-004-MY3 (SJL), as well as NSC 96-2320-B-038-005/NSC 97-2320-B-038-012-MY2 (YYY). We are also grateful to Dr Nagase from the Kazusa DNA Research Institute for kindly providing the FJ10213 plasmid to facilitate the SIK3 study, and thank National Research Program for Genomic Medicine, Taiwan (National Clinical Core, NSC-95-3112-B-001-010 and National Genotyping Core, NSC-95-3112-B-001-011) for supply of interfering small hairpin RNA plasmids.	Ahmed AA, 2010, CANCER CELL, V18, P109, DOI 10.1016/j.ccr.2010.06.018; Amin N, 2009, P NATL ACAD SCI USA, V106, P8941, DOI 10.1073/pnas.0812469106; Baron AT, 2005, CANCER EPIDEM BIOMAR, V14, P306, DOI 10.1158/1055-9965.EPI-04-0423; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Brewer BG, 2009, EXP MOL PATHOL, V86, P192, DOI 10.1016/j.yexmp.2008.12.002; Bright NJ, 2009, ACTA PHYSIOL, V196, P15, DOI 10.1111/j.1748-1716.2009.01971.x; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang GC, 2006, CLIN CANCER RES, V12, P5746, DOI 10.1158/1078-0432.CCR-06-0324; Cheng HL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000369; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Gagnon A, 2008, CLIN CANCER RES, V14, P764, DOI 10.1158/1078-0432.CCR-07-0856; GIANCOTTI FR, 1990, GYNECOL ONCOL, V37, P24, DOI 10.1016/0090-8258(90)90301-Z; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; Katoh Y, 2004, MOL CELL ENDOCRINOL, V217, P109, DOI 10.1016/j.mce.2003.10.016; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Kowanetz M, 2008, J CELL BIOL, V182, P655, DOI 10.1083/jcb.200804107; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Mizrachy-Schwartz S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000628; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; Okamoto M, 2004, TRENDS ENDOCRIN MET, V15, P21, DOI 10.1016/j.tem.2003.11.002; Old Lloyd J, 2008, Cancer Immun, V8 Suppl 1, P1; Paciga M, 2003, J BIOL CHEM, V278, P49549, DOI 10.1074/jbc.M307302200; Reuschenbach M, 2009, CANCER IMMUNOL IMMUN, V58, P1535, DOI 10.1007/s00262-009-0733-4; Rosenthal AN, 2006, CLIN OBSTET GYNECOL, V49, P433, DOI 10.1097/00003081-200609000-00004; Ruda JM, 2006, INVEST NEW DRUG, V24, P377, DOI 10.1007/s10637-006-6271-4; Runnebaum IB, 2001, J CANCER RES CLIN, V127, P73, DOI 10.1007/s004320000153; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Serlachius M, 2002, BRIT J HAEMATOL, V119, P359, DOI 10.1046/j.1365-2141.2002.03916.x; Sjostrom M, 2007, P NATL ACAD SCI USA, V104, P16922, DOI 10.1073/pnas.0706838104; Taylor DD, 2009, GYNECOL ONCOL, V115, P112, DOI 10.1016/j.ygyno.2009.06.031	33	30	44	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3570	3584		10.1038/onc.2011.77	http://dx.doi.org/10.1038/onc.2011.77			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21399663	Bronze			2022-12-28	WOS:000294005100002
J	Dhawan, P; Ahmad, R; Chaturvedi, R; Smith, JJ; Midha, R; Mittal, MK; Krishnan, M; Chen, X; Eschrich, S; Yeatman, TJ; Harris, RC; Washington, MK; Wilson, KT; Beauchamp, RD; Singh, AB				Dhawan, P.; Ahmad, R.; Chaturvedi, R.; Smith, J. J.; Midha, R.; Mittal, M. K.; Krishnan, M.; Chen, X.; Eschrich, S.; Yeatman, T. J.; Harris, R. C.; Washington, M. K.; Wilson, K. T.; Beauchamp, R. D.; Singh, A. B.			Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation	ONCOGENE			English	Article						tight junction; claudin; EGFR; colon cancer; proliferation	INFLAMMATORY-BOWEL-DISEASE; EPITHELIAL TIGHT JUNCTIONS; EGF-RECEPTOR; TRANSEPITHELIAL RESISTANCE; DIFFERENTIAL EXPRESSION; JUXTACRINE ACTIVATION; ULCERATIVE-COLITIS; COLORECTAL-CANCER; TYROSINE KINASE; CROHNS-DISEASE	Claudin-2 is a unique member of the claudin family of transmembrane proteins, as its expression is restricted to the leaky epithelium in vivo and correlates with epithelial leakiness in vitro. However, recent evidence suggests potential functions of claudin-2 that are relevant to neoplastic transformation and growth. In accordance, here we report, on the basis of analysis of mRNA and protein expression using a total of 309 patient samples that claudin-2 expression is significantly increased in colorectal cancer and correlates with cancer progression. We also report similar increases in claudin-2 expression in inflammatory bowel disease-associated colorectal cancer. Most importantly, we demonstrate that the increased claudin-2 expression in colorectal cancer is causally associated with tumor growth as forced claudin-2 expression in colon cancer cells that do not express claudin-2 resulted in significant increases in cell proliferation, anchorage-independent growth and tumor growth in vivo. We further show that the colonic microenvironment regulates claudin-2 expression in a manner dependent on signaling through the EGF receptor (EGFR), a key regulator of colon tumorigenesis. In addition, claudin-2 expression is specifically decreased in the colon of waved-2 mice, naturally deficient in EGFR activation. Furthermore, genetic silencing of claudin-2 expression in Caco-2, a colon cancer cell line, prevents the EGF-induced increase in cell proliferation. Taken together, these results uncover a novel role for claudin-2 in promoting colon cancer, potentially via EGFR transactivation. Oncogene (2011) 30, 3234-3247; doi:10.1038/onc.2011.43; published online 7 March 2011	[Dhawan, P.; Ahmad, R.; Smith, J. J.; Midha, R.; Mittal, M. K.; Krishnan, M.; Beauchamp, R. D.; Singh, A. B.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [Dhawan, P.; Wilson, K. T.; Beauchamp, R. D.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Chaturvedi, R.; Harris, R. C.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Chen, X.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Eschrich, S.; Yeatman, T. J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Vanderbilt University	Singh, AB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, CCC-4513,1161 21st Ave S, Nashville, TN 37232 USA.	amar.singh@vanderbilt.edu	Eschrich, Steven/K-6848-2013; Smith, Jesse Joshua/AAN-5440-2020	Eschrich, Steven/0000-0002-9833-2788; Smith, Jesse Joshua/0000-0003-2538-5456; Beauchamp, Robert Daniel/0000-0002-8446-4114; Wilson, Keith/0000-0003-4421-1830; Mittal, Mukul/0000-0002-9795-7372	Pilot projects [5P50DK044757, P30DK058404]; NIH [CA119005, CA124977]; NATIONAL CANCER INSTITUTE [R01CA124977, R21CA119005] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK088902, P50DK044757] Funding Source: NIH RePORTER	Pilot projects; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by 5P50DK044757 and P30DK058404 Pilot projects (ABS) and by NIH grants CA119005, CA124977 (PD). We thank Dr Ambra Pozzi and Mingjian Shi for providing waved-2 mice and Dr Wael El-Rifai for providing 5-FU.	Amasheh M, 2009, SCAND J GASTROENTERO, V44, P1226, DOI 10.1080/00365520903131973; Angelow S, 2007, J MEMBRANE BIOL, V215, P147, DOI 10.1007/s00232-007-9014-3; ANSFIELD F, 1977, CANCER-AM CANCER SOC, V39, P34, DOI 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2; Bos M, 1997, CLIN CANCER RES, V3, P2099; Buchert M, 2010, P NATL ACAD SCI USA, V107, P2628, DOI 10.1073/pnas.0903747107; Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107; Cereijido M, 2004, PHYSIOL REV, V84, P1229, DOI 10.1152/physrev.00001.2004; Cutler NS, 2003, CANCER RES, V63, P1748; D'Inca R, 1999, AM J GASTROENTEROL, V94, P2956, DOI 10.1111/j.1572-0241.1999.01444.x; Dahlhoff M, 2008, FEBS LETT, V582, P2911, DOI 10.1016/j.febslet.2008.07.026; DAVIES RJ, 1989, ARCH SURG-CHICAGO, V124, P480; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Escaffit F, 2005, J CELL PHYSIOL, V203, P15, DOI 10.1002/jcp.20189; Flores-Benitez D, 2007, AM J PHYSIOL-RENAL, V292, pF828, DOI 10.1152/ajprenal.00369.2006; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Guillemot L, 2006, MOL BIOL CELL, V17, P3569, DOI 10.1091/mbc.E06-02-0122; Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002; Helmrath MA, 1998, J SURG RES, V77, P17, DOI 10.1006/jsre.1998.5362; Holmes JL, 2006, GENE EXPR PATTERNS, V6, P581, DOI 10.1016/j.modgep.2005.12.001; Kim EC, 1998, AM J PHYSIOL-CELL PH, V275, pC988, DOI 10.1152/ajpcell.1998.275.4.C988; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; Kinugasa T, 2007, ANTICANCER RES, V27, P3729; Krishnan M, 2010, ONCOGENE, V29, P305, DOI 10.1038/onc.2009.324; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Mankertz J, 2004, BIOCHEM BIOPH RES CO, V314, P1001, DOI 10.1016/j.bbrc.2003.12.185; Mankertz J, 2009, CELL TISSUE RES, V336, P67, DOI 10.1007/s00441-009-0751-8; Mima S, 2008, CARCINOGENESIS, V29, P1994, DOI 10.1093/carcin/bgn134; MULLIN JM, 1992, J CELL PHYSIOL, V152, P35, DOI 10.1002/jcp.1041520106; MULLIN JM, 1986, AM J PHYSIOL, V251, pC597, DOI 10.1152/ajpcell.1986.251.4.C597; MULLIN JM, 1987, FEBS LETT, V221, P359, DOI 10.1016/0014-5793(87)80956-0; MULLIN JM, 2004, SCI STKE, pPE2, DOI DOI 10.1126/STKE.2162004PE2; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Peter Y, 2009, MOL CARCINOGEN, V48, P488, DOI 10.1002/mc.20485; Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316; Rego RL, 2009, BRIT J CANCER, V102, P165; Reyes JL, 2002, KIDNEY INT, V62, P476, DOI 10.1046/j.1523-1755.2002.00479.x; Ridyard AE, 2007, J HISTOCHEM CYTOCHEM, V55, P1049, DOI 10.1369/jhc.7A7211.2007; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh AB, 2004, J BIOL CHEM, V279, P3543, DOI 10.1074/jbc.M308682200; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Singh AB, 2007, AM J PHYSIOL-CELL PH, V293, pC1660, DOI 10.1152/ajpcell.00274.2007; Singh AB, 2007, J BIOL CHEM, V282, P32890, DOI 10.1074/jbc.M702677200; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Takehara M, 2009, BIOL PHARM BULL, V32, P825, DOI 10.1248/bpb.32.825; Weber CR, 2008, LAB INVEST, V88, P1110, DOI 10.1038/labinvest.2008.78; Yabana T, 2009, J PATHOL, V218, P350, DOI 10.1002/path.2535; Yamaoka T, 2008, P NATL ACAD SCI USA, V105, P11772, DOI 10.1073/pnas.0801463105; Zeissig S, 2007, GUT, V56, P61, DOI 10.1136/gut.2006.094375; Zhu YT, 2003, CANCER RES, V63, P522	54	108	109	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3234	3247		10.1038/onc.2011.43	http://dx.doi.org/10.1038/onc.2011.43			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21383692	Green Accepted			2022-12-28	WOS:000293006800003
J	Palmieri, D; Valentino, T; D'Angelo, D; De Martino, I; Postiglione, I; Pacelli, R; Croce, CM; Fedele, M; Fusco, A				Palmieri, D.; Valentino, T.; D'Angelo, D.; De Martino, I.; Postiglione, I.; Pacelli, R.; Croce, C. M.; Fedele, M.; Fusco, A.			HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents	ONCOGENE			English	Article						HMGA; ATM; DNA repair	DNA-DAMAGE RESPONSE; GROUP-A PROTEINS; ATAXIA-TELANGIECTASIA; RADIOSENSITIZING AGENT; IONIZING-RADIATION; KINASE; GENE; P53; TARGET; TUMORIGENESIS	DNA-damaging therapies represent a keystone in cancer treatment. Unfortunately, many tumors often relapse because of a group of cancer cells, which are resistant to conventional therapies. High-mobility group A (HMGA) proteins has a key role in cell transformation, and their overexpression is a common feature of human malignant neoplasias, representing a poor prognostic index often correlated to anti-cancer drug resistance. Our previous results demonstrated that HMGA1 is a substrate of ataxia-telangiectasia mutated (ATM), the main cellular sensor of genotoxic stress. Here we also report that HMGA2, the other member of the HMGA family, is a novel substrate of ATM. Interestingly, we found that HMGA proteins positively regulate ATM gene expression. Moreover, induction of ATM kinase activity by DNA-damaging agents enhances HMGA-dependent transcriptional activation of ATM promoter, suggesting that ATM expression is modulated by a DNA-damage-and HMGA-dependent positive feedback loop. Finally, inhibition of HMGA expression in mouse embryonic fibroblasts and in cancer cells strongly reduces ATM protein levels, impairing the cellular DNA-damage response and enhancing the sensitivity to DNA-damaging agents. These findings indicate this novel HMGA-ATM pathway as a new potential target to improve the effectiveness of conventional anti-neoplastic treatments on the genotoxic-drug resistant cancer cells. Oncogene (2011) 30, 3024-3035; doi: 10.1038/onc.2011.21; published online 21 February 2011	[Palmieri, D.; Valentino, T.; D'Angelo, D.; De Martino, I.; Postiglione, I.; Fedele, M.; Fusco, A.] Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale,Fac Med & Chi, Naples, Italy; [Pacelli, R.] CNR, Ist Biostrutture & Bioimmagini, I-80125 Naples, Italy; [Palmieri, D.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA; [Fusco, A.] NOGEC Naples Oncogenom Ctr CEINGE, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Fusco, A (corresponding author), CNR, Ist Oncol & Endocrinol Sperimentale G Salvatore, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Fedele, Monica/C-1417-2015; D'Angelo, Daniela/GVT-9143-2022; Pacelli, Roberto/AFS-0333-2022; Young, Richard A/F-6495-2012	Fedele, Monica/0000-0002-9171-1312; Young, Richard A/0000-0001-8855-8647; Fusco, Alfredo/0000-0003-3332-5197; Palmieri, Dario/0000-0002-0797-4268; Pacelli, Roberto/0000-0002-2048-7675	Associazione Italiana Ricerca sul Cancro (AIRC); Fondazione Italiana per la Ricerca sul Cancro (FIRC)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italiana per la Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank V Costanzo for revision of the paper and I Pellegrino for technical support. We are grateful to MB Kastan for providing the pFLAG-ATM expression construct and to D Ginsberg for the pLuc-ATM reporter vector. This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC). DP is recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chiappetta G, 1996, ONCOGENE, V13, P2439; Crescenzi E, 2008, CLIN CANCER RES, V14, P1877, DOI 10.1158/1078-0432.CCR-07-4298; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Fedele M, 2001, CANCER RES, V61, P4583; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 2006, CANCER CELL, V9, P459, DOI 10.1016/j.ccr.2006.04.024; Fedele M, 2010, BBA-GENE REGUL MECH, V1799, P48, DOI 10.1016/j.bbagrm.2009.11.007; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Jackson SP, 2009, BIOCHEM SOC T, V37, P483, DOI 10.1042/BST0370483; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pentimalli F, 2008, EUR J CANCER, V44, P2668, DOI 10.1016/j.ejca.2008.07.033; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; PIERANTONI GM, 2006, CELL DEATH DIFFER, V5, P2045; Reeves R, 2005, DNA REPAIR, V4, P926, DOI 10.1016/j.dnarep.2005.04.010; REEVES R, 1990, J BIOL CHEM, V265, P8573; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 2001, SEMIN RADIAT ONCOL, V11, P316, DOI 10.1053/srao.2001.26030; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Wood LJ, 2000, CANCER RES, V60, P4256; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	41	45	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3024	3035		10.1038/onc.2011.21	http://dx.doi.org/10.1038/onc.2011.21			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339738				2022-12-28	WOS:000292510100003
J	Garofalo, C; Manara, MC; Nicoletti, G; Marino, MT; Lollini, PL; Astolfi, A; Pandini, G; Lopez-Guerrero, JA; Schaefer, KL; Belfiore, A; Picci, P; Scotlandi, K				Garofalo, C.; Manara, M. C.; Nicoletti, G.; Marino, M. T.; Lollini, P-L; Astolfi, A.; Pandini, G.; Lopez-Guerrero, J. A.; Schaefer, K-L; Belfiore, A.; Picci, P.; Scotlandi, K.			Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling	ONCOGENE			English	Article						sarcomas; IGF-1R; insulin signaling; drug resistance	FACTOR-I RECEPTOR; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; INHIBITOR BMS-536924; DOWN-REGULATION; CELL-LINES; BREAST; SENSITIVITY; PATHWAY; GENE	Identification of patient selection criteria and understanding of the potential mechanisms involved in the development of resistance are crucial for an appropriate and successful design of clinical trials with anti-insulinlike growth factor (IGF)-1R therapies. Few Ewing's sarcomas are highly sensitive to IGF-1R targeting and understanding the reason why, may hold the secret to improve successful treatments. In this paper, we show that a major mechanism of resistance to highly specific inhibitors of IGF-1R, either antibodies or tyrosine kinase inhibitors may involve enhanced insulin receptor (IR)-A homodimer formation and IGF-2 production. Resistant cells are able to switch from IGF-1/IGF-1R to IGF-2/IRA dependency to maintain sustained activation of AKT and ERK1/2, proliferation, migration and metastasis. These cells also showed higher proliferative response to insulin, in keeping with a switch towards insulin pathways sustaining proliferation and malignancy, rather than metabolism. Our findings demonstrate a role for IR-A in eliciting intrinsic and adaptive resistance to anti-IGF-1R therapies. Thus, we indicate that tumors with low IGF1R: IR ratio are unlikely to greatly benefit from anti-IGF1R therapies and that the efficacy of anti-IGF-1R therapies should be evaluated in relationship to the IRA: IGF-1R ratio in cancer cells. Moreover, we provide evidences supporting IR-A as an important target in sarcoma therapy. Oncogene (2011) 30, 2730-2740; doi: 10.1038/onc.2010.640; published online 31 January 2011	[Scotlandi, K.] Ist Ortoped Rizzoli, CRS Dev Biomol Therapies, I-40136 Bologna, Italy; [Garofalo, C.; Manara, M. C.; Nicoletti, G.; Marino, M. T.; Picci, P.; Scotlandi, K.] Ist Ortoped Rizzoli, Expt Oncol Lab, I-40136 Bologna, Italy; [Lollini, P-L] Univ Bologna, Dept Hematol & Oncol Sci LA Seragnoli, St Orsola Malpighi Hosp, Bologna, Italy; [Astolfi, A.] Univ Bologna, G Prodi Canc Res Ctr, Bologna, Italy; [Pandini, G.] Univ Catania, Dept Internal Med & Med Specialties, Catania, Italy; [Lopez-Guerrero, J. A.] Fdn Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain; [Schaefer, K-L] Univ Med Ctr, Inst Pathol, Dusseldorf, Germany; [Belfiore, A.] Univ Catanzaro, Dept Clin & Expt Med, Catanzaro, Italy	IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna; University of Catania; Instituto Valenciano De Oncologia; Magna Graecia University of Catanzaro	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Belfiore, Antonino/B-4652-2011; Guerrero, Jose Antonio Lopez/Z-2413-2019; Astolfi, Annalisa/K-3034-2016; Pandini, Giuseppe/AAB-9650-2019; Manara, Maria Cristina/K-3366-2018; Garofalo, Cecilia/B-3834-2017; Scotlandi, Katia/J-9009-2016; Lollini, Pier Luigi/A-7644-2008; Picci, Piero/J-5979-2016	Belfiore, Antonino/0000-0002-6181-4193; Guerrero, Jose Antonio Lopez/0000-0002-7369-8388; Astolfi, Annalisa/0000-0002-2732-0747; Pandini, Giuseppe/0000-0003-3747-7649; Manara, Maria Cristina/0000-0001-5686-720X; Garofalo, Cecilia/0000-0001-5334-8930; Scotlandi, Katia/0000-0001-6114-9499; Lollini, Pier Luigi/0000-0003-1702-4108; Picci, Piero/0000-0002-8519-4101	Italian Association for Cancer Research; Italian Ministry of Health [RFPS-2006-3-340280]; Italian Ministry of Research and Instruction; EU [018814]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of Research and Instruction; EU(European Commission)	We thank Cristina Ghinelli and Alba Balladelli for their help in editing the manuscript. Studies are supported by grants from the Italian Association for Cancer Research (KS and AB), the Italian Ministry of Health (Strategico Oncologia RFPS-2006-3-340280; RF2008 to KS); the Italian Ministry of Research and Instruction (PRIN 2009) and the EU project Eurobonet (#018814).	Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008-5472.CAN-08-2645; Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047; Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.3.CO;2-F; Brierley GV, 2010, ENDOCRINOLOGY, V151, P1418, DOI 10.1210/en.2009-1006; Buck E, 2010, MOL CANCER THER, V9, P2652, DOI 10.1158/1535-7163.MCT-10-0318; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Casa AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3273, DOI 10.2741/2925; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Desbois-Mouthon C, 2009, CLIN CANCER RES, V15, P5445, DOI 10.1158/1078-0432.CCR-08-2980; Dinchuk JE, 2010, ENDOCRINOLOGY, V151, P4123, DOI 10.1210/en.2010-0032; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Gualberto A, 2010, CLIN CANCER RES, V16, P4654, DOI 10.1158/1078-0432.CCR-10-0089; Hendrickson AEW, 2009, CANCER RES, V69, P7635, DOI 10.1158/0008-5472.CAN-09-0511; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; KULL FC, 1983, J BIOL CHEM, V258, P6561; Machado I, 2009, DIAGN MOL PATHOL, V18, P189, DOI 10.1097/PDM.0b013e3181a06f66; Maloney EK, 2003, CANCER RES, V63, P5073; Manara MC, 2010, CLIN CANCER RES, V16, P530, DOI 10.1158/1078-0432.CCR-09-0816; Mukohara T, 2009, CANCER LETT, V282, P14, DOI 10.1016/j.canlet.2009.02.056; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Scotlandi K, 1996, CANCER RES, V56, P4570; Scotlandi K, 2008, CURR OPIN ONCOL, V20, P419, DOI 10.1097/CCO.0b013e328302edab; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; Zha JP, 2009, MOL CANCER THER, V8, P2110, DOI 10.1158/1535-7163.MCT-09-0381; Zhang H, 2010, ONCOGENE, V29, P2517, DOI 10.1038/onc.2010.17; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhou QL, 2004, BIOCHEM SOC T, V32, P817, DOI 10.1042/BST0320817	41	96	102	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2730	2740		10.1038/onc.2010.640	http://dx.doi.org/10.1038/onc.2010.640			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278796				2022-12-28	WOS:000291678500004
J	Janssen, A; Medema, RH				Janssen, A.; Medema, R. H.			Mitosis as an anti-cancer target	ONCOGENE			English	Review						mitosis; aneuploidy; CIN; therapy; cancer	SMALL-MOLECULE INHIBITOR; SPINDLE ASSEMBLY CHECKPOINT; CHROMOSOME MIS-SEGREGATION; CELL-CYCLE PROGRESSION; POLO-LIKE KINASE-1; AURORA-B KINASE; GROWTH IN-VIVO; CANCER-CELLS; MITOTIC CHECKPOINT; MAMMALIAN-CELLS	Most of the current drugs used to treat cancer can be classified as anti-proliferative drugs. These drugs perturb the proliferative cycle of tumor cells at diverse stages of the cell cycle. Examples of such drugs are DNA-damaging agents and inhibitors of cyclin-dependent kinases that arrest cell cycle progression at different stages of interphase. Another class of anti-proliferative drugs is the so-called anti-mitotic drugs, which selectively perturb progression through mitosis. Mitosis is the shortest and final stage in the cell cycle and has evolved to accurately divide the duplicated genome over the two daughter cells. This review deals with the different strategies that are currently considered to perturb mitotic progression in the treatment of cancer. Oncogene (2011) 30, 2799-2809; doi: 10.1038/onc.2011.30; published online 21 February 2011	[Janssen, A.; Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, Canc Genom Ctr, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, Canc Genom Ctr, Univ Weg 100,Str 2-233, NL-3584 CG Utrecht, Netherlands.	r.h.medema@umcutrecht.nl	Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381; Janssen, Aniek/0000-0001-6731-6657				Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Barr FA, 2007, CELL, V131, P847, DOI 10.1016/j.cell.2007.11.011; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; Brier S, 2006, J MOL BIOL, V360, P360, DOI 10.1016/j.jmb.2006.04.062; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Brito DA, 2009, CELL MOTIL CYTOSKEL, V66, P437, DOI 10.1002/cm.20316; Buffin E, 2007, NAT CELL BIOL, V9, P565, DOI 10.1038/ncb1570; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cohen J, 2002, SCIENCE, V296, P2164, DOI 10.1126/science.296.5576.2164; Colombo R, 2010, CANCER RES, V70, P10255, DOI 10.1158/0008-5472.CAN-10-2101; Cox CD, 2008, J MED CHEM, V51, P4239, DOI 10.1021/jm800386y; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duesberg P, 2000, CANCER GENET CYTOGEN, V119, P83, DOI 10.1016/S0165-4608(99)00236-8; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Godinho S, 2009, CANCER METAST REV, V28, P85, DOI 10.1007/s10555-008-9163-6; Goodin S, 2008, AM J HEALTH-SYST PH, V65, pS10, DOI 10.2146/ajhp080089; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Ha GH, 2007, CANCER RES, V67, P7155, DOI 10.1158/0008-5472.CAN-06-3392; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Huszar D, 2009, CANCER METAST REV, V28, P197, DOI 10.1007/s10555-009-9185-8; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Keen N, 2009, CANCER METAST REV, V28, P185, DOI 10.1007/s10555-009-9184-9; Khodjakov A, 2002, J CELL BIOL, V158, P1171, DOI 10.1083/jcb.200205102; Kitzen JJEM, 2010, CRIT REV ONCOL HEMAT, V73, P99, DOI 10.1016/j.critrevonc.2009.03.009; Kops GJPL, 2008, FRONT BIOSCI-LANDMRK, V13, P3606, DOI 10.2741/2953; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Lok W, 2010, ANTI-CANCER DRUG, V21, P339, DOI 10.1097/CAD.0b013e3283350dd1; Maliga Zoltan, 2006, BMC Chemical Biology, V6, P2, DOI 10.1186/1472-6769-6-2; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Mazumdar M, 2006, CURR BIOL, V16, P1559, DOI 10.1016/j.cub.2006.06.029; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Oke A, 2009, CANCER RES, V69, P4150, DOI 10.1158/0008-5472.CAN-08-3203; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; Pihan GA, 2001, CANCER RES, V61, P2212; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rieder CL, 2009, CANCER CELL, V16, P274, DOI 10.1016/j.ccr.2009.09.021; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; ROWINSKY EK, 1988, CANCER RES, V48, P4093; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1; Rusan NM, 2008, J CELL BIOL, V181, P719, DOI 10.1083/jcb.200802107; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schafer-Hales K, 2007, MOL CANCER THER, V6, P1317, DOI 10.1158/1535-7163.MCT-06-0703; Schmidt M, 2006, CELL CYCLE, V5, P159, DOI 10.4161/cc.5.2.2309; Schoffski P, 2009, ONCOLOGIST, V14, P559, DOI 10.1634/theoncologist.2009-0010; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Stobbe CC, 2002, INT J RADIAT BIOL, V78, P1149, DOI 10.1080/09553000210166570; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tanenbaum ME, 2009, CURR BIOL, V19, P1703, DOI 10.1016/j.cub.2009.08.027; Tcherniuk S, 2010, BIOCHEM PHARMACOL, V79, P864, DOI 10.1016/j.bcp.2009.11.001; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; TUXEN MK, 1994, CANCER TREAT REV, V20, P191, DOI 10.1016/0305-7372(94)90027-2; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, J CELL BIOL, V176, P173, DOI 10.1083/jcb.200607073; Uetake Y, 2010, CURR BIOL, V20, P1666, DOI 10.1016/j.cub.2010.08.018; Vader G, 2006, J CELL BIOL, V173, P833, DOI 10.1083/jcb.200604032; Vanneste D, 2009, CURR BIOL, V19, P1712, DOI 10.1016/j.cub.2009.09.019; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vitale I, 2008, CELL CYCLE, V7, P1956, DOI 10.4161/cc.7.13.6073; Wang ZGC, 2004, CANCER RES, V64, P64, DOI 10.1158/0008-5472.CAN-03-2570; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; WESTRA A, 1971, INT J RADIAT BIOL RE, V19, P467, DOI 10.1080/09553007114550601; Wilkinson RW, 2007, CLIN CANCER RES, V13, P3682, DOI 10.1158/1078-0432.CCR-06-2979; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Wood KW, 2010, P NATL ACAD SCI USA, V107, P5839, DOI 10.1073/pnas.0915068107; Wu LM, 2011, J BIOL CHEM, V286, P2236, DOI 10.1074/jbc.M110.174755; Yang Z, 2008, NAT CELL BIOL, V10, P748, DOI 10.1038/ncb1738; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yue QX, 2010, PLANTA MED, V76, P1037, DOI 10.1055/s-0030-1250073; Yuen KWY, 2005, CURR OPIN CELL BIOL, V17, P576, DOI 10.1016/j.ceb.2005.09.012; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010	131	87	93	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2799	2809		10.1038/onc.2011.30	http://dx.doi.org/10.1038/onc.2011.30			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21339734				2022-12-28	WOS:000291977800001
J	Hacker, S; Karl, S; Mader, I; Cristofanon, S; Schweitzer, T; Krauss, J; Rutkowski, S; Debatin, KM; Fulda, S				Haecker, S.; Karl, S.; Mader, I.; Cristofanon, S.; Schweitzer, T.; Krauss, J.; Rutkowski, S.; Debatin, K-M; Fulda, S.			Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation	ONCOGENE			English	Article						HDACI; apoptosis; medulloblastoma; mitochondria; chemotherapy	IN-VIVO; KU70 ACETYLATION; PROSTATE-CANCER; EXPRESSION; RESISTANCE; CASPASE-8; THERAPY; TRAIL; SENSITIZATION; SYSTEM	Despite aggressive therapies, the prognosis of children with high-risk medulloblastoma is still poor, thus underscoring the need to develop novel treatment strategies. Here, we report that histone deacetylase inhibitors (HDACI), that is, MS-275, valproic acid or SAHA, provide a novel strategy for sensitization of medulloblastoma to DNA-damaging drugs such as Doxorubicin, VP16 and Cisplatin by promoting p53-dependent, mitochondrial apoptosis. Mechanistic studies reveal that single-agent treatment with MS-275 causes acetylation of the non-histone protein Ku70, an event reported to release Bax from Ku70, whereas DNA-damaging drugs trigger p53 acetylation and accumulation. Combined treatment with MS-275 and Doxorubicin or VP16 cooperates to promote binding of p53 to Bax and p53-dependent Bax activation, resulting in enhanced loss of mitochondrial membrane potential, cytochrome c release and caspase-dependent apoptosis. Overexpression of Bcl-2 almost completely abolishes the MS-275-mediated chemosensitization, underlining the importance of the mitochondrial pathway for inducing apoptosis. Also, MS-275 cooperates with chemotherapeutics to inhibit long-term clonogenic survival. Most importantly, MS-275 increases chemotherapeutic drug-induced apoptosis in primary medulloblastoma samples, and cooperates with Doxorubicin to suppress medulloblastoma growth in an in vivo model, which underscores the clinical relevance of the findings. Thus, HDACI such as MS-275 present a promising approach for chemosensitization of medulloblastoma by enhancing mitochondrial apoptosis in a p53-dependent manner. These findings have important clinical implications for the design of experimental treatment protocols for medulloblastoma. Oncogene (2011) 30, 2275-2281; doi:10.1038/onc.2010.599; published online 17 January 2011	[Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Haecker, S.; Karl, S.; Mader, I.; Debatin, K-M] Univ Childrens Hosp, Ulm, Germany; [Schweitzer, T.; Krauss, J.] Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany; [Rutkowski, S.] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Schweitzer, Tilmann/K-6471-2014; Debatin, Klaus-Michael/J-9704-2014	Fulda, Simone/0000-0002-0459-6417; Debatin, Klaus-Michael/0000-0002-8397-1886	Deutsche Forschungsgemeinschaft [IAP6/18]; European Community	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community(European Commission)	We thank R Agami (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for kindly providing pRETRO-SUPER vector, CA Schmitt (Berlin, Germany) for providing mouse Bcl-2 vector and A Dittrich for expert technical assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, Else Kroner-Fresenius-Stiftung, IAP6/18 and the European Community (ApopTrain, APO-SYS) (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CS, 2007, CANCER RES, V67, P5318, DOI 10.1158/0008-5472.CAN-06-3996; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009; Jaboin J, 2002, CANCER RES, V62, P6108; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; Lee MJ, 2008, CURR OPIN ONCOL, V20, P639, DOI 10.1097/CCO.0b013e3283127095; Rossi A, 2008, CLIN CANCER RES, V14, P971, DOI 10.1158/1078-0432.CCR-07-2072; Rutkowski S, 2007, CLIN CANCER RES, V13, P2651, DOI 10.1158/1078-0432.CCR-06-1779; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Sykes SM, 2009, J BIOL CHEM, V284, P20197, DOI 10.1074/jbc.M109.026096; Tabori U, 2010, J CLIN ONCOL, V28, P1345, DOI 10.1200/JCO.2009.23.5952; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamaguchi H, 2009, J BIOL CHEM, V284, P11171, DOI 10.1074/jbc.M809268200	24	38	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2275	2281		10.1038/onc.2010.599	http://dx.doi.org/10.1038/onc.2010.599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21562496				2022-12-28	WOS:000290514600010
J	Kucejova, B; Sunny, NE; Nguyen, AD; Hallac, R; Fu, X; Pena-Llopis, S; Mason, RP; DeBerardinis, RJ; Xie, XJ; DeBose-Boyd, R; Kodibagkar, VD; Burgess, SC; Brugarolas, J				Kucejova, B.; Sunny, N. E.; Nguyen, A. D.; Hallac, R.; Fu, X.; Pena-Llopis, S.; Mason, R. P.; DeBerardinis, R. J.; Xie, X-J; DeBose-Boyd, R.; Kodibagkar, V. D.; Burgess, S. C.; Brugarolas, J.			Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death	ONCOGENE			English	Article						Vhl; Hif; liver steatosis; mitochondrial respiration	LINDAU TUMOR-SUPPRESSOR; RENAL-CELL CARCINOMA; CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; FATTY-ACID OXIDATION; RETINOID-X-RECEPTOR; HEPATIC GLUCONEOGENESIS; PROLINE HYDROXYLATION; PROLYL HYDROXYLATION; HIF-ALPHA; IN-VIVO	As the ultimate electron acceptor in oxidative phosphorylation, oxygen plays a critical role in metabolism. When oxygen levels drop, heterodimeric hypoxia-inducible factor (Hif) transcription factors become active and facilitate adaptation to hypoxia. Hif regulation by oxygen requires the protein von Hippel-Lindau (pVhl) and pVhl disruption results in constitutive Hif activation. The liver is a critical organ for metabolic homeostasis, and Vhl inactivation in hepatocytes results in a Hif-dependent shortening in life span. While albumin-Cre; Vhl(F/F) mice develop hepatic steatosis and impaired fatty acid oxidation, the variable penetrance and unpredictable life expectancy has made the cause of death elusive. Using a system in which Vhl is acutely disrupted and a combination of ex vivo liver perfusion studies and in vivo oxygen measurements, we demonstrate that Vhl is essential for mitochondrial respiration in vivo. Adenovirus-Cre mediated acute Vhl disruption in the liver caused death within days. Deprived of pVhl, livers accumulated tryglicerides and circulating ketone and glucose levels dropped. The phenotype was reminiscent of inborn defects in fatty acid oxidation and of fasted PPAR alpha-deficient mice and while death was unaffected by pharmacologic PPAR alpha activation, it was delayed by glucose administration. Ex vivo liver perfusion analyses and acylcarnitine profiles showed mitochondrial impairment and a profound inhibition of liver ketone and glucose production. By contrast, other mitochondrial functions, such as ureagenesis, were unaffected. Oxygen consumption studies revealed a marked suppression of mitochondrial respiration, which, as determined by magnetic resonance oximetry in live mice, was accompanied by a corresponding increase in liver pO(2). Importantly, simultaneous inactivation of Hif-1 beta suppressed liver steatosis and rescued the mice from death. These data demonstrate that constitutive Hif activation in mice is sufficient to suppress mitochondrial respiration in vivo and that no other pathway exists in the liver that can allow oxygen utilization when Hif is active precluding thereby metabolic collapse. Oncogene (2011) 30, 2147-2160; doi:10.1038/onc.2010.587; published online 10 January 2011	[Kucejova, B.; Pena-Llopis, S.; Brugarolas, J.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Kucejova, B.; Pena-Llopis, S.; Brugarolas, J.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Oncol, Dallas, TX 75390 USA; [Kucejova, B.; Pena-Llopis, S.; Xie, X-J; Brugarolas, J.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Sunny, N. E.; Fu, X.; Burgess, S. C.] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Nguyen, A. D.; DeBose-Boyd, R.] Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; [Hallac, R.; Mason, R. P.; Kodibagkar, V. D.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [DeBerardinis, R. J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Xie, X-J] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Brugarolas, J (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.brugarolas@utsouthwestern.edu	Peña-Llopis, Samuel/ABH-2358-2020; Mason, Ralph/C-8472-2012	Mason, Ralph/0000-0001-7517-3721; Pena-Llopis, Samuel/0000-0003-3847-1353; Kucejova, Blanka/0000-0002-5058-330X; Hallac, Rami/0000-0001-9025-399X; Nguyen, Andrew/0000-0002-9492-9472	American Cancer Society [115739, RO1CA129387]; Generalitat Valenciana (Spain);  [K08NS051843];  [RO1DK078184]; NATIONAL CANCER INSTITUTE [U24CA126608, R21CA132096, R01CA139043, R01CA129387] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS051843] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Generalitat Valenciana (Spain)(Center for Forestry Research & Experimentation (CIEF)); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs Frank J Gonzalez, Volker H Haase, William Y Kim and William G Kaelin Jr for mouse strains and reagents, Dr Michael Brown for discussions, and Dr Jay D Horton for critically reading the manuscript, TianTeng He for help with liver perfusion experiments, and members of the Brugarolas lab for discussions. This work was supported by the following grants to J.B: K08NS051843, American Cancer Society Research Scholar Grant (115739) and RO1CA129387 as well as an RO1DK078184 to S.B. MRI was performed in conjunction with R01CA139043 (R.P.M.) R21CA132096 (V.D.K.) and the UT Southwestern small animal imaging research program U24 CA126608 and P41 RR02584. S.P.-L. was supported in part by a fellowship from the Generalitat Valenciana (Spain). J.B. is a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.	Belanger AJ, 2007, BIOCHEM BIOPH RES CO, V364, P567, DOI 10.1016/j.bbrc.2007.10.062; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; Burgess SC, 2004, J BIOL CHEM, V279, P48941, DOI 10.1074/jbc.M407120200; Burgess SC, 2007, CELL METAB, V5, P313, DOI 10.1016/j.cmet.2007.03.004; Burgess SC, 2006, J BIOL CHEM, V281, P19000, DOI 10.1074/jbc.M600050200; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chen SF, 2010, ANGIOGENESIS, V13, P59, DOI 10.1007/s10456-010-9164-2; Chow TFF, 2010, CLIN BIOCHEM, V43, P150, DOI 10.1016/j.clinbiochem.2009.07.020; Ciana P, 2007, MOL ENDOCRINOL, V21, P388, DOI 10.1210/me.2006-0152; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; DOHM GL, 1972, AM J PHYSIOL, V223, P783, DOI 10.1152/ajplegacy.1972.223.4.783; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEBHARD RL, 1987, J LIPID RES, V28, P1177; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hong SB, 2006, LAB INVEST, V86, P664, DOI 10.1038/labinvest.3700431; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Juan D, 2010, UROLOGY, V75, P835, DOI 10.1016/j.urology.2009.10.033; Jung M, 2009, J CELL MOL MED, V13, P3918, DOI 10.1111/j.1582-4934.2009.00705.x; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Kuriyama H, 2005, CELL METAB, V1, P41, DOI 10.1016/j.cmet.2004.11.004; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lei L, 2008, MOL CELL BIOL, V28, P3790, DOI 10.1128/MCB.01580-07; Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-51; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; MASON RP, 1994, ARTIF CELL BLOOD SUB, V22, P1141, DOI 10.3109/10731199409138809; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDonald JM, 2009, J ANIM SCI, V87, P3105, DOI 10.2527/jas.2009-1935; MILLINGTON DS, 1990, J INHERIT METAB DIS, V13, P321, DOI 10.1007/BF01799385; Nguyen AD, 2007, J BIOL CHEM, V282, P27436, DOI 10.1074/jbc.M704976200; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 2006, NEOPLASIA, V8, P623, DOI 10.1593/neo.06442; Ozer A, 2007, NAT CHEM BIOL, V3, P144, DOI 10.1038/nchembio863; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Park SK, 2007, INT J ONCOL, V30, P341; Peyssonnaux C, 2007, J CLIN INVEST, V117, P1926, DOI 10.1172/JCI31370; Rankin EB, 2008, ONCOGENE, V27, P5354, DOI 10.1038/onc.2008.160; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Rankin EB, 2009, MOL CELL BIOL, V29, P4527, DOI 10.1128/MCB.00200-09; Saudubray JM, 1999, J INHERIT METAB DIS, V22, P488; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor CT, 2008, BIOCHEM J, V409, P19, DOI 10.1042/BJ20071249; Tomita S, 2000, MOL ENDOCRINOL, V14, P1674, DOI 10.1210/me.14.10.1674; Tosi MR, 2004, INT J MOL MED, V14, P93; Wakil SJ, 2009, J LIPID RES, V50, pS138, DOI 10.1194/jlr.R800079-JLR200; WILSON CA, 1992, EXP EYE RES, V55, P119, DOI 10.1016/0014-4835(92)90099-E; Wood PA, 1999, CURR OPIN LIPIDOL, V10, P107, DOI 10.1097/00041433-199904000-00004; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zambrano NR, 1999, J UROLOGY, V162, P1246, DOI 10.1016/S0022-5347(05)68259-6; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	65	38	41	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2147	2160		10.1038/onc.2010.587	http://dx.doi.org/10.1038/onc.2010.587			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217781	Green Accepted			2022-12-28	WOS:000290249600006
J	Brisson, L; Gillet, L; Calaghan, S; Besson, P; Le Guennec, JY; Roger, S; Gore, J				Brisson, L.; Gillet, L.; Calaghan, S.; Besson, P.; Le Guennec, J-Y; Roger, S.; Gore, J.			Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H+ efflux in caveolae	ONCOGENE			English	Article						cancer; caveolae; invasion; Na (broken vertical bar)/H (broken vertical bar) exchanger; voltage-gated sodium channels	GATED SODIUM-CHANNELS; CATHEPSIN-B; EXPRESSION; EXCHANGER	Na(V)1.5 sodium channels enhance the invasiveness of breast cancer cells through the acidic-dependent activation of cysteine cathepsins. Here, we showed that the Na+/H+ exchanger type 1 (NHE1) was an important regulator of H+ efflux in breast cancer cells MDA-MB-231 and that its activity was increased by Na(V)1.5. Na(V)1.5 and NHE1 were colocalized in membrane rafts containing caveolin-1. The inhibition of Na(V)1.5 or NHE1 induced a similar reduction in cell invasiveness and extracellular matrix degradation; no additive effect was observed when they were simultaneously inhibited. Our study suggests that NaV1.5 and NHE1 are functionally coupled and enhance the invasiveness of cancer cells by increasing H+ efflux. Oncogene (2011) 30, 2070-2076; doi:10.1038/onc.2010.574; published online 20 December 2010	[Brisson, L.; Gillet, L.; Besson, P.; Roger, S.; Gore, J.] Univ Tours, Fac Med, INSERM, U921, F-37032 Tours, Region Center, France; [Calaghan, S.] Univ Leeds, Inst Syst & Membrane Biol, Leeds, W Yorkshire, England; [Le Guennec, J-Y] Univ Montpellier 2, INSERM, Physiopathol cardiovasc U637, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; University of Leeds; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Roger, S (corresponding author), Univ Tours, Fac Med, INSERM, U921, 10 Blvd Tonnelle, F-37032 Tours, Region Center, France.	sebastien.roger@univ-tours.fr	Brisson, Lucie/R-1179-2016; LE GUENNEC, Jean-Yves/P-1067-2016	Brisson, Lucie/0000-0001-7811-1382; Roger, Sebastien/0000-0002-9852-5248; Gillet, Ludovic/0000-0002-4990-6212; Calaghan, Sarah/0000-0002-9145-2576	Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (Inserm); Association CANCEN; Ligue Nationale Contre le Cancer; Region Centre	Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association CANCEN; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Region Centre(Region Centre-Val de Loire)	We thank Dr Lin-Hua Jiang (University of Leeds, UK) for comments about the manuscript. We are grateful to Dr Ming Lei (University of Manchester, UK) for the generous gift of the anti-Na<INF>V</INF>1.5 antibody. This work was supported by the 'Ministere de la Recherche et des Technologies' and the 'Institut National de la Sante et de la Recherche Medicale' (Inserm), the 'Association CANCEN' and a grant from the 'Ligue Nationale Contre le Cancer'. Lucie Brisson and Ludovic Gillet were recipients of fellowships from the 'Region Centre'.	Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Busco G, 2010, FASEB J, V24, P3903, DOI 10.1096/fj.09-149518; Calaghan S, 2008, J MOL CELL CARDIOL, V45, P88, DOI 10.1016/j.yjmcc.2008.04.004; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Diaz D, 2007, J CELL PHYSIOL, V210, P469, DOI 10.1002/jcp.20871; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fraser SP, 2005, CLIN CANCER RES, V11, P5381, DOI 10.1158/1078-0432.CCR-05-0327; Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922; Gillet L, 2009, J BIOL CHEM, V284, P8671, DOI 10.1074/jbc.M806891200; Giusti I, 2008, NEOPLASIA, V10, P481, DOI 10.1593/neo.08178; GORE J, 1994, AM J PHYSIOL, V266, pC110, DOI 10.1152/ajpcell.1994.266.1.C110; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Kraus M, 1996, TUMOR BIOL, V17, P133, DOI 10.1159/000217977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laniado ME, 1997, AM J PATHOL, V150, P1213; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Moellering RE, 2008, CLIN EXP METASTAS, V25, P411, DOI 10.1007/s10585-008-9145-7; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Roger S, 2003, BBA-BIOMEMBRANES, V1616, P107, DOI 10.1016/j.bbamem.2003.07.001; Roger S, 2007, INT J BIOCHEM CELL B, V39, P774, DOI 10.1016/j.biocel.2006.12.007; Roger S, 2006, CURR PHARM DESIGN, V12, P3681, DOI 10.2174/138161206778522047; ROZHIN J, 1994, CANCER RES, V54, P6517; Stock C, 2009, PFLUG ARCH EUR J PHY, V458, P981, DOI 10.1007/s00424-009-0677-8; Tekpli X, 2008, J CELL PHYSIOL, V216, P207, DOI 10.1002/jcp.21395; Xu SZ, 2005, NAT BIOTECHNOL, V23, P1289, DOI 10.1038/nbt1148; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305	27	135	144	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2070	2076		10.1038/onc.2010.574	http://dx.doi.org/10.1038/onc.2010.574			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21170089	Green Submitted			2022-12-28	WOS:000289977400010
J	Algire, C; Amrein, L; Bazile, M; David, S; Zakikhani, M; Pollak, M				Algire, C.; Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.; Pollak, M.			Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo	ONCOGENE			English	Article						metformin; insulin; cancer; LKB1	HIGH-ENERGY DIET; BREAST-CANCER; DIABETES-MELLITUS; LKB1-AMPK PATHWAY; GLUCOSE-UPTAKE; RISK; GROWTH; KINASE; ACTIVATION; INSULIN	Hypothesis-generating epidemiological research has suggested that cancer burden is reduced in diabetics treated with metformin and experimental work has raised questions regarding the role of direct adenosine monophosphate-activated protein kinase (AMPK)-mediated antineoplastic effects of metformin as compared with indirect effects attributable to reductions in circulating insulin levels in the host. We treated both tumor LKB1 expression and host diet as variables, and observed that metformin inhibited tumor growth and reduced insulin receptor activation in tumors of mice with diet-induced hyperinsulinemia, independent of tumor LKB1 expression. In the absence of hyperinsulinemia, metformin inhibited only the growth of tumors transfected with short hairpin RNA against LKB1, a finding attributable neither to an effect on host insulin level nor to activation of AMPK within the tumor. Further investigation in vitro showed that cells with reduced LKB1 expression are more sensitive to metformin-induced adenosine triphosphate depletion owing to impaired ability to activate LKB1-AMPK-dependent energy-conservation mechanisms. Thus, loss of function of LKB1 can accelerate proliferation in contexts where it functions as a tumor suppressor, but can also sensitize cells to metformin. These findings predict that any clinical utility of metformin or similar compounds in oncology will be restricted to subpopulations defined by host insulin levels and/or loss of function of LKB1. Oncogene (2011) 30, 1174-1182; doi:10.1038/onc.2010.483; published online 22 November 2010	[Algire, C.; Pollak, M.] McGill Univ, Segal Canc Ctr E423, Jewish Gen Hosp, Dept Expt Med, Montreal, PQ H3T 1E2, Canada; [Algire, C.; Pollak, M.] McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University; Lady Davis Institute; McGill University	Pollak, M (corresponding author), McGill Univ, Segal Canc Ctr E423, Jewish Gen Hosp, Dept Expt Med, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	michael.pollak@mcgill.ca	Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604	Terry Fox Research Institute; Montreal Centre for Experimental Therapeutics in Cancer; Canadian Institute of Health Research Canada	Terry Fox Research Institute; Montreal Centre for Experimental Therapeutics in Cancer; Canadian Institute of Health Research Canada(Canadian Institutes of Health Research (CIHR))	We thank Dr Andre Veillette for his advice and technical expertise, Dr Pnina Brodt for the MC38 cells, Drs Lawrence Panasci and Ernesto Schiffrin for sharing laboratory resources, and Dr Nahum Sonenberg and Dr Russell Jones for reviewing the manuscript prior to submission. This work was supported by a grant from the Terry Fox Research Institute. Ms Algire is supported through the Montreal Centre for Experimental Therapeutics in Cancer student fellowship and the Canadian Institute of Health Research Canada Graduate Fellowship.	Algire C, 2008, ENDOCR-RELAT CANCER, V15, P833, DOI 10.1677/ERC-08-0038; Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252; BLAKE DA, 1989, ANAL BIOCHEM, V177, P156, DOI 10.1016/0003-2697(89)90031-6; Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Dykens JA, 2008, TOXICOL APPL PHARM, V233, P203, DOI 10.1016/j.taap.2008.08.013; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Engelman JA, 2010, CANCER PREV RES, V3, P1049, DOI 10.1158/1940-6207.CAPR-10-0178; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2006, GASTROENTEROLOGY, V131, P973, DOI 10.1053/j.gastro.2006.07.032; HOSONO K, 2007, CAN PREV RES, V3, P1077; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Larsson SC, 2005, JNCI-J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375; Larsson SC, 2007, INT J CANCER, V121, P856, DOI 10.1002/ijc.22717; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175; Pollak M, 2009, CELL METAB, V9, P401, DOI 10.1016/j.cmet.2009.04.006; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x; van Lier MGF, 2010, AM J GASTROENTEROL, V105, P1258, DOI 10.1038/ajg.2009.725; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081	48	150	158	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1174	1182		10.1038/onc.2010.483	http://dx.doi.org/10.1038/onc.2010.483			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21102522				2022-12-28	WOS:000288202400004
J	Huynh, C; Segura, MF; Gaziel-Sovran, A; Menendez, S; Darvishian, F; Chiriboga, L; Levin, B; Meruelo, D; Osman, I; Zavadil, J; Marcusson, EG; Hernando, E				Huynh, C.; Segura, M. F.; Gaziel-Sovran, A.; Menendez, S.; Darvishian, F.; Chiriboga, L.; Levin, B.; Meruelo, D.; Osman, I.; Zavadil, J.; Marcusson, E. G.; Hernando, E.			Efficient in vivo microRNA targeting of liver metastasis	ONCOGENE			English	Article						microRNA; melanoma; metastasis; liver; miR-182	ANTISENSE OLIGONUCLEOTIDES; LUNG-CANCER; MELANOMA; THERAPY; CELLS; EXPRESSION; MIR-182; SIRNA; PROGRESSION; PRIMATES	Targeting oncogenic microRNAs ( miRNAs) is emerging as a promising strategy for cancer therapy. In this study, we provide proof of principle for the safety and efficacy of miRNA targeting against metastatic tumors. We tested the impact of targeting miR-182, a pro-metastatic miRNA frequently overexpressed in melanoma, the in vitro silencing of which represses invasion and induces apoptosis. Specifically, we assessed the effect of anti-miR-182 oligo-nucleotides synthesized with 20 sugar modifications and a phosphorothioate backbone in a mouse model of melanoma liver metastasis. Luciferase imaging showed that mice treated with anti-miR-182 had a lower burden of liver metastases compared with control. We confirmed that miR-182 levels were effectively downregulated in the tumors of anti-miR-treated mice compared with tumors of control-treated mice, both in the liver and in the spleen. This effect was accompanied by an upregulation of multiple miR-182 direct targets. Transcriptional profiling of tumors treated with anti-miR-182 or with control oligo-nucleotides revealed an enrichment of genes controlling survival, adhesion and migration modulated in response to anti-miR-182 treatment. These data indicate that in vivo administration of anti-miRs allows for efficient miRNA targeting and concomitant upregulation of miRNA-controlled genes. Our results demonstrate that the use of anti-miR-182 is a promising therapeutic strategy for metastatic melanoma and provide a solid basis for testing similar strategies in human metastatic tumors. Oncogene (2011) 30, 1481-1488; doi:10.1038/onc.2010.523; published online 22 November 2010	[Huynh, C.; Segura, M. F.; Gaziel-Sovran, A.; Menendez, S.; Darvishian, F.; Chiriboga, L.; Levin, B.; Meruelo, D.; Zavadil, J.; Hernando, E.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Huynh, C.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Osman, I.] NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; [Zavadil, J.] NYU, Sch Med, NYU Ctr Hlth Informat & Bioinformat, New York, NY 10016 USA; [Huynh, C.; Segura, M. F.; Gaziel-Sovran, A.; Menendez, S.; Darvishian, F.; Chiriboga, L.; Osman, I.; Hernando, E.] NYU, Sch Med, Interdisciplinary Melanoma Cooperat Grp, New York, NY 10016 USA; [Marcusson, E. G.] Regulus Therapeut Inc, San Diego, CA USA	New York University; New York University; New York University; New York University; New York University; Isis Pharmaceuticals Inc	Hernando, E (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave,Smilow 305, New York, NY 10016 USA.	eva.hernando@med.nyu.edu	Segura, Miguel F/J-4749-2013; Zavadil, Jiri/ABG-1780-2020	Segura, Miguel F/0000-0003-0916-3618; Zavadil, Jiri/0000-0003-0640-5562; Marcusson, Eric/0000-0002-0504-8674; Hernando, Eva/0000-0003-1023-0312; Chiriboga, Luis/0000-0002-2028-6873	ConCerN foundation; Harry Lloyd Charitable Trust; NYU; National Cancer Center; NIH [T32 CA09454-19]; NATIONAL CANCER INSTITUTE [T32CA009454] Funding Source: NIH RePORTER	ConCerN foundation; Harry Lloyd Charitable Trust; NYU; National Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the NYU Cancer Institute Genomics Facility for array profiling. We are grateful to Dr Cindy Loomis and members of the NYU Histopathology (Tim Macatee) and the Immunohistochemistry Core Laboratories for tissue processing and histological staining, and to Dr Elisa de Stanchina (MSKCC Antitumor Assessment core facility) for mouse blood work. This work was funded by the ConCerN foundation and the Harry Lloyd Charitable Trust. CH is supported by the NYU Physician Scientist Training Program, National Cancer Center Postdoctoral fellowship and the NIH T32 CA09454-19 fellowship training grant. MFS by a National Cancer Center Postdoctoral fellowship.	Bandres E, 2007, ONCOL REP, V17, P1089; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Camacho LH, 2009, J CLIN ONCOL, V27, P1075, DOI 10.1200/JCO.2008.19.2435; Chi KN, 2008, CLIN CANCER RES, V14, P833, DOI 10.1158/1078-0432.CCR-07-1310; Chijiwa Tsuyoshi, 2009, Int J Oncol, V34, P5; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Davis S, 2009, NUCLEIC ACIDS RES, V37, P70, DOI 10.1093/nar/gkn904; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Garbe C, 2009, CLIN DERMATOL, V27, P3, DOI 10.1016/j.clindermatol.2008.09.001; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hau P, 2009, EXPERT REV ANTICANC, V9, P1663, DOI [10.1586/era.09.138, 10.1586/ERA.09.138]; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389; Jiang LL, 2010, AM J PATHOL, V177, P29, DOI 10.2353/ajpath.2010.090812; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krumschnabel G, 2009, ONCOGENE, V28, P3093, DOI 10.1038/onc.2009.173; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Paschos KA, 2010, HEPATOL RES, V40, P83, DOI 10.1111/j.1872-034X.2009.00578.x; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rubin Krista M, 2009, Oncology (Williston Park), V23, P13; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; Tong AW, 2008, CANCER GENE THER, V15, P341, DOI 10.1038/cgt.2008.8; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Treisman J, 2010, CLIN PLAST SURG, V37, P127, DOI 10.1016/j.cps.2009.07.008; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Valastyan S, 2009, RNA BIOL, V6, P541, DOI 10.4161/rna.6.5.10081; Valastyan S, 2009, CELL CYCLE, V8, P3506, DOI 10.4161/cc.8.21.9802; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646	43	82	88	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1481	1488		10.1038/onc.2010.523	http://dx.doi.org/10.1038/onc.2010.523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102518				2022-12-28	WOS:000288743800010
J	Andradas, C; Caffarel, MM; Perez-Gomez, E; Salazar, M; Lorente, M; Velasco, G; Guzman, M; Sanchez, C				Andradas, C.; Caffarel, M. M.; Perez-Gomez, E.; Salazar, M.; Lorente, M.; Velasco, G.; Guzman, M.; Sanchez, C.			The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK	ONCOGENE			English	Article						G protein-coupled receptors; GPR55; cancer; cannabinoids	L-ALPHA-LYSOPHOSPHATIDYLINOSITOL; CANNABINOID RECEPTOR; LIGAND; IDENTIFICATION; TRANSCRIPTION; ACTIVATION; PATHWAYS; BRAIN	GPR55 is an orphan G protein-coupled receptor that may be engaged by some lipid ligands such as lysophosphatidylinositol and cannabinoid-type compounds. Very little is known about its expression pattern and physio-pathological relevance, and its pharmacology and signaling are still rather controversial. Here we analyzed the expression and function of GPR55 in cancer cells. Our data show that GPR55 expression in human tumors from different origins correlates with their aggressiveness. Moreover, GPR55 promotes cancer cell proliferation, both in cell cultures and in xenografted mice, through the overactivation of the extracellular signal-regulated kinase cascade. These findings reveal the importance of GPR55 in human cancer, and suggest that it could constitute a new biomarker and therapeutic target in oncology. Oncogene (2011) 30, 245-252; doi:10.1038/onc.2010.402; published online 6 September 2010	[Andradas, C.; Caffarel, M. M.; Perez-Gomez, E.; Salazar, M.; Lorente, M.; Velasco, G.; Guzman, M.; Sanchez, C.] Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Sanchez, C (corresponding author), Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, C Jose Antonio Novais 2, E-28040 Madrid, Spain.	cristina.sanchez@quim.ucm.es	Roa, Maria Salazar/I-1168-2015; Pérez-Gómez, Eduardo/GYA-5856-2022; Perez-gomez, Eduardo/F-5906-2015; Velasco, Guillermo/H-5260-2012; Velasco, Guillermo/AAU-9189-2020; Lorente, Mar/K-2401-2014; Lorente, Mar/O-5106-2017; Sanchez, Cristina/H-4980-2017; Sanchez, Cristina/AFQ-4745-2022	Roa, Maria Salazar/0000-0001-6784-9541; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Perez-gomez, Eduardo/0000-0003-0160-5565; Velasco, Guillermo/0000-0002-1994-2386; Velasco, Guillermo/0000-0002-1994-2386; Lorente, Mar/0000-0003-0982-0956; Sanchez, Cristina/0000-0002-1428-3078; Guzman, Manuel/0000-0001-7475-118X; Caffarel, Maria/0000-0002-7442-6827	Ministerio de Ciencia e Innovacion; Fundacion Ferrer para la Investigacion; Comunidad de Madrid; Fondo de Investigaciones Sanitarias; Fundacion Mutua Madrilena; GW Pharmaceuticals/Otsuka Pharmaceuticals	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion Ferrer para la Investigacion; Comunidad de Madrid(Comunidad de Madrid); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); GW Pharmaceuticals/Otsuka Pharmaceuticals(Otsuka Pharmaceutical)	We are indebted to the members of our laboratory for technical support and critical discussions on this work. CA and MMC were recipients of fellowships from Ministerio de Ciencia e Innovacion and from Fundacion Ferrer para la Investigacion, respectively. MS and ML were recipients of contracts (Research Formation and Postdoctoral, respectively) from Comunidad de Madrid. This work was supported by grants from Fondo de Investigaciones Sanitarias (C Sanchez), Fundacion Mutua Madrilena (C Sanchez), Ministerio de Ciencia e Innovacion (G Velasco and M Guzman), Comunidad de Madrid (M Guzman) and GW Pharmaceuticals/Otsuka Pharmaceuticals (C Sanchez).	Brown AJ, 2009, VITAM HORM, V81, P111, DOI 10.1016/S0083-6729(09)81005-4; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Caffarel MM, 2006, CANCER RES, V66, P6615, DOI 10.1158/0008-5472.CAN-05-4566; Daly CJ, 2010, BRIT J PHARMACOL, V159, P787, DOI 10.1111/j.1476-5381.2009.00608.x; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; ELSTON EW, 1993, J CLIN PATHOL, V46, P189; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Henstridge CM, 2010, BRIT J PHARMACOL, V160, P604, DOI 10.1111/j.1476-5381.2009.00625.x; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Murph M, 2006, CLIN CANCER RES, V12, P6598, DOI 10.1158/1078-0432.CCR-06-1721; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; Oka S, 2009, J BIOCHEM, V145, P13, DOI 10.1093/jb/mvn136; Pietr M, 2009, FEBS LETT, V583, P2071, DOI 10.1016/j.febslet.2009.05.028; Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169-328X(98)00277-0; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Waldeck-Weiermair M, 2008, J CELL SCI, V121, P1704, DOI 10.1242/jcs.020958; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106; Worzfeld T, 2008, TRENDS PHARMACOL SCI, V29, P582, DOI 10.1016/j.tips.2008.08.002; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200	31	137	144	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					245	252		10.1038/onc.2010.402	http://dx.doi.org/10.1038/onc.2010.402			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818416				2022-12-28	WOS:000286438900012
J	Haberkorn, U; Markert, A; Mier, W; Askoxylakis, V; Altmann, A				Haberkorn, U.; Markert, A.; Mier, W.; Askoxylakis, V.; Altmann, A.			Molecular imaging of tumor metabolism and apoptosis	ONCOGENE			English	Review						glucose metabolism; amino-acid transport; PET; imaging; tumor; apoptosis	AMINO-ACID-TRANSPORT; MAGNETIC-RESONANCE-SPECTROSCOPY; CHOLINE PHOSPHOLIPID-METABOLISM; POSITRON-EMISSION-TOMOGRAPHY; ALPHA-AMINOISOBUTYRIC-ACID; MAMMARY EPITHELIAL-CELLS; HSV THYMIDINE KINASE; BREAST-CANCER CELLS; GLUCOSE-TRANSPORTER; PROTEIN-SYNTHESIS	Increased metabolism in a number of cellular pathways is a common feature of malignant tumors. This metabolic hallmark of neoplastic tissue led to the development of radiopharmaceuticals for the assessment of transport and enzymatic activity for tumor diagnosis and staging. The malignant transformation causes the activation of oncogenic proteins and signaling pathways that stimulate glycolysis. The resulting high-glucose metabolism of cancer cells allows PET imaging using FDG. Other molecules frequently applied in preclinical and clinical studies are C-11-methionine, tyrosine analogs and choline-based tracers. Using quantitative procedures they enable therapy monitoring by assessment of changes in transport and metabolization. As apoptosis is an important mechanism of cell death in tumors responding to treatment, non-invasive assessment of apoptosis using tracers for detection of phosphatidyl-serine presentation and/or caspase activation could be used as a surrogate marker for therapeutic efficacy. Oncogene (2011) 30, 4141-4151; doi:10.1038/onc.2011.169; published online 16 May 2011	[Haberkorn, U.; Markert, A.; Mier, W.; Askoxylakis, V.; Altmann, A.] Univ Heidelberg Hosp, Dept Nucl Med, D-69120 Heidelberg, Germany; [Haberkorn, U.; Markert, A.; Altmann, A.] DKFZ, Clin Cooperat Unit Nucl Med, D-69120 Heidelberg, Germany; [Askoxylakis, V.] Heidelberg Univ, Dept Radiat Therapy, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Haberkorn, U (corresponding author), Univ Heidelberg Hosp, Dept Nucl Med, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Uwe.Haberkorn@med.uni-heidelberg.de						Aboagye EO, 1999, CANCER RES, V59, P80; Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Bassa P, 1996, J NUCL MED, V37, P931; Bauer C, 2005, J NUCL MED, V46, P1066; BERGSTROM M, 1987, J COMPUT ASSIST TOMO, V11, P815, DOI 10.1097/00004728-198709000-00014; Blankenberg FG, 1999, J NUCL MED, V40, P184; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Bogin L, 1998, BBA-LIPID LIPID MET, V1392, P217, DOI 10.1016/S0005-2760(98)00035-6; Brown RS, 1999, J NUCL MED, V40, P556; BUSCH H, 1959, CANCER RES, V19, P1030; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CUADRADO A, 1993, ONCOGENE, V8, P2959; CUADRADO A, 1994, J CELL PHYSIOL, V159, P434, DOI 10.1002/jcp.1041590307; DAEMEN BJG, 1991, J NUCL MED, V32, P1587; de Domenech E. E. Machado, 1980, FEBS LETT, V119, P174, DOI DOI 10.1016/0014-5793(80)81024-6; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; DeGrado TR, 2001, CANCER RES, V61, P110; DeGrado TR, 2001, J NUCL MED, V42, P1805; DUNZENDORFER U, 1981, EUR J NUCL MED, V6, P535; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; GALLAGHER BM, 1977, J NUCL MED, V18, P990; GALONS JP, 1995, MAGN RESON MED, V33, P422, DOI 10.1002/mrm.1910330317; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Gribbestad IS, 1999, ANTICANCER RES, V19, P1737; GUTHRIDGE CJ, 1994, CANCER LETT, V86, P11, DOI 10.1016/0304-3835(94)90175-9; HABERKORN U, 1994, NUCL MED BIOL, V21, P827, DOI 10.1016/0969-8051(94)90162-7; Haberkorn U, 1997, J NUCL MED, V38, P1048; Haberkorn U, 2005, CURR MED CHEM, V12, P779, DOI 10.2174/0929867053507351; HABERKORN U, 1993, J NUCL MED, V34, P12; HABERKORN U, 1992, J NUCL MED, V33, P1981; HABERKORN U, 1991, J NUCL MED, V32, P1485; Haberkorn U, 2001, EUR J NUCL MED, V28, P1690, DOI 10.1007/s002590100644; Haberkorn U, 2001, NUCL MED BIOL, V28, P793, DOI 10.1016/S0969-8051(01)00247-5; Haberkorn U, 2001, EUR J NUCL MED, V28, P418, DOI 10.1007/s002590100489; Haberkorn U, 1997, J NUCL MED, V38, P1215; Haberkorn U, 1998, GENE THER, V5, P880, DOI 10.1038/sj.gt.3300679; HAEFFNER EW, 1975, EUR J BIOCHEM, V51, P219, DOI 10.1111/j.1432-1033.1975.tb03922.x; Hara T, 2002, J NUCL MED, V43, P187; Hara T, 1998, J NUCL MED, V39, P990; HAYES N, 1993, BIOCHEM BIOPH RES CO, V190, P881, DOI 10.1006/bbrc.1993.1131; Heiss P, 1999, J NUCL MED, V40, P1367; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HIGASHI K, 1993, J NUCL MED, V34, P773; HUGHES CS, 1989, CANCER RES, V49, P4452; Ishiwata K, 1996, J NUCL MED, V37, P279; ISSELBACHER KJ, 1972, NEW ENGL J MED, V286, P929; Jager PL, 2001, J NUCL MED, V42, P432; JANSSON T, 1995, J CLIN ONCOL, V13, P1470, DOI 10.1200/JCO.1995.13.6.1470; Katz-Brull R, 1996, ANTICANCER RES, V16, P1375; KISS Z, 1993, FEBS LETT, V336, P115, DOI 10.1016/0014-5793(93)81622-7; Kobori D, 1999, CANCER-AM CANCER SOC, V86, P1638, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1638::AID-CNCR4>3.0.CO;2-U; Kurhanewicz J, 2000, NEOPLASIA, V2, P166, DOI 10.1038/sj.neo.7900081; Kuwert T, 1997, J NUCL MED, V38, P1551; Kwee SA, 2006, J NUCL MED, V47, P262; Kwee SA, 2004, J NEUROIMAGING, V14, P285, DOI 10.1177/1051228404264957; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Langen KJ, 1997, J NUCL MED, V38, P517; Leach MO, 1998, NMR BIOMED, V11, P314, DOI 10.1002/(SICI)1099-1492(1998110)11:7<314::AID-NBM522>3.0.CO;2-Z; Li XJ, 2002, J MAGN RESON IMAGING, V16, P229, DOI 10.1002/jmri.10147; Lindholm P, 1998, J NUCL MED, V39, P1393; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McConathy J, 2002, J MED CHEM, V45, P2240, DOI 10.1021/jm010241x; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NEGENDANK W, 1992, NMR BIOMED, V5, P303, DOI 10.1002/nbm.1940050518; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; OGAWA T, 1991, ACTA RADIOL, V32, P197; Pauleit D, 2005, BRAIN, V128, P678, DOI 10.1093/brain/awh399; Popperl G, 2004, EUR J NUCL MED MOL I, V31, P1464, DOI 10.1007/s00259-004-1590-1; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Rau FC, 2002, EUR J NUCL MED MOL I, V29, P1039, DOI 10.1007/s00259-002-0821-6; Ronen SM, 2001, BRIT J CANCER, V84, P691, DOI 10.1054/bjoc.2000.1663; ROZENTAL JM, 1989, ARCH NEUROL-CHICAGO, V46, P1302, DOI 10.1001/archneur.1989.00520480044018; SAIER MH, 1988, J MEMBRANE BIOL, V104, P1, DOI 10.1007/BF01871898; Salber D, 2007, J NUCL MED, V48, P2056, DOI 10.2967/jnumed.107.046615; SCANLON KJ, 1987, CANCER CHEMOTH PHARM, V19, P21, DOI 10.1007/BF00296249; SCANLON KJ, 1983, CANCER RES, V43, P4211; Schaider H, 1996, EUR J NUCL MED, V23, P55, DOI 10.1007/BF01736990; SHAWVER LK, 1987, MOL CELL BIOL, V7, P2112, DOI 10.1128/MCB.7.6.2112; Shoup TM, 1999, J NUCL MED, V40, P331; Sieger S, 2004, CANCER GENE THER, V11, P41, DOI 10.1038/sj.cgt.7700654; Sieger S, 2003, EUR J NUCL MED MOL I, V30, P748, DOI 10.1007/s00259-002-1099-4; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; SOLS A, 1954, J BIOL CHEM, V210, P581; Uehara H, 1997, J CEREBR BLOOD F MET, V17, P1239, DOI 10.1097/00004647-199711000-00013; VAALBURG W, 1992, NUCL MED BIOL, V19, P227, DOI 10.1016/0883-2897(92)90011-M; Vansteenkiste JF, 1999, J CLIN ONCOL, V17, P3201, DOI 10.1200/JCO.1999.17.10.3201; Vees H, 2009, EUR J NUCL MED MOL I, V36, P182, DOI 10.1007/s00259-008-0943-6; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; Wester HJ, 1999, J NUCL MED, V40, P205; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; WIENHARD K, 1991, J NUCL MED, V32, P1338; WILLEMSEN ATM, 1995, J NUCL MED, V36, P411; Wurker M, 1996, EUR J NUCL MED, V23, P583; Zhou D, 2009, ORG BIOMOL CHEM, V7, P1337, DOI 10.1039/b819024k; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	99	29	32	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	40					4141	4151		10.1038/onc.2011.169	http://dx.doi.org/10.1038/onc.2011.169			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21577202				2022-12-28	WOS:000295924600001
J	Hannigan, GE; McDonald, PC; Walsh, MP; Dedhar, S				Hannigan, G. E.; McDonald, P. C.; Walsh, M. P.; Dedhar, S.			Integrin-linked kinase: Not so 'pseudo' after all	ONCOGENE			English	Review						integrin-linked kinase; phosphorylation; cancer	SMOOTH-MUSCLE CONTRACTION; PROTEIN-KINASE; CANCER-CELLS; MOLECULAR DISSECTION; DEPENDENT REGULATION; THERAPEUTIC TARGET; B/AKT ACTIVATION; PLASMA-MEMBRANE; FOCAL ADHESIONS; BREAST-CANCER	Integrin-linked kinase (ILK) is a highly evolutionarily conserved intracellular protein that was originally identified as an integrin-interacting protein, and extensive genetic and biochemical studies have shown that ILK expression is vital during both embryonic development and tissue homeostasis. At the cellular and tissue levels, ILK regulates signaling pathways for cell adhesion-mediated cell survival (anoikis), apoptosis, proliferation and mitosis, migration, invasion, and vascularization and tumor angiogenesis. ILK also has central roles in cardiac and smooth-muscle contractility, and ILK dysregulation causes cardiomyopathies in humans. ILK protein levels are increased in several human cancers and often the expression level predicts poor patient outcome. Abundant evidence has accumulated suggesting that, of the diverse functions of ILK, some may require kinase activity whereas others depend on protein-protein interactions and are, therefore, independent of kinase activity. However, the past several years have seen an ongoing debate about whether ILK indeed functions as a protein serine/threonine kinase. This debate centers on the atypical protein kinase domain of ILK, which lacks some amino-acid residues thought to be essential for phosphotransferase activity. However, similar deficiencies are present in the catalytic domains of other kinases now known to possess protein kinase activity. Numerous studies have shown that ILK phosphorylates peptide substrates in vitro, corresponding to ILK-mediated phosphorylations in intact cells, and a recent report characterizing in vitro phosphotransferase activity of highly purified, full-length ILK, accompanied by detailed enzyme kinetic analyses, shows that, at least in vitro, ILK is a bona fide protein kinase. However, several genetic studies suggest that, not all biological functions of ILK require kinase activity, and that it can function as an adaptor/scaffold protein. Here, we review evidence for and against ILK being an active kinase, and provide a framework for strategies to further analyze the kinase and adaptor functions of ILK in different cellular contexts. Oncogene (2011) 30, 4375-4385; doi:10.1038/onc.2011.177; published online 23 May 2011	[McDonald, P. C.; Dedhar, S.] BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada; [Hannigan, G. E.] Monash Inst Med Res, Ctr Canc Res, Melbourne, Vic, Australia; [Walsh, M. P.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; Monash University; University of Calgary; University of British Columbia	Dedhar, S (corresponding author), BC Canc Res Ctr, Dept Integrat Oncol, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657	Canadian Institutes of Health Research; Canadian Cancer Society Research Institute; National Health and Medical Research Council (NHMRC) of Australia	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by funding from the Canadian Institutes of Health Research (to SD and MPW), the Canadian Cancer Society Research Institute (to SD) and the National Health and Medical Research Council (NHMRC) of Australia (to GEH).	Acconcia F, 2007, P NATL ACAD SCI USA, V104, P6782, DOI 10.1073/pnas.0701999104; Akhtar N, 2009, DEVELOPMENT, V136, P1019, DOI 10.1242/dev.028423; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bendig G, 2006, GENE DEV, V20, P2361, DOI 10.1101/gad.1448306; Boppart MD, 2011, BBA-MOL BASIS DIS, V1812, P439, DOI 10.1016/j.bbadis.2011.01.002; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Chiswell BP, 2008, P NATL ACAD SCI USA, V105, P20677, DOI 10.1073/pnas.0811415106; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2002, BIOCHEM J, V367, P517, DOI 10.1042/BJ20020522; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Dobreva I, 2008, J PROTEOME RES, V7, P1740, DOI 10.1021/pr700852r; Erdodi F, 2003, BIOCHEM BIOPH RES CO, V306, P382, DOI 10.1016/S0006-291X(03)00976-8; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Eto M, 2009, J BIOL CHEM, V284, P35273, DOI 10.1074/jbc.R109.059972; Fielding AB, 2011, ONCOGENE, V30, P521, DOI 10.1038/onc.2010.431; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Fukuda K, 2009, MOL CELL, V36, P819, DOI 10.1016/j.molcel.2009.11.028; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hannigan GE, 2007, CIRC RES, V100, P1408, DOI 10.1161/01.RES.0000265233.40455.62; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; Huang JA, 2006, BIOCHEM J, V396, P193, DOI 10.1042/BJ20051772; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Knight ZA, 2007, CELL, V128, P425, DOI 10.1016/j.cell.2007.01.021; Knoll R, 2007, CIRCULATION, V116, P515, DOI 10.1161/CIRCULATIONAHA.107.689984; Kogata N, 2009, GENE DEV, V23, P2278, DOI 10.1101/gad.535409; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Lange A, 2009, NATURE, V461, P1002, DOI 10.1038/nature08468; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Liu J, 2006, J THORAC ONCOL, V1, P771, DOI 10.1097/01243894-200610000-00004; Lorenz K, 2007, J CELL BIOL, V177, P501, DOI 10.1083/jcb.200608125; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Maydan M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012356; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Montanez E, 2009, EMBO J, V28, P3132, DOI 10.1038/emboj.2009.295; Mukherjee K, 2008, CELL, V133, P328, DOI 10.1016/j.cell.2008.02.036; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Muranyi AL, 2010, LEUKEMIA RES, V34, P1358, DOI 10.1016/j.leukres.2010.01.006; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Oloumi A, 2006, ONCOGENE, V25, P7747, DOI 10.1038/sj.onc.1209752; Oloumi A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2592; Pasquali C, 2007, MOL CELL PROTEOMICS, V6, P1829, DOI 10.1074/mcp.T600066-MCP200; Pereira JA, 2009, J CELL BIOL, V185, P147, DOI 10.1083/jcb.200809008; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Postel R, 2008, DEV BIOL, V318, P92, DOI 10.1016/j.ydbio.2008.03.024; Quelo I, 2004, J BIOL CHEM, V279, P43893, DOI 10.1074/jbc.M406310200; Rallis C, 2010, DEVELOPMENT, V137, P3591, DOI 10.1242/dev.050070; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Suh HN, 2011, J CELL PHYSIOL, V226, P3422, DOI 10.1002/jcp.22697; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Taylor SS, 2010, P NATL ACAD SCI USA, V107, P8047, DOI 10.1073/pnas.1003436107; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Wang HV, 2008, J CELL BIOL, V180, P1037, DOI 10.1083/jcb.200707175; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; White DE, 2006, GENE DEV, V20, P2355, DOI 10.1101/gad.1458906; Wickstrom SA, 2010, DEV CELL, V19, P574, DOI 10.1016/j.devcel.2010.09.007; Wickstrom SA, 2010, EMBO J, V29, P281, DOI 10.1038/emboj.2009.376; Wilson DP, 2005, BIOCHEM J, V392, P641, DOI 10.1042/BJ20051173; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	82	105	107	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4375	4385		10.1038/onc.2011.177	http://dx.doi.org/10.1038/onc.2011.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21602880				2022-12-28	WOS:000296356500001
J	Nishikata, I; Nakahata, S; Saito, Y; Kaneda, K; Ichihara, E; Yamakawa, N; Morishita, K				Nishikata, I.; Nakahata, S.; Saito, Y.; Kaneda, K.; Ichihara, E.; Yamakawa, N.; Morishita, K.			Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation	ONCOGENE			English	Article						MEL1; sumoylation; CtBP; G-CSF	TERMINAL BINDING-PROTEINS; CELL-LINE 32D; TRANSCRIPTIONAL REPRESSION; SUMO MODIFICATION; GENE FAMILY; LEUKEMOGENESIS; COMPLEX; BROWN; T(1-3)(P36-Q21); DISORDERS	MEL1 (MDS1/EVI1-like gene 1/PRDM16), which was identified as a gene near the chromosomal breakpoint in t(1;3)(p36;q21)-positive human acute myeloid leukemia cells, belongs to the (P) under bar RDI-BF1-(R) under bar IZ1 homologous (PR) domain (PRDM) family of transcription repressors. The short form of MEL1 (MEL1S), which lacks the PR-domain at the N-terminus, is the main form expressed in t(1; 3)(p36; q21)-positive acute myeloid leukemia cells. The overexpression of MEL1S blocks granulocyte colony-stimulating factor (G-CSF)-induced myeloid differentiation in interleukin-3-dependent murine myeloid L-G3 cells. In this study, we show that treatment with the histone deacetylase inhibitor trichostatin A abolished the blockade of myeloid differentiation in L-G3 cells over-expressing MEL1S. The expression of MEL1S containing mutated CtBP-interacting motif (CIM) in L-G3 cells still blocked the myeloid differentiation induced by G-CSF. We found that the small ubiquitin-related modifier (SUMO) motif (SM) at lysine 568 (V (K) under bar AE) adjacent to the CIM was necessary to obtain the maximum transcriptional repressor activity of MEL1S. L-G3 cells expressing MEL1S, and bearing mutated CIM and SM differentiated into granulocytes in response to G-CSF; this indicated that both the SUMO modification at lysine 568 and CtBP binding were required for MEL1S-mediated transcriptional repression and blockade of differentiation, which might be relevant for the process of leukemogenesis. Oncogene (2011) 30, 4194-4207; doi:10.1038/onc.2011.132; published online 25 April 2011	[Nishikata, I.; Nakahata, S.; Saito, Y.; Kaneda, K.; Ichihara, E.; Yamakawa, N.; Morishita, K.] Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, Miyazaki 8891692, Japan	University of Miyazaki	Morishita, K (corresponding author), Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, 5200 Kihara, Miyazaki 8891692, Japan.	kmorishi@med.miyazaki-u.ac.jp	Kaneda-Nakashima, Kazuko/GZM-6591-2022	Kaneda-Nakashima, Kazuko/0000-0001-6657-5059	Ministry of Education, Culture, Sports, Science and Technology in Japan	Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by Grants-in-Aid for Scientific Research of Priority Area from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	BLOOMFIELD CD, 1985, BLOOD, V66, P1409; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FRIEDMAN AD, 1991, BLOOD, V78, P2426; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108; Kajimura S, 2009, NATURE, V460, P1154, DOI 10.1038/nature08262; KINASHI T, 1991, J EXP MED, V173, P1267, DOI 10.1084/jem.173.5.1267; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Maki K, 2008, CANCER SCI, V99, P1878, DOI 10.1111/j.1349-7006.2008.00956.x; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MOIR DJ, 1984, BLOOD, V64, P553; Morishita K, 2007, INT J HEMATOL, V85, P279, DOI 10.1532/IJH97.06174; Morita Y, 2005, MOL BIOL CELL, V16, P5433, DOI 10.1091/mbc.E05-08-0731; Nishikata I, 2003, BLOOD, V102, P3323, DOI 10.1182/blood-2002-12-3944; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Shimahara A, 2010, J BIOL CHEM, V285, P16967, DOI 10.1074/jbc.M110.102046; Shimizu S, 2000, GENE CHROMOSOME CANC, V27, P229, DOI 10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0; Tillmanns S, 2007, MOL CELL BIOL, V27, P5554, DOI 10.1128/MCB.01811-06; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WELBORN JL, 1987, CANCER GENET CYTOGEN, V28, P277, DOI 10.1016/0165-4608(87)90214-7	33	17	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4194	4207		10.1038/onc.2011.132	http://dx.doi.org/10.1038/onc.2011.132			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21516122				2022-12-28	WOS:000295924600006
J	Shao, H; Cai, L; Grichnik, JM; Livingstone, AS; Velazquez, OC; Liu, ZJ				Shao, H.; Cai, L.; Grichnik, J. M.; Livingstone, A. S.; Velazquez, O. C.; Liu, Z-J			Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1	ONCOGENE			English	Article						tumor microenvironment; melanoma; fibroblasts; Notch; WISP-1	EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-GROWTH; CANCER-THERAPY; BREAST-CANCER; LUNG-CANCER; ANGIOGENESIS; CELLS; PROGRESSION; DLL4; DIFFERENTIATION	The tumor microenvironment is emerging as an important target for cancer therapy. Fibroblasts (Fbs) within the tumor stroma are critically involved in promoting tumor growth and angiogenesis through secretion of soluble factors, synthesis of extracellular matrix and direct cell-cell interaction. In this work, we aim to alter the biological activity of stromal Fbs by modulating the Notch1 signaling pathway. We show that Fbs engineered to constitutively activate the Notch1 pathway significantly inhibit melanoma growth and tumor angiogenesis. We determine that the inhibitory effect of 'Notch-engineered' Fbs is mediated by increased secretion of Wnt-induced secreted protein-1 (WISP-1) as the effects of Notch1 activation in Fbs are reversed by shRNA-mediated blockade of WISP-1. When 'Notch-engineered' Fbs are co-grafted with melanoma cells in SCID mice, shRNA-mediated blockade of WISP-1 reverses the tumor-suppressive phenotype of the 'Notch-engineered' Fbs, significantly increases melanoma growth and tumor angiogenesis. Consistent with these findings, supplement of recombinant WISP-1 protein inhibits melanoma cell growth in vitro. In addition, WISP-1 is modestly expressed in melanoma-activated Fbs but highly expressed in inactivated Fbs. Evaluation of human melanoma skin biopsies indicates that expression of WISP-1 is significantly lower in melanoma nests and surrounding areas filled with infiltrated immune cells than in the adjacent dermis unaffected by the melanoma. Overall, our study shows that constitutive activation of the Notch1 pathway confers Fbs with a suppressive phenotype to melanoma growth, partially through WISP-1. Thus, targeting tumor stromal Fbs by activating Notch signaling and/or increasing WISP-1 may represent a novel therapeutic approach to combat melanoma. Oncogene (2011) 30, 4316-4326; doi: 10.1038/onc.2011.142; published online 25 April 2011	[Liu, Z-J] Univ Miami, Sylvester Comprehens Canc Ctr, Sch Med, Dept Surg, Miami, FL 33136 USA; [Shao, H.; Cai, L.; Livingstone, A. S.; Velazquez, O. C.; Liu, Z-J] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Cai, L.] Hangzhou Red Cross Hosp, Hangzhou, Zhejiang, Peoples R China; [Grichnik, J. M.] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Liu, ZJ (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Sch Med, Dept Surg, RMSB 1046,1600 NW 10th Ave, Miami, FL 33136 USA.	zliu@med.miami.edu	Livingstone, Alan/AAA-4026-2019; Grichnik, James/R-3887-2019	Grichnik, James/0000-0002-9185-0056; Shao, Hongwei/0000-0001-9770-4132	James & Esther King Biomedical Research Program [08KN-10]; Bankhead-Coley Cancer Research [09BN-11]	James & Esther King Biomedical Research Program; Bankhead-Coley Cancer Research	We thank Dr M Herlyn for providing the melanoma cells (1205Lu, WM35, WM3248, Sbcl2, WM278 and WM3899) and Dr G McNamara for laser-scanning confocal microscopy. The work of Dr Liu was supported by grants from the James & Esther King Biomedical Research Program (08KN-10) and the Bankhead-Coley Cancer Research Program (09BN-11).	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Anton K, 2009, CURR PHARM BIOTECHNO, V10, P185, DOI 10.2174/138920109787315088; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Davies SR, 2007, ANN SURG ONCOL, V14, P1909, DOI 10.1245/s10434-007-9376-x; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Hayward SW, 2001, CANCER RES, V61, P8135; Ishikawa Y, 2008, ONCOGENE, V27, P6164, DOI 10.1038/onc.2008.216; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Liu ZJ, 2010, ANN SURG, V252, P625, DOI 10.1097/SLA.0b013e3181f5a079; Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; LIU ZJ, 2005, MOL BIOL CUTANEOUS M; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Midwood KS, 2004, INT J BIOCHEM CELL B, V36, P1031, DOI 10.1016/j.biocel.2003.12.003; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Tanaka S, 2001, ONCOGENE, V20, P5525, DOI 10.1038/sj.onc.1204723; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Urs S, 2008, AM J PATHOL, V173, P865, DOI 10.2353/ajpath.2008.080006; Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026; Zeisberg M, 2008, FRONT BIOSCI, V13, P6991	40	48	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4316	4326		10.1038/onc.2011.142	http://dx.doi.org/10.1038/onc.2011.142			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21516124				2022-12-28	WOS:000296356400003
J	Goetz, EM; Shankar, B; Zou, Y; Morales, JC; Luo, X; Araki, S; Bachoo, R; Mayo, LD; Boothman, DA				Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Bachoo, R.; Mayo, L. D.; Boothman, D. A.			ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability	ONCOGENE			English	Article						secretory clusterin; ATM; IGF-1; p53; ionizing radiation; genetic instability	Y TRANSCRIPTION FACTOR; GROWTH-FACTOR-BETA; NF-Y; GENOMIC INSTABILITY; ATAXIA-TELANGIECTASIA; SIGNALING PATHWAY; PROSTATE-CANCER; MELANOMA-CELLS; IN-VITRO; P53	Secretory clusterin (sCLU) is a stress-induced, prosurvival glycoprotein elevated in early-stage cancers, in particular in APC/Min-defective colon cancers. sCLU is upregulated after exposure to various cytotoxic agents, including ionizing radiation (IR), leading to a survival advantage. We found that stimulation of insulin-like growth factor-1 (IGF-1) and IGF-1R protein kinase signaling was required for sCLU induction after IR exposure. Here, we show that activation of Ataxia telangiectasia-mutated kinase (ATM) by endogenous or exogenous forms of DNA damage was required to relieve basal repression of IGF-1 transcription by the p53/NF-YA complex, leading to sCLU expression. Although p53 levels were stabilized and elevated after DNA damage, dissociation of NF-YA, and thereby p53, from the IGF-1 promoter resulted in IGF-1 induction, indicating that NF-YA was rate limiting. Cells with elevated endogenous DNA damage (deficient in H2AX, MDC1, NBS1, mTR or hMLH1) or cells exposed to DNA-damaging agents had elevated IGF-1 expression, resulting in activation of IGF-1R signaling and sCLU induction. In contrast, ATM-deficient cells were unable to induce sCLU after DNA damage. Our results integrate DNA damage resulting from genetic instability, IR, or chemotherapeutic agents, to ATM activation and abrogation of p53/NF-YA-mediated IGF-1 transcriptional repression, that induces IGF-1-sCLU expression. Elucidation of this pathway should uncover new mechanisms for cancer progression and reveal new targets for drug development to overcome resistance to therapy. Oncogene (2011) 30, 3745-3754; doi:10.1038/onc.2011.92; published online 4 April 2011	[Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Oncol, Lab Mol Stress Responses, Dallas, TX 75390 USA; [Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Lab Mol Stress Responses, Dallas, TX 75390 USA; [Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Lab Mol Stress Responses, Dallas, TX 75390 USA; [Bachoo, R.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Neurooncol, Program Cell Stress & Canc Nanomed, Dallas, TX 75390 USA; [Mayo, L. D.] Indiana Univ Sch Med, Indiana Univ Simon Canc Ctr, Dept Pediat, Herman B Wells Ctr Pediat Res,Dept Biochem & Mol, Indianapolis, IN USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University Bloomington	Boothman, DA (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Oncol, Lab Mol Stress Responses, 6001 Forest Pk Rd,ND2-210K, Dallas, TX 75390 USA.	David.Boothman@UTSouthwestern.edu	Boothman, David/Q-7776-2019	Morales, Julio/0000-0002-0854-7866	DOE [DE-FG02-06ER64186-17]; DOD BCRP [W81XWH-06-0748]; DOD PCRP [X8IXWH-09-1-0168]; Robert B and Virginia Payne Endowment; SAIR NIH [CA126608]; Imaging Shared Resource of the Simmons Cancer Center; NATIONAL CANCER INSTITUTE [U24CA126608, P30CA142543, R01CA139217] Funding Source: NIH RePORTER	DOE(United States Department of Energy (DOE)); DOD BCRP(United States Department of Defense); DOD PCRP; Robert B and Virginia Payne Endowment; SAIR NIH; Imaging Shared Resource of the Simmons Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by DOE grant (#DE-FG02-06ER64186-17) to DAB, a DOD BCRP pre-doctoral fellowship (W81XWH-06-0748) to EMG and a DOD PCRP post-doctoral fellowship (X8IXWH-09-1-0168) to XL. We are grateful to the Robert B and Virginia Payne Endowment for support of this work. We also thank the support received from the SAIR NIH U24 grant CA126608 and the Imaging Shared Resource of the Simmons Cancer Center. This is CSCN #024 and used the Flow Cytometry and Biostatistics cores of the Simmons Comprehensive Cancer Center.	Andarawewa KL, 2007, CANCER RES, V67, P8662, DOI 10.1158/0008-5472.CAN-07-1294; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bentle MS, 2006, J BIOL CHEM, V281, P33684, DOI 10.1074/jbc.M603678200; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; Boggs LN, 1996, J NEUROCHEM, V67, P1324; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Criswell T, 2003, CANCER BIOL THER, V2, P372, DOI 10.4161/cbt.2.4.430; DARPA P, 1990, CANCER RES, V50, P6919; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hao LY, 2004, CHROMOSOMA, V113, P62, DOI 10.1007/s00412-004-0291-7; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Klokov D, 2004, MUTAT RES-FUND MOL M, V568, P97, DOI 10.1016/j.mrfmmm.2004.06.049; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mittanck DW, 1997, MOL CELL ENDOCRINOL, V126, P153, DOI 10.1016/S0303-7207(96)03979-2; Miyake H, 2000, CANCER RES, V60, P2547; Peng Y, 2007, ONCOGENE, V26, P7576, DOI 10.1038/sj.onc.1210565; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Ryan PD, 2008, ONCOLOGIST, V13, P16, DOI 10.1634/theoncologist.2007-0199; Shahrabani-Gargir L, 2004, ENDOCRINOLOGY, V145, P5679, DOI 10.1210/en.2004-0613; So A, 2005, MOL CANCER THER, V4, P1837, DOI 10.1158/1535-7163.MCT-05-0178; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Sulkowski S, 2009, CLIN CHEM LAB MED, V47, P1439, DOI 10.1515/CCLM.2009.305; Wagner MW, 2008, J BIOL CHEM, V283, P21382, DOI 10.1074/jbc.M709953200; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	46	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3745	3754		10.1038/onc.2011.92	http://dx.doi.org/10.1038/onc.2011.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21460853	Green Accepted			2022-12-28	WOS:000294481400002
J	Reimer, D; Hubalek, M; Kiefel, H; Riedle, S; Skvortsov, S; Erdel, M; Hofstetter, G; Concin, N; Fiegl, H; Muller-Holzner, E; Marth, C; Altevogt, P; Zeimet, AG				Reimer, D.; Hubalek, M.; Kiefel, H.; Riedle, S.; Skvortsov, S.; Erdel, M.; Hofstetter, G.; Concin, N.; Fiegl, H.; Mueller-Holzner, E.; Marth, C.; Altevogt, P.; Zeimet, A. G.			Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer	ONCOGENE			English	Article						E2F3a; EGFR; miR-34a; 6p22 amplification; ovarian cancer; prognosis	COMPARATIVE GENOMIC HYBRIDIZATION; BLADDER; AMPLIFICATION; APOPTOSIS; GROWTH; OVEREXPRESSION; PROLIFERATION; CARCINOMA; MIR-34A	Recently we showed an integral epidermal growth factor receptor (EGFR)-E2F3a signaling path, in which E2F3a was found to be essential in EGFR-mediated proliferation in ovarian cancer cells. The present work evaluates the clinical relevance of this novel axis and of E2F3a itself in a large set of 130 ovarian cancer specimens. For this purpose E2F3a and its counterpart, E2F3b, were measured by RT-PCR and activated EGFR was assessed by immunohistochemistry. When compared with healthy control tissue, both E2F3 isoforms were overexpressed in the cancers, but only E2F3a expression correlated with tumor stage (rho = 0.349, P = 0.0001) and residual disease (rho = 0.254, P = 0.004). Univariate survival analyses showed E2F3a and activated EGFR to be associated with poor PFS and OS. Furthermore, a strong, positive correlation between activated EGFR and E2F3a expression was shown (P 0.0001). We further identified two EGFR-independent mechanisms that regulate E2F3a expression, namely one, acting by promoter methylation of miR-34a, which by its physical interaction with E2F3a transcripts causes their degradation, and the second based on 6p22 gene locus amplification. MiRIDIAN-based knockdown and induction of miR-34a evidenced a direct regulatory link between miR-34a and E2F3a, and the tumor-suppressive character of miR-34a was documented by its association with improved survival. Although, 6p22 gene locus amplification was detected in a significant number of ovarian cancer specimens, 6p22 ploidy was not relevant in predicting survival. In Cox regression analysis, E2F3a, but not activated EGFR or miR-34a expression, retained independent prognostic significance (PFS: hazards ratio 3.785 (1.326-9.840), P = 0.013; OS: hazards ratio 4.651 (1.189-15.572), P 0.013). These clinical findings highlight the relevance of E2F3a in the biology of ovarian cancer. Moreover, identification of EGFR-independent mechanisms in E2F3a control can be helpful in explaining the non-responsiveness of therapeutic EGFR targeting in ovarian cancer. Oncogene (2011) 30, 4038-4049; doi:10.1038/onc.2011.119; published online 25 April 2011	[Reimer, D.; Hubalek, M.; Hofstetter, G.; Concin, N.; Fiegl, H.; Mueller-Holzner, E.; Marth, C.; Zeimet, A. G.] Innsbruck Med Univ, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria; [Kiefel, H.; Riedle, S.; Altevogt, P.] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Skvortsov, S.] Innsbruck Med Univ, Dept Radiotherapy, A-6020 Innsbruck, Austria; [Erdel, M.] Krankenhaus Barmherzigen Schwestern Linz, Lab Mol Biol & Cytogenet, Linz, Austria	Medical University of Innsbruck; Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Innsbruck; Konventhospital Der Barmherzigen Bruder	Zeimet, AG (corresponding author), Innsbruck Med Univ, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.	alain.zeimet@i-med.ac.at	Hubalek, Michael/ABD-8041-2021; Fiegl, Heidi/K-4445-2017	Concin, Nicole/0000-0002-9795-2643; Hofstetter, Gerda/0000-0001-8912-3725; Fiegl, Heidi/0000-0002-1236-6806	Verein fur Krebsforschung in der Frauenheilkunde; Department of Obstetrics and Gynecology; Innsbruck Medical University	Verein fur Krebsforschung in der Frauenheilkunde; Department of Obstetrics and Gynecology; Innsbruck Medical University	This work was supported by the 'Verein fur Krebsforschung in der Frauenheilkunde', Department of Obstetrics and Gynecology, Innsbruck Medical University. We thank Annemarie Wiedemair, Martina Champson, Julia Rossler and Martina Fleischer for technical assistance. We also thank Dr Wolfgang A Schulz (Department of Urology, University Hospital Dusseldorf, Germany) for his generous gift of the bladder cancer cell lines.	Bruch J, 2000, CANCER RES, V60, P4526; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Chen CX, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000912; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Gordon AN, 2005, INT J GYNECOL CANCER, V15, P785, DOI 10.1111/j.1525-1438.2005.00137.x; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Krugmann J, 2004, J CLIN PATHOL, V57, P360, DOI 10.1136/jcp.2003.012369; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Markman M, 2008, DRUGS, V68, P771, DOI 10.2165/00003495-200868060-00004; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780; Reimer D, 2010, CANCER RES, V70, P4613, DOI 10.1158/0008-5472.CAN-09-3551; Schilder RJ, 2009, GYNECOL ONCOL, V113, P21, DOI 10.1016/j.ygyno.2008.12.003; Simon R, 2000, INT J ONCOL, V17, P1025; Stadlmann S, 2006, MODERN PATHOL, V19, P607, DOI 10.1038/modpathol.3800575; Takai Daiya, 2003, In Silico Biology, V3, P235; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Van Cutsem E, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.2; Veltman JA, 2003, CANCER RES, V63, P2872; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Zeimet AG, 2009, INT J CANCER, V124, P2353, DOI 10.1002/ijc.24214	24	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4038	4049		10.1038/onc.2011.119	http://dx.doi.org/10.1038/onc.2011.119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21516127				2022-12-28	WOS:000295121600005
J	Cheng, F; Liu, J; Teh, C; Chong, SW; Korzh, V; Jiang, YJ; Deng, LW				Cheng, F.; Liu, J.; Teh, C.; Chong, S-W; Korzh, V.; Jiang, Y-J; Deng, L-W			Camptothecin-induced downregulation of MLL5 contributes to the activation of tumor suppressor p53	ONCOGENE			English	Article						MLL5; camptothecin; p53; p53 tetramer; Serine 392	HISTONE METHYLTRANSFERASE COMPLEX; TOPOISOMERASE-I INHIBITORS; DNA-DAMAGE; CELL-CYCLE; INDUCED PHOSPHORYLATION; H3K4 METHYLATION; PROTEIN-KINASE; DEGRADATION; ATR; TETRAMERIZATION	Mixed lineage leukemia 5 (MLL5) has been implicated in multiple aspects of cell physiology, such as hematopoiesis, cell cycle control and chromatin regulatory network. In this study, we present evidence that MLL5 is involved in the camptothecin (CPT)-induced p53 activation. CPT promoted the degradation of MLL5 protein in a time-and dose-dependent manner in actively replicating cells. The downregulation of MLL5 led to phosphorylation of p53 at Ser392, which was abrogated by exogenous overexpression of MLL5. In MLL5-knockdown cells, p53 protein was stabilized and bound to DNA with higher affinity, leading to activation of downstream genes. Co-immunoprecipitation showed that MLL5 preferentially interacted with the tetramerized form of p53, and knockdown of MLL5 promoted chromatin accumulation of p53 tetramers, suggesting that the association of MLL5 with p53 may prevent the p53 tetramers from binding to the chromatin target sites. The role of MLL5 in CPT-induced p53 activation was conserved in developing zebrafish, where CPT downregulated zebrafish Mll5 protein, and the microinjection of zebrafish mll5 mRNA substantially blocked the CPT-induced apoptosis. In summary, our study proposed MLL5 as a novel component in the regulation of p53 homeostasis and a new cellular determinant of CPT. Oncogene (2011) 30, 3599-3611; doi:10.1038/onc.2011.71; published online 21 March 2011	[Cheng, F.; Liu, J.; Deng, L-W] Natl Univ Singapore, Natl Univ Hlth Syst, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117597, Singapore; [Teh, C.; Korzh, V.] ASTAR, Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, Singapore, Singapore; [Chong, S-W; Jiang, Y-J] ASTAR, Inst Mol & Cell Biol, Genes & Dev Div, Singapore, Singapore; [Jiang, Y-J] Natl Hlth Res Inst, Div Mol & Genom Med, Miaoli Cty, Taiwan	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National Health Research Institutes - Taiwan	Deng, LW (corresponding author), Natl Univ Singapore, Natl Univ Hlth Syst, Dept Biochem, Yong Loo Lin Sch Med, 8 Med Dr, Singapore 117597, Singapore.	lih_wen_deng@nuhs.edu.sg	Xie, Huangming/B-2260-2012; Jiang, Yun-Jin/E-3995-2010; Korzh, Vladimir P/H-1596-2011	Jiang, Yun-Jin/0000-0003-0499-7306; Korzh, Vladimir P/0000-0002-6580-7986; Deng, Lih-Wen/0000-0002-4985-7844	BMRC-A*STAR [R-183-000-164-305]; NMRC-A*STAR [R-183-000-220-275]; Ministry of Education [Tier2, R-183-000-195-112]; A*STAR-IMCB; Ministry of Education, Singapore	BMRC-A*STAR(Agency for Science Technology & Research (A*STAR)); NMRC-A*STAR; Ministry of Education; A*STAR-IMCB(Agency for Science Technology & Research (A*STAR)); Ministry of Education, Singapore(Ministry of Education, Singapore)	We are grateful to Dr Thilo Hagen and Dr Qiang Yu for their valuable suggestions. We thank Dr Bert Vogelstein for HCT116 p53<SUP>+/+</SUP> and HCT116 p53 / cells and Dr Victor Yu for pXJ-HA-p53 plasmid. This work was supported in part by BMRC-A*STAR, R-183-000-164-305; NMRC-A*STAR, R-183-000-220-275; and Ministry of Education Academic Research Fund Tier2, R-183-000-195-112 to LWD, and A*STAR-IMCB funding to YJJ and VK Both FC and JL are recipients of research scholarships from Ministry of Education, Singapore.	Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang F, 2008, INT J BIOCHEM CELL B, V40, P2472, DOI 10.1016/j.biocel.2008.04.012; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Claudio PP, 2006, J CELL PHYSIOL, V208, P602, DOI 10.1002/jcp.20698; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Dambacher S, 2010, HEREDITY, V105, P24, DOI 10.1038/hdy.2010.49; Deng LW, 2004, P NATL ACAD SCI USA, V101, P757, DOI 10.1073/pnas.2036345100; Desai SD, 2001, CANCER RES, V61, P5926; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Dul BE, 2007, J BIOL CHEM, V282, P18397, DOI 10.1074/jbc.M700729200; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Emerling BM, 2002, ONCOGENE, V21, P4849, DOI 10.1038/sj.onc.1205615; ENG WK, 1988, MOL PHARMACOL, V34, P755; Foo RSY, 2007, P NATL ACAD SCI USA, V104, P20826, DOI 10.1073/pnas.0710017104; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Fujiki R, 2009, NATURE, V459, P455, DOI 10.1038/nature07954; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Houser S, 2001, BIOCHEM BIOPH RES CO, V289, P998, DOI 10.1006/bbrc.2001.6073; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kim T, 2009, CELL, V137, P259, DOI 10.1016/j.cell.2009.02.045; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Liu J, 2010, J BIOL CHEM, V285, P20904, DOI 10.1074/jbc.M109.098558; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pommier Y, 1999, DRUG RESIST UPDATE, V2, P307, DOI 10.1054/drup.1999.0102; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sarkaria JN, 1999, CANCER RES, V59, P4375; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Sebastian S, 2009, P NATL ACAD SCI USA, V106, P4719, DOI 10.1073/pnas.0807136106; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zhao H, 2008, CELL CYCLE, V7, P3048, DOI 10.4161/cc.7.19.6750	57	11	12	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	33					3599	3611		10.1038/onc.2011.71	http://dx.doi.org/10.1038/onc.2011.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423215				2022-12-28	WOS:000294005100004
J	Anania, MC; Sensi, M; Radaelli, E; Miranda, C; Vizioli, MG; Pagliardini, S; Favini, E; Cleris, L; Supino, R; Formelli, F; Borrello, MG; Pierotti, MA; Greco, A				Anania, M. C.; Sensi, M.; Radaelli, E.; Miranda, C.; Vizioli, M. G.; Pagliardini, S.; Favini, E.; Cleris, L.; Supino, R.; Formelli, F.; Borrello, M. G.; Pierotti, M. A.; Greco, A.			TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells	ONCOGENE			English	Article						TIMP3; thyroid tumors; PTC	TISSUE INHIBITOR; GENE-EXPRESSION; DOWN-REGULATION; CARCINOMA; CANCER; GROWTH; METALLOPROTEINASE-3; ANGIOGENESIS; METHYLATION; LINE	Papillary thyroid carcinoma (PTC) arises from the thyroid follicular epithelium and represents the most frequent thyroid malignancy. PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation. A role of tumor-suppressor genes in the pathogenesis of PTC has not been assessed yet. The tissue inhibitor of metalloproteinase-3 (TIMP3) gene, encoding a metalloproteinases inhibitor and capable of inhibiting growth, angiogenesis, invasion and metastasis of several cancers, was found to be silenced by promoter methylation in a consistent fraction of PTCs, in association with tumor aggressiveness and BRAFV600E mutation, thus suggesting an oncosuppressor role. To explore this possibility, in this study we performed gene expression and functional studies. Analysis of gene expression data produced in our laboratory as well as meta-analysis of publicly available data sets confirmed the downregulation of TIMP3 gene expression in PTC with respect to normal thyroid. The functional consequences of TIMP3 downregulation were investigated in the PTC-derived NIM1 cell line, in which the expression of TIMP3 is silenced. Restoration of TIMP3 expression by exposure to soluble TIMP3 protein or by complementary DNA transfection had no effect on the growth rate of NIM1 cells. Instead, it affected the adhesive, migratory and invasive capabilities of NIM1 cells by modulating several proteins involved in these processes. A striking effect was observed in vivo, as TIMP3 reduced the tumorigenicity of NIM1 cells by repressing angiogenesis and macrophage infiltration. Our data indicate that the loss of TIMP3 expression exerts a functional role in the pathogenesis of PTC. Oncogene (2011) 30, 3011-3023; doi:10.1038/onc.2011.18; published online 21 February 2011	[Anania, M. C.; Miranda, C.; Vizioli, M. G.; Pagliardini, S.; Borrello, M. G.; Greco, A.] IRCCS Fdn Ist Nazl Tumori, Mol Mechanisms Unit, I-20133 Milan, Italy; [Sensi, M.] IRCCS Fdn Ist Nazl Tumori, Funct Genom Core Facil, I-20133 Milan, Italy; [Sensi, M.] IRCCS Fdn Ist Nazl Tumori, Human Tumors Immunobiol Unit, I-20133 Milan, Italy; [Radaelli, E.] Univ Milan, Fac Vet Med, Dept Vet Pathol, Milan, Italy; [Radaelli, E.] Fdn Filarete, Mouse & Anim Pathol Lab, Milan, Italy; [Favini, E.; Supino, R.] IRCCS Fdn Ist Nazl Tumori, Mol Pharmacol Unit, I-20133 Milan, Italy; [Cleris, L.; Formelli, F.] IRCCS Fdn Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Chemoprevent Unit, I-20133 Milan, Italy; [Pierotti, M. A.] IRCCS Fdn Ist Nazl Tumori, Sci Directorate, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), IRCCS Fdn Ist Nazl Tumori, Mol Mechanisms Unit, Via GA Amadeo 42, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Sensi, Marialuisa/K-5631-2014; Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Cleris, Loredana/T-3144-2018; Greco, Angela/C-1953-2017; Anania, Maria Chiara/B-9339-2017; Anania, Maria Chiara/N-4853-2019; Oliveira Ribeiro, Ciro Alberto de/A-5199-2008	Sensi, Marialuisa/0000-0002-7643-0248; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332; Cleris, Loredana/0000-0001-8778-7931; Greco, Angela/0000-0003-2994-0349; Anania, Maria Chiara/0000-0003-4012-1870; Anania, Maria Chiara/0000-0003-4012-1870; Oliveira Ribeiro, Ciro Alberto de/0000-0002-3168-9272	AIRC, ACC [4472]; Ministry of Health and Progetto Strategico Istituzionale (PSI) 5xmille	AIRC, ACC(Fondazione AIRC per la ricerca sul cancro); Ministry of Health and Progetto Strategico Istituzionale (PSI) 5xmille	We thank Drs Daniele Lecis, Francesca Micciche and Anna De Filippo for providing reagents and advice for the detection of soluble TNF alpha and ALCAM, and Mrs Cristina Mazzadi for secretarial help. This work was supported by AIRC grant N. 4472, ACC, Ministry of Health and Progetto Strategico Istituzionale (PSI) 5xmille, 2008.	Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Akslen LA, 2000, HUM PATHOL, V31, P439, DOI 10.1053/1-ip.2000.6548; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; [Anonymous], 1988, BRIT J CANCER, V58, P109, DOI 10.1038/bjc.1988.174; Bachman KE, 1999, CANCER RES, V59, P798; Barski D, 2010, BRAIN PATHOL, V20, P623, DOI 10.1111/j.1750-3639.2009.00340.x; Bordeleau F, 2010, MOL BIOL CELL, V21, P1698, DOI 10.1091/mbc.E09-05-0373; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Calabro V, 1996, INT J CANCER, V67, P29, DOI 10.1002/(SICI)1097-0215(19960703)67:1<29::AID-IJC7>3.0.CO;2-1; Degl'Innocenti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012701; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Dineen SP, 2008, CANCER RES, V68, P4340, DOI 10.1158/0008-5472.CAN-07-6705; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Ferrario C, 2008, LAB INVEST, V88, P474, DOI 10.1038/labinvest.2008.17; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Greco A, 2009, Q J NUCL MED MOL IM, V53, P440; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hedinger CE., 1988, HISTOLOGICAL TYPING; Hu SY, 2006, INT J CANCER, V119, P2322, DOI 10.1002/ijc.22110; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Latini FRM, 2008, ENDOCR-RELAT CANCER, V15, P787, DOI 10.1677/ERC-08-0079; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Margineanu Eliana, 2008, Rev Med Chir Soc Med Nat Iasi, V112, P432; Masson D, 2010, EUR J CANCER, V46, P1430, DOI 10.1016/j.ejca.2010.01.009; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Nakamura M, 2005, LAB INVEST, V85, P165, DOI 10.1038/labinvest.3700223; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280; Rosso O, 2007, MOL CANCER RES, V5, P1246, DOI 10.1158/1541-7786.MCR-07-0060; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vizioli MG, 2010, ONCOGENE, V29, P3835, DOI 10.1038/onc.2010.136; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Xing MZ, 2007, ENDOCRINOLOGY, V148, P948, DOI 10.1210/en.2006-0927; Xing MZ, 2008, OTOLARYNG CLIN N AM, V41, P1135, DOI 10.1016/j.otc.2008.07.001; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812	46	65	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3011	3023		10.1038/onc.2011.18	http://dx.doi.org/10.1038/onc.2011.18			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339735				2022-12-28	WOS:000292510100002
J	Mudduluru, G; Ceppi, P; Kumarswamy, R; Scagliotti, GV; Papotti, M; Allgayer, H				Mudduluru, G.; Ceppi, P.; Kumarswamy, R.; Scagliotti, G. V.; Papotti, M.; Allgayer, H.			Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer	ONCOGENE			English	Article						non-small cell lung cancer; breast cancer; colorectal cancer; Axl; microRNA	VASCULAR SMOOTH-MUSCLE; TUMOR-SUPPRESSOR GENES; DNA METHYLATION; CPG METHYLATION; GAS6; CELLS; APOPTOSIS; METASTASIS; MICRORNAS; SURVIVAL	Axl is a receptor that induces proliferation, migration and invasion in cancer. In this study, we show that specific microRNAs (miRNAs) target the 3'-UTR of Axl. Luciferase-reporter assays with wild-type and deleted miR-34 and miR-199a/b seed sequences of Axl 3'-UTR confirmed the specificity of targeting. An inverse correlation between Axl protein and miR-34a expression in a panel of non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BRC) cell lines was observed, while miR-199a/b expression was completely suppressed. Pre-miR transfection inhibited in vitro migration and invasion and, in vivo, reduced the number of distant lung-or liver-metastases in a chorion-allantoic-membrane (CAM) assay. Moreover, methylation-specific PCR on bisulfite-converted DNA obtained from the cell lines showed that the miR-34a promoter methylation status was inversely correlated with its expression, and that miR-199a/b promoter regions were methylated in all cells tested. In a panel of NSCLC tissues (n = 44), miR-34a and miR-199a/b were found to be downregulated and significantly co-expressed. A lower expression of all three miRs was significantly associated with squamous histo-types, and, in a preliminary series, NSCLC patients with miR-34a upregulation showed a positive association towards a longer survival. These results indicate that Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells. Oncogene (2011) 30, 2888-2899; doi:10.1038/onc.2011.13; published online 14 February 2011	[Allgayer, H.] Univ Heidelberg, Dept Expt Surg Mol Oncol Solid Tumors, Collaborat Unit German Canc Res Ctr DKFZ Heidelbe, Med Fac Mannheim, D-68167 Mannheim, Germany; [Mudduluru, G.; Ceppi, P.; Kumarswamy, R.; Allgayer, H.] German Canc Res Ctr DKFZ Heidelberg, Mannheim, Germany; [Ceppi, P.; Scagliotti, G. V.; Papotti, M.] Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Orbassano, Italy	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Turin	Allgayer, H (corresponding author), Univ Heidelberg, Dept Expt Surg Mol Oncol Solid Tumors, Collaborat Unit German Canc Res Ctr DKFZ Heidelbe, Med Fac Mannheim, D-68167 Mannheim, Germany.	heike.allgayer@umm.de	Kumarswamy, Regalla/AAC-5766-2019; Ceppi, Paolo/GPS-8668-2022	Ceppi, Paolo/0000-0002-3632-8476; Scagliotti, Giorgio/0000-0001-6646-958X	Alfried Krupp von Bohlen und Halbach Foundation, Essen; Hella-Buhler-Foundation, Heidelberg; Dr Ingrid zu Solms Foundation, Frankfurt/Main; Hector Foundation, Weinheim, Germany; FRONTIER Excellence Initiative of the University of Heidelberg; BMBF, Bonn, Germany; Walter Schulz Foundation, Munich, Germany	Alfried Krupp von Bohlen und Halbach Foundation, Essen; Hella-Buhler-Foundation, Heidelberg; Dr Ingrid zu Solms Foundation, Frankfurt/Main; Hector Foundation, Weinheim, Germany; FRONTIER Excellence Initiative of the University of Heidelberg; BMBF, Bonn, Germany(Federal Ministry of Education & Research (BMBF)); Walter Schulz Foundation, Munich, Germany	HA was supported by Alfried Krupp von Bohlen und Halbach Foundation, Essen, Hella-Buhler-Foundation, Heidelberg, Dr Ingrid zu Solms Foundation, Frankfurt/Main, Hector Foundation, Weinheim, Germany, FRONTIER Excellence Initiative of the University of Heidelberg, the BMBF, Bonn, Germany, and Walter Schulz Foundation, Munich, Germany. We thank Erika Hillerich and Laura Nelson for excellent help and critical appraisal of the manuscript.	Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Budagian V, 2005, MOL CELL BIOL, V25, P9324, DOI 10.1128/MCB.25.21.9324-9339.2005; Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Erson AE, 2008, CLIN GENET, V74, P296, DOI 10.1111/j.1399-0004.2008.01076.x; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Garzia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004998; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; Melaragno MG, 2004, J MOL CELL CARDIOL, V37, P881, DOI 10.1016/j.yjmcc.2004.06.018; Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Valeri N, 2009, MAMM GENOME, V20, P573, DOI 10.1007/s00335-009-9206-5; van Ginkel PR, 2004, CANCER RES, V64, P128, DOI 10.1158/0008-5472.CAN-03-0245; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yeligar S, 2009, J IMMUNOL, V183, P5232, DOI 10.4049/jimmunol.0901084; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006	45	190	202	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	25					2888	2899		10.1038/onc.2011.13	http://dx.doi.org/10.1038/onc.2011.13			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317930				2022-12-28	WOS:000291977800008
J	Wang, R; Wang, ZX; Yang, JS; Pan, X; De, W; Chen, LB				Wang, R.; Wang, Z-X; Yang, J-S; Pan, X.; De, W.; Chen, L-B			MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14)	ONCOGENE			English	Article						microRNA; non-small cell lung cancer; miR-451; RAB14	EXPRESSION; GROWTH; RNA; RESISTANCE; PATTERNS; MIR-451	Accumulating evidence suggests that microRNAs (miRNAs) are important gene regulators, which can have critical roles in diverse biological processes including tumorigenesis. In this study, we analyzed the miRNA expression profiles in non-small cell lung carcinoma (NSCLC) by use of a miRNA microarray platform and identified 40 differentially expressed miRNAs. We showed that miRNA (miR)-451 was the most downregulated in NSCLC tissues. The expression level of miR-451 was found to be significantly correlated with tumor differentiation, pathological stage and lymph-node metastasis. Moreover, low miR-451 expression level was also correlated with shorter overall survival of NSCLC patients (P<0.001). Ectopic miR-451 expression significantly suppressed the in vitro proliferation and colony formation of NSCLC cells and the development of tumors in nude mice by enhancing apoptosis, which might be associated with inactivation of Akt signaling pathway. Interestingly, ectopic miR-451 expression could significantly inhibit RAB14 protein expression and decrease a luciferase-reporter activity containing the RAB14 3'-untranslated region (UTR). In addition,, RNA interference silencing of RAB14 gene could recapitulate the tumor suppressor function of miR-451, whereas restoration of RAB14 expression could partially attenuate the tumor suppressor function of miR-451 in NSCLC cells. Furthermore, we also showed that strong positive immunoreactivity of RAB14 protein was significantly associated with downregulation of miR-451 (P = 0.01). These findings suggest that miR-451 regulates survival of NSCLC cells partially through the downregulation of RAB14. Therefore, targeting with the miR-451/RAB14 interaction might serve as a novel therapeutic application to treat NSCLC patients. Oncogene (2011) 30, 2644-2658; doi:10.1038/onc.2010.642; published online 28 February 2011	[Wang, R.; Chen, L-B] Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Nanjing 210002, Jiangsu, Peoples R China; [Wang, Z-X; Pan, X.] Nanjing Med Univ, Affiliated Hosp 2, Dept Oncol, Nanjing 210002, Jiangsu, Peoples R China; [Yang, J-S] Nanjing Med Univ, Affiliated Nanjing Hosp 1, Dept Oncol, Nanjing 210002, Jiangsu, Peoples R China; [Yang, J-S; De, W.] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing 210002, Jiangsu, Peoples R China	Nanjing University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Chen, LB (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, 315 Zhongshan E Rd, Nanjing 210002, Jiangsu, Peoples R China.	dewei_nanjing@yahoo.com.cn; chenlongbang@yeah.net			National Science Foundation of China (NSFC) [30872979, 30901440, 30973477]; National Natural Science Foundation of China [30973477, BK2010590]; Medical Science Development Subject in Science and Technology Project of Nanjing [ZKX08017, YKK08091]	National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science Development Subject in Science and Technology Project of Nanjing	We acknowledge the excellent technical support and sincere help of the Functional Genomics and Bioinformatics cores of Harbin Medical University, and the Animal Resources Center of School of Medicine, Nanjing University. We thank Zhang Ai-Ping and Cao Lei for assistance with obtaining tissue samples, Huang Gui-Chun for assistance with BALB/c athymic node mouse, and Xu Lin-Yong for assistance with statistical analysis. This study was supported by the National Science Foundation of China (NSFC 30872979, 30901440, and 30973477), the National Natural Science Foundation of China (No. 30973477 and BK2010590), and the Medical Science Development Subject in Science and Technology Project of Nanjing (Grant No. ZKX08017 and YKK08091).	Agarwal R, 2009, TRAFFIC, V10, P1561, DOI 10.1111/j.1600-0854.2009.00969.x; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Behm-Ansmant I, 2006, COLD SPRING HARB SYM, V71, P523, DOI 10.1101/sqb.2006.71.013; Brognard J, 2001, CANCER RES, V61, P3986; Caruso P, 2010, ARTERIOSCL THROM VAS, V30, P716, DOI 10.1161/ATVBAHA.109.202028; Chaudhuri K, 2007, DNA CELL BIOL, V26, P321, DOI 10.1089/dna.2006.0549; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Gal H, 2008, BIOCHEM BIOPH RES CO, V376, P86, DOI 10.1016/j.bbrc.2008.08.107; Gordeladze JO, 2009, ACTA PHARMACOL SIN, V30, P1369, DOI 10.1038/aps.2009.143; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hu Z, 2005, CLIN CANCER RES, V11, P4646, DOI 10.1158/1078-0432.CCR-04-2013; Hui ABY, 2010, CLIN CANCER RES, V16, P1129, DOI 10.1158/1078-0432.CCR-09-2166; Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ju XL, 2009, PEDIATR HEMAT ONCOL, V26, P1, DOI 10.1080/08880010802378338; Kardassis D, 2009, FEBS J, V276, P2947, DOI 10.1111/j.1742-4658.2009.07031.x; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Peter ME, 2010, ONCOGENE, V29, P2161, DOI 10.1038/onc.2010.59; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Skaftnesmo KO, 2007, CURR PHARM BIOTECHNO, V8, P320, DOI 10.2174/138920107783018390; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsuchiya S, 2009, NUCLEIC ACIDS RES, V37, P3821, DOI 10.1093/nar/gkp255; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Wu FS, 2009, BIOCHEM BIOPH RES CO, V386, P549, DOI 10.1016/j.bbrc.2009.06.075; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yang F, 2000, J INVEST DERMATOL, V114, P157, DOI 10.1046/j.1523-1747.2000.00836.x; Yokoi S, 2003, CANCER SCI, V94, P344, DOI 10.1111/j.1349-7006.2003.tb01444.x; Yousef GM, 2008, BIOL CHEM, V389, P689, DOI 10.1515/BC.2008.068; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang HC, 2009, LIFE SCI J, V6, P71; Zhang SZ, 2005, MOL CANCER THER, V4, P1577, DOI 10.1158/1535-7163.MCT-05-0106; Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007	38	264	290	0	54	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2644	2658		10.1038/onc.2010.642	http://dx.doi.org/10.1038/onc.2010.642			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21358675				2022-12-28	WOS:000291677800005
J	Jelassi, B; Chantome, A; Alcaraz-Perez, F; Baroja-Mazo, A; Cayuela, ML; Pelegrin, P; Surprenant, A; Roger, S				Jelassi, B.; Chantome, A.; Alcaraz-Perez, F.; Baroja-Mazo, A.; Cayuela, M. L.; Pelegrin, P.; Surprenant, A.; Roger, S.			P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness	ONCOGENE			English	Article						P2X(7) receptors; migration; SK3 channels; cancer cell invasion; cystein cathepsins	GATED SODIUM-CHANNELS; EPITHELIAL-CELLS; P2X7 RECEPTOR; ATP RECEPTOR; EXPRESSION; CALCIUM; POLYMORPHISM; MACROPHAGES; PROGRESSION; MECHANISM	ATP-gated P2X(7) receptors (P2X(7)R) are unusual plasma membrane ion channels that have been extensively studied in immune cells. More recently, P2X(7)R have been described as potential cancer cell biomarkers. However, mechanistic links between P2X(7)R and cancer cell processes are unknown. Here, we show, in the highly aggressive human breast cancer cell line MDA-MB-435s, that P2X(7) receptor is highly expressed and fully functional. Its activation is responsible for the extension of neurite-like cellular prolongations, of the increase in cell migration by 35% and in cell invasion through extracellular matrix by 150%. The change in cancer cell morphology and the increased migration appeared to be due to the activation of Ca2+-activated SK3 potassium channels. The enhanced invasion through the extracellular matrix was related to the increase of mature forms of cysteine cathepsins in the extracellular medium, which was independent of SK3 channel activity and not associated with cell death. Pharmacological targeting of P2X(7)R in vivo was crucial for cell invasiveness in a zebrafish model of metastases. Our results demonstrate a novel mechanistic link between P2X(7)R functionality in cancer cells and invasiveness, a key parameter in tumour growth and in the development of metastases. They also suggest a potential therapeutic role for the newly developed P2X(7)R antagonists. Oncogene (2011) 30, 2108-2122; doi:10.1038/onc.2010.593; published online 17 January 2011	[Jelassi, B.; Chantome, A.; Roger, S.] Univ Tours, INSERM, U921, F-37032 Tours, France; [Alcaraz-Perez, F.; Cayuela, M. L.] Univ Hosp Virgen Arrixaca FFIS, Canc & Aging Grp, Carretera Palmar, Murcia, Spain; [Baroja-Mazo, A.; Pelegrin, P.] Univ Hosp Virgen Arrixaca FFIS, Inflammat & Expt Surg Grp, Carretera Palmar, Murcia, Spain; [Pelegrin, P.; Surprenant, A.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; University of Manchester	Roger, S (corresponding author), Univ Tours, INSERM, U921, 10 Blvd Tonnelle, F-37032 Tours, France.	sebastien.roger@univ-tours.fr	Pelegrin, Pablo/M-2007-2014; Baroja-Mazo, Alberto/E-6270-2016; cayuela, maria l/S-1148-2019	Pelegrin, Pablo/0000-0002-9688-1804; Baroja-Mazo, Alberto/0000-0001-5212-5006; Roger, Sebastien/0000-0002-9852-5248; Alcaraz Perez, Francisca/0000-0003-1802-4943	Biotechnology and Biological Sciences Research Council; Ligue Nationale Contre le Cancer Region Centre; Association CANCEN; Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (INSERM); 'Partenariat Hubert Curien-Alliance' from the French Foreign and European Ministry; French Embassy in the United Kingdom; Institut National du Cancer (INCa)	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Ligue Nationale Contre le Cancer Region Centre(Ligue nationale contre le cancer); Association CANCEN; Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); 'Partenariat Hubert Curien-Alliance' from the French Foreign and European Ministry; French Embassy in the United Kingdom; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France)	We thank Pr Jean-Christophe Pages, Dr Christine Collin and Dr Virginie Joulin for the development of small hairpin RNA cell lines, Elizabeth Martin, Mari C. Banos, Encarnacion Sanchez and Isabelle Domingo for technical assistance. We are grateful to Pr Gilles Lalmanach for helpful discussions and Pierre-Yves Sizaret for his help with confocal microscopy. We thank Dr Michael Jarvis (Abbott Laboratories, USA) for the generous gift of A740003. This work was supported by the Biotechnology and Biological Sciences Research Council, by a grant from the 'Ligue Nationale Contre le Cancer Region Centre', the 'Association CANCEN', the 'Ministere de la Recherche et des Technologies', the 'Institut National de la Sante et de la Recherche Medicale' (INSERM) and the 'Partenariat Hubert Curien-Alliance' from the French Foreign and European Ministry and the French Embassy in the United Kingdom. A C was funded by the 'Institut National du Cancer (INCa)'.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Burnstock G, 2006, BRIT J PHARMACOL, V147, pS172, DOI 10.1038/sj.bjp.0706429; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Chantome A, 2009, EXP CELL RES, V315, P3620, DOI 10.1016/j.yexcr.2009.07.021; Deli T, 2007, INT J CANCER, V121, P55, DOI 10.1002/ijc.22621; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Gillet L, 2009, J BIOL CHEM, V284, P8671, DOI 10.1074/jbc.M806891200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hibell AD, 2000, BRIT J PHARMACOL, V130, P167, DOI 10.1038/sj.bjp.0703302; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Li X, 2006, CANCER EPIDEM BIOMAR, V15, P1906, DOI 10.1158/1055-9965.EPI-06-0407; Lopez-Castejon G, 2010, J IMMUNOL, V185, P2611, DOI 10.4049/jimmunol.1000436; Marques IJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-128; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Potier M, 2006, MOL CANCER THER, V5, P2946, DOI 10.1158/1535-7163.MCT-06-0194; Potier M, 2010, BIOCHEM BIOPH RES CO, V397, P42, DOI 10.1016/j.bbrc.2010.05.046; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Roger B, 2008, J NEUROSCI, V28, P6393, DOI 10.1523/JNEUROSCI.0696-08.2008; Roger S, 2007, INT J BIOCHEM CELL B, V39, P774, DOI 10.1016/j.biocel.2006.12.007; Roger S, 2006, CURR PHARM DESIGN, V12, P3681, DOI 10.2174/138161206778522047; Roger S, 2010, J BIOL CHEM, V285, P17514, DOI 10.1074/jbc.M109.053082; Roger S, 2010, J PSYCHIATR RES, V44, P347, DOI 10.1016/j.jpsychires.2009.10.005; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Shemon AN, 2006, J BIOL CHEM, V281, P2079, DOI 10.1074/jbc.M507816200; Slater M, 2005, J MOL HISTOL, V36, P159, DOI 10.1007/s10735-004-6166-7; Slater M, 2004, HISTOPATHOLOGY, V44, P206, DOI 10.1111/j.0309-0167.2004.01798.x; Slater M, 2004, BREAST CANCER RES TR, V83, P1, DOI 10.1023/B:BREA.0000010670.85915.0f; Solini A, 2008, ENDOCRINOLOGY, V149, P389, DOI 10.1210/en.2007-1223; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wang QF, 2004, AM J PHYSIOL-CELL PH, V287, pC1349, DOI 10.1152/ajpcell.00256.2004; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Zhang XJ, 2004, LEUKEMIA RES, V28, P1313, DOI 10.1016/j.leukres.2004.04.001	43	154	157	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2108	2122		10.1038/onc.2010.593	http://dx.doi.org/10.1038/onc.2010.593			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21242969				2022-12-28	WOS:000290249600003
J	Xu, S; Feng, Z; Zhang, M; Wu, Y; Sang, Y; Xu, H; Lv, X; Hu, K; Cao, J; Zhang, R; Chen, L; Liu, M; Yun, JP; Zeng, YX; Kang, T				Xu, S.; Feng, Z.; Zhang, M.; Wu, Y.; Sang, Y.; Xu, H.; Lv, X.; Hu, K.; Cao, J.; Zhang, R.; Chen, L.; Liu, M.; Yun, J-P; Zeng, Y-X; Kang, T.			hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas	ONCOGENE			English	Article						cell cycle; hSSB1; p21; ubiquitin; hepatocellular; carcinomas	HUMAN BREAST-CARCINOMA; P21(WAF1/CIP1) EXPRESSION; DNA-DAMAGE; CELL-CYCLE; GENOMIC STABILITY; INHIBITION; P53; PROTEASOME; APOPTOSIS; SURVIVAL	Downregulation of hSSB1, a single-stranded DNA-binding protein, causes increased radiosensitivity, defective checkpoint activation and genomic instability. However, the mechanisms of hSSB1 function in these responses remain to be uncovered. Here, we present evidence that hSSB1 directly binds p21 and this interaction may prevent p21 from ubiquitin-mediated degradation. Furthermore, both promotion of the G1/S transition and abrogation of the G2/M checkpoints induced by hSSB1 knockdown are partially dependent on p21. Most importantly, hSSB1 and p21 levels are positively correlated in human hepatocellular carcinomas (HCC), as determined by immuno-staining. Therefore, hSSB1 may positively modulate p21 to regulate cell cycle progression and DNA damage response, implicating hSSB1 as a novel, promising therapeutic target for cancers such as HCC. Oncogene (2011) 30, 2219-2229; doi:10.1038/onc.2010.596; published online 17 January 2011	[Xu, S.; Wu, Y.; Sang, Y.; Lv, X.; Hu, K.; Cao, J.; Zhang, R.; Chen, L.; Zeng, Y-X; Kang, T.] Sun Yat Sen Univ, Dept Expt Res, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Xu, S.; Feng, Z.; Zhang, M.; Wu, Y.; Sang, Y.; Xu, H.; Lv, X.; Hu, K.; Cao, J.; Zhang, R.; Chen, L.; Liu, M.; Yun, J-P; Zeng, Y-X; Kang, T.] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Feng, Z.; Xu, H.; Liu, M.] Sun Yat Sen Univ, Dept Radiat Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Zhang, M.; Yun, J-P] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Kang, T (corresponding author), Sun Yat Sen Univ, Dept Expt Res, Ctr Canc, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	kangtb@mail.sysu.edu.cn	Lv, Xiao-Bin/T-7607-2019; Feng, Zizhen/G-2322-2014	Sang, Yi/0000-0001-6534-0741; Feng, Zizhen/0000-0002-7763-1869	NSFC [30772492, 30973506, U0732005, 30930045]; 863 project [2006AA02A404]; 973 project [2010CB912201]	NSFC(National Natural Science Foundation of China (NSFC)); 863 project(National High Technology Research and Development Program of China); 973 project(National Basic Research Program of China)	We thank the members of the laboratory for their helpful comments on the manuscript. This work was supported by grants from NSFC (30772492 and 30973506 to J-PY, U0732005 to Y-XZ, and 30930045 to TK), from the 863 project (2006AA02A404 to Y-XZ), and from the 973 project (2010CB912201 to TK).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brustmann H, 2005, GYNECOL ONCOL, V98, P396, DOI 10.1016/j.ygyno.2005.04.035; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferguson AM, 2005, MOL CELL BIOL, V25, P2853, DOI 10.1128/MCB.25.7.2853-2860.2005; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2006, MOL CANCER THER, V5, P1385, DOI 10.1158/1535-7163.MCT-06-0163; Huang J, 2009, MOL CELL, V35, P384, DOI 10.1016/j.molcel.2009.06.011; Inagaki Y, 2008, CANCER GENET CYTOGEN, V180, P30, DOI 10.1016/j.cancergencyto.2007.09.013; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Kao JT, 2007, LIVER INT, V27, P772, DOI 10.1111/j.1478-3231.2007.01499.x; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lee YH, 2009, MODERN PATHOL, V22, P1121, DOI 10.1038/modpathol.2009.76; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li XS, 1996, CANCER RES, V56, P5055; Li YJ, 2009, J BIOL CHEM, V284, P23525, DOI 10.1074/jbc.C109.039586; Liu SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI 10.1016/S1368-7646(03)00044-X; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MICHIELI P, 1994, CANCER RES, V54, P3391; Miyazaki M, 2004, CANCER RES, V64, P4155, DOI 10.1158/0008-5472.CAN-03-2750; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; O'Reilly MA, 2005, ANTIOXID REDOX SIGN, V7, P108, DOI 10.1089/ars.2005.7.108; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Richard DJ, 2008, NATURE, V453, P677, DOI 10.1038/nature06883; Schoniger-Hekele M, 2005, LIVER INT, V25, P62, DOI 10.1111/j.1478-3231.2004.0997.x; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; Shiraki K, 2006, LIVER INT, V26, P1018, DOI 10.1111/j.1478-3231.2006.01320.x; Skaar JR, 2009, J CELL BIOL, V187, P25, DOI 10.1083/jcb.200907026; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Xu SB, 2009, J CANCER RES CLIN, V135, P1791, DOI 10.1007/s00432-009-0627-z; Zhang F, 2009, J BIOL CHEM, V284, P30408, DOI 10.1074/jbc.M109.039404; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	48	44	52	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2219	2229		10.1038/onc.2010.596	http://dx.doi.org/10.1038/onc.2010.596			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242961				2022-12-28	WOS:000290514600005
J	He, M; Zhao, M; Shen, B; Prise, KM; Shao, C				He, M.; Zhao, M.; Shen, B.; Prise, K. M.; Shao, C.			Radiation-induced intercellular signaling mediated by cytochrome-c via a p53-dependent pathway in hepatoma cells	ONCOGENE			English	Article						irradiation; hepatoma cells; bystander effect; p53; cytochrome-c	ALPHA-PARTICLES; NITRIC-OXIDE; BYSTANDER RESPONSES; IONIZING-RADIATION; ADAPTIVE RESPONSE; HUMAN FIBROBLASTS; PIFITHRIN-ALPHA; GLIOMA-CELLS; P53; GROWTH	The tumor suppressor p53 has a crucial role in cellular response to DNA damage caused by ionizing radiation, but it is still unclear whether p53 can modulate radiation-induced bystander effects (RIBE). In the present work, three different hepatoma cell lines, namely HepG2 (wild p53), PLC/PRF/5 (mutation p53) and Hep3B (p53 null), were irradiated with c-rays and then co-cultured with normal Chang liver cell (wild p53) in order to elucidate the mechanisms of RIBE. Results showed that the radiosensitivity of HepG2 cells was higher than that of PLC/PRF/5 and Hep3B cells. Only irradiated HepG2 cells, rather than irradiated PLC/PRF/5 or Hep3B cells, could induce bystander effect of micronuclei (MN) formation in the neighboring Chang liver cells. When HepG2 cells were treated with 20 mu M pifithrin-alpha, an inhibitor of p53 function, or 5 lM cyclosporin A (CsA), an inhibitor of cytochrome- c release from mitochondria, the MN induction in bystander Chang liver cells was diminished. In fact, it was found that after irradiation, cytochrome- c was released from mitochondria into the cytoplasm only in HepG2 cells in a p53- dependent manner, but not in PLC/PRF/5 and Hep3B cells. Interestingly, when 50 lg/ml exogenous cytochrome- c was added into cell co- culture medium, RIBE was significantly triggered by irradiated PLC/PRF/5 and Hep3B cells, which previously failed to provoke a bystander effect. In addition, this exogenous cytochrome- c also partly recovered the RIBE induced by irradiated HepG2 cells even with CsA treatment. Our results provide new evidence that the RIBE can be modulated by the p53 status of irradiated hepatoma cells and that a p53- dependent release of cytochrome- c may be involved in the RIBE. Oncogene (2011) 30, 1947- 1955; doi: 10.1038/onc. 2010.567; published online 6 December 2010	[He, M.; Zhao, M.; Shen, B.; Shao, C.] Fudan Univ, Inst Radiat Med, Shanghai 200032, Peoples R China; [Prise, K. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland	Fudan University; Queens University Belfast	Shao, C (corresponding author), Fudan Univ, Inst Radiat Med, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.	clshao@shmu.edu.cn	Prise, Kevin/N-7872-2015	Prise, Kevin/0000-0001-6134-7946; Shao, Chunlin/0000-0001-9336-9912	National Nature Science Foundation of China [30770644, 31070758]; Shanghai Health Bureau [08GWD09, 08GWZX0602]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Health Bureau	We thank the National Nature Science Foundation of China Grant numbers 30770644 and 31070758, the Shanghai Health Bureau (08GWD09, 08GWZX0602) for funding this work.	AIN JF, 1994, J SURG RES, V57, P366, DOI 10.1006/jsre.1994.1156; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 2003, ONCOGENE, V22, P7050, DOI 10.1038/sj.onc.1206961; BARTEK J, 1991, ONCOGENE, V6, P1699; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Chen HH, 2008, INT J RADIAT ONCOL, V72, P1560, DOI 10.1016/j.ijrobp.2008.07.038; Chen S, 2008, BRIT J CANCER, V98, P1839, DOI 10.1038/sj.bjc.6604358; Chhipa RR, 2007, J CELL BIOCHEM, V101, P68, DOI 10.1002/jcb.21153; Coates P, 2008, J PATHOL, V214, P610, DOI 10.1002/path.2321; Concin N, 2000, CANCER LETT, V150, P191, DOI 10.1016/S0304-3835(99)00393-6; Emerit I, 1996, P NATL ACAD SCI USA, V93, P12799, DOI 10.1073/pnas.93.23.12799; Han W, 2010, CARCINOGENESIS, V31, P275, DOI 10.1093/carcin/bgp301; Harada K, 2009, CANCER SCI, V100, P684, DOI 10.1111/j.1349-7006.2009.01093.x; Iyer R, 2000, CANCER RES, V60, P1290; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Lehnert BE, 1997, ENVIRON HEALTH PERSP, V105, P1095, DOI 10.2307/3433515; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; Ma SM, 2010, CANCER TREAT REV, V36, P157, DOI 10.1016/j.ctrv.2009.11.008; Mancuso M, 2008, P NATL ACAD SCI USA, V105, P12445, DOI 10.1073/pnas.0804186105; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Mitchell SA, 2004, INT J RADIAT BIOL, V80, P465, DOI 10.1080/09553000410001725116; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 2007, MUTAT RES-FUND MOL M, V616, P159, DOI 10.1016/j.mrfmmm.2006.11.009; MOSES AC, 1983, J CLIN ENDOCR METAB, V56, P1003, DOI 10.1210/jcem-56-5-1003; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Murphy JEJ, 2005, MUTAT RES-GEN TOX EN, V585, P127, DOI 10.1016/j.mrgentox.2005.04.011; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Ng LT, 2006, AM J CHINESE MED, V34, P125, DOI 10.1142/S0192415X06003692; Peixoto PM, 2009, BIOCHEM BIOPH RES CO, V390, P38, DOI 10.1016/j.bbrc.2009.09.054; Preta G, 2009, BIOCHEM BIOPH RES CO, V389, P575, DOI 10.1016/j.bbrc.2009.09.021; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Ryan LA, 2008, RADIAT RES, V169, P188, DOI 10.1667/RR1141.1; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2008, ONCOGENE, V27, P434, DOI 10.1038/sj.onc.1210653; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2008, MUTAT RES-FUND MOL M, V638, P139, DOI 10.1016/j.mrfmmm.2007.09.007; Shao CL, 2010, NUCL INSTRUM METH B, V268, P627, DOI 10.1016/j.nimb.2009.12.024; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, FASEB J, V17, P1422, DOI 10.1096/fj.02-1115com; Shao CL, 2003, RADIAT ENVIRON BIOPH, V42, P183, DOI 10.1007/s00411-003-0202-y; Shao CL, 2003, RADIAT RES, V160, P318, DOI 10.1667/RR3044; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Tsai KKC, 2009, RADIAT RES, V172, P306, DOI 10.1667/RR1764.1; Viani P, 2003, J BIOL CHEM, V278, P9592, DOI 10.1074/jbc.M207729200; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang B, 2000, RADIAT RES, V154, P277, DOI 10.1667/0033-7587(2000)154[0277:ARIEIR]2.0.CO;2; Yang G, 2009, BRIT J CANCER, V100, P1912, DOI 10.1038/sj.bjc.6605087; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Yuan DX, 2010, MUTAT RES-FUND MOL M, V688, P66, DOI 10.1016/j.mrfmmm.2010.03.010; Zhang XP, 2009, P NATL ACAD SCI USA, V106, P12245, DOI 10.1073/pnas.0813088106; Zhang Y, 2008, RADIAT RES, V169, P197, DOI 10.1667/RR1189.1; Zhou HN, 2005, P NATL ACAD SCI USA, V102, P14641, DOI 10.1073/pnas.0505473102; Zhou HN, 2008, CANCER RES, V68, P2233, DOI 10.1158/0008-5472.CAN-07-5278	61	58	65	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1947	1955		10.1038/onc.2010.567	http://dx.doi.org/10.1038/onc.2010.567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21132005	Green Accepted			2022-12-28	WOS:000289777700010
J	Arun, SN; Kaddour-Djebbar, I; Shapiro, BA; Bollag, WB				Arun, S. N.; Kaddour-Djebbar, I.; Shapiro, B. A.; Bollag, W. B.			Ultraviolet B irradiation and activation of protein kinase D in primary mouse epidermal keratinocytes	ONCOGENE			English	Article						apoptosis; epidermis; protein kinase C; protein kinase D; skin; Src	NF-KAPPA-B; RADIATION-INDUCED APOPTOSIS; POTENTIATES DNA-SYNTHESIS; D-DEPENDENT ACTIVATION; G(Q)-COUPLED RECEPTORS; LOOP PHOSPHORYLATION; SKIN-CANCER; C-MU; PROLIFERATION; EXPRESSION	Our previous studies demonstrated that protein kinase D (PKD), a serine/threonine kinase implicated in various cell processes, is upregulated in basal cell carcinoma (BCC), supporting a possible tumorigenic role for PKD in skin. As the greatest risk factor for BCC is sun exposure, the ability of ultraviolet B (UVB) irradiation to activate PKD in primary mouse keratinocytes was investigated. Using western analysis with two autophosphorylation-specific antibodies, we show for the first time that UVB activated PKD in a time-and dose-dependent manner. UVB-induced PKD activation was verified using an in vitro kinase assay. Furthermore, activation was reduced by antioxidant pretreatment, suggesting a link with oxidative stress. UVB-induced PKD activation was mediated primarily by Src family tyrosine kinases rather than protein kinase C (PKC), and in fact, UVB did not alter PKC-mediated transphosphorylation. UVB induced apoptosis dose dependently, and this death could be prevented by overexpression of wild-type PKD, but not mutant PKD or the empty adenovirus. Indeed, a mutant that cannot be phosphorylated by Src kinases exacerbated UVB-elicited apoptosis. Thus, our data indicate that UVB irradiation of keratinocytes induces Src-mediated activation of PKD, which protects cells from UVB-stimulated apoptosis, providing a possible explanation for the observed upregulation of PKD in BCC. Oncogene (2011) 30, 1586-1596; doi: 10.1038/onc.2010.540; published online 6 December 2010	[Bollag, W. B.] Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; [Arun, S. N.; Shapiro, B. A.; Bollag, W. B.] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; [Kaddour-Djebbar, I.; Bollag, W. B.] Charlie Norwood VA Med Ctr, Augusta, GA USA; [Bollag, W. B.] Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; [Bollag, W. B.] Med Coll Georgia, Dept Dermatol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Georgia; Augusta University; University System of Georgia; Augusta University	Bollag, WB (corresponding author), Med Coll Georgia, Dept Physiol, 1120 15th St, Augusta, GA 30912 USA.	wbollag@mcg.edu		Bollag, Wendy/0000-0003-3146-162X	Veterans' Administration; National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases [AR45212, AR57321]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR057321, R01AR045212, R29AR045212] Funding Source: NIH RePORTER	Veterans' Administration(US Department of Veterans Affairs); National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This project was supported by a Merit Award from the Veterans' Administration and grants from the National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases #AR45212 and AR57321 (WBB). We thank Dr Alex Toker for generously providing the various PKD constructs as well as for his useful discussions, and Dr Bert Vogelstein for his kind gift of the AdEasy adenovirus system. We appreciate the expert technical assistance of Mr Peter Parker and Ms Mariya Wilson. This work was submitted in partial fulfilment of the requirements for a doctoral degree from the Medical College of Georgia (SNA).	Assefa Z, 2005, BBA-REV CANCER, V1755, P90, DOI 10.1016/j.bbcan.2005.04.001; Assefa Z, 2003, FEBS LETT, V540, P125, DOI 10.1016/S0014-5793(03)00238-2; Bollag WB, 2004, DRUG NEWS PERSPECT, V17, P117, DOI 10.1358/dnp.2004.17.2.829045; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Dodd ME, 2005, J INVEST DERMATOL, V125, P294, DOI 10.1111/j.0022-202X.2005.23780.x; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jacamo R, 2008, J BIOL CHEM, V283, P12877, DOI 10.1074/jbc.M800442200; Jadali A, 2010, J BIOL CHEM, V285, P23385, DOI 10.1074/jbc.M110.105619; Jung EM, 1999, CARCINOGENESIS, V20, P569, DOI 10.1093/carcin/20.4.569; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Marathe GK, 2005, J BIOL CHEM, V280, P35448, DOI 10.1074/jbc.M503811200; Matsumura M, 2003, BIOCHEM BIOPH RES CO, V303, P350, DOI 10.1016/S0006-291X(03)00345-0; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Przybyszewski J, 1998, CARCINOGENESIS, V19, P1467, DOI 10.1093/carcin/19.8.1467; Reelfs O, 2004, J INVEST DERMATOL, V122, P1440, DOI 10.1111/j.0022-202X.2004.22620.x; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Ristich VL, 2006, BRIT J DERMATOL, V154, P586, DOI 10.1111/j.1365-2133.2005.07073.x; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Sinnett-Smith J, 2009, J BIOL CHEM, V284, P13434, DOI 10.1074/jbc.M806554200; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Song J, 2006, AM J PHYSIOL-CELL PH, V290, pC1469, DOI 10.1152/ajpcell.00486.2005; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	41	20	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1586	1596		10.1038/onc.2010.540	http://dx.doi.org/10.1038/onc.2010.540			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21132013	Green Accepted			2022-12-28	WOS:000288998300009
J	Godshalk, SE; Paranjape, T; Nallur, S; Speed, W; Chan, E; Molinaro, AM; Bacchiocchi, A; Hoyt, K; Tworkoski, K; Stern, DF; Sznol, M; Ariyan, S; Lazova, R; Halaban, R; Kidd, KK; Weidhaas, JB; Slack, FJ				Godshalk, S. E.; Paranjape, T.; Nallur, S.; Speed, W.; Chan, E.; Molinaro, A. M.; Bacchiocchi, A.; Hoyt, K.; Tworkoski, K.; Stern, D. F.; Sznol, M.; Ariyan, S.; Lazova, R.; Halaban, R.; Kidd, K. K.; Weidhaas, J. B.; Slack, F. J.			A Variant in a MicroRNA complementary site in the 3 ' UTR of the KIT oncogene increases risk of acral melanoma	ONCOGENE			English	Article						melanoma; acral; microRNA; cancer risk; miR-221; KIT	CELL GROWTH-FACTOR; C-KIT; IMATINIB MESYLATE; EXPRESSION; DATABASE; CANCER; PROGRESSION; ACTIVATION; KINASE; CKIT	MicroRNAs (miRNAs) are small similar to 22nt single stranded RNAs that negatively regulate protein expression by binding to partially complementary sequences in the 3' untranslated region (3' UTRs) of target gene messenger RNAs (mRNA). Recently, mutations have been identified in both miRNAs and target genes that disrupt regulatory relationships, contribute to oncogenesis and serve as biomarkers for cancer risk. KIT, an established oncogene with a multifaceted role in melanogenesis and melanoma pathogenesis, has recently been shown to be upregulated in some melanomas, and is also a target of the miRNA miR-221. Here, we describe a genetic variant in the 3' UTR of the KIT oncogene that correlates with a greater than fourfold increased risk of acral melanoma. This KIT variant results in a mismatch in the seed region of a miR-221 complementary site and reporter data suggests that this mismatch can result in increased expression of the KIT oncogene. Consistent with the hypothesis that this is a functional variant, KIT mRNA and protein levels are both increased in the majority of samples harboring the KIT variant. This work identifies a novel genetic marker for increased heritable risk of melanoma. Oncogene (2011) 30, 1542-1550; doi: 10.1038/onc.2010.536; published online 29 November 2010	[Paranjape, T.; Nallur, S.; Chan, E.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; [Godshalk, S. E.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Speed, W.; Kidd, K. K.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; [Molinaro, A. M.] Yale Univ, Sch Publ Hlth, Div Biostat, New Haven, CT 06520 USA; [Bacchiocchi, A.; Hoyt, K.; Lazova, R.; Halaban, R.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; [Tworkoski, K.; Stern, D. F.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Sznol, M.] Yale Univ, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA; [Ariyan, S.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University	Weidhaas, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 208040, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu; frank.slack@yale.edu	Paranjape, Trupti/E-4338-2012; ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X; Slack, Frank/0000-0001-8263-0409; Sznol, Mario/0000-0002-4359-8749; Weidhaas, Joanne/0000-0002-5096-3281	National Cancer Institute [1 P50 CA121974]; National Center for Research Resources (NCRR), National Institutes of Health (NIH) [UL1 RR024139]; NIH roadmap for Medical Research;  [K08 CA124484]; NATIONAL CANCER INSTITUTE [P50CA121974, K08CA124484] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources (NCRR), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Yale SPORE in Skin Cancer funded by the National Cancer Institute grant number 1 P50 CA121974 (R Halaban, PI) and by a generous gift from Milstein-Meyer Center for Melanoma Research. JW is supported by K08 CA124484. AMM is supported by the CTSA Grant number UL1 RR024139 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. The testing of the samples from the several world populations was supported by 1 P01 GM057672 (KK Kidd, PI).	Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; Ashida A, 2009, INT J CANCER, V124, P862, DOI 10.1002/ijc.24048; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Gershenwald JE, 2010, ANN SURG ONCOL, V17, P1475, DOI 10.1245/s10434-010-0986-3; Godshalk SE, 2008, CELL CYCLE, V7, P3595, DOI 10.4161/cc.7.22.7120; Halaban R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004563; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 1996, ONCOGENE, V13, P2339; Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152; Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109; LASSAM N, 1992, ONCOGENE, V7, P51; Lee CT, 2007, DNA CELL BIOL, V26, P209, DOI 10.1089/dna.2006.0545; Lutzky J, 2008, PIGM CELL MELANOMA R, V21, P492, DOI 10.1111/j.1755-148X.2008.00475.x; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Meyle KD, 2009, HUM GENET, V126, P499, DOI 10.1007/s00439-009-0715-9; Mishra PJ, 2009, PHARMACOGENOMICS, V10, P399, DOI 10.2217/14622416.10.3.399; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; Rajeevan H, 2005, EVOL BIOINFORM, V1, P1; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Rigel DS, 2010, ARCH DERMATOL, V146, P318, DOI 10.1001/archdermatol.2009.379; Saetrom P, 2009, CANCER RES, V69, P7459, DOI 10.1158/0008-5472.CAN-09-1201; Sayers EW, 2009, NUCLEIC ACIDS RES, V37, pD5, DOI 10.1093/nar/gkp967; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Smalley KSM, 2008, CANCER RES, V68, P5743, DOI 10.1158/0008-5472.CAN-08-0235; Smalley KSM, 2009, CANCER RES, V69, P3241, DOI 10.1158/0008-5472.CAN-08-4305; Smalley KSM, 2009, HISTOL HISTOPATHOL, V24, P643, DOI 10.14670/HH-24.643; Speed WC, 2009, PHARMACOGENOMICS J, V9, P283, DOI 10.1038/tpj.2009.10; Stefani G, 2007, EXPERT OPIN BIOL TH, V7, P1833, DOI 10.1517/14712598.7.12.1833; Went PT, 2004, J CLIN ONCOL, V22, P4514, DOI 10.1200/JCO.2004.10.125; ZAKUT R, 1993, ONCOGENE, V8, P2221	40	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1542	1550		10.1038/onc.2010.536	http://dx.doi.org/10.1038/onc.2010.536			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119596	Green Accepted, Green Submitted			2022-12-28	WOS:000288998300005
J	Boissinot, M; Cleyrat, C; Vilaine, M; Jacques, Y; Corre, I; Hermouet, S				Boissinot, M.; Cleyrat, C.; Vilaine, M.; Jacques, Y.; Corre, I.; Hermouet, S.			Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F	ONCOGENE			English	Article						Polycythemia vera; JAK2V617F; hepatocyte growth factor (HGF); interleukin 11 (IL-11); interleukin 6 (IL-6); inflammation	MARROW STROMAL CELLS; INDUCIBLE FACTOR-I; MYELOPROLIFERATIVE NEOPLASMS; MULTIPLE-MYELOMA; INTERFERON-ALPHA; COLONY FORMATION; TYROSINE KINASE; JAK2 HAPLOTYPE; MUTATION; MET	The V617F activating mutation of janus kinase 2 (JAK2), a kinase essential for cytokine signalling, characterizes Polycythemia vera (PV), one of the myeloproliferative neoplasms (MPN). However, not all MPNs carry mutations of JAK2, and in JAK2-mutated patients, expression of JAK2V617F does not always result in clone expansion. In the present study, we provide evidence that inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors. In a first series of experiments, we searched for cytokines over-expressed in PV using cytokine antibody (Ab) arrays, and enzyme-linked immunosorbent assays for analyses of serum and bone marrow (BM) plasma, and quantitative reverse transcription-PCRs for analyses of cells purified from PV patients and controls. We found that PV patients over-expressed anti-inflammatory hepatocyte growth factor (HGF) and interleukin-11 (IL-11), BM mesenchymal stromal cells (BMMSCs) and erythroblasts being the main producers. In a second series of experiments, autocrine/paracrine cytokine stimulation of erythroblasts was blocked using neutralizing Abs specific for IL-11 or c-MET, the HGF receptor. The growth of JAK2V617F-mutated HEL cells and PV erythroblasts was inhibited, indicating that JAK2-mutated cells depend on HGF and IL-11 for their growth. Additional experiments showed that transient expression of JAK2V617F in BaF-3/erythropoietin receptor cells, and invalidation of JAK2V617F in HEL cells using anti-JAK2 small interfering RNA, did not affect HGF and IL-11 expression. Thus, anti-inflammatory HGF and IL-11 are upregulated in PV and their overproduction is not a consequence of JAK2V617F. As both cytokines contribute to the proliferation of PV erythroblasts, blocking the c-MET/HGF/IL-11 pathways could be of interest as an additional therapeutic option in PV. Oncogene (2011) 30, 990-1001; doi:10.1038/onc.2010.479; published online 1 November 2010	[Boissinot, M.; Cleyrat, C.; Vilaine, M.; Jacques, Y.; Corre, I.; Hermouet, S.] CHU Nantes, Inst Biol, INSERM, UMR 892, F-44093 Nantes, France; [Hermouet, S.] CHU Nantes, Inst Biol, Hematol Lab, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Hermouet, S (corresponding author), CHU Nantes, Inst Biol, INSERM, UMR 892, F-44093 Nantes, France.	sylvie.hermouet@chu-nantes.fr	Vilaine, Mathias/L-3054-2015; Jacques, Yannick/K-9294-2015; Corre, Isabelle/L-2583-2015; Cleyrat, Cedric/F-1824-2016	Cleyrat, Cedric/0000-0002-1928-6497; CORRE, Isabelle/0000-0001-6444-1145; Boissinot, Marjorie/0000-0002-5241-2520	Ligue Nationale contre le Cancer (Comite de Loire-Atlantique); Association pour la Recherche contre le Cancer; French Ministry of Research [MB: 2004-2007, CC: 2007-2010, MV: 2009-2010]	Ligue Nationale contre le Cancer (Comite de Loire-Atlantique); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); French Ministry of Research(Ministry of Research, FranceEuropean Commission)	We are indebted to Mrs Danielle Pineau for excellent technical help and to colleagues of the Clinical Hematology Departments of the hospitals of Nantes, La Roche-sur-Yon and Lorient for providing patient samples. The study was supported by grants from the Ligue Nationale contre le Cancer (Comite de Loire-Atlantique) and the Association pour la Recherche contre le Cancer. MB, CC and MV have been recipients of scholarships from the French Ministry of Research (MB: 2004-2007; CC: 2007-2010; MV: 2009-2010) and from the Association pour la Recherche contre le Cancer (MB, 2008).	Aman MJ, 1996, EXP HEMATOL, V24, P863; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bernet Agnes, 2007, Bull Cancer, V94, pE12; Cleyrat C, 2010, LEUKEMIA, V24, P1069, DOI 10.1038/leu.2010.23; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Coppo P, 2009, CELL SIGNAL, V21, P52, DOI 10.1016/j.cellsig.2008.09.006; Corre-Buscail I, 2005, EXP HEMATOL, V33, P1299, DOI 10.1016/j.exphem.2005.07.002; Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875; Dobo L, 2004, HEMATOL J, V5, P161, DOI 10.1038/sj.thj.6200344; Du WL, 2007, BLOOD, V109, P3042, DOI 10.1182/blood-2006-02-003103; Ferguson LR, 2010, MUTAT RES-FUND MOL M, V690, P108, DOI 10.1016/j.mrfmmm.2010.01.017; Geissler K, 1998, BLOOD, V92, P1967, DOI 10.1182/blood.V92.6.1967.418k27_1967_1972; Girodon F, 2008, HAEMATOL-HEMATOL J, V93, P1723, DOI 10.3324/haematol.13081; Giuliani N, 2004, HAEMATOLOGICA, V89, P1118; Hermouet S, 2002, CYTOKINE, V20, P178, DOI 10.1006/cyto.2002.1994; Hitoshi Y, 2010, INT J HEMATOL, V91, P189, DOI 10.1007/s12185-010-0531-y; Ho CL, 2007, LEUKEMIA RES, V31, P1389, DOI 10.1016/j.leukres.2006.12.024; Ishii T, 2007, LEUKEMIA, V21, P2433, DOI 10.1038/sj.leu.2404899; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jenkins BJ, 2005, BLOOD, V105, P3512, DOI 10.1182/blood-2004-09-3751; Jenkins BJ, 2007, BLOOD, V109, P2380, DOI 10.1182/blood-2006-08-040352; Jones AV, 2009, NAT GENET, V41, P446, DOI 10.1038/ng.334; Kiladjian JJ, 2006, BLOOD, V108, P2037, DOI 10.1182/blood-2006-03-009860; Kilpivaara O, 2009, NAT GENET, V41, P455, DOI 10.1038/ng.342; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; Kralovics R, 2008, LEUKEMIA, V22, P1841, DOI 10.1038/leu.2008.233; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lambert JR, 2009, BLOOD, V114, P3018, DOI 10.1182/blood-2009-03-209916; Le Bousse-Kerdiles MC, 1999, ANN HEMATOL, V78, P437, DOI 10.1007/s002770050595; Lippert E, 2006, BLOOD, V108, P1865, DOI 10.1182/blood-2006-01-013540; Lippert E, 2009, HAEMATOL-HEMATOL J, V94, P38, DOI 10.3324/haematol.13486; Matsuda-Hashii Y, 2004, EXP HEMATOL, V32, P955, DOI 10.1016/j.exphem.2004.06.012; Musolino C, 2002, AM J HEMATOL, V69, P159, DOI 10.1002/ajh.10020; Naifeld V, 2007, EXP HEMATOL, V35, P1668, DOI 10.1016/j.exphem.2007.08.025; Nussenzveig RH, 2007, EXP HEMATOL, V35, P32, DOI 10.1016/j.exphem.2006.11.012; Olcaydu D, 2009, NAT GENET, V41, P450, DOI 10.1038/ng.341; Panteli KE, 2005, BRIT J HAEMATOL, V130, P709, DOI 10.1111/j.1365-2141.2005.05674.x; QUESNIAUX VFJ, 1992, BLOOD, V80, P1218; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Sattler Martin, 2007, Curr Oncol Rep, V9, P102, DOI 10.1007/s11912-007-0005-4; Schaub FX, 2009, BLOOD, V113, P2022, DOI 10.1182/blood-2008-07-167056; Schwertschlag US, 1999, LEUKEMIA, V13, P1307, DOI 10.1038/sj.leu.2401514; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Stellrecht CM, 2007, CANCER RES, V67, P9913, DOI 10.1158/0008-5472.CAN-07-0770; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; TEFFERI A, 2010, HEMATOLOGIST, V7, P5; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; UCHIYAMA H, 1993, BLOOD, V82, P3712; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Verstovsek S, 2010, CLIN CANCER RES, V16, P1988, DOI 10.1158/1078-0432.CCR-09-2836; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Wickenhauser C, 1999, LEUKEMIA, V13, P327, DOI 10.1038/sj.leu.2401314; Zdzisinska B, 2008, ARCH IMMUNOL THER EX, V56, P207, DOI 10.1007/s00005-008-0022-5	55	43	46	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					990	1001		10.1038/onc.2010.479	http://dx.doi.org/10.1038/onc.2010.479			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21042281				2022-12-28	WOS:000287695900010
J	Hsu, CC; Chiang, CW; Cheng, HC; Chang, WT; Chou, CY; Tsai, HW; Lee, CT; Wu, ZH; Lee, TY; Chao, A; Chow, NH; Ho, CL				Hsu, C-C; Chiang, C-W; Cheng, H-C; Chang, W-T; Chou, C-Y; Tsai, H-W; Lee, C-T; Wu, Z-H; Lee, T-Y; Chao, A.; Chow, N-H; Ho, C-L			Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach	ONCOGENE			English	Article						oncofetal genes; expressed sequence tags; LRRC16B	LEUCINE-RICH REPEAT; ALPHA-FETOPROTEIN; TUMOR-MARKERS; FLIGHTLESS I; STEM-CELLS; PROTEIN; WNT; EXPRESSION; GROWTH; BETA	Oncofetal genes are expressed in embryos or fetuses, are downregulated or undetectable in adult tissues, and then re-expressed in tumors. Known oncofetal genes, such as AFP, GCB, FGF18, IMP-1 and SOX1, often have important clinical applications or pivotal biological functions. To find new oncofetal-like genes, we used the public information of expressed sequence tags to systematically analyze gene expression patterns and identified a novel oncofetal-like gene, LRRC16B. It increased the proliferation, anchorage-independent growth and tumorigenesis of transformed cells in xenografts, possibly through its effects on cyclin B1 protein levels. These findings exemplify the feasibility of using bioinformatics to find new oncofetal-like genes and suggest that more genes with important functional roles will be uncovered in the candidate gene list. Oncogene (2011) 30, 654-667; doi:10.1038/onc.2010.451; published online 22 November 2010	[Chou, C-Y; Tsai, H-W; Chow, N-H; Ho, C-L] Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan 70428, Taiwan; [Hsu, C-C; Chiang, C-W; Cheng, H-C; Chang, W-T; Lee, T-Y; Chow, N-H; Ho, C-L] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chiang, C-W; Wu, Z-H; Chow, N-H; Ho, C-L] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan 70101, Taiwan; [Chou, C-Y] Natl Cheng Kung Univ Hosp, Dept Obstet & Gynecol, Tainan 70428, Taiwan; [Chao, A.] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Dept Ophthalmol, Tao Yuan, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; Chang Gung Memorial Hospital; Chang Gung University	Ho, CL (corresponding author), Natl Cheng Kung Univ Hosp, Dept Pathol, 138 Sheng Li Rd, Tainan 70428, Taiwan.	clh9@mail.ncku.edu.tw			National Science Council, Taiwan [NSC-95-2320-B-006-057-MY2]; Department of Health, Taiwan [DOH99-TD-C-111-003]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Department of Health, Taiwan	This was supported by Grant NSC-95-2320-B-006-057-MY2 from the National Science Council, Taiwan, and Grant DOH99-TD-C-111-003 from the Department of Health, Taiwan. There is no competing financial interest in relation to this work.	Adachi-Yamada T, 2005, MOL CELL BIOL, V25, P3140, DOI 10.1128/MCB.25.8.3140-3150.2005; ALEXANDER P, 1970, MEDICINA, V30, P176; Aouacheria A, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-94; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BERGSTRAND CG, 1956, SCAND J CLIN LAB INV, V8, P174, DOI 10.3109/00365515609049266; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Campagne F, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-481; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Cleynen I, 2007, MOL CANCER RES, V5, P363, DOI 10.1158/1541-7786.MCR-06-0331; Colantuoni C, 2000, J NEUROSCI RES, V59, P1, DOI 10.1002/(SICI)1097-4547(20000101)59:1<1::AID-JNR1>3.0.CO;2-2; Cowin AJ, 2007, J PATHOL, V211, P572, DOI 10.1002/path.2143; Dao DY, 2007, ANN NY ACAD SCI, V1116, P82, DOI 10.1196/annals.1402.082; Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987; Eisenmann KM, 2007, CURR BIOL, V17, P579, DOI 10.1016/j.cub.2007.03.024; Esteve P, 2006, CURR OPIN NEUROBIOL, V16, P13, DOI 10.1016/j.conb.2006.01.001; FARGHALY SA, 1992, GYNECOL OBSTET INVES, V34, P65, DOI 10.1159/000292728; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Gabory A, 2006, CYTOGENET GENOME RES, V113, P188, DOI 10.1159/000090831; Garcia-Barcelo MM, 2007, ANN HUM GENET, V71, P746, DOI 10.1111/j.1469-1809.2007.00384.x; Gilboa E, 1999, CANCER IMMUNOL IMMUN, V48, P382, DOI 10.1007/s002620050590; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grozdanov PN, 2006, LAB INVEST, V86, P1272, DOI 10.1038/labinvest.3700479; Hishinuma M, 2006, HISTOPATHOLOGY, V49, P479, DOI 10.1111/j.1365-2559.2006.02522.x; Hossain MS, 2008, ONCOGENE, V27, P6075, DOI 10.1038/onc.2008.200; Imamura F, 2006, J COMP NEUROL, V495, P754, DOI 10.1002/cne.20896; Kato T, 2007, CLIN CANCER RES, V13, P434, DOI 10.1158/1078-0432.CCR-06-1297; Katoh M, 2007, STEM CELL REV, V3, P30, DOI 10.1007/s12015-007-0006-6; Katoh M, 2007, INT J MOL MED, V19, P197; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kopecki Z, 2008, INT J BIOCHEM CELL B, V40, P1415, DOI 10.1016/j.biocel.2007.04.011; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Liu CI, 2005, DEV BIOL, V285, P238, DOI 10.1016/j.ydbio.2005.05.045; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; MCNAMEE D, 1995, LANCET, V345, P1169, DOI 10.1016/S0140-6736(95)90998-2; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Niemann H, 2007, THERIOGENOLOGY, V68, pS165, DOI 10.1016/j.theriogenology.2007.05.041; Park TJ, 2009, EXP CELL RES, V315, P3152, DOI 10.1016/j.yexcr.2009.07.009; Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008-5472.CAN-07-0877; Sarandakou A, 2007, CRIT REV CL LAB SCI, V44, P151, DOI 10.1080/10408360601003143; Shimokawa T, 2003, CANCER RES, V63, P6116; Sugimori M, 2008, DEVELOPMENT, V135, P1271, DOI 10.1242/dev.015370; TROJAN J, 1995, MOL REPROD DEV, V42, P369, DOI 10.1002/mrd.1080420402; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang R, 2010, BIOL CELL, V102, P173, DOI 10.1042/BC20090091; Xu L, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-275	48	13	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					654	667		10.1038/onc.2010.451	http://dx.doi.org/10.1038/onc.2010.451			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	21102520	Bronze			2022-12-28	WOS:000287192000003
J	DeCicco-Skinner, KL; Trovato, EL; Simmons, JK; Lepage, PK; Wiest, JS				DeCicco-Skinner, K. L.; Trovato, E. L.; Simmons, J. K.; Lepage, P. K.; Wiest, J. S.			Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis	ONCOGENE			English	Article						Tpl2; skin cancer; inflammation; MAP3K8; NF-kappa B	NF-KAPPA-B; PROTEIN-KINASE-C; NF-KAPPA-B1 P105; MOUSE SKIN; SIGNALING PATHWAYS; CANCER DEVELOPMENT; TRANSGENIC MICE; T-CELLS; IN-VIVO; ACTIVATION	Tumor progression locus 2 (Tpl2) is a serine/threonine kinase in the mitogen-activated protein kinase signal transduction cascade known to regulate inflammatory pathways. Previously identified as an oncogene, its mutation or overexpression is reported in a variety of human cancers. To address its role in skin carcinogenesis, Tpl2(-/-) or wild-type (WT) C57BL/6 mice were subjected to a two-stage dimethylbenzanthracene/12-O-tetradecanoylphorbol- 13-acetate (TPA) mouse skin carcinogenesis model. Tpl2(-/-) mice developed a significantly higher incidence of tumors (80%) than WT mice (17%), as well as a reduced tumor latency and a significantly higher number of total tumors (113 vs 6). Moreover, Tpl2(-/-) mice treated with TPA experienced significantly higher nuclear factor kappaB (NF-kappa B) activation, edema, infiltrating neutrophils and production of proinflammatory cytokines than did WT mice. We investigated the role of the p38, JNK, MEK and NF-kappa B signaling pathways both in vitro and in vivo in WT and Tpl2(-/-) mice by using inhibitors for each of these pathways. We confirmed that the proinflammatory effect in Tpl2(-/-) mice was due to heightened activity of the NF-kappa B pathway. These studies indicate that Tpl2 may serve more as a tumor suppressor than as an oncogene in chemically induced skin carcinogenesis, with its absence contributing to both tumorigenesis and inflammation. Oncogene (2011) 30, 389-397; doi: 10.1038/onc.2010.447; published online 11 October 2010	[DeCicco-Skinner, K. L.; Trovato, E. L.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Trovato, E. L.; Simmons, J. K.; Lepage, P. K.; Wiest, J. S.] American Univ, Dept Biol, Washington, DC 20016 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American University	Wiest, JS (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, 37 Convent Dr, Bethesda, MD 20892 USA.	wiestj@mail.nih.gov		DeCicco-Skinner, Kathleen/0000-0002-0256-5609	NCI/NIH; NATIONAL CANCER INSTITUTE [ZIABC011108] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jyotsna Pandey for her assistance with confocal microscopy. This work was supported by the NCI/NIH Intramural Research Program.	AOKI M, 1991, ONCOGENE, V6, P1515; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; Cataisson C, 2005, J IMMUNOL, V174, P1686, DOI 10.4049/jimmunol.174.3.1686; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Clark AM, 2004, GENE CHROMOSOME CANC, V41, P99, DOI 10.1002/gcc.20069; Colombo MP, 1996, CANCER RES, V56, P2531; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; DIGIOVANNI J, 1984, CARCINOGENESIS, V5, P1493, DOI 10.1093/carcin/5.11.1493; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Glick A, 2007, MOL CARCINOGEN, V46, P605, DOI 10.1002/mc.20345; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hu YH, 2006, BIOORG MED CHEM LETT, V16, P6067, DOI 10.1016/j.bmcl.2006.08.102; Jansen AP, 2001, CANCER RES, V61, P808; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kimura YN, 2007, CANCER SCI, V98, P2009, DOI 10.1111/j.1349-7006.2007.00633.x; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mueller MM, 2006, EUR J CANCER, V42, P735, DOI 10.1016/j.ejca.2006.01.014; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Reddig PJ, 1999, CANCER RES, V59, P5710; RIJZEWIJK JJ, 1989, ACTA DERM-VENEREOL, V69, P512; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sharma SD, 2009, CARCINOGENESIS, V30, P1970, DOI 10.1093/carcin/bgp228; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Sugimoto K, 2004, J CLIN INVEST, V114, P857, DOI 10.1172/JCI200420014; Sur I, 2008, INT REV IMMUNOL, V27, P205, DOI 10.1080/08830180802130319; TAHARA H, 1994, CANCER RES, V54, P182; Tomczak MF, 2006, J IMMUNOL, V176, P1244, DOI 10.4049/jimmunol.176.2.1244; Tsatsanis C, 2000, INT J MOL MED, V5, P583; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 2008, P NATL ACAD SCI USA, V105, P2987, DOI 10.1073/pnas.0708381104; Van Acker GJD, 2007, J BIOL CHEM, V282, P22140, DOI 10.1074/jbc.M702225200; Velasco-Sampayo A, 2001, J IMMUNOL, V166, P6084, DOI 10.4049/jimmunol.166.10.6084; Watford WT, 2008, J EXP MED, V205, P2803, DOI 10.1084/jem.20081461; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	44	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					389	397		10.1038/onc.2010.447	http://dx.doi.org/10.1038/onc.2010.447			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20935675	Green Accepted			2022-12-28	WOS:000286621600002
J	Lavergne, E; Hendaoui, I; Coulouarn, C; Ribault, C; Leseur, J; Eliat, PA; Mebarki, S; Corlu, A; Clement, B; Musso, O				Lavergne, E.; Hendaoui, I.; Coulouarn, C.; Ribault, C.; Leseur, J.; Eliat, P-A; Mebarki, S.; Corlu, A.; Clement, B.; Musso, O.			Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active beta-catenin	ONCOGENE			English	Article						frizzled; collagen XVIII; Wnt; beta-catenin; colorectal cancer; secreted frizzled-related proteins	HUMAN COLORECTAL-CANCER; BASEMENT-MEMBRANE ZONES; COLON-CANCER; XVIII COLLAGEN; EXPRESSION; GENE; PATHWAY; CARCINOMA; MOUSE; ACTIVATION	Constitutive activation of Wnt/beta-catenin signaling in cancer results from mutations in pathway components, which frequently coexist with autocrine Wnt signaling or epigenetic silencing of extracellular Wnt antagonists. Among the extracellular Wnt inhibitors, the secreted frizzled-related proteins (SFRPs) are decoy receptors that contain soluble Wnt-binding frizzled domains. In addition to SFRPs, other endogenous molecules harboring frizzled motifs bind to and inhibit Wnt signaling. One of such molecules is V3Nter, a soluble SFRP-like frizzled polypeptide that binds to Wnt3a and inhibits Wnt signaling and expression of the beta-catenin target genes cyclin D1 and c-myc. V3Nter is derived from the cell surface extracellular matrix component collagen XVIII. Here, we used HCT116 human colon cancer cells carrying the Delta S45 activating mutation in one of the alleles of beta-catenin to show that V3Nter and SFRP-1 decrease baseline and Wnt3a-induced beta-catenin stabilization. Consequently, V3Nter reduces the growth of human colorectal cancer xenografts by specifically controlling cell proliferation and cell cycle progression, without affecting angiogenesis or apoptosis, as shown by decreased [H-3]-thymidine (in vitro) or BrdU (in vivo) incorporation, clonogenesis assays, cell cycle analysis and magnetic resonance imaging in living mice. Additionally, V3Nter switches off the beta-catenin target gene expression signature in vivo. Moreover, experiments with b-catenin allele-targeted cells showed that the DS45 beta-catenin allele hampers, but does not abrogate, inhibition of Wnt signaling by SFRP-1 or by the SFRP-like frizzled domain. Finally, neither SFRP-1 nor V3Nter affect beta-catenin signaling in SW480 cells carrying nonfunctional Adenomatous polyposis coli. Thus, SFRP-1 and the SFRP-like molecule V3Nter can inhibit tumor growth of beta-catenin-activated tumor cells in vivo. Oncogene (2011) 30, 423-433; doi: 10.1038/onc.2010.432; published online 20 September 2010	[Musso, O.] Univ Rennes, INSERM, UMR991, Hop Pontchaillou, F-35033 Rennes, France; [Lavergne, E.; Hendaoui, I.; Coulouarn, C.; Ribault, C.; Leseur, J.; Eliat, P-A; Mebarki, S.; Corlu, A.; Clement, B.; Musso, O.] Univ Rennes 1, Rennes, France; [Leseur, J.] Ctr Reg Lutte Canc, Rennes, France; [Eliat, P-A] PRISM, IFR 140, Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Universite de Rennes	Musso, O (corresponding author), Univ Rennes, INSERM, UMR991, Hop Pontchaillou, Rue Henri le Guilloux, F-35033 Rennes, France.	orlando.musso@inserm.fr	Coulouarn, Cedric/E-5472-2011; Corlu, Anne/U-8030-2018; Musso, Orlando/N-5756-2017; Clement, Bruno/E-5546-2016; Eliat, Pierre-Antoine/AAL-2600-2020	Coulouarn, Cedric/0000-0002-5692-9586; Corlu, Anne/0000-0002-7370-0564; Clement, Bruno/0000-0001-8827-146X; Eliat, Pierre-Antoine/0000-0002-8082-4477; Musso, Orlando/0000-0001-8881-6925	Institut National de la Sante et de la Recherche Medicale; Institut National du Cancer; Agence Nationale de la Recherche; Universite de Rennes 1; Region Bretagne	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale de la Recherche(French National Research Agency (ANR)); Universite de Rennes 1; Region Bretagne(Region Bretagne)	We thank technical assistance from C Rocher at the Small Animal Imaging Platform, A Fautrel and P Bellaud at the Core HistoPathology Platform, R Le Guevel at the ImpactCell Platform, D Le Quilleuc and B Turlin at the Center for Biological Ressources and the animal husbandry group. We are indebted to B Vogelstein, S Bayling and H Suzuki, R Moon, R Nusse, T Pihlajaniemi and J Pouyssegur for generously providing cells, cDNAs or antibodies and to Christine Perret (Institut Cochin, Department Endocrinology, Metabolism and Cancer, Paris, France) for critical reading of the paper. This study was supported by Institut National de la Sante et de la Recherche Medicale, Institut National du Cancer, Agence Nationale de la Recherche (Emergence-BIO Program 2008), Universite de Rennes 1, Region Bretagne.	Ahmed N, 2003, PROTEOMICS, V3, P288, DOI 10.1002/pmic.200390042; Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; Dimitrova YN, 2010, J BIOL CHEM, V285, P13507, DOI 10.1074/jbc.M109.049411; Elamaa H, 2003, MATRIX BIOL, V22, P427, DOI 10.1016/S0945-053X(03)00073-8; Elamaa H, 2002, MECH DEVELOP, V114, P109, DOI 10.1016/S0925-4773(02)00014-X; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hu J, 2009, CANCER RES, V69, P6951, DOI 10.1158/0008-5472.CAN-09-0541; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kenny PA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-3; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kyle AH, 2003, CANCER RES, V63, P5707; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Musso O, 2001, HEPATOLOGY, V33, P868, DOI 10.1053/jhep.2001.23189; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Quelard D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001878; Ramanujan S, 2000, CANCER RES, V60, P1442; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sekine S, 2002, ONCOGENE, V21, P5906, DOI 10.1038/sj.onc.1205756; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Takeuchi T, 2004, CLIN CANCER RES, V10, P5572, DOI 10.1158/1078-0432.CCR-03-0656; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Treanor D, 2007, CLIN ONCOL-UK, V19, P769, DOI 10.1016/j.clon.2007.08.012; Ueno K, 2008, NEOPLASIA, V10, P697, DOI 10.1593/neo.08320; Vider BZ, 1996, ONCOGENE, V12, P153; Wang ZH, 2003, CANCER RES, V63, P5234; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200	53	63	67	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					423	433		10.1038/onc.2010.432	http://dx.doi.org/10.1038/onc.2010.432			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856206	Green Accepted, Green Submitted			2022-12-28	WOS:000286621600005
J	Xiao, Y; Ye, Y; Zou, X; Jones, S; Yearsley, K; Shetuni, B; Tellez, J; Barsky, SH				Xiao, Y.; Ye, Y.; Zou, X.; Jones, S.; Yearsley, K.; Shetuni, B.; Tellez, J.; Barsky, S. H.			The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction	ONCOGENE			English	Article						inflammatory breast cancer; lymphovascular emboli; Notch 3 signaling; gamma-secretase inhibitors; Notch 3 siRNA; apoptosis	STEM-CELLS; IN-VITRO; E-CADHERIN; C-MYC; MAMMARY; EXPRESSION; GENE; ACTIVATION; PATHWAY; DIFFERENTIATION	Inflammatory breast carcinoma (IBC) is characterized by exaggerated lymphovascular invasion (LVI), recapitulated in our human xenograft, MARY-X. This model exhibited lymphovascular emboli in vivo and corresponding spheroids in vitro. Owing to the morphological and gene profile resemblance of these spheroids to embryonal blastocysts, we wondered whether they might exhibit embryonic stem cell signaling. Specifically we investigated Notch and observed selective Notch 3 activation by expression profiling, reverse transcriptase- and real-time PCR, western blot and immunofluorescence in vitro, and immunohistochemistry in vivo. Notch 3 intracellular domain (N3icd) and six target genes, HES-5, HEY-1, c-Myc, Deltex-1, NRARP and PBX1, markedly increased in MARY-X. In addition, a significant percentage of MARY-X cells expressed aldehyde dehydrogenase (ALDH), a stem cell marker. Only the ALDH(+) cells were capable of secondary spheroidgenesis, tumorigenicity and self-renewal. Inhibiting Notch 3 activation in vitro with gamma-secretase inhibitors (GSIs) or small interfering RNA resulted in a downregulation of Notch target genes, including CD133, and an induction of caspase 3-mediated apoptosis. Transfection of N3icd but not Notch 1 intracellular domain into normal human mammary epithelial cells resulted in increased expression of Notch target genes and induction of spheroidgenesis. GSI in vivo resulted in inhibitory but diffusion-limited effects on Notch 3 signaling, resulting in xenograft growth reduction. The lymphovascular emboli of human IBC exhibited dual N3icd and ALDH1 immunoreactivities independently of molecular subtype. This Notch 3 addiction of lymphovascular emboli might be exploited in future therapeutic strategies. Oncogene (2011) 30, 287-300; doi:10.1038/onc.2010.405; published online 13 September 2010	[Ye, Y.; Tellez, J.; Barsky, S. H.] Univ Nevada, Sch Med, Dept Pathol, Reno, NV 89557 USA; [Xiao, Y.; Zou, X.; Jones, S.; Yearsley, K.; Shetuni, B.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Barsky, S. H.] Nevada Canc Inst, Las Vegas, NV USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University System of Ohio; Ohio State University; University of California System; University of California San Diego	Barsky, SH (corresponding author), Univ Nevada, Sch Med, Dept Pathol, 1 Manville Med Bldg, Reno, NV 89557 USA.	sbarsky@medicine.nevada.edu	zou, Xianghong/E-4374-2011		American Airlines-Susan G Komen for the Cure [KGO81287]; Department of Defense [BC990959, BC024258, BC053405]; Strategic Initiative, at Ohio State; Donald A Senhauser Endowment; NATIONAL CANCER INSTITUTE [R01CA113579] Funding Source: NIH RePORTER	American Airlines-Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); Strategic Initiative, at Ohio State; Donald A Senhauser Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the American Airlines-Susan G Komen for the Cure Promise Grant KGO81287, Department of Defense Breast Cancer Research Program Grants BC990959, BC024258, BC053405, the Strategic Initiative Grant Program at Ohio State and The Donald A Senhauser Endowment. Figures 1a, b, c and 2e were, in part, reprinted from Am J Pathol 2008, 173: 561-574 with permission from the American Society For Investigative Pathology.	Alpaugh ML, 1999, CANCER RES, V59, P5079; Alpaugh ML, 2002, AM J PATHOL, V161, P619, DOI 10.1016/S0002-9440(10)64217-4; Alpaugh ML, 2002, HUM GENE THER, V13, P1245, DOI 10.1089/104303402320139023; Alpaugh ML, 2002, ONCOGENE, V21, P3631, DOI 10.1038/sj.onc.1205389; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Barsky SH, 2003, EXP MOL PATHOL, V74, P113, DOI 10.1016/S0014-4800(03)00011-X; Bellavia D, 2008, ONCOGENE, V27, P5092, DOI 10.1038/onc.2008.230; Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115; Bertucci F, 2006, CANCER RES, V66, P4636, DOI 10.1158/0008-5472.CAN-06-0031; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Cariati M, 2005, SURG ONCOL, V14, P133, DOI 10.1016/j.suronc.2005.07.004; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; Cuevas IC, 2005, CANCER RES, V65, P5070, DOI 10.1158/0008-5472.CAN-05-0240; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Giraldez AJ, 2002, MECH DEVELOP, V115, P101, DOI 10.1016/S0925-4773(02)00124-7; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; PALANGIE T, 1994, EUR J CANCER, V30A, P921, DOI 10.1016/0959-8049(94)90115-5; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; POLITI K, 2006, SEMIN CANCER BIOL, V14, P341; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; RACHEL E, 2001, CURR BIOL, V11, P514; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rizzo P, 2008, ONCOGENE, V27, P5124, DOI 10.1038/onc.2008.226; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; SHEILA K, 2004, NATURE, V432, P396; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sun YP, 2005, ONCOGENE, V24, P5365, DOI 10.1038/sj.onc.1208528; Tomlinson JS, 2001, CANCER RES, V61, P5231; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Xiao Y, 2008, AM J PATHOL, V173, P561, DOI 10.2353/ajpath.2008.071214; Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	65	38	40	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					287	300		10.1038/onc.2010.405	http://dx.doi.org/10.1038/onc.2010.405			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20838375				2022-12-28	WOS:000286418800004
J	Castedo, M; Vitale, I; Kroemer, G				Castedo, M.; Vitale, I.; Kroemer, G.			A novel source of tetraploid cancer cell precursors: telomere insufficiency links aging to oncogenesis	ONCOGENE			English	Review						tetraploidy; oncogenesis; telomere; aging	CHROMOSOMAL INSTABILITY; CARCINOGENESIS; APOPTOSIS; LENGTH; P53; MITOSIS	Epithelial cancers of the elderly are caused by a combination of telomere dysfunction and the mutational invalidation of major tumor suppressors including p53. A recent article published in Cell by Davoli et al. shows that the simultaneous elimination of p53 and telomerase causes a state of chronic DNA damage that results in tetraploidization through endoreplication, that is, two consecutive S phases that are not separated by mitosis. As tetraploid cells represent a metastable intermediate between normal diploidy and cancer-associated aneuploidy, this novel route to tetraploidization may constitute (one of) the functional link(s) between aging and carcinogenesis. Oncogene (2010) 29, 5869-5872; doi:10.1038/onc.2010.392; published online 30 August 2010	[Castedo, M.; Vitale, I.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Castedo, M.; Vitale, I.; Kroemer, G.] Univ Paris 11, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Castedo, M (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	castedo@igr.fr; kroemer@orange.fr	Vitale, Ilio/M-3960-2017; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	Vitale, Ilio/0000-0002-5918-1841; KROEMER, Guido/0000-0002-9334-4405	Ligue Nationale contre le Cancer; Agence Nationale pour la Recherche (ANR); European Commission; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France)	GK was supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, Chemo Res, ApopTrain), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa) and Canceropole Ile-de-France. IV was supported by the Ligue Nationale contre le Cancer.	Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; DANES BS, 1978, CANCER-AM CANCER SOC, V41, P2330, DOI 10.1002/1097-0142(197806)41:6<2330::AID-CNCR2820410635>3.0.CO;2-X; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; Duelli DM, 2007, CURR BIOL, V17, P431, DOI 10.1016/j.cub.2007.01.049; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; Engelhardt M, 1997, CLIN CANCER RES, V3, P1849; Finley JC, 2006, CANCER EPIDEM BIOMAR, V15, P1451, DOI 10.1158/1055-9965.EPI-05-0837; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lantuejoul S, 2005, CLIN CANCER RES, V11, P2074, DOI 10.1158/1078-0432.CCR-04-1376; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; Maruyama Y, 1997, JPN J CLIN ONCOL, V27, P216, DOI 10.1093/jjco/27.4.216; Meeker AK, 2004, CLIN CANCER RES, V10, P3317, DOI 10.1158/1078-0432.CCR-0984-03; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; Rello-Varona S, 2009, CELL CYCLE, V8, P1030, DOI 10.4161/cc.8.7.7950; Roumier T, 2005, CELL DEATH DIFFER, V12, P91, DOI 10.1038/sj.cdd.4401521; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Senovilla L, 2009, CELL CYCLE, V8, P1380, DOI 10.4161/cc.8.9.8305; Skyldberg BM, 1999, MODERN PATHOL, V12, P675; Vitale I, 2010, EMBO J, V29, P1272, DOI 10.1038/emboj.2010.11	25	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	44					5869	5872		10.1038/onc.2010.392	http://dx.doi.org/10.1038/onc.2010.392			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20802535				2022-12-28	WOS:000283843400001
J	Kuphal, S; Shaw-Hallgren, G; Eberl, M; Karrer, S; Aberger, F; Bosserhoff, AK; Massoumi, R				Kuphal, S.; Shaw-Hallgren, G.; Eberl, M.; Karrer, S.; Aberger, F.; Bosserhoff, A. K.; Massoumi, R.			GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma	ONCOGENE			English	Article						CYLD; GLI1; Snail1; BCC; Bcl-3	CYCLE PROGRESSION; HEDGEHOG PATHWAY; EXPRESSION; TUMOR; GLI1; MICE; DIFFERENTIATION; TRANSFORMATION; MANIPULATION; INHIBITION	CYLD is a deubiquitination enzyme that regulates different cellular processes, such as cell proliferation and cell survival. Mutation and loss of heterozygosity of the CYLD gene causes development of cylindromatosis, a benign tumour originating from the skin. Our study shows that CYLD expression is dramatically downregulated in basal cell carcinoma (BCC), the most common cancer in humans. Reduced CYLD expression in basal cell carcinoma was mediated by GLI1-dependent activation of the transcriptional repressor Snail. Inhibition of GLI1 restored the CYLD expression-mediated Snail signaling pathway, and caused a significant delay in the G1 to S phase transition, as well as proliferation. Our data suggest that GLI1-mediated suppression of CYLD has a significant role in basal cell carcinoma progression. Oncogene (2011) 30, 4523-4530; doi: 10.1038/onc.2011.163; published online 16 May 2011	[Shaw-Hallgren, G.; Massoumi, R.] Lund Univ, UMAS, Dept Lab Med, S-20502 Malmo, Sweden; [Kuphal, S.; Bosserhoff, A. K.] Univ Regensburg, Inst Pathol, Regensburg, Germany; [Eberl, M.; Aberger, F.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Karrer, S.] Univ Regensburg, Dept Dermatol, Regensburg, Germany	Lund University; Skane University Hospital; University of Regensburg; Salzburg University; University of Regensburg	Massoumi, R (corresponding author), Lund Univ, UMAS, Dept Lab Med, Entrance 78, S-20502 Malmo, Sweden.	Ramin.Massoumi@med.lu.se	Massoumi, Ramin/AAG-4786-2019; Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022; Aberger, Fritz/B-6357-2012	Aberger, Fritz/0000-0003-2009-6305; Bosserhoff, Anja/0000-0001-8147-394X	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council; Crafoordska Foundation; Royal Physiographic Society in Lund; Gunnar Nilsson Cancer Foundation; U-MAS Research Foundations; ERC; Austrian Science Fund FWF [P20652]; University of Salzburg; Austrian Genome program Gen-AU	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Crafoordska Foundation; Royal Physiographic Society in Lund; Gunnar Nilsson Cancer Foundation; U-MAS Research Foundations; ERC(European Research Council (ERC)European Commission); Austrian Science Fund FWF(Austrian Science Fund (FWF)); University of Salzburg; Austrian Genome program Gen-AU	We thank Rudolf Jung and Elise Nilsson for excellent technical assistance, Dr Anders Edsjo, for discussion, Dr Ervin H Epstein for the mouse BCC cell line ASZ001 and CSZ-1. This work was supported by the Swedish Society for Medical Research, Swedish Cancer Foundation, Swedish Medical Research Council, Crafoordska Foundation, Royal Physiographic Society in Lund, Gunnar Nilsson Cancer Foundation, U-MAS Research Foundations and ERC grant to RM and the Austrian Science Fund FWF (projects P20652), the priority program of the University of Salzburg and the Austrian Genome program Gen-AU to FA.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper Maria, 2007, V397, P67; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Li X, 2007, ONCOGENE, V26, P4489, DOI 10.1038/sj.onc.1210241; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Louro ID, 2002, CANCER RES, V62, P5867; Massoumi R, 2006, J INVEST DERMATOL, V126, P1182, DOI 10.1038/sj.jid.5700218; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2010, TRENDS BIOCHEM SCI, V35, P392, DOI 10.1016/j.tibs.2010.02.007; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Moriwaki K, 2007, J INVEST DERMATOL, V127, pS107; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nitzki F, 2010, CANCER RES, V70, P2739, DOI 10.1158/0008-5472.CAN-09-3743; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; So PL, 2006, EXP DERMATOL, V15, P742, DOI 10.1111/j.1600-0625.2006.00465.x; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wickstrom SA, 2010, EMBO J, V29, P131, DOI 10.1038/emboj.2009.317; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386	28	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4523	4530		10.1038/onc.2011.163	http://dx.doi.org/10.1038/onc.2011.163			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21577203				2022-12-28	WOS:000296733200007
J	Nitzki, F; Zibat, A; Frommhold, A; Schneider, A; Schulz-Schaeffer, W; Braun, T; Hahn, H				Nitzki, F.; Zibat, A.; Frommhold, A.; Schneider, A.; Schulz-Schaeffer, W.; Braun, T.; Hahn, H.			Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous Patched1-mutant mice	ONCOGENE			English	Article						rhabdomyosarcoma; ERMS; time of initiation; hedgehog; patched1	HEDGEHOG SIGNALING PATHWAY; SONIC HEDGEHOG; ALVEOLAR RHABDOMYOSARCOMA; MUTANT MICE; GENE; PTCH; MEDULLOBLASTOMA; INACTIVATION; EXPRESSION; SPECIFICATION	Embryonal rhabdomyosarcoma (ERMS) is a tumor of the skeletal muscle in children and is frequently initiated by heterozygous germline mutations in the Hedgehog (Hh) receptor Patched1 (Ptch), both in humans and mice. Using a conditional knock-out strategy in Ptch(flox/+) mice, we demonstrate that early embryonic stages are more susceptible to ERMS development than later stages and that cells normally not committed to undergo myogenesis at this stage represent the major source of ERMS. We found that deletion of a single copy of the Ptch allele at E9.5 using the ubiquitously active Rosa26CreERT2 resulted in a tumor incidence of 88% but reached only 44% and 12% when the Ptch allele was inactivated at E11.5 and E13.5, respectively. Induction of the Ptch mutation at E9.5 did also significantly shorten ERMS-free survival and increased tumor multiplicity compared with tumor induction at E11.5 and E13.5. Interestingly, we observed a more that 10-fold reduction of ERMS incidence when the Ptch mutation was specifically introduced in Myf5-expressing cells, which is the myogenic factor expressed in all muscle cells at E9.5. We conclude that Myf5-negative cells are more susceptible to ERMS development than Myf5-positive embryonic precursors. As the propensity to undergo tumorigenic transformation declined with age, concomitant with the increase of stably committed muscle cells, it seems likely that the Ptch mutation favors tumor formation in progenitor cells, which have not yet acquired a muscle cell fate. Oncogene (2011) 30, 4428-4436; doi:10.1038/onc.2011.157; published online 23 May 2011	[Nitzki, F.; Zibat, A.; Hahn, H.] Univ Gottingen, Dept Human Genet, D-37073 Gottingen, Lower Saxony, Germany; [Schneider, A.; Braun, T.] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling, Bad Nauheim, Germany; [Schulz-Schaeffer, W.] Univ Gottingen, Dept Neuropathol, D-37073 Gottingen, Lower Saxony, Germany	University of Gottingen; Max Planck Society; University of Gottingen	Hahn, H (corresponding author), Univ Gottingen, Dept Human Genet, Heinrich Dueker Weg 12, D-37073 Gottingen, Lower Saxony, Germany.	hhahn@gwdg.de	Braun, Thomas/B-2310-2008; Schneider, Andre/C-5270-2013	Braun, Thomas/0000-0002-6165-4804	Wilhelm Sander Stiftung [2003.112.3]	Wilhelm Sander Stiftung	We thank Susan Peter and Stefan Wolf for excellent animal care and Simone Fulda for critical comments on the manuscript. This work was supported by the grant 2003.112.3 of the Wilhelm Sander Stiftung to HH.	Asakura A, 1998, DEV BIOL, V203, P276, DOI 10.1006/dbio.1998.9050; Biressi S, 2007, DEV BIOL, V308, P281, DOI 10.1016/j.ydbio.2007.06.006; Biressi S, 2007, DEV BIOL, V304, P633, DOI 10.1016/j.ydbio.2007.01.016; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1994, DEVELOPMENT, V120, P3083; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; Diwan BA, 1997, CARCINOGENESIS, V18, P2009, DOI 10.1093/carcin/18.10.2009; Ecke I, 2009, CANCER RES, V69, P887, DOI 10.1158/0008-5472.CAN-08-0946; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Gensch N, 2008, DEVELOPMENT, V135, P1597, DOI 10.1242/dev.019331; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 2004, GENOMICS, V84, P853, DOI 10.1016/j.ygeno.2004.07.002; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hameyer D, 2007, PHYSIOL GENOMICS, V31, P32, DOI 10.1152/physiolgenomics.00019.2007; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kruger M, 2001, DEVELOPMENT, V128, P743; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Merlino G, 2007, GENE DEV, V21, P1275, DOI 10.1101/gad.1563707; Nagao K, 2005, HUM MOL GENET, V14, P3379, DOI 10.1093/hmg/ddi369; Resende TP, 2010, P NATL ACAD SCI USA, V107, P12907, DOI 10.1073/pnas.1000979107; RIVERA OJ, 2006, 97 AACR ANN M 1 5 AP; Tallquist MD, 2000, DEVELOPMENT, V127, P5059; Taniguchi E, 2009, PEDIATR BLOOD CANCER, V53, P136, DOI 10.1002/pbc.21968; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Uhmann A, 2005, INT J ONCOL, V27, P1567; Uhmann A, 2007, BLOOD, V110, P1814, DOI 10.1182/blood-2007-02-075648; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068	39	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	43					4428	4436		10.1038/onc.2011.157	http://dx.doi.org/10.1038/onc.2011.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21602886				2022-12-28	WOS:000296356500005
J	Boulay, PL; Schlienger, S; Lewis-Saravalli, S; Vitale, N; Ferbeyre, G; Claing, A				Boulay, P-L; Schlienger, S.; Lewis-Saravalli, S.; Vitale, N.; Ferbeyre, G.; Claing, A.			ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein	ONCOGENE			English	Article						ADP-ribosylation factor; breast cancer; cell cycle; proliferation; retinoblastoma protein	ADP-RIBOSYLATION FACTOR; CELLULAR SENESCENCE; CYCLIN D1; IN-VIVO; TUMOR SUPPRESSION; ONCOGENIC RAS; ACTIVATION; PATHWAY; GENE; INHIBITION	The ADP-ribosylation factors (ARFs) 1 and 6 are small GTP-binding proteins, highly expressed and activated in several breast cancer cell lines and are associated with enhanced migration and invasiveness. In this study, we report that ARF1 has a critical role in cell proliferation. Depletion of this GTPase or expression of a dominant negative form, which both resulted in diminished ARF1 activity, led to sustained cell-growth arrest. This cellular response was associated with the induction of senescent markers in highly invasive breast cancer cells as well as in control mammary epithelial cells by a mechanism regulating retinoblastoma protein (pRB) function. When examining the role of ARF1, we found that this GTPase was highly activated in normal proliferative conditions, and that a limited amount could be found in the nucleus, associated with the chromatin of MDA-MB-231 cells. However, when cells were arrested in the G(0)/G(1) phase or transfected with a dominant negative form of ARF1, the total level of activated ARF1 was markedly reduced and the GTPase significantly enriched in the chromatin. Using biochemical approaches, we demonstrated that the GDP-bound form of ARF1 directly interacted with pRB, but not other members of this family of proteins. In addition, depletion of ARF1 or expression of ARF1T(31)N resulted in the constitutive association of pRB and E2F1, thereby stabilizing the interaction of E2F1 as well as pRB at endogenous sites of target gene promoters, preventing expression of E2F target genes, such as cyclin D1, Mcm6 and E2F1, important for cell-cycle progression. These novel findings provide direct physiological and molecular evidence for the role of ARF1 in controlling cell proliferation, dependent on its ability to regulate pRB/E2F1 activity and gene expression for enhanced proliferation and breast cancer progression. Oncogene (2011) 30, 3846-3861; doi:10.1038/onc.2011.100; published online 11 April 2011	[Boulay, P-L; Schlienger, S.; Lewis-Saravalli, S.; Claing, A.] Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; [Ferbeyre, G.; Claing, A.] Univ Montreal, Fac Med, Dept Biochem, Montreal, PQ H3C 3J7, Canada; [Vitale, N.] Univ Strasbourg, Inst Neurosci Cellulaires & Integrat, CNRS, Unite Propre Rech 3212, Strasbourg, France	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Claing, A (corresponding author), Univ Montreal, Fac Med, Dept Pharmacol, POB 6128, Montreal, PQ H3C 3J7, Canada.	audrey.claing@umontreal.ca	Vitale, Nicolas/G-5967-2014; Ferbeyre, Gerardo/A-1569-2010	Vitale, Nicolas/0000-0002-4752-4907; Ferbeyre, Gerardo/0000-0002-2146-618X	Canadian Institutes of Health Research (CIHR) [MOP-79470]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We would like to thank Dr Tony Kouzarides (The Gurdon Institute, University of Cambridge, UK) for GST-pRB. We thank Raphaelle Lambert from genomic platform of IRIC (Montreal, Canada). We are grateful to Dr Christian Beausejour (University of Montreal, Montreal, Canada) for reagents and helpful discussion. We thank Dr Stephane A Laporte (McGill University, Montreal, Canada) for the use of his confocal microscope and Dr Denis de Blois and Julie-Emilie Huot-Marchand (University of Montreal, Montreal, Canada) for the use of their photo-microscopy plateform. We thank Dr Veronique Bourdeau (University of Montreal, Montreal, Canada) for helpful discussion and critical reading of the paper. This work was supported by the Canadian Institutes of Health Research (CIHR) grant MOP-79470 to AC. PLB is the recipient of a Frederick Banting and Charles Best PhD Research Award from the CIHR. AC is the recipient of a New Investigator Award from the CIHR.	Altan-Bonnet N, 2003, P NATL ACAD SCI USA, V100, P13314, DOI 10.1073/pnas.2234055100; Azab AK, 2009, BLOOD, V114, P619, DOI 10.1182/blood-2009-01-199281; Bartholomew JN, 2009, CANCER RES, V69, P2878, DOI 10.1158/0008-5472.CAN-08-2857; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Boulay PL, 2008, J BIOL CHEM, V283, P36425, DOI 10.1074/jbc.M803603200; Boyer SN, 1996, CANCER RES, V56, P4620; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Cohen LA, 2007, MOL BIOL CELL, V18, P2244, DOI 10.1091/mbc.E06-11-0998; Cotton M, 2007, MOL BIOL CELL, V18, P501, DOI 10.1091/mbc.E06-06-0567; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; Dubois T, 2003, BIOCHEM BIOPH RES CO, V301, P502, DOI 10.1016/S0006-291X(02)03010-3; Dunphy JL, 2007, TRAFFIC, V8, P661, DOI 10.1111/j.1600-0854.2007.00561.x; DURO D, 1995, ONCOGENE, V11, P21; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hafner M, 2006, NATURE, V444, P941, DOI 10.1038/nature05415; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Houndolo T, 2005, J BIOL CHEM, V280, P5598, DOI 10.1074/jbc.M411456200; Hui R, 2000, CLIN CANCER RES, V6, P2777; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lin CY, 2002, J CELL SCI, V115, P4433, DOI 10.1242/jcs.00123; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Miller CL, 2007, MOL CELL PROTEOMICS, V6, P1027, DOI 10.1074/mcp.M700056-MCP200; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita Y, 2002, CANCER RES, V62, P6764; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Padilla PI, 2008, P NATL ACAD SCI USA, V105, P3357, DOI 10.1073/pnas.0712387105; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Roninson IB, 2003, J CELL BIOCHEM, V88, P83, DOI 10.1002/jcb.10320; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SOULE HD, 1990, CANCER RES, V50, P6075; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Takahashi Y, 2000, GENE DEV, V14, P804; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; Vernier M, 2011, GENE DEV, V25, P41, DOI 10.1101/gad.1975111; Viaud J, 2007, P NATL ACAD SCI USA, V104, P10370, DOI 10.1073/pnas.0700773104; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu D, 2009, ONCOGENE, V28, P2219, DOI 10.1038/onc.2009.96; YAGATA H, 2011, BREAST CANC; Yakes FM, 2002, CANCER RES, V62, P4132; Yudin D, 2009, J CELL SCI, V122, P587, DOI 10.1242/jcs.015289; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	62	37	37	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3846	3861		10.1038/onc.2011.100	http://dx.doi.org/10.1038/onc.2011.100			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21478909				2022-12-28	WOS:000294687200003
J	Li, Y; Cai, L; Wang, H; Wu, P; Gu, W; Chen, Y; Hao, H; Tang, K; Yi, P; Liu, M; Miao, S; Ye, D				Li, Y.; Cai, L.; Wang, H.; Wu, P.; Gu, W.; Chen, Y.; Hao, H.; Tang, K.; Yi, P.; Liu, M.; Miao, S.; Ye, D.			Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2	ONCOGENE			English	Article						formyl peptide receptor-2; macrophage colony-stimulating factor; monocyte chemoattractant protein-1; macrophages; tumorigenesis	TUMOR-ASSOCIATED MACROPHAGES; NF-KAPPA-B; IN-VIVO; SIGNAL TRANSDUCER; LIPID MEDIATORS; A(4) RECEPTOR; CANCER-CELLS; INFLAMMATION; ACTIVATION; RESOLUTION	Cancer cells recruit monocytes, macrophages and other inflammatory cells by producing abundant chemo-attractants and growth factors, such as macrophage colony-stimulating factor (M-CSF/CSF-1) and monocyte chemoattractant protein-1 (MCP-1/CCL2), to promote tumor growth and dissemination. An understanding of the mechanisms that target cancer cells and regulate tumor microenvironment is essential in designing anticancer therapies. Here, we showed that serum amyloid-A (SAA) and cathelicidin (LL-37) stimulated M-CSF and MCP-1 expression with or without lipopolysaccharide (LPS) administration; conversely, lipoxin-A(4) (LXA(4)) and annexin-A1 (ANXA1) inhibited LPS-induced M-CSF and MCP-1 production by human (HepG2) and mouse (H22) hepatocellular carcinoma cells (HCCs). The effects of LXA(4), ANXA1, SAA and LL-37 were dependent on the activation of their mutual cell-surface receptor formyl peptide receptor-2 (FPR2) and subsequent ROS-MAPK-NF-kB signalings. Furthermore, our results indicated that LPS switched macrophages into an IL-10(low)IL-12(high) M1 profile, whereas M-CSF + MCP-1 and FPR2 agonists skewed them into M2 (IL-10(high)IL-12(low)). In that respect, through modulating the phosphorylation of signal transducer and activator of transcription-3 (STAT3), LXA(4) and ANXA1 induced monocyte differentiation into M2a + M2c-like cells and showed antitumorigenetic activities, whereas SAA, LL-37 and M-CSF + MCP-1 led to M2b- or M2d-like polarization, which exacerbated HCC invasion in vitro and in vivo, respectively. Our results suggest that FPR2 has an appreciable pleiotropic regulator role in tumor immunoediting. Oncogene (2011) 30, 3887-3899; doi:10.1038/onc.2011.112; published online 18 April 2011	[Li, Y.; Cai, L.; Wu, P.; Gu, W.; Hao, H.; Tang, K.; Yi, P.; Liu, M.; Miao, S.; Ye, D.] Huazhong Univ Sci & Technol, Dept Pathophysiol, Tongji Med Coll, Wuhan 430030, Peoples R China; [Li, Y.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol, Boston, MA 02115 USA; [Wang, H.] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Chen, Y.] Univ Aizu, Grad Sch Comp Sci & Engn, Biomed Informat Technol Lab, Aizu Wakamatsu, Japan	Huazhong University of Science & Technology; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Aizu	Li, Y (corresponding author), Huazhong Univ Sci & Technol, Dept Pathophysiol, Tongji Med Coll, Wuhan 430030, Peoples R China.	yli@zeus.bwh.harvard.edu; yedy@mails.tjmu.edu.cn		Li, Yongsheng/0000-0003-2175-9449	China Scholarship Council [2009616073]; National Natural Science Foundation of China [30570726, 30772154]	China Scholarship Council(China Scholarship Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Professor Charles N Serhan for helpful comments about FPR2. We also appreciate all anonymous reviewers for helpful suggestions on quality improvement of the paper. This work was supported by China Scholarship Council Fellowship No. 2009616073 and National Natural Science Foundation of China Grants 30570726 and 30772154.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cocco E, 2010, CANCER-AM CANCER SOC, V116, P843, DOI 10.1002/cncr.24838; Coimbra M, 2009, CURR PHARM DESIGN, V15, P1825, DOI 10.2174/138161209788453220; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Craig M, 2008, J CELL BIOCHEM, V103, P1, DOI 10.1002/jcb.21379; Duff MD, 2007, J SURG RES, V142, P119, DOI 10.1016/j.jss.2006.12.542; Duluc D, 2007, BLOOD, V110, P4319, DOI 10.1182/blood-2007-02-072587; Duluc D, 2009, INT J CANCER, V125, P367, DOI 10.1002/ijc.24401; El Kebir D, 2008, J LEUKOCYTE BIOL, V84, P600, DOI 10.1189/jlb.1107765; EMOTO M, 1992, J EXP MED, V176, P363, DOI 10.1084/jem.176.2.363; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; FIORE S, 1992, J BIOL CHEM, V267, P16168; Fujimoto H, 2009, INT J CANCER, V125, P1276, DOI 10.1002/ijc.24378; GAO JL, 1993, J BIOL CHEM, V268, P25395; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kuninaka S, 2000, CYTOKINE, V12, P8, DOI 10.1006/cyto.1998.0504; Lawrence T, 2007, TRENDS PHARMACOL SCI, V28, P162, DOI 10.1016/j.tips.2007.02.003; Li Y, 2010, CURR CANCER DRUG TAR, V10, P782, DOI 10.2174/156800910793605857; Li YS, 2008, ARCH BIOCHEM BIOPHYS, V478, P110, DOI 10.1016/j.abb.2008.07.002; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; McMahon B, 2000, J BIOL CHEM, V275, P27566; Miao T, 2006, J NEUROSCI, V26, P9512, DOI 10.1523/JNEUROSCI.2160-06.2006; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Panzer U, 2009, AM J PHYSIOL-RENAL, V297, pF429, DOI 10.1152/ajprenal.90435.2008; Peng J, 2010, CELL RES, V20, P62, DOI 10.1038/cr.2009.128; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; Perretti M, 2002, J IMMUNOL, V169, P2085, DOI 10.4049/jimmunol.169.4.2085; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Sandri S, 2008, J LEUKOCYTE BIOL, V83, P1174, DOI 10.1189/jlb.0407203; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; Sironi M, 2006, J LEUKOCYTE BIOL, V80, P342, DOI 10.1189/jlb.1005586; Spite M, 2010, CIRC RES, V107, P1170, DOI 10.1161/CIRCRESAHA.110.223883; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Teng MWL, 2010, P NATL ACAD SCI USA, V107, P8328, DOI 10.1073/pnas.1003251107; Varney ML, 2002, IN VIVO, V16, P471; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Zhang L, 2007, CHINESE MED J-PEKING, V120, P981, DOI 10.1097/00029330-200706010-00008; Zhang T, 2010, CANCER IMMUNOL IMMUN, V59, P1097, DOI 10.1007/s00262-010-0836-y; Zhang ZQ, 2010, CANCER RES, V70, P2379, DOI 10.1158/0008-5472.CAN-09-4204	49	114	123	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	36					3887	3899		10.1038/onc.2011.112	http://dx.doi.org/10.1038/onc.2011.112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21499310				2022-12-28	WOS:000294687200006
J	Takada, Y; Gresh, L; Bozec, A; Ikeda, E; Kamiya, K; Watanabe, M; Kobayashi, K; Asano, K; Toyama, Y; Wagner, EF; Matsuo, K				Takada, Y.; Gresh, L.; Bozec, A.; Ikeda, E.; Kamiya, K.; Watanabe, M.; Kobayashi, K.; Asano, K.; Toyama, Y.; Wagner, E. F.; Matsuo, K.			Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1	ONCOGENE			English	Article						Fra-1; gefitinib; interstitial lung disease; MCP-1; AP-1; TLR	SYSTEMIC INFLAMMATORY RESPONSE; DOUBLE-EDGED-SWORD; NF-KAPPA-B; PULMONARY-FIBROSIS; C-FOS; OSTEOCLAST DIFFERENTIATION; TYROSINE KINASE; INNATE IMMUNITY; BONE-FORMATION; JUN PROTEINS	The role of the AP-1 transcription factor Fra-1 (encoded by Fosl1) in inflammatory responses associated with lung disease is largely unknown. Here, we show that Fra-1 overexpression in mice reduced proinflammatory cytokine production in response to injection of lipopolysaccharide (LPS), a Toll-like receptor (TLR)-ligand. Unexpectedly, Fra-1 transgenic mice died rapidly following LPS treatment, showing severe interstitial lung disease and displaying massive accumulation of macrophages and overproduction of several chemokines, including macrophage chemoattractant protein-1 (MCP-1, encoded by Ccl2). To assess the clinical relevance of Fra-1 in lung pathology, mice were treated with the anticancer drug gefitinib (Iressa), which can lead to interstitial lung disease in patients. Gefitinib-treated mice showed increased Fosl1 and Ccl2 expression and developed interstitial lung disease in response to LPS, endogenous TLR ligands and chemotherapy. Moreover, deletion of Fra-1 or blocking MCP-1 receptor signaling in mice attenuated gefitinib-enhanced lethality in response to LPS. Importantly, human alveolar macrophages showed enhanced LPS-induced FOSL1 and CCL2 expression after gefitinib treatment. These results indicate that Fra-1 is an important mediator of interstitial lung disease following gefitinib treatment. Oncogene (2011) 30, 3821-3832;doi:10.1038/onc.2011.101; published online 4 April 2011	[Matsuo, K.] Keio Univ, Lab Cell & Tissue Biol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Gresh, L.] Res Inst Mol Pathol IMP, Vienna, Austria; [Bozec, A.; Wagner, E. F.] Spanish Natl Canc Res Ctr CNIO, Canc Cell Biol Programme, Madrid, Spain; [Ikeda, E.] Keio Univ, Dept Pathol, Sch Med, Tokyo 1608582, Japan; [Kamiya, K.; Watanabe, M.; Kobayashi, K.] Keio Univ, Dept Surg, Sch Med, Tokyo 1608582, Japan; [Asano, K.] Keio Univ, Dept Med, Sch Med, Tokyo 1608582, Japan; [Toyama, Y.] Keio Univ, Dept Orthopaed Surg, Sch Med, Tokyo 1608582, Japan	Keio University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Centro Nacional de Investigaciones Oncologicas (CNIO); Keio University; Keio University; Keio University; Keio University	Matsuo, K (corresponding author), Keio Univ, Lab Cell & Tissue Biol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	matsuo@sc.itc.keio.ac.jp	Toyama, Yoshiaki/K-5743-2013; Matsuo, Koichi/K-5695-2012	Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196; Gresh, Lionel/0000-0002-2333-1748	global COE; MEXT of Japan [21390425]; Naito Foundation; EMBO; Boehringer Ingelheim; Grants-in-Aid for Scientific Research [23791663] Funding Source: KAKEN	global COE(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); EMBO(European Molecular Biology Organization (EMBO)); Boehringer Ingelheim(Boehringer Ingelheim); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank A Oide, M Asakawa and S Fukuse for technical support; T Yamaguchi for Fra-1 mouse maintenance; A Dent, A Ueda and M Busslinger for plasmids; H Daub for AX14596; and H Handa, S Sakamoto, K Maruyama, T Mitsudomi and L Bakiri for helpful input. We thank the Core Instrumentation Facility, Keio University School of Medicine, for technical assistance. This work was funded by a grant-in-aid from the global COE program, a grant-in-aid for Scientific Research (B) from MEXT of Japan (21390425), and a grant-in-aid for Scientific Research on Priority Areas and the Naito Foundation (YT). LG was funded by an EMBO Long-Term Fellowship. IMP is funded by Boehringer Ingelheim.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Bakiri L, 2007, BONE, V40, P867, DOI 10.1016/j.bone.2006.11.005; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019; Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111; Brehmer D, 2005, CANCER RES, V65, P379; Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282; Eferl R, 2008, P NATL ACAD SCI USA, V105, P10525, DOI 10.1073/pnas.0801414105; Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Guinea-Viniegra J, 2009, GENE DEV, V23, P2663, DOI 10.1101/gad.543109; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Inoue A, 2003, LANCET, V361, P137, DOI 10.1016/S0140-6736(03)12190-3; Ishii Y, 2006, AM J RESP CRIT CARE, V174, P550, DOI 10.1164/rccm.200509-1534OC; Ishizaka A, 2001, CRIT CARE MED, V29, P896, DOI 10.1097/00003246-200104000-00043; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kida H, 2005, AM J PHYSIOL-LUNG C, V288, pL342, DOI 10.1152/ajplung.00016.2004; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lee DH, 2010, CLIN CANCER RES, V16, P1307, DOI 10.1158/1078-0432.CCR-09-1903; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08; Morishita H, 2009, INT IMMUNOL, V21, P457, DOI 10.1093/intimm/dxp015; PAINE R, 1993, J IMMUNOL, V150, P4561; PETERSGOLDEN M, 1987, AM REV RESPIR DIS, V135, P1020; Pircher A, 2010, LUNG CANCER, V69, P265, DOI 10.1016/j.lungcan.2010.01.017; Ray N, 2006, INT IMMUNOL, V18, P671, DOI 10.1093/intimm/dxl004; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Suzuki H, 2003, CANCER RES, V63, P5054; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2010, J IMMUNOL, V184, P1014, DOI 10.4049/jimmunol.0901196; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; ULICH TR, 1991, AM J PATHOL, V138, P1485; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Watanabe M, 2003, ANN THORAC SURG, V76, P1668, DOI 10.1016/S0003-4975(03)01015-4; Wolter S, 2008, MOL CELL BIOL, V28, P4407, DOI 10.1128/MCB.00535-07; Yamaguchi T, 2009, J BONE MINER RES, V24, P2056, DOI [10.1359/JBMR.090603, 10.1359/jbmr.090603]; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012	51	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3821	3832		10.1038/onc.2011.101	http://dx.doi.org/10.1038/onc.2011.101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21460858				2022-12-28	WOS:000294687200001
J	Dulak, AM; Gubish, CT; Stabile, LP; Henry, C; Siegfried, JM				Dulak, A. M.; Gubish, C. T.; Stabile, L. P.; Henry, C.; Siegfried, J. M.			HGF-independent potentiation of EGFR action by c-Met	ONCOGENE			English	Article						c-Met; c-Src; EGFR; cross-talk	GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; GASTRIN-RELEASING-PEPTIDE; TYROSINE KINASE-ACTIVITY; EPIDERMAL-GROWTH; SCATTER-FACTOR; THERAPEUTIC INHIBITION; GEFITINIB RESISTANCE; CARCINOMA-CELLS; BREAST-CANCER	The c-Met receptor is a potential therapeutic target for non-small cell lung cancer (NSCLC). Signaling interactions between c-Met and the mutant epidermal growth factor receptor (EGFR) have been studied extensively, but signaling intermediates and biological consequences of lateral signaling to c-Met in EGFR wild-type tumors are minimally understood. Our observations indicate that delayed c-Met activation in NSCLC cell lines is initiated by wild-type EGFR, the receptor most often found in NSCLC tumors. EGFR ligands induce accumulation of activated c-Met, which begins at 8 h and continues for 48 h. This effect is accompanied by an increase in c-Met expression and phosphorylation of critical c-Met tyrosine residues without activation of mitogen-activated protein kinase (MAPK) or Akt. Gene transcription is required for delayed c-Met activation; however, phosphorylation of c-Met by EGFR occurs without production of hepatocyte growth factor (HGF) or another secreted factor, supporting a ligand-independent mechanism. Lateral signaling is blocked by two selective c-Met tyrosine kinase inhibitors (TKIs), PF2341066 and SU11274, or with gefitinib, an EGFR TKI, suggesting kinase activity of both receptors is required for this effect. Prolonged c-Src phosphorylation is observed, and c-Src pathway is essential for EGFR to c-Met communication. Pretreatment with pan-Src family kinase inhibitors, PP2 and dasatinib, abolishes delayed c-Met phosphorylation. A c-Src dominant-negative construct reduces EGF-induced c-Met phosphorylation compared with control, further confirming a c-Src requirement. Inhibition of c-Met with PF2341066 and siRNA decreases EGF-induced phenotypes of invasion by similar to 86% and motility by similar to 81%, suggesting that a novel form of c-Met activation is utilized by EGFR to maximize these biological effects. Combined targeting of c-Met and EGFR leads to increased xenograft antitumor activity, demonstrating that inhibition of downstream and lateral signaling from the EGFR-c-Src-c-Met axis might be effective in treatment of NSCLC. Oncogene (2011) 30, 3625-3635; doi:10.1038/onc.2011.84; published online 21 March 2011	[Siegfried, J. M.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Siegfried, J. M.] Univ Pittsburgh, Univ Pittsburgh Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Siegfried, JM (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hillman Canc Ctr, Suite 2-18,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	siegfriedjm@upmc.edu	Stabile, Laura/AAE-9235-2020		NIH, National Cancer Institute [R01 CA79882]; America Foundation; Predoctoral Fellowship in Pharmacology by Pharmaceutical Research; NATIONAL CANCER INSTITUTE [R01CA079882] Funding Source: NIH RePORTER	NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); America Foundation; Predoctoral Fellowship in Pharmacology by Pharmaceutical Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant R01 CA79882 to JMS from the National Cancer Institute and by a Predoctoral Fellowship in Pharmacology by Pharmaceutical Research and Manufacturers of America Foundation awarded to Austin M Dulak. We would like to thank Pfizer for kindly providing PF2341066.	Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Liu XW, 2007, EXP CELL RES, V313, P1361, DOI 10.1016/j.yexcr.2007.01.016; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Molina JR, 2006, CHEST, V130, P1211, DOI 10.1378/chest.130.4.1211; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nakajima M, 1999, CANCER, V85, P1894; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Presnell SC, 1997, MOL CARCINOGEN, V18, P244, DOI 10.1002/(SICI)1098-2744(199704)18:4<244::AID-MC8>3.3.CO;2-Y; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Siegfried JM, 2007, MOL PHARMACOL, V72, P769, DOI 10.1124/mol.107.034215; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; Stabile LP, 2008, MOL CANCER THER, V7, P1913, DOI 10.1158/1535-7163.MCT-07-2169; Stabile LP, 2004, GENE THER, V11, P325, DOI 10.1038/sj.gt.3302169; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tang Z, 2008, BRIT J CANCER, V99, P911, DOI 10.1038/sj.bjc.6604559; Thomas SM, 2006, CANCER RES, V66, P11831, DOI 10.1158/0008-5472.CAN-06-2876; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wu CC, 2008, CANCER, V113, P3199, DOI 10.1002/cncr.23925; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643	44	87	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3625	3635		10.1038/onc.2011.84	http://dx.doi.org/10.1038/onc.2011.84			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423210	Green Accepted			2022-12-28	WOS:000294005100006
J	Hou, X; Liu, JE; Liu, W; Liu, CY; Liu, ZY; Sun, ZY				Hou, X.; Liu, J-E; Liu, W.; Liu, C-Y; Liu, Z-Y; Sun, Z-Y			A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation	ONCOGENE			English	Article						NUAK1; p53; LKB1; cell proliferation; phosphorylation	TUMOR INVASION; KINASE; LKB1; ARK5; IDENTIFICATION; ACTIVATION; GROWTH; CANCER; SENESCENCE; EXPRESSION	It has been suggested that adenosine monophosphate-activated protein kinase (AMPK) and 12 AMPK-related kinases (ARK), including novel (nua) kinase family 1 (NUAK1), are activated by master kinase LKB1, a major tumor suppressor. Apart from evidence to suggest that NUAK1 participates in induction of tumor survival, invasion and p53-independent cellular senescence, its detailed biological functions remain unclear. Here we showed that in the presence of wild-type LKB1, NUAK1 directly interacts with and phosphorylates p53 in vitro and in vivo. The phosphorylation of p53 induced by LKB1 required the kinase activity of NUAK1 and phosphorylation of NUAK1 at Thr211 by LKB1 was essential for its kinase activity, which leads to the conclusion that LKB1 activates NUAK1 and regulates phosphorylation of p53 through the NUAK1 kinase, at least partially. LKB1/NUAK1 activation leads to cell cycle arrest at the G(1)/S border by inducing expression of p21/WAF1. Under the regulation of LKB1, NUAK1 interacts with p53 in the nucleus and binds to the p53-responsive element of p21/WAF1 promoter. These findings have highlighted a novel role for NUAK1 in LKB1-related signaling pathways; NUAK1 can regulate cell proliferation and exert tumor suppression through direct interaction with p53. Oncogene (2011) 30, 2933-2942; doi:10.1038/onc.2011.19; published online 14 February 2011	[Hou, X.; Liu, J-E; Liu, W.; Liu, C-Y; Liu, Z-Y; Sun, Z-Y] Inner Mongolia Univ, Coll Life Sci, Hohhot 010021, Inner Mongolia, Peoples R China	Inner Mongolia University	Hou, X (corresponding author), Inner Mongolia Univ, Coll Life Sci, 235 Daxue W Rd, Hohhot 010021, Inner Mongolia, Peoples R China.	houxinliu@yahoo.com.cn	Liu, June/C-7871-2009		Science and Technology Foundation of Education Ministry of China [209025]; Inner Mongolia National Natural Science Foundation [2009ZD007]	Science and Technology Foundation of Education Ministry of China; Inner Mongolia National Natural Science Foundation	We thank Professor Tingmao Hu for helpful discussion. We are grateful to Dr Jinghua Yan for providing the plasmids. This study was supported by the Key Project of the Science and Technology Foundation of Education Ministry of China (209025) and the Key Project of the Inner Mongolia National Natural Science Foundation (2009ZD007).	Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kusakai G, 2004, J EXP CLIN CANC RES, V23, P263; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Niesler CU, 2007, EXP PHYSIOL, V92, P207, DOI 10.1113/expphysiol.2006.034736; ONCOGENE W, ONCOGENE; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Suzuki A, 2006, J BIOL CHEM, V281, P13915, DOI 10.1074/jbc.M511354200; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zeng PY, 2006, CANCER RES, V66, P10701, DOI 10.1158/0008-5472.CAN-06-0999	32	49	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2933	2942		10.1038/onc.2011.19	http://dx.doi.org/10.1038/onc.2011.19			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317932				2022-12-28	WOS:000292245100004
J	Soond, SM; Chantry, A				Soond, S. M.; Chantry, A.			Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGF beta signalling and EMT	ONCOGENE			English	Article						TGF beta; Smads; transcription; Ubiquitin ligase	E3; AUTOINHIBITION; APOPTOSIS; PATHWAY; FAMILY; SMURF2; BINDS	Ubiquitin-dependent mechanisms have emerged as essential regulatory elements controlling cellular levels of Smads and TGF beta-dependent biological outputs such as epithelial-mesenchymal transition (EMT). In this study, we identify a HECT E3 ubiquitin ligase known as WWP2 (Full-length WWP2-FL), together with two WWP2 isoforms (N-terminal, WWP2-N; C-terminal WWP2-C), as novel Smad-binding partners. We show that WWP2-FL interacts exclusively with Smad2, Smad3 and Smad7 in the TGF beta pathway. Interestingly, the WWP2-N isoform interacts with Smad2 and Smad3, whereas WWP2-C interacts only with Smad7. In addition, WWP2-FL and WWP2-C have a preference for Smad7 based on protein turnover and ubiquitination studies. Unexpectedly, we also find that WWP2-N, which lacks the HECT ubiquitin ligase domain, can also interact with WWP2-FL in a TGF beta-regulated manner and activate endogenous WWP2 ubiquitin ligase activity causing degradation of unstimulated Smad2 and Smad3. Consistent with our protein interaction data, overexpression and knockdown approaches reveal that WWP2 isoforms differentially modulate TGF beta-dependent transcription and EMT. Finally, we show that selective disruption of WWP2 interactions with inhibitory Smad7 can stabilise Smad7 protein levels and prevent TGF beta-induced EMT. Collectively, our data suggest that WWP2-N can stimulate WWP2-FL leading to increased activity against unstimulated Smad2 and Smad3, and that Smad7 is a preferred substrate for WWP2-FL and WWP2-C following prolonged TGF beta stimulation. Significantly, this is the first report of an interdependent biological role for distinct HECT E3 ubiquitin ligase isoforms, and highlights an entirely novel regulatory paradigm that selectively limits the level of inhibitory and activating Smads. Oncogene (2011) 30, 2451-2462; doi:10.1038/onc.2010.617; published online 24 January 2011	[Soond, S. M.; Chantry, A.] Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Chantry, A (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	a.chantry@uea.ac.uk			Association for International Research (AICR); BigC Charity; British Skin Foundation; Dunhill Medical Trust; The Dunhill Medical Trust [R162/0510] Funding Source: researchfish	Association for International Research (AICR); BigC Charity; British Skin Foundation; Dunhill Medical Trust(Dunhill Medical Trust); The Dunhill Medical Trust(Dunhill Medical Trust)	We thank Fiona McDonald, Caroline Hill, and Hans Clevers for generously providing cells/plasmids, and Ian Clark and Tracey Swingler for generously providing ATDC5 cDNA samples. This work was supported by the Association for International Research (AICR), with additional funding provided by the BigC Charity, the British Skin Foundation and the Dunhill Medical Trust.	ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Danckwardt S, 2008, EMBO J, V27, P482, DOI 10.1038/sj.emboj.7601932; Ellenrieder V, 2001, CANCER RES, V61, P4222; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; Foot NJ, 2008, BLOOD, V112, P4268, DOI 10.1182/blood-2008-04-150953; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hong S, 2007, CANCER RES, V67, P9577, DOI 10.1158/0008-5472.CAN-07-1179; Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008-5472.CAN-06-3950; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Li H, 2007, MOL CELL BIOL, V27, P5296, DOI 10.1128/MCB.01667-06; Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487; Lonn P, 2009, CELL RES, V19, P21, DOI 10.1038/cr.2008.308; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; Mund T, 2009, EMBO REP, V10, P501, DOI 10.1038/embor.2009.30; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Raikwar NS, 2008, AM J PHYSIOL-RENAL, V294, pF1157, DOI 10.1152/ajprenal.00339.2007; Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wicks SJ, 2005, ONCOGENE, V24, P8080, DOI 10.1038/sj.onc.1208944; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Xu HM, 2009, CELL RES, V19, P561, DOI 10.1038/cr.2009.31; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	34	55	58	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2451	2462		10.1038/onc.2010.617	http://dx.doi.org/10.1038/onc.2010.617			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258410	Green Accepted			2022-12-28	WOS:000291008000007
J	Astro, V; Asperti, C; Cangi, G; Doglioni, C; de Curtis, I				Astro, V.; Asperti, C.; Cangi, G.; Doglioni, C.; de Curtis, I.			Liprin-alpha 1 regulates breast cancer cell invasion by affecting cell motility, invadopodia and extracellular matrix degradation	ONCOGENE			English	Article						cell migration; invadopodia; invasion; lamellipodia; liprins	PROTEIN-TYROSINE-PHOSPHATASE; SUPPRESSOR GENE; IDENTIFICATION; CORTACTIN; ADHESION; LIPRINS	Migration of cells and degradation of the extracellular matrix (ECM) are required for efficient tumor cell invasion, but the underlying molecular mechanisms are only partially known. The PPFIA1 gene for liprin-alpha 1 is frequently amplified in human breast cancers. We recently demonstrated that liprin-alpha 1 is an important regulator of cell edge dynamics during motility. We show, herein, that the liprin-alpha 1 protein is highly expressed in human breast tumors. Functional analysis shows that liprin-alpha 1 is specifically required for the migration and invasion of highly invasive human breast cancer MDA-MB-231 cells. We used time-lapse analysis to demonstrate defects in the motility of liprin-alpha 1-depleted cells that include a striking instability of the lamellipodia. Liprin-alpha 1 levels altered by either RNA interference or overexpression affected also cell spreading and the number of invadopodia per cell, but not the density of invadopodia per unit of surface area. On the other hand, silencing of liprin-alpha 1 inhibited the degradation of the ECM, whereas its overexpression enhanced degradation, resulting in significant negative or positive effects, respectively, on the area of degradation per invadopodium. Transfection of fluorescent-labeled cortactin revealed that depletion of liprin-alpha 1 also affected the assembly and disassembly of invadopodia, with decrease of their lifetime. Our results strongly support a novel important role of liprin-alpha 1 in the regulation of human tumor cell invasion. Oncogene (2011) 30, 1841-1849; doi:10.1038/onc.2010.562; published online 13 December 2010	[Astro, V.; Asperti, C.; de Curtis, I.] Ist Sci San Raffaele, Div Neurosci, Cell Adhes Unit, I-20132 Milan, Italy; [Astro, V.; Asperti, C.; Cangi, G.; Doglioni, C.; de Curtis, I.] San Raffaele Univ, Milan, Italy; [Cangi, G.; Doglioni, C.] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	de Curtis, I (corresponding author), Ist Sci San Raffaele, Div Neurosci, Cell Adhes Unit, Via Olgettina 58, I-20132 Milan, Italy.	decurtis.ivan@hsr.it	Asperti, Claudia/ABG-5481-2020; Cangi, M.Giulia/CAF-1459-2022	Cangi, M.Giulia/0000-0002-9472-0935; Astro, Veronica/0000-0001-7852-7046; DE CURTIS, Ivanmatteo/0000-0002-7651-1515; DOGLIONI, Claudio/0000-0002-4969-5216	AIRC (Italian Association for Cancer Research) [5060]; Italian Telethon Foundation [GGP09078]	AIRC (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro); Italian Telethon Foundation(Fondazione Telethon)	Support to I de Curtis by the AIRC (Italian Association for Cancer Research, grant no. 5060) and by the Italian Telethon Foundation (grant no. GGP09078) is gratefully acknowledged. The plasmid for DsRed-Cortactin was generously provided by Mark A McNiven (Mayo Clinic, Rochester, MN, USA). We thank Cesare Covino of the Alembic facility at our Institute for his support in the morphological analysis, Rosanna Latino and Maurizio Ferrari for the cytogenetic analysis, and Jacopo Meldolesi for critical reading of the manuscript.	Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Asperti C, 2010, EXP CELL RES, V316, P915, DOI 10.1016/j.yexcr.2010.01.017; Asperti C, 2009, J CELL SCI, V122, P3225, DOI 10.1242/jcs.054155; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; de Curtis I, 2011, EXP CELL RES, V317, P1, DOI 10.1016/j.yexcr.2010.09.014; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Jarvinen AK, 2006, ONCOGENE, V25, P6997, DOI 10.1038/sj.onc.1209690; Katoh M, 2005, INT J ONCOL, V27, P281; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Nachat R, 2009, J CELL SCI, V122, P4035, DOI 10.1242/jcs.047266; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shaw Leslie M., 2004, V294, P97; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Spangler SA, 2007, BIOCHEM SOC T, V35, P1278, DOI 10.1042/BST0351278; Tan KD, 2008, GENE CHROMOSOME CANC, V47, P353, DOI 10.1002/gcc.20539; Totaro A, 2007, MOL BIOL CELL, V18, P5124, DOI 10.1091/mbc.E07-06-0550; Weaver AM, 2008, CURR BIOL, V18, pR362, DOI 10.1016/j.cub.2008.02.028	23	42	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1841	1849		10.1038/onc.2010.562	http://dx.doi.org/10.1038/onc.2010.562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151172				2022-12-28	WOS:000289512200011
J	Deng, W; Tsao, SW; Mak, GWY; Tsang, CM; Ching, YP; Guan, XY; Huen, MSY; Cheung, ALM				Deng, W.; Tsao, S. W.; Mak, G. W. Y.; Tsang, C. M.; Ching, Y. P.; Guan, X-Y; Huen, M. S. Y.; Cheung, A. L. M.			Impact of G(2) checkpoint defect on centromeric instability	ONCOGENE			English	Article						G(2) checkpoint; defect; centromere; instability	SQUAMOUS-CELL CARCINOMAS; CYCLIN B1; CHROMOSOMAL REARRANGEMENTS; HEPATOCELLULAR-CARCINOMA; ATAXIA-TELANGIECTASIA; GENOMIC INSTABILITY; EPITHELIAL-CELLS; ATM KINASE; CANCER; EXPRESSION	Centromeric instability is characterized by dynamic formation of centromeric breaks, deletions, isochromosomes and translocations, which are commonly observed in cancer. So far, however, the mechanisms of centromeric instability in cancer cells are still poorly understood. In this study, we tested the hypothesis that G(2) checkpoint defect promotes centromeric instability. Our observations from multiple approaches consistently support this hypothesis. We found that overexpression of cyclin B1, one of the pivotal genes driving G(2) to M phase transition, impaired G(2) checkpoint and promoted the formation of centromeric aberrations in telomerase-immortalized cell lines. Conversely, centromeric instability in cancer cells was ameliorated through reinforcement of G(2) checkpoint by cyclin B1 knockdown. Remarkably, treatment with KU55933 for only 2.5 h, which abrogated G(2) checkpoint, was sufficient to produce centromeric aberrations. Moreover, centromeric aberrations constituted the major form of structural abnormalities in G(2) checkpoint-defective ataxia telangiectasia cells. Statistical analysis showed that the frequencies of centromeric aberrations in G(2) checkpoint-defective cells were always significantly over-represented compared with random assumption. As there are multiple pathways leading to G(2) checkpoint defect, our finding offers a broad explanation for the common occurrence of centromeric aberrations in cancer cells. Oncogene (2011) 30, 1281-1289; doi:10.1038/onc.2010.508; published online 8 November 2010	[Deng, W.; Tsao, S. W.; Mak, G. W. Y.; Tsang, C. M.; Ching, Y. P.; Huen, M. S. Y.; Cheung, A. L. M.] Univ Hong Kong, Dept Anat, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China; [Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Cheung, ALM (corresponding author), Univ Hong Kong, Fac Med Bldg, Dept Anat, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	lmcheung@hkucc.hku.hk	Deng, Wen/C-4154-2009; Deng, Wen/M-5208-2019; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	/0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017; CHING, Yick Pang/0000-0002-6461-8358	Research Grants Council of Hong Kong Special Administrative Region, China [HKU 7556/06M]	Research Grants Council of Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council)	We thank Dr Prochownik, Children's Hospital of Pittsburgh, Pittsburgh, PA, for the kind gift of pApuro-CyclinB1 plasmids, and Department of Pediatrics and Adolescent Medicine, The University of Hong Kong for use of SKY facilities. We also thank Dr JC Tang (Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University) and Professor G Srivastava (Department of Pathology, The University of Hong Kong) for the SLMT-1 cell line, and Dr R Glaser (Department of Medical Microbiology and Immunology, Ohio State University Medical Center) for the HNE-1 cell line; T Chan, PY Cheung, CS Leung, P Mak, J Cheung, A Li and B Lai for technical assistance. This study was supported by a grant from the Research Grants Council of Hong Kong Special Administrative Region, China, Project No. HKU 7556/06M.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Beheshti B, 2000, MOL DIAGN, V5, P23, DOI 10.2165/00066982-200005010-00008; Cheung PY, 2010, CANCER LETT, V293, P41, DOI 10.1016/j.canlet.2009.12.015; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Deng W, 2007, CHROMOSOMA, V116, P557, DOI 10.1007/s00412-007-0120-x; Deng W, 2003, CYTOM PART A, V51A, P46, DOI 10.1002/cyto.a.10004; Deng W, 2008, CANCER RES, V68, P7200, DOI 10.1158/0008-5472.CAN-07-6569; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S; Eichler EE, 2003, SCIENCE, V301, P793, DOI 10.1126/science.1086132; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ito Y, 2000, ONCOLOGY-BASEL, V59, P68, DOI 10.1159/000012140; JIN YS, 1995, CANCER RES, V55, P3204; JOHANSSON M, 1995, CANCER GENET CYTOGEN, V81, P46, DOI 10.1016/0165-4608(94)00207-X; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KOJIS TL, 1989, HUM GENET, V83, P347, DOI 10.1007/BF00291379; Leach TJ, 2000, MOL CELL BIOL, V20, P6308, DOI 10.1128/MCB.20.17.6308-6316.2000; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Nakamura N, 2005, HUM PATHOL, V36, P828, DOI 10.1016/j.humpath.2005.03.012; Padilla-Nash HM, 2001, GENE CHROMOSOME CANC, V30, P349, DOI 10.1002/gcc.1101; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Perrod S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI 10.1007/s00018-003-3246-x; PINCHEIRA J, 1991, MUTAT RES, V251, P71, DOI 10.1016/0027-5107(91)90216-B; Rainey MD, 2008, CANCER RES, V68, P7466, DOI 10.1158/0008-5472.CAN-08-0763; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; Suzuki T, 2007, CANCER SCI, V98, P644, DOI 10.1111/j.1349-7006.2007.00444.x; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Terzoudi GI, 2005, CANCER RES, V65, P11292, DOI 10.1158/0008-5472.CAN-05-2148; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; Wong N, 2000, HEPATOLOGY, V32, P1060, DOI 10.1053/jhep.2000.19349; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yin XY, 2001, CANCER RES, V61, P6487; Yoshida T, 2004, ANN ONCOL, V15, P252, DOI 10.1093/annonc/mdh073; ZHU D, 1995, CANCER GENET CYTOGEN, V80, P63, DOI 10.1016/0165-4608(94)00128-X	43	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1281	1289		10.1038/onc.2010.508	http://dx.doi.org/10.1038/onc.2010.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057540	Green Submitted			2022-12-28	WOS:000288492100003
J	Majeti, R				Majeti, R.			Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells	ONCOGENE			English	Review						acute myeloid leukemia; cancer stem cells; monoclonal antibodies	ACUTE MYELOGENOUS LEUKEMIA; LECTIN-LIKE MOLECULE-1; RECEPTOR-ALPHA CHAIN; ABILITY IN-VITRO; INTERLEUKIN-3 RECEPTOR; PROGENITOR CELLS; GEMTUZUMAB OZOGAMICIN; IMMUNODEFICIENT MICE; RESIDUAL DISEASE; INITIATING CELLS	Accumulating evidence indicates that many human cancers are organized as a cellular hierarchy initiated and maintained by self-renewing cancer stem cells. This cancer stem cell model has been most conclusively established for human acute myeloid leukemia (AML), although controversies still exist regarding the identity of human AML stem cells (leukemia stem cell (LSC)). A major implication of this model is that, in order to eradicate the cancer and cure the patient, the cancer stem cells must be eliminated. Monoclonal antibodies have emerged as effective targeted therapies for the treatment of a number of human malignancies and, given their target antigen specificity and generally minimal toxicity, are well positioned as cancer stem cell-targeting therapies. One strategy for the development of monoclonal antibodies targeting human AML stem cells involves first identifying cell surface antigens preferentially expressed on AML LSC compared with normal hematopoietic stem cells. In recent years, a number of such antigens have been identified, including CD123, CD44, CLL-1, CD96, CD47, CD32, and CD25. Moreover, monoclonal antibodies targeting CD44, CD123, and CD47 have demonstrated efficacy against AML LSC in xenotransplantation models. Hopefully, these antibodies will ultimately prove to be effective in the treatment of human AML. Oncogene (2011) 30, 1009-1019; doi:10.1038/onc.2010.511; published online 15 November 2010	[Majeti, R.] Stanford Univ, Sch Med, Stanford Inst Stem Cell Biol & Regenerat Med, Div Hematol,Dept Internal Med,Canc Ctr, Stanford, CA 94305 USA; [Majeti, R.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Majeti, R (corresponding author), Stanford Univ, Sch Med, Stanford Inst Stem Cell Biol & Regenerat Med, Div Hematol,Dept Internal Med,Canc Ctr, 265 Campus Dr,G3021B, Stanford, CA 94305 USA.	rmajeti@stanford.edu		Majeti, Ravindra/0000-0002-5814-0984	American Association for Cancer Research; Burroughs Wellcome Fund	American Association for Cancer Research; Burroughs Wellcome Fund(Burroughs Wellcome Fund)	I would like to acknowledge Mark Chao and Max Jan for critical review of the manuscript and Irv Weissman for support and mentorship. This work was supported in part by a grant from the American Association for Cancer Research. RM holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. RM has filed the US Patent Application Serial No. 12/321,215 entitled 'Methods For Manipulating Phagocytosis Mediated by CD47'.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Ailles LE, 1997, BLOOD, V90, P2555, DOI 10.1182/blood.V90.7.2555.2555_2555_2564; Ailles LE, 1999, BLOOD, V94, P1761, DOI 10.1182/blood.V94.5.1761.417k23_1761_1772; Bakker ABH, 2004, CANCER RES, V64, P8443, DOI 10.1158/0008-5472.CAN-04-1659; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Blair A, 1998, BLOOD, V92, P4325, DOI 10.1182/blood.V92.11.4325; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Burnett AK, 2006, SEMIN HEMATOL, V43, P96, DOI 10.1053/j.seminhematol.2006.01.003; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Cheson BD, 2008, NEW ENGL J MED, V359, P613, DOI 10.1056/NEJMra0708875; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Florian S, 2006, LEUKEMIA LYMPHOMA, V47, P207, DOI 10.1080/10428190500272507; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gramatzki M, 1998, EXP HEMATOL, V26, P1209; Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jawad M, 2010, LEUKEMIA, V24, P74, DOI 10.1038/leu.2009.199; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Levis M, 2005, BLOOD, V106, P673, DOI 10.1182/blood-2004-05-1902; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Majeti R, 2007, CELL STEM CELL, V1, P635, DOI 10.1016/j.stem.2007.10.001; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MURRAY L, 1995, BLOOD, V85, P368; Okazawa H, 2005, J IMMUNOL, V174, P2004, DOI 10.4049/jimmunol.174.4.2004; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roberts A. W., 2008, BLOOD, V112, p2956a; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Stasi R, 2008, CANCER TREAT REV, V34, P49, DOI 10.1016/j.ctrv.2007.09.001; Subramanian S, 2006, BLOOD, V107, P2548, DOI 10.1182/blood-2005-04-1463; Takenaka K, 2007, NAT IMMUNOL, V8, P1313, DOI 10.1038/ni1527; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072; Terwijn M, 2009, EUR J CANCER, V45, P1692, DOI 10.1016/j.ejca.2009.02.021; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; van Rhenen A, 2007, BLOOD, V110, P2659, DOI 10.1182/blood-2007-03-083048; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; WANG PL, 1992, J IMMUNOL, V148, P2600; Yalcintepe L, 2006, BLOOD, V108, P3530, DOI 10.1182/blood-2006-04-013813; Zhao XX, 2010, HAEMATOL-HEMATOL J, V95, P71, DOI 10.3324/haematol.2009.009811	66	122	138	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1009	1019		10.1038/onc.2010.511	http://dx.doi.org/10.1038/onc.2010.511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21076471				2022-12-28	WOS:000287964100001
J	Fang, L; Deng, Z; Shatseva, T; Yang, J; Peng, C; Du, WW; Yee, AJ; Ang, LC; He, C; Shan, SW; Yang, BB				Fang, L.; Deng, Z.; Shatseva, T.; Yang, J.; Peng, C.; Du, W. W.; Yee, A. J.; Ang, L. C.; He, C.; Shan, S. W.; Yang, B. B.			MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta 8	ONCOGENE			English	Article						microRNA; siRNA; integrin; angiogenesis; tumorigenesis	MIR-17-92 CLUSTER; FACTOR-BETA; ALPHA-V-BETA-8-MEDIATED ACTIVATION; CELL-SURVIVAL; LUNG CANCERS; EXPRESSION; SUPPRESSOR; ROLES; APOPTOSIS; BLOOD	It has been reported that the miR-106b similar to 25 cluster, a paralog of the miR-17 similar to 92 cluster, possesses oncogenic activities. However, the precise role of each microRNA (miRNA) in the miR-106b similar to 25 cluster is not yet known. In this study, we examined the function of miR-93, one of the microRNAs within the miR-106b similar to 25 cluster, in angiogenesis and tumor formation. We found that miR-93 enhanced cell survival, promoted sphere formation and augmented tumor growth. Most strikingly, when miR-93-overexpressing U87 cells were co-cultured with endothelial cells, they supported endothelial cell spreading, growth, migration and tube formation. In vivo studies revealed that miR-93-expressing cells induced blood vessel formation, allowing blood vessels to extend to tumor tissues in high densities. Angiogenesis promoted by miR-93 in return facilitated cell survival, resulting in enhanced tumor growth. We further showed that integrin-beta 8 is a target of miR-93. Higher levels of integrin-beta 8 are associated with cell death in tumor mass and in human glioblastoma. Silencing of integrin-beta 8 expression using small interfering RNA promoted cell proliferation, whereas ectopic expression of integrin-beta 8 decreased cell growth. These findings showed that miR-93 promotes tumor growth and angiogenesis by suppressing, at least in part, integrin-beta 8 expression. Our results suggest that inhibition of miR-93 function may be a feasible approach to suppress angiogenesis and tumor growth. Oncogene (2011) 30, 806-821; doi:10.1038/onc.2010.465; published online 18 October 2010	[Fang, L.; Deng, Z.; Shatseva, T.; Du, W. W.; Yee, A. J.; Shan, S. W.; Yang, B. B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Fang, L.; He, C.] Jilin Univ, China Japan Union Hosp, Jilin, Peoples R China; [Yang, J.; Peng, C.] York Univ, Dept Biol, Toronto, ON M3J 2R7, Canada; [Ang, L. C.] Univ Western Ontario, Dept Pathol, London, ON, Canada; [Fang, L.; Deng, Z.; Shatseva, T.; Shan, S. W.; Yang, B. B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Jilin University; York University - Canada; Western University (University of Western Ontario); University of Toronto	Yang, BB (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	byang@sri.utoronto.ca	Yang, Bai/F-6483-2012	SHAN, SW/0000-0001-6876-9914	Heart and Stroke Foundation of Ontario [NA6282, CI5958]; Canadian Institutes of Health Research [MOP-102635]; China Scholarship Council; Ontario Women's Health Council/CIHR	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); China Scholarship Council(China Scholarship Council); Ontario Women's Health Council/CIHR(Canadian Institutes of Health Research (CIHR))	We thank the Brain Tumour Tissue Bank (London, Ontario) for glioblastoma slides. This work was supported by a grant from the Heart and Stroke Foundation of Ontario (NA6282) and a grant from Canadian Institutes of Health Research (MOP-102635) to BBY, who is the recipient of a Career Investigator Award (CI5958) from the Heart and Stroke Foundation of Ontario. LF is supported by a Scholarship from China Scholarship Council. CP is supported by a Mid-Career Award from Ontario Women's Health Council/CIHR.	Aguda BD, 2008, P NATL ACAD SCI USA, V105, P19678, DOI 10.1073/pnas.0811166106; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bullitt E, 2007, RADIOLOGY, V245, P824, DOI 10.1148/radiol.2453061889; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Cambier S, 2000, CANCER RES, V60, P7084; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Du LQ, 2009, MOL CANCER RES, V7, P1234, DOI 10.1158/1541-7786.MCR-08-0507; Fjellbirkeland L, 2003, AM J PATHOL, V163, P533, DOI 10.1016/S0002-9440(10)63681-4; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Hagendoorn J, 2006, CANCER RES, V66, P3360, DOI 10.1158/0008-5472.CAN-05-2655; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Novotny GW, 2007, CELL DEATH DIFFER, V14, P879, DOI 10.1038/sj.cdd.4402090; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Sharma A, 2009, P NATL ACAD SCI USA, V106, P5761, DOI 10.1073/pnas.0808743106; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Takakura S, 2008, CANCER SCI, V99, P1147, DOI 10.1111/j.1349-7006.2008.00800.x; Tomari Y, 2005, CURR BIOL, V15, pR61, DOI 10.1016/j.cub.2004.12.057; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002420; Wang Q, 2008, P NATL ACAD SCI USA, V105, P2889, DOI 10.1073/pnas.0800178105; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje	39	252	263	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					806	821		10.1038/onc.2010.465	http://dx.doi.org/10.1038/onc.2010.465			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956944				2022-12-28	WOS:000287444600005
J	Maretzky, T; Zhou, W; Huang, XY; Blobel, CP				Maretzky, T.; Zhou, W.; Huang, X-Y; Blobel, C. P.			A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17	ONCOGENE			English	Article						ADAM17; Src; EGF receptor; EGF-receptor ligands; protein ectodomain shedding; ERK	NECROSIS-FACTOR-ALPHA; UP-REGULATED EXPRESSION; GROWTH-FACTOR-ALPHA; CONVERTING-ENZYME; DISINTEGRIN; CLEAVAGE; TRANSACTIVATION; INACTIVATION; COEXPRESSION; ACTIVATION	ADAM17 (a disintegrin and metalloproteinase 17, also referred to as TNF alpha converting enzyme or TACE) is a cell-surface metalloproteinase that regulates signaling via the epidermal growth factor receptor (EGFR) and has important roles in diseases such as cancer and rheumatoid arthritis. ADAM17 can be activated by stimulation of several tyrosine kinase receptors, raising questions about whether oncogenic tyrosine kinases could also enhance EGFR signaling and activation of extracellular signal-regulated kinase (ERK) via stimulation of ADAM17. The main goal of this study was to evaluate the role of Src in activating ADAM17. We provide evidence that a constitutively active transforming form of Src, the E378G mutant, as well as v-Src enhance ADAM17-mediated shedding of the EGFR ligand TGF alpha. Moreover, we demonstrate that constitutive shedding of TGF alpha can be reduced by inhibition of Src in several cell lines, including COS7, MCF7 (the human breast cancer cell line), PAE (a pig aortic endothelial cell line) and HaCaT (the human keratinocyte cell line) cells. Src(E378G)-stimulated shedding of TGF alpha is abolished in Adam17(-/-) cells, but can be rescued by wild-type (wt) ADAM17 and a mutant ADAM17 lacking its cytoplasmic domain. These findings demonstrate that ADAM17 is the principal TGF alpha sheddase that is activated by Src in a manner that does not require the cytoplasmic domain of ADAM17. Finally, we show that stimulation of ADAM17 by Src(E378G) leads to enhanced paracrine signaling via release of EGFR ligands into the culture supernatant. These results raise the possibility that activation of ADAM17 by oncogenic forms of Src can aid in promoting tumorigenesis by enhancing signaling via the EGFR and ERK in an autocrine and paracrine manner. Enhanced autocrine signaling could further activate tumor cells expressing oncogenic mutants of Src, whereas paracrine signaling could stimulate EGFR and ERK signaling in surrounding non-transformed cells such as stromal cells, thereby contributing to crosstalk between tumor cells and stromal cells. Oncogene (2011) 30, 611-618; doi: 10.1038/onc.2010.443; published online 27 September 2010	[Maretzky, T.; Zhou, W.; Blobel, C. P.] Cornell Univ, Hosp Special Surg, Weill Med Coll, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA; [Huang, X-Y] Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	Cornell University; Cornell University	Blobel, CP (corresponding author), Cornell Univ, Hosp Special Surg, Weill Med Coll, Arthrit & Tissue Degenerat Program, 535 E 70th St, New York, NY 10021 USA.	blobelc@hss.edu	Maretzky, Thorsten/GSN-2981-2022; Maretzky, Thorsten/AEN-1915-2022	Maretzky, Thorsten/0000-0003-1282-6080; Zhou, Wenhui/0000-0002-3857-8567	NIH [R01 GM64750]; Emerald Foundation; Tri-Institutional MD/PhD Program Gateway Program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064750] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emerald Foundation; Tri-Institutional MD/PhD Program Gateway Program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by NIH R01 GM64750, and TM was supported by the Emerald Foundation. WZ was supported by the Tri-Institutional MD/PhD Program Gateway Program. We are grateful to Drs Daniel Lundell and Xioada Niu from the Schering Plough Research Institute in Kenilworth, NJ, for providing SP26, and to Dr Robert Waltermire from Bristol-Myers Squibb for DPC333, and to Andreas Ludwig at the University of Aachen, Germany, for providing GI254023X.	Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blanchot-Jossic F, 2005, J PATHOL, V207, P156, DOI 10.1002/path.1814; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; COOPER JA, 1983, J VIROL, V48, P752, DOI 10.1128/JVI.48.3.752-764.1983; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Horiuchi K, 2007, J IMMUNOL, V179, P2686, DOI 10.4049/jimmunol.179.5.2686; Horiuchi K, 2007, MOL BIOL CELL, V18, P176, DOI 10.1091/mbc.E06-01-0014; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Le Gall SM, 2009, MOL BIOL CELL, V20, P1785, DOI 10.1091/mbc.E08-11-1135; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Mazzola RD, 2008, BIOORG MED CHEM LETT, V18, P5809, DOI 10.1016/j.bmcl.2008.09.045; McGowan PM, 2008, ANN ONCOL, V19, P1075, DOI 10.1093/annonc/mdm609; Merchant NB, 2008, CLIN CANCER RES, V14, P1182, DOI 10.1158/1078-0432.CCR-07-1216; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Nakagawa M, 2009, CANCER SCI, V100, P654, DOI 10.1111/j.1349-7006.2009.01089.x; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qian MX, 2007, DRUG METAB DISPOS, V35, P1916, DOI 10.1124/dmd.107.015933; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sahin Umut, 2006, V327, P99; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Sun YT, 2007, EMBO J, V26, P53, DOI 10.1038/sj.emboj.7601502; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; Van Schaeybroeck S, 2008, CANCER RES, V68, P8312, DOI 10.1158/0008-5472.CAN-07-6736; Weskamp G, 2010, CIRC RES, V106, P932, DOI 10.1161/CIRCRESAHA.109.207415; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	36	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					611	618		10.1038/onc.2010.443	http://dx.doi.org/10.1038/onc.2010.443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20871631	Green Accepted			2022-12-28	WOS:000286922300009
J	Wang, B; Hasan, MK; Alvarado, E; Yuan, H; Wu, H; Chen, WY				Wang, B.; Hasan, M. K.; Alvarado, E.; Yuan, H.; Wu, H.; Chen, W. Y.			NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response	ONCOGENE			English	Article						prostate cancer; NAMPT; SIRT1; NAD; nicotinamide; Foxo3a	COLONY-ENHANCING FACTOR; TRANSCRIPTION FACTOR FOXO3A; LIFE-SPAN EXTENSION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; CALORIE RESTRICTION; COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; P53-DEFICIENT MICE; ANDROGEN RECEPTOR; NAD BIOSYNTHESIS	Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in regenerating nicotinamide adenine dinucleotide (NAD(+)) from nicotinamide in mammals. NAMPT has crucial roles for many cellular functions by regulating NAD(+)-dependent SIRT1 deacetylase. However, roles of NAMPT in cancer are poorly defined. In this study, we show that NAMPT is prominently over-expressed in human prostate cancer cells along with SIRT1. Elevation of NAMPT expression occurs early for the prostate neoplasia. Inhibition of NAMPT significantly suppresses cell growth in culture, soft agar colony formation, cell invasion and growth of xenografted prostate cancer cells in mice. NAMPT knockdown sensitizes prostate cancer cells to oxidative stress caused by H2O2 or chemotherapeutic treatment. Overexpression of NAMPT increases prostate cancer cell resistance to oxidative stress, which is partially blocked by SIRT1 knockdown. We demonstrate that in addition to modulating SIRT1 functions, the NAMPT inhibition reduces forkhead box, class 'O' (FOXO)3a protein expression and its downstream anti-oxidant genes catalase and manganese superoxide dismutase. Our results suggest important roles of concomitant upregulation of NAMPT and SIRT1 along with increased FOXO3a protein level for prostate carcinogenesis and their contribution to oxidative stress resistance of prostate cancer cells. These findings may have implications for exploring the NAMPT pathway for prostate cancer prevention and treatment. Oncogene (2011) 30, 907-921; doi:10.1038/onc.2010.468; published online 18 October 2010	[Chen, W. Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Alvarado, E.] Calif State Univ Long Beach, Dept Biol, Long Beach, CA 90840 USA; [Wu, H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; California State University System; California State University Long Beach; City of Hope; Beckman Research Institute of City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	wechen@coh.org	Chen, WenYong/D-6748-2012; yuan, hongfeng/A-3633-2012	Chen, WenYong/0000-0001-6913-5729	City of Hope; STOPCANCER foundation; American Cancer Society; California Institute of Regenerative Medicine	City of Hope; STOPCANCER foundation; American Cancer Society(American Cancer Society); California Institute of Regenerative Medicine(California Institute for Regenerative Medicine)	This study is supported by the start-up fund from City of Hope, career development award from STOPCANCER foundation and research scholar award from American Cancer Society (WYC). EA was supported by a training grant awarded to CSULB from California Institute of Regenerative Medicine.	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267; Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chu F, 2005, CANCER RES, V65, P10183, DOI 10.1158/0008-5472.CAN-05-2002; Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Drevs J, 2003, ANTICANCER RES, V23, P4853; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Garten A, 2009, TRENDS ENDOCRIN MET, V20, P130, DOI 10.1016/j.tem.2008.10.004; Gartner EM, 2010, CANCER J, V16, P83, DOI 10.1097/PPO.0b013e3181d78223; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hasmann M, 2003, CANCER RES, V63, P7436; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1; Hwang CS, 2010, SCIENCE, V327, P973, DOI 10.1126/science.1183147; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jang KY, 2009, PATHOLOGY, V41, P366, DOI 10.1080/00313020902884451; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Karger S, 2009, ENDOCR-RELAT CANCER, V16, P189, DOI 10.1677/ERC-07-0283; Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590; Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muruganandham M, 2005, CLIN CANCER RES, V11, P3503, DOI 10.1158/1078-0432.CCR-04-1399; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Ognjanovic S, 2001, J MOL ENDOCRINOL, V26, P107, DOI 10.1677/jme.0.0260107; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Revollo JR, 2007, CELL METAB, V6, P363, DOI 10.1016/j.cmet.2007.09.003; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Shukla S, 2009, INT J ONCOL, V34, P1613, DOI 10.3892/ijo_00000291; Skokowa J, 2009, NAT MED, V15, P151, DOI 10.1038/nm.1913; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Turkbey B, 2009, NAT REV UROL, V6, P191, DOI 10.1038/nrurol.2009.27; van Beijnum JR, 2002, INT J CANCER, V101, P118, DOI 10.1002/ijc.10584; van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Warburg O., 1931, METABOLISM TUMORS; Watson M, 2009, MOL CELL BIOL, V29, P5872, DOI 10.1128/MCB.00112-09; Williams AC, 2005, J CLIN NEUROSCI, V12, P6, DOI 10.1016/j.jocn.2004.10.002; Xiao D, 2006, CARCINOGENESIS, V27, P2223, DOI 10.1093/carcin/bgl087; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103	79	183	196	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					907	921		10.1038/onc.2010.468	http://dx.doi.org/10.1038/onc.2010.468			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20956937				2022-12-28	WOS:000287695900003
J	He, H; Hua, X; Yan, J				He, H.; Hua, X.; Yan, J.			Epigenetic regulations in hematopoietic Hox code	ONCOGENE			English	Review						Hox code; epigenetic; hematopoiesis; leukemia; polycomb and trithorax groups	HISTONE METHYLTRANSFERASE ACTIVITY; HOMEOBOX GENE-EXPRESSION; DNA METHYLATION; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; CELLULAR MEMORY; STEM-CELLS; MLL; POLYCOMB; PROTEIN	Hox genes encode DNA-binding proteins that are deployed in overlapping domains along various body axes during embryonic development. This sequential activation of Hox genes in temporal and spatial mode, the Hox code, is critical for the proper positioning of segmented structures along those axes, which include the vertebrate, limbs and, also digestive and reproductive tracts. It remains unknown how Hox genes are regulated to determine the identity of hematopoietic stem cells and their derivatives, which migrate and express most Hox genes. The key questions are whether the hematopoietic system has an axis, how epigenetic mechanisms restrict expression of Hox genes to specific cell types and what role Hox genes play in leukemic transformation? Taking in account these questions, we propose a combinatorial axial model of hematopoietic Hox code to predict the positional identity of the hematopoietic cells. This model will provide new insight into epigenetic therapy in leukemia. Oncogene (2011) 30, 379-388; doi:10.1038/onc.2010.484; published online 25 October 2010	[He, H.; Yan, J.] Shanghai Ocean Univ, Inst Marine Biosyst & Neurosci, Coll Fisheries & Life Sci, Dept Hydrobiol, Shanghai 201306, Peoples R China; [Hua, X.] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	Shanghai Ocean University; University of Pennsylvania; Pennsylvania Medicine	Yan, J (corresponding author), Shanghai Ocean Univ, Inst Marine Biosyst & Neurosci, Coll Fisheries & Life Sci, Dept Hydrobiol, 999 Hucheng Huan Rd, Shanghai 201306, Peoples R China.	jyan2@shou.edu.cn		Yan, Jizhou/0000-0001-7482-7842	Shanghai Ocean University [A2302100002]; Shanghai Leading Academic Discipline Project [S30701]	Shanghai Ocean University; Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project)	We apologize to authors whose work has not been cited here owing to the stringent limit of space and our knowledge. We thank Shivani Sethi's assistance in editing the manuscript. This work was supported by the International Cooperation Initiative Program of Shanghai Ocean University (A2302100002) and the Shanghai Leading Academic Discipline Project (S30701).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052; Akin ZN, 2005, CELL MOL NEUROBIOL, V25, P697, DOI 10.1007/s10571-005-3971-9; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Arderiu G, 2007, CELL ADHES MIGR, V1, P185, DOI 10.4161/cam.1.4.5448; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bel-Vialar S, 2002, DEVELOPMENT, V129, P5103; Bullinger L, 2010, CANCER CELL, V17, P1, DOI 10.1016/j.ccr.2009.12.033; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; CELETTI A, 1993, INT J CANCER, V53, P237, DOI 10.1002/ijc.2910530211; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; Dejardin J, 2004, EMBO J, V23, P857, DOI 10.1038/sj.emboj.7600108; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Deschamps J, 2005, DEVELOPMENT, V132, P2931, DOI 10.1242/dev.01897; Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Duboule D, 2004, DEV CELL, V6, P738, DOI 10.1016/j.devcel.2004.05.016; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Esteller M, 2006, CARCINOGENESIS, V27, P1121, DOI 10.1093/carcin/bgl033; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; FAIELLA A, 1994, P NATL ACAD SCI USA, V91, P5335, DOI 10.1073/pnas.91.12.5335; Felsenfeld G, 2004, COLD SPRING HARB SYM, V69, P245, DOI 10.1101/sqb.2004.69.245; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Garcia-Fernandez J, 2005, HEREDITY, V94, P145, DOI 10.1038/sj.hdy.6800621; Gaufo GO, 2003, DEVELOPMENT, V130, P5191, DOI 10.1242/dev.00730; Gaunt SJ, 2004, INT J DEV BIOL, V48, P613, DOI 10.1387/ijdb.041829sg; Gaunt SJ, 2008, DEVELOPMENT, V135, P2511, DOI 10.1242/dev.015909; Geisen MJ, 2008, PLOS BIOL, V6, P1178, DOI 10.1371/journal.pbio.0060142; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Gruss P, 1991, CURR OPIN GENET DEV, V1, P204, DOI 10.1016/S0959-437X(05)80071-1; Guo YL, 2003, STEM CELLS, V21, P15, DOI 10.1634/stemcells.21-1-15; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; Hazzalin CA, 2005, PLOS BIOL, V3, P2111, DOI 10.1371/journal.pbio.0030393; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Huynh HD, 2008, STEM CELLS, V26, P1628, DOI 10.1634/stemcells.2008-0064; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jackson JP, 2004, CHROMOSOMA, V112, P308, DOI 10.1007/s00412-004-0275-7; Johnson JJ, 2003, BLOOD, V101, P3229, DOI 10.1182/blood-2002-05-1515; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Kmita M, 2000, NAT GENET, V26, P451, DOI 10.1038/82593; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Kobrossy L, 2006, J BIOL CHEM, V281, P25926, DOI 10.1074/jbc.M602555200; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; Kwan CT, 2001, DEV BIOL, V232, P176, DOI 10.1006/dbio.2001.0157; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Lehoczky JA, 2004, EVOL DEV, V6, P423, DOI 10.1111/j.1525-142X.2004.04050.x; Leroy P, 2004, J LEUKOCYTE BIOL, V75, P680, DOI 10.1189/jlb.0503246; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Lohnes D, 2003, BIOESSAYS, V25, P971, DOI 10.1002/bies.10340; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Mace KA, 2005, J CELL SCI, V118, P2567, DOI 10.1242/jcs.02399; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; Manley NR, 1997, DEV BIOL, V192, P274, DOI 10.1006/dbio.1997.8765; Manzanares M, 2001, DEVELOPMENT, V128, P3595; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Mathieu O, 2005, EMBO J, V24, P2783, DOI 10.1038/sj.emboj.7600743; Maves L, 2005, DEV BIOL, V285, P593, DOI 10.1016/j.ydbio.2005.07.015; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Monge I, 2003, DEV BIOL, V256, P212, DOI 10.1016/S0012-1606(02)00136-7; Morgan R, 2008, INT J HEMATOL, V87, P246, DOI 10.1007/s12185-008-0057-8; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nowling T, 1999, DEV BIOL, V208, P134, DOI 10.1006/dbio.1998.9189; Oosterveen T, 2003, J BIOL CHEM, V278, P24103, DOI 10.1074/jbc.M300774200; Oosterveen T, 2003, EMBO J, V22, P262, DOI 10.1093/emboj/cdg029; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Popovic R, 2005, J CELL BIOCHEM, V95, P234, DOI 10.1002/jcb.20430; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rinn JL, 2006, PLOS GENET, V2, P1084, DOI 10.1371/journal.pgen.0020119; Roelen BAJ, 2002, MECH DEVELOP, V119, P81, DOI 10.1016/S0925-4773(02)00329-5; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sharpe J, 1998, EMBO J, V17, P1788, DOI 10.1093/emboj/17.6.1788; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SORENSEN PHB, 1994, J CLIN INVEST, V93, P429, DOI 10.1172/JCI116978; Spirov AV, 2002, NUCLEIC ACIDS RES, V30, P351, DOI 10.1093/nar/30.1.351; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Suemori H, 2000, DEV BIOL, V220, P333, DOI 10.1006/dbio.2000.9651; Tabaries S, 2005, MOL CELL BIOL, V25, P1389, DOI 10.1128/MCB.25.4.1389-1401.2005; Taghon T, 2003, LEUKEMIA, V17, P1157, DOI 10.1038/sj.leu.2402947; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vasanthi D, 2008, J GENET GENOMICS, V35, P413, DOI 10.1016/S1673-8527(08)60059-4; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang KC, 2009, TRENDS CELL BIOL, V19, P268, DOI 10.1016/j.tcb.2009.03.007; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Yan JZ, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000047; Yan JZ, 2006, MOL CELL BIOL, V26, P155, DOI 10.1128/MCB.26.1.155-168.2006; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; Zaret KS, 2008, COLD SH Q B, V73, P119, DOI 10.1101/sqb.2008.73.040; Zhou JM, 2004, MOL CELL, V16, P500, DOI 10.1016/S1097-2765(04)00680-X	122	25	28	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					379	388		10.1038/onc.2010.484	http://dx.doi.org/10.1038/onc.2010.484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20972460				2022-12-28	WOS:000286621600001
J	Neely, RJ; Brose, MS; Gray, CM; McCorkell, KA; Leibowitz, JM; Ma, C; Rothstein, JL; May, MJ				Neely, R. J.; Brose, M. S.; Gray, C. M.; McCorkell, K. A.; Leibowitz, J. M.; Ma, C.; Rothstein, J. L.; May, M. J.			The RET/PTC3 oncogene activates classical NF-kappa B by stabilizing NIK	ONCOGENE			English	Article						Hashimoto's thyroiditis; IKK; NIK; NF-kappa B; RET/PTC; thyroid cancer	GENE-EXPRESSION; FUSION GENE; IKK-ALPHA; RET; NUCLEAR; ONCOPROTEIN; CARCINOMA; PATHWAY; REARRANGEMENTS; LOCALIZATION	The oncogenic fusion protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimoto's thyroiditis activates nuclear factor-kappa B (NF-kappa B) and induces pro-inflammatory gene expression; however, the mechanism of this activation is unknown. To address this, we expressed RP3 in murine embryonic fibroblasts (MEFs) lacking key classical and noncanonical NF-kappa B signaling components. In wild-type MEFs, RP3 upregulated CCL2, CXCL1, granulocyte-macrophage colony-stimulating factor and tumor necrosis factor expression and activated classical but not noncanonical NF-kappa B. RP3-activated NF-kappa B in I kappa B kinase (IKK)beta(-/-) MEFs but not IKK alpha- or NF-kappa B essential modulator (NEMO)-deficient cells and activation was inhibited by a peptide that blocks NEMO binding to the IKKs. RP3 increased the levels of NF-kappa B-inducing kinase (NIK) and did not activate NF-kappa B in NIK-deficient MEFs. Notably, NIK stabilization was not accompanied by TRAF3 degradation demonstrating that RP3 disrupts normal basal NIK regulation. Dominant-negative NIK blocked RP3-induced NF-kappa B activation and an RP3 signaling mutant (RP3(Y588F)) did not stabilize NIK. Finally, examination of PTC specimens revealed strong positive staining for NIK. We therefore conclude that RP3 activates classical NF-kappa B via NIK, NEMO and IKK alpha. Importantly, our findings reveal a novel mechanism for oncogene-induced NF-kappa B activation via stabilization of NIK. Oncogene (2011) 30, 87-96; doi: 10.1038/onc.2010.396; published online 6 September 2010	[Neely, R. J.; Gray, C. M.; McCorkell, K. A.; May, M. J.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Neely, R. J.; Rothstein, J. L.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol Otolaryngol Head & Neck, Philadelphia, PA 19107 USA; [Brose, M. S.; Leibowitz, J. M.; Ma, C.] Univ Penn, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Rothstein, J. L.] Amgen Inc, Inflammat Res, Seattle, WA USA; [May, M. J.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Jefferson University; University of Pennsylvania; Amgen; University of Pennsylvania	May, MJ (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,OVH 200E, Philadelphia, PA 19104 USA.	maym@vet.upenn.edu		May, Michael/0000-0002-2485-3716	National Institutes of Health [RO1HL080612, R21CA135602, T32CA009683, T32GM07229]; Mari Lowe Center for Comparative Oncology; NATIONAL CANCER INSTITUTE [T32CA009683, R21CA135602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mari Lowe Center for Comparative Oncology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Institutes of Health (RO1HL080612, R21CA135602 and T32CA009683, T32GM07229) and the Mari Lowe Center for Comparative Oncology.	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Birbach A, 2004, J CELL SCI, V117, P3615, DOI 10.1242/jcs.01224; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Bunone G, 2000, CANCER RES, V60, P2845; Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Eisenlohr LC, 2006, AUTOIMMUN REV, V6, P107, DOI 10.1016/j.autrev.2006.04.002; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He JQ, 2007, J BIOL CHEM, V282, P3688, DOI 10.1074/jbc.M610271200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lodyga M, 2009, ONCOGENE, V28, P937, DOI 10.1038/onc.2008.447; Ludwig L, 2001, CANCER RES, V61, P4526; Madge LA, 2008, J IMMUNOL, V180, P3467, DOI 10.4049/jimmunol.180.5.3467; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Muzza M, 2010, CLIN ENDOCRINOL, V72, P702, DOI 10.1111/j.1365-2265.2009.03699.x; Nellore A, 2009, J CLIN ENDOCR METAB, V94, P1026, DOI 10.1210/jc.2008-1042; Nibu K, 2005, EUR ARCH OTO-RHINO-L, V262, P368, DOI 10.1007/s00405-004-0835-8; Nishina T, 2009, BIOCHEM BIOPH RES CO, V388, P96, DOI 10.1016/j.bbrc.2009.07.125; Pacifico F, 2004, J BIOL CHEM, V279, P54610, DOI 10.1074/jbc.M403492200; Pacifico F, 2010, MOL CELL ENDOCRINOL, V321, P29, DOI 10.1016/j.mce.2009.10.010; Pufnock JS, 2009, J IMMUNOL, V182, P5498, DOI 10.4049/jimmunol.0801284; Razani B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000778; Rhoden KJ, 2006, J CLIN ENDOCR METAB, V91, P2414, DOI 10.1210/jc.2006-0240; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Solt LA, 2007, J BIOL CHEM, V282, P8724, DOI 10.1074/jbc.M609613200; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Veiga-Fernandes H, 2007, NATURE, V446, P547, DOI 10.1038/nature05597; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wells SA, 2009, CLIN CANCER RES, V15, P7119, DOI 10.1158/1078-0432.CCR-08-2742; Wharry CE, 2009, CANCER BIOL THER, V8, P1567, DOI 10.4161/cbt.8.16.8961; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zarnegar B, 2008, P NATL ACAD SCI USA, V105, P3503, DOI 10.1073/pnas.0707959105	43	22	23	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					87	96		10.1038/onc.2010.396	http://dx.doi.org/10.1038/onc.2010.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818435	Green Accepted			2022-12-28	WOS:000285959300008
J	Park, JH; Lee, JY; Shin, DH; Jang, KS; Kim, HJ; Kong, G				Park, J-H; Lee, J-Y; Shin, D-H; Jang, K-S; Kim, H-J; Kong, Gu			Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1 alpha mediated by the PTEN/PI3K/Akt pathway	ONCOGENE			English	Article						Mel-18; polycomb group proteins; Akt; angiogenesis	INDUCIBLE FACTOR 1-ALPHA; FORKHEAD TRANSCRIPTION FACTOR; REGULATES CELL-PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER; SUPPRESSOR PROTEIN; UBIQUITIN LIGASE; VEGF EXPRESSION; POOR-PROGNOSIS; HYPOXIA	Mel-18 has been implicated in several processes in tumor progression, in which the Akt pathway is involved as an important key molecular event. However, the function of Mel-18 in human cancers has not been fully established yet. Here, we examined the effect of Mel-18 on tumor angiogenesis in human breast cancer, and found that Mel-18 was a novel regulator of HIF-1 alpha. Mel-18 negatively regulated the HIF-1 alpha expression and its target gene VEGF transcription during both normoxia and hypoxia. We demonstrated that Mel-18 regulated the HIF-1 alpha expression and activity via the PI3K/Akt pathway. Loss of Mel-18 downregulated Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression, consequently activating the PI3K/Akt/MDM2 pathway, and leading to an increase of HIF-1 alpha protein level. Mel-18 modulated the HIF-1 alpha transcriptional activity via regulating the cytoplasmic retention of FOXO3a, a downstream effector of Akt, and recruitment of HIF-1 alpha/CBP complex to the VEGF promoter. Furthermore, our data shows that Mel-18 blocked tumor angiogenesis both in vitro and in vivo. Mel-18 overexpression inhibited in vitro tube formation in human umbilical endothelial cells (HUVECs). Xenografts in NOD/SCID mice derived from stably Mel-18 knocked down MCF7 human breast cancer cells showed increased tumor volume, microvessel density, and phospho-Akt and HIF-1a expression levels. In conclusion, our findings provide that Mel-18 is a novel regulator of tumor angiogenesis through regulating HIF-1 alpha and its target VEGF expressions mediated by the PTEN/PI3K/Akt pathway, suggesting a new tumor-suppressive role of Mel-18 in human breast cancer. Oncogene (2011) 30, 4578-4589; doi: 10.1038/onc.2011.174; published online 23 May 2011	[Park, J-H; Shin, D-H; Jang, K-S; Kim, H-J; Kong, Gu] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; [Lee, J-Y; Kong, Gu] Hanyang Univ, IBBR, Seoul 133791, South Korea	Hanyang University; Hanyang University	Kong, G (corresponding author), Hanyang Univ, Coll Med, Dept Pathol, 17 Haengdang Dong, Seoul 133791, South Korea.	gkong@hanyang.ac.kr	Jang, Kiseok/P-2048-2015	Jang, Kiseok/0000-0002-6585-3990	National Research Foundation of Korea (NRF); Korean government (MEST) [2010K001350, 2010-0020534]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2010K001350 and 2010-0020534).	Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Brahimi-Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Davis R, 2009, ONCOL REP, V22, P1473, DOI 10.3892/or_00000589; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Fang J, 2007, CELL SIGNAL, V19, P2487, DOI 10.1016/j.cellsig.2007.07.025; Flugel D, 2007, MOL CELL BIOL, V27, P3253, DOI 10.1128/MCB.00015-07; Guo BH, 2010, ANN ONCOL, V21, P2361, DOI 10.1093/annonc/mdq241; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Jung JH, 2010, BIOCHEM BIOPH RES CO, V400, P523, DOI 10.1016/j.bbrc.2010.08.086; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Lee YM, 2009, CARCINOGENESIS, V30, P1768, DOI 10.1093/carcin/bgp196; Li W, 2008, ONCOL REP, V20, P713, DOI 10.3892/or_00000064; Li XY, 2007, ACTA BIOCH BIOPH SIN, V39, P745, DOI 10.1111/j.1745-7270.2007.00337.x; Ma JC, 2009, MOL CELL BIOCHEM, V331, P161, DOI 10.1007/s11010-009-0154-x; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 2001, EXP NEPHROL, V9, P235; Merritt WM, 2010, MOL CANCER THER, V9, P985, DOI 10.1158/1535-7163.MCT-09-0967; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Qian T, 2010, ONCOGENE, V29, P5818, DOI 10.1038/onc.2010.317; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; Tan M, 2008, ONCOGENE, V27, P1404, DOI 10.1038/sj.onc.1210780; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian T, 2010, CARCINOGENESIS, V31, P1211, DOI 10.1093/carcin/bgq085; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Vemula S, 2010, BLOOD, V115, P1785, DOI 10.1182/blood-2009-08-237222; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Zhong H, 2000, CANCER RES, V60, P1541	48	51	55	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 10	2011	30	45					4578	4589		10.1038/onc.2011.174	http://dx.doi.org/10.1038/onc.2011.174			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21602890				2022-12-28	WOS:000296890700005
J	Wagh, PK; Gray, JK; Zinser, GM; Vasiliauskas, J; James, L; Monga, SP; Waltz, SE				Wagh, P. K.; Gray, J. K.; Zinser, G. M.; Vasiliauskas, J.; James, L.; Monga, S. P.; Waltz, S. E.			beta-Catenin is required for Ron receptor-induced mammary tumorigenesis	ONCOGENE			English	Article						beta-catenin; hepatocyte growth factor-like protein; Ron receptor; breast cancer; receptor tyrosine kinase	BREAST-CANCER; TUMOR-FORMATION; OVEREXPRESSION; ACTIVATION; PATHWAY; CARCINOMAS; EXPRESSION; GENE; MICE; DIFFERENTIATION	Our previous studies demonstrated that selective overexpression of the Ron receptor tyrosine kinase in the murine mammary epithelium leads to mammary tumor formation. Biochemical analysis of mammary tumor lysates showed that Ron overexpression was associated with increases in beta-catenin expression and tyrosine phosphorylation. beta-Catenin has also been shown to be regulated through tyrosine phosphorylation by the receptor tyrosine kinases Met, Fer and Fyn. However, the molecular and physiological roles of beta-catenin and beta-catenin tyrosine phosphorylation downstream of Ron are not known. To investigate this association, we show that Ron and beta-catenin are coordinately elevated in human breast cancers. Our data also demonstrate that activation of Ron, through ligand binding by hepatocyte growth factor-like protein (HGFL), induces the tyrosine phosphorylation of beta-catenin, primarily on tyrosine residues Tyr 654 and Tyr 670. In addition, HGFL-mediated Ron activation induces both beta-catenin nuclear localization and transcriptional activity, with Tyr 654 and Tyr 670 residues of beta-catenin being critical for these processes. We also demonstrate that a knockdown of Ron in breast cancer cell lines leads to a loss of HGFL-induced beta-catenin-dependent transcriptional activation and cell growth, which can be rescued by activation of canonical Wnt/beta-catenin signaling. Moreover, we show that HGFL-dependent Ron activation mediates upregulation of the beta-catenin target genes cyclin D1 and c-myc, and that expression of these target genes in breast cancer cells is decreased following inhibition of Ron and/or beta-catenin. Finally, we show that genetic ablation of beta-catenin in Ron-expressing breast cancer cells decreases cellular proliferation in vitro, as well as mammary tumor growth and metastasis, following orthotopic transplantation into the mammary fat pad. Together, our data suggest that beta-catenin is a crucial downstream regulator of Ron receptor activation and is an important mediator of mammary tumorigenesis. Oncogene (2011) 30, 3694-3704; doi:10.1038/onc.2011.86; published online 21 March 2011	[Wagh, P. K.; Gray, J. K.; Vasiliauskas, J.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA; [Zinser, G. M.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [James, L.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; [Monga, S. P.] Univ Pittsburgh, Div Expt Pathol, Pittsburgh, PA USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Waltz, SE (corresponding author), Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Vontz Bldg Mol Studies,3125 Eden Ave, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu		Waltz, Susan/0000-0003-3572-4642; Monga, Satdarshan/0000-0002-8437-3378	National Institutes of Health [CA100002]; Cincinnati Veteran's Administration Medical Center [1I01BX000803]; University of Cincinnati Cancer Center; University of Cincinnati Research Council; NATIONAL CANCER INSTITUTE [R01CA100002, T32CA059268, T32CA117846] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000803] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cincinnati Veteran's Administration Medical Center; University of Cincinnati Cancer Center; University of Cincinnati Research Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We would like to acknowledge Dr Susanne I Wells for providing adenoviral reagents and Allie K Varner for her technical support. This work was supported by Public Health Service Grant CA100002 (SEW) from the National Institutes of Health, by grant 1I01BX000803 (SEW) from the Cincinnati Veteran's Administration Medical Center, by a University of Cincinnati Cancer Center Grant (SEW) and University of Cincinnati Research Council Grant (PKW).	Apte U, 2006, HEPATOLOGY, V44, P992, DOI 10.1002/hep.21317; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Graveel CR, 2009, P NATL ACAD SCI USA, V106, P12909, DOI 10.1073/pnas.0810403106; Gujral TS, 2008, CANCER RES, V68, P1338, DOI 10.1158/0008-5472.CAN-07-6052; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Hynes NE, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2406; Kizildag S, 2008, J BUON, V13, P533; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; Meyer SE, 2009, DEV BIOL, V333, P173, DOI 10.1016/j.ydbio.2009.06.028; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Miller KD, 2006, CLIN CANCER RES, V12, P281, DOI 10.1158/1078-0432.CCR-05-0219; Nakopoulou L, 2006, MODERN PATHOL, V19, P556, DOI 10.1038/modpathol.3800562; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Ranganathan S, 2005, PEDIATR DEVEL PATHOL, V8, P435, DOI 10.1007/s10024-005-0028-5; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Shien T, 2005, J CLIN PATHOL, V58, P1299, DOI 10.1136/jcp.2005.026096; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Taneja P, 2010, CLIN MED INSIGHTS-ON, V4, P15; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Zeng G, 2006, EXP CELL RES, V312, P3620, DOI 10.1016/j.yexcr.2006.08.003; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	35	43	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	34					3694	3704		10.1038/onc.2011.86	http://dx.doi.org/10.1038/onc.2011.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423209	Green Accepted			2022-12-28	WOS:000294244500005
J	Fagerli, UM; Ullrich, K; Stuhmer, T; Holien, T; Kochert, K; Holt, RU; Bruland, O; Chatterjee, M; Nogai, H; Lenz, G; Shaughnessy, JD; Mathas, S; Sundan, A; Bargou, RC; Dorken, B; Borset, M; Janz, M				Fagerli, U-M; Ullrich, K.; Stuehmer, T.; Holien, T.; Koechert, K.; Holt, R. U.; Bruland, O.; Chatterjee, M.; Nogai, H.; Lenz, G.; Shaughnessy, J. D., Jr.; Mathas, S.; Sundan, A.; Bargou, R. C.; Doerken, B.; Borset, M.; Janz, M.			Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells	ONCOGENE			English	Article						multiple myeloma; cytokines; SGK1; STAT3	PROTEIN-KINASE; BONE-MARROW; EPITHELIAL-CELLS; SURVIVAL; SERUM; PATHWAY; ACTIVATION; EXPRESSION; APOPTOSIS; DOWNSTREAM	Multiple myeloma (MM) is a paradigm for a malignant disease that exploits external stimuli of the microenvironment for growth and survival. A thorough understanding of the complex interactions between malignant plasma cells and their surrounding requires a detailed analysis of the transcriptional response of myeloma cells to environmental signals. We determined the changes in gene expression induced by interleukin (IL)-6, tumor necrosis factor-alpha, IL-21 or co-culture with bone marrow stromal cells in myeloma cell lines. Among a limited set of genes that were consistently activated in response to growth factors, a prominent transcriptional target of cytokine-induced signaling in myeloma cells was the gene encoding the serine/threonine kinase serum/glucocorticoid-regulated kinase 1 (SGK1), which is a down-stream effector of PI3-kinase. We could demonstrate a rapid, strong and sustained induction of SGK1 in the cell lines INA-6, ANBL-6, IH-1, OH-2 and MM.1S as well as in primary myeloma cells. Pharmacologic inhibition of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway abolished STAT3 phosphorylation and SGK1 induction. In addition, small hairpin RNA (shRNA)-mediated knock-down of STAT3 reduced basal and induced SGK1 levels. Furthermore, downregulation of SGK1 by shRNAs resulted in decreased proliferation of myeloma cell lines and reduced cell numbers. On the molecular level, this was reflected by the induction of cell cycle inhibitory genes, for example, CDKNA1/p21, whereas positively acting factors such as CDK6 and RBL2/p130 were downregulated. Our results indicate that SGK1 is a highly cytokine-responsive gene in myeloma cells promoting their malignant growth. Oncogene (2011) 30, 3198-3206; doi:10.1038/onc.2011.79; published online 11 April 2011	[Ullrich, K.; Koechert, K.; Nogai, H.; Lenz, G.; Mathas, S.; Doerken, B.; Janz, M.] Campus Virchow Klinikum, Univ Med Sch Berlin, Charite, Dept Hematol Oncol & Tumorimmunol, D-13092 Berlin, Germany; [Fagerli, U-M; Holien, T.; Holt, R. U.; Sundan, A.; Borset, M.] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway; [Fagerli, U-M] St Olavs Univ Hosp, Dept Oncol, Trondheim, Norway; [Ullrich, K.; Koechert, K.; Mathas, S.; Doerken, B.; Janz, M.] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Stuehmer, T.; Chatterjee, M.; Bargou, R. C.] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany; [Stuehmer, T.; Chatterjee, M.; Bargou, R. C.] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Div Hematol, Wurzburg, Germany; [Holt, R. U.] Sor Trondelag Univ Coll, Fac Technol, Dept Biomed Sci, Trondheim, Norway; [Bruland, O.] Haukeland Univ Hosp Bergen, Ctr Med Genet & Mol Med, Bergen, Norway; [Shaughnessy, J. D., Jr.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA; [Borset, M.] St Olavs Univ Hosp, Dept Immunol & Transfus Med, Trondheim, Norway	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Wurzburg; University of Wurzburg; Norwegian University of Science & Technology (NTNU); University of Bergen; Haukeland University Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Norwegian University of Science & Technology (NTNU)	Janz, M (corresponding author), Campus Virchow Klinikum, Univ Med Sch Berlin, Charite, Dept Hematol Oncol & Tumorimmunol, Robert Rossle Str 10, D-13092 Berlin, Germany.	mjanz@mdc-berlin.de	Mathas, Stephan/I-5589-2015; Borset, Magne/AAY-1713-2021; Lenz, Georg/I-6844-2012; Holien, Toril/M-6253-2018	Borset, Magne/0000-0001-5179-2835; Kochert, Karl/0000-0002-5548-2022; Bruland, Oyvind Sverre/0000-0003-1631-3733; Janz, Martin/0000-0002-1127-0044; Holien, Toril/0000-0002-2051-5824	Deutsche Krebshilfe [10-2225-Ja 1]; Berlin Cancer Society; Deutsche Forschungsgemeinschaft [KFO 216]; Norwegian Cancer Society; St Olavs Hospital, Trondheim; Research Council of Norway	Deutsche Krebshilfe(Deutsche Krebshilfe); Berlin Cancer Society; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Norwegian Cancer Society(Norwegian Cancer Society); St Olavs Hospital, Trondheim; Research Council of Norway(Research Council of Norway)	We thank Brigitte Wollert-Wulf, Mandy Terne, Pia Herrmann (Berlin), Berit Stordal and Hanne Hella (Trondheim) for excellent technical assistance and Hans-Peter Rahn (Berlin) for cell sorting. Reuven Agami (Amsterdam, The Netherlands) kindly provided the pSUPER vector and Matthias Truss (Berlin) the pRepH1 construct. This work was supported by grants from the Deutsche Krebshilfe (10-2225-Ja 1), the Berlin Cancer Society, the Deutsche Forschungsgemeinschaft (KFO 216 to TS, MC and RCB), the Norwegian Cancer Society, the Cancer Fund of St Olavs Hospital, Trondheim, and the Research Council of Norway.	Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Meng FM, 2005, AM J PHYSIOL-CELL PH, V289, pC971, DOI 10.1152/ajpcell.00081.2005; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Ogata A, 1997, CLIN CANCER RES, V3, P1017; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259; Sahoo S, 2005, EUR J CANCER, V41, P2754, DOI 10.1016/j.ejca.2005.07.018; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Tu YP, 2000, CANCER RES, V60, P6763; van Zaanen HCT, 1998, BRIT J HAEMATOL, V102, P783; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zollinger A, 2008, BLOOD, V112, P3403, DOI 10.1182/blood-2007-11-119362	22	57	60	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	28					3198	3206		10.1038/onc.2011.79	http://dx.doi.org/10.1038/onc.2011.79			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21478911				2022-12-28	WOS:000292726300008
J	Kim, HD; Kim, TS; Kim, J				Kim, H. D.; Kim, T-S; Kim, J.			Aberrant ribosome biogenesis activates c-Myc and ASK1 pathways resulting in p53-dependent G1 arrest	ONCOGENE			English	Article						ASK1; c-Myc; p53; rpL11; rpS3; ribosomal stress	DIAMOND-BLACKFAN ANEMIA; RIBOTOXIC STRESS-RESPONSE; CELL-CYCLE; MESSENGER-RNA; PROTEIN L26; P53; TRANSLATION; CANCER; CHECKPOINT; L11	The largest energy consumer in the cell is the ribosome biogenesis whose aberrancy elicits various diseases in humans. It has been recently revealed that p53 induction, along with cell cycle arrest, is related with abnormal ribosome biogenesis, but the exact mechanism still remains unknown. In this study, we have found that aberrant ribosome biogenesis activates two parallel cellular pathways, c-Myc and ASK1/p38, which result in p53 induction and G1 arrest. The c-Myc stabilizes p53 by rpL11-mediated HDM2 inhibition, and ASK1/p38 activates p53 by phosphorylation on serine 15 and 33. Our studies demonstrate the relationship between these two pathways and p53 induction. The changes caused by impaired ribosomal stress, such as p53 induction and G1 arrest, were completely disappeared by inhibition of either pathway. These findings suggest a monitoring mechanism of c-Myc and ASK1/p38 against abnormal ribosome biogenesis through controlling the stability and activity of p53 protein. Oncogene (2011) 30, 3317-3327; doi:10.1038/onc.2011.47; published online 7 March 2011	[Kim, J.] Korea Univ, Biochem Lab, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; [Kim, J.] Korea Univ, BioInst, Seoul 136701, South Korea	Korea University; Korea University	Kim, J (corresponding author), Korea Univ, Biochem Lab, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	joonkim@korea.ac.kr			Ministry of Education and Science of Korea [FPR08B1-230, 2008-0059301, 2009-0086319]	Ministry of Education and Science of Korea(Ministry of Education (MOE), Republic of Korea)	We thank Professor E-J Choi (Korea University, Seoul, Korea) for the kind gifts of ASK1 antibody and GST-MKK6 protein. This work was supported in part by FPR08B1-230, 2008-0059301 and 2009-0086319 NRF Grants from Ministry of Education and Science of Korea.	Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Cleveland JL, 2004, CANCER CELL, V6, P309, DOI 10.1016/j.ccr.2004.09.020; Dai MS, 2007, CELL CYCLE, V6, P2735, DOI 10.4161/cc.6.22.4895; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Ellis SR, 2008, CURR TOP DEV BIOL, V82, P217, DOI 10.1016/S0070-2153(07)00008-7; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Granneman S, 2004, EXP CELL RES, V296, P43, DOI 10.1016/j.yexcr.2004.03.016; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Idol RA, 2007, BLOOD CELL MOL DIS, V39, P35, DOI 10.1016/j.bcmd.2007.02.001; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Kim HD, 2010, J CELL BIOCHEM, V110, P294, DOI 10.1002/jcb.22537; Kim TS, 2009, BBA-MOL CELL RES, V1793, P395, DOI 10.1016/j.bbamcr.2008.10.017; Kim TS, 2006, MOL BIOL CELL, V17, P824, DOI 10.1091/mbc.E05-08-0713; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Laskin JD, 2002, TOXICOL SCI, V69, P289, DOI 10.1093/toxsci/69.2.289; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood-2005-12-4831; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Maggi LB, 2005, CANCER INVEST, V23, P599, DOI 10.1080/07357900500283085; Menne TF, 2007, NAT GENET, V39, P486, DOI 10.1038/ng1994; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; Opferman JT, 2006, CELL DEATH DIFFER, V13, P898, DOI 10.1038/sj.cdd.4401923; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zimmermann RA, 2003, CELL, V115, P130, DOI 10.1016/S0092-8674(03)00804-3	45	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	30					3317	3327		10.1038/onc.2011.47	http://dx.doi.org/10.1038/onc.2011.47			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21383696				2022-12-28	WOS:000293215700002
J	Roberts, CG; Millar, EKA; O'Toole, SA; McNeil, CM; Lehrbach, GM; Pinese, M; Tobelmann, P; McCloy, RA; Musgrove, EA; Sutherland, RL; Butt, AJ				Roberts, C. G.; Millar, E. K. A.; O'Toole, S. A.; McNeil, C. M.; Lehrbach, G. M.; Pinese, M.; Tobelmann, P.; McCloy, R. A.; Musgrove, E. A.; Sutherland, R. L.; Butt, A. J.			Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer	ONCOGENE			English	Article						PUMA; breast cancer; tamoxifen	ENDOCRINE RESISTANCE; BH3-ONLY PROTEIN; C-MYC; EXPRESSION; P53; SURVIVAL; THERAPY; DETERMINANTS; NETWORKS	Recognition of the pivotal role of estrogen in the aetiology of breast cancer has led to the development of antiestrogens (AE), such as tamoxifen (TAM) as effective therapies for the treatment and prevention of this disease. However, despite their widespread clinical efficacy, response to AEs is often short-lived, and acquired or innate therapeutic resistance remains a major obstacle in the successful treatment of breast cancer. Thus, delineating the intracellular pathways that mediate the cellular response to estrogen could potentially lead to new, more effective approaches to the treatment of breast cancer, particularly endocrine-resistant disease. Here, we have identified the BCL-2 homology 3 (BH3)-only, proapoptotic regulator, PUMA (p53 upregulated modulator of apoptosis) as an estrogen target gene that is acutely downregulated in response to estrogen in breast cancer cell lines, independently of their p53 status. PUMA is transcriptionally upregulated following treatment with TAM, and knock down of PUMA expression in these cells attenuates the apoptotic response to TAM. Furthermore, low PUMA expression in breast carcinomas is significantly associated with breast cancer-specific death (P=0.0014 and P=0.0115, for mRNA and protein, respectively), and worse outcome in TAM-treated patients (mRNA, P=1.49e-05). These findings suggest that the dysregulation of apoptotic signaling pathways such as those executed through PUMA, can significantly impact on both the progression and therapeutic responsiveness of breast cancer. Moreover, they provide a convincing rationale for exploring new therapeutic approaches involving endocrine and non-endocrine therapies that target apoptotic pathways as an effective strategy for tackling endocrine refractory disease. Oncogene (2011) 30, 3186-3197; doi:10.1038/onc.2011.36; published online 7 March 2011	[Butt, A. J.] St Vincents Hosp, Garvan Inst Med Res, Apoptosis Res Grp, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Millar, E. K. A.] St George Hosp, S Eastern Area Lab Serv, Dept Anat Pathol, Kogarah, NSW, Australia; [Millar, E. K. A.; Musgrove, E. A.; Sutherland, R. L.; Butt, A. J.] Univ Western Sydney, Sch Med, Campbelltown, NSW, Australia; [O'Toole, S. A.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [O'Toole, S. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia; [O'Toole, S. A.] Univ Sydney, Sydney Med Sch, Cent Clin Sch, Sydney, NSW 2006, Australia; [McNeil, C. M.] Westmead Hosp, Dept Med Oncol, Westmead, NSW 2145, Australia; [McNeil, C. M.] Univ Sydney, Western Clin Sch, Sydney, NSW 2006, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; St George Hospital; Western Sydney University; University of New South Wales Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Butt, AJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Apoptosis Res Grp, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	abutt@garvan.org.au	Millar, Ewan/ABE-9127-2020; Sutherland, Robert L/A-8378-2008	Millar, Ewan/0000-0002-9778-3253; Pinese, Mark/0000-0001-5078-6687; Butt, Alison/0000-0002-6216-5105; McCloy, Rachael/0000-0001-7791-4044	National Health and Medical Research Council (NHMRC) of Australia [535903]; Australian Cancer Research Fund; RT Hall Trust; Petre Foundation	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Cancer Research Fund; RT Hall Trust; Petre Foundation	This research was supported by a National Health and Medical Research Council (NHMRC) of Australia Program Grant 535903, the Australian Cancer Research Fund, the RT Hall Trust, the Petre Foundation, a Cancer Institute NSW Career Development and Support Fellowship (AJB), Cancer Institute NSW Clinical Research Fellowships (EKAM and SAO'T) and an NHMRC health professional training fellowship (SAO'T).	Anderson LR, 2010, ONCOGENE, V29, P527, DOI 10.1038/onc.2009.362; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Butt AJ, 2008, ADV EXP MED BIOL, V630, P189; Butt AJ, 2006, MOL CANCER THER, V5, P2300, DOI 10.1158/1535-7163.MCT-06-0170; Butt AJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1779; Cannings E, 2007, BREAST CANCER RES TR, V102, P173, DOI 10.1007/s10549-006-9323-8; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Ellis MJ, 2003, J STEROID BIOCHEM, V86, P301, DOI 10.1016/S0960-0760(03)00371-6; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hammerich-Hille S, 2010, J BIOL CHEM, V285, P3608, DOI 10.1074/jbc.M109.066431; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Hurvitz SA, 2008, CANCER-AM CANCER SOC, V113, P2385, DOI 10.1002/cncr.23875; JEFFERS JR, 2003, CANCER RES, V52, P5204; Jordan VC, 2009, CANCER RES, V69, P1243, DOI 10.1158/0008-5472.CAN-09-0029; Karst AM, 2005, ONCOGENE, V24, P1111, DOI 10.1038/sj.onc.1208374; MILLAR EKA, 2008, BRIT J CANCER, V100, P123; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Musgrove EA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002987; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naresh A, 2008, CANCER RES, V68, P6387, DOI 10.1158/0008-5472.CAN-08-0538; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Reimer T, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr456; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Swaby RF, 2007, REV ENDOCR METAB DIS, V8, P229, DOI 10.1007/s11154-007-9034-4; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vousden KH, 2005, SCIENCE, V309, P1685, DOI 10.1126/science.1118232; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	36	18	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3186	3197		10.1038/onc.2011.36	http://dx.doi.org/10.1038/onc.2011.36			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383694				2022-12-28	WOS:000292726300007
J	Cheung, LWT; Mak, ASC; Cheung, ANY; Ngan, HYS; Leung, PCK; Wong, AST				Cheung, L. W. T.; Mak, A. S. C.; Cheung, A. N. Y.; Ngan, H. Y. S.; Leung, P. C. K.; Wong, A. S. T.			P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin	ONCOGENE			English	Article						ovarian cancer; GnRH; P-cadherin; p(120ctn); motility; IGF-1R	TYROSINE PHOSPHORYLATION; PROGNOSTIC-FACTOR; RHO-GTPASES; EXPRESSION; ACTIVATION; ADHESION; KINASE; EPITHELIUM; INDUCTION; INVASION	Gonadotropin-releasing hormone (GnRH) is a potent prometastatic factor in ovarian cancer, but the intracellular signaling events are not well understood. The classical G alpha(q)-phospholipase C signal transduction pathway known to operate in the pituitary is not involved in GnRH actions at non-pituitary targets. Here we showed that GnRH treatment of ovarian cancer cells led to a rapid and remarkable tyrosine phosphorylation of p120 catenin (p120(ctn)), which was mediated by P-cadherin. The use of P-cadherin small interfering RNA or neutralizing antibodies to inhibit P-cadherin expression and function resulted in diminished p120(ctn) activation, confirming that the effect was P-cadherin specific. On exploring how P-cadherin, which lacks intrinsic kinase activity, might regulate the activation of p120ctn, we found that P-cadherin could induce the ligand-independent activation of insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R expression or its activity significantly inhibited GnRH-induced p120(ctn) activation, and the subsequent cell migration and invasion. In addition, we showed that IGF-1R regulation by P-cadherin was associated with complex formation between IGF-1R and P-cadherin, and this regulation was also observed to be in vivo correlated with metastasis. Furthermore, using a mouse model of ovarian cancer metastasis, GnRH receptor knockdown was shown to diminish peritoneal dissemination of tumors and ascites formation. These findings suggest for the first time that GnRH can initiate an outside-in p120(ctn) signal transduction through the cross-talk between P-cadherin and IGF-1R, thus providing a novel molecular mechanism by which GnRH may control the high level of aggressiveness and invasion and metastasis potential that are characteristic of ovarian cancer. Oncogene (2011) 30, 2964-2974; doi:10.1038/onc.2011.7; published online 14 February 2011	[Cheung, L. W. T.; Mak, A. S. C.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Cheung, A. N. Y.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Ngan, H. Y. S.] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; [Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of British Columbia	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biological Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022; Cheung, Annie Nga Yin/C-4231-2009	Wong, Alice/0000-0002-0676-6475; Leung, Peter/0000-0003-3152-3800; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Lydia Wai Ting/0000-0003-1137-3200; Cheung, Annie Nga Yin/0000-0002-1584-7568	Hong Kong Research Grant Council [778108]; HKU	Hong Kong Research Grant Council(Hong Kong Research Grants Council); HKU(University of Hong Kong)	We thank Dr N Auersperg for cell lines. This work was supported by Hong Kong Research Grant Council 778108 and HKU Outstanding Young Researcher Award (AST Wong).	Alonso L, 2009, CLIN TRANSL ONCOL, V11, P748, DOI 10.1007/s12094-009-0437-4; Brokaw J, 2007, GROWTH FACTORS, V25, P346, DOI 10.1080/08977190701838402; Chen GTC, 2002, MOL REPROD DEV, V62, P289, DOI 10.1002/mrd.10121; Cheung LWT, 2010, ONCOGENE, V29, P2427, DOI 10.1038/onc.2009.523; Cheung LWT, 2008, FEBS J, V275, P5479, DOI 10.1111/j.1742-4658.2008.06677.x; Cheung LWT, 2006, CANCER RES, V66, P10902, DOI 10.1158/0008-5472.CAN-06-2217; Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; Dunn SE, 1998, CANCER RES, V58, P3353; Ellerbroek SM, 2001, CANCER RES, V61, P1855; EMONS G, 1989, EUR J CANCER CLIN ON, V25, P215, DOI 10.1016/0277-5379(89)90011-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; GRZES A, 1978, ENDOKRINOLOGIE, V71, P40; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; Holzman JL, 2007, AM J PHYSIOL-RENAL, V292, pF1219, DOI 10.1152/ajprenal.00214.2006; IRMER G, 1995, CANCER RES, V55, P817; Ishiyama N, 2010, CELL, V141, P117, DOI 10.1016/j.cell.2010.01.017; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KAWAMURA Y, 1980, FERTIL STERIL, V34, P444; Liao JK, 2003, BIOCHEM SOC T, V31, P66, DOI 10.1042/bst0310066; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Patel IS, 2003, INT J CANCER, V106, P172, DOI 10.1002/ijc.11086; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Pennisi PA, 2002, CANCER RES, V62, P6529; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Soubry A, 2005, CANCER RES, V65, P2224, DOI 10.1158/0008-5472.CAN-04-2020; Spentzos D, 2007, ENDOCR-RELAT CANCER, V14, P781, DOI 10.1677/ERC-06-0073; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Steele IA, 2001, ONCOGENE, V20, P5878, DOI 10.1038/sj.onc.1204755; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Takahari D, 2009, ONCOLOGY-BASEL, V76, P42, DOI 10.1159/000178164; Wilkinson SJ, 2008, HUM PATHOL, V39, P1197, DOI 10.1016/j.humpath.2007.12.011; Wong AST, 1999, INT J CANCER, V81, P180; Yin M, 2009, AM J TRANSL RES, V1, P101	43	24	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2964	2974		10.1038/onc.2011.7	http://dx.doi.org/10.1038/onc.2011.7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317933				2022-12-28	WOS:000292245100007
J	Feng, M; Li, Z; Aau, M; Wong, CH; Yang, X; Yu, Q				Feng, M.; Li, Z.; Aau, M.; Wong, C. H.; Yang, X.; Yu, Q.			Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation	ONCOGENE			English	Article						Myc; miR-378; TOB2; cyclin D1	C-MYC; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; CANCER METASTASIS; MIR-200 FAMILY; E-CADHERIN; MICRORNA; TARGET; RAS; APOPTOSIS	The c-Myc transcription factor activates a cascade of downstream targets to form a complex transcriptional program that ultimately leads to cellular transformation. Although a large number of protein-encoding genes as well as non-coding RNAs were identified as Myc targets, only a few have been validated to be functionally important for c-Myc-driven transformation. Here, we identify a microRNA (miRNA), miR-378, as a novel target of the c-Myc oncoprotein that is able to cooperate with activated Ras or HER2 to promote cellular transformation. Mechanistically, miR-378 achieves this oncogenic effect, at least in part, by targeting and inhibiting the anti-proliferative BTG family member, TOB2, which is further elucidated as a candidate tumor suppressor to transcriptionally repress proto-oncogene cyclin D1. Therefore, our study identifies miR-378-TOB2-cyclin D1 as a functional module to mediate the cross talk between Myc and Ras signaling in cellular transformation. Oncogene (2011) 30, 2242-2251; doi:10.1038/onc.2010.602; published online 17 January 2011	[Feng, M.; Li, Z.; Aau, M.; Wong, C. H.; Yang, X.; Yu, Q.] ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, Biopolis 138672, Singapore; [Yu, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore; [Yu, Q.] DUKE NUS Med Sch, Dept Canc & Stem Cell Biol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore	Yu, Q (corresponding author), ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, 60 Biopolis St, Biopolis 138672, Singapore.	yuq@gis.a-star.edu.sg	Yang, Xiaojing/G-9201-2012	Yu, Qiang/0000-0003-2132-8278	Agency for Science, Technology & Research (A*Star) of Singapore	Agency for Science, Technology & Research (A*Star) of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr William Hahn for the HMLE and HMLER cells. This work was supported by Agency for Science, Technology & Research (A*Star) of Singapore.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Yang XJ, 2009, GENE DEV, V23, P2388, DOI 10.1101/gad.1819009; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	29	68	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2242	2251		10.1038/onc.2010.602	http://dx.doi.org/10.1038/onc.2010.602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242960				2022-12-28	WOS:000290514600007
J	Wang, ZA; Shen, MM				Wang, Z. A.; Shen, M. M.			Revisiting the concept of cancer stem cells in prostate cancer	ONCOGENE			English	Review						cancer stem cell; prostate cancer; mouse models; cell of origin; tumor-initiating cell	TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; BASAL-CELLS; IN-VIVO; PROSPECTIVE IDENTIFICATION; RECOMBINASE ACTIVITY; MOLECULAR-GENETICS; EPITHELIAL-CELLS; MURINE PROSTATE; BREAST-CANCER	The cancer stem cell (CSC) model proposes that cells within a tumor are organized in a hierarchical lineage relationship and display different tumorigenic potential, suggesting that effective therapeutics should target rare CSCs that sustain tumor malignancy. Here we review the current status of studies to identify CSCs in human prostate cancer as well as mouse models, with an emphasis on discussing different functional assays and their advantages and limitations. We also describe current controversies regarding the identification of prostate epithelial stem cells and cell types of origin for prostate cancer, and present potential resolutions of these issues. Although definitive evidence for the existence of CSCs in prostate cancer is still lacking, future directions pursuing the identification of tumor-initiating stem cells in the mouse may provide important advances in evaluating the CSC model for prostate cancer. Oncogene (2011) 30, 1261-1271; doi: 10.1038/onc.2010.530; published online 29 November 2010	[Shen, M. M.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Med, New York, NY 10032 USA; Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University	Shen, MM (corresponding author), Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Med, 1130 St Nicholas Ave, New York, NY 10032 USA.	mshen@columbia.edu	Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657; Wang, Zhu/0000-0002-8855-8951	NIH; DOD	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense)	We would like to thank Cory Abate-Shen for comments on the manuscript. We apologize for our inability to cite many relevant papers due to length constraints. This work was supported by grants to MMS from the NIH and the DOD Prostate Cancer Research Program. MMS is a member of the NCI Mouse Models of Human Cancer Consortium.	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abate-Shen C, 2008, DIFFERENTIATION, V76, P717, DOI 10.1111/j.1432-0436.2008.00292.x; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Attard G, 2009, CANCER CELL, V16, P458, DOI 10.1016/j.ccr.2009.11.006; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Birnie R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-r83; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bonkhoff H, 1996, PROSTATE, V28, P98; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Collins AT, 2001, J CELL SCI, V114, P3865; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; CUNHA GR, 1978, J EXP ZOOL, V205, P181, DOI 10.1002/jez.1402050203; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EVANS GS, 1987, PROSTATE, V11, P339, DOI 10.1002/pros.2990110406; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Garraway IP, 2010, PROSTATE, V70, P491, DOI 10.1002/pros.21083; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Isaacs JT, 1985, BENIGN PROSTATIC HYP, P85; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Korsten H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005662; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Liao CP, 2010, CANCER RES, V70, P7294, DOI 10.1158/0008-5472.CAN-09-3982; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124; Mazzucchelli R, 2008, BJU INT, V102, P1369, DOI 10.1111/j.1464-410X.2008.08074.x; Meeker AK, 2002, CANCER RES, V62, P6405; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Missol-Kolka E, 2011, PROSTATE, V71, P254, DOI 10.1002/pros.21239; Mlarotta LLC, 2009, CURR OPIN GENET DEV, V19, P44, DOI 10.1016/j.gde.2008.12.003; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Mosquera JM, 2009, CLIN CANCER RES, V15, P4706, DOI 10.1158/1078-0432.CCR-08-2927; Mulholland DJ, 2009, CANCER RES, V69, P8555, DOI 10.1158/0008-5472.CAN-08-4673; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Peehl DM, 2005, ENDOCR-RELAT CANCER, V12, P19, DOI 10.1677/erc.1.00795; Pfeiffer MJ, 2010, EUR UROL, V57, P246, DOI 10.1016/j.eururo.2009.01.015; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Risbridger GP, 2008, ENDOCRINOLOGY, V149, P4303, DOI 10.1210/en.2008-0465; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Sharifi N, 2006, CANCER BIOL THER, V5, P901, DOI 10.4161/cbt.5.8.2949; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Simak R, 2000, HISTOL HISTOPATHOL, V15, P365, DOI 10.14670/HH-15.365; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Spradling AC, 2008, COLD SH Q B, V73, P49, DOI 10.1101/sqb.2008.73.023; Tang Y, 2010, INT J CLIN EXP PATHO, V3, P128; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Ugolkov AV, 2011, PROSTATE, V71, P18, DOI 10.1002/pros.21217; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; VERHAGEN APM, 1988, PROSTATE, V13, P25, DOI 10.1002/pros.2990130104; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wei C, 2007, CANCER BIOL THER, V6, P763, DOI 10.4161/cbt.6.5.3996; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	98	81	86	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1261	1271		10.1038/onc.2010.530	http://dx.doi.org/10.1038/onc.2010.530			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21119602				2022-12-28	WOS:000288492100001
J	Queiroz, KCS; Ruela-de-Sousa, RR; Fuhler, GM; Aberson, HL; Ferreira, CV; Peppelenbosch, MP; Spek, CA				Queiroz, K. C. S.; Ruela-de-Sousa, R. R.; Fuhler, G. M.; Aberson, H. L.; Ferreira, C. V.; Peppelenbosch, M. P.; Spek, C. A.			Hedgehog signaling maintains chemoresistance in myeloid leukemic cells	ONCOGENE			English	Article						Hedgehog; multidrug resistance; P-glycoprotein; leukemia	DRUG-RESISTANCE; STEM-CELLS; MULTIDRUG-RESISTANCE; PATHWAY; INHIBITION; RADIATION; THERAPY; GROWTH; TARGET	The development of resistance against chemotherapy remains one of the major challenges in the clinical management of leukemia. There is still limited insight into the molecular mechanisms that maintain the chemotherapy-resistant phenotype, despite the obvious clinical relevance that such knowledge would have. In this study, we show that the chemotherapy-resistant phenotype of myeloid leukemia cells correlates with activation of the Hedgehog (Hh) pathway, whereas in chemosensitive cells, such activation is less pronounced. Importantly, the overexpression of Hh pathway components induces chemoprotection and inhibition of the pathway reverts chemoresistance of Lucena-1 cells, apparently by interfering with P-glycoprotein-dependent drug resistance. Our data thus identify the Hh pathway as an essential component of multidrug resistance (MDR) myeloid leukemia and suggest that targeting the Hh pathway might be an interesting therapeutic avenue for overcoming MDR resistance in myeloid leukemia. Oncogene (2010) 29, 6314-6322; doi:10.1038/onc.2010.375; published online 30 August 2010	[Queiroz, K. C. S.; Aberson, H. L.; Spek, C. A.] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, NL-1105 AZ Amsterdam, Netherlands; [Queiroz, K. C. S.; Ruela-de-Sousa, R. R.; Ferreira, C. V.] Univ Estadual Campinas, Inst Biol, Dept Biochem, Sao Paulo, Brazil; [Queiroz, K. C. S.; Ruela-de-Sousa, R. R.; Fuhler, G. M.; Peppelenbosch, M. P.] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Universidade de Sao Paulo; Universidade Estadual de Campinas; Erasmus University Rotterdam; Erasmus MC	Queiroz, KCS (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	k.c.desouzaqueiroz@amc.uva.nl	Fuhler, Gwenny/AAC-7122-2019; Queiroz, Karla/L-6438-2014; Spek, Arnold/AAC-5866-2019; Ruela de Sousa, Roberta/C-6825-2012	Fuhler, Gwenny/0000-0001-9221-4855; Spek, Arnold/0000-0002-2149-4068; Ruela de Sousa, Roberta/0000-0002-3762-2247; Peppelenbosch, Maikel/0000-0001-9112-6028	CNPq; Top-Institute pharma; Maag-, Lever-, Darmstichting	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Top-Institute pharma; Maag-, Lever-, Darmstichting	KCS Queiroz is supported by the Maag-, Lever-, Darmstichting. CV Ferreira is supported by a research fellowship from CNPq. MP Peppelenbosch and CA Spek acknowledge the support of the Top-Institute pharma. We are grateful to Professor Vivian Rumjanek (Federal University of Rio de Janeiro) for donating Lucena-1 cells.	Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; DEAN M, 1997, BIOCHIM BIOPHYS ACTA, V1332, P43; Diehl KM, 2007, MOL CANCER THER, V6, P418, DOI 10.1158/1535-7163.MCT-06-0603; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Kobune M, 2009, CANCER SCI, V100, P948, DOI 10.1111/j.1349-7006.2009.01111.x; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lauth M, 2007, CURR OPIN INVEST DR, V8, P457; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lowenberg B, 2007, J CLIN ONCOL, V25, P1, DOI 10.1200/JCO.2006.08.6462; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Rumjanek VM, 2001, AN ACAD BRAS CIENC, V73, P57, DOI 10.1590/S0001-37652001000100007; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhao Y, 2007, NATURE, V450, P252, DOI 10.1038/nature06225	22	107	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	48					6314	6322		10.1038/onc.2010.375	http://dx.doi.org/10.1038/onc.2010.375			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20802532				2022-12-28	WOS:000284874700002
J	Leung, WKC; Ching, AKK; Chan, AWH; Poon, TCW; Mian, H; Wong, AST; To, KF; Wong, N				Leung, W. K. C.; Ching, A. K. K.; Chan, A. W. H.; Poon, T. C. W.; Mian, H.; Wong, A. S. T.; To, K-F; Wong, N.			A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility	ONCOGENE			English	Article						PFTK1; hepatocellular carcinoma; cell migration; TAGLN2; actin	COMPARATIVE-GENOMIC-HYBRIDIZATION; HEPATOCELLULAR-CARCINOMA; ACTIN-BINDING; TRANSGELIN; BREAST; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION; PROGRESSION; GENE	The PFTK1 gene encodes a cdc2-related serine/threonine protein kinase that has been shown to confer cell migratory properties in hepatocellular carcinoma (HCC). However, the prognostic value and biological mechanism by which PFTK1 promotes HCC motility remain largely unknown. Here, we showed from tissue microarray that common upregulations of PFTK1 in primary HCC tumors (n = 133/180) correlated significantly with early age onset (<= 40 years), advance tumor grading and presence of microvascular invasion (P <= 0.05). To understand downstream phosphorylated substrate(s) of PFTK1, phospho-proteins in PFTK1 expressing and knockdown Hep3B cells were profiled by two-dimensional- polyacrylamide gel electrophoresis mass spectrometric analysis. Protein identification of differential spots revealed beta-actin (ACTB) and transgelin2 (TAGLN2) as the two most profound phosphorylated changes affected by PFTK1. We verified the presence of TAGLN2 serine phosphorylation and ACTB tyrosine phosphorylation. Moreover, reduced TAGLN2 and ACTB phosphorylations in PFTK1-suppressed Hep3B corresponded to distinct actin depolymerizations and marked inhibition on cell invasion and motility. Given that TAGLN2 is a tumor suppressor whose function has been ascribed in cancer metastasis, we examined if TAGLN2 is an intermediate substrate in the biological path of PFTK1. We showed in PFTK1-suppressed cells that knockdown of TAGLN2 over-rode the inhibitory effect on cell invasion and motility, and a recovery on actin polymerization was evident. Interestingly, we also found that unphosphorylated TAGLN2 in PFTK1-suppressed cells elicited strong actin-binding ability, a mechanism that possibly halts the actin cytoskeleton dynamics. Site-directed mutagenesis of TAGLN2 suggested that PFTK1 regulates the actin-binding affinity of TAGLN2 through the S83 and S163 residues, which if mutated can significantly affect HCC cell motility. Taken together, our data propose a novel, oncogene-tumor suppressor interplay, where oncogenic PFTK1 confers HCC cell motility through inactivating the actin-binding motile suppressing function of TAGLN2 via phosphorylation. Oncogene (2011) 30, 4464-4475; doi: 10.1038/onc.2011.161; published online 16 May 2011	[Leung, W. K. C.; Ching, A. K. K.; Chan, A. W. H.; Mian, H.; To, K-F; Wong, N.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; [Leung, W. K. C.; Ching, A. K. K.; Poon, T. C. W.; Mian, H.; To, K-F; Wong, N.] Chinese Univ Hong Kong, State Key Lab Oncol S China, Shatin, Hong Kong, Peoples R China; [Poon, T. C. W.] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Pokfulam, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong	Wong, N (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.	natwong@cuhk.edu.hk	Wong, Alice/AFJ-4595-2022; Chan, Anthony Wing Hung/HGB-4311-2022; MIAN, HE/AAK-1900-2021; Chan, Anthony/U-7768-2019; Chan, Anthony W.H./N-6719-2016	Wong, Alice/0000-0002-0676-6475; Chan, Anthony Wing Hung/0000-0002-1771-163X; Chan, Anthony/0000-0002-1771-163X; Chan, Anthony W.H./0000-0002-1771-163X; Leung, Wilson/0000-0002-6196-4984	Hong Kong Research Grants Council [CUHK 4/CRF/08, CUHK 4410/06M]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	This work was supported by a Collaborative Research Fund from the Hong Kong Research Grants Council (Ref. No.: CUHK 4/CRF/08) and an Earmarked Grant from the Hong Kong Research Grants Council (Ref. No.: CUHK 4410/06M). We thank AH Bai and NL Wong for technical assistance.	Assinder SJ, 2009, INT J BIOCHEM CELL B, V41, P482, DOI 10.1016/j.biocel.2008.02.011; Baek K, 2008, P NATL ACAD SCI USA, V105, P11748, DOI 10.1073/pnas.0805852105; Fu YP, 2000, J APPL PHYSIOL, V89, P1985, DOI 10.1152/jappl.2000.89.5.1985; Garcia JL, 2003, LEUKEMIA, V17, P2016, DOI 10.1038/sj.leu.2403080; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Katoh H, 2007, GASTROENTEROLOGY, V133, P1475, DOI 10.1053/j.gastro.2007.08.038; KIRSCHNER M, 1992, TRENDS BIOCHEM SCI, V17, P281, DOI 10.1016/0968-0004(92)90435-C; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kubota H, 2009, J BIOL CHEM, V284, P35251, DOI 10.1074/jbc.M109.013565; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Nair RR, 2006, J BIOL CHEM, V281, P26424, DOI 10.1074/jbc.M602703200; Nakao K, 2001, CANCER, V91, P721, DOI 10.1002/1097-0142(20010215)91:4<721::AID-CNCR1057>3.3.CO;2-V; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Pang E, 2002, GENE CHROMOSOME CANC, V33, P150, DOI 10.1002/gcc.1220; Pang EYT, 2007, HEPATOLOGY, V46, P436, DOI 10.1002/hep.21691; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; Poon RTP, 1999, ANN SURG, V229, P216, DOI 10.1097/00000658-199902000-00009; Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Shields JM, 2002, J BIOL CHEM, V277, P9790, DOI 10.1074/jbc.M110086200; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STEWART BW, 2003, WHO WORLD CANC REPOR; Strohmeyer DM, 2004, PROSTATE, V59, P43, DOI 10.1002/pros.20028; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wong N, 2009, INT J CANCER, V124, P644, DOI 10.1002/ijc.23968; Wulfkuhle JD, 2002, CANCER RES, V62, P6740; Xu SG, 2010, J CANCER RES CLIN, V136, P1545, DOI 10.1007/s00432-010-0812-0; Yang T, 2001, GENE, V267, P165, DOI 10.1016/S0378-1119(01)00391-2; Yang ZM, 2007, MOL ENDOCRINOL, V21, P343, DOI 10.1210/me.2006-0104; Zhao L, 2009, MODERN PATHOL, V22, P786, DOI 10.1038/modpathol.2009.29	30	68	73	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	44					4464	4475		10.1038/onc.2011.161	http://dx.doi.org/10.1038/onc.2011.161			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21577206				2022-12-28	WOS:000296733200002
J	Sriram, G; Reichman, C; Tunceroglu, A; Kaushal, N; Saleh, T; Machida, K; Mayer, B; Ge, Q; Li, J; Hornbeck, P; Kalodimos, CG; Birge, RB				Sriram, G.; Reichman, C.; Tunceroglu, A.; Kaushal, N.; Saleh, T.; Machida, K.; Mayer, B.; Ge, Q.; Li, J.; Hornbeck, P.; Kalodimos, C. G.; Birge, R. B.			Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation	ONCOGENE			English	Article						Crk tyrosine phosphorylation; SH2 domains; Abl transactivation	ADAPTER PROTEIN CRK; BREAST-CANCER CELLS; C-ABL; SIGNALING PROTEIN; MALIGNANT FEATURE; STRUCTURAL BASIS; FACTOR C3G; GROWTH; ACTIVATION; BINDING	Here, we report the identification and characterization of a novel tyrosine phosphorylation site in the carboxyterminal Src Homology 3 (SH3) (SH3C) domain of the Crk adaptor protein. Y251 is located in the highly conserved RT loop structure of the SH3C, a region of Crk involved in the allosteric regulation of the Abl kinase. Exploiting kinase assays to show that Y251 is phosphorylated by Abl in vitro, we generated affinity-purified antisera against phosphorylated Y251 in Crk and showed that Abl induces phosphorylation at Y251 in vivo, and that the kinetics of phosphorylation at Y251 and the negative regulatory Y221 site in vitro are similar. Y251 on endogenous Crk was robustly phosphorylated in chronic myelogenous leukemia cell lines and in A431 and MDA-MB-468 cells stimulated with epidermal growth factor. Using streptavidin-biotin pull downs and unbiased high-throughput Src Homology 2 (SH2) profiling approaches, we found that a pY251 phospho-peptide binds specifically to a subset of SH2 domains, including Abl and Arg SH2, and that binding of pY251 to Abl SH2 induces transactivation of Abl 1b. Finally, the Y251F Crk mutant significantly abrogates Abl transactivation in vitro and in vivo. These studies point to a yet unrealized positive regulatory role resulting from tyrosine phosphorylation of Crk, and identify a novel mechanism by which an adaptor protein activates a non-receptor tyrosine kinase by SH2 domain displacement. Oncogene (2011) 30, 4645-4655; doi:10.1038/onc.2011.170; published online 23 May 2011	[Sriram, G.; Reichman, C.; Tunceroglu, A.; Kaushal, N.; Birge, R. B.] UMDNJ New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ USA; [Saleh, T.; Kalodimos, C. G.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ USA; [Machida, K.; Mayer, B.] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet Mol Med, Farmington, CT USA; [Ge, Q.; Li, J.; Hornbeck, P.] Cell Signaling Technol, Danvers, MA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Connecticut	Birge, RB (corresponding author), Univ Med & Dent New Jersey, Sch Med, Dept Biochem & Mol Biol, MSB E647,185 S Orange Ave, Newark, NJ 07103 USA.	birgera@umdnj.edu	Hornbeck, Peter V/K-2226-2017; Kalodimos, Charalampos/Q-9846-2018; Saleh, Tamjeed/M-8698-2016	Hornbeck, Peter V/0000-0002-1126-5149; Kalodimos, Charalampos/0000-0001-6354-2796; Saleh, Tamjeed/0000-0002-7539-7300	NIH [RO1GM080308]; NJCCR [08-1093-CCR-EO]; NATIONAL CANCER INSTITUTE [R01CA082258, R01CA165077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055760, R01GM080308] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NJCCR; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was in part supported by the NIH grant RO1GM080308 to CK and RBB, as well as NJCCR pre-doctoral fellowship 08-1093-CCR-EO to AT. We thank Leszek Kotula, Eric Haura and Khanh Nguyen for helpful discussion, and Neil Devoe for critical comments on the MS.	Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Birge RB, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-13; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Dubielecka PM, 2010, FEBS LETT, V584, P3279, DOI 10.1016/j.febslet.2010.06.029; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Fathers KE, 2010, AM J PATHOL, V176, P446, DOI 10.2353/ajpath.2010.090383; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Johnson KJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007439; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Machida K, 2007, MOL CELL, V26, P899, DOI 10.1016/j.molcel.2007.05.031; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsumoto T, 2000, BIOCHEM BIOPH RES CO, V270, P28, DOI 10.1006/bbrc.2000.2374; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Muralidharan V, 2006, BIOCHEMISTRY-US, V45, P8874, DOI 10.1021/bi060590z; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Park TJ, 2006, MOL CELL BIOL, V26, P6272, DOI 10.1128/MCB.00472-06; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Reichman C, 2005, ONCOGENE, V24, P8187, DOI 10.1038/sj.onc.1208988; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004; Sarkar P, 2011, NAT CHEM BIOL, V7, P51, DOI 10.1038/NCHEMBIO.494; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Wang L, 2007, BIOCHEM BIOPH RES CO, V362, P976, DOI 10.1016/j.bbrc.2007.08.106; Xiong XL, 2008, BBA-MOL CELL RES, V1783, P737, DOI 10.1016/j.bbamcr.2008.01.028; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvara A, 2001, ONCOGENE, V20, P951, DOI 10.1038/sj.onc.1204173	51	13	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	46					4645	4655		10.1038/onc.2011.170	http://dx.doi.org/10.1038/onc.2011.170			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21602891	Green Accepted			2022-12-28	WOS:000297252100004
J	Cheng, JC; Auersperg, N; Leung, PCK				Cheng, J-C; Auersperg, N.; Leung, P. C. K.			Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells	ONCOGENE			English	Article						serous borderline ovarian tumors; p53; ovarian cancer; DNMT1; E-cadherin; methylation	EPITHELIAL-MESENCHYMAL TRANSITION; DE-NOVO METHYLATION; MOLECULE E-CADHERIN; EPIGENETIC REGULATION; SUPPRESSOR GENE; LOW-GRADE; CANCER; CPG; TUMORIGENESIS; PROTEIN	The mechanisms underlying the progression of noninvasive serous borderline ovarian tumors (SBOT) to low-grade invasive carcinomas are poorly understood. We recently showed that inhibition of p53 induces SBOT invasion by activating the PI3K/Akt pathway and transcriptionally repressing E-cadherin. In human cancers, aberrant DNA methylation is a common phenomenon, and it is thought to be involved in the progression from noninvasive to invasive ovarian carcinomas. In this study, we tested the hypothesis that inhibition of p53 downregulates E-cadherin by regulating the methylation of its promoter in SBOT cells. Here, we show that DNA methyltransferase-1 (DNMT1), but not DNMT3a or DNMT3b, was increased in SV40 LT-infected SBOT4 cells, SBOT4-LT and the low-grade invasive serous ovarian carcinoma-derived cell line MPSC1. Treatment with 5-Aza-dC, a DNMT1 inhibitor, restored E-cadherin promoter methylation and expression, and inhibited cell invasion in both invasive SBOT4-LT and MPSC1 cells. Moreover, knockdown of endogenous p53 using siRNA in SBOT3.1 cells induced DNMT1 expression and led to an increase in E-cadherin promoter methylation. Additionally, activation of the PI3K/Akt pathway is required for p53 inhibition-induced DNMT1 expression. The increase in DNMT1 was associated with the inhibition of p53-induced downregulation of E-cadherin and cell invasion. Our findings show an important role for p53 in the progression of SBOT to an invasive carcinoma, and suggest that downregulation of E-cadherin by DNMT1-mediated promoter methylation contributes to this process. Oncogene (2011) 30, 3930-3942; doi:10.1038/onc.2011.117; published online 11 April 2011	[Cheng, J-C; Auersperg, N.; Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3V5, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3V5, Canada.	peleung@interchange.ubc.ca	Cheng, Jung-Chien/T-4258-2019	Cheng, Jung-Chien/0000-0002-5399-9327; Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health Research; National Cancer Institute of Canada; Canadian Cancer Society; Child & Family Research Institute; University of British Columbia	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Child & Family Research Institute; University of British Columbia	This work was supported by grants from the Canadian Institutes of Health Research to PCKL and National Cancer Institute of Canada with funds from the Canadian Cancer Society to NA. PCKL is the recipient of a Child & Family Research Institute Distinguished Investigator Award. JCC is the recipient of four year fellowships for PhD students from University of British Columbia.	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Asadollahi R, 2010, GYNECOL ONCOL, V118, P81, DOI 10.1016/j.ygyno.2010.03.015; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404; Benton G, 2009, FASEB J, V23, P3884, DOI 10.1096/fj.08-128702; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cheng JC, 2011, ONCOGENE, V30, P1020, DOI 10.1038/onc.2010.486; Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Fan H, 2007, EUR J GASTROEN HEPAT, V19, P952, DOI 10.1097/MEG.0b013e3282c3a89e; Gershenson DM, 1998, CANCER, V83, P2157, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Grille SJ, 2003, CANCER RES, V63, P2172; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peterson EJ, 2003, CANCER RES, V63, P6579; Pohl G, 2005, CANCER RES, V65, P1994, DOI 10.1158/0008-5472.CAN-04-3625; Rahnama F, 2006, ENDOCRINOLOGY, V147, P5275, DOI 10.1210/en.2006-0288; Rahnama F, 2009, ENDOCRINOLOGY, V150, P1466, DOI 10.1210/en.2008-1142; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; Sheng SJ, 2009, J CELL PHYSIOL, V218, P451, DOI 10.1002/jcp.21616; Shi HD, 2003, CANCER RES, V63, P2164; Shieh YS, 2005, CANCER-AM CANCER SOC, V104, P1013, DOI 10.1002/cncr.21278; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Sun LD, 2007, CELL SIGNAL, V19, P2255, DOI 10.1016/j.cellsig.2007.06.014; Tam KF, 2007, J CANCER RES CLIN, V133, P331, DOI 10.1007/s00432-006-0178-5; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Vergara D, 2010, CURR CANCER DRUG TAR, V10, P107, DOI 10.2174/156800910790980269; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	53	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	37					3930	3942		10.1038/onc.2011.117	http://dx.doi.org/10.1038/onc.2011.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21478913				2022-12-28	WOS:000294890400003
J	Clem, BF; Clem, AL; Yalcin, A; Goswami, U; Arumugam, S; Telang, S; Trent, JO; Chesney, J				Clem, B. F.; Clem, A. L.; Yalcin, A.; Goswami, U.; Arumugam, S.; Telang, S.; Trent, J. O.; Chesney, J.			A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signaling	ONCOGENE			English	Article						chemotherapy; choline kinase; metabolism; in silico; phosphocholine	BREAST-CANCER-CELLS; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; PROSTATE-CANCER; RAS ACTIVATION; GROWTH-FACTORS; PHOSPHATIDYLCHOLINE; INHIBITORS; RAF-1; P-31	Choline kinase-alpha expression and activity are increased in multiple human neoplasms as a result of growth factor stimulation and activation of cancer-related signaling pathways. The product of choline kinase-alpha, phosphocholine, serves as an essential metabolic reservoir for the production of phosphatidylcholine, the major phospholipid constituent of membranes and substrate for the production of lipid second messengers. Using in silico screening for small molecules that may interact with the choline kinase-alpha substrate binding domain, we identified a novel competitive inhibitor, N-(3,5-dimethylphenyl)-2-[[5-(4-ethylphenyl)-1H-1,2,4-triazol-3-yl] sulfanyl] acetamide (termed CK37) that inhibited purified recombinant human choline kinase-alpha activity, reduced the steady-state concentration of phosphocholine in transformed cells, and selectively suppressed the growth of neoplastic cells relative to normal epithelial cells. Choline kinase-alpha activity is required for the downstream production of phosphatidic acid, a promoter of several Ras signaling pathways. CK37 suppressed mitogen-activated protein kinase and phosphatidylinositol 3-kinase/AKT signaling, disrupted actin cytoskeletal organization, and reduced plasma membrane ruffling. Finally, administration of CK37 significantly decreased tumor growth in a lung tumor xenograft mouse model, suppressed tumor phosphocholine, and diminished activating phosphorylations of extracellular signal-regulated kinase and AKT in vivo. Together, these results further validate choline kinase-alpha as a molecular target for the development of agents that interrupt Ras signaling pathways, and indicate that receptor-based computational screening should facilitate the identification of new classes of choline kinase-alpha inhibitors. Oncogene (2011) 30, 3370-3380; doi:10.1038/onc.2011.51; published online 21 March 2011	[Clem, B. F.; Clem, A. L.; Yalcin, A.; Goswami, U.; Arumugam, S.; Telang, S.; Trent, J. O.; Chesney, J.] Univ Louisville, Dept Med, Louisville, KY 40202 USA; [Clem, B. F.; Yalcin, A.; Telang, S.; Trent, J. O.; Chesney, J.] Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; [Clem, B. F.; Clem, A. L.; Yalcin, A.; Goswami, U.; Telang, S.; Trent, J. O.; Chesney, J.] Univ Louisville, Mol Targets Grp, Louisville, KY 40202 USA; [Arumugam, S.; Trent, J. O.] Univ Louisville, Struct Biol Program, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; [Yalcin, A.] Uludag Univ, Dept Biochem, Sch Vet Med, Bursa, Turkey	University of Louisville; University of Louisville; University of Louisville; University of Louisville; Uludag University	Chesney, J (corresponding author), Univ Louisville, Dept Med, 505 S Hancock St,CTRB,Room 424, Louisville, KY 40202 USA.	jotrent01@louisville.edu; jason.chesney@louisville.edu	Yalcin, Abdullah/ABI-4164-2020; Yalcin, Abdullah/AAA-6938-2022	Yalcin, Abdullah/0000-0001-8519-8375; trent, John/0000-0002-7346-4231	Brown Foundation; NCCRR [1P20 RR18733]; James Graham Brown Cancer Center; Ky Lung Cancer Research Program; National Cancer Institute [2R56CA116428-0509]; NATIONAL CANCER INSTITUTE [R01CA116428, R56CA116428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018733] Funding Source: NIH RePORTER	Brown Foundation; NCCRR; James Graham Brown Cancer Center; Ky Lung Cancer Research Program; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We acknowledge Deanna Siow and Binks Wattenburg for assistance with the thin layer chromatography protocol, Erin Brock for assisting with the confocal microscopy experiments, Bennet Jenson for histopathology assistance, and Andrew Lane for NMR interpretation. We also thank Dr Arnon Lavie for providing the Delta 49N-hCK alpha 2 plasmid for the expression of recombinant choline kinase. NMR experiments were carried out at the James Graham Brown Cancer Center NMR facility, supported in part by the Brown Foundation and NCCRR Grant 1P20 RR18733. This work was supported by institutional funds from the James Graham Brown Cancer Center and by grants from the Ky Lung Cancer Research Program (JC & BFC) and the National Cancer Institute (JC: 2R56CA116428-0509).	Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Chua BT, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-131; Chung TW, 2000, CELL SIGNAL, V12, P279, DOI 10.1016/S0898-6568(00)00065-6; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; de Molina AR, 2004, CANCER LETT, V206, P137, DOI 10.1016/j.canlet.2003.08.031; DEGANI H, 1986, RADIOLOGY, V161, P53, DOI 10.1148/radiology.161.1.3020609; Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fan TWM, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-79; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2008, CANCER RES, V68, P172, DOI 10.1158/0008-5472.CAN-07-2678; Glunde K, 2007, LANCET ONCOL, V8, P855, DOI 10.1016/S1470-2045(07)70289-9; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Iorio E, 2005, CANCER RES, V65, P9369, DOI 10.1158/0008-5472.CAN-05-1146; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; Jain AN, 2007, J COMPUT AID MOL DES, V21, P281, DOI 10.1007/s10822-007-9114-2; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; KO KWS, 1986, J BIOL CHEM, V261, P7846; Li GP, 1997, J BIOL CHEM, V272, P10337; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; McCubrey JA, 2007, ADV ENZYME REGUL, V47, P64, DOI 10.1016/j.advenzreg.2006.12.013; NEEMAN M, 1989, P NATL ACAD SCI USA, V86, P5585, DOI 10.1073/pnas.86.14.5585; ONODERA K, 1986, JPN J CANCER RES, V77, P1201; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 2002, PHARMACOL THERAPEUT, V94, P35, DOI 10.1016/S0163-7258(02)00170-5; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Scales SJ, 1999, NATURE, V401, P123, DOI 10.1038/43582; TAETLE R, 1987, CANCER TREAT REP, V71, P297; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; Wu GS, 2008, J BIOL CHEM, V283, P1456, DOI 10.1074/jbc.M708766200; Yalcin A, 2010, ONCOGENE, V29, P139, DOI 10.1038/onc.2009.317; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	54	54	60	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3370	3380		10.1038/onc.2011.51	http://dx.doi.org/10.1038/onc.2011.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21423211	Green Accepted			2022-12-28	WOS:000293215700007
J	Duque-Afonso, J; Yalcin, A; Berg, T; Abdelkarim, M; Heidenreich, O; Lubbert, M				Duque-Afonso, J.; Yalcin, A.; Berg, T.; Abdelkarim, M.; Heidenreich, O.; Luebbert, M.			The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO	ONCOGENE			English	Article						chromosomal translocations; acute myeloid leukemia; adaptor molecule; HDAC inhibitor; epigenetic regulation	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; T-CELL-ACTIVATION; T(8/21) FUSION PROTEIN; NEGATIVE REGULATION; VALPROIC ACID; DNA METHYLATION; C/EBP-ALPHA; DIFFERENTIATION; EXPRESSION	The chromosomal translocation (8; 21) fuses the hematopoietic transcription factor AML1 (RUNX1) with ETO (RUNX1T1, MTG8), resulting in the leukemia-specific chimeric protein AML1/ETO. This fusion protein has been implicated in epigenetic silencing, recruiting histone deacetylases (HDACs) and DNA methyltransferases to target promoters. Previously, we have identified a novel in vivo AML1/ETO target gene, LAT2 (NTAL/LAB/WBSCR5), which is involved in FceR I, c-Kit, B-cell and T-cell receptor signalling. We have now addressed the molecular mechanisms of AML1/ETO-mediated LAT2 repression. In Kasumi-1 cells, where AML1/ETO bound to the LAT2 gene, small interfering RNA (siRNA)mediated AML1/ETO depletion caused upregulation of LAT2, suggesting a possible direct mechanism of repression. Expression of AML1/ETO was associated with a decrease in acetylation of histones H3, H3K9 and H4, and an increase in H3K9 and H3K27 trimethylation. The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4. The combination of entinostat and decitabine increased acetylation of histones H3 and H4, as well as LAT2 mRNA expression, in an at least additive fashion. In conclusion, several repressive histone modifications mark the LAT2 gene in the presence of AML1/ETO, and LAT2 gene derepression is achieved by pharmacological inhibition of HDACs. Oncogene (2011) 30, 3062-3072; doi: 10.1038/onc.2011.32; published online 16 May 2011	[Duque-Afonso, J.; Yalcin, A.; Berg, T.; Abdelkarim, M.; Luebbert, M.] Univ Freiburg, Univ Med Ctr Freiburg, Dept Med, Div Hematol Oncol, D-79106 Freiburg, Germany; [Heidenreich, O.] Newcastle Univ, No Inst Canc Res, Dept Mol Paediat Oncol, Newcastle Upon Tyne, Tyne & Wear, England; [Berg, T.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of Freiburg; Newcastle University - UK; British Columbia Cancer Agency	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Dept Med, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	michael.luebbert@uniklinik-freiburg.de	Heidenreich, Olaf/AAP-5045-2021; Berg, Tobias/AAT-5094-2021	Heidenreich, Olaf/0000-0001-5404-6483; Berg, Tobias/0000-0003-2668-0449	LaCaixa-DAAD [314, A/05/29785]; Department of Hematology/Oncology of the University of Freiburg; German Jose-Carreras Foundation [R 06/40f]; DFG [SPP 1463, Lu 429/7-1]	LaCaixa-DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); Department of Hematology/Oncology of the University of Freiburg; German Jose-Carreras Foundation; DFG(German Research Foundation (DFG))	We would like to thank Constanze Bonifer (Leeds, UK) and Manfred Jung (Freiburg, Germany) for critically reviewing the manuscript, Eric Metzger and Roland Schule (Freiburg) for many helpful comments during establishment of the chromatin immunoprecipitation assay, and Harald Binder (Freiburg) for statistical support. Bernhard Kleine performed the bisulfite sequencing analysis of the LAT2 promoter. We are grateful to Joost Martens and Henk Stunnenberg (Nijmegen, The Netherlands) for sharing unpublished data. J Duque-Afonso was funded by a grant from LaCaixa-DAAD (ref. 314, A/05/29785) and the fellowship program of the Department of Hematology/Oncology of the University of Freiburg. This work was supported by the German Jose-Carreras Foundation (R 06/40f). ML is supported by the DFG (SPP 1463, Lu 429/7-1).	Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Berg T, 2007, LEUKEMIA RES, V31, P497, DOI 10.1016/j.leukres.2006.08.008; Berg T, 2008, HAEMATOL-HEMATOL J, V93, P1728, DOI 10.3324/haematol.13044; Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Claus R, 2006, J LEUKOCYTE BIOL, V80, P1462, DOI 10.1189/jlb.0106005; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dunne J, 2006, ONCOGENE, V25, P6067, DOI 10.1038/sj.onc.1209638; DUQUEAFONSO J, 2011, BR J HAEMATOL; ERICKSON P, 1992, BLOOD, V80, P1825; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fazi F, 2007, BLOOD, V109, P4432, DOI 10.1182/blood-2006-09-045781; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Hauswald S, 2009, CLIN CANCER RES, V15, P3705, DOI 10.1158/1078-0432.CCR-08-2048; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Hoogenkamp M, 2009, BLOOD, V114, P299, DOI 10.1182/blood-2008-11-191890; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Lubbert M, 2003, LEUKEMIA, V17, P1762, DOI 10.1038/sj.leu.2403045; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Maslak P, 2006, LEUKEMIA, V20, P212, DOI 10.1038/sj.leu.2404050; Nightingale KP, 2007, J BIOL CHEM, V282, P4408, DOI 10.1074/jbc.M606773200; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paul TA, 2010, BLOOD, V115, P3098, DOI 10.1182/blood-2009-07-233858; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Pober BR, 2010, NEW ENGL J MED, V362, P239, DOI 10.1056/NEJMra0903074; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Stork B, 2004, IMMUNITY, V21, P681, DOI 10.1016/j.immuni.2004.09.007; Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Volna P, 2004, J EXP MED, V200, P1001, DOI 10.1084/jem.20041213; Wang Y, 2005, MOL CELL BIOL, V25, P4455, DOI 10.1128/MCB.25.11.4455-4465.2005; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760; Zhu MH, 2004, J EXP MED, V200, P991, DOI 10.1084/jem.20041223; Zhu MH, 2006, IMMUNITY, V25, P757, DOI 10.1016/j.immuni.2006.08.025	51	36	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3062	3072		10.1038/onc.2011.32	http://dx.doi.org/10.1038/onc.2011.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21577204				2022-12-28	WOS:000292510100006
J	Renault, VM; Thekkat, PU; Hoang, KL; White, JL; Brady, CA; Broz, DK; Venturelli, OS; Johnson, TM; Oskoui, PR; Xuan, Z; Santo, EE; Zhang, MQ; Vogel, H; Attardi, LD; Brunet, A				Renault, V. M.; Thekkat, P. U.; Hoang, K. L.; White, J. L.; Brady, C. A.; Broz, D. Kenzelmann; Venturelli, O. S.; Johnson, T. M.; Oskoui, P. R.; Xuan, Z.; Santo, E. E.; Zhang, M. Q.; Vogel, H.; Attardi, L. D.; Brunet, A.			The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor	ONCOGENE			English	Article						FoxO transcription factors; p53; tumor suppression; cancer; aging; longevity	TRANSCRIPTION FACTOR FOXO3A; PROMOTES CELL-SURVIVAL; WILD-TYPE P53; LIFE-SPAN; P53-DEPENDENT APOPTOSIS; CALORIC RESTRICTION; COLORECTAL-CANCER; DIRECT ACTIVATION; DNA-DAMAGE; EXPRESSION	FoxO transcription factors have a conserved role in longevity, and act as tissue-specific tumor suppressors in mammals. Several nodes of interaction have been identified between FoxO transcription factors and p53, a major tumor suppressor in humans and mice. However, the extent and importance of the functional interaction between FoxO and p53 have not been fully explored. Here, we show that p53 regulates the expression of FoxO3, one of the four mammalian FoxO genes, in response to DNA damaging agents in both mouse embryonic fibroblasts and thymocytes. We find that p53 transactivates FoxO3 in cells by binding to a site in the second intron of the FoxO3 gene, a genomic region recently found to be associated with extreme longevity in humans. While FoxO3 is not necessary for p53-dependent cell cycle arrest, FoxO3 appears to modulate p53-dependent apoptosis. We also find that FoxO3 loss does not interact with p53 loss for tumor development in vivo, although the tumor spectrum of p53-deficient mice appears to be affected by FoxO3 loss. Our findings indicate that FoxO3 is a p53 target gene, and suggest that FoxO3 and p53 are part of a regulatory transcriptional network that may have an important role during aging and cancer. Oncogene (2011) 30, 3207-3221; doi:10.1038/onc.2011.35; published online 21 March 2011	[Renault, V. M.; Thekkat, P. U.; Hoang, K. L.; White, J. L.; Venturelli, O. S.; Oskoui, P. R.; Attardi, L. D.; Brunet, A.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Brady, C. A.; Broz, D. Kenzelmann; Johnson, T. M.; Attardi, L. D.] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; [Brady, C. A.; Johnson, T. M.; Attardi, L. D.; Brunet, A.] Stanford Univ, Canc Biol Grad Program, Stanford, CA 94305 USA; [Xuan, Z.; Zhang, M. Q.] Univ Texas Dallas, Ctr Syst Biol, Dept Mol & Cell Biol, Richardson, TX 75083 USA; [Santo, E. E.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; [Zhang, M. Q.] Tsinghua Univ, TNLIS, MOE, Key Lab Bioinformat, Beijing 100084, Peoples R China; [Zhang, M. Q.] Tsinghua Univ, TNLIS, Bioinformat Div, Beijing 100084, Peoples R China; [Vogel, H.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; University of Texas System; University of Texas Dallas; University of Amsterdam; Academic Medical Center Amsterdam; Tsinghua University; Tsinghua University; Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, 300 Pasteur Dr, Stanford, CA 94305 USA.	anne.brunet@stanford.edu		Vogel, Otto Hannes/0000-0002-0960-3508; Xuan, Zhenyu/0000-0001-9344-8493	NIH [R01 AG026648, R01 HG001696]; McCormick Award for Women in Science; Stanford University; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG026648] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McCormick Award for Women in Science; Stanford University(Stanford University); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Ron DePinho for his generous gift of the FoxO3 <SUP>/</SUP> mice. We thank Julien Sage for critical discussion, reading of the manuscript, help with tumor analysis and for taking the pictures for Figure 8d. We thank Jamie Brett for reading the manuscript. We thank Pauline Chu (Comparative Medicine Department, Stanford Medical School) for her help in processing the histopathology samples. We thank Dan Calnan for participating in earlier aspects of this work. This work was supported by NIH R01 AG026648 and a McCormick Award for Women in Science (AB). ZX, EES and MQZ were supported partly by NIH R01 HG001696. VMR received support from the Dean's Fellowship at Stanford University. Author contributions: VMR designed, performed and analyzed the lifespan and tumor spectrum of compound FoxO3/p53 mice (Figure 8). PUT completed Figure 1b, Figure 5b, Figure 6b, Figure 6e, Figure 7a and helped with Figure 2 and Figure 6d. KLH completed Figure 5d, Figure 5e, Figure 6a, Figure 6b and Figure 6c. JLW completed Figure 2, Figure 6d, and helped with Figure 3 and Figure 7b. CAB completed Figure 3 and Figure 7b. DKB completed Figure 5c. OSV initiated this project as her Honors Thesis and completed Figure 1a. TMJ completed Figure 4b. PRO completed Figure 6f. ZX and EES identified p53 binding sites in FoxO3 regulatory regions (Figure 5a) under the supervision of MQZ. HV performed the tumor identification (Figure 8b). LDA supervised CAB, DKB and TMJ, and provided ideas. AB supervised VMR, PUT, KLH, JLW, OSV and PRO. The manuscript was written by AB, VMR and OSV, with input from LDA.	Anselmi CV, 2009, REJUV RES, V12, P95, DOI 10.1089/rej.2008.0827; Arum O, 2007, J GERONTOL A-BIOL, V62, P951, DOI 10.1093/gerona/62.9.951; Attardi LD, 2000, GENE DEV, V14, P704; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; de la Torre-Ubieta L, 2010, GENE DEV, V24, P799, DOI 10.1101/gad.1880510; DENG G, 1994, CANCER RES, V54, P499; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Essaghir A, 2009, J BIOL CHEM, V284, P10334, DOI 10.1074/jbc.M808848200; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Flachsbart F, 2009, P NATL ACAD SCI USA, V106, P2700, DOI 10.1073/pnas.0809594106; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Furuyama T, 2002, MICROSC RES TECHNIQ, V59, P331, DOI 10.1002/jemt.10213; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs SBR, 2007, CELL DEATH DIFFER, V14, P1374, DOI 10.1038/sj.cdd.4402128; Johnson TM, 2008, P NATL ACAD SCI USA, V105, P1215, DOI 10.1073/pnas.0706764105; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kurinna S, 2010, HEPATOLOGY, V52, P1023, DOI 10.1002/hep.23746; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LOCOCO F, 1993, BLOOD, V82, P2289; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Marusyk A, 2007, MOL CELL BIOL, V27, P5336, DOI 10.1128/MCB.01316-06; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miyaguchi Y, 2009, CELL BIOL INT, V33, P853, DOI 10.1016/j.cellbi.2009.04.017; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nowak K, 2007, BBA-GENE STRUCT EXPR, V1769, P244, DOI 10.1016/j.bbaexp.2007.04.001; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Pawlikowska L, 2009, AGING CELL, V8, P460, DOI 10.1111/j.1474-9726.2009.00493.x; QUINLAN DC, 1992, CANCER RES, V52, P4828; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sharpless NE, 2002, CANCER RES, V62, P2761; Shen J, 2010, EXP GERONTOL, V45, P97, DOI 10.1016/j.exger.2009.10.009; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang F, 2008, J MOL BIOL, V384, P590, DOI 10.1016/j.jmb.2008.09.025; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhao RB, 2000, GENE DEV, V14, P981	94	93	94	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	29					3207	3221		10.1038/onc.2011.35	http://dx.doi.org/10.1038/onc.2011.35			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21423206	Green Accepted			2022-12-28	WOS:000293006800001
J	Switzer, CH; Cheng, RYS; Vitek, TM; Christensen, DJ; Wink, DA; Vitek, MP				Switzer, C. H.; Cheng, R. Y. S.; Vitek, T. M.; Christensen, D. J.; Wink, D. A.; Vitek, M. P.			Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy	ONCOGENE			English	Article						SET/I(2)PP2A; PP2A; Akt; nm23-H1; Rac1	PROTEIN PHOSPHATASE 2A; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE UNDIFFERENTIATED LEUKEMIA; TUMOR-SUPPRESSOR; APOLIPOPROTEIN-E; GENE-EXPRESSION; CARCINOMA CELLS; BLAST CRISIS; HUMAN BREAST; C-MYC	The SET oncoprotein participates in cancer progression by affecting multiple cellular processes, inhibiting the tumor suppressor protein phosphatase 2A (PP2A), and inhibiting the metastasis suppressor nm23-H1. On the basis of these multiple activities, we hypothesized that targeted inhibition of SET would have multiple discrete and measurable effects on cancer cells. Here, the effects of inhibiting SET oncoprotein function on intracellular signaling and proliferation of human cancer cell lines was investigated. We observed the effects of COG112, a novel SET interacting peptide, on PP2A activity, Akt signaling, nm23-H1 activity and cellular migration/invasion in human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cancer cell lines. We found that COG112 interacted with SET protein and inhibited the association between SET and PP2A catalytic subunit (PP2A-c) and nm23-H1. The interaction between COG112 and SET caused PP2A phosphatase and nm23-H1 exonuclease activities to increase. COG112-mediated increases in PP2A activity resulted in the inhibition of Akt signaling and cellular proliferation. Additionally, COG112 inhibited SET association with Ras-related C-3 botulinum toxin substrate 1 (Rac1), leading to decreased cellular migration and invasion. COG112 treatment releases the SET-mediated inhibition of the tumor suppressor PP2A, as well as the metastasis suppressor nm23-H1. These results establish SET as a novel molecular target and that the inhibition of SET may have beneficial effects in cancer chemotherapy. Oncogene (2011) 30, 2504-2513; doi: 10.1038/onc.2010.622; published online 7 February 2011	[Switzer, C. H.; Cheng, R. Y. S.; Vitek, T. M.; Wink, D. A.] NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; [Christensen, D. J.; Vitek, M. P.] Cognosci Inc, Res Triangle Pk, NC 27709 USA; [Vitek, M. P.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University	Wink, DA (corresponding author), NCI, Radiat Biol Branch, NIH, Bldg 10,Room B3-B35, Bethesda, MD 20892 USA.	wink@mail.nih.gov; mikevitek@cognosci.com	Switzer, Christopher/D-9203-2013; Cheng, Robert/E-9799-2013	Cheng, Robert/0000-0003-0287-6439; Azad, Mahan/0000-0002-8633-3513; Vitek, Michael/0000-0001-8140-8048; Wink, David/0000-0002-5652-7480	Intramural NIH HHS [ZIA SC007281-17, ZIA BC010899-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC007281, ZIABC010899] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2008, CANCER METAST REV, V27, P147, DOI 10.1007/s10555-008-9128-9; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; CHRISTENSEN D, 2011, J IMMUNOL IN PRESS, V186; Compagnone NA, 2000, MOL ENDOCRINOL, V14, P875, DOI 10.1210/me.14.6.875; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Freije JMP, 1998, BIOCHEM SOC SYMP, P261; Fukukawa C, 2000, CANCER LETT, V161, P89, DOI 10.1016/S0304-3835(00)00598-X; Gotz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925-4773(00)00267-7; Guichard C, 2006, CARCINOGENESIS, V27, P1812, DOI 10.1093/carcin/bgl009; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; LoPiccolo J, 2007, ANTI-CANCER DRUG, V18, P861; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; Madeira A, 2005, FASEB J, V19, P1905, DOI 10.1096/fj.05-3839fje; Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Ozbek U, 2007, AM J PATHOL, V171, P654, DOI 10.2353/ajpath.2007.060934; Palmieri D, 2005, JNCI-J NATL CANCER I, V97, P632, DOI 10.1093/jnci/dji111; Perrotti D, 2006, BRIT J CANCER, V95, P775, DOI 10.1038/sj.bjc.6603317; Perrotti D, 2008, CANCER METAST REV, V27, P159, DOI 10.1007/s10555-008-9119-x; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Samanta AK, 2009, ONCOGENE, V28, P1669, DOI 10.1038/onc.2009.7; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; STEEG PS, 1988, CANCER RES, V48, P6550; Stewart TJ, 2008, ONCOGENE, V27, P5894, DOI 10.1038/onc.2008.268; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Switzer CH, 2009, ONCOGENE, V28, P3837, DOI 10.1038/onc.2009.244; ten Klooster JP, 2007, EMBO J, V26, P336, DOI 10.1038/sj.emboj.7601518; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Zhang QB, 2011, INT J CANCER, V128, P40, DOI 10.1002/ijc.25307; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu F, 2008, Curr Mol Pharmacol, V1, P213	49	128	131	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2504	2513		10.1038/onc.2010.622	http://dx.doi.org/10.1038/onc.2010.622			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21297667	Green Accepted			2022-12-28	WOS:000291198400002
J	Cha, B; Kim, W; Kim, YK; Hwang, BN; Park, SY; Yoon, JW; Park, WS; Cho, JW; Bedford, MT; Jho, EH				Cha, B.; Kim, W.; Kim, Y. K.; Hwang, B. N.; Park, S. Y.; Yoon, J. W.; Park, W. S.; Cho, J. W.; Bedford, M. T.; Jho, E-h			Methylation by protein arginine methyltransferase 1 increases stability of Axin, a negative regulator of Wnt signaling	ONCOGENE			English	Article						Axin; PRMT1; Wnt; protein methylation; GSK3 beta	BETA-CATENIN; COLORECTAL-CANCER; PATHWAY; PHOSPHORYLATION; UBIQUITINATION; ACTIVATION; COMPLEX; BINDING; PRMT1; INHIBITION	Axin, a negative regulator of Wnt signaling, is a key scaffold protein for the beta-catenin destruction complex. It has been previously shown that multiple post-translational modification enzymes regulate the level of Axin. Here, we provide evidence that protein arginine methyltransferase 1 (PRMT1) directly interacts with and methylates the 378th arginine residue of Axin both in vitro and in vivo. We found that the transient expression of PRMT1 led to an increased level of Axin and that knockdown of endogenous PRMT1 by short hairpin RNA reduced the level of Axin. These results suggest that methylation by PRMT1 enhanced the stability of Axin. Methylation of Axin by PRMT1 also seemingly enhanced the interaction between Axin and glycogen synthase kinase 3 beta, leading to decreased ubiquitination of Axin. Consistent with the role of PRMT1 in the regulation of Axin, knockdown of PRMT1 enhanced the level of cytoplasmic beta-catenin as well as beta-catenin-dependent transcription activity. In summary, we show that the methylation of Axin occurred in vivo and controlled the stability of Axin. Therefore, methylation of Axin by PRMT1 may serve as a finely tuned regulation mechanism for Wnt/beta-catenin signaling. Oncogene (2011) 30, 2379-2389; doi: 10.1038/onc.2010.610; published online 17 January 2011	[Cha, B.; Kim, W.; Hwang, B. N.; Jho, E-h] Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; [Kim, Y. K.; Bedford, M. T.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX USA; [Park, S. Y.; Cho, J. W.] Yonsei Univ, Dept Biol, Seoul 120749, South Korea; [Park, S. Y.; Cho, J. W.] Yonsei Univ, Dept Integrated OMICS Biomed Sci, World Class Univ Program, Seoul 120749, South Korea; [Yoon, J. W.; Park, W. S.] Catholic Univ Korea, Dept Pathol, Coll Med, Seoul, South Korea	University of Seoul; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Yonsei University; Catholic University of Korea	Jho, EH (corresponding author), Univ Seoul, Dept Life Sci, 90 Jeonnong Dong, Seoul 130743, South Korea.	ej70@uos.ac.kr	Bedford, Mark T/E-7856-2011	Jho, Eek-hoon/0000-0003-2414-6234	Korea Research Foundation [C00339]; Ministry for Health and Welfare, Republic of Korea [1020240]; Brain Korea 21 program; Seoul Science Fellowship	Korea Research Foundation(National Research Foundation of Korea); Ministry for Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); Seoul Science Fellowship	This work was supported by grants from the Korea Research Foundation (C00339) and the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (1020240) to E Jho B Cha, W Kim and B Hwang were supported by the Brain Korea 21 program. B Cha and W Kim were recipients of the Seoul Science Fellowship.	Bedford MT, 2007, J CELL SCI, V120, P4243, DOI 10.1242/jcs.019885; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BOISVERT FM, 2005, SCI STKE, pRE2, DOI DOI 10.1126/STKE.2712005RE2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200; Gupta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002658; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jernigan KK, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000647; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Jung H, 2009, EXP MOL MED, V41, P695, DOI 10.3858/emm.2009.41.10.076; Kim MJ, 2008, FASEB J, V22, P3785, DOI 10.1096/fj.08-113910; Kim S, 2010, J BIOL CHEM, V285, P36420, DOI 10.1074/jbc.M110.137471; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Lyu J, 2008, DEV CELL, V15, P773, DOI 10.1016/j.devcel.2008.10.004; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nicholson TB, 2009, PHARMACOL RES, V60, P466, DOI 10.1016/j.phrs.2009.07.006; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Polakis P, 2000, GENE DEV, V14, P1837; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shimizu Y, 2002, GENE CHROMOSOME CANC, V33, P73, DOI 10.1002/gcc.1226; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yu ZB, 2009, MOL CELL BIOL, V29, P2982, DOI 10.1128/MCB.00042-09; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608	51	53	53	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2379	2389		10.1038/onc.2010.610	http://dx.doi.org/10.1038/onc.2010.610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21242974				2022-12-28	WOS:000290789200009
J	Luo, Y; Zhou, H; Liu, L; Shen, T; Chen, W; Xu, B; Han, X; Zhang, F; Scott, RS; Alexander, JS; Alam, A; Huang, S				Luo, Y.; Zhou, H.; Liu, L.; Shen, T.; Chen, W.; Xu, B.; Han, X.; Zhang, F.; Scott, R. S.; Alexander, J. S.; Alam, A.; Huang, S.			The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway	ONCOGENE			English	Article						ciclopirox; lymphatic endothelial cells; tube formation; VEGFR-3; ERK	TUMOR LYMPHANGIOGENESIS; CANDIDA-ALBICANS; VEGF RECEPTOR-3; GROWTH; METASTASIS; PROMOTES; PHOSPHORYLATION; ANGIOGENESIS; LYMPHEDEMA; ACTIVATION	Ciclopirox olamine (CPX), an off-patent antifungal agent used to treat mycoses of skin and nails, has recently been demonstrated to be a potential anticancer agent. However, the underlying mechanism is not well understood. Here, for the first time, we show that CPX inhibited lymphangiogenesis in an in vitro model (tube formation). This effect was, in part, associated with inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3) expression, as overexpression of VEGFR-3 conferred partial resistance to CPX inhibitory effect on tube formation in lymphatic endothelial cells (LECs), whereas downregulation of VEGFR-3 mimicked the effect of CPX, blocking the tube formation. Further study revealed that CPX did not alter mRNA level, but inhibited protein synthesis and promoted protein degradation of VEGFR-3. In addition, we found that CPX inhibited phosphorylation of the extracellular signal-related kinase 1/2 (ERK1/2), a downstream effector of VEGFR-3. Overexpression of VEGFR-3 attenuated CPX inhibition of ERK1/2 phosphorylation, whereas downregulation of VEGFR-3 inhibited ERK1/2 phosphorylation in LECs. Ectopic expression of constitutively active mitogen-activated protein kinase kinase 1 (MKK1) resulted in activation of ERK1/2 and partially prevented CPX inhibition of LEC tube formation. The results suggest that CPX inhibits LEC tube formation at least, in part, through inhibiting VEGFR-3-mediated ERK signaling pathway. Oncogene (2011) 30, 2098-2107; doi:10.1038/onc.2010.590; published online 10 January 2011	[Luo, Y.; Zhou, H.; Liu, L.; Shen, T.; Chen, W.; Xu, B.; Han, X.; Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Luo, Y.] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Zhang, F.; Scott, R. S.] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; [Alam, A.] Sanofi Aventis R&D, Toulouse, France; [Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Sichuan University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Sanofi-Aventis; Sanofi France; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Huang, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Xu, Baoshan/H-6435-2011; luo, yan/I-5305-2015; Chen, Wenxing/GSI-9910-2022; Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072; Xu, Baoshan/0000-0001-8902-1243; Chen, Wenxing/0000-0003-4571-7622	NIH [CA115414]; Louisiana Board of Regents [LEQSF (2006-09)-RD-A-18]; American Cancer Society [RSG-08-135-01-CNE]; NATIONAL CANCER INSTITUTE [R01CA115414] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Board of Regents; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in part, by the NIH grant CA115414 (SH), Louisiana Board of Regents grant (LEQSF (2006-09)-RD-A-18) (SH), and American Cancer Society grant RSG-08-135-01-CNE (SH). We thank Dr Natalie Ahn for providing MKK1 constructs.	Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Ando T., 2005, Lymphatic Research and Biology, V3, P105, DOI 10.1089/lrb.2005.3.105; Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515; Cueni LN, 2006, J INVEST DERMATOL, V126, P2167, DOI 10.1038/sj.jid.5700464; DITTMAR W, 1973, ARZNEIMITTEL-FORSCH, V23, P670; Dixelius J, 2003, J BIOL CHEM, V278, P40973, DOI 10.1074/jbc.M304499200; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; Fang Changge, 2009, Lymphatic Research and Biology, V7, P189, DOI 10.1089/lrb.2009.0033; Fournier E, 1999, ONCOGENE, V18, P507, DOI 10.1038/sj.onc.1202315; Fritz-Six KL, 2008, J CLIN INVEST, V118, P40, DOI 10.1172/JCI33302; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Jin DH, 2008, CARDIOVASC RES, V80, P339, DOI 10.1093/cvr/cvn228; JUE SG, 1985, DRUGS, V29, P330, DOI 10.2165/00003495-198529040-00002; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Karpanen T, 2001, CANCER RES, V61, P1786; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Karpanen T, 2006, AM J PATHOL, V169, P708, DOI 10.2353/ajpath.2006.051200; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje; Liu L, 2008, ONCOGENE, V27, P4998, DOI 10.1038/onc.2008.137; Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691; Liu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010578; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Ming J, 2009, PATHOLOGY, V41, P118, DOI 10.1080/00313020802579268; Niewerth M, 2003, ANTIMICROB AGENTS CH, V47, P1805, DOI 10.1128/AAC.47.6.1805-1817.2003; Nisato RE, 2004, AM J PATHOL, V165, P11, DOI 10.1016/S0002-9440(10)63271-3; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Ruggeri B, 2003, CANCER RES, V63, P5978; Salameh A, 2005, BLOOD, V106, P3423, DOI 10.1182/blood-2005-04-1388; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Sigle HC, 2005, J ANTIMICROB CHEMOTH, V55, P663, DOI 10.1093/jac/dki089; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Sunavala-Dossabhoy G, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-1; Wissmann C, 2006, CLIN CANCER RES, V12, P6865, DOI 10.1158/1078-0432.CCR-06-1800; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255	43	27	27	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	18					2098	2107		10.1038/onc.2010.590	http://dx.doi.org/10.1038/onc.2010.590			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217783	Green Accepted			2022-12-28	WOS:000290249600002
J	Hagner, PR; Mazan-Mamczarz, K; Dai, B; Balzer, EM; Corl, S; Martin, SS; Zhao, XF; Gartenhaus, RB				Hagner, P. R.; Mazan-Mamczarz, K.; Dai, B.; Balzer, E. M.; Corl, S.; Martin, S. S.; Zhao, X. F.; Gartenhaus, R. B.			Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5 ' terminal oligopyrimidine tract	ONCOGENE			English	Article						RPS6; diffuse large B-cell lymphoma; 5 ' terminal oligopyrimidine; p53	TRANSLATIONAL CONTROL; P53 EXPRESSION; PHOSPHORYLATION; GENE; PATHWAY; CANCER; TRANSDUCTION; ACTIVATION; INDUCTION; CARCINOMA	The molecular mechanism(s) linking tumorigenesis and morphological alterations in the nucleolus are presently coming into focus. The nucleolus is the cellular organelle in which the formation of ribosomal subunits occurs. Ribosomal biogenesis occurs through the transcription of ribosomal RNA (rRNA), rRNA processing and production of ribosomal proteins. An error in any of these processes may lead to deregulated cellular translation, evident in multiple cancers and 'ribosomopathies'. Deregulated protein synthesis may be achieved through the overexpression of ribosomal proteins as seen in primary leukemic blasts with elevated levels of ribosomal proteins S11 and S14. In this study, we demonstrate that ribosomal protein S6 (RPS6) is highly expressed in primary diffuse large B-cell lymphoma (DLBCL) samples. Genetic modulation of RPS6 protein levels with specifically targeted short hairpin RNA (shRNA) lentiviruses led to a decrease in the actively proliferating population of cells compared with control shRNA. Low-dose rapamycin treatments have been shown to affect the translation of 5' terminal oligopyrimidine (5' TOP) tract mRNA, which encodes the translational machinery, implicating RPS6 in 5' TOP translation. Recently, it was shown that disruption of 40S ribosomal biogenesis through specific small inhibitory RNA knockdown of RPS6 defined RPS6 as a critical regulator of 5' TOP translation. For the first time, we show that RPS6 associates with multiple mRNAs containing a 5' TOP tract. These findings expand our understanding of the mechanism(s) involved in ribosomal biogenesis and deregulated protein synthesis in DLBCL. Oncogene (2011) 30, 1531-1541; doi: 10.1038/onc.2010.533; published online 22 November 2010	[Hagner, P. R.; Mazan-Mamczarz, K.; Dai, B.; Balzer, E. M.; Corl, S.; Martin, S. S.; Zhao, X. F.; Gartenhaus, R. B.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, Baltimore, MD 21201 USA; [Hagner, P. R.] Harvard Univ, Sch Med, Dept Biochem & Mol Pharmacol, Boston, MA USA; [Gartenhaus, R. B.] Vet Adm Med Ctr, Baltimore, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gartenhaus, RB (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, 9-011 BRB,655 W Baltimore St,22 S Greene St, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu			Department of Veterans Affairs; National Institutes of Health [R01AA017972]; NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017972] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The WT-RPS16-hGH and Cm5-RPS16-hGH constructs that contain the coding region of hGH fused to the first 29 nucleotides of the RPS16 5' untranslated region (WT-RPS16-hGH) or to the mutant in which five of the eight pyrimidines within the 5' TOP have been mutated to purines (Cm5) were kindly provided by the laboratories of Dr Oded Meyuhas and Dr George Thomas, This work was funded in part by a Merit Review Award from the Department of Veterans Affairs (RBG) and R01AA017972 from the National Institutes of Health (RBG).	Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; Badis G, 2004, MOL CELL, V15, P5, DOI 10.1016/j.molcel.2004.06.028; Dai BJ, 2006, CANCER RES, V66, P8058, DOI 10.1158/0008-5472.CAN-06-1364; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Espinosa L, 1997, BBA-GENE STRUCT EXPR, V1354, P58, DOI 10.1016/S0167-4781(97)00124-3; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; FERRARI S, 1990, CANCER RES, V50, P5825; Fewell SW, 1999, MOL CELL BIOL, V19, P826; FRANCO R, 1990, J BIOL CHEM, V265, P4321; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Ganapathi KA, 2008, BRIT J HAEMATOL, V141, P376, DOI 10.1111/j.1365-2141.2008.07095.x; GROSS T, 1988, CURR GENET, V13, P57, DOI 10.1007/BF00365757; Iadevaia V, 2008, RNA, V14, P1730, DOI 10.1261/rna.1037108; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kapasi P, 2007, MOL CELL, V25, P113, DOI 10.1016/j.molcel.2006.11.028; Koduru PRK, 1997, BLOOD, V90, P4078, DOI 10.1182/blood.V90.10.4078; Kondoh N, 2001, ANTICANCER RES, V21, P2429; Law PTW, 1996, BBA-GENE STRUCT EXPR, V1305, P105, DOI 10.1016/0167-4781(95)00224-3; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lerner RS, 2003, RNA, V9, P1123, DOI 10.1261/rna.5610403; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mitrovich QM, 2000, GENE DEV, V14, P2173, DOI 10.1101/gad.819900; Nakamura JL, 2008, CANCER RES, V68, P6516, DOI 10.1158/0008-5472.CAN-07-6188; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Perry RP, 2007, GENE, V401, P1, DOI 10.1016/j.gene.2007.07.007; Pianese G., 1896, BEITR PATHOL ANAT AL, V142, P1; Reinert LS, 2006, CANCER RES, V66, P8994, DOI 10.1158/0008-5472.CAN-06-1999; ROMMENS JM, 1995, GENOMICS, V28, P530, DOI 10.1006/geno.1995.1185; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005618; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vladimirov SN, 1996, EUR J BIOCHEM, V239, P144, DOI 10.1111/j.1432-1033.1996.0144u.x; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302	47	37	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1531	1541		10.1038/onc.2010.533	http://dx.doi.org/10.1038/onc.2010.533			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21102526	Green Accepted			2022-12-28	WOS:000288998300004
J	He, Y; Northey, JJ; Primeau, M; Machado, RD; Trembath, R; Siegel, PM; Lamarche-Vane, N				He, Y.; Northey, J. J.; Primeau, M.; Machado, R. D.; Trembath, R.; Siegel, P. M.; Lamarche-Vane, N.			CdGAP is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion	ONCOGENE			English	Article						Rho GTPases; RhoGAPs; TGF beta; breast cancer; cell migration and invasion	GTPASE-ACTIVATING PROTEIN; MAMMARY EPITHELIAL-CELLS; RHO-GTPASES; MESENCHYMAL TRANSITION; PHOSPHORYLATES CDGAP; TUMOR-SUPPRESSOR; FOCAL ADHESION; FAMILY; TUMORIGENESIS; INDUCTION	RhoA, Rac1 and Cdc42, the best-characterized members of the Rho family of small GTPases, are critical regulators of many cellular activities. Cdc42 GTPase-activating protein (CdGAP) is a serine-and proline-rich RhoGAP protein showing GAP activity against both Cdc42 and Rac1 but not RhoA. CdGAP is phosphorylated downstream of the MEK-ERK (extracellular signal-regulated kinase) pathway in response to serum and is required for normal cell spreading and polarized lamellipodia formation. In this study, we found that CdGAP protein and mRNA levels are highly increased in mammary tumor explants expressing an activated Neu/ErbB-2 (Neu-NT) receptor. In response to transforming growth factor-beta (TGF beta) stimulation, Neu-NT-expressing mammary tumor explants demonstrate a clear induction in cell motility and invasion. We show that downregulation of CdGAP expression by small interfering RNA abrogates the ability of TGF beta to induce cell motility and invasion of Neu-NT-expressing mammary tumor explants. However, it has no effect on TGF beta-mediated cell adhesion on type 1 collagen and fibronectin. Interestingly, protein expression of E-Cadherin is highly increased in Neu-NT-expressing mammary tumor explants depleted of CdGAP. In addition, complete loss of E-Cadherin expression is not observed in CdGAP-depleted cells during TGF beta-mediated epithelial to mesenchymal transition. Downregulation of the CdGAP expression also decreases cell proliferation of Neu-NT-expressing mammary tumor explants independently of TGF beta. Rescue analysis using re-expression of various CdGAP deletion-mutant proteins revealed that the proline-rich domain (PRD) but not the GAP domain of CdGAP is essential to mediate TGF beta-induced cell motility and invasion. Finally, we found that TGF beta induces the expression and phosphorylation of CdGAP in mammary epithelial NMuMG cells. Taken together, these studies identify CdGAP as a novel molecular target in TGF beta signaling and implicate CdGAP as an essential component in the synergistic interaction between TGF beta and Neu/ErbB-2 signaling pathways in breast cancer cells. Oncogene (2011) 30, 1032-1045; doi:10.1038/onc.2010.477; published online 1 November 2010	[He, Y.; Primeau, M.; Lamarche-Vane, N.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; [Northey, J. J.; Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 2B2, Canada; [Northey, J. J.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 2B2, Canada; [Machado, R. D.; Trembath, R.] Kings Coll London, Dept Med & Mol Genet, Sch Med, London WC2R 2LS, England; [Trembath, R.] Guys Hosp, Dept Clin Studies, London SE1 9RT, England	McGill University; McGill University; McGill University; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Lamarche-Vane, N (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3460 Univ St, Montreal, PQ H3A 2B2, Canada.	nathalie.lamarche@mcgill.ca	Northey, Jason/AAX-6365-2021; Machado, Rajiv D./AAD-7813-2019	Machado, Rajiv D./0000-0001-9247-0744; Northey, Jason/0000-0003-3115-2560; Trembath, Richard/0000-0003-0550-3400	Canadian Institute of Health Research (CIHR) [MOP-84449]; Cancer Research Society; Research Institute of the McGill University Health Centre; National Institute for Health Research [NF-SI-0507-10379] Funding Source: researchfish	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Research Institute of the McGill University Health Centre; National Institute for Health Research(National Institute for Health Research (NIHR))	This research was supported by grants from Canadian Institute of Health Research (CIHR) MOP-84449 to NL-V and the Cancer Research Society to PMS. JJN is supported by a studentship from the Research Institute of the McGill University Health Centre. MP was a recipient of a CIHR Canada Graduate scholarship. NL-V is a recipient of a FRSQ chercheur-boursier senior. PMS is a research scientist of the Canadian Cancer Society. RDM is a British Heart Foundation Intermediate Research Fellow (BHF-FS/07/036).	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Danek EI, 2007, J BIOL CHEM, V282, P3624, DOI 10.1074/jbc.M610073200; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Jiang W, 2008, J BIOL CHEM, V283, P20978, DOI 10.1074/jbc.M802588200; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kim T, 2009, CANCER METAST REV, V28, P77, DOI 10.1007/s10555-008-9167-2; LALONDE D, 2006, CURR BIOL, V16, P1; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nagaraj NS, 2010, EXPERT OPIN INV DRUG, V19, P77, DOI 10.1517/13543780903382609; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pardali E, 2009, FRONT BIOSCI-LANDMRK, V14, P4848, DOI 10.2741/3573; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHGATE L, N ENGL J MED UNPUB; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Tcherkezian J, 2006, BIOL CELL, V98, P445, DOI 10.1042/BC20050101; Titus B, 2005, CRIT REV EUKAR GENE, V15, P103, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.20; Tomar A, 2009, J CELL SCI, V122, P1852, DOI 10.1242/jcs.046870; Tybulewicz VLJ, 2009, NAT REV IMMUNOL, V9, P630, DOI 10.1038/nri2606; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333	45	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1032	1045		10.1038/onc.2010.477	http://dx.doi.org/10.1038/onc.2010.477			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042277				2022-12-28	WOS:000287964100003
J	Yang, L; Wang, H; Kornblau, SM; Graber, DA; Zhang, N; Matthews, JA; Wang, M; Weber, DM; Thomas, SK; Shah, JJ; Zhang, L; Lu, G; Zhao, M; Muddasani, R; Yoo, SY; Baggerly, KA; Orlowski, RZ				Yang, L.; Wang, H.; Kornblau, S. M.; Graber, D. A.; Zhang, N.; Matthews, J. A.; Wang, M.; Weber, D. M.; Thomas, S. K.; Shah, J. J.; Zhang, L.; Lu, G.; Zhao, M.; Muddasani, R.; Yoo, S-Y; Baggerly, K. A.; Orlowski, R. Z.			Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma	ONCOGENE			English	Article						ZKSCAN3; cyclin D2; multiple myeloma; transcription regulation; pathogenesis	ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW; CANCER PROGRESSION; PRECLINICAL MODELS; C-MAF; CELL; TRANSLOCATION; VEGF; DYSREGULATION; OVEREXPRESSION	Dysregulation of cyclin D2 contributes to the pathogenesis of multiple myeloma, and can occur through translocations that activate MAF/MAFB or MMSET/FGFR3. However, cyclin D2 induction can also be seen in the absence of such translocations, such as in patients with hyperdiploid disease, through unknown mechanisms. In UniGene cluster data-mining and ECgene analysis, we found that zinc-finger with KRAB and SCAN domains 3 (ZKSCAN3), a novel transcription factor, is overrepresented in this malignancy, and three consensus ZKSCAN3 binding sites were found in the cyclin D2 promoter. Analysis of a panel of myeloma cell lines, primary patient samples and datasets from Oncomine and the Multiple Myeloma Genomics Portal (MMGP) revealed expression of ZKSCAN3 messenger RNA (mRNA) in a majority of samples. Studies of cell lines by western blotting, and of primary tissue microarrays by immunohistochemistry, showed ZKSCAN3 protein expression in a majority, and in a manner that paralleled messenger levels in cell lines. ZKSCAN3 overexpression was associated with increased gene copy number or genomic DNA gain/amplification in a subset based on analysis of data from the MMGP, and from fluorescence in situ hybridization studies of cell lines and primary samples. Overexpression of ZKSCAN3 induced cyclin D2 promoter activity in a MAF/MAFB-independent manner, and to an extent that was influenced by the number of consensus ZKSCAN3 binding sites. Moreover, ZKSCAN3 protein expression correlated with cyclin D2 levels in cell lines and primary samples, and its overexpression induced cyclin D2. Conversely, ZKSCAN3 suppression using small hairpin RNAs (shRNAs) reduced cyclin D2 levels, and, importantly, inhibited myeloma cell line proliferation. Finally, ZKSCAN3 was noted to specifically bind to oligonucleotides representing sequences from the cyclin D2 promoter, and to the endogenous promoter itself in myeloma cells. Taken together, the data support the conclusion that ZKSCAN3 induction represents a mechanism by which myeloma cells can induce cyclin D2 dysregulation, and contribute to disease pathogenesis. Oncogene (2011) 30, 1329-1340; doi:10.1038/onc.2010.515; published online 8 November 2010	[Yang, L.] Soochow Univ, Cyrus Tang Hematol Ctr, SIP, Suzhou 215123, Jiangsu, Peoples R China; [Yang, L.; Wang, H.; Matthews, J. A.; Wang, M.; Weber, D. M.; Thomas, S. K.; Shah, J. J.; Orlowski, R. Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Wang, H.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Kornblau, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Kornblau, S. M.; Graber, D. A.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Zhang, N.; Zhang, L.; Yoo, S-Y; Baggerly, K. A.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Lu, G.; Zhao, M.; Muddasani, R.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Orlowski, R. Z.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med, Houston, TX 77030 USA	Soochow University - China; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yang, L (corresponding author), Soochow Univ, Cyrus Tang Hematol Ctr, SIP, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.	yanglin@suda.edu.cn; rorlowsk@mdanderson.org		Muddasani, Ramya/0000-0002-2651-8276; Orlowski, Robert/0000-0002-5723-4129	Leukemia & Lymphoma Society [6096-07]; National Cancer Institute [R01 CA102278]; NATIONAL CANCER INSTITUTE [P50CA142509, P30CA016672, R01CA102278] Funding Source: NIH RePORTER	Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Dr Douglas Boyd for his contributions to the studies of the role of ZKSCAN3 in colon cancer. RZO, a Leukemia & Lymphoma Society Scholar in Clinical Research, would like to acknowledge support from the Leukemia & Lymphoma Society (6096-07) and the National Cancer Institute (R01 CA102278).	Arora T, 1998, J BIOL CHEM, V273, P11799, DOI 10.1074/jbc.273.19.11799; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Chang H, 2006, BRIT J HAEMATOL, V135, P486, DOI 10.1111/j.1365-2141.2006.06325.x; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; FERTI A, 1984, CANCER GENET CYTOGEN, V12, P247, DOI 10.1016/0165-4608(84)90036-0; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; Gutierrez NC, 2004, BLOOD, V104, P2661, DOI 10.1182/blood-2004-04-1319; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood-2007-01-065888; Kumar S, 2003, LEUKEMIA, V17, P2025, DOI 10.1038/sj.leu.2403084; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Largo C, 2007, HAEMATOLOGICA, V92, P795, DOI 10.3324/haematol.11052; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Lu G, 2010, CANCER GENET CYTOGEN, V196, P56, DOI 10.1016/j.cancergencyto.2009.08.021; Markovic O, 2008, MED ONCOL, V25, P451, DOI 10.1007/s12032-008-9066-y; Perez-Simon JA, 1998, BLOOD, V91, P3366, DOI 10.1182/blood.V91.9.3366.3366_3366_3371; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Ria R, 2004, THROMB HAEMOSTASIS, V92, P1438, DOI 10.1160/TH04-06-0334; Santos GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Voorhees PM, 2007, CLIN CANCER RES, V13, P6469, DOI 10.1158/1078-0432.CCR-07-1293; Yang L, 2008, CANCER RES, V68, P4321, DOI 10.1158/0008-5472.CAN-08-0407; Yang L, 2008, J BIOL CHEM, V283, P35295, DOI 10.1074/jbc.M806965200	29	38	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	11					1329	1340		10.1038/onc.2010.515	http://dx.doi.org/10.1038/onc.2010.515			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057542	Green Accepted			2022-12-28	WOS:000288492100007
J	Kumar, M; Lu, Z; Takwi, AAL; Chen, W; Callander, NS; Ramos, KS; Young, KH; Li, Y				Kumar, M.; Lu, Z.; Takwi, A. A. L.; Chen, W.; Callander, N. S.; Ramos, K. S.; Young, K. H.; Li, Y.			Negative regulation of the tumor suppressor p53 gene by microRNAs	ONCOGENE			English	Article						microRNA; p53; senescence; apoptosis; cell cycle arrest; multiple myeloma	MIR-34A; TARGET; IDENTIFICATION; RESTORATION; ACTIVATION; APOPTOSIS; PATHWAY; ARREST; TP53	The tumor suppressor p53, encoded by the TP53 gene, is recognized as the guardian of the human genome because it regulates many downstream genes to exercise its function in cell cycle and cell death. Recent studies have revealed that several microRNAs (miRNAs) are important components of the p53 tumor suppressor network with miR-125b and miR-504 directly targeting TP53. In this study, we use a screening method to identify that two miRNAs (miR-25 and miR-30d) directly target the 3'UTR of TP53 to downregulate p53 protein levels and reduce the expression of genes that are transcriptionally activated by p53. Correspondingly, both miR-25 and miR-30d adversely affect apoptotic cell death, cell cycle arrest and cellular senescence. Inhibition of either miR-25 or miR-30d expression increases endogenous p53 expression and elevates cellular apoptosis in several cell lines, including one from multiple myeloma that has little TP53 mutations. Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d. Oncogene (2011) 30, 843-853; doi:10.1038/onc.2010.457; published online 11 October 2010	[Kumar, M.; Lu, Z.; Takwi, A. A. L.; Chen, W.; Ramos, K. S.; Li, Y.] Univ Louisville, Sch Med, Ctr Genet & Mol Med, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; [Callander, N. S.; Young, K. H.] Univ Wisconsin, Sch Med & Publ Hlth, Paul P Carbone Comprehens Canc Ctr, Dept Pathol & Lab Med Oncol, Madison, WI USA	University of Louisville; University of Wisconsin System; University of Wisconsin Madison	Li, Y (corresponding author), Univ Louisville, Sch Med, Ctr Genet & Mol Med, Dept Biochem & Mol Biol, 319 Abraham Flexner Way,Room 513-A Bldg, Louisville, KY 40202 USA.	yong.li@louisville.edu	Kumar, Munish/Z-4106-2019; Xie, Huangming/B-2260-2012	Callander, Natalie/0000-0002-6975-1086	NIEHS/NIH [P30ES014443]; NCI/NIH [R01CA138688, P20CA103697, 1RC1CA146299]; NCRR/NIH [P20 RR024489]; University of Wisconsin Paul Carbone Comprehensive Cancer Center; Gundersen Medical Foundation; University of Wisconsin; NATIONAL CANCER INSTITUTE [RC1CA146299, P20CA103697, R01CA138688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES014443] Funding Source: NIH RePORTER	NIEHS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); University of Wisconsin Paul Carbone Comprehensive Cancer Center; Gundersen Medical Foundation; University of Wisconsin; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Y L is supported by the Director's Biomarker Award from the Center for Environmental Genomics and Integrative Biology, funded by NIEHS/NIH (P30ES014443), Kentucky Lung Cancer Research Program, NCI/NIH (R01CA138688) and NCRR/NIH (P20 RR024489). K H Y is supported by the University of Wisconsin Paul Carbone Comprehensive Cancer Center Award, the Gundersen Medical Foundation Award, the University of Wisconsin Pathology R & D Fund and by NCI/NIH (P20CA103697 and 1RC1CA146299). We are grateful to the critical reviews from Drs Korise E Rasmusson and Nancy C Martin.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chng WJ, 2007, LEUKEMIA, V21, P582, DOI 10.1038/sj.leu.2404524; Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Prendergast NJ, 1996, J UROLOGY, V155, P1685, DOI 10.1016/S0022-5347(01)66165-2; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; VOELLER HJ, 1994, J UROLOGY, V151, P492; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Xiong W, 2008, BLOOD, V112, P4235, DOI 10.1182/blood-2007-10-119123; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	39	209	219	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					843	853		10.1038/onc.2010.457	http://dx.doi.org/10.1038/onc.2010.457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20935678	Green Accepted			2022-12-28	WOS:000287444600008
J	Savelyeva, I; Dobbelstein, M				Savelyeva, I.; Dobbelstein, M.			Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A	ONCOGENE			English	Article						adenovirus; E1A; E1B; p53; Sp1; p300	TUMOR-SUPPRESSOR P53; CELL-CYCLE; PROTEIN; ONYX-015; TYPE-5; TRANSCRIPTION; REPLICATION; PROMOTER; P300/CBP; BINDING	Wild-type adenovirus type 5 eliminates p53 through the E1B-55 kDa and E4-34 kDa gene products. Deletion or mutation of E1B-55 kDa has long been thought to confer p53-selective replication of oncolytic viruses. We show here that infection with E1B-defective adenovirus mutants induces massive accumulation of p53, without obvious defects in p53 localization, phosphorylation, conformation and oligomerization. Nonetheless, p53 completely failed to induce its target genes in this scenario, for example, p21/CDKN1A, Mdm2 and PUMA. Two regions of the E1A gene products independently contributed to the suppression of p21 transcription. Depending on the E1A conserved region 3, E1B-defective adenovirus impaired the ability of the transcription factor Sp1 to bind the p21 promoter. Moreover, the amino terminal region of E1A, binding the acetyl transferases p300 and CREB-binding protein, blocked p53 K382 acetylation in infected cells. Mutating either of these E1A regions, in addition to E1B, partially restored p21 mRNA levels. Our findings argue that adenovirus attenuates p53-mediated p21 induction, through at least two E1B-independent mechanisms. Other virus species and cancer cells may employ analogous strategies to impair p53 activity. Oncogene (2011) 30, 865-875; doi:10.1038/onc.2010.461; published online 11 October 2010	[Savelyeva, I.; Dobbelstein, M.] Univ Gottingen, Gottingen Ctr Mol Biosci, Dept Mol Oncol, D-37077 Gottingen, Lower Saxony, Germany; [Savelyeva, I.; Dobbelstein, M.] Univ So Denmark, Inst Med Biol, Ctr Med Biotechnol, Odense C, Denmark	University of Gottingen; University of Southern Denmark	Dobbelstein, M (corresponding author), Univ Gottingen, Gottingen Ctr Mol Biosci, Dept Mol Oncol, Ernst Caspari Haus,Justus von Liebig Weg 11, D-37077 Gottingen, Lower Saxony, Germany.	mdobbel@uni-goettingen.de		Dobbelstein, Matthias/0000-0001-5052-3967	German Cancer Aid/Dr Mildred Scheel Stiftung; EU; German Research Foundation (DFG); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society; Novonordisk fonden	German Cancer Aid/Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); EU(European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society(Danish Cancer Society); Novonordisk fonden(Novo Nordisk Foundation)	We thank JS Mymryk, RJA Grand, X Zhang and G Ketner for viruses, K Roemer for plasmids, AJ Levine for antibodies, OG Opitz for cells, C Hippel and A Dickmanns for excellent technical assistance, and S Johnsen for the help with ChIP experiments. The work was supported by the German Cancer Aid/Dr Mildred Scheel Stiftung, the EU 6th Framework Program (Integrated Project Active p53), the German Research Foundation (DFG), the Wilhelm Sander Stiftung, the Statens Sundhedsvidenskabelige Forskningsrad of Denmark, the Danish Cancer Society, and the Novonordisk fonden.	Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Beckerman R, 2009, GENE DEV, V23, P1364, DOI 10.1101/gad.1795709; Bernat A, 2003, ONCOGENE, V22, P7871, DOI 10.1038/sj.onc.1206896; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; CARLOCK LR, 1981, J VIROL, V40, P657, DOI 10.1128/JVI.40.3.657-664.1981; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Ferreon JC, 2009, P NATL ACAD SCI USA, V106, P13260, DOI 10.1073/pnas.0906770106; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Harada H, 2003, MOL CANCER RES, V1, P729; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hsu CH, 2004, EMBO J, V23, P2269, DOI 10.1038/sj.emboj.7600239; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Koch P, 2001, CANCER RES, V61, P5941; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Wang XY, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-44; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wong KS, 2005, J BIOL CHEM, V280, P9390, DOI 10.1074/jbc.M408643200; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	49	15	18	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					865	875		10.1038/onc.2010.461	http://dx.doi.org/10.1038/onc.2010.461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20935676				2022-12-28	WOS:000287444600010
J	Zhan, Y; Modi, N; Stewart, AM; Hieronimus, RI; Liu, J; Gutmann, DH; Chadee, DN				Zhan, Y.; Modi, N.; Stewart, A. M.; Hieronimus, R. I.; Liu, J.; Gutmann, D. H.; Chadee, D. N.			Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer	ONCOGENE			English	Article						MLK3; NF2; MAPK; B-Raf; Cdc42	NF2 TUMOR-SUPPRESSOR; MEDIATES CONTACT INHIBITION; TYPE-2 GENE-PRODUCT; N-TERMINAL KINASE; CELL-PROLIFERATION; B-RAF; ACTIVATION LOOP; NIH 3T3-CELLS; SCHWANN-CELLS; MERLIN	The Neurofibromatosis-2 (NF2) tumor suppressor merlin negatively regulates cell proliferation in numerous cell types. We have previously shown that the NF2 protein (merlin/schwannomin) associates with mixed lineage kinase 3 (MLK3), a mitogen-activated protein kinase (MAPK) kinase kinase that is required for the proliferation of normal and neoplastic cells. In this study, we show that merlin inhibits MLK3 activity, as well as the activation of its downstream effectors, B-Raf, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). The ability of merlin to regulate MLK3 activity requires a direct association between MLK3 and residues in the C-terminal region of merlin. Merlin integrates Rho GTPase family signaling with MAPK activity by inhibiting the binding between MLK3 and its upstream activator, Cdc42. Furthermore, we demonstrate that MLK3 is required for merlin-mediated suppression of cell proliferation and invasion. Collectively, these results establish merlin as a potent inhibitor of MLK3, ERK and JNK activation in cancer, and provide a mechanistic link between deregulated MAPK and Rho GTPase signaling in NF2 growth control. Oncogene (2011) 30, 781-789; doi:10.1038/onc.2010.453; published online 4 October 2010	[Zhan, Y.; Modi, N.; Stewart, A. M.; Hieronimus, R. I.; Chadee, D. N.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; [Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	University System of Ohio; University of Toledo; University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)	Chadee, DN (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	deborah.chadee@utoledo.edu	ZHAN, YU/P-4025-2014	Gutmann, David/0000-0002-3127-5045	National Institutes of Health [1 R15 CA132006-01]; American Cancer Society (Ohio Division); NATIONAL CANCER INSTITUTE [R15CA132006] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society (Ohio Division)(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J Kyriakis for the FLAG-Cdc42 constructs and Dr D Lim for HEI193 cells. This work was supported by National Institutes of Health Grant 1 R15 CA132006-01 and by an American Cancer Society (Ohio Division) grant (to D.N.C.).	Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chadee DN, 2004, CELL CYCLE, V3, P1227, DOI 10.4161/cc.3.10.1187; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Du Y, 2005, J BIOL CHEM, V280, P42984, DOI 10.1074/jbc.M502671200; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 2001, HUM MOL GENET, V10, P825, DOI 10.1093/hmg/10.8.825; Hartkamp J, 1999, CANCER RES, V59, P2195; Hung G, 2002, INT J ONCOL, V20, P475; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee JY, 2006, ONCOGENE, V25, P1143, DOI 10.1038/sj.onc.1209150; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; LUTCHMAN M, 1995, CANCER RES, V55, P2270; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Ramesh V, 2004, NAT REV NEUROSCI, V5, P462, DOI 10.1038/nrn1407; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Rennefahrt U, 2004, CANCER LETT, V215, P113, DOI 10.1016/j.canlet.2004.05.015; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Velho S, 2010, HUM MOL GENET, V19, P697, DOI 10.1093/hmg/ddp536; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200	46	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					781	789		10.1038/onc.2010.453	http://dx.doi.org/10.1038/onc.2010.453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20890305	Green Accepted			2022-12-28	WOS:000287444600003
J	Sengupta, S; Mantha, AK; Mitra, S; Bhakat, KK				Sengupta, S.; Mantha, A. K.; Mitra, S.; Bhakat, K. K.			Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1	ONCOGENE			English	Article						APE1; acetylation; YB-1/p300; RNA pol II; MDR1	BASE EXCISION-REPAIR; DNA-BINDING ACTIVITY; KINASE-C-ALPHA; APURINIC/APYRIMIDINIC ENDONUCLEASE; OXIDATIVE STRESS; P-GLYCOPROTEIN; HUMAN AP-ENDONUCLEASE-1; ANTICANCER AGENTS; ALTERED EXPRESSION; ELECTRON-TRANSFER	The overexpression of human apurinic/apyrimidinic (AP) endonuclease 1 (APE1/Ref-1), a key enzyme in the DNA base excision repair (BER) pathway, is often associated with tumor cell resistance to various anticancer drugs. In this study, we examined the molecular basis of transcriptional regulatory (nonrepair) function of APE1 in promoting resistance to certain types of drugs. We have recently shown that APE1 stably interacts with Y-box-binding protein 1 (YB-1), and acts as its coactivator for the expression of multidrug resistance gene MDR1, thereby causing drug resistance. In this study, we show, to the best of our knowledge, for the first time that APE1 is stably associated with the basic transcription factor RNA polymerase II (RNA pol II) and the coactivator p300 on the endogenous MDR1 promoter. The depletion of APE1 significantly reduces YB-1-p300 recruitment to the promoter, resulting in reduced RNA pol II loading. Drug-induced APE1 acetylation, which is mediated by p300, enhances formation of acetylated APE1 (AcAPE1)-YB-1-p300 complex on the MDR1 promoter. Enhanced recruitment of this complex increases MDR1 promoter-dependent luciferase activity and its endogenous expression. Using APE1-downregulated cells and cells overexpressing wild-type APE1 or its nonacetylable mutant, we have demonstrated that the loss of APE1's acetylation impaired MDR1 activation and sensitizes the cells to cisplatin or etoposide. We have thus established the basis for APE1's acetylation-dependent regulatory function in inducing MDR1-mediated drug resistance. Oncogene (2011) 30, 482-493; doi: 10.1038/onc.2010.435; published online 20 September 2010	[Sengupta, S.; Mantha, A. K.; Mitra, S.; Bhakat, K. K.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Mitra, S.; Bhakat, K. K.] Univ Texas Med Branch, Sealy Ctr Mol Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Bhakat, KK (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 6-136 Med Res Bldg, Galveston, TX 77555 USA.	kkbhakat@utmb.edu	Sengupta, Shiladitya/L-5951-2015; Mantha, Anil/AAM-5035-2021; Bhakat, Kishor/C-8072-2012	Sengupta, Shiladitya/0000-0001-9558-2741	 [RO1 ESO8457];  [RO1 CA53791];  [P50 ES66076]; NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008457] Funding Source: NIH RePORTER	; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the help of Dr Gianluca Tell, University of Udine, Italy for the APE1 siRNA construct, Larry J Bellot, University of Texas Medical Branch, Galveston and Dr Ranajay Chattopadhyay, University of Virginia, Charlottesville in this study. This study was supported by Grants: RO1 ESO8457, RO1 CA53791 and P50 ES66076 to SM.	AHMAD S, 1993, MOL PHARMACOL, V43, P858; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; Ambudkar SV, 2005, TRENDS PHARMACOL SCI, V26, P385, DOI 10.1016/j.tips.2005.06.001; Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; Bapat A, 2009, ANTIOXID REDOX SIGN, V11, P651, DOI [10.1089/ars.2008.2218, 10.1089/ARS.2008.2218]; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Bhakat KK, 2006, MOL CELL BIOL, V26, P1654, DOI 10.1128/MCB.26.5.1654-1665.2006; Bhakat KK, 2003, METHOD ENZYMOL, V371, P292; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Bhakat KK, 2000, J BIOL CHEM, V275, P34197, DOI 10.1074/jbc.M005447200; Bhattacharyya A, 2009, GASTROENTEROLOGY, V136, P2258, DOI 10.1053/j.gastro.2009.02.014; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Bobola MS, 2005, CLIN CANCER RES, V11, P7405, DOI 10.1158/1078-0432.CCR-05-1068; Busso CS, 2009, ONCOGENE, V28, P1616, DOI 10.1038/onc.2009.5; Chattopadhyay R, 2008, MOL CELL BIOL, V28, P7066, DOI 10.1128/MCB.00244-08; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Curtis CD, 2009, MOL ENDOCRINOL, V23, P1346, DOI 10.1210/me.2009-0093; Das S, 2007, J BIOL CHEM, V282, P28474, DOI 10.1074/jbc.M704672200; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fan JS, 2005, FREE RADICAL BIO MED, V38, P1121, DOI 10.1016/j.freeradbiomed.2005.01.012; Fantini D, 2008, FREE RADICAL RES, V42, P20, DOI 10.1080/10715760701765616; Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Germann UA, 1998, CYTOTECHNOLOGY, V27, P31, DOI 10.1023/A:1008023629269; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jiang YL, 2008, CANCER RES, V68, P6425, DOI 10.1158/0008-5472.CAN-08-1173; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kaina B, 2002, INT J CLIN PHARM TH, V40, P354; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kelley MR, 2001, CLIN CANCER RES, V7, P824; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; KOHNO K, 1994, J BIOL CHEM, V269, P20503; Kovacic P, 2000, CURR PHARM DESIGN, V6, P277, DOI 10.2174/1381612003401046; Kovacic P, 2007, MED HYPOTHESES, V69, P510, DOI 10.1016/j.mehy.2006.08.046; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Mantha AK, 2008, J MOL BIOL, V379, P28, DOI 10.1016/j.jmb.2008.03.052; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McNeill DR, 2009, MOL CANCER RES, V7, P897, DOI 10.1158/1541-7786.MCR-08-0519; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Okamura H, 2004, INT J ONCOL, V25, P1031; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; Ordway JM, 2003, MOL CELL BIOL, V23, P4257, DOI 10.1128/MCB.23.12.4257-4266.2003; Pajic M, 2009, CANCER RES, V69, P6396, DOI 10.1158/0008-5472.CAN-09-0041; Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Robertson KA, 2001, CANCER RES, V61, P2220; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Vascotto C, 2009, PROTEOMICS, V9, P1058, DOI 10.1002/pmic.200800638; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; Wang D, 2004, MOL CANCER THER, V3, P679; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Xu Y, 1997, ANTICANCER RES, V17, P3713; Yamamori T, 2010, NUCLEIC ACIDS RES, V38, P832, DOI 10.1093/nar/gkp1039; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	73	95	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	4					482	493		10.1038/onc.2010.435	http://dx.doi.org/10.1038/onc.2010.435			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856196	Green Accepted			2022-12-28	WOS:000286621600010
J	Li, CG; Nyman, JE; Braithwaite, AW; Eccles, MR				Li, C. G.; Nyman, J. E.; Braithwaite, A. W.; Eccles, M. R.			PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein	ONCOGENE			English	Article						cell cycle; E2F1; PAX8; RB; senescence	UBIQUITIN-INDEPENDENT DEGRADATION; RETINOBLASTOMA PROTEIN; SUPPRESSOR PROTEIN; PROTEASOME PATHWAY; GENE-EXPRESSION; BINDING-SITES; THYROID-GLAND; WILMS-TUMORS; CYCLE; PRB	The retinoblastoma protein (RB)-E2F1 pathway has a central role in regulating the cell cycle. Several PAX proteins (tissue-specific developmental regulators), including PAX8, interact with the RB protein, and thus regulate the cell cycle directly or indirectly. Here, we report that PAX8 expression is frequent in renal cell carcinoma, bladder, ovarian and thyroid cancer cell lines, and that silencing of PAX8 in cancer cell lines leads to a striking reduction in the expression of E2F1 and its target genes, as well as a proteasome-dependent destabilization of RB protein, with the RB1 mRNA level remaining unaffected. Cancer cells expressing PAX8 undergo a G(1)/S arrest and eventually senesce following PAX8 silencing. We demonstrate that PAX8 transcriptionally regulates the E2F1 promoter directly, and E2F1 transcription is enhanced after RB depletion. RB is recruited to the PAX8-binding site, and is involved in PAX8-mediated E2F1 transcription in cancer cells. Therefore, our results suggest that, in cancer, frequent and persistent expression of PAX8 is required for cell growth control through transcriptional activation of E2F1 expression and upregulation of the RB-E2F1 pathway. Oncogene (2011) 30, 4824-4834; doi: 10.1038/onc.2011.190; published online 23 May 2011	[Li, C. G.; Nyman, J. E.; Braithwaite, A. W.; Eccles, M. R.] Univ Otago, Dept Pathol, Dunedin Sch Med, Dunedin 9054, Otago, New Zealand; [Braithwaite, A. W.] Univ Sydney, Childrens Med Res Inst, Cell Transformat Unit, Sydney, NSW 2006, Australia	University of Otago; Children's Medical Research Institute - Australia; University of Sydney	Eccles, MR (corresponding author), Univ Otago, Dept Pathol, Dunedin Sch Med, POB 913,Great King St, Dunedin 9054, Otago, New Zealand.	michael.eccles@otago.ac.nz			New Zealand Institute for Cancer Research Trust (Otago); CMRI (Sydney); Health Research Council; University of Otago; Dunedin School of Medicine; Health Research Council of New Zealand; University of Otago Faculty of Medicine Trust	New Zealand Institute for Cancer Research Trust (Otago); CMRI (Sydney); Health Research Council; University of Otago; Dunedin School of Medicine; Health Research Council of New Zealand(Health Research Council of New Zealand); University of Otago Faculty of Medicine Trust	MRE and AWB are supported by funds from the New Zealand Institute for Cancer Research Trust (Otago) and the CMRI (Sydney), respectively. CGL was supported by the Health Research Council, the University of Otago International Fees Scholarship and Postgraduate Publishing Bursary and the Dunedin School of Medicine Finishing Your PhD Scholarship. This work was supported by grants from the Health Research Council of New Zealand and the University of Otago Faculty of Medicine Trust Fund.	Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Boyer SN, 1996, CANCER RES, V56, P4620; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Buttitta LA, 2007, CURR OPIN CELL BIOL, V19, P697, DOI 10.1016/j.ceb.2007.10.004; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen YJ, 2008, CANCER RES, V68, P5724, DOI 10.1158/0008-5472.CAN-08-0058; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Dahl JA, 2008, NAT PROTOC, V3, P1032, DOI 10.1038/nprot.2008.68; Daniel L, 2001, HUM PATHOL, V32, P282, DOI 10.1053/hupa.2001.22753; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ECCLES MR, 1995, AM J PATHOL, V146, P40; Esposito C, 1998, BIOCHEM J, V331, P37, DOI 10.1042/bj3310037; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; He SJ, 2010, J INVEST DERMATOL, V130, P1465, DOI 10.1038/jid.2009.434; Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hooghe B, 2008, NUCLEIC ACIDS RES, V36, pW128, DOI 10.1093/nar/gkn195; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Hueber PA, 2006, KIDNEY INT, V69, P1139, DOI 10.1038/sj.ki.5000136; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Knight JS, 2005, P NATL ACAD SCI USA, V102, P18562, DOI 10.1073/pnas.0503886102; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; Little MH, 2009, J AM SOC NEPHROL, V20, P2112, DOI 10.1681/ASN.2009010066; Long KB, 2010, AM J SURG PATHOL, V34, P723, DOI 10.1097/PAS.0b013e3181da0a20; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Miccadei S, 2005, ONCOGENE, V24, P6993, DOI 10.1038/sj.onc.1208861; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1995, EUR J BIOCHEM, V228, P899, DOI 10.1111/j.1432-1033.1995.tb20338.x; ROSSI DL, 1995, J BIOL CHEM, V270, P23139, DOI 10.1074/jbc.270.39.23139; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Skapek SX, 2006, ONCOGENE, V25, P5268, DOI 10.1038/sj.onc.1209710; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Tong GX, 2009, MODERN PATHOL, V22, P1218, DOI 10.1038/modpathol.2009.88; Tong GX, 2006, MODERN PATHOL, V19, P356, DOI 10.1038/modpathol.3800535; Vilain C, 2001, J CLIN ENDOCR METAB, V86, P234, DOI 10.1210/jc.86.1.234; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; Yen A, 1997, EUR J CELL BIOL, V72, P159; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zhang L, 2007, BIOCHEM BIOPH RES CO, V361, P611, DOI 10.1016/j.bbrc.2007.07.089; Zhang P, 2006, PATHOL INT, V56, P240, DOI 10.1111/j.1440-1827.2006.01959.x	62	42	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	48					4824	4834		10.1038/onc.2011.190	http://dx.doi.org/10.1038/onc.2011.190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21602887	hybrid, Green Published			2022-12-28	WOS:000298134700006
J	Jiang, J; Liu, W; Guo, X; Zhang, R; Zhi, Q; Ji, J; Zhang, J; Chen, X; Li, J; Zhang, J; Gu, Q; Liu, B; Zhu, Z; Yu, Y				Jiang, J.; Liu, W.; Guo, X.; Zhang, R.; Zhi, Q.; Ji, J.; Zhang, J.; Chen, X.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.			IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer	ONCOGENE			English	Article						gastric carcinoma; IRX1; angiogenesis; vasculogenic mimicry; BDKRB2	VASCULAR CHANNEL FORMATION; ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELL PLASTICITY; VASCULOGENIC MIMICRY; IN-VIVO; DOWN-REGULATION; FACTOR RECEPTOR; MELANOMA-CELLS; BREAST-CANCER; ANGIOGENESIS	The overexpression of IRX1 gene correlates with the growth arrest in gastric cancer. Furthermore, overexpression of IRX1 gene suppresses peritoneal spreading and long distance metastasis. To explore the precise mechanisms, we investigated whether restoring IRX1 expression affects the angiogenesis or vasculogenic mimicry (VM). Human umbilical vein endothelial cells (HUVECs) and chick embryo and SGC-7901 gastric cancer cells were used for angiogenesis and VM analysis. Small interfering RNA was used for analyzing the function of BDKRB2, a downstream target gene of IRX1. As results, the remarkable suppression on peritoneal spreading and pulmonary metastasis of SGC-7901 cells by IRX1 transfectant correlates to reduced angiogenesis as well as VM formation. Using the supernatant from SGC-7901/ IRX1 cells, we found a strong inhibiting effect on angiogenesis both in vitro and in chick embryo. SGC-7901/IRX1 cells revealed strong inhibiting effect on VM formation too. By gene-specific RNA interference for BDKRB2, or its effector PAK1, we got an effective inhibition on tube formation, cell proliferation, cell migration and invasion in vitro. In conclusion, enforcing IRX1 expression effectively suppresses peritoneal spreading and pulmonary metastasis via anti-angiogenesis and anti-VM mechanisms, in addition to previously found cell growth and invasion. BDKRB2 and its downstream effector might be potential targets for anti-cancer strategy. Oncogene (2011) 30, 4498-4508; doi:10.1038/onc.2011.154; published online 23 May 2011	Shanghai Jiao Tong Univ, Sch Med, Dept Surg, Shanghai Ruijin Hosp, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Surg, Shanghai Key Lab Diag & Treatment Gastr Canc, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Ruijin Er Rd 197, Shanghai 200025, Peoples R China.	surgeryzhu@yahoo.com.cn; yingyan3y@yahoo.com.cn	Liu, Bingya/GMW-5655-2022	Liu, Bingya/0000-0002-4406-3762	National Natural Science Foundation of China [30572127, 30770961, 30973486]; Chinese National High Tech Program [863-2006AA02A402, 2006AA02A301]; Shanghai Science and Technology Commission [09DZ1950101, 09JC1409600]; Shanghai Charity Foundation for Cancer Research	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese National High Tech Program(National High Technology Research and Development Program of China); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Charity Foundation for Cancer Research	This work was supported, in part, by grants from the National Natural Science Foundation of China (30572127, 30770961 and 30973486), the Chinese National High Tech Program (863-2006AA02A402 and 2006AA02A301), Key Research Project from Shanghai Science and Technology Commission (09DZ1950101 and 09JC1409600) and Shanghai Charity Foundation for Cancer Research.	Alarcon P, 2008, DEVELOPMENT, V135, P3197, DOI 10.1242/dev.023697; Altundag K, 2004, CANCER, V100, P1768, DOI 10.1002/cncr.20175; Andoh T, 2010, PEPTIDES, V31, P238, DOI 10.1016/j.peptides.2009.12.003; Basu GD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1626; Becker MB, 2001, MECH DEVELOP, V106, P155, DOI 10.1016/S0925-4773(01)00412-9; Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509; Bennett KL, 2009, CANCER RES, V69, P9301, DOI 10.1158/0008-5472.CAN-09-3073; Bessard A, 2008, ONCOGENE, V27, P5315, DOI 10.1038/onc.2008.163; Cai XZ, 2009, CANCER BIOL THER, V8, P1360, DOI 10.4161/cbt.8.14.8720; Calderon Adrian J, 2005, P R Health Sci J, V24, P27; Deryugina EI, 2008, METHOD ENZYMOL, V444, P21, DOI 10.1016/S0076-6879(08)02802-4; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Fryer BH, 2005, CANCER LETT, V229, P13, DOI 10.1016/j.canlet.2004.12.009; Fujimoto A, 2006, ANTICANCER RES, V26, P59; Moya EMG, 2009, CELL SIGNAL, V21, P1727, DOI 10.1016/j.cellsig.2009.08.006; Gartel AL, 2006, BIOMOL ENG, V23, P17, DOI 10.1016/j.bioeng.2006.01.002; Getmanova EV, 2006, CHEM BIOL, V13, P549, DOI 10.1016/j.chembiol.2005.12.009; Gu Wenyi, 2008, V442, P159, DOI 10.1007/978-1-59745-191-8_12; Guo X, 2010, ONCOGENE, V29, P3908, DOI 10.1038/onc.2010.143; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hao Xishan, 2002, Zhonghua Yi Xue Za Zhi, V82, P1298; Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589; Ishihara K, 2002, INT IMMUNOPHARMACOL, V2, P499, DOI 10.1016/S1567-5769(01)00193-X; Kramarenko II, 2010, MOL PHARMACOL, V78, P126, DOI 10.1124/mol.110.064840; Krankel N, 2008, CIRC RES, V103, P1335, DOI 10.1161/CIRCRESAHA.108.179952; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li XD, 2010, EXPERT OPIN THER TAR, V14, P419, DOI 10.1517/14728221003642019; Liu FN, 2009, INT J CANCER, V125, P2511, DOI 10.1002/ijc.24588; Lorch JH, 2007, CANCER RES, V67, P727, DOI 10.1158/0008-5472.CAN-06-2162; Lu Y, 2005, CANCER LETT, V224, P329, DOI 10.1016/j.canlet.2004.11.057; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Masamune A, 2008, AM J PHYSIOL-GASTR L, V295, pG709, DOI 10.1152/ajpgi.90356.2008; Matsuda KM, 2000, CANCER GENE THER, V7, P589, DOI 10.1038/sj.cgt.7700147; Mirshahi P, 2009, LEUKEMIA, V23, P1039, DOI 10.1038/leu.2009.10; Nogueras S, 2008, AM J PHYSIOL-HEART C, V294, pH708, DOI 10.1152/ajpheart.00466.2007; Oleinikov AV, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni091; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Shirakawa K, 2003, BREAST CANCER RES, V5, P136, DOI 10.1186/bcr585; Sood AK, 2001, AM J PATHOL, V158, P1279, DOI 10.1016/S0002-9440(10)64079-5; Su M, 2008, INT J GYNECOL CANCER, V18, P476, DOI 10.1111/j.1525-1438.2007.01034.x; Sun BC, 2008, HUM PATHOL, V39, P444, DOI 10.1016/j.humpath.2007.07.018; Sun BC, 2006, ONCOL REP, V16, P693; Sun BC, 2004, INT J ONCOL, V25, P1609; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/0008-5472.CAN-05-2468; Veeravalli KK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011583; Wu J, 2002, INT J CANCER, V98, P29, DOI 10.1002/ijc.10142; Yue WY, 2005, J HISTOCHEM CYTOCHEM, V53, P997, DOI 10.1369/jhc.4A6521.2005; Zhang J, 2008, J CHONGQING MED U, V33, P1603; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhang WP, 2008, MOL CANCER RES, V6, P1946, DOI 10.1158/1541-7786.MCR-07-2197	51	52	59	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4498	4508		10.1038/onc.2011.154	http://dx.doi.org/10.1038/onc.2011.154			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21602894	Green Published, hybrid			2022-12-28	WOS:000296733200005
J	Jeter, CR; Liu, B; Liu, X; Chen, X; Liu, C; Calhoun-Davis, T; Repass, J; Zaehres, H; Shen, JJ; Tang, DG				Jeter, C. R.; Liu, B.; Liu, X.; Chen, X.; Liu, C.; Calhoun-Davis, T.; Repass, J.; Zaehres, H.; Shen, J. J.; Tang, D. G.			NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation	ONCOGENE			English	Article						Nanog; prostate cancer; cancer stem cells; castration resistance; self-renewal	TUMOR-INITIATING CELLS; GENE-EXPRESSION; PROSPECTIVE IDENTIFICATION; SIDE POPULATION; MARKER NANOG; BREAST; PROLIFERATION; PLURIPOTENCY; PROGRESSION; BINDING	Cancer cell molecular mimicry of stem cells (SC) imbues neoplastic cells with enhanced proliferative and renewal capacities. In support, numerous mediators of SC self-renewal have been evinced to show oncogenic potential. We have recently reported that short-hairpin RNA-mediated knockdown of the embryonic stem cell (ESC) self-renewal gene NANOG significantly reduced the clonogenic and tumorigenic capabilities of various cancer cells. In this study, we sought to test the potential pro-tumorigenic functions of NANOG, particularly, in prostate cancer (PCa). Using qRT-PCR, we first confirmed that PCa cells expressed NANOG mRNA primarily from the NANOGP8 locus on chromosome 15q14. We then constructed a lentiviral promoter reporter in which the -3.8-kb NANOGP8 genomic fragment was used to drive the expression of green fluorescence protein (GFP). We observed that NANOGP8-GFP PCa cells showed cancer stem cell (CSC) characteristics such as enhanced clonal growth and tumor regenerative capacity. To further investigate the functions and mechanisms of NANOG in tumorigenesis, we established tetracycline-inducible NANOG-overexpressing cancer cell lines, including both PCa (Du145 and LNCaP) and breast (MCF-7) cancer cells. NANOG induction promoted drug resistance in MCF-7 cells, tumor regeneration in Du145 cells and, most importantly, castration-resistant tumor development in LNCaP cells. These pro-tumorigenic effects of NANOG were associated with key molecular changes, including an upregulation of molecules such as CXCR4, IGFBP5, CD133 and ALDH1. The present gain-of-function studies, coupled with our recent loss-of-function work, establish the integral role for NANOG in neoplastic processes and shed light on its mechanisms of action. Oncogene (2011) 30, 3833-3845; doi:10.1038/onc.2011.114; published online 18 April 2011	[Jeter, C. R.; Liu, B.; Liu, X.; Chen, X.; Liu, C.; Calhoun-Davis, T.; Repass, J.; Shen, J. J.; Tang, D. G.] Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; [Liu, B.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA; [Chen, X.; Liu, C.; Tang, D. G.] Grad Sch Biol Sci, Program Mol Carcinogenesis, Houston, TX USA; [Zaehres, H.] Max Planck Inst Mol Biomed, Munster, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; Max Planck Society	Jeter, CR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA.	cjeter@mdanderson.org; dtang@mdanderson.org	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Liu, Xin/0000-0003-0847-182X; Jeter, Collene/0000-0002-9627-4529; Chen, Xin/0000-0002-0566-7678	NIH [R01-ES015888, R21-ES015893, R21-CA150009]; Department of Defense [W81XWH-07-1-0616, W81XWH-08-1-0472]; Elsa Pardee Foundation; Center Grants [CCSG-5 P30 CA016672-34, ES007784]; AUA Foundation; NATIONAL CANCER INSTITUTE [R21CA150009, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, R01ES015888, R21ES015893] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Elsa Pardee Foundation; Center Grants; AUA Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank P Whitney for FACS, N Otto and the Histology Core for help in IHC analysis, J Moore for assistance in animal breeding and experiments, and other members of the Tang laboratory for support and discussions. This work was supported, in part, by grants from NIH (R01-ES015888, R21-ES015893, R21-CA150009), Department of Defense (W81XWH-07-1-0616, W81XWH-08-1-0472) and the Elsa Pardee Foundation (DGT), and by two Center Grants (CCSG-5 P30 CA016672-34 and ES007784). CR Jeter and C Liu were supported in part by fellowships from the AUA Foundation and DOD, respectively.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Engelmann K, 2008, CANCER RES, V68, P2419, DOI 10.1158/0008-5472.CAN-07-2249; Frigo DE, 2009, MOL ENDOCRINOL, V23, P1385, DOI 10.1210/me.2009-0010; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Huss WJ, 2005, CANCER RES, V65, P6640, DOI 10.1158/0008-5472.CAN-04-2548; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Li H, 2009, METHODS MOL BIOL, V568, P85, DOI 10.1007/978-1-59745-280-9_7; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu YQ, 2009, CELL STEM CELL, V4, P336, DOI 10.1016/j.stem.2009.02.015; Ma TH, 2009, J BIOL CHEM, V284, P16071, DOI 10.1074/jbc.M109.005041; Machida K, 2009, P NATL ACAD SCI USA, V106, P1548, DOI 10.1073/pnas.0807390106; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Medeiros RB, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-59; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Miyake H, 2000, ENDOCRINOLOGY, V141, P2257, DOI 10.1210/en.141.6.2257; Nickerson T, 2001, CANCER RES, V61, P6276; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piestun D, 2006, BIOCHEM BIOPH RES CO, V343, P279, DOI 10.1016/j.bbrc.2006.02.152; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Singh SK, 2003, CANCER RES, V63, P5821; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xu C, 2007, PROSTATE, V67, P1621, DOI 10.1002/pros.20655; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang JY, 2005, BIOCHEM BIOPH RES CO, V338, P1098, DOI 10.1016/j.bbrc.2005.10.071; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhang X, 2009, J CELL BIOL, V184, P67, DOI 10.1083/jcb.200801009; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	48	271	285	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3833	3845		10.1038/onc.2011.114	http://dx.doi.org/10.1038/onc.2011.114			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21499299	Green Accepted			2022-12-28	WOS:000294687200002
J	Wang, Q; Li, DC; Li, ZF; Liu, CX; Xiao, YM; Zhang, B; Li, XD; Zhao, J; Chen, LP; Xing, XM; Tang, SF; Lin, YC; Lai, YD; Yang, P; Zeng, JL; Xiao, Q; Zeng, XW; Lin, ZN; Zhuang, ZX; Zhuang, SM; Chen, W				Wang, Q.; Li, D-C; Li, Z-F; Liu, C-X; Xiao, Y-M; Zhang, B.; Li, X-D; Zhao, J.; Chen, L-P; Xing, X-M; Tang, S-F; Lin, Y-C; Lai, Y-D; Yang, P.; Zeng, J-L; Xiao, Q.; Zeng, X-W; Lin, Z-N; Zhuang, Z-X; Zhuang, S-M; Chen, W.			Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen	ONCOGENE			English	Article						viral oncogene; SV40 small T antigen; miR-27a; protein phosphatase 2A; transformation; human cells	PROTEIN PHOSPHATASE 2A; SMALL TUMOR-ANTIGEN; HUMAN HEPATOCELLULAR-CARCINOMA; BREAST-CANCER CELLS; EARLY MESSENGER-RNA; SIMIAN VIRUS-40; CELLULAR-TRANSFORMATION; MICRORNA TARGETS; UBIQUITIN LIGASE; C-MYC	The introduction of the Simian virus 40 (SV40) early region, the telomerase catalytic subunit (hTERT) and an oncogenic allele of H-Ras directly transforms primary human cells. SV40 small T antigen (ST), which forms a complex with protein phosphatase 2A (PP2A) and inhibits PP2A activity, is believed to have a critical role in the malignant transformation of human cells. Recent evidence has shown that aberrant microRNA (miRNA) expression patterns are correlated with cancer development. Here, we identified miR-27a as a differentially expressed miRNA in SV40 ST-expressing cells. miR-27a is upregulated in SV40 ST-transformed human bronchial epithelial cells (HBERST). Suppression of miR-27a expression in HBERST cells or lung cancer cell lines (NCI-H226 and SK-MES-1) that exhibited high levels of miR-27a expression lead to cell growth arrested in the G(0)-G(1) phase. In addition, suppression of miR-27a in HBERST cells attenuated the capacity of such cells to grow in an anchorage-independent manner. We also found that suppression of the PP2A B56 gamma expression resulted in upregulation of miR-27a similar to that achieved by the introduction of ST, indicating that dysregulation of miR-27a expression in ST-expressing cells was mediated by the ST-PP2A interaction. Moreover, we discovered that Fbxw7 gene encoding F-box/WD repeat-containing protein 7 was a potential miR-27a target validated by dual-luciferase reporter system analysis. The inverse correlation between miR-27a expression levels and Fbxw7 protein expression was further confirmed in both cell models and human tumor samples. Fbxw7 regulates cell-cycle progression through the ubiquitin-dependent proteolysis of a set of substrates, including c-Myc, c-Jun, cyclin E1 and Notch 1. Thus, promotion of cell growth arising from the suppression of Fbxw7 by miR-27a overexpression might be responsible for the viral oncoprotein ST-induced malignant transformation. These observations demonstrate that miR-27a functions as an oncogene in human tumorigenesis. Oncogene (2011) 30, 3875-3886; doi:10.1038/onc.2011.103; published online 4 April 2011	[Chen, W.] Sun Yat Sen Univ, Sch Publ Hlth, Fac Prevent Med,Dept Toxicol, Guangdong Prov Key Lab Food Nutr & Hlth, Guangzhou 510080, Guangdong, Peoples R China; [Li, X-D] Sun Yat Sen Univ, Dept Thorac Surg, Ctr Canc, Guangzhou 510080, Guangdong, Peoples R China; [Zhao, J.] Guangzhou Med Univ, Dept Thorac Surg, Affiliated Canc Hosp, Guangzhou, Guangdong, Peoples R China; [Zhuang, Z-X] Shenzhen Ctr Dis Control & Prevent, Dept Toxicol, Shenzhen, Peoples R China; [Zhuang, S-M] Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Engn, Minist Educ,State Key Lab Biocontrol, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Shenzhen Center for Disease Control & Prevention (SZCDC); Sun Yat Sen University	Chen, W (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Fac Prevent Med,Dept Toxicol, Guangdong Prov Key Lab Food Nutr & Hlth, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	chenwen@mail.sysu.edu.cn	ZHANG, BO/K-4561-2013	ZHANG, BO/0000-0002-6352-1757; Zhuang, Shi-Mei/0000-0002-2512-3942	NSFC [30925029, 30925036, 30630055, 30800930, 30771832, 30901211]; National Key Basic Research and Development Program [2010CB912803]; National High Technology Research and Development Key Program of China [2008AA062504]; Ministry of Health of China [200902006]; Fundamental Research Funds for the Central Universities [10ykjc05, 10lgzd10]; Guangdong Province Universities; Colleges Pearl River Scholar Funded Scheme GDUPS	NSFC(National Natural Science Foundation of China (NSFC)); National Key Basic Research and Development Program(National Basic Research Program of China); National High Technology Research and Development Key Program of China(National High Technology Research and Development Program of China); Ministry of Health of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Province Universities; Colleges Pearl River Scholar Funded Scheme GDUPS	This work was supported by program of Distinguished Young Scholar of NSFC (30925029, 30925036), a Key NSFC Program (30630055) and NSFC (30800930, 30771832, 30901211), National Key Basic Research and Development Program (2010CB912803), National High Technology Research and Development Key Program of China (2008AA062504), Ministry of Health of China (200902006), the Fundamental Research Funds for the Central Universities (10ykjc05 and 10lgzd10), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme GDUPS (2010).	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Connolly E, 2008, AM J PATHOL, V173, P856, DOI 10.2353/ajpath.2008.080096; CRAWFORD LV, 1978, P NATL ACAD SCI USA, V75, P117, DOI 10.1073/pnas.75.1.117; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; Godshalk SE, 2008, CELL CYCLE, V7, P3595, DOI 10.4161/cc.7.22.7120; Grochola LF, 2009, CLIN CANCER RES, V15, P6301, DOI 10.1158/1078-0432.CCR-09-0797; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Huang SL, 2008, INT J CANCER, V123, P972, DOI 10.1002/ijc.23580; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KHALILI K, 1987, CELL, V48, P639, DOI 10.1016/0092-8674(87)90242-X; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lai EC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-115; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Ma YH, 2010, CANCER LETT, V298, P150, DOI 10.1016/j.canlet.2010.06.012; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; Moreno CS, 2004, CANCER RES, V64, P6978, DOI 10.1158/0008-5472.CAN-04-1150; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pang YQ, 2008, TOXICOL APPL PHARM, V232, P478, DOI 10.1016/j.taap.2008.08.009; Perez-Losada J, 2005, CANCER RES, V65, P6488, DOI 10.1158/0008-5472.CAN-05-1294; Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sablina AA, 2008, CANCER METAST REV, V27, P137, DOI 10.1007/s10555-008-9116-0; SHENK TE, 1976, J VIROL, V18, P664, DOI 10.1128/JVI.18.2.664-671.1976; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sontag JM, 2006, CELL MOL LIFE SCI, V63, P2979, DOI 10.1007/s00018-006-6300-7; Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036; TOMITA M, 2009, INT J CANC IN PRESS; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030	62	60	65	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	36					3875	3886		10.1038/onc.2011.103	http://dx.doi.org/10.1038/onc.2011.103			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21460851				2022-12-28	WOS:000294687200005
J	Chen, X; Zhang, H; Aravindakshan, JP; Gotlieb, WH; Sairam, MR				Chen, X.; Zhang, H.; Aravindakshan, J. P.; Gotlieb, W. H.; Sairam, M. R.			Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization	ONCOGENE			English	Article						ovarian cancer; tumor suppressor; splicing; G2 arrest; apoptosis; drug sensitivity	CARCINOMA CELL-LINE; CANCER CELLS; INDUCE APOPTOSIS; INHIBITS GROWTH; FSH RECEPTOR; FORKO MICE; CIDE-B; EXPRESSION; MODEL; SUPPRESSOR	In studying the age dependence and chronology of ovarian tumors in follicle stimulating hormone receptor knockout mice, we identified a novel ovarian tumor associated gene-12 (OTAG-12), which is progressively downregulated and maps to Chr. 8B3.3. OTAG-12 protein overexpression in mouse ovarian and mammary tumor cells suggested powerful anti-proliferative effects. In human epithelial ovarian cancers (OCs) and OC cell lines, OTAG-12 mRNA expression is downregulated in comparison with normal ovaries. Cloning and identification revealed that human OTAG-12 mapping to gene-rich Chr. 19p13.12 is expressed in three spliced forms: hOTAG-12a, hOTAG-12b and hOTAG-12c, of which b is predominant in the normal ovary. Functionally active hOTAG-12b is a simple protein with no disulfide bonds and a nuclear localization signal is present in all variants. Transfection of OTAG-12 variants in OC and tumorigenic HEK293 cells confirmed nuclear localization. hOTAG-12b overexpression in OC and HEK293 cells effectively suppressed cell growth, anchorage-dependent and independent colony formation followed by apoptosis, whereas hOTAG-12a and hOTAG-12c had no such effects. Deletion mutants identified the critical importance of carboxyl terminus for hOTAG-12b function. Doxycycline-inducible growth inhibition of HEK293 cells by hOTAG-12a was associated with effects on G2 cell cycle arrest and apoptosis induction. hOTAG-12b expression rendered tumorigenic cells more sensitive to four apoptotic stimuli including etoposide-a topoisomerase-II inhibitor. Doxycycline-induced hOTAG-12b expression blocked xenograft tumor growth in nude mice, whereas hOTAG-12a was ineffective. Although p53-pathway-dependent apoptotic agents could upregulate endogenous hOTAG-12b and p53 in UCI-101/107 OC cells, hOTAG-12b could also induce apoptosis in p53-null and platinum-resistant SKOV3 OC cells and Doxycycline-induced hOTAG-12b did not alter p53. Further study showed that hOTAG-12b increases mRNAs of pro-apoptotic genes such as BAD, GADD45 alpha and CIEDB, while inhibiting anti-apoptotic NAIP and Akt1 expression, suggesting that hOTAG-12b-induced apoptosis might be p53-independent. These results indicate that hOTAG-12b is a putative ovarian tumor suppressor gene warranting further studies. Oncogene (2011) 30, 2874-2887; doi:10.1038/onc.2011.11; published online 21 February 2011	[Chen, X.; Zhang, H.; Aravindakshan, J. P.; Sairam, M. R.] Clin Res Inst Montreal, Mol Endocrinol Lab, Montreal, PQ H2W 1R7, Canada; [Gotlieb, W. H.] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada; [Sairam, M. R.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Sairam, M. R.] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ, Canada; [Sairam, M. R.] McGill Univ, Dept Physiol, Montreal, PQ, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal; McGill University; McGill University	Sairam, MR (corresponding author), Clin Res Inst Montreal, Mol Endocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	sairamm@ircm.qc.ca			NCIC; CIHR	NCIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CIHR(Canadian Institutes of Health Research (CIHR))	We are grateful to Dr P Carpenter (UC Irvine) for providing ovarian cancer cell lines UCI101 and UCI107, Dr Roby KF (Univ Kansas) for ID8 cells, Drs Jolicoeur for HC11-26 cells and Seidah at IRCM for the modified HEK293 cell lines. We appreciate the useful suggestions provided by Drs Zhongjun Dong and Hua Lin during this investigation. We also acknowledge the help of Drs Marie-Claude Beauchamp and Amber Yasmeen in this study. This investigation was supported in part by the NCIC and the CIHR.	Al-Romaih K, 2008, NEOPLASIA, V10, P471, DOI 10.1593/neo.08174; Allen S, 2001, CLIN DIAGN LAB IMMUN, V8, P460, DOI 10.1128/CDLI.8.2.460-464.2001; Aravindakshan J, 2006, BIOCHEM BIOPH RES CO, V351, P507, DOI 10.1016/j.bbrc.2006.10.069; Aravindakshan J, 2010, MOL CELL ENDOCRINOL, V329, P37, DOI 10.1016/j.mce.2010.05.015; Aravindakshan J, 2006, NEOPLASIA, V8, P984, DOI 10.1593/neo.06529; Barnes BJ, 2003, CANCER RES, V63, P6424; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bignone PA, 2007, ONCOGENE, V26, P683, DOI 10.1038/sj.onc.1209827; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Bruening W, 1999, CANCER RES, V59, P4973; Chen F, 2001, ONCOGENE, V20, P3585, DOI 10.1038/sj.onc.1204442; Chen XL, 2007, NEOPLASIA, V9, P521, DOI 10.1593/neo.07238; Chen XL, 2006, CARCINOGENESIS, V27, P903, DOI 10.1093/carcin/bgi305; Chen ZM, 2000, J BIOL CHEM, V275, P22619, DOI 10.1074/jbc.C000207200; Corney DC, 2008, ADV EXP MED BIOL, V622, P99, DOI 10.1007/978-0-387-68969-2_9; Dai Y, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-392; Danilovich N, 2001, ENDOCRINOLOGY, V142, P3673, DOI 10.1210/en.142.8.3673; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; FUCHTNER C, 1993, GYNECOL ONCOL, V48, P203, DOI 10.1006/gyno.1993.1034; GAMBOA G, 1995, GYNECOL ONCOL, V58, P336, DOI 10.1006/gyno.1995.1239; Grimwood J, 2004, NATURE, V428, P529, DOI 10.1038/nature02399; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Nowak-Markwitz E, 2004, EUR J GYNAECOL ONCOL, V25, P465; O'Riordan MXD, 2008, DEV CELL, V15, P497, DOI 10.1016/j.devcel.2008.09.012; Pal T, 2005, CANCER-AM CANCER SOC, V104, P2807, DOI 10.1002/cncr.21536; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Schwartz MF, 2003, CELL CYCLE, V2, P384, DOI 10.4161/cc.2.4.457; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Wagner MW, 2008, J BIOL CHEM, V283, P21382, DOI 10.1074/jbc.M709953200; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Wu ZZ, 2005, J LIPID RES, V46, P1396, DOI 10.1194/jlr.M500071-JLR200; Yan XJ, 2006, GYNECOL ONCOL, V102, P348, DOI 10.1016/j.ygyno.2005.12.033; Yin BWT, 2002, INT J CANCER, V98, P737, DOI 10.1002/ijc.10250; Zhu QS, 2008, CANCER RES, V68, P2895, DOI 10.1158/0008-5472.CAN-07-6268	46	7	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2874	2887		10.1038/onc.2011.11	http://dx.doi.org/10.1038/onc.2011.11			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21339736				2022-12-28	WOS:000291977800007
J	Dettman, EJ; Simko, SJ; Ayanga, B; Carofino, BL; Margolin, JF; Morse, HC; Justice, MJ				Dettman, E. J.; Simko, S. J.; Ayanga, B.; Carofino, B. L.; Margolin, J. F.; Morse, H. C., III; Justice, M. J.			Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors	ONCOGENE			English	Article						leukemia; Prdm14; leukemia-initiating cell; pluripotency; common lymphoid progenitor; acute lymphoblastic leukemia	BREAST-CANCER; STEM-CELLS; RETROVIRAL INSERTIONS; MEIOTIC RECOMBINATION; BONE-MARROW; IN-VITRO; C-KIT; GENE; MICE; EXPRESSION	Understanding the heterogeneous genetic mechanisms of tumor initiation in lymphoid leukemias (LL) will lead to improvements in prognostic classification and treatment regimens. In previous studies of mouse leukemias, we showed that retroviral insertion at the ecotropic viral insertion site 32 locus leads to increased expression of Prdm14, a pluripotency gene implicated in the self-renewal capacity of embryonic stem cells and the early stages of breast cancer. Here, we show that PRDM14 is also overexpressed in similar to 25% of human lymphoid neoplasms, with increased frequencies in T-cell acute LL and hyperdiploid precursor B-cell acute LL. To test if Prdm14 overexpression could initiate leukemia, mice were transduced with bone marrow cells transfected with a Prdm14 expression vector. LLs developed in 96% of female mice and 42% of male mice. Before the onset of leukemia, differentiation of transduced cells was biased up to 1000-fold toward cells with features of common lymphoid progenitors (CLPs), and lymphoid differentiation showed a relative block at the pro-B stage. Microarray gene expression analysis of expanded CLP-like cells before the onset of leukemia demonstrated upregulation of genes involved in pluripotency, tumor initiation, early B-lineage commitment, Wnt/Ras signaling and the epithelial-to-mesenchymal transition. Among the dysregulated genes were imprinted genes and non-coding RNAs including Dlk1 and Meg3, which are also key pluripotency mediators. Heightened expression of the estrogen-dependent oncogene, Myb, in tumors suggests a basis for the increased frequency of cancer in female mice. These data provide the first direct evidence for the association of Prdm14 with cancer initiation in an in vivo mouse model and in human lymphoid malignancies, while suggesting mechanisms for Prdm14's mode of action. Oncogene (2011) 30, 2859-2873; doi:10.1038/onc.2011.12; published online 21 February 2011	[Dettman, E. J.; Ayanga, B.; Carofino, B. L.; Justice, M. J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Simko, S. J.; Margolin, J. F.] Baylor Coll Med, Sect Hematol & Oncol, Dept Pediat, Houston, TX 77030 USA; [Morse, H. C., III] NIAID, Immunopathol Lab, NIH, Rockville, MD USA; [Justice, M. J.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, MS227,1 Baylor Plaza R804, Houston, TX 77030 USA.	mjustice@bcm.edu	liang, yan/H-3894-2011	Morse, Herbert/0000-0002-9331-3705; Carofino, Brandi/0000-0003-0717-6917; Dettman, E.J./0000-0002-0059-836X; Simko, Stephen/0000-0002-4790-4117	NIH [R01 CA63229, R01 CA15530]; Baylor College of Medicine; NIH National Research Service [3 T32 CA115303-04]; NIH, National Institute of Allergy and Infectious Diseases; NATIONAL CANCER INSTITUTE [R01CA115503, R01CA063229, T32CA115303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001024, ZIAAI000858] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baylor College of Medicine; NIH National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work by MJJ was supported by NIH R01 CA63229, R01 CA15530 and a Baylor College of Medicine Interim funding award. SJS was supported by an NIH National Research Service Award Institutional Training Grant 3 T32 CA115303-04, 'Pediatric Oncology Research Training Program.' HCM was supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. We thank John Belmont and Molly Bray at the Laboratory for Translational Genomics at BCM for microarray data production; Jill Crowe for excellent technical assistance; and Frank Probst for the critical reading of the paper.	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439; BESMER P, 1993, DEVELOPMENT, P125; Bhojwani D, 2006, BLOOD, V108, P711, DOI 10.1182/blood-2006-02-002824; Boles MK, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000759; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chia NY, 2010, NATURE, V468, P316, DOI 10.1038/nature09531; Davi F, 1996, BLOOD, V88, P609, DOI 10.1182/blood.V88.2.609.bloodjournal882609; Davidsson J, 2010, LEUKEMIA, V24, P924, DOI 10.1038/leu.2010.39; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dettman EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003823; DOWNING JR, 2006, HEMATOL-AM SOC HEMAT, V508, P118; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; Ford AM, 2001, BLOOD, V98, P558, DOI 10.1182/blood.V98.3.558; Fredrickson T N, 1995, Curr Top Microbiol Immunol, V194, P109; Fumasoni I, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-187; Greig KT, 2010, BLOOD, V115, P2796, DOI 10.1182/blood-2009-08-239210; GUERIN M, 1990, ONCOGENE, V5, P131; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hao XP, 2006, LEUKEMIA RES, V30, P397, DOI 10.1016/j.leukres.2005.08.021; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Hayashi K, 2005, NATURE, V438, P374, DOI 10.1038/nature04112; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; JONKERS S, 1996, BIOCHIM BIOPHYS ACTA, V1287, P29; Jordan CT, 2006, CANCER CELL, V10, P253, DOI 10.1016/j.ccr.2006.09.010; Khoury H, 2010, BLOOD, V115, P2260, DOI 10.1182/blood-2009-03-212746; Kim KC, 2003, CANCER BIOL THER, V2, P491, DOI 10.4161/cbt.2.5.629; Kim KC, 2003, CANCER RES, V63, P7619; Kinameri E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003859; Ko CD, 2003, CLIN EXP METASTAS, V20, P593, DOI 10.1023/A:1027323210736; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kurimoto K, 2008, CELL CYCLE, V7, P3514, DOI 10.4161/cc.7.22.6979; Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995; Lossos IS, 2003, LEUKEMIA, V17, P789, DOI 10.1038/sj.leu.2402880; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Moelans CB, 2010, MODERN PATHOL, V23, P1029, DOI 10.1038/modpathol.2010.84; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Mullighan CG, 2005, CANCER J, V11, P268, DOI 10.1097/00130404-200507000-00003; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Myers S, 2010, SCIENCE, V327, P876, DOI 10.1126/science.1182363; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111; Ohinata Y, 2009, CELL, V137, P571, DOI 10.1016/j.cell.2009.03.014; Palmu S, 2002, ANTICANCER RES, V22, P411; PARVANOV ED, 2010, SCIENCE, P327; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Pizzo PA, 2006, PRINCIPLES PRACTICE; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Sakajiri S, 2005, LEUKEMIA, V19, P1404, DOI 10.1038/sj.leu.2403832; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sorich MJ, 2008, PLOS MED, V5, P646, DOI 10.1371/journal.pmed.0050083; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tremblay M, 2010, GENE DEV, V24, P1093, DOI 10.1101/gad.1897910; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Tsuneyoshi N, 2008, BIOCHEM BIOPH RES CO, V367, P899, DOI 10.1016/j.bbrc.2007.12.189; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Weiser KC, 2007, MAMM GENOME, V18, P709, DOI 10.1007/s00335-007-9060-2; Yamaji M, 2008, NAT GENET, V40, P1016, DOI 10.1038/ng.186; Yan XQ, 1996, BLOOD, V88, P402, DOI 10.1182/blood.V88.2.402.bloodjournal882402	69	45	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2859	2873		10.1038/onc.2011.12	http://dx.doi.org/10.1038/onc.2011.12			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21339739	Green Accepted			2022-12-28	WOS:000291977800006
J	Merlin, J; Stechly, L; de Beauce, S; Monte, D; Leteurtre, E; van Seuningen, I; Huet, G; Pigny, P				Merlin, J.; Stechly, L.; de Beauce, S.; Monte, D.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P.			Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; galectin-3; MUC1; EGFR; intracellular localization; endocytosis	GROWTH-FACTOR RECEPTOR; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PRIMARY TUMORS; BETA-CATENIN; C-SRC; ENDOCYTOSIS; CARCINOMA; TRAFFICKING	MUC1 is a transmembrane glycoprotein which is typically expressed at the apical membrane of normal epithelial cells. In cancer cells, the over-expression of MUC1 and its aberrant localization around the cell membrane and in the cytoplasm favours its interaction with different protein partners such as epidermal growth factor receptor (EGFR) and can promote tumour proliferation through the activation of oncogenic signalling pathways. Our aims were to study the mechanisms inducing MUC1 cytoplasmic localization in pancreatic cancer cells, and to decipher their impact on EGFR cellular localization and activation. Our results showed that galectin-3, an endogenous lectin, is co-expressed with MUC1 in human pancreatic ductal adenocarcinoma, and that it favours the endocytosis of MUC1 and EGFR. Depletion of galectin-3 by RNA interference increased the interaction between MUC1 and EGFR, EGFR and ERK-1,2 phosphorylation, and translocation of EGFR to the nucleus. On the contrary, silencing of galectin-3 led to a decrease of cyclin-D1 levels and of cell proliferation. The galectin-3-dependent regulation of MUC1/EGFR functions may represent an interesting mechanism modulating the EGFR-stimulated cell growth of pancreatic cancer cells. Oncogene (2010) 30, 2514-2525; doi: 10.1038/onc.2010.631; published online 24 January 2011	[Merlin, J.; Stechly, L.; de Beauce, S.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P.] INSERM, U837, Equipe Mucines Differenciat & Cancerogenese Epith, F-59045 Lille, France; [Merlin, J.; Stechly, L.; de Beauce, S.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P.] Univ Lille 2, Ctr Rech Jean Pierre Aubert, Lille, France; [Stechly, L.; Huet, G.; Pigny, P.] CHRU, Ctr Biol & Pathol, Lab Biochimie & Hormonol, Lille, France; [Leteurtre, E.] CHRU, Ctr Biol & Pathol, Serv Anat Pathol, Lille, France; [Monte, D.] Univ Lille 1, Ctr Hyperfrequences & Semicond, CNRS, Inst Rech Interdisciplinaire,USR3078, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Pigny, P (corresponding author), INSERM, U837, Equipe Mucines Differenciat & Cancerogenese Epith, Team 5 Pl Verdun, F-59045 Lille, France.	pascal.pigny@inserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; monte, didier/0000-0002-0613-6203	Comite du Nord de la Ligue Nationale contre le Cancer; french Ligue Nationale contre le Cancer (comite du Nord); Universite de Lille 2; Region Nord-Pas de Calais	Comite du Nord de la Ligue Nationale contre le Cancer; french Ligue Nationale contre le Cancer (comite du Nord); Universite de Lille 2; Region Nord-Pas de Calais(Region Hauts-de-France)	We acknowledge expert support provided by D Trinel, N Jouy and M Figeac. We thank Professor N Porchet and MP Ducourouble for their constant support; G Grard, E Creme, MH Gevaert, R Siminsky, M Samyn and V Dumetz for their technical assistance. J Merlin is a recipient of a PhD fellowship from the Universite de Lille 2 and Region Nord-Pas de Calais. This work was supported by a grant from the Comite du Nord de la Ligue Nationale contre le Cancer (to PP). This work was supported by a grant from the french Ligue Nationale contre le Cancer (comite du Nord).	Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Andre S, 2006, BIOORGAN MED CHEM, V14, P6314, DOI 10.1016/j.bmc.2006.05.045; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661; Davidson PJ, 2006, GLYCOBIOLOGY, V16, P602, DOI 10.1093/glycob/cwj088; Delacour D, 2007, TRAFFIC, V8, P379, DOI 10.1111/j.1600-0854.2007.00539.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Furtak V, 2001, BIOCHEM BIOPH RES CO, V289, P845, DOI 10.1006/bbrc.2001.6064; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Henderson NC, 2006, P NATL ACAD SCI USA, V103, P5060, DOI 10.1073/pnas.0511167103; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; HUANG L, 2003, CANC BIOL THERAP, V2, P1; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jonckheere N, 2009, BRIT J CANCER, V101, P637, DOI 10.1038/sj.bjc.6605190; Lahm H, 2000, INT J ONCOL, V17, P519; Langbein S, 2007, HISTOPATHOLOGY, V51, P681, DOI 10.1111/j.1365-2559.2007.02852.x; Leroy X, 2003, UROLOGY, V62, P771, DOI 10.1016/S0090-4295(03)00560-0; Leroy X, 2002, AM J CLIN PATHOL, V118, P47; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Loukopoulos P, 2004, PANCREAS, V29, P193, DOI 10.1097/00006676-200410000-00004; Maitra A, 2003, MODERN PATHOL, V16, P902, DOI 10.1097/01.MP.0000086072.56290.FB; Monges GM, 1999, AM J CLIN PATHOL, V112, P635; Nakahara S, 2006, J BIOL CHEM, V281, P39649, DOI 10.1074/jbc.M608069200; Nassar H, 2004, MODERN PATHOL, V17, P1045, DOI 10.1038/modpathol.3800166; Ozaki N, 2009, MOL CANCER RES, V7, P1572, DOI 10.1158/1541-7786.MCR-08-0567; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Peng W, 2008, CANCER RES, V68, P7228, DOI 10.1158/0008-5472.CAN-08-1245; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Reddish MA, 1998, TUMOR BIOL, V19, P57, DOI 10.1159/000056505; Reis CA, 1998, TUMOR BIOL, V19, P127, DOI 10.1159/000056514; Resat H, 2003, BIOPHYS J, V85, P730, DOI 10.1016/S0006-3495(03)74516-0; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Song SM, 2009, CANCER RES, V69, P1343, DOI 10.1158/0008-5472.CAN-08-4153; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Stechly L, 2009, TRAFFIC, V10, P438, DOI 10.1111/j.1600-0854.2009.00882.x; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang Y, 2007, INT J CANCER, V121, P2716, DOI 10.1002/ijc.22997; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Yu LG, 2007, J BIOL CHEM, V282, P773, DOI 10.1074/jbc.M606862200; Zhao QC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-154	53	82	83	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2514	2525		10.1038/onc.2010.631	http://dx.doi.org/10.1038/onc.2010.631			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258405	Green Published			2022-12-28	WOS:000291198400003
J	Melis, JPM; Hoogervorst, EM; van Oostrom, CTM; Zwart, E; Breit, TM; Pennings, JLA; de Vries, A; van Steeg, H				Melis, J. P. M.; Hoogervorst, E. M.; van Oostrom, C. T. M.; Zwart, E.; Breit, T. M.; Pennings, J. L. A.; de Vries, A.; van Steeg, H.			Genotoxic exposure: novel cause of selection for a functional Delta N-p53 isoform	ONCOGENE			English	Article						DNA damage; gene expression; N-terminal p53 isoform (Delta N-p53, p44, p47); nonsense mutations; mouse urinary bladder tumor	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; MOUSE MODELS; MUTANT P53; EXTRACELLULAR-MATRIX; CANCER; MUTATIONS; MICE; TRANSLATION; INDUCTION	The p53 gene is frequently mutated in cancers and it is vital for cell cycle control, homeostasis and carcinogenesis. We describe a novel p53 mutational spectrum, different to those generally observed in human and murine tumors. Our study shows a high prevalence of nonsense mutations in the p53 N terminus of 2-acetylaminofluorene (2-AAF)-induced urinary bladder tumors. These nonsense mutations forced downstream translation initiation at codon 41 of Trp53, resulting in the aberrant expression of the p53 isoform Delta N-p53 (or p44). We propose a novel mechanism for the origination and the selection for this isoform. We show that chemical exposure can act as a novel cause of selection for this truncated protein. In addition, our data suggest that the occurrence of Delta N-p53 accounts, at least in mice, for a cancer phenotype. We also show that gene expression profiles of embryonic stem (ES) cells carrying the Delta N-p53 isoform in a p53-null background are divergent from p53 knockout ES cells, and therefore postulate that Delta N-p53 itself has functional transcriptional properties. Oncogene (2011) 30, 1764-1772; doi:10.1038/onc.2010.552; published online 13 December 2010	[Melis, J. P. M.; Hoogervorst, E. M.; van Oostrom, C. T. M.; Zwart, E.; Pennings, J. L. A.; de Vries, A.; van Steeg, H.] Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, NL-3720 BA Utrecht, Netherlands; [Breit, T. M.] Univ Amsterdam, Fac Sci, MicroArray Dept, Amsterdam, Netherlands	Netherlands National Institute for Public Health & the Environment; University of Amsterdam	van Steeg, H (corresponding author), Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, POB 1, NL-3720 BA Utrecht, Netherlands.	Harry.van.Steeg@rivm.nl		Pennings, Jeroen L.A./0000-0002-9188-6358	NIH/NIEHS (Comparative Mouse Genomics Centers Consortium) [1UO1 ES11044]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011044] Funding Source: NIH RePORTER	NIH/NIEHS (Comparative Mouse Genomics Centers Consortium)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the Animal Facilities of the Netherlands Vaccine Institute (NVI) for their skillful (bio)technical support. The work presented here was in part financially supported by NIH/NIEHS (Comparative Mouse Genomics Centers Consortium) Grant 1UO1 ES11044.	Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; de Leeuw Wim C, 2008, BMC Res Notes, V1, P66, DOI 10.1186/1756-0500-1-66; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Denys H, 2009, CURR PHARM DESIGN, V15, P1373, DOI 10.2174/138161209787846711; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Hailfinger S, 2007, INT J CANCER, V120, P1459, DOI 10.1002/ijc.22519; Heinlein C, 2008, INT J CANCER, V122, P1701, DOI 10.1002/ijc.23317; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hoogervorst EM, 2005, MUTAT RES-FUND MOL M, V574, P3, DOI 10.1016/j.mrfmmm.2005.01.018; Hoogervorst EM, 2005, CANCER RES, V65, P3610, DOI 10.1158/0008-5472.CAN-04-4328; Hoogervorst EM, 2004, CANCER RES, V64, P5118, DOI 10.1158/0008-5472.CAN-04-0350; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iwakuma T, 2007, ONCOGENE, V26, P2177, DOI 10.1038/sj.onc.1210278; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Matheu A, 2008, CANCER RES, V68, P6031, DOI 10.1158/0008-5472.CAN-07-6851; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Ross JA, 1998, MUTAGENESIS, V13, P173, DOI 10.1093/mutage/13.2.173; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; Wijnhoven SWP, 2005, CANCER RES, V65, P8166, DOI 10.1158/0008-5472.CAN-05-1650; Xu Y, 2008, ONCOGENE, V27, P3501, DOI 10.1038/sj.onc.1211023; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	40	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1764	1772		10.1038/onc.2010.552	http://dx.doi.org/10.1038/onc.2010.552			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151170				2022-12-28	WOS:000289512200004
J	Martins, I; Kepp, O; Schlemmer, F; Adjemian, S; Tailler, M; Shen, S; Michaud, M; Menger, L; Gdoura, A; Tajeddine, N; Tesniere, A; Zitvogel, L; Kroemer, G				Martins, I.; Kepp, O.; Schlemmer, F.; Adjemian, S.; Tailler, M.; Shen, S.; Michaud, M.; Menger, L.; Gdoura, A.; Tajeddine, N.; Tesniere, A.; Zitvogel, L.; Kroemer, G.			Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress	ONCOGENE			English	Article						apoptosis; autophagy; ER stress; necrosis; stress granules	CALRETICULIN EXPOSURE; TUMOR-CELLS; APOPTOSIS; CARCINOMA; PROTEINS; IMMUNITY; SURFACE; DNA; TRANSLOCATION; CHEMOTHERAPY	In contrast to other cytotoxic agents including anthracyclins and oxaliplatin (OXP), cisplatin (CDDP) fails to induce immunogenic tumor cell death that would allow to stimulate an anticancer immune response and hence to amplify its therapeutic efficacy. This failure to induce immunogenic cell death can be attributed to CDDP's incapacity to elicit the translocation of calreticulin (CRT) from the lumen of the endoplasmic reticulum (ER) to the cell surface. Here, we show that, in contrast to OXP, CDDP is unable to activate the protein kinase-like ER kinase (PERK)-dependent phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2 alpha). Accordingly, CDDP also failed to stimulate the formation of stress granules and macroautophagy, two processes that only occur after eIF2 alpha phosphorylation. Using a screening method that monitors the voyage of CRT from the ER lumen to the cell surface, we identified thapsigargin (THAPS), an inhibitor of the sarco/ER Ca2+-ATPase as a molecule that on its own does not stimulate CRT exposure, yet endows CDDP with the capacity to do so. The combination of ER stress inducers (such as THAPS or tunicamycin) and CDDP effectively induced the translocation of CRT to the plasma membrane, as well as immunogenic cell death, although ER stress or CDDP alone was insufficient to induce CRT exposure and immunogenic cell death. Altogether, our results underscore the contribution of the ER stress response to the immunogenicity of cell death. Oncogene (2011) 30, 1147-1158; doi:10.1038/onc.2010.500; published online 13 December 2010	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, Val De Marne, France; [Martins, I.; Kepp, O.; Schlemmer, F.; Adjemian, S.; Tailler, M.; Shen, S.; Michaud, M.; Menger, L.; Gdoura, A.; Tajeddine, N.; Tesniere, A.; Zitvogel, L.] Univ Paris 11, Villejuif, France; [Zitvogel, L.] INSERM, U1015, Villejuif, France; [Zitvogel, L.] CICBT507, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, Val De Marne, France.	kroemer@orange.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; ADJEMIAN, Sandy/K-7632-2012; Kepp, Oliver/N-2763-2017; Kepp, Oliver/GPX-8627-2022; SHEN, Shensi/AAW-2735-2020	KROEMER, Guido/0000-0002-9334-4405; ADJEMIAN, Sandy/0000-0001-5594-5499; Kepp, Oliver/0000-0002-6081-9558; SHEN, Shensi/0000-0002-5087-8220; Schlemmer, Frederic/0000-0003-2113-7113; Menger, Laurie/0000-0003-0949-6607; ZITVOGEL, laurence/0000-0003-1596-0998	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); European Commission (Apo-Sys, ChemoRes, Apop-Train); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France; AICR; FRM	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission (Apo-Sys, ChemoRes, Apop-Train)(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); AICR; FRM(Fondation pour la Recherche Medicale)	GK is supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Apo-Sys, ChemoRes, Apop-Train), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa) and Canceropole Ile-de-France. IM is supported by the Ligue Nationale contre le Cancer, OK is supported by AICR and FS by FRM.	Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gourdier I, 2004, ONCOGENE, V23, P7449, DOI 10.1038/sj.onc.1208047; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kepp O, 2010, CELL CYCLE, V9, P3072, DOI 10.4161/cc.9.15.12459; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Orvedahl A, 2009, CURR TOP MICROBIOL, V335, P267, DOI 10.1007/978-3-642-00302-8_13; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Rello-Varona S, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.6; Snapp EL, 2006, P NATL ACAD SCI USA, V103, P6536, DOI 10.1073/pnas.0510657103; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Vandenabeele P, 2008, TRENDS BIOCHEM SCI, V33, P352, DOI 10.1016/j.tibs.2008.05.007; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Yang ZJ, 2006, CLIN CANCER RES, V12, P5817, DOI 10.1158/1078-0432.CCR-06-1037; Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015	36	260	268	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1147	1158		10.1038/onc.2010.500	http://dx.doi.org/10.1038/onc.2010.500			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21151176				2022-12-28	WOS:000288202400002
J	Schmidt, C; Bloomston, M; Shah, MH				Schmidt, C.; Bloomston, M.; Shah, M. H.			Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies	ONCOGENE			English	Review						neuroendocrine tumors; somatostatin; chemoembolization	PHASE-II TRIAL; HEPATIC METASTASES; RADIONUCLIDE THERAPY; INTERFERON-ALPHA; CARCINOID-TUMORS; ENDOCRINE TUMORS; CLINICAL-TRIAL; EFFICACY; CHEMOEMBOLIZATION; COMBINATION	Neuroendocrine tumors (NETs) are a complex group of malignancies with variable prognosis and response to treatment. For pancreatic neuroendocrine and carcinoid tumors, traditional cytotoxic chemotherapies have demonstrated minimal activity. Current approaches for treatment of metastatic disease use a combination of loco-regional and targeted biological therapies. Clinical trials remain critical for evaluation of new and promising therapeutic options for patients with NETs. Oncogene (2011) 30, 1497-1505; doi: 10.1038/onc.2010.548; published online 6 December 2010	[Shah, M. H.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Schmidt, C.; Bloomston, M.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Shah, MH (corresponding author), Ohio State Univ, Dept Internal Med, A438 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.	manisha.shah@osumc.edu	Schmidt, Carl/E-4039-2011		NCI NIH HHS [K12 CA133250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA133250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agaram NP, 2007, CLIN CANCER RES, V13, P170, DOI 10.1158/1078-0432.CCR-06-1508; Ansell SM, 2001, CANCER-AM CANCER SOC, V91, P1543, DOI 10.1002/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N; Anthony LB, 2002, SEMIN NUCL MED, V32, P123, DOI 10.1053/snuc.2002.31769; Asnacios A, 2008, J CLIN ONCOL, V26, P963, DOI 10.1200/JCO.2007.12.7431; Bajetta E, 2002, ANN ONCOL, V13, P614, DOI 10.1093/annonc/mdf064; Berkovic MC, 2007, COLLEGIUM ANTROPOL, V31, P531; Bloomston M, 2007, J GASTROINTEST SURG, V11, P264, DOI 10.1007/s11605-007-0089-z; Bushnell DL, 2010, J CLIN ONCOL, V28, P1652, DOI 10.1200/JCO.2009.22.8585; Calhoun K, 2003, AM J SURG, V186, P28, DOI 10.1016/S0002-9610(03)00115-6; Delpassand ES, 2008, CANCER BIOTHER RADIO, V23, P292, DOI 10.1089/cbr.2007.0448; Duran I, 2006, BRIT J CANCER, V95, P1148, DOI 10.1038/sj.bjc.6603419; Faiss S, 2003, J CLIN ONCOL, V21, P2689, DOI 10.1200/JCO.2003.12.142; Fjallskog MLH, 2001, CANCER, V92, P1101, DOI 10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V; Forrer F, 2006, ANTICANCER RES, V26, P703; Grover AC, 2004, SURGERY, V136, P1176, DOI 10.1016/j.surg.2004.06.044; Hodul Pamela J, 2008, Cancer Control, V15, P314; Kaubisch A, 2004, CANCER CHEMOTH PHARM, V53, P337, DOI 10.1007/s00280-003-0727-4; Kennedy AS, 2008, AM J CLIN ONCOL-CANC, V31, P271, DOI 10.1097/COC.0b013e31815e4557; Kiely JM, 2006, J VASC INTERV RADIOL, V17, P47, DOI 10.1097/01.RVI.0000195074.43474.2F; Kolby L, 2003, BRIT J SURG, V90, P687, DOI 10.1002/bjs.4149; KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765; Krug LM, 2005, CANCER, V103, P2128, DOI 10.1002/cncr.21000; Kulke MH, 2008, J CLIN ONCOL, V26, P3403, DOI 10.1200/JCO.2007.15.9020; Kulke MH, 2006, J CLIN ONCOL, V24, P3555, DOI 10.1200/JCO.2006.05.6762; Kulke MH, 2006, DIGEST DIS SCI, V51, P1033, DOI 10.1007/s10620-006-8001-3; Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476; Kulke MH, 2006, J CLIN ONCOL, V24, P401, DOI 10.1200/JCO.2005.03.6046; Kulke MH, 2004, CANCER INVEST, V22, P353, DOI 10.1081/CNV-200029058; Kulke MH, 2004, CANCER, V101, P934, DOI 10.1002/cncr.20466; Kwekkeboom DJ, 2008, J CLIN ONCOL, V26, P2124, DOI 10.1200/JCO.2007.15.2553; Le Treut YP, 2008, AM J TRANSPLANT, V8, P1205, DOI 10.1111/j.1600-6143.2008.02233.x; Modlin IM, 2005, GASTROENTEROLOGY, V128, P1717, DOI 10.1053/j.gastro.2005.03.038; Osborne DA, 2006, ANN SURG ONCOL, V13, P572, DOI 10.1245/ASO.2006.03.071; Pavel Marianne E, 2005, Int J Gastrointest Cancer, V35, P179, DOI 10.1385/IJGC:35:3:179; Pavel ME, 2006, J INTERF CYTOK RES, V26, P8, DOI 10.1089/jir.2006.26.8; QUE FG, 1995, AM J SURG, V169, P36, DOI 10.1016/S0002-9610(99)80107-X; Reidy DL, 2009, NAT CLIN PRACT ONCOL, V6, P143, DOI 10.1038/ncponc1326; Rindi G, 2007, VIRCHOWS ARCH, V451, P757, DOI 10.1007/s00428-007-0452-1; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Rinke A, 2009, J CLIN ONCOL, V27, P4656, DOI 10.1200/JCO.2009.22.8510; Ruszniewski P, 2004, NEUROENDOCRINOLOGY, V80, P244, DOI 10.1159/000082875; Shah MH, 2006, CLIN CANCER RES, V12, P3997, DOI 10.1158/1078-0432.CCR-05-2689; Shah MH, 2004, CLIN CANCER RES, V10, P6111, DOI 10.1158/1078-0432.CCR-04-0422; SOLCIA E, 2000, WHO INT HISTOLOGIC C; Stuart K, 2004, INVEST NEW DRUG, V22, P75, DOI 10.1023/B:DRUG.0000006177.46798.1f; Sun WJ, 2005, J CLIN ONCOL, V23, P4897, DOI 10.1200/JCO.2005.03.616; Touzios JG, 2005, ANN SURG, V241, P776, DOI 10.1097/01.sla.0000161981.58631.ab; Varker KA, 2008, CANCER CHEMOTH PHARM, V61, P661, DOI 10.1007/s00280-007-0521-9; Varker KA, 2007, J GASTROINTEST SURG, V11, P1680, DOI 10.1007/s11605-007-0235-7; Vinik AI, 2009, PANCREAS, V38, P876, DOI 10.1097/MPA.0b013e3181bc0e77; Yao JC, 2008, J CLIN ONCOL, V26, P4311, DOI 10.1200/JCO.2008.16.7858; Yao JC, 2008, J CLIN ONCOL, V26, P1316, DOI 10.1200/JCO.2007.13.6374; Yao JC, 2007, CLIN CANCER RES, V13, P234, DOI 10.1158/1078-0432.CCR-06-1618	53	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1497	1505		10.1038/onc.2010.548	http://dx.doi.org/10.1038/onc.2010.548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21132004	Green Accepted			2022-12-28	WOS:000288998300001
J	Li, X; Martinez-Ferrer, M; Botta, V; Uwamariya, C; Banerjee, J; Bhowmick, NA				Li, X.; Martinez-Ferrer, M.; Botta, V.; Uwamariya, C.; Banerjee, J.; Bhowmick, N. A.			Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness	ONCOGENE			English	Article						Hic-5/ARA55; c-myc; AR; TGF-beta; prostate cancer; castration	GROWTH-FACTOR-BETA; ANDROGEN RECEPTOR COACTIVATORS; CANCER CELLS; CELLULAR SENESCENCE; TUMOR PROGRESSION; SIGNALING AXIS; STROMAL CELLS; LIM PROTEIN; C-MYC; HIC-5	Stromal-epithelial interactions dictate prostate tumorigenesis and response to castration. Hydrogen peroxide-inducible clone 5 (Hic-5/ARA55) is a transforming growth factor-beta (TGF-beta)-induced coactivator of androgen receptor (AR) expressed in the prostate stroma. Interestingly, following castration, we identified epithelial expression of Hic-5/ARA55 in mouse and human prostate tissues. To determine the role of epithelial Hic-5 in prostate cancer progression and castration responsiveness, we compared LNCaP cells having Hic-5 stably expressed with the parental LNCaP cells following tissue recombination xenografts with mouse prostate stromal cells. We previously identified knocking out prostate stromal TGF-beta signaling potentiated castrate-resistant prostate tumors, in a Wnt-dependent manner. The LNCaP chimeric tumors containing prostate fibroblasts conditionally knocked out for the TGF-beta type II receptor (Tgfbr2-KO) resulted in larger, more invasive, and castration-resistant tumors compared those with floxed (control) stromal cells. However, the LNCaP-Hic5 associated with Tgfbr2-KO fibroblasts generated chimeric tumors with reduced tumor volume, lack of invasion and restored castration dependence. Neutralization of canonical Wnt signaling is shown to reduce prostate tumor size and restore regression following castration. Thus, we hypothesized that epithelial Hic-5/ARA55 expression negatively regulated Wnt signaling. The mechanism of the Hic-5/ARA55 effects on castration was determined by analysis of the c-myc promoter. C-myc luciferase reporter activity suggested Hic-5/ARA55 expression inhibited c-myc activity by beta-catenin. Sequential ChIP analysis indicated beta-catenin and T-cell-specific 4 (TCF4) bound the endogenous c-myc promoter in the absence of Hic-5 expression. However, the formation of a TCF4/Hic-5 repressor complex inhibited c-myc promoter activity, by excluding beta-catenin binding with TCF4 on the promoter. The data indicate Hic-5/ARA55 expression in response to castration-enabled epithelial regression through the repression of c-myc gene at the chromatin level. Oncogene (2011) 30, 167-177; doi:10.1038/onc.2010.400; published online 6 September 2010	[Bhowmick, N. A.] Cedars Sinai Med Ctr, Urooncol Res Program, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Bhowmick, N. A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Li, X.; Martinez-Ferrer, M.; Botta, V.; Uwamariya, C.; Banerjee, J.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Li, X.; Martinez-Ferrer, M.; Botta, V.; Uwamariya, C.; Banerjee, J.] Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37212 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Vanderbilt University; Vanderbilt University	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Urooncol Res Program, Samuel Oschin Comprehens Canc Inst, 8750 Beverly Blvd,Atrium 103, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989; , Xiaohong/0000-0001-5074-193X	Department of Defense [DAMD17-02-1-0063, PC081246]; NIH [CA108646, CA126505]; NATIONAL CANCER INSTITUTE [U54CA126505, R01CA108646] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert Matusik, Roger Jackson and Veronica Placencio for help in the preparation of this paper. The work was supported through Department of Defense (DAMD17-02-1-0063, PC081246) and NIH grants (CA108646, CA126505). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.	Ayala G, 2003, CLIN CANCER RES, V9, P4792; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Cunha GR, 2008, DIFFERENTIATION, V76, P578, DOI 10.1111/j.1432-0436.2008.00290.x; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Fujimoto N, 2007, CANCER INVEST, V25, P32, DOI 10.1080/07357900601130698; Ghogomu SM, 2006, J BIOL CHEM, V281, P1755, DOI 10.1074/jbc.M505869200; GLEAVE M, 1991, CANCER RES, V51, P3753; Guerrero-Santoro J, 2004, J CELL BIOCHEM, V92, P810, DOI 10.1002/jcb.20109; Guo YP, 1999, CANCER RES, V59, P1366; Gurel B, 2008, MODERN PATHOL, V21, p159A; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heitzer MD, 2007, STEROIDS, V72, P218, DOI 10.1016/j.steroids.2006.11.010; Heitzer MD, 2006, CANCER RES, V66, P7326, DOI 10.1158/0008-5472.CAN-05-2379; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jakowlew SB, 1997, ANTICANCER RES, V17, P1849; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johansson A, 2007, PROSTATE, V67, P1664, DOI 10.1002/pros.20657; Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025; Kaur M, 2010, NEOPLASIA, V12, P415, DOI 10.1593/neo.10188; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lee SE, 2000, ANTICANCER RES, V20, P417; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Litvinov IV, 2006, P NATL ACAD SCI USA, V103, P15085, DOI 10.1073/pnas.0603057103; Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483; Lu WY, 2009, EUR J PHARMACOL, V602, P8, DOI 10.1016/j.ejphar.2008.10.053; Mestayer C, 2003, PROSTATE, V56, P192, DOI 10.1002/pros.10229; Miyoshi Y, 2003, PROSTATE, V56, P280, DOI 10.1002/pros.10262; Moon Randall T, 2005, Sci STKE, V2005, pcm1; MUIR GH, 1994, BRIT J CANCER, V69, P130, DOI 10.1038/bjc.1994.21; Mukaratirwa S, 2005, INT J EXP PATHOL, V86, P219, DOI 10.1111/j.0959-9673.2005.00425.x; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Rahman MM, 2003, P NATL ACAD SCI USA, V100, P5124, DOI 10.1073/pnas.0530097100; Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-4; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Taylor RA, 2008, CURR CANCER DRUG TAR, V8, P490, DOI 10.2174/156800908785699351; Thomas SM, 1999, J CELL SCI, V112, P181; Truica CI, 2000, CANCER RES, V60, P4709; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; UKE E, 1983, J UROLOGY, V129, P171, DOI 10.1016/S0022-5347(17)51976-X; Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Zhang J, 2000, MOL CARCINOGEN, V27, P177, DOI 10.1002/(SICI)1098-2744(200003)27:3<177::AID-MC4>3.3.CO;2-J; Zhu ML, 2008, PROSTATE, V68, P287, DOI 10.1002/pros.20698	53	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					167	177		10.1038/onc.2010.400	http://dx.doi.org/10.1038/onc.2010.400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818421	hybrid, Green Published			2022-12-28	WOS:000286438900005
J	Zibat, A; Missiaglia, E; Rosenberger, A; Pritchard-Jones, K; Shipley, J; Hahn, H; Fulda, S				Zibat, A.; Missiaglia, E.; Rosenberger, A.; Pritchard-Jones, K.; Shipley, J.; Hahn, H.; Fulda, S.			Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; hedgehog; ERMS; ARMS	SIGNALING PATHWAY; EXPRESSION; GLI; MEDULLOBLASTOMA; CANCER; CLASSIFICATION; IDENTIFICATION; AMPLIFICATION; INHIBITION; SARCOMA	Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and comprises two major histological subtypes: alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS). Seventy-five percent of ARMS harbor reciprocal chromosomal translocations leading to fusion genes of the forkhead transcription factor FOXO1 and PAX3 or PAX7. The hedgehog (Hh) pathway has been implied in tumor formation and progression of various cancers including RMS. However, whether Hh pathway activation presents a general feature of RMS or whether it is restricted to specific subgroups has not yet been addressed. Here, we report that marker genes of active Hh signaling, that is, Patched1 (Ptch1), Gli1, Gli3 and Myf5, are expressed at significantly higher levels in ERMS and fusion gene-negative ARMS compared with fusion gene-positive ARMS in two distinct cohorts of RMS patients. Consistently, Gli1 expression correlates with Ptch1 expression in ERMS and fusion gene-negative ARMS, but not in fusion gene-positive ARMS. In addition, expression levels of MyoD1 are significantly lower in ERMS and fusion gene-negative ARMS, pointing to an inverse association of Hh activation and early muscle differentiation. Moreover, Myf5 is identified as a novel excellent class predictor for RMS by receiver operating characteristic analysis. Importantly, high expression of Ptch1 or low MyoD1 expression significantly correlate with reduced cumulative survival in fusion gene-negative RMS underscoring the clinical relevance of these findings. By showing that Hh signaling is preferentially activated in specific subgroups of RMS, our study has important implications for molecular targeted therapies, such as small molecule Hh inhibitors, in RMS. Oncogene (2010) 29, 6323-6330; doi:10.1038/onc.2010.368; published online 6 September 2010	[Zibat, A.; Hahn, H.] Univ Goettingen, Inst Human Genet, Gottingen, Germany; [Missiaglia, E.; Pritchard-Jones, K.; Shipley, J.] Inst Canc Res, Dept Mol Cytogenet, Sutton, Surrey, England; [Rosenberger, A.] Univ Goettingen, Dept Genet Epidemiol, Gottingen, Germany; [Fulda, S.] Univ Childrens Hosp, Dept Hematol Oncol, Ulm, Baden Wuerttemb, Germany	University of Gottingen; University of London; Institute of Cancer Research - UK; University of Gottingen; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Pritchard-Jones, Kathy/F-4286-2014; Fulda, Simone/D-5864-2011	Pritchard-Jones, Kathy/0000-0002-2384-9475; missiaglia, edoardo/0000-0001-9221-0117; Fulda, Simone/0000-0002-0459-6417; Shipley, Janet/0000-0001-6748-8678	Deutsche Forschungsgemeinschaft; Bundesministerium fur Bildung und Forschung; European Community; Wilhelm-Sander-Stiftung [2003.112.3]; Chris Lucas Trust;  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); European Community(European Commission); Wilhelm-Sander-Stiftung; Chris Lucas Trust; 	This work has been supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium fur Bildung und Forschung, the European Community (ApopTrain, APOSYS) and IAP6/18 (to SF), and from the Wilhelm-Sander-Stiftung 2003.112.3 (to HH). We would like to thank the Chris Lucas Trust for their support (to EM) and the Children's Cancer and Leukemia Group for providing tumor material and clinical information. La Ligue Nationale Contre Le Cancer in collaboration with Olivier Delattre kindly supported the expression profiling of tumors.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Barr FG, 2002, CANCER RES, V62, P4704; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Gerber AN, 2007, ONCOGENE, V26, P1122, DOI 10.1038/sj.onc.1209891; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; KHATIB ZA, 1993, CANCER RES, V53, P5535; Koleva M, 2005, CELL MOL LIFE SCI, V62, P1863, DOI 10.1007/s00018-005-5072-9; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Missiaglia E, 2009, GENE CHROMOSOME CANC, V48, P455, DOI 10.1002/gcc.20655; Nicol K, 2007, PEDIATR DEVEL PATHOL, V10, P89, DOI 10.2350/06-03-0068.1; Oue T, 2010, J PEDIATR SURG, V45, P387, DOI 10.1016/j.jpedsurg.2009.10.081; Ragazzini P, 2004, HISTOL HISTOPATHOL, V19, P401, DOI 10.14670/HH-19.401; ROBERTS WM, 1989, CANCER RES, V49, P5407; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tomczak KK, 2003, FASEB J, V17, P403, DOI 10.1096/f.03-0568fje; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814	39	85	93	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6323	6330		10.1038/onc.2010.368	http://dx.doi.org/10.1038/onc.2010.368			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20818440				2022-12-28	WOS:000284874700003
J	Fang, X; Cai, Y; Liu, J; Wang, Z; Wu, Q; Zhang, Z; Yang, CJ; Yuan, L; Ouyang, G				Fang, X.; Cai, Y.; Liu, J.; Wang, Z.; Wu, Q.; Zhang, Z.; Yang, C. J.; Yuan, L.; Ouyang, G.			Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal	ONCOGENE			English	Article						Twist2; epithelial-mesenchymal transition; cancer stem cell; breast cancer; metastasis	UP-REGULATION; EMT; GROWTH; ACTIVATION; DERMO-1; PROTEIN; GENE; MORPHOGENESIS; METASTASIS; INVASION	The epithelial to mesenchymal transition (EMT) is a highly conserved cellular programme that has an important role in normal embryogenesis and in cancer invasion and metastasis. We report here that Twist2, a tissue-specific basic helix-loop-helix transcription factor, is overexpressed in human breast cancers and lymph node metastases. In mammary epithelial cells and breast cancer cells, ectopic overexpression of Twist2 results in morphological transformation, downregulation of epithelial markers and upregulation of mesenchymal markers. Moreover, Twist2 enhances the cell migration and colony-forming abilities of mammary epithelial cells and breast cancer cells in vitro and promotes tumour growth in vivo. Ectopic expression of Twist2 in mammary epithelial cells and breast cancer cells increases the size and number of their CD44(high)/CD24(low) stem-like cell sub-populations, promotes the expression of stem cell markers and enhances the self-renewal capabilities of stem-like cells. In addition, exogenous expression of Twist2 leads to constitutive activation of STAT3 (signal transducer and activator of transcription 3) and downregulation of E-cadherin. Thus, the overexpression of Twist2 may contribute to breast cancer progression by activating the EMT programme and enhancing the self-renewal of cancer stem-like cells. Oncogene (2011) 30, 4707-4720; doi:10.1038/onc.2011.181; published online 23 May 2011	[Fang, X.; Cai, Y.; Liu, J.; Wang, Z.; Yuan, L.; Ouyang, G.] Xiamen Univ, Sch Life Sci, State Key Lab Stress Cell Biol, Xiamen 361005, Peoples R China; [Wu, Q.; Zhang, Z.] Xiamen Univ, Affiliated Hosp 1, Dept Breast Surg, Xiamen 361005, Peoples R China; [Yang, C. J.] Xiamen Univ, Coll Chem & Chem Engn, Xiamen 361005, Peoples R China	Xiamen University; Xiamen University; Xiamen University	Ouyang, G (corresponding author), Xiamen Univ, Sch Life Sci, State Key Lab Stress Cell Biol, Xiamen 361005, Peoples R China.	oygldz@yahoo.com.cn	yang, chaoyong/F-9741-2010; Fang, Xiaoguang/N-2313-2014; Yang, Chaoyong/Q-5734-2019	yang, chaoyong/0000-0002-2374-5342; Yang, Chaoyong/0000-0002-2374-5342	National Nature Science Foundation of China [30871242, 31071302]; National Basic Research Program of China [2009CB941601, 2010CB732402]; Fundamental Research Funds for the Central Universities [2010121095]; Science Planning Program of Fujian Province [2009J1010]; Outstanding Young Science Foundation of Fujian Province [2010J06013]; Xiamen University [985]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Science Planning Program of Fujian Province; Outstanding Young Science Foundation of Fujian Province; Xiamen University(Xiamen University)	We thank Professor Kunxin Luo (Department of Molecular and Cell Biology, University of California, Berkeley), Professor Shideng Bao (Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic) and reviewers for critical comments. This work was supported by grants from the National Nature Science Foundation of China (no. 30871242, 31071302), National Basic Research Program of China (no. 2009CB941601, 2010CB732402), the Fundamental Research Funds for the Central Universities (no. 2010121095), the Science Planning Program of Fujian Province (2009J1010), the Outstanding Young Science Foundation of Fujian Province (no. 2010J06013) and the 985 Project grant from Xiamen University.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ansieau S, 2010, ONCOGENE, V29, P3173, DOI 10.1038/onc.2010.92; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dimri GP, 2002, CANCER RES, V62, P4736; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fernando RI, 2010, J CLIN INVEST, V120, P533, DOI 10.1172/JCI38379; Franco HL, 2011, NUCLEIC ACIDS RES, V39, P1177, DOI 10.1093/nar/gkq890; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lee MS, 2000, BONE, V27, P591, DOI 10.1016/S8756-3282(00)00380-X; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018-009-0013-7; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Song G, 2009, J CELL MOL MED, V13, P1706, DOI 10.1111/j.1582-4934.2008.00540.x; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang YN, 2006, CANCER RES, V66, P8617, DOI 10.1158/0008-5472.CAN-06-1308; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	57	152	162	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4707	4720		10.1038/onc.2011.181	http://dx.doi.org/10.1038/onc.2011.181			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602879				2022-12-28	WOS:000298033700003
J	Tanori, M; Pasquali, E; Leonardi, S; Giardullo, P; Di Majo, V; Taccioli, G; Essers, J; Kanaar, R; Mullenders, LH; Atkinson, MJ; Mancuso, M; Saran, A; Pazzaglia, S				Tanori, M.; Pasquali, E.; Leonardi, S.; Giardullo, P.; Di Majo, V.; Taccioli, G.; Essers, J.; Kanaar, R.; Mullenders, L. H.; Atkinson, M. J.; Mancuso, M.; Saran, A.; Pazzaglia, S.			Opposite modifying effects of HR and NHEJ deficiency on cancer risk in Ptc1 heterozygous mouse cerebellum	ONCOGENE			English	Article						radiation; Rad54; DNA-PKcs; LOH; medulloblastoma	DOUBLE-STRAND BREAKS; DNA-DAMAGE; SUPPRESS MEDULLOBLASTOMA; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; GENOME INSTABILITY; REPAIR; RAD54; DISRUPTION; DELETION	Heterozygous Patched1 (Ptc1(+/-)) mice are prone to medulloblastoma (MB), and exposure of newborn mice to ionizing radiation dramatically increases the frequency and shortens the latency of MB. In Ptc1(+/-) mice, MB is characterized by loss of the normal remaining Ptc1 allele, suggesting that genome rearrangements may be key events in MB development. Recent evidence indicates that brain tumors may be linked to defects in DNA-damage repair processes, as various combinations of targeted deletions in genes controlling cell-cycle checkpoints, apoptosis and DNA repair result in MB in mice. Non-homologous end joining (NHEJ) and homologous recombination (HR) contribute to genome stability, and deficiencies in either pathway predispose to genome rearrangements. To test the role of defective HR or NHEJ in tumorigenesis, control and irradiated Ptc1(+/-) mice with two, one or no functional Rad54 or DNA-protein kinase catalytic subunit (DNA-PKcs) alleles were monitored for MB development. We also examined the effect of Rad54 or DNA-PKcs deletion on the processing of endogenous and radiation-induced double-strand breaks (DSBs) in neural precursors of the developing cerebellum, the cells of origin of MB. We found that, although HR and NHEJ collaborate in protecting cells from DNA damage and apoptosis, they have opposite roles in MB tumorigenesis. In fact, although Rad54 deficiency increased both spontaneous and radiation-induced MB development, DNA-PKcs disruption suppressed MB tumorigenesis. Together, our data provide the first evidence that Rad54-mediated HR in vivo is important for suppressing tumorigenesis by maintaining genomic stability. Oncogene (2011) 30, 4740-4749; doi:10.1038/onc.2011.178; published online 23 May 2011	[Tanori, M.; Leonardi, S.; Di Majo, V.; Mancuso, M.; Saran, A.; Pazzaglia, S.] Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy; [Pasquali, E.; Giardullo, P.] Univ Guglielmo Marconi, Dept Radiat Phys, Rome, Italy; [Taccioli, G.] Boston Univ, Goldman Sch Dent Med, Dept Mol & Cellular Biol, Boston, MA 02215 USA; [Essers, J.; Kanaar, R.] Erasmus MC, Canc Genom Ctr, Dept Cell Biol & Genet, Rotterdam, Netherlands; [Essers, J.; Kanaar, R.] Erasmus MC, Dept Radiat Oncol, Rotterdam, Netherlands; [Mullenders, L. H.] Leiden Univ, Med Ctr, Dept Toxicogenet, Leiden, Netherlands; [Atkinson, M. J.] German Res Ctr Environm & Hlth, Helmholtz Zentrum Munchen, Inst Pathol, Neuherberg, Germany; [Essers, J.] Erasmus MC, Dept Vasc Surg, Rotterdam, Netherlands	Italian National Agency New Technical Energy & Sustainable Economics Development; Guglielmo Marconi University; Boston University; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Erasmus University Rotterdam; Erasmus MC	Saran, A (corresponding author), Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy.	anna.saran@enea.it; simonetta.pazzaglia@enea.it	Pasquali, Emanuela/CAG-4451-2022; Atkinson, Michael/AAU-5127-2020; Atkinson, Michael J/E-5537-2011	Atkinson, Michael/0000-0003-3358-2089; Atkinson, Michael J/0000-0003-3358-2089; Saran, Anna/0000-0002-5587-064X	EU [FI6R-CT-2003-508842 RISC-RAD]; Associazione Italiana Ricerca sul Cancro (AIRC) [10357]; Netherlands Genomics Initiative/Netherlands Organization for Scientific Research	EU(European Commission); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Netherlands Genomics Initiative/Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	This work was supported by EU Contract FI6R-CT-2003-508842 RISC-RAD, by Grant 10357 from the Associazione Italiana Ricerca sul Cancro (AIRC) and the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research.	Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Bakhshi S, 2003, J PEDIAT HEMATOL ONC, V25, P248, DOI 10.1097/00043426-200303000-00013; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Cahill D, 2006, FRONT BIOSCI-LANDMRK, V11, P1958, DOI 10.2741/1938; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Deans B, 2003, CANCER RES, V63, P8181; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frappart PO, 2007, EMBO J, V26, P2732, DOI 10.1038/sj.emboj.7601703; Frappart PO, 2009, P NATL ACAD SCI USA, V106, P1880, DOI 10.1073/pnas.0806882106; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Holcomb VB, 2008, CANCER RES, V68, P9497, DOI 10.1158/0008-5472.CAN-08-2085; Lee Y, 2002, CANCER RES, V62, P6395; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Li H, 2007, MOL CELL BIOL, V27, P8205, DOI 10.1128/MCB.00785-07; Li X, 2008, CELL RES, V18, P99, DOI 10.1038/cr.2008.1; Liu YH, 2010, CARCINOGENESIS, V31, P1762, DOI 10.1093/carcin/bgq141; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; McKinnon PJ, 2009, NAT REV NEUROSCI, V10, P100, DOI 10.1038/nrn2559; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Moynahan ME, 1997, P NATL ACAD SCI USA, V19; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Pazzaglia S, 2006, ONCOGENE, V25, P5575, DOI 10.1038/sj.onc.1209544; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Pazzaglia S, 2000, MOL CARCINOGEN, V27, P219, DOI 10.1002/(SICI)1098-2744(200003)27:3<219::AID-MC9>3.0.CO;2-S; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Schmuckli-Maurer J, 2003, NUCLEIC ACIDS RES, V31, P1013, DOI 10.1093/nar/gkg190; Smiraldo PG, 2005, CANCER RES, V65, P2089, DOI 10.1158/0008-5472.CAN-04-2079; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tanori M, 2008, CARCINOGENESIS, V29, P1911, DOI 10.1093/carcin/bgn174; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103; Yoshihara T, 2004, EMBO J, V23, P670, DOI 10.1038/sj.emboj.7600087	49	9	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4740	4749		10.1038/onc.2011.178	http://dx.doi.org/10.1038/onc.2011.178			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602895				2022-12-28	WOS:000298033700006
J	Akita, H; Nagano, H; Takeda, Y; Eguchi, H; Wada, H; Kobayashi, S; Marubashi, S; Tanemura, M; Takahashi, H; Ohigashi, H; Tomita, Y; Ishikawa, O; Mori, M; Doki, Y				Akita, H.; Nagano, H.; Takeda, Y.; Eguchi, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Takahashi, H.; Ohigashi, H.; Tomita, Y.; Ishikawa, O.; Mori, M.; Doki, Y.			Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity	ONCOGENE			English	Article						pancreatic cancer; Ep-CAM; prognosis; invasion; surgery	CARCINOMA-ASSOCIATED ANTIGEN; ADHESION MOLECULE; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGET; POOR SURVIVAL; EXPRESSION; ADENOCARCINOMA; EPCAM; GEMCITABINE	The identification of molecular markers useful for predicting prognosis in pancreatic cancer patients is crucial for advances in disease management. The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy. However, the clinical significance of Ep-CAM expression in pancreatic cancer is not well-known. We determined the difference of malignant potential between parental and Ep-CAM-transfected pancreatic cancer cell lines by using proliferation, invasion and migration assay. Furthermore, we determined the relationship between tumoral Ep-CAM expression of resected specimens and clinical prognosis in 95 pancreatic cancer patients receiving radical surgery at two different cancer centers. One of the three Ep-CAM-transfected cell lines showed significantly low proliferation rate compared with the parental cell, while there was no difference in the other two cell lines. In invasion and migration assays, Ep-CAM-transfected cells showed significantly lower malignant potential than parental in all of the three cell lines. In 95 pancreatic cancer patients, 47 patients showed high-Ep-CAM expression, while 48 patients showed low, and there was no difference of clinicopathological features between Ep-CAM high and low-expression group. High-Ep-CAM expression group showed significantly good prognosis in overall survival (3-year survival; 56.2 versus 19.2%, P = 0.0018) as well as in disease-free survival (3-year survival; 40.3 versus 14.4%, P = 0.038) compared with low-expression group. In addition, the impact of Ep-CAM was observed strongly in LN-negative group when the influence of Ep-CAM was examined with dividing patients into LN-positive and negative group. In multivariate analysis, Ep-CAM expression was one of the independent prognostic factors as well as histology and lymph node metastasis. Ep-CAM expression was found to be related to the suppression of pancreatic cancer cell activity and the good prognosis in pancreatic cancer patients receiving the curative resection. Oncogene (2011) 30, 3468-3476; doi:10.1038/onc.2011.59; published online 14 March 2011	[Akita, H.; Nagano, H.; Takeda, Y.; Eguchi, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Mori, M.; Doki, Y.] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; [Takahashi, H.; Ohigashi, H.; Ishikawa, O.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka, Japan; [Tomita, Y.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol & Cytol, Osaka, Japan	Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases	Nagano, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Surg, 2-2,Yamadaoka E-2, Suita, Osaka 5650871, Japan.	hnagano@gesurg.med.osaka-u.ac.jp	Takahashi, Hidenori/I-1231-2019	Takahashi, Hidenori/0000-0003-4801-3540	Grants-in-Aid for Scientific Research [21590412] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451; Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Balzar M, 1999, EXP CELL RES, V246, P108, DOI 10.1006/excr.1998.4263; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891; Cirulli V, 1998, J CELL BIOL, V140, P1519, DOI 10.1083/jcb.140.6.1519; EDWARDS DP, 1986, CANCER RES, V46, P1306; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Fong D, 2008, J CLIN PATHOL, V61, P31, DOI 10.1136/jcp.2006.037333; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; GEER RJ, 1993, AM J SURG, V165, P68, DOI 10.1016/S0002-9610(05)80406-4; Gonzalez B, 2009, STEM CELLS, V27, P1782, DOI 10.1002/stem.97; Gosens MJEM, 2007, MODERN PATHOL, V20, P221, DOI 10.1038/modpathol.3800733; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Jojovic M, 1998, HISTOCHEM J, V30, P723, DOI 10.1023/A:1003486630314; Kahlert C, 2009, BRIT J CANCER, V101, P457, DOI 10.1038/sj.bjc.6605136; KAYAHARA M, 1993, CANCER, V72, P2118, DOI 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4; Kimura H, 2007, INT J ONCOL, V30, P171; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Litvinov SV, 1996, AM J PATHOL, V148, P865; Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639; MOMBURG F, 1987, CANCER RES, V47, P2883; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097/00000658-199501000-00007; Noda T, 2009, BRIT J CANCER, V100, P1647, DOI 10.1038/sj.bjc.6605064; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Ogawa M, 2004, HEPATOLOGY, V39, P528, DOI 10.1002/hep.20048; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Rao CG, 2005, INT J ONCOL, V27, P49; ROSS AH, 1986, BIOCHEM BIOPH RES CO, V135, P297, DOI 10.1016/0006-291X(86)90976-9; Rothenberg ML, 1996, ANN ONCOL, V7, P347; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Schmidt M, 2008, CLIN CANCER RES, V14, P5849, DOI 10.1158/1078-0432.CCR-08-0669; Seligson DB, 2004, CLIN CANCER RES, V10, P2659, DOI 10.1158/1078-0432.CCR-1132-03; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Staley CA, 1996, AM J SURG, V171, P118, DOI 10.1016/S0002-9610(99)80085-3; Stoecklein NH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-165; Tai KY, 2007, ONCOGENE, V26, P3989, DOI 10.1038/sj.onc.1210176; Trzpis M, 2007, AM J PATHOL, V171, P386, DOI 10.2353/ajpath.2007.070152; Tsujie M, 2003, EXP CELL RES, V289, P143, DOI 10.1016/S0014-4827(03)00263-5; Varga M, 2004, CLIN CANCER RES, V10, P3131, DOI 10.1158/1078-0432.CCR-03-0528; Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Zhang SL, 1998, CLIN CANCER RES, V4, P2669	50	28	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	31					3468	3476		10.1038/onc.2011.59	http://dx.doi.org/10.1038/onc.2011.59			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21399662				2022-12-28	WOS:000293508100007
J	Oh, JH; Cho, MC; Kim, JH; Lee, SY; Kim, HJ; Park, ES; Ban, JO; Kang, JW; Lee, DH; Shim, JH; Han, SB; Moon, DC; Park, YH; Yu, DY; Kim, JM; Kim, SH; Yoon, DY; Hong, JT				Oh, J. H.; Cho, M-C; Kim, J-H; Lee, S. Y.; Kim, H. J.; Park, E. S.; Ban, J. O.; Kang, J-W; Lee, D-H; Shim, J-H; Han, S. B.; Moon, D. C.; Park, Y. H.; Yu, D-Y; Kim, J-M; Kim, S. H.; Yoon, D-Y; Hong, J. T.			IL-32 gamma inhibits cancer cell growth through inactivation of NF-kappa B and STAT3 signals	ONCOGENE			English	Article						IL-32; cytokine; colon cancer; NF-kappa B; STAT3	PROINFLAMMATORY CYTOKINE; TUMOR-METASTASIS; PROSTATE-CANCER; TRANSGENIC MICE; T-CELLS; INTERLEUKIN-10; IL-32; INFLAMMATION; EXPRESSION; IDENTIFICATION	Several studies have shown physiological functions of interleukin (IL)-32, a novel cytokine. However, the role of IL-32 in cancer development has not been reported. In this study, we showed that IL-32 gamma inhibited tumor growth in IL-32 gamma-overexpressing transgenic mice inoculated with melanoma as well as colon tumor growth in xenograft nude mice inoculated with IL-32 gamma-transfected colon cancer cells (SW620). The inhibitory effect of IL-32 gamma on tumor growth was associated with the inhibition of constitutive activated nuclear transcription factor-kappa B (NF-kappa B) and of signal transducer and activator of transcription 3 (STAT3). The expression of antiapoptotic, cell proliferation and tumor-promoting genes (bcl-2, X-chromosome inhibitor of apoptosis protein (IAP), cellular IAP and cellular FADD-like IL-1 beta-converting enzyme-inhibitory protein, cyclin D), cyclin-dependent kinase 4, cycolooxygenase-2 and inducible nitric oxide synthase was decreased, whereas the expression of apoptotic target genes (caspase-3 and -9, bax) increased. In tumor, spleen and blood, the number of cytotoxic CD8(+) T cells and CD57(+) natural killer cells and the levels of IL-10 increased, but that of tumor necrosis factor-alpha (TNF-alpha), IL-1 beta and IL-6 decreased. We also found that forced overexpression of IL-32 gamma inhibited colon cancer cell (SW620 and HCT116) growth accompanied with the inhibition of activated NF-kappa B and STAT3 in vitro. In addition, when IL-32 gamma was knocked down by small interfering RNA (siRNA) or neutralized with an anti-IL-32 gamma antibody, IL-32 gamma-induced colon cancer cell growth inhibition, the IL-32 gamma-induced decrease of TNF-alpha, IL-1 and IL-6 production, and the increase of IL-10 production were abolished. However, siRNA of NF kappa B and STAT3 augmented IL-32 gamma-induced colon cancer cell growth inhibition. These findings indicate significant pathophysiological roles of IL-32 gamma in cancer development. Oncogene (2011) 30, 3345-3359; doi:10.1038/onc.2011.52; published online 21 March 2011	[Oh, J. H.; Cho, M-C; Lee, S. Y.; Park, E. S.; Ban, J. O.; Han, S. B.; Moon, D. C.; Hong, J. T.] Chungbuk Natl Univ, Coll Pharm, Cheongju 361463, Chungbuk, South Korea; [Oh, J. H.; Cho, M-C; Lee, S. Y.; Park, E. S.; Han, S. B.; Moon, D. C.; Hong, J. T.] Chungbuk Natl Univ, Med Res Ctr, Cheongju 361463, Chungbuk, South Korea; [Kim, J-H; Kim, H. J.; Kang, J-W; Lee, D-H; Shim, J-H; Yoon, D-Y] Konkuk Univ, Dept Biosci & Biotechnol, Bio Mol Informat Ctr, Seoul 143701, South Korea; [Park, Y. H.; Yu, D-Y] Korea Res Inst Biosci & Biotechnol, Anim Dis Res Ctr, Taejon, South Korea; [Kim, J-M] Chungnam Natl Univ, Pathol Lab, Taejon, South Korea; [Kim, S. H.] Konkuk Univ, Lab Cytokine Immunol, Med Immunol Ctr, Inst Biomed Sci & Technol, Seoul 143701, South Korea	Chungbuk National University; Chungbuk National University; Konkuk University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Konkuk University; Konkuk University Medical Center	Hong, JT (corresponding author), Chungbuk Natl Univ, Coll Pharm, 12 Gaeshin Dong, Cheongju 361463, Chungbuk, South Korea.	ydy4218@konkuk.ac.kr; jinthong@chungbuk.ac.kr		kim, sunghoon/0000-0002-1570-3230; Shim, Jung-Hyun/0000-0002-4062-4016; KIM, JIN MAN/0000-0003-0905-9730	Korea Research Foundation (MRC) [R13-2008-001-00000-00]; Ministry for Health, Welfare and Family affairs, Republic of Korea [0920080]; National Research Foundation of Korea [2009-0093824, 2010-0019306]; KRIBB Research Initiative	Korea Research Foundation (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)National Research Foundation of Korea); Ministry for Health, Welfare and Family affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea(National Research Foundation of Korea); KRIBB Research Initiative	This work was supported by the Korea Research Foundation Grant (MRC, R13-2008-001-00000-00) and the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0920080). D Yoon was partially from National Research Foundation of Korea (2009-0093824, 2010-0019306) and D Yu from KRIBB Research Initiative Program Grant. We thank Dr Howard P Glauert (University of Kentucky) who provided invaluable assistance with English legal manuscripts.	Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Ban JO, 2009, MOL CANCER THER, V8, P1613, DOI 10.1158/1535-7163.MCT-08-0694; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cacev T, 2008, CARCINOGENESIS, V29, P1572, DOI 10.1093/carcin/bgn164; Calabrese F, 2008, AM J RESP CRIT CARE, V178, P894, DOI 10.1164/rccm.200804-646OC; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Choi JD, 2009, IMMUNOLOGY, V126, P535, DOI 10.1111/j.1365-2567.2008.02917.x; Choi J, 2010, P NATL ACAD SCI USA, V107, P21082, DOI 10.1073/pnas.1015418107; CHOI KC, 2002, CANCER RES, V69, P583; DAHL CA, 1992, J IMMUNOL, V148, P597; Dinarello CA, 2006, ANN RHEUM DIS, V65, P61, DOI 10.1136/ard.2006.058511; Fujimoto J, 2002, ANN ONCOL, V13, P1598, DOI 10.1093/annonc/mdf248; Goda C, 2006, INT IMMUNOL, V18, P233, DOI 10.1093/intimm/dxh339; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; GROSCURTH P, 1990, INT J CANCER, V45, P694, DOI 10.1002/ijc.2910450422; Hardwick JCH, 2001, ONCOGENE, V20, P819, DOI 10.1038/sj.onc.1204162; Hisada M, 2004, CANCER RES, V64, P1152, DOI 10.1158/0008-5472.CAN-03-2084; Hou T, 2008, J BIOL CHEM, V283, P30725, DOI 10.1074/jbc.M805941200; Huang SY, 1996, CLIN CANCER RES, V2, P1969; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; Jenkins BJ, 2005, BLOOD, V105, P3512, DOI 10.1182/blood-2004-09-3751; Kang JW, 2009, IMMUNOLOGY, V128, pe532, DOI 10.1111/j.1365-2567.2008.03025.x; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim KS, 2008, POLYM-KOREA, V32, P38; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Kundu N, 1997, CELL IMMUNOL, V180, P55, DOI 10.1006/cimm.1997.1176; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee J, 1998, CANCER RES, V58, P1478; Lee S, 2010, HYBRIDOMA, V29, P501, DOI 10.1089/hyb.2010.0059; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Lu C, 2004, J CLIN ONCOL, V22, P4575, DOI 10.1200/JCO.2004.01.091; Ma XY, 2010, J IMMUNOL, V184, P4898, DOI 10.4049/jimmunol.1000142; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marcondes AM, 2008, P NATL ACAD SCI USA, V105, P2865, DOI 10.1073/pnas.0712391105; Moretta L, 2000, IMMUNOL TODAY, V21, P420, DOI 10.1016/S0167-5699(00)01673-X; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Nishida A, 2009, J BIOL CHEM, V284, P17868, DOI 10.1074/jbc.M900368200; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Ray S, 2008, NUCLEIC ACIDS RES, V36, P4510, DOI 10.1093/nar/gkn419; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Seo EH, 2008, J MICROBIOL BIOTECHN, V18, P1606; Shurin MR, 2006, CANCER METAST REV, V25, P333, DOI 10.1007/s10555-006-9010-6; Son DJ, 2007, MOL CANCER THER, V6, P675, DOI 10.1158/1535-7163.MCT-06-0328; Sorrentino C, 2009, AM J RESP CRIT CARE, V180, P769, DOI 10.1164/rccm.200903-0400OC; Wang AG, 2005, J HEPATOL, V43, P836, DOI 10.1016/j.jhep.2005.04.012; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Westbrook AM, 2009, CANCER RES, V69, P4827, DOI 10.1158/0008-5472.CAN-08-4416; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang F, 2009, CELL SIGNAL, V21, P1085, DOI 10.1016/j.cellsig.2009.02.018; Zheng LM, 1996, J EXP MED, V184, P579, DOI 10.1084/jem.184.2.579	54	80	84	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	30					3345	3359		10.1038/onc.2011.52	http://dx.doi.org/10.1038/onc.2011.52			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21423208	Green Published, hybrid			2022-12-28	WOS:000293215700005
J	Cash, TP; Gruber, JJ; Hartman, TR; Henske, EP; Simon, MC				Cash, T. P.; Gruber, J. J.; Hartman, T. R.; Henske, E. P.; Simon, M. C.			Loss of the Birt-Hogg-Dube tumor suppressor results in apoptotic resistance due to aberrant TGF beta-mediated transcription	ONCOGENE			English	Article						BHD; apoptosis; Bim; TGF beta; mTOR	RENAL-CELL CARCINOMA; BH3-ONLY PROTEIN BIM; BHD GENE; YOLK-SAC; SIGNALING PATHWAYS; MTOR ACTIVATION; EXPRESSION; GROWTH; MUTATIONS; CANCER	Birt-Hogg-Dube (BHD) syndrome is an inherited cancer susceptibility disease characterized by skin and kidney tumors, as well as cystic lung disease, which results from loss-of-function mutations in the BHD gene. BHD is also inactivated in a significant fraction of patients with sporadic renal cancers and idiopathic cystic lung disease, and little is known about its mode of action. To investigate the molecular and cellular basis of BHD tumor suppressor activity, we generated mutant Bhd mice and embryonic stem cell lines. BHD-deficient cells exhibited defects in cell-intrinsic apoptosis that correlated with reduced expression of the BH3-only protein Bim, which was similarly observed in all human and murine BHD-related tumors examined. We further demonstrate that Bim deficiency in Bhd(-/-) cells is not a consequence of elevated mTOR or ERK activity, but results instead from reduced Bim transcription associated with a general loss of TGF beta-mediated transcription and chromatin modifications. In aggregate, this work identifies a specific tumor suppressive mechanism for BHD in regulating TGF beta-dependent transcription and apoptosis, which has implications for the development of targeted therapies. Oncogene (2011) 30, 2534-2546; doi:10.1038/onc.2010.628; published online 24 January 2011	[Cash, T. P.; Gruber, J. J.; Simon, M. C.] Abramson Family Canc Res Inst, Philadelphia, PA USA; [Cash, T. P.; Simon, M. C.] Univ Penn, Sch Med, Dept Cell & Mol Biol, Philadelphia, PA 19104 USA; [Hartman, T. R.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; [Henske, E. P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; [Simon, M. C.] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Fox Chase Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute; University of Pennsylvania	Simon, MC (corresponding author), 451 BRB 2-2,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021		Myrovlytis Trust (London, UK); NIH [CA104838]; NATIONAL CANCER INSTITUTE [P01CA104838] Funding Source: NIH RePORTER	Myrovlytis Trust (London, UK); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Myrovlytis Trust (London, UK) and NIH grant no. CA104838 for funding this work, Marc Yudkoff, Ilana Nissim, Evgueni Daikhin, Hongwei Yu, Anja Runge, and Terri Richardson for technical assistance and Brian Keith, Guoliang Qing, and Xianxin Hua for critically reviewing the manuscript. MCS is an investigator of the Howard Hughes Medical Institute.	Adelman DM, 1999, GENE DEV, V13, P2478, DOI 10.1101/gad.13.19.2478; Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; Goumans MJ, 1999, DEVELOPMENT, V126, P3473; Gruber JJ, 2009, CELL, V138, P328, DOI 10.1016/j.cell.2009.04.046; Gunji Y, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049874; Guo Y, 2009, ONCOGENE, V28, P1864, DOI 10.1038/onc.2009.35; Hartman TR, 2009, ONCOGENE, V28, P1594, DOI 10.1038/onc.2009.14; Hasumi Y, 2009, P NATL ACAD SCI USA, V106, P18722, DOI 10.1073/pnas.0908853106; Hong SB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-160; Houde N, 2009, J BIOL CHEM, V284, P23397, DOI 10.1074/jbc.M109.019372; Hudon V, 2010, J MED GENET, V47, P182, DOI 10.1136/jmg.2009.072009; Khoo SK, 2003, CANCER RES, V63, P4583; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Lademann UA, 2008, THROMB HAEMOSTASIS, V100, P1041, DOI 10.1160/TH08-04-0266; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McRonald FE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-31; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Ramesh S, 2008, EMBO REP, V9, P990, DOI 10.1038/embor.2008.158; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Savatier P, 1996, ONCOGENE, V12, P309; Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842; Singh SR, 2006, ONCOGENE, V25, P5933, DOI 10.1038/sj.onc.1209593; Su H, 2009, GENE DEV, V23, P304, DOI 10.1101/gad.1749809; Toro JR, 2008, J MED GENET, V45, P321, DOI 10.1136/jmg.2007.054304; van Slegtenhorst M, 2007, J BIOL CHEM, V282, P24583, DOI 10.1074/jbc.M700857200; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Woodward ER, 2008, CLIN CANCER RES, V14, P5925, DOI 10.1158/1078-0432.CCR-08-0608; Yu J, 2008, J CELL PHYSIOL, V215, P422, DOI 10.1002/jcp.21325; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	48	46	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2534	2546		10.1038/onc.2010.628	http://dx.doi.org/10.1038/onc.2010.628			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258407	Green Published, hybrid			2022-12-28	WOS:000291198400005
J	Goding, CR				Goding, C. R.			A picture of Mitf in melanoma immortality	ONCOGENE			English	Editorial Material							PROLIFERATION; SENESCENCE; CELLS	The Mitf gene has a key role in melanocytes and melanoma by regulating cell cycle progression, survival and differentiation. Two papers in this issue of Oncogene (Cheli et al., 2011; Strub et al., 2011) reveal that low-Mitf cells can initiate tumors with high efficiency, and that Mitf blocks senescence by regulating genes implicated in S-phase progression and mitosis. Oncogene (2011) 30, 2304-2306; doi: 10.1038/onc.2010.641; published online 31 January 2011	Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford OX3 7DQ, England	Ludwig Institute for Cancer Research; University of Oxford	Goding, CR (corresponding author), Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Old Rd Campus,Res Bldg, Oxford OX3 7DQ, England.	colin.goding@ludwig.ox.ac.uk		Goding, Colin/0000-0002-1614-3909				Arnheiter H, 2010, PIGM CELL MELANOMA R, V23, P729, DOI 10.1111/j.1755-148X.2010.00759.x; Bennett DC, 2008, PIGM CELL MELANOMA R, V21, P27, DOI 10.1111/j.1755-148X.2007.00433.x; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045	10	50	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	20					2304	2306		10.1038/onc.2010.641	http://dx.doi.org/10.1038/onc.2010.641			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21278792				2022-12-28	WOS:000290789200002
J	Sidler, D; Renzulli, P; Schnoz, C; Berger, B; Schneider-Jakob, S; Fluck, C; Inderbitzin, D; Corazza, N; Candinas, D; Brunner, T				Sidler, D.; Renzulli, P.; Schnoz, C.; Berger, B.; Schneider-Jakob, S.; Flueck, C.; Inderbitzin, D.; Corazza, N.; Candinas, D.; Brunner, T.			Colon cancer cells produce immunoregulatory glucocorticoids	ONCOGENE			English	Article						extra-adrenal steroidogenesis; colon cancer; immune escape; nuclear receptors	INTESTINAL EPITHELIAL-CELLS; COLORECTAL-CANCER; TUMOR SURVEILLANCE; IMMUNE PRIVILEGE; LRH-1; LYMPHOCYTES; ACTIVATION; EXPRESSION; APOPTOSIS; SURVIVAL	Glucocorticoids (GC) have important anti-inflammatory and pro-apoptotic activities. Initially thought to be exclusively produced by the adrenal glands, there is now increasing evidence for extra-adrenal sources of GCs. We have previously shown that the intestinal epithelium produces immunoregulatory GCs and that intestinal steroidogenesis is regulated by the nuclear receptor liver receptor homolog-1 (LRH-1). As LRH-1 has been implicated in the development of colon cancer, we here investigated whether LRH-1 regulates GC synthesis in colorectal tumors and whether tumor-produced GCs suppress T-cell activation. Colorectal cancer cell lines and primary tumors were found to express steroidogenic enzymes and regulatory factors required for the de novo synthesis of cortisol. Both cell lines and primary tumors constitutively produced readily detectable levels of cortisol, as measured by radioimmunoassay, thin-layer chromatography and bioassay. Whereas overexpression of LRH-1 significantly increased the expression of steroidogenic enzymes and the synthesis of cortisol, downregulation or inhibition of LRH-1 effectively suppressed these processes, indicating an important role of LRH-1 in colorectal tumor GC synthesis. An immunoregulatory role of tumor-derived GCs could be further confirmed by demonstrating a suppression of T-cell activation. This study describes for the first time cortisol synthesis in a non-endocrine tumor in humans, and suggests that the synthesis of bioactive GCs in colon cancer cells may account as a novel mechanism of tumor immune escape. Oncogene (2011) 30, 2411-2419; doi:10.1038/onc.2010.629; published online 24 January 2011	[Brunner, T.] Univ Konstanz, Dept Biol, Div Biochem Pharmacol, D-78457 Constance, Germany; [Sidler, D.; Schnoz, C.; Berger, B.; Schneider-Jakob, S.; Corazza, N.] Univ Bern, Inst Pathol, Div Expt Pathol, Bern, Switzerland; [Renzulli, P.; Inderbitzin, D.; Candinas, D.] Univ Bern, Insel Univ Hosp, Dept Visceral Surg & Med, Bern, Switzerland; [Flueck, C.] Univ Bern, Univ Childrens Hosp, Div Pediat Endocrinol, Bern, Switzerland	University of Konstanz; University of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Brunner, T (corresponding author), Univ Konstanz, Dept Biol, Div Biochem Pharmacol, Box 660,Univ Str 10, D-78457 Constance, Germany.	thomas.brunner@uni-konstanz.de	Sidler, Daniel/G-2447-2019; Renzulli, Pietro/GQH-9366-2022	Renzulli, Pietro/0000-0001-5557-5512; Flueck, Christa/0000-0002-4568-5504	Oncosuisse [OCS-02025-02-2007]; Swiss National Science Foundation [310000-121854]	Oncosuisse; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Mario Noti, Pamela Bianchi, Andrea Hirsch, Gabi Hofer and Andreas Kappeler for technical help and advice, the members of the Division of Clinical Histopathology for preparation of tissue sections, and Sam Okret and Kristina Schoonjans for reagents. This work was supported by research grants from Oncosuisse (OCS-02025-02-2007) and the Swiss National Science Foundation (310000-121854) to TB. DS was supported by an MD-PhD fellowship from the Swiss National Science Foundation.	Atanasov AG, 2008, FASEB J, V22, P4117, DOI 10.1096/fj.08-114157; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Brunner T, 2001, CELL DEATH DIFFER, V8, P706, DOI 10.1038/sj.cdd.4400854; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95; Cima I, 2004, J EXP MED, V200, P1635, DOI 10.1084/jem.20031958; Cima I, 2006, IMMUNOL LETT, V106, P99, DOI 10.1016/j.imlet.2006.04.005; Coste A, 2007, P NATL ACAD SCI USA, V104, P13098, DOI 10.1073/pnas.0702440104; Dardis A, 2003, J ENDOCRINOL, V179, P131, DOI 10.1677/joe.0.1790131; Davies E, 2003, CLIN EXP PHARMACOL P, V30, P437, DOI 10.1046/j.1440-1681.2003.03867.x; Davies RJ, 2005, NAT REV CANCER, V5, P199, DOI 10.1038/nrc1569; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He N, 2008, GASTROENTEROLOGY, V134, P793, DOI 10.1053/j.gastro.2008.01.006; Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907; Kempna P, 2007, MOL PHARMACOL, V71, P787, DOI 10.1124/mol.106.028902; Lee YK, 2006, J BIOL CHEM, V281, P7850, DOI 10.1074/jbc.M509115200; MacKenzie SM, 2000, J MOL ENDOCRINOL, V24, P321, DOI 10.1677/jme.0.0240321; Miller Walter L., 2008, V13, P1, DOI 10.1159/000134751; Mueller M, 2007, ENDOCRINOLOGY, V148, P1445, DOI 10.1210/en.2006-0591; Mueller M, 2006, J EXP MED, V203, P2057, DOI 10.1084/jem.20060357; Noti M, 2009, SEMIN IMMUNOPATHOL, V31, P237, DOI 10.1007/s00281-009-0159-2; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Pazirandeh A, 1999, FASEB J, V13, P893, DOI 10.1096/fasebj.13.8.893; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; TAKEDA Y, 1994, ENDOCRINOLOGY, V135, P2283, DOI 10.1210/en.135.5.2283; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781; Wahl SM, 2006, IMMUNOL REV, V213, P213, DOI 10.1111/j.1600-065X.2006.00437.x	35	65	65	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	21					2411	2419		10.1038/onc.2010.629	http://dx.doi.org/10.1038/onc.2010.629			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258413	Green Submitted			2022-12-28	WOS:000291008000003
J	Kim, JH; Yoon, S; Park, M; Park, HO; Ko, JJ; Lee, K; Bae, J				Kim, J-H; Yoon, S.; Park, M.; Park, H-O; Ko, J-J; Lee, K.; Bae, J.			Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W)	ONCOGENE			English	Article						FOXL2; granulosa cell tumor; apoptosis; caspase; BAK; death receptors	OUTER-MEMBRANE PERMEABILIZATION; DEATH RECEPTORS; CYTOCHROME-C; MYELOID-LEUKEMIA; OVARY; COMPLEX; BAX; TRANSCRIPTION; ACTIVATION; REPRESSES	Some mutations in FOXL2 result in premature ovarian failure accompanied by blepharophimosis, ptosis, epicanthus inversus syndrome type I disease, and FOXL2-null mice exhibit developmental defects in granulosa cells. Recently, FOXL2 c.402C>G, a new somatic mutation that leads to a p. C134W change, was found in the majority of adult-type ovarian granulosa cell tumors (GCTs). In this study, we investigated the possible mechanisms by which the C134W mutation contributes to the development of GCTs. Wild-type (WT) and mutant FOXL2 displayed differential apoptotic activities. Specifically, WT FOXL2 induced significant granulosa cell death, but the mutant exhibited minimal cell death. The FOXL2-induced apoptotic response was greatly dependent on caspase 8, BID and BAK because the depletion of any of these three proteins inhibited FOXL2 from eliciting the full apoptotic response. Activation of caspase 8 and subsequent increased production of truncated BID, and oligomerization of BAK, and release of cytochrome c were all associated with the apoptosis induced by WT FOXL2 expression. In contrast, the mutant FOXL2 was unable to elicit the full array of apoptotic signaling responses. In addition, we found differential TNF-R1 (tumor necrosis factor-receptor 1) and Fas (CD95/APO-1) upregulation between the WT and the mutant, and the silencing of TNF-R1 or Fas and the blockage of the death signaling mediated by TNF-R1 or Fas using TNF-Fc or Fas-Fc, respectively, resulted in significant attenuations of FOXL2-induced apoptosis. Moreover, granulosa cells that expressed either WT FOXL2 or mutant exhibited distinct cell death sensitivities on activation of death receptors and deprivation of serum. Thus, the differential activities of FOXL2 and its mutant may partially account for the pathophysiology of GCT development. Oncogene (2011) 30, 1653-1663; doi:10.1038/onc.2010.541; published online 29 November 2010	[Kim, J-H; Yoon, S.; Park, M.; Park, H-O; Ko, J-J; Bae, J.] CHA Univ, Coll Life Sci, Dept Biomed Sci, Songnam 463836, South Korea; [Lee, K.] Chung Ang Univ, Dept Life Sci, Seoul 156756, South Korea	Pochon Cha University; Chung Ang University	Bae, J (corresponding author), CHA Univ, Coll Life Sci, Dept Biomed Sci, 222 Yatap Dong, Songnam 463836, South Korea.	jeehyeon@cha.ac.kr			National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology [2009-0066320, 2009-0093821]; Ministry of Health, Welfare and Family Affairs [A084923]	National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology(National Research Foundation of Korea); Ministry of Health, Welfare and Family Affairs(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by the Basic Science Research Program (2009-0066320) and the Priority Research Centers Program (2009-0093821) through the National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology and by a grant (A084923) from the Korea Healthcare Technology R&D Project from the Ministry of Health, Welfare and Family Affairs.	Arnoult D, 2008, METHODS, V44, P229, DOI 10.1016/j.ymeth.2007.11.003; Benayoun BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008789; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Ganju N, 2003, CELL DEATH DIFFER, V10, P652, DOI 10.1038/sj.cdd.4401234; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Hail N, 2005, APOPTOSIS, V10, P687, DOI 10.1007/s10495-005-0792-8; Jabbour AM, 2009, CELL DEATH DIFFER, V16, P555, DOI 10.1038/cdd.2008.179; Kang BPS, 2003, AM J PHYSIOL-RENAL, V284, pF455, DOI 10.1152/ajprenal.00137.2002; Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688; Kornblau SM, 2010, CLIN CANCER RES, V16, P1865, DOI 10.1158/1078-0432.CCR-09-2551; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI P, 2004, CELL, V116, P57; Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011; Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Park M, 2010, MOL ENDOCRINOL, V24, P1024, DOI 10.1210/me.2009-0375; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Pisarska MD, 2004, ENDOCRINOLOGY, V145, P3424, DOI 10.1210/en.2003-1141; Schrader KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007988; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Uda M, 2004, HUM MOL GENET, V13, P1171, DOI 10.1093/hmg/ddh124; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	35	78	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	14					1653	1663		10.1038/onc.2010.541	http://dx.doi.org/10.1038/onc.2010.541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21119601				2022-12-28	WOS:000289239400004
J	Lui, VWY; Yau, DMS; Cheung, CSF; Wong, SCC; Chan, AKC; Zhou, Q; Wong, EL; Lau, CPY; Lam, EKY; Hui, EP; Hong, B; Hui, CWC; Chan, ASK; Ng, PKS; Ng, YK; Lo, KW; Tsang, CM; Tsui, SKW; Tsao, SW; Chan, ATC				Lui, V. W. Y.; Yau, D. M-S; Cheung, C. S-F; Wong, S. C. C.; Chan, A. K-C; Zhou, Q.; Wong, EY-L; Lau, C. P. Y.; Lam, E. K. Y.; Hui, E. P.; Hong, B.; Hui, C. W. C.; Chan, A. S-K; Ng, P. K. S.; Ng, Y-K; Lo, K-W; Tsang, C. M.; Tsui, S. K. W.; Tsao, S-W; Chan, A. T. C.			FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation	ONCOGENE			English	Article						FGF8b; NPC; LMP1; NF-kappa B	INDUCED GROWTH-FACTOR; ANDROGEN RECEPTORS; FGF-8 ISOFORMS; FIBROBLAST-GROWTH-FACTOR-8 EXPRESSION; ESOPHAGEAL ADENOCARCINOMA; OVER-EXPRESSION; PROSTATE-CANCER; PROGRESSION; ACTIVATION; SURVIVAL	The fibroblast growth factor 8b (FGF8b) oncogene is known to be primarily involved in the tumorigenesis and progression of hormone-related cancers. Its role in other epithelial cancers has not been investigated, except for esophageal cancer, in which FGF8b overexpression was mainly found in tumor biopsies of male patients. These observations were consistent with previous findings in these cancer types that the male sex-hormone androgen is responsible for FGF8b expression. Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer of head and neck commonly found in Asia. It is etiologically associated with Epstein-Barr Virus (EBV) infection, inflammatory tumor microenvironment and relatively higher male predominance. Here, we reported for the first time that FGF8b is overexpressed in this EBV-associated non-hormone-related cancer of the head and neck, NPC. More importantly, overexpression of FGF8b mRNA and protein was detected in a large majority of NPC tumors from both male and female genders, in addition to multiple NPC cell lines. We hypothesized that FGF8b overexpression may contribute to NPC tumorigenesis. Using EBV-associated NPC cell lines, we demonstrated that specific knockdown of FGF8b by small interfering RNA inhibited cell proliferation, migration and invasion, whereas exogenous FGF8b stimulated these multiple phenotypes. Further mechanistic investigation revealed that in addition to NF-kappa B signaling (a major inflammatory signaling pathway known to be activated in NPC), an important EBV oncoprotein, the latent membrane protein 1 (LMP1), was found to be a direct inducer of FGF8b overexpression in NPC cells, whereas androgen (testosterone) has minimal effect on FGF8b expression in EBV-associated NPC cells. In summary, our study has identified LMP1 as the first viral oncogene capable of directly inducing FGF8b (an important cellular oncogene) expression in human cancer cells. This novel mechanism of viral-mediated FGF8 upregulation may implicate a new role of oncoviruses in human carcinogenesis. Oncogene (2011) 30, 1518-1530; doi: 10.1038/onc.2010.529; published online 29 November 2010	[Lui, V. W. Y.; Yau, D. M-S; Cheung, C. S-F; Wong, S. C. C.; Zhou, Q.; Wong, EY-L; Lau, C. P. Y.; Lam, E. K. Y.; Hui, E. P.; Hong, B.; Hui, C. W. C.; Chan, A. S-K; Chan, A. T. C.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China; [Chan, A. K-C] Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Ng, P. K. S.; Tsui, S. K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Ng, Y-K] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Lo, K-W] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, C. M.; Tsao, S-W] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong	Chan, ATC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China.	vivian@clo.cuhk.edu.hk; anthony@clo.cuhk.edu.hk	Hui, Edwin/ABC-1818-2021; Tsui, Stephen Kwok-Wing/E-4385-2015; Hong, Bo/ABA-3687-2021; Ng, Yuen-Keng/ABC-3906-2020; Lui, Vivian W. Y./I-5458-2016; Chan, Anthony Tak Cheung/R-3940-2018	Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Hong, Bo/0000-0001-8117-5029; Ng, Yuen-Keng/0000-0003-4491-5221; Lui, Vivian W. Y./0000-0001-6918-1573; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Lo, Kwok Wai/0000-0002-3488-6124; WONG, Sze Chuen Cesar/0000-0003-0058-140X	Clinical Oncology, CUHK	Clinical Oncology, CUHK(Chinese University of Hong Kong)	Financial support by research fund, Clinical Oncology, CUHK (VWYL). We thank Drs Q Tao and GT Chung for experimental assistance.	Anderson KE, 2006, CANC EPIDEMIOLOGY PR, P721; Armstrong K, 2006, PROSTATE, V66, P1223, DOI 10.1002/pros.20376; Awan AK, 2007, EJSO-EUR J SURG ONC, V33, P561, DOI 10.1016/j.ejso.2006.12.001; Bhattacharyya N, 2004, AM J OTOLARYNG, V25, P94, DOI 10.1016/j.amjoto.2003.11.005; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Castellano I, 2010, BREAST CANCER RES TR, V124, P607, DOI 10.1007/s10549-010-0761-y; Chan ATC, 2002, ANN ONCOL, V13, P1007, DOI 10.1093/annonc/mdf179; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Cui D, 2001, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V15, P202; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hong B, 2009, INVEST NEW DRUGS; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Ishibe T, 2005, CLIN CANCER RES, V11, P2702, DOI 10.1158/1078-0432.CCR-04-2057; Kuo Wen-Rei, 1994, Journal of the Formosan Medical Association, V93, P569; Leung HY, 1996, ONCOGENE, V12, P1833; Liao Wei, 2001, Zhonghua Zhongliu Zazhi, V23, P199; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883; Lui VWY, 2009, CARCINOGENESIS, V30, P2085, DOI 10.1093/carcin/bgp253; Lui VWY, 2009, INT J CANCER, V125, P1884, DOI 10.1002/ijc.24567; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Mattila MA, 2007, CYTOKINE GROWTH F R, V18, P257, DOI 10.1016/j.cytogfr.2007.04.010; Ohshima K, 1998, CANCER LETT, V122, P43, DOI 10.1016/S0304-3835(97)00368-6; Olsen SK, 2006, GENE DEV, V20, P185, DOI 10.1101/gad.1365406; Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 2001, CANCER RES, V61, P4229; Shi W, 2006, INT J CANCER, V119, P2467, DOI 10.1002/ijc.22107; SKINNER DW, 1991, ANN OTO RHINOL LARYN, V100, P544, DOI 10.1177/000348949110000705; Song ZG, 2000, CANCER RES, V60, P6730; Song ZG, 2002, CANCER RES, V62, P5096; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; Tanaka A, 2002, VIRCHOWS ARCH, V441, P380, DOI 10.1007/s00428-002-0687-9; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Tanaka S, 2001, DIGEST DIS SCI, V46, P1016, DOI 10.1023/A:1010753826788; Thaver V, 2009, CELL BIOCHEM FUNCT, V27, P205, DOI 10.1002/cbf.1557; Thornburg NJ, 2003, CANCER RES, V63, P8293; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tucker AS, 1999, DEVELOPMENT, V126, P51; Valta MP, 2008, INT J CANCER, V123, P22, DOI 10.1002/ijc.23422; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; Wong JHT, 2010, CANCER LETT, V287, P23, DOI 10.1016/j.canlet.2009.05.022; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; YAMASHITA Y, 1989, JPN J SURG, V19, P195, DOI 10.1007/BF02471585; Zhong C, 2006, CANCER RES, V66, P2188, DOI 10.1158/0008-5472.CAN-05-3440	60	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1518	1530		10.1038/onc.2010.529	http://dx.doi.org/10.1038/onc.2010.529			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119603				2022-12-28	WOS:000288998300003
J	Yagi, R; Tanaka, M; Sasaki, K; Kamata, R; Nakanishi, Y; Kanai, Y; Sakai, R				Yagi, R.; Tanaka, M.; Sasaki, K.; Kamata, R.; Nakanishi, Y.; Kanai, Y.; Sakai, R.			ARAP3 inhibits peritoneal dissemination of scirrhous gastric carcinoma cells by regulating cell adhesion and invasion	ONCOGENE			English	Article						ARAP3; scirrhous gastric carcinoma; Rho-GAP; cell-ECM adhesion; invasion	DEPENDENT MANNER; SRC; CANCER; RHO; TRAFFICKING; PROTEINS; KINASES	During the analysis of phosphotyrosine-containing proteins in scirrhous gastric carcinoma cell lines, we observed an unusual expression of Arf-GAP with Rho-GAP domain, ankyrin repeat and PH domain 3 (ARAP3), a multimodular signaling protein that is a substrate of Src family kinases. Unlike other phosphotyrosine proteins, such as CUB domain-containing protein 1 (CDCP1) and Homo sapiens chromosome 9 open reading frame 10/oxidative stress-associated Src activator (C9orf10/Ossa), which are overexpressed and hyperphosphorylated in scirrhous gastric carcinoma cell lines, ARAP3 was underexpressed in cancerous human gastric tissues. In this study, we found that overexpression of ARAP3 in the scirrhous gastric carcinoma cell lines significantly reduced peritoneal dissemination. In vitro studies also showed that ARAP3 regulated cell attachment to the extracellular matrix, as well as invasive activities. These effects were suppressed by mutations in the Rho-GTPase-activating protein (GAP) domain or in the C-terminal two tyrosine residues that are phosphorylated by Src. Thus, the expression and phosphorylation state of ARAP3 may affect the invasiveness of cancer by modulating cell adhesion and motility. Our results suggest that ARAP3 is a unique Src substrate that suppresses peritoneal dissemination of scirrhous gastric carcinoma cells. Oncogene (2011) 30, 1413-1421; doi:10.1038/onc.2010.522; published online 15 November 2010	[Sakai, R.] Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; [Tanaka, M.] Akita Univ, Sch Med, Dept Mol Med & Biochem, Akita 010, Japan; [Sasaki, K.] Natl Cerebral & Cardiovasc Ctr, Dept Pharmacol, Res Inst, Suita, Osaka, Japan; [Nakanishi, Y.; Kanai, Y.] Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 104, Japan	National Cancer Center - Japan; Akita University; National Cerebral & Cardiovascular Center - Japan; National Cancer Center - Japan	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@ncc.go.jp	Kanai, Yae/AAE-6987-2019	Sakai, Ryuichi/0000-0001-6833-1103	Ministry of Education, Culture, Science and Technology of Japan; Grants-in-Aid for Scientific Research [23650590] Funding Source: KAKEN	Ministry of Education, Culture, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The pEGFP-ARAP3 plasmid was a kind gift from Krugmann S (Cambridge, UK). This work was supported by a Grant-in-Aid for Cancer Research and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Science and Technology of Japan for the Third Term Comprehensive 10-Year Strategy for Cancer Control.	Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Carramusa L, 2007, J CELL SCI, V120, P3870, DOI 10.1242/jcs.014365; Chen TJ, 2006, J NEUROBIOL, V66, P103, DOI 10.1002/neu.20204; Daniele T, 2008, TRAFFIC, V9, P2221, DOI 10.1111/j.1600-0854.2008.00823.x; Faix J, 2006, DEV CELL, V10, P693, DOI 10.1016/j.devcel.2006.05.001; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kim HS, 2010, J NEUROCHEM, V113, P1565, DOI 10.1111/j.1471-4159.2010.06713.x; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Krugmann S, 2006, J CELL SCI, V119, P425, DOI 10.1242/jcs.02755; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Matsuoka T, 1998, CLIN EXP METASTAS, V16, P381; Nishimura S, 1996, BRIT J CANCER, V74, P1406, DOI 10.1038/bjc.1996.556; Raaijmakers JH, 2007, CELL SIGNAL, V19, P1249, DOI 10.1016/j.cellsig.2006.12.015; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Tanaka M, 2009, MOL CELL BIOL, V29, P402, DOI 10.1128/MCB.01035-08; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yoon HY, 2008, TRAFFIC, V9, P2236, DOI 10.1111/j.1600-0854.2008.00839.x; 2004, J CELL SCI, V117, P6071	24	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1413	1421		10.1038/onc.2010.522	http://dx.doi.org/10.1038/onc.2010.522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21076469				2022-12-28	WOS:000288743800004
J	Delston, RB; Matatall, KA; Sun, Y; Onken, MD; Harbour, JW				Delston, R. B.; Matatall, K. A.; Sun, Y.; Onken, M. D.; Harbour, J. W.			p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis	ONCOGENE			English	Article						apoptosis; p38; phosphorylation; retinoblastoma protein; Hdm2	S-PHASE ENTRY; RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR; E2F1-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; NEURONAL APOPTOSIS; MULTIPLE SITES; FAMILY-MEMBERS; PROTEIN PRB	The retinoblastoma protein (Rb) inhibits both cell division and apoptosis, but the mechanism by which Rb alternatively regulates these divergent outcomes remains poorly understood. Cyclin-dependent kinases (Cdks) promote cell division by phosphorylating and reversibly inactivating Rb by a hierarchical series of phosphorylation events and sequential conformational changes. The stress-regulated mitogen-activated protein kinase p38 also phosphorylates Rb, but it does so in a cell cycle-independent manner that is associated with apoptosis rather than with cell division. Here, we show that p38 phosphorylates Rb by a novel mechanism that is distinct from that of Cdks. p38 bypasses the cell cycle-associated hierarchical phosphorylation and directly phosphorylates Rb on Ser567, which is not phosphorylated during the normal cell cycle. Phosphorylation by p38, but not Cdks, triggers an interaction between Rb and the human homolog of murine double minute 2 (Hdm2), leading to degradation of Rb, release of E2F1 and cell death. These findings provide a mechanistic explanation as to how Rb regulates cell division and apoptosis through different kinases, and reveal how Hdm2 may functionally link the tumor suppressors Rb and p53. Oncogene (2011) 30, 588-599; doi: 10.1038/onc.2010.442; published online 27 September 2010	[Delston, R. B.; Matatall, K. A.; Sun, Y.; Onken, M. D.; Harbour, J. W.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Harbour, JW (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	harbour@wustl.edu	Onken, Michael D/H-5620-2013; Harbour, J. William/B-1448-2015	Onken, Michael D/0000-0003-4082-1105; Harbour, J. William/0000-0002-1104-9809	Vision Training Grant [5T32EY013360-09]; NIH [EY013169-09, P30 EY 02687]; Barnes-Jewish Hospital Foundation; Horncrest Foundation; Kling Family Foundation; Research to Prevent Blindness; NATIONAL EYE INSTITUTE [T32EY013360, P30EY002687, R01EY013169] Funding Source: NIH RePORTER	Vision Training Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Barnes-Jewish Hospital Foundation; Horncrest Foundation; Kling Family Foundation; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Doug Dean and members of the Harbour Lab for helpful discussions. This work was supported by the Vision Training Grant 5T32EY013360-09, and grants from the NIH (EY013169-09), the Barnes-Jewish Hospital Foundation, the Horncrest Foundation, The Kling Family Foundation and a Research to Prevent Blindness David F Weeks Professorship. This work was also supported by awards to the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness Inc. Unrestricted grant, and the NIH Vision Core Grant P30 EY 02687.	ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Askari N, 2009, BIOCHEMISTRY-US, V48, P2497, DOI 10.1021/bi900024v; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Chau BN, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000082; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Fattman CL, 1998, CANCER LETT, V130, P103, DOI 10.1016/S0304-3835(98)00121-9; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hallstrom TC, 2008, CANCER CELL, V13, P11, DOI 10.1016/j.ccr.2007.11.031; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Hauck L, 2002, CIRC RES, V91, P782, DOI 10.1161/01.RES.0000041030.98642.41; Hayashi T, 2000, NEUROPATH APPL NEURO, V26, P390, DOI 10.1046/j.1365-2990.2000.00264.x; Heidkamp MC, 2005, AM J PHYSIOL-CELL PH, V289, pC471, DOI 10.1152/ajpcell.00130.2005; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoglinger GU, 2007, P NATL ACAD SCI USA, V104, P3585, DOI 10.1073/pnas.0611671104; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kishore R, 2003, CIRC RES, V93, P932, DOI 10.1161/01.RES.0000102400.22370.20; Kitagawa M, 2008, ONCOGENE, V27, P5303, DOI 10.1038/onc.2008.164; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee EJ, 2003, INT J ONCOL, V23, P503; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Lemaire C, 2005, ONCOGENE, V24, P3297, DOI 10.1038/sj.onc.1208493; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Proctor BM, 2008, CIRCULATION, V118, P658, DOI 10.1161/CIRCULATIONAHA.107.734848; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ramalho RM, 2004, J NEUROCHEM, V90, P567, DOI 10.1111/j.1471-4159.2004.02517.x; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Sun BH, 2010, CELL CYCLE, V9, P1122, DOI 10.4161/cc.9.6.10990; Sun Y, 2005, INVEST OPHTH VIS SCI, V46, P1561, DOI 10.1167/iovs.04-1362; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Thakur A, 2008, INT J CLIN EXP PATHO, V1, P134; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Valentini A, 2007, CANCER BIOL THER, V6, P185, DOI 10.4161/cbt.6.2.3578; von Willebrand M, 2003, CANCER RES, V63, P1420; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang WH, 2008, J BIOL CHEM, V283, P25455, DOI 10.1074/jbc.M801934200; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Yeste-Velasco M, 2009, NEUROCHEM INT, V54, P99, DOI 10.1016/j.neuint.2008.10.004; Yilmaz S, 1998, Hum Mutat, V12, P434, DOI 10.1002/(SICI)1098-1004(1998)12:6<434::AID-HUMU16>3.3.CO;2-Z; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Yu BD, 2003, P NATL ACAD SCI USA, V100, P14881, DOI 10.1073/pnas.2431391100; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	95	32	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					588	599		10.1038/onc.2010.442	http://dx.doi.org/10.1038/onc.2010.442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20871633	Green Accepted			2022-12-28	WOS:000286922300007
J	Tommasi, S; Besaratinia, A; Wilczynski, SP; Pfeifer, GP				Tommasi, S.; Besaratinia, A.; Wilczynski, S. P.; Pfeifer, G. P.			Loss of Rassf1a enhances p53-mediated tumor predisposition and accelerates progression to aneuploidy	ONCOGENE			English	Article						aneuploidy; chromosomal abnormalities; cytokinesis; tetraploidy; tumor suppressor gene	DOMAIN FAMILY PROTEIN; SUPPRESSOR RASSF1A; EPIGENETIC INACTIVATION; MICROTUBULE STABILITY; GENOMIC INSTABILITY; P53; ASSOCIATION; CHECKPOINT; GENE; TETRAPLOIDY	Loss of RASSF1A leads to several mitotic abnormalities, including cytokinesis failure and tetraploidization. Uncontrolled proliferation of tetraploid cells is known to trigger genomic instability and tumor development and is normally prevented through activation of a p53-dependent tetraploidy checkpoint. RASSF1A is the most commonly silenced and p53 is the most frequently mutated tumor suppressor gene in human cancer. However, their mutual contribution to tumorigenesis has never been investigated in animal models. Here, we explore whether concomitant loss of RASSF1A and p53 will result in increased levels of aneuploidy, genomic instability and tumorigenesis. We have intercrossed Rassf1a-knockout mice with mice lacking the p53 gene and generated a combination of single-and compound-mutant animals. Rassf1a(-/-) p53(-/-) mice were viable and fertile and developed normally. However, these mice were remarkably tumor prone and succumbed to malignancies significantly faster than single-mutant littermates, with a median survival time of 136 days (versus 158 days in p53(-/-) mice, P = 0.0207, and > 600 days in Rassf1a(-/-) animals, P<0.0001). Rassf1a-null mice with one functional p53 allele displayed a more moderate, yet tumor-prone phenotype, characterized by increased tumor multiplicity as compared with single knockouts. On cell-cycle profiling and cytogenetic analysis, cells derived from Rassf1a(-/-) p53(-/-) mice exhibited several mitotic defects associated with high levels of tetraploidy/ aneuploidy. Conversely, cells with a proficient p53 allele could better cope with the mitotic failures imposed by Rassf1a loss. Altogether, we provide the first experimental evidence for a pivotal role of Rassf1a as an early 'gatekeeper' gene, whose loss of function deteriorates cellular fitness by enhancing tetraploidization. Concomitant loss of p53, which causes unrestrained propagation of tetraploids into aneuploid cells, further undermines genomic stability and accelerates tumorigenesis. Oncogene (2011) 30, 690-700; doi:10.1038/onc.2010.440; published online 4 October 2010	[Tommasi, S.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Ctr Canc, Duarte, CA 91010 USA; [Wilczynski, S. P.] City Hope Natl Med Ctr, Ctr Canc, Dept Pathol Anat, Duarte, CA USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope	Tommasi, S (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Ctr Canc, Duarte, CA 91010 USA.	stommasi@coh.org	Tommasi, Stefania/J-6732-2012	Tommasi, Stefania/0000-0002-2157-2978; Besaratinia, Ahmad/0000-0001-7231-228X; Tommasi, Stella/0000-0001-6897-4985	University of California [17RT-0116]	University of California(University of California System)	We would like to thank Donna Isbell, Stefanie Wright-Golightly and Armando Amaya for mouse colony management; Lucy Brown and Claudio Spalla for FACS analysis; Dr Marilyn Slovak, Dr Joyce Collins and Victoria Bedell for cytogenetics on mouse cell lines and tumor PET sections. This work was supported by a grant from the University of California Tobacco related Disease Research Program (TRDRP grant 17RT-0116 to GPP).	Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; Caldwell CM, 2007, J CELL BIOL, V178, P1109, DOI 10.1083/jcb.200703186; Chi YH, 2009, INT J CANCER, V124, P1483, DOI 10.1002/ijc.24094; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Duensing A, 2005, BIOCHEM BIOPH RES CO, V331, P694, DOI 10.1016/j.bbrc.2005.03.157; Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; GIARETTI W, 1994, LAB INVEST, V71, P904; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; PURDIE CA, 1994, ONCOGENE, V9, P603; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; SEGERS P, 1994, CANCER GENET CYTOGEN, V75, P120, DOI 10.1016/0165-4608(94)90163-5; Senovilla L, 2009, CELL CYCLE, V8, P1380, DOI 10.4161/cc.8.9.8305; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Tommasi S, 2005, CANCER RES, V65, P92; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; VERDOODT B, 1994, CANCER GENET CYTOGEN, V78, P53, DOI 10.1016/0165-4608(94)90046-9; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	50	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					690	700		10.1038/onc.2010.440	http://dx.doi.org/10.1038/onc.2010.440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890300	Bronze			2022-12-28	WOS:000287192000006
J	Leclercq, TM; Moretti, PAB; Pitson, SM				Leclercq, T. M.; Moretti, P. A. B.; Pitson, S. M.			Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis	ONCOGENE			English	Article						sphingosine kinase; sphingosine 1-phosphate; eEF1A; PTI-1; TCTP	CONTROLLED TUMOR PROTEIN; PTI-1 ONCOGENE; FACTOR EEF1A; CANCER; PHOSPHORYLATION; COMPLEX; GROWTH; REVERSION; ISOFORM; CLONING	Sphingosine kinase 1 (SK1) catalyses the formation of bioactive phospholipid sphingosine 1-phosphate (S1P). Elevated cellular SK1 activity and S1P levels enhance cell proliferation and survival, and are strongly implicated in tumourigenesis. Regulation of SK1 activity can occur through various mechanisms, including phosphorylation and protein-protein interactions. We have previously shown that eukaryotic elongation factor 1A (eEF1A) interacts with and directly activates SK1, but the mechanisms regulating this were undefined. Notably, eEF1A has GTPase activity and can exist in GTP- or GDP-bound forms, which are associated with distinct structural conformations of the protein. Here, we show that the guanine nucleotide-bound state of eEF1A regulates its ability to activate SK1, with eEF1A.GDP, but not eEF1A.GTP, enhancing SK1 activity in vitro. Furthermore, we show that enhancing cellular eEF1A. GDP levels through expression of a guanine nucleotide dissociation inhibitor of eEF1A, translationally controlled tumour protein (TCTP), increased SK1 activity in cells. We also examined a truncated isoform of eEF1A1, termed prostate tumour inducer-1 (PTI-1), which can induce neoplastic cell transformation through undefined mechanisms. PTI-1 lacks the G protein domain of eEF1A1 and is therefore unable to undergo the GTP-binding-induced conformational change. Notably, we found that PTI-1 can directly activate SK1 and that this seems to be essential for neoplastic transformation induced by PTI-1, as chemical SK1 inhibitors or overexpression of a dominant- negative SK1 blocked this process. Thus, this study defines the mechanism regulating eEF1A-mediated SK1 activation, and also establishes SK1 as being integral for PTI-1-induced oncogenesis. Oncogene (2011) 30, 372-378; doi:10.1038/onc.2010.420; published online 13 September 2010	[Pitson, S. M.] SA Pathol, Ctr Canc Biol, Div Human Immunol, Mol Signalling Lab, Adelaide, SA 5000, Australia; [Leclercq, T. M.; Pitson, S. M.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Centre for Cancer Biology; SA Pathology; University of Adelaide	Pitson, SM (corresponding author), SA Pathol, Ctr Canc Biol, Div Human Immunol, Mol Signalling Lab, Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@health.sa.gov.au	Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740; Moretti, Paul/0000-0002-3523-1496	Fay Fuller Foundation; Cancer Council of South Australia [399330]; National Health and Medical Research Council of Australia	Fay Fuller Foundation; Cancer Council of South Australia(Cancer Council South Australia); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the Fay Fuller Foundation, an Australian Postgraduate Award (to TML), Project Grant 399330 from the Cancer Council of South Australia and a Senior Research Fellowship from the National Health and Medical Research Council of Australia (to SMP).	Abbott CM, 2004, TRENDS BIOCHEM SCI, V29, P25, DOI 10.1016/j.tibs.2003.11.006; Al-Maghrebir M, 2005, ANTICANCER RES, V25, P2573; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2003, TRENDS BIOCHEM SCI, V28, P434, DOI 10.1016/S0968-0004(03)00162-2; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Cuvillier O, 2008, EXPERT OPIN THER TAR, V12, P1009, DOI [10.1517/14728222.12.8.1009, 10.1517/14728222.12.8.1009 ]; Ejiri S, 2002, BIOSCI BIOTECH BIOCH, V66, P1, DOI 10.1271/bbb.66.1; French KJ, 2003, CANCER RES, V63, P5962; Gopalkrishnan RV, 1999, INT J BIOCHEM CELL B, V31, P151, DOI 10.1016/S1357-2725(98)00138-1; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Leclercq TM, 2008, J BIOL CHEM, V283, P9606, DOI 10.1074/jbc.M708782200; Lee Jonathan M, 2003, Reprod Biol Endocrinol, V1, P69, DOI 10.1186/1477-7827-1-69; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Mansilla F, 2005, BBA-GENE STRUCT EXPR, V1727, P116, DOI 10.1016/j.bbaexp.2004.12.012; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; Panasyuk G, 2008, INT J BIOCHEM CELL B, V40, P63, DOI 10.1016/j.biocel.2007.08.014; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; Soares DC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006315; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yu L, 2006, TOHOKU J EXP MED, V209, P141, DOI 10.1620/tjem.209.141	35	35	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					372	378		10.1038/onc.2010.420	http://dx.doi.org/10.1038/onc.2010.420			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20838377				2022-12-28	WOS:000286418800012
J	Sevenich, L; Werner, F; Gajda, M; Schurigt, U; Sieber, C; Muller, S; Follo, M; Peters, C; Reinheckel, T				Sevenich, L.; Werner, F.; Gajda, M.; Schurigt, U.; Sieber, C.; Mueller, S.; Follo, M.; Peters, C.; Reinheckel, T.			Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice	ONCOGENE			English	Article						protease; tumor microenvironment; tumor-associated inflammation; lysosome	CYSTEINE CATHEPSINS; TUMOR-GROWTH; MAST-CELLS; DEGRADING PROTEASES; VEGF-A; ANGIOGENESIS; INVASION; DEGRADATION; MACROPHAGES; CARCINOMAS	Elevated expression of the cysteine protease cathepsin B (CTSB) has been correlated with a poor prognosis for cancer patients. In order to model high CTSB expression in mammary cancer, transgenic mice expressing human CTSB were crossed with transgenic polyoma virus middle T oncogene breast cancer mice (mouse mammary tumor virus-PymT), resulting in a 20-fold increase in cathepsin B activity in the tumors of double-transgenic animals. CTSB expression did not affect tumor onset, but CTSB transgenic mice showed accelerated tumor growth with significant increase in weight for end-stage tumors, as well as an overall worsening in their histopathological grades. Notably, the lung metastases in the CTSB transgenic animals were found to be both significantly larger and to occur at a significantly higher frequency. Ex vivo analysis of primary PymT tumor cells revealed no significant effects from elevated CTSB levels on tumor cell characteristics, that is, the formation of tumor cell colonies and the sprouting of invasive strands from PymT cell spheroids. However, tumors from CTSB-overexpressing mice showed increased numbers of tumor-associated B cells and mast cells. In addition, more CD31+ endothelial cells were detected in these tumors, correlating with higher levels of vascular endothelial growth factor (VEGF) being present in the tumor and serum. We conclude that elevated proteolytic CTSB activity facilitates progression and metastasis of PymT-induced mammary carcinomas, and is associated with increased immune cell infiltration, enhanced VEGF levels and the promotion of tumor angiogenesis. Oncogene (2011) 30, 54-64; doi: 10.1038/onc.2010.387; published online 6 September 2010	[Sevenich, L.; Werner, F.; Schurigt, U.; Sieber, C.; Mueller, S.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Sevenich, L.; Werner, F.] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Werner, F.] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany; [Gajda, M.] Univ Jena, Inst Pathol, Jena, Germany; [Follo, M.] Univ Med Ctr, Core Facil, Dept Hematol & Oncol, Freiburg, Germany; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ludwig Heilmeyer Comprehens Canc Ctr, D-79104 Freiburg, Germany; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ctr Biol Signalling Studies Bioss, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Friedrich Schiller University of Jena; University of Freiburg; University of Freiburg; University of Freiburg	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.	thomas.reinheckel@uniklinik-freiburg.de	Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Follo, Marie/0000-0002-3090-7442; Schurigt, Uta/0000-0003-4423-5955; Muller, Sebastian/0000-0001-8071-8853	European Commission [201279]; Deutsche Forschungsgemeinschaft [SFB 850, B7]; Excellence Initiative of the German Federal and State Governments [EXC 294, GSC-4]	European Commission(European CommissionEuropean Commission Joint Research Centre); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Excellence Initiative of the German Federal and State Governments	The Tg(CTSB)<SUP>+/0</SUP> mice were kindly provided by Dr L Pennacchio, Genomics Division, Lawrence Berkeley Laboratory. We thank Anne Schwinde, Ulrike Reif, Lisa Christiansson and Anna Heisswolf for excellent technical assistance. This work was supported by European Commission FP7 Grant 201279 (Microenvimet), Deutsche Forschungsgemeinschaft SFB 850 Project B7, and by the Excellence Initiative of the German Federal and State Governments (EXC 294 and GSC-4, Spemann Graduate School).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; BARRETT AJ, 1992, ANN NY ACAD SCI, V674, P1; Berdowska I, 2004, CLIN CHIM ACTA, V342, P41, DOI 10.1016/j.cccn.2003.12.016; Brix K, 2008, BIOCHIMIE, V90, P194, DOI 10.1016/j.biochi.2007.07.024; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; Caglic D, 2009, BIOL CHEM, V390, P175, DOI 10.1515/BC.2009.021; Chang SH, 2009, CANCER RES, V69, P4537, DOI 10.1158/0008-5472.CAN-08-4539; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Crivellato E, 2008, CANCER LETT, V269, P1, DOI 10.1016/j.canlet.2008.03.031; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Del Rosso M, 2002, CLIN EXP METASTAS, V19, P193, DOI 10.1023/A:1015531321445; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; Dennemarker J, 2010, ONCOGENE, V29, P1611, DOI 10.1038/onc.2009.466; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Gondi CS, 2004, CANCER RES, V64, P4069, DOI 10.1158/0008-5472.CAN-04-1243; Green KA, 2005, BIOESSAYS, V27, P894, DOI 10.1002/bies.20281; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; KATZ HR, 1995, INT ARCH ALLERGY IMM, V107, P76, DOI 10.1159/000236936; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Premzl A, 2003, EXP CELL RES, V283, P206, DOI 10.1016/S0014-4827(02)00055-1; Rawlings ND, 2010, NUCLEIC ACIDS RES, V38, pD227, DOI 10.1093/nar/gkp971; Ribatti D, 2001, BRIT J HAEMATOL, V115, P514, DOI 10.1046/j.1365-2141.2001.03202.x; ROZHIN J, 1994, CANCER RES, V54, P6517; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shin M, 2007, BIOL CHEM, V388, P1173, DOI 10.1515/BC.2007.154; Takai T, 2005, J CLIN IMMUNOL, V25, P1, DOI 10.1007/s10875-005-0353-8; Tummalapalli P, 2007, INT J ONCOL, V31, P1039; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; Van Damme J, 2004, SEMIN CANCER BIOL, V14, P201, DOI 10.1016/j.semcancer.2003.10.007; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x	53	69	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					54	64		10.1038/onc.2010.387	http://dx.doi.org/10.1038/onc.2010.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818432				2022-12-28	WOS:000285959300005
J	Lazzari, C; Prodosmo, A; Siepi, F; Rinaldo, C; Galli, F; Gentileschi, M; Bartolazzi, A; Costanzo, A; Sacchi, A; Guerrini, L; Soddu, S				Lazzari, C.; Prodosmo, A.; Siepi, F.; Rinaldo, C.; Galli, F.; Gentileschi, M.; Bartolazzi, A.; Costanzo, A.; Sacchi, A.; Guerrini, L.; Soddu, S.			HIPK2 phosphorylates Delta Np63 alpha and promotes its degradation in response to DNA damage	ONCOGENE			English	Article						HIPK2; chemotherapy; Delta Np63; phosphorylation; degradation	SQUAMOUS-CELL CARCINOMA; INTERACTING PROTEIN KINASE-2; INDUCED APOPTOSIS; P53 FAMILY; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; CANCER-CELLS; P63	Homeodomain-interacting protein kinase 2 (HIPK2) is an emerging player in cell response to genotoxic agents that senses damage intensity and contributes to the cell's choice between cell cycle arrest and apoptosis. Phosphorylation of p53 at S46, an apoptosis-specific p53 posttranslational modification, is the most characterized HIPK2 function in response to lethal doses of ultraviolet (UV), ionizing radiation or different anticancer drugs, such as cisplatin, roscovitine and doxorubicin (DOX). Indeed, like p53, HIPK2 has been shown to contribute to the effectiveness of these treatments. Interestingly, p53-independent mechanisms of HIPK2-induced apoptosis were described for UV and tumor growth factor-beta treatments; however, it is unknown whether these mechanisms are relevant for the responses to anticancer drugs. Because of the importance of the so-called 'p53-independent apoptosis and drug response' in human cancer chemotherapy, we asked whether p53-independent factor(s) might be involved in HIPK2-mediated chemosensitivity. Here, we show that HIPK2 depletion by RNA interference induces resistance to different anticancer drugs even in p53-null cells, suggesting the involvement of HIPK2 targets other than p53 in response to chemotherapy. In particular, we found that HIPK2 phosphorylates and promotes proteasomal degradation of Delta Np63 alpha, a prosurvival Delta N isoform of the p53 family member, p63. Indeed, effective cell response to different genotoxic agents was shown to require phosphorylation-induced proteasomal degradation of Delta Np63 alpha. In DOX-treated cells, we show that HIPK2 depletion interferes with Delta Np63 alpha degradation, and expression of a HIPK2-resistant Delta Np63 alpha-Delta 390 mutant induces chemoresistance. We identify T397 as the Delta Np63 alpha residue phosphorylated by HIPK2, and show that the non-phosphorylatable Delta Np63 alpha-T397A mutant is not degraded in the face of either HIPK2 overexpression or DOX treatment. These results indicate Delta Np63 alpha as a novel target of HIPK2 in response to genotoxic drugs. Oncogene (2011) 30, 4802-4813; doi: 10.1038/onc.2011.182; published online 23 May 2011	[Lazzari, C.; Prodosmo, A.; Siepi, F.; Rinaldo, C.; Gentileschi, M.; Sacchi, A.; Soddu, S.] Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy; [Galli, F.; Guerrini, L.] Univ Milan, Dept Biomol & Biotechnol Sci, Milan, Italy; [Bartolazzi, A.] Karolinska Hosp, Canc Ctr Karolinska, S-10401 Stockholm, Sweden; [Bartolazzi, A.] St Andrea Univ Hosp, Dept Pathol, Rome, Italy; [Costanzo, A.] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Milan; Karolinska Institutet; Karolinska University Hospital; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Rome Tor Vergata	Soddu, S (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi dOro 156, I-00158 Rome, Italy.	soddu@ifo.it	Soddu, Silvia/ABH-6774-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; prodosmo, andrea/AAA-7766-2020; Soddu, Silvia/K-2467-2018; Rinaldo, Cinzia/A-4252-2015; Bartolazzi, Armando/K-9708-2016	Soddu, Silvia/0000-0001-8526-0044; Costanzo, Antonio/0000-0001-9697-2557; Soddu, Silvia/0000-0001-8526-0044; Rinaldo, Cinzia/0000-0001-6124-762X; Bartolazzi, Armando/0000-0001-7820-5127; PRODOSMO, ANDREA/0000-0001-5828-8586	Ministero della Salute; Scientific Direction of the Regina Elena Cancer Institute; Fondazione Italiana per la Ricerca sul Cancro; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Ministero della Salute(Ministry of Health, Italy); Scientific Direction of the Regina Elena Cancer Institute; Fondazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are grateful to all people cited in the text for their kind gifts of cells and reagents and to Dr F Socciarelli for technical support. This work was supported by Ministero della Salute and 'New Idea Award' form the Scientific Direction of the Regina Elena Cancer Institute to SS. FS was a recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro.	Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Bracaglia G, 2009, EMBO REP, V10, P1327, DOI 10.1038/embor.2009.217; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Calzado MA, 2009, CELL CYCLE, V8, P1659, DOI 10.4161/cc.8.11.8597; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Cecchinelli B, 2006, CELL DEATH DIFFER, V13, P1994, DOI 10.1038/sj.cdd.4401933; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Di Costanzo A, 2009, CELL CYCLE, V8, P1185, DOI 10.4161/cc.8.8.8202; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Du ZJ, 2010, CANCER SCI, V101, P2417, DOI 10.1111/j.1349-7006.2010.01700.x; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Galli F, 2010, J CELL SCI, V123, P2423, DOI 10.1242/jcs.061010; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Gresko E, 2009, ONCOGENE, V28, P698, DOI 10.1038/onc.2008.420; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang YP, 2008, CELL CYCLE, V7, P2846, DOI 10.4161/cc.7.18.6627; Huang YP, 2010, CELL CYCLE, V9, P328, DOI 10.4161/cc.9.2.10432; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Lanza M, 2006, CELL CYCLE, V5, P1996, DOI 10.4161/cc.5.17.3188; Lavra L, 2011, PLOS ONE IN PRESS; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Li Y, 2008, CELL DEATH DIFFER, V15, P1941, DOI 10.1038/cdd.2008.134; Liefer KM, 2000, CANCER RES, V60, P4016; Lin ZH, 2006, J CANCER RES CLIN, V132, P811, DOI 10.1007/s00432-006-0130-8; MacPartlin M, 2008, J BIOL CHEM, V283, P15754, DOI 10.1074/jbc.M801394200; Moll UM, 2004, MOL CANCER RES, V2, P371; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Papoutsaki M, 2005, ONCOGENE, V24, P6970, DOI 10.1038/sj.onc.1208835; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Puca R, 2008, CANCER RES, V68, P3707, DOI 10.1158/0008-5472.CAN-07-6776; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; Wang N, 2010, EMBO REP, V11, P633, DOI 10.1038/embor.2010.82; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu GJ, 2005, CANCER RES, V65, P758; Yamada D, 2009, ONCOGENE, V28, P2535, DOI 10.1038/onc.2009.109; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Zangen R, 2005, CELL CYCLE, V4, P1313, DOI 10.4161/cc.4.10.2066; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	63	39	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4802	4813		10.1038/onc.2011.182	http://dx.doi.org/10.1038/onc.2011.182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21602882	Bronze			2022-12-28	WOS:000298134700004
J	Werbowetski-Ogilvie, TE; Schnerch, A; Rampalli, S; Mills, CE; Lee, JB; Hong, SH; Levadoux-Martin, M; Bhatia, M				Werbowetski-Ogilvie, T. E.; Schnerch, A.; Rampalli, S.; Mills, C. E.; Lee, J. B.; Hong, S-H; Levadoux-Martin, M.; Bhatia, M.			Evidence for the transmission of neoplastic properties from transformed to normal human stem cells	ONCOGENE			English	Article						transformation; human stem cells; self-renewal; differentiation	STROMAL FIBROBLASTS; HEMATOPOIETIC DEVELOPMENT; TUMOR-GROWTH; IN-VIVO; CANCER; LEUKEMIA; PROTEIN; DIFFERENTIATION; PROGENITORS; EXPRESSION	The in vivo relationship between human tumor cells and interacting normal cells in their local environment is poorly understood. Here, using a uniquely developed in vitro co-culture system for human embryonic stem cells (hESCs), we examined the interactions between transformed and normal human stem cells. Co-culture of transformed-hESCs (t-hESCs) with normal hESCs led to enhanced self-renewal and niche independence in normal hESCs. Global gene expression analysis of normal hESCs after timed exposure to t-hESCs indicated a transition of the molecular network controlling the hESC state, which included epigenetic changes, towards neoplastic features. These included enhanced pluripotent marker expression and a differentiation blockade as major hallmark changes. Functional studies revealed a loss in normal terminal differentiation programs for both hematopoiesis and neural lineages after normal stem cell co-culture with transformed variants. This transmission of neoplastic properties from t-hESCs to normal hESCs was dependent on direct cell-cell contact. Our study indicates that normal human stem cells can co-opt neoplastic cancer stem cell properties, raising the possibility that assimilation of healthy cells towards neoplastic behavior maybe a contributing feature of sustained tumorigenesis in vivo. Oncogene (2011) 30, 4632-4644; doi:10.1038/onc.2011.175; published online 30 May 2011	[Werbowetski-Ogilvie, T. E.; Schnerch, A.; Rampalli, S.; Lee, J. B.; Hong, S-H; Levadoux-Martin, M.; Bhatia, M.] McMaster Univ, Michael G Degroote Sch Med, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Werbowetski-Ogilvie, T. E.; Schnerch, A.; Rampalli, S.; Lee, J. B.; Hong, S-H; Levadoux-Martin, M.; Bhatia, M.] McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; [Mills, C. E.] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Bhatia, M (corresponding author), McMaster Univ, Fac Hlth Sci, McMaster Stem Cell & Canc Res Inst SCC RI, 1200 Main St W,MDCL 5029, Hamilton, ON L8N 3Z5, Canada.	mbhatia@mcmaster.ca		Rampalli, Shravanti/0000-0002-6391-6409; Werbowetski-Ogilvie, Tamra/0000-0002-5469-0559	Canadian Institute of Health Research (CIHR); Canadian Cancer Society (CCS); Ontario Institute of Cancer Research (OICR); Canadian Cancer Society Research Institute (CCSRI); Canada Research Chair Program	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society (CCS)(Canadian Cancer Society (CCS)); Ontario Institute of Cancer Research (OICR); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Canada Research Chair Program(Canada Research Chairs)	We thank Dr Borhane Guezguez for critical review of this manuscript. This work was funded by the Canadian Institute of Health Research (CIHR), the Canadian Cancer Society (CCS) and the Ontario Institute of Cancer Research (OICR). A fellowship from the Canadian Cancer Society Research Institute (CCSRI) supports TEWO. MB is supported by the Canada Research Chair Program.	Azcoitia V, 2005, DEV BIOL, V280, P307, DOI 10.1016/j.ydbio.2005.01.004; Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285; Bedford L, 2005, DEV BIOL, V280, P386, DOI 10.1016/j.ydbio.2005.02.001; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003; Carpenter MK, 2001, EXP NEUROL, V172, P383, DOI 10.1006/exnr.2001.7832; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Damjanov I, 2007, NAT BIOTECHNOL, V25, P1212, DOI 10.1038/nbt1107-1212a; Davidson KC, 2007, MOL CELL NEUROSCI, V36, P408, DOI 10.1016/j.mcn.2007.07.013; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Dvash T, 2007, STEM CELLS, V25, P465, DOI 10.1634/stemcells.2006-0179; El Wakil A, 2006, DEVELOPMENT, V133, P2155, DOI 10.1242/dev.02377; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Hogan C, 2009, NAT CELL BIOL, V11, P460, DOI 10.1038/ncb1853; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Ivins S, 2003, ONCOGENE, V22, P3685, DOI 10.1038/sj.onc.1206328; Ji JF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008065; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kajita M, 2010, J CELL SCI, V123, P171, DOI 10.1242/jcs.057976; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; Lensch MW, 2007, NAT BIOTECHNOL, V25, P1211, DOI 10.1038/nbt1107-1211a; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Mishra P, 2011, J LEUKOCYTE BIOL, V89, P31, DOI 10.1189/jlb.0310182; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Moreno E, 2008, NAT REV CANCER, V8, P141, DOI 10.1038/nrc2252; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Smith JR, 2008, DEV BIOL, V313, P107, DOI 10.1016/j.ydbio.2007.10.003; Snyder A, 2004, J CELL BIOCHEM, V93, P224, DOI 10.1002/jcb.20191; Staal FJT, 2008, EUR J IMMUNOL, V38, P1788, DOI 10.1002/eji.200738118; Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005; Stewart MH, 2006, NAT METHODS, V3, P807, DOI 10.1038/nmeth939; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vijayaragavan K, 2009, CELL STEM CELL, V4, P248, DOI 10.1016/j.stem.2008.12.011; Wang LS, 2004, IMMUNITY, V21, P31, DOI 10.1016/j.immuni.2004.06.006; Werbowetski-Ogilvie TE, 2009, NAT BIOTECHNOL, V27, P91, DOI 10.1038/nbt.1516; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Yenerel MN, 2005, EXP HEMATOL, V33, P758, DOI 10.1016/j.exphem.2005.03.015; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722; Zangenberg M, 2009, EUR J HAEMATOL, V83, P439, DOI 10.1111/j.1600-0609.2009.01309.x; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	55	12	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4632	4644		10.1038/onc.2011.175	http://dx.doi.org/10.1038/onc.2011.175			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21625212				2022-12-28	WOS:000297252100003
J	Davies, AH; Barrett, I; Pambid, MR; Hu, K; Stratford, AL; Freeman, S; Berquin, IM; Pelech, S; Hieter, P; Maxwell, C; Dunn, SE				Davies, A. H.; Barrett, I.; Pambid, M. R.; Hu, K.; Stratford, A. L.; Freeman, S.; Berquin, I. M.; Pelech, S.; Hieter, P.; Maxwell, C.; Dunn, S. E.			YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification	ONCOGENE			English	Article						YB-1; premalignancy; centrosome; cell cycle; HER2 amplification; breast cancer	MAMMARY EPITHELIAL-CELLS; BOX-BINDING-PROTEIN; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; COLD SHOCK DOMAIN; CHROMOSOMAL INSTABILITY; CENTROSOME AMPLIFICATION; TUMOR-SUPPRESSOR; DRUG-RESISTANCE; LIM KINASES	Y-box binding protein-1 (YB-1) expression in the mammary gland promotes breast carcinoma that demonstrates a high degree of genomic instability. In the present study, we developed a model of pre-malignancy to characterize the role of this gene during breast cancer initiation and early progression. Antibody microarray technology was used to ascertain global changes in signal transduction following the conditional expression of YB-1 in human mammary epithelial cells (HMEC). Cell cycle-associated proteins were frequently altered with the most dramatic being LIM kinase 1/2 (LIMK1/2). Consequently, the misexpression of LIMK1/2 was associated with cytokinesis failure that acted as a precursor to centrosome amplification. Detailed investigation revealed that YB-1 localized to the centrosome in a phosphorylation-dependent manner, where it complexed with pericentrin and gamma-tubulin. This was found to be essential in maintaining the structural integrity and microtubule nucleation capacity of the organelle. Prolonged exposure to YB-1 led to rampant acceleration toward tumorigenesis, with the majority of cells acquiring numerical and structural chromosomal abnormalities. Slippage through the G(1)/S checkpoint due to overexpression of cyclin E promoted continued proliferation of these genomically compromised cells. As malignancy further progressed, we identified a subset of cells harboring HER2 amplification. Our results recognize YB-1 as a cancer susceptibility gene, with the capacity to prime cells for tumorigenesis. Oncogene (2011) 30, 3649-3660; doi:10.1038/onc.2011.82; published online 21 March 2011	[Davies, A. H.; Pambid, M. R.; Hu, K.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Pediat, Lab Oncogenom Res, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Davies, A. H.; Pambid, M. R.; Hu, K.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Expt Med, Lab Oncogenom Res, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Barrett, I.; Hieter, P.] Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 4H4, Canada; [Freeman, S.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 4H4, Canada; [Berquin, I. M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Pelech, S.] Wake Forest Univ, Brain Res Ctr, Div Neurol, Winston Salem, NC USA; [Pelech, S.] Kinexus Bioinformat Corp, Vancouver, BC, Canada	Child & Family Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; University of British Columbia; University of British Columbia; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University	Dunn, SE (corresponding author), Univ British Columbia, Dept Pediat, Lab Oncogenom Res, Child & Family Res Inst, 950 W 28th Ave,Room 3083, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca	Maxwell, Christopher A/B-3044-2011	Maxwell, Christopher A/0000-0002-0713-7136; Maxwell, Christopher/0000-0002-0860-4031	National Institutes of Health [RO1 CA114017]; Michael Smith Foundation for Health Research; Canadian Institutes of Health Research; Canadian Breast Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA114017] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ching-Shih Chen (The Ohio State University) for providing BI-D1870 and Michel Lebel (l'Universite Laval) for providing plasmid encoding GFP-tagged YB-1. This study was supported by the National Institutes of Health RO1 CA114017 (SED, IMB), the Michael Smith Foundation for Health Research (AHD), the Canadian Institutes of Health Research (AHD, SED) and the Canadian Breast Cancer Foundation (ALS).	Alliegro MC, 2006, P NATL ACAD SCI USA, V103, P9034, DOI 10.1073/pnas.0602859103; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Basaki Y, 2010, EUR J CANCER, V46, P954, DOI 10.1016/j.ejca.2009.12.024; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Chakrabarti R, 2007, CELL CYCLE, V6, P2944, DOI 10.4161/cc.6.23.4957; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Dhillon J, 2010, ONCOGENE, V29, P6294, DOI 10.1038/onc.2010.365; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Guay D, 2006, INT J BIOCHEM CELL B, V38, P1300, DOI 10.1016/j.biocel.2006.01.008; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Ise T, 1999, CANCER RES, V59, P342; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Raouf A, 2005, JNCI-J NATL CANCER I, V97, P1302, DOI 10.1093/jnci/dji254; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Scully R, 2000, BREAST CANCER RES, V2, P324, DOI 10.1186/bcr76; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shibao K, 1999, INT J CANCER, V83, P732; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Yu YN, 2010, INT J ONCOL, V37, P483, DOI 10.3892/ijo_00000697	52	43	43	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3649	3660		10.1038/onc.2011.82	http://dx.doi.org/10.1038/onc.2011.82			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423216	Green Accepted			2022-12-28	WOS:000294244500001
J	Gao, XN; Lin, J; Li, YH; Gao, L; Wang, XR; Wang, W; Kang, HY; Yan, GT; Wang, LL; Yu, L				Gao, X-N; Lin, J.; Li, Y-H; Gao, L.; Wang, X-R; Wang, W.; Kang, H-Y; Yan, G-T; Wang, L-L; Yu, L.			MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia	ONCOGENE			English	Article						c-kit; microRNAs; DNA methylation; acute myeloid leukemia; proto-oncogenes; tumor suppressor genes	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN CANCER; PROGNOSTIC IMPACT; DNA METHYLATION; GENE-EXPRESSION; CELL-LINES; MUTATIONS; AML; HYPERMETHYLATION; T(8/21)	Aberrant activation of c-kit proto-oncogene contributes to abnormal cell proliferation by altering the tyrosine kinase signaling and constitutes a crucial impetus for leukemo-genesis. Epigenetic silencing of tumor-suppressive microRNAs (miRNAs) is a key oncogenic mechanism for the activation of oncogenes in tumors. In this study, several miRNAs potentially binding to the 3'-untranslated region of human c-kit mRNA were screened by luciferase reporter assays. Among these miRNAs, miR-193a was embedded in a CpG island and epigenetically repressed by promoter hypermethylation in acute myeloid leukemia (AML) cell lines and primary AML blasts, but not in normal bone marrow cells. Importantly, miR-193a levels were inversely correlated with c-kit levels measured in 9 leukemia cell lines and 27 primary AML samples. Restoring miR-193a expression in AML cells harboring c-kit mutation and/or overexpression, either by synthetic miR-193a transfection or by DNA hypomethylating agent 5-azacytidine (5-aza) treatment, resulted in a significant reduction in c-kit expression at both RNA and protein levels and inhibition of cell growth. The growth-inhibitory activity of miR-193a was associated with apoptosis and granulocytic differentiation. Moreover, 5-aza-induced c-kit reduction could be partially blocked by miR-193a inhibitor, leading to a reversal of antiproliferative and proapoptotic effects of 5-aza. These data reveal a critical role for methylation-repressed miR-193a in myeloid leukemogenesis and the therapeutic promise of upregulating miR-193a expression for c-kit-positive AML. Oncogene (2011) 30, 3416-3428; doi:10.1038/onc.2011.62; published online 14 March 2011	[Gao, X-N; Li, Y-H; Gao, L.; Wang, X-R; Wang, W.; Kang, H-Y; Wang, L-L; Yu, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China; [Lin, J.; Yan, G-T] Chinese Peoples Liberat Army Gen Hosp, Basic Med Inst, Beijing 100853, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Yu, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, 28 Fuxing Rd, Beijing 100853, Peoples R China.	chunhuiliyu@yahoo.com	yang, xiao-jun/B-1927-2009	Yu, Li/0000-0001-6872-2665	National Natural Science Foundation of China [81000221, 90919044, 30971297]; National 973 Project of China [2005CB522400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 973 Project of China(National Basic Research Program of China)	We thank Y Ding, Y-Y Xu, N Wang, C-W Xu, M Li, M-X Chen and W-D Han for excellent technical assistance. We also thank Professor X-F Zheng and H-J Fu from Beijing Institute of Radiation Medicine, China, for presenting the modified pGL3-control plasmid and miRNA expression plasmids. This work was supported by the National Natural Science Foundation of China (nos 81000221, 90919044 and 30971297) and the National 973 Project of China (no. 2005CB522400).	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Agrawal S, 2007, CANCER RES, V67, P1370, DOI 10.1158/0008-5472.CAN-06-1681; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beghini A, 2004, HAEMATOLOGICA, V89, P920; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Berg T, 2007, LEUKEMIA RES, V31, P497, DOI 10.1016/j.leukres.2006.08.008; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2008, LEUKEMIA, V22, P1095, DOI 10.1038/leu.2008.30; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Heidel F, 2007, CANCER, V109, P907, DOI 10.1002/cncr.22471; Jacquel A, 2007, ONCOGENE, V26, P2445, DOI 10.1038/sj.onc.1210034; Jiao B, 2009, LEUKEMIA, V23, P1598, DOI 10.1038/leu.2009.104; Jun C, 2007, PROG BIOCHEM BIOPHYS, V34, P389; Kindler T, 2004, BLOOD, V103, P3644, DOI 10.1182/blood-2003-06-2071; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Larizza L, 2005, LEUKEMIA LYMPHOMA, V46, P247, DOI 10.1080/10428190400007565; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Marcucci G, 2008, NEW ENGL J MED, V358, P1919, DOI 10.1056/NEJMoa074256; Osada H, 2007, CARCINOGENESIS, V28, P2, DOI 10.1093/carcin/bgl185; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Reilly JT, 2003, BLOOD REV, V17, P241, DOI 10.1016/S0268-960X(03)00024-9; Renneville A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19; Roman-Gomez J, 2009, J CLIN ONCOL, V27, P1316, DOI 10.1200/JCO.2008.19.3441; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Schnittger S, 2006, BLOOD, V107, P1791, DOI 10.1182/blood-2005-04-1466; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Wang YY, 2005, P NATL ACAD SCI USA, V102, P1104, DOI 10.1073/pnas.0408831102; Youssef EM, 2004, CANCER RES, V64, P2411, DOI 10.1158/0008-5472.CAN-03-0164	45	128	139	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3416	3428		10.1038/onc.2011.62	http://dx.doi.org/10.1038/onc.2011.62			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21399664				2022-12-28	WOS:000293508100003
J	Mullany, LK; Fan, HY; Liu, Z; White, LD; Marshall, A; Gunaratne, P; Anderson, ML; Creighton, CJ; Xin, L; Deavers, M; Wong, KK; Richards, JS				Mullany, L. K.; Fan, H-Y; Liu, Z.; White, L. D.; Marshall, A.; Gunaratne, P.; Anderson, M. L.; Creighton, C. J.; Xin, L.; Deavers, M.; Wong, K-K; Richards, J. S.			Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo	ONCOGENE			English	Article						Kras; Pten; Trp53; ovarian cancer; serous	GENE-EXPRESSION PROFILES; SEROUS CARCINOMA; GRANULOSA-CELLS; PATHWAY ACTIVATION; WNT/BETA-CATENIN; K-RAS; CANCER; P53; ORIGIN; PROLIFERATION	Ovarian cancer is a complex and deadly disease that remains difficult to detect at an early curable stage. Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear. We recently generated Pten(fl/fl); Kras(G12D); Amhr2-Cre mice to disrupt the Pten gene and express a stable mutant form of Kras(G12D) in ovarian surface epithelial (OSE) cells. On the basis of histopathologic criteria, the mutant mice developed low-grade ovarian serous papillary adenocarcinomas at an early age and with 100% penetrance. This highly reproducible phenotype provides the first mouse model in which to study this ovarian cancer subtype. OSE cells isolated from ovaries of mutant mice at 5 and 10 weeks of age exhibit temporal changes in the expression of specific Mullerian epithelial marker genes, grow in soft agar and develop ectopic invasive tumors in recipient mice, indicating that the cells are transformed. Gene profiling identified specific mRNAs and microRNAs differentially expressed in purified OSE cells derived from tumors of the mutant mice compared with wild-type OSE cells. Mapping of transcripts or genes between the mouse OSE mutant data sets, the Kras signature from human cancer cell lines and the human ovarian tumor array data sets, documented significant overlap, indicating that KRAS is a key driver of OSE transformation in this context. Two key hallmarks of the mutant OSE cells in these mice are the elevated expression of the tumor-suppressor Trp53 (p53) and its microRNA target, miR-34a-c. We propose that elevated TRP53 and miR-34a-c may exert negatively regulatory effects that reduce the proliferative potential of OSE cells leading to the low-grade serous adenocarcinoma phenotype. Oncogene (2011) 30, 3522-3536; doi:10.1038/onc.2011.70; published online 21 March 2011	[Mullany, L. K.; Fan, H-Y; Liu, Z.; Marshall, A.; Xin, L.; Richards, J. S.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [White, L. D.; Creighton, C. J.] Baylor Coll Med, Dept Mol & Human Genet & Mol & Cellular Biol, Houston, TX 77030 USA; [White, L. D.; Creighton, C. J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Gunaratne, P.] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Anderson, M. L.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Deavers, M.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Wong, K-K] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Houston System; University of Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Richards, JS (corresponding author), Baylor Coll Med BCM130, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	joanner@bcm.tmc.edu	Parry, Lee/A-9623-2011; Wong, K.-k./AAA-6589-2020; Anderson, Matthew/C-4755-2019	Parry, Lee/0000-0002-4467-9196; Wong, K.-k./0000-0002-0375-6669; Anderson, Matthew/0000-0002-2081-4672; Marshall, Alexandra/0000-0003-4888-643X	NRSA; Ovarian Cancer Research Fund; The University of Texas MD Anderson Cancer Center [P50 CA08369];  [NIH-HD-16229]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495, R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229, R56HD016229] Funding Source: NIH RePORTER	NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Fund; The University of Texas MD Anderson Cancer Center; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We Alan J Herron DVM, Professor and Head of the Comparative Pathology Laboratory for his advice and insights into the mouse ovarian tumor phenotype, Yuet Lo and Azam Zariff for technical assistance and the Microscopy Core at Baylor College of Medicine for their expertise. We also thank the Immunohistochemistry Laboratory at The University of Texas MD Anderson Cancer Center for performing the calretinin and ESR1 immunostaining. Supported in part by NIH-HD-16229 (JSR), NRSA (LM), a Program Project Development Grant from the Ovarian Cancer Research Fund (CJC, PG, MA) and The University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence in Ovarian Cancer (P50 CA08369) (KKW).	Abdullah M, 2009, PATHOL RES PRACT, V205, P639, DOI 10.1016/j.prp.2009.04.007; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Auersperg N, 2008, GYNECOL ONCOL, V110, P452, DOI 10.1016/j.ygyno.2008.05.031; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bohlig L, 2008, CELL CYCLE, V7, P1254, DOI 10.4161/cc.7.9.5812; Bowen NJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-71; Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230; Cho KR, 2009, ARCH PATHOL LAB MED, V133, P1775, DOI 10.1043/1543-2165-133.11.1775; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Clark-Knowles KV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008534; Connolly DC, 2003, CANCER RES, V63, P1389; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Costa BM, 2010, CANCER RES, V70, P453, DOI 10.1158/0008-5472.CAN-09-2189; Creighton CJ, 2010, CANCER RES, V70, P1906, DOI 10.1158/0008-5472.CAN-09-3875; Crum CP, 2007, CLIN MED RES, V5, P35, DOI 10.3121/cmr.2007.702; DAHLYA N, 2008, PLOS ONE, V3, P1; Despierre E, 2010, GYNECOL ONCOL, V117, P358, DOI 10.1016/j.ygyno.2010.02.012; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dubeau L, 2008, LANCET ONCOL, V9, P1191, DOI 10.1016/S1470-2045(08)70308-5; Fan HY, 2008, DEVELOPMENT, V135, P2127, DOI 10.1242/dev.020560; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Fan HY, 2009, SCIENCE, V324, P938, DOI 10.1126/science.1171396; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Gaval N, 2008, J MOL ENDOCRINOL, V40, P281, DOI 10.1677/JME-07-0149; Gorringe KL, 2009, MOL ONCOL, V3, P157, DOI 10.1016/j.molonc.2008.12.005; *GSK, 2008, CANC CELL LIN GEN PR; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; KAPLINAS K, 2009, J CELL BIOCHEM, V108, P216; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Ko SY, 2010, MOL CELL ENDOCRINOL, V317, P112, DOI 10.1016/j.mce.2009.12.025; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Liang S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004295; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; PAGE CL, 2006, BRIT J CANCER, V94, P436; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Raimondi AR, 2009, CANCER RES, V69, P4159, DOI 10.1158/0008-5472.CAN-08-4645; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schwartz DR, 2002, CANCER RES, V62, P4722; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wong KK, 2007, INT J GYNECOL PATHOL, V26, P404, DOI 10.1097/pgp.0b013e31803025cd; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311; Xing D, 2009, CANCER RES, V69, P8231, DOI 10.1158/0008-5472.CAN-09-2543; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Zhang CC, 2006, NAT MED, V12, P240, DOI 10.1038/nm1342; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710	68	62	64	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3522	3536		10.1038/onc.2011.70	http://dx.doi.org/10.1038/onc.2011.70			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423204	Green Accepted			2022-12-28	WOS:000293782300005
J	Roe, JS; Kim, HR; Hwang, IY; Cho, EJ; Youn, HD				Roe, J-S; Kim, H-R; Hwang, I-Y; Cho, E-J; Youn, H-D			von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage	ONCOGENE			English	Article						von Hippel-Lindau; Skp2; DNA damage; renal cell carcinoma; tumorigenesis	RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTOR-1; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR; PROLYL HYDROXYLATION; TISSUE MICROARRAY; MOLECULAR-BASIS; INHIBITOR P27; TARGET GENE; HIF-ALPHA	Germline mutations in the von Hippel-Lindau (VHL) tumor suppressor gene cause VHL disease, a rare and autosomal-dominant genetic syndrome. Because VHL protein (pVHL) is the master regulator of hypoxia-inducible factor alpha (HIF alpha), the most prominent feature of VHL disease is the deregulation of HIF alpha proteins. However, the precise mechanism by which the loss of pVHL function contributes to tumorigenesis is not fully understood. Here, we show that pVHL destabilizes the F-box protein Skp2, a chief component of Skp, Cullin, F-box-containing complex that promotes DNA synthesis in the S phase. The beta-domain of pVHL interacts with Skp2, stimulating proteasome-dependent Skp2 degradation, but the destabilization of Skp2 does not depend on the E3 ubiquitin ligase activity of pVHL. Notably, the generation of DNA damage induces Skp2 degradation, which is attenuated by the suppression of endogenous pVHL expression. One possible mechanism of pVHL-dependent Skp2 degradation entails the antagonizing of Akt-mediated Skp2 phosphorylation, which maintains Skp2 stability. Reintroduction of VHL into VHL-null renal cell carcinoma (RCC) cells decreased Skp2 levels and restored DNA damage-dependent Skp2 degradation. These results identify the tumor suppressor function of pVHL in delaying the S-phase progression to inhibit cell proliferation on DNA damage. Clinically, this report explains as to why Skp2 accumulates abnormally in RCC tissues. Oncogene (2011) 30, 3127-3138; doi:10.1038/onc.2011.40; published online 28 February 2011	[Roe, J-S; Kim, H-R; Hwang, I-Y; Youn, H-D] Seoul Natl Univ, Coll Med, Natl Res Lab Metab Checkpoint, Dept Biomed Sci,Canc Res Inst, Seoul 110799, South Korea; [Roe, J-S; Kim, H-R; Hwang, I-Y; Youn, H-D] Seoul Natl Univ, Coll Med, Natl Res Lab Metab Checkpoint, Dept Biochem & Mol Biol,Canc Res Inst, Seoul 110799, South Korea; [Cho, E-J] Sungkyunkwan Univ, Coll Pharm, Natl Res Lab Chromatin Dynam, Suwon, South Korea	Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU)	Youn, HD (corresponding author), Seoul Natl Univ, Coll Med, Natl Res Lab Metab Checkpoint, Dept Biomed Sci,Canc Res Inst, 28 Yongon Dong, Seoul 110799, South Korea.	hdyoun@snu.ac.kr	Hwang, Inyoung/AAS-3325-2021; Cho, Eun-Jung/AAR-1785-2020; Youn, Hong-Duk/J-2774-2012	Hwang, Inyoung/0000-0002-4633-3658; Cho, Eun-Jung/0000-0002-6610-5329; Roe, Jae-Seok/0000-0002-9994-3062	Korea government (MEST) [0720460, A090281, NRF-2010-0018896, A080181, S2-2008-000-00400-1]	Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare (0720460), the Korea Healthcare Technology R&D Project (A090281), and National Research Foundation Grant (NRF-2010-0018896) to H-DY, a grant from the Korea Healthcare R&D Project (A080181) to E-JC and by the Korea Student Aid Foundation (KOSAF) grant, funded by the Korea government (MEST) (S2-2008-000-00400-1) to JSR. We thank Dr B Bruene (Johann Wolfgang Goethe-University) and Dr DS Lim (KAIST) for invaluable materials.	Balasubramanian S, 1999, ONCOGENE, V18, P1297, DOI 10.1038/sj.onc.1202417; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cohen HT, 1999, CURR OPIN NEPHROL HY, V8, P325, DOI 10.1097/00041552-199905000-00008; Cuadrado M, 2009, CANCER RES, V69, P8726, DOI 10.1158/0008-5472.CAN-09-0729; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feng X, 2009, ONCOGENE, V28, P3320, DOI 10.1038/onc.2009.185; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; He G, 2006, BRIT J CANCER, V95, P1514, DOI 10.1038/sj.bjc.6603448; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Ishizaki H, 2007, PATHOL INT, V57, P672, DOI 10.1111/j.1440-1827.2007.02156.x; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kawasaki T, 1999, ONCOL REP, V6, P329; Kim M, 2004, BIOCHEM BIOPH RES CO, V320, P945, DOI 10.1016/j.bbrc.2004.06.042; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kitagawa M, 2008, MOL CELL, V29, P217, DOI 10.1016/j.molcel.2007.11.036; Lam JS, 2005, UROLOGY, V66, P1, DOI 10.1016/j.urology.2005.06.112; Langner C, 2004, VIRCHOWS ARCH, V445, P631, DOI 10.1007/s00428-004-1121-2; Leonardi E, 2009, FEBS LETT, V583, P3704, DOI 10.1016/j.febslet.2009.10.070; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu Z, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-51; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mizutani Y, 2007, INT J ONCOL, V30, P919; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Nho Richard Seonghun, 2003, Prog Cell Cycle Res, V5, P249; Nyhan MJ, 2008, BIOCHEM SOC T, V36, P472, DOI 10.1042/BST0360472; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Osipov V, 2002, APPL IMMUNOHISTO M M, V10, P344, DOI 10.1097/00022744-200212000-00010; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Vikhanskaya F, 1996, EXP CELL RES, V227, P380, DOI 10.1006/excr.1996.0288; Vivo C, 2003, BRIT J CANCER, V88, P388, DOI 10.1038/sj.bjc.6600736; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Zhou H, 2004, TOXICOL APPL PHARM, V200, P111, DOI 10.1016/j.taap.2004.04.003	52	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	28					3127	3138		10.1038/onc.2011.40	http://dx.doi.org/10.1038/onc.2011.40			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21358672				2022-12-28	WOS:000292726300002
J	Seux, M; Peuget, S; Montero, MP; Siret, C; Rigot, V; Clerc, P; Gigoux, V; Pellegrino, E; Pouyet, L; N'Guessan, P; Garcia, S; Dufresne, M; Iovanna, JL; Carrier, A; Andre, F; Dusetti, NJ				Seux, M.; Peuget, S.; Montero, M. P.; Siret, C.; Rigot, V.; Clerc, P.; Gigoux, V.; Pellegrino, E.; Pouyet, L.; N'Guessan, P.; Garcia, S.; Dufresne, M.; Iovanna, J. L.; Carrier, A.; Andre, F.; Dusetti, N. J.			TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression	ONCOGENE			English	Article						TP53INP1; SPARC; migration; pancreatic cancer; PanIN	GROWTH-FACTOR-BETA; PROTEIN P53-INDUCED NUCLEAR-PROTEIN-1; CA2+-BINDING EF-HAND; GENE-EXPRESSION; NULL MICE; MATRICELLULAR PROTEIN; EXTRACELLULAR-MATRIX; MICROARRAY ANALYSIS; TUMOR-SUPPRESSOR; ENHANCED GROWTH	Tumor protein 53 induced nuclear protein 1 (TP53INP1) is a p53 target gene that induces cell growth arrest and apoptosis by modulating p53 transcriptional activity. TP53INP1 interacts physically with p53 and is a major player in the p53-driven oxidative stress response. Previously, we demonstrated that TP53INP1 is down-regulated in an early stage of pancreatic cancerogenesis and when restored is able to suppress pancreatic tumor development. TP53INP1 downregulation in pancreas is associated with an oncogenic microRNA miR-155. In the present work, we studied the effects of TP53INP1 on cell migration. We found that TP53INP1 inactivation correlates with increased cell migration both in vivo and in vitro. The impact of TP53INP1 expression on cell migration was studied in different cellular contexts: mouse embryonic fibroblast and different pancreatic cancer cell lines. Its expression decreases cell migration by the transcriptional downregulation of secreted protein acidic and rich in cysteine (SPARC). SPARC is a matrix cellular protein, which governs diverse cellular functions and has a pivotal role in regulating cell-matrix interactions, cellular proliferation and migration. SPARC was also showed to be upregulated in normal pancreas and in pancreatic intraepithelial neoplasia lesions in a pancreatic adenocarcinoma mouse model only in the TP53INP1-deficient animals. This novel TP53INP1 activity on the regulation of SPARC expression could explain in part its tumor suppressor function in pancreatic adenocarcinoma by modulating cellular spreading during the metastatic process. Oncogene (2011) 30, 3049-3061; doi: 10.1038/onc.2011.25; published online 21 February 2011	[Seux, M.; Peuget, S.; Pouyet, L.; N'Guessan, P.; Garcia, S.; Iovanna, J. L.; Carrier, A.; Dusetti, N. J.] INSERM, Stress Cellulaire U624, F-13288 Marseille, France; [Seux, M.; Peuget, S.; Pouyet, L.; N'Guessan, P.; Garcia, S.; Iovanna, J. L.; Carrier, A.; Dusetti, N. J.] Aix Marseille Univ, Marseille, France; [Montero, M. P.; Siret, C.; Rigot, V.; Pellegrino, E.; Andre, F.] Aix Marseille Univ, INSERM, CRO2, U911, Marseille, France; [Clerc, P.; Gigoux, V.; Dufresne, M.] Univ Toulouse, INSERM, IFR150, I2MR,U858, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse	Dusetti, NJ (corresponding author), INSERM, U624, Parc Sci Luminy,Case 915, F-13288 Marseille, France.	nelson.dusetti@inserm.fr	Gigoux, Véronique/AAE-6090-2020; Dusetti, Nelson/O-7919-2017; Dufresne, Marlène/M-6332-2014; Iovanna, Juan/M-9805-2017; Peuget, Sylvain/AAB-4730-2022	Gigoux, Véronique/0000-0003-1408-5335; Dusetti, Nelson/0000-0002-6161-8483; Iovanna, Juan/0000-0003-1822-2237; Montero, Marie-Pierre/0000-0003-4280-0674; Peuget, Sylvain/0000-0002-3315-1935	Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique; Institut National du Cancer; La Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Club Franicais du Pancreas; Ministeere de la Recherche et de la Technologie	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer(Institut National du Cancer (INCA) France); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Agence Nationale de la Recherche(French National Research Agency (ANR)); Club Franicais du Pancreas; Ministeere de la Recherche et de la Technologie	This work was supported in part by Institut National de la Sante et de la Recherche Medicale (INSERM) and Centre National de la Recherche Scientifique and grants from the Institut National du Cancer, La Ligue Nationale Contre le Cancer, Association pour la Recherche sur le Cancer and the Agence Nationale de la Recherche. M Seux was supported by Association pour la Recherche sur le Cancer and S Peuget by the Club Franicais du Pancreas and Ministeere de la Recherche et de la Technologie. Authors acknowledge Tony George JACOB and Antoine Baud for critically reading the manuscript and helpful comments respectively.	Arnold S, 2008, EXP BIOL MED, V233, P860, DOI 10.3181/0801-RM-12; Basu A, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-15; Baumgart M, 2005, CELL ONCOL, V27, P3; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Bradshaw AD, 2002, J HISTOCHEM CYTOCHEM, V50, P1; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brune K, 2008, CANCER EPIDEM BIOMAR, V17, P3536, DOI 10.1158/1055-9965.EPI-08-0630; Chen G, 2010, BRIT J CANCER, V102, P188, DOI 10.1038/sj.bjc.6605440; FORD R, 1993, EXP CELL RES, V206, P261, DOI 10.1006/excr.1993.1146; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Gommeaux J, 2007, MOL CELL BIOL, V27, P2215, DOI 10.1128/MCB.01454-06; Guweidhi A, 2005, ANN SURG, V242, P224, DOI 10.1097/01.sla.0000171866.45848.68; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hunzelmann N, 1998, J INVEST DERMATOL, V110, P122, DOI 10.1046/j.1523-1747.1998.00094.x; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Ito Y, 2006, ANTICANCER RES, V26, P4391; Jiang PH, 2006, WORLD J GASTROENTERO, V12, P691, DOI 10.3748/wjg.v12.i5.691; Loging WT, 2000, GENOME RES, V10, P1393, DOI 10.1101/gr.138000; Lomberk G, 2008, CURR OPIN GASTROEN, V24, P597, DOI 10.1097/MOG.0b013e32830b111d; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Ogawa Kumiko, 2005, Medical Molecular Morphology, V38, P23, DOI 10.1007/s00795-004-0265-0; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rempel SA, 2001, J NEURO-ONCOL, V53, P149, DOI 10.1023/A:1012201300188; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Ryu B, 2001, CANCER RES, V61, P1833; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Seno T, 2009, INT J ONCOL, V34, P707, DOI 10.3892/ijo_00000197; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Suzuki S, 2004, CARCINOGENESIS, V25, P439, DOI 10.1093/carcin/bgh030; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Tomasini R, 2002, EUR J CELL BIOL, V81, P294, DOI 10.1078/0171-9335-00248; Vasseur S, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-25; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yoshida K, 2006, J BIOL CHEM, V281, P5734, DOI 10.1074/jbc.M512074200	54	55	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	27					3049	3061		10.1038/onc.2011.25	http://dx.doi.org/10.1038/onc.2011.25			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339733				2022-12-28	WOS:000292510100005
J	Jean, C; Gravelle, P; Fournie, JJ; Laurent, G				Jean, C.; Gravelle, P.; Fournie, J-J; Laurent, G.			Influence of stress on extracellular matrix and integrin biology	ONCOGENE			English	Review						stress; ECM; integrin biology; remodeling; cellular response	MEDIATED DRUG-RESISTANCE; FOCAL ADHESION KINASE; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; CARCINOMA CELL INVASION; HUMAN-ENDOTHELIAL-CELLS; HAIRLESS MOUSE SKIN; GENE-EXPRESSION; IN-VITRO; TUMOR-CELLS	Dynamic interactions between cells and extracellular matrix (ECM) through integrins influence most cellular functions. Normal cells, but even more, tumor cells are subjected to different forms of stress, including ischemia, radical oxygen species production, starvation, mechanical stress or genotoxic insults due to anti-cancer drugs or irradiation. In these situations, an adaptative cellular response occurs, integrating a complex network of intracellular signaling modules, which, depending on stress intensity, may result to either damage repair followed by complete restitution of cellular functions, or programmed cell death. Because of its implication in oncogenesis and anti-cancer therapy, cellular stress response has been thoroughly investigated. However, most of these studies have been performed in the context of isolated cells without taking into consideration that most cells are part of the tissue within which they interact with ECM through integrin. Few studies have described the influence of stress on cell-to-ECM interaction. However, one can speculate that, in these conditions, cells could functionally interact with protein microenvironment either to create positive interactions to survive (for example by facilitating protective pathways) or negative interaction to die (for example by facilitating detachment). In this review, we summarize the knowledge relative to the influence of different stress modalities on ECM remodeling, integrin expression and/or function modifications, and possible functional consequences, independently from the cellular model as these findings came from a large variety of cells (mesenchymal, endothelial, muscular, epithelial and glandular) and fields of application (cancer, vascular biology and tissue engineering). Most studies support the general notion that non-lethal stress favors ECM stiffness, integrin activation and enhanced survival. This field opens large perspectives not only in tumor biology but also in anti-cancer therapy by targeting one or several steps of the integrin-mediated signaling pathway, including integrin ligation, or activation of integrin-linked enzymes or integrin adaptors. Oncogene (2011) 30, 2697-2706; doi: 10.1038/onc.2011.27; published online 21 February 2011	[Jean, C.] CHU Purpan, INSERM, CPTP, UMR1037,Canc Res Ctr Toulouse, F-31024 Toulouse, France; [Jean, C.; Gravelle, P.; Fournie, J-J; Laurent, G.] Univ Toulouse, Toulouse, France; [Laurent, G.] CHU Purpan, Serv Hematol, F-31024 Toulouse, France; [Jean, C.; Gravelle, P.; Fournie, J-J; Laurent, G.] CNRS ERL, Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS)	Jean, C (corresponding author), CHU Purpan, INSERM, CPTP, UMR1037,Canc Res Ctr Toulouse, Pavillon Lefebvre Bat B,Pl Dr Baylac,BP 3028, F-31024 Toulouse, France.	christine.jean@inserm.fr	jean, christine/P-2920-2014; Fournie, Jean-Jacques/J-7805-2013; GRAVELLE, PAULINE/D-1405-2015	jean, christine/0000-0002-6936-289X; Fournie, Jean-Jacques/0000-0001-6542-6908; GRAVELLE, PAULINE/0000-0002-0462-5652				Beinke C, 2003, INT J RADIAT BIOL, V79, P721, DOI 10.1080/09553000310001610231; Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Blaschke F, 2002, BIOCHEM BIOPH RES CO, V296, P890, DOI 10.1016/S0006-291X(02)02033-8; BOYER B, 1992, J PHOTOCH PHOTOBIO B, V14, P247, DOI 10.1016/1011-1344(92)85102-Z; Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Casanova I, 2008, INT J CANCER, V123, P217, DOI 10.1002/ijc.23516; Case D, 2007, AM J PHYSIOL-LUNG C, V292, pL154, DOI 10.1152/ajplung.00192.2006; Cha MC, 2010, CELL BIOL INT, V34, P587, DOI 10.1042/CBI20090096; Cheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706; Chiarugi P, 2008, IUBMB LIFE, V60, P301, DOI 10.1002/iub.45; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Dahl KDC, 2005, MOL BIOL CELL, V16, P1901; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; De Croos JNA, 2010, J ORTHOP RES, V28, P921, DOI 10.1002/jor.21064; De Toni F, 2006, ONCOGENE, V25, P3113, DOI 10.1038/sj.onc.1209346; De Toni-Costes F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009807; Demou ZN, 2010, ANN BIOMED ENG, V38, P3509, DOI 10.1007/s10439-010-0097-0; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; DiDonato A, 1997, NEPHRON, V76, P192, DOI 10.1159/000190168; Duensing S, 1996, INVAS METAST, V16, P65; Eckes B, 2006, J INVEST DERM SYMP P, V11, P66, DOI 10.1038/sj.jidsymp.5650003; Estrugo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000269; Fouquet S, 2004, J BIOL CHEM, V279, P43061, DOI 10.1074/jbc.M405095200; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Ghosh S, 2005, J CELL PHYSIOL, V204, P522, DOI 10.1002/jcp.20320; Gong LM, 2004, LIFE SCI, V74, P1225, DOI 10.1016/j.lfs.2003.07.046; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hannafin JA, 2006, J ORTHOP RES, V24, P149, DOI 10.1002/jor.20018; Hazane F, 2005, J PHOTOCH PHOTOBIO B, V79, P171, DOI 10.1016/j.jphotobiol.2005.02.001; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hernandez-Pigeon H, 2006, J BIOL CHEM, V281, P13525, DOI 10.1074/jbc.M512694200; Hernandez-Pigeon H, 2007, J BIOL CHEM, V282, P8157, DOI 10.1074/jbc.M607436200; Hofmann C, 2007, GASTROENTEROLOGY, V132, P587, DOI 10.1053/j.gastro.2006.11.017; Horino Y, 2002, LIFE SCI, V71, P3031, DOI 10.1016/S0024-3205(02)02142-2; Horning JL, 2008, MOL PHARMACEUT, V5, P849, DOI 10.1021/mp800047v; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hoyt DG, 1996, CANCER RES, V56, P4146; Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; Iovine B, 2009, BIOCHIMIE, V91, P364, DOI 10.1016/j.biochi.2008.10.017; Ise K, 2004, TRANSPL P, V36, P1183, DOI 10.1016/j.transproceed.2004.04.029; Ishikawa J, 2005, HYPERTENS RES, V28, P995, DOI 10.1291/hypres.28.995; Janig E, 2007, AM J PATHOL, V171, P1474, DOI 10.2353/ajpath.2007.061064; Jean C, 2009, CANCER RES, V69, P3291, DOI 10.1158/0008-5472.CAN-08-1909; Jikko A, 1996, RADIAT RES, V146, P93, DOI 10.2307/3579401; Katsumi A, 2005, J BIOL CHEM, V280, P16546, DOI 10.1074/jbc.C400455200; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kim SH, 2010, CANCER RES, V70, P4054, DOI 10.1158/0008-5472.CAN-09-2110; Kizaki K, 2006, PHARMACOL RES, V53, P341, DOI 10.1016/j.phrs.2006.01.001; Kligman LH, 1999, PHOTODERMATOL PHOTO, V15, P198, DOI 10.1111/j.1600-0781.1999.tb00085.x; KLIGMAN LH, 1989, J INVEST DERMATOL, V93, P210, DOI 10.1111/1523-1747.ep12277573; Kock LM, 2009, J BIOMECH, V42, P2177, DOI 10.1016/j.jbiomech.2009.05.039; Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Kozlova NI, 2004, BIOCHEM BIOPH RES CO, V316, P1173, DOI 10.1016/j.bbrc.2004.03.004; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lahiji K, 2004, IN VITRO CELL DEV-AN, V40, P138, DOI 10.1290/1543-706X(2004)40<138:CSSPCA>2.0.CO;2; LAMBERT CA, 1992, LAB INVEST, V66, P444; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Lee SH, 2011, J CELL PHYSIOL, V226, P484, DOI 10.1002/jcp.22358; Lee SH, 2009, CARCINOGENESIS, V30, P1997, DOI 10.1093/carcin/bgp233; Liang Y, 2001, EUR J CANCER, V37, P1041, DOI 10.1016/S0959-8049(01)00086-7; Lugo-Martinez VH, 2009, AM J PHYSIOL-GASTR L, V296, pG235, DOI 10.1152/ajpgi.90313.2008; Matsunaga T, 2008, LEUKEMIA, V22, P353, DOI 10.1038/sj.leu.2405017; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Milner R, 2008, MOL CELL NEUROSCI, V38, P43, DOI 10.1016/j.mcn.2008.01.013; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Miyazaki Y, 2008, INT J ONCOL, V32, P145; Miyoshi A, 2006, INT J ONCOL, V29, P1533; Monferran S, 2008, INT J CANCER, V123, P357, DOI 10.1002/ijc.23498; Moore SW, 2010, DEV CELL, V19, P194, DOI 10.1016/j.devcel.2010.07.018; Munoz J, 2010, J CELL PHYSIOL, V222, P111, DOI 10.1002/jcp.21927; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Muszynska A, 2001, EUR J PHARMACOL, V411, P17, DOI 10.1016/S0014-2999(00)00847-5; Myllyharju J, 2010, CELL TISSUE RES, V339, P19, DOI 10.1007/s00441-009-0841-7; Neitmann M, 1999, BRIT J DERMATOL, V141, P794, DOI 10.1046/j.1365-2133.1999.03151.x; Netti PA, 2000, CANCER RES, V60, P2497; Noborio-Hatano K, 2009, ONCOGENE, V28, P231, DOI 10.1038/onc.2008.385; Orr AW, 2006, MOL BIOL CELL, V17, P4686, DOI 10.1091/mbc.E06-04-0289; Oswald J, 2006, STEM CELLS, V24, P494, DOI 10.1634/stemcells.2005-0276; Provenzano PP, 2009, ONCOGENE, V28, P4326, DOI 10.1038/onc.2009.299; Quan TH, 2004, AM J PATHOL, V165, P741, DOI 10.1016/S0002-9440(10)63337-8; REPESH LA, 1993, CLIN EXP METASTAS, V11, P91, DOI 10.1007/BF00880070; Rohwer N, 2008, CANCER RES, V68, P10113, DOI 10.1158/0008-5472.CAN-08-1839; Salo S, 2009, INT J CANCER, V125, P1814, DOI 10.1002/ijc.24532; SASAKI T, 1987, J CLIN INVEST, V80, P1735, DOI 10.1172/JCI113265; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood-2003-12-4218; SCHUETZ JD, 1993, CELL GROWTH DIFFER, V4, P31; Schwartz MA, 2008, CURR OPIN CELL BIOL, V20, P551, DOI 10.1016/j.ceb.2008.05.005; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Song JH, 2009, INT J CANCER, V125, P1074, DOI 10.1002/ijc.24386; Sood AK, 2010, J CLIN INVEST, V120, P1515, DOI 10.1172/JCI40802; StCroix B, 1996, NAT MED, V2, P1204; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Ta HQ, 2008, CANCER RES, V68, P8796, DOI 10.1158/0008-5472.CAN-08-2426; Takahashi I, 2003, EUR J CELL BIOL, V82, P182, DOI 10.1078/0171-9335-00307; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Thao LB, 2009, CANCER BIOL THER, V8, P683, DOI 10.4161/cbt.8.8.7779; Ulrich TA, 2009, CANCER RES, V69, P4167, DOI 10.1158/0008-5472.CAN-08-4859; van Nimwegen MJ, 2006, MOL PHARMACOL, V70, P1330, DOI 10.1124/mol.106.026195; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Verhaar R, 2008, BLOOD, V112, P4935, DOI 10.1182/blood-2008-04-151043; Walsh C, 2010, CANCER BIOL THER, V9, P778, DOI 10.4161/cbt.9.10.11433; Walton HL, 2000, J CELL BIOCHEM, V78, P674, DOI 10.1002/1097-4644(20000915)78:4<674::AID-JCB16>3.0.CO;2-G; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Weber LM, 2008, TISSUE ENG PT A, V14, P1959, DOI 10.1089/ten.tea.2007.0238; Wen HA, 2009, INT WOUND J, V6, P149, DOI 10.1111/j.1742-481X.2009.00591.x; Westhoff MA, 2008, ONCOGENE, V27, P5169, DOI 10.1038/onc.2008.148; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Yao J, 2009, INT J MOL MED, V24, P153, DOI 10.3892/ijmm_00000218; Zamir E, 2001, J CELL SCI, V114, P3583	123	71	78	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2697	2706		10.1038/onc.2011.27	http://dx.doi.org/10.1038/onc.2011.27			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21339741				2022-12-28	WOS:000291678500001
J	Sotillo, E; Laver, T; Mellert, H; Schelter, JM; Cleary, MA; McMahon, S; Thomas-Tikhonenko, A				Sotillo, E.; Laver, T.; Mellert, H.; Schelter, J. M.; Cleary, M. A.; McMahon, S.; Thomas-Tikhonenko, A.			Myc overexpression brings out unexpected antiapoptotic effects of miR-34a	ONCOGENE			English	Article						microRNA; Myc; p53	B-CELL LINE; TUMOR-SUPPRESSOR; DOWN-REGULATION; C-MYC; P53; MICRORNAS; ACTIVATION; REPRESSION; EXPRESSION; APOPTOSIS	Downregulation of microRNA-34a by Myc is known to be essential for tumorigenesis and improve tumor-cell survival. Conversely, upregulation of miR-34a by p53 is thought to enhance its acetylation and activity and contribute to the pro-apoptotic effects of this tumor suppressor. We sought to determine whether restoration of miR-34a levels in B-lymphoid cells with Myc overexpression would aid therapeutic apoptosis. Unexpectedly, delivery of miR-34a, which doesn't target p53 directly, severely compromised steady-state p53 levels. This effect was preceded and mediated by direct targeting of Myc, which sustained p53 protein levels via the Arf-Hdm2 pathway. As a result, in the presence of Myc, miR-34a inhibited p53-dependent bortezomib-induced apoptosis as efficiently as anti-p53 small interfering RNA. Conversely, inhibition of miR-34a using antisense RNA sensitized lymphoma cells to therapeutic apoptosis. Thus, in tumors with deregulated Myc expression, miR-34a confers drug resistance and could be considered a therapeutic target. Oncogene (2011) 30, 2587-2594; doi:10.1038/onc.2010.634; published online 7 February 2011	[Sotillo, E.; Thomas-Tikhonenko, A.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Canc Pathobiol, Philadelphia, PA 19104 USA; [Laver, T.; Thomas-Tikhonenko, A.] Univ Penn, NIH Merck Summer Program, Philadelphia, PA 19104 USA; [Mellert, H.; McMahon, S.; Thomas-Tikhonenko, A.] Univ Penn, Canc Biol CAMB Grad Program, Philadelphia, PA 19104 USA; [Schelter, J. M.; Cleary, M. A.] Rosetta Inpharmat, Seattle, WA USA; [McMahon, S.] Thomas Jefferson Med Coll, Dept Canc Biol, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Merck & Company; Jefferson University	Thomas-Tikhonenko, A (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Canc Pathobiol, 4056 Colket Translat Res Bldg,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	andreit@mail.med.upenn.edu	laver, travis/AAA-2025-2020; Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206; Sotillo, Elena/0000-0002-3993-1932; McMahon, Steven/0000-0002-3405-1768	US National Institutes of Health [CA 122334]; Children's Hospital of Philadelphia; NIH [R01CA098172-07, R21CA152786-01, R01CA090465-08]; NATIONAL CANCER INSTITUTE [R21CA152786, R01CA098172, R01CA122334, R01CA090465] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital of Philadelphia; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Joshua Mendell and Tsung-Cheng Chang (Johns Hopkins University) for sharing unpublished data on miR-34a function in B-cells. Current and past members of our laboratories (in particular Drs Duonan Yu, James Psathas, Michael Dews and Elaine Chung) are acknowledged for many stimulating discussions. We are grateful to the Rosetta Gene Expression Laboratory for performing microarray hybridization experiments and Miho Kibukawa (Merck & Co., Inc.)-for technical support. We thank Dr Dirk Eick (GSF Research Centre, Munich) for P493-6 cells, Dr Carlo Croce (Ohio State University, Columbus) for GM607 cells and Dr Joelle Wiels (Institut Gustave Roussy, Villejuif, France) for Ly47cells. This work was supported by US National Institutes of Health grant CA 122334 to ATT and the Institutional Development Fund of the Children's Hospital of Philadelphia (ATT), as well as NIH grants R01CA098172-07, R21CA152786-01 and R01CA090465-08 to SBM.	Adachi N, 2006, DNA CELL BIOL, V25, P19, DOI 10.1089/dna.2006.25.19; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; BHATIA KG, 1992, CANCER RES, V52, P4273; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Dalgard CL, 2009, INVEST OPHTH VIS SCI, V50, P4542, DOI 10.1167/iovs.09-3520; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Kong YW, 2008, P NATL ACAD SCI USA, V105, P8866, DOI 10.1073/pnas.0800650105; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254; Lindstrom MS, 2002, SEMIN CANCER BIOL, V12, P381, DOI 10.1016/S1044-579X(02)00058-5; Lindstrom MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Luan SH, 2010, ARCH MED RES, V41, P67, DOI 10.1016/j.arcmed.2010.02.007; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Navarro F, 2009, BLOOD, V114, P2181, DOI 10.1182/blood-2009-02-205062; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sala A, 2009, ADV CANCER RES, V105, P115, DOI 10.1016/S0065-230X(09)05007-6; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753; Yu DN, 2005, CANCER RES, V65, P5454, DOI 10.1158/0008-5472.CAN-04-4197; Yu DN, 2002, ONCOGENE, V21, P1922, DOI 10.1038/sj.onc.1205244; Yu DN, 2007, BLOOD, V109, P4936, DOI 10.1182/blood-2006-10-050294	58	66	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2587	2594		10.1038/onc.2010.634	http://dx.doi.org/10.1038/onc.2010.634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21297663	Green Accepted			2022-12-28	WOS:000291198400010
J	Vinnedge, LMP; McClaine, R; Wagh, PK; Wikenheiser-Brokamp, KA; Waltz, SE; Wells, SI				Vinnedge, L. M. Privette; McClaine, R.; Wagh, P. K.; Wikenheiser-Brokamp, K. A.; Waltz, S. E.; Wells, S. I.			The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer	ONCOGENE			English	Article						DEK; breast cancer; metastasis; beta-catenin; cancer stem cells	PROTOONCOGENE PROTEIN DEK; HUMAN-PAPILLOMAVIRUS E7; STEM-CELLS; EXPRESSION SIGNATURE; IDENTIFICATION; CHROMATIN; BINDING; DNA; CARCINOGENESIS; RETINOBLASTOMA	Breast cancer is a major cause of cancer-related deaths in American women; therefore, the identification of novel breast cancer-related molecules for the discovery of new markers and drug targets remains essential. The human DEK gene, which encodes a chromatin-binding protein and DNA topology regulator, is upregulated in many types of cancer. DEK has been implicated as an oncogene in breast cancer based on mRNA expression studies, but its functional significance in breast cancer growth and progression has not yet been tested directly. We demonstrate that DEK is highly expressed in breast cancer cells compared with normal tissue, and functionally important for cellular growth, invasion and mammosphere formation. DEK overexpression in non-tumorigenic MCF10A cells resulted in increased growth and motility, with a concomitant downregulation of E-cadherin. Conversely, DEK knockdown in MCF7 and MDA-MB-468 breast cancer cells resulted in decreased growth and motility with upregulation of E-cadherin. The use of DEK-proficient and -deficient breast cancer cells in orthotopic xenografts provided further in vivo evidence that DEK contributes to tumor growth. Activation of the beta-catenin signaling pathway is important for normal and cancer stem cell character, growth and metastasis. We show that DEK expression stimulated, and DEK knockdown repressed beta-catenin nuclear translocation and activity. Importantly, the expression of constitutively active beta-catenin rescued breast cancer invasion defects of DEK knockdown cells. Together, our data indicate that DEK expression stimulates the growth, stem cell character and motility of breast cancer cells, and that DEK-dependent cellular invasion occurs at least in part via beta-catenin activation. Oncogene (2011) 30, 2741-2752; doi: 10.1038/onc.2011.2; published online 14 February 2011	[Vinnedge, L. M. Privette; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Dept Hematol, Cincinnati, OH 45229 USA; [Vinnedge, L. M. Privette; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Dept Oncol, Cincinnati, OH 45229 USA; [McClaine, R.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; [Wagh, P. K.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH USA; [Wikenheiser-Brokamp, K. A.] Cincinnati Childrens Hosp Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Wells, SI (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Dept Hematol, TCHRF Room S7-206,MLC 7013,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Susanne.Wells@cchmc.org	Vinnedge, Lisa Privette/H-5869-2019	Vinnedge, Lisa Privette/0000-0003-2087-4920	NIH [AR-47363]; National Cancer Institute [F32CA139931, T32HL091805]; Public Health Service [CA116316, CA100002, HL079193]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	We thank Yi Zheng for critical evaluation of this manuscript. We also thank James Lessard, Aaron Zorn, Jose Cancelas, James Mulloy and James Wells for reagents and discussion, Gerard Grosveld for Dek knockout mice, Gina Kavanaugh for the immortalized Dek wild-type and knockout mouse embryonic fibroblasts and the Viral Vector Core at CCHMC. We would like to acknowledge the assistance of the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center, supported in part by NIH AR-47363. This research was supported by Kirschstein National Research Service Awards (NRSA) F32CA139931 and T32HL091805 from the National Cancer Institute (L.M.P.V.), and Public Health Service grants CA116316 (S.I.W.), CA100002 (S.E.W.), and HL079193 (K. W-B.)	Abba MC, 2007, MOL CANCER RES, V5, P881, DOI 10.1158/1541-7786.MCR-07-0055; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alexiadis V, 2000, GENE DEV, V14, P1308; Allan AL, 2006, AM J PATHOL, V169, P233, DOI 10.2353/ajpath.2006.051152; American Cancer Society [ACS], 2009, BREAST CANC FACTS FI; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Bowles E, 2007, GENE CHROMOSOME CANC, V46, P118, DOI 10.1002/gcc.20383; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dontu G, 2005, STEM CELL REV, V1, P207, DOI 10.1385/SCR:1:3:207; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Kondoh N, 1999, CANCER RES, V59, P4990; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lu ZL, 2005, WORLD J GASTROENTERO, V11, P3850; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Soares LMM, 2006, SCIENCE, V312, P1961, DOI 10.1126/science.1128659; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Prahalad P, 2004, AM J PHYSIOL-CELL PH, V286, pC693, DOI 10.1152/ajpcell.00124.2003; Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ribeiro-Silva A, 2003, ARCH PATHOL LAB MED, V127, P336; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sammons M, 2006, J BIOL CHEM, V281, P26802, DOI 10.1074/jbc.M600915200; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shibata T, 2010, ONCOGENE, V29, P4671, DOI 10.1038/onc.2010.217; SOULE HD, 1990, CANCER RES, V50, P6075; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tubiana M, 1999, ACTA ONCOL, V38, P295; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Waldmann T, 2003, NUCLEIC ACIDS RES, V31, P7003, DOI 10.1093/nar/gkg864; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	52	72	74	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2741	2752		10.1038/onc.2011.2	http://dx.doi.org/10.1038/onc.2011.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21317931	Green Accepted			2022-12-28	WOS:000291678500005
J	Jung, J; Kim, HY; Kim, M; Sohn, K; Kim, M; Lee, K				Jung, J.; Kim, H. Y.; Kim, M.; Sohn, K.; Kim, M.; Lee, K.			Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src	ONCOGENE			English	Article						Na; K-ATPase; Src; TCTP; tumorigenesis	HISTAMINE-RELEASING FACTOR; NA,K-ATPASE ALPHA-SUBUNIT; GROWTH-FACTOR RECEPTOR; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; NA+/K+-ATPASE; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATES SYNTHESIS; SIGNAL-TRANSDUCTION; EGF RECEPTOR	Translationally controlled tumor protein (TCTP) is implicated in cell growth and malignant transformation. TCTP has been found to interact directly with the third cytoplasmic domain of the alpha subunit of Na, K-ATPase, but whether this interaction has a role in tumorigenesis is unclear. In this study, we examined TCTP-induced tumor progression signaling networks in human breast epithelial cells, using adenoviral infection. We found that TCTP (a) induces Src release from Na, K-ATPase alpha subunit and Src activation; (b) phosphorylates tyrosine residues 845, 992, 1086, 1148 and 1173 on anti-epidermal growth factor receptor (EGFR); (c) activates PI3K (phosphatidylinositol 3-kinase)-AKT, Ras-Raf-MEK-ERK1/2, Rac-PAK1/2, MKK3/6-p38 and phospholipase C (PLC)-gamma pathways; (d) enhances NADPH oxidase-dependent reactive oxygen species (ROS) generation; (e) stimulates cytoskeletal remodeling and cell motility and (f) upregulates matrix metalloproteinase (MMP) 3 and 13. These findings suggest that TCTP induces tumorigenesis through distinct multicellular signaling pathways involving Src-dependent EGFR transactivation, ROS generation and MMP expression. Oncogene (2011) 30, 2264-2274; doi:10.1038/onc.2010.604; published online 31 January 2011	[Jung, J.; Kim, H. Y.; Kim, M.; Sohn, K.; Kim, M.; Lee, K.] Ewha Womans Univ, Coll Pharm, Ctr Cell Signalling & Drug Discovery Res, Seoul 120750, South Korea	Ewha Womans University	Lee, K (corresponding author), Ewha Womans Univ, Coll Pharm, Ctr Cell Signalling & Drug Discovery Res, Daehyun Dong 11-1, Seoul 120750, South Korea.	klyoon@ewha.ac.kr			Ministry for Health, Welfare Family Affairs [A090030]; Korean Government [2009-0064401]; MEST [R01-2007-000-20263-0]; Seoul RBD Program [ST090801]; MOST/KOSEF [R15-2006-020]	Ministry for Health, Welfare Family Affairs; Korean Government(Korean Government); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); Seoul RBD Program(Seoul RBD program); MOST/KOSEF(Korea Science and Engineering Foundation)	This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs (A090030), NRF of Korea Grant funded by the Korean Government (2009-0064401), Mid-career Research Program through NRF grant funded by the MEST (R01-2007-000-20263-0), Seoul R&BD Program (ST090801) and the NCRC program of MOST/KOSEF (R15-2006-020).	Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barwe SP, 2005, MOL BIOL CELL, V16, P1082, DOI 10.1091/mbc.E04-05-0427; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen JQ, 2006, BREAST CANCER RES TR, V96, P1, DOI 10.1007/s10549-005-9053-3; Cheon MS, 2008, BIOMED CHROMATOGR, V22, P1091, DOI 10.1002/bmc.1029; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Espineda C, 2003, CANCER-AM CANCER SOC, V97, P1859, DOI 10.1002/cncr.11267; Gnanasekar M, 2007, PARASITOL RES, V101, P1533, DOI 10.1007/s00436-007-0671-z; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Haux J, 1999, MED HYPOTHESES, V53, P543, DOI 10.1054/mehy.1999.0985; Impola U, 2005, BRIT J DERMATOL, V152, P720, DOI 10.1111/j.1365-2133.2005.06447.x; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Jung J, 2006, CELL SIGNAL, V18, P2033, DOI 10.1016/j.cellsig.2006.03.014; Kim M, 2009, ARCH BIOCHEM BIOPHYS, V485, P82, DOI 10.1016/j.abb.2009.02.002; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Liu J, 2000, J BIOL CHEM, V275, P27838; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Nagano-Ito M, 2009, FEBS LETT, V583, P1363, DOI 10.1016/j.febslet.2009.03.045; Nielsen HV, 1998, ALLERGY, V53, P642, DOI 10.1111/j.1398-9995.1998.tb03950.x; Oikawa K, 2002, BIOCHEM BIOPH RES CO, V290, P984, DOI 10.1006/bbrc.2001.6302; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P3717, DOI 10.1091/mbc.12.12.3717; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Teshima S, 1998, J IMMUNOL, V161, P6356; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749-6632.2003.tb07234.x; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	45	43	45	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2264	2274		10.1038/onc.2010.604	http://dx.doi.org/10.1038/onc.2010.604			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21278788				2022-12-28	WOS:000290514600009
J	Barbash, O; Lee, EK; Diehl, JA				Barbash, O.; Lee, E. K.; Diehl, J. A.			Phosphorylation-dependent regulation of SCFFbx4 dimerization and activity involves a novel component, 14-3-3 epsilon	ONCOGENE			English	Article						cdk4; cyclin D1; Fbx4; 14-3-3	CYCLIN D1; STRUCTURAL BASIS; 14-3-3 PROTEINS; KINASE-ACTIVITY; NUCLEAR EXPORT; UBIQUITINATION; ACTIVATION; 14-3-3-PROTEINS; LOCALIZATION; PROTEOLYSIS	Fbx4 is an F-box constituent of Skp-Cullin-F-box (SCF) ubiquitin ligases that directs ubiquitylation of cyclin D1. Ubiquitylation of cyclin D1 requires phosphorylation of both cyclin D1 and Fbx4 by GSK3 beta. GSK3 beta-mediated phosphorylation of Fbx4 Ser12 during the G1/S transition regulates Fbx4 dimerization, which in turn governs Fbx4-driven E3 ligase activity. In esophageal carcinomas that overexpress cyclin D1, Fbx4 is subject to inactivating mutations that specifically disrupt dimerization, highlighting the biological significance of this regulatory mechanism. In an effort to elucidate the mechanisms that regulate dimerization, we sought to identify proteins that differentially bind to wild-type Fbx4 versus a cancer-derived dimerization-deficient mutant. We provide evidence that phosphorylation of Ser12 generates a docking site for 14-3-3 epsilon. 14-3-3 epsilon binds to endogenous Fbx4 and this association is impaired by mutations that target either Ser8 or Ser12 in Fbx4, suggesting that this N-terminal motif in Fbx4 directs its interaction with 14-3-3 epsilon. Knockdown of 14-3-3 epsilon inhibited Fbx4 dimerization, reduced SCFFbx4 E3 ligase activity and stabilized cyclin D1. Collectively, the current results suggest a model wherein 14-3-3 epsilon binds to Ser12-phosphorylated Fbx4 to mediate dimerization and function. Oncogene (2011) 30, 1995-2002; doi:10.1038/onc.2010.584; published online 17 January 2011	[Barbash, O.; Lee, E. K.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Barbash, O.; Lee, E. K.; Diehl, J. A.] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; [Barbash, O.; Lee, E. K.; Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, 454 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NIH [P01-CA098101]; Leukemia & Lymphoma Scholar award; NATIONAL CANCER INSTITUTE [P01CA098101, R01CA133154, P30CA016520] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Scholar award(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Margarita Romero for excellent technical assistance. This work was supported by a grant from the NIH (P01-CA098101) and a Leukemia & Lymphoma Scholar award (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Barbash O, 2009, ONCOGENE, V28, P4317, DOI 10.1038/onc.2009.287; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Che XH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-306; Chew EH, 2007, CELL SIGNAL, V19, P1071, DOI 10.1016/j.cellsig.2006.12.002; Dhillon AS, 2009, CELL SIGNAL, V21, P1645, DOI 10.1016/j.cellsig.2009.07.001; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Konishi H, 2002, CANCER RES, V62, P271; KORCHEVA VB, 2010, APPL IMMUNOHISTOCHEM; Li YF, 2010, J BIOL CHEM, V285, P13896, DOI 10.1074/jbc.M110.111518; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Paul G, 2009, GENOMICS, V94, P287, DOI 10.1016/j.ygeno.2009.07.004; Pignataro L, 2005, Acta Otorhinolaryngol Ital, V25, P75; Skaar JR, 2009, CURR OPIN CELL BIOL, V21, P816, DOI 10.1016/j.ceb.2009.08.004; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Heusden GPH, 2006, YEAST, V23, P159, DOI 10.1002/yea.1338; Wang J, 2009, J BIOL CHEM, V284, P14011, DOI 10.1074/jbc.M901310200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng ZX, 2010, DEV CELL, V18, P214, DOI 10.1016/j.devcel.2010.01.007; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang W, 2006, MOL CANCER RES, V4, P935, DOI 10.1158/1541-7786.MCR-06-0253	35	27	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					1995	2002		10.1038/onc.2010.584	http://dx.doi.org/10.1038/onc.2010.584			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242966	Green Accepted			2022-12-28	WOS:000289977400003
J	Fernandez, RMH; Ruiz-Miro, M; Dolcet, X; Aldea, M; Gari, E				Fernandez, R. M. H.; Ruiz-Miro, M.; Dolcet, X.; Aldea, M.; Gari, E.			Cyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility	ONCOGENE			English	Article						cyclin D1; Ral GTPases; exocyst; cell motility cell adhesion; tumor spreading	MIGRATION; PHOSPHORYLATION; ACTIVATION; EXOCYST; CANCER; INDUCTION; COMPLEXES; INVASION; FILAMIN; NUMBER	Alterations in the levels of adhesion and motility of cells are critical events in the development of metastasis. Cyclin D1 (CycD1) is one of the most frequently amplified oncogenes in many types of cancers and it is also associated with the development of metastasis. Despite this, we still do not know which are all the relevant pathways by which CycD1 induces oncogenic processes. CycD1 functions can be either dependent or independent of the cyclin-dependent kinase Cdk4, and they affect several cellular aspects such as proliferation, cell attachment and migration. In this work, we reveal a novel function of CycD1 that fosters our understanding of the oncogenic potential of CycD1. We show that CycD1 binds to the small GTPases Ral A and B, which are involved, through exocyst regulation, in the progression of metastatic cancers, inducing anchorage-independent growth and cell survival of transformed cells. We show that CycD1 binds active Ral complexes and the exocyst protein Sec6, and co-localizes with Ral GTPases in trans-Golgi and exocyst-rich regions. We have also observed that CycD1-Cdk4 phosphorylates the Ral GEF Rgl2 'in vitro' and that CycD1-Cdk4 activity stimulates accumulation of the Ral GTP active forms. In accordance with this, our data suggest that CycD1-Cdk4 enhances cell detachment and motility in collaboration with Ral GTPases. This new function may help explain the contribution of CycD1 to tumor spreading. Oncogene (2011) 30, 1936-1946; doi: 10.1038/onc.2010.577; published online 17 January 2011	[Fernandez, R. M. H.; Ruiz-Miro, M.; Dolcet, X.; Aldea, M.; Gari, E.] Univ Lleida, Fac Med, Dept Ciencies Med Basiques, IRBLleida, Lleida 25008, Catalonia, Spain; [Dolcet, X.] IRBLleida, Oncol Pathol Grp, Catalonia, Spain; [Aldea, M.] CSIC, Inst Biol Mol Barcelona, Barcelona, Spain	Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Gari, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, IRBLleida, Montserrat Roig 2, Lleida 25008, Catalonia, Spain.	eloi.gari@cmb.udl.cat	Fernández Hernández, Rita María/C-4477-2011; Aldea, Marti/K-3962-2014; Dolcet, Xavi/B-5665-2009; Garí, Eloi/A-5996-2010	Aldea, Marti/0000-0002-8710-5336; Dolcet, Xavi/0000-0003-1921-0449; Garí, Eloi/0000-0002-3505-4901	Ministry of Education and Science of Spain [BFU2007-65640/BMC, BFU2007-67929-C02- 01]; Consolider-Ingenio [CSD2007-00015]	Ministry of Education and Science of Spain(Spanish Government); Consolider-Ingenio(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We thank N Agell, C Yeaman, JL Bos, M Matsuda, X Bustelo, P Crespo, MA del Pozo and J Herreros for the gift of plasmids and reagents, and also N Eritja, MBozic, JM Valdivielso, Lluis Fajas, Eloi Montanez and SaraWickstrom for technical advice. We are grateful to J Odajima and P Sicinski for providing CCND1<SUP>-/-</SUP> and CCND1<SUP>+/+</SUP> immortalized MEFs, and M Hendrix and E Seftor for providing R3327-50A cells. We thank S Rius, I Navarro, I Montoliu and MA Cornado for their technical assistance and the members of CYC lab for helpful discussions. This work was funded by the Ministry of Education and Science of Spain BFU2007-65640/BMC (Eloi Gari) and BFU2007-67929-C02- 01 (Marti Aldea) and Consolider-Ingenio 2010 (CSD2007-00015). RMH Fernandez and M Ruiz-Miro were supported by predoctoral fellowships from the Ministry of Education and Science of Spain.	Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-7; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Knaus M, 2007, EMBO J, V26, P4501, DOI 10.1038/sj.emboj.7601873; Kono K, 2008, MOL BIOL CELL, V19, P1763, DOI 10.1091/mbc.E07-09-0950; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Lalli G, 2009, J CELL SCI, V122, P1499, DOI 10.1242/jcs.044339; Li ZP, 2006, CANCER RES, V66, P9986, DOI 10.1158/0008-5472.CAN-06-1596; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lu FM, 2003, CANCER RES, V63, P7056; Luo Jan, 1997, Pathol Oncol Res, V3, P264; Marampon F, 2008, MOL BIOL CELL, V19, P2566, DOI 10.1091/mbc.E06-12-1110; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi JH, 2006, EXP CELL RES, V312, P3432, DOI 10.1016/j.yexcr.2006.07.016; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spiczka KS, 2008, J CELL SCI, V121, P2880, DOI 10.1242/jcs.031641; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhong ZJ, 2010, CANCER RES, V70, P2105, DOI 10.1158/0008-5472.CAN-08-1108	48	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1936	1946		10.1038/onc.2010.577	http://dx.doi.org/10.1038/onc.2010.577			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21242975				2022-12-28	WOS:000289777700009
J	Harada, T; Lopez-Chavez, A; Xi, L; Raffeld, M; Wang, Y; Giaccone, G				Harada, T.; Lopez-Chavez, A.; Xi, L.; Raffeld, M.; Wang, Y.; Giaccone, G.			Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry	ONCOGENE			English	Article						EGFR; mutation; African American; EGFR-TKI	TYROSINE KINASE; GEFITINIB TREATMENT; GENE-MUTATIONS; EGFR MUTANTS; RESISTANCE; ACTIVATION; INHIBITOR; SENSITIVITY; ERLOTINIB; MECHANISM	Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors. Oncogene (2011) 30, 1744-1752; doi:10.1038/onc.2010.545; published online 6 December 2010	[Harada, T.; Lopez-Chavez, A.; Wang, Y.; Giaccone, G.] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Xi, L.; Raffeld, M.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Giaccone, G (corresponding author), NCI, Med Oncol Branch, Ctr Canc Res, NIH, 10 Ctr Dr,Bldg 10,Room 12N226, Bethesda, MD 20892 USA.	giacconeg@mail.nih.gov	Giaccone, Giuseppe/E-8297-2017	Giaccone, Giuseppe/0000-0002-5023-7562	NATIONAL CANCER INSTITUTE [ZIABC011269, ZICBC011079] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC010854, Z01 BC010453-07] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Calvo E, 2006, J CLIN ONCOL, V24, P2158, DOI 10.1200/JCO.2006.06.5961; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; de Gunst MM, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-56; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Eskens F, 2008, BRIT J CANCER, V98, P80, DOI 10.1038/sj.bjc.6604108; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hughes AN, 2009, J CLIN ONCOL, V27, P1220, DOI 10.1200/JCO.2008.19.3995; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Krishnaswamy S, 2009, CLIN CANCER RES, V15, P5714, DOI 10.1158/1078-0432.CCR-09-0070; Leidner RS, 2009, J CLIN ONCOL, V27, P5620, DOI 10.1200/JCO.2009.23.1431; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Niculescu-Duvaz D, 2007, CANCER CELL, V11, P209, DOI 10.1016/j.ccr.2007.02.021; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sos ML, 2010, CANCER RES, V70, P868, DOI 10.1158/0008-5472.CAN-09-3106; Wong KK, 2007, CLIN CANCER RES, V13, p4593S, DOI 10.1158/1078-0432.CCR-07-0369; Wu JY, 2008, CLIN CANCER RES, V14, P4877, DOI 10.1158/1078-0432.CCR-07-5123; Yang SH, 2005, CLIN CANCER RES, V11, P2106, DOI 10.1158/1078-0432.CCR-04-1853; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	25	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1744	1752		10.1038/onc.2010.545	http://dx.doi.org/10.1038/onc.2010.545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21132006	Green Accepted			2022-12-28	WOS:000289512200002
J	Mochmann, LH; Bock, J; Ortiz-Tanchez, J; Schlee, C; Bohne, A; Neumann, K; Hofmann, WK; Thiel, E; Baldus, CD				Mochmann, L. H.; Bock, J.; Ortiz-Tanchez, J.; Schlee, C.; Bohne, A.; Neumann, K.; Hofmann, W. K.; Thiel, E.; Baldus, C. D.			Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG	ONCOGENE			English	Article						ETS-related gene (ERG); WNT11; acute leukemia; ERG target genes; 6-bromoindirubin-3-oxime (BIO); morphological transformation	ACUTE MYELOID-LEUKEMIA; EMBRYONIC STEM-CELLS; T-LYMPHOBLASTIC LEUKEMIA; PROSTATE-CANCER; FAMILY; EXPRESSION; DIFFERENTIATION; TUMORIGENESIS; OVEREXPRESSION; TRANSFORMATION	E26 transforming sequence-related gene (ERG) is a transcription factor involved in normal hematopoiesis and is dysregulated in leukemia. ERG mRNA overexpression was associated with poor prognosis in a subset of patients with T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Herein, a genome-wide screen of ERG target genes was conducted by chromatin immunoprecipitation-on-chip (ChIP-chip) in Jurkat cells. In this screen, 342 significant annotated genes were derived from this global approach. Notably, ERG-enriched targets included WNT signaling genes: WNT11, WNT2, WNT9A, CCND1 and FZD7. Furthermore, chromatin immunoprecipitation (ChIP) of normal and primary leukemia bone marrow material also confirmed WNT11 as a target of ERG in six of seven patient samples. A larger sampling of patient diagnostic material revealed that ERG and WNT11 mRNA were co-expressed in 80% of AML (n = 30) and 40% in T-ALL (n = 30) bone marrow samples. Small interfering RNA (siRNA)-mediated knockdown of ERG confirmed down-regulation of WNT11 transcripts. Conversely, in a tet-on ERG-inducible assay, WNT11 transcripts were co-stimulated. A WNT pathway agonist, 6-bromoindirubin-3-oxime (BIO), was used to determine the effect of cell growth on the ERG-inducible cells. The addition of BIO resulted in an ERG-dependent proliferative growth advantage over ERG-uninduced cells. Finally, ERG induction prompted morphological transformation whereby round unpolarized K562 cells developed elongated protrusions and became polarized. This morphological transformation could effectively be inhibited with BIO and with siRNA knockdown of WNT11. In conclusion, ERG transcriptional networks in leukemia converge on WNT signaling targets. Specifically, WNT11 emerged as a direct target of ERG. Potent ERG induction promoted morphological transformation through WNT11 signals. The findings in this study unravel new ERG-directed molecular signals that may contribute to the resistance of current therapies in acute leukemia patients with poor prognosis characterized by high ERG mRNA expression. Oncogene (2011) 30, 2044-2056; doi:10.1038/onc.2010.582; published online 17 January 2011	[Mochmann, L. H.; Bock, J.; Ortiz-Tanchez, J.; Schlee, C.; Bohne, A.; Thiel, E.; Baldus, C. D.] Charite, Dept Hematol & Oncol, D-12203 Berlin, Germany; [Neumann, K.] Charite, Inst Biometr & Clin Epidemiol, Berlin, Germany; [Hofmann, W. K.] Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg	Baldus, CD (corresponding author), Charite, Dept Hematol & Oncol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany.	claudia.baldus@charite.de			Deutsche Krebshilfe (Max Eder Nachwuchsforderung)	Deutsche Krebshilfe (Max Eder Nachwuchsforderung)(Deutsche Krebshilfe)	This study was supported by a grant from the Deutsche Krebshilfe (Max Eder Nachwuchsforderung) to CDB. We thank Dr Martin Neumann (Department of Hematology and Oncology, Charite, Berlin, Germany) for his critical reading of the manuscript. We also thank Dr Anja Kuhl (Research Center ImmunoSciences, Charite, Berlin, Germany) for helpful advice and fluorescence microscopy assistance.	Anderson MK, 1999, DEVELOPMENT, V126, P3131; Anton R, 2007, FEBS LETT, V581, P5247, DOI 10.1016/j.febslet.2007.10.012; Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101; Baldus CD, 2007, BRIT J HAEMATOL, V137, P387, DOI 10.1111/j.1365-2141.2007.06566.x; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854; Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Bohne A, 2009, LEUKEMIA RES, V33, P817, DOI 10.1016/j.leukres.2008.11.012; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; CHIANG J, 2009, P NATL ACAD SCI USA, V106, P3396; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Eisenberg CA, 1997, DEVELOPMENT, V124, P525; Ellett F, 2009, MECH DEVELOP, V126, P220, DOI 10.1016/j.mod.2008.11.001; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Flaherty MP, 2008, TRENDS CARDIOVAS MED, V18, P260, DOI 10.1016/j.tcm.2008.12.001; GOMEZ JR, 2007, BLOOD, V109, P3462; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Holmes T, 2008, STEM CELLS, V26, P1288, DOI 10.1634/stemcells.2007-0600; Hu D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006640; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iwamoto M, 2007, DEV BIOL, V305, P40, DOI 10.1016/j.ydbio.2007.01.037; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kong XT, 1997, BLOOD, V90, P1192; Lai SL, 2009, CELL RES, V19, P532, DOI 10.1038/cr.2009.41; LELINEK J, 2008, LEUKEMIA, V22, P1529; Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Marcucci G, 2005, J CLIN ONCOL, V23, P9234, DOI 10.1200/JCO.2005.03.6137; MARTIN V, 2009, CANCER SCI, V3, P1; Narod SA, 2008, BRIT J CANCER, V99, P847, DOI 10.1038/sj.bjc.6604558; O'Neil J, 2007, ONCOGENE, V26, P6838, DOI 10.1038/sj.onc.1210766; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629; Singla DK, 2006, BIOCHEM BIOPH RES CO, V345, P789, DOI 10.1016/j.bbrc.2006.04.125; Soda M, 2008, CELL SIGNAL, V20, P2317, DOI 10.1016/j.cellsig.2008.09.001; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stankiewicz MJ, 2009, BLOOD, V113, P3337, DOI 10.1182/blood-2008-08-174813; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Uysal-Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-55; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; WU D, 2009, TREND BIOCH SCI, V722, P1; Zhou WL, 2007, NAT GENET, V39, P1225, DOI 10.1038/ng2112; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	50	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2044	2056		10.1038/onc.2010.582	http://dx.doi.org/10.1038/onc.2010.582			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242973	Green Submitted			2022-12-28	WOS:000289977400008
J	Merrell, KW; Crofts, JD; Smith, RL; Sin, JH; Kmetzsch, KE; Merrell, A; Miguel, RO; Candelaria, NR; Lin, CY				Merrell, K. W.; Crofts, J. D.; Smith, R. L.; Sin, J. H.; Kmetzsch, K. E.; Merrell, A.; Miguel, R. O.; Candelaria, N. R.; Lin, C-Y			Differential recruitment of nuclear receptor coregulators in ligand-dependent transcriptional repression by estrogen receptor-alpha	ONCOGENE			English	Article						estrogen receptor; transcriptional regulation; hormonal carcinogenesis; coregulators	HUMAN BREAST-CANCER; SURGICAL ADJUVANT BREAST; BOWEL PROJECT P-1; TARGET GENES; HORMONE-RECEPTORS; BINDING-SITES; EXPRESSION; ACTIVATION; MECHANISMS; TAMOXIFEN	Estrogen receptors (ERs) are normally expressed in breast tissues and mediate hormonal functions during development and in female reproductive physiology. In the majority of breast cancers, ERs are involved in regulating tumor cell proliferation and serve as prognostic markers and therapeutic targets in the management of hormone-dependent tumors. At the molecular level, ERs function as ligand-dependent transcription factors and activate target-gene expression following hormone stimulation. Recent transcriptomic and whole-genome-binding studies suggest, however, that ligand-activated ERs can also repress the expression of a significant subset of target genes. To characterize the molecular mechanisms of transcriptional repression by ERs, we examined recruitment of nuclear receptor coregulators, histone modifications and RNA polymerase II docking at ER-binding sites and cis-regulatory regions adjacent to repressed target genes. Moreover, we utilized gene expression data from patient samples to determine potential roles of repressed target genes in breast cancer biology. Results from these studies indicate that nuclear receptor corepressor recruitment is a key feature of ligand-dependent transcriptional repression by ERs, and some repressed target genes are associated with disease progression and response to endocrine therapy. These findings provide preliminary insights into a novel aspect of the molecular mechanisms of ER functions and their potential roles in hormonal carcinogenesis and breast cancer biology. Oncogene (2011) 30, 1608-1614; doi: 10.1038/onc.2010.528; published online 22 November 2010	[Merrell, K. W.; Crofts, J. D.; Smith, R. L.; Sin, J. H.; Kmetzsch, K. E.; Merrell, A.; Miguel, R. O.; Candelaria, N. R.; Lin, C-Y] Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA	Brigham Young University	Lin, CY (corresponding author), Brigham Young Univ, Dept Microbiol & Mol Biol, 753 WIDB, Provo, UT 84602 USA.	clin23@central.uh.edu		Lin, Chin-Yo/0000-0002-4461-6216	Brigham Young University; Women's Research Institute; NIH [R03CA143981]; BYU Cancer Research Center; NATIONAL CANCER INSTITUTE [R03CA143981] Funding Source: NIH RePORTER	Brigham Young University; Women's Research Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BYU Cancer Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Mentoring Environment Grant (CYL) from Brigham Young University, a research grant (CYL) from the Women's Research Institute, NIH award number R03CA143981 (CYL) and summer research fellowships (KWM, JDC, RLS, KEK and NRC) from the BYU Cancer Research Center.	Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bookman MA, 2005, INT J GYNECOL CANCER, V15, P291, DOI 10.1111/j.1525-1438.2005.00442.x; Cappelletti V, 2004, ENDOCR-RELAT CANCER, V11, P761, DOI 10.1677/erc.1.00822; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Lin CY, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1667; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	44	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1608	1614		10.1038/onc.2010.528	http://dx.doi.org/10.1038/onc.2010.528			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21102521				2022-12-28	WOS:000288998300011
J	Li, J; Cheng, Y; Tai, D; Martinka, M; Welch, DR; Li, G				Li, J.; Cheng, Y.; Tai, D.; Martinka, M.; Welch, D. R.; Li, G.			Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis	ONCOGENE			English	Article						BRMS1; melanoma; tumor progression; prognosis; angiogenesis	BREAST-CANCER METASTASIS; SUPPRESSOR GENE; CARCINOMA METASTASIS; MICROVESSEL DENSITY; OVARIAN-CARCINOMA; CHROMOSOME 11Q13; HIGH-RISK; OSTEOPONTIN; GROWTH; MECHANISMS	Breast cancer metastasis suppressor 1 (BRMS1) has been reported to suppress metastasis without significantly affecting tumorigenicity in breast cancer and ovarian cancer. To investigate the role of BRMS1 in human melanoma progression and prognosis, we established tissue microarray and BRMS1 expression was evaluated by immunohistochemistry in 41 dysplastic nevi, 90 primary melanomas and 47 melanoma metastases. We found that BRMS1 expression was significantly decreased in metastatic melanoma compared with primary melanoma or dysplastic nevi (P = 0.021 and 0.001, respectively, chi(2) test). In addition, reduced BRMS1 staining was significantly correlated with American Joint Committee on Cancer stages (P = 0.011, chi(2) test), but not associated with tumor thickness, tumor ulceration and other clinicopathological parameters. Furthermore, BRMS1 expression was significantly correlated with disease-specific 5-year survival of melanoma patients (P = 0.007, log-rank test). Multivariate Cox regression analysis revealed that BRMS1 staining was an independent prognostic factor for melanoma patients (relative risk 0.51; confidence interval = 0.29-0.91; P = 0.022). Moreover, we demonstrated that BRMS1 overexpression inhibited endothelial cell growth and tube formation ability by suppressing NF-kappa B activity and IL-6 expression in vitro. We also showed that knockdown of BRMS1 increased IL-6 expression and promoted endothelial cell growth and tube formation. In addition, our data revealed that the BRMS1-mediated IL-6 expression is dependent on NF-kappa B. Strikingly, our in vivo studies using nude mice confirmed that BRMS1 inhibited blood vessel formation and the recruitment of CD31-positive cells in matrigel plugs. Taken together, BRMS1 expression was decreased in metastatic melanomas, which resulted in deficient suppression of angiogenesis and contributed to melanoma progression. BRMS1 may serve an important prognostic marker and therapeutic target for melanoma patients. Oncogene (2011) 30, 896-906; doi: 10.1038/onc.2010.470; published online 11 October 2010	[Li, G.] Univ British Columbia, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver Coastal Hlth Res Inst, Vancouver, BC V6H 3Z6, Canada; [Martinka, M.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Pathol, Vancouver, BC V6H 3Z6, Canada; [Welch, D. R.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health Research Institute; University of Alabama System; University of Alabama Birmingham	Li, G (corresponding author), Univ British Columbia, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver Coastal Hlth Res Inst, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Cheng, Yabin/AAY-2178-2020; Welch, Danny R/B-7310-2009; Li, Gang/A-8257-2011; Cheng, Yabin/P-7071-2015	Cheng, Yabin/0000-0002-6205-3648; Welch, Danny R/0000-0002-1951-4947; Cheng, Yabin/0000-0002-6205-3648	Canadian Institutes of Health Research [MOP-84559, MOP-93810]; Canadian Dermatology Foundation; Natural Sciences and Engineering Research Council of Canada; University of British Columbia; CIHR Skin Research Training Centre; NATIONAL CANCER INSTITUTE [R01CA087728, R01CA134981] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Dermatology Foundation; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); University of British Columbia; CIHR Skin Research Training Centre(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steve Hendy for technical assistance with EMSA. This work was supported by the Canadian Institutes of Health Research (MOP-84559 and MOP-93810) and Canadian Dermatology Foundation to GL. JL is a recipient of Postgraduate Scholarship from the Natural Sciences and Engineering Research Council of Canada and University of British Columbia Graduate Fellowship. Both JL and YC are recipients of CIHR Skin Research Training Centre Trainee Award.	Angeletti CA, 1996, CANCER-AM CANCER SOC, V78, P409, DOI 10.1002/(SICI)1097-0142(19960801)78:3<409::AID-CNCR5>3.0.CO;2-E; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Ballo MT, 2003, SURG CLIN N AM, V83, P323, DOI 10.1016/S0039-6109(02)00096-8; Brawer MK, 1996, EUR UROL, V29, P19; Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139; Cicek M, 2009, CLIN EXP METASTAS, V26, P229, DOI 10.1007/s10585-009-9235-1; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189; Dauda M M, 2005, Niger Postgrad Med J, V12, P125; Diao HY, 2004, IMMUNITY, V21, P539, DOI 10.1016/j.immuni.2004.08.012; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Garate M, 2007, FASEB J, V21, P3705, DOI 10.1096/fj.07-8069com; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Hedley BD, 2008, INT J CANCER, V123, P526, DOI 10.1002/ijc.23542; Hersey P, 2003, INTERN MED J, V33, P33, DOI 10.1046/j.1445-5994.2002.00289.x; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; HOLLINGSWORTH HC, 1995, AM J PATHOL, V147, P33; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; MAEDA K, 1995, BRIT J CANCER, V72, P319, DOI 10.1038/bjc.1995.331; Maffey AH, 2007, MOL CELL ENDOCRINOL, V268, P10, DOI 10.1016/j.mce.2007.01.009; MANSFIELD PF, 1994, CURR PROB SURG, V31, P257; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Meehan WJ, 2003, CLIN EXP METASTAS, V20, P45, DOI 10.1023/A:1022542519586; Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x; Ostmeier H, 1999, CANCER-AM CANCER SOC, V85, P2391, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2391::AID-CNCR14>3.0.CO;2-I; Phadke PA, 2008, AM J PATHOL, V172, P809, DOI 10.2353/ajpath.2008.070772; REMMELE W, 1987, PATHOLOGE, V8, P138; Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6; Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690; Seraj MJ, 2000, CANCER RES, V60, P2764; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Standal T, 2004, EXP ONCOL, V26, P179; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; Vaidya KS, 2008, J BIOL CHEM, V283, P28354, DOI 10.1074/jbc.M710068200; WEIDNER N, 1995, AM J PATHOL, V147, P9; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; Welch DR, 1997, PATHOBIOLOGY, V65, P311, DOI 10.1159/000164143; WIGGINS DL, 1995, GYNECOL ONCOL, V56, P353, DOI 10.1006/gyno.1995.1062; YAMAZAKI K, 1994, CANCER, V74, P2245, DOI 10.1002/1097-0142(19941015)74:8<2245::AID-CNCR2820740807>3.0.CO;2-X; Yang JY, 2008, CANCER LETT, V269, P46, DOI 10.1016/j.canlet.2008.04.016; Zainabadi K, 2005, GENOMICS, V85, P704, DOI 10.1016/j.ygeno.2005.02.014; Zhang S, 2006, INT J GYNECOL CANCER, V16, P522, DOI 10.1111/j.1525-1438.2006.00547.x	52	39	43	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					896	906		10.1038/onc.2010.470	http://dx.doi.org/10.1038/onc.2010.470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20935672	Green Accepted			2022-12-28	WOS:000287695900002
J	He, X; Arslan, AD; Pool, MD; Ho, TT; Darcy, KM; Coon, JS; Beck, WT				He, X.; Arslan, A. D.; Pool, M. D.; Ho, T-T; Darcy, K. M.; Coon, J. S.; Beck, W. T.			Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer	ONCOGENE			English	Article						splicing factors; polypyrimidine tract-binding protein; SRp20; siRNA; tissue microarray; epithelial ovarian cancer	TRACT-BINDING-PROTEIN; HUMAN BREAST-CANCER; MESSENGER-RNA; CONTINGENCY-TABLES; EXON; CD44; GENE; ABERRANT; VARIANT; PHOSPHORYLATION	Our previous study revealed that two splicing factors, polypyrimidine tract-binding protein (PTB) and SRp20, were upregulated in epithelial ovarian cancer (EOC) and knockdown of PTB expression inhibited ovarian tumor cell growth and transformation properties. In this report, we show that knockdown of SRp20 expression in ovarian cancer cells also causes substantial inhibition of tumor cell growth and colony formation in soft agar and the extent of such inhibition appeared to correlate with the extent of suppression of SRp20. Massive knockdown of SRp20 expression triggered remarkable apoptosis in these cells. These results suggest that overexpression of SRp20 is required for ovarian tumor cell growth and survival. Immunohistochemical staining for PTB and SRp20 of two specialized tissue microarrays, one containing benign ovarian tumors, borderline/low malignant potential (LMP) ovarian tumors as well as invasive EOC and the other containing invasive EOC ranging from stage I to stage IV disease, reveals that PTB and SRp20 are both expressed differentially between benign tumors and invasive EOC, and between borderline/LMP tumors and invasive EOC. There were more all-negative or mixed staining cases (at least two evaluable section cores per case) in benign tumors than in invasive EOC, whereas there were more all-positive staining cases in invasive EOC than in the other two disease classifications. Among invasive EOC, the majority of cases were stained all positive for both PTB and SRp20, and there were no significant differences in average staining or frequency of positive cancer cells between any of the tumor stages. Therefore, the expression of PTB and SRp20 is associated with malignancy of ovarian tumors but not with stage of invasive EOC. Oncogene (2011) 30, 356-365; doi:10.1038/onc.2010.426; published online 20 September 2010	[He, X.; Arslan, A. D.; Ho, T-T; Beck, W. T.] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; [He, X.; Beck, W. T.] Univ Illinois, Coll Pharm, Core Lab Mol Pharmacol, GOG, Chicago, IL 60612 USA; [He, X.; Arslan, A. D.; Ho, T-T; Beck, W. T.] Univ Illinois, Ctr Canc, Chicago, IL 60612 USA; [Pool, M. D.; Coon, J. S.] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA; [Darcy, K. M.] Roswell Pk Canc Inst, GOG Stat & Data Ctr, Buffalo, NY 14263 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; Roswell Park Cancer Institute	Beck, WT (corresponding author), Univ Illinois, Dept Biopharmaceut Sci MC 865, 833 S Wood St, Chicago, IL 60612 USA.	xiaohe@uic.edu; WTBeck@uic.edu			National Cancer Institute [CA40570, CA138762, CA27469, CA37517]; Rush University Medical Center; University of Illinois at Chicago; NCRR NIH [C06RR15482]; NATIONAL CANCER INSTITUTE [U10CA037517, R01CA040570, R01CA138762, U10CA027469] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015482] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Rush University Medical Center; University of Illinois at Chicago; NCRR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the Gynecologic Oncology Group (GOG) Tissue Bank for providing unstained ovarian tumor TMAs. We thank our colleague, Martina Vaskova, for her outstanding administrative assistance. We also thank Dr Richard Gemeinhart for allowing us to use his IX70 microscope and Ernest Gemeinhart for his excellent technical assistance with microscopy. This work was supported by the National Cancer Institute Grants CA40570 and CA138762 to WTB, CA27469 to the GOG, GOG Tissue Bank and GOG Molecular Pharmacology Core Lab and CA37517 to the GOG Statistical and Data Center as well as the Ovarian Cancer Research Fund (XH), Rush University Medical Center and the University of Illinois at Chicago. It was conducted in a facility constructed with support from the NCRR NIH grant C06RR15482.	Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004; Cornelis S, 2005, NUCLEIC ACIDS RES, V33, P3095, DOI 10.1093/nar/gki611; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; de la Mata M, 2006, NAT STRUCT MOL BIOL, V13, P973, DOI 10.1038/nsmb1155; De Marzo AM, 1998, PROSTATE, V34, P162; Feltes CM, 2002, CANCER RES, V62, P6688; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; Galiana-Arnoux D, 2003, J BIOL CHEM, V278, P32943, DOI 10.1074/jbc.M301090200; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jin W, 2000, CANCER RES, V60, P1221; Jin W, 2003, CANCER RES, V63, P6154; Jumaa H, 2000, BBA-GENE STRUCT EXPR, V1494, P137, DOI 10.1016/S0167-4781(00)00233-5; Jumaa H, 1999, CURR BIOL, V9, P899, DOI 10.1016/S0960-9822(99)80394-7; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Kosinski PA, 2003, J IMMUNOL, V170, P979, DOI 10.4049/jimmunol.170.2.979; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lockhart MS, 2001, ONCOL REP, V8, P145; Loomis RJ, 2009, MOL CELL, V33, P450, DOI 10.1016/j.molcel.2009.02.003; Lou H, 1999, MOL CELL BIOL, V19, P78; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Lukas J, 2001, CANCER RES, V61, P3212; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Ries LAG, 2007, SEER CANC STAT REV 1; Schroder W, 1999, ANTICANCER RES, V19, P3901; Sen S, 2009, MOL CELL BIOL, V29, P871, DOI 10.1128/MCB.01709-08; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang ZN, 2003, CANCER RES, V63, P655; Watermann DO, 2006, CANCER RES, V66, P4774, DOI 10.1158/0008-5472.CAN-04-3294; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Xie JY, 2003, P NATL ACAD SCI USA, V100, P8776, DOI 10.1073/pnas.1432696100; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu QM, 2004, J NEUROCHEM, V90, P164, DOI 10.1111/j.1471-4159.2004.02477.x; Zang WQ, 2001, J VIROL, V75, P10779, DOI 10.1128/JVI.75.22.10779-10786.2001	55	73	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					356	365		10.1038/onc.2010.426	http://dx.doi.org/10.1038/onc.2010.426			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856201	Green Accepted			2022-12-28	WOS:000286418800010
J	Rorke, EA; Adhikary, G; Jans, R; Crish, JF; Eckert, RL				Rorke, E. A.; Adhikary, G.; Jans, R.; Crish, J. F.; Eckert, R. L.			AP1 factor inactivation in the suprabasal epidermis causes increased epidermal hyperproliferation and hyperkeratosis but reduced carcinogen-dependent tumor formation	ONCOGENE			English	Article						TAM67; c-jun; keratinocyte differentiation; epidermis; skin cancer	HUMAN INVOLUCRIN PROMOTER; NEGATIVE C-JUN; CONDITIONAL GENE-EXPRESSION; ACTIVATED PROTEIN-KINASES; DISTAL REGULATORY REGION; CELL-PROLIFERATION; MOUSE EPIDERMIS; TRANSGENIC MICE; IN-VIVO; KERATINOCYTE DIFFERENTIATION	Activator protein one (AP1) (jun/fos) factors comprise a family of transcriptional regulators (c-jun, junB, junD, c-fos, FosB, Fra-1 and Fra-2) that are key controllers of epidermal keratinocyte survival and differentiation, and are important drivers of cancer development. Understanding the role of these factors in epidermis is complicated by the fact that each member is expressed in defined cell layers during epidermal differentiation, and because AP1 factors regulate competing processes (that is, proliferation, apoptosis and differentiation). We have proposed that AP1 factors function differently in basal versus suprabasal epidermis. To test this, we inactivated suprabasal AP1 factor function in mouse epidermis by targeted expression of dominant-negative c-jun (TAM67), which inactivates function of all AP1 factors. This produces increased basal keratinocyte proliferation, delayed differentiation and extensive hyperkeratosis. These findings contrast with previous studies showing that basal layer AP1 factor inactivation does not perturb resting epidermis. It is interesting that in spite of extensive keratinocyte hyper-proliferation, susceptibility to carcinogen-dependent tumor induction is markedly attenuated. These novel observations strongly suggest that AP1 factors have distinct roles in the basal versus suprabasal epidermis, confirm that AP1 factor function is required for normal terminal differentiation, and suggest that AP1 factors have a different role in normal epidermis versus cancer progression. Oncogene (2010) 29, 5873-5882; doi:10.1038/onc.2010.315; published online 6 September 2010	[Rorke, E. A.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; [Adhikary, G.; Jans, R.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Crish, J. F.] Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Obstet & Genecol & Reprod Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Rorke, EA (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, 108 N Greene St, Baltimore, MD 21201 USA.	erorke@SOM.umaryland.edu; reckert@umaryland.edu	Jans, Ralph/F-2150-2013		NIH [RO1 AR046494]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049713, R01AR046494] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NIH RO1 AR046494 (R Eckert).	Adhikary G, 2004, INVEST OPHTH VIS SCI, V45, P1080, DOI 10.1167/iovs.03-1180; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Bickenbach J R, 2000, Adv Dermatol, V16, P159; BROWN PH, 1994, ONCOGENE, V9, P791; Cooper SJ, 2003, MOL CANCER RES, V1, P848; Crish JF, 2008, J INVEST DERMATOL, V128, P530, DOI 10.1038/sj.jid.5701049; Crish JF, 2006, J INVEST DERMATOL, V126, P305, DOI 10.1038/sj.jid.5700019; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Crish JF, 2002, ONCOGENE, V21, P738, DOI 10.1038/sj.onc.1205038; Cutler TJ, 2004, VET CLIN N AM-EQUINE, V20, pXI, DOI 10.1016/S0749-0739(04)00029-X; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Diamond I, 2000, J INVEST DERMATOL, V115, P788, DOI 10.1046/j.1523-1747.2000.00144.x; Dunnwald M, 2001, EXP DERMATOL, V10, P45, DOI 10.1034/j.1600-0625.2001.100106.x; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1996, CELL DEATH DIFFER, V3, P373; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Florin L, 2006, J INVEST DERMATOL, V126, P902, DOI 10.1038/sj.jid.5700123; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; HEYDEN A, 1994, EPITHELIAL CELL BIOL, V3, P96; HEYDEN A, 1994, DIFFERENTIATION, V57, P187, DOI 10.1046/j.1432-0436.1994.5730187.x; Iizuka H, 2004, J DERMATOL, V31, P271, DOI 10.1111/j.1346-8138.2004.tb00672.x; Jaubert J, 2004, J INVEST DERMATOL, V123, P313, DOI 10.1111/j.0022-202X.2004.23203.x; KAHN CR, 1993, INVEST OPHTH VIS SCI, V34, P3429; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Matthews CP, 2007, CANCER RES, V67, P2430, DOI 10.1158/0008-5472.CAN-06-0522; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Mizuno H, 2006, MOL CARCINOGEN, V45, P1, DOI 10.1002/mc.20160; MOLLOY CJ, 1987, CANCER RES, V47, P4674; Nickoloff B J, 2001, J Invest Dermatol, V117, P1; Nickoloff B J, 1999, Expert Opin Investig Drugs, V8, P393, DOI 10.1517/13543784.8.4.393; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008; Rutberg SE, 2000, CANCER RES, V60, P6332; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; She QB, 2002, CANCER RES, V62, P1343; Shi B, 2005, EXP DERMATOL, V14, P519, DOI 10.1111/j.0906-6705.2005.00317.x; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SUN TT, 1983, J INVEST DERMATOL, V81, pS109, DOI 10.1111/1523-1747.ep12540831; Sun TT, 1984, CANCER CELLS, V1, P169; Takahashi H, 2002, J DERMATOL SCI, V30, P94, DOI 10.1016/S0923-1811(02)00064-6; Thompson EJ, 2002, CANCER RES, V62, P3044; TOFTGARD R, 1985, CANCER RES, V45, P5845; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2002, MOL CARCINOGEN, V34, P72, DOI 10.1002/mc.10050; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963	70	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5873	5882		10.1038/onc.2010.315	http://dx.doi.org/10.1038/onc.2010.315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20818430	Green Accepted			2022-12-28	WOS:000283843400002
J	Yang, D; Tao, J; Li, L; Kedei, N; Toth, ZE; Czap, A; Velasquez, JF; Mihova, D; Michalowski, AM; Yuspa, SH; Blumberg, PM				Yang, D.; Tao, J.; Li, L.; Kedei, N.; Toth, Z. E.; Czap, A.; Velasquez, J. F.; Mihova, D.; Michalowski, A. M.; Yuspa, S. H.; Blumberg, P. M.			RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma	ONCOGENE			English	Article						Ras activator; Akt; HGF; melanoma; cell transformation; guanine nucleotide exchange factor	POLYMERASE-CHAIN-REACTION; PHORBOL ESTERS; KINASE ACTIVATION; B-RAF; FUNCTIONAL-ANALYSIS; CELL PROLIFERATION; COLORECTAL TUMORS; REGULATED KINASE; BRAF MUTATIONS; PHOSPHORYLATION	RasGRP3, an activator for H-Ras, R-Ras and Ras-associated protein-1/2, has emerged as an important mediator of signaling downstream from receptor coupled phosphoinositide turnover in B and T cells. Here, we report that RasGRP3 showed a high level of expression in multiple human melanoma cell lines as well as in a subset of human melanoma tissue samples. Suppression of endogenous RasGRP3 expression in these melanoma cell lines reduced Ras-GTP formation as well as c-Met expression and Akt phosphorylation downstream from hepatocyte growth factor (HGF) or epidermal growth factor (EGF) stimulation. RasGRP3 suppression also inhibited cell proliferation and reduced both colony formation in soft agar and xenograft tumor growth in immunodeficient mice, demonstrating the importance of RasGRP3 for the transformed phenotype of the melanoma cells. Reciprocally, overexpression of RasGRP3 in human primary melanocytes altered cellular morphology, markedly enhanced cell proliferation and rendered the cells tumorigenic in a mouse xenograft model. Suppression of RasGRP3 expression in these cells inhibited downstream RasGRP3 responses and suppressed cell growth, confirming the functional role of RasGRP3 in the altered behavior of these cells. The identification of the role of RasGRP3 in melanoma highlights its importance, as a Ras activator, in the phosphoinositide signaling pathway in human melanoma and provides a new potential therapeutic target. Oncogene (2011) 30, 4590-4600; doi: 10.1038/onc.2011.166; published online 23 May 2011	[Yang, D.; Tao, J.; Li, L.; Kedei, N.; Czap, A.; Velasquez, J. F.; Mihova, D.; Michalowski, A. M.; Yuspa, S. H.; Blumberg, P. M.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Toth, Z. E.] Semmelweis Univ, Dept Anat Histol & Embryol, Neuromorphol & Neuroendocrine Res Lab, Budapest, Hungary; [Toth, Z. E.] Hungarian Acad Sci, Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Semmelweis University; Hungarian Academy of Sciences	Blumberg, PM (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, Room 4048,Bldg 37,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov	Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091	NIH, Center for Cancer Research, National Cancer Institute [Z1A BC 005270]; ETT [495/09]; Bolyai fellowship; NATIONAL CANCER INSTITUTE [ZIABC004504, ZIABC005445, ZIABC005270, Z01BC005270] Funding Source: NIH RePORTER	NIH, Center for Cancer Research, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ETT; Bolyai fellowship(Hungarian Academy of Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by the intramural program of the NIH, Center for Cancer Research, National Cancer Institute (project number Z1A BC 005270) and in part by grant ETT 495/09. ZE Toth is supported by the Bolyai fellowship. We thank Glenn Merlino for helpful comments.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Aiba Y, 2004, P NATL ACAD SCI USA, V101, P16612, DOI 10.1073/pnas.0407468101; BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bauer J, 2006, DERMATOL THER, V19, P40, DOI 10.1111/j.1529-8019.2005.00055.x; Brodie C, 2004, MOL PHARMACOL, V66, P76, DOI 10.1124/mol.66.1.76; Coughlin JJ, 2005, J IMMUNOL, V175, P7179, DOI 10.4049/jimmunol.175.11.7179; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Gawecka JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011269; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Haluska Frank G, 2006, Curr Oncol Rep, V8, P400, DOI 10.1007/s11912-006-0065-x; Hingorani SR, 2003, CANCER RES, V63, P5198; Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6; Huang HP, 2008, J AGR FOOD CHEM, V56, P9286, DOI 10.1021/jf8013102; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Lorenzo PS, 2001, CANCER RES, V61, P943; Oh-Hora M, 2003, J EXP MED, V198, P1841, DOI 10.1084/jem.20031547; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Oki-Idouchi CE, 2007, CANCER RES, V67, P276, DOI 10.1158/0008-5472.CAN-06-3080; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Powell MB, 1999, CARCINOGENESIS, V20, P1747, DOI 10.1093/carcin/20.9.1747; Pu YM, 2005, J BIOL CHEM, V280, P27329, DOI 10.1074/jbc.M414132200; Roberts DM, 2004, MOL CELL BIOL, V24, P10515, DOI 10.1128/MCB.24.24.10515-10528.2004; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Satyamoorthy K, 2003, CANCER RES, V63, P756; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Stone JC, 2006, BIOCHEM SOC T, V34, P858, DOI 10.1042/BST0340858; Stope MB, 2004, MOL CELL BIOL, V24, P4664, DOI 10.1128/MCB.24.11.4664-4676.2004; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutlovic D, 2005, CROAT MED J, V46, P556; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; van Elsas A, 1995, Recent Results Cancer Res, V139, P57; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yang DZ, 2010, CANCER RES, V70, P7905, DOI 10.1158/0008-5472.CAN-09-4729; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zheng Y, 2005, BLOOD, V105, P3648, DOI 10.1182/blood-2004-10-3916	54	40	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4590	4600		10.1038/onc.2011.166	http://dx.doi.org/10.1038/onc.2011.166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	22139084	Green Accepted			2022-12-28	WOS:000296890700006
